PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Tanghetti, E; Ria, R; Dell'Era, P; Urbinati, C; Rusnati, M; Ennas, MG; Presta, M				Tanghetti, E; Ria, R; Dell'Era, P; Urbinati, C; Rusnati, M; Ennas, MG; Presta, M			Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts	ONCOGENE			English	Article						cell adhesion; cell proliferation; angiogenesis; integrin; FGF; tyrosine kinase; FGF receptor	EXTRACELLULAR-MATRIX; INTEGRIN EXPRESSION; IN-VITRO; ANGIOGENESIS; UROKINASE; PROTEIN; ACTIVATION; BINDING; INVITRO; ALPHA(V)BETA(3)	Substrate-bound FGF2 promotes endothelial cell adhesion by interacting With alpha(nu)beta(3) integrin. Here, endothelial GM7373 cells spread and organize focal adhesion plaques on immobilized FGF2, fibronectin (FN), and vitronectin (VN). alpha(nu)beta(3) integrin, paxillin, focal adhesion kinase, vinculin and pp60(src) localize in cell-substratum contact sites on FGF2, FN or VN. However, only immobilized FGF2 induces a long-lasting activation of extracellular signal-regulated kinases(1/2) (ERK1/2) and cell proliferation that was inhibited by the ERK1/2 inhibitor PD 098059 and the tyrosine kinase (TK) inhibitor tyrphostin 23, pointing to the engagement of FGF receptor (FGFR) at the basal side of the cell. To assess this hypothesis, GM7373 cells were transfected with a dominant negative TK--DeltaFGFR1 mutant (GM7373-DeltaFGFR1 cells) or with the full-length receptor (GM7373-FGFR1 cells). Both transfectants adhere and spread on FGF2 but GM7373-DeltaFGFR1 cells do not proliferate. Also, parental and GM7373-FGFR1 cells, but not GM7373-DeltaFGFR1 cells, undergo morphological changes and increased motility on FGF2-coated plastic. Finally, FGFR1, but not TK--DeltaFGFR1, localizes in cell adhesion contacts on immobilized FGF2. In conclusion, substrate-bound FGF2 induces endothelial cell proliferation, motility, and the recruitment of FGFR1 in cell-substratum contacts. This may contribute to the cross talk among intracellular signaling pathways activated by FGFR1 and alpha(nu)beta(3) integrin in endothelial cells.	Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Univ Cagliari, Dept Cytomorphol, Cagliari, Italy; Univ Bari, Sch Med, Dept Biomed Sci & Human Oncol, Bari, Italy	University of Brescia; University of Cagliari; Universita degli Studi di Bari Aldo Moro	Presta, M (corresponding author), Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, Via Valsabbina 19, I-25123 Brescia, Italy.		Dell'Era, Patrizia/ABD-5848-2020; Rusnati, Marco/F-1168-2010; Presta, Marco/B-4345-2010; Dell'Era, Patrizia/G-5294-2010; Dell'Era, Patrizia/N-6964-2019; Ria, Roberto/I-4263-2015	Rusnati, Marco/0000-0001-9968-5908; Dell'Era, Patrizia/0000-0001-6682-6321; Ennas, Maria Grazia/0000-0002-9448-715X; PRESTA, Marco/0000-0002-4398-8376; Urbinati, Chiara Eva/0000-0002-0138-7871; Ria, Roberto/0000-0002-1515-0090				ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BOYER B, 1993, J CELL BIOL, V120, P767, DOI 10.1083/jcb.120.3.767; BROADLEY KN, 1989, LAB INVEST, V61, P571; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CULP LA, 1976, BIOCHEMISTRY-US, V15, P4094, DOI 10.1021/bi00663a028; DAVIS CM, 1993, J CELL BIOCHEM, V51, P206, DOI 10.1002/jcb.240510213; DELROSSO M, 1992, EXP CELL RES, V203, P427; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giuliani R, 1999, J CELL SCI, V112, P2597; GRINSPAN JB, 1983, J CELL PHYSIOL, V114, P328, DOI 10.1002/jcp.1041140312; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LI Y, 1994, MOL CELL BIOL, V14, P7600; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; RIBATTI D, 1995, DEV BIOL, V170, P39, DOI 10.1006/dbio.1995.1193; Ribatti D, 1999, J CELL SCI, V112, P4213; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; Rusnati M, 1996, MOL BIOL CELL, V7, P369, DOI 10.1091/mbc.7.3.369; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SMITH JC, 1982, NATURE, V296, P154, DOI 10.1038/296154a0; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; ZHANG WW, 1994, CANCER GENE THER, V1, P4	47	58	64	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3889	3897		10.1038/sj.onc.1205407	http://dx.doi.org/10.1038/sj.onc.1205407			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032827				2022-12-28	WOS:000175847200008
J	Stubbs, MC; Hall, DJ				Stubbs, MC; Hall, DJ			The amino-terminus of the E2F-1 transcription factor inhibits DNA replication of autonomously replicating plasmids in mammalian cells	ONCOGENE			English	Article						S phase checkpoint; E2F-1; replication inhibition; elongation phase	ZINC-FINGER PROTEIN; S-PHASE; CORE ORIGIN; APOPTOSIS; INDUCTION; EXPRESSION; INITIATION; BINDING; DAMAGE; BRCA1	The E2F1 transcription factor plays a pivotal role in driving cells out of a quiescent state and into the S phase of the cell cycle, in part by transactivating genes needed for DNA replication including DHFR, thymidine kinase, and DNA Polymerase x. E2F1 has also been implicated in regulating an S phase checkpoint, however its role in this checkpoint is not well defined. To determine how E2F1 affects such a checkpoint, we utilized an in vivo replication assay employing a plasmid based SV40 origin of replication, transfected into cells expressing SV40 large T antigen. Here we show that expression of full length E2F1, or only its N terminus, represses replication from plasmids containing the SV40 origin, while N terminal deletions of E2F1 do not. E2F1 appears to inhibit the elongation phase of replication and not the initiation phase since it does not affect the replication of other cotransfected plasmids containing only the SV40 origin. Further, inhibition of replication is dependent on both the amino-terminus of the E2F1 protein and on a DNA sequence that is contained within the 3' end of the E2F1 cDNA. Additionally, both full-length E2F1, or just its N-terminus, form protein complexes with two portions of the 3' end of the E2F1 cDNA. These data provide a clue to the mechanism by which E2F1 regulates transit through the S phase checkpoint, by acting on a specific DNA sequence via its amino-terminal region, to inhibit elongation of DNA replication.	NIAMSD, Cartilage & Orthopaed Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Hall, DJ (corresponding author), NIAMSD, Cartilage & Orthopaed Branch, NIH, MSC 5755,9000 Rockville Pk, Bethesda, MD 20892 USA.	halld@ep.niams.nih.gov		, Matthew/0000-0003-3771-7083	NCI NIH HHS [CA67032] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; CHITTENDEN T, 1991, J VIROL, V65, P5944, DOI 10.1128/JVI.65.11.5944-5951.1991; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; DEB S, 1987, J VIROL, V61, P2143, DOI 10.1128/JVI.61.7.2143-2149.1987; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Deng CX, 2000, BIOESSAYS, V22, P728; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; HARLOW F, 1988, ANTIBODIES LAB MANUA; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Izzo MW, 1999, J BIOL CHEM, V274, P19498, DOI 10.1074/jbc.274.27.19498; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOrdan KL, 1996, BIOCHEMISTRY-US, V35, P12320, DOI 10.1021/bi9611927; Jordan-Sciutto KL, 1998, BIOCHEM CELL BIOL, V76, P37; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; LOGAN TJ, 1995, CANCER RES, V55, P2883; LOGAN TJ, 1994, MOL BIOL CELL, V5, P667, DOI 10.1091/mbc.5.6.667; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Stubbs MC, 1999, BIOCHEM BIOPH RES CO, V258, P77, DOI 10.1006/bbrc.1999.0603; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	44	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3715	3726		10.1038/sj.onc.1205473	http://dx.doi.org/10.1038/sj.onc.1205473			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032840				2022-12-28	WOS:000175676000007
J	Foster, CJ; Lozano, G				Foster, CJ; Lozano, G			Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland	ONCOGENE			English	Article						proliferation; cell cycle; p53	TUMOR-SUPPRESSOR; S-PHASE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; INK4A LOCUS; P53 PROTEIN; GENE; AMPLIFICATION; PRODUCT; ASSOCIATION	The protein encoded by the murine double minute 2 (Mdm2) gene inactivates the function of the tumor suppressor p53. The targeted expression of the mdm2 transgene (BLGmdm2) to the mammary epithelium disrupts the cell cycle, causing multiple rounds of DNA synthesis without proper cell division and consequently poor mammary gland development. These phenotypes in the mammary epithelia of the transgenic mice are not dependent on either p53 or the transcription factor E2F1, as mice null for these genes carrying the BLGmdm2 transgene exhibit similar defects to mice carrying the BLGmdm2 transgene alone. p19ARF, an alternative splice product of the INK4a/ARF locus, has been shown to interact directly with MDM2. Therefore, BLGmdm2 transgenic mice null for p19ARF were created to gain insight into the mechanism by which mdm2 overexpression disrupts the cell cycle. The BLGmdm2 phenotype in the absence of p19ARF was worse than BLGmdm2 mice and visible as early as day 15 of pregnancy. By day 5 of lactation the phenotype was very pronounced. Histological analysis of the mammary gland showed a decrease in ductal branching, smaller and fewer lobuloalveolar structures, and a decrease in luminal secretions. Multinucleated and enlarged cells were present due to continued replication in the absence of cytokinesis. Thus, the absence of p19ARF in this in vivo system enhanced the defect caused by mdm2 overexpression.	Univ Texas, MD Anderson Canc Ctr, Sect Canc Genet, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sect Canc Genet, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gglozano@mdanderson.org		Vivian, Carolyn J./0000-0001-9598-0109	NATIONAL CANCER INSTITUTE [R29CA047296, R01CA047296, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kucera GT, 1996, DEV BIOL, V173, P162, DOI 10.1006/dbio.1996.0014; LEACH FS, 1993, CANCER RES, V53, P2231; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MAO L, 1995, CANCER RES, V55, P2995; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MCCANN AH, 1995, BRIT J CANCER, V71, P981, DOI 10.1038/bjc.1995.189; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; NAKAYAMA T, 1995, INT J CANCER, V64, P342, DOI 10.1002/ijc.2910640511; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; STONE S, 1995, CANCER RES, V55, P2988; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	36	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3525	3531		10.1038/sj.onc.1205441	http://dx.doi.org/10.1038/sj.onc.1205441			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032854				2022-12-28	WOS:000175793700003
J	Allsopp, RC; Weissman, IL				Allsopp, RC; Weissman, IL			Replicative senescence of hematopoietic stem cells during serial transplantation: does telomere shortening play a role?	ONCOGENE			English	Article						telomere; hematopoietic stem cell; senescence; transplantation	TERMINAL TRANSFERASE; END-REPLICATION; IMMORTAL CELLS; LIFE-SPAN; CHROMOSOMES; TETRAHYMENA; EXPRESSION; EXTENSION; DNA; PROLIFERATION	Hematopoietic stem cells (HSC) have a finite proliferative lifespan, based upon the limited number of times they can be serially transplanted in mice. Telomeres have been shown to shorten during the division of many normal somatic cells in humans, and the attrition of telomeres has been shown to ultimately cause replicative senescence in vitro for a number of different human cell strains. Whereas most human cell types have little to no detectable levels of telomerase activity, hematopoietic cells, including HSC, express low to moderate levels of telomerase, and yet telomeres shorten considerably during replicative aging of these cells. Here we consider the role telomerase may play in the hematopoietic system as well as the effect that over-expression of telomerase reverse transcriptase may have on the replicative capacity of hematopoietic stem cells during transplantation.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA	Stanford University	Allsopp, RC (corresponding author), Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.	rallsopp@cmgm.Stanford.edu			NCI NIH HHS [CA 86065] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed S, 1998, GENETICS, V150, P643; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Effros RB, 1998, AM J HUM GENET, V62, P1003, DOI 10.1086/301845; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; GUERRINI AM, 1993, HUM MOL GENET, V2, P455, DOI 10.1093/hmg/2.4.455; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRISON DE, 1978, J EXP MED, V147, P1526, DOI 10.1084/jem.147.5.1526; HARRISON DE, 1982, J EXP MED, V156, P1767, DOI 10.1084/jem.156.6.1767; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Kruk PA, 1996, BIOCHEM BIOPH RES CO, V224, P487, DOI 10.1006/bbrc.1996.1054; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; McClintock B, 1941, GENETICS, V26, P234; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yasumoto S, 1996, ONCOGENE, V13, P433	52	51	55	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3270	3273		10.1038/sj.onc.1205314	http://dx.doi.org/10.1038/sj.onc.1205314			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032768				2022-12-28	WOS:000175633300003
J	Steinman, RA				Steinman, RA			Cell cycle regulators and hematopoiesis	ONCOGENE			English	Review						hematopoiesis; quiescence; cyclin-dependent; p21 kinases; differentiation	GROWTH-FACTOR-BETA; TERMINAL ERYTHROID-DIFFERENTIATION; CCAAT/ENHANCER-BINDING PROTEIN; DEPENDENT KINASE INHIBITORS; LINEAGE-SPECIFIC REGULATION; COLONY-STIMULATING FACTOR; MYELOID PROGENITOR CELLS; BLOOD CD34(+) CELLS; GENE-EXPRESSION; STEM-CELLS	The cell cycle behavior of hematopoietic cells varies from extended quiescence to spectacular proliferation. Cell cycle regulators choreograph these transitions through variation in the makeup of cyclin-dependent kinase (cdk)-containing complexes and through alteration in protein expression levels and subcellular localization. The mechanisms through which cell cycle regulators couple proliferation, differentiation and survival is coming into sharper focus. Cdk-inhibitors, once thought of solely in terms of a checkpoint function on cycling, are now known to interact directly with proteins and pathways central to differentiation and apoptosis. By shuttling between binding partners committed to discrete functional pathways, cell cycle regulators may directly coordinate proliferation with differentiation, migration and apoptosis.	Dept Med & Pharmacol, Pittsburgh, PA 15213 USA		Steinman, RA (corresponding author), Dept Med & Pharmacol, E1052 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.	Steinman@imap.pitt.edu			NHLBI NIH HHS [HL65172] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065172] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi M, 1997, BLOOD, V90, P126; Amanullah A, 2000, BLOOD, V96, P475; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANDO K, 1995, ONCOGENE, V10, P751; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; Bradford GB, 1997, EXP HEMATOL, V25, P445; Braun SE, 1998, BLOOD CELL MOL DIS, V24, P138, DOI 10.1006/bcmd.1998.0181; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; BURGER C, 1994, J CELL SCI, V107, P2047; CAPEL B, 1990, BLOOD, V75, P2267; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Chen G, 1999, DNA CELL BIOL, V18, P305, DOI 10.1089/104454999315367; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; Dai MS, 2000, BLOOD, V96, P3985, DOI 10.1182/blood.V96.12.3985.h8003985_3985_3987; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Decesse JT, 2001, ONCOGENE, V20, P962, DOI 10.1038/sj.onc.1204169; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; DellaRagione F, 1997, BIOCHEM BIOPH RES CO, V231, P73, DOI 10.1006/bbrc.1997.5938; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Duarte RF, 2000, BLOOD, V96, P3422; Ducos K, 2000, J CELL PHYSIOL, V184, P80, DOI 10.1002/(SICI)1097-4652(200007)184:1<80::AID-JCP8>3.0.CO;2-Q; EAVES CJ, 1991, BLOOD, V78, P110; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Englert C, 1997, CANCER RES, V57, P1429; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fortunel N, 2000, STEM CELLS, V18, P102, DOI 10.1634/stemcells.18-2-102; Fortunel NO, 2000, BLOOD, V96, P2022; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Furukawa Y, 2000, BRIT J HAEMATOL, V110, P663, DOI 10.1046/j.1365-2141.2000.02253.x; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Glimm H, 2000, BLOOD, V96, P4185, DOI 10.1182/blood.V96.13.4185.h8004185_4185_4193; Glimm H, 1999, BLOOD, V94, P2161, DOI 10.1182/blood.V94.7.2161.419k32_2161_2168; Gonze D, 2001, J THEOR BIOL, V210, P167, DOI 10.1006/jtbi.2000.2294; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; Gothot A, 1998, EXP HEMATOL, V26, P562; Gothot A, 1998, BLOOD, V92, P2641, DOI 10.1182/blood.V92.8.2641.420k36_2641_2649; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Hoshikawa Y, 1998, ANAL BIOCHEM, V261, P211, DOI 10.1006/abio.1998.2742; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; JIANG HP, 1994, ONCOGENE, V9, P3397; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Josefsen D, 2000, STEM CELLS, V18, P261, DOI 10.1634/stemcells.18-4-261; Karanu FN, 2001, BLOOD, V97, P1960, DOI 10.1182/blood.V97.7.1960; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Leemhuis T, 1996, EXP HEMATOL, V24, P1215; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Mahmud N, 2001, BLOOD, V97, P3061, DOI 10.1182/blood.V97.10.3061; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Marone M, 2000, BRIT J HAEMATOL, V110, P654, DOI 10.1046/j.1365-2141.2000.02227.x; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; Mayol X, 1996, ONCOGENE, V13, P237; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; McDonald E, 1996, CANCER RES, V56, P2250; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Meiyanto E, 2001, BIOCHEM BIOPH RES CO, V282, P278, DOI 10.1006/bbrc.2001.4564; Mori A, 1999, ONCOGENE, V18, P6209, DOI 10.1038/sj.onc.1203044; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Okada S, 1999, BLOOD, V93, P816, DOI 10.1182/blood.V93.3.816.403k21_816_825; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Phelps DE, 1998, CELL GROWTH DIFFER, V9, P595; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; PIETRZYK ME, 1985, BLOOD, V66, P1460; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Reid S, 1999, CYTOKINES CELL MOL T, V5, P129; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Romond PC, 1999, ANN NY ACAD SCI, V879, P180, DOI 10.1111/j.1749-6632.1999.tb10419.x; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHERR CJ, 1994, STEM CELLS, V12, P47; Shimizu T, 2000, ONCOGENE, V19, P4640, DOI 10.1038/sj.onc.1203821; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Sriuranpong V, 2001, CANCER RES, V61, P3200; Srour EF, 2000, BLOOD, V96, P1609, DOI 10.1182/blood.V96.4.1609.h8001608b_1609_1612; Steinman R. A., 1997, Blood, V90, p164A; Steinman RA, 2000, MOL MED, V6, P736, DOI 10.1007/BF03402190; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Steinman RA, 2000, LEUKEMIA RES, V24, P601, DOI 10.1016/S0145-2126(00)00020-5; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Tamir A, 2000, CELL GROWTH DIFFER, V11, P269; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Tian JQ, 1999, AM J PHYSIOL-GASTR L, V276, pG1094, DOI 10.1152/ajpgi.1999.276.5.G1094; Tian JQ, 1999, AM J PHYSIOL-CELL PH, V276, pC1245, DOI 10.1152/ajpcell.1999.276.6.C1245; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Tsukiyama T, 2001, J IMMUNOL, V166, P304, DOI 10.4049/jimmunol.166.1.304; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Wilpshaar J, 2000, BLOOD, V96, P2100; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Yaroslavskiy B, 2001, J CELL BIOCHEM, V83, P380, DOI 10.1002/jcb.1243; YEN A, 1990, CANCER RES, V50, P1411; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zhou P, 1999, ANTICANCER RES, V19, P4935	131	87	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3403	3413		10.1038/sj.onc.1205325	http://dx.doi.org/10.1038/sj.onc.1205325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032778				2022-12-28	WOS:000175633300013
J	Feitelson, MA; Sun, B; Tufan, NLS; Liu, J; Pan, JB; Lian, ZR				Feitelson, MA; Sun, B; Tufan, NLS; Liu, J; Pan, JB; Lian, ZR			Genetic mechanisms of hepatocarcinogenesis	ONCOGENE			English	Review						hepatocellular carcinoma; hepatitis viruses; loss of heterozygosity; mutations	HEPATITIS-B-VIRUS; HUMAN HEPATOCELLULAR-CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; P53 TUMOR-SUPPRESSOR; GROWTH-FACTOR-BETA; ABERRANT DNA METHYLATION; E-CADHERIN GENE; NF-KAPPA-B; C VIRUS	The development of hepatocellular carcinoma (HCC is a multistep process associated with changes in host gene expression, some of which correlate with the appearance and progression of tumor. Preneoplastic changes in gene expression result from altered DNA methylation, the actions of hepatitis B and C viruses, and point mutations or loss of heterozygosity (LOH) in selected cellular genes. Tumor progression is characterized by LOH involving tumor suppressor genes on many chromosomes and by gene amplification of selected oncogenes. The changes observed in different HCC nodules are often distinct, suggesting heterogeneity on the molecular level. These observations suggest that there are multiple, perhaps redundant negative growth regulatory pathways that protect cells against transformation. An understanding of the molecular pathogenesis of HCC may provide new markers for tumor staging, for assessment of the relative risk of tumor formation, and open new opportunities for therapeutic intervention.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Feitelson, MA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 222 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Mark.Feitelson@mail.tju.edu	Lian, Zhaorui/AAW-2379-2020	Satiroglu Tufan, N Lale/0000-0001-9399-0960	NCI NIH HHS [CA 79512, CA 66971, CA 48656] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA048656, R01CA066971, R01CA079512, R01CA048656] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT PJ, 1977, BRIT J CANCER, V34, P310; Aihara T, 1998, HEPATOLOGY, V28, P86, DOI 10.1002/hep.510280113; Andersson, 1991, FLORA ECUADOR, P1; Attallah AM, 1999, CANCER LETT, V142, P65, DOI 10.1016/S0304-3835(99)00165-2; Bando K, 1999, GENE CHROMOSOME CANC, V25, P284, DOI 10.1002/(SICI)1098-2264(199907)25:3<284::AID-GCC11>3.0.CO;2-I; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Boige V, 1997, CANCER RES, V57, P1986; Boix-Ferrero J, 1999, VIRCHOWS ARCH, V434, P497, DOI 10.1007/s004280050374; BOURDON JC, 1995, GASTROENTEROLOGY, V108, P1176, DOI 10.1016/0016-5085(95)90217-1; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Cadoret A, 2001, CANCER RES, V61, P3245; Calvisi DF, 2001, CANCER RES, V61, P2085; Cao GW, 1997, GASTROENTEROLOGY, V112, P501, DOI 10.1053/gast.1997.v112.pm9024304; CHANG MH, 1989, CANCER-AM CANCER SOC, V64, P2377, DOI 10.1002/1097-0142(19891201)64:11<2377::AID-CNCR2820641130>3.0.CO;2-8; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; Chen QY, 1997, HEPATOLOGY, V26, P59; Collier J, 1998, HEPATOLOGY, V27, P273, DOI 10.1002/hep.510270140; DARVILLE CN, 1991, HEPATOLOGY, V13, P310, DOI 10.1002/hep.1840130217; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DEJEAN A, 1990, MOL BIOL MED, V7, P213; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; DING SF, 1995, J HEPATOL, V22, P230, DOI 10.1016/0168-8278(95)80434-X; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUNSFORD HA, 1990, CANCER RES, V50, P3400; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Factor VM, 1997, CANCER RES, V57, P2089; Falls JG, 1999, AM J PATHOL, V154, P635, DOI 10.1016/S0002-9440(10)65309-6; Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.3.CO;2-B; Feitelson MA, 1999, FALK SYMP, V103C, P156; FEITELSON MA, 1986, CONCEPTS VIRAL PATHO, V2, P269; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Greenblatt MS, 1997, CANCER RES, V57, P426; Guo XZ, 1998, HEPATOLOGY, V28, P1481, DOI 10.1002/hep.510280606; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; Huang SF, 1999, CANCER GENET CYTOGEN, V111, P21, DOI 10.1016/S0165-4608(98)00215-5; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; Ido A, 2001, CANCER RES, V61, P3016; Ishido S, 1998, FEBS LETT, V438, P258, DOI 10.1016/S0014-5793(98)01312-X; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; Kanai Y, 1996, JPN J CANCER RES, V87, P1210, DOI 10.1111/j.1349-7006.1996.tb03135.x; Kanai Y, 1997, INT J CANCER, V71, P355; Katagiri T, 1996, CANCER RES, V56, P4575; Kato N, 1997, J VIROL, V71, P8856, DOI 10.1128/JVI.71.11.8856-8859.1997; Kawamura N, 1999, JPN J CANCER RES, V90, P413, DOI 10.1111/j.1349-7006.1999.tb00763.x; Kawate S, 1999, INT J ONCOL, V14, P127; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim SO, 1996, CANCER RES, V56, P3831; Kimura H, 1996, CANCER, V77, P271, DOI 10.1002/(SICI)1097-0142(19960115)77:2<271::AID-CNCR8>3.0.CO;2-P; Kishimoto Y, 1996, J CANCER RES CLIN, V122, P585, DOI 10.1007/BF01221189; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; Koyama M, 1999, JPN J CANCER RES, V90, P951, DOI 10.1111/j.1349-7006.1999.tb00840.x; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee SM, 1996, HEPATOLOGY, V24, P987; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LENCIONI R, 1994, ITAL J GASTROENTEROL, V26, P163; LIANG TJ, 1995, HEPATOLOGY, V22, P1330, DOI 10.1002/hep.1840220445; Liew CT, 1999, INT J CANCER, V81, P319, DOI 10.1002/(SICI)1097-0215(19990505)81:3<319::AID-IJC1>3.0.CO;2-K; Livezey KW, 1997, MUTAT RES-FUND MOL M, V377, P187, DOI 10.1016/S0027-5107(97)00068-7; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; Maki CG, 1996, CANCER RES, V56, P2649; Mao TL, 2001, J PATHOL, V193, P95, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; Masuda T, 2000, IN VITRO CELL DEV-AN, V36, P387; MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384; Miyoshi Y, 1998, CANCER RES, V58, P2524; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; MURAKAMI H, 1993, CANCER RES, V53, P1719; MURAKAMI Y, 1991, CANCER RES, V51, P5520; Nagai H, 2001, J HEPATOL, V34, P416, DOI 10.1016/S0168-8278(00)00038-6; NG IOL, 1994, CANCER-AM CANCER SOC, V74, P30, DOI 10.1002/1097-0142(19940701)74:1<30::AID-CNCR2820740107>3.0.CO;2-4; Niketeghad F, 2001, BRIT J CANCER, V85, P697, DOI 10.1054/bjoc.2001.1963; NISHIDA N, 1994, CANCER RES, V54, P3107; Noguchi O, 1996, J HEPATOL, V24, P286, DOI 10.1016/S0168-8278(96)80006-7; Ogden SK, 2000, J BIOL CHEM, V275, P27806; Ohsawa N, 1996, J HEPATOL, V25, P655, DOI 10.1016/S0168-8278(96)80235-2; Okabe H, 2001, CANCER RES, V61, P2129; Okazaki I, 1997, HEPATOLOGY, V25, P580, DOI 10.1002/hep.510250315; Okuda K, 1997, J GASTROEN HEPATOL, V12, pS314, DOI 10.1111/j.1440-1746.1997.tb00515.x; Ozaki I, 2000, CANCER RES, V60, P6519; Park US, 2000, ONCOGENE, V19, P3384, DOI 10.1038/sj.onc.1203674; PASCALE RM, 1993, ANTICANCER RES, V13, P1341; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Peng CY, 2000, ANTICANCER RES, V20, P1487; Peng Shian-Yang, 1993, Journal of the Formosan Medical Association, V92, P866; Piao Z, 1999, CANCER LETT, V138, P227, DOI 10.1016/S0304-3835(99)00019-1; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Pontisso P, 1998, CANCER, V83, P1489; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ray RB, 1997, J BIOL CHEM, V272, P10983; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Sirivatanauksorn Y, 1999, GUT, V45, P761, DOI 10.1136/gut.45.5.761; Sirma H, 1999, FALK SYMP, V103C, P171; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402; Sugimoto K, 1999, HEPATOLOGY, V30, P920, DOI 10.1002/hep.510300424; Sun M, 2001, HEPATOLOGY, V33, P1415, DOI 10.1053/jhep.2001.24751; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Tu H, 2001, CANCER RES, V61, P7803; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ueki T, 1997, HEPATOLOGY, V25, P862, DOI 10.1002/hep.510250413; Wada I, 1999, HEPATOLOGY, V29, P1718, DOI 10.1002/hep.510290635; Wang G, 2001, GENE CHROMOSOME CANC, V31, P221, DOI 10.1002/gcc.1138; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wong IHN, 1999, CANCER RES, V59, P71; Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; Wong N, 2000, CLIN CANCER RES, V6, P4000; WU TC, 1987, HEPATOLOGY, V7, P46, DOI 10.1002/hep.1840070111; Xu L, 2001, CANCER RES, V61, P3176; Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674; Yano M, 1999, INT J ONCOL, V14, P447; Yeh SH, 2001, GASTROENTEROLOGY, V121, P699, DOI 10.1053/gast.2001.27211; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhang ZS, 2000, J BIOL CHEM, V275, P15157, DOI 10.1074/jbc.M910378199; Zhao XT, 2001, CANCER RES, V61, P7383	153	256	282	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2593	2604		10.1038/sj.onc.1205434	http://dx.doi.org/10.1038/sj.onc.1205434			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971194				2022-12-28	WOS:000174918400016
J	Chua, SS; Ma, ZQ; Gong, L; Lin, SH; DeMayo, FJ; Tsai, SY				Chua, SS; Ma, ZQ; Gong, L; Lin, SH; DeMayo, FJ; Tsai, SY			Ectopic expression of FGF-3 results in abnormal prostate and Wolffian duct development	ONCOGENE			English	Article						FGF-3; transgenic mice; prostate; Wolffian duct derivatives; hyperplasia	FIBROBLAST-GROWTH-FACTOR; MAMMARY-TUMOR VIRUS; PROTO-ONCOGENE INT-2; TRANSGENIC MICE; EPITHELIAL-CELLS; GENE-EXPRESSION; NUCLEAR-LOCALIZATION; SEMINAL-VESICLE; TRAMP MODEL; MOUSE	To evaluate the effects of FGF-3 expression in the prostate and male reproductive tract, we employed a bitransgenic system to target FGF-3 to these organs. We present a first study that ectopic FGF-3 expression resulted in exuberant hyperplasia of all bigenic prostatic lobes typified by epithelial stratification, cribiform structures and papillary tufts. These cells displayed increased nuclear-to-cytoplasmic ratios and bromodeoxyuridine (BrdU) proliferative index but retained relatively uniform nuclear androgen receptor (AR) and the tumor suppressor C-CAM1 staining. Furthermore, the dysmorphogenic prostatic cells also resembled PIN (prostatic intraepithelial neoplasia)-like lesions but did not appear to have invaded the basal lamina. In addition to these phenotypes, profound disorders of the bigenic Wolffian duct derivatives were observed. The bigenic ampullary glands and vas deferens were extremely cystic, hypertrophic and hyperplastic; the enlarged epididymi showed a reduction of spermatozoa and the seminal vesicles exhibited a dramatic reduction of seminal secretions. Because of these severe abnormalities, these infertile males presented with diaphragmatic hernias, hemoperitoneum and many secondary abnormalities at sacrifice. Taken together, we show that ectopic FGF-3 expression severely perturbs normal prostate development and our system should be useful for the analyses of early changes in prostatic hyperplasia.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol & Genitourinary Med Oncol, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Tsai, SY (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336				Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DARBRE P, 1986, MOL CELL BIOL, V6, P2847, DOI 10.1128/MCB.6.8.2847; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Donjacour AA, 1998, DIFFERENTIATION, V62, P227, DOI 10.1046/j.1432-0436.1998.6250227.x; Feng SJ, 1997, CANCER RES, V57, P5369; Foster BA, 1999, PROSTATE CANCER P D, V2, P76; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj/pcan/4500296; GOSPODAROWICZ D, 1978, IN VITRO CELL DEV B, V14, P85; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PRINS GS, 1995, ENDOCRINOLOGY, V136, P1303, DOI 10.1210/en.136.3.1303; Pu YS, 1999, J UROLOGY, V162, P892, DOI 10.1097/00005392-199909010-00085; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; Robinson ML, 1998, DEV BIOL, V198, P13, DOI 10.1016/S0012-1606(98)80026-2; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; Tekmal Rajeshwar Rao, 1997, Frontiers in Bioscience, V2, pD519; Thomson AA, 1999, DEVELOPMENT, V126, P3693; Thomson AA, 1997, DEVELOPMENT, V124, P2431; Thomson AA, 2001, REPRODUCTION, V121, P187, DOI 10.1530/rep.0.1210187; Wang Y, 1997, GENE THER, V4, P432, DOI 10.1038/sj.gt.3300402; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; Xue LX, 1997, CARCINOGENESIS, V18, P995, DOI 10.1093/carcin/18.5.995; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Zhao BH, 2001, P NATL ACAD SCI USA, V98, P5898, DOI 10.1073/pnas.101116598	48	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1899	1908		10.1038/sj.onc.1205096	http://dx.doi.org/10.1038/sj.onc.1205096			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896623				2022-12-28	WOS:000174284500013
J	Singh, J; Murata, K; Itahana, Y; Desprez, PY				Singh, J; Murata, K; Itahana, Y; Desprez, PY			Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex	ONCOGENE			English	Article						helix-loop-helix protein; proliferation; invasion; metastasis; transcription	LOOP-HELIX PROTEINS; HISTONE DEACETYLASE; DNA-BINDING; GENE; DIFFERENTIATION; ID1; REGULATOR; CARCINOMA; ROLES	The helix-loop-helix protein Id-1 is a dominant negative regulator of basic helix -loop- helix transcription factors, and plays a key role in the control of breast epithelial cell growth, invasion and differentiation. Previous investigations in our laboratory have shown that Id-1 mRNA was constitutively expressed in highly aggressive and invasive human breast cancer cells in comparison to non-transformed or non-aggressive cancerous cells, and that this loss of regulation is mediated by a 2.2-kb region of the human Id-1 promoter. Here we show that a 31 bp sequence within this 2.2-kb promoter, located 200 bp upstream of the initiation of transcription, is responsible for the constitutive expression of Id-1 in metastatic human breast cancer cells. Using gel shift experiments, we identified a high molecular weight complex present only in non-aggressive breast cancer cells cultured in serum-free medium and which appear to be necessary for proper Id-1 repression. In contrast, nuclear extracts from highly aggressive and metastatic cell lines do not contain this large molecular weight complex. Using DNA affinity precipitation assays (DAPA), we show that this complex contains SP-1, NF-1, Rb and HDAC-1 proteins. On the basis of these findings, we propose a mechanism for the loss of regulation of Id-1 promoter in invasive and metastatic human breast cancer cells.	Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA	California Pacific Medical Center	Desprez, PY (corresponding author), Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, 2330 Clay St,Stern Bldg, San Francisco, CA 94115 USA.	pdesprez@cooper.cpmc.org			NCI NIH HHS [R01 CA82548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; CHEN HC, 1994, ONCOGENE, V9, P2905; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hu YC, 2001, CLIN CANCER RES, V7, P2213; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Kaluz S, 1999, BIOTECHNIQUES, V26, P446, DOI 10.2144/99263bm18; Kebebew E, 2000, SURGERY, V128, P952, DOI 10.1067/msy.2000.111082; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Langlands K, 2000, CANCER RES, V60, P5929; Lin CQ, 2000, CANCER RES, V60, P1332; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Nayak BK, 1999, MOL BIOL REP, V26, P223, DOI 10.1023/A:1007006011253; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Polsky D, 2001, CANCER RES, V61, P6008; Schindl M, 2001, CANCER RES, V61, P5703; Singh J, 2001, J BIOL CHEM, V276, P11852, DOI 10.1074/jbc.M006931200; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5; TAMURA G, 1994, PATHOL INT, V44, P34, DOI 10.1111/j.1440-1827.1994.tb02583.x; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	45	61	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1812	1822		10.1038/sj.onc.1205252	http://dx.doi.org/10.1038/sj.onc.1205252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896613				2022-12-28	WOS:000174284500003
J	Paterson, IC; Davies, M; Stone, A; Huntley, S; Smith, E; Pring, M; Eveson, JW; Robinson, CM; Parkinson, EK; Prime, SS				Paterson, IC; Davies, M; Stone, A; Huntley, S; Smith, E; Pring, M; Eveson, JW; Robinson, CM; Parkinson, EK; Prime, SS			TGF-beta 1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest	ONCOGENE			English	Article						TGF-beta 1; keratinocytcs; Smad 4; tumor suppression	GROWTH-FACTOR-BETA; SQUAMOUS-CELL CARCINOMAS; TRANSFORMING GROWTH-FACTOR-BETA-1; FUNCTIONAL-CHARACTERIZATION; DOWN-REGULATION; GENE-MUTATIONS; RECEPTOR GENE; II RECEPTOR; SKIN TUMORS; HIGH-RISK	This study examined the role of TGF-beta1 in human keratinocyte malignancy. Two carcinoma-derived human oral keratinocyte cell lines, BICR 31 and H314, were selected on the basis of their known resistance to TGF-beta1-induced G(1) arrest, the presence of wild type TGF-beta cell surface receptors and normal Ras. Smad 4 protein was undetectable in both cell lines, but Smad 2 and Smad 3 were expressed at levels comparable with a fully TGF-beta responsive cell line, and treatment of the cells with TGF-beta1 resulted in the phosphorylation of Smad 2. Treatment with exogenous TGF-beta1 resulted in a failure to induce transcription from an artificial Smad-dependent promoter and a failure to down-regulate c-myc, but resulted in an up-regulation of AP-1 associated genes (Fra-1, JunB and fibronectin). Transient transfection of Smad 4 into BICR 31 restored TGF-beta1-induced growth inhibition and Smad-dependent transcriptional activation. Protracted treatment of cells with exogenous TGF-beta1 resulted in the attenuation of cell growth in vitro. To over-express TGF-beta1, both cell lines were transfected with latent TGF-beta1 cDNA; neutralization studies of conditioned media demonstrated that whilst the majority of the peptide was in the latent form, a small proportion was present as the active peptide. Cells that overexpressed endogenous TGF-beta1 grew more slowly in vitro compared to both the vector-only controls and cells that did not over-express the peptide. Orthotopic transplantation of cells that over-expressed endogenous TGF-beta1 to the floor of the mouth in athymic mice resulted in marked inhibition of primary tumor formation compared to controls. Expression of a dominant-negative TGF-beta1 type II receptor in cells that over-expressed endogenous TGF-beta1 resulted in enhanced cell growth in vitro and diminished the tumor suppressor effect of the ligand in vivo, indicating that the endogenous TGF-beta1 was acting in an autocrine capacity. The results demonstrate that over-expression of endogenous TGF-beta1 in human malignant oral keratinocytes leads to growth inhibition in vivo and tumor suppression in vitro by mechanisms that are independent of Small 4 expression and TGF-beta1-induced G(1) arrest.	Univ Bristol, Dept Oral & Dent Sci, Bristol BS1 2LY, Avon, England; CRC, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Bristol; Beatson Institute	Paterson, IC (corresponding author), Bristol Dent Hosp & Sch, Div Oral Med Pathol & Microbiol, Lower Maudlin St, Bristol BS1 2LY, Avon, England.	ian.paterson@bristol.ac.uk	Paterson, Ian/G-8688-2011; Robinson, Max/R-5280-2018	Paterson, Ian/0000-0001-9156-401X; Robinson, Max/0000-0003-4491-6865; Pring, Miranda/0000-0003-4658-5772				Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen TP, 2001, INT J CANCER, V93, P653, DOI 10.1002/ijc.1381; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; CUI W, 1994, CANCER RES, V54, P5831; Davies M, 1997, INT J CANCER, V73, P68, DOI 10.1002/(SICI)1097-0215(19970926)73:1<68::AID-IJC12>3.3.CO;2-D; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Fink SP, 2001, CANCER RES, V61, P256; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim SK, 1996, CANCER RES, V56, P2519; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Korchynskyi O, 1999, INT J CANCER, V82, P197, DOI 10.1002/(SICI)1097-0215(19990719)82:2<197::AID-IJC8>3.0.CO;2-V; LEDAI J, 1999, MOL CARCINOG, V26, P37; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; PATERSON IC, 1995, BRIT J CANCER, V72, P922, DOI 10.1038/bjc.1995.434; Paterson IC, 2001, J PATHOL, V193, P458, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH822>3.0.CO;2-V; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; PRIME SS, 1994, INT J CANCER, V56, P406, DOI 10.1002/ijc.2910560320; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Riggins GJ, 1997, CANCER RES, V57, P2578; Schutte M, 1996, CANCER RES, V56, P2527; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Wilentz RE, 2000, CANCER RES, V60, P2002; Wong C, 1999, MOL CELL BIOL, V19, P1821; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yan W, 2000, ONCOL RES, V12, P157; YEUDALL WA, 1995, ORAL ONCOL, V31B, P136, DOI 10.1016/0964-1955(94)00030-8; YEUDALL WA, 1993, ORAL ONCOL, V29B, P63, DOI 10.1016/0964-1955(93)90012-4; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	45	25	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1616	1624		10.1038/sj.onc.1205217	http://dx.doi.org/10.1038/sj.onc.1205217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896591				2022-12-28	WOS:000173956800018
J	Kulesza, CA; Van Buskirk, HA; Cole, MD; Reese, JC; Smith, MM; Engel, DA				Kulesza, CA; Van Buskirk, HA; Cole, MD; Reese, JC; Smith, MM; Engel, DA			Adenovirus E1A requires the yeast SAGA histone acetyltransferase complex and associates with SAGA components Gcn5 and Tra1	ONCOGENE			English	Article						gene regulation; transcription; genetics; yeast; adenovirus	TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME ACETYLATION; GENE ACTIVATION; ADA COMPLEX; PCAF; P300; ONCOPROTEIN; EXPRESSION	The budding yeast Saccharomyces cerevisiae was used as a model system to study the function of the adenovirus E1A oncoprotein. Previously we demonstrated that expression of the N-terminal 82 amino acids of E1A in yeast causes pronounced growth inhibition and specifically interferes with SWI/SNF-dependent transcriptional activation. Further genetic analysis identified the yeast transcription factor Adr1 as a high copy suppressor of E1A function. Transcriptional activation by Adr1 requires interaction with co-activator proteins Ada2 and Gcn5, components of histone acetyltransferase complexes including ADA and SAGA. Analysis of mutant alleles revealed that several components of the SAGA complex, including proteins from the Ada, Spt, and Taf classes were required for E1A-induced growth inhibition. Growth inhibition also depended on the Gcn5 histone acetyltransferase, and point mutations within the Gen5 HAT domain rendered cells E1A-resistant. Also required was SAGA component Tra1, a homologue of the mammalian TRRAP protein which is required for c-myc and E1A induced cellular transformation. Additionally, Gcn5 protein could associate with E1A in vitro in a manner that depended on the N-terminal domain of E1A, and Tra1 protein was co-immunoprecipitated with E1A in vivo. These results indicate a strong requirement for intact SAGA complex for E1A to function in yeast, and suggest a role for SAGA-like complexes in mammalian cell transformation.	Univ Virginia, Sch Med, Dept Microbiol & Canc Ctr, Charlottesville, VA 22908 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Virginia; Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Engel, DA (corresponding author), Univ Virginia, Sch Med, Dept Microbiol & Canc Ctr, Charlottesville, VA 22908 USA.	dae2s@virginia.edu			NCI NIH HHS [CA60675, CA87620] Funding Source: Medline; NIGMS NIH HHS [5T32GM08136, R01 GM058672-05, R01 GM028920, GM28920, R01 GM058672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060675, R01CA060675, R01CA087620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028920, T32GM008136, R01GM058672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Berk AJ, 1998, COLD SPRING HARB SYM, V63, P243, DOI 10.1101/sqb.1998.63.243; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, J BIOL CHEM, V271, P5237; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DYSON N, 1992, CANCER SURV, V12, P161; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Eckner R, 1996, MOL CELL BIOL, V16, P3454; EISENMANN DM, 1994, GENETICS, V137, P647; FASSLER JS, 1988, GENETICS, V118, P203; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HANDA H, 1987, GENE, V58, P127; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MILLER ME, 1995, ONCOGENE, V11, P1623; Miller ME, 1996, MOL CELL BIOL, V16, P5737; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Roberts SM, 1997, GENETICS, V147, P451; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; SIMCHEN G, 1984, P NATL ACAD SCI-BIOL, V81, P2431, DOI 10.1073/pnas.81.8.2431; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; VANDENELSEN P, 1983, VIROLOGY, V128, P377; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; WINSTON F, 1984, GENETICS, V107, P179; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	74	22	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1411	1422		10.1038/sj.onc.1205201	http://dx.doi.org/10.1038/sj.onc.1205201			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857084				2022-12-28	WOS:000173861000011
J	Simpson, DJ; Clayton, RN; Farrell, WE				Simpson, DJ; Clayton, RN; Farrell, WE			Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion	ONCOGENE			English	Article						DAP kinase; methylation; homozygous deletion; pituitary tumours	PROGRAMMED CELL-DEATH; DAP-KINASE; DNA METHYLATION; PROMOTER HYPERMETHYLATION; CANCER PATIENTS; LUNG-CANCER; APOPTOSIS; GENES; ADENOMAS; TUMORS	Death Associated Protein kinase (DAP kinase) a novel calmodulin-dependent serine/threonine kinase was first identified as a positive mediator of programmed cell death. Loss of DAP kinase expression was first demonstrated in highly metastatic cells, whilst reexpression of the protein resulted in delayed local tumour growth and a decreased incidence of metastasis. Although loss of DAP kinase expression has been reported in several cell lines derived from human malignancies the mechanisms responsible have not been defined. In this study we have examined 32 sporadic pituitary tumours for expression of the DAP kinase protein and transcript. In addition, we examined the methylation and deletion status of the DAP kinase CpG island as possible mechanisms for the inactivation of the DAP kinase gene. Eleven of 32 (34%) tumours had undetectable DAP kinase expression, by Western blot and/or RT-PCR analysis. Loss of DAP kinase expression was significantly (P=0.004) associated with invasive tumours (10 of 17; 59%) compared to their noninvasive (1 of 15; 7%) counterparts. Of 11 tumours that failed to express DAP kinase, five (45%) showed de novo methylation of the CpG island contained within the promoter region, while four (36%) had evidence of homozygous deletion of this region. Statistical analysis showed that loss of DAP kinase expression was significantly (P= <0.001) associated with methylation or deletion of the DAP kinase CpG island. With two exceptions, none of the remaining tumours or five histologically normal post-mortem pituitaries examined had evidence of methylation or deletion within this region. To our knowledge this is the first report that describes two mutually exclusive mechanisms associated with loss of DAP kinase gene expression. In addition, we also show that loss of the DAP kinase protein and associated genetic aberrations preferentially segregates with tumours that show an invasive phenotype.	Keele Univ, N Staffordshire Hosp, Postgrad Med Sch, Ctr Cell & Mol Med, Stoke On Trent ST4 7QB, Staffs, England	Keele University; University Hospital of North Staffordshire NHS Trust	Farrell, WE (corresponding author), Keele Univ, N Staffordshire Hosp, Postgrad Med Sch, Ctr Cell & Mol Med, Stoke On Trent ST4 7QB, Staffs, England.	w.e.farrell@keele.ac.uk						Bates AS, 1997, J CLIN ENDOCR METAB, V82, P818, DOI 10.1210/jc.82.3.818; Baylin SB, 1998, ADV CANCER RES, V72, P141; BOGGILD MD, 1994, J CLIN ENDOCR METAB, V78, P387, DOI 10.1210/jc.78.2.387; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Costello JF, 1996, CANCER RES, V56, P2405; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Esteller M, 1999, CANCER RES, V59, P67; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farrell WE, 1997, CANCER RES, V57, P2703; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; FEINSTEIN E, 1995, TIBS, P342; Grigg GW, 1996, DNA SEQUENCE, V6, P189, DOI 10.3109/10425179609008443; Hardy J., 1979, RECENT ADV DIAGNOSIS, P375; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jones PA, 1996, CANCER RES, V56, P2463; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; LASTER SM, 1988, J IMMUNOL, V141, P2629; LIN JK, 1992, CANCER RES, V52, P385; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; Nakatsuka S, 2000, LAB INVEST, V80, P1651, DOI 10.1038/labinvest.3780175; NOVELLI F, 1994, J IMMUNOL, V152, P496; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; Simpson DJ, 1999, CANCER RES, V59, P1562; Simpson DJ, 1999, GENE CHROMOSOME CANC, V24, P328; Simpson DJ, 2001, CARCINOGENESIS, V22, P1801, DOI 10.1093/carcin/22.11.1801; Simpson DJ, 2000, CANCER RES, V60, P1211; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Ueki T, 2000, CANCER RES, V60, P1835; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	36	74	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1217	1224		10.1038/sj.onc.1205195	http://dx.doi.org/10.1038/sj.onc.1205195			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850841				2022-12-28	WOS:000173729400009
J	Chen, Q; Ash, JD; Branton, P; Fromm, L; Overbeek, PA				Chen, Q; Ash, JD; Branton, P; Fromm, L; Overbeek, PA			Inhibition of crystallin expression and induction of apoptosis by lens-specific E1A expression in transgenic mice	ONCOGENE			English	Article						E1A; CBP/p300; crystallin; apoptosis; transgenic mice	MOUSE LENS; CELL-CYCLE; RETINOBLASTOMA PROTEIN; DIFFERENTIATION; GENE; BINDING; CBP; P53; P300; TRANSACTIVATION	Previous studies have shown that the adenovirus E1A oncoprotein can bind to and inactivate the retinoblastoma tumor suppressor protein (pRb) and the transcriptional coactivators CBP/p300. In this study, wild-type E1A12S or two deletion mutants (delN. which binds pRb but not CBP/p300; delCR2. which binds to CBP/p300 but not pRb) were linked to the lens-specific alphaA-crystallin promoter, and used to generate transgenic mice. Lens fiber cells expressing E1A12S or delCR2, both of which bind to CBP/p300, failed to upregulate beta-crystallin and gamma-crystallin expression. In contrast, lens fiber cells expressing delN showed significant expression of beta- and gamma-crystallins. Lens fiber cells expressing delN showed cell cycle entry, marked apoptosis, and evidence for p53 activation, while cells expressing either E1A12S or delCR2 showed limited apoptosis and no evidence for upregulation of the p53-inducible gene p21. Our results suggest that the transcriptional coactivators CBP and/or p300 are required for the dramatic increases in crystallin expression that accompany terminal differentiation in the lens, and also for activation of p53 in response to inactivation of pRb in the lens.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; NYU, Sch Med, Skirball Inst, New York, NY 10012 USA	Baylor College of Medicine; McGill University; New York University	Overbeek, PA (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			Overbeek, Paul/0000-0001-9784-2084; Ash, John/0000-0002-8330-7301	NEI NIH HHS [EY-11348, EY-06708, EY-10803, EY-10448] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010803, R01EY011348, R01EY010448, F32EY006708] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARBEAU D, 1994, ONCOGENE, V9, P359; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fromm L, 1996, ONCOGENE, V12, P69; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Ring BZ, 2000, DEVELOPMENT, V127, P307; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TRETON JA, 1991, DIFFERENTIATION, V47, P143, DOI 10.1111/j.1432-0436.1991.tb00232.x; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162	31	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1028	1037		10.1038/sj.onc.1205050	http://dx.doi.org/10.1038/sj.onc.1205050			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850820				2022-12-28	WOS:000173580100006
J	Caldwell, MC; Hough, C; Furer, S; Linehan, WM; Morin, PJ; Gorospe, M				Caldwell, MC; Hough, C; Furer, S; Linehan, WM; Morin, PJ; Gorospe, M			Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNF alpha cytotoxicity	ONCOGENE			English	Article						VHL; SAGE; renal cell carcinoma; gene expression; TNF alpha	ENDOTHELIAL GROWTH-FACTOR; HIPPEL-LINDAU PROTEIN; TUMOR-SUPPRESSOR PROTEIN; NECROSIS-FACTOR-ALPHA; APOPTOSIS; ELONGATION; PRODUCT; ARREST; DEATH	We have used serial analysis of gene expression (SAGE) to investigate the influence of the von Hippel-Lindau (VHL) gene on global gene expression profiles. SAGE libraries were prepared from renal cell carcinoma (RCC) lines that either lack (parental) or express wild-type VHL (wtVHL). Comparison of these libraries revealed some differentially expressed genes (Glut-1, for example) that were known to be influenced by VHL, but the majority of genes had not previously been reported to be affected by the cell's VHL status. The identification of several genes involved in TNFalpha-mediated events prompted us to compare the sensitivity of cells with different VHL status in TNFalpha cytotoxicity assays. Strikingly, VHL-deficient cells were much more resistant to the toxic influence of TNFalpha. We propose that VHL-dependent sensitization of RCC cells to TNFalpha-mediated killing may contribute to VHL's growth suppressive function.	NIA, GRC, IRP,NIH, Cellular & Mol Biol Lab, Baltimore, MD 21224 USA; NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gorospe, M (corresponding author), NIA, GRC, IRP,NIH, Cellular & Mol Biol Lab, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON AGING [Z01AG000512] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FAJARDO LF, 1992, AM J PATHOL, V140, P539; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hough CD, 2000, CANCER RES, V60, P6281; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Kroll SL, 1999, J BIOL CHEM, V274, P30109, DOI 10.1074/jbc.274.42.30109; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Moutet M, 1998, FREE RADICAL BIO MED, V25, P270, DOI 10.1016/S0891-5849(98)00038-0; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; OHH M, 2000, J BIOL CHEM, V275, P25733; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; SATO K, 1994, TOHOKU J EXP MED, V173, P355, DOI 10.1620/tjem.173.355; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012	26	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2002	21	6					929	936		10.1038/sj.onc.1205140	http://dx.doi.org/10.1038/sj.onc.1205140			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840338				2022-12-28	WOS:000173427100008
J	Grant, SL; Hammacher, A; Douglas, AM; Goss, GA; Mansfield, RK; Heath, JK; Begley, CG				Grant, SL; Hammacher, A; Douglas, AM; Goss, GA; Mansfield, RK; Heath, JK; Begley, CG			An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells	ONCOGENE			English	Article						breast cancer; oncostatin M; epidermal growth factor; ErbB; gp130; receptors	EPIDERMAL GROWTH-FACTOR; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN-M RECEPTOR; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; TYROSINE KINASES; GENE-EXPRESSION; CARCINOMA-CELLS; DIFFERENTIATION; INTERLEUKIN-6	Oncostatin M (OSM), an interleukin-6 type cytokine, acts via the gp130 signaling receptor to inhibit proliferation and induce differentiation of breast cancer cells. EGF, a mitogen for breast cells, signals via EGFR/ErbB tyrosine kinase receptors which are implicated in breast cancer pathogenesis. Here we show paradoxically that EGF enhanced the OSM-induced inhibition of proliferation and induction of cellular differentiation in both estrogen receptor positive and negative breast cancer cells. This functional synergism was also seen with heregulin but not SCF, PDGF or IGF-1, indicating that it was specific to EGF-related growth factors. Immunoprecipitation experiments revealed that gp130 was constitutively associated with ErbB-2 and ErbB-3. There was a similar association between the OSMRbeta and ErbB-2. Furthermore, EGF unexpectedly induced tyrosine phosphorylation of gp130. We show that OSM induced phosphorylation of STAT3. Both OSM and EGF activated the p42/44 MAP kinases, but while the MEK inhibitor, PD98059, ablated the OSM-induced inhibition, it only partially ablated the inhibitory effects of OSM plus EGF. Thus, we have demonstrated that the receptors and signalling pathways of two apparently unrelated growth factors were intimately linked, resulting in an unexpected biological effect. This provides a new mechanism for generating signalling diversity and has potential clinical implications in breast cancer.	Rotary Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Melbourne Tumour Biol Branch, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia; Univ Birmingham, Sch Biochem, Growth Factors Grp, Canc Res Campaign, Birmingham B15 2TT, W Midlands, England; Univ Western Australia, TVW Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA, Australia; Western Australian Inst Med Res, Perth, WA, Australia	Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Birmingham; Telethon Kids Institute; University of Western Australia; University of Western Australia	Grant, SL (corresponding author), Inst Child Htlh Res, Subiaco, WA 6008, Australia.	suzieg@ichr.uwa.edu.au						Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Baselga J, 2000, SEMIN ONCOL, V27, P20; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; De Leon DD, 1992, GROWTH FACTORS, V6, P327, DOI 10.3109/08977199209021544; DICKSON RB, 1988, BREAST CANCER CELLUL, P119; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; FIDDES RJ, 1995, CELL GROWTH DIFFER, V6, P1567; FITZPATRICK SL, 1984, CANCER RES, V44, P3448; FITZPATRICK SL, 1984, CANCER RES, V44, P3442; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Halfter H, 1999, Mol Cell Biol Res Commun, V1, P109, DOI 10.1006/mcbr.1999.0117; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Hoffmann M, 1998, CANCER IMMUNOL IMMUN, V47, P167, DOI 10.1007/s002620050517; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Klapper LN, 2000, ADV CANCER RES, V77, P25; KOGA M, 1987, BIOCHEM BIOPH RES CO, V146, P739, DOI 10.1016/0006-291X(87)90591-2; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; METCALF D, 1988, LEUKEMIA, V2, P216; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Murakami-Mori K, 1999, BIOCHEM BIOPH RES CO, V264, P676, DOI 10.1006/bbrc.1999.1574; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OSBORNE CK, 1980, CANCER RES, V40, P2361; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; RAO KVS, 1987, CANCER RES, V47, P5888; ROSE TM, 1994, CYTOKINE, V6, P48, DOI 10.1016/1043-4666(94)90007-8; SARUP JC, 1988, CANCER RES, V48, P5071; SEYMOUR L, 1994, BREAST CANCER RES TR, V32, P229, DOI 10.1007/BF00665774; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Taga T, 1996, J NEUROCHEM, V67, P1; Taylor ML, 2000, HEMATOL ONCOL CLIN N, V14, P517, DOI 10.1016/S0889-8588(05)70294-X; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	45	48	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					460	474		10.1038/sj.onc.1205100	http://dx.doi.org/10.1038/sj.onc.1205100			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821958				2022-12-28	WOS:000173311200014
J	Aguilar-Lemarroy, A; Gariglio, P; Whitaker, NJ; Eichhorst, ST; zur Hausen, H; Krammer, PH; Rosl, F				Aguilar-Lemarroy, A; Gariglio, P; Whitaker, NJ; Eichhorst, ST; zur Hausen, H; Krammer, PH; Rosl, F			Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis	ONCOGENE			English	Article						CD95; cervical cancer; myc; p53; HPV; proteasome inhibitor	PROGRAMMED CELL-DEATH; RETINOBLASTOMA GENE-PRODUCT; FAS-MEDIATED APOPTOSIS; IN-VIVO; EPITHELIAL-CELLS; CANCER-CELLS; PROTEASOME INHIBITORS; MONOCLONAL-ANTIBODY; SIGNALING COMPLEX; MOLECULAR-CLONING	To understand the function of the individual oncogenes of HPV16 in modulating the cellular response to apoptogenic signals, we used human keratinocytes immortalized with either E6, E7 or E6/E7 oncoproteins as model system. Applying CD95 antibodies or recombinant CD95 ligand, only the E7-immortalized cells underwent extensive apoptosis. In contrast, E6- and E6/E7-expressing keratinocytes were resistant. Dominance of E6 correlated with significant down-regulation of p53, c-Myc, p21 and Bcl-2. CD95 was found to be reduced in resistant HPV-positive cells, while there were no quantitative differences in expression levels of FADD, FLICE/caspase-8 or caspase-3. Notably, in contrast to primary human keratinocytes, all immortalized cells showed a general reduction of c-FLIP, an inhibitory protein which normally prevents unscheduled CD95-induced apoptosis. E6- and E6/E7-positive keratinocytes, however, can be sensitized to CD95 apoptosis by blocking proteasome-mediated proteolysis. CD95-resistant HPV-positive cells underwent apoptosis within 3-5 h upon co-incubation with MG132 and agonistic antibodies or CD95 ligand, which was preceded by a strong re-expression of p53 and c-Myc, but not of other half-life controlled proteins such as Bax or I kappaB alpha. Blockage of proteasomal activity alone did not result in apoptosis, although the same set of pro-apoptotic proteins was up-regulated. Performing similar experiments with cervical carcinoma cells expressing mutated p53 (C33a) or with P53-'null' lung carcinoma cells (H1299), no CD95 cell killing occurred eventhough c-Myc was strong induced. These data indicate that the reduced bioavailability of p53 is a key-regulatory event in perturbation of CD95 signaling in HPV16 immortalized keratinocytes.	Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, D-69120 Heidelberg, Germany; Inst Politecn Nacl, CINVESTAV, Dept Mol Biol & Genet, Mexico City, DF, Mexico; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Tumorimmunol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; University of New South Wales Sydney; Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	F.Roesl@DKFZ.de	Aguilar-Lemarroy, Adriana/Y-7001-2018	Aguilar-Lemarroy, Adriana/0000-0001-9288-4824				BARBOSA MS, 1989, ONCOGENE, V4, P1529; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Boyer SN, 1996, CANCER RES, V56, P4620; BRISTOW RG, 1994, ONCOGENE, V9, P1527; Brown J, 1997, J CELL BIOCHEM, V66, P245, DOI 10.1002/(SICI)1097-4644(19970801)66:2<245::AID-JCB11>3.0.CO;2-G; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DHEIN J, 1992, J IMMUNOL, V149, P3166; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Duerksen-Hughes PJ, 1999, VIROLOGY, V264, P55, DOI 10.1006/viro.1999.9977; EL DW, 1993, CELL, V75, P817; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Gehring S, 2000, J BIOL CHEM, V275, P10413, DOI 10.1074/jbc.275.14.10413; Griffiths DJ, 1997, J VIROL, V71, P2866, DOI 10.1128/JVI.71.4.2866-2872.1997; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hengstermann A, 1998, ONCOGENE, V17, P2933, DOI 10.1038/sj.onc.1202282; IFTNER T, 1992, J VIROL, V66, P4639, DOI 10.1128/JVI.66.8.4639-4646.1992; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KHANDJIAN EW, 1986, ANAL BIOCHEM, V159, P227, DOI 10.1016/0003-2697(86)90332-5; Kim CY, 1997, CANCER RES, V57, P4200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; LANGONE JJ, 1982, J IMMUNOL METHODS, V51, P3, DOI 10.1016/0022-1759(82)90376-3; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Leverkus M, 2000, CANCER RES, V60, P553; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIANG XH, 1993, ONCOGENE, V8, P2645; Maki CG, 1996, CANCER RES, V56, P2649; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nair P, 1999, Pathol Oncol Res, V5, P95, DOI 10.1053/paor.1999.0161; NATOLI G, 1995, ONCOGENE, V11, P1157; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OEHM A, 1992, J BIOL CHEM, V267, P10709; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Seewaldt VL, 2001, CANCER RES, V61, P616; Sheets EE, 1996, GYNECOL ONCOL, V63, P94, DOI 10.1006/gyno.1996.0285; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; von Reyher U, 1998, CANCER RES, V58, P526; Winoto A, 1997, CURR OPIN IMMUNOL, V9, P365, DOI 10.1016/S0952-7915(97)80083-0; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; YEE C, 1985, AM J PATHOL, V119, P361; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	85	55	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					165	175		10.1038/sj.onc.1204979	http://dx.doi.org/10.1038/sj.onc.1204979			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803460				2022-12-28	WOS:000173026200001
J	Bowe, DB; Kenney, NJ; Adereth, Y; Maroulakou, IG				Bowe, DB; Kenney, NJ; Adereth, Y; Maroulakou, IG			Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E	ONCOGENE			English	Article						Neu; mice; mammary gland; cyclin E; cyclin D1	NEGATIVE BREAST-CANCER; TRANSGENIC MICE; POINT MUTATION; ONCOGENIC ACTIVATION; GLAND HYPERPLASIA; SIGNALING PATHWAY; INDUCTION; RAS; EXPRESSION; OVEREXPRESSION	Amplification and/or overexpression of the receptor tyrosine kinase HER2/Neu and the cell cycle regulatory gene cyclin D1 are frequently associated with human breast cancer. We studied the functional significance of cyclin D1 in Neu-induced mammary oncogenesis by developing mice overexpressing either wild-type or mutant Neu in a cyclin D1 deficient background. The absence of cyclin D1 suppresses mammary tumor formation induced by the wild-type or activated mutant form of Neu, which promote multi- and single-step progression of tumorigenesis, respectively. These data indicate that cyclin D1 is preferentially required for Neu-mediated signal transduction pathways in mammary oncogenesis. Significantly, 35% of mutant Neu/cyclin D1(-/-) mice regained mammary tumor potential due to compensation by cyclin E. Thus, shared targets of cyclins D1 and E are important in modulating Neu function in mammary tumorigenesis. Our results imply that the combinatorial inhibition of cyclins D1 and E might be useful in the treatment of malignancies induced by Neu.	Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Dept Med, Charleston, SC 29425 USA; Hampton Univ, Dept Biol Sci, Hampton, VA 23668 USA	Medical University of South Carolina; Medical University of South Carolina; Hampton University	Maroulakou, IG (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Room 337,86 Jonathan Lucas St, Charleston, SC 29425 USA.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BRISCOE WT, 1993, BREAST CANCER RES TR, V28, P45, DOI 10.1007/BF00666355; Evron E, 2001, CANCER RES, V61, P2782; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FILMUS J, 1994, ONCOGENE, V9, P3627; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; JANES PW, 1994, ONCOGENE, V9, P3601; KEYOMARSI K, 1994, CANCER RES, V54, P380; Kurebayashi  J, 2001, Breast Cancer, V8, P45, DOI 10.1007/BF02967477; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRESS MF, 1993, CANCER RES, V53, P4960; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	35	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					291	298		10.1038/sj/onc/1205025	http://dx.doi.org/10.1038/sj/onc/1205025			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803472				2022-12-28	WOS:000173026200013
J	Sprenger, CC; Vail, ME; Evans, K; Simurdak, J; Plymate, SR				Sprenger, CC; Vail, ME; Evans, K; Simurdak, J; Plymate, SR			Over-expression of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis	ONCOGENE			English	Article						IGFBP-rP1/mac25; prostate cancer; cell cycle; apoptosis; G1 delay	MAMMARY EPITHELIAL-CELLS; SENESCENCE; ARREST; MAC25; IDENTIFICATION; SUPPRESSOR; SUBLINES; GENE	In the present study, we examined the effects of overexpression of the potential tumor suppressor gene IGFBP-rP1/mac25 on cell-cycle kinetics in prostate cancer cells. The majority of the high expressing IGFBP-rP1/mac25 cell population was located in the GI and sub-G0/G1 peaks; synchronizing cells in G2/M with nocodazole demonstrated the high expressing IGFBP-rP1/mac25 clones were delayed in the G1 phase of the cell cycle. Unscheduled expression of cyclin A in the sub-G0/G1 peak occurred in the IGFBP-rp1/mac25 clones. Immunoblots showed decreased cyclin DI and p21 and increased cyclin E, p16, and p27 in the high expressing IGFBP-rP1/mac25 clones compared to the control cells. Cyclin D1/cdk-4,6 and cyclin E/cdk-2 kinase activities decreased but cyclin A/cdk-2 kinase activity increased for the high expressing IGFBP-rP1/mac25 clones compared to control cells. A pRb immunoprecipitation demonstrated more binding of E2F-1 to pRb in the high expressing IGFBP-rP1/mac25 clones than in control cells. Finally, cell senescence, as assessed by senescence-associated beta -galactosidase, demonstrated significantly more staining in the IGFBP-rP1/mac25 cells than control cells. These results suggest that IGFBP-rP1/mac25 alters the cell cycle kinetics of the M12 prostate cell line by delaying the cells in the GI phase of the cell cycle. In addition, the appearance of cyclin A in the sub-G0/G1 phase of the cell cycle and the increased kinase activity of cyclin A/cdk-2 in the IGFBP-rP1/mac25 clones suggests that cyclin A is associated with the apoptotic cells.	Amer Lake VAMC, GRECC 182B, VAPSHCS, Tacoma, WA 98493 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Madigan Army Med Ctr, Dept Urol, Tacoma, WA 98433 USA; Madigan Army Med Ctr, Dept Pathol, Tacoma, WA 98433 USA; Univ Washington, Dept Med, Seattle, WA 98165 USA	Geriatric Research Education & Clinical Center; University of Washington; University of Washington Seattle; Madigan Army Medical Center; Madigan Army Medical Center; University of Washington; University of Washington Seattle	Plymate, SR (corresponding author), Amer Lake VAMC, GRECC 182B, VAPSHCS, Bldg 85,Rm 128, Tacoma, WA 98493 USA.	splymate@u.washington.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052683] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52683] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi S, 2001, CIRC RES, V88, P408, DOI 10.1161/01.res.88.4.408; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 1997, J AM GERIATR SOC, V45, P482, DOI 10.1111/j.1532-5415.1997.tb05175.x; Chang BD, 1999, CANCER RES, V59, P3761; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1; Ho YS, 2001, INT J CANCER, V91, P393, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1070&gt;3.0.CO;2-#; Hwa V, 1998, J CLIN ENDOCR METAB, V83, P4355, DOI 10.1210/jc.83.12.4355; JacksonCook C, 1996, CANCER GENET CYTOGEN, V87, P14, DOI 10.1016/0165-4608(95)00232-4; Jarrard DF, 1999, CANCER RES, V59, P2957; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Juan G, 1996, CELL PROLIFERAT, V29, P259, DOI 10.1046/j.1365-2184.1996.01000.x; Juan G, 1998, METH MOL B, V91, P67; Kato MV, 1996, ONCOGENE, V12, P1361; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; Komatsu S, 2000, BIOCHEM BIOPH RES CO, V267, P109, DOI 10.1006/bbrc.1999.1937; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sandhu C, 2000, CANCER RES, V60, P2616; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sprenger CC, 1999, CANCER RES, V59, P2370; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369; Wartenberg M, 1999, J BIOL CHEM, V274, P27759, DOI 10.1074/jbc.274.39.27759; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilson EM, 1997, J CLIN ENDOCR METAB, V82, P1301, DOI 10.1210/jc.82.4.1301; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	33	67	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					140	147		10.1038/sj.onc.1205021	http://dx.doi.org/10.1038/sj.onc.1205021			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791184				2022-12-28	WOS:000172887800014
J	Toouli, CD; Huschtscha, LI; Neumann, AA; Noble, JR; Colgin, LM; Hukku, B; Reddel, RR				Toouli, CD; Huschtscha, LI; Neumann, AA; Noble, JR; Colgin, LM; Hukku, B; Reddel, RR			Comparison of human mammary epithelial cells immortalized by simian virus 40 T-Antigen or by the telomerase catalytic subunit	ONCOGENE			English	Article						hTERT; SV40-TAg; human mammary epithelial cells; immortalization; differentiation	MUTANT P53-INDUCED IMMORTALIZATION; LIFE-SPAN; HUMAN FIBROBLASTS; REVERSE-TRANSCRIPTASE; P53 PROTEIN; WILD-TYPE; EXPRESSION; GROWTH; INACTIVATION; EXTENSION	We directly compared two methods of immortalizing human mammary epithelial cells (HMECs). Cells were transfected with an expression plasmid either for hTERT, the catalytic subunit of telomerase, or for the simian virus 40 (SV40) early region genes. Under standard culture conditions, HMECs were not immortalized by hTERT unless they had spontaneously ceased expression of the p16(INK4a) tumor suppressor gene. Untransfected HMECs had low levels of telomerase expression, and immortalization by both methods was associated with an increase in telomerase activity and prevention of telomere shortening. SV40-induced immortalization was accompanied by aberrant differentiation, loss of DNA damage response, karyotypic instability and, in some cases, tumorigenicity. hTERT-immortalized cells had fewer karyotypic changes, but had intact DNA damage responses, and features of normal differentiation. Although SV40-immortalized cells are useful for studies of carcinogenesis, hTERT-immortalized cells retain more properties of normal cells.	Childrens Med Res Inst, Westmead, NSW 2145, Australia; Childrens Hosp Michigan, Cell Culture Lab, Detroit, MI 48201 USA	Children's Medical Research Institute - Australia; Children's Hospital of Michigan	Reddel, RR (corresponding author), Childrens Med Res Inst, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.		Reddel, Roger R/A-6635-2014; Neumann, Axel/D-3319-2012	Reddel, Roger R/0000-0002-6302-6107; 				ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cao YA, 1997, CANCER RES, V57, P5584; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Foster SA, 1996, ONCOGENE, V12, P1773; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gao QS, 1996, CANCER RES, V56, P3129; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Gollahon LS, 1996, ONCOGENE, V12, P715; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Huschtscha LI, 1998, CANCER RES, V58, P3508; Huschtscha LI, 2001, EXP CELL RES, V265, P125, DOI 10.1006/excr.2001.5178; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KAO CY, 1995, CARCINOGENESIS, V16, P531, DOI 10.1093/carcin/16.3.531; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LEBEAU J, 1995, INT J CANCER, V60, P244, DOI 10.1002/ijc.2910600219; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; Migliaccio M, 2000, J IMMUNOL, V165, P4978, DOI 10.4049/jimmunol.165.9.4978; Mitelman F., 1995, ISCN INT SYSTEM HUMA; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nonet GH, 2001, CANCER RES, V61, P1250; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Peterson W D Jr, 1979, Methods Enzymol, V58, P164; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sack MN, 1998, INT J MOL MED, V1, P17; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SMYTH CM, 1993, PATHOLOGY, V25, P388, DOI 10.3109/00313029309090865; Sprung CN, 1999, EXP CELL RES, V247, P29, DOI 10.1006/excr.1998.4293; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Sun W, 1999, CANCER RES, V59, P6118; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yeager TR, 1999, CANCER RES, V59, P4175; YILMAZ A, 1993, BRIT J CANCER, V68, P868, DOI 10.1038/bjc.1993.447	59	83	93	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					128	139		10.1038/sj.onc.1205014	http://dx.doi.org/10.1038/sj.onc.1205014			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791183	Green Submitted			2022-12-28	WOS:000172887800013
J	Yokota, Y				Yokota, Y			Id and development	ONCOGENE			English	Article						Id; basic helix-loop-helix (bHLR); differentiation; proliferation; development	LOOP-HELIX PROTEIN; NATURAL-KILLER-CELLS; PERIPHERAL LYMPHOID ORGANS; T-CELL; DNA-BINDING; MICE LACKING; TRANSCRIPTION FACTOR; EXPRESSION PATTERN; REGULATORY ROLES; GENE-EXPRESSION	During development, it is obvious that enormous multiplication and diversification of cells is required to build a body plan from a single fertilized egg and that these two processes, proliferation and differentiation, must be coordinated properly. Id proteins, negative regulators of basic helix -loop - helix transcription factors, possess the ability to inhibit differentiation and to stimulate proliferation, and are useful molecules for investigating the mechanisms regulating development. In the past few years, our understanding of the roles of Id proteins has been substantially enhanced by the detailed investigation of genetically modified animals. The data have indicated that the functions of Id proteins in vivo are functionally related to those revealed by earlier work in cell culture systems. However, unexpected organs and cell types have also been found to require Id proteins for their normal development. This review looks at the advances made in our understanding of the in vivo functions of Id proteins. The topics discussed include neurogenesis, natural killer cell development, lymphoid organogenesis, mammary gland development and spermatogenesis.	Fukui Med Univ, Dept Biochem, Fukui 9101193, Japan	University of Fukui	Yokota, Y (corresponding author), Fukui Med Univ, Dept Biochem, Shimoaizuki 23-3, Fukui 9101193, Japan.	yyokota@fmsrsa.fukui-med.ac.jp						Andres-Barquin PJ, 2000, HISTOL HISTOPATHOL, V15, P603, DOI 10.14670/HH-15.603; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BARRES BA, 1994, DEVELOPMENT, V120, P1097; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Blom B, 1999, EMBO J, V18, P2793, DOI 10.1093/emboj/18.10.2793; Cai L, 2000, DEVELOPMENT, V127, P3021; Carlyle JR, 1998, IMMUNOL REV, V165, P63, DOI 10.1111/j.1600-065X.1998.tb01230.x; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; Duncan MK, 1997, DEV DYNAM, V208, P107, DOI 10.1002/(SICI)1097-0177(199701)208:1<107::AID-AJA10>3.0.CO;2-3; Durand B, 2000, BIOESSAYS, V22, P64; EVANS SM, 1993, DEV BIOL, V159, P485, DOI 10.1006/dbio.1993.1258; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ikawa T, 1999, J EXP MED, V190, P1617, DOI 10.1084/jem.190.11.1617; Ikawa T, 2001, P NATL ACAD SCI USA, V98, P5164, DOI 10.1073/pnas.091537598; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Inoue T, 1999, BIOCHEM BIOPH RES CO, V266, P147, DOI 10.1006/bbrc.1999.1779; Inoue T, 2000, GENES CELLS, V5, P699, DOI 10.1046/j.1365-2443.2000.00362.x; Jen Y, 1996, DEV DYNAM, V207, P235; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; Kim D, 1999, MOL CELL BIOL, V19, P8240; Kondo T, 2000, EMBO J, V19, P1998, DOI 10.1093/emboj/19.9.1998; Kondo T, 2000, DEVELOPMENT, V127, P2989; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; Mebius RE, 2001, J IMMUNOL, V166, P6593, DOI 10.4049/jimmunol.166.11.6593; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; Neville M. C., 1987, MAMMARY GLAND DEV RE; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; RIECHMANN V, 1995, CELL GROWTH DIFFER, V6, P837; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; RUSSELL LD, 1990, HIST HISTOPATHOLOGIC; Sablitzky F, 1998, CELL GROWTH DIFFER, V9, P1015; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sharpe Richard M., 1994, P1363; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Spits H, 1998, IMMUNOL REV, V165, P75, DOI 10.1111/j.1600-065X.1998.tb01231.x; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Tzeng SF, 1998, GLIA, V24, P372, DOI 10.1002/(SICI)1098-1136(199812)24:4<372::AID-GLIA2>3.0.CO;2-B; Wang SL, 2001, NEURON, V29, P603, DOI 10.1016/S0896-6273(01)00237-9; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310; Williams NS, 1998, IMMUNOL REV, V165, P47, DOI 10.1111/j.1600-065X.1998.tb01229.x; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Yoshida H, 1999, INT IMMUNOL, V11, P643, DOI 10.1093/intimm/11.5.643; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3; ZHU WJ, 1995, MOL BRAIN RES, V30, P312, DOI 10.1016/0169-328X(95)00017-M; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; Zhuang YA, 1998, MOL CELL BIOL, V18, P3340, DOI 10.1128/MCB.18.6.3340	88	158	166	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8290	8298		10.1038/sj.onc.1205090	http://dx.doi.org/10.1038/sj.onc.1205090			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840321				2022-12-28	WOS:000173319500002
J	Movilla, N; Dosil, M; Zheng, Y; Bustelo, XR				Movilla, N; Dosil, M; Zheng, Y; Bustelo, XR			How Vav proteins discriminate the GTPases Rac1 and RhoA from Cdc42	ONCOGENE			English	Article						Vav family; Rho GEFs; DH domain; RhoA; Rac; Cdc42; cytoskeleton	CRYSTAL-STRUCTURE; T-CELL; EXCHANGE; FAMILY; ACTIVATION; PROTOONCOGENE; PHOSPHORYLATION; THYMOCYTES; SELECTION; COMPLEX	Vav proteins are GDP/GTP exchange factors for Rho/Rac GTPases that are activated by tyrosine phosphorylation. These proteins activate Rac1, RhoG, and RhoA but not the highly related Cdc42 protein. At present, there is no available information to explain this substrate selectivity at the structural level. Here we show that the selection of Vav proteins substrates is achieved at two different levels. On one hand, Vav proteins utilize some residues of the beta2/beta3 region of Rho/Rac GTPases (D49 and E54) to assure the specific binding to its substrate. In addition, these exchange factors need a second structural signal located in the beta5 region of Rho/Rac proteins (residue K118) to promote proper GDP/GTP exchange. These results identify the amino acid residues that allow the discrimination of the Vav family substrates from Cdc42 and, in addition, demonstrate that the activation of specific Rho/Rac GTPases by these GEFs requires two concatenated events, binding and subsequent enzyme reaction, whose specificities are determined by two separate regions of Rho proteins.	Univ Salamanca, CSIC, Ctr Invest Canc, Salamanca 37007, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Salamanca 37007, Spain; Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA; Univ Salamanca, Dept Biochem, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Tennessee System; University of Tennessee Health Science Center; University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Salamanca 37007, Spain.		Bustelo, Xose R./AAD-2081-2022; Zheng, Yi/J-7235-2015; Bustelo, Xose R./A-9526-2010; Dosil, Mercedes/A-9536-2016	Bustelo, Xose R./0000-0001-9398-6072; Zheng, Yi/0000-0001-7089-6074; Bustelo, Xose R./0000-0001-9398-6072; Dosil, Mercedes/0000-0001-8119-8263	NCI NIH HHS [CA73735-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hoffman GR, 2000, CELL, V102, P403, DOI 10.1016/S0092-8674(00)00045-3; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	17	57	63	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8057	8065		10.1038/sj.onc.1205000	http://dx.doi.org/10.1038/sj.onc.1205000			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781818				2022-12-28	WOS:000172396800002
J	Ling, G; Ahmadian, A; Persson, A; Unden, AB; Afink, G; Williams, C; Uhlen, M; Toftgard, R; Lundeberg, J; Ponten, F				Ling, G; Ahmadian, A; Persson, A; Unden, AB; Afink, G; Williams, C; Uhlen, M; Toftgard, R; Lundeberg, J; Ponten, F			PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer	ONCOGENE			English	Article						BCC; p53; PATCHED; loss of heterozygosity; in situ hybridization; mutation	SKIN-CANCER; SUNLIGHT EXPOSURE; HUMAN HOMOLOG; MUTATIONS; CARCINOMA; KERATINOCYTES; ULTRAVIOLET; CLONES; CARCINOGENESIS; POLYMORPHISM	It is widely accepted that disruption of the hedgehog-patched pathway is a key event in development of basal cell cancer. In addition to patched gene alterations, p53 gene mutations are also frequent in basal cell cancer. We determined loss of heterozygosity in the patched and p53 loci as well as sequencing the p53 gene in tumors both from sporadic and hereditary cases. A total of 70 microdissected samples from tumor and adjacent skin were subjected to PCR followed by fragment analysis and DNA sequencing. We found allelic loss in the patched locus in 6/8 sporadic basal cell cancer and 17/19 hereditary tumors. All sporadic and 7/20 hereditary tumors showed p53 gene mutations. Loss of heterozygosity in the p53 locus was rare in both groups. The p53 mutations detected in hereditary tumors included rare single nucleotide deletions and unusual double-base substitutions compared to the typical ultraviolet light induced missense mutations found in sporadic tumors. Careful microdissection of individual tumors revealed genetically linked subclones with different p53 and/or patched genotype providing an insight on time sequence of genetic events. The high frequency and co-existence of genetic alterations in the patched and p53 genes suggest that both these genes are important in the development of basal cell cancer.	Univ Uppsala Hosp, Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Royal Inst Technol, Dept Biotechnol, S-10044 Stockholm, Sweden; Karolinska Inst, Dept Dermatol, S-17176 Stockholm, Sweden; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Uppsala University; Uppsala University Hospital; Royal Institute of Technology; Karolinska Institutet; Karolinska Institutet	Ponten, F (corresponding author), Univ Uppsala Hosp, Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden.		Uhlen, Mathias/AAV-8746-2021; Afink, Gijs/A-2025-2009; Williams, Cecilia/A-6677-2009; Afink, Gijs/AAB-2832-2021; Uhlen, Mathias/B-3262-2016	Afink, Gijs/0000-0002-2155-725X; Williams, Cecilia/0000-0002-0602-2062; Uhlen, Mathias/0000-0002-4858-8056; Gao, Ling/0000-0001-7320-1442				Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; BERG C, 1995, CLIN CHEM, V41, P1461; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1998, CANCER SURV, V32, P69; D'Errico M, 2000, ONCOGENE, V19, P463, DOI 10.1038/sj.onc.1203313; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Gailani MR, 1996, J NATL CANCER I, V88, P349, DOI 10.1093/jnci/88.6.349; GALLAGHER RP, 1995, ARCH DERMATOL, V131, P157, DOI 10.1001/archderm.131.2.157; Green A, 1996, AM J EPIDEMIOL, V144, P1034, DOI 10.1093/oxfordjournals.aje.a008875; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; Kawanishi S, 2001, MUTAT RES-REV MUTAT, V488, P65, DOI 10.1016/S1383-5742(00)00059-4; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; Ling G, 2001, AM J PATHOL, V159, P1247, DOI 10.1016/S0002-9440(10)62511-4; MOLES JP, 1993, ONCOGENE, V8, P583; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Ponten F, 1997, ONCOGENE, V15, P1059, DOI 10.1038/sj.onc.1201435; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Ratner D, 2001, J AM ACAD DERMATOL, V44, P293, DOI 10.1067/mjd.2001.112361; Rebel H, 2001, CANCER RES, V61, P977; Ren ZP, 1996, ONCOGENE, V12, P765; Ren ZP, 1997, AM J PATHOL, V150, P1791; Sarasin A, 1999, MUTAT RES-FUND MOL M, V428, P5, DOI 10.1016/S1383-5742(99)00025-3; Tabata H, 1999, J INVEST DERMATOL, V113, P972, DOI 10.1046/j.1523-1747.1999.00810.x; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Unden AB, 1997, CANCER RES, V57, P2336; Williams C, 1998, CANCER RES, V58, P2449; Zhang H, 2001, AM J PATHOL, V158, P381, DOI 10.1016/S0002-9440(10)63980-6; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	37	98	101	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7770	7778		10.1038/sj.onc.1204946	http://dx.doi.org/10.1038/sj.onc.1204946			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753655				2022-12-28	WOS:000172161700008
J	Griffiths, GJ; Corfe, BM; Savory, P; Leech, S; Esposti, MD; Hickman, JA; Dive, C				Griffiths, GJ; Corfe, BM; Savory, P; Leech, S; Esposti, MD; Hickman, JA; Dive, C			Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak	ONCOGENE			English	Article						apoptosis; chemotherapy; Bak; Bcl-x(L); cytochrome c	INDUCED CONFORMATIONAL CHANGE; CYTOCHROME-C RELEASE; BCL-X-L; SURVIVAL SIGNALS; DEATH; MITOCHONDRIA; BCL-X(L); MEMBRANE; LOCALIZATION; DIMERIZATION	The pro-apoptotic protein Bak is converted from a latent to an active form by damage-induced signals. This process involves an early exposure of an occluded N-terminal epitope of Bak in intact cells. Here we report a subsequent damage-induced change in Bak, detected using an antibody to the central BH-1 domain. Bak coimmunoprecipitated with Bcl-x(L) both in undamaged cells and early after damage, when the N-terminal epitope was exposed but the BH-1 epitope remained occluded. A subsequent decrease in binding of Bak to Bcl-x(L) correlated with exposure of an epitope in the Bak BH-1 domain. Overexpression of Bcl-x(L) did not affect the kinetics of exposure of the Bak N-terminal epitope but delayed exposure of the BH-1 domain. Cytochrome c release from mitochondria facilitates the activation of apoptotic caspases. The majority of cells with exposed Bak BH-1 domains contained cytosolic cytochrome c. However, a small proportion of cells exhibited exposed Bak BH-1 domains that co-localized with mitochondrial cytochrome c. The data are consistent with a two-step model for the activation of Bak by drug-induced damage signals where dissociation of Bcl-x(L) from the BH-1 domain of Bak occurs immediately prior to or concomitantly with cytochrome c release.	Univ Manchester, Sch Biol Sci, CRC, Mol Pharmacol Grp, Manchester M13 9PT, Lancs, England; Inst Rech Servier, F-92150 Suresnes, France	University of Manchester; Servier; Institut de Recherches Internationales Servier	Dive, C (corresponding author), Univ Manchester, Sch Biol Sci, G38 Stopford Bldg,Oxford Rd, Manchester B13 9PT, Lancs, England.		Degli Esposti, Mauro/C-3270-2012	Dive, Caroline/0000-0002-1726-8850; Corfe, Bernard/0000-0003-0449-2228; Degli Esposti, Mauro/0000-0002-0977-119X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MIYASHITA T, 1995, CELL, V80, P293; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Taylor ST, 2000, J NATL CANCER I, V92, P18, DOI 10.1093/jnci/92.1.18; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	30	69	72	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7668	7676		10.1038/sj.onc.1204995	http://dx.doi.org/10.1038/sj.onc.1204995			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753644				2022-12-28	WOS:000172124100009
J	Neve, RM; Ylstra, B; Chang, CH; Albertson, DG; Benz, CC				Neve, RM; Ylstra, B; Chang, CH; Albertson, DG; Benz, CC			ErbB2 activation of ESX gene expression	ONCOGENE			English	Article						ErbB2; ESX; breast cancer; Ets	ETS TRANSCRIPTION FACTOR; GENOMIC ORGANIZATION; ELF3; DIFFERENTIATION; AMPLICON; PROMOTER; TISSUES; CANCER; FAMILY; CELLS	Various members of the Ets multigene family exhibit diverse roles in development, cell differentiation, tissue-specific gene expression and human malignancy. In the search for Ets factors involved in mammary gland development and malignancy, ESX was found to be upregulated in a subset of breast tumours and cell lines. We report the transcriptional regulation of ESX in epithelial breast cancer cells. Transient reporter assays using the ESX promoter show that ESX transcription is regulated by ErbB receptor signalling. In cell lines and in 45 primary ductal breast cancers we show that ESX transcript expression significantly correlates with ErbB2 transcript levels. Moreover, expression of ErbB2 in cells upregulates ESX promoter activity while inhibition of ErbB2 or its downstream signaling pathways decrease both ESX promoter activity and endogenous ESX protein levels. These results indicate that the ESX promoter represents a transcriptional target of ErbB2, and ESX expression may represent a downstream mediator of ErbB2 signaling and ErbB2-induced gene expression.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	Buck Institute for Research on Aging; University of California System; University of California San Francisco	Benz, CC (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.		Ylstra, Bauke/D-2906-2012	Ylstra, Bauke/0000-0001-9479-3010	NATIONAL CANCER INSTITUTE [P01CA044768, R01CA036773] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 36773, P01 CA 44768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Brembeck FH, 2000, ONCOGENE, V19, P1941, DOI 10.1038/sj.onc.1203441; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R; Godfrey TE, 2000, J MOL DIAGN, V2, P84, DOI 10.1016/S1525-1578(10)60621-6; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Neve RM, 2001, BIOCHEM BIOPH RES CO, V280, P274, DOI 10.1006/bbrc.2000.4104; NG AYN, 2002, IN PRESS GASTROENTER; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; RUDDERS S, 2000, J BIOL CHEM, V17, P17; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; Shridhar V, 2001, CANCER RES, V61, P5895; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Yoshida N, 2000, MECH DEVELOP, V97, P27, DOI 10.1016/S0925-4773(00)00419-6	19	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3934	3938		10.1038/sj.onc.1205503	http://dx.doi.org/10.1038/sj.onc.1205503			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032832				2022-12-28	WOS:000175847200013
J	Smiraglia, DJ; Szymanska, J; Kraggerud, SM; Lothe, RA; Peltomaki, P; Plass, C				Smiraglia, DJ; Szymanska, J; Kraggerud, SM; Lothe, RA; Peltomaki, P; Plass, C			Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors	ONCOGENE			English	Article						DNA methylation; nonseminoma; seminoma; RLGS; genome scan	CARCINOMA IN-SITU; DNA METHYLATION; PATTERNS; EXPRESSION; CANCER; PATHOGENESIS; ORIGIN	The genetic nature of testicular germ cell tumors and the molecular mechanisms underlying the morphological and clinical differences between the two subtypes, seminomas and nonseminomas, remains unclear. Genetic studies show that both subtypes exhibit many of the same regional genomic disruptions, although the frequencies vary and few clear differences are found. We demonstrate significant epigenetic differences between seminomas and nonseminomas by restriction landmark genomic scanning. Seminomas show almost no CpG island methylation, in contrast to nonseminomas that show CpG island methylation at a level similar to other solid tumors. We find an average of 1.11% of CpG islands methylation in nonseminomas, but only 0.08% methylated in seminomas. Furthermore, we demonstrate that seminomas are more highly hypomethylated than nonseminomas throughout their genome. Since both subtypes are thought to arise from primordial germ cells, the epigenetic differences seen between these subtypes may reflect the normal developmental switch in primordial germ cells from an undermethylated genome to a normally methylated genome. We discuss these findings in relation to different developmental models for seminomatous and nonseminomatous testicular germ cell tumors.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Med Res Facil, Columbus, OH 43210 USA; Univ Helsinki, Dept Med Genet, Helsinki, Finland; Norwegian Radium Hosp, Dept Genet, Inst Canc Res, N-0310 Oslo, Norway	University System of Ohio; Ohio State University; University of Helsinki; University of Oslo	Smiraglia, DJ (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Med Res Facil, 420 W 12th Ave,Room 470A, Columbus, OH 43210 USA.	Smiraglia.l@postbox.acs.ohio-state.edu	Smiraglia, Dominic/R-2069-2019; Plass, Christoph/H-7192-2014	Smiraglia, Dominic/0000-0001-8852-1510; Lothe, Ragnhild A./0000-0002-1693-1032; Peltomaki, Paivi/0000-0001-8819-2980	NCI NIH HHS [T32 CA 09338-20, P30 CA 16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009338, P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bestor TH, 1998, AM J HUM GENET, V62, P1269, DOI 10.1086/301891; Chaganti RSK, 1998, APMIS, V106, P80, DOI 10.1111/j.1699-0463.1998.tb01322.x; Coffigny H, 1999, CYTOGENET CELL GENET, V87, P175, DOI 10.1159/000015460; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Davis TL, 1999, GENOMICS, V58, P18, DOI 10.1006/geno.1999.5813; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Jones PA, 2001, NATURE, V409, P141, DOI 10.1038/35051677; Looijenga LHJ, 1997, AM J PATHOL, V151, P581; Looijenga LHJ, 1998, APMIS, V106, P187, DOI 10.1111/j.1699-0463.1998.tb01335.x; LOOIJENGA LHJ, 1993, LAB INVEST, V68, P211; Lutzker SG, 1998, MOL MED TODAY, V4, P404, DOI 10.1016/S1357-4310(98)01329-X; Murty VVVS, 1998, SEMIN ONCOL, V25, P133; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; PELTOMAKI P, 1991, BIOCHIM BIOPHYS ACTA, V1096, P187, DOI 10.1016/0925-4439(91)90004-S; PELTOMAKI P, 1991, BRIT J CANCER, V63, P851, DOI 10.1038/bjc.1991.189; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; Rajpert-De Meyts E, 1998, APMIS, V106, P198; RajpertDeMeyts E, 1996, VIRCHOWS ARCH, V428, P133; ROTH M, 2000, SCAND J UROL NEPHR S, V205, P166; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Skakkebaek NE, 1998, APMIS, V106, P3, DOI 10.1111/j.1699-0463.1998.tb01314.x; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Summersgill B, 1998, DIAGN MOL PATHOL, V7, P260, DOI 10.1097/00019606-199810000-00005; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Trasler JM, 1998, SEMIN CELL DEV BIOL, V9, P467, DOI 10.1006/scdb.1998.0225	33	136	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3909	3916		10.1038/sj.onc.1205488	http://dx.doi.org/10.1038/sj.onc.1205488			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032829				2022-12-28	WOS:000175847200010
J	Osada, H; Tatematsu, Y; Yatabe, Y; Nakagawa, T; Konishi, H; Harano, T; Tezel, E; Takada, M; Takahashi, T				Osada, H; Tatematsu, Y; Yatabe, Y; Nakagawa, T; Konishi, H; Harano, T; Tezel, E; Takada, M; Takahashi, T			Frequent and histological type-specific inactivation of 14-3-3 sigma in human lung cancers	ONCOGENE			English	Article						lung cancer; 14-3-3 sigma; methylation; MSP	SIGMA GENE; SMALL-CELL; HYPERMETHYLATION; IDENTIFICATION; INVOLVEMENT; IMPAIRMENT; CHECKPOINT; EXPRESSION; PROTEIN; P53	One isoform of the 14-3-3 family, 14-3-3sigma, plays a crucial role in the G2 checkpoint by sequestering Cdc2-cyclinB1 in the cytoplasm, and the expression of 14-3-3sigma is frequently lost in breast cancers. This loss of expression is thought to cause a G2 checkpoint defect, resulting in chromosomal aberrations. Since lung cancers frequently carry numerous chromosomal aberrations, we examined the DNA methylation status and expression level of the 14-3-3sigma gene in 37 lung cancer cell lines and 30 primary lung tumor specimens. We found that small cell lung cancer (SCLC) cell lines frequently showed DNA hypermethylation (9 of 13 lines, 69%), and subsequent silencing of the 14-3-3sigma gene. Among nonsmall cell lung cancers (NSCLC), large cell lung cancer cell lines showed frequent hypermethylation and silencing of 14-3-3sigma (4 or 7 lines, 57%). In contrast, in other NSCLC cell lines, hypermethylation occurred very rarely (1 of 17 lines, 6%). All eight primary SCLC specimens examined also showed a loss or significant reduction in 14-3-3sigma expression in vivo, while a loss or reduction of 14-3-3sigma expression was very rare in primary NSCLC specimens (I of 22 tissues, 5%). This is the first description that indicates lung cancers frequently show significant inactivation of the 14-3-3sigma gene mainly due to DNA hypermethylation in SCLC, but rarely in NSCLC, suggesting involvement of the 14-3-3sigma gene in lung tumorigenesis in a histological type-specific manner.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4348681, Japan; Rinku Gen Med Ctr, Osaka 5988577, Japan	Aichi Cancer Center; Aichi Cancer Center	Osada, H (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	hosada@aichi-cc.jp	YATABE, Yasushi/J-6461-2014; Takahashi, Takashi/I-7262-2014; Osada, Hiroyuki/AAY-6254-2020	YATABE, Yasushi/0000-0003-1788-559X; Takahashi, Takashi/0000-0003-0615-7001; Konishi, Hiroyuki/0000-0003-1131-4905				Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Haruki N, 2001, AM J PATHOL, V159, P1345, DOI 10.1016/S0002-9440(10)62521-7; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; Konishi H, 2002, CANCER RES, V62, P271; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Nomoto S, 2000, GENE CHROMOSOME CANC, V28, P342, DOI 10.1002/1098-2264(200007)28:3<342::AID-GCC13>3.0.CO;2-A; Osada H, 2001, CANCER RES, V61, P8331; Osada H, 1996, BIOCHEM BIOPH RES CO, V229, P582, DOI 10.1006/bbrc.1996.1847; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Suzuki H, 2000, CANCER RES, V60, P4353; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; TSUCHIYA E, 1995, J CANCER RES CLIN, V121, P577, DOI 10.1007/BF01197773; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438	21	132	141	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2418	2424		10.1038/sj.onc.1205303	http://dx.doi.org/10.1038/sj.onc.1205303			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948426				2022-12-28	WOS:000174635600015
J	Finkeltov, I; Kuhn, S; Glaser, T; Idelman, G; Wright, JJ; Roberts, CT; Werner, H				Finkeltov, I; Kuhn, S; Glaser, T; Idelman, G; Wright, JJ; Roberts, CT; Werner, H			Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein	ONCOGENE			English	Article						DSRCT; IGF-I receptor; EWS; WT1; translocation	ROUND-CELL TUMOR; HUMAN MYXOID CHONDROSARCOMA; WILMS-TUMOR; EWS GENE; EWINGS-SARCOMA; CHROMOSOME-TRANSLOCATION; PROMOTER ACTIVITY; MALIGNANT-MELANOMA; GENOMIC STRUCTURE; SUPPRESSOR WT1	The EWS family of genes is involved in numerous chromosomal translocations that are characteristic of a variety of sarcomas. A recently described member of this group is desmoplastic small round cell tumor (DSRCT), which is characterized by a recurrent t(11;22)(p13;q12) translocation that fuses the 5' exons of the EWS gene to the 3' exons of the WT1 gene. The originally described chimera comprises exons 1 - 7 of EWS and exons 8 - 10 of WT1. We have previously reported that the WT1 protein represses the expression of the IGF-I receptor gene, whereas the EWS(1 - 7)-WT 1(8 - 10) fusion protein activates IGF-I receptor gene expression. It has recently become apparent that EWS-WT1 chimeras produced in DSCRT are heterogeneous as a result of fusions of different regions of the EWS gene to the WT1 gene. We have recently characterized additional EWS-WT1 translocations that involve the juxtaposition of EWS exons 7 or 8 to WT1 exon 8, and an EWS-WT1 chimera that lacks EWS exon 6. The chimeric transcription factors encoded by these various translocations differ in their DNA-binding characteristics and their ability to transactivate the IGF-I receptor promoter. These data suggest that the molecular pathology of DSRCT is more complex than previously appreciated, and that this diversity may provide the foundation for predictive genotype-phenotype correlations in the future.	Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Ramat Aviv, Israel; NCI, Med Branch, Div Clin Sci, NIH, Bethesda, MD 20889 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Oregon Health & Science University	Werner, H (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Ramat Aviv, Israel.	hwerner@post.tau.ac.il	Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772	NIDDK NIH HHS [DK50810] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050810] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonescu CR, 1998, DIAGN MOL PATHOL, V7, P24, DOI 10.1097/00019606-199802000-00005; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; Bosilevac JM, 1999, J BIOL CHEM, V274, P34811, DOI 10.1074/jbc.274.49.34811; BRODIE SG, 1995, HUM PATHOL, V26, P1370, DOI 10.1016/0046-8177(95)90303-8; Chan AS, 1999, PEDIATR DEVEL PATHOL, V2, P188, DOI 10.1007/s100249900108; Clark J, 1996, ONCOGENE, V12, P229; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; GANSLER T, 1989, AM J PATHOL, V135, P961; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GILL S, 1995, GENE CHROMOSOME CANC, V12, P307, DOI 10.1002/gcc.2870120412; GONZALEZCRUSSI F, 1990, AM J SURG PATHOL, V14, P633, DOI 10.1097/00000478-199007000-00004; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; JEON IS, 1995, ONCOGENE, V10, P1229; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; KURODA M, 1995, AM J PATHOL, V147, P1221; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LADANYI M, 1994, CANCER RES, V54, P2837; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Liu J, 2000, CLIN CANCER RES, V6, P3522; Maor SB, 2000, MOL GENET METAB, V69, P130, DOI 10.1006/mgme.1999.2958; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; OHNO T, 1994, ONCOGENE, V9, P3087; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; RESNICOFF M, 1995, CANCER RES, V55, P3739; SAWYER JR, 1992, AM J SURG PATHOL, V16, P411, DOI 10.1097/00000478-199204000-00010; Shimizu Y, 1998, CANCER GENET CYTOGEN, V106, P156, DOI 10.1016/S0165-4608(98)00062-4; Tajinda K, 1999, ENDOCRINOLOGY, V140, P4713, DOI 10.1210/en.140.10.4713; WERNER H, 1994, VITAM HORM, V48, P1, DOI 10.1016/S0083-6729(08)60495-1; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Werner H, 1996, J MOL NEUROSCI, V7, P111, DOI 10.1007/BF02736791; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	48	27	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1890	1898		10.1038/sj.onc.1205042	http://dx.doi.org/10.1038/sj.onc.1205042			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896622				2022-12-28	WOS:000174284500012
J	Howlett, CJ; Robbins, SM				Howlett, CJ; Robbins, SM			Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated cellular transformation	ONCOGENE			English	Article						Src family kinases; Cbl; ubiquitination; transformation	C-CBL; GENE HCK; NEGATIVE REGULATOR; CSF-1 RECEPTOR; SRC; GROWTH; PHOSPHORYLATION; DEGRADATION; UBIQUITINATION; ASSOCIATION	The mammalian proto-oncogene CbI and its cellular homologues in Caenorhabtlitis elegans (Sli-1) and Drosophila (D-Cbl) are negative regulators of some growth factor receptor signaling pathways. Herein we show that CbI can negatively regulate another signaling molecule, namely the Src-family kinase Hck by targeting it for degradation. Hck-mediated cellular transformation of murine fibroblasts is reverted by ectopic expression of a membrane-anchored allele of CbI as assessed by the cellular morphology, suppression of anchorage independent growth, and an overall reduction in the total tyrosine phosphorylation levels within the cells. The expression of CbI at the plasma membrane targets both Hck and itself for ubiquitination and degradation, requiring an intact RING finger. Pharmacological inhibition of the proteasome prevents the degradation of Hck correlating with an increase in the phosphotyrosine levels within the cells. Activated Hck and membrane-anchored CbI are present in similar subcellular localizations and co-immunoprecipitate, suggesting that their interaction is required for subsequent ubiquitination and degradation. Interestingly, both constitutively active and kinase-inactive Hck interact with and are targeted for degradation by Cbl. This work illustrates alternate means to regulate Src-family kinases, and suggests that CbI may be able to suppress many signaling pathways that are activated in various proliferative syndromes including cancer.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Robbins, SM (corresponding author), Univ Calgary, Dept Oncol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	srobbins@ucalgary.ca		Robbins, Stephen/0000-0001-7475-1665				Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson TM, 2000, J BIOL CHEM, V275, P33353, DOI 10.1074/jbc.M002022200; LAW DA, 1992, MOL IMMUNOL, V29, P917, DOI 10.1016/0161-5890(92)90130-P; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LICHTENBERG U, 1992, ONCOGENE, V7, P849; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Okamura-Oho Y, 1997, FEBS LETT, V419, P231, DOI 10.1016/S0014-5793(97)01461-0; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Pawson T, 1997, NATURE, V385, P582, DOI 10.1038/385582b0; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Scholz G, 2000, J BIOL CHEM, V275, P14615, DOI 10.1074/jbc.275.19.14615; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	42	20	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1707	1716		10.1038/sj.onc.1205228	http://dx.doi.org/10.1038/sj.onc.1205228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896602				2022-12-28	WOS:000174214200009
J	Frade, R; Balbo, M; Barel, M				Frade, R; Balbo, M; Barel, M			RB18A regulates p53-dependent apoptosis	ONCOGENE			English	Article						RB18A; TRAP220; DRIP205; PBP; p53-dependent apoptosis; co-transcriptional factor	NUCLEAR RECEPTORS; PROTEIN; P53; INTERACTS; TRAP220; SUBUNIT; GENE	We previously demonstrated that RB18A, a member of TRAP220/DRIP205/PBP family, in vivo acted as a cofactor of transcription by differently regulating p53wt transactivating activity on physiological promoters. Using p53-negative cells transfected with different constructs, we herein demonstrated that RB18A down-regulated p53wt-dependent apoptosis. This biological regulation was due to a specific diminution of p53wt protein level, as level of p91mut and GAPDH proteins was not modified. This p53wt diminution was dependent on proteasome activity, as inhibited by MG-132 inhibitor. This specific p53wt degradation was correlated with an increase in expression of MDM2, which promoted p53wt degradation into proteasome. RB18A up-regulated MDM2 expression by activating MDM2 promoter, even in absence of p53wt. Altogether, these data emphasized that RB18A could regulate p53wt function not only by direct interaction between both proteins, but also by up-regulating promoter activity of MDM2, a p53-regulating partner.	Hop St Antoine, Ctr INSERM, INSERM,U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Frade, R (corresponding author), Hop St Antoine, Ctr INSERM, INSERM,U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France.	frade354@easynet.fr	BAREL, Monique/K-3772-2017	BAREL, Monique/0000-0001-8171-7027				Atkins GB, 1999, MOL ENDOCRINOL, V13, P1550, DOI 10.1210/me.13.9.1550; BAREL M, 1989, P NATL ACAD SCI USA, V86, P10054, DOI 10.1073/pnas.86.24.10054; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Frade R, 2000, CANCER RES, V60, P6585; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P14584; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	19	15	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					861	866		10.1038/sj.onc.1205177	http://dx.doi.org/10.1038/sj.onc.1205177			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840331				2022-12-28	WOS:000173427100001
J	Sanchez-Prieto, R; Sanchez-Arevalo, VJ; Servitja, JM; Gutkind, JS				Sanchez-Prieto, R; Sanchez-Arevalo, VJ; Servitja, JM; Gutkind, JS			Regulation of p73 by c-Abl through the p38 MAP kinase pathway	ONCOGENE			English	Article						p73; c-Abl; p38; p53; DNA damage	ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; DNA-DAMAGE; CELL-DEATH; APOPTOTIC RESPONSE; P53 GENE; STRESS; FAMILY; AGENTS	p73 is a novel member of the p53 family of tumor suppressor proteins which is involved in cellular differentiation, tumor suppression, and the response to genotoxic stress. The molecular mechanisms regulating p73 activity are still poorly understood. Recently, p73 was found to be a target of the enzymatic activity of c-Abl, a non-receptor tyrosine kinase that potently activated in response to DNA damage. Here, we present evidence that c-Abl induces the phosphorylation of p73 in threonine residues adjacent to prolines, and that the p38 MAP kinase pathway mediates this response. Furthermore, we found that activation of p38 is sufficient to enhance the stability of p73, and that the transcriptional activation of p73 by c-Abl requires the activity of p38. These findings indicate that members of the MAP kinases superfamily of signaling molecules can regulate p73, and support a role for the p38 MAP kinase in a novel biochemical pathway by which c-Abl regulates this p53-related molecule.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Clin Puerta Hierro, Dept Anat Patol, Unidad Patol Mol, Madrid 28035, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Sanchez-Prieto, Ricardo/AAY-4271-2021; Sanchez-Prieto, Ricardo/B-6877-2008; Prieto, Ricardo/AAZ-7221-2021; Gutkind, J. Silvio/A-1053-2009; Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019	Gutkind, J. Silvio/0000-0002-5150-4482; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505; SERVITJA, JOAN-MARC/0000-0002-1241-8004	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agami R, 1999, NATURE, V399, P809; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gong JG, 1999, NATURE, V399, P806; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	32	93	94	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2002	21	6					974	979		10.1038/sj.onc.1205134	http://dx.doi.org/10.1038/sj.onc.1205134			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840343				2022-12-28	WOS:000173427100013
J	Davis, RL; Turner, DL				Davis, RL; Turner, DL			Vertebrate hairy and Enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning	ONCOGENE			English	Review						basic-helix-loop-helix; transcription; Notch; corepressor; hairy	LOOP-HELIX REPRESSOR; PROMOTES NEURONAL DIFFERENTIATION; SOMITE BOUNDARY FORMATION; CENTRAL-NERVOUS-SYSTEM; PAN-NEURAL GENE; LUNATIC-FRINGE; XENOPUS-EMBRYOS; PRESOMITIC MESODERM; NOTCH PATHWAY; FATE SPECIFICATION	The basic-helix-loop-helix (bHLH) proteins are a superfamily of DNA-binding transcription factors that regulate numerous biological processes in both invertebrates and vertebrates. One family of bRLH transcriptional repressors is related to the Drosophila hairy and Enhancer-of-split proteins. These repressors contain a tandem arrangement of the bHLH domain and an adjacent sequence known as the Orange domain, so we refer to these proteins as bHLH-Orange or bHLH-O proteins. Phylogenetic analysis reveals the existence of four bHLH-O subfamilies, with distinct, evolutionarily conserved features. A principal function of bHLH-O proteins is to bind to specific DNA sequences and recruit transcriptional corepressors to inhibit target gene expression. However, it is likely that bHLH-O proteins repress transcription by additional mechanisms as well. Many vertebrate bHLH-O proteins are effectors of the Notch signaling pathway, and bHLH-O proteins are involved in regulating neurogenesis, vasculogenesis, mesoderm segmentation, myogenesis, and T lymphocyte development. In this review, we discuss mechanisms of action and biological roles for the vertebrate bHLH-O proteins, as well as some of the unresolved questions about the functions and regulation of these proteins during development and in human disease.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48104 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48104 USA	Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Turner, DL (corresponding author), Neurosci Lab Bldg,1103 E Huron, Ann Arbor, MI 48104 USA.	dlturner@umich.edu						AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Alifragis P, 1997, P NATL ACAD SCI USA, V94, P13099, DOI 10.1073/pnas.94.24.13099; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aulehla A, 1999, DEV BIOL, V207, P49, DOI 10.1006/dbio.1998.9164; Bae SK, 2000, DEVELOPMENT, V127, P2933; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Bally-Cuif L, 2000, GENE DEV, V14, P1664; Barrantes ID, 1999, CURR BIOL, V9, P470, DOI 10.1016/S0960-9822(99)80212-7; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Bessho Y, 2001, GENES CELLS, V6, P175, DOI 10.1046/j.1365-2443.2001.00409.x; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Cau E, 2000, DEVELOPMENT, V127, P2323; Cau E, 1997, DEVELOPMENT, V124, P1611; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Cooke J, 1998, TRENDS GENET, V14, P85, DOI 10.1016/S0168-9525(98)01396-1; COOKE J, 1975, NATURE, V254, P196, DOI 10.1038/254196a0; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Damen WGM, 2000, P NATL ACAD SCI USA, V97, P4515, DOI 10.1073/pnas.97.9.4515; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Davis RL, 2001, DEV CELL, V1, P553, DOI 10.1016/S1534-5807(01)00054-5; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Deblandre GA, 1999, DEVELOPMENT, V126, P4715; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; FEDER JN, 1993, MOL CELL BIOL, V13, P105, DOI 10.1128/MCB.13.1.105; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Forsberg H, 1998, CURR BIOL, V8, P1027, DOI 10.1016/S0960-9822(07)00424-1; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Gao XM, 2001, J CELL BIOL, V154, P1161, DOI 10.1083/jcb.200104058; Garriga-Canut M, 2001, J BIOL CHEM, V276, P14821, DOI 10.1074/jbc.M011619200; Giebel B, 1997, P NATL ACAD SCI USA, V94, P6250, DOI 10.1073/pnas.94.12.6250; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; Handler M, 2000, DEVELOPMENT, V127, P2593; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hirata H, 2000, J BIOL CHEM, V275, P19083, DOI 10.1074/jbc.M001075200; Hirsinger E, 2001, DEVELOPMENT, V128, P107; Hojo M, 2000, DEVELOPMENT, V127, P2515; Holley SA, 2000, GENE DEV, V14, P1678; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Ito T, 2000, DEVELOPMENT, V127, P3913; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Izon DJ, 2001, IMMUNITY, V14, P253, DOI 10.1016/S1074-7613(01)00107-8; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jen WC, 1999, GENE DEV, V13, P1486, DOI 10.1101/gad.13.11.1486; Jen WC, 1997, DEVELOPMENT, V124, P1169; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; Jennings BH, 1999, MOL CELL BIOL, V19, P4600; Jiang YJ, 1998, CURR BIOL, V8, pR868, DOI 10.1016/S0960-9822(07)00547-7; Jiang YJ, 2000, NATURE, V408, P475, DOI 10.1038/35044091; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Jouve C, 2000, DEVELOPMENT, V127, P1421; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kim HK, 1998, MOL CELL BIOL, V18, P7166, DOI 10.1128/MCB.18.12.7166; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Koyano-Nakagawa N, 2000, DEVELOPMENT, V127, P4203; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; LANGELAND JA, 1993, DEVELOPMENT, V117, P585; Lawrence P., 1992, MAKING FLY GENETICS; Lee JS, 1999, FEBS LETT, V455, P276, DOI 10.1016/S0014-5793(99)00901-1; Leimeister C, 2000, DEV BIOL, V227, P91, DOI 10.1006/dbio.2000.9884; Leimeister C, 2000, MECH DEVELOP, V98, P175, DOI 10.1016/S0925-4773(00)00459-7; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Lin MH, 2000, DEVELOPMENT, V127, P2421; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; McGrew MJ, 1998, CURR BIOL, V8, P979, DOI 10.1016/S0960-9822(98)70401-4; MEINHARDT H, 1986, SOMITES DEV EMBRYOS, P179; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Moore AW, 2000, P NATL ACAD SCI USA, V97, P10436, DOI 10.1073/pnas.170301897; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Nellesen DT, 1999, DEV BIOL, V213, P33, DOI 10.1006/dbio.1999.9324; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; NYE JS, 1994, DEVELOPMENT, V120, P2421; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; OKA C, 1995, DEVELOPMENT, V121, P3291; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Palmeirim I, 1998, DEV GENET, V23, P77, DOI 10.1002/(SICI)1520-6408(1998)23:1<77::AID-DVG8>3.0.CO;2-3; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Phippen TM, 2000, J BIOL CHEM, V275, P37628, DOI 10.1074/jbc.M004234200; Pissarra L, 2000, MECH DEVELOP, V95, P275, DOI 10.1016/S0925-4773(00)00348-8; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Pourquie O, 2000, CURR TOP DEV BIOL, V47, P81; Pourquie O, 1999, CURR OPIN GENET DEV, V9, P559, DOI 10.1016/S0959-437X(99)00011-8; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Rostomily RC, 1997, CANCER RES, V57, P3526; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Satow T, 2001, J NEUROSCI, V21, P1265; SCHNEIDER ML, 2001, IN PRESS MOL CELL NE, V18; Shawber C, 1996, DEVELOPMENT, V122, P3765; SOMMER RJ, 1993, NATURE, V361, P448, DOI 10.1038/361448a0; Stern CD, 2000, CURR TOP DEV BIOL, V47, P107; Stern CD, 1998, BIOESSAYS, V20, P528, DOI 10.1002/(SICI)1521-1878(199807)20:7<528::AID-BIES2>3.0.CO;2-G; Strom A, 1997, GENE DEV, V11, P3168, DOI 10.1101/gad.11.23.3168; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Takke C, 1999, DEVELOPMENT, V126, P3005; Takke C, 1999, DEVELOPMENT, V126, P1811; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; Vasiliauskas D, 2000, MECH DEVELOP, V98, P133, DOI 10.1016/S0925-4773(00)00443-3; Wettstein DA, 1997, DEVELOPMENT, V124, P693; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5; Zhang HL, 1999, P NATL ACAD SCI USA, V96, P535, DOI 10.1073/pnas.96.2.535; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625; Zheng JL, 2000, DEVELOPMENT, V127, P4551; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820	139	305	312	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8342	8357		10.1038/sj.onc.1205094	http://dx.doi.org/10.1038/sj.onc.1205094			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840327				2022-12-28	WOS:000173319500008
J	Kasof, GM; Lu, JJ; Liu, DR; Speer, B; Mongan, KN; Gomes, BC; Lorenzi, MV				Kasof, GM; Lu, JJ; Liu, DR; Speer, B; Mongan, KN; Gomes, BC; Lorenzi, MV			Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappa B	ONCOGENE			English	Article						prostate cancer; apoptosis; androgens; transcription; chromosome 6p21.1; TNF-alpha	PROSTATIC INTRAEPITHELIAL NEOPLASIA; TRAIL-INDUCED APOPTOSIS; CELL-DEATH; CANCER-CELLS; MEDIATED APOPTOSIS; KINASE-ALPHA; LIGAND TRAIL; GENE; PROTEIN; FADD	The tumor necrosis factor (TNF) receptor family are ligand-regulated transmembrane proteins that mediate apoptosis as well as activation of the transcription factor NF-kappaB. Exogenous expression of DR6, a recently identified member of the TNF receptor family, induced apoptosis in untransformed or tumor-derived cells and the apoptotic function of DR6 was inhibited by coexpression of Bcl-2, Bcl-X-L or the inhibitor-of-apoptosis (IAP) family member, survivin. Expression of a dominant negative mutant of FADD failed to protect from DR6-mediated apoptosis indicating that unlike TNFR1 and Fas, DR6 induced apoptosis via a FADD-independent mechanism. Despite the ability of exogenous DR6 expression to induce apoptosis, DR6 mRNA and protein were found to be elevated in prostate tumor cell lines and in advanced stages of prostate cancer. Analysis of several anti-apoptotic proteins revealed that Bcl-X-L levels and serine 32 phosphorylation of I kappaB, the natural inhibitor of NF-kappaB, were similarly elevated in cells expressing high levels of DR6, suggesting that NF-kappaB-regulated survival proteins may protect from DR6-induced apoptosis and that DR6 is a target of NF-kappaB regulation. Treatment of LnCAP cells with TNF-alpha resulted in increases in both DR6 mRNA and protein levels, and this induction was suppressed by inhibitors of NF-kappaB. Similarly, treatment of cells expressing high levels of DR6 with indomethacin and ibuprofen, compounds also known to perturb NF-kappaB function, resulted in a dose-dependent decrease in DR6 protein and mRNA levels. These results demonstrate that TNF-alpha signaling induces the expression of a member of its own receptor family through activation of NF-kappaB.	AstraZeneca Pharmaceut, Dept Enabling Sci & Technol, Worcester, MA 01605 USA	AstraZeneca	Kasof, GM (corresponding author), AstraZeneca Pharmaceut, Dept Enabling Sci & Technol, 3 Biotech Pk,1 Innovat Dr, Worcester, MA 01605 USA.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bonavida B, 1999, INT J ONCOL, V15, P793; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Granville DJ, 1998, LAB INVEST, V78, P893; Haussler O, 1999, HUM PATHOL, V30, P1077, DOI 10.1016/S0046-8177(99)90226-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson MI, 1998, PROSTATE, V37, P223, DOI 10.1002/(SICI)1097-0045(19981201)37:4<223::AID-PROS3>3.0.CO;2-O; Kasof GM, 2000, FEBS LETT, V473, P285, DOI 10.1016/S0014-5793(00)01473-3; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; LORENZI MV, 1995, ONCOGENE, V10, P2051; Lorenzi MV, 1999, GENOMICS, V62, P59, DOI 10.1006/geno.1999.5980; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Ravi R, 1998, CANCER RES, V58, P882; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Tamm I, 1998, CANCER RES, V58, P5315; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu R, 2000, CANCER RES, V60, P2384; Zhang XD, 1999, CANCER RES, V59, P2747	42	82	87	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7965	7975		10.1038/sj.onc.1204985	http://dx.doi.org/10.1038/sj.onc.1204985			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753679				2022-12-28	WOS:000172288700005
J	Krug, U; Ganser, A; Koeffler, HP				Krug, U; Ganser, A; Koeffler, HP			Tumor suppressor genes in normal and malignant hematopoiesis	ONCOGENE			English	Review						tumor suppressor gene; hematopoiesis; malignancies; myeloid differentiation	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; BINDING-PROTEIN-ALPHA; ACUTE MYELOGENOUS LEUKEMIA; NON-HODGKINS-LYMPHOMA; 2 DISTINCT REGIONS; DEPENDENT KINASE INHIBITORS; DOMINANT-NEGATIVE MUTATIONS; COLORECTAL-CARCINOMA GENE	Over the last decade, a growing number of tumor suppressor genes have been discovered to play a role in tumorigenesis. Mutations of p53 have been found in hematological malignant diseases, but the frequency of these alterations is much lower than in solid tumors. These mutations occur especially as hematopoietic abnormalities become more malignant such as going from the chronic phase to the blast crisis of chronic myeloid leukemia. A broad spectrum of tumor suppressor gene alterations do occur in hematological malignancies, especially structural alterations of p15(INK4A), p15(INK4B) and p14(ARF) in acute lymphoblastic leukemia as well as methylation of these genes in several myeloproliferative disorders. Tumor suppressor genes are altered via different mechanisms, including deletions and point mutations, which may result in an inactive or dominant negative protein. Methylation of the promoter of the tumor suppressor gene can blunt its expression. Chimeric proteins formed by chromosomal translocations (i.e. AML1-ETO, PML-RARalpha, PLZF-RARalpha) can produce a dominant negative transcription factor that can decrease expression of tumor suppressor genes. This review provides an overview of the current knowledge about the involvement of tumor suppressor genes in hematopoietic malignancies including those involved in cell cycle control, apoptosis and transcriptional control.	Univ Calif Los Angeles, Div Hematol Oncol, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Hannover Med Sch, Dept Hematol Oncol, D-3000 Hannover, Germany	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Hannover Medical School	Krug, U (corresponding author), Univ Calif Los Angeles, Div Hematol Oncol, Cedars Sinai Med Ctr, Sch Med, 8700 Beverly Blvd,Suite B213, Los Angeles, CA 90048 USA.	utzkrug@hotmail.com						ADAMSON DJA, 1995, BRIT J HAEMATOL, V89, P61, DOI 10.1111/j.1365-2141.1995.tb08910.x; ADAMSON DJA, 1995, BRIT J CANCER, V72, P150, DOI 10.1038/bjc.1995.292; Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; AHUJA HG, 1991, BLOOD, V78, P3259; Algar E, 1997, LEUKEMIA, V11, P110, DOI 10.1038/sj.leu.2400521; Amiel A, 1997, CANCER GENET CYTOGEN, V97, P97, DOI 10.1016/S0165-4608(96)00341-X; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAIRD PN, 1992, ONCOGENE, V7, P2141; Baird PN, 1997, EXP HEMATOL, V25, P312; Baldi A, 1996, CLIN CANCER RES, V2, P1239; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARBOSA DM, 1998, LEUKEMIA RES, V22, P787; Barnabas N, 2001, CANCER, V91, P285, DOI 10.1002/1097-0142(20010115)91:2<285::AID-CNCR1000>3.0.CO;2-X; Batova A, 1999, CANCER RES, V59, P1492; Batova A, 1997, CANCER RES, V57, P832; Batova A, 1996, BLOOD, V88, P3083, DOI 10.1182/blood.V88.8.3083.bloodjournal8883083; Beck Z, 2000, LEUKEMIA LYMPHOMA, V38, P587, DOI 10.3109/10428190009059278; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Beltinger C, 1998, BLOOD, V91, P3943; Bench AJ, 2000, ONCOGENE, V19, P3902, DOI 10.1038/sj.onc.1203728; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; Bergh G, 1999, BLOOD, V94, P1971; Bergmann L, 1997, BLOOD, V90, P1217, DOI 10.1182/blood.V90.3.1217.1217_1217_1225; BHATIA KG, 1992, CANCER RES, V52, P4273; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; BROWN KW, 1992, ONCOGENE, V7, P763; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Bullinger L, 2000, LEUKEMIA, V14, P1490, DOI 10.1038/sj.leu.2401834; Bullrich F, 1999, CANCER RES, V59, P24; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cano I, 1996, CANCER GENET CYTOGEN, V90, P118, DOI 10.1016/S0165-4608(96)00063-5; Carapeti M, 1997, EUR J HAEMATOL, V58, P346; Carter TL, 2001, BLOOD, V97, P572, DOI 10.1182/blood.V97.2.572; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Castro PD, 1998, LEUKEMIA LYMPHOMA, V30, P443, DOI 10.3109/10428199809057556; Cave H, 1997, LEUKEMIA, V11, P1459, DOI 10.1038/sj.leu.2400798; CESARMAN E, 1992, BLOOD, V80, P3205; Chambon-Pautas C, 1998, LEUKEMIA, V12, P1107, DOI 10.1038/sj.leu.2401069; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen PM, 1999, CANCER, V85, P718, DOI 10.1002/(SICI)1097-0142(19990201)85:3<718::AID-CNCR22>3.0.CO;2-Y; Chim CS, 2001, CANCER, V91, P2222, DOI 10.1002/1097-0142(20010615)91:12<2222::AID-CNCR1252>3.0.CO;2-R; Chim CS, 2001, J CLIN ONCOL, V19, P2033, DOI 10.1200/JCO.2001.19.7.2033; Christiansen DH, 2001, J CLIN ONCOL, V19, P1405, DOI 10.1200/JCO.2001.19.5.1405; Cinti C, 2000, CANCER RES, V60, P383; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Clodi K, 1997, BRIT J HAEMATOL, V98, P913, DOI 10.1046/j.1365-2141.1997.3143131.x; CONDORELLI GL, 1995, P NATL ACAD SCI USA, V92, P4808, DOI 10.1073/pnas.92.11.4808; Cook DM, 1996, ONCOGENE, V13, P1789; COPPES MJ, 1994, NEW ENGL J MED, V331, P586; Corn PG, 1999, CANCER RES, V59, P3352; CORRADINI P, 1994, LEUKEMIA, V8, P758; DAO DD, 1994, LEUKEMIA, V8, P1280; Davies R, 1999, CANCER RES, V59, p1747S; Deuel TF, 1999, BIOCHEM BIOPH RES CO, V254, P192, DOI 10.1006/bbrc.1998.9896; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; Di Bacco A, 2000, Oncologist, V5, P405, DOI 10.1634/theoncologist.5-5-405; DICCIANNI MB, 1994, BLOOD, V84, P3105; Dictor M, 1999, AM J CLIN PATHOL, V112, pS40; DOHNER H, 1992, GENE CHROMOSOME CANC, V5, P392, DOI 10.1002/gcc.2870050415; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Dreyling MH, 1998, GENE CHROMOSOME CANC, V22, P72, DOI 10.1002/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.3.CO;2-G; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; ELROUBY S, 1993, BLOOD, V82, P3452; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Englert C, 1997, CANCER RES, V57, P1429; Faderl S, 2001, LEUKEMIA RES, V25, P39, DOI 10.1016/S0145-2126(00)00084-9; Faderl S, 2000, CANCER, V89, P1976, DOI 10.1002/1097-0142(20001101)89:9<1976::AID-CNCR14>3.3.CO;2-E; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FELIX CA, 1994, LEUKEMIA, V8, P963; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FENAUX P, 1992, LEUKEMIA, V6, P42; FENAUX P, 1992, LEUKEMIA, V6, P246; FENAUX P, 1991, BLOOD, V78, P1652; FENAUX P, 1990, NOUV REV FR HEMATOL, V32, P341; FINNEGAN MCM, 1994, CANCER LETT, V86, P215, DOI 10.1016/0304-3835(94)90081-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Furukawa Y, 2000, BRIT J HAEMATOL, V110, P663, DOI 10.1046/j.1365-2141.2000.02253.x; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GAIDANO G, 1993, LEUKEMIA, V7, P946; Gaidano G, 1997, GENE CHROMOSOME CANC, V19, P250; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GAIDANO G, 1994, ANN HEMATOL, V68, P3, DOI 10.1007/BF01695912; GAIDANO G, 1994, LEUKEMIA, V8, pS27; Gaiger A, 1999, EUR J HAEMATOL, V63, P86; Garcia JF, 1999, LAB INVEST, V79, P1453; GarciaMarco JA, 1996, BLOOD, V88, P1568; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; Gerard B, 1997, LEUKEMIA, V11, P228, DOI 10.1038/sj.leu.2400566; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1993, GENE CHROMOSOME CANC, V7, P131, DOI 10.1002/gcc.2870070304; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gombart AF, 1997, LEUKEMIA, V11, P1673, DOI 10.1038/sj.leu.2400840; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Gonzalez M, 2000, LEUKEMIA, V14, P183, DOI 10.1038/sj.leu.2401617; Gronbaek K, 1998, BLOOD, V92, P3018; Guan LS, 1998, J BIOL CHEM, V273, P27047, DOI 10.1074/jbc.273.42.27047; Gustafsson B, 1998, PEDIATR HEMAT ONCOL, V15, P519, DOI 10.3109/08880019809018313; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Hatta Y, 1998, BLOOD, V92, P2113, DOI 10.1182/blood.V92.6.2113.418k25_2113_2117; Hatta Y, 1999, BLOOD, V93, P613, DOI 10.1182/blood.V93.2.613.402k13_613_616; Hatta Y, 1997, LEUKEMIA, V11, P984, DOI 10.1038/sj.leu.2400686; HAWTHORN LA, 1993, ONCOGENE, V8, P1415; Herman JG, 1997, CANCER RES, V57, P837; HERNANDEZ A, 1993, ANN HEMATOL, V66, P81, DOI 10.1007/BF01695889; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HEWITT SM, 1995, CANCER RES, V55, P5386; HIRAMA T, 1995, BLOOD, V86, P841; Hofmann WK, 2001, LEUKEMIA RES, V25, P855, DOI 10.1016/S0145-2126(01)00037-6; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Horiike S, 1999, LEUKEMIA, V13, P1235, DOI 10.1038/sj.leu.2401466; Horrigan SK, 1996, BLOOD, V88, P2665, DOI 10.1182/blood.V88.7.2665.bloodjournal8872665; Horwitz M, 1997, AM J HUM GENET, V61, P873, DOI 10.1086/514894; Hosoya N, 1998, JPN J CANCER RES, V89, P821, DOI 10.1111/j.1349-7006.1998.tb00634.x; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; ICHIKAWA A, 1992, BLOOD, V79, P2701; Ichikawa A, 1997, NEW ENGL J MED, V337, P529, DOI 10.1056/NEJM199708213370804; Im HJ, 1999, PEDIATR HEMAT ONCOL, V16, P109; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Inokuchi K, 1996, J CLIN INVEST, V97, P852, DOI 10.1172/JCI118486; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; Inoue K, 2000, LEUKEMIA RES, V24, P255, DOI 10.1016/S0145-2126(99)00182-4; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; Iolascon A, 1997, LEUKEMIA, V11, P359, DOI 10.1038/sj.leu.2400596; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jadayel DM, 1997, LEUKEMIA, V11, P64, DOI 10.1038/sj.leu.2400555; Jamal R, 1996, BRIT J HAEMATOL, V94, P342, DOI 10.1046/j.1365-2141.1996.d01-1804.x; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; JONVEAUX P, 1991, LEUKEMIA, V5, P839; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KANEKO H, 1995, INT J HEMATOL, V61, P113; Kaneko H, 1996, LEUKEMIA LYMPHOMA, V21, P449, DOI 10.3109/10428199609093443; Kawamata N, 1996, DIAGN MOL PATHOL, V5, P33, DOI 10.1097/00019606-199603000-00006; Kawamua M, 1997, Rinsho Ketsueki, V38, P719; KAWAMURA M, 1995, BLOOD, V85, P2546, DOI 10.1182/blood.V85.9.2546.bloodjournal8592546; Kawamura M, 1999, LEUKEMIA RES, V23, P115, DOI 10.1016/S0145-2126(98)00146-5; Kawano S, 1999, BLOOD, V94, P1113; Kees UR, 1997, BLOOD, V89, P4161, DOI 10.1182/blood.V89.11.4161; KELMAN Z, 1989, BLOOD, V74, P2318; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; King-Underwood L, 1998, BLOOD, V91, P2961, DOI 10.1182/blood.V91.8.2961.2961_2961_2968; KingUnderwood L, 1996, BLOOD, V87, P2171, DOI 10.1182/blood.V87.6.2171.bloodjournal8762171; Klangby U, 1998, BLOOD, V91, P1680, DOI 10.1182/blood.V91.5.1680.1680_1680_1687; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOCIALKOWSKI S, 1995, BRIT J HAEMATOL, V89, P55, DOI 10.1111/j.1365-2141.1995.tb08911.x; Koduru PRK, 1997, BLOOD, V90, P4078, DOI 10.1182/blood.V90.10.4078; Koike M, 1999, LEUKEMIA RES, V23, P307, DOI 10.1016/S0145-2126(98)00159-3; Kornblau SM, 1998, CLIN CANCER RES, V4, P1955; Kornblau SM, 1999, LEUKEMIA LYMPHOMA, V35, P283, DOI 10.3109/10428199909145731; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krskova-Honzatkova L, 2001, LEUKEMIA RES, V25, P45, DOI 10.1016/S0145-2126(00)00086-2; Kung AL, 2000, GENE DEV, V14, P272; Kupper M, 2001, BRIT J HAEMATOL, V112, P768, DOI 10.1046/j.1365-2141.2001.02566.x; KUROSAWA M, 1995, ANN HEMATOL, V71, P83, DOI 10.1007/BF01699251; LAI JL, 1995, LEUKEMIA, V9, P370; Lai R, 1998, MODERN PATHOL, V11, P642; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; Lane MD, 1996, INT J OBESITY, V20, pS91; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lazaridou A, 2000, LEUKEMIA LYMPHOMA, V36, P503, DOI 10.3109/10428190009148398; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LEE YY, 1995, STEM CELLS, V13, P556, DOI 10.1002/stem.5530130514; Leoncini L, 1999, CLIN CANCER RES, V5, P4065; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lewis JL, 2001, BLOOD, V97, P2604, DOI 10.1182/blood.V97.9.2604; Liang DC, 1996, LEUKEMIA, V10, P991; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Liu ML, 2001, LEUKEMIA RES, V25, P441, DOI 10.1016/S0145-2126(00)00148-X; LO CF, 1993, BLOOD, V82, P2289; Lo YMD, 1999, CANCER RES, V59, P3899; LUDWIG L, 1993, LEUKEMIA, V7, P1058; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MacGrogan D, 2001, ONCOGENE, V20, P4150, DOI 10.1038/sj.onc.1204540; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maloney KW, 1999, BLOOD, V93, P2380, DOI 10.1182/blood.V93.7.2380.407k27_2380_2385; Marasca R, 1996, LEUKEMIA LYMPHOMA, V24, P175, DOI 10.3109/10428199609045726; Marks DI, 1997, J CLIN ONCOL, V15, P1158, DOI 10.1200/JCO.1997.15.3.1158; Marks DI, 1996, BLOOD, V87, P1155, DOI 10.1182/blood.V87.3.1155.bloodjournal8731155; Martin A, 1998, BRIT J HAEMATOL, V101, P311, DOI 10.1046/j.1365-2141.1998.00692.x; MASHAL R, 1990, BLOOD, V75, P180; Massaro-Giordano M, 1999, CLIN CANCER RES, V5, P1455; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; Mateo M, 1999, AM J PATHOL, V154, P1583, DOI 10.1016/S0002-9440(10)65411-9; Maurer U, 1997, EXP HEMATOL, V25, P945; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; McLean TW, 1996, BLOOD, V88, P4252; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; Misawa Shinichi, 1997, Leukemia (Basingstoke), V11, P533; MIWA H, 1992, LEUKEMIA, V6, P405; Miyagawa K, 1999, GENE CHROMOSOME CANC, V25, P176, DOI 10.1002/(SICI)1098-2264(199906)25:2<176::AID-GCC14>3.3.CO;2-6; MIYAGI T, 1993, LEUKEMIA, V7, P970; MIYAKE K, 1993, BLOOD, V82, P927; Moller MB, 1999, LEUKEMIA, V13, P453, DOI 10.1038/sj.leu.2401315; Montesinos-Rongen M, 1999, BLOOD, V94, P1755, DOI 10.1182/blood.V94.5.1755.417a26_1755_1760; Moreno TC, 2000, EUR J HAEMATOL, V65, P390; Morente MM, 1997, BLOOD, V90, P2429; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mori N, 1995, LEUKEMIA RES, V19, P869, DOI 10.1016/0145-2126(95)00058-5; Mori N, 1999, BRIT J HAEMATOL, V105, P844, DOI 10.1046/j.1365-2141.1999.01497.x; Mori N, 1997, BLOOD, V90, P2010, DOI 10.1182/blood.V90.5.2010; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Murata Y, 1997, FEBS LETT, V409, P41, DOI 10.1016/S0014-5793(97)00477-8; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; Nagai H, 1999, GENE CHROMOSOME CANC, V25, P277, DOI 10.1002/(SICI)1098-2264(199907)25:3<277::AID-GCC10>3.0.CO;2-L; Nakahara Y, 1998, LEUKEMIA, V12, P1277, DOI 10.1038/sj.leu.2401099; NAKAI H, 1992, CANCER RES, V52, P6588; NAKAMURA H, 1993, BLOOD, V82, P920, DOI 10.1182/blood.V82.3.920.bloodjournal823920; Nakano Y, 2000, EUR J HAEMATOL, V65, P23, DOI 10.1034/j.1600-0609.2000.90138.x; Neri A, 1996, BRIT J HAEMATOL, V93, P670, DOI 10.1046/j.1365-2141.1996.d01-1690.x; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEWCOMB EW, 1995, MOL CARCINOGEN, V14, P141, DOI 10.1002/mc.2940140302; Ng M, 1999, LEUKEMIA LYMPHOMA, V34, P463, DOI 10.3109/10428199909058473; Nieder C, 2001, ANN HEMATOL, V80, P2, DOI 10.1007/s002770000226; Niegemann E, 1999, ACTA HAEMATOL-BASEL, V102, P72, DOI 10.1159/000040973; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NISHIMURA S, 1995, LEUKEMIA, V9, P598; Nobori T, 1996, P NATL ACAD SCI USA, V93, P6203, DOI 10.1073/pnas.93.12.6203; NUCIFORA G, 1995, BLOOD, V86, P1; Ohnishi H, 1996, LEUKEMIA, V10, P1104; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OMarcaigh AS, 1997, J PEDIAT HEMATOL ONC, V19, P551, DOI 10.1097/00043426-199711000-00015; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Padua RA, 1998, LEUKEMIA, V12, P887, DOI 10.1038/sj.leu.2401044; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Patmasiriwat P, 1999, LEUKEMIA, V13, P891, DOI 10.1038/sj.leu.2401414; Patmasiriwat P, 1996, LEUKEMIA, V10, P1127; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; PIGNON JM, 1994, HUM MUTAT, V3, P126, DOI 10.1002/humu.1380030207; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; PREUDHOMME C, 1994, BRIT J HAEMATOL, V87, P61, DOI 10.1111/j.1365-2141.1994.tb04871.x; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; PREUDHOMME C, 1993, LEUKEMIA, V7, P1291; PREUDHOMME C, 1992, BRIT J HAEMATOL, V81, P440, DOI 10.1111/j.1365-2141.1992.tb08253.x; PREUDHOMME C, 1994, LEUKEMIA, V8, P1589; PRITCHARDJONES K, 1994, HUM MOL GENET, V3, P1633, DOI 10.1093/hmg/3.9.1633; QUELLE DE, 1995, CELL, V83, P993; Quesnel B, 1996, BRIT J HAEMATOL, V95, P291, DOI 10.1046/j.1365-2141.1996.d01-1913.x; QUESNEL B, 1994, LEUKEMIA, V8, P878; Quesnel B, 1998, BLOOD, V91, P2985, DOI 10.1182/blood.V91.8.2985.2985_2985_2990; QUESNEL B, 1994, BRIT J HAEMATOL, V88, P415, DOI 10.1111/j.1365-2141.1994.tb05044.x; Ramakers-van Woerden NL, 2001, BRIT J HAEMATOL, V112, P680, DOI 10.1046/j.1365-2141.2001.02586.x; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; Rasmussen SA, 2000, AM J EPIDEMIOL, V151, P33, DOI 10.1093/oxfordjournals.aje.a010118; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; RIDGE SA, 1994, BRIT J HAEMATOL, V86, P407, DOI 10.1111/j.1365-2141.1994.tb04754.x; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROVIRA A, 1995, ANN HEMATOL, V70, P129; Rowley JD, 1997, BLOOD, V90, P535; Rubnitz JE, 1997, LEUKEMIA, V11, P1201, DOI 10.1038/sj.leu.2400779; SAKASHITA A, 1992, BLOOD, V79, P477; SanchezBeato M, 1996, BRIT J CANCER, V74, P1056, DOI 10.1038/bjc.1996.489; Sankar M, 1998, LEUKEMIA, V12, P510, DOI 10.1038/sj.leu.2400973; SANTOS A, 1993, HUM GENET, V92, P83, DOI 10.1007/BF00216151; Sauerbrey A, 1998, LEUKEMIA LYMPHOMA, V28, P275, DOI 10.3109/10428199809092683; Scarisbrick JJ, 2000, BLOOD, V95, P2937, DOI 10.1182/blood.V95.9.2937.009k15_2937_2942; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; Schmid D, 1997, LEUKEMIA, V11, P639, DOI 10.1038/sj.leu.2400620; SCHOTTELIUS A, 1994, LEUKEMIA, V8, P1673; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Seeberger H, 2001, LAB INVEST, V81, P977, DOI 10.1038/labinvest.3780310; SEKIYA M, 1994, BLOOD, V83, P1876; Seliger B, 1996, EUR J HAEMATOL, V57, P230; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHANNON KM, 1992, BLOOD, V79, P1311; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2000, CANCER RES, V60, P3689; Shieh SY, 2000, GENE DEV, V14, P289; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Sidransky D, 1996, CURR BIOL, V6, P523, DOI 10.1016/S0960-9822(02)00532-8; SIRAGANIAN PA, 1989, MED PEDIATR ONCOL, V17, P485; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; SLINGERLAND JM, 1991, BLOOD, V77, P1500; Smith SI, 1998, BLOOD, V91, P764, DOI 10.1182/blood.V91.3.764.764_764_773; Smith SI, 2000, CANCER RES, V60, P808; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Starostik P, 2000, BLOOD, V95, P1180, DOI 10.1182/blood.V95.4.1180.004k14_1180_1187; Starostik P, 1998, CANCER RES, V58, P4552; Stilgenbauer S, 1999, BLOOD, V94, P3262, DOI 10.1182/blood.V94.9.3262.421a33_3262_3264; Stilgenbauer S, 1996, P NATL ACAD SCI USA, V93, P11837, DOI 10.1073/pnas.93.21.11837; Stilgenbauer S, 1998, ONCOGENE, V16, P1891, DOI 10.1038/sj.onc.1201764; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; Stirewalt DL, 2001, BLOOD, V97, P3589, DOI 10.1182/blood.V97.11.3589; Stokke T, 2000, INT J CANCER, V89, P313, DOI 10.1002/1097-0215(20000720)89:4<313::AID-IJC1>3.0.CO;2-D; Stoppa-Lyonnet D, 1998, BLOOD, V91, P3920, DOI 10.1182/blood.V91.10.3920.3920_3920_3926; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Susini T, 2001, HUM PATHOL, V32, P360, DOI 10.1053/hupa.2001.23514; Susini T, 1998, J CLIN ONCOL, V16, P1085, DOI 10.1200/JCO.1998.16.3.1085; Svedberg H, 1998, ONCOGENE, V16, P925, DOI 10.1038/sj.onc.1201613; Takeuchi S, 1996, BLOOD, V87, P3368, DOI 10.1182/blood.V87.8.3368.bloodjournal8783368; Takeuchi S, 1998, CANCER RES, V58, P2618; Takeuchi S, 1998, BRIT J HAEMATOL, V103, P536, DOI 10.1046/j.1365-2141.1998.00993.x; Takimoto H, 1998, BIOCHEM BIOPH RES CO, V251, P264, DOI 10.1006/bbrc.1998.9459; Tamaki H, 1999, LEUKEMIA, V13, P393, DOI 10.1038/sj.leu.2401341; Tanaka N, 1999, ORAL ONCOL, V35, P321, DOI 10.1016/S1368-8375(98)00089-X; Tanaka N, 2001, ORAL ONCOL, V37, P308, DOI 10.1016/S1368-8375(00)00107-X; Tasaka T, 1998, BRIT J HAEMATOL, V101, P558, DOI 10.1046/j.1365-2141.1998.00724.x; Tavor S, 2001, LEUKEMIA LYMPHOMA, V42, P517, DOI 10.3109/10428190109064610; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Tien HF, 2001, BRIT J HAEMATOL, V112, P148, DOI 10.1046/j.1365-2141.2001.02496.x; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; TOWATARI M, 1991, BLOOD, V78, P2178, DOI 10.1182/blood.V78.9.2178.bloodjournal7892178; TRECCA D, 1994, AM J HEMATOL, V46, P304, DOI 10.1002/ajh.2830460409; Tsai T, 1996, LEUKEMIA, V10, P1901; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsukasaki K, 2001, ONCOGENE, V20, P3301, DOI 10.1038/sj.onc.1204421; Uchida T, 2001, LEUKEMIA, V15, P157, DOI 10.1038/sj.leu.2401991; Urashima M, 1997, BLOOD, V90, P4106, DOI 10.1182/blood.V90.10.4106; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; WADA M, 1993, BLOOD, V82, P3163; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang XW, 1999, ANTICANCER RES, V19, P4759; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WATANABE T, 1994, BLOOD, V84, P3158; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Wong IHN, 2000, BLOOD, V95, P1942, DOI 10.1182/blood.V95.6.1942; Wu XS, 1999, GENOMICS, V60, P161, DOI 10.1006/geno.1999.5911; XERRI L, 1995, AM J CLIN PATHOL, V104, P424; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; YOUNES A, 1995, BLOOD, V85, P2813, DOI 10.1182/blood.V85.10.2813.bloodjournal85102813; Zamparelli A, 2001, HUM PATHOL, V32, P4, DOI 10.1053/hupa.2001.20371; ZANDECKI M, 1995, LEUKEMIA LYMPHOMA, V18, P497, DOI 10.3109/10428199509059651; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhou M, 2000, LEUKEMIA, V14, P61, DOI 10.1038/sj.leu.2401619; Zhou MX, 1997, PEDIATR HEMAT ONCOL, V14, P141, DOI 10.3109/08880019709030900; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; Zhu JH, 1998, CANCER RES, V58, P5061; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; Zhu YM, 1999, BLOOD, V94, P733, DOI 10.1182/blood.V94.2.733.414k03_733_740	389	194	207	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3475	3495		10.1038/sj.onc.1205322	http://dx.doi.org/10.1038/sj.onc.1205322			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032783				2022-12-28	WOS:000175633300018
J	Catalano, A; Romano, M; Martinotti, S; Procopio, A				Catalano, A; Romano, M; Martinotti, S; Procopio, A			Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen	ONCOGENE			English	Article						SV40; Tag; VEGF; mesothelioma	ANGIOGENESIS; GENE; P53; MESOTHELIOMA; SUPPRESSION; SEQUENCES; RECEPTOR; CELLS	Vascular endothelial growth factor (VEGF), an important angiogenic factor, regulates cell proliferation, differentiation, and apoptosis through activation of its tyrosine-kinase receptors, such as Flt-1 and Flk-1/Kdr. Human malignant mesothelioma cells (HMC), which have wild-type p53, express VEGF and exhibit cell growth increased by VEGF. Here, we demonstrate that early transforming proteins of simian virus (SV) 40, large tumor antigen (Tag) and small tumor antigen (tag). which have been associated with mesotheliomas, enhanced HNIC proliferation by inducing VEGF expression. SV40-Tag expression potently increased VEGF protein and mRNA levels in several HNIC lines. This effect was suppressed by the protein synthesis inhibitor, cycloheximide. Inactivation of the VEGF signal transduction pathway by expression of soluble form of FIt-1 inhibited Flk-1/Kdr activation and HNIC proliferation induced by SV40 early genes. Experiments with SV40 mutants revealed that SV40-Tag, but not -tag, is involved in the VEGF promoter activation. However, concomitant expression of SV40-tag enhanced Tag function. In addition, SV40-Tag expression sustained VEGF induction in colon carcinoma cell line (CCL)-233, which have wild-type p53, but not in CCL-238, which lack functional p53. These data indicate that VEGF regulation by SV40 transforming proteins can represent a key event in SV40 signaling relevant for tumor progression.	Univ Ancona, Fac Med, Inst Expt Pathol, I-60131 Ancona, Italy; Univ Messina, Dept Human Pathol, I-98125 Messina, Italy; Univ G DAnnunzio, Dept Oncol & Neurosci, Chieti, Italy	Marche Polytechnic University; University of Messina; G d'Annunzio University of Chieti-Pescara	Procopio, A (corresponding author), Univ Ancona, Fac Med, Inst Expt Pathol, Via Ranieri, I-60131 Ancona, Italy.	mromano@unich.it; procopio@poscsi.unian.it	Romano, Mario/I-7986-2012; Procopio, Antonio Domenico/AAB-2451-2021	Romano, Mario/0000-0001-8512-1458; Procopio, Antonio Domenico/0000-0001-6897-8724				Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Browne K, 2001, ANN OCCUP HYG, V45, P327, DOI 10.1016/S0003-4878(01)00029-1; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Claudio PP, 2001, CANCER RES, V61, P462; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Gaetano C, 2001, CIRC RES, V88, pE38; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Kumar-Singh S, 1999, J PATHOL, V189, P72, DOI 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; Orengo AM, 1999, EUR RESPIR J, V13, P527, DOI 10.1183/09031936.99.13352799; Pal S, 2001, CANCER RES, V61, P6952; Paley EL, 1996, CARCINOGENESIS, V17, P939, DOI 10.1093/carcin/17.5.939; Procopio A, 2000, GENE CHROMOSOME CANC, V29, P173, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1019>3.0.CO;2-B; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Takayama K, 2000, CANCER RES, V60, P2169; Zhang LL, 2000, CANCER RES, V60, P3655	20	48	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2896	2900		10.1038/sj.onc.1205382	http://dx.doi.org/10.1038/sj.onc.1205382			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973650				2022-12-28	WOS:000175063700015
J	Kim, SS; Chae, HS; Bach, JH; Lee, MW; Kim, KY; Lee, WB; Jung, YM; Bonventre, JV; Suh, YH				Kim, SS; Chae, HS; Bach, JH; Lee, MW; Kim, KY; Lee, WB; Jung, YM; Bonventre, JV; Suh, YH			P53 mediates ceramide-induced apoptosis in SKN-SH cells	ONCOGENE			English	Article						p53; apoptosis; ceramide; Bcl-2; Bax; caspase	PC12 CELLS; FACTOR WITHDRAWAL; NEURONAL DEATH; BCL-2; BAX; ACTIVATION; PROTEIN; DISTINCT; PATHWAY; HETERODIMERIZES	Ceramide induces apoptotic cell death in a dose- and time-dependent manner in neuroblastoma SKN-SH cells. Pretreatment with caspase inhibitors blocks cell death, suggesting that a set of caspase activities including caspase 1, as well as caspase 3, are involved in ceramide-induced apoptosis in SKN-SH cells. Treatment with a caspase inhibitor 3 h after ceramide addition did not inhibit cell death, although caspase activity was substantially reduced. Ceramide-induced apoptosis is accompanied by accumulation of p53 followed by an increase of Bax and decrease of Bcl-2 levels. Inhibition of p53 expression with p53 antisense oligonucleotides inhibits apoptosis and prevents the increase in Bax and decrease in Bcl-2. Furthermore, pretreatment with p53 antisense oligonucleotides markedly inhibits the induction of caspase activity. These results suggest that p53 regulates the ratio Bcl-2/Bax and the expression/activation of caspases during ceramide-induced apoptosis in SKN-SH cells. Caspase inhibition did not alter the expression of p53, Bcl-2 and Bax. Thus ceramide-induced reduction in the Bcl-2/Bax ratio, increase in caspase activity, and apoptosis is dependent upon increases in cellular p53 levels which play a critical role in the regulation of apoptotic cell death.	Chung Ang Univ, Coll Med, Dept Anat, BioGrand Inc,MRC, Seoul 156756, South Korea; NIH, Biomed Brain Res Ctr, Seoul 122701, South Korea; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Seoul Natl Univ, Coll Med, Dept Pharmacol,Neurosci Res Inst,MRC, Natl Creat Res Initiat Ctr Alzheimers Dementia, Seoul 110799, South Korea	Chung Ang University; Chung Ang University Hospital; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Harvard University; Harvard Medical School; Seoul National University (SNU)	Bonventre, JV (corresponding author), Massachusetts Gen Hosp E, Suite 4002,149 13th St, Charlestown, MA 02129 USA.	joseph_bonventre@hms.harvard.edu	Suh, Yoo-Hun/J-2761-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039773, P01DK038452, R01DK039773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38452, DK39773] Funding Source: Medline; NINDS NIH HHS [NS10828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali ST, 1997, BIOCHEM J, V325, P321, DOI 10.1042/bj3250321; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Anjum R, 1998, FEBS LETT, V439, P81, DOI 10.1016/S0014-5793(98)01343-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brugg B, 1996, J NEUROCHEM, V66, P733; Choisy-Rossi C, 1998, TOXICOL LETT, V103, P491, DOI 10.1016/S0378-4274(98)00238-0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; El-Assaad W, 1998, BIOCHEM J, V336, P735, DOI 10.1042/bj3360735; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hartfield PJ, 1998, J NEUROCHEM, V71, P161; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; Kim SS, 1997, BIOCHEM BIOPH RES CO, V237, P583, DOI 10.1006/bbrc.1997.7133; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lightle SA, 2000, MECH AGEING DEV, V120, P111, DOI 10.1016/S0047-6374(00)00191-3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	38	32	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2020	2028	PII 10.1038/sj/onc/1205037	10.1038/sj.onc.1205037	http://dx.doi.org/10.1038/sj.onc.1205037			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960374				2022-12-28	WOS:000174827000008
J	Morrison, BH; Bauer, JA; Hu, JD; Grane, RW; Ozdemir, AM; Chawla-Sarkar, M; Gong, BD; Almasan, A; Kalvakolanu, DV; Lindner, DJ				Morrison, BH; Bauer, JA; Hu, JD; Grane, RW; Ozdemir, AM; Chawla-Sarkar, M; Gong, BD; Almasan, A; Kalvakolanu, DV; Lindner, DJ			Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics	ONCOGENE			English	Article						inositol hexakisphosphate kinase; apoptosis; radiation; interferon	IONIZING-RADIATION; APOPTOSIS; INDUCTION; EXPRESSION; RECEPTORS; CASPASE-8; BINDING; LIGAND; TRAIL; IDENTIFICATION	dWe recently identified inositol hexakisphosphate kinase 2 (IP6K2) as a positive regulator of apoptosis. Overexpression of IP6K2 enhances apoptosis induced by interferon-beta (IFN-beta) and cytotoxic agents in NIH-OVCAR-3 ovarian carcinoma cells. In this study, we contrast and compare IFN-beta and radiation-induced death, and show that IP6K2 expression sensitizes tumor cells. Unirradiated NIH-OVCAR-3 cells transfected with IP6K2 formed fewer colonies compared to unirradiated vector-expressing cells. IP6K2 overexpression caused increased radiosensitivity, evidenced by decreased colony forming units (CFU). Both IFN-beta and radiation induced caspase 8. IFN-beta, but not gamma-irradiation, induced TRAIL in NIH-OVCAR-3 cells. Gamma irradiation, but not IFN-beta, induced DR4 mRNA. Apoptotic effects of IFN-beta or gamma-irradiation were blocked by expression of a dominant negative mutant death receptor 5 (DR5Delta) or by Bcl-2. Caspase-8 mRNA induction was more pronounced in IP6K2-expressing cells compared to vector-expressing cells. These data suggest that overexpression of IP6K2 enhances sensitivity of some ovarian carcinomas to radiation and IFN-beta. IP6K2 may function to enhance the expression and/or function of caspase 8 and DR4 following cell injury. Both IFN-beta and gamma-irradiation induce apoptosis through the extrinsic, receptor-mediated pathway, IFN-beta through TRAIL, radiation through DR4, and both through caspase 8. The function of both death inducers is positively regulated by IP6K2.	Cleveland Clin Fdn, Ctr Canc Drug Discovery & Dev, Taussig Canc Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Radiat Oncol, Cleveland, OH 44195 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Maryland; University of Maryland Baltimore	Lindner, DJ (corresponding author), 9500 Euclid Ave,R40, Cleveland, OH 44195 USA.	lindned@cc.ccf.org	Lindner, Daniel/ABB-5440-2020; Almasan, Alex/C-2715-2008	Almasan, Alex/0000-0002-8916-6650; Bauer, Joseph/0000-0003-4972-6008	NATIONAL CANCER INSTITUTE [R01CA095020, R01CA081504, R01CA078282, R01CA082858, R01CA071401] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095020-01A1, CA78282, R01 CA081504-03, R01 CA081504-02, R01 CA078282, CA71401, R01 CA082858-02, R01 CA082858-01, CA82858, R01 CA082858, R01 CA081504, CA81504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gong BD, 2000, CANCER RES, V60, P5754; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; Lackinger D, 2001, MUTAGENESIS, V16, P233, DOI 10.1093/mutage/16.3.233; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mehrotra B, 2000, BIOCHEMISTRY-US, V39, P9679, DOI 10.1021/bi000487o; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; MURAKAMI M, 1995, EUR J ENDOCRINOL, V133, P80, DOI 10.1530/eje.0.1330080; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; RIMESSI P, 1994, ONCOGENE, V9, P3467; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Taneja N, 2001, ONCOGENE, V20, P167, DOI 10.1038/sj.onc.1204054; Togashi S, 1997, BIOCHEM J, V326, P221, DOI 10.1042/bj3260221; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; YAGINUMA Y, 1992, CANCER RES, V52, P4196; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Yount GL, 2001, ONCOGENE, V20, P2826, DOI 10.1038/sj.onc.1204393; Zhang HF, 1999, EXP CELL RES, V247, P133, DOI 10.1006/excr.1998.4329	35	56	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1882	1889		10.1038/sj.onc.1205265	http://dx.doi.org/10.1038/sj.onc.1205265			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896621	Green Accepted			2022-12-28	WOS:000174284500011
J	Amanullah, A; Liebermann, DA; Hoffman, B				Amanullah, A; Liebermann, DA; Hoffman, B			Deregulated c-Myc prematurely recruits both Type I and IICD95/Fas apoptotic pathways associated with terminal myeloid differentiation	ONCOGENE			English	Article						myeloid; c-myc; differentiation; apoptosis; CD95; Fas	DNA-REPLICATION ORIGIN; FAS-LIGAND; LEUKEMIA CELLS; DEATH DOMAIN; T-CELLS; GROWTH; EXPRESSION; GENE; PROTEASE; MICE	Previously we have reported that deregulated expression of c-myc in normal and leukemic myeloid cells blocked differentiation and, concomitantly, induced p53-independent apoptosis. Here, we show that this morbidity was due to premature recruitment of the Fas/CD95 cell death pathway which normally operates to induce apoptosis at the end of the terminal myeloid differentiation program. Analysis of the regulated components of this pathway revealed that IL6-mediated induction of differentiation resulted in rapid cell surface expression of CD95 receptor. Deregulated c-myc prevented the downregulation of CD95 ligand by maintaining its transcription, but caused premature downregulation of c-FLIP. First, the Type II (mitochondria-dependent, bcl-2-sensitive) and, then, the Type I (mitochondria-independent, bcl-2-insensitive) pathway were activated. Stable exogenous c-FLIP expression completely rescued the apoptotic phenotype. Furthermore, when the deregulated c-myc transgene was stably transduced into bone marrow cells from Fas(lpr/lpr) (CD95 receptor mutant) and Fas(gld/gld) (CD95 ligand mutant) mice, cell death was significantly suppressed relative to c-myc-transduced wild type bone marrow cells upon induction of differentiation. These data indicate that c-myc-mediated apoptosis associated with blocks in myeloid differentiation is dependent on the Fas/CD95 pathway. Our findings offer important new insights into understanding how deregulated c-myc alters normal blood cell homeostasis, and how additional mutations might promote leukemogenesis.	Temple Univ, Sch Med, Fels Inst Canc Res, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@unix.temple.edu; hoffman@unix.temple.edu			NCI NIH HHS [R01CA81168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Eilers M, 1999, MOL CELLS, V9, P1; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Fecho K, 1998, CELL IMMUNOL, V188, P19, DOI 10.1006/cimm.1998.1339; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELLICER A, 1978, CELL, V14, P133, DOI 10.1016/0092-8674(78)90308-2; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TAIRA T, 1994, MOL CELL BIOL, V14, P6386, DOI 10.1128/MCB.14.9.6386; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	47	25	25	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1600	1610		10.1038/sj.onc.1205231	http://dx.doi.org/10.1038/sj.onc.1205231			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896589				2022-12-28	WOS:000173956800016
J	Chauhan, D; Auclair, D; Robinson, EK; Hideshima, T; Li, GL; Podar, K; Gupta, D; Richardson, P; Schlossman, RL; Krett, N; Chen, LB; Munshi, NC; Anderson, KC				Chauhan, D; Auclair, D; Robinson, EK; Hideshima, T; Li, GL; Podar, K; Gupta, D; Richardson, P; Schlossman, RL; Krett, N; Chen, LB; Munshi, NC; Anderson, KC			Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays	ONCOGENE			English	Article						multiple myeloma; dexamethasone; interleukin-6	NF-KAPPA-B; BRUTONS TYROSINE KINASE; MARROW STROMAL CELLS; GROWTH-FACTOR; INDUCED APOPTOSIS; EXPRESSION; INTERLEUKIN-6; RECEPTOR; TRANSCRIPTION; INDUCTION	Our previous studies have characterized Dexamethasone (Dex)-induced apoptotic signaling pathways in multiple myeloma (MM) cells; however, related transcriptional events are not fully defined. In the present study, gene expression profiles of Dex-treated MM cells were determined using oligonucleotide arrays. Dex triggers early transient induction of many genes involved in cell defense/repair-machinery. This is followed by induction of genes known to mediate cell death and repression of growth/survival-related genes. The molecular and genetic alterations associated with Dex resistance in MM cells are also unknown. We compared the gene expression profiles of Dex-sensitive and Dex-resistant MM cells and identified a number of genes which may confer Dex-resistance. Finally, gene profiling of freshly isolated MM patient cells validates our in vitro MM cell line data, confirming an in vivo relevance of these studies. Collectively, these findings provide insights into the basic mechanisms of Dex activity against MM, as well as mechanisms of Dex-resistance in MM cells. These studies may therefore allow improved therapeutic uses of Dex, based upon targeting genes that regulate MM cell growth and survival.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol Jerome Lipper Multiple, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Northwestern Univ, Med Sch, Robert H Lurie Canc Ctr, Chicago, IL USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol Jerome Lipper Multiple, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021; Podar, Klaus/ABD-1112-2020	Podar, Klaus/0000-0002-7414-3632	NCI NIH HHS [CA 78373] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANIAN R, 1992, BLOOD, V80, P887; Anderson KC, 1999, SEMIN HEMATOL, V36, P14; ANDERSON KC, 1989, BLOOD, V73, P1915; Anderson KC, 2001, SEMIN HEMATOL, V38, P286, DOI 10.1053/shem.2001.26010; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BARUT B, 1993, J CLIN INVEST, V92, P2346, DOI 10.1172/JCI116839; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; CHAUDHRY A, 1994, ANTICANCER RES, V14, P2085; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; CHAUHAN D, 1994, CANCER RES, V54, P2234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2001, APOPTOSIS, V6, P47, DOI 10.1023/A:1009620027205; CHAUHAN D, 1993, BLOOD, V81, P1540; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Desai SD, 2000, ANN NY ACAD SCI, V922, P306; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feinman R, 1999, BLOOD, V93, P3044; Fischer CP, 1996, ANN SURG, V223, P610, DOI 10.1097/00000658-199605000-00017; Fraticelli P, 2001, J CLIN INVEST, V107, P1173, DOI 10.1172/JCI11517; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; GOLDMANLEIKIN RE, 1989, J LAB CLIN MED, V113, P335; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HARDIN J, 1994, BLOOD, V84, P3063; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; JUGEMORINEAU N, 1995, BRIT J HAEMATOL, V90, P707, DOI 10.1111/j.1365-2141.1995.tb05605.x; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KLEIN B, 1989, BLOOD, V73, P517; Kohler HBK, 2001, VET DERMATOL, V12, P129, DOI 10.1046/j.1365-3164.2001.00237.x; Krett NL, 1997, CLIN CANCER RES, V3, P1781; Kudoh K, 2000, CANCER RES, V60, P4161; Levy Y, 1996, CLIN EXP IMMUNOL, V104, P167, DOI 10.1046/j.1365-2249.1996.d01-637.x; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MOALLI PA, 1993, CANCER RES, V53, P3877; MOALLI PA, 1992, BLOOD, V79, P213; Mori S, 1998, ANTICANCER RES, V18, P4403; Ogata A, 1997, J IMMUNOL, V159, P2212; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Rowland TL, 2001, INT IMMUNOPHARMACOL, V1, P49, DOI 10.1016/S0162-3109(00)00265-4; SALMON SE, 1984, CANCER TREAT REP, V68, P117; Smith MR, 1998, BRIT J HAEMATOL, V102, P1090, DOI 10.1046/j.1365-2141.1998.00850.x; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Tassone P, 2000, CELL DEATH DIFFER, V7, P327, DOI 10.1038/sj.cdd.4400635; UCHIYAMA H, 1993, BLOOD, V82, P3712; Urashima M, 1996, BLOOD, V87, P1928; Volin MV, 2001, AM J PATHOL, V159, P1521, DOI 10.1016/S0002-9440(10)62537-0; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Zimmermann J, 2000, ONCOGENE, V19, P2913, DOI 10.1038/sj.onc.1203606	67	128	131	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1346	1358		10.1038/sj.onc.1205205	http://dx.doi.org/10.1038/sj.onc.1205205			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857078				2022-12-28	WOS:000173861000005
J	Wilhelmsen, K; Burkhalter, S; van der Geer, P				Wilhelmsen, K; Burkhalter, S; van der Geer, P			C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel phosphorylation site in the receptor's carboxy-terminus	ONCOGENE			English	Article						phosphotyrosine; protein-tyrosine kinase; v-fms; ubiquitination	COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; FMS PROTO-ONCOGENE; MEDIATED NEGATIVE REGULATION; FACTOR-I RECEPTOR; V-FMS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; KINASE INSERT; RING FINGER	The colony-stimulating factor-1 (CSF-1) receptor is a protein-tyrosine kinase that regulates the proliferation and differentiation of monocyte and macrophage precursors. Binding of CSF-1 to its receptor results in activation of the kinase domain and autophosphorylation on a number of tyrosine residues. Phosphorylated tyrosine residues function as binding sites for SH2 domain-containing signaling proteins. It is known that activated receptors are internalized and degraded, but the mechanics of this process remain largely unknown. Recently, evidence has started to emerge that the ubiquitin-protein ligase c-Cbl is involved in CSF-1 receptor degradation. In addition, there is evidence that the CSF-1 receptor carboxy-terminus is involved in down regulation of the receptor. Here we show that the c-Cbl tyrosine kinase-binding (TKB) domain binds in vitro and in vivo to the CSF-1 receptor. Binding is dependent on the receptor's protein-kinase activity. Deletion of the carboxy-terminus or mutation of Tyr 973 blocks binding. We further provide evidence that the CSF-1 receptor's carboxy-terminus is a substrate for autophosphorylation. Our observations are consistent with a model in which receptor autophosphorylation at Tyr 973 creates a binding site for c-Cbl. Association of c-Cbl with the receptor leads to ubiquitination, followed by receptor degradation.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	van der Geer, P (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.	geer@ucsd.edu			NCI NIH HHS [5T32 CA 09523] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWNING PJ, 1986, P NATL ACAD SCI USA, V83, P7800, DOI 10.1073/pnas.83.20.7800; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEISTERKAMP N, 1983, VIROLOGY, V126, P248, DOI 10.1016/0042-6822(83)90476-2; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KACINSKI BM, 1995, ANN MED, V27, P79, DOI 10.3109/07853899509031941; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Novak U, 1996, ONCOGENE, V13, P2607; Ota J, 2000, FEBS LETT, V466, P96, DOI 10.1016/S0014-5793(99)01767-6; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	53	62	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1079	1089		10.1038/sj.onc.1205166	http://dx.doi.org/10.1038/sj.onc.1205166			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850825				2022-12-28	WOS:000173580100011
J	Agazie, Y; Ischenko, I; Hayman, M				Agazie, Y; Ischenko, I; Hayman, M			Concomitant activation of the PI3K-Akt and the Ras-ERK signaling pathways is essential for transformation by the V-SEA tyrosine kinase oncogene	ONCOGENE			English	Article						V-SEA; oncogene; Ras-ERK; PI3K-Akt; transformation	AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTORS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MET RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; CELL-TRANSFORMATION; CATALYTIC SUBUNIT; DOCKING SITE; MAP KINASE	V-SEA is the transforming component of S13 Avian Erythroblastosis Retrovirus that causes erythroblastosis and anemia in chicken. Like all members in the family (MET, RON, SEA), its cytosolic domain possesses two tyrosine autophosphorylation sites in the tandemly arranged bidentate motif that serve as docking sites for SH2 domain-containing proteins. Here, we investigated phosphotyrosine-dependent activation of signaling pathways and their significance in V-SEA-induced transformation and/or proliferation. We demonstrated that V-SEA activates the PI3K-Akt signaling pathway primarily in Y557- and secondarily in Y564-dependent manner. V-SEA was also shown to induce the tyrosine phosphorylation of the Gab2 protein, leading to PI3K association and thus providing an alternative route for PI3K activation. On the other hand, activation of the Ras-ERK pathway is primarily via Y564 and secondarily via Y557. A dominant-negative form of Ras inhibited V-SEA-induced ERK phosphorylation in concentration dependent manner suggesting the importance of the Grb2-Ras signaling axis in V-SEA-induced ERK activation. The biological significance of activation of the PI3K-Akt and the Ras-ERK pathways in V-SEA-induced transformation was analysed in the V-SEARATI and V-SEA-3T3 cell lines by employing specific inhibitors, LV294002 and PD98059 compounds. Both the PD and LY compounds inhibited cell growth, but only the PD compound caused reversion of the transformed phenotype. In addition, both compounds inhibited focal colony formation by the transformants in soft agar. Thus, transformation by the V-SEA oncogene is a function of the concomitant activation of, at least, the PI3K-Akt and Ras-ERK signaling pathways that regulate cell growth and morphology.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, M (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	mhayman@ms.cc.sunysb.edu						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Borlado LR, 2000, FASEB J, V14, P895; BORNFELDT KE, 1991, DIABETOLOGIA, V34, P307, DOI 10.1007/BF00405001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; END P, 1993, J BIOL CHEM, V268, P10066; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRECO A, 1992, ONCOGENE, V7, P237; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KNIGHT J, 1990, VIROLOGY, V178, P232, DOI 10.1016/0042-6822(90)90398-B; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MORIMOTO AM, 1994, J VIROL, V68, P1837, DOI 10.1128/JVI.68.3.1837-1842.1994; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1984, PNAS, V84, P6379; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Wahl RC, 1999, J BIOL CHEM, V274, P26361, DOI 10.1074/jbc.274.37.26361; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	54	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					697	707		10.1038/sj.onc.1205115	http://dx.doi.org/10.1038/sj.onc.1205115			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850798				2022-12-28	WOS:000173427000001
J	Mercer, K; Chiloeches, A; Huser, M; Kiernan, M; Marais, R; Pritchard, C				Mercer, K; Chiloeches, A; Huser, M; Kiernan, M; Marais, R; Pritchard, C			ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf	ONCOGENE			English	Article						A-Raf; knockout; ERK activation; oncogene transformation	PROTEIN-KINASE; B-RAF; EXPRESSION; PROTOONCOGENES; STIMULATE; LETHALITY; MICE	Previous studies have indicated an important role for the Raf family of protein kinases in controlling cellular responses to extracellular stimuli and activated oncogenes, through their ability to activate the MEK/ERKs. To investigate the specific role of A-Raf in this process we generated A-Raf deficient mouse embryonic fibroblasts (MEFs) and embryonic stem (ES) cells by gene targeting and characterized their ability to undergo proliferation, differentiation, apoptosis, ERK activation, and transformation by oncogenic Ras and Src. The A-Raf deficient cells are not disrupted for any of these processes, despite the fact that this protein is normally expressed at high levels in both cell types. This implies either that A-Raf plays no role in MEK/ERK activation, that its function is fully compensated by other Raf proteins or MEK kinases or that its role in MEK/ERK activation is highly tissue-specific. Interestingly, B-Raf and Raf-1 activity towards MEK as measured by the immunoprecipitation kinase cascade assay are both significantly increased in the A-Raf deficient MEFs.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Inst Canc Res, London SW3 6JB, England; Univ Plymouth, Dept Biol Sci, Plymouth PL4 8AA, Devon, England	University of Leicester; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Plymouth	Pritchard, C (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	cap8@le.ac.uk	Chiloeches, Antonio/Z-5993-2019; Dorner, Martin/C-5703-2013	Marais, Richard/0000-0001-7484-4183; Pritchard, Catrin/0000-0003-1859-4487; Antonio, Chiloeches Galvez/0000-0001-7162-330X; Dorner, Martin/0000-0002-8176-797X				BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Luckett JCA, 2000, CELL GROWTH DIFFER, V11, P163; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SLADEK TL, 1992, ONCOGENE, V7, P1305; STORM SM, 1990, ONCOGENE, V5, P345; Treinies I, 1999, MOL CELL BIOL, V19, P321; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yuryev A, 2000, MOL CELL BIOL, V20, P4870, DOI 10.1128/MCB.20.13.4870-4878.2000	23	52	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					347	355		10.1038/sj.onc.1205101	http://dx.doi.org/10.1038/sj.onc.1205101			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821947				2022-12-28	WOS:000173311200003
J	Yang, L; Xia, L; Wu, DY; Wang, HB; Chansky, HA; Schubach, WH; Hickstein, DD; Zhang, Y				Yang, L; Xia, L; Wu, DY; Wang, HB; Chansky, HA; Schubach, WH; Hickstein, DD; Zhang, Y			Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor	ONCOGENE			English	Article						histone methyltransferase; ESET; ERG	HUMAN MYELOID-LEUKEMIA; EWINGS-SARCOMA; CHROMOSOMAL TRANSLOCATION; EWS-ERG; GENE; PROTEINS; DOMAIN; FAMILY; RNA; METHYLATION	The ets-related gene erg encodes a transcription factor that is implicated in the control of cell growth and differentiation. To identify interacting partners of ERG, we screened a yeast two-hybrid cDNA library constructed from mouse hematopoietic cells using the N-terminal region of ERG as a bait. We isolated a 4.6 kb full-length mouse cDNA encoding a 1307-amino acid protein migrating as a 180 kD band, which was termed ESET (ERG-associated protein with SET domain). ESET is 92% identical to the human protein SETDB1 (SET domain, bifurcated 1). The interaction between ESET and ERG was supported by in vitro pull-down using glutathione S-transferase (GST) fusion protein, by transfection and co-immunoprecipitation experiments, and by association of endogenous SETDB1 with ERG. Since ESET possesses evolutionarily conserved SET, preSET, and postSET domains implicated in histone methylation, we tested the ability of ESET to methylate core histones. The results of these studies demonstrated that ESET is a histone H3-specific methyltransferase, and that mutations within ESET abolished its methyltransferase activity. Together, these findings raise the possibility that transcription factor ERG may participate in transcriptional regulation through ESET-mediated histone methylation.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; NCI, Dept Expt Transplantat & Immunol, Bethesda, MD 20892 USA; Univ Washington, Dept Med Oncol, Seattle, WA 98108 USA; Univ Washington, Dept Orthoped, Seattle, WA 98108 USA; Univ Washington, VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Zhang, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.			Wang, Hengbin/0000-0003-2414-0609	NIGMS NIH HHS [GM63067-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063067] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Harte PJ, 1999, CYTOGENET CELL GENET, V84, P83, DOI 10.1159/000015220; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Im YH, 2000, CANCER RES, V60, P1536; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; Raouf A, 2000, ONCOGENE, V19, P6455, DOI 10.1038/sj.onc.1204037; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TACHIBANA M, 2001, J BIOL CHEM, V20, P20; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	30	198	207	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					148	152		10.1038/sj.onc.1204998	http://dx.doi.org/10.1038/sj.onc.1204998			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791185				2022-12-28	WOS:000172887800015
J	Boyd, M; Mairs, RJ; Mairs, SC; Wilson, L; Livingstone, A; Cunningham, SH; Brown, MM; Quigg, M; Keith, WN				Boyd, M; Mairs, RJ; Mairs, SC; Wilson, L; Livingstone, A; Cunningham, SH; Brown, MM; Quigg, M; Keith, WN			Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [I-131]MIBG and clonogenic cell kill	ONCOGENE			English	Article						gene therapy; hTR promoter; noradrenaline transporter; [I-131]MIBG; spheroids	THYMIDINE KINASE GENE; COLORECTAL-CARCINOMA; THERAPY; TUMOR; NEUROBLASTOMA; RADIOTHERAPY; CANCER; LINES	One of the most effective ways to kill cancer cells is by treatment of tumours with radiation. However, the administered dose of radiation to the tumour is limited by normal tissue toxicity. Strategies which decrease normal tissue exposure relative to tumour dose are urgently sought. One such promising scheme involves gene transfer, leading to the introduction of transporters specific for pharmaceuticals which can be labelled with radionuclides. We have previously demonstrated in vitro, that transfer of the noradrenaline transporter (NAT) gene, under viral promoter control, induces in host cells the active accumulation of the radiopharmaceutical [I-131]meta-iodobenzylguanidine ([I-131],MIBG) which results in kill of clonogens. We now report 17-fold enhancement of [I-131]MIBG uptake by UVW glioma cells transfected with the NAT gene whose expression is driven by the human telomerase RNA (hTR) promoter (70% the uptake achieved by the strong viral promoter). Multicellular spheroids composed of hTR-NAT-transfected UVW cells exhibited dose-dependent susceptibility to treatment with [I-131]MIBG. This was demonstrated by decreased survival of clonogens and complete sterilization of clonogens derived from spheroids and also failure of spheroids to regrow after administration of 7 MBq/ml [I-131]MIBG. These data suggest hTR regulated expression of NAT may be an effective gene therapy strategy.	Univ Glasgow, Dept Radiat Oncol, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Yorkhill Hosp, Dept Child Hlth, Glasgow, Lanark, Scotland; Western Infirm, Beatson Oncol Ctr, Dept Clin Phys, Glasgow, Lanark, Scotland; Gartnavel Hosp, Dept Urol, Glasgow, Lanark, Scotland; Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow; Beatson Oncology Centre; Beatson Institute; University of Glasgow	Boyd, M (corresponding author), Univ Glasgow, Dept Radiat Oncol, CRC, Beatson Labs, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.		Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Boyd, Marie/0000-0003-4120-2218				Boyd M, 2001, J GENE MED, V3, P165, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM158>3.0.CO;2-C; Boyd M, 1999, GENE THER, V6, P1147, DOI 10.1038/sj.gt.3300905; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brown JM, 1998, CANCER RES, V58, P1408; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cao G, 1999, GENE THER, V6, P83, DOI 10.1038/sj.gt.3300823; Chen J, 1998, CANCER RES, V58, P3504; Cunningham SH, 1998, BRIT J CANCER, V77, P2061, DOI 10.1038/bjc.1998.348; DEKRAKER J, 1995, EUR J CANCER, V31A, P600, DOI 10.1016/0959-8049(95)00063-O; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Gaze MN, 1996, EUR J CANCER, V32A, P93, DOI 10.1016/0959-8049(95)00511-0; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; Hoefnagel CA, 2001, EUR J NUCL MED, V28, P359, DOI 10.1007/s002590000454; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; Kanai F, 1996, HEPATOLOGY, V23, P1359, DOI 10.1002/hep.510230611; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Lavelle F, 2000, CRIT REV ONCOL HEMAT, V34, P111, DOI 10.1016/S1040-8428(00)00057-3; Meller S, 1997, ARCH DIS CHILD, V77, P389, DOI 10.1136/adc.77.5.389; Nettelbeck DM, 1999, GENE THER, V6, P1276, DOI 10.1038/sj.gt.3300943; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Tahara H, 1999, ONCOGENE, V18, P1561, DOI 10.1038/sj.onc.1202458; Vandier D, 1998, CANCER RES, V58, P4577; Wheldon TE, 2000, PHYS MED BIOL, V45, pR77, DOI 10.1088/0031-9155/45/7/201; Zhao JQ, 1998, ONCOGENE, V16, P1345, DOI 10.1038/sj.onc.1201892	29	30	33	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7804	7808		10.1038/sj.onc.1204955	http://dx.doi.org/10.1038/sj.onc.1204955			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753659				2022-12-28	WOS:000172161700012
J	Wang, TT; Fan, LQ; Watanabe, Y; McNeill, P; Fanger, GR; Persing, DH; Reed, SG				Wang, TT; Fan, LQ; Watanabe, Y; McNeill, P; Fanger, GR; Persing, DH; Reed, SG			L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma	ONCOGENE			English	Article						tumor antigen; lung adenocarcinoma; lung squamous cell carcinoma (LSCC); XAGE-1; cancer testis antigen	CYTOLYTIC T-LYMPHOCYTES; CANCER/TESTIS ANTIGENS; INSITU HYBRIDIZATION; HUMAN-MELANOMA; GENES; IDENTIFICATION; SARCOMA; FAMILY; CANCER	Using a combination of cDNA subtraction and microarray analysis, we report here the identification and characterization of L552S, an over-expressed, alternatively spliced isoform of XAGE-1 in lung adenocarcinoma. Real-time RT-PCR analysis shows that L552S is expressed at levels greater than 10-fold in 12 of 25 lung adenocarcinoma tumors compared with the highest expression level found in all normal tissues tested. L552S is expressed in both early and late stages of lung adenocarcinoma, but it was not detected in large cell carcinoma, small cell carcinoma, or atypical lung neuroendocrine carcinoid. The full-length cDNA for L552S comprises 770 bp and encodes a polypeptide of 160 amino acids. C-terminal 94 amino acids of L552S are identical to a cancer testis antigen, XAGE-1, found in Ewing's sarcoma. Genomic sequence analysis has revealed that L552S and XAGE-1 are alternatively spliced isoforms, and expression of both L552S and XAGE-1 isoforms are present in lung adenocarcinoma. Immunohistochemistry analysis using affinity purified L552S polyclonal antibodies demonstrated specific nuclear staining in 10 of 12 lung adenocarcinoma samples. Furthermore, antibody responses to recombinant L552S protein were observed in seven of 17 lung pleural effusion fluids of lung cancer patients. These results strongly imply that L552S protein is immunogenic and suggest that it might have use as a vaccine target for lung cancer.	Corixa Corp, Dept Tumor Antigen Discovery, Seattle, WA 98104 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	Corixa; University of Washington; University of Washington Seattle	Wang, TT (corresponding author), Corixa Corp, Dept Tumor Antigen Discovery, 1124 Columbia St, Seattle, WA 98104 USA.							BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0; Brinckerhoff LH, 2000, CURR OPIN ONCOL, V12, P163, DOI 10.1097/00001622-200003000-00012; Brinkmann U, 1999, CANCER RES, V59, P1445; Chen YT, 1999, CANCER J SCI AM, V5, P16; Chen YT, 1998, P NATL ACAD SCI USA, V95, P6919, DOI 10.1073/pnas.95.12.6919; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Jungbluth AA, 2000, BRIT J CANCER, V83, P493, DOI 10.1054/bjoc.2000.1291; Liu XF, 2000, CANCER RES, V60, P4752; Martelange V, 2000, CANCER RES, V60, P3848; Robbins PF, 1996, CURR OPIN IMMUNOL, V8, P628, DOI 10.1016/S0952-7915(96)80078-1; Tureci O, 1996, CANCER RES, V56, P4766; Tureci O, 1998, P NATL ACAD SCI USA, V95, P5211, DOI 10.1073/pnas.95.9.5211; VANDENEYNDE B, 1995, J EXP MED, V182, P689, DOI 10.1084/jem.182.3.689; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Yoshimatsu T, 1998, J SURG ONCOL, V67, P126	17	31	37	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7699	7709		10.1038/sj.onc.1204939	http://dx.doi.org/10.1038/sj.onc.1204939			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753648				2022-12-28	WOS:000172161700001
J	Yamaguchi, H; Wang, HG				Yamaguchi, H; Wang, HG			The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change	ONCOGENE			English	Article						IL-3; Akt; Bax conformational change; apoptosis; mitochondria	CYTOCHROME-C RELEASE; BCL-2 FAMILY PROTEINS; NF-KAPPA-B; DEATH; MITOCHONDRIA; AKT; ACTIVATION; TRANSLOCATION; PHOSPHORYLATION; MEMBERS	The serine-threonine kinase Akt exerts its anti-apoptotic effects through several downstream targets, including the pro-apoptotic Bcl-2 family member Bad, Forkhead transcription factors, and the cyclic AMT response element-binding protein (CREB). In this report we demonstrate that Akt inhibits a conformational change in the pro-apoptotic Bax protein and its translocation to mitochondria, thus preventing the disruption of the mitochondrial inner membrane potential (Delta psi (m)), caspase-3 activation, and apoptosis in pre-B hematopoietic cells FL5.12 following interleukin-3 (IL-3) withdrawal. Inhibition of PI-3 kinase, but not MAPK kinase, promotes this conformational change in Bax. Moreover, overexpression of Akt suppresses the relocalization of GFP-Bax to mitochondria and apoptosis in Hela cells induced by the DNA-damaging agent methyl methanesulphonate. However, Akt does not abolish the ability of a conformationally changed Bax mutant, GFP-Bax (Delta S184), to translocate to mitochondria and to induce apoptosis. These findings indicate that Akt exerts its anti-apoptotic effects in cells at a premitochondrial stage, at least in part, by inhibiting Bax conformational change and its redistribution to the mitochondrial membranes.	Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program,Dept Interdisciplinary Onc, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wang, HG (corresponding author), Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program,Dept Interdisciplinary Onc, 12902 Magnolia Dr, Tampa, FL 33612 USA.	wanghg@moffitt.usf.edu	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NATIONAL CANCER INSTITUTE [R01CA082197] Funding Source: NIH RePORTER; NCI NIH HHS [CA82197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ozes ON, 1999, NATURE, V401, P82; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	46	327	334	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7779	7786		10.1038/sj.onc.1204984	http://dx.doi.org/10.1038/sj.onc.1204984			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753656				2022-12-28	WOS:000172161700009
J	Seo, YR; Sweeney, C; Smith, ML				Seo, YR; Sweeney, C; Smith, ML			Selenomethionine induction of DNA repair response in human fibroblasts	ONCOGENE			English	Article						cancer-chemoprevention; selenium; nutrition; DNA-repair	NUCLEOTIDE EXCISION-REPAIR; SELENIUM-COMPOUNDS; CANCER PREVENTION; MAMMARY-CANCER; TRIPHENYLSELENONIUM CHLORIDE; CHEMOPREVENTION; GROWTH; P53; SUPPLEMENTATION; SELENOPROTEINS	Selenium compounds have a long history in chemoprevention of mammary and colon cancers in rodent models. Selenium compounds are in current clinical trials, having shown promise in prevention of prostate and other human cancers. In human tissues, it has been estimated that each cell sustains approximately 10 000 potentially mutagenic (if not repaired) lesions per day due to endogenous DNA damage. Almost no studies have addressed the potential for selenium compounds to induce DNA repair, a potential mechanism for their cancer-preventive actions. We show that selenium in the form of selenomethionine induces a DNA repair response in normal human fibroblasts in vitro, and protects cells from DNA damage. We show a possible mechanism for the inducible DNA repair response, in which enhanced repair complex formation was observed in selenomethionine-treated cells.	Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Hematol Oncol Sect, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Smith, ML (corresponding author), Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, 1044 W Walnut,Room 155, Indianapolis, IN 46202 USA.	marlsmit@iupui.edu						ABOUSSEKHRA A, 1995, EXP CELL RES, V221, P326, DOI 10.1006/excr.1995.1382; Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; Ames BN, 1997, ENVIRON HEALTH PERSP, V105, P865, DOI 10.2307/3433296; Baines AT, 2000, CANCER LETT, V160, P193, DOI 10.1016/S0304-3835(00)00585-1; Berggren MM, 1999, BIOCHEM PHARMACOL, V57, P187, DOI 10.1016/S0006-2952(98)00283-4; Cheo DL, 1999, CANCER RES, V59, P771; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6; Combs G F Jr, 1997, Biomed Environ Sci, V10, P356; DOETSCH PW, 1995, BIOCHEMISTRY-US, V34, P737, DOI 10.1021/bi00003a005; Ganesan AK, 1999, MUTAT RES-DNA REPAIR, V433, P117, DOI 10.1016/S0921-8777(98)00070-6; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gniadecki R, 2000, J CELL BIOCHEM, V80, P216; Grossman L, 1997, ENVIRON HEALTH PERSP, V105, P927, DOI 10.2307/3433305; He ZG, 1997, NUCLEIC ACIDS RES, V25, P1136, DOI 10.1093/nar/25.6.1136; Ip C, 1999, ANTICANCER RES, V19, P2875; IP C, 1981, CANCER RES, V41, P4386; Ip C, 1998, ANTICANCER RES, V18, P9; IP C, 1994, CARCINOGENESIS, V15, P187, DOI 10.1093/carcin/15.2.187; IP C, 1994, CARCINOGENESIS, V15, P2879, DOI 10.1093/carcin/15.12.2879; Karmakar P, 2001, MUTAGENESIS, V16, P225, DOI 10.1093/mutage/16.3.225; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LU JX, 1995, BIOCHEM PHARMACOL, V50, P213, DOI 10.1016/0006-2952(95)00119-K; Morris EJ, 1999, BIOTECHNIQUES, V26, P282, DOI 10.2144/99262st02; Parshad R, 1996, BRIT J CANCER, V74, P1, DOI 10.1038/bjc.1996.307; Patterson BH, 1997, CANCER EPIDEM BIOMAR, V6, P63; Redman C, 1998, CANCER LETT, V125, P103, DOI 10.1016/S0304-3835(97)00497-7; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Sinha R, 1996, CANCER LETT, V107, P277, DOI 10.1016/0304-3835(96)04373-X; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Stewart MS, 1999, FREE RADICAL BIO MED, V26, P42, DOI 10.1016/S0891-5849(98)00147-6; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001	38	96	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3663	3669		10.1038/sj.onc.1205468	http://dx.doi.org/10.1038/sj.onc.1205468			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032834				2022-12-28	WOS:000175676000001
J	Kuo, MT; Liu, ZS; Wei, YJ; Lin-Lee, YC; Tatebe, S; Mills, GB; Unate, H				Kuo, MT; Liu, ZS; Wei, YJ; Lin-Lee, YC; Tatebe, S; Mills, GB; Unate, H			Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappa B signaling	ONCOGENE			English	Article						2-acetylaminofluorene; MDR; P13 kinase; Akt; rac	TUMOR-SUPPRESSOR GENE; MULTIDRUG-RESISTANCE; PHOSPHATIDYLINOSITOL 3-KINASE; P-GLYCOPROTEIN; PROTEIN-KINASE; HEPATOCELLULAR-CARCINOMA; PROMOTER ACTIVITY; NADPH OXIDASE; RHO GTPASES; HEAT-SHOCK	The expression of P-glycoprotein encoded by the multidrug resistance (MDR1) gene is associated with the emergence of the NIDR phenotype in cancer cells. Human MDR1 and its rodent homolog mdr1a and mdr1b are frequently overexpressed in liver cancers. However, the underlying mechanisms are largely unknown. The hepatocarcinogen 2-acetylaminofluorene (2-AAF) efficiently activates rat mdr1b expression in cultured cells and in Fisher 344 rats. We recently reported that activation of rat mdr1b in cultured cells by 2-AAF involves a cis-activating element containing a NF-kappaB binding site located - 167 to - 158 of the rat mdr1b promoter. 2-AAF activates IkappaB kinase (IKK), resulting in degradation of IkappaBbeta and activation of NF-kappaB. In this study, we report that 2-AAF could also activate the human MDR1 gene in human hepatoma and embryonic fibroblast 293 cells. Induction of MDR1 by AAF was mediated by DNA sequence located at -6092 which contains a NF-kappaB binding site. Treating hepatoma cells with 2-AAF activated phosphoinositide 3-kinase (PI3K) and its downstream effectors Rac1, and NAD(P)H oxidase. Transient transfection assays demonstrated that constitutively activated PI3K and Rac1 enhanced the activation of the MDR1 promoter by 2-AAF. Treatment of hepatoma cells with 2-AAF also activated another PI3K downstream effector Akt. Transfection of recombinant encoding a dominant activated Akt also enhanced the activation of MDR1 promoter activation by 2-AAF. These results demonstrated that 2-AAF up-regulates MDR1 expression is mediated by the multiple effectors of the PI3K signaling pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuo, MT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.	tkuo@mail.mdanderson.org			NCI NIH HHS [CA16672, CA79085, CA72404] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072404, P30CA016672, R01CA079085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Borst P, 1997, SEMIN CANCER BIOL, V8, P131, DOI 10.1006/scbi.1997.0072; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHIN KV, 1990, J BIOL CHEM, V265, P221; Cieslik K, 2001, J BIOL CHEM, V276, P1211, DOI 10.1074/jbc.M005305200; CORNWELL MM, 1993, J BIOL CHEM, V268, P15347; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; Deng L, 2001, J BIOL CHEM, V276, P413, DOI 10.1074/jbc.M004551200; DENG LS, 2001, IN PRESS CLIN RELEVA; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujiwara Y, 2000, JPN J CANCER RES, V91, P287, DOI 10.1111/j.1349-7006.2000.tb00943.x; Hopkin K, 1998, SCIENCE, V282, P1027, DOI 10.1126/science.282.5391.1027; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Ng IOL, 2000, AM J CLIN PATHOL, V113, P355, DOI 10.1309/AC1M-4TY4-U0TN-EN7T; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; OZES MN, 2000, NATURE, V406, P307; Ozes ON, 1999, NATURE, V401, P82; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POIRIER MC, 1991, CARCINOGENESIS, V12, P895, DOI 10.1093/carcin/12.5.895; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHEN CJ, 1990, J BIOL CHEM, V265, P506; SILVERMAN JA, 1995, MOL CARCINOGEN, V13, P50, DOI 10.1002/mc.2940130109; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Soini Y, 1996, J CLIN PATHOL, V49, P470, DOI 10.1136/jcp.49.6.470; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; TEETER LD, 1993, MOL CARCINOGEN, V8, P67, DOI 10.1002/mc.2940080202; TEETER LD, 1993, INT J ONCOL, V2, P73; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Verna L, 1996, PHARMACOL THERAPEUT, V71, P83, DOI 10.1016/0163-7258(96)00063-0; Vilaboa NE, 2000, J BIOL CHEM, V275, P24970, DOI 10.1074/jbc.M909136199; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; Yeh KT, 2000, CANCER INVEST, V18, P123, DOI 10.3109/07357900009038243; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhou G, 1996, CELL GROWTH DIFFER, V7, P1369	72	174	187	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1945	1954		10.1038/sj.onc.1205117	http://dx.doi.org/10.1038/sj.onc.1205117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960367				2022-12-28	WOS:000174827000001
J	Driouch, K; Prydz, H; Monese, R; Johansen, H; Lidereau, R; Frengen, E				Driouch, K; Prydz, H; Monese, R; Johansen, H; Lidereau, R; Frengen, E			Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors	ONCOGENE			English	Article						breast cancer; expression analysis; tumor suppressor genes	FRAGILE SITE FRA16D; CHROMOSOME ARM 16Q; ALLELIC IMBALANCE; MULTIPLE-MYELOMA; PROSTATE-CANCER; DELETED REGIONS; HIGH-FREQUENCY; HETEROZYGOSITY; CARCINOMAS; PROGRESSION	The presence of putative tumor-suppressor genes on chromosome 16q23.2-24.1 has been suggested by LOH analysis in several cancer types. This region overlaps with the fragile site FRA16D and the region of homozygous deletions found in several cancer types. The candidate gene WWOX/FOR has been mapped within this region. The mouse homologue of the WWOX protein has been defined as an apoptogenic protein and an essential partner of p53 in cell death, supporting WWOX as a tumor suppressor gene candidate. We performed an expression study of the WWOX/FOR gene in a series of human breast tumors and breast cancer cell lines, and detected reduced expression of the WWOX/ FOR transcript in a series of breast cancer cells. Furthermore, identification of two distinct alternative WWOX transcripts expressed at high levels in human tumors suggests an involvement of the WWOX gene in breast cancer progression.	Ctr Rene Huguenin, INSERM E0017, F-92211 St Cloud, France; Univ Oslo, Ctr Biotechnol, N-0349 Oslo, Norway	Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; University of Oslo	Driouch, K (corresponding author), Ctr Rene Huguenin, INSERM E0017, 35 Rue Dailly, F-92211 St Cloud, France.			Frengen, Eirik/0000-0002-8387-2247				ALDAZ CM, 1995, CANCER RES, V55, P3976; Bednarek AK, 2000, CANCER RES, V60, P2140; Bieche I, 1999, CANCER RES, V59, P2546; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; DENG G, 1994, CANCER RES, V54, P499; DORIONBONNET F, 1995, GENE CHROMOSOME CANC, V14, P171, DOI 10.1002/gcc.2870140304; Driouch K, 1997, GENE CHROMOSOME CANC, V19, P185, DOI 10.1002/(SICI)1098-2264(199707)19:3<185::AID-GCC8>3.0.CO;2-U; Driouch K, 1998, CANCER RES, V58, P2081; Elo JP, 1997, CANCER RES, V57, P3356; Frengen E, 2000, GENOMICS, V68, P118, DOI 10.1006/geno.2000.6286; Grundy RG, 1998, BRIT J CANCER, V78, P1181, DOI 10.1038/bjc.1998.651; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; LARSEN F, 1992, GENET ANAL-BIOMOL E, V9, P80, DOI 10.1016/1050-3862(92)90002-M; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; LATIF F, 1992, CANCER RES, V52, P1451; Latil A, 1997, CANCER RES, V57, P1058; Li CD, 1999, GENE CHROMOSOME CANC, V24, P175, DOI 10.1002/(SICI)1098-2264(199903)24:3<175::AID-GCC1>3.3.CO;2-8; LINDBLOM A, 1993, CANCER RES, V53, P3707; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Mashimo T, 1998, CANCER RES, V58, P4572; Osoegawa K, 2001, GENOME RES, V11, P483, DOI 10.1101/gr.169601; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Paige AJW, 2000, CANCER RES, V60, P1690; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; SATO T, 1991, CANCER RES, V51, P5794; SHEN Y, 1994, GENOMICS, V22, P68, DOI 10.1006/geno.1994.1346; SKIRNISDOTTIR S, 1995, INT J CANCER, V64, P112, DOI 10.1002/ijc.2910640207; Suzuki H, 1996, GENE CHROMOSOME CANC, V17, P225, DOI 10.1002/(SICI)1098-2264(199612)17:4<225::AID-GCC4>3.0.CO;2-5; TAKITA K, 1992, CANCER RES, V52, P3914; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; TSUDA H, 1994, CANCER RES, V54, P513; Watson JEV, 1999, GENOME RES, V9, P226	38	94	97	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1832	1840		10.1038/sj.onc.1205273	http://dx.doi.org/10.1038/sj.onc.1205273			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896615				2022-12-28	WOS:000174284500005
J	Gasco, M; Sullivan, A; Repellin, C; Brooks, L; Farrell, PJ; Tidy, JA; Dunne, B; Gusterson, B; Evans, DJ; Crook, T				Gasco, M; Sullivan, A; Repellin, C; Brooks, L; Farrell, PJ; Tidy, JA; Dunne, B; Gusterson, B; Evans, DJ; Crook, T			Coincident inactivation of 14-3-3 sigma and p16(INK4a) is an early event in vulval squamous neoplasia	ONCOGENE			English	Article						14-3-3 sigma; p16(INK4a); vulval cancer; CpG methylation	PRIMARY HUMAN KERATINOCYTES; HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; 5'-CPG ISLAND; CPG ISLANDS; CARCINOMA; GENE; HYPERMETHYLATION; CLONING; CANCER	The structure and expression of 14-3-3 sigma(sigma) was analysed in squamous carcinomas (SCC) of the vulva and in the vulval pre-malignant lesion vulval intraepithetial neoplasia (VIN). Sequence analysis of the sigma coding region did not detect mutations in any case of SCC or VIN III and loss of heterozygosity (LOH) occurred in only 2 out of 27 informative cases. In contrast to the absence of genetic change, methylation-specific PCR (MSP) analysis revealed dense CpG methylation within the a gene in approximately 60% of cases of vulval SCC, but methylation was not detected in matched, normal epithelial tissue. Methylation was associated in all cases with reduced or absent expression of a mRNA. There was no correlation between sigma methylation and HPV or p53 status. Analysis of pre-malignant vulval intraepithelial neoplasia (VIN) revealed that sigma methylation was detectable early in neoplastic development. Coincident methylation, accompanied by loss of expression, of sigma and p16(INK4a) was commonly detected in both SCC and VIN 111, suggesting that epigenetic silencing of these two genes is an early and important event in vulval neoplasia.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, London W2 1PG, England; Azienda Osped S Croce & Carle, UO Oncol Med, I-12100 Cuneo, Italy; Univ Sheffield, No Gen Hosp, Dept Gynaecol Oncol, Sheffield S5 7AU, S Yorkshire, England; Univ Glasgow, Western Infirm, Dept Pathol, Glasgow G11 6NT, Lanark, Scotland; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Histopathol, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research; Northern General Hospital; University of Sheffield; University of Glasgow; Imperial College London	Crook, T (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.		gusterson, barry a/D-3752-2009	Farrell, Paul/0000-0002-6754-9351				Basta A, 1999, EUR J GYNAECOL ONCOL, V20, P111; Brooks LA, 2000, CANCER RES, V60, P6875; CRUM CP, 1992, OBSTET GYNECOL, V79, P448, DOI 10.1097/00006250-199203000-00025; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Jones RW, 2000, OBSTET GYNECOL, V96, P470, DOI 10.1016/S0029-7844(00)00949-2; JONES RW, 1994, OBSTET GYNECOL, V84, P741; Kagie MJ, 1997, GYNECOL ONCOL, V67, P178, DOI 10.1006/gyno.1997.4834; LEE YY, 1994, ONCOGENE, V9, P1655; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; Munro J, 1999, CANCER RES, V59, P2516; O'Nions J, 2001, BRIT J CANCER, V85, P1551, DOI 10.1054/bjoc.2001.2138; Pinto AP, 1999, AM J PATHOL, V154, P1009, DOI 10.1016/S0002-9440(10)65353-9; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; SMITS HL, 1992, J GEN VIROL, V73, P3263, DOI 10.1099/0022-1317-73-12-3263; Suzuki H, 2000, CANCER RES, V60, P4353; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9	26	84	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1876	1881		10.1038/sj.onc.1205256	http://dx.doi.org/10.1038/sj.onc.1205256			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896620				2022-12-28	WOS:000174284500010
J	Platt, G; Carbone, A; Mittnacht, S				Platt, G; Carbone, A; Mittnacht, S			P16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma	ONCOGENE			English	Article						p16INK4a; retinoblastoma (Rb); Kaposi's sarcoma associated herpes virus (KSHV); human herpesvirus 8 (HHV8); primary effusion lymphoma (PEL)	KAPOSIS-SARCOMA; T-CELL; HOMOZYGOUS DELETIONS; DNA-SEQUENCES; RETINOBLASTOMA-PROTEIN; NUCLEAR ANTIGEN; B-CELL; CYCLIN; EXPRESSION; GENES	The Kaposi's Sarcoma associated Herpes virus (KSHV) encodes two genes with the potential to affect the activity of the retinoblastoma protein (Rb). Open reading frame (orf) 72 encodes a D type cyclin (kcyc) that can elicit p16INK4a resistant cdk activity and orf73 encodes the latency associated nuclear antigen (LNA) that can bind Rb and neutralize E2F regulation. This indicates that, like papilloma and adenovirus associated malignancies, those associated with KSHV are defective with respect to their Rb pathway. To address this we investigated whether KSHV associated primary effusion lymphoma (PEL) derived cell lines are resistant to growth inhibition by p16INK4a. We provide evidence that ectopic expression of p16INK4a in these cells causes an Rb dependent G1 cell cycle block. Importantly, endogenous p16INK4a expression is not detected in six PEL derived cell lines and four primary PEL samples and examination of the p16INK4a locus shows deletion in two out of six and hypermethylation in four out of six PEL lines. Treatment of the latter with the demethylating agent 5'-aza-2' deoxycytidine leads to re-expression of p16INK4a protein. Taken together these results suggest that p16INK4a loss may be a cellular change frequently associated with PEL. They furthermore argue that despite the presence of KSHV DNA and expression of a latent gene program Rb function is intact in PEL.	Inst Canc Res, Chester Beatty Labs, Ctr Mol & Cell Biol, London SW3 6JB, England; Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Div Pathol, Aviano, Italy	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; IRCCS Aviano (CRO)	Mittnacht, S (corresponding author), Inst Canc Res, Chester Beatty Labs, Ctr Mol & Cell Biol, 237 Fulham Rd, London SW3 6JB, England.	sibylle@icr.ac.uk	Carbone, Antonino/AAA-2217-2019	Carbone, Antonino/0000-0003-2211-639X				Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Boshoff C, 1998, BLOOD, V91, P1671, DOI 10.1182/blood.V91.5.1671.1671_1671_1679; Carbone A, 2000, AM J PATHOL, V156, P1209, DOI 10.1016/S0002-9440(10)64991-7; Carbone A, 2000, LEUKEMIA, V14, P1301, DOI 10.1038/sj.leu.2401802; Carbone A, 2000, BRIT J HAEMATOL, V111, P247, DOI 10.1046/j.1365-2141.2000.02329.x; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Child ES, 2001, ONCOGENE, V20, P3311, DOI 10.1038/sj.onc.1204447; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Gaidano G, 1999, GENE CHROMOSOME CANC, V24, P16, DOI 10.1002/(SICI)1098-2264(199901)24:1<16::AID-GCC3>3.0.CO;2-F; Gessain A, 1997, LEUKEMIA, V11, P266, DOI 10.1038/sj.leu.2400549; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kellam P, 1997, J Hum Virol, V1, P19; KELLEY MJ, 1995, INT J CANCER, V63, P226, DOI 10.1002/ijc.2910630214; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Klangby U, 1998, BLOOD, V91, P1680, DOI 10.1182/blood.V91.5.1680.1680_1680_1687; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Oksenhendler E, 1998, NEW ENGL J MED, V338, P1585, DOI 10.1056/NEJM199805283382204; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Pinyol M, 1998, BLOOD, V91, P2977, DOI 10.1182/blood.V91.8.2977.2977_2977_2984; Platt GM, 2000, VIROLOGY, V272, P257, DOI 10.1006/viro.2000.0343; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SILL H, 1995, BLOOD, V85, P2013, DOI 10.1182/blood.V85.8.2013.bloodjournal8582013; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Villuendas R, 1998, AM J PATHOL, V153, P887, DOI 10.1016/S0002-9440(10)65630-1; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778	46	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1823	1831		10.1038/sj.onc.1205360	http://dx.doi.org/10.1038/sj.onc.1205360			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896614				2022-12-28	WOS:000174284500004
J	Dhanalakshmi, S; Singh, RP; Agarwal, C; Agarwal, R				Dhanalakshmi, S; Singh, RP; Agarwal, C; Agarwal, R			Silibinin inhibits constitutive and TNF alpha-induced activation of NF-alpha B and sensitizes human prostate carcinoma DU145 cells to TNF alpha-induced apoptosis	ONCOGENE			English	Article						prostate cancer; NF-kappa B; apoptosis; silibinin	I-KAPPA-B; TUMOR-NECROSIS-FACTOR; FLAVONOID ANTIOXIDANT SILYMARIN; CANCER-CELLS; MEDIATED APOPTOSIS; CYCLOOXYGENASE 2; DNA-SYNTHESIS; KINASE; EXPRESSION; GROWTH	Prostate cancer (PCA) is one of the most common invasive malignancies of men in the US, however, there have been Limited successes so far in its therapy. Even most potent agents (e.g. TNFalpha) are ineffective in killing human PCA cells possibly due to constitutive activation of NF-kappaB that subsequently activates a large number of anti-apoptotic genes. In such a scenario, strong apoptotic agent TNFalpha, further induces NF-kappaB activation rather than inducing apoptosis. In several recent studies, we have demonstrated both cancer preventive and anti-cancer efficacy of silymarin and its constituent silibinin in a variety of experimental tumor models and cell culture systems. Here we examined whether silibinin is effective in inhibiting constitutive NF-kappaB activation in human PCA cells, which would help in overcoming TNFY-insensitivity. Our studies reveal that silibinin effectively inhibits constitutive activation of NF-kappaB in advanced human prostate carcinoma DU145 cells. Consistent with this, nuclear levels of p65 and p50 sub-units of NF-kappaB were also reduced. In the studies assessing molecular mechanism of this effect, silibinin treatment resulted in a significant increase in the level of IkappaBalpha with a concomitant decrease in phospho-IkappaBalpha. Kinase assays revealed that silibinin dose-dependently decreases IKKalpha kinase activity. The effect of silibinin on IKKalpha seemed to be direct as evidenced by the in vitro kinase assay, where immunoprecipitated IKKalpha was incubated with silibinin. This shows that silibinin does not necessarily need an upstream event to bring about its inhibitory effect on IKKalpha and downstream effectors. Additional studies showed that silibinin also inhibits TNFalpha-induced activation of NF-kappaB via IkappaBalpha pathway and subsequently sensitizes DU145 cells to TNFa-induced apoptosis. These results indicate that silibinin could be used to enhance the effectiveness of TNFalpha-based chemotherapy in advanced PCA.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@uchsc.edu		Singh, Rana Pratap/0000-0003-4261-7044	NCI NIH HHS [CA64514, CA83741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064514, R01CA064514, R01CA083741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 1998, BIOCHEM BIOPH RES CO, V247, P294, DOI 10.1006/bbrc.1998.8748; BACUERLE PA, 1996, CELL, V87, P13; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Davis JN, 1999, NUTR CANCER, V35, P167, DOI 10.1207/S15327914NC352_11; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dong G, 1999, CANCER RES, V59, P3495; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; JONES S, 1997, WORKING PAPERS LIT, V1, P17; Lahiri-Chatterjee M, 1999, CANCER RES, V59, P622; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LETTERON P, 1990, BIOCHEM PHARMACOL, V39, P2027, DOI 10.1016/0006-2952(90)90625-U; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Manna SK, 1999, J IMMUNOL, V163, P6800; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; NAKAJIMA Y, 1995, UROL RES, V23, P205, DOI 10.1007/BF00393299; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Ripple MO, 1999, JNCI-J NATL CANCER I, V91, P1227, DOI 10.1093/jnci/91.14.1227; Rokhlin OW, 1997, CANCER RES, V57, P1758; Sharma Y, 2001, MOL CARCINOGEN, V30, P224, DOI 10.1002/mc.1032; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; SINHA BK, 1995, BBA-MOL BASIS DIS, V1270, P12, DOI 10.1016/0925-4439(94)00065-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X; WAGNER H, 1974, ARZNEIMITTEL-FORSCH, V24, P466; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Yu R, 2000, CANCER RES, V60, P2384; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhao JF, 1999, MOL CARCINOGEN, V26, P321, DOI 10.1002/(SICI)1098-2744(199912)26:4<321::AID-MC11>3.3.CO;2-0; Zi XL, 2000, CANCER RES, V60, P5617; Zi XL, 1998, CANCER RES, V58, P1920; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	59	140	144	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1759	1767		10.1038/sj.onc.1205240	http://dx.doi.org/10.1038/sj.onc.1205240			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896607				2022-12-28	WOS:000174214200014
J	Li, H; Myeroff, L; Kasturi, L; Krumroy, L; Schwartz, S; Willson, JKV; Stanbridge, E; Casey, G; Markowitz, S				Li, H; Myeroff, L; Kasturi, L; Krumroy, L; Schwartz, S; Willson, JKV; Stanbridge, E; Casey, G; Markowitz, S			Chromosomal autonomy of hMLH1 methylation in colon cancer	ONCOGENE			English	Article						colon cancer; methylation; hMLH1	DNA METHYLATION; FUNCTIONAL EVIDENCE; SUPPRESSOR GENE; PROMOTER; INACTIVATION; EXPRESSION	Silencing of hMLH1 expression by aberrant hMLH1 promoter methylation accounts for the majority of sporadic colon cancers with microsatellite instability. We have previously shown hMLH1 silencing is biallelic and actively maintained. To study the mechanism of aberrant hMLH1 methylation, we assayed whether an hMLH1 methylated cell could transfer methylation and silencing to an exogenous hMLH1 promoter in somatic cell hybrids between hMLH1 methylated-silenced and hMLH1 unmethylated-expressing colon cancer cells. Conversely, we assayed whether these hybrids could reactivate expression of initially methylated and silenced hMLH1 alleles. Compellingly, within the hybrids each hMLH1 allele remained unchanged, retaining the expression status of its parental cell of origin. This chromosomal autonomy may not be simply determined by DNA methylation, as it is reasserted after experimentally forced demethylation of all hMLH1 alleles in the hybrids. Confirming findings included hMLH1 methylated cells being unable to methylate single transferred exogenous hMLH1 expressing chromosomes or transfected hMLH1 reporter constructs. hMLH1 silencing does not conform to either a dominant or recessive model, and is not determined by trans-acting factors differing between hMLH1 expressing or silenced genomes. We posit that hMLH1 methylation is dependent on and maintained by cis chromosomal marks, whose nature remains to be elucidated.	Case Western Reserve Univ, Dept Microbiol & Mol Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Univ Calif Irvine, Irvine, CA 92697 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University Hospitals of Cleveland; Howard Hughes Medical Institute; Cleveland Clinic Foundation; Case Western Reserve University; University of California System; University of California Irvine	Markowitz, S (corresponding author), Case Western Reserve Univ, Dept Microbiol & Mol Biol, 2 Rm 200 11001 Cedar Rd, Cleveland, OH 44106 USA.	sxm10@po.cwru.edu			NCI NIH HHS [P30 CA43703, R01 CA67409, R01 CA72160] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067409, P30CA043703, R01CA072160] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arad U, 1998, BIOTECHNIQUES, V24, P760, DOI 10.2144/98245bm14; Baylin SB, 1998, ADV CANCER RES, V72, P141; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Deng GR, 1999, CANCER RES, V59, P2029; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; GEISER AG, 1989, CANCER RES, V49, P1572; Grady WM, 2001, CANCER RES, V61, P900; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hsieh CL, 2000, CURR OPIN GENET DEV, V10, P224, DOI 10.1016/S0959-437X(00)00064-2; Issa JP, 2000, ANN NY ACAD SCI, V910, P140; Ito E, 1999, BIOCHEM BIOPH RES CO, V256, P488, DOI 10.1006/bbrc.1999.0368; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Kane MF, 1997, CANCER RES, V57, P808; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Kuzmin I, 1999, ONCOGENE, V18, P5672, DOI 10.1038/sj.onc.1202959; LEE YW, 1995, MOL CELL BIOL, V15, P2547; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wiesner GL, 2001, J NATL CANCER I, V93, P635, DOI 10.1093/jnci/93.8.635; WILLSON JKV, 1987, CANCER RES, V47, P2704	26	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1443	1449		10.1038/sj.onc.1205247	http://dx.doi.org/10.1038/sj.onc.1205247			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857087				2022-12-28	WOS:000173861000014
J	Ramirez de Molina, A; Penalva, V; Lucas, L; Lacal, JC				Ramirez de Molina, A; Penalva, V; Lucas, L; Lacal, JC			Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K	ONCOGENE			English	Article						ras; oncogenes; choline kinase; Ras effectors; Raf; Ral-GDS; PI3K	PHOSPHOLIPASE-D; PHOSPHOINOSITIDE 3-KINASE; STRUCTURAL REQUIREMENTS; NIH 3T3-CELLS; CELL-CYCLE; V-SRC; ACTIVATION; CANCER; TRANSFORMATION; PROLIFERATION	Ras proteins are molecular switches that control signaling pathways critical in the onset of a variety of human cancers. The signaling pathways activated by Ras proteins are those controlled by its direct effectors such as the serine-threonine protein kinase Raf-1, the exchange factor for other GTPases Ral-GDS, and the lipid kinase PI3K. As a consequence of Ras activation, a number of additional enzymes are affected, including several members of the serine-threonine intracellular proteins kinases as well as enzymes related to phospholipid metabolism regulation such as phospholipases A2 and D, and choline kinase. The precise mechanisms by which ras oncogenes impinge into these later molecules and their relevance to the onset of the carcinogenic process is still not fully understood. Here we have investigated the mechanism of regulation of choline kinase by Ras proteins and found no direct link between PLD and choline kinase activation. We provide evidence that Ras proteins regulate the activity of choline kinase through its direct effectors Ral-GDS and PI3K, while the Raf pathways seems to be not relevant in this process. The importance of Ras-dependent activation of choline kinase is discussed.	CSIC, Inst Invest Biomed, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28049, Spain.		de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBADELLI A, 1999, ONCOGENE, V18, P1139; BERNHARED EJ, 2000, CANCER RES, V60, P6577; Bhakoo KK, 1996, CANCER RES, V56, P4630; BOS JL, 1989, CANCER RES, V49, P4682; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; CUADRADO A, 1993, ONCOGENE, V8, P2959; de Molina AR, 2001, BIOCHEM BIOPH RES CO, V285, P873, DOI 10.1006/bbrc.2001.5250; De molina AR, 2001, INT J ONCOL, V19, P5; DECERTAINES JD, 1993, NMR BIOMED, V6, P345, DOI 10.1002/nbm.1940060602; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; GRATAS C, 1993, ANTICANCER RES, V13, P1239; Guillemain I, 1998, BBA-MOL CELL RES, V1405, P161, DOI 10.1016/S0167-4889(98)00107-4; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; Hernandez-Alcoceba R, 2000, CELL MOL LIFE SCI, V57, P65, DOI 10.1007/s000180050499; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; Lacal J C, 2001, IDrugs, V4, P419; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; Lucas L, 2001, ONCOGENE, V20, P1110, DOI 10.1038/sj.onc.1204216; Lucas L, 2000, ONCOGENE, V19, P431, DOI 10.1038/sj.onc.1203323; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MALUMBRES M, 1999, REV ONCOLOGIA, V1, P66; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; MOODIE SA, 1995, ONCOGENE, V11, P447; Moore SM, 1998, CANCER RES, V58, P5239; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Muller SM, 2000, BIOCHEM BIOPH RES CO, V270, P892, DOI 10.1006/bbrc.2000.2531; Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349-7006.1999.tb00764.x; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUIZCABELLO J, 1992, NMR BIOMED, V5, P226, DOI 10.1002/nbm.1940050506; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH TAD, 1993, NMR BIOMED, V6, P318, DOI 10.1002/nbm.1940060506; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	55	95	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					937	946		10.1038/sj.onc.1205144	http://dx.doi.org/10.1038/sj.onc.1205144			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840339				2022-12-28	WOS:000173427100009
J	Dagon, Y; Dovrat, S; Vilchik, S; Hacohen, D; Shlomo, G; Sredni, B; Salzberg, S; Nir, U				Dagon, Y; Dovrat, S; Vilchik, S; Hacohen, D; Shlomo, G; Sredni, B; Salzberg, S; Nir, U			Double-stranded RNA-dependent protein kinase, PKR, down-regulates CDC2/cyclin B1 and induces apoptosis in non-transformed but not in v-mos transformed cells	ONCOGENE			English	Article						PKR; v-mos; cell cycle; CDC2	TUMOR-SUPPRESSOR P53; BREAST-CANCER CELLS; NF-KAPPA-B; XENOPUS-OOCYTES; MALIGNANT TRANSFORMATION; MAP KINASE; INTERFERON; EXPRESSION; ACTIVATION; P68	The interferon (IFN)-induced, double stranded RNA (dsRNA)-activated serine/threonine kinase, PKR, is a potent negative regulator of cell growth when overexpressed in yeast or mammalian cells. Paradoxically, while it can function as a tumor suppressor and inducer of apoptosis, it is overexpressed in a variety of human cancers. To resolve this enigma, we established cell-lines that overexpress PKR in non-transformed and in v-mos transformed CHO cells. Overexpression of PKR suppressed the proliferation of CHO cells by inducing a transient G0/G1 arrest, followed by a delayed G2/M arrest, which attenuated cell cycle progression. These effects were accompanied by early induction of p21/ WAF-1 and delayed downregulation of CDC2 and cyclin B1. Induction of proapoptotic activity of the ectopic PKR paralleled the onset of G2/M arrest in CHO cells. However, while transiently inducing p21/WAF-1, PKR did not impose G2/M arrest or apoptosis in v-mos-transformed cells, nor was CDC2 or cyclin B1 downregulated in those cells. These findings link the proapoptotic activity of PKR to the arrest of cell cycle at the G2/M phase. Consequently, the apoptotic activity of PKR could be counter-acted by an oncogene-like v-mos that overrides the G2/M arrest induced by PKR.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Nir, U (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Salzberg, Steven L/F-6162-2011; Dagon, Yossi/AAI-5882-2020; Salzberg, Steven/Q-6514-2019	Salzberg, Steven L/0000-0002-8859-7432; Salzberg, Steven/0000-0002-8859-7432				Afshari CA, 1997, ONCOGENE, V14, P3029, DOI 10.1038/sj.onc.1201157; BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; Chen F W, 1999, Int Rev Immunol, V18, P429, DOI 10.3109/08830189909088492; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CRADDOCK BL, 1995, BIOCHEM J, V309, P1009, DOI 10.1042/bj3091009; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gil J, 1999, MOL CELL BIOL, V19, P4653; Gil J, 2000, BIOCHEMISTRY-US, V39, P7521, DOI 10.1021/bi992868b; HAINES GK, 1993, VIRCHOWS ARCH B, V63, P289, DOI 10.1007/BF02899275; HAINES GK, 1992, VIRCHOWS ARCH B, V62, P151, DOI 10.1007/BF02899677; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; HAINES GK, 1993, ARCH OTOLARYNGOL, V119, P1142; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HENRY GL, 1994, J BIOL REG HOMEOS AG, V8, P15; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; KERR IM, 1977, NATURE, V268, P540, DOI 10.1038/268540a0; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Kishimoto T, 1999, DEV BIOL, V214, P1, DOI 10.1006/dbio.1999.9393; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; Kronfeld-Kinar Y, 1999, CELL GROWTH DIFFER, V10, P201; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Li SY, 2000, EUR J BIOCHEM, V267, P1598, DOI 10.1046/j.1432-1327.2000.01134.x; Li SY, 2001, J BIOL CHEM, V276, P13881, DOI 10.1074/jbc.M008140200; LOHKA MJ, 1989, J CELL SCI, V92, P131; LORCA T, 1993, PATHOL BIOL, V41, P260; Lu JF, 1999, J BIOL CHEM, V274, P32198, DOI 10.1074/jbc.274.45.32198; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; Melville MW, 2000, CELL MOL LIFE SCI, V57, P311, DOI 10.1007/PL00000692; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MEURS EF, 1992, J VIROL, V66, P5804; MUNDSCHAU LJ, 1994, BIOCHIMIE, V76, P792, DOI 10.1016/0300-9084(94)90083-3; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Rhodes N, 1997, ONCOGENE, V14, P3017, DOI 10.1038/sj.onc.1201158; Rivas C, 1999, J INTERF CYTOK RES, V19, P1229, DOI 10.1089/107999099312885; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; Salzberg S, 2000, EXP CELL RES, V254, P45, DOI 10.1006/excr.1999.4721; Shang YF, 1998, J BIOL CHEM, V273, P30608, DOI 10.1074/jbc.273.46.30608; Singh A, 1997, ENVIRON PROG, V16, P281, DOI 10.1002/ep.3300160417; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; SQUIRE J, 1993, GENOMICS, V16, P768, DOI 10.1006/geno.1993.1263; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Ueda K, 1999, ONCOL RES, V11, P125; Vojdani A, 1997, J INTERN MED, V242, P465, DOI 10.1111/j.1365-2796.1997.tb00019.x; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Yoshida N, 2000, MOL REPROD DEV, V57, P88, DOI 10.1002/1098-2795(200009)57:1<88::AID-MRD12>3.0.CO;2-9; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293	67	23	24	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8045	8056		10.1038/sj.onc.1204945	http://dx.doi.org/10.1038/sj.onc.1204945			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781817				2022-12-28	WOS:000172396800001
J	Zhao, YF; Oberley, TD; Chaiswing, L; Lin, SM; Epstein, CJ; Huang, TT; St Clair, D				Zhao, YF; Oberley, TD; Chaiswing, L; Lin, SM; Epstein, CJ; Huang, TT; St Clair, D			Manganese superoxide dismutase deficiency enhances cell turnover via tumor promoter-induced alterations in AP-1 and p53-mediated pathways in a skin cancer model	ONCOGENE			English	Article						MnSOD; apoptosis; AP-1; p53; skin cancer	PROTEIN-KINASE-C; GENE-EXPRESSION; CYTOCHROME-C; ORNITHINE-DECARBOXYLASE; MALIGNANT PHENOTYPE; XANTHINE-OXIDASE; APOPTOSIS; OVEREXPRESSION; P53; SUPPRESSION	Previous studies in our laboratories demonstrated that overexpression of manganese superoxide dismutase (MnSOD) suppressed both the incidence and multiplicity of papillomas in a DMBA/TPA multi-stage skin carcinogenesis model. The activity of activator protein- 1 (AP-1), which is associated with tumor promotion, was reduced in MnSOD transgenic mice overexpressing MnSOD in the skin, suggesting that MnSOD may reduce tumor incidence by suppressing AP-1 activation. In the present study, we report that reduction of MnSOD by heterozygous knockout of the MnSOD gene (Sod2 -/+, MnSOD KO) increased the levels of oxidative damage proteins and the activity of AP-1 following TPA treatment. RNA levels of ornithine decarboxylase (ODC) were also increased, suggesting an increase in cell proliferation in the KO mice. Histological examination confirmed that the number of proliferating cells in DMBA/TPA-treated mouse skin were higher in the KO mice. Interestingly, histological examination also demonstrated greater numbers of apoptotic cells in the KO mice after DMBA/TPA treatment. Evidence of apoptosis, including DNA fragmentation, cytochrome e release from mitochondria, and caspase 3 activation were also observed by biochemical assays of the skin tissues. Apoptosis was associated with an increase in nuclear levels of p53 as determined by Western analysis. Quantitative immuno-gold ultrastructural analysis confirmed that p53 immunoreactive protein levels were increased to a greater level in the nuclei of epidermal cells from MnSOD KO mice compared to epidermal nuclei from wild type mice similarly treated. Moreover, p53 levels further increased in the mitochondria of DMBA/TPA treated mice, and this increase was much greater in the MnSOD KO than in the wild type mice, suggesting a link between MnSOD deficiency and mitochondrial-mediated apoptosis. Pathological examination reveals no difference in the incidence and frequency of papillomas comparing the KO mice and their wild type littermates. Taken together, these results suggest that: (1) MnSOD deficiency enhanced TPA-induced oxidative stress and AP-1 and p53 levels, consistent with the increase in both proliferation and apoptosis events in the MnSOD KO mice, and (2) increased apoptosis may negate increased proliferation in the MnSOD deficient mice during an early stage of tumor development.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand; Univ Wisconsin, VA Hosp, Madison, WI 53705 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53705 USA	University of Kentucky; University of California System; University of California San Francisco; Mahidol University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	St Clair, D (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.	dstc100@pop.uky.edu			NCI NIH HHS [CA 73599-S1, CA 73599] Funding Source: Medline; NIA NIH HHS [AG 08938] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG008938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGARWAL R, 1993, MOL CARCINOGEN, V8, P290, DOI 10.1002/mc.2940080412; Amstad PA, 1997, CARCINOGENESIS, V18, P479, DOI 10.1093/carcin/18.3.479; BERNSTEIN LR, 1991, ENVIRON HEALTH PERSP, V93, P111, DOI 10.2307/3431178; BOWDEN GT, 1995, SKIN CANC MECH HUMAN, P99; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Das KC, 1998, J BIOL CHEM, V273, P34639, DOI 10.1074/jbc.273.51.34639; Donahue RJ, 2001, FASEB J, V15, P635, DOI 10.1096/fj.00-0262com; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Epperly MW, 2000, INT J CANCER, V90, P128, DOI 10.1002/1097-0215(20000620)90:3<128::AID-IJC2>3.0.CO;2-U; FISCHER SM, 1989, CANCER RES, V49, P6693; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GUIDOT DM, 1995, J CLIN INVEST, V96, P1131, DOI 10.1172/JCI118100; Hohmeier HE, 1998, J CLIN INVEST, V101, P1811, DOI 10.1172/JCI1489; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Keller JN, 1998, J NEUROSCI, V18, P687; Khajuria A, 1998, MOL CELL BIOCHEM, V189, P113, DOI 10.1023/A:1006877614411; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Lam EWN, 1997, CANCER RES, V57, P5550; Lam EWN, 1999, FREE RADICAL BIO MED, V27, P572, DOI 10.1016/S0891-5849(99)00109-4; LI JJ, 1995, ONCOGENE, V10, P1989; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; McGarrity TJ, 2001, CANCER LETT, V163, P33, DOI 10.1016/S0304-3835(00)00663-7; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Nakamura Y, 1999, CANCER LETT, V140, P37, DOI 10.1016/S0304-3835(99)00048-8; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PENCE BC, 1987, CANCER RES, V47, P6388; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; REINERS JJ, 1987, CANCER RES, V47, P1775; REINERS JJ, 1991, CARCINOGENESIS, V12, P2337, DOI 10.1093/carcin/12.12.2337; RUGGERI BA, 1995, SKIN CANC MECH HUMAN, P339; SAFFORD SE, 1994, CANCER RES, V54, P4261; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; URANO M, 1995, CANCER RES, V55, P2490; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; VERMA AK, 1986, CANCER RES, V46, P6149; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu Y, 1999, ONCOGENE, V18, P93, DOI 10.1038/sj.onc.1202265; Yan T, 1996, CANCER RES, V56, P2864; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhao YF, 2001, CANCER RES, V61, P6082; Zhao YF, 2001, ANTIOXID REDOX SIGN, V3, P375, DOI 10.1089/15230860152409022; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	61	82	85	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3836	3846		10.1038/sj.onc.1205477	http://dx.doi.org/10.1038/sj.onc.1205477			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032821				2022-12-28	WOS:000175847200002
J	List, K; Haudenschild, CC; Szabo, R; Chen, WJ; Wahl, SM; Swaim, W; Engelholm, LH; Behrendt, N; Bugge, TH				List, K; Haudenschild, CC; Szabo, R; Chen, WJ; Wahl, SM; Swaim, W; Engelholm, LH; Behrendt, N; Bugge, TH			Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis	ONCOGENE			English	Article						apoptosis; cell-surface proteolysis; skin; thymus; barrier function	HEPATOCYTE GROWTH-FACTOR; PROTEASE-ACTIVATED RECEPTOR-2; TRANSMEMBRANE SERINE-PROTEASE; FACTOR HGF ACTIVATOR; PLASMINOGEN-ACTIVATOR; STRATUM-CORNEUM; IN-VITRO; GENE; MUTATIONS; MICE	Matriptase/MT-SP1 is a novel tumor-associated type II transmembrane serine protease that is highly expressed in the epidermis, thymic stroma, and other epithelia. A null mutation was introduced into the Matriptase/MT-SP1 gene of mice to determine the role of Matriptase/MT-SP1 in epidermal development and neoplasia. Matriptase/MT-SP1-deficient mice developed to term but uniformly died within 48 h of birth. All epidermal surfaces of newborn mice were grossly abnormal with a dry, red, shiny, and wrinkled appearance. Matriptase/MT-SP1-deficiency caused striking malformations of the stratum corneum, characterized by dysmorphic and pleomorphic corneocytes and the absence of vesicular bodies in transitional layer cells. This aberrant skin development seriously compromised both inward and outward epidermal barrier function, leading to the rapid and fatal dehydration of Matriptase/MT-SP1-deficient pups. Loss of Matriptase/MT-SP1 also seriously affected hair follicle development resulting in generalized follicular hypoplasia, absence of erupted vibrissae, lack of vibrissal hair canal formation, ingrown vibrissae, and wholesale abortion of vibrissal follicles. Furthermore, Matriptase/MT-SP1-deficiency resulted in dramatically increased thymocyte apoptosis, and depletion of thymocytes. This study demonstrates that Matriptase/MT-SP1 has pleiotropic functions in the development of the epidermis, hair follicles, and cellular immune system.	Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Cellular Imaging Core, NIH, Bethesda, MD 20892 USA; Finsen Lab, DK-2100 Copenhagen, Denmark; Amer Red Cross, Dept Expt Pathol, Rockville, MD 20855 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); American Red Cross	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov	Christian, Haudenschild C/D-1602-2009	Engelholm, Lars/0000-0002-6616-1232; Behrendt, Niels/0000-0003-1833-3922	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000046, ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699, Z01DE000046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDREASEN PA, 1986, MOL CELL ENDOCRINOL, V45, P137, DOI 10.1016/0303-7207(86)90141-3; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Chen WJ, 2001, J EXP MED, V194, P439, DOI 10.1084/jem.194.4.439; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; DAVIDSON P, 1952, J ANAT, V86, P342; DAVISSON MT, 1994, J HERED, V85, P134, DOI 10.1093/oxfordjournals.jhered.a111411; DeLaurenzi V, 1996, NAT GENET, V12, P52; Elias PM, 2001, J CELL BIOL, V153, P243, DOI 10.1083/jcb.153.2.243; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Jensen PJ, 1999, J INVEST DERMATOL, V112, P240, DOI 10.1046/j.1523-1747.1999.00494.x; Jindo T, 1998, J INVEST DERMATOL, V110, P338, DOI 10.1046/j.1523-1747.1998.00144.x; KAUFMANN MH, 1999, ANAT BASIS MOUSE DEV; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; KUBILUS J, 1979, AM J HUM GENET, V31, P50; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lee YR, 2001, J DERMATOL SCI, V25, P156, DOI 10.1016/S0923-1811(00)00124-9; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lindner G, 2000, FASEB J, V14, P319, DOI 10.1096/fasebj.14.2.319; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Luttun A, 2000, Curr Atheroscler Rep, V2, P407, DOI 10.1007/s11883-000-0079-z; Magerl M, 2001, J INVEST DERMATOL, V116, P947, DOI 10.1046/j.0022-202x.2001.01368.x; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Manley NR, 2000, SEMIN IMMUNOL, V12, P421, DOI 10.1006/smim.2000.0263; MANN NS, 1994, P SOC EXP BIOL MED, V206, P114; Matrisian LM, 1999, CURR BIOL, V9, pR776, DOI 10.1016/S0960-9822(00)80011-1; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; RESKEKUNZ AB, 1979, J EXP MED, V149, P228, DOI 10.1084/jem.149.1.228; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; Scott HS, 2001, NAT GENET, V27, P59, DOI 10.1038/83768; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SHAPIRO LJ, 1978, LANCET, V2, P756; SHULTZ LD, 1988, CURR TOP MICROBIOL, V137, P216; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Tanimoto H, 2001, TUMOR BIOL, V22, P104, DOI 10.1159/000050604; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; Williams O, 2001, TRENDS IMMUNOL, V22, P107, DOI 10.1016/S1471-4906(00)01797-X; Yamada K, 2000, GENE, V252, P209, DOI 10.1016/S0378-1119(00)00225-0; Yamazaki M, 1999, J INVEST DERM SYMP P, V4, P312, DOI 10.1038/sj.jidsp.5640236; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097; Zhang Y, 1998, CYTOGENET CELL GENET, V83, P56, DOI 10.1159/000015125	60	271	280	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3765	3779		10.1038/sj.onc.1205502	http://dx.doi.org/10.1038/sj.onc.1205502			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032844				2022-12-28	WOS:000175676000011
J	Shiraishi, M; Sekiguchi, A; Terry, MJ; Oates, AJ; Miyamoto, Y; Chuu, YH; Munakata, M; Sekiya, T				Shiraishi, M; Sekiguchi, A; Terry, MJ; Oates, AJ; Miyamoto, Y; Chuu, YH; Munakata, M; Sekiya, T			A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes	ONCOGENE			English	Article						CpG island; DNA methylation; lung adenocarcinoma; methylated DNA binding domain column; chromatography; segregation of partly melted molecules	DE-NOVO METHYLATION; DNA METHYLATION; CHROMATIN-STRUCTURE; BINDING DOMAIN; FRAGMENTS; REPLICATION; EXPRESSION; RECEPTOR; REGIONS; COMPLEX	CpG island methylation is an important mechanism in gene silencing and is a key epigenetic event in cancer development. As yet, the number and identities of the genes that are inactivated in cancer cells has not been determined. In order to address this issue, we have performed a comprehensive isolation of CpG islands that are methylated in human lung adenocarcinomas. We have isolated approximately 200 CpG islands that are methylated in tumor DNA including those of known tumor-associated genes such as the HOXA5 gene. As the library contains the CpG islands of a number of known tumor suppressor genes it is highly likely that additional, previously unidentified tumor suppressor genes, will be present. On average, 1-2% of CpG islands were methylated specifically in tumors although this figure differed greatly between patients. This study provides an important resource in the search for genes inactivated in tumors and for the investigation of epigenetic dysregulation of gene expression by CpG island methylation.	Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Shiraishi, M (corresponding author), Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	mshirais@ncc.go.jp		Miyamoto, Yuji/0000-0003-3948-5044				Ahuja N, 1998, CANCER RES, V58, P5489; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Brock GJR, 1999, GENE, V240, P269, DOI 10.1016/S0378-1119(99)00442-4; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CROSS SH, 1994, NAT GENET, V6, P126; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; HASHIMOTOGOTOH T, 1993, GENE, V137, P211; Hughes J, 1999, HUM MOL GENET, V8, P543, DOI 10.1093/hmg/8.3.543; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; SCHMIDT M, 1990, P NATL ACAD SCI USA, V87, P3685, DOI 10.1073/pnas.87.10.3685; Shiraishi M, 1999, P NATL ACAD SCI USA, V96, P2913, DOI 10.1073/pnas.96.6.2913; SHIRAISHI M, 1995, P NATL ACAD SCI USA, V92, P4229, DOI 10.1073/pnas.92.10.4229; Shiraishi M, 1998, NUCLEIC ACIDS RES, V26, P5544, DOI 10.1093/nar/26.24.5544; Shiraishi M, 2001, P JPN ACAD B-PHYS, V77, P208, DOI 10.2183/pjab.77.208; Shiraishi M, 1999, BIOL CHEM, V380, P1127, DOI 10.1515/BC.1999.141; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SHIRAISHI M, 2000, GENE THER MOL BIOL, V5, P35; SHIRAISHI M, 2002, IN PRESS BIOL CHEM; SHORT JM, 1992, METHOD ENZYMOL, V216, P495; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Thibonnier M, 1996, GENOMICS, V31, P327, DOI 10.1006/geno.1996.0055; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	39	33	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3804	3813		10.1038/sj.onc.1205454	http://dx.doi.org/10.1038/sj.onc.1205454			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032849				2022-12-28	WOS:000175676000016
J	Shi, PA; Hematti, P; von Kalle, C; Dunbar, CE				Shi, PA; Hematti, P; von Kalle, C; Dunbar, CE			Genetic marking as an approach to studying in vivo hematopoiesis: progress in the non-human primate model	ONCOGENE			English	Article						hematopoietic stem cells; retroviral vectors; in vivo gene tracking; clonality	STEM-CELL FACTOR; COLONY-STIMULATING FACTOR; X-CHROMOSOME INACTIVATION; RHESUS PERIPHERAL-BLOOD; LONG-TERM ENGRAFTMENT; CD34(+) CELLS; COMPETITIVE REPOPULATION; LIFELONG HEMATOPOIESIS; HUMAN INTERLEUKIN-3; CLONAL ANALYSIS	Retroviral insertion site analysis following transplantation of marked hematopoietic stem cells (HSCs) is a powerful method for studying hematopoiesis in vivo. High-level gene transfer efficiency was achieved in murine models in the late 1980s, but early human gene transfer protocols into hematopoietic stem and progenitor cells using the murine methodology showed consistently poor results. The utility of non-human primates as pre-clinical models has since become apparent. Modifications in retroviral transduction conditions have resulted in stable long-term gene transfer efficiency as high as 15-20% to primitive repopulating cells in non-human primate models. This has permitted, for the first time in a large animal model, tracking of individual stem and progenitor cell clones via insertion site analysis, an advantage over competitive transplantation studies, which cannot firmly evaluate the number or life span of individual clones contributing to hematopoiesis. Retroviral tracking studies in mice suggest that stable hematopoiesis may be dominated by a small number of clones, but these studies have been limited by insensitive detection methods, low numbers of transplanted stem cells, and limited life span of immunodeficient mice. Autologous transplantation studies in non-human primates have just begun and have the potential to shed light on controversial issues such as the number of clones contributing to stable hematopoiesis, clonal succession, and lineage commitment, as well as the effect of clinically relevant manipulations such as cytokines, chemotherapy, and radiation on hematopoiesis. These approaches will have significant impact in studying various aspects of stem cell biology including the phenomenon of stem cell plasticity.	NHLBI, Mol Hematopoiesis Sect, Hematol Branch, NIH, Bethesda, MD 20892 USA; Univ Freiburg, Dept Internal Med, D-7800 Freiburg, Germany	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Freiburg	Dunbar, CE (corresponding author), NHLBI, Mol Hematopoiesis Sect, Hematol Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	dunbarc@nhlbi.nih.gov		Shi, Patricia/0000-0002-7954-0055; Dunbar, Cynthia/0000-0002-7645-838X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002339, Z01HL002339] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abkowitz JL, 2000, BLOOD, V96, P3399, DOI 10.1182/blood.V96.10.3399.h8003399_3399_3405; ABKOWITZ JL, 1995, P NATL ACAD SCI USA, V92, P2031, DOI 10.1073/pnas.92.6.2031; ABKOWITZ JL, 1990, P NATL ACAD SCI USA, V87, P9062, DOI 10.1073/pnas.87.22.9062; Abkowitz JL, 1996, NAT MED, V2, P190, DOI 10.1038/nm0296-190; Abkowitz JL, 1998, P NATL ACAD SCI USA, V95, P3862, DOI 10.1073/pnas.95.7.3862; An DS, 2000, J VIROL, V74, P1286, DOI 10.1128/JVI.74.3.1286-1295.2000; ANDERSON WF, 1986, COLD SPRING HARB SYM, V51, P1073, DOI 10.1101/SQB.1986.051.01.125; ANDREWS RG, 1995, BLOOD, V85, P15, DOI 10.1182/blood.V85.1.15.bloodjournal85115; BERENSON RJ, 1988, J CLIN INVEST, V81, P951, DOI 10.1172/JCI113409; BOCK TA, 1995, J EXP MED, V182, P2037, DOI 10.1084/jem.182.6.2037; BODINE DM, 1991, EXP HEMATOL, V19, P206; BODINE DM, 1994, BLOOD, V84, P1482; BOGGS DR, 1982, J CLIN INVEST, V70, P242, DOI 10.1172/JCI110611; Brenner M, 1996, HUM GENE THER, V7, P1927, DOI 10.1089/hum.1996.7.16-1927; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; BROWN CJ, 2000, BLOOD, V95, P2449; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; BURGER H, 1990, BLOOD, V76, P2229; Busque L, 1996, BLOOD, V88, P59; CAPEL B, 1989, P NATL ACAD SCI USA, V86, P4564, DOI 10.1073/pnas.86.12.4564; Cashman JD, 1997, BLOOD, V89, P4307, DOI 10.1182/blood.V89.12.4307; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Champion KM, 1997, BRIT J HAEMATOL, V97, P920, DOI 10.1046/j.1365-2141.1997.1933010.x; Christensen K, 2000, BLOOD, V95, P2449, DOI 10.1182/blood.V95.7.2449.007k06_2449_2451; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; Donahue RE, 1996, BLOOD, V87, P1644, DOI 10.1182/blood.V87.4.1644.bloodjournal8741644; Donahue RE, 2001, HUM GENE THER, V12, P607, DOI 10.1089/104303401300057289; Dorrell C, 2000, BLOOD, V95, P102; Drize NJ, 1996, BLOOD, V88, P2927, DOI 10.1182/blood.V88.8.2927.bloodjournal8882927; Drize NJ, 2001, EXP HEMATOL, V29, P786, DOI 10.1016/S0301-472X(01)00634-8; Dunbar CE, 1996, ANNU REV MED, V47, P11; Dunbar CE, 1996, P NATL ACAD SCI USA, V93, P11871, DOI 10.1073/pnas.93.21.11871; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; Emerson SG, 1996, BLOOD, V87, P3082, DOI 10.1182/blood.V87.8.3082.bloodjournal8783082; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; Gale RE, 1997, BRIT J HAEMATOL, V98, P512, DOI 10.1046/j.1365-2141.1997.2573078.x; Gothot A, 1998, BLOOD, V92, P2641, DOI 10.1182/blood.V92.8.2641.420k36_2641_2649; Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166; Guenechea G, 2001, NAT IMMUNOL, V2, P75, DOI 10.1038/83199; Habibian HK, 1998, J EXP MED, V188, P393, DOI 10.1084/jem.188.2.393; Hanania EG, 1996, P NATL ACAD SCI USA, V93, P15346, DOI 10.1073/pnas.93.26.15346; Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; HARRISON DE, 1980, BLOOD, V55, P77; HARRISON DE, 1991, BLOOD, V78, P1237; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KANTOFF PW, 1987, J EXP MED, V166, P219, DOI 10.1084/jem.166.1.219; KARLSSON S, 1991, BLOOD, V78, P2481; KAY HEM, 1965, LANCET, V2, P418; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KELLER G, 1990, J EXP MED, V171, P1407, DOI 10.1084/jem.171.5.1407; Kelly PF, 2001, ANN NY ACAD SCI, V938, P262; Kiem HP, 1997, BLOOD, V90, P4638; Kiem HP, 1998, BLOOD, V92, P1878, DOI 10.1182/blood.V92.6.1878.418k39_1878_1886; Kim HJ, 2000, BLOOD, V96, P1; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Lemischka I, 1999, P NATL ACAD SCI USA, V96, P14193, DOI 10.1073/pnas.96.25.14193; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LUSKEY BD, 1992, BLOOD, V80, P396; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; NASH R, 1988, BLOOD, V72, P2031; NOLTA JA, 1994, BLOOD, V83, P3041, DOI 10.1182/blood.V83.10.3041.3041; Nolta JA, 1996, P NATL ACAD SCI USA, V93, P2414, DOI 10.1073/pnas.93.6.2414; OCHMAN H, 1988, GENETICS, V120, P621; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, ANN NY ACAD SCI, V938, P221; Orlic D, 1996, P NATL ACAD SCI USA, V93, P11097, DOI 10.1073/pnas.93.20.11097; Petzer AL, 1996, J EXP MED, V183, P2551, DOI 10.1084/jem.183.6.2551; Rebel VI, 1999, BLOOD, V93, P2217, DOI 10.1182/blood.V93.7.2217.407a01_2217_2224; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; SNODGRASS R, 1987, EMBO J, V6, P3955, DOI 10.1002/j.1460-2075.1987.tb02737.x; Srour EF, 1999, J HEMATOTHER, V8, P93, DOI 10.1089/106161299320370; Takatoku M, 2001, J CLIN INVEST, V108, P447, DOI 10.1172/JCI12593; Tisdale JF, 1998, BLOOD, V92, P1131, DOI 10.1182/blood.V92.4.1131.416k41_1131_1141; Tonon L, 1998, BRIT J HAEMATOL, V102, P996, DOI 10.1046/j.1365-2141.1998.00867.x; VANBEKKUM DW, 1978, TRANSPL P, V10, P105; vanBeusechem VW, 1996, HUM GENE THER, V7, P1649, DOI 10.1089/hum.1996.7.14-1649; Wu T, 2000, MOL THER, V1, P285, DOI 10.1006/mthe.2000.0034; Yokota T, 1998, BLOOD, V91, P3263, DOI 10.1182/blood.V91.9.3263.3263_3263_3272; Zanjani ED, 1996, INT J HEMATOL, V63, P179; Zhong RK, 1996, J IMMUNOL, V157, P138	86	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3274	3283		10.1038/sj.onc.1205320	http://dx.doi.org/10.1038/sj.onc.1205320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032769				2022-12-28	WOS:000175633300004
J	Wang, DG; Patil, S; Li, WH; Humphrey, LE; Brattain, MG; Howell, GM				Wang, DG; Patil, S; Li, WH; Humphrey, LE; Brattain, MG; Howell, GM			Activation of the TGF alpha autocrine loop is downstream of IGF-1 receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells	ONCOGENE			English	Article						colon carcinoma; autocrine transforming growth factor alpha; insulin growth factor-1 receptor; IGF-1R competence factor; growth factor dependence	FACTOR-I RECEPTOR; DIFFERENTIAL REGULATION; GENE-EXPRESSION; TRANSGENIC MICE; EGF RECEPTOR; C-MYC; TRANSCRIPTION; REQUIREMENTS; GLUCOSAMINE; KINASE	The inappropriate expression of TGFalpha in growth arrest contributes to malignant progression in human colon carcinoma cells. Early stage, non-progressed colon tumor cells show a down-regulation of TGFalpha in growth arrest and require both nutrients and growth factors for re-entry into the cell cycle. In contrast, highly progressed cells up-regulate TGFalpha during growth arrest and require only nutrients for re-entry. Given the importance of TGFalpha in malignant progression, this work addressed the regulation of TGFalpha expression in the early stage colon carcinoma cell line, FET. Growth-arrested FET cells down-regulated the expression of TGFalpha, EGFr and, in turn, EGFr activation. These quiescent cells continued to express high levels of IGF-IR protein, but IGF-IR activation was undetectable. Cell cycle re-entry required exogenous growth factor activation of the IGF-IR by insulin or IGF-I. This IGF-IR activation resulted in S phase re-entry and was accompanied by an approximate threefold induction of TGFalpha expression along with EGFr activation at 1 h following release from growth arrest. Activation of IGF-IR occurred within 5 min of cell-cycle re-entry. Previously identified DNA binding proteins which bind to a unique TGFalpha/EGF response element within the TGFalpha promoter were similarly induced following IGF-IR activation. The addition of EGFr neutralizing antibodies abolished the activated IGF-IR stimulated S phase re-entry. Moreover, disruption of the growth arrest associated down-regulation of TGFalpha in FET cells by constitutive TGFalpha expression abrogated the requirement for IGF-IR activation for cell cycle re-entry. Consequently, this study indicates, for the first time, that IGF-IR activation up-regulates components of the TGFalpha autocrine loop resulting in TGFalpha-mediated EGFr activation which was critical for IGF-IR mediated re-entry into the cell cycle from the growth-arrested state.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA	Roswell Park Cancer Institute	Howell, GM (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	gillian.howell@roswellpark.org			NCI NIH HHS [CA54870, CA34432] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034432] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Blakesley VA, 1997, J ENDOCRINOL, V152, P339, DOI 10.1677/joe.0.1520339; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; BRATTAIN MG, 1981, ONCODEV BIOL MED, V2, P355; Brattain Michael G., 1994, Current Opinion in Oncology, V6, P77, DOI 10.1097/00001622-199401000-00011; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CAMPOSGONZALEZ R, 1991, CELL REGUL, V2, P663, DOI 10.1091/mbc.2.8.663; CHANTRET I, 1988, CANCER RES, V48, P1936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1987, CANCER RES, V47, P707; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P707; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HOWELL GM, 1995, J CELL PHYSIOL, V162, P256, DOI 10.1002/jcp.1041620211; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MULDER KM, 1991, CANCER RES, V51, P2256; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PITTELKOW MR, 1993, CELL GROWTH DIFFER, V4, P513; ROOS MD, 1996, AM J PHYSIOL, V270, P803; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHLECHTE W, 1990, CANCER COMMUN, V2, P173; SCHMID C, 1995, CELL BIOL INT, V19, P445, DOI 10.1006/cbir.1995.1088; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; TANAKA S, 1991, AM J PATHOL, V139, P123; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; Yang HS, 2000, ONCOGENE, V19, P1901, DOI 10.1038/sj.onc.1203513; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	43	35	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2785	2796		10.1038/sj.onc.1205375	http://dx.doi.org/10.1038/sj.onc.1205375			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973637				2022-12-28	WOS:000175063700002
J	Yang, C; Yu, B; Zhou, DJ; Chen, SA				Yang, C; Yu, B; Zhou, DJ; Chen, SA			Regulation of aromatase promoter activity in human breast tissue by nuclear receptors	ONCOGENE			English	Article						aromatase; gene regulation; nuclear receptors; breast cancer	ESTROGEN-RELATED RECEPTOR; CYTOCHROME-P450 GENE-EXPRESSION; ORPHAN RECEPTORS; TRANSCRIPTION FACTOR; RESPONSE ELEMENTS; MESSENGER-RNA; UPSTREAM; BINDING; ALPHA; ARP-1	Using the yeast one-hybrid approach to screen a human breast tissue hybrid cDNA expression library, we have found that four orphan/nuclear receptors, ERRalpha-1, EAR-2, COUP-TFI (EAR-3), and RARgamma, bind to the silencer (SI) region of the human aromatase gene. S1 down regulates promoters 1.3 and 11 of the human aromatase gene. In this study, the interaction of EAR-2, COUP-TFI, and RARgamma with SI was confirmed by DNA mobility shift analysis. In contrast to the findings that ERRalpha-1 behaves as a positive regulatory factor, these three nuclear receptors were found, by, mammalian cell transfection experiments, to act as negative regulatory factors by binding to SI. Furthermore, the negative action of these three nuclear receptors could override the positive effect of ERRalpha-1. RT-PCR analysis of 11 cell lines and 55 human breast tumor specimens has shown that these nuclear receptors are expressed in human breast tissue. Since EAR-2, COUP-TFI, and RARgamma are expressed at high levels, it is likely that SI is a negative regulatory element that suppresses aromatase promoters 1.3 and 11 in normal breast tissue. In cancer tissue, SI may function as a positive element since ERRYalpha-1 is expressed, but EAR-2 and RARgamma are only present in a small number of tumor specimens. This hypothesis is sustained by the finding that there is a weak inverse correlation between the expression of COUP-TFI and that of aromatase in breast tumor tissue. Our studies have revealed that estrogen receptor alpha (ERalpha) can also bind to SI, in a ligand-dependent manner. By binding to S1, ERalpha down-regulates the aromatase promoter activity. These results demonstrate that nuclear receptors play important roles in modulating aromatase expression in human breast tissue.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Chen, SA (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	schen@coh.org			NCI NIH HHS [CA44735, CA65767] Funding Source: Medline; NIEHS NIH HHS [ES08258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Bulun SE, 1997, J STEROID BIOCHEM, V61, P133; CHOMCZYMSKI P, 1998, CURRENT PROTOCOLS MO, V1; Chu K, 1998, MOL CELL ENDOCRINOL, V137, P145, DOI 10.1016/S0303-7207(97)00241-4; Dotzlaw H, 1999, CLIN CANCER RES, V5, P2103; Harada N, 1997, J STEROID BIOCHEM, V61, P175; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; Kao YC, 1996, CANCER RES, V56, P3451; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; Nakamura J, 1999, J CLIN ENDOCR METAB, V84, P1432, DOI 10.1210/jc.84.4.1432; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEGEL IH, 1976, BIOCH CALCULATIONS, P218; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vorgia P, 1998, J BIOL CHEM, V273, P4188, DOI 10.1074/jbc.273.7.4188; Widschwendter M, 1997, CANCER RES, V57, P4158; Yang C, 1999, CANCER RES, V59, P4519; Yang C, 1998, CANCER RES, V58, P5695; Zeitoun K, 1999, MOL ENDOCRINOL, V13, P239, DOI 10.1210/me.13.2.239; Zhou CB, 1996, J STEROID BIOCHEM, V59, P163, DOI 10.1016/S0960-0760(96)00100-8; Zhou DJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P179, DOI 10.1006/abbi.1999.1454; Zhou DJ, 1998, ARCH BIOCHEM BIOPHYS, V353, P213, DOI 10.1006/abbi.1998.0641; Zhou DJ, 2000, MOL ENDOCRINOL, V14, P986, DOI 10.1210/me.14.7.986; ZHOU F, 1995, P NATL ACAD SCI USA, V92, P8586; 周茂堂, 1993, Chinese Journal of Polymer Science, V11, P46	36	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2854	2863		10.1038/sj.onc.1205386	http://dx.doi.org/10.1038/sj.onc.1205386			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973645				2022-12-28	WOS:000175063700010
J	Satoh, T; Toyoda, M; Hoshino, H; Monden, T; Yamada, M; Shimizu, H; Miyamoto, K; Mori, M				Satoh, T; Toyoda, M; Hoshino, H; Monden, T; Yamada, M; Shimizu, H; Miyamoto, K; Mori, M			Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells	ONCOGENE			English	Article						PPAR-gamma; thiazolidinediones; GADD153; apoptosis; lung carcinoma	PREPROTHYROTROPIN-RELEASING HORMONE; HUMAN BREAST-CANCER; PPAR-GAMMA; BINDING PROTEIN; TERMINAL DIFFERENTIATION; INSULIN-RESISTANCE; IN-VITRO; APOPTOSIS; CHOP; EXPRESSION	Activation of peroxisome proliferator-activated receptor (PPAR)-gamma by the thiazolidinedione (TZD) class of antidiabetic drugs elicits growth inhibition in a variety of malignant tumors. We clarified the effects of TZDs on growth of human non-small cell lung carcinoma (NSCLC) cells that express endogenous PPAR-gamma Troglitazone and pioglitazone caused inhibition of cellular growth and induced apoptosis of NSCLC cells, in a time- and dose-dependent manner. Subtraction, cloning analysis identified that troglitazone stimulated, expression of the growth arrest and DNA-damage inducible (GADD) 153 gene, and the increased expression, of GADD153 mRNA was also confirmed by an array analysis of the 160 apoptosis-related genes. Western blot analysis revealed that troglitazone also increased, GADD153 protein levels in a time-dependent manner., Troglitazone did not stimulate GADD153 mRNA levels in undifferentiated 3T3-L1 cells lacking PPAR-gamma expression, whereas its induction was clearly observed in differentiated adipocytes expressing PPAR-gamma. Activity of the GADD153 promoter occurred in a NSCLC cell line in transient transcription assays and was significantly stimulated by troglitazone, although binding of PPAR/retinoid X receptor heterodimer was not detected in the promoter region in gel retardation assays. Inhibition of GADD153 gene expression by an antisense phosphorothionate oligonucleotide attenuated the troglitazone-induced growth inhibition. These findings collectively indicated that activation of PPAR-gamma by TZDs, could cause growth inhibition and apoptosis of NSCLC cells and that GADD153 might be a candidate factor implicated in these processes.	Gunma Univ, Sch Med, Dept Internal Med 1, Maebashi, Gumma 3718511, Japan; Gunma Univ, Sch Med, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718511, Japan	Gunma University; Gunma University	Mori, M (corresponding author), Gunma Univ, Sch Med, Dept Internal Med 1, Maebashi, Gumma 3718511, Japan.	mmori@med.gunma-u.ac.jp						APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang TH, 2000, CANCER RES, V60, P1129; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Eymin B, 1997, CANCER RES, V57, P686; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kameda T, 1999, BBA-GENE STRUCT EXPR, V1445, P31, DOI 10.1016/S0167-4781(99)00018-4; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubota T, 1998, CANCER RES, V58, P3344; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LEUTHY JD, 1990, J BIOL CHEM, V265, P16251; LEVY Y, 1991, J CLIN INVEST, V88, P696, DOI 10.1172/JCI115355; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; Monden T, 1999, MOL ENDOCRINOL, V13, P1695, DOI 10.1210/me.13.10.1695; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Ohtani K, 1998, ENDOCRINOLOGY, V139, P172, DOI 10.1210/en.139.1.172; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Palakurthi SS, 2001, CANCER RES, V61, P6213; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; Qiao DH, 2000, J BIOL CHEM, V275, P15090, DOI 10.1074/jbc.M908890199; Ren Y, 1998, ENDOCRINOLOGY, V139, P195, DOI 10.1210/en.139.1.195; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; SATOH T, 1993, MOL BRAIN RES, V20, P353, DOI 10.1016/0169-328X(93)90062-T; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tolon RM, 1998, J BIOL CHEM, V273, P26652, DOI 10.1074/jbc.273.41.26652; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	54	88	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2171	2180		10.1038/sj.onc.1205279	http://dx.doi.org/10.1038/sj.onc.1205279			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948400				2022-12-28	WOS:000174555300006
J	Guzzi, F; Zanchetta, D; Cassoni, P; Guzzi, V; Francolini, M; Parenti, M; Chini, B				Guzzi, F; Zanchetta, D; Cassoni, P; Guzzi, V; Francolini, M; Parenti, M; Chini, B			Localization of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response	ONCOGENE			English	Article						cell growth; oxytocin receptor; G-protein coupled receptor; caveolin; MDCK cells	SIGNAL-TRANSDUCTION; ADENYLYL-CYCLASE; CHOLESTEROL; VASOPRESSIN; SEQUESTRATION; MECHANISMS; COMPLEXES; PROTEINS	In this study, we investigated the functional role of the localization of human OTR in caveolin-1 enriched membrane domains. Biochemical fractionation of MDCK cells stably expressing the WT OTR-GFP indicated that only minor quantities of receptor are partitioned in caveolin-1 enriched domains. However, when fused to caveolin-2, the OTR protein proved to be exclusively localized in caveolin-1 enriched fractions, where it bound the agonist with increased affinity and efficiently coupled to Galpha(q/11). Interestingly, the chimeric protein was unable to undergo agonist-induced internalization and remained confined to the plasma membrane even after prolonged agonist exposure (120 min). A striking difference in receptor stimulation was observed when the OT-induced effect on cell proliferation was analysed: stimulation of the human WT OTR inhibited cell growth, whereas the chimeric protein had a proliferative effect. These data indicate that the localization of human OTR in caveolin-1 enriched microdomains radically alters its regulatory effects on cell growth; the fraction of OTR residing in caveolar structures may therefore play a crucial role in regulating cell proliferation.	CNR, Cellular & Mol Pharmacol Ctr, I-20129 Milan, Italy; Univ Milan, Dept Expt & Environm Med, I-20052 Monza, Italy; Univ Turin, Dept Biomed Sci & Oncol, I-10126 Turin, Italy; Univ Milan, Dept Pharmacol, I-20129 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Turin; University of Milan	Chini, B (corresponding author), CNR, Cellular & Mol Pharmacol Ctr, I-20129 Milan, Italy.	B.Chini@csfic.mi.cnr.it	Cassoni, Paola/I-8544-2018	Chini, Bice/0000-0002-1686-284X; FRANCOLINI, MAURA/0000-0002-3126-1575				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Cassoni P, 1997, INT J CANCER, V72, P340, DOI 10.1002/(SICI)1097-0215(19970717)72:2<340::AID-IJC23>3.0.CO;2-I; Cassoni P, 1998, INT J CANCER, V77, P695, DOI 10.1002/(SICI)1097-0215(19980831)77:5<695::AID-IJC6>3.0.CO;2-Q; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dessy C, 2000, EMBO J, V19, P4272, DOI 10.1093/emboj/19.16.4272; ELANDS J, 1988, AM J PHYSIOL, V254, pE31, DOI 10.1152/ajpendo.1988.254.1.E31; Gimpl G, 2000, EUR J BIOCHEM, V267, P2483, DOI 10.1046/j.1432-1327.2000.01280.x; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hailstones D, 1998, J LIPID RES, V39, P369; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hoare S, 1999, J BIOL CHEM, V274, P28682, DOI 10.1074/jbc.274.40.28682; KIRK CJ, 1986, BIOCHEM J, V240, P197, DOI 10.1042/bj2400197; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; OHMICHI M, 1995, ENDOCRINOLOGY, V136, P2082, DOI 10.1210/en.136.5.2082; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; STRAKOVA Z, 1997, AM J PHYSIOL, V272, P870; STRAKOVA Z, 1998, AM J PHYSL SE, V274, P634; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304	34	85	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1658	1667		10.1038/sj.onc.1205219	http://dx.doi.org/10.1038/sj.onc.1205219			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896597				2022-12-28	WOS:000174214200004
J	Faivre, J; Frank-Vaillant, M; Poulhe, R; Mouly, H; Jessus, C; Brechot, C; Sobczak-Thepot, J				Faivre, J; Frank-Vaillant, M; Poulhe, R; Mouly, H; Jessus, C; Brechot, C; Sobczak-Thepot, J			Centrosome overduplication, increased ploidy and transformation in cells expressing endoplasmic reticulum-associated cyclin A2	ONCOGENE			English	Article						cell cycle; cyclins; cytoplasm; endoplasmic reticulum	HEPATITIS-B-VIRUS; TRANSMEMBRANE ORIENTATION; MALIGNANT-TRANSFORMATION; ONCOGENIC ACTIVATION; NUCLEAR-LOCALIZATION; DEPENDENT KINASES; REQUIRES E2F; G(1) CYCLIN; IN-VITRO; PROTEIN	Cyclin A2 is predominantly, but not exclusively, localized in the nucleus from G1/S transition onwards. It is degraded when cells enter mitosis after nuclear envelope breakdown. We previously showed that a fusion protein (S2A) between the hepatitis B virus (HBV) surface antigen protein and a non-degradable fragment of human cyclin A2 (Delta152) resides in the endoplasmic reticulum membranes, escapes degradation and transforms normal rat fibroblasts. The present study investigates whether cytoplasmic cyclin A2 may play a role in oncogenesis. We show that the sequestration of non-degradable cyclin A2-Delta152 by a cellular ER targeting domain (PRL-A2) leads to cell transformation when coexpressed with activated Ha-ras. REF52 cells constitutively expressing PRL-A2 are found to have a high incidence of multinucleate giant cells, polyploidy and abnormal centrosome numbers, giving rise to the nucleation of multipolar spindles. Injection of these cells into athymic nude mice causes tumors, even in the absence of a cooperating Ha-ras oncogene. These results demonstrate that, independently of any viral context, an intracellular redistribution of non-degradable cyclin A2 is capable of deregulating the normal cell cycle to the point where it promotes aneuploidy and cancer.	Inst Pasteur, INSERM, U370, Fac Med Necker, F-75015 Paris, France; Univ Paris 06, CNRS, UMR 7622, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite	Faivre, J (corresponding author), Inst Pasteur, INSERM, U370, Fac Med Necker, 156 Rue Vaugirard, F-75015 Paris, France.	faivre@necker.fr	Sobczak, Joelle/HHZ-5610-2022	Sobczak, Joelle/0000-0001-7180-2789				Aaltomaa S, 1999, PROSTATE, V38, P175; Aaltomaa S, 1999, BRIT J CANCER, V80, P2001, DOI 10.1038/sj.bjc.6690634; Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; Allan K, 2000, ARCH PATHOL LAB MED, V124, P216; BAILLY E, 1992, J CELL SCI, V101, P529; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CASTRO A, 1994, BIOCHEM BIOPH RES CO, V201, P1072, DOI 10.1006/bbrc.1994.1814; Coverley D, 2000, J CELL SCI, V113, P1929; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; Faivre J, 2001, FEBS LETT, V506, P243, DOI 10.1016/S0014-5793(01)02920-9; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Grzanka A, 2001, NEOPLASMA, V48, P112; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HALL FL, 1991, J BIOL CHEM, V266, P17430; Handa K, 1999, INT J CANCER, V84, P225, DOI 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A; Hildt E, 1998, RECENT RES CANCER, V154, P315; Huuhtanen RL, 1999, CANCER RES, V59, P2885; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; Kaufmann H, 2001, J BIOL CHEM, V276, P29987, DOI 10.1074/jbc.M005452200; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; LU XP, 1992, J BIOL CHEM, V267, P2841; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; MARIDOR G, 1993, J CELL SCI, V106, P535; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; PRANGE R, 1995, EMBO J, V14, P247, DOI 10.1002/j.1460-2075.1995.tb06998.x; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; Sluder G, 1999, BIOL CELL, V91, P413, DOI 10.1016/S0248-4900(99)80083-5; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; THOMAS L, 1992, J BIOL CHEM, V267, P6183; Verges M, 1997, BIOCHEM BIOPH RES CO, V230, P49, DOI 10.1006/bbrc.1996.5851; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Winston N, 2000, DEV BIOL, V223, P139, DOI 10.1006/dbio.2000.9721; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; WOODMAN PG, 1993, MOL BIOL CELL, V4, P541, DOI 10.1091/mbc.4.5.541; YOST CS, 1983, CELL, V34, P759; Zhai YL, 1999, INT J CANCER, V84, P244, DOI 10.1002/(SICI)1097-0215(19990621)84:3<244::AID-IJC8>3.0.CO;2-2	54	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1493	1500		10.1038/sj.onc.1205215	http://dx.doi.org/10.1038/sj.onc.1205215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896577				2022-12-28	WOS:000173956800004
J	Gao, YN; Lu, YJ; Xue, SA; Chen, HL; Wedderburn, N; Griffin, BE				Gao, YN; Lu, YJ; Xue, SA; Chen, HL; Wedderburn, N; Griffin, BE			Hypothesis: a novel route for immortalization of epithelial cells by Epstein-Barr virus	ONCOGENE			English	Article						'hit and run'; gene amplification; telomeres; chromosomal instability; double minute chromosomes (DMs)	DOUBLE-MINUTE CHROMOSOMES; HUMAN B-LYMPHOCYTES; NASOPHARYNGEAL CARCINOMA; RUN ONCOGENESIS; COMMON MARMOSET; GENE-EXPRESSION; KILOBASE PAIRS; SIMPLEX VIRUS; DNA-SEQUENCE; BAMHI-A	Transfection of primate tissue explants with a specific sub-fragment (p31) of EBV DNA results in epithelial (but no other) cells proliferating indefinitely (becoming 'immortalized') without evidence of a 'growth crisis'. Molecular evidence supports integration of viral information into the host chromosome, and an early genotypic alteration involving specific amplification of a subcomponent (IR1) of p31 DNA, followed by apparent loss of viral DNA from chromosomes, consistent with a 'hit and run' mechanism. However, analysis at the individual cell level during long-term culture, by FISH techniques, reveals chromosomal alferations, and viral sequences surviving within double minute (DM) bodies. Changing growth patterns occurring at different stages during propagation (>a year in culture) may be explained by sporadic reintegration of surviving viral DNA into the host chromosome. Notably, throughout culture, telomere lengths in chromosomal DNAs do not alter but rather retain the length observed in the primary cell populations. Introduction of a growth stimulating function of EBV, BARF1, into the immortalized, nonclonable epithelial cells under conditions which permit overexpression, allows clonal populations to be derived. Based on the data, mechanisms of immortalization, in the absence of a proven viral oncogene in p31 DNA, and possible genes involved, are considered.	Univ London Imperial Coll Sci Technol & Med, Dept Med, Viral Oncol Unit, London W2 1PG, England; Inst Canc Res, Sect Cell Biol & Expt Pathol, Sutton SM2 5NG, Surrey, England; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	Imperial College London; University of London; Institute of Cancer Research - UK; University of Hong Kong	Griffin, BE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Med, Viral Oncol Unit, Norfolk Pl, London W2 1PG, England.	b.griffin@ic.ac.uk	Xue, Shao-An/A-2735-2011; Chen, Honglin/C-4224-2009	Chen, Honglin/0000-0001-5108-8338; Lu, Yong-Jie/0000-0001-6174-6621				Ambinder RF, 2000, AM J PATHOL, V156, P1, DOI 10.1016/S0002-9440(10)64697-4; Antunes SG, 1998, P NATL ACAD SCI USA, V95, P11745, DOI 10.1073/pnas.95.20.11745; ARRAND JR, 1981, NUCLEIC ACIDS RES, V9, P2999, DOI 10.1093/nar/9.13.2999; ARRAND JR, 1983, EMBO J, V2, P1673, DOI 10.1002/j.1460-2075.1983.tb01642.x; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAR AI, 1992, GENE CHROMOSOME CANC, V4, P314; BAUER G, 1992, INT J CANCER, V51, P754, DOI 10.1002/ijc.2910510515; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Brink AATP, 1998, J CLIN MICROBIOL, V36, P3164, DOI 10.1128/JCM.36.11.3164-3169.1998; BROERS JLV, 1986, J CELL SCI, V83, P37; CHEN HL, 1992, VIROLOGY, V191, P193, DOI 10.1016/0042-6822(92)90181-N; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Cox C, 1996, J GEN VIROL, V77, P1173, DOI 10.1099/0022-1317-77-6-1173; Delecluse HJ, 1997, J PATHOL, V182, P475; EIJWUNMI AB, 1987, THESIS U OXFORD UK; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; Farrell PJ, 1997, J GEN VIROL, V78, P1417, DOI 10.1099/0022-1317-78-6-1417; FRESHNEY RI, 1983, CULTURE ANIMAL CELLS; FRESHNEY RI, 1996, CULTURE IMMORTALIZED; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURUYA T, 1993, CANCER GENET CYTOGEN, V70, P132, DOI 10.1016/0165-4608(93)90183-M; GALLOWAY DA, 1983, NATURE, V302, P21, DOI 10.1038/302021a0; GALLOWAY DA, 1990, J MED VIROL, V31, P36, DOI 10.1002/jmv.1890310108; GELB L, 1984, J INVEST DERMATOL, V83, pS77, DOI 10.1111/1523-1747.ep12281388; GRIFFIN BE, 1984, NATURE, V309, P78, DOI 10.1038/309078a0; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; Harris A., 1996, EPITHELIAL CELL CULT; Hayes DP, 1999, J CLIN PATHOL-MOL PA, V52, P97, DOI 10.1136/mp.52.2.97; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; IWASAKA T, 1992, ACTA OBSTET GYN SCAN, V71, P219, DOI 10.3109/00016349209009922; JOX A, 1997, AM J PATHOL, V151, P1387; KARRAN L, 1990, INT J CANCER, V45, P763, DOI 10.1002/ijc.2910450432; KEMPKES B, 1995, J VIROL, V69, P231, DOI 10.1128/JVI.69.1.231-238.1995; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LIN CT, 1993, LAB INVEST, V68, P716; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; NIELSEN JL, 1993, CANCER GENET CYTOGEN, V65, P120, DOI 10.1016/0165-4608(93)90219-C; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; Rao PH, 1998, CANCER GENET CYTOGEN, V105, P160, DOI 10.1016/S0165-4608(98)00013-2; ROBERTSON E, 1995, J VIROL, V69, P983, DOI 10.1128/JVI.69.2.983-993.1995; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; Sambrook J., 1989, MOL CLONING LABORATO, V2, P916; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Shen YQ, 1997, P NATL ACAD SCI USA, V94, P3341, DOI 10.1073/pnas.94.7.3341; SKINNER GRB, 1976, BRIT J EXP PATHOL, V57, P361; SMITH KT, 1988, VIROLOGY, V164, P39, DOI 10.1016/0042-6822(88)90617-4; SMITH KT, 1993, ONCOGENE, V8, P151; Smith PR, 2000, J VIROL, V74, P3082, DOI 10.1128/JVI.74.7.3082-3092.2000; SMITH PR, 1993, J VIROL, V67, P3217, DOI 10.1128/JVI.67.6.3217-3225.1993; Srinivas SK, 1998, J INFECT DIS, V177, P1705, DOI 10.1086/517427; Steinberg Mark L., 1996, P95; Strockbine LD, 1998, J VIROL, V72, P4015, DOI 10.1128/JVI.72.5.4015-4021.1998; TRASK BJ, 1991, METHOD CELL BIOL, V35, P3; VANDERBLIEK AM, 1988, NUCLEIC ACIDS RES, V16, P4841, DOI 10.1093/nar/16.11.4841; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; WOLF J, 1995, VIROLOGY, V212, P179, DOI 10.1006/viro.1995.1466; Xue SA, 2000, J VIROL, V74, P2793, DOI 10.1128/JVI.74.6.2793-2803.2000; YAO K, 1990, INT J CANCER, V45, P83, DOI 10.1002/ijc.2910450116; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988; Zhang JX, 1998, J MED VIROL, V55, P227, DOI 10.1002/(SICI)1096-9071(199807)55:3<227::AID-JMV8>3.0.CO;2-3	68	21	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					825	835		10.1038/sj.onc.1205130	http://dx.doi.org/10.1038/sj.onc.1205130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850810				2022-12-28	WOS:000173427000013
J	Hiyama, E; Hiyama, K				Hiyama, E; Hiyama, K			Clinical utility of telomerase in cancer	ONCOGENE			English	Article						telomerase; telomerase reverse transcriptase (hTERT); cytology; diagnosis; prognosis; immunohistochemistry	HTERT MESSENGER-RNA; CELL LUNG-CANCER; PROGNOSTIC INDICATOR; COLORECTAL-CANCER; BLADDER-CANCER; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; GASTRIC-CANCER; BREAST-LESIONS; EXPRESSION	This review will focus on the clinical utilities of telomerase for human cancer diagnosis. Much attention has been focused on detection of telomerase activity and its essential components (hTR and hTERT) in cancer and noncancerous tissues. Expression of hTR and hTERT is upregulated in almost all human malignant tumors but not in benign or normal tissues with the exception of germline cells, proliferative stem cells, activated lymphocytes, and certain benign tumors. Thus, telomerase is a useful marker for cancer diagnosis and in some instance as a prognostic indicator of outcome. Telomerase detection in cells derived from breast fine needle aspirates, bronchial washes, and pancreatic juices show high sensitivity and specificity for cancer detection. In tissue samples, the level of telomerase activity is a useful prognostic indicator in certain adult cancers such as gastric and colon cancers and in neuroblastomas. Immunohistochemical detection of hTERT will facilitate exact diagnosis of the telomerase positive cells and expand the application of telomerase in cancer diagnosis.	Hiroshima Univ, Sch Med, Fac Med, Dept Gen Med,Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Sch Med, Fac Med, Dept Internal Med 2,Minami Ku, Hiroshima 7348551, Japan	Hiroshima University; Hiroshima University	Hiyama, E (corresponding author), Hiroshima Univ, Sch Med, Fac Med, Dept Gen Med,Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Hiyama, Eiso/A-2013-2019	Hiyama, Eiso/0000-0001-9179-5037				Ahn MJ, 1997, EUR J CANCER, V33, P1309, DOI 10.1016/S0959-8049(97)00113-5; Bonatz G, 2001, HUM PATHOL, V32, P605, DOI 10.1053/hupa.2001.25002; BRENTNALL TA, 1995, CANCER RES, V55, P4264; Carey LA, 1999, J CLIN ONCOL, V17, P3075, DOI 10.1200/JCO.1999.17.10.3075; CHADENEAU C, 1995, CANCER RES, V55, P2533; Clark GM, 1997, J NATL CANCER I, V89, P1874, DOI 10.1093/jnci/89.24.1874; Dhaene K, 2000, VIRCHOWS ARCH, V437, P1, DOI 10.1007/s004280000189; Dome JS, 1999, CANCER RES, V59, P4301; Falchetti ML, 1999, J CLIN PATHOL, V52, P234, DOI 10.1136/jcp.52.3.234; Fang DC, 1999, J GASTROEN HEPATOL, V14, P328, DOI 10.1046/j.1440-1746.1999.01862.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Heine B, 1998, J PATHOL, V184, P71; Hirashima T, 2000, ANTICANCER RES, V20, P2181; Hiyama E, 1997, EUR J CANCER, V33, P1932, DOI 10.1016/S0959-8049(97)00226-8; Hiyama E, 1996, INT J ONCOL, V9, P453; Hiyama E, 1997, CANCER RES, V57, P326; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA E, 1995, CANCER RES, V55, P3258; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; Hiyama E, 2000, CANCER CYTOPATHOL, V90, P235, DOI 10.1002/1097-0142(20000825)90:4<235::AID-CNCR6>3.3.CO;2-Q; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Hiyama K, 1998, INT J MOL MED, V1, P545; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hou M, 2001, CLIN CHEM, V47, P519; Huang F, 1999, J NEURO-ONCOL, V43, P137, DOI 10.1023/A:1006258817785; Inoue H, 2001, CANCER, V91, P35, DOI 10.1002/1097-0142(20010101)91:1<35::AID-CNCR5>3.0.CO;2-A; Iwao T, 1997, J NATL CANCER I, V89, P1621, DOI 10.1093/jnci/89.21.1621; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, EUR J CANCER, V33, P781, DOI 10.1016/S0959-8049(97)00057-9; Kinoshita H, 1997, J NATL CANCER I, V89, P724, DOI 10.1093/jnci/89.10.724; Koyanagi K, 2000, CANCER, V88, P1524, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1524::AID-CNCR4>3.0.CO;2-6; Koyanagi Y, 2000, ANTICANCER RES, V20, P773; Lancelin F, 2000, BJU INT, V85, P526, DOI 10.1046/j.1464-410x.2000.00466.x; Langford LA, 1997, HUM PATHOL, V28, P416, DOI 10.1016/S0046-8177(97)90029-0; Leris C, 2000, J SURG ONCOL, V75, P72, DOI 10.1002/1096-9098(200009)75:1<72::AID-JSO14>3.0.CO;2-Z; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Marchetti A, 1999, CLIN CANCER RES, V5, P2077; Matthews P, 2001, J PATHOL, V194, P183, DOI 10.1002/path.848; Mokbel K, 1999, J CLIN ONCOL, V17, P3856; Morales CP, 1998, GASTROINTEST ENDOSC, V48, P402, DOI 10.1016/S0016-5107(98)70011-2; Muller M, 1996, INT J ONCOL, V9, P1169; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakashio R, 1997, INT J CANCER, V74, P141, DOI 10.1002/(SICI)1097-0215(19970422)74:2<141::AID-IJC1>3.0.CO;2-Z; Nakatani K, 1997, CANCER, V80, P471, DOI 10.1002/(SICI)1097-0142(19970801)80:3<471::AID-CNCR15>3.0.CO;2-U; Ohta K, 1997, J GASTROENTEROL, V32, P791, DOI 10.1007/BF02936956; Ohyashiki JH, 1997, CLIN CANCER RES, V3, P619; Okayasu I, 1997, JPN J CANCER RES, V88, P965, DOI 10.1111/j.1349-7006.1997.tb00316.x; Orlando C, 2001, J UROLOGY, V166, P666, DOI 10.1016/S0022-5347(05)66040-5; Parris CN, 1999, BRIT J CANCER, V79, P47, DOI 10.1038/sj.bjc.6690010; Pearson AS, 2000, INT J ONCOL, V17, P381; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Poremba C, 1999, J CLIN ONCOL, V17, P2020, DOI 10.1200/JCO.1999.17.7.2020; Poremba C, 1999, ANN ONCOL, V10, P715, DOI 10.1023/A:1008333500733; Rahat MA, 1999, CANCER, V85, P919; Reddy VG, 2001, INT J GYNECOL CANCER, V11, P100; Reynolds CP, 1997, EUR J CANCER, V33, P1929, DOI 10.1016/S0959-8049(97)00287-6; Sangiorgi L, 2001, INT J CANCER, V95, P156, DOI 10.1002/1097-0215(20010520)95:3<156::AID-IJC1027>3.0.CO;2-L; Schneider-Stock R, 2000, INT J CANCER, V89, P63, DOI 10.1002/(SICI)1097-0215(20000120)89:1<63::AID-IJC10>3.0.CO;2-V; Sen S, 2001, LUNG CANCER, V33, P41, DOI 10.1016/S0169-5002(01)00193-3; Shay J W, 1997, Ciba Found Symp, V211, P148; Shay JW, 1996, LEUKEMIA, V10, P1255; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Streutker CJ, 2001, PEDIATR DEVEL PATHOL, V4, P62, DOI 10.1007/s100240010108; Suehara N, 1997, CLIN CANCER RES, V3, P2479; Tahara H, 1995, CLIN CANCER RES, V1, P1245; Tang RP, 1998, CANCER RES, V58, P4052; Tatsumoto N, 2000, CLIN CANCER RES, V6, P2696; TAYLOR RS, 1996, J INVEST DERMATOL, V106, P756; Ulaner GA, 1998, CANCER RES, V58, P4168; Wisman GBA, 2001, INT J CANCER, V91, P658, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1099>3.0.CO;2-7; Wright WE, 1996, DEV GENET, V18, P173; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yahata N, 1998, J NATL CANCER I, V90, P684, DOI 10.1093/jnci/90.9.684; Yoshida K, 1997, BRIT J CANCER, V75, P548, DOI 10.1038/bjc.1997.96; Zheng PS, 2000, GYNECOL ONCOL, V77, P394, DOI 10.1006/gyno.2000.5779	76	163	189	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					643	649		10.1038/sj.onc.1205070	http://dx.doi.org/10.1038/sj.onc.1205070			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850791				2022-12-28	WOS:000173390500018
J	Muller, M				Muller, M			Telomerase: Its clinical relevance in the diagnosis of bladder cancer	ONCOGENE			English	Article						telomerase; bladder cancer; diagnosis; hTR; hTERT	TRANSITIONAL-CELL-CARCINOMA; TRANSCRIPTASE MESSENGER-RNA; CATALYTIC SUBUNIT GENE; VOIDED URINE SAMPLES; MICROSATELLITE ANALYSIS; UROTHELIAL CANCER; EXFOLIATED CELLS; POTENTIAL MARKER; EARLY EVENT; EXPRESSION	More than 50 years ago, Papanicolaou recognized the importance of a non-invasive technique for the diagnosis and follow-up of patients with carcinoma of the urinary bladder. Cystoscopy, however, has remained the 'gold standard' since no currently available non-invasive method can compete with cystoscopy's sensitivity and specificity. The detection of the ribonucleoprotein telomerase or the telomerase subunits human telomerase RNA (hTR) and human telomerase reverse transcriptase (hTERT) in urine samples offer new diagnostic perspectives. The present article presents a review of publications in the literature and evaluates their clinical relevance. The experimental studies reported to date are very promising and show that telomerase exactly fulfils the requirements for a good diagnostic marker for carcinoma of the urinary bladder. The diagnostic application remains in an experimental stage and telomerase is still several steps away for routine use as a clinical parameter. The remaining steps leading to its routine clinical application will be discussed.	Free Univ Berlin, Klinikum Benjamin Franklin, Dept Urol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Muller, M (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Dept Urol, Hindenburgdamm 30, D-12200 Berlin, Germany.							ABEL PD, 1988, BRIT J UROL, V62, P103, DOI 10.1111/j.1464-410X.1988.tb04286.x; Arai Y, 2000, CLIN CHIM ACTA, V296, P35, DOI 10.1016/S0009-8981(00)00202-3; Avilion AA, 1996, CANCER RES, V56, P645; Bialkowska-Hobrzanska H, 2000, MOL DIAGN, V5, P267, DOI 10.1054/modi.2000.20314; Cassel A, 2001, J UROLOGY, V166, P841, DOI 10.1016/S0022-5347(05)65848-X; Dalbagni G, 1997, CLIN CANCER RES, V3, P1593; de Kok JB, 2000, CLIN CHEM, V46, P2014; De Kok JB, 2000, INT J CANCER, V87, P217, DOI 10.1002/1097-0215(20000715)87:2<217::AID-IJC10>3.0.CO;2-2; de Kok JB, 2000, CLIN CHEM, V46, P313; DUNCAN RE, 1977, J UROLOGY, V118, P43, DOI 10.1016/S0022-5347(17)57880-5; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GAMARRA MC, 1984, UROLOGY, V23, P23, DOI 10.1016/S0090-4295(84)80110-7; Gelmini S, 2000, CLIN CANCER RES, V6, P2771; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Heine B, 1998, J PATHOL, V185, P139, DOI 10.1002/(SICI)1096-9896(199806)185:2<139::AID-PATH79>3.0.CO;2-L; HENEY NM, 1983, J UROLOGY, V130, P1083, DOI 10.1016/S0022-5347(17)51695-X; Hiyama T, 1999, VIRCHOWS ARCH, V434, P483, DOI 10.1007/s004280050372; Ito H, 1998, CLIN CANCER RES, V4, P2807; Ito H, 1998, CLIN CANCER RES, V4, P1603; Kamata S, 1996, BRIT J UROL, V78, P704, DOI 10.1046/j.1464-410X.1996.01957.x; Kavaler E, 1998, CANCER, V82, P708, DOI 10.1002/(SICI)1097-0142(19980215)82:4<708::AID-CNCR14>3.0.CO;2-1; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, EUR J CANCER, V33, P781, DOI 10.1016/S0959-8049(97)00057-9; Kinoshita H, 1997, J NATL CANCER I, V89, P724, DOI 10.1093/jnci/89.10.724; Kitsukawa SI, 1999, INT J ONCOL, V15, P505; Kriegmair M, 1996, J UROLOGY, V155, P105, DOI 10.1016/S0022-5347(01)66559-5; Kuniyasu H, 1997, JPN J CANCER RES, V88, P103, DOI 10.1111/j.1349-7006.1997.tb00353.x; Kyo S, 1997, AM J CLIN PATHOL, V107, P555; Lancelin F, 2000, BJU INT, V85, P526, DOI 10.1046/j.1464-410x.2000.00466.x; Lee DH, 1998, CLIN CANCER RES, V4, P535; Lin Y, 1996, CLIN CANCER RES, V2, P929; Linn JF, 1997, INT J CANCER, V74, P625, DOI 10.1002/(SICI)1097-0215(19971219)74:6<625::AID-IJC12>3.3.CO;2-4; Maitra A, 2001, CANCER CYTOPATHOL, V93, P73, DOI 10.1002/1097-0142(20010225)93:1<73::AID-CNCR9010>3.0.CO;2-I; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; Mayfield MP, 1998, INT J MOL MED, V1, P835; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORRISON AS, 1984, J UROLOGY, V131, P650, DOI 10.1016/S0022-5347(17)50559-5; Muller M, 1998, CLIN CANCER RES, V4, P1949; Muller M, 1996, INT J ONCOL, V9, P1169; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PAPANICOLAOU GN, 1945, SCIENCE, V101, P519, DOI 10.1126/science.101.2629.519; Rahat MA, 1999, CANCER, V85, P919; Ramakumar S, 1999, J UROLOGY, V161, P388, DOI 10.1016/S0022-5347(01)61899-8; Rehn L, 1895, ARCH KLIN CHIR, V50, P588; Sallinen P, 1997, AM J PATHOL, V150, P1159; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; Wu YY, 2000, CLIN CHIM ACTA, V293, P199, DOI 10.1016/S0009-8981(99)00238-7; YAMAMOTO M, 1992, CANCER RES, V52, P5329; Yashima K, 1997, J CLIN PATHOL, V50, P110, DOI 10.1136/jcp.50.2.110; Yokota K, 1998, BRIT J UROL, V82, P727, DOI 10.1046/j.1464-410x.1998.00827.x; Yoshida K, 1997, CANCER, V79, P362, DOI 10.1002/(SICI)1097-0142(19970115)79:2<362::AID-CNCR20>3.0.CO;2-Y	53	49	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					650	655		10.1038/sj.onc.1205071	http://dx.doi.org/10.1038/sj.onc.1205071			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850792				2022-12-28	WOS:000173390500019
J	Okorokov, AL; Rubbi, CP; Metcalfe, S; Milner, J				Okorokov, AL; Rubbi, CP; Metcalfe, S; Milner, J			The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage	ONCOGENE			English	Article						p53; nuclear F-actin; FRET; DNA damage	NORMAL HUMAN-FIBROBLASTS; C-TERMINAL DOMAIN; WILD-TYPE P53; ULTRAVIOLET-LIGHT; NONACTIVATED P53; TRANSCRIPTION; PROTEIN; COMPLEX; BINDING; CELLS	The tumour suppressor protein p53 is localized in the cell nucleus where it serves to initiate cellular responses to a variety of stresses, particularly DNA damage and has the capacity to transactivate stress response genes. An emerging body of evidence indicates that its action is also exerted through direct protein-protein interactions. An approach to understanding p53 function has been to analyse its positioning in relation to nuclear structures and we have shown that p53 can associate with the nuclear matrix. A potential nuclear matrix component for this association is actin. Here we show that p53 interacts with nuclear F-actin and we map the domains involved in this interaction. Using fluorescence resonance energy transfer, we demonstrate that the partition of p53 between F-actin bound and unbound forms is not constant, but is modulated by the presence of DNA damage, which increases binding. Our results indicate that the dynamic interaction of p53 with the nuclear matrix has to be considered for a full understanding of the mechanisms of the p53-mediated cellular response to DNA damage.	Univ York, Dept Biol, Res Grp, York YO10 5DD, N Yorkshire, England; Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England	University of York - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Milner, J (corresponding author), Univ York, Dept Biol, Res Grp, YCR P53, York YO10 5DD, N Yorkshire, England.			Okorokov, Andrei/0000-0003-2477-3254				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Haugland R., 1996, HDB FLUORESCENT PROB; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Iborra FJ, 1996, J CELL SCI, V109, P1427; JaresErijman EA, 1996, J MOL BIOL, V257, P597, DOI 10.1006/jmbi.1996.0188; Jiang M, 2001, ONCOGENE, V20, P5449, DOI 10.1038/sj.onc.1204705; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MCCREADY SJ, 1984, J CELL SCI, V70, P189; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Metcalfe S, 1999, ONCOGENE, V18, P2351, DOI 10.1038/sj.onc.1202559; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10607, DOI 10.1093/nar/16.22.10607; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NAKAYASU H, 1985, EXP CELL RES, V160, P319, DOI 10.1016/0014-4827(85)90179-X; Nguyen E, 1998, MOL REPROD DEV, V50, P263, DOI 10.1002/(SICI)1098-2795(199807)50:3&lt;263::AID-MRD2&gt;3.0.CO;2-H; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Okorokov AL, 1999, MOL CELL BIOL, V19, P7501; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Szak ST, 1999, J BIOL CHEM, V274, P3904, DOI 10.1074/jbc.274.6.3904; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188	40	55	60	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					356	367		10.1038/sj.onc.1205112	http://dx.doi.org/10.1038/sj.onc.1205112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821948				2022-12-28	WOS:000173311200004
J	Zhang, YW; Wang, LM; Jove, R; Vande Woude, GF				Zhang, YW; Wang, LM; Jove, R; Vande Woude, GF			Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis	ONCOGENE			English	Article						HGF/SF; Met; Stat3; Stat3 beta; anchorage independent growth; tumorigenesis	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; ANCHORAGE-INDEPENDENT GROWTH; RECEPTOR TYROSINE KINASE; FACTOR/SCATTER FACTOR; SOMATIC MUTATIONS; CELLULAR-TRANSFORMATION; EPITHELIAL-CELLS; SPLICE VARIANT; IN-VIVO	Hepatocyte Growth Factor/Scatter Factor (HGF/SF) mediates a wide variety of cellular responses by acting through the Met tyrosine kinase receptor. Inappropriate expression of HGF/SF and/or Met has been found in most types of solid tumors and is often associated with poor prognosis. Importantly, constitutional and sporadic activating mutations in Met have been discovered in human papillary renal carcinomas and other cancers, while autocrine and paracrine signaling of this receptor/ligand pair has been shown to contribute to tumorigenesis and metastasis. Numerous downstream signaling molecules have been implicated in HGF/SF-Met mediated tumorigenesis and metastasis. Stat3 is a downstream signaling molecule activated by HGF/SF-Met signaling, and is reported to contribute to cell transformation induced by a diverse set of oncoproteins. Stat3 is constitutively activated in many primary tumors and tumor cell lines, suggesting that signaling by this molecule may be important for cell transformation. To address whether Stat3 is required for HGF/SF-Met mediated tumorigenesis and metastasis, we introduced a dominant-negative form of Stat3, Stat3 beta into the human leiomyosarcoma cell line SK-LMS-1. We found that Stat3 beta has no effect on the transformed morphology, proliferation, invasion or branching morphogenesis in vitro. By contrast, expression of Stat3 beta affected HGF/SF-Met mediated anchorage-independent colony formation and prevented tumorigenic growth in athymic nu/nu mice. Thus, Met signaling through Stat3 provides an essential function for tumorigenic growth, which is manifested in vitro by loss of anchorage-independent growth.	Van Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	Van Andel Institute; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Vande Woude, GF (corresponding author), Van Andel Res Inst, Mol Oncol Lab, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.							Besser D, 1999, MOL CELL BIOL, V19, P1401; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CORTNER J, 1995, MET HGF SF AUTOCRINE; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Faletto D L, 1993, EXS, V65, P107; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1988, J CELL BIOCHEM, V38, P229, DOI 10.1002/jcb.240380402; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Jakubczak JL, 1998, MOL CELL BIOL, V18, P1275, DOI 10.1128/MCB.18.3.1275; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Koochekpour S, 1997, CANCER RES, V57, P5391; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Matsumoto K, 1993, EXS, V65, P225; Niu GL, 1999, CANCER RES, V59, P5059; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Park WS, 1999, CANCER RES, V59, P307; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; REDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREIT A, 1995, DEVELOPMENT, V121, P813; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	58	152	156	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					217	226		10.1038/sj/onc/1205004	http://dx.doi.org/10.1038/sj/onc/1205004			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803465				2022-12-28	WOS:000173026200006
J	Blaker, H; von Herbay, A; Penzel, R; Gross, S; Otto, HF				Blaker, H; von Herbay, A; Penzel, R; Gross, S; Otto, HF			Genetics of adenocarcinomas of the small intestine: frequent deletions at chromosome 18q and mutations of the SMAD4 gene	ONCOGENE			English	Article						small intestine; adenocarcinoma; LOH; CGH; SMAD4	COMPARATIVE GENOMIC HYBRIDIZATION; INTERNATIONAL COLLABORATIVE GROUP; NONPOLYPOSIS COLORECTAL-CANCER; K-RAS MUTATIONS; MICROSATELLITE INSTABILITY; CARCINOMAS; POLYPOSIS; LOSSES; GAINS; DPC4	The small intestinal mucosa makes up about 90% of the total surface of the gastrointestinal tract. However, adenocarcinomas arise rarely in this location. To elucidate genetic alterations underlying tumour development in the small intestine we investigated 17 sporadic adenocarcinomas. By comparative genomic hybridization recurrent gains of chromosomal material were found at chromosomes 7, 8, 13q, and 20 (5/17, each), while non-random losses were seen at 8p, 17p (4/17, each), and 18 (8/17 cases). Deletions at 5q, the location of the APC tumour suppressor gene, were seen in three cases. Microsatellite analysis with markers on chromosomal arms 1p, 5q, 8p, 17p, 18q, 19p, and 22q revealed a microsatellite instable phenotype in two cases and a high frequency of loss at 18q21-q22 (80%). Given the high incidence of 18q21-q22 deletions, we performed sequencing analysis of SMAD4, a downstream component of the TGF beta -pathway, located at 18q21. Four tumours displayed mutations in highly conserved domains of the gene indicating disruption of TGF beta -signalling. Our data reveal complex genetic alterations in sporadic small intestinal carcinomas. However, most tumours share deletions of 18q21-q22, which frequently target SMAD4. This indicates that disruption of TGF beta -signalling plays a critical role in small intestinal tumorigenesis.	Heidelberg Univ, Dept Pathol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Blaker, H (corresponding author), Heidelberg Univ, Dept Pathol, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany.	hendrik.blaeker@med.uni-heidelberg.de						Arai M, 1997, INT J CANCER, V70, P390, DOI 10.1002/(SICI)1097-0215(19970207)70:4<390::AID-IJC3>3.0.CO;2-R; Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; Blaker H, 1999, GENE CHROMOSOME CANC, V25, P399; De Angelis PM, 1999, BRIT J CANCER, V80, P526; EMI M, 1992, CANCER RES, V52, P5368; Houlston R, 1998, HUM MOL GENET, V7, P1907, DOI 10.1093/hmg/7.12.1907; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; ISOLA J, 1994, AM J PATHOL, V145, P1301; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; KIM HG, 1994, AM J PATHOL, V145, P148; LENNARDJONES JE, 1977, GASTROENTEROLOGY, V73, P1280; Lerebours F, 1999, GENE CHROMOSOME CANC, V25, P147, DOI 10.1002/(SICI)1098-2264(199906)25:2<147::AID-GCC10>3.0.CO;2-Z; LIGHTDALE CJ, 1994, BOCKUS GASTROENTEROL, P1274; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; Mahlamaki EH, 1997, GENE CHROMOSOME CANC, V20, P383, DOI 10.1002/(SICI)1098-2264(199712)20:4<383::AID-GCC10>3.0.CO;2-O; Messerini L, 1997, J PATHOL, V182, P380; MING SC, 1992, PATHOLOGY GASTROINTE, P816; Moore PS, 2000, HUM MUTAT, V15; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Moskaluk CA, 1997, DIAGN MOL PATHOL, V6, P85, DOI 10.1097/00019606-199704000-00003; Murata M, 2000, AM J GASTROENTEROL, V95, P1576; Negri E, 1999, INT J CANCER, V82, P171, DOI 10.1002/(SICI)1097-0215(19990719)82:2&lt;171::AID-IJC3&gt;3.0.CO;2-T; Neugut AI, 1998, CANCER EPIDEM BIOMAR, V7, P243; Park JG, 1999, DIS COLON RECTUM, V42, P710, DOI 10.1007/BF02236922; Pohl C, 2000, HEPATO-GASTROENTEROL, V47, P57; Rashid A, 1997, GASTROENTEROLOGY, V113, P127, DOI 10.1016/S0016-5085(97)70087-8; Roth S, 1999, GENE CHROMOSOME CANC, V26, P54, DOI 10.1002/(SICI)1098-2264(199909)26:1<54::AID-GCC8>3.0.CO;2-D; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SPIGELMAN AD, 1989, LANCET, V2, P783, DOI 10.1016/s0140-6736(89)90840-4; Sutter T, 1996, DIGEST DIS SCI, V41, P115, DOI 10.1007/BF02208591; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Thibodeau SN, 1998, CANCER RES, V58, P1713; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VISAKORPI T, 1995, CANCER RES, V55, P342; Whitelaw SC, 1997, GASTROENTEROLOGY, V112, P327, DOI 10.1053/gast.1997.v112.pm9024286; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yustein AS, 1999, CANCER RES, V59, P1437	40	70	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					158	164		10.1038/sj.onc.1205041	http://dx.doi.org/10.1038/sj.onc.1205041			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791187				2022-12-28	WOS:000172887800017
J	Tobin, SW; Douville, K; Benbow, U; Brinckerhoff, CE; Memoli, VA; Arrick, BA				Tobin, SW; Douville, K; Benbow, U; Brinckerhoff, CE; Memoli, VA; Arrick, BA			Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects	ONCOGENE			English	Article						TGF-beta; autocrine; paracrine; breast cancer	GROWTH-FACTOR-BETA; COLON-CARCINOMA CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; PROSTATE-CANCER; II RECEPTOR; DISEASE PROGRESSION; GASTRIC-CARCINOMA; MAMMARY-TUMOR; IN-VIVO; TUMORIGENICITY	To characterize the impact of increased production of TGF-beta in a xenograft model of human breast cancer, TGF-beta -responsive MDA-231 cells were genetically modified by stable transfection so as to increase their production of active TGF-beta1. Compared with control cells, cells that produced increased amounts of TGF-beta proliferated in vitro more slowly. In vivo, however, tumors derived from these cells exhibited increased proliferation and grew at an accelerated pace. To evaluate the role of autocrine TGF-beta signaling, cells were also transfected with a dominant-negative truncated type II TGF-beta receptor (T beta RII). Disruption of autocrine TGF-beta signaling in the TGF-beta -overexpressing cells reduced their in vivo growth rate. Co-inoculation of Matrigel with the TGF-beta -overexpressing cells expressing the truncated T beta RII compensated for their diminished in vivo growth capacity, compared with the TGF-beta -overexpressing cells with an intact autocrine loop. Tissue invasion by the tumor was a distinctive feature of the TGF-beta -overexpressing cells, whether or not the autocrine loop was intact. Furthermore, tumors derived from TGF-beta -overexpressing cells, irrespective of the status of the autocrine TGF-beta -signaling pathway, had a higher incidence of lung metastasis. Consistent with the suggestion that TGF-beta 's enhancement of invasion and metastasis is paracrine-based, we observed no significant differences among the cell clones in an in vitro invasion assay. Thus, in this experimental model system in vitro assays of cell proliferation and invasion do not accurately reflect in vivo observations, perhaps due to autocrine and paracrine effects of TGF-beta that influence the important in vivo-based phenomena of tumor growth, invasion, and metastasis.	Dartmouth Coll Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Pathol, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Dartmouth College	Arrick, BA (corresponding author), Dartmouth Coll Sch Med, Dept Med, Kellogg Box 0128, Hanover, NH 03755 USA.	Bradley.Arrick@dartmouth.edu			NATIONAL CANCER INSTITUTE [T32CA009658, R01CA060928] Funding Source: NIH RePORTER; NCI NIH HHS [CA09658, CA60928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Anbazhagan R, 1999, CANCER RES, V59, P3363; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ARRICK BA, 1996, MOL ENDOCRINOLOGY CA, P51; Arteaga CL, 1999, JNCI-J NATL CANCER I, V91, P46, DOI 10.1093/jnci/91.1.46; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; BAO L, 1994, BRIT J CANCER, V70, P228, DOI 10.1038/bjc.1994.284; Benbow U, 1999, CLIN EXP METASTAS, V17, P231, DOI 10.1023/A:1006639214618; BRAND T, 1995, J BIOL CHEM, V270, P8274, DOI 10.1074/jbc.270.14.8274; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; CHANG HL, 1993, CANCER RES, V53, P4391; Chen TP, 1998, CANCER RES, V58, P4805; DALAL BI, 1993, AM J PATHOL, V143, P381; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; Gobbi H, 2000, HISTOPATHOLOGY, V36, P168; GORSCH SM, 1992, CANCER RES, V52, P6949; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; INGE TH, 1992, CANCER RES, V52, P1386; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kinugasa S, 1998, ONCOLOGY-BASEL, V55, P582, DOI 10.1159/000011916; Koli KM, 1996, J MAMMARY GLAND BIOL, V1, P373, DOI 10.1007/BF02017393; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Lu ML, 2000, ONCOGENE, V19, P6351, DOI 10.1038/sj.onc.1204025; Maehara Y, 1999, J CLIN ONCOL, V17, P607, DOI 10.1200/JCO.1999.17.2.607; Matsuzaki K, 2000, CANCER RES, V60, P1394; Matthews E, 2000, BRIT J CANCER, V83, P519, DOI 10.1054/bjoc.2000.1257; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Mullen P, 1996, INT J CANCER, V67, P816, DOI 10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Ohmori T, 1998, EXP CELL RES, V245, P350, DOI 10.1006/excr.1998.4261; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Saito H, 1999, CANCER, V86, P1455, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1455::AID-CNCR11>3.0.CO;2-L; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TAKANAMI I, 1994, J CLIN PATHOL, V47, P1098, DOI 10.1136/jcp.47.12.1098; Tobin SW, 2001, CELL GROWTH DIFFER, V12, P109; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; UEKI N, 1993, JPN J CANCER RES, V84, P589, DOI 10.1111/j.1349-7006.1993.tb02017.x; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; VANSLOOTEN HJ, 1995, BRIT J CANCER, V72, P22, DOI 10.1038/bjc.1995.271; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Wikstrom P, 1998, PROSTATE, V37, P19, DOI 10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3; Ye SC, 1999, CANCER RES, V59, P4725; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	55	46	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					108	118		10.1038/sj.onc.1205026	http://dx.doi.org/10.1038/sj.onc.1205026			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791181				2022-12-28	WOS:000172887800011
J	Causevic, M; Hislop, RG; Kernohan, NM; Carey, FA; Kay, RA; Steele, RJC; Fuller-Pace, FV				Causevic, M; Hislop, RG; Kernohan, NM; Carey, FA; Kay, RA; Steele, RJC; Fuller-Pace, FV			Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours	ONCOGENE			English	Article						p68 RNA helicase; colorectal cancer; overexpression; ubiquitylation	UBIQUITIN-PROTEASOME PATHWAY; NUCLEAR-PORE COMPLEX; PROTEIN-DEGRADATION; SUMO-1 MODIFICATION; C-MYC; GENE; P53; COAMPLIFICATION; NEUROBLASTOMA; PROTEOLYSIS	The DEAD box RNA helicase, p68, is upregulated in exponentially growing cells and shows cell cycle-dependent changes in nuclear localization. Although some other DEAD box proteins have been implicated in cancer, there have been no reports of any link between p68 status and carcinogenesis. In the present study we have analysed specimens from 50 patients with colorectal adenocarcinomas, including cases in which an adenomatous polyp was also present, by immunohistochemistry and Western blotting. Our data indicate that p68 protein is consistently overexpressed in tumours as compared with matched normal tissue. Examination of the levels of p68 mRNA from both normal and tumour tissue showed no obvious specific increase in p68 mRNA levels in tumours nor any evidence of underlying mutations in the p68 coding region. Interestingly, however, the accumulated p68 appears to be poly-ubiquitylated, suggesting a possible defect in proteasome-mediated degradation in these tumours. This overexpression/ubiquitylation is observed in both pre-invasive and invasive lesions suggesting that the dysregulation of p68 expression occurs early during tumour development. Finally, we demonstrate that ubiquitylation of p68 occurs in cultured cells, thereby providing a model for the molecular analysis of this process and its potential role in tumorigenesis.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Dent, Dept Cell & Mol Biol, Dundee DD1 4HR, Scotland	University of Dundee; University of Dundee; University of Dundee	Fuller-Pace, FV (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Causevic, Mirsada/AAM-7423-2020	Causevic, Mirsada/0000-0002-6099-6415; Steele, Robert JC/0000-0003-4248-6785				AKAO Y, 1995, CANCER RES, V55, P3444; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; SQUIRE JA, 1995, ONCOGENE, V10, P1417; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Webster GA, 1999, MOL CELL BIOL, V19, P3485	33	116	122	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7734	7743		10.1038/sj.onc.1204976	http://dx.doi.org/10.1038/sj.onc.1204976			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753651				2022-12-28	WOS:000172161700004
J	Plumb, JA; Bilsland, A; Kakani, R; Zhao, JQ; Glasspool, RM; Knox, RJ; Evans, TRJ; Keith, WN				Plumb, JA; Bilsland, A; Kakani, R; Zhao, JQ; Glasspool, RM; Knox, RJ; Evans, TRJ; Keith, WN			Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954	ONCOGENE			English	Article						telomerase; hTERT; hTR; gene therapy; nitroreductase; GDEPT	ESCHERICHIA-COLI NITROREDUCTASE; IN-SITU HYBRIDIZATION; CATALYTIC SUBUNIT; RNA COMPONENT; PROMOTER SEQUENCES; HTERT GENE; ACTIVATION; STRATEGIES; IDENTIFICATION; CLONING	Telomerase activation is considered to be a critical step in cancer progression due to its role in cellular immortalization. The prevalence of telomerase expression in human cancers makes it an attractive candidate for new mechanism-based targets for cancer therapy. The selective killing of cancer cells can be achieved by gene-directed enzyme pro-drug therapy (GDEPT). In this study we have tested the feasibility of using the transcriptional regulatory sequences from the hTERT and hTR genes to regulate expression of the bacterial nitroreductase enzyme in combination with the pro-drug CB1954 in a suicide gene therapy strategy. hTERT and hTR promoter activity was compared in a panel of 10 cell lines and showed a wide distribution in activity; low activity was observed in normal cells and telomerase-negative immortal ALT cell lines, with up to 300-fold higher activity observed in telomerase positive cancer lines. Placing the nitroreductase gene under the control of the telomerase gene promoters sensitized cancer cells in tissue culture to the pro-drug CB1954 and promoter activity was predictive of sensitization to the pro-drug (2-20-fold sensitization), with cell death restricted to lines exhibiting high levels of promoter activity. The in vivo relevance of these data was tested using two xenograft models (C33a and GLC4 cells). Significant tumour reduction was seen with both telomerase promoters and the promoter-specific patterns of sensitization observed in tissue culture were retained in xenograft models. Thus, telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.	Univ Glasgow, CRC, Dept Med Oncol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Enact Pharma Plc, Salisbury SP4 0JQ, Wilts, England	Beatson Institute; University of Glasgow	Keith, WN (corresponding author), Univ Glasgow, CRC, Dept Med Oncol, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Keith, Nicol/D-3325-2009; Bilsland, Alan/G-2629-2010	Keith, Nicol/0000-0001-7862-3580; Zhao, Jiangqin/0000-0003-4672-0735; Glasspool, Rosalind/0000-0002-5000-1680; Bilsland, Alan/0000-0003-0957-3908				Abdul-Ghani R, 2000, MOL THER, V2, P539, DOI 10.1006/mthe.2000.0196; Bailey SM, 1996, GENE THER, V3, P1143; Bailey SM, 1997, GENE THER, V4, P80, DOI 10.1038/sj.gt.3300400; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Greco O, 2001, J CELL PHYSIOL, V187, P22, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO;2-H; Gu J, 2000, CANCER RES, V60, P5359; Gunes C, 2000, CANCER RES, V60, P2116; Harrington KJ, 2000, ADV DRUG DELIVER REV, V44, P167, DOI 10.1016/S0169-409X(00)00093-4; Heine B, 1998, J PATHOL, V185, P139, DOI 10.1002/(SICI)1096-9896(199806)185:2<139::AID-PATH79>3.0.CO;2-L; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; Hiyama T, 1999, VIRCHOWS ARCH, V434, P483, DOI 10.1007/s004280050372; Hoare SF, 2001, CANCER RES, V61, P27; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Maitra A, 1999, CANCER-AM CANCER SOC, V85, P741, DOI 10.1002/(SICI)1097-0142(19990201)85:3<741::AID-CNCR25>3.0.CO;2-6; Majumdar AS, 2001, GENE THER, V8, P568, DOI 10.1038/sj.gt.3301421; Mistry P, 2001, CANCER RES, V61, P749; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; Nowak R, 1998, CANCER J SCI AM, V4, P148; Park TW, 1999, INT J CANCER, V84, P426, DOI 10.1002/(SICI)1097-0215(19990820)84:4<426::AID-IJC17>3.3.CO;2-T; Plumb JA, 2000, CANCER RES, V60, P6039; Sarvesvaran J, 1999, CARCINOGENESIS, V20, P1649, DOI 10.1093/carcin/20.8.1649; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Soder AI, 1998, ONCOGENE, V16, P979, DOI 10.1038/sj.onc.1201620; Stanta G, 1999, FEBS LETT, V460, P285, DOI 10.1016/S0014-5793(99)01357-5; Takakura M, 1999, CANCER RES, V59, P551; Urquidi V, 1998, ANN MED, V30, P419, DOI 10.3109/07853899809002483; Vile RG, 1998, MOL MED TODAY, V4, P84, DOI 10.1016/S1357-4310(97)01157-X; Weedon SJ, 2000, INT J CANCER, V86, P848, DOI 10.1002/(SICI)1097-0215(20000615)86:6<848::AID-IJC14>3.0.CO;2-B; Weng NP, 1997, J IMMUNOL, V158, P3215; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; Wisman GBA, 2000, HUM PATHOL, V31, P1304, DOI 10.1053/hupa.2000.19299; Yashima K, 1998, CELL GROWTH DIFFER, V9, P805; Yi XM, 1999, MOL CELL BIOL, V19, P3989; Zhao JQ, 1998, ONCOGENE, V16, P1345, DOI 10.1038/sj.onc.1201892; Zhao JQ, 2000, NEOPLASIA, V2, P531, DOI 10.1038/sj.neo.7900114	37	96	101	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7797	7803		10.1038/sj.onc.1204954	http://dx.doi.org/10.1038/sj.onc.1204954			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753658				2022-12-28	WOS:000172161700011
J	Wang, Y; Hu, L; Yao, RS; Wang, M; Crist, KA; Grubbs, CJ; Johanning, GL; Lubet, RA; You, M				Wang, Y; Hu, L; Yao, RS; Wang, M; Crist, KA; Grubbs, CJ; Johanning, GL; Lubet, RA; You, M			Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor	ONCOGENE			English	Article						rat; mammary; adenocarcinoma; gene expression; competitive cDNA library screening; vorozole; chemoprevention	CYCLIN D1; BREAST-CARCINOMA; DNA MICROARRAY; CANCER; MODELS; CELLS; DIFFERENTIATION; CLASSIFICATION; TRANSFORMATION; MASPIN	In the present study, competitive cDNA library screening (CCLS) and cDNA microarray analyses were employed to identify differentially expressed genes in methylnitrosourea-induced rat mammary adenocarcinomas. The preliminary screening of 100 000 plaques by CCLS identified 1217 clones with differential expression. Dot-blot analysis of the isolated clones verified differential expression in 471 distinct genes. Confirmation of these 471 genes was conducted by performing reverse transcription-polymerase chain reactions, and a total of 160 genes were confirmed after comparing six rat mammary adenocarcinomas and three normal rat mammary glands. Fifty-nine of these showed lower expression in the adenocarcinomas while the remaining 101 were overexpressed in the tumors. Employing a cDNA microarray containing 588 known genes revealed an additional 33 differentially expressed genes in these tumors. Importantly, most of the identified genes demonstrated relatively reproducible overexpression or underexpression in individual tumors. Many of the altered genes determined by cDNA microarray analysis were oncogenes, tumor suppressor genes, or genes involved in cell cycle control and apoptosis. CCLS identified many others not previously associated with mammary carcinogenesis, including a novel gene named RMT-7. Preliminary studies to determine the applicability of this gene expression approach for detecting potential biomarkers for cancer chemoprevention was evaluated in rat mammary tumors obtained from animals treated with vorozole, a potent aromatase inhibitor. When genes exhibiting differential expression as determined by CCLS or cDNA microarray analysis were examined in control and vorozole-treated tumors, expression of 19 genes was found to be modulated significantly in tumors treated with vorozole. Further investigations into these identified genes should contribute significantly to our understanding of the molecular mechanisms of rat mammary tumorigenesis. In addition, the identified genes may become useful targets for drug development and potential biomarkers for monitoring treatment and prevention of breast cancer in humans.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Sch Publ Hlth, Columbus, OH 43210 USA; Med Coll Ohio, Toledo, OH 43614 USA; Ohio State Univ, Div Human Canc Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Alabama Birmingham, Chemoprevent Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Sch Publ Hlth, Columbus, OH 43210 USA.		Johanning, Gary L/A-9671-2008		NCI NIH HHS [CN05113, CA58554, CA16058, CA78797] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005113] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R29CA058554, R01CA078797, P30CA016058, R01CA058554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Burk RF, 1997, HISTOCHEM CELL BIOL, V108, P11, DOI 10.1007/s004180050141; Chen H, 2001, MOL CARCINOGEN, V30, P79, DOI 10.1002/1098-2744(200102)30:2<79::AID-MC1016>3.0.CO;2-F; Christov K, 2000, BREAST CANCER RES TR, V60, P117, DOI 10.1023/A:1006384026252; COLE PA, 1990, J MED CHEM, V33, P2933, DOI 10.1021/jm00173a001; DECOSTER R, 1992, CANCER RES, V52, P1240; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; Dukes M, 1997, ONCOLOGY, V54, P6; EASTON DF, 1993, AM J HUM GENET, V52, P678; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; FILMUS J, 1994, ONCOGENE, V9, P3627; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; GOULD MN, 1995, SEMIN CANCER BIOL, V6, P147, DOI 10.1006/scbi.1995.0023; GRUBBS CJ, 1974, EUR J CANCER, V10, P707, DOI 10.1016/0014-2964(74)90108-X; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hu L, 1997, J CELL BIOCHEM, P117; HU L, 1997, J CELL BIOCHEM, P28; Kelly DL, 2000, MOL REPROD DEV, V56, P113, DOI 10.1002/(SICI)1098-2795(200006)56:2&lt;113::AID-MRD1&gt;3.0.CO;2-Q; Koga M, 1998, BIOL REPROD, V58, P261, DOI 10.1095/biolreprod58.1.261; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lubet RA, 1998, CARCINOGENESIS, V19, P1345, DOI 10.1093/carcin/19.8.1345; LUBET RA, 1994, CARCINOGENESIS, V15, P2775, DOI 10.1093/carcin/15.12.2775; Maass N, 2000, ACTA ONCOL, V39, P931; MARTIKAINEN H, 1992, FERTIL STERIL, V58, P543; Martin K, 2000, CANCER RES, V60, P2232; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Nacht M, 1999, CANCER RES, V59, P5464; Popovici RM, 2000, ENDOCRINOLOGY, V141, P3510, DOI 10.1210/en.141.9.3510; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; Russo J, 1996, BREAST CANCER RES TR, V39, P7, DOI 10.1007/BF01806074; Russo J, 2000, J MAMMARY GLAND BIOL, V5, P187, DOI 10.1023/A:1026443305758; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sallinen SL, 2000, CANCER RES, V60, P6617; Schedin P, 2000, J MAMMARY GLAND BIOL, V5, P211, DOI 10.1023/A:1026447506666; Schultz Linda B., 1999, Current Opinion in Oncology, V11, P429, DOI 10.1097/00001622-199911000-00002; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STEELE VE, 1994, J CELL BIOCHEM, P32; SUIKKARI AM, 1991, FERTIL STERIL, V55, P895; Thompson HJ, 2000, J MAMMARY GLAND BIOL, V5, P201, DOI 10.1023/A:1026495322596; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WOUTERS W, 1990, J STEROID BIOCHEM, V37, P1049, DOI 10.1016/0960-0760(90)90464-V; YAMASHITA H, 1993, JPN J CANCER RES, V84, P871, DOI 10.1111/j.1349-7006.1993.tb02060.x	46	21	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7710	7721		10.1038/sj.onc.1204941	http://dx.doi.org/10.1038/sj.onc.1204941			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753649				2022-12-28	WOS:000172161700002
J	Hoffman, B; Amanullah, A; Shafarenko, M; Liebermann, DA				Hoffman, B; Amanullah, A; Shafarenko, M; Liebermann, DA			The proto-oncogene c-myc in hematopoietic development and leukemogenesis	ONCOGENE			English	Article						c-myc; hematopoiesis; differentiation; leukemogenesis	TRANSCRIPTION FACTOR EGR-1; CELL-CYCLE PROGRESSION; MYELOID-LEUKEMIA CELLS; DNA-BINDING; FAS LIGAND; MACROPHAGE DIFFERENTIATION; HISTONE DEACETYLASE; MOLECULAR CONTROL; ENHANCER-BINDING; ANTAGONIST MAD1	The proto-oncogene c-myc has been shown to play a pivotal role in cell cycle regulation, metabolism, apoptosis, differentiation, cell adhesion, and tumorigenesis, and participates in regulating hematopoietic homeostasis. It is a transcription regulator that is part of an extensive network of interacting factors. Most probably, different biological responses are elicited by different overlapping subsets of c-Myc target genes, both induced and suppressed. Results obtained from studies employing mouse models are consistent with the need for at least one, and possibly two, mutations in addition to deregulated c-myc for malignant tumor formation. Repression of c-myc is required for terminal differentiation of many cell types, including hematopoietic cells. It has been shown that deregulated expression of c-myc in both M1 myeloid leukemic cells and normal myeloid cells derived from murine bone marrow, not only blocked terminal differentiation and its associated growth arrest, but also induced apoptosis, which is dependent on the Fas/CD95 pathway. There is evidence to suggest that the CD95/Fas death receptor pathway is an integral part of the apoptotic response associated with the end of the normal terminal myeloid differentiation program, and that deregulated c-myc expression can activate this signaling pathway prematurely. The ability of egr-1 to promote terminal myeloid differentiation when co-expressed with c-myc, and of c-fos to partially abrogate the block imparted by deregulated c-myc on myeloid differentiation, make these two genes candidate tumor suppressors. Several different transcription factors have been implicated in the down-regulation of c-myc expression during differentiation, including C/EBPalpha, CTCF, BLIMP-1, and RFX1. Alterations in the expression and/or function of these transcription factors, or of the c-Myc and Max interacting proteins, such as MM-1 and Mxil, can influence the neoplastic process. Understanding how c-Myc controls cellular phenotypes, including the leukemic phenotype, should provide novel tools for designing drugs to promote differentiation and/ or apoptosis of leukemic cells.	Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Hoffman, B (corresponding author), Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	hoffman@unix.temple.edu			NCI NIH HHS [R01 CA81168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Amanullah A, 2002, ONCOGENE, V21, P1600, DOI 10.1038/sj.onc.1205231; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Bhatia K, 1995, Curr Top Microbiol Immunol, V194, P389; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Cambier N, 1999, ONCOGENE, V18, P343, DOI 10.1038/sj.onc.1202302; Cameron ER, 2000, CELL DEATH DIFFER, V7, P80, DOI 10.1038/sj.cdd.4400630; Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Crossen PE, 1999, CANCER GENET CYTOGEN, V112, P144, DOI 10.1016/S0165-4608(98)00260-X; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; Dang CV, 1999, MOL CELL BIOL, V19, P1; Davies J, 1999, ONCOGENE, V18, P3643, DOI 10.1038/sj.onc.1202956; Delgado MD, 1999, FEBS LETT, V444, P5, DOI 10.1016/S0014-5793(99)00013-7; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fecho K, 1998, CELL IMMUNOL, V188, P19, DOI 10.1006/cimm.1998.1339; Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HAUPT Y, 1993, INT J CANCER, V55, P623, DOI 10.1002/ijc.2910550418; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Hoffman B, 1996, CURR TOP MICROBIOL, V211, P17; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liebermann DA, 1998, INT J ONCOL, V12, P685; LINDEMAN GJ, 1995, ONCOGENE, V10, P1013; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; O'Malley F, 1999, CANCER GENET CYTOGEN, V109, P123, DOI 10.1016/S0165-4608(98)00160-5; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; QUESENBERRY PJ, 1990, HEMATOLOGY, P129; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Rao G, 1996, ONCOGENE, V12, P1165; Rasko JEJ, 2001, CANCER RES, V61, P6002; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Ryan KM, 1997, ONCOGENE, V14, P2835, DOI 10.1038/sj.onc.1201124; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Wu SJ, 1996, ONCOGENE, V12, P621; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; ZORNIG M, 1995, ONCOGENE, V10, P2397	94	172	196	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3414	3421		10.1038/sj.onc.1205400	http://dx.doi.org/10.1038/sj.onc.1205400			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032779	Bronze			2022-12-28	WOS:000175633300014
J	Kitada, S; Pedersen, IM; Schimmer, AD; Reed, JC				Kitada, S; Pedersen, IM; Schimmer, AD; Reed, JC			Dysregulation of apoptosis genes in hematopoietic malignancies	ONCOGENE			English	Review						apoptosis; programmed cell death; malignancy	NF-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BUTYRATE-INDUCED APOPTOSIS; BCL-2 PROTEIN EXPRESSION; NECROSIS-FACTOR RECEPTOR; ACUTE MYELOID LEUKEMIAS; TRAIL-INDUCED APOPTOSIS; NON-HODGKINS-LYMPHOMA; CELL-SURFACE ANTIGEN	Ever since the discovery of Bel-2 and the elucidation of its role in apoptosis, tremendous interest has arisen in prospects for triggering suicide of malignant cells by exploiting knowledge emerging from apoptosis research. In this review, we summarize information about the multiple genetic lesions which have been identified in apoptosis-regulatory genes of hematopoietic and lymphoid neoplasms. Emerging data about the structural and biochemical details of apoptosis proteins and their upstream regulators have reveal novel strategies for therapeutic intervention, some of which are under interrogation in clinical trials currently.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham.org		Schimmer, Aaron/0000-0003-4023-3899				Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; AHMED NN, 1993, ONCOGENE, V8, P1957; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Anthoney DA, 1996, CANCER RES, V56, P1374; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Bergmann L, 1997, BLOOD, V90, P1217, DOI 10.1182/blood.V90.3.1217.1217_1217_1225; Bladergroen BA, 2001, J IMMUNOL, V166, P3218, DOI 10.4049/jimmunol.166.5.3218; Borlado LR, 2000, FASEB J, V14, P895; Boultwood J, 2001, J CLIN PATHOL, V54, P512, DOI 10.1136/jcp.54.7.512; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; CAMPOS L, 1993, BLOOD, V81, P3091; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dalton WS, 1999, SEMIN ONCOL, V26, P23; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Ergin M, 2001, EXP HEMATOL, V29, P1082, DOI 10.1016/S0301-472X(01)00688-9; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FU TB, 1994, CANCER RES, V54, P6297; Gascoyne RD, 1997, BLOOD, V90, P244; GAUWERKY CE, 1988, ONCOGENE, V2, P431; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Gil J, 1999, CANCER RES, V59, P2034; Gill S, 1999, BRIT J CANCER, V80, P1565, DOI 10.1038/sj.bjc.6990561; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Goke R, 2000, CELL IMMUNOL, V201, P77, DOI 10.1006/cimm.2000.1650; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graubert TA, 1997, J CLIN INVEST, V100, P904, DOI 10.1172/JCI119606; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Gronbaek K, 1998, BLOOD, V92, P3018; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hague A, 1997, INT J CANCER, V72, P898, DOI 10.1002/(SICI)1097-0215(19970904)72:5<898::AID-IJC30>3.0.CO;2-2; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; Hess JL, 1998, NAT GENET, V20, P220, DOI 10.1038/3014; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Houldsworth J, 1996, BLOOD, V87, P25; HUANG MT, 1994, CANCER RES, V54, P701; Inoue K, 2000, LEUKEMIA RES, V24, P255, DOI 10.1016/S0145-2126(99)00182-4; Ito Y, 2000, CELL GROWTH DIFFER, V11, P261; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamihira S, 1999, BRIT J HAEMATOL, V107, P851, DOI 10.1046/j.1365-2141.1999.01792.x; Karanewsky DS, 1998, BIOORG MED CHEM LETT, V8, P2757, DOI 10.1016/S0960-894X(98)00498-3; Karnolsky I N, 2000, Folia Med (Plovdiv), V42, P5; KAUFMANN SH, 1991, EXP CELL RES, V192, P524, DOI 10.1016/0014-4827(91)90072-3; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kornblau SM, 2000, CLIN CANCER RES, V6, P1401; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kupper M, 2001, BRIT J HAEMATOL, V112, P768, DOI 10.1046/j.1365-2141.2001.02566.x; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liu TC, 2000, BRIT J HAEMATOL, V109, P250, DOI 10.1046/j.1365-2141.2000.01969.x; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lowin B, 1995, Curr Top Microbiol Immunol, V198, P1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; McConkey DJ, 1996, J IMMUNOL, V156, P2624; Medh RD, 2000, CELL TISSUE RES, V301, P101, DOI 10.1007/s004419900159; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; MIYASHITA T, 1995, CELL, V80, P293; Morgan JA, 1999, CANCER RES, V59, P6205; Motegi M, 2000, AM J PATHOL, V156, P807, DOI 10.1016/S0002-9440(10)64948-6; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Niitsu N, 1999, LEUKEMIA, V13, P1434, DOI 10.1038/sj.leu.2401502; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OEHM A, 1992, J BIOL CHEM, V267, P10709; Ong YL, 2000, BRIT J HAEMATOL, V111, P182, DOI 10.1046/j.1365-2141.2000.02315.x; Osorio LM, 2001, EUR J HAEMATOL, V66, P342, DOI 10.1034/j.1600-0609.2001.066005342.x; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Ozes ON, 1999, NATURE, V401, P82; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Pathan N, 2001, J BIOL CHEM, V276, P32220, DOI 10.1074/jbc.M100433200; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Pepper C, 1996, BRIT J HAEMATOL, V95, P513, DOI 10.1046/j.1365-2141.1996.d01-1927.x; Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487; Pepper C, 1998, LEUKEMIA LYMPHOMA, V28, P355, DOI 10.3109/10428199809092690; Perucho M, 1996, BIOL CHEM, V377, P675; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Radich JP, 2001, HEMATOL ONCOL CLIN N, V15, P21, DOI 10.1016/S0889-8588(05)70198-2; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; REED JC, 1993, LEUKEMIA LYMPHOMA, V10, P157, DOI 10.3109/10428199309145877; Reed JC, 1999, J NATL CANCER I, V91, P1099, DOI 10.1093/jnci/91.13.1099; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shikami M, 1999, LEUKEMIA, V13, P358, DOI 10.1038/sj.leu.2401343; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Simms LA, 1998, ONCOGENE, V17, P2003, DOI 10.1038/sj.onc.1202109; Slupianek A, 2001, CANCER RES, V61, P2194; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Soulier J, 2001, GENE CHROMOSOME CANC, V31, P248, DOI 10.1002/gcc.1141; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Stankovic T, 2001, BLOOD, V97, P1517, DOI 10.1182/blood.V97.5.1517; Strasser A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P151; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; Suh N, 1999, CANCER RES, V59, P5671; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; TANAKA S, 1992, BLOOD, V79, P229; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wuchter C, 2001, LEUKEMIA, V15, P921, DOI 10.1038/sj.leu.2402131; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; Wyllie AH, 1997, BRIT MED BULL, V53, P451; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Yuille MR, 1998, LEUKEMIA, V12, P1696, DOI 10.1038/sj.leu.2401176; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	208	133	140	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3459	3474		10.1038/sj.onc.1205327	http://dx.doi.org/10.1038/sj.onc.1205327			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032782				2022-12-28	WOS:000175633300017
J	Satoh, M; Toma, H; Sugahara, K; Etoh, K; Shiroma, Y; Kiyuna, S; Takara, M; Matsuoka, M; Yamaguchi, K; Nakada, K; Fujita, K; Kojima, S; Hori, E; Tanaka, Y; Kamihira, S; Sato, Y; Watanabe, T				Satoh, M; Toma, H; Sugahara, K; Etoh, K; Shiroma, Y; Kiyuna, S; Takara, M; Matsuoka, M; Yamaguchi, K; Nakada, K; Fujita, K; Kojima, S; Hori, E; Tanaka, Y; Kamihira, S; Sato, Y; Watanabe, T			Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4(+)25(+) HTLV-1-infected T-cells in human carriers of both HTLV-1 and S-stercoralis	ONCOGENE			English	Article						HTLV-1 provirus load; clonality; S. stercoralis antigen; IL-2; ATL	VIRUS TYPE-I; BLOOD MONONUCLEAR-CELLS; LEUKEMIA-VIRUS; PROVIRAL DNA; MONOCLONAL INTEGRATION; CLONAL PROLIFERATION; GENE-EXPRESSION; INFECTED-CELLS; INTERLEUKIN-2; LINES	The intermediate state of HTLV-1 infection, often found in individuals dually infected with Strongyloides stercoralis (S. stercoralis) and HTLV-1. is assumed to be a preleukemic state of adult T-cell leukemia (ATL). To investigate the effects of S. stercoralis superinfection on the natural history of HTLV-1 infection, we characterized peripheral blood samples of these individuals in Okinawa. Japan, an endemic area for both HTLV-1 and S. stercoralis and we studied effects of the parasite antigen on T-cells. The dually infected individuals showed a significantly higher provirus load and an increase in CD4(+)25(+) T cell population, with a significant, positive correlation. This increase was attributable to polyclonal expansion of HTLV-1-infected cells, as demonstrated by inverse-long PCR analysis of the integration sites. S. stercoralis antigen activated the IL-2 promoter in reporter gene assays, induced production of IL-2 by PBMC in vitro, and supported growth of IL-2 dependent cell lines immortalized by HTLV-1 infection or the transduction of Tax. Taken collectively, these results indicate that S. stercoralis infection induces polyclonal expansion of HTLV-1-infected cells by activating the IL-2/IL-2R system in dually infected carriers, an event which may be a precipitating factor for ATL and inflammatory diseases.	Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, Tokyo 1088639, Japan; Saitama Med Sch, Dept Med Zool, Moroyama, Saitama, Japan; Ryukoku Univ, Sch Med, Dept Parasitol, Okinawa, Japan; Nagasaki Univ, Sch Med, Dept Lab Med, Nagasaki 852, Japan; Kumamoto Univ, Sch Med, Dept Internal Med, Kumamoto 860, Japan; Izumizaki Hosp, Okinawa, Japan; Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; Gushikawa Clin, Okinawa, Japan; Kumamoto Univ, Sch Med, Blood Transfus Serv, Kumamoto 8608556, Japan; Okinawa Kyodo Hosp, Okinawa, Japan; Tokyo Med & Dent Univ, Fac Med, Dept Med Zool, Tokyo 113, Japan; Univ Tokyo, Inst Med Sci, Dept Parasitol, Tokyo, Japan; Univ Ryukyus, Fac Med, Okinawa Asia Res Ctr Med Sci, Dept Infect Dis & Immunol, Okinawa, Japan	University of Tokyo; Saitama Medical University; Ryukoku University; Nagasaki University; Kumamoto University; Kyoto University; Kumamoto University; Tokyo Medical & Dental University (TMDU); University of Tokyo; University of the Ryukyus	Watanabe, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tnabe@ims.u-tokyo.ac.jp		Matsuoka, Masao/0000-0002-0473-754X				AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Arakaki T., 1988, Japanese Journal of Tropical Medicine and Hygiene, V16, P11; BLANK A, 1993, LEUKEMIA LYMPHOMA, V9, P407, DOI 10.3109/10428199309148542; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Etoh K, 1997, CANCER RES, V57, P4862; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJITA K, 1985, Tropical Medicine, V27, P203; FURUKAWA Y, 1992, BLOOD, V80, P1012; Gabet AS, 2000, ONCOGENE, V19, P4954, DOI 10.1038/sj.onc.1203870; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1985, LANCET, V2, P407; GREENBERG SJ, 1989, J INFECT DIS, V159, P741, DOI 10.1093/infdis/159.4.741; Grove DI, 1996, ADV PARASIT, V38, P251, DOI 10.1016/S0065-308X(08)60036-6; HATTORI T, 1981, BLOOD, V58, P645; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITOYAMA Y, 1988, NEUROLOGY, V38, P816, DOI 10.1212/WNL.38.5.816; Kamihira S, 2000, INT J HEMATOL, V72, P79; Kreuzer KA, 1999, CANCER RES, V59, P3171; LAM KMC, 1991, LANCET, V337, P876, DOI 10.1016/0140-6736(91)90203-2; LANGRIDGE WHR, 1987, METHOD ENZYMOL, V153, P336; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; MOCHIZUKI M, 1992, LANCET, V339, P1110, DOI 10.1016/0140-6736(92)90699-4; MOCHIZUKI M, 1992, J INFECT DIS, V166, P943, DOI 10.1093/infdis/166.4.943; Mori N, 2000, BLOOD, V95, P3915; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; NAKADA K, 1984, LANCET, V1, P633; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; NEVA FA, 1986, J INFECT DIS, V153, P397, DOI 10.1093/infdis/153.3.397; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Ono A, 1998, JPN J CANCER RES, V89, P608, DOI 10.1111/j.1349-7006.1998.tb03262.x; ONO A, 1995, BRIT J OPHTHALMOL, V79, P270, DOI 10.1136/bjo.79.3.270; OSAME M, 1986, LANCET, V1, P1031; PATEY O, 1992, AIDS, V6, P575, DOI 10.1097/00002030-199206000-00009; PLUMELLE Y, 1993, HEMATOL PATHOL, V7, P251; SATO Y, 1990, Japanese Journal of Parasitology, V39, P213; SATO Y, 1989, CLIN IMMUNOL IMMUNOP, V53, P430, DOI 10.1016/0090-1229(89)90005-6; SATO Y, 1985, T ROY SOC TROP MED H, V79, P51, DOI 10.1016/0035-9203(85)90233-0; SATOH M, 1991, INT ARCH ALLER A IMM, V96, P95, DOI 10.1159/000235541; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; TAJIMA K, 1986, HEMATOL ONCOL, V4, P31, DOI 10.1002/hon.2900040106; TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TATEWAKI M, 1995, BLOOD, V86, P3109; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; Watanabe T, 1997, INT J HEMATOL, V66, P257; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; YAMAGUCHI K, 1987, LANCET, V2, P94, DOI 10.1016/S0140-6736(87)92752-8; YAMAGUCHI K, 1988, BRIT J HAEMATOL, V68, P169, DOI 10.1111/j.1365-2141.1988.tb06185.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1989, ANN NEUROL, V26, P331, DOI 10.1002/ana.410260304; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA K, 1993, AM J OPHTHALMOL, V116, P156, DOI 10.1016/S0002-9394(14)71279-6	59	57	59	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2466	2475		10.1038/sj.onc.1205329	http://dx.doi.org/10.1038/sj.onc.1205329			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971181				2022-12-28	WOS:000174918400003
J	Fulda, S; Meyer, E; Debatin, KM				Fulda, S; Meyer, E; Debatin, KM			Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression	ONCOGENE			English	Article						TRAIL; apoptosis; caspases; IAP	X-LINKED INHIBITOR; CD95 APO-1/FAS; TUMORICIDAL ACTIVITY; DEATH; NEUROBLASTOMA; PROTEIN; LIGAND; CELLS; ACTIVATION; CHEMOTHERAPY	Primary or acquired resistance to current treatment protocols remains a major concern in clinical oncology and may be caused by defects in apoptosis programs. Since recent data suggest that TRAIL can bypass apoptosis resistance caused by Bcl-2, we further investigated the role of Bcl-2 in TRAIL-induced apoptosis. Here we report that overexpression of Bcl-2 conferred protection against TRAIL in neuroblastoma, glioblastoma or breast carcinoma cell lines. Bcl-2 overexpression reduced TRAIL-induced cleavage of caspase-8 and Bid indicating that caspase-8 was activated upstream and also downstream of mitochondria in a feedback amplification loop. Importantly Bcl-2 blocked cleavage of caspases-9, -7 and -3 into active subunits and cleavage of the caspase substrates DFF45 or PARP. Also, Bcl-2 blocked cleavage of XIAP and overexpression of XIAP conferred resistance against TRAIL indicating that apoptosis was also amplified through a feedforward loop between caspases and XIAP. In contrast, in SKW lymphoblastoid cells, TRAIL-induced activation of caspase-8 directly translated into full activation of caspases, cleavage of XIAP, DFF45 or PARP and apoptosis independent of Bcl-2 overexpression, although Bcl-2 similarly inhibited loss of mitochondrial membrane potential and the release of cytochrome c, AIF and Smac from mitochondria in all cell types. By demonstrating a cell type dependent regulation of the TRAIL signaling pathway at different level, e.g. by Bcl-2 and by XIAP, these findings may have important clinical implication. Thus, strategies targeting the molecular basis of resistance towards TRAIL may be necessary in some tumors for cancer therapy with TRAIL.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				BERTHOLD F, 1990, KLIN PADIATR, V202, P262, DOI 10.1055/s-2007-1025531; Debatin KM, 1997, J NATL CANCER I, V89, P750, DOI 10.1093/jnci/89.11.750; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fels C, 2000, J NEURO-ONCOL, V48, P207, DOI 10.1023/A:1006484801654; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2000, CANCER RES, V60, P3947; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; HOEHNER JC, 1995, INT J CANCER, V62, P19, DOI 10.1002/ijc.2910620106; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EJ, 2001, INT J ONCOL, V18, P187; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mitsiades N, 2000, CANCER RES, V60, P4122; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Sasaki H, 2000, CANCER RES, V60, P5659; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651	45	323	336	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2283	2294		10.1038/sj.onc.1205258	http://dx.doi.org/10.1038/sj.onc.1205258			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948412				2022-12-28	WOS:000174635600001
J	Bloom, D; Dhakshinamoorthy, S; Jaiswal, AK				Bloom, D; Dhakshinamoorthy, S; Jaiswal, AK			Site-directed mutagenesis of cysteine to serine in the DNA binding region of Nrf2 decreases its capacity to upregulate antioxidant response element-mediated expression and antioxidant induction of NAD(P)H : quinone oxidoreductase1 gene	ONCOGENE			English	Article						NQO1; ARE; detoxifying genes; Nrf2; cysteine; redox regulation	GLUTATHIONE S-TRANSFERASES; DT-DIAPHORASE; TRANSCRIPTION FACTOR; ACTIVATION; CANCER; CELLS; FOS; XENOBIOTICS; RADICALS; MAFG	NF-E2 related factor 2 (Nrf2) is a CNC/b-zip protein that regulates antioxidant response element (ARE)mediated expression, and antioxidant induction, of detoxifying enzyme genes, including NAD(P)H:quinone oxidoreductasel (NQO1). A comparison of Nrf2 from different species, and with other b-zip proteins, revealed the presence of a highly conserved cysteine residue at position 506 in the DNA binding domain of Nrf2. Site-directed mutagenesis was used to mutate this cysteine, to serine. Transfection/over expression experiments in human hepatoblastoma (Hep-G2) cells demonstrated that mutant Nrf2 (mNrf2), containing the C506S mutation, was significantly less efficient in activating ARE-mediated gene expression, and induction in response to tert-butyl hydroquinone (t-BHQ), as copmpared with wild-type Nrf2. N-ethyl malemide (NEM), a sulfhydryl cross- linker, inhibited Nrf2 but not mNrf2C506S-mediated expression of NQO1. This further implicated the cysteine at position 506 in Nrf2 regulation of ARE-mediated gene expression. Nuclear localization experiments revealed that C506S mutation did not affect the retention of Nrf2 by INrf2/Keap1 in the cytosol, or its release in response to antioxidants. However, band and supershift assays showed a significant reduction in the binding of mNrf2C506S to the NQO1 gene ARE as compared with wild-type Nrf2. Therefore, the C506S mutation in Nrf2 lowered its affinity for the ARE, leading to decreased expression, and antioxidant induction, of NQO1.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Pl, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; BERGELSON S, 1994, CANCER RES, V54, P36; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Grisham MB, 1986, PHYSL OXYGEN RADICAL, P01; Huang HC, 2001, P NATL ACAD SCI USA, V98, P379; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JAYEPAUL J, 2000, BIOCHEM PHARMACOL, V59, P1433; JOSEPH P, 1994, ONCOL RES, V6, P525; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; OESCH F, 1991, NATO ADV SCI I A-LIF, V202, P447; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; Radjendirane Venugopal, 1997, P441; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SHERTZER HG, 1995, CHEM RES TOXICOL, V8, P431, DOI 10.1021/tx00045a015; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	40	83	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2191	2200		10.1038/sj.onc.1205288	http://dx.doi.org/10.1038/sj.onc.1205288			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948402				2022-12-28	WOS:000174555300008
J	Hurd, C; Waldron, RT; Rozengurt, E				Hurd, C; Waldron, RT; Rozengurt, E			Protein kinase D complexes with C-Jun N-terminal kinase via activation loop phosphorylation and phosphorylates the C-Jun N-terminus	ONCOGENE			English	Article						protein kinase D; c-Jun N-terminal kinase; c-Jun phosphorylation	NECROSIS-FACTOR-ALPHA; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; INTACT-CELLS; MU; JNK; IDENTIFICATION; INVOLVEMENT; EXPRESSION; SUPPRESS	Protein kinase D (PKD), a downstream effector of protein kinase C (PKC), is implicated in suppression of the c-Jun N-terminal kinase (JNK) signaling pathway, however, its mechanism of action is unclear. Transphosphorylation of the PKD activation loop at serines 744/ 748 by a PKC mediated signal transduction pathway enhances its catalytic activity. Here we show that PKD activation loop phosphorylation at serines 744/748 via PKC, or mutation of these serines to glutamic acid (PKD-S744/748E) also results in complex formation with JNK, indicating that suppression of JNK signaling by PKD involves a direct interaction with JNK. Because catalytically active PKD associates with JNK we determined whether it could phosphorylate the e-Jun N-terminus as a potential mechanism by which it suppresses c-Jun Ser 63 phosphorylation when it complexes with JNK. Purified human PKD and either wild-type PKD from phorbol 12, 13-dibutyrate (PDB)-stimulated cells or unstimulated constitutively active PKD (PKD-S744/ 748E), phosphorylated the c-Jun N-terminus between amino acids 1-89 at sites distinct from those phosphorylated by JNK. These results demonstrate, for the first time, phosphorylation dependent association of PKD with another signaling molecule and reveal a potential mechanism by which PKD could modulate the ability of JNK to phosphorylate e-Jun by phosphorylating alternative sites in the c-Jun N-terminus when it is complexed with JNK.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Digest Dis,Unit Signal Transduct & Gastronint, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Digest Dis,Unit Signal Transduct & Gastronint, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu	Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002	NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002834, R01DK056930] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90388-01] Funding Source: Medline; NIDDK NIH HHS [K01 DK 02834-01, DK 55003, DK56930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akkaraju GR, 2000, BIOCHEM BIOPH RES CO, V279, P103, DOI 10.1006/bbrc.2000.3903; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Guo BC, 2001, CELL RES, V11, P101, DOI 10.1038/sj.cr.7290074; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Shinohara H, 2001, BIOCHEM BIOPH RES CO, V284, P1162, DOI 10.1006/bbrc.2001.5104; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; ZHUKOVA E, 2001, J BIOL CHEM, V20, P20; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	37	56	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2154	2160		10.1038/sj.onc.1205290	http://dx.doi.org/10.1038/sj.onc.1205290			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948398				2022-12-28	WOS:000174555300004
J	Wong, JC; Lee, SB; Bell, MD; Reynolds, PA; Fiore, E; Stamenkovic, I; Truong, V; Oliner, JD; Gerald, WL; Haber, DA				Wong, JC; Lee, SB; Bell, MD; Reynolds, PA; Fiore, E; Stamenkovic, I; Truong, V; Oliner, JD; Gerald, WL; Haber, DA			Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product	ONCOGENE			English	Article						EWS-WT1; desmoplastic small round cell tumor; Wilms tumor; interleukin-2/15 receptor; microarrays; tumor-stromal interaction	TUMOR-SUPPRESSOR GENE; ROUND-CELL TUMOR; WILMS-TUMOR; IL-2 RECEPTOR; ALPHA-CHAIN; TRANSCRIPTIONAL ACTIVATOR; DNA-BINDING; EXPRESSION; FUSION; PROMOTER	EWS - WT1 is a chimeric transcription factor resulting from fusion of the N-terminal domain of the Ewing sarcoma gene EWS to the three C-terminal zinc fingers of the Wilms tumor suppressor WT1. This translocation underlies desmoplastic small round cell tumor (DSRCT), which is noted for the abundance of reactive stroma surrounding islets of tumor cells, suggestive of paracrine signals contributing to tumor cell proliferation. Hybridization to high-density oligonucleotide microarrays can be used to identify targets of EWS - WT1. Expression of EWS - WT1 from a tetracycline-regulated promoter leads to the induction of growth-associated genes, of which the most remarkable is the beta-chain of the interleukin-2/15 receptor (IL-2/15Rbeta). Potent transcriptional activation by the chimeric protein maps to two bindings sites within the IL-2/15Rbeta promoter. Analysis of primary DSRCT tumor specimens demonstrates high levels of IL-2/15Rbeta within the tumor cells, along with expression of IL-2 and IL-15 by the abundant hyperplastic endothelial cells within the reactive stroma. Activation of this cytokine signaling pathway is consistent with the nuclear localization of its downstream effectors, phosphorylated STAT3 and STAT5. These observations suggest that the transcriptional induction of a cytokine receptor by a tumor-associated translocation product enables a proliferative response of epithelial cancer cells to ligands secreted by the surrounding stroma.	Massachusetts Gen Hosp, Canc Ctr CNY 7, Mol Genet Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA; Affymetrix, Santa Clara, CA 95051 USA	Harvard University; Massachusetts General Hospital; Harvard University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Harvard University; Massachusetts General Hospital; Affymetrix	Haber, DA (corresponding author), Massachusetts Gen Hosp, Canc Ctr CNY 7, Mol Genet Lab, Bldg 149,13th St, Charlestown, MA 02129 USA.	Haber@helix.mgh.harvard.edu		Lee, Sean/0000-0001-6211-3498; Reynolds, Paul/0000-0001-8738-1245; Wong, Jenise C./0000-0003-0573-6650	NCI NIH HHS [CA68273, CA58596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068273, R37CA058596, R01CA058596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; Azzarone B, 1996, EUR CYTOKINE NETW, V7, P27; Barzegar C, 1998, ONCOGENE, V16, P2503, DOI 10.1038/sj.onc.1201775; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; De Giovanni C, 1998, BRIT J CANCER, V78, P1541, DOI 10.1038/bjc.1998.721; Dobbeling U, 1998, BLOOD, V92, P252, DOI 10.1182/blood.V92.1.252.413k08_252_258; Doucet C, 1997, MELANOMA RES, V7, pS7; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; Frank DA, 1999, MOL MED, V5, P432; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hjorth-Hansen H, 1999, BRIT J HAEMATOL, V106, P28, DOI 10.1046/j.1365-2141.1999.01510.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LADANYI M, 1994, CANCER RES, V54, P2837; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; LIN WC, 1995, J IMMUNOL, V155, P4805; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miller MJ, 1996, J BIOL CHEM, V271, P23345; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Pileri SA, 1997, J PATHOL, V183, P116; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Suminami Y, 1998, ONCOGENE, V16, P1309, DOI 10.1038/sj.onc.1201640; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tinhofer I, 2000, BLOOD, V95, P610, DOI 10.1182/blood.V95.2.610; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053; Yamada Y, 1998, BLOOD, V91, P4265, DOI 10.1182/blood.V91.11.4265.411k06_4265_4272; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	51	34	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2009	2019		10.1038/sj.onc.1205262	http://dx.doi.org/10.1038/sj.onc.1205262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960373				2022-12-28	WOS:000174827000007
J	Amicone, L; Terradillos, O; Calvo, L; Costabile, B; Cicchini, C; Della Rocca, C; Lozupone, F; Piacentini, M; Buendia, MA; Tripodi, M				Amicone, L; Terradillos, O; Calvo, L; Costabile, B; Cicchini, C; Della Rocca, C; Lozupone, F; Piacentini, M; Buendia, MA; Tripodi, M			Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: Importance of TGF-beta signalling in the control of liver homeostasis and transformation	ONCOGENE			English	Article						apoptosis; hepatocyte proliferation; liver mass homeostasis; oncogene cooperation	HEPATOCYTE GROWTH-FACTOR; FACTOR-SCATTER FACTOR; TRANSGENIC MICE; FACTOR-RECEPTOR; CELL-PROLIFERATION; IN-SITU; EXPRESSION; HEPATOCARCINOGENESIS; GENE; OVEREXPRESSION	The c-Met tyrosine kinase receptor and its ligand, Hepatocyte Growth Factor/ Scatter Factor, have been implicated in human cancer. We have previously described that the transgenic expression of a truncated form of human c-Met (cyto-Met) in the liver confers resistance to several apoptotic stimuli. Here we show the impact of cyto-Met expression on liver proliferation and transformation. Despite a sixfold increase of hepatocyte proliferation, adult transgenic livers displayed normal size and architecture. We present evidence showing that activation of TGF-beta1 signalling controls the liver mass in cyto-Met mice. The oncogenic potential of cyto-Met was further assessed in the context of c-Myc-induced hepatocarcinogenesis, using WHV/c-Myc transgenic mice. Co-expression of cyto-Met and c-Myc further enhanced hepatocyte proliferation and caused a dramatic acceleration of the Myc-induced tumorigenesis, leading to the emergence of hepatocarcinomas in 3-4-month-old animals. Importantly, the TGF-beta receptor type 11 expression was strongly downregulated in most tumours, indicating that impairment of TGF-beta1-mediated growth inhibition plays a major role in accelerated neoplastic development. The strong potential of cyto-Met for oncogenic cooperation without direct transforming activity designates cyto-Met mice as an ideal tool for studying the early steps of multistage hepatocarcinogenesis and for identification of prognostic markers of transformation.	Univ Roma La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Fondaz Ist Pasteur Cenci Bolognetti, I-00161 Rome, Italy; Inst Pasteur, Dept Retrovirus, Unite Recombinaison & Express Genet, F-75724 Paris 15, France; Univ Roma La Sapienza, Sez Anat Patol, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; IRCCS L Spallanzani, Ist Nazl Malattie Infett, Rome, Italy	Sapienza University Rome; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Sapienza University Rome; University of Rome Tor Vergata; IRCCS Lazzaro Spallanzani	Tripodi, M (corresponding author), Univ Roma La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Fondaz Ist Pasteur Cenci Bolognetti, I-00161 Rome, Italy.	tripodi@bce.med.uniroma1.it	Lozupone, Francesco/H-2998-2016; Piacentini, Mauro/I-2411-2016; Tripodi, Marco/ABO-1160-2022; Tripodi, Marco/F-1143-2011	Lozupone, Francesco/0000-0002-4959-9400; Piacentini, Mauro/0000-0003-2919-1296; Tripodi, Marco/0000-0001-6135-971X; Tripodi, Marco/0000-0001-6135-971X; Amicone, Laura/0000-0002-3487-5740; CICCHINI, Carla/0000-0003-4662-5674				AMICONE L, 1995, GENE, V162, P323, DOI 10.1016/0378-1119(95)00277-D; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BENEDETTI A, 1988, J HEPATOL, V6, P137, DOI 10.1016/S0168-8278(88)80024-2; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BLOCH B, 1993, J HISTOCHEM CYTOCHEM, V41, P1751, DOI 10.1177/41.12.8245422; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURSCH W, 1986, ARCH TOXICOL, V59, P221, DOI 10.1007/BF00290542; Clifford SC, 1998, BRIT J CANCER, V77, P1420, DOI 10.1038/bjc.1998.235; Columbano A, 1984, Toxicol Pathol, V12, P89; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Desiderio MA, 1998, EXP CELL RES, V242, P401, DOI 10.1006/excr.1998.4073; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; ETIEMBLE J, 1994, ONCOGENE, V9, P727; Factor VM, 1997, CANCER RES, V57, P2089; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; Grippo PJ, 2000, AM J PATHOL, V157, P805, DOI 10.1016/S0002-9440(10)64594-4; HUANG SN, 1995, HEPATOLOGY, V21, P620, DOI 10.1002/hep.1840210303; Jansen AP, 2001, CANCER RES, V61, P808; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; JIRTLE RL, 1991, J BIOL CHEM, V266, P22444; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Santoni-Rugiu E, 1999, AM J PATHOL, V154, P1693, DOI 10.1016/S0002-9440(10)65425-9; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; SHULTEHERMANN R, 1995, APOPTOSIS HEPATOEARC, P141; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; von Schweinitz D, 2000, INT J CANCER, V85, P151, DOI 10.1002/(SICI)1097-0215(20000115)85:2<151::AID-IJC1>3.0.CO;2-6; WEBBER EM, 1994, AM J PATHOL, V145, P398; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; ZHEN Z, 1994, ONCOGENE, V9, P1691	43	19	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1335	1345		10.1038/sj.onc.1205199	http://dx.doi.org/10.1038/sj.onc.1205199			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857077				2022-12-28	WOS:000173861000004
J	Reisman, DN; Strobeck, MW; Betz, BL; Sciariotta, J; Funkhouser, W; Murchardt, C; Yaniv, M; Sherman, LS; Knudsen, ES; Weissman, BE				Reisman, DN; Strobeck, MW; Betz, BL; Sciariotta, J; Funkhouser, W; Murchardt, C; Yaniv, M; Sherman, LS; Knudsen, ES; Weissman, BE			Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression	ONCOGENE			English	Article						chromatin remodeling; RB; CD44; tumor suppression	CHROMATIN-REMODELING COMPLEX; SWI-SNF COMPLEX; CENTRAL-NERVOUS-SYSTEM; YEAST SWI/SNF COMPLEX; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; RHABDOID TUMOR; ACTIVE CHROMATIN; BREAST-CANCER	Mammalian cells express two homologs of the SWI2 subunit of the SWI/SNF chromatin-remodeling complex called BRGI and BRM. Whether the SWI/SNF complexes formed by these two subunits perform identical or different functions remains an important question. In this report, we show concomitant down-regulation of BRGI and BRM in six human tumor cell lines. This down-regulation occurs at the level of mRNA abundance. We tested whether BRM could affect aberrant cellular functions attributed to BRGI in tumor cell lines. By transient transfection, we found that BRM can restore RB-mediated cell cycle arrest. induce expression of CD44 protein and suppress Cyclin A expression. Therefore, BRM may be consistently down-regulated with BRGI during neoplastic progression because they share some redundant functions. However, assorted tissues from BRM null/BRG1-positive mice lack CD44 expression, suggesting that BRM-containing SWI/SNF complexes regulate expression of this gene under physiological conditions. Our studies further define the mechanism by which chromatin-remodeling complexes participate in RB-mediated cell cycle arrest and provide additional novel evidence that the functions of SWI/SNF complexes containing BRG1 or BRM are not completely interchangeable.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Inst Pasteur, Dept Biotechnol, CNRS, URA 1644,Unite Virus Oncogenes, F-75724 Paris 15, France	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; University of Cincinnati; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Weissman, BE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [T32CA009156, R01CA082525, R01CA063176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039550] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63176, CA 82525, T32 CA 09156] Funding Source: Medline; NIDCR NIH HHS [DE/CA 12355] Funding Source: Medline; NINDS NIH HHS [NS 39550] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Biegel JA, 2000, GENE CHROMOSOME CANC, V28, P31, DOI 10.1002/(SICI)1098-2264(200005)28:1<31::AID-GCC4>3.0.CO;2-Y; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bourachot B, 1999, MOL CELL BIOL, V19, P3931; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Herrlich P, 1998, CELL ADHES COMMUN, V6, P141, DOI 10.3109/15419069809004470; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Iau PTC, 2001, EUR J CANCER, V37, P300, DOI 10.1016/S0959-8049(00)00378-6; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Krebs JE, 2000, CRIT REV EUKAR GENE, V10, P1; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; LAURENT BC, 1993, COLD SPRING HARB SYM, V58, P257, DOI 10.1101/SQB.1993.058.01.030; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rosty C, 1998, GENE CHROMOSOME CANC, V21, P82, DOI 10.1002/(SICI)1098-2264(199802)21:2<82::AID-GCC2>3.0.CO;2-3; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Schnitzler GR, 1998, COLD SPRING HARB SYM, V63, P535, DOI 10.1101/sqb.1998.63.535; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Sherman L, 1996, CURR TOP MICROBIOL, V213, P249; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; SumiIchinose C, 1997, MOL CELL BIOL, V17, P5976, DOI 10.1128/MCB.17.10.5976; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Wong AKC, 2000, CANCER RES, V60, P6171; Wu C, 1998, COLD SPRING HARB SYM, V63, P525, DOI 10.1101/sqb.1998.63.525; Wu DY, 2000, J VIROL, V74, P8893, DOI 10.1128/JVI.74.19.8893-8903.2000; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	68	125	132	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1196	1207		10.1038/sj.onc.1205188	http://dx.doi.org/10.1038/sj.onc.1205188			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850839				2022-12-28	WOS:000173729400007
J	Bartunek, P; Pajer, P; Karafiat, V; Blendinger, G; Dvorak, M; Zenke, M				Bartunek, P; Pajer, P; Karafiat, V; Blendinger, G; Dvorak, M; Zenke, M			bFGF signaling and v-Myb cooperate in sustained growth of primitive erythroid progenitors	ONCOGENE			English	Article						v-Myb; Myb; FGF; FGF receptor; erythropoiesis; signaling	BLOOD-CELL DIFFERENTIATION; C-MYB; TRANSFORMING GROWTH-FACTOR-BETA-1; TERMINAL DIFFERENTIATION; HEMATOPOIETIC-CELLS; NEURORETINA CELLS; TYROSINE KINASE; SELF-RENEWAL; MIM-1 GENE; RECEPTOR	The development of red blood cells from hematopoietic progenitors requires the interplay of specific extracellular factors and transcriptional regulators. Here we have identified an erythroid progenitor that is critically dependent on bFGF and requires expression of AMV v-Myb for sustained proliferation in vitro, indicating that bFGF and Myb proteins cooperate in these cells. In the presence of bFGF such v-Myb cells are completely blocked in their ability to differentiate and exhibit an exceptionally high proliferative potential and long life-span in vitro. Interestingly, in the absence of bFGF cells effectively differentiate into mature erythrocytes, irrespective of constitutive and elevated levels of v-Myb. We also demonstrate that these cells express high levels of FGF receptor type 1 (FGFR1) and that phospholipase Cgamma (PLC)gamma) is one of the important molecules in FGF receptor signaling. Our studies suggest that bFGF, in cooperation with Myb proteins, represents an important factor for determining erythroid lineage choice. These findings unravel a so far unidentified link between extracellular signaling and Myb in hematopoietic cells.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Acad Sci Czech Republ, Inst Mol Genet, CR-16637 Prague 6, Czech Republic	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Zenke, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	zenke@mdc-berlin.de	Pajer, Petr/G-5869-2014; Bartunek, Petr/J-3897-2014; Dvořák, Michal/I-9939-2014; Dvorak, Michal/G-5861-2014	Bartunek, Petr/0000-0002-6202-7650; 				Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; ALLOUCHE M, 1995, LEUKEMIA, V9, P937; Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; Bartunek P, 1998, MOL ENDOCRINOL, V12, P1269, DOI 10.1210/mend.12.9.0173; Beug H, 1996, CURR TOP MICROBIOL, V211, P29; BEUG H, 1995, METHOD ENZYMOL, V254, P41; Briegel K, 1996, DEVELOPMENT, V122, P3839; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; BRUNNER G, 1993, BLOOD, V81, P631; Cross MA, 1997, CURR OPIN GENET DEV, V7, P609, DOI 10.1016/S0959-437X(97)80007-X; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Faloon P, 2000, DEVELOPMENT, V127, P1931; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GORDONTHOMSON C, 1994, DEVELOPMENT, V120, P3571; Graf T, 1998, CURR BIOL, V8, pR353, DOI 10.1016/S0960-9822(98)70220-9; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Huber TL, 1998, BLOOD, V92, P4128, DOI 10.1182/blood.V92.11.4128.423k46_4128_4137; Karafiat V, 2001, BLOOD, V98, P3668, DOI 10.1182/blood.V98.13.3668; KLINT P, 1999, FRONT BIOSCI, V4, P165; Koritschoner NP, 1999, ONCOGENE, V18, P5904, DOI 10.1038/sj.onc.1202979; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KRANTZ SB, 1991, BLOOD, V77, P419; KRYSTAL G, 1994, J EXP MED, V180, P851, DOI 10.1084/jem.180.3.851; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; Mead P E, 1998, Curr Opin Hematol, V5, P156; Mink S, 1996, MOL CELL BIOL, V16, P1316; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; Orkin SH, 2000, NAT MED, V6, P1212, DOI 10.1038/81303; Orkin SH, 1996, CURR OPIN GENET DEV, V6, P597, DOI 10.1016/S0959-437X(96)80089-X; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P129; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHMIDT JA, 1986, EXP CELL RES, V164, P71, DOI 10.1016/0014-4827(86)90455-6; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Turque N, 1997, J VIROL, V71, P9778, DOI 10.1128/JVI.71.12.9778-9781.1997; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yuen D, 1998, BLOOD, V91, P3202, DOI 10.1182/blood.V91.9.3202.3202_3202_3209; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	51	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					400	410		10.1038/sj/onc/1205103	http://dx.doi.org/10.1038/sj/onc/1205103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821952				2022-12-28	WOS:000173311200008
J	Nam, SY; Amoscato, AA; Lee, YJ				Nam, SY; Amoscato, AA; Lee, YJ			Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway	ONCOGENE			English	Article						akt; apoptosis; FLIP; glucose deprivation; TRAIL	APOPTOSIS-INDUCING LIGAND; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; CYTOCHROME-C RELEASE; HIGH LACTATE LEVELS; DEATH DOMAIN; IONIZING-RADIATION; DECOY RECEPTORS; HUMAN-TUMORS; IN-VIVO	To examine whether the tumor microenvironment alters cytokine-induced cytotoxicity, human prostate adenocarcinoma DU-145 cells were exposed to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and/or glucose deprivation, a common characteristic of the tumor microenvironment. TRAIL alone reduced cell survival in a dose-dependent manner. Glucose deprivation alone induced no cytotoxicity within 4 h. However, the combination of TRAIL (50 ng/ml) and glucose deprivation for 4 h increased cell death and PARP cleavage by promoting activation of caspase-8 and caspase-3, relative to that of TRAIL alone. Similar results were observed in human colorectal carcinoma CX-1 cells. Data from immunoblotting analysis reveal that glucose deprivation-enhanced TRAIL cytotoxicity is inversely related to the intracellular level of FLICE inhibitory protein (FLIP) but not that of death receptor 5 (DR5). Results from mass spectrometry show that glucose deprivation elevates ceramide. The elevation of ceramide may cause dephosphorylation of Akt and maintain dephosphorylation of Akt in the presence of TRAIL and then subsequently down-regulate the expression of FLIP. Taken together, the present studies suggest that glucose deprivation enhances TRAIL-induced cytotoxicity through the ceramide - Akt - FLIP pathway.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Pharmacol, E1056 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.			Amoscato, Andrew/0000-0002-1340-9150	NCI NIH HHS [CA48000] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Burow ME, 1998, CANCER RES, V58, P4940; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gong BD, 2000, CANCER RES, V60, P5754; Griffith TS, 1998, J IMMUNOL, V161, P2833; GULLINO PM, 1975, CANCER, V3, P327; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; IRMIER M, 1997, NATURE, V388, P190; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lee YJ, 2001, J CELL SCI, V114, P677; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Leverkus M, 2000, CANCER RES, V60, P553; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane DF, 1997, DERMATOL SURG, V23, P848, DOI 10.1111/j.1524-4725.1997.tb00434.x; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MUELLERKLIESER WF, 1989, PREDICTION TUMOR TRE, P265; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nagane M, 2000, CANCER RES, V60, P847; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; SARTORELLI A C, 1988, Cancer Research, V48, P775; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; SCHWICKERT G, 1995, CANCER RES, V55, P4757; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; VAUPEL P, 1991, CANCER RES, V51, P3316; VAUPEL P, 1989, CANCER RES, V49, P6449; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Walenta S, 1997, AM J PATHOL, V150, P409; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	71	58	59	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					337	346		10.1038/sj.onc.1205068	http://dx.doi.org/10.1038/sj.onc.1205068			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821946				2022-12-28	WOS:000173311200002
J	Yuan, XJ; Whang, YE				Yuan, XJ; Whang, YE			PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway	ONCOGENE			English	Article						PTEN; apoptosis; FADD; death receptors	NF-KAPPA-B; TUMOR-SUPPRESSOR GENE; CYTOCHROME-C RELEASE; PHOSPHATASE-ACTIVITY; PTEN/MMAC1; ACTIVATION; PHOSPHORYLATION; PROTEIN; DOMAIN; MICE	The PTEN tumor suppressor is frequently mutated in human tumors. Loss of PTEN function is associated with constitutive survival signaling through the phosphatidylinositol-3 kinase/Akt pathway. Therefore, we asked if reconstitution of PTEN function would lead to the reversal of resistance to apoptosis in prostate cancer cells. Adenovirus-mediated expression of PTEN completely suppressed constitutive Akt activation in LNCaP prostate cancer cells and enhanced apoptosis induced by a broad range of apoptotic stimuli. PTEN expression sensitized cells to death receptor-mediated apoptosis induced by tumor necrosis factor, anti-Fas antibody, and TRAIL. PTEN also sensitized cells to non-receptor mediated apoptosis induced by a kinase inhibitor staurosporine and chemotherapeutic agents mitoxantrone and etoposide. PTEN-mediated apoptosis was accompanied by caspase-3 and caspase-8 activation and was inhibited by a broad specificity caspase inhibitor Z-VAD-fmk. Bcl-2 overexpression also blocked PTEN-mediated apoptosis. Lipid phosphatase activity of PTEN is required for apoptosis as the PTEN G129E mutant selectively deficient in lipid phosphatase activity was unable to sensitize cells to apoptosis. PTEN-mediated apoptosis involves a FADD-dependent pathway for both death receptor-mediated and drug-induced apoptosis as coexpression of a dominant negative FADD mutant blocked PTEN-mediated apoptosis. Since in death receptor signaling, FADD mediates activation of caspase-8, which in turn cleaves BID, and since caspase-8 is activated in PTEN-mediated apoptosis, we examined BID cleavage in PTEN-mediated apoptosis. PTEN facilitated BID cleavage after treatment with low doses of staurosporine and mitoxantrone. BID cleavage was inhibited by dominant negative FADD. Taken together, these data are consistent with the hypothesis that PTEN promotes drug-induced apoptosis by facilitating caspase-8 activation and BID cleavage through a FADD-dependent pathway.	Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Whang, YE (corresponding author), Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA.		Whang, Young/AAK-7435-2021	Whang, Young/0000-0002-1621-6661	NATIONAL CANCER INSTITUTE [K08CA085772] Funding Source: NIH RePORTER; NCI NIH HHS [CA85772] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; DEL PL, 1997, SCIENCE, V278, P687; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hlobilkova A, 2000, EXP CELL RES, V256, P571, DOI 10.1006/excr.2000.4867; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Kulik G, 2001, CANCER RES, V61, P2713; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maier D, 1999, CANCER RES, V59, P5479; Marcelli M, 1999, CANCER RES, V59, P382; McMenamin ME, 1999, CANCER RES, V59, P4291; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 1998, CANCER RES, V58, P204; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	52	111	114	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					319	327		10.1038/sj/onc/1205054	http://dx.doi.org/10.1038/sj/onc/1205054			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803475				2022-12-28	WOS:000173026200016
J	Yi, KS; Chung, JH; Lee, YH; Chung, HG; Kim, IJ; Suh, BC; Kim, E; Cocco, L; Ryu, SH; Suh, PG				Yi, KS; Chung, JH; Lee, YH; Chung, HG; Kim, IJ; Suh, BC; Kim, E; Cocco, L; Ryu, SH; Suh, PG			Inhibition of the EGF-induced activation of phospholipase C-gamma 1 by a single chain antibody fragment	ONCOGENE			English	Article						PLC-gamma 1; single chain antibody (scFv); EGF	C ISOZYMES; INTRACELLULAR EXPRESSION; TYROSINE RESIDUES; ELEVATED CONTENT; SCFV FRAGMENT; DNA-SYNTHESIS; SH3 DOMAIN; GROWTH; RECEPTOR; CELLS	Phospholipase C-gamma (PLC-gamma1) is known to play an essential role in various cellular responses, such as proliferation and tumorigenesis, and PLC-gamma1 -specific inhibitors are commonly employed to investigate the mechanism of the PLC-gamma1-mediated signaling pathway. In this study, we developed a single chain antibody fragment (scFv) as a blocker for PLC-gamma1 mediated signaling. scFv, designated F7-scFv, specifically bound to PLC-gammal with high affinity (K-d= 1.9 x 10(-8) M) in vitro. F7-scFv also bound to PLC-gamma1 in vivo and altered the distribution pattern of PLC-gamma1 from the cytoplasm to the intracellular aggregates, where F7-scFv was localized. Moreover, F7-scFv interrupted the EGF-induced translocation of PLC-gamma1 from the cytosol to the membrane ruffle and attenuated EGF-induced inositol phosphates generation and intracellular calcium mobilization. These results indicate that F7-scFv blocks EGF-induced PLC-gamma1 activation by causing sequestering of PLC-gamma1 into intracellular aggregates, and may therefore be useful in studies of the PLC-gamma1-mediated signaling pathway.	Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang 7907840, Kyungbuk, South Korea; Seoul Natl Univ, Coll Med, Dept Biochem, Seoul 110799, South Korea; Yeungnam Univ, Coll Med, Dept Biochem, Kyongsan 712749, South Korea; Dongguk Univ, Coll Med, Dept Microbiol, Kyungju 780140, South Korea; Univ Bologna, Cellular Signaling Lab, Dept Anat Sci, I-40126 Bologna, Italy	Pohang University of Science & Technology (POSTECH); Seoul National University (SNU); Yeungnam University; Dongguk University; University of Bologna	Suh, PG (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang 7907840, Kyungbuk, South Korea.		Kim, In-San/D-3956-2017; Suh, Pann-Ghill/F-3610-2010; Chung, Junho/J-2792-2012	Ryu, Sung Ho/0000-0003-0913-3048				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; Bae SS, 2000, FASEB J, V14, P1083, DOI 10.1096/fasebj.14.9.1083; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIOCCA S, 1995, TRENDS CELL BIOL, V5, P248, DOI 10.1016/S0962-8924(00)89019-4; Cardinale A, 1998, FEBS LETT, V439, P197, DOI 10.1016/S0014-5793(98)01369-6; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; Chang JS, 1997, CANCER RES, V57, P5465; Cochet O, 1998, CANCER RES, V58, P1170; COCKCROFT S, 1992, BIOCHEM J, V288, P1; DIAKONOVA M, 1995, J CELL SCI, V108, P2499; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kabat EA, 1991, SEQUENCES PROTEINS I; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kim MJ, 2000, BIOCHEMISTRY-US, V39, P8674, DOI 10.1021/bi992558t; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEE SJ, 1995, J BIOL CHEM, V270, P16378, DOI 10.1074/jbc.270.27.16378; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MCCAFFERTY J, 1996, ANTIBODY ENG PRACTIC; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Nebigil CG, 1997, BIOCHEMISTRY-US, V36, P15949, DOI 10.1021/bi971721m; Nieba L, 1997, PROTEIN ENG, V10, P435, DOI 10.1093/protein/10.4.435; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; PARK JG, 1994, CANCER RES, V54, P2240; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RICHARDSON JH, 1995, TRENDS BIOTECHNOL, V13, P306, DOI 10.1016/S0167-7799(00)88970-2; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; SUH PG, 1988, J BIOL CHEM, V263, P14497; Tsumoto K, 1998, J IMMUNOL METHODS, V219, P119, DOI 10.1016/S0022-1759(98)00127-6; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; Yi K, 1999, HYBRIDOMA, V18, P243, DOI 10.1089/027245799315899	42	13	13	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7954	7964		10.1038/sj.onc.1204959	http://dx.doi.org/10.1038/sj.onc.1204959			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753678				2022-12-28	WOS:000172288700004
J	Wach, S; Schirmacher, P; Protschka, M; Blessing, M				Wach, S; Schirmacher, P; Protschka, M; Blessing, M			Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members	ONCOGENE			English	Article						BMP-6; skin; carcinogenesis; apoptosis, AP-1	GROWTH-FACTOR-BETA; PROGRAMMED CELL-DEATH; TRANSGENIC MICE; C-FOS; MOUSE SKIN; KINASE-C; TRANSFORMING GROWTH-FACTOR-BETA-1; KERATINOCYTE DIFFERENTIATION; ORNITHINE DECARBOXYLASE; EMBRYONIC-DEVELOPMENT	Bone morphogenetic protein-6 (BMP-6) is a member of the transforming growth factor-beta superfamily. In murine skin, BMP-6 is highly expressed in postmitotic keratinocytes from day 15.5 p.c. till day 6 p.p. Expression in adult skin remains at very low levels, but pathological conditions such as wounding induce the expression of BMP-6. We demonstrate that tumor promotion by TPA (12-O-tetradecanoylphorbol-13-acetate) also induces expression of BMP-6 in suprabasal keratinocytes. This induction is due to post-transcriptional regulation since the level of BMP-6 mRNA remained unchanged. We performed two-stage skin carcinogenesis experiments with transgenic mice epidermally overexpressing BMP-6. These mice display augmented mitotic indices in normal and TPA-treated epidermis when compared to controls. Despite this hyperproliferation, BMP-6 transgenics showed a delayed development and strong suppression of benign and malignant skin tumor formation. In order to resolve this paradox we determined apoptotic frequencies as well as the expression of constituents of AP-1 (activator protein-1) which is essential for tumor promotion. A higher rate of apoptotic keratinocytes was detectable in transgenic mice versus controls and a downregulation of mRNA for jun/fos family members in transgenic skin after TPA-treatment. Thus expression of BMP-6 augments apoptosis and downregulates the transcription of AP-1 family members thereby establishing tumor resistance.	Johannes Gutenberg Univ Mainz, Dept Med 1, Sect Pathophysiol, D-55131 Mainz, Germany; Univ Cologne, Inst Pathol, D-50931 Cologne, Germany	Johannes Gutenberg University of Mainz; University of Cologne	Blessing, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 1, Sect Pathophysiol, Obere Zahlbacher Str 63, D-55131 Mainz, Germany.	blessing@mail.uni-mainz.de						Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BLESSING M, 1995, TERATOGEN CARCIN MUT, V15, P11, DOI 10.1002/tcm.1770150103; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; Choi SE, 1999, CELL SIGNAL, V11, P71, DOI 10.1016/S0898-6568(98)00033-3; Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Denning MF, 1998, EXP CELL RES, V239, P50, DOI 10.1006/excr.1997.3890; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DROZDOFF V, 1994, P NATL ACAD SCI USA, V91, P5528, DOI 10.1073/pnas.91.12.5528; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; GREENHALGH DA, 1995, CELL GROWTH DIFFER, V6, P579; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; Guo YP, 1999, CANCER RES, V59, P1366; Hamdy FC, 1997, CANCER RES, V57, P4427; Heikinheimo AK, 1999, CANCER RES, V59, P5815; HENNINGS H, 1993, P SOC EXP BIOL MED, V202, P1; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kaiser S, 1998, J INVEST DERMATOL, V111, P1145, DOI 10.1046/j.1523-1747.1998.00407.x; KENNARD MD, 1995, MOL CARCINOGEN, V12, P14, DOI 10.1002/mc.2940120104; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MEGOSH L, 1995, CANCER RES, V55, P4205; Merino R, 1998, DEV BIOL, V200, P35, DOI 10.1006/dbio.1998.8946; Motyl T, 1998, EUR J CELL BIOL, V75, P367, DOI 10.1016/S0171-9335(98)80070-8; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; POTTEN CS, 1975, BRIT J DERMATOL, V93, P649, DOI 10.1111/j.1365-2133.1975.tb05115.x; POTTEN CS, 1984, BRIT J DERMATOL, V111, P695, DOI 10.1111/j.1365-2133.1984.tb14153.x; Raida M, 1999, INT J CANCER, V83, P38, DOI 10.1002/(SICI)1097-0215(19990924)83:1<38::AID-IJC8>3.3.CO;2-2; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; ROSS R, 1995, PCR METH APPL, V4, P371; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Tang MK, 2000, DEV BIOL, V218, P89, DOI 10.1006/dbio.1999.9578; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; Ueyama T, 1998, J MOL CELL CARDIOL, V30, P551, DOI 10.1006/jmcc.1997.0619; WALL NA, 1993, J CELL BIOL, V120, P493, DOI 10.1083/jcb.120.2.493; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203	52	43	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7761	7769		10.1038/sj.onc.1204962	http://dx.doi.org/10.1038/sj.onc.1204962			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753654				2022-12-28	WOS:000172161700007
J	Wang, ZO; Kyo, S; Maida, Y; Takakura, M; Tanaka, M; Yatabe, N; Kanaya, T; Nakamura, M; Koike, K; Hisamoto, K; Ohmichi, M; Inoue, M				Wang, ZO; Kyo, S; Maida, Y; Takakura, M; Tanaka, M; Yatabe, N; Kanaya, T; Nakamura, M; Koike, K; Hisamoto, K; Ohmichi, M; Inoue, M			Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells	ONCOGENE			English	Article						tamoxifen; telomerase; hTERT; endometrial cancer; breast cancer	ACTIVATED PROTEIN-KINASE; HUMAN ESTROGEN-RECEPTOR; PROMOTER-CONTEXT; IMMORTAL CELLS; PATHWAY; PHOSPHORYLATION; GROWTH	Tamoxifen is widely applied as an antiestrogenic agent for adjuvant therapy in the treatment of breast cancer, while its estrogen-agonistic activity occasionally causes proliferative disorders or carcinogenesis at other sites, such as the uterus. We reported that estrogen activates telomerase in breast and endometrial cancer cells. The present study examines the effects of tamoxifen on the gene expression of human telomerase reverse transcriptase (hTERT) in breast and endometrial cancer cells. Tamoxifen inhibited the cell growth of MCF-7 cells, as well as hTERT mRNA expression in the presence of estrogen (E2), antagonizing the E2 effects. In contrast, tamoxifen stimulated the growth of Ishikawa cells and activated hTERT mRNA expression in the absence or presence of E2, exhibiting estrogen-agonistic action. Transient expression assays revealed that these actions of tamoxifen are achieved by transcriptional regulation of the hTERT promoter. An estrogen responsive element (ERE) in the hTERT 5' regulatory region was partly responsible for both the E2-antagonistic and -agonistic actions of tamoxifen. Tamoxifen activated the MAP kinase cascade in Ishikawa cells, but not in MCF-7 cells, and the activation of hTERT mRNA expression was effectively blocked by MEK inhibitor, suggesting that the MAP kinase pathway is involved in the tamoxifen-induced activation of hTERT. These findings indicate that tamoxifen regulates hTERT expression in a cell-type specific manner. Tamoxifen-induced activation of hTERT may be one component of estrogen agonistic function of tamoxifen that is involved in endometrial carcinogenesis induced by this agent.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 6560871, Japan	Kanazawa University; Osaka University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	satoruky@med.kanazawa-u.ac.jp	Takakura, Masahiro/E-1080-2011					Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Colacurci N, 2000, PANMINERVA MED, V42, P45; Collins P, 1999, NAT MED, V5, P1130, DOI 10.1038/13453; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; Goldstein SR, 2000, EUR J CANCER, V36, pS54; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Ito H, 1998, CLIN CANCER RES, V4, P1603; JAMIL A, 1991, J MOL ENDOCRINOL, V6, P215, DOI 10.1677/jme.0.0060215; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Kyo S, 1999, CANCER RES, V59, P5917; Lasset C, 2001, LANCET, V357, P66, DOI 10.1016/S0140-6736(05)71563-4; Mandlekar S, 2000, CANCER RES, V60, P5995; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Schwartz LB, 1997, AM J OBSTET GYNECOL, V176, P129, DOI 10.1016/S0002-9378(97)80025-7; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Singer CA, 1999, J NEUROSCI, V19, P2455; Smith SMR, 2000, AM J SURG, V180, P249, DOI 10.1016/S0002-9610(00)00453-0; Soda H, 2000, PROSTATE, V43, P161, DOI 10.1002/(SICI)1097-0045(20000515)43:3<161::AID-PROS1>3.0.CO;2-O; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wang Z, 2000, CANCER RES, V60, P5376; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; Zhang CC, 2000, J BIOL CHEM, V275, P479, DOI 10.1074/jbc.275.1.479	36	42	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3517	3524		10.1038/sj.onc.1205463	http://dx.doi.org/10.1038/sj.onc.1205463			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032853				2022-12-28	WOS:000175793700002
J	Mizuno, K; Osada, H; Konishi, H; Tatematsu, Y; Yatabe, Y; Mitsudomi, T; Fujii, Y; Takahashi, T				Mizuno, K; Osada, H; Konishi, H; Tatematsu, Y; Yatabe, Y; Mitsudomi, T; Fujii, Y; Takahashi, T			Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers	ONCOGENE			English	Article						lung cancer; CHFR; hypermethylation; checkpoint; prophase	MITOTIC CHECKPOINT; EPIGENETIC INACTIVATION; EXPRESSION; MUTATION; ABNORMALITIES; GROWTH; HBUB1; P53	The CHFR gene, which was recently cloned by Scolnick and Halazonetis in search for a novel mitotic checkpoint gene with fork-head association motifs, has been suggested to play a key role in the mitotic prophase checkpoint. In this study, we demonstrated tumor-specific aberrant hypermethylation of the promoter region of the CHFR gene in a significant fraction of lung cancers in association with loss of detectable levels of CHFR transcripts. Aberrant hypermethylation was observed in seven of 37 primary lung cancer cases. Treatment with the demethylating agent 5-aza-2'-deoxycytidine restored expression of the CHFR gene in lung cancer cell lines exhibiting aberrant hypermethylation and loss of its expression. In contrast, genetic alterations were found to be infrequent in lung cancers. This is the first description of aberrant hypermethylation of the CHFR gene in any type of human cancer, and provides further evidence of the involvement of multiple checkpoint alterations in lung cancer.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Anat & Mol Diagnost Pathol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678061, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya City University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014; Osada, Hiroyuki/AAY-6254-2020	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Mitsudomi, Tetsuya/0000-0001-9860-8505; Konishi, Hiroyuki/0000-0003-1131-4905				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gemma A, 2000, GENE CHROMOSOME CANC, V29, P213, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1027>3.0.CO;2-G; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Haruki N, 2000, CANCER RES, V60, P4689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Masuda A, 1997, CANCER RES, V57, P4898; Matsuoka S, 2001, CANCER RES, V61, P5362; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; REDDEL RR, 1988, CANCER RES, V48, P1904; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	20	108	115	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2328	2333		10.1038/sj.onc.1205402	http://dx.doi.org/10.1038/sj.onc.1205402			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948416				2022-12-28	WOS:000174635600005
J	Meza-Zepeda, LA; Forus, A; Lygren, B; Dahlberg, AB; Godager, LH; South, AP; Marenholz, I; Lioumi, M; Florenes, VA; Maelandsmo, GM; Serra, M; Mischke, D; Nizetic, D; Ragoussis, J; Tarkkanen, M; Nesland, JM; Knuutila, S; Myklebost, O				Meza-Zepeda, LA; Forus, A; Lygren, B; Dahlberg, AB; Godager, LH; South, AP; Marenholz, I; Lioumi, M; Florenes, VA; Maelandsmo, GM; Serra, M; Mischke, D; Nizetic, D; Ragoussis, J; Tarkkanen, M; Nesland, JM; Knuutila, S; Myklebost, O			Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21	ONCOGENE			English	Article						peptidyl-prolyl isomerase; cyclophilin; breast cancer; sarcoma; amplification; chromosome1	IMMUNOSUPPRESSANT FK506; CYCLOSPORINE-A; HUMAN SARCOMAS; BREAST-CANCER; IMBALANCES; GAINS; DNA; AMPLIFICATION; SEQUENCES; COMPLEX	Gains of 1q21-q23 have been associated with metastasis and chemotherapy response, particularly in bladder cancer, hepatocellular carcinomas and sarcomas. By positional cloning of amplified genes by yeast artificial chromosome-mediated cDNA capture using magnetic beads, we have identified three candidate genes (COAS1, -2 and -3) in the amplified region in sarcomas. COAS1 and -2 showed higher amplification levels than COAS3. Most notably, amplification was very common in osteosarcomas, where in particular COAS2 was highly expressed. COAS1 has multiple repeats and shows no homology to previously described genes, whereas COAS2 is a novel member of the cyclosporin-binding peptidylprolyl isomerase family, very similar to cyclophilin A. COAS2 was overexpressed almost exclusively in aggressive metastatic or chemotherapy resistanti tumours. Although COAS2 was generally more amplified than COAS1, it was not expressed in well-differentiated liposarcomas, where amplification of this region is very common. All three genes were found to be amplified and over-expressed also in breast carcinomas. The complex nature of the 1q21-23 amplicons and close proximity of the genes make unequivocal determination of the gene responsible difficult. Quite likely, the different genes may give selective advantages to different subsets of tumours.	Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway; Klinikum Rudolf Virchow, Inst Expt Onkol Transplantat Med, Berlin, Germany; Univ London Sch Pharm, Ctr Appl Mol Biol, London, England; Guys Hosp, UMDS, Div Med Genet, Genom Lab, London, England; Inst Ortoped Rizzoli, Lab Ricerca Oncol, Bologna, Italy; Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Univ Helsinki, Haartman Inst, Dept Med Genet, Helsinki, Finland; Univ Oslo, Inst Biochem, N-0316 Oslo, Norway	University of Oslo; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of London; University College London; University of London School of Pharmacy; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oslo; University of Helsinki; University of Oslo	Myklebost, O (corresponding author), Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway.	ola.myklebost@biokjemi.uio.no	Ragoussis, Ioannis/AAD-9790-2022; Meza-Zepeda, Leonardo Andres/CAG-5229-2022; Nizetic, Dean/F-9509-2015; Myklebost, Ola/E-9335-2010; Serra, Massimo/J-4878-2016	Meza-Zepeda, Leonardo Andres/0000-0003-3056-212X; Myklebost, Ola/0000-0002-2866-3223; Serra, Massimo/0000-0003-0742-1177; Nizetic, Dean/0000-0001-5486-5761				Alers JC, 2000, LAB INVEST, V80, P931, DOI 10.1038/labinvest.3780096; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ambros PF, 2001, MED PEDIATR ONCOL, V36, P1; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Corton JC, 1998, CANCER LETT, V134, P61, DOI 10.1016/S0304-3835(98)00241-9; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; Forus A, 1998, BRIT J CANCER, V78, P495, DOI 10.1038/bjc.1998.521; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Forus A, 2001, CANCER GENET CYTOGEN, V125, P100, DOI 10.1016/S0165-4608(00)00369-1; Fukuda K, 1998, DEVELOPMENT, V125, P3535; Groet J, 1998, GENOME RES, V8, P385, DOI 10.1101/gr.8.4.385; Gronwald J, 1997, CANCER RES, V57, P481; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HARDAS BD, 1994, GENOMICS, V21, P359, DOI 10.1006/geno.1994.1277; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Hemenway CS, 1996, J BIOL CHEM, V271, P18527, DOI 10.1074/jbc.271.31.18527; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; Kiechle M, 2000, AM J PATHOL, V156, P1827, DOI 10.1016/S0002-9440(10)65055-9; Kim JO, 1998, ONCOGENE, V17, P1019, DOI 10.1038/sj.onc.1202006; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; Kudoh K, 1999, CLIN CANCER RES, V5, P2526; Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5; Lioumi M, 1998, GENOMICS, V49, P200, DOI 10.1006/geno.1998.5234; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; Mairal A, 2000, GENE CHROMOSOME CANC, V28, P370, DOI 10.1002/1098-2264(200008)28:4<370::AID-GCC2>3.0.CO;2-8; Malamou-Mitsi VD, 1999, J EXP CLIN CANC RES, V18, P357; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; Meza-Zepeda LA, 2001, GENE CHROMOSOME CANC, V31, P264, DOI 10.1002/gcc.1143; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; NIZETIC D, 1994, MAMM GENOME, V5, P801, DOI 10.1007/BF00292017; Ozaki K, 1996, CYTOGENET CELL GENET, V72, P242, DOI 10.1159/000134199; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; Rey O, 1999, ONCOGENE, V18, P827, DOI 10.1038/sj.onc.1202328; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; Szymanska J, 1997, CANCER GENET CYTOGEN, V99, P14, DOI 10.1016/S0165-4608(96)00436-0; Tarkkanen M, 1999, INT J CANCER, V84, P114, DOI 10.1002/(SICI)1097-0215(19990420)84:2<114::AID-IJC4>3.0.CO;2-Q; TARKKANEN M, 1995, CANCER RES, V55, P1334; Weber RG, 2000, AM J PATHOL, V157, P571, DOI 10.1016/S0002-9440(10)64567-1; Weber T, 2000, BRAIN PATHOL, V10, P73; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11081, DOI 10.1073/pnas.92.24.11081	49	43	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2261	2269		10.1038/sj.onc.1205339	http://dx.doi.org/10.1038/sj.onc.1205339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948409				2022-12-28	WOS:000174555300015
J	Barda-Saad, M; Shav-Tal, Y; Rozenszajn, AL; Cohen, M; Zauberman, A; Karmazyn, A; Parameswaran, R; Schori, H; Ashush, H; Ben-Nun, A; Zipori, D				Barda-Saad, M; Shav-Tal, Y; Rozenszajn, AL; Cohen, M; Zauberman, A; Karmazyn, A; Parameswaran, R; Schori, H; Ashush, H; Ben-Nun, A; Zipori, D			The mesenchyme expresses T cell receptor mRNAs: relevance to cell growth control	ONCOGENE			English	Article						mesenchyme; stroma; TCR; cell growth; tumors	D-MU PROTEIN; STEM-CELLS; GENE; TRANSCRIPTS; MATURATION; SEQUENCE; LACKING; SURFACE; STROMA	The mesenchyme plays a crucial regulatory role in organ formation and maintenance. However, comprehensive molecular characterization of these cells is lacking. We found unexpectedly that primary mesenchyme, as well as mesenchymal cell clones, express T cell receptor (TCR)chibeta mRNAs, lacking the variable region. Immunological and genetic evidence support the expression of a corresponding TCRbeta protein. Additionally, mRNAs encoding TCR complex components including CD3 and chain are present. A relatively higher expression of the mesenchymal TCRbeta mRNA by cultured mesenchymal cell clones correlates with fast growth, whereas poorly expressing cells are slow growers and are contact inhibited. The clones that express relatively higher amount of the TCR mRNA exhibit an increased capacity to form tumors in nude mice. However, the expression of this mRNA in the mesenchyme is not per se leading to tumorigenesis, as demonstrated by primary mesenchyme that does not form tumors in mice while expressing moderate amounts of the TCR transcripts. The expression of mesencymal TCRbeta was confined to the G2/M phases of the cell cycle in the MBA-13 mesenchymal cell line. This cell cycle dependent expression, considered together with the correlation between growth properties and the level of TCR expression by cell clones, implies association of mesenchymal TCR with cell growth control.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Bar Ilan Univ, Dept Life Sci, Ramat Gan, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Bar Ilan University	Zipori, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	dov.zipori@weizmann.ac.il		Shav-Tal, Yaron/0000-0002-8017-948X				Barda-Saad M, 1999, EXP HEMATOL, V27, P834, DOI 10.1016/S0301-472X(99)00010-7; CALMAN AF, 1986, J EXP MED, V164, P1940, DOI 10.1084/jem.164.6.1940; Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471-4914(01)02016-0; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EISEMANN A, 1991, ONCOGENE, V6, P1195; Essand M, 1999, P NATL ACAD SCI USA, V96, P9287, DOI 10.1073/pnas.96.16.9287; FAGIOLI M, 1991, EUR J IMMUNOL, V21, P1529, DOI 10.1002/eji.1830210629; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; Hilyard Katherine L., 1995, P403; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Hwang A, 1998, J BIOL CHEM, V273, P31505, DOI 10.1074/jbc.273.47.31505; HWANG A, 1995, J BIOL CHEM, V270, P28419; Jacobs H, 1996, ONCOGENE, V12, P2089; Lee BC, 1996, BLOOD, V87, P2283, DOI 10.1182/blood.V87.6.2283.bloodjournal8762283; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; MADRENAS J, 1994, MOL IMMUNOL, V31, P993, DOI 10.1016/0161-5890(94)90094-9; MADRENAS J, 1991, TRANSPLANT P, V23, P837; MADRENAS J, 1992, J IMMUNOL, V148, P612; OSSENDORP F, 1992, J IMMUNOL, V148, P3714; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; QIAN L, 1993, J IMMUNOL, V151, P6801; RETH MG, 1984, NATURE, V312, P418, DOI 10.1038/312418a0; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Shav-Tal Y, 2000, EXP HEMATOL, V28, P1029, DOI 10.1016/S0301-472X(00)00510-5; Shoham T, 2001, LEUKEMIA, V15, P1102, DOI 10.1038/sj.leu.2402145; Snell R.S., 2000, CLIN ANATOMY MED STU; Sutton KA, 1998, IMMUNOLOGY, V93, P213, DOI 10.1046/j.1365-2567.1998.00410.x; Tremain N, 2001, STEM CELLS, V19, P408, DOI 10.1634/stemcells.19-5-408; TSUBATA T, 1991, EUR J IMMUNOL, V21, P1359, DOI 10.1002/eji.1830210605; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; VANNESS BG, 1981, CELL, V27, P593, DOI 10.1016/0092-8674(81)90401-3; Wallace, 1981, VERTEBRATE LIMB REGE; Wolfgang CD, 2000, P NATL ACAD SCI USA, V97, P9437, DOI 10.1073/pnas.160270597; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0; ZIPORI D, 1988, BLOOD, V71, P586; ZIPORI D, 1989, HDB HEMOPOIETIC MICR, P287	37	16	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2029	2036		10.1038/sj.onc.1205269	http://dx.doi.org/10.1038/sj.onc.1205269			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960375				2022-12-28	WOS:000174827000009
J	Perez-Mancera, PA; Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Flores, T; Battaner, E; Gutierrez-Adan, A; Pintado, B; Sanchez-Garcia, I				Perez-Mancera, PA; Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Flores, T; Battaner, E; Gutierrez-Adan, A; Pintado, B; Sanchez-Garcia, I			Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice	ONCOGENE			English	Article						chromosomal abnormality; malignant solid tumors; adipose tissue; cancer development	HUMAN MYELOID-LEUKEMIA; RNA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; MYXOID LIPOSARCOMA; FUS/TLS-CHOP; GENE; ERG; TRANSLOCATION; C/EBP; MALIGNANCIES	Fusion proteins created by chromosomal abnormalities are key components of mesenchymal cancer development. The most common chromosomal translocation in liposarcomas, t(12;16)(q13;p11), creates the FUS-CHOP fusion gene. In the past, we generated FUS-CHOP and CHOP transgenic mice and have shown that while FUS-CHOP transgenic develop liposarcomas, mice expressing CHOP, which lacks the FUS domain, display essentially normal white adipose tissue (WAT) development, suggesting that the FUS domain of FUS-CHOP plays a specific and critical role in the pathogenesis of liposarcoma. To test the significance of FUS and CHOP domain interactions within a living mouse, we generated mice expressing the FUS domain and crossed them with CHOP-transgenic mice to generate double-transgenic FUSxCHOP animals. Here we report that expression of the FUS domain restores liposarcoma development in CHOP-transgenic mice. Our results provide genetic evidence that FUS and CHOP domains function in trans for the mutual restoration of liposarcoma. These results identify a new mechanism of tumor-associated fusion genes and might have impact beyond myxoid liposarcoma.	Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Salamanca 37007, Spain; Univ Salamanca, Serv Anat Patol, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Campus Unamuno, Salamanca 37007, Spain.	isg@gugu.usal.es	Sanchez-Martin, Manuel/N-5327-2016; Gutierrez-Adan, Alfonso/A-1485-2014; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Pintado, Belen/N-3233-2014; Pérez-Losada, Jesús/A-5883-2019	Sanchez-Martin, Manuel/0000-0001-8370-1336; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; Pintado, Belen/0000-0002-8485-2520; Pérez-Losada, Jesús/0000-0003-2400-624X; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER; NCI NIH HHS [1 R01 CA79955-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHANG HR, 1989, CANCER, V64, P1514, DOI 10.1002/1097-0142(19891001)64:7<1514::AID-CNCR2820640726>3.0.CO;2-2; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KNIGHT JC, 1995, CANCER RES, V55, P24; MACK TM, 1995, CANCER-AM CANCER SOC, V75, P211, DOI 10.1002/1097-0142(19950101)75:1+<211::AID-CNCR2820751309>3.0.CO;2-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Perez-Losada J, 2000, ONCOGENE, V19, P6015, DOI 10.1038/sj.onc.1204018; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; PRASAD DDK, 1994, ONCOGENE, V9, P3717; PRICE BD, 1992, CANCER RES, V52, P3814; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	25	18	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1679	1684		10.1038/sj.onc.1205220	http://dx.doi.org/10.1038/sj.onc.1205220			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896599				2022-12-28	WOS:000174214200006
J	Lui, WO; Chen, JD; Glasker, S; Bender, BU; Madura, C; Khoo, SK; Kort, E; Larsson, C; Neumann, HPH; Teh, BT				Lui, WO; Chen, JD; Glasker, S; Bender, BU; Madura, C; Khoo, SK; Kort, E; Larsson, C; Neumann, HPH; Teh, BT			Selective loss of chromosome 11 in pheochromocytomas associated with the VHL syndrome	ONCOGENE			English	Article						von Hippel-Lindau; VHL; pheochromocytoma; comparative genomic hybridization	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; MUTATIONS; DISEASE; TUMORIGENESIS; COMPLEX; PROTEIN; 1P; 3Q	By using comparative genomic hybridization (CGH), we characterized the genetic profiles of 36 VHL-related pheochromocytomas. We then compared the results with those of sporadic and MEN 2-related pheochromocytomas. In 36 VHL-related tumors, loss of chromosome 3 and chromosome 11 were found in 34 tumors (94%) and 31 tumors (86%), respectively. There was significant concordance of deletions in chromosomes 3 and 11 (Kappa = 0.64, P = 0.0095), suggesting that they are involved in two different but necessary and complementary genetic pathways. The loss of chromosome 11 appeared to be specific for VHL-related pheochromocytoma as it was not present in any of the 10 VHL-related CNS hemangioblastomas studied and was significantly less common when compared with (a) sporadic pheochromocytomas from previously published results (13%; P = <0.0001), and (b) MEN 2-related pheochromocytomas from this and previously published studies (30%; P = 0.0012). In summary, this is the first report of a novel consistent genetic alteration that is selected and specific for VHL-related pheochromocytoma, besides the two hits of the VHL gene.	Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; Karolinska Hosp, Dept Mol Med, S-10401 Stockholm, Sweden; Univ Freiburg, Dept Hypertens & Nephrol, Freiburg, Germany; Van Andel Res Inst, Lab Analyt Cellular & Mol Microscopy, Grand Rapids, MI 49503 USA	Van Andel Institute; Karolinska Institutet; Karolinska University Hospital; University of Freiburg; Van Andel Institute	Teh, BT (corresponding author), Van Andel Res Inst, Canc Genet Lab, 333 Bostwick NE, Grand Rapids, MI 49503 USA.		Lui, Weng-Onn/X-5957-2019; Lui, Weng-Onn/G-6703-2013; Gläsker, Sven/AAB-9362-2022	Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473; Khoo, Sok Kean/0000-0003-3836-5497				Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Bender BU, 2000, J CLIN ENDOCR METAB, V85, P4568, DOI 10.1210/jc.85.12.4568; Benn DE, 2000, CANCER RES, V60, P7048; BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; Canzian F, 1996, CANCER RES, V56, P3331; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Dannenberg H, 2000, AM J PATHOL, V157, P353, DOI 10.1016/S0002-9440(10)64547-6; Edstrom E, 2000, AM J PATHOL, V156, P651, DOI 10.1016/S0002-9440(10)64769-4; Farnebo F, 1999, J CLIN ENDOCR METAB, V84, P3775, DOI 10.1210/jc.84.10.3775; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gimm O, 2000, CANCER RES, V60, P6822; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ramus SJ, 1999, GENE CHROMOSOME CANC, V25, P91, DOI 10.1002/(SICI)1098-2264(199906)25:2<91::AID-GCC3>3.0.CO;2-5; Schussheim DH, 2001, TRENDS ENDOCRIN MET, V12, P173, DOI 10.1016/S1043-2760(00)00372-6; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565	20	37	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1117	1122		10.1038/sj.onc.1205149	http://dx.doi.org/10.1038/sj.onc.1205149			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850829				2022-12-28	WOS:000173580100015
J	Ducrest, AL; Szutorisz, H; Lingner, J; Nabholz, M				Ducrest, AL; Szutorisz, H; Lingner, J; Nabholz, M			Regulation of the human telomerase reverse transcriptase gene	ONCOGENE			English	Review						telomerase; hTERT; regulation; transcription; repression; tumor	NORMAL HUMAN-CELLS; MESSENGER-RNA EXPRESSION; CATALYTIC SUBUNIT; HTERT GENE; CANCER-CELLS; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; IMMORTAL CELLS; TUMOR-CELLS; LIFE-SPAN	Most somatic human cells lack telomerase activity because they do not express the telomerase reverse transcriptase (hTERT) gene. Conversely, most cancer cells express hTERT and are telomerase positive. For most tumors it is not clear whether hTERT expression is due to their origin from telomerase positive stem cells or to reactivation of the gene during tumorigenesis. Telomerase negative cells lack detectable cytoplasmic and nuclear hTERT transcripts; in telomerase positive cells 0.2 to 6 mRNA molecules/cell can be detected. This suggests that expression is regulated by changes in the rate of hTERT gene transcription. In tumor cell lines hTERT expression behaves like a recessive trait, indicating that lack of expression in normal cells is due to one or several repressors. Studies with monochromosomal hybrids indicate that several chromosomes may code for such repressors. A number of transcription factors, tumor suppressors, cell cycle inhibitors, cell fate determining molecules, hormone receptors and viral proteins have been implicated in the control of hTERT expression; but these studies have not yet provided a clear explanation for the tumor specific expression of the hTERT gene, and the cis-acting elements which are the targets of repression in normal cells still have to be identified.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Nabholz, M (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.			Lingner, Joachim/0000-0002-2853-5803				Aldous WK, 1999, CANCER, V85, P1523, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1523::AID-CNCR13>3.3.CO;2-G; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Backsch C, 2001, GENE CHROMOSOME CANC, V31, P196, DOI 10.1002/gcc.1134; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Bednarek AK, 1998, ONCOGENE, V16, P381, DOI 10.1038/sj.onc.1201553; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Braunstein I, 2001, CANCER RES, V61, P5529; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Carroll T, 1999, J PATHOL, V188, P395; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dessain SK, 2000, CANCER RES, V60, P537; Devereux TR, 1999, CANCER RES, V59, P6087; Ducrest AL, 2001, CANCER RES, V61, P7594; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Evans SK, 2000, J CELL SCI, V113, P3357; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Friedmann T, 2000, MOL THER, V1, P9, DOI 10.1006/mthe.1999.0015; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greaves M, 1996, TRENDS GENET, V12, P127, DOI 10.1016/0168-9525(96)30016-4; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Gunes C, 2000, CANCER RES, V60, P2116; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hande MP, 1998, MUTAT RES-FUND MOL M, V404, P205, DOI 10.1016/S0027-5107(98)00115-8; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Horikawa I, 1998, MOL CARCINOGEN, V22, P65, DOI 10.1002/(SICI)1098-2744(199806)22:2<65::AID-MC1>3.0.CO;2-J; Horikawa I, 1999, CANCER RES, V59, P826; Huffman KE, 2000, J BIOL CHEM, V275, P19719, DOI 10.1074/jbc.M002843200; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kitagawa Y, 2000, CLIN CANCER RES, V6, P2868; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kugoh H, 1999, DNA Res, V6, P165, DOI 10.1093/dnares/6.3.165; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1999, CANCER RES, V59, P5917; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; McClintock B, 1941, GENETICS, V26, P234; Meeker AK, 1996, ENDOCRINOLOGY, V137, P5743, DOI 10.1210/en.137.12.5743; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakabayashi K, 1999, EXP CELL RES, V252, P376, DOI 10.1006/excr.1999.4619; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NING Y, 1992, CYTOGENET CELL GENET, V60, P79, DOI 10.1159/000133300; Nishimoto A, 2001, ONCOGENE, V20, P828, DOI 10.1038/sj.onc.1204165; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; Parshad R, 2001, CRIT REV ONCOL HEMAT, V37, P87, DOI 10.1016/S1040-8428(00)00111-6; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; Saito T, 1997, BIOCHEM BIOPH RES CO, V231, P610, DOI 10.1006/bbrc.1997.6164; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Tanaka H, 1999, MOL CARCINOGEN, V25, P249, DOI 10.1002/(SICI)1098-2744(199908)25:4<249::AID-MC3>3.0.CO;2-Z; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; Ulaner GA, 2001, INT J CANCER, V91, P644, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1103>3.3.CO;2-M; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Varley H, 2000, AM J HUM GENET, V67, P610, DOI 10.1086/303050; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang Z, 2000, CANCER RES, V60, P5376; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wright WE, 1996, DEV GENET, V18, P173; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yan P, 1999, CANCER RES, V59, P3166; Yan P, 2001, J PATHOL, V193, P21, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH728>3.0.CO;2-G; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yang XQ, 1999, INT J ONCOL, V15, P629; Yu CC, 2001, BIOCHEM J, V355, P459, DOI 10.1042/0264-6021:3550459; Zhang AJ, 2000, CANCER RES, V60, P6230	110	159	176	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					541	552		10.1038/sj.onc.1205081	http://dx.doi.org/10.1038/sj.onc.1205081			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850779	Green Submitted			2022-12-28	WOS:000173390500006
J	Venkateswarlu, S; Dawson, DM; St Clair, P; Gupta, A; Willson, JKV; Brattain, MG				Venkateswarlu, S; Dawson, DM; St Clair, P; Gupta, A; Willson, JKV; Brattain, MG			Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells	ONCOGENE			English	Article						ErbB2; constitutive activation; heregulin	NEU DIFFERENTIATION FACTOR; FACTOR-RELATED PEPTIDES; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN-BREAST; CONSTITUTIVE ACTIVATION; SIGNALING NETWORK; OVARIAN-CANCER; FACTOR-ALPHA; EPITHELIAL-CELLS	The aim of this study was to determine whether constitutive ErbB2 activation controls growth and apoptosis in colon cancer cells. Growth arrested GEO cells showed constitutive activation of ErbB2 in the absence of exogenous growth factors or serum supplementation. Higher levels of heregulin and ErbB2 activation were observed in the growth-arrested state and cell cycle re-entry was independent of exogenous growth factors. Blockade of ErbB2 activation by heregulin neutralizing antibodies and by AG879 resulted in prevention of cell cycle re-entry. This indicated that autocrine heregulin activity was responsible for growth factor independence and for cell cycle re-entry. Activation of ErbB2 was the result of heregulin mediated interaction with ErbB3 and generated downstream activation of the ERK and the PI3K/AKT pathways. Heregulin neutralizing antibody treatment of growth arrested GEO cells also generated apoptosis as reflected by PARP cleavage and DNA fragmentation indicating a cell survival signal was also induced by the constitutively activated ErbB2. The activation of AKT but not the MAPK pathway was responsible for cell survival in these cells.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA; Case Western Reserve Univ, Ireland Canc Ctr, Dept Med, Cleveland, OH 44106 USA	University of Texas System; University of Texas Health San Antonio; Case Western Reserve University	Brattain, MG (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA054807, R01CA034432, K08CA084337, R01CA068316] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68316, CA 34432, CA 54807, CA84337-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Coffer PJ, 1998, BIOCHEM J, V335, P1; COFFEY RJ, 1988, CANCER RES, V48, P1596; Daly JM, 1997, CANCER RES, V57, P3804; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; Grammer TC, 1996, CANCER SURV, V27, P271; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Gullick WJ, 1996, CANCER SURV, V27, P339; Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kristt DA, 1996, CANCER-AM CANCER SOC, V78, P1272, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1272::AID-CNCR16>3.0.CO;2-Y; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lewis GD, 1996, CANCER RES, V56, P1457; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MORALI F, 1993, ANN ONCOL, V4, P775, DOI 10.1093/oxfordjournals.annonc.a058663; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; MULDER KM, 1989, J CELL PHYSIOL, V138, P450, DOI 10.1002/jcp.1041380303; Noguchi H, 1999, GASTROENTEROLOGY, V117, P1119, DOI 10.1016/S0016-5085(99)70397-5; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PITTELKOW MR, 1993, CELL GROWTH DIFFER, V4, P513; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Saeki T, 1995, JPN J CLIN ONCOL, V25, P240; Scoccia B, 1998, J SOC GYNECOL INVEST, V5, P161, DOI 10.1016/S1071-5576(98)00006-9; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; VANDEVIJVER MJ, 1988, ONCOGENE, V2, P175; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594	55	65	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					78	86		10.1038/sj.onc.1205011	http://dx.doi.org/10.1038/sj.onc.1205011			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791178				2022-12-28	WOS:000172887800008
J	Miethe, J; Schwartz, C; Wottrich, K; Wenning, D; Klempnauer, KH				Miethe, J; Schwartz, C; Wottrich, K; Wenning, D; Klempnauer, KH			Crosstalk between Myc and activating transcription factor 2 (ATF2): Myc prolongs the half-life and induces phosphorylation of ATF2	ONCOGENE			English	Article						Myc; ATF2; phosphorylation; protein turnover	CYCLIN-A PROMOTER; C-MYC; DNA-BINDING; CELL-CYCLE; V-MYB; SIGNAL-TRANSDUCTION; RESPONSE ELEMENT; EXPRESSION; PROTEIN; GENE	Myc is a key regulator of cell growth, differentiation and apoptosis, and affects cell fate decisions by activating as well as by inhibiting the expression of cellular genes. Myc is a member of the basic region-helix-loop-helix-leucine zipper (b-HLH-Zip) class of transcription factors, which heterodimerizes with the Max protein and recognizes a consensus Myc binding motif. Stimulation of gene expression by Myc is thought to be mediated by direct binding of Myc-Max heterodimers to specific target genes. So far, only a few genes have been identified as direct binding targets of Myc, raising the possibility that Myc affects gene expression also by indirect mechanisms. In this work we present evidence that v-Myc encoded by the avian retrovirus MC29 stimulates activating transcription factor 2 (ATF2)-dependent transcription. Analysis of the effect of Myc on ATF2 shows that v-Myc prolongs the half-life of ATF2 and induces the phosphorylation of N-terminal sites of ATF2 (Thr-69 and Thr-71) which have previously been identified as the target sites of stress-activated protein kinases and implicated in the regulation of ATF2 activity. Taken together, our results suggest that v-Myc can affect gene expression indirectly by modulating the activity of ATF2.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, MOL CELL BIOL, V19, P1; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kamano H, 1995, ONCOGENE, V11, P2575; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGTON C, 1995, EMBO J, V14, P1798; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; SYMONDS G, 1986, MOL CELL BIOL, V6, P1796, DOI 10.1128/MCB.6.5.1796; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	58	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2001	20	56					8116	8124		10.1038/sj.onc.1204966	http://dx.doi.org/10.1038/sj.onc.1204966			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781825				2022-12-28	WOS:000172396800009
J	Burke, WM; Jin, XH; Lin, HJ; Huang, M; Liu, R; Reynolds, RK; Lin, JY				Burke, WM; Jin, XH; Lin, HJ; Huang, M; Liu, R; Reynolds, RK; Lin, JY			Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells	ONCOGENE			English	Article						Stat3; AG490; Bcl-X-L; JAK2; apoptosis; ovarian cancer; breast cancer	CHEMOTHERAPY-INDUCED APOPTOSIS; BCL-X-L; CARCINOMA CELLS; KINASE-ACTIVITY; ACTIVATION; BCL-X(L); FAMILY; PHOSPHORYLATION; TRANSCRIPTION; RESISTANCE	Signal transducers and activators of transcription (STATs) are transcription factors activated in response to cytokines and growth factors. Constitutively active Stat3 has been shown to mediate oncogenic transformation in cultured cells and induce tumor formation in mice. An increasing number of tumor-derived cell lines as well as samples from human cancer have been reported to express constitutively active Stat3 protein. We previously demonstrated that ovarian cancer cell lines express high levels of constitutively active Stat3. In this study, we show that inhibition of the Stat3 signaling pathway using the Janus Kinase-selective inhibitor, AG490, and a dominant negative Stat3 (Stat3 beta) significantly suppresses the growth of ovarian and breast cancer cell lines harboring constitutively active Stat3. In the ovarian cancer cell lines, AG490 also diminished the phosphorylation of Stat3, Stat3 DNA binding activity, and the expression of Bcl-X-L. Further, AG490 induced significant apoptosis in ovarian and breast cancer cell lines expressing high levels of constitutively active Stat3 but had a less profound effect on normal cells lacking constitutively active Stat3. AG490 also enhanced apoptosis induced by cisplatin in ovarian cancer cells. These results suggest that inhibition of Stat3 signaling may provide a potential therapeutic approach for treating ovarian and breast cancers.	Univ Michigan, Ctr Comprehens Canc, Div Gynecol Oncol, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Lin, JY (corresponding author), Univ Michigan, Ctr Comprehens Canc, Div Gynecol Oncol, Dept Obstet & Gynecol, 1500 E Med Ctr Dr,CCGC 4215, Ann Arbor, MI 48109 USA.		Lin, Huey-Jen/E-3514-2011; Lin, Jiayuh/E-3515-2011					Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; Bromberg J, 2000, BREAST CANCER RES, V2, P86, DOI 10.1186/bcr38; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BUDDE RJA, 1994, CANCER BIOCHEM BIOPH, V14, P171; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DOLE MG, 1995, CANCER RES, V55, P2576; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Liu JR, 1998, GYNECOL ONCOL, V70, P398, DOI 10.1006/gyno.1998.5125; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Ni Z, 2000, CANCER RES, V60, P1225; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu GL, 1999, CANCER RES, V59, P5059; Niu GL, 2001, CANCER RES, V61, P3276; Page C, 2000, INT J ONCOL, V17, P23; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Sartor CI, 1997, CANCER RES, V57, P978; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	36	242	279	1	16	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7925	7934		10.1038/sj.onc.1204990	http://dx.doi.org/10.1038/sj.onc.1204990			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753675				2022-12-28	WOS:000172288700001
J	Daury, L; Busson, M; Tourkine, N; Casas, F; Cassar-Malek, I; Wrutniak-Cabello, C; Castellazzi, M; Cabello, G				Daury, L; Busson, M; Tourkine, N; Casas, F; Cassar-Malek, I; Wrutniak-Cabello, C; Castellazzi, M; Cabello, G			Opposing functions of ATF2 and Fos-like transcription factors in e-Jun-mediated myogenin expression and terminal differentiation of avian myoblasts	ONCOGENE			English	Article						Jun; Fos; ATF; myoblasts; differentiation; Myogenin	NEGATIVE REGULATOR; GENE MYF-5; V-JUN; MUSCLE; INDUCTION; AP-1; INACTIVATION; STIMULATION; PROMOTER; ELEMENT	With the aim to identify the oncoprotein partners implicated in the c-Jun myogenic influence, we carried out stable transfection experiments of c-Jun and/or ATF2, Fra2, c-Fos overexpression in avian myoblasts. Before induction of differentiation, c-Jun repressed myoblast withdrawal from the cell cycle, as did a TPA treatment. However, after serum removal, unlike TPA, c-Jun significantly stimulated myoblast differentiation. In search for specific partners involved in this dual influence, we found that a reduction in the amounts of c-Fos and Fra2 and an increase in c-Jun proteins occurred at cell confluence, a situation likely to favor cooperation between c-Jun and ATF2 during terminal differentiation. Whereas c-Fos and Fra2 cooperated with c-Jun to abrogate myoblast withdrawal from the cell cycle and terminal differentiation, ATF2 co-expression potentiated the positive myogenic e-Jun influence. In addition, myogenin expression was a positive target of this cooperation and this regulation occurred through a stimulation of myogenin promoter activity: (1) whereas c-Fos or Fra2 co-expression abrogated c-Jun stimulatory activity on this promoter, ATF2 co-expression potentiated this influence; (2) using a dominant negative ATF2 mutant, we established that c-Jun transcriptional activity required functionality of endogenous ATF2. These data suggest that through this dual myogenic influence due to cooperations with different partners, c-Jun is involved in the control of duration of myoblast proliferation and thereafter of fusion efficiency.	INRA, UMR Differenciat Cellulaire & Croissance, Unite Endocrinol Cellulaire, F-34060 Montpellier 1, France; Ecole Normale Super Lyon, INSERM, Unite Virol Humaine, U412, F-69364 Lyon 07, France	INRAE; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Cabello, G (corresponding author), INRA, UMR Differenciat Cellulaire & Croissance, Unite Endocrinol Cellulaire, 2 Pl Viala, F-34060 Montpellier 1, France.	cabello@ensam.inra.fr	, Cassar-Malek/AAW-6386-2020	, Cassar-Malek/0000-0001-7407-1408; Francois, Casas/0000-0002-5535-8195; Daury, Laetitia/0000-0002-1296-7150				ANDAM H, 2001, ONCOGENE, V20, P2453; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CassarMalek I, 1996, J BIOL CHEM, V271, P11392, DOI 10.1074/jbc.271.19.11392; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hebrok M, 1997, EXP CELL RES, V232, P295, DOI 10.1006/excr.1997.3541; HILL CS, 1986, J CELL BIOL, V103, P2185, DOI 10.1083/jcb.103.6.2185; HIRAYAMA E, 1995, CELL STRUCT FUNCT, V20, P377, DOI 10.1247/csf.20.377; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PARK K, 1992, J BIOL CHEM, V267, P10810; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SNEDECOR GW, 1961, STAT METHODS, P534; SU HY, 1991, ONCOGENE, V6, P1759; SULAKHE PV, 1985, FEBS LETT, V186, P281, DOI 10.1016/0014-5793(85)80725-0; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715	34	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2001	20	55					7998	8008		10.1038/sj.onc.1204967	http://dx.doi.org/10.1038/sj.onc.1204967			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753683				2022-12-28	WOS:000172288700009
J	Neary, CL; Cho-Chung, YS				Neary, CL; Cho-Chung, YS			Nuclear translocation of the catalytic subunit of protein kinase A induced by an antisense oligonucleotide directed against the RI alpha regulatory subunit	ONCOGENE			English	Article						cAMP; protein kinase A; antisense; immunocytochemistry; nuclear localization	CYCLIC-AMP; SOMATOSTATIN GENE; RESPONSE ELEMENT; OVARIAN-CANCER; FACTOR CREB; CAMP; GROWTH; DIFFERENTIATION; BINDING; CELLS	The regulatory (R) subunits of cAMP-dependent protein kinase (PKA) are implicated in the regulation of cell proliferation and differentiation. There are two isoforms of PKA that are distinguished by two types of R subunit, RI and RII Evidence suggests that RI is associated with proliferation and RII is associated with cell differentiation. Previous work in this laboratory has demonstrated that depletion of the RI alpha subunit by treatment with an antisense oligonucleotide (ODN) induces differentiation in leukemia cells and growth arrest and apoptosis in epithelial cancer cells. Using the prostate cancer cell line PC3M as a model system, we have developed a cell line that overexpresses a retroviral vector construct containing the RI alpha antisense gene. This cell tine has been characterized and the effectiveness of the construct determined. In the work presented here, we demonstrate by immunocytochemistry that treatment with RI alpha antisense ODN induces translocation of the C alpha subunit of PKA to the nucleus of PC3M prostate cancer cells. The translocation of Ca triggered by exogenous antisense ODN treatment mirrors that observed in cells endogenously overexpressing the antisense gene. Triggering the nuclear translocation of the C alpha subunit of PKA in the cell may be an important mechanism of action of RIa antisense that regulates cell growth independent of adenylate cyclase and cellular cAMP levels. The nuclear localization of the Ca subunit of PKA may be an essential step in revealing the mechanism whereby this critical kinase regulates cell growth.	NCI, Cellular Biochem Sect, Basic Res Labs, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cho-Chung, YS (corresponding author), Bldg 10,Room 5B05, Bethesda, MD 20892 USA.				NCI NIH HHS [N02-BC-76212] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BEEBE SJ, 1986, ENZYMES CONTROL PHOS; BOLD RJ, 1994, REGUL PEPTIDES, V53, P61, DOI 10.1016/0167-0115(94)90159-7; BRADBURY AW, 1994, BRIT J CANCER, V69, P738, DOI 10.1038/bjc.1994.139; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; Chen HX, 2000, CLIN CANCER RES, V6, P1259; Cho YS, 2001, P NATL ACAD SCI USA, V98, P9819, DOI 10.1073/pnas.171314398; CHOCHUNG YS, 1989, CANCER INVEST, V7, P161, DOI 10.3109/07357908909038282; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CHOCHUNG YS, 1998, APPL ANTISENSE OLIGO; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Levin AA, 1999, BBA-GENE STRUCT EXPR, V1489, P69, DOI 10.1016/S0167-4781(99)00140-2; McDaid HM, 1999, BRIT J CANCER, V79, P933, DOI 10.1038/sj.bjc.6690149; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MILLER WR, 1993, EUR J CANCER, V29A, P989, DOI 10.1016/S0959-8049(05)80207-2; MILLER WR, 1993, BREAST CANCER RES TR, V26, P89, DOI 10.1007/BF00682703; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Nesterova M, 2000, CLIN CANCER RES, V6, P3434; Nesterova M, 2000, ANTISENSE NUCLEIC A, V10, P423, DOI 10.1089/oli.1.2000.10.423; Schiavone N, 2000, BIOCHEM BIOPH RES CO, V270, P406, DOI 10.1006/bbrc.2000.2433; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Simpson BJB, 1996, CLIN CANCER RES, V2, P201; Srivastava RK, 1998, P NATL ACAD SCI USA, V95, P6687, DOI 10.1073/pnas.95.12.6687; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TORTORA G, 1990, J BIOL CHEM, V265, P18067; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOUNG MRI, 1995, INT J CANCER, V61, P104, DOI 10.1002/ijc.2910610118; Zhao QY, 1999, BIOORG MED CHEM LETT, V9, P3453	33	16	17	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					8019	8024		10.1038/sj.onc.1204992	http://dx.doi.org/10.1038/sj.onc.1204992			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753685				2022-12-28	WOS:000172288700011
J	Schilling, D; Pittelkow, MR; Kumar, R				Schilling, D; Pittelkow, MR; Kumar, R			IEX-1, an immediate early gene, increases the rate of apoptosis in keratinocytes	ONCOGENE			English	Article						IEX-1; immediate early gene; apoptosis; cellular growth; cell stress	EARLY-RESPONSE GENE; IDENTIFICATION; EXPRESSION; RADIATION; P22/PRG1	IEX-1, an immediate early gene, is widely expressed in epithelial and endothelial tissues, and is altered by a variety of growth regulatory factors. We have shown that expression of IEX-1 in keratinocytes increases the growth rate of these cells. The effects of IEX-1 on apoptosis, however, are unclear. To clarify the effects of IEX-1 on apoptosis, we investigated the effects of IEX-1 expression in keratinocytes (HaCaT cells) in the basal state and after the induction of cellular stress. Under normal, non-stressed conditions, both control (HaCaT) and 1EX-1-transfected (IEX-HaCaT) cell lines showed no significant differences in the activity of a key apoptotic enzyme, caspase 3 despite significantly higher levels of IEX-1 expression. IEX-HaCaT cells grew faster than HaCaT cells. When both cell lines were irradiated with ultraviolet B radiation, caspase 3 activity increased to a greater extent in the IEX-HaCaT cells than in HaCaT cells. Camptothecin increased caspase 3 activity twice as much in the IEX-HaCaT cells when compared to HaCaT cells. When histone-complex DNA fragments were measured in IEX-HaCaT or HaCaT cells following UVB irradiation or treatment with camptothecin, significantly higher amounts of nucleosomes were seen in the IEX-HaCaT transfected cells. Likewise, serum deprivation induced higher degrees of apoptosis in IEX-HaCaT cells than in HaCaT cells. We conclude that overexpression of IEX-1 in HaCaT keratinocytes increases the growth rate of cells under basal conditions; in the basal state the rate of apoptosis is unchanged. However, the rate of apoptosis increases in IEX-1 overexpressing HaCaT keratinocytes after cells are subjected to stress.	Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Kumar, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, 200 1st St SW,911A Guggenheim, Rochester, MN 55905 USA.			Kumar, Rajiv/0000-0003-3497-3057	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR027032, R01AR027032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058546, R01DK025409] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-27032] Funding Source: Medline; NIDDK NIH HHS [DK 58546, DK 25409, R01 DK025409, R01 DK058546] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; CHARLES CH, 1993, ONCOGENE, V8, P797; Feldmann KA, 2001, HISTOCHEM CELL BIOL, V115, P489; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998	13	61	63	2	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7992	7997		10.1038/sj.onc.1204965	http://dx.doi.org/10.1038/sj.onc.1204965			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753682				2022-12-28	WOS:000172288700008
J	Zhu, WG; Dai, ZY; Ding, HM; Srinivasan, K; Hall, J; Duan, WR; Villalona-Calero, MA; Plass, C; Otterson, GA				Zhu, WG; Dai, ZY; Ding, HM; Srinivasan, K; Hall, J; Duan, WR; Villalona-Calero, MA; Plass, C; Otterson, GA			Increased expression of unmethylated CDKN2D by 5-aza-2 '-deoxycytidine in human lung cancer cells	ONCOGENE			English	Article						DNA methylation; histone acetylation; CDKN2D; p16(INK4a); p19(INK4d)	CPG-ISLAND METHYLATION; DNA METHYLATION; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; IMPRINTED EXPRESSION; PROMOTER SEQUENCES; GENE; HYPERMETHYLATION; PROTEIN; COMPLEX	DNA hypermethylation of CpG islands in the promoter region of genes is associated with transcriptional silencing. Treatment with hypo-methylating agents can lead to expression of these silenced genes. However, whether inhibition of DNA methylation influences the expression of unmethylated genes has not been extensively studied. We analysed the methylation status of CDKN2A and CDKN2D in human lung cancer cell lines and demonstrated that the CDKN2A CpG island is methylated, whereas CDKN2D is unmethylated. Treatment of cells with 5-aza-2 ' -deoxycytidine (5-Aza-CdR), an inhibitor of DNA methyltransferase 1, induced a dose and duration dependent increased expression of both p16(INK4a) and p19(INK4d), the products of CDKN2A and CDKN2D, respectively. These data indicate that global DNA demethylation not only influences the expression of methylated genes but also of unmethylated genes. Histone acetylation is linked to methylation induced transcriptional silencing. Depsipeptide, an inhibitor of histone deacetylase, acts synergistically with 5-Aza-CdR in inducing expression of p16(INK4a) and p19(INK4d). However, when cells were treated with higher concentrations of 5-Aza-CdR and depsipeptide, p16(INK4a) expression was decreased together with significant suppression of cell growth. Interestingly, p19(INK4d) expression was enhanced even more by the higher concentrations of 5-Aza-CdR and depsipeptide. Our data suggest that p19(INK4d) plays a distinct role from other INK4 family members in response to the cytotoxicity induced by inhibition of DNA methylation and histone deacetylation.	Ohio State Univ, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Otterson, GA (corresponding author), Ohio State Univ, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Room B415,Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA.	otterson-1@medctr.osu.edu	zhu, wei-guo/E-1334-2012; Plass, Christoph/H-7192-2014	duan, wenrui/0000-0001-6512-7350; Zhu, Wei-Guo/0000-0001-8385-6581	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chan MF, 2000, CURR TOP MICROBIOL, V249, P75; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Elson DA, 1997, MOL CELL BIOL, V17, P309, DOI 10.1128/MCB.17.1.309; Evron E, 2001, CANCER RES, V61, P2782; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Glenn CC, 1996, AM J HUM GENET, V58, P335; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Knudsen S, 1999, BIOINFORMATICS, V15, P356, DOI 10.1093/bioinformatics/15.5.356; Kumar KS, 2000, WIND STRUCT, V3, P1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Loeb DM, 2001, CANCER RES, V61, P921; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Ohler U, 2000, Pac Symp Biocomput, P380; OKUDA T, 1995, GENOMICS, V29, P623, DOI 10.1006/geno.1995.9957; OTTERSON GA, 1995, ONCOGENE, V11, P1211; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; STAIGER D, 1989, P NATL ACAD SCI USA, V86, P6930, DOI 10.1073/pnas.86.18.6930; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; Zhu WG, 2001, CANCER RES, V61, P1327	51	96	98	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7787	7796		10.1038/sj.onc.1204970	http://dx.doi.org/10.1038/sj.onc.1204970			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753657				2022-12-28	WOS:000172161700010
J	Zelivianski, S; Igawa, T; Lim, S; Taylor, R; Lin, MF				Zelivianski, S; Igawa, T; Lim, S; Taylor, R; Lin, MF			Identification and characterization of regulatory elements of the human prostatic acid phosphatase promoter	ONCOGENE			English	Article						prostatic acid phosphatase; tissue-specific expression; promoter analysis; DNA injection	GENE-EXPRESSION; TRANSGENIC MICE; PRIMARY MYOBLASTS; ANTIGEN GENE; FACTOR-IX; ANDROGEN; CARCINOMA; THERAPY; PROTEIN; SPECIFICITY	Human prostatic acid phosphatase (PAcP) is a prostate epithelium-specific differentiation antigen. The cellular form of PAcP functions as a neutral protein-tyrosine phosphatase, and is involved in regulating prostate cell growth. Although some information on the PAcP gene structure has been obtained, little is known regarding the cis- and traps-acting factors that regulate its expression. Due to the biological importance of PAcP, we investigated the regulation of its expression. A region upstream of the PAcP gene from -2899 to +87 base pairs was linked to the coding sequence of the chloramphenicol acetyltransferase (CAT) gene. Sequential deletions of the sequence between -2899 and -205 revealed that, in addition to the basic promoter, the region between -1258 and -779 represents a positive regulatory element. This -1258/-779 fragment could enhance the PAcP promoter activity in PC-3 and DU 145 human prostate cancer cells, but not in non-prostate cancer cells, including WI-38 lung diploid cells, A-431 epidermoid carcinoma cells, and HeLa cervix epitheloid carcinoma cells. Furthermore, this cis-element together with the promoter sequence could drive a high level of expression of green fluorescent protein (GFP) in PC-3 cells, but not in HeLa cells. The prostate-specific expression was further examined by injecting naked plasmid DNA into the prostate and the hamstring muscle of mice. The fluorescence pattern clearly showed that the level of GFP expression is consistently higher in prostate cells than in muscle cells of the intact animal. The data collectively indicate that region between -1258 and -779 is involved in governing the cell type-specific expression of the PAcP gene.	Univ Nebraska, Med Ctr,Dept Biochem Mol Biol, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525,Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Sect Urol Surg, Omaha, NE USA; Univ Nebraska, Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA; Omaha VA Hosp, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr,Dept Biochem Mol Biol, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525,Coll Med, Omaha, NE 68198 USA.	mlin@unmc.edu	Zelivianski, Stanislav/G-3043-2010		NCI NIH HHS [CA88184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON J, 1989, MOL CELL BIOL, V9, P2254, DOI 10.1128/MCB.9.5.2254; BANAS B, 1994, BBA-GENE STRUCT EXPR, V1217, P188, DOI 10.1016/0167-4781(94)90033-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brookes DE, 1998, PROSTATE, V35, P18, DOI 10.1002/(SICI)1097-0045(19980401)35:1<18::AID-PROS3>3.0.CO;2-D; Chu TM, 1998, J CLIN LIGAND ASSAY, V21, P24; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; Gotoh A, 1998, J UROLOGY, V160, P220, DOI 10.1016/S0022-5347(01)63094-5; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; HENGGE UR, 1995, NAT GENET, V10, P161, DOI 10.1038/ng0695-161; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; PRIGOZY T, 1993, SOMAT CELL MOLEC GEN, V19, P111, DOI 10.1007/BF01233527; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROMAN M, 1992, SOMAT CELL MOLEC GEN, V18, P247, DOI 10.1007/BF01233861; Ruokonen M, 1996, BIOCHEM BIOPH RES CO, V218, P794, DOI 10.1006/bbrc.1996.0141; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAFFNER DL, 1995, LAB INVEST, V72, P283; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Shan JD, 1997, ENDOCRINOLOGY, V138, P3764, DOI 10.1210/en.138.9.3764; SHARIEF FS, 1994, BIOCHEM MOL BIOL INT, V33, P561; SOLIN T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P72, DOI 10.1016/0167-4781(90)90024-V; VIRKKUNEN P, 1994, BIOCHEM BIOPH RES CO, V202, P49, DOI 10.1006/bbrc.1994.1892; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386; Zelivianski S, 2000, BBA-GENE STRUCT EXPR, V1491, P123, DOI 10.1016/S0167-4781(00)00037-3; Zhang XQ, 2001, J BIOL CHEM, V276, P2544, DOI 10.1074/jbc.M006661200	38	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3696	3705		10.1038/sj.onc.1205471	http://dx.doi.org/10.1038/sj.onc.1205471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032838				2022-12-28	WOS:000175676000005
J	Arai, A; Kanda, E; Miura, O				Arai, A; Kanda, E; Miura, O			Rac is activated by erythropoietin or interleukin-3 and is involved in activation of the Erk signaling pathway	ONCOGENE			English	Article						rac; erythropoietin; IL-3; signal transduction; hematopoietic cells	GUANOSINE TRIPHOSPHATASES; TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; CELL ADHESION; RHO GTPASES; PROTEIN; RECEPTOR; BINDING; EXCHANGE; CRKL	Previous studies have shown that hematopoietic cytokines, including erythropoietin (Epo) and interleukin (IL)-3, activate the Ras GTPase and the downstream Raf/Erk/Elk-1 signaling pathway. Here we report that Epo or IL-3 rapidly and transiently activates Rac, a Rho family GTPase, in hernatopoietic cell lines, 32D/EpoR-Wt and UT-7. The cytokine-induced activation of Rac was augmented in a 32D/EpoR-Wt clone that inducibly overexpresses the adaptor protein CrkL or the Ras guanine nucleotide exchange factor C3G, which forms a complex with CrkL. Furthermore, the Rac activation was enhanced or inhibited in cells inducibly expressing an activated Ras mutant, H-Ras61L, or a dominant negative Ras mutant, H-Ras17N, respectively. In addition, the cytokine-induced Rac activation was inhibited by a phosphatidyl-inositol 3'-kinase (PI3K) inhibitor, LY294002, which also inhibited the Erk activation. A dominant negative Rac mutant, Rac17N, also inhibited the cytokine-induced activation of Erk as well as Elk-1. On the other hand, activation of Akt downstream of PI3K was found to play an inhibitory role in cytokine activation of Erk/Elk-1. Together, these results indicate that Rac is activated by Epo or IL-3 at downstream of the Ras/PI3K pathway in parallel with Akt and plays a role in activation of the Erk/Elk-1 signaling pathway in hematopoietic cells.	Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.	miura.med1@med.tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Arai A, 2001, J BIOL CHEM, V276, P33282, DOI 10.1074/jbc.M102924200; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chin H, 1998, BLOOD, V91, P3734; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Gu Y, 2001, J BIOL CHEM, V276, P15929, DOI 10.1074/jbc.M010445200; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hasegawa T, 1996, IEEE T POWER DELIVER, V11, P1776, DOI 10.1109/61.544257; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KOMATSU N, 1991, CANCER RES, V51, P341; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Matsuzaki T, 2000, ONCOGENE, V19, P1500, DOI 10.1038/sj.onc.1203461; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; Nosaka Y, 2001, BIOCHEM BIOPH RES CO, V285, P675, DOI 10.1006/bbrc.2001.5222; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; VAN AL, 1997, GENE DEV, V11, P2295; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	40	42	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2641	2651		10.1038/sj.onc.1205346	http://dx.doi.org/10.1038/sj.onc.1205346			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965537				2022-12-28	WOS:000174996500004
J	Billard, LM; Magdinier, F; Lenoir, GM; Frappart, L; Dante, R				Billard, LM; Magdinier, F; Lenoir, GM; Frappart, L; Dante, R			MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland	ONCOGENE			English	Article						breast cancer; prenatal developments; methyl binding proteins; RT-PCR	HISTONE DEACETYLASE COMPLEX; BINDING-PROTEIN MECP2; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; CHROMATIN; IDENTIFICATION; CANCER	During the last years, a direct link between DNA methylation and repressive chromatin structure has been established. This structural modification is mediated by histone deacetylases targeted to the methylated sequences by Methyl Binding Proteins (MBD). Human cancer cells exhibit both a global hypomethylation and some localized hypermethylations suggesting that the deregulation of the methylation machinery is a central event in tumorigenesis. Therefore, we have investigated in human tissues the expression of two major MBDs, MeCP2 and MBD2, during the proliferation of normal breast and in benign and neoplasic breast tumors. Quantitation of the transcripts indicates that MBD2 mRNAs are 20-30-fold more abundant than MeCP2 transcripts in the adult and fetal human mammary gland. In pathological tissues samples MBD2 mRNA levels are significantly higher (P = 0.001) in benign tumors compared with normal breast tissues, whereas MeCP2 expression is not modified in these specimens. In neoplasic samples a deregulation of the expression of both genes was found. The amounts of MBD2 and MeCP2 transcripts vary greatly between samples in cancer cells compared to normal breast tissues or benign tumors, and in invasive ductal carcinomas the amount of MBD2 mRNA is significantly (P = 0.03) associated with the tumor size. Taken together these data suggest that upregulation of VBD2 might be associated with breast cell proliferation. In line with this hypothesis MBD2 is also upregulated during the prenatal development of the human mammary gland, but in contrast to that observed in tumor cells, MeCP2 is also coordinately upregulated in the fetal breast tissues, suggesting that deregulation of MeCP2 and MBD2 occurs in human breast cancers.	UCBLI, Genet Lab, UMR 5641, F-67373 Lyon 08, France; Hop Edouard Herriot, Anat Pathol Lab, Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon	Dante, R (corresponding author), UCBLI, Genet Lab, UMR 5641, 8 Ave Rockefeller, F-67373 Lyon 08, France.		Magdinier, Frederique/I-4735-2016	Magdinier, Frederique/0000-0002-0159-9559				ARNAUD M, 1985, BIOCHEM BIOPH RES CO, V13, P108; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Eads CA, 2001, CANCER RES, V61, P3410; Ehrlich Melanie, 2000, P273; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kanai Y, 1999, BIOCHEM BIOPH RES CO, V264, P962, DOI 10.1006/bbrc.1999.1613; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; POULSEN HE, 1975, INT HISTOLOGICAL CLA, P13; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Russo J., 1987, The mammary gland. Development, regulation, and function., P67; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd, P28; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	36	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2704	2712		10.1038/sj/onc/1205357	http://dx.doi.org/10.1038/sj/onc/1205357			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965543	Green Published			2022-12-28	WOS:000174996500010
J	Fiucci, G; Ravid, D; Reich, R; Liscovitch, M				Fiucci, G; Ravid, D; Reich, R; Liscovitch, M			Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells	ONCOGENE			English	Article						anchorage-independent growth; anoikis; breast cancer; caveolin; invasiveness; MCF-7 cells; multidrug resistance	PHOSPHOINOSITIDE 3-OH KINASE; MULTIDRUG-RESISTANCE; IN-VIVO; METASTATIC ACTIVITIES; UROKINASE RECEPTOR; UP-REGULATION; EXPRESSION; PROTEIN; MEMBRANE; INTEGRIN	Caveolin-1 is an essential structural constituent of caveolae that has been implicated in mitogenic signaling and oncogenesis. Caveolin-1 is down-regulated in oncogene-transformed and tumor-derived cells. Antisense suppression of caveolin-1 or expression of a dominant negative form are sufficient for inducing cellular transformation. Expression of recombinant caveolin-1 inhibits anchorage-independent growth in cancer cells. The present study was designed to determine whether this is caused by inhibition of cancer cell survival or cell proliferation, and to test if another important property of cancer cells, i.e. matrix invasion, is modulated by expression of caveolin. Utilizing MCF-7 human breast adenocarcinoma cells stably transfected with caveolin-1 (MCF-7/Cav1), we demonstrate that caveolin-1 expression decreases MCF-7 cell proliferation rate and markedly reduces their capacity to form colonies in soft agar. The loss of anchorage-independent growth is not associated with stimulation of anoikis; in fact, MCF-7/Cav1 cells exhibit increased survival after detachment as compared with MCF-7 cells, indicating that in these cells caveolin-1 inhibits anoikis. Analysis of matrix metalloprotease release and matrix invasion revealed that expression of caveolin-1 inhibits also these important metastasis-related phenomena. Plating MCF-7 cells on a laminin matrix resulted in activation of ERK1/2, which was dramatically inhibited in MCF-7/Cav1 cells. We conclude that high expression level of caveolin-1 in human breast cancer cells exerts a negative modulatory effect on anchorage-independent growth by inhibiting cell proliferation even though matrix-independent cell survival is enhanced. Caveolin-1 expression inhibits also matrix invasion and blocks laminin-dependent activation of ERK1/2. The inhibitory effect of caveolin-1 on these transformation-dependent processes supports the hypothesis that caveolin-1 acts as a tumor suppressor protein which may impose major phenotypic changes when expressed in human cancer cells.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Fac Med, Dept Pharmacol, Jerusalem, Israel	Weizmann Institute of Science; Hebrew University of Jerusalem	Liscovitch, M (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, POB 26, IL-76100 Rehovot, Israel.	moti.liscovitch@weizmann.ac.il						Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BENARD J, 1989, INT J CANCER, V43, P471, DOI 10.1002/ijc.2910430322; Bender FC, 2000, CANCER RES, V60, P5870; BIEDLER JL, 1994, CANCER METAST REV, V13, P191, DOI 10.1007/BF00689636; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Campbell L, 1999, BIOCHEM BIOPH RES CO, V262, P744, DOI 10.1006/bbrc.1999.1280; Carriero MV, 1999, CANCER RES, V59, P5307; Chao C, 1996, CANCER RES, V56, P4811; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gargalovic P, 2001, J BIOL CHEM, V276, P26164, DOI 10.1074/jbc.M011291200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hayashi K, 2001, CANCER RES, V61, P2361; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li LK, 2001, CANCER RES, V61, P4386; Li WP, 2001, J CELL SCI, V114, P1397; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Lisanti MP, 1999, METH MOL B, V116, P51; Liscovitch M, 2000, TRENDS BIOCHEM SCI, V25, P530, DOI 10.1016/S0968-0004(00)01668-6; Liu J, 2001, AM J PHYSIOL-CELL PH, V280, pC823, DOI 10.1152/ajpcell.2001.280.4.C823; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; MATTERN J, 1990, ANTICANCER RES, V10, P177; Matveev S, 1999, J LIPID RES, V40, P1647; Mikol DD, 1999, GLIA, V27, P39; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Montesano R, 1999, CELL GROWTH DIFFER, V10, P317; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Razani B, 2001, J BIOL CHEM, V276, P38121; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; REICH R, 1989, BIOCHEM BIOPH RES CO, V160, P559, DOI 10.1016/0006-291X(89)92469-8; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Scotlandi K, 1996, CANCER RES, V56, P2434; Scotlandi K, 1999, ONCOGENE, V18, P739, DOI 10.1038/sj.onc.1202330; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SHTIL A, 1994, EXP TOXICOL PATHOL, V46, P257, DOI 10.1016/S0940-2993(11)80096-5; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; TERRANOVA VP, 1986, JNCI-J NATL CANCER I, V77, P311; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Welch DR, 2000, CANCER RES, V60, P1552; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	81	236	253	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2365	2375		10.1038/sj.onc.1205300	http://dx.doi.org/10.1038/sj.onc.1205300			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948420				2022-12-28	WOS:000174635600009
J	Rippin, TM; Bykov, VJN; Freund, SMV; Selivanova, G; Wiman, KG; Fersht, AR				Rippin, TM; Bykov, VJN; Freund, SMV; Selivanova, G; Wiman, KG; Fersht, AR			Characterization of the p53-rescue drug CP-31398 in vitro and in living cells	ONCOGENE			English	Article						tumour suppressor; DNA binding; stability; NMR	P53 CORE DOMAIN; DNA-BINDING; RESCUE; MUTATIONS	The Pfizer compound CP-31398 has been reported to stabilize the core domain of the tumour suppressor p53 in vitro and be an effective anti-cancer drug by virtue of rescuing destabilized mutants of p53. We did not detect any interaction between the p53 core domain and CP-31398 in vitro by a wide range of quantitative biophysical techniques over a wide range of conditions. CP-31398 did not stabilize p53 in our experiments. However, we found that CP-31398 intercalated with DNA and also altered and destabilized the DNA-p53 core domain complex. We analysed by NMR TROSY the interaction of the domain with a DNA oligomer and identified the changes in the complex on the binding of CP-31398. CP-31398 also decreased sequence-specific DNA binding of wild-type p53 and His-273 mutant p53. CP-31398 had a non-specific toxic effect independent of mutant p53 expression in several cell lines carrying Tet-regulated mutant p53. CP-31398 caused a small increase in MDM-2 expression and a more pronounced p53-independent increase in Bax expression. CP-31398 did, however, induce the PAb1620 epitope (characteristic of native p53) in cells expressing His-175 mutant p53. This was prevented by cycloheximide, suggesting that,my stabilizing action of CP-31398 would have to be on newly synthesized p53. One of the unstable mutants that was reported to have been rescued by CP-31398, R249S, does not bind DNA when folded at lower temperatures.	Univ Cambridge, Chem Lab, Cambridge CB2 2QH, England; Karolinska Hosp, CCK, Karolinska Inst, Dept Pathol Oncol, SE-17176 Stockholm, Sweden; Cambridge Ctr Prot Engn, MRC Ctr, Cambridge CB2 2QH, England	University of Cambridge; Karolinska Institutet; Karolinska University Hospital; MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), Univ Cambridge, Chem Lab, Hills Rd, Cambridge CB2 2QH, England.	arf10@cam.ac.uk	Fersht, Alan R/B-2189-2008; Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Nakade Bykov, Vladimir/0000-0002-7199-8942; Selivanova, Galina/0000-0002-8698-4332				Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jayaraman L, 1997, METHOD ENZYMOL, V283, P245; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE W, 1994, STRUCT BIOL, V1, P877; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Prives C, 1999, J PATHOL, V187, P112; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438	15	131	141	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2119	2129		10.1038/sj.onc.1205362	http://dx.doi.org/10.1038/sj.onc.1205362			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948395				2022-12-28	WOS:000174555300001
J	Carbone, R; Pearson, M; Minucci, S; Pelicci, PG				Carbone, R; Pearson, M; Minucci, S; Pelicci, PG			PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage	ONCOGENE			English	Article						promyelocytic leukaemia nuclear bodies; p53; hMre11; checkpoint; DNA repair	NIJMEGEN BREAKAGE SYNDROME; NUCLEAR-BODIES; PROTEIN COMPLEX; RETINOIC ACID; HISTONE H2AX; REPAIR; GENE; MRE11; ND10; DISRUPTION	PML nuclear bodies (PML NBs) respond to many cellular stresses including viral infection, heat shock, arsenic and oncogenes and have been implicated in the regulation of p53-dependent replicative senescence and apoptosis. Recently, the hMre11/Rad50/NBSI repair complex, involved in Double Strand Breaks (DSBs) repair, was found to colocalize within PML NBs, suggesting a role for these nuclear sub-domains in the DNA repair signalling pathway. We report here that in normal human fibroblasts, after ionizing radiation (IR), the PML NBs are modified and recognize sites of DNA breaks (ssDNA breaks and DSBs). Eight to 12 h after radiation PML NBs associate with hMre11 Ionizing Radiation-Induced Foci (IRIF), and subsequently with p53 within discrete foci. The PML, hMre11 and p53 colocalizing structures mark sites of DSBs as identified by immunolocalization with anti phosphorylated histone gamma-H2AX. Furthermore, we demonstrate that ionizing radiation induces the stable association of p53 with hMre11 and PML. These results suggest that the PML NBs are involved in the recognition and/or processing of DNA breaks and possibly in the recruitment of proteins (p53 and hMre11) required for both checkpoint and DNA-repair responses.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; FIRC Inst Mol Oncol, FIMO, I-20139 Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	pgpelicci@ieo.it	Minucci, Saverio/J-9669-2012; Pelicci, Pier Giuseppe/AAL-6572-2020					Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Andre C, 1996, EXP CELL RES, V229, P253, DOI 10.1006/excr.1996.0368; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Everett RD, 1999, J CELL SCI, V112, P3443; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lombard DB, 2000, CANCER RES, V60, P2331; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Wang Y, 2000, GENE DEV, V14, P927; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	46	154	157	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1633	1640		10.1038/sj.onc.1205227	http://dx.doi.org/10.1038/sj.onc.1205227			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896594				2022-12-28	WOS:000174214200001
J	Jinno, S; Yageta, M; Nagata, A; Okayama, H				Jinno, S; Yageta, M; Nagata, A; Okayama, H			Cdc6 requires anchorage for its expression	ONCOGENE			English	Article						Cdc6; anchorage; Cdk6; cyclin D3; NRK	EPIDERMAL-GROWTH-FACTOR; CYCLIN-DEPENDENT KINASES; CELL-CYCLE; RETINOBLASTOMA PROTEIN; MAMMALIAN CDC6; DNA-REPLICATION; G(1) CONTROL; NRK CELLS; S-PHASE; PHOSPHORYLATION	Fibroblasts need anchorage to extracellular matrix to transit from G(1) to S phase, but no longer after oncogenic transformation. Here we report that Cdc6 protein essential for the activation of replication origins requires anchorage or oncogenic stimulation for its execution. Upon anchorage loss, Cdc6 expression is shut off both transcriptionally and post-transcriptionally in a rat fibroblast despite enforced activation of E2F-dependent promoters. However, stimulation of this cell with oncogenic growth factors suppresses this shutoff and concurrently activates Cdk2 and Cdk6/4, thereby overriding the anchorage requirement for the G(1)-S transition and consequently enabling cells to perform anchorage-independent S phase entry. Analysis with enforced expression of Cdc6 indicates that the G(1) cyclin-dependent kinases and Cdc6 constitute major cell cycle targets for the restriction of the G(1)-S transition by anchorage loss.	Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Jinno, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan.	jinno@m.u-tokyo.ac.jp; okayama@m.u-tokyo.ac.jp	Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cifone M A, 1982, Cancer Metastasis Rev, V1, P335, DOI 10.1007/BF00124216; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Coverley D, 2000, J CELL SCI, V113, P1929; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Hosokawa Y, 1995, BIOCHEM MOL BIOL INT, V37, P393; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; KATO J, 1993, GENE DEV, V7, P331; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kizaka-Kondoh S, 2000, FEBS LETT, V466, P160, DOI 10.1016/S0014-5793(99)01784-6; KUME K, 1992, NEW BIOL, V4, P504; Lahaye DHTP, 1999, FEBS LETT, V446, P256, DOI 10.1016/S0014-5793(99)00216-1; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; Lin J, 2001, ONCOGENE, V20, P2000, DOI 10.1038/sj.onc.1204375; Liu KY, 2000, J BIOL CHEM, V275, P31093, DOI 10.1074/jbc.M005451200; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Madine MA, 2000, J STRUCT BIOL, V129, P198, DOI 10.1006/jsbi.2000.4218; MASUDA A, 1992, NEW BIOL, V4, P489; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Reed SI, 1997, CANCER SURV, V29, P7; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	49	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1777	1784		10.1038/sj.onc.1205249	http://dx.doi.org/10.1038/sj.onc.1205249			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896609				2022-12-28	WOS:000174214200016
J	Croxton, R; Ma, YH; Cress, WD				Croxton, R; Ma, YH; Cress, WD			Differences in DNA binding properties between E2F1 and E2F4 specify repression of the Mcl-1 promoter	ONCOGENE			English	Article						apoptosis; DNA binding; E2F1; E2F4; Mcl-1; specificity	S-PHASE ENTRY; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; EXPRESSION PATTERNS; SIGNALING PATHWAY; PROTEIN; FAMILY; LEADS; RB; IDENTIFICATION	E2F1 is a potent inducer of apoptosis whereas its relative, E2F4, generally does not promote cell death. Other work from our laboratory has demonstrated that E2F1 can directly bind and represss the Mcl-1 promoter - contributing to E2F1-mediated apoptosis. Here we show that while E2F1 can repress the Mcl-1 promoter, other members of the E2F family (such as E2F4) cannot. Characterization of the Mcl-1 promoter demonstrates that the -143/+10 region is critical for E2F1-mediated downregulation. We demonstrate that the ability of E2F1 to repress the Mcl-1 promoter correlates with its ability to bind within the required -143/+10 region of this promoter. In contrast, E2F4 is unable to bind to the -143/+10 region of the Mcl-1 promoter. We propose that E2F4 is unable to repress the Mcl-1 promoter primarily as a result of insufficient binding to the essential regulatory region. This is the first evidence of DNA binding specificity among E2F family members that results in differential regulation of a naturally occurring promoter.	H Lee Moffit Comprehens Canc Ctr & Res Inst, Program Mol Oncol, Tampa, FL 33612 USA; Dept Oncol, Tampa, FL 33612 USA; Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Inst Biomol Sci, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Cress, WD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NCI NIH HHS [CA78214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CROXTON R, 2001, IN PRESS ONCOGENE; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muller H, 1997, MOL CELL BIOL, V17, P5508; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wang JM, 1999, MOL CELL BIOL, V19, P6195; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZHANG YH, 1995, ONCOGENE, V10, P2085	55	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1563	1570		10.1038/sj.onc.1205232	http://dx.doi.org/10.1038/sj.onc.1205232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896585				2022-12-28	WOS:000173956800012
J	Rozenfeld-Granot, G; Krishnamurthy, J; Kannan, K; Toren, A; Amariglio, N; Givol, D; Rechavi, G				Rozenfeld-Granot, G; Krishnamurthy, J; Kannan, K; Toren, A; Amariglio, N; Givol, D; Rechavi, G			A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1	ONCOGENE			English	Article						apoptosis; Apaf-1; p53 target; Zac-1 coactivation; promoter luciferase assay	TUMOR-SUPPRESSOR P53; BCL-2 FAMILY; APOPTOSIS; GENE; TARGET; CASPASE-9; PROTEINS; BINDING; DOMAIN; PUMA	p53 exerts its tumor suppressor effects by activating genes involved in cell growth arrest and programmed cell death. The p53 target genes inducing growth arrest are well defined whereas those inducing apoptosis are not fully characterized. Proapoptotic activity of p53 was shown to involve several genes like Bax, Noxa and Puma, which may function in the release of cytochrome c from the mitochondria. Cytochrome c associates with Apaf-1 and caspase 9 to form the apoptosome. Genetic and cellular data indicate that Apaf-1 deficiency abrogates the apoptotic effect of p53 and substitutes for p53 loss in promoting tumor formation. Here we show that Apaf-1, the mammalian homologue of C. elegans CED4, is a direct target of p53 as demonstrated by gel shift analysis of the target site sequence in the presence of p53 and by Apaf-1 promoter-luciferase assays. We also show that the p53 activation of the Apaf-1 luciferase construct can be enhanced by the putative tumor suppressor gene product, Zac-1, a transcription factor that has previously been shown to inhibit cell proliferation. Furthermore, we demonstrate that Zac-1 is a possible direct target of p53 since the sequence upstream to the first coding exon of Zac-1 contains a p53 recognition site and the luciferase construct containing this region is activated by p53. These results suggests the existence of a tightly controlled self amplifying mechanism of transcriptional activation leading to apoptosis by p53.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematooncol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	david.givol@weizmann.ac.il						Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Arima T, 2000, GENOMICS, V67, P248, DOI 10.1006/geno.2000.6266; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Huang SM, 2001, ONCOGENE, V20, P2134, DOI 10.1038/sj.onc.1204298; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Robles AI, 2001, CANCER RES, V61, P6660; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Varrault A, 2001, J BIOL CHEM, V276, P18653, DOI 10.1074/jbc.C100095200; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	35	55	56	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1469	1476		10.1038/sj.onc.1205218	http://dx.doi.org/10.1038/sj.onc.1205218			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896574				2022-12-28	WOS:000173956800001
J	Wu, YF; Renard, CA; Apiou, F; Huerre, M; Tiollais, P; Dutrillaux, B; Buendia, MA				Wu, YF; Renard, CA; Apiou, F; Huerre, M; Tiollais, P; Dutrillaux, B; Buendia, MA			Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors	ONCOGENE			English	Article						hepatocellular carcinoma; c-Myc; LOH; CGH; INK4A/ARF	BETA-CATENIN MUTATIONS; COPY NUMBER CHANGES; HEPATOCELLULAR-CARCINOMA; C-MYC; SUPPRESSOR GENE; TRANSGENIC MICE; HETEROZYGOSITY; VIRUS; FREQUENT; P53	Transgenic mice expressing the c-Myc oncogene driven by woodchuck hepatitis virus (WHV) regulatory sequences develop hepatocellular carcinoma with a high frequency. To investigate genetic lesions that cooperate with Myc in liver carcinogenesis, we conducted a genome-wide scan for loss of heterozygosity (LOH) and mutational analysis of beta-catenin in 37 hepatocellular adenomas and carcinomas from C57BL/6 x castaneus F1 transgenic mice. In a subset of these tumors, chromosome imbalances were examined by comparative genomic hybridization (CGH). Allelotyping with 99 microsatellite markers spanning all autosomes revealed allelic imbalances at one or more chromosomes in 83.8% of cases. The overall fractional allelic loss was rather low, with a mean index of 0.066. However, significant LOH rates involved chromosomes 4 (21.6% of tumors), 14, 9 and 1 (11 to 16%). Interstitial LOH on chromosome 4 was mapped at band C4-C7 that contains the INK4a/ARF and INK4b loci, and on chromosome 14 at band B - D including the RB locus. In man, the homologous chromosomal regions 9p21, 13q14 and 8p21 - 23 are frequently deleted in liver cancer. LOH at chromosomes 1 and 14, and beta-catenin mutations (12.5% of cases) were seen only in HCCs. All tumors examined were found to be aneuploid. CGH analysis of 10 representative cases revealed recurrent gains at chromosomes 16 and 19, but losses or deletions involving mostly chromosomes 4 and 14 generally prevailed over gains. Thus, Myc activation in the liver might select for inactivation of tumor suppressor genes on regions of chromosomes 4 and 14 in a context of low genomic instability. Myc transgenic mice provide a useful model for better defining crosstalks between oncogene and tumor suppressor pathways in liver tumorigenesis.	Inst Pasteur, Unite Recombinat & Express Genet, Dept Retrovirus, INSERM,U163, F-75724 Paris 15, France; Inst Pasteur, Unite Histopathol, F-75015 Paris, France; Inst Curie, CNRS, UMR 147, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Buendia, MA (corresponding author), Inst Pasteur, Unite Recombinat & Express Genet, Dept Retrovirus, INSERM,U163, 28 Rue Dr Roux, F-75724 Paris 15, France.	mbuendia@pasteur.fr						Boige V, 1997, CANCER RES, V57, P1986; Bosch FX, 1997, LIVER CANCER, P13; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; DURO D, 1995, ONCOGENE, V11, P21; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; ETIEMBLE J, 1994, ONCOGENE, V9, P727; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; HEGI ME, 1994, CANCER RES, V54, P6257; HERZOG CR, 1994, CANCER RES, V54, P4007; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Lander JK, 1997, J VIROL, V71, P3940, DOI 10.1128/JVI.71.5.3940-3952.1997; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Marchio AS, 2000, ONCOGENE, V19, P3733, DOI 10.1038/sj.onc.1203713; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; MURAKAMI Y, 1991, CANCER RES, V51, P5520; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Ogawa K, 1999, CARCINOGENESIS, V20, P2083, DOI 10.1093/carcin/20.11.2083; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; QUELLE DE, 1995, CELL, V83, P993; Renard CA, 2000, ONCOGENE, V19, P2678, DOI 10.1038/sj.onc.1203617; Ritland SR, 1997, CANCER RES, V57, P3520; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Sargent LM, 1999, AM J PATHOL, V154, P1047, DOI 10.1016/S0002-9440(10)65357-6; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Shao CS, 2001, NAT GENET, V28, P169, DOI 10.1038/88897; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Shi YP, 1997, GENE CHROMOSOME CANC, V19, P104, DOI 10.1002/(SICI)1098-2264(199706)19:2<104::AID-GCC6>3.3.CO;2-S; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300	48	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1518	1526		10.1038/sj.onc.1205208	http://dx.doi.org/10.1038/sj.onc.1205208			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896580				2022-12-28	WOS:000173956800007
J	Foddis, R; De Rienzo, A; Broccoli, D; Bocchetta, M; Stekala, E; Rizzo, P; Tosolini, A; Grobelny, JV; Jhanwar, SC; Pass, HI; Testa, JR; Carbone, M				Foddis, R; De Rienzo, A; Broccoli, D; Bocchetta, M; Stekala, E; Rizzo, P; Tosolini, A; Grobelny, JV; Jhanwar, SC; Pass, HI; Testa, JR; Carbone, M			SV40 infection induces telomerase activity in human mesothelial cells	ONCOGENE			English	Article						SV40; telomerase; asbestos; mesothelioma	LARGE-T-ANTIGEN; IMMORTALIZATION; ASSOCIATION; SIMIAN-VIRUS-40; TRANSFORMATION; EXPRESSION; PROTEIN; FIBROBLASTS; ELONGATION; ACTIVATION	Mesotheliomas are malignant tumors of the pleural and peritoneal membranes which are often associated with asbestos exposure and with Simian virus 40 (SV40) infection. Telomerase activity is repressed in somatic cells and tissues but is activated in immortal and malignant cells. We evaluated telomerase activity in seven primary malignant mesothelioma biopsies and matched lung specimens and 20 mesothelioma cell lines and eight corresponding primary tumor cultures. All the tumor biopsies, and nearly all primary cell mesothelioma cultures and cell lines were telomerase positive. The findings in cell lines paralleled those observed in primary cultures in cases where paired samples were available. Next, we found that SV40, a DNA tumor virus present in similar to50% of mesothelioma biopsies in the USA, induced telomerase activity in primary human mesothelial cells, but not in primary fibroblasts. Telomerase activity became detectable as early as 72 h following wild-type (strain 776) SV40 infection, and a clear DNA ladder was detectable I week after infection. The amount of telomerase activity increased during passage in cell culture and appeared to parallel increases in the cellular amounts of the SV40 large T-antigen. Thus, SV40 infection leads to telomerase activity before the infected mesothelial cells become transformed and immortalized. SV40 infection of human fibroblasts did not cause detectable telomerase activity. We also determined that the SV40 small t-antigen (tag) plays an important role in inducing telomerase activity because this activity was undetectable or minimal in mesothelial cells infected and/or transformed by SV40 tag mutants. Asbestos alone did not induce telomerase activity, and asbestos did not influence telomerase activity in mesothelial cells infected with SV40. Induction of telomerase activity by SV40 may be related to the very high rate of mesothelial cell immortalization that is characteristically associated with SV40 infection of mesothelial cells.	Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Dept Pathol, Canc Immunol Program, Maywood, IL 60153 USA; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Wayne State Univ, Karmanos Canc Inst, Aerodigest Program, Detroit, MI 48201 USA	Loyola University Chicago; Fox Chase Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; Barbara Ann Karmanos Cancer Institute; Wayne State University	Carbone, M (corresponding author), Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Dept Pathol, Canc Immunol Program, Rm 205 2160 S 1st Ave, Maywood, IL 60153 USA.	mcarbon@orion.it.luc.edu		rizzo, paola/0000-0001-7174-9674; Pass, Harvey/0000-0003-3222-3471	NCI NIH HHS [CA-45745, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; CARBONE M, 1991, NATO ADV SCI I A-LIF, V209, P195; CARBONE M, 2002, IN PRESS SEMIN ONCOL; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KE Y, 1989, AM J PATHOL, V134, P979; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; Klein G, 2000, P NATL ACAD SCI USA, V97, P9830, DOI 10.1073/pnas.190325697; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Rizzo P, 1998, Monaldi Arch Chest Dis, V53, P202; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; SAGER R, 1984, CANCER CELL, V2, P487; Schrump DS, 2001, SEMIN CANCER BIOL, V11, P73, DOI 10.1006/scbi.2000.0348; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Testa JR, 1998, CANCER RES, V58, P4505; Testa JR, 2001, SEMIN CANCER BIOL, V11, P31, DOI 10.1006/scbi.2000.0344; Testa JR, 2001, CANC PRINCIPLES PRAC, P1937; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wright WE, 1996, DEV GENET, V18, P173; Yeager TR, 1999, CANCER RES, V59, P4175; YU J, 2002, VIROLOGY, V230, P132; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	46	83	91	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1434	1442		10.1038/sj.onc.1205203	http://dx.doi.org/10.1038/sj.onc.1205203			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857086				2022-12-28	WOS:000173861000013
J	Vortmeyer, A; Huang, SC; Pack, SD; Koch, CA; Lubensky, IA; Oldfield, EH; Zhuang, ZP				Vortmeyer, A; Huang, SC; Pack, SD; Koch, CA; Lubensky, IA; Oldfield, EH; Zhuang, ZP			Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion	ONCOGENE			English	Article						VHL disease; VHL gene; mutation; deletion	VONHIPPEL-LINDAU DISEASE; SUPPRESSOR GENE; CARCINOMA	The majority of patients with Von Hippel-Lindau (VHL) disease are affected by a VHL germline mutation involving one copy of the VHL gene. Loss of heterozygosity of the second VHL allele can be consistently demonstrated in tumor tissue from these patients, suggesting that allelic deletion is a very early or even initiating event for tumorigenesis. Approximately 20% of VHL disease patients, however, exhibit germline deletion of one entire copy or at least a substantial part of the VHL gene. To investigate the nature of the 'second genetic hit' in this patient population, we analysed two renal cell carcinomas and one CNS hemangioblastoma from three unrelated patients for genetic changes of the second copy of the VHL gene. All three tumors showed retention of one VHL allele by FISH. Single-strand conformation polymorphism and mutation analysis of microdissected tumor DNA revealed somatic point mutations of the wild-type VHL copies in each of the three tumors. The results indicate that the 'two hit model' is equally applicable to patients with VHL germline mutation and VHL germline deletion. In contrast to tumors from patients with VHL germline mutation, however, point mutations of the wild-type allele can be detected in tumors from patients with VHL germline deletion.	NINCDS, Surg Neurol Branch, Mol Pathogenesis Unit, Bethesda, MD 20892 USA; NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Zhuang, ZP (corresponding author), NINCDS, Surg Neurol Branch, Mol Pathogenesis Unit, Bldg 10,Room 5D37, Bethesda, MD 20892 USA.	zhuangp@ninds.nih.gov	Pack, Svetlana D./C-2020-2014; Koch, Christian A/A-4699-2008	Pack, Svetlana D./0000-0003-3256-6626; Koch, Christian A/0000-0003-3127-5739; Koch, Christian/0000-0003-0678-1242				CHOYKE PL, 1995, RADIOLOGY, V194, P629, DOI 10.1148/radiology.194.3.7862955; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; KNUDSON AG, 1985, CANCER RES, V45, P1437; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lubensky IA, 1996, AM J PATHOL, V149, P2089; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Pack SD, 1999, CANCER RES, V59, P5560; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; Zhuang Z, 1998, Cell Vis, V5, P43	11	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1167	1170		10.1038/sj.onc.1205121	http://dx.doi.org/10.1038/sj.onc.1205121			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850836				2022-12-28	WOS:000173729400004
J	Dinda, S; Sanchez, A; Moudgil, V				Dinda, S; Sanchez, A; Moudgil, V			Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells	ONCOGENE			English	Article						estrogen; thyroid hormone; p53; retinoblastoma protein; tumor suppressor proteins; breast cancer	RECEPTOR; PROLIFERATION; ACTIVATION; GENE; KINASE; PHOSPHORYLATION; ANTIPROGESTINS; PROGESTIN; PROMOTER; BIOLOGY	T47D cells represent an estrogen-responsive human ductal carcinoma cell line which expresses detectable levels of estrogen receptor (ER). We have previously shown that estradiol (E-2) treatment of T47D cells causes an increase in the level of p53 and a concomitant phosphorylation of retinoblastoma protein (pRb). In the present study, we have analysed the expression of p53 and phosphorylation state of pRb and compared the effects of E-2 and triiodothyronine (T-3) on these phenomena. Cells were grown in a medium containing charcoal-treated serum to deplete the levels of endogenous steroids. Upon confluency, the cells were treated with T-3 (10 (12) to 10(-7) M) for 24 h and the presence of p53 and pRb was detected by Western analysis. E-2 treatment of cells caused a 2-3-fold increase in the level of p53. Presence of T-3 in the medium caused a gradual increase in the level of p53 in a concentration-dependent manner. Under the above conditions, pRb was phosphorylated (detected as an upshift during SDS-PAGE) in the presence of E-2 and T-3. Supplementation of growth medium with T-3 (1 muM) caused an increase in the rate of proliferation of T47D cells and induced hyperphosphorylation of pRb within 4 h; this effect was maintained for up to 12 h. When ICI 164 384 (ICI) (1 muM), an ER antagonist, was combined with E-2 (1 muM) or T-3 (1 muM), effects of hormones on cell proliferation and hyperphosphorylation of pRb were blocked. Western analysis of p53 was supplemented with its cytolocalization by immuno-labeling using laser scanning confocal fluorescence microscopy, which revealed an ICI-sensitive increase in the abundance of p53 in hormone-treated cells. Steroid binding analysis revealed lack of competition by T-3 for the [H-3]E-2 binding. These results indicate that T-3 regulates T47D cell cycle progression and proliferation raising the p53 level and causing hyperphosphorylation of pRb by a common mechanism involving ER and T-3 receptor (T3R)-mediated pathways.	Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA; Oakland Univ, Ctr Biomed Res, Rochester, MI 48309 USA	Oakland University; Oakland University	Moudgil, V (corresponding author), Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.							ALVARADOPISANI AR, 1986, ANTICANCER RES, V6, P1347; Barrera-Hernandez G, 1999, ENDOCRINOLOGY, V140, P5267, DOI 10.1210/en.140.11.5267; Bhat MK, 1997, J BIOL CHEM, V272, P28989, DOI 10.1074/jbc.272.46.28989; Blohmer J U, 1999, Zentralbl Gynakol, V121, P522; BURKE RE, 1978, CANCER RES, V38, P3769; CERBON MA, 1981, CANCER RES, V41, P4167; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; Dellovade TL, 1999, NEUROENDOCRINOLOGY, V70, P168, DOI 10.1159/000054473; Dellovade TL, 2000, NAT NEUROSCI, V3, P472, DOI 10.1038/74846; DELLOVADE TL, 1995, J STEROID BIOCHEM, V53, P27, DOI 10.1016/0960-0760(95)00037-Z; DINDA S, 1998, P 80 ANN M END SOC N; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRANKLYN JA, 1988, CLIN ENDOCRINOL, V29, P337, DOI 10.1111/j.1365-2265.1988.tb01232.x; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; HORWITZ KB, 1985, ENDOCRINOLOGY, V116, P2236, DOI 10.1210/endo-116-6-2236; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; Hurd C, 1997, ONCOGENE, V15, P991, DOI 10.1038/sj.onc.1201233; Hurd C, 1999, ONCOGENE, V18, P1067, DOI 10.1038/sj.onc.1202398; Iwasaki K, 1999, MOL CELL BIOCHEM, V198, P141, DOI 10.1023/A:1006945813508; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; Lin HY, 1999, BIOCHEM J, V338, P427, DOI 10.1042/0264-6021:3380427; Morgan MA, 2000, HORM BEHAV, V37, P15, DOI 10.1006/hbeh.1999.1553; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nogueira CR, 1996, J STEROID BIOCHEM, V59, P271, DOI 10.1016/S0960-0760(96)00117-3; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; Parhar IS, 2000, ENDOCRINOLOGY, V141, P1618, DOI 10.1210/en.141.5.1618; Qi JS, 1997, MOL CELL BIOL, V17, P7195, DOI 10.1128/MCB.17.12.7195; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; SHAO ZM, 1995, EXP CELL RES, V218, P1, DOI 10.1006/excr.1995.1124; Shih A, 2001, BIOCHEMISTRY-US, V40, P2870, DOI 10.1021/bi001978b; WAFIK S, 1994, CANCER RES, V54, P1169; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273	38	92	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					761	768		10.1038/sj.onc.1205136	http://dx.doi.org/10.1038/sj.onc.1205136			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850804				2022-12-28	WOS:000173427000007
J	Stewart, SA; Weinberg, RA				Stewart, SA; Weinberg, RA			Senescence: does it all happen at the ends?	ONCOGENE			English	Article						telomere; senescence; telomerase; capping; immortality	TELOMERASE ACTIVITY; HUMAN-CELLS; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; GROWTH; FIBROBLASTS; EXTENSION; APOPTOSIS; CANCER; LENGTH	Over 60 years ago Barbara McClintock described the telomere and suggested that it protected the chromosome from illegitimate or end-to-end fusion, thus functioning to protect the genome. Since that time we have discovered that the telomere is a complex structure composed of both DNA and a growing list of associated proteins that together serve to regulate the length of the telomere and, as predicted by McClintock, protect genomic integrity. In addition to its protective role, the telomere has also been hypothesized to serve as a molecular clock that tallies the number of cell divisions and limits further divisions at a predetermined point. However, the precise role of telomeres in predicting and limiting cellular lifespan remains a matter of much debate. In this review, we highlight some of the salient points of basic telomere biology and relate them to the current controversies surrounding the role of telomeres and telomerase in cellular senescence.	MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Weinberg, RA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	weinberg@wi.mit.edu	Stewart, Sheila A/C-5213-2012		NATIONAL CANCER INSTITUTE [R01CA078461] Funding Source: NIH RePORTER; NCI NIH HHS [5R01 CA78461] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brozmanova J, 2001, NEOPLASMA, V48, P85; Chen QM, 2001, EXP CELL RES, V265, P294, DOI 10.1006/excr.2001.5182; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Friedrich U, 2000, MECH AGEING DEV, V119, P89, DOI 10.1016/S0047-6374(00)00173-1; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Gajdusek C, 2001, J CELL PHYSIOL, V188, P8, DOI 10.1002/jcp.1091; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holt SE, 1999, MOL CARCINOGEN, V25, P241, DOI 10.1002/(SICI)1098-2744(199908)25:4<241::AID-MC2>3.0.CO;2-9; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Mondello C, 1999, EXP CELL RES, V248, P234, DOI 10.1006/excr.1999.4398; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; Schulz VP, 1996, HUM GENET, V97, P750; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY M, 1991, ANN HEMATOL, V63, P116, DOI 10.1007/BF01707284; Shiloh Y, 1985, Kroc Found Ser, V19, P111; Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; von Zglinicki T, 2001, EXP GERONTOL, V36, P1049, DOI 10.1016/S0531-5565(01)00111-5; Walter CA, 1997, MECH AGEING DEV, V98, P203, DOI 10.1016/S0047-6374(97)00108-5; Watt PM, 1996, GENETICS, V144, P935; Wei S, 1999, CANCER RES, V59, P1539; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yudoh K, 2001, J BONE MINER RES, V16, P1453, DOI 10.1359/jbmr.2001.16.8.1453; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	47	64	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					627	630		10.1038/sj.onc.1205062	http://dx.doi.org/10.1038/sj.onc.1205062			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850788				2022-12-28	WOS:000173390500015
J	Koch, CA; Huang, SC; Zhuang, ZP; Stolle, C; Azumi, N; Chrousos, GP; Vortmeyer, AO; Pacak, K				Koch, CA; Huang, SC; Zhuang, ZP; Stolle, C; Azumi, N; Chrousos, GP; Vortmeyer, AO; Pacak, K			Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma	ONCOGENE			English	Article						RET; MEN 2; VHL; pheochromocytoma; deletion	HIPPEL-LINDAU-DISEASE; TUMOR-SUPPRESSOR GENE; RET PROTOONCOGENE; SPORADIC PHEOCHROMOCYTOMAS; GERMLINE MUTATIONS; SHORT ARM; HETEROZYGOSITY; EVENTS; ALLELE; 1P	Multiple endocrine neoplasia type 2 (MEN 2) is an inherited cancer syndrome that includes pheochromocytoma. Germline mutations in RET are responsible for MEN 2 but the precise pathogenetic mechanisms of tumorigenesis are unknown. We have recently identified possible mechanisms of tumor formation in patients with MEN 2A-related pheochromocytoma. Two of nine tumors investigated, however, did not reveal either of these mechanisms. In the present study, we therefore searched for other possible mechanisms underlying the pathogenesis of MEN 2A-related pheochromocytoma. Hereditary pheochromocytoma also occurs in patients with von Hippel-Lindau (VHL) disease, a syndrome consisting of tumors caused by inactivation of the VHL tumor suppressor gene. A subset of sporadic pheochromocytomas have somatic mutations in RET or VHL, suggesting that both genes contribute to pheochromocytoma pathogenesis in a subset of tumors. It is unknown, however; whether VHL gene alterations would be associated with tumorigenesis in hereditary, MEN 2-related pheochromocytoma. We therefore investigated four pheochromocytomas from patients with MEN 2A and RET germline mutations for the presence of allelic deletion and/or somatic mutation of the VHL gene. LOH analysis using the polymorphic markers D3S1038 and D3S1110 that map to the VHL gene locus 3p25/26, revealed evidence for somatic VHL gene deletion in all four MEN 2A-related pheochromocytomas. Mutation analysis of the VHL gene showed frameshift mutations in two tumors and a splice acceptor mutation in one tumor. The remaining tumor did show LOH but not mutation of the VHL gene. These results suggest that somatic genetic alterations of the VHL gene may play a role in the tumorigenesis of some MEN 2A-related pheochromocytomas.	NICHHD, PREB, NIH, Bethesda, MD 20892 USA; NINCDS, Surg Neurol Branch, Mol Pathogenesis Unit, NIH, Bethesda, MD 20892 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Georgetown Univ, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Pennsylvania; Georgetown University	Koch, CA (corresponding author), NICHHD, PREB, NIH, Bldg 10,Rm 9D42, Bethesda, MD 20892 USA.	kochc@exchange.nih.gov	Koch, Christian A/A-4699-2008	Koch, Christian A/0000-0003-3127-5739; Koch, Christian/0000-0003-0678-1242	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000615, ZIAHD000618] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000615, Z01HD000618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BELDJORD C, 1995, J CLIN ENDOCR METAB, V80, P2063, DOI 10.1210/jc.80.7.2063; Bender BU, 2000, J CLIN ENDOCR METAB, V85, P4568, DOI 10.1210/jc.85.12.4568; Benn DE, 2000, CANCER RES, V60, P7048; Brauch H, 1997, J CLIN ENDOCR METAB, V82, P4101, DOI 10.1210/jc.82.12.4101; CHOYKE PL, 1995, RADIOLOGY, V194, P629, DOI 10.1148/radiology.194.3.7862955; CROSSEY PA, 1994, HUM GENET, V93, P53; CROSSEY PA, 1995, J MED GENET, V32, P885, DOI 10.1136/jmg.32.11.885; Dannenberg H, 2000, AM J PATHOL, V157, P353, DOI 10.1016/S0002-9440(10)64547-6; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huang SC, 2000, CANCER RES, V60, P6223; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LINDOR NM, 1995, J CLIN ENDOCR METAB, V80, P627, DOI 10.1210/jc.80.2.627; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; MOLEY JF, 1992, CANCER RES, V52, P770; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Prowse AH, 1997, AM J HUM GENET, V60, P765; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; Vargas MP, 1997, HUM PATHOL, V28, P411, DOI 10.1016/S0046-8177(97)90028-9; Walther MM, 1999, J UROLOGY, V162, P659, DOI 10.1097/00005392-199909010-00004; ZEIGER MA, 1995, GENE CHROMOSOME CANC, V13, P151, DOI 10.1002/gcc.2870130303; Zhuang Z, 1998, Cell Vis, V5, P43	30	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					479	482		10.1038/sj.onc.1205133	http://dx.doi.org/10.1038/sj.onc.1205133			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821960				2022-12-28	WOS:000173311200016
J	Terradillos, O; de la Coste, A; Pollicino, T; Neuveut, C; Sitterlin, D; Lecoeur, H; Gougeon, ML; Kahn, A; Buendia, MA				Terradillos, O; de la Coste, A; Pollicino, T; Neuveut, C; Sitterlin, D; Lecoeur, H; Gougeon, ML; Kahn, A; Buendia, MA			The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver	ONCOGENE			English	Article						HBV; apoptosis; liver; mitochondria; cytochrome c; caspase	CYTOCHROME-C RELEASE; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; IN-VIVO; CELL-LINES; BCL-2; GENE; HBX; MITOCHONDRIA; DEATH	The role of the hepatitis B virus protein HBx in liver cell proliferation and apoptosis remains controversial. Using a transgenic mouse model, we have recently shown that HBx stimulates the apoptotic turnover of hepatocytes, independently of p53. In this paper, we tested whether the proapoptotic function of HBx can interfere with Bcl-2 during hepatic apoptosis in vivo. HBx transgenic mice were crossed with PK-hBcl-2 mice that are protected against Fas killing by constitutive overexpression of Bcl-2 in hepatocytes. In a lethal challenge with Fas antibodies, HBx expressed at low levels restored sensitivity to Fas-mediated apoptosis and fulminant hepatic failure in mice overexpressing Bcl-2. Furthermore, cytochrome c release from mitochondria and caspase 3 activation were restored to normal levels in HBx/Bcl-2 mice during transduction of the Fas signal. Thus, the proapoptotic activity of HBx overcomes or bypasses the inhibitory effect of Bcl-2 against Fas cytotoxicity. This effect was not apparently mediated through downregulation of the PK-hBcl-2 transgene or via delocalization of the Bcl-2 protein, and a direct interaction of HBx with Bcl-2, Bcl-X-L or Bax could not be evidenced in yeast two-hybrid assays. We further show that apoptosis induced by ectopic expression of HBx is associated with mitochondrial membrane alterations and caspase 3 activation. Our data indicate that the dominant function of HBx upon Bcl-2-regulated control of apoptosis might play an important role in the pathogenesis of chronic hepatitis B.	Inst Pasteur, Inserm U163, Dept SIDA & Retrovirus, F-75724 Paris, France; Univ Geneva Sci III, Dept Biol Cellulaire, Geneva, Switzerland; Univ Paris 05, Inserm U129, Paris, France; Inst Pasteur, Inserm U163, Unite Recombinaison & Express Genet, F-75724 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Buendia, MA (corresponding author), Inst Pasteur, Inserm U163, Dept SIDA & Retrovirus, 28 Rue Dr Roux, F-75724 Paris, France.	mbuendia@pasteur.fr	Pollicino, Teresa/HDN-3708-2022; Pollicino, Teresa/K-5790-2016	Pollicino, Teresa/0000-0001-6602-3035; Neuveut, Christine/0000-0001-6520-271X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; BALSANO C, 1993, ARCH VIROL, P63; BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; De la Coste A, 1999, AM J PHYSIOL-GASTR L, V277, pG702, DOI 10.1152/ajpgi.1999.277.3.G702; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Flajolet M, 2000, GENE, V242, P369, DOI 10.1016/S0378-1119(99)00511-9; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; GraslKraupp B, 1997, HEPATOLOGY, V25, P906, DOI 10.1002/hep.510250420; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARPER JW, 1993, CELL, V75, P805; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Lecoeur H, 1996, J IMMUNOL METHODS, V198, P87, DOI 10.1016/0022-1759(96)00148-2; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Pan JB, 2001, J GEN VIROL, V82, P171, DOI 10.1099/0022-1317-82-1-171; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Pollicino T, 1998, BIOMED PHARMACOTHER, V52, P363, DOI 10.1016/S0753-3322(99)80003-1; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Spengler U, 1996, CYTOKINE, V8, P864, DOI 10.1006/cyto.1996.0115; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Su F, 2001, J VIROL, V75, P215, DOI 10.1128/JVI.75.1.215-225.2001; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; WANG XW, 1995, CANCER RES, V55, P6012; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yeh CT, 2000, ONCOGENE, V19, P5213, DOI 10.1038/sj.onc.1203903; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	69	62	69	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					377	386		10.1038/sj.onc.1205110	http://dx.doi.org/10.1038/sj.onc.1205110			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821950				2022-12-28	WOS:000173311200006
J	Comtesse, N; Niedermayer, I; Glass, B; Heckel, D; Maldener, E; Nastainczyk, W; Feiden, W; Meese, E				Comtesse, N; Niedermayer, I; Glass, B; Heckel, D; Maldener, E; Nastainczyk, W; Feiden, W; Meese, E			MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies	ONCOGENE			English	Article						tumor antigen; overexpression; central nervous-system neoplasm; meningioma; glioma	CANCER PATIENTS; ANTIGENS; MENINGIOMA; CLONING; PROTEIN	Tumorigenesis of meningioma has been associated with chromosome 22, most notably the NF2 gene, but additional genes have also been implicated in meningioma development. Previously, we have cloned the cDNAs for the meningioma expressed antigen 6 (MGEA6) and its splice variant MGEA11. Here, we show that antibodies against recombinantly expressed MGEA6/11 are found in 41.7% (10/24) of the sera from meningioma patients and in 2/8 sera of glioblastoma patients, whereas no response was seen in 12 sera from healthy persons. Western-blot analyses using generated polyclonal antibodies, revealed overexpression in meningioma and glioma tumor samples compared to normal brain. Immunohistochemical staining of tissue sections confirms reactivity in meningioma tumor cells and tumor cells of glial origin. We found no reactivity to normal astrocytes and only faint reactivity to normal leptomeninges. Sequence analysis predicted membranic localization of MGEA6/11, that was confirmed by cell fractionation. The immune response to MGEA6/11 is frequent in both meningioma and glioma patients and may likely be attributed to overexpression of the MGEA6/11 protein in the tumor cells.	Univ Saarlandes Kliniken, Inst Humangenet, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Abt Neuropathol, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Med Biochem, D-66421 Homburg, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Meese, E (corresponding author), Univ Saarland, Dept Human Genet, Bldg 60, D-66421 Homburg, Germany.		Meese, Eckart Ulrich/ABD-1983-2021					AKAGI K, 1995, INT J CANCER, V60, P178, DOI 10.1002/ijc.2910600208; BARKER CF, 1977, ADV IMMUNOL, V25, P1; BECKER I, 1989, J NEUROIMMUNOL, V25, P161, DOI 10.1016/0165-5728(89)90133-1; BENMAHREZ K, 1990, INT J CANCER, V46, P35, DOI 10.1002/ijc.2910460109; Boon T, 1997, CURR OPIN IMMUNOL, V9, P681, DOI 10.1016/S0952-7915(97)80049-0; Comtesse N, 2001, GENOMICS, V75, P43, DOI 10.1006/geno.2001.6576; Comtesse N, 1999, CLIN CANCER RES, V5, P3560; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; DISIS ML, 1994, CANCER RES, V54, P16; GALLAGER G, 1991, BRIT J CANCER, V61, P35; Harlow E., 1988, ANTIBODIES LAB MANUA; Heckel D, 1997, HUM MOL GENET, V6, P2031, DOI 10.1093/hmg/6.12.2031; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; Kleihues P, 2000, PATHOLOGY GENETICS T; MARCIAS MJ, 1996, NATURE, V382, P646; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PEES HW, 1979, ACTA NEUROCHIR, V50, P217, DOI 10.1007/BF01808518; PEES HW, 1976, CLIN EXP IMMUNOL, V24, P310; PUPA SM, 1993, CANCER RES, V53, P5864; REAL FX, 1988, P NATL ACAD SCI USA, V85, P3965, DOI 10.1073/pnas.85.11.3965; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; TABUCHI K, 1979, ACTA NEUROCHI WIEN, V55, P201; Yamamoto A, 1996, INT J CANCER, V69, P283, DOI 10.1002/(SICI)1097-0215(19960822)69:4<283::AID-IJC8>3.3.CO;2-D	23	23	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					239	247		10.1038/sj/onc/1205005	http://dx.doi.org/10.1038/sj/onc/1205005			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803467				2022-12-28	WOS:000173026200008
J	Hong, F; Kim, WH; Tian, ZG; Jaruga, B; Ishac, E; Shen, XN; Gao, B				Hong, F; Kim, WH; Tian, ZG; Jaruga, B; Ishac, E; Shen, XN; Gao, B			Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-X-L proteins	ONCOGENE			English	Article						IL-6; Bcl-2; Bax; apoptosis; liver; alcoholic liver disease	NECROSIS-FACTOR-ALPHA; MEDIATED APOPTOSIS; RAT HEPATOCYTES; PLASMA INTERLEUKIN-6; ALCOHOLIC HEPATITIS; REGENERATING LIVER; OXIDATIVE STRESS; IN-VIVO; DISEASE; MICE	Elevation of serum interleukin-6 (IL-6) levels is always associated with alcoholic liver disease (ALD), but the significance of such elevation is not clear. Here we show that chronic ethanol consumption induces significant apoptosis in the liver of IL-6 (-/-) mice but not IL-6 (+/+) mice. IL-6 (-/-) hepatocytes are more susceptible to ethanol- and tumor necrosis factor alpha- (TNF alpha-) induced apoptotic killing, which can be corrected by IL-6. Expression of both anti-apoptotic (such as Bcl-2 and Bcl-X-L) and proapoptotic (such as Bax) proteins is markedly elevated in the liver of human ALD and chronically ethanol-fed IL-6 (+/+) mice. On the contrary, induction of Bcl-2 and Bcl-X-L is not observed in the liver of chronically ethanol-fed IL-6 (-/-) mice, whereas expression of Bax protein remains elevated. Injection of IL-6 markedly induces expression of Bcl-2 and Bcl-XL but not Bax in the liver. Finally, high concentrations of ethanol inhibit IL-6-activated anti-apoptotic signal, but increasing the concentrations of IL-6 is able to overcome such inhibitory effect. These findings suggest that elevated serum IL-6 levels in ALD may overcome the inhibitory effect of ethanol on IL-6-mediated anti-apoptotic signals and prevent alcohol-induced hepatic apoptosis by induction of Bcl-2 and Bcl-X-L.	NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Virginia Commonwealth University; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Gao, B (corresponding author), NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Pk Bldg,Room 120,12420 Parklawn Dr,MSC 8115, Bethesda, MD 20892 USA.		Tian, Zhigang/J-3512-2013	Kim, Won-Ho/0000-0002-4849-472X	NIAAA NIH HHS [R01AA12637] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000369, Z01AA000369, Z01AA000368, Z01AA000366, R01AA012637, ZIAAA000368] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abittan, 1999, Curr Treat Options Gastroenterol, V2, P72, DOI 10.1007/s11938-999-0022-5; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; BENEDETTI A, 1988, J HEPATOL, V6, P137, DOI 10.1016/S0168-8278(88)80024-2; BIRD G, 1994, ACTA GASTRO-ENT BELG, V57, P255; Chang YC, 2000, CELL RES, V10, P233, DOI 10.1038/sj.cr.7290052; Chen JP, 1999, FEBS LETT, V457, P162, DOI 10.1016/S0014-5793(99)01031-5; Chen JP, 1997, BIOCHEM BIOPH RES CO, V239, P666, DOI 10.1006/bbrc.1997.7531; Chen JP, 1998, BIOCHEM J, V334, P669, DOI 10.1042/bj3340669; Chen MC, 2000, J BIOL CHEM, V275, P38794, DOI 10.1074/jbc.M003292200; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Deaciuc IV, 1996, ALCOHOL CLIN EXP RES, V20, P293, DOI 10.1111/j.1530-0277.1996.tb01642.x; Deaciuc IV, 2001, HEPATOL RES, V19, P306, DOI 10.1016/S1386-6346(00)00112-1; Diehl AM, 1999, ALCOHOL CLIN EXP RES, V23, P1419, DOI 10.1097/00000374-199909000-00001; Diehl AM, 1999, CLIN BIOCHEM, V32, P571, DOI 10.1016/S0009-9120(99)00057-0; DIEHL AM, 1989, MED CLIN N AM, V73, P815, DOI 10.1016/S0025-7125(16)30640-X; Ezure T, 2000, AM J PATHOL, V156, P1627, DOI 10.1016/S0002-9440(10)65034-1; Fontanilla CV, 2000, ALCOHOL CLIN EXP RES, V24, P1392, DOI 10.1097/00000374-200009000-00010; FUCHS D, 1994, IMMUNOL TODAY, V15, P496, DOI 10.1016/0167-5699(94)90197-X; Galun E, 2000, FASEB J, V14, P1979, DOI 10.1096/fj.99-0913com; GOLDIN RD, 1993, J PATHOL, V171, P73, DOI 10.1002/path.1711710115; Gonzalez-Quintela A, 2000, CYTOKINE, V12, P1437, DOI 10.1006/cyto.2000.0715; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Hall P D, 1994, Alcohol Alcohol Suppl, V2, P303; Halsted CH, 1996, HEPATOLOGY, V23, P497, DOI 10.1002/hep.510230314; Hecht N, 2001, MOL THER, V3, P683, DOI 10.1006/mthe.2001.0313; HILL DB, 1992, J LAB CLIN MED, V119, P547; Hong F, 2001, FASEB J, V15, P1595, DOI 10.1096/fj.00-0908fje; Hong F, 2000, BIOCHEM BIOPH RES CO, V279, P974, DOI 10.1006/bbrc.2000.4044; KAMIMURA S, 1995, HEPATOLOGY, V22, P1304, DOI 10.1002/hep.1840220441; KIM W, 2001, IN PRESS FASEB J, V15; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Kurose I, 1997, HEPATOLOGY, V25, P368; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Laso FJ, 1999, ALCOHOL CLIN EXP RES, V23, P1306, DOI 10.1097/00000374-199908000-00003; Maddrey W C, 2000, Clin Liver Dis, V4, P115, DOI 10.1016/S1089-3261(05)70099-4; MARTINEZ F, 1992, ALCOHOL, V9, P455, DOI 10.1016/0741-8329(92)90080-T; McClain CJ, 1999, SEMIN LIVER DIS, V19, P205, DOI 10.1055/s-2007-1007110; Mi LJ, 2000, ALCOHOL CLIN EXP RES, V24, P207, DOI 10.1111/j.1530-0277.2000.tb04592.x; Panesar N, 1999, J SURG RES, V85, P251, DOI 10.1006/jsre.1999.5648; Pastorino JG, 2000, HEPATOLOGY, V31, P1141, DOI 10.1053/he.2000.7013; Pennington HL, 1997, J GASTROEN HEPATOL, V12, P305, DOI 10.1111/j.1440-1746.1997.tb00426.x; Rashid A, 1999, HEPATOLOGY, V29, P1131, DOI 10.1002/hep.510290428; Rollwagen FM, 1998, CLIN IMMUNOL IMMUNOP, V89, P205, DOI 10.1006/clin.1998.4600; SASAKI Y, 1994, BIOCHEM BIOPH RES CO, V199, P403, DOI 10.1006/bbrc.1994.1243; SHERON N, 1991, CLIN EXP IMMUNOL, V84, P449; Slomiany A, 1999, ALCOHOL CLIN EXP RES, V23, P334, DOI 10.1097/00000374-199902000-00021; Tuma DJ, 1996, ALCOHOL CLIN EXP RES, V20, P579, DOI 10.1111/j.1530-0277.1996.tb01096.x; Walsh K, 2000, POSTGRAD MED J, V76, P280, DOI 10.1136/pmj.76.895.280; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; YACOUB LK, 1995, ALCOHOL CLIN EXP RES, V19, P854, DOI 10.1111/j.1530-0277.1995.tb00958.x; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9; Zhang B, 2000, Zhonghua Gan Zang Bing Za Zhi, V8, P215; Zhao M, 1997, VIRCHOWS ARCH, V431, P337, DOI 10.1007/s004280050108	56	139	148	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					32	43		10.1038/sj.onc.1205016	http://dx.doi.org/10.1038/sj.onc.1205016			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791174				2022-12-28	WOS:000172887800004
J	Segrelles, C; Ruiz, S; Perez, P; Murga, C; Santos, M; Budunova, IV; Martinez, J; Larcher, F; Slaga, TJ; Gutkind, JS; Jorcano, JL; Paramio, JM				Segrelles, C; Ruiz, S; Perez, P; Murga, C; Santos, M; Budunova, IV; Martinez, J; Larcher, F; Slaga, TJ; Gutkind, JS; Jorcano, JL; Paramio, JM			Functional roles of Akt signaling in mouse skin tumorigenesis	ONCOGENE			English	Article						skin carcinogenesis; signal transduction; ras; Akt; PTEN	INTEGRIN-LINKED KINASE; PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR GENE; CYCLIN D1; PHOSPHOINOSITIDE 3-KINASE; PREMALIGNANT PROGRESSION; INCREASING COMPLEXITY; RAS TRANSFORMATION; CELL-PROLIFERATION	The mouse skin carcinogenesis protocol is a unique model for understanding the molecular events leading to oncogenic transformation. Mutations in the Ha-ras gene, and the presence of functional cyclin D1 and the EGF receptor, have proven to he important in this system. However, the signal transduction pathways connecting these elements during mouse skin carcinogenesis are poorly understood. This paper studies the relevance of the Akt and ERK pathways in the different stages of chemically induced mouse skin tumors. Akt activity increases throughout the entire process, and its early activation is detected prior to increased cyclin D1 expression. ERK activity rises only during the later stages of malignant conversion. The observed early increase in Akt activity appears to be due to raised PI-3K activity. Other factors acting on Akt such as ILK activation and decreased PTEN phosphatase activity appear to be involved at the conversion stage. To further confirm the involvement of Akt in this process, PB keratinocytes were transfected with Akt and subsequently injected into nude mice. The expression of Akt accelerates tumorigenesis and contributes to increased malignancy of these keratinocytes as demonstrated by the rate of appearance, the growth and the histological characteristics of the tumors. Collectively, these data provide evidence that Akt activation is one of the key elements during the different steps of mouse skin tumorigenesis.	CIEMAT, Program Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; AMC Canc Res Ctr, Denver, CO 80214 USA	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); AMC Cancer Research Center	Paramio, JM (corresponding author), CIEMAT, Program Cell & Mol Biol & Gene Therapy, Ed 7,Av Complutense 22, E-28040 Madrid, Spain.		Larcher, Fernando/J-1527-2016; Paramio, Jesus M/M-8482-2014; Santos, Mirentxu/AAA-1727-2020; Murga, Cristina/E-1965-2014; Gutkind, J. Silvio/A-1053-2009; Perez, Paloma/K-8841-2017; Gutkind, J. Silvio/J-1201-2016; Segrelles, Carmen/E-3655-2016; Ruiz, Sergio/G-1561-2016	Larcher, Fernando/0000-0002-6771-3561; Paramio, Jesus M/0000-0001-7520-3177; Murga, Cristina/0000-0002-8964-4077; Perez, Paloma/0000-0002-7166-2824; Gutkind, J. Silvio/0000-0002-5150-4482; Segrelles, Carmen/0000-0001-9340-2102; Ruiz, Sergio/0000-0002-0177-6965	NATIONAL CANCER INSTITUTE [R01CA079065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA79065-01, CA79065-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Conti C. J, 1994, HDB MOUSE MUTATIONS, P39; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DIAZGUERRA M, 1992, CANCER RES, V52, P680; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DiGiovanni J, 2000, CANCER RES, V60, P1561; Dlugosz AA, 1997, CANCER RES, V57, P3180; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Hansen LA, 2000, CANCER RES, V60, P3328; HARPER JR, 1987, CARCINOGENESIS, V8, P1821, DOI 10.1093/carcin/8.12.1821; LARCHER F, 1992, MOL CARCINOGEN, V6, P112, DOI 10.1002/mc.2940060206; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 1999, CELL GROWTH DIFFER, V10, P467; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; Rodriguez-Viciana P, 2001, METHOD ENZYMOL, V333, P37; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Xie W, 1998, AM J PATHOL, V153, P367, DOI 10.1016/S0002-9440(10)65580-0; YUSPA SH, 1986, CARCINOGENESIS, V7, P949, DOI 10.1093/carcin/7.6.949; YUSPA SH, 1994, CANCER RES, V54, P1178; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	61	160	160	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					53	64		10.1038/sj.onc.1205032	http://dx.doi.org/10.1038/sj.onc.1205032			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791176				2022-12-28	WOS:000172887800006
J	Monk, M; Holding, C				Monk, M; Holding, C			Human embryonic genes re-expressed in cancer cells	ONCOGENE			English	Article						human developmental genes; human preimplantation embryo; OCT4; embryo/cancer genes; cancer gene expression	PRIMORDIAL GERM-CELLS; DNA METHYLATION; 5-METHYLCYTOSINE CONTENT; PREIMPLANTATION EMBRYOS; ENDOGENOUS RETROVIRUSES; MOUSE EMBRYOS; SEQUENCES; CULTURE; LINE; HYPOMETHYLATION	Human preimplantation embryonic cells are similar in phenotype to cancer cells. Both types of cell undergo deprogramming to a proliferative stem cell state and become potentially immortal and invasive. To investigate the hypothesis that embryonic genes are re-expressed in cancer cells, we prepare amplified cDNA from human individual preimplantation embryos and isolate embryo-specific sequences. We show that three novel embryonic genes, and also the known gene, OCT4, are expressed in human tumours but not expressed in normal somatic tissues. Genes specific to this unique phase of the human life cycle and not expressed in somatic cells may have greater potential for targeting in cancer treatment.	Inst Child Hlth, Mol Embryol Unit, London WC1N 1EH, England	University of London; University College London	Monk, M (corresponding author), Inst Child Hlth, Mol Embryol Unit, 30 Guilford St, London WC1N 1EH, England.		Pillay, Nischalan/F-9536-2012		Medical Research Council [G9826762, G9900837] Funding Source: Medline; MRC [G9900837, G9826762] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABDELRAHMAN B, 1995, HUM REPROD, V10, P2787, DOI 10.1093/oxfordjournals.humrep.a135792; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FEINBERG AP, 1988, CANCER RES, V48, P1159; FUJIMOTO T, 1977, ANAT REC, V188, P315, DOI 10.1002/ar.1091880305; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Goto T, 1999, MOL HUM REPROD, V5, P851, DOI 10.1093/molehr/5.9.851; Holding C, 2000, MOL HUM REPROD, V6, P801, DOI 10.1093/molehr/6.9.801; HSIEH LL, 1987, CANCER RES, V47, P3421; Jin TR, 1999, INT J CANCER, V81, P104, DOI 10.1002/(SICI)1097-0215(19990331)81:1<104::AID-IJC18>3.0.CO;2-Q; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jurgens B, 1996, CANCER RES, V56, P5698; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KARLIN S, 1993, P NATL ACAD SCI USA, V90, P5873, DOI 10.1073/pnas.90.12.5873; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Mager DL, 1999, GENOMICS, V59, P255, DOI 10.1006/geno.1999.5877; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V74, P207; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; MONK M, 1991, DEVELOPMENT, V112, P189; Monk M, 2001, INT J DEV BIOL, V45, P497; MONK M, 1987, DEVELOPMENT, V99, P371; P Liang, 1997, DIFFERENTIAL DISPLAY; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; PIKO L, 1984, P NATL ACAD SCI-BIOL, V81, P488, DOI 10.1073/pnas.81.2.488; SALPEKAR A, 2001, MOL HUM REPROD, V7, P101; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; Solter D, 2000, NAT REV GENET, V1, P199, DOI 10.1038/35042066; Urnovitz HB, 1996, CLIN MICROBIOL REV, V9, P72, DOI 10.1128/CMR.9.1.72	37	275	295	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8085	8091		10.1038/sj.onc.1205088	http://dx.doi.org/10.1038/sj.onc.1205088			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781821				2022-12-28	WOS:000172396800005
J	Zhao, BH; Bepler, G				Zhao, BH; Bepler, G			Transcript map and complete genomic sequence for the 310 kb region of minimal allele loss on chromosome segment 11p15.5 in non-small-cell lung cancer	ONCOGENE			English	Article						lung cancer; chromosome 11p15.5; transcript map; genomic sequence; SSA/Ro52; RRM1	FULL-LENGTH CDNA; SHORT ARM; RIBONUCLEOTIDE REDUCTASE; GENES; HETEROZYGOSITY; ADENOCARCINOMA; 11P; AMPLIFICATION; ESTABLISHMENT; PROGRESSION	Molecular, functional, and clinical analyses strongly suggest that chromosome segment 11p15.5 contains a gene involved in lung cancer pathogenesis. The critical region of allele loss is 310 kb in size. We used our contig of P1-phage artificial chromosome (PAC) clones together with newly identified bacterial artificial chromosome (BAC) clones and the draft human genome sequence to complete a contiguous string of 380 407 bp. Three PAC clones that span the region were used to identify transcripts by exon trapping. Computational gene prediction algorithms were used to query the sequence for potential genes and exons. Screening for expression was performed with tissue-specific and cell line derived mRNA arrays. The region contains the complete SSA/Ro52 and RRM1 genes, exons 7-12 of the GOK gene, and the psi rad pseudo-gene. A cluster of six nearly identical genes with an intact open reading frame (ORF) of 585 bp that share 75% identity with the HSPC182 gene was found. In addition, five putative novel genes were identified. Sequence tagged sites (STS) and polymorphic markers were used to screen 117 lung cancer cell lines for homozygous deletions and none were identified. These data provide the basis for the identification of a lung cancer suppressor gene on 11p15.5.	Roswell Pk Canc Inst, Dept Med, Lung Canc Program, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Canc Genet, Lung Canc Program, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute	Bepler, G (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program, MRC MOLONC, 12902 Magnolia St, Tampa, FL 33612 USA.	beplerg@moffitt.usf.edu			NCI NIH HHS [P30 CA 16056, 5R01 CA 70317] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA070317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEPLER G, 1988, DIFFERENTIATION, V37, P158, DOI 10.1111/j.1432-0436.1988.tb00806.x; Bepler G, 1995, CANCER GENET CYTOGEN, V84, P39, DOI 10.1016/0165-4608(95)00063-1; Bepler G, 1998, CANCER DETECT PREV, V22, P14; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Bepler G, 1999, GENOMICS, V55, P164, DOI 10.1006/geno.1998.5659; BEPLER G, 1987, J CANCER RES CLIN, V113, P31, DOI 10.1007/BF00389964; BEPLER G, 2000, P AN M AM SOC CLIN, V19, pA485; Bork P, 2001, NATURE, V409, P818, DOI 10.1038/35057274; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; CARNEY DN, 1985, CANCER RES, V45, P2913; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Dickson D, 1999, NATURE, V401, P311, DOI 10.1038/43722; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FONG KM, 1994, GENE CHROMOSOME CANC, V10, P183, DOI 10.1002/gcc.2870100306; Frengen E, 1999, GENOMICS, V58, P250, DOI 10.1006/geno.1998.5693; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Karnik P, 1998, HUM MOL GENET, V7, P895, DOI 10.1093/hmg/7.5.895; Kim YC, 2000, INT J CANCER, V87, P61, DOI 10.1002/1097-0215(20000701)87:1<61::AID-IJC9>3.0.CO;2-R; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lu KH, 1997, CANCER RES, V57, P387; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; Matz M, 1999, NUCLEIC ACIDS RES, V27, P1558, DOI 10.1093/nar/27.6.1558; OBriant K, 1997, ANTICANCER RES, V17, P3243; Phelps RM, 1996, J CELL BIOCHEM, P32; Pitterle Diana M., 2000, Current Genomics, V1, P281, DOI 10.2174/1389202003351373; Pitterle DM, 1999, MAMM GENOME, V10, P916, DOI 10.1007/s003359901114; RANZANI GN, 1993, HUM GENET, V92, P244; Reese MG, 2000, GENOME RES, V10, P529, DOI 10.1101/gr.10.4.529; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; SKINNER MA, 1990, CANCER RES, V50, P2303; Stubbe J, 1998, P NATL ACAD SCI USA, V95, P2723, DOI 10.1073/pnas.95.6.2723; Tran YK, 1996, CANCER RES, V56, P2916; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Uberbacher EC, 1996, METHOD ENZYMOL, V266, P259; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VIEL A, 1992, BRIT J CANCER, V66, P1030, DOI 10.1038/bjc.1992.405; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WINQVIST R, 1993, CANCER RES, V53, P4486; Zhumabayeva B, 1999, BIOTECHNIQUES, V27, P834, DOI 10.2144/99274rr06	49	27	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2001	20	56					8154	8164		10.1038/sj.onc.1205027	http://dx.doi.org/10.1038/sj.onc.1205027			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781830				2022-12-28	WOS:000172396800014
J	Ichaso, N; Dilworth, SM				Ichaso, N; Dilworth, SM			Cell transformation by the middle T-antigen of polyoma virus	ONCOGENE			English	Review						middle T-antigen; cell transformation; signalling pathways; tyrosine kinases; PP2A	PROTEIN PHOSPHATASE 2A; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; MEDIUM TUMOR-ANTIGEN; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; COMPLEX-FORMATION; NEOPLASTIC TRANSFORMATION; ONCOGENIC TRANSFORMATION; MONOCLONAL-ANTIBODIES; SH2 DOMAINS	The polyoma virus region expressed early in the lytic cycle encodes three proteins, or T-antigens, that together cause the infected cell to enter the cell cycle and so provide a suitable cellular environment for replication of the viral genome. Under some circumstances infection does not kill the cell, but the T-antigens are still produced, resulting in the cell becoming transformed and tumorigenic. Most of this transforming action is exerted by the middle T-antigen, which has the ability to convert established cell lines to an oncogenic state. Middle T is a membrane bound polypeptide that interacts with a number of the proteins used by tyrosine kinase associated receptors to stimulate mitogenesis, so MT can be considered as a permanently active analogue of a receptor. Through a defined series of interactions, MT assembles a large multi-protein complex at the cell membrane, consisting of MT, the core dimer of protein phosphatase 2A, an si-c-family tyrosine kinase, and via phosphotyrosines, ShcA, phosphatidylinositol (3') kinase, and phospholipase C gamma -1. Tyrosine phosphorylation stimulates PI3K and PLC gamma -1 enzymatic activity, and on ShcA creates binding sites for Grb2 with its associated Sos1 and Gab1. This activates p21(ras), and hence, the MAP kinase cascade. Consequently, MT can be used as a model for studying cell transformation and growth factor receptor signalling pathways.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Metab Med, London W12 0NN, England	Imperial College London	Dilworth, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Metab Med, Du Cane Rd, London W12 0NN, England.	s.dilworth@ic.ac.uk						Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Chen YC, 1999, ONCOGENE, V18, P139, DOI 10.1038/sj.onc.1202272; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; Cullere X, 1998, J VIROL, V72, P558; DAHL J, 1992, MOL CELL BIOL, V12, P5050, DOI 10.1128/MCB.12.11.5050; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; Dunant N, 1997, CELL SIGNAL, V9, P385, DOI 10.1016/S0898-6568(97)00040-5; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; Dunant NM, 1997, J VIROL, V71, P199, DOI 10.1128/JVI.71.1.199-206.1997; EDDY BE, 1958, P SOC EXP BIOL MED, V98, P848; Elliott J, 1998, ONCOGENE, V17, P1797, DOI 10.1038/sj.onc.1202083; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; Glover HR, 1999, ONCOGENE, V18, P4364, DOI 10.1038/sj.onc.1202816; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Goutebroze L, 1997, J VIROL, V71, P1436, DOI 10.1128/JVI.71.2.1436-1442.1997; GROSS L, 1953, P SOC EXP BIOL MED, V83, P414; Helmbrecht K, 2000, CELL PROLIFERAT, V33, P341, DOI 10.1046/j.1365-2184.2000.00189.x; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kennedy AP, 1998, J BIOL CHEM, V273, P11505, DOI 10.1074/jbc.273.19.11505; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MAGNUSSON G, 1981, J VIROL, V39, P673, DOI 10.1128/JVI.39.3.673-683.1981; MARCELLUS R, 1991, ONCOGENE, V6, P1037; MARKLAND W, 1986, J VIROL, V59, P384, DOI 10.1128/JVI.59.2.384-391.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MATTHEWS JT, 1986, J VIROL, V58, P239, DOI 10.1128/JVI.58.2.239-246.1986; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Messerschmitt AS, 1997, VIROLOGY, V227, P271, DOI 10.1006/viro.1996.8316; METCALF D, 1987, EMBO J, V6, P3703, DOI 10.1002/j.1460-2075.1987.tb02704.x; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUSER J, 1989, ONCOGENE, V4, P1433; NICHOLSON PR, 2001, VIRUSES CELL TRANSFO, P85; Ogris E, 1999, J VIROL, V73, P7390, DOI 10.1128/JVI.73.9.7390-7398.1999; PALLAS DC, 1989, J VIROL, V63, P4533, DOI 10.1128/JVI.63.11.4533-4539.1989; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Platko JD, 1998, EXP CELL RES, V238, P42, DOI 10.1006/excr.1997.3782; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; SALCINI AE, 1994, ONCOGENE, V9, P2827; SCHERNECK S, 1990, Archiv fuer Geschwulstforschung, V60, P271; Senften M, 1997, J VIROL, V71, P6990, DOI 10.1128/JVI.71.9.6990-6995.1997; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TEMPLETON D, 1984, MOL CELL BIOL, V4, P282, DOI 10.1128/MCB.4.2.282; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VICIANA PR, 1994, NATURE, V370, P527; WALTER G, 1987, J VIROL, V61, P405, DOI 10.1128/JVI.61.2.405-410.1987; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905; Zhu WJ, 1998, ONCOGENE, V17, P565, DOI 10.1038/sj.onc.1201979	89	70	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7908	7916		10.1038/sj.onc.1204859	http://dx.doi.org/10.1038/sj.onc.1204859			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753673				2022-12-28	WOS:000172336500010
J	Imperiale, MJ				Imperiale, MJ			Oncogenic transformation by the human polyomaviruses	ONCOGENE			English	Review						T antigen; polyomavirus; human cancer; tumor suppressor proteins	LARGE-T-ANTIGEN; JC-VIRUS-DNA; SV40 LARGE T; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TRANSCRIPTIONAL CONTROL REGION; RETINOBLASTOMA GENE-PRODUCT; HUMAN-BRAIN-TUMORS; PERIPHERAL-BLOOD LEUKOCYTES; EMBRYONIC KIDNEY-CELLS; NONPASSAGED BK VIRUS		Univ Michigan, Sch Med, Dept Microbiol & Immunol, Canc Ctr 6310, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Imperiale, MJ (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Canc Ctr 6310, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.							Agostini HT, 1996, J CLIN MICROBIOL, V34, P159, DOI 10.1128/JCM.34.1.159-164.1996; ARTHUR RR, 1994, J NEURO-ONCOL, V20, P55, DOI 10.1007/BF01057961; AULT GS, 1993, J GEN VIROL, V74, P1499, DOI 10.1099/0022-1317-74-8-1499; Barbanti-Brodano G, 1987, Antibiot Chemother (1971), V38, P113; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; BUTEL JS, 1986, CANCER SURV, V5, P343; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CAPUTO A, 1983, J MED VIROL, V12, P37, DOI 10.1002/jmv.1890120105; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHOO KB, 1993, VIROLOGY, V193, P1042; Ciappi S, 1999, J GEN VIROL, V80, P1017, DOI 10.1099/0022-1317-80-4-1017; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; COLE CN, 1996, VIROLOGY, P1997; CORALLINI A, 1987, INT J CANCER, V39, P60, DOI 10.1002/ijc.2910390111; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; DALRYMPLE SA, 1990, J VIROL, V64, P1182, DOI 10.1128/JVI.64.3.1182-1191.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; DEVRIES CR, 1990, J UROLOGY, V143, P1; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Elsner C, 1998, J GEN VIROL, V79, P789, DOI 10.1099/0022-1317-79-4-789; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIORI M, 1976, P NATL ACAD SCI USA, V73, P4662, DOI 10.1073/pnas.73.12.4662; FLAEGSTAD T, 1991, VIROLOGY, V180, P553, DOI 10.1016/0042-6822(91)90069-N; Flaegstad T, 1999, CANCER RES, V59, P1160; Franks RR, 1996, ONCOGENE, V12, P2573; FREUND R, 1992, ONCOGENE, V7, P1979; FRISQUE RJ, 1980, J VIROL, V35, P265, DOI 10.1128/JVI.35.1.265-269.1980; GARDNER SD, 1973, BMJ-BRIT MED J, V1, P77, DOI 10.1136/bmj.1.5845.77; GARDNER SD, 1971, LANCET, V1, P1253; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOUDSMIT J, 1982, J MED VIROL, V10, P91, DOI 10.1002/jmv.1890100203; GROSSI MP, 1982, J GEN VIROL, V63, P393, DOI 10.1099/0022-1317-63-2-393; Guo J, 1996, J GEN VIROL, V77, P919, DOI 10.1099/0022-1317-77-5-919; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; Harris KF, 1998, DEV BIOLOGICALS, V94, P81; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; HOWLEY PM, 1980, J VIROL, V36, P878, DOI 10.1128/JVI.36.3.878-882.1980; Imperiale MJ, 2000, VIROLOGY, V267, P1, DOI 10.1006/viro.1999.0092; IWASAKA T, 1993, GYNECOL ONCOL, V48, P104, DOI 10.1006/gyno.1993.1016; KATO K, 1994, JPN J MED SCI BIOL, V47, P167, DOI 10.7883/yoken1952.47.167; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Khalili K, 1999, LANCET, V353, P1152, DOI 10.1016/S0140-6736(99)00357-8; KITAMURA T, 1994, J CLIN MICROBIOL, V32, P2359, DOI 10.1128/JCM.32.10.2359-2363.1994; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; KUNITAKE T, 1995, J CLIN MICROBIOL, V33, P1448, DOI 10.1128/JCM.33.6.1448-1451.1995; Laghi L, 1999, P NATL ACAD SCI USA, V96, P7484, DOI 10.1073/pnas.96.13.7484; Lazutka JR, 1996, CANCER LETT, V109, P177, DOI 10.1016/S0304-3835(96)04448-5; LOEBER G, 1988, J VIROL, V62, P1730, DOI 10.1128/JVI.62.5.1730-1735.1988; MARKOWITZ RB, 1991, J VIROL, V65, P4515, DOI 10.1128/JVI.65.8.4515-4519.1991; MARTIN JD, 1985, J VIROL, V53, P306, DOI 10.1128/JVI.53.1.306-311.1985; Monao MCG, 1998, J VIROL, V72, P9918, DOI 10.1128/JVI.72.12.9918-9923.1998; MONINI P, 1995, VIROLOGY, V214, P273, DOI 10.1006/viro.1995.9928; Monini P, 1995, INTERVIROLOGY, V38, P304, DOI 10.1159/000150455; Monini P, 1996, INT J CANCER, V66, P717, DOI 10.1002/(SICI)1097-0215(19960611)66:6<717::AID-IJC1>3.3.CO;2-N; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGRE S, 1994, J VIROL, V68, P1675, DOI 10.1128/JVI.68.3.1675-1681.1994; NEGRINI M, 1990, J GEN VIROL, V71, P2731, DOI 10.1099/0022-1317-71-11-2731; NEGRINI M, 1991, J VIROL, V65, P5092, DOI 10.1128/JVI.65.9.5092-5095.1991; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Newman JT, 1999, J MED VIROL, V58, P79, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;79::AID-JMV13&gt;3.0.CO;2-V; PADGETT BL, 1971, LANCET, V1, P1257; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PATER A, 1986, J VIROL, V58, P680, DOI 10.1128/JVI.58.2.680-683.1986; PATER MM, 1980, VIRUSES NATURALLY OC, P329; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; PORTOLANI M, 1978, J GEN VIROL, V38, P369, DOI 10.1099/0022-1317-38-2-369; PURCHIO AF, 1979, J VIROL, V29, P763, DOI 10.1128/JVI.29.2.763-769.1979; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; Ricciardiello L, 2001, J VIROL, V75, P1996, DOI 10.1128/JVI.75.4.1996-2001.2001; RUBINSTEIN R, 1987, J VIROL, V61, P1747, DOI 10.1128/JVI.61.5.1747-1750.1987; RUBINSTEIN R, 1991, J VIROL, V65, P1600, DOI 10.1128/JVI.65.3.1600-1604.1991; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAH KV, 1976, P SOC EXP BIOL MED, V153, P180, DOI 10.3181/00379727-153-39506; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Sugimoto C, 1997, P NATL ACAD SCI USA, V94, P9191, DOI 10.1073/pnas.94.17.9191; TAGUCHI F, 1982, MICROBIOL IMMUNOL, V26, P1057, DOI 10.1111/j.1348-0421.1982.tb00254.x; TAKEMOTO KK, 1979, J VIROL, V29, P1177, DOI 10.1128/JVI.29.3.1177-1185.1979; TAVIS JE, 1994, VIROLOGY, V199, P384, DOI 10.1006/viro.1994.1136; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; Tognon M, 1996, CANCER GENET CYTOGEN, V90, P17, DOI 10.1016/0165-4608(96)00067-2; TOMINAGA T, 1992, VIROLOGY, V186, P736; Trabanelli C, 1998, VIROLOGY, V243, P492, DOI 10.1006/viro.1998.9080; Tretiakova A, 1999, J NEUROSCI RES, V55, P588, DOI 10.1002/(SICI)1097-4547(19990301)55:5<588::AID-JNR6>3.0.CO;2-A; TROWBRIDGE PW, 1995, J NEUROVIROL, V1, P195, DOI 10.3109/13550289509113966; TROWBRIDGE PW, 1993, VIROLOGY, V196, P458, DOI 10.1006/viro.1993.1502; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waheed I, 1999, CANCER RES, V59, P6068; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WATANABE S, 1985, J VIROL, V55, P823, DOI 10.1128/JVI.55.3.823-825.1985; WATANABE S, 1982, J VIROL, V42, P978, DOI 10.1128/JVI.42.3.978-985.1982; Weber T, 1997, INTERVIROLOGY, V40, P98, DOI 10.1159/000150537; WHITE FA, 1992, J VIROL, V66, P5726, DOI 10.1128/JVI.66.10.5726-5734.1992; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YOGO Y, 1991, J CLIN MICROBIOL, V29, P2130, DOI 10.1128/JCM.29.10.2130-2138.1991; YOGO Y, 1994, VIRUS GENES, V8, P99, DOI 10.1007/BF01703608; YOGO Y, 1990, J VIROL, V64, P3139, DOI 10.1128/JVI.64.6.3139-3143.1990; ZERRAHN J, 1993, EMBO J, V12, P4739, DOI 10.1002/j.1460-2075.1993.tb06162.x; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	115	35	35	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	2001	20	54					7917	7923		10.1038/sj.onc.1204916	http://dx.doi.org/10.1038/sj.onc.1204916			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753674				2022-12-28	WOS:000172336500011
J	Koshikawa, K; Osada, H; Kozaki, K; Konishi, H; Masuda, A; Tatematsu, Y; Mitsudomi, T; Nakao, A; Takahashi, T				Koshikawa, K; Osada, H; Kozaki, K; Konishi, H; Masuda, A; Tatematsu, Y; Mitsudomi, T; Nakao, A; Takahashi, T			Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo	ONCOGENE			English	Article						lung cancer; metastasis; CLCP1	ENDOTHELIAL GROWTH-FACTOR; CELL-LINE NCI-H460-LNM35; TUMOR-CELLS; SEMAPHORIN-III; FACTOR VEGF; NEUROPILIN; RECEPTOR; ANGIOGENESIS; FAMILY	Most lung cancer patients are unfortunately uncurable and die because of widespread metastases, thus indicating the importance of identification of molecules with a crucial role in this process. Our previous expression profiling analysis of a highly metastatic lung cancer cell line, NCI-H460-LNM35, and its parental low metastatic line, NCI-H460-N15, revealed significant up-regulation of both known and unknown genes in LNM35. In this study, we describe the isolation and detailed characterizations of a novel gene, named CLCP1, which corresponds to one of such expression sequence tags with up-regulated expression in LNM35. The CLCP1 gene was found to encode a protein with 775 amino acids with structural similarities to, but distinct from neuropilins, cell surface receptors for VEGF(165), and semaphorins. Notably, CLCP1 was shown to be upregulated not only in LNM35 in association with its acquisition of metastatic phenotype during in vivo selection, but also in a significant fraction of lung cancers in vivo with high frequency in metastatic lesions, warranting future studies for a better understanding of the molecular mechanisms of lung cancer metastasis.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Surg 2, Showa Ku, Nagoya, Aichi 4668550, Japan	Aichi Cancer Center; Aichi Cancer Center; Nagoya University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Kozaki, Ken-ichi/M-6281-2014; Takahashi, Takashi/I-7262-2014	Kozaki, Ken-ichi/0000-0003-3286-819X; Takahashi, Takashi/0000-0003-0615-7001; Mitsudomi, Tetsuya/0000-0001-9860-8505; Konishi, Hiroyuki/0000-0003-1131-4905				Bachelder RE, 2001, CANCER RES, V61, P5736; Bagnard D, 1998, DEVELOPMENT, V125, P5043; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; FIDLER IJ, 2001, BIOL CANC ANGIOGENES, P917; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; Hayashibara T, 2001, CLIN CANCER RES, V7, P2719; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kozaki K, 2000, CANCER RES, V60, P2535; Kozaki K, 2001, ONCOGENE, V20, P4228, DOI 10.1038/sj.onc.1204561; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Miao HQ, 2000, CANCER METAST REV, V19, P29, DOI 10.1023/A:1026579711033; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; SEKIDO Y, 2001, CANC PRINCIPLES PRAC, P917; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2001, AM J PATHOL, V159, P651, DOI 10.1016/S0002-9440(10)61736-1; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; *STAT INF DEP MIN, 1999, VIT STAT JAP 1999, V3, P398; STETLERSTEVENSO.WG, 2001, MOL BIOL CANC INVASI, P123; Trexler M, 2000, EUR J BIOCHEM, V267, P5751, DOI 10.1046/j.1432-1327.2000.01641.x; Veikkola T, 2000, CANCER RES, V60, P203	28	44	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2822	2828		10.1038/sj.onc.1205405	http://dx.doi.org/10.1038/sj.onc.1205405			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973641				2022-12-28	WOS:000175063700006
J	Nakamura, S; Roth, JA; Mukhopadhyay, T				Nakamura, S; Roth, JA; Mukhopadhyay, T			Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells	ONCOGENE			English	Article						MDM2; p53; E6	TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; P53-MEDIATED APOPTOSIS; STABILIZES P53; ONCOPROTEIN; PROMOTES; UBIQUITINATION; ASSOCIATION; ONCOGENE; TARGETS	We have recently shown that lysine mutations in p53's putative C-terminal acetylation sites result in increased stability and cytoplasmic distribution of the p53 protein in a human lung cancer cell line. In the present study, we showed that when lysine residues 372, 373, 381, and 382 of p53 were substituted with alanine, the resulting A4 protein was resistant to MDM2-mediated proteosomal degradation but was highly sensitive to human papillomavirus E6-mediated proteolysis. When A4 and wildtype p53 were transfected into MDM2-overexpressing MCF-7 cells, A4 significantly reduced colony formation in vitro, when compared with wild-type p53. Our results suggest that A4 exerts a growth-inhibitory effect more efficiently than wild-type p53 does in cell lines that overexpress MDM2 and may therefore be a better therapeutic tool than wild-type p53 for certain cancers in which MDM2 is amplified or overexpressed.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, 1515 Holcombe Blvd,Box 445, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P01CA078778, P50CA070907, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA-70907, P01 CA 78778-01A1, 2P50-CA 70970-04, P50-CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Buschmann T, 2001, J BIOL CHEM, V276, P13852, DOI 10.1074/jbc.M007955200; Chen JD, 1996, MOL CELL BIOL, V16, P2445; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meng RD, 1998, CLIN CANCER RES, V4, P251; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; NAKAMURA S, 2002, IN PRESS ONCOGENE; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; REIHSAUS E, 1990, ONCOGENE, V5, P137; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thomas M, 1996, ONCOGENE, V13, P265; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	39	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2605	2610		10.1038/sj.onc.1205343	http://dx.doi.org/10.1038/sj.onc.1205343			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971195				2022-12-28	WOS:000174918400017
J	Sullivan, A; Yuille, M; Repellin, C; Reddy, A; Reelfs, O; Bell, A; Dunne, B; Gusterson, BA; Osin, P; Farrell, PJ; Yulug, I; Evans, A; Ozcelik, T; Gasco, M; Crook, T				Sullivan, A; Yuille, M; Repellin, C; Reddy, A; Reelfs, O; Bell, A; Dunne, B; Gusterson, BA; Osin, P; Farrell, PJ; Yulug, I; Evans, A; Ozcelik, T; Gasco, M; Crook, T			Concomitant inactivation of p53 and Chk2 in breast cancer	ONCOGENE			English	Article						p53; Chk2; breast cancer	MUTATIONS; BRCA1; GENE; FAMILIES; PHOSPHORYLATION; METHYLATION; CARCINOMAS; CHECKPOINT	The structure and expression of the human Rad53 homologue Chk2 was analysed in breast cancer. The previously described silent polymorphism at nucleotide 252 in codon 84 (GAA > GAG) was observed in 5/141 cases. Somatic Chk2 coding mutations were detected in 7/141 cases, these occurring in 4/18 BRCA1-associated breast cancers, 1/78 sporadic breast cancers and 2/25 typical medullary carcinomas. Each of the BRCA1-associated cancers with Chk2 mutations also contained mutations in p53, whereas the single sporadic cancer with Chk2 mutation was wild-type for p53. Expression of Chk2 was ubiquitously detected in normal ductal epithelium of the breast, but there was loss of expression in a significant proportion of breast carcinomas, and this occurred in cancers both with and without p53 mutation. A CpG island was identified 5' of the Chk2 transcriptional start site, but there was no evidence of cytosine methylation in any of the cancers with down-regulated Chk2 expression. Analysis of the germ-line of 45 individuals with hereditary or early onset breast cancer revealed wild-type Chk2 sequence in all cases. Thus, despite the rarity of somatic mutations in Chk2 in sporadic breast carcinomas, our results nevertheless reveal that concomitant loss of function in Chk2 (via down-regulation of expression) and p53 (via mutation) occurs in a proportion of sporadic cases. However, consistent with other studies, we show that germ-line mutations in Chk2 are unlikely to account for a significant proportion of non BRCA1-, non BRCA2-associated hereditary breast cancers.	Univ London Imperial Coll Sci & Technol, Fac Med, Ludwig Inst Canc Res, London W2 1PG, England; HGMC, Hinxton, England; Univ Glasgow, Western Infirm, Dept Pathol, Glasgow, Lanark, Scotland; UCL, Dept Hist, London WC1, England; Middlesex Hosp, Med Sch, London WC1, England; Bilkent Univ, Dept Mol Genet, Ankara, Turkey; Poole Gen Hosp, Dept Surg, Poole, Dorset, England; Azienda Osped S Croce & Carle, UO Oncol Med, I-12100 Cuneo, Italy	Imperial College London; Ludwig Institute for Cancer Research; University of Glasgow; University of London; University College London; University of London; University College London; Ihsan Dogramaci Bilkent University; Poole Hospital	Crook, T (corresponding author), Univ London Imperial Coll Sci & Technol, Fac Med, Ludwig Inst Canc Res, St Marys Campus Norfolk Pl, London W2 1PG, England.	t.crook@ic.ac.uk	gusterson, barry a/D-3752-2009; /AAD-1866-2020	Yulug, Isik/0000-0002-7577-2502; Farrell, Paul/0000-0002-6754-9351; Yuille, Martin/0000-0002-4992-5405				Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; Banelli B, 2000, ONCOGENE, V19, P4553, DOI 10.1038/sj.onc.1203807; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brooks LA, 2000, CANCER RES, V60, P6875; Chehab NH, 2000, GENE DEV, V14, P278; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Eisinger F, 1998, CANCER RES, V58, P1588; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Greenblatt MS, 2001, CANCER RES, V61, P4092; Haruki N, 2000, CANCER RES, V60, P4689; HERMAN JG, 1995, CANCER RES, V55, P4525; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Lakhani SR, 2000, CLIN CANCER RES, V6, P782; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Ozdag H, 2000, EUR J CANCER, V36, P2076, DOI 10.1016/S0959-8049(00)00277-X; Phillips KA, 1999, J NATL CANCER I, V91, P469, DOI 10.1093/jnci/91.5.469; Sodha N, 2000, Science, V289, P359; Vahteristo P, 2001, CANCER RES, V61, P5718; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200	27	66	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1316	1324		10.1038/sj.onc.1205207	http://dx.doi.org/10.1038/sj.onc.1205207			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857075	Green Published			2022-12-28	WOS:000173861000002
J	Lundblad, V				Lundblad, V			Telomere maintenance without telomerase	ONCOGENE			English	Article						telomerase; EST1; ALT; recombination; break-induced replication	SACCHAROMYCES-CEREVISIAE; HUMAN-CELLS; YEAST TELOMERE; RECOMBINATION; REPLICATION; LENGTH; ELONGATION; SENESCENCE; ENDS; BACTERIOPHAGE-T4	Recombination-dependent maintenance of telomeres, first discovered in budding yeast, has revealed an alternative pathway for telomere maintenance that does not require the enzyme telomerase. Experiments conducted in two budding yeasts, S. cerevisiae and K. lactis, have shown recombination can replenish terminal G-rich telomeric tracts that would otherwise shorten in the absence of telomerase, as well as disperse and amplify sub-telomeric repeat elements. Investigation of the genetic requirements for this process have revealed that at least two different recombination pathways, defined by RAD50 and RAD51, can promote telomere maintenance. Although critically short telomeres are very recombinogenic, recombination among telomeres that have only partially shortened in the absence of telomerase can also contribute to telomerase-independent survival. These observations provide new insights into the mechanism(s) by which recombination can restore telomere function in yeast, and suggest future experiments for the investigation of potentially similar pathways in human cells.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine	Lundblad, V (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.							BAIRD DM, 1995, EMBO J, V14, P5433, DOI 10.1002/j.1460-2075.1995.tb00227.x; Baird DM, 2000, AM J HUM GENET, V66, P235, DOI 10.1086/302721; BERNARDS A, 1983, NATURE, V303, P592, DOI 10.1038/303592a0; Biessmann H, 1997, CHROMOSOMA, V106, P63, DOI 10.1007/s004120050225; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bosco G, 1998, GENETICS, V150, P1037; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bucholc M, 2001, MOL CELL BIOL, V21, P6559, DOI 10.1128/MCB.21.19.6559-6573.2001; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; DUNN B, 1984, CELL, V39, P191, DOI 10.1016/0092-8674(84)90205-8; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; HOROWITZ H, 1985, MOL CELL BIOL, V5, P2369, DOI 10.1128/MCB.5.9.2369; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Hughes TR, 2000, CURR BIOL, V10, P809, DOI 10.1016/S0960-9822(00)00562-5; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; Le S, 1999, GENETICS, V152, P143; Lendvay TS, 1996, GENETICS, V144, P1399; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; Lundblad V, 2000, MUTAT RES-FUND MOL M, V451, P227, DOI 10.1016/S0027-5107(00)00052-X; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Malkova A, 2001, GENE DEV, V15, P1055, DOI 10.1101/gad.875901; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; McEachern MJ, 2001, MOL CELL, V7, P695, DOI 10.1016/S1097-2765(01)00215-5; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Morris DK, 1997, CURR BIOL, V7, P969, DOI 10.1016/S0960-9822(06)00416-7; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Novick RP, 1998, TRENDS BIOCHEM SCI, V23, P434, DOI 10.1016/S0968-0004(98)01302-4; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Signon L, 2001, MOL CELL BIOL, V21, P2048, DOI 10.1128/MCB.21.6.2048-2056.2001; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(00)00092-7; Teng SC, 1999, MOL CELL BIOL, V19, P8083; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WILKIE AOM, 1991, CELL, V64, P595, DOI 10.1016/0092-8674(91)90243-R; Yeager TR, 1999, CANCER RES, V59, P4175; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	58	126	133	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					522	531		10.1038/sj.onc.1205079	http://dx.doi.org/10.1038/sj.onc.1205079			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850777				2022-12-28	WOS:000173390500004
J	Polager, S; Kalma, Y; Berkovich, E; Ginsberg, D				Polager, S; Kalma, Y; Berkovich, E; Ginsberg, D			E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis	ONCOGENE			English	Article						E2F; cell cycle; mitosis; DNA replication; DNA repair; DNA microarrays	TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; CELL-CYCLE; PROTEIN; INDUCTION; PROMOTER; BINDING; MICE; SAK; NUCLEAR	The E2F family of transcription factors plays a pivotal role in the regulation of cell proliferation in higher eukaryotes. We used DNA microarrays and cell lines containing either inducible E2F-1 or inducible E2F-3 to identify novel E2F target genes. Our data indicate that E2F up-regulates the expression of genes not previously described as E2F target genes. A number of these E2F-regulated genes are involved in DNA replication, DNA repair and mitosis. These results suggest that E2F affects cell cycle progression both at S phase and during mitosis. Furthermore, our findings indicate that E2F-dependent gene activation may contribute to the cellular response to DNA damage.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	doron.ginsberg@weizmann.ac.il		ginsberg, doron/0000-0002-1257-4920				Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Davenport JW, 1999, GENOMICS, V55, P113, DOI 10.1006/geno.1998.5629; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hudson JW, 2000, GENE, V241, P65, DOI 10.1016/S0378-1119(99)00467-9; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Humbert PO, 2000, GENE DEV, V14, P690; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Iwahashi Y, 1998, GENE, V213, P141, DOI 10.1016/S0378-1119(98)00187-5; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Lavia P, 1999, BIOESSAYS, V21, P221; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Scherer SJ, 1996, HUM GENET, V97, P114; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOMPAYRAC L, 1994, VIROLOGY, V200, P849, DOI 10.1006/viro.1994.1255; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WALSH MJ, 1995, J BIOL CHEM, V270, P5289, DOI 10.1074/jbc.270.10.5289; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wu CL, 1996, MOL CELL BIOL, V16, P3698; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	45	214	217	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					437	446		10.1038/sj.onc.1205102	http://dx.doi.org/10.1038/sj.onc.1205102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821956				2022-12-28	WOS:000173311200012
J	Le, XF; Marcelli, M; McWatters, A; Nan, BC; Mills, GB; O'Brian, CA; Bast, RC				Le, XF; Marcelli, M; McWatters, A; Nan, BC; Mills, GB; O'Brian, CA; Bast, RC			Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity	ONCOGENE			English	Article						heregulin; protein kinase C; apoptosis; Bcl-2; caspase-7; HER2	BREAST-CANCER CELLS; NEU DIFFERENTIATION FACTOR; TUMOR-CELLS; GROWTH-FACTOR; SIGNALING NETWORK; PROSTATE-CANCER; LINE LNCAP; IN-VIVO; RECEPTOR; LIGAND	Heregulins are a group of growth factors that play diverse and critical roles in the signaling network of the human epidermal growth factor receptor (HER or EGFR) superfamily. Our earlier studies have shown that recombinant heregulin beta1 (HRG) induces apoptosis in SKBr3 breast cancer cells that overexpress HER2. Here we report molecular mechanisms of HRG-induced apoptosis. HRG treatment of SKBr3 cells for 72 h decreased the level of Bcl-2 protein. HRG treatment led to degradation of poly (ADP-ribose) polymerase (PARP) and activated both caspase-9 and caspase-7. No significant activation of caspase-3, -6, or -8 was detected. Expression of exogenous caspase-7 by adenovirus-caspase-7 (Ad-casp-7) in SKBr3 cells resulted in apoptosis, which mimicked the effect of HRG treatment. Expression of exogenous caspase-7 had no impact on Bcl-2 expression, but promoted PARP degradation. Two highly selective inhibitors of protein kinase C (PKC), GF109203X (GF) and Ro318425 (Ro), significantly enhanced HRG-induced apoptosis as determined by flow cytometric analysis and DNA fragmentation assay. Accordingly, the PKC inhibitor GF further decreased the level of Bcl-2 protein and further degraded PARP in HRG-treated cells. Assay of PKC activity indicated that HRG activated PKC in SKBr3 cells, predominantly affecting the PKC alpha isoform. To confirm which PKC isoform(s) mediated potentiation of HRG-induced apoptosis, the profile of PKC isoforms was measured in SKBr3 cells. Five PKC isoforms, PKC alpha, PKCi, PKC zeta, PKC lambda, and PKC delta as well as their receptors (RACK1) were expressed in this cell line. Treatment with PKC inhibitors GF and Ro decreased protein levels of both PKC alpha and PKC delta at 24 h. PKC alpha levels were still depressed at 72 h. GF and Ro had little effect on the expression of other PKC isoforms. An inhibitor of classical PKC isoforms (Go6976) enhanced HRG-induced apoptosis, whereas the PKC delta selective inhibitor rottlerin did not. As PKCa was the only classical isoform expressed in SKBr3 cells, the effect of Go6976 on HRG-induced apoptosis largely related to inhibition of PKCa. Constitutive expression of wild-type PKC alpha attenuated the apoptosis produced by HRG and GF. Consequently, HRG-induced apoptosis in SKBr3 cells appeared to involve down-regulation of Bcl-2 protein, activation of caspase-9 and caspase-7, and degradation of PARP. Inhibition of PKC function enhanced HRG-induced apoptosis, leading to synergistic down-regulation of Bcl-2 expression. Impairment of the PKC alpha isoform alone was sufficient to potentiate HRG-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine	Bast, RC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 355, Houston, TX 77030 USA.		Bast, Robert C/E-6585-2011; marcelli, marco/AGR-6853-2022	Bast, Robert C/0000-0003-4621-8462; 	NCI NIH HHS [CA39930] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Alexandre S, 2000, EXP CELL RES, V255, P30, DOI 10.1006/excr.1999.4759; Alexandre S, 2000, BIOCHIMIE, V82, P1115, DOI 10.1016/S0300-9084(00)01194-9; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; Bagheri-Yarmand R, 2000, J BIOL CHEM, V275, P39451, DOI 10.1074/jbc.M006150200; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Emoto Y, 1996, BLOOD, V87, P1990; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Gottlieb RA, 2000, FEBS LETT, V482, P6, DOI 10.1016/S0014-5793(00)02010-X; Grimm S, 1998, J EXP MED, V188, P1535, DOI 10.1084/jem.188.8.1535; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Guerra-Vladusic FK, 1999, INT J ONCOL, V15, P883; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Harris LN, 1998, CLIN CANCER RES, V4, P1005; Hijazi MM, 2000, INT J ONCOL, V17, P629; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Krane IM, 1996, ONCOGENE, V12, P1781; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 2000, CLIN CANCER RES, V6, P260; Le XF, 2000, CANCER RES, V60, P3522; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lewis GD, 1996, CANCER RES, V56, P1457; Machleidt T, 1998, FEBS LETT, V436, P51, DOI 10.1016/S0014-5793(98)01095-3; Marcelli M, 1999, CANCER RES, V59, P382; Marcelli M, 1998, CANCER RES, V58, P76; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Panvichian R, 1998, CANCER RES, V58, P4667; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rokhlin OW, 1998, CANCER RES, V58, P5870; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Tan M, 1999, CANCER RES, V59, P1620; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Ward NE, 2000, BIOCHEMISTRY-US, V39, P10319, DOI 10.1021/bi000781g; Weinstein EJ, 2000, CANCER RES, V60, P3856; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Xu FJ, 1997, CLIN CANCER RES, V3, P1629; Xu FJ, 1999, CLIN CANCER RES, V5, P3653; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685; Zhang LM, 1997, PARASITE, V4, P94; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	62	41	44	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8258	8269		10.1038/sj.onc.1205039	http://dx.doi.org/10.1038/sj.onc.1205039			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781840				2022-12-28	WOS:000172507800009
J	Lefevre, SH; Vogt, N; Dutrillaux, AM; Chauveinc, K; Stoppa-Lyonnet, D; Doz, F; Desjardins, L; Dutrillaux, B; Chevillard, S; Malfoy, B				Lefevre, SH; Vogt, N; Dutrillaux, AM; Chauveinc, K; Stoppa-Lyonnet, D; Doz, F; Desjardins, L; Dutrillaux, B; Chevillard, S; Malfoy, B			Genome instability in secondary solid tumors developing after radiotherapy of bilateral retinoblastoma	ONCOGENE			English	Article						ionizing radiation; secondary cancers; retinoblastoma; chromosome instability; TP53; predisposition	P53 GENE-MUTATIONS; THYROID CARCINOMAS; MICROSATELLITE INSTABILITY; HODGKINS-DISEASE; MAMMALIAN-CELLS; HIGH PREVALENCE; RET GENES; RADIATION; CANCER; DNA	Genome alterations of seven secondary tumors (five osteosarcomas, one malignant peripheral sheath nerve tumor, one leiomyosarcoma) occurring in the field of irradiation of patients treated for bilateral retinoblastoma have been studied. These patients were predisposed to develop radiation-induced tumors because of the presence of a germ line mutation in the retinoblastoma gene (RB1). Tumor cells were characterized by a high chromosome instability whereas microsatellites and minisatellites were found to be stable. In all tumors, the normal RBI allele was lost with the corresponding chromosome 13, whereas the germ line mutated allele was retained. The two alleles of TP53 were inactivated, one by deletion of the short arm of chromosome 17, the other by mutation. As compared with non-radiation induced tumors, the observed panel of TP53 mutations was uncommon with sites not recurrently found otherwise and a high rate of deletions (3/7). In these predisposed patients, the loss of the single normal allele of RB1 is rather due to the radiation-induced chromosome instability than a direct effect of ionizing radiation.	Inst Curie, CNRS UMR 147, F-75248 Paris 05, France; Inst Curie, Serv Radiotherapie, F-75248 Paris, France; Inst Curie, Serv Genet Oncol, F-75248 Paris 05, France; Inst Curie, Serv Pediat, F-75248 Paris 05, France; Inst Curie, Serv Ophthalmol, F-75248 Paris 05, France; CEA, DSV, DRR, F-92265 Fontenay Aux Roses, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CEA	Malfoy, B (corresponding author), Inst Curie, CNRS UMR 147, 26 Rue Ulm, F-75248 Paris 05, France.			Doz, Francois/0000-0001-9286-4831; Chevillard, Sylvie/0000-0001-5889-4041				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Behrens C, 2000, CANCER EPIDEM BIOMAR, V9, P1027; Bernardino J, 1997, CANCER GENET CYTOGEN, V96, P123, DOI 10.1016/S0165-4608(96)00258-0; Boland CR, 1998, CANCER RES, V58, P5248; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; BRACHMAN DG, 1991, CANCER RES, V51, P6393; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brat DJ, 1999, AM J PATHOL, V154, P1431, DOI 10.1016/S0002-9440(10)65397-7; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; CAHAN WG, 1948, CANCER, V1, P3, DOI 10.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-7; Calvo R, 1998, J NATL CANCER I, V90, P1095, DOI 10.1093/jnci/90.14.1095; Chauveinc L, 1999, CANCER GENET CYTOGEN, V114, P1, DOI 10.1016/S0165-4608(99)00038-2; Chevillard S, 1997, CLIN CANCER RES, V3, P2471; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; DeBenedetti VMG, 1996, CANCER EPIDEM BIOMAR, V5, P93; DEVATHAIRE F, 1992, BRIT J CANCER, V65, P425, DOI 10.1038/bjc.1992.87; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; Dutrillaux B, 1981, PRATIQUE ANAL CHROMO; Fennelly J, 1997, LEUKEMIA, V11, P807, DOI 10.1038/sj.leu.2400674; Fogelfeld L, 1996, J CLIN ENDOCR METAB, V81, P3039, DOI 10.1210/jc.81.8.3039; Gafanovich A, 1999, CANCER-AM CANCER SOC, V85, P504; Gamble SC, 1999, MUTAT RES-FUND MOL M, V425, P231, DOI 10.1016/S0027-5107(99)00045-7; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jeffreys AJ, 1997, ELECTROPHORESIS, V18, P1501, DOI 10.1002/elps.1150180903; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Klugbauer S, 1995, ONCOGENE, V11, P2459; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Le Page F, 1999, BIOCHIMIE, V81, P147, DOI 10.1016/S0300-9084(99)80047-9; LEFRANCOIS D, 1989, INT J CANCER, V44, P871, DOI 10.1002/ijc.2910440521; LEPAGE F, 1995, CARCINOGENESIS, V16, P2779; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; Lohmann DR, 1999, HUM MUTAT, V14, P283, DOI 10.1002/(SICI)1098-1004(199910)14:4<283::AID-HUMU2>3.0.CO;2-J; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MARTINS MB, 1993, MUTAT RES, V285, P229, DOI 10.1016/0027-5107(93)90111-R; Mertens F, 2000, CANCER GENET CYTOGEN, V116, P89, DOI 10.1016/S0165-4608(99)00105-3; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Nakanishi H, 1998, LAB INVEST, V78, P727; Nikiforov YE, 1999, ONCOGENE, V18, P6330, DOI 10.1038/sj.onc.1203019; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 1996, ONCOGENE, V13, P687; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; Richter HE, 1999, CARCINOGENESIS, V20, P2247, DOI 10.1093/carcin/20.12.2247; ROBINSON E, 1988, JNCI-J NATL CANCER I, V80, P233, DOI 10.1093/jnci/80.4.233; SAJANTILA A, 1992, AM J HUM GENET, V50, P816; Shoshan Y, 2000, J NEUROPATH EXP NEUR, V59, P614, DOI 10.1093/jnen/59.7.614; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; SOUSSI T, 1990, ONCOGENE, V5, P945; Tada M, 1997, NEUROSURGERY, V40, P393, DOI 10.1097/00006123-199702000-00034; United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), 1993, REP SOURC EFF RISKS; VOGEL F, 1979, HUM GENET, V52, P1; Wallace SS, 1998, RADIAT RES, V150, pS60, DOI 10.2307/3579809; Wong FL, 1997, JAMA-J AM MED ASSOC, V278, P1262, DOI 10.1001/jama.278.15.1262; Wright E G, 2000, Med Confl Surviv, V16, P117, DOI 10.1080/13623690008409501	63	23	23	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8092	8099		10.1038/sj.onc.1205009	http://dx.doi.org/10.1038/sj.onc.1205009			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781822				2022-12-28	WOS:000172396800006
J	Bernardi, R; Grisendi, S; Pandolfi, PP				Bernardi, R; Grisendi, S; Pandolfi, PP			Modelling haematopoietic malignancies in the mouse and therapeutical implications	ONCOGENE			English	Article						animal models; leukaemias and lymphomas; transgenic mice; knock-in; tetracycline-inducible system; Cre-loxP system	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; ACID RECEPTOR-ALPHA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANS-RETINOIC ACID; TYROSINE KINASE INHIBITOR; ARSENIC TRIOXIDE AS2O3; ZINC-FINGER GENE; C-MYC ONCOGENE; PML/RAR-ALPHA	Modelling human disease in the mouse has become an essential activity in biomedical research in order to unravel molecular mechanisms underlying pathological conditions as well as to determine in vivo the consequences of aberrant gene function. The mouse is by far the most accessible mammalian system physiologically similar to humans. Furthermore, the development of novel techniques for manipulating the murine genome, which allow the in vivo modification of virtually any genomic region in a time and/or tissue specific manner, renders the mouse an ideal model system to study human pathological conditions. Modelling human diseases in mice has reached an even greater relevance in the field of haematological malignancies, due to the already advanced characterization of the molecular basis of many haematological disorders. In this review, we describe the most important technological developments that made it possible to reproduce in the mouse the genetic lesions that characterize human haematological malignancies, thus often generating faithful mouse models of the human condition. We provide specific examples of the advantages and limitations of the various genetic approaches utilized to model leukaemia and lymphoma in the mouse. Finally, we discuss the power of mouse modelling in developing and testing novel therapeutic modalities in pre-clinical studies.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst,Mol Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst,Dept Pathol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst,Mol Biol Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	bernardi, rosa/B-1650-2013	bernardi, rosa/0000-0002-3607-6336				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Benedetti L, 1996, BLOOD, V87, P1939; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Buchdunger E, 1996, CANCER RES, V56, P100; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; Chen GQ, 1997, BLOOD, V89, P3345; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Condorelli GL, 1996, CANCER RES, V56, P5113; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CROCE CM, 1984, CURR TOP MICROBIOL, V113, P133; Curtis DJ, 1997, ONCOGENE, V15, P2975, DOI 10.1038/sj.onc.1201467; David G, 1997, ONCOGENE, V14, P1547, DOI 10.1038/sj.onc.1200989; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Ding W, 1998, BLOOD, V92, P1172, DOI 10.1182/blood.V92.4.1172.416k02_1172_1183; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fenaux P, 1997, NEW ENGL J MED, V337, P1076, DOI 10.1056/NEJM199710093371509; Glass CK, 2000, GENE DEV, V14, P121; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LARSON RC, 1994, ONCOGENE, V9, P3675; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Nason-Burchenal K, 1998, BLOOD, V92, P1758, DOI 10.1182/blood.V92.5.1758.417k28_1758_1767; O'Neil J, 2001, ONCOGENE, V20, P3897, DOI 10.1038/sj.onc.1204519; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Reichert A, 2001, BLOOD, V97, P1399, DOI 10.1182/blood.V97.5.1399; Rhoades KL, 2000, BLOOD, V96, P2108; RUBNITZ JE, 1994, BLOOD, V84, P1747; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; STRASSER A, 1993, ONCOGENE, V8, P1; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, BLOOD, V82, P1949, DOI 10.1182/blood.V82.7.1949.bloodjournal8271949; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; WILDIN RS, 1995, J IMMUNOL, V155, P1286; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	96	41	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3445	3458		10.1038/sj.onc.1205313	http://dx.doi.org/10.1038/sj.onc.1205313			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032781				2022-12-28	WOS:000175633300016
J	Friedman, AD				Friedman, AD			Transcriptional regulation of granulocyte and monocyte development	ONCOGENE			English	Review						granulocyte; monocyte; differentiation; C/EBP; PU.1	COLONY-STIMULATING FACTOR; WILMS-TUMOR SUPPRESSOR; BINDING PROTEIN ALPHA; ZINC-FINGER GENE; EOSINOPHIL LINEAGE COMMITMENT; CHICKEN LYSOZYME ENHANCER; FACTOR-RECEPTOR PROMOTER; MAF NUCLEAR ONCOPROTEIN; CENTRAL-NERVOUS-SYSTEM; EARLY MYELOID GENE	Granulocytes and monocytes develop from a common myeloid progenitor. Early granulopoiesis requires the C/ EBPalpha, PU.1, RAR, CBF, and c-Myb transcription factors, and terminal neutrophil differentiation is dependent upon C/EBPepsilon, PU.1, Sp1, CDP, and HoxA10. Monopoiesis can be induced by Maf-B, c-Jun, or Egr-1 and is dependent upon PU.1, Sp1, and ICSBP. Signals eminating from cytokine receptors modulate factor activities but do not determine cell fates. Orchestration of the myeloid developmental program is achieved via cooperative gene regulation, via synergistic and inhibitory protein-protein interactions, via promoter auto-regulation and cross-regulation, via regulation of factor levels, and via induction of cell cycle arrest: For example, c-Myb and C/EBPalpha cooperate to activate the mim-1 and NE promoters, PU.1, C/EBPalpha,, and CBF, regulate the NE, MPO, and M-CSF Receptor genes. PU.1:GATA-1 interaction and C/EBP suppression of FOG transcription inhibits erythroid and megakaryocyte gene expression. c-Jun:PU.1, ICSBP:PU.1, and perhaps Maf:Jun complexes induce monocytic genes. PU.1 and C/EBPa activate their own promoters, C/EBPalpha rapidly induces PU.1 and C/EBPepsilon RNA expression, and RARalpha activates the C/ EBPepsilon promoter. Higher levels of PU.1 are required for monopoiesis than for B-lymphopoiesis, and higher C/ EBP levels may favor granulopoiesis over monopoiesis. CBF and c-Myb stimulate proliferation whereas C/EBPa induces a G1/S arrest; cell cycle arrest is required for terminal myelopoiesis, perhaps due to expression of p53 or hypo-phosphorylated Rb.	Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA	Johns Hopkins University	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Canc Res Bldg,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.	adfrdman@jhmi.edu						AHNE B, 1994, J BIOL CHEM, V269, P17794; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAE SC, 1993, ONCOGENE, V8, P809; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BAVISOTTO L, 1991, J EXP MED, V174, P1097, DOI 10.1084/jem.174.5.1097; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 1999, BLOOD, V94, p684A; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Bergh G, 1999, BLOOD, V94, P1971; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Calkhoven CF, 2000, GENE DEV, V14, P1920; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; CARLSSON L, 1995, EUR J IMMUNOL, V25, P2308, DOI 10.1002/eji.1830250829; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Catt D, 1999, BLOOD, V94, P3151, DOI 10.1182/blood.V94.9.3151.421k38_3151_3160; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN HM, 1995, ONCOGENE, V11, P1549; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Chiang MY, 2001, J IMMUNOL, V166, P6091, DOI 10.4049/jimmunol.166.10.6091; Chih DY, 1997, BLOOD, V90, P2987, DOI 10.1182/blood.V90.8.2987; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Christensen JE, 2001, INT IMMUNOL, V13, P593, DOI 10.1093/intimm/13.4.593; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P561; Collins SJ, 2001, BLOOD, V98, P2382, DOI 10.1182/blood.V98.8.2382; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; Corsetti MT, 1997, BLOOD, V89, P2359, DOI 10.1182/blood.V89.7.2359; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; Du J, 1998, BLOOD, V92, p191A; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Ehinger M, 1998, EXP HEMATOL, V26, P1043; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Erickson PF, 1996, BLOOD, V88, P1813; Faust N, 1999, DNA CELL BIOL, V18, P631, DOI 10.1089/104454999315042; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Friedman AD, 1996, CANCER RES, V56, P3250; Friedman AD, 1996, CURR TOP MICROBIOL, V211, P149; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; GOETHE R, 1994, J BIOL CHEM, V269, P31302; GOLAY J, 1991, BLOOD, V77, P149; Gombart AF, 2001, BLOOD, V97, P2561, DOI 10.1182/blood.V97.9.2561; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hegde SP, 1999, BLOOD, V94, P1578, DOI 10.1182/blood.V94.5.1578.417k18_1578_1589; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Henkel GW, 1999, BLOOD, V93, P2849; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hetherington CJ, 1999, J IMMUNOL, V162, P503; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; HROMAS R, 1991, J BIOL CHEM, V266, P14183; Hu HM, 1998, J IMMUNOL, V160, P2334; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; KASTAN MB, 1991, CANCER RES, V51, P4279; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kataoka K, 1996, ONCOGENE, V12, P53; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Khanna-Gupta A, 2000, BLOOD, V95, P3734; Khanna-Gupta A, 2001, P NATL ACAD SCI USA, V98, P8000, DOI 10.1073/pnas.141229598; KhannaGupta A, 1997, BLOOD, V90, P2784, DOI 10.1182/blood.V90.7.2784.2784_2784_2795; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LAWRENCE HJ, 1995, EXP HEMATOL, V23, P1160; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; LI JM, 1994, CELL GROWTH DIFFER, V5, P743; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; Liu FL, 1997, BLOOD, V90, P2583, DOI 10.1182/blood.V90.7.2583.2583_2583_2590; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Loeb DM, 2000, BLOOD, V96, p284A; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Lutz PG, 2001, BLOOD, V97, P2449, DOI 10.1182/blood.V97.8.2449; Manz MG, 2001, BLOOD, V97, P3333, DOI 10.1182/blood.V97.11.3333; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Martinelli R, 1997, ONCOGENE, V15, P607, DOI 10.1038/sj.onc.1201218; Maurer U, 1997, EXP HEMATOL, V25, P945; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Meraro D, 1999, J IMMUNOL, V163, P6468; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Montecino-Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210; MORRIS JF, 1995, BLOOD, V86, P3640; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nerlov C, 1998, GENE DEV, V12, P2413, DOI 10.1101/gad.12.15.2413; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Peters UR, 1999, CANCER RES, V59, P4233; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Querfurth E, 2000, GENE DEV, V14, P2515, DOI 10.1101/gad.177200; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rodel JE, 1996, BLOOD, V87, P858, DOI 10.1182/blood.V87.3.858.bloodjournal873858; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SCOTT LM, 1992, BLOOD, V80, P1725; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seymour JF, 1997, BLOOD, V90, P3037, DOI 10.1182/blood.V90.8.3037; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Smith SI, 1998, BLOOD, V91, P764, DOI 10.1182/blood.V91.3.764.764_764_773; Soddu S, 1996, MOL CELL BIOL, V16, P487; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Traver D, 2001, BLOOD, V98, P627, DOI 10.1182/blood.V98.3.627; Tsai FY, 1998, DEV BIOL, V196, P218, DOI 10.1006/dbio.1997.8842; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; van Dijk TB, 1998, BLOOD, V91, P2126, DOI 10.1182/blood.V91.6.2126.2126_2126_2132; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG Q, 2002, IN PRESS BLOOD, V99; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wang W, 2001, LEUKEMIA, V15, P779, DOI 10.1038/sj.leu.2402094; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Williamson EA, 1998, J BIOL CHEM, V273, P14796, DOI 10.1074/jbc.273.24.14796; Yamaguchi Y, 1999, BLOOD, V94, P1429, DOI 10.1182/blood.V94.4.1429.416k13_1429_1439; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhang P., 1996, Blood, V88, p631A	234	252	259	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3377	3390		10.1038/sj.onc.1205324	http://dx.doi.org/10.1038/sj.onc.1205324			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032776				2022-12-28	WOS:000175633300011
J	Ghosh, AK; Majumder, M; Steele, R; Liu, TJ; Ray, RB				Ghosh, AK; Majumder, M; Steele, R; Liu, TJ; Ray, RB			MBP-1 mediated apoptosis involves cytochrome c release from mitochondria	ONCOGENE			English	Article						apoptosis; Bcl-x(L); cytochrome c; MBP-1	SQUAMOUS-CELL CARCINOMA; BINDING PROTEIN MBP-1; MYC PROMOTER; BCL-X; GENE-TRANSFER; FUNCTIONAL DOMAINS; MAMMARY-TUMORS; MESSENGER-RNA; BREAST-CANCER; INDUCTION	MBP-1, a cellular factor, appears to be involved in multiple functions, including transcriptional modulation, apoptosis and cell growth regulation. In this study, we have investigated the signaling pathway involved in MBP-1 mediated apoptotic cell death. Human carcinoma cells infected with a replication deficient adenovirus expressing MBP-1 (AdMBP-1) induced apoptosis, when compared with cells infected by replication-defective adenovirus (d1312) as a negative control. Transduction of MBP-1 in carcinoma cells releases cytochrome c from mitochondria into the cytosol leading to activation of procaspase-9, procaspase-3 and PARP cleavage. We previously observed that MBP-1 mediated apoptosis can be protected by Bcl-2, although MBP-1 does not share a homology with the BH domain of the Bcl-2 family member of proteins. To further understand the mechanism of MBP-1 mediated apoptosis, we examined whether MBP-1 modulates the Bcl-2 gene family. Our results demonstrated that human breast carcinoma cells infected with AdMBP-1 selectively reduced Bcl-x(L) mRNA and protein expression when compared with d1312 infected negative control cells. An in vitro transient reporter assay also suggested repression of the Bcl-x promoter activity by MBP-1. Additional studies indicated that MBP-1 modulates Ets family protein function, thereby downregulating Bcl-x(L) expression. Taken together, our results suggest that MBP-1 selectively represses Bcl-x(L) expression in MCF-7 cells and induces mitochondrial involvement in the apoptotic process.	St Louis Univ, Dept Pathol, St Louis, MO 63104 USA; St Louis Univ, Div Infect Dis, St Louis, MO 63104 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA	Saint Louis University; Saint Louis University; University of Texas System; UTMD Anderson Cancer Center	Ray, RB (corresponding author), St Louis Univ, Dept Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rayrb@slu.edu			NCI NIH HHS [CA52799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052799, R29CA052799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHAUDHARY D, 1995, BIOCHEMISTRY-US, V34, P3438, DOI 10.1021/bi00010a036; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Ealovega MW, 1996, CANCER RES, V56, P1965; Feo S, 2000, FEBS LETT, V473, P47, DOI 10.1016/S0014-5793(00)01494-0; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Ghosh AK, 1999, MOL CELL BIOL, V19, P2880; Ghosh AK, 2001, MOL CELL BIOL, V21, P655, DOI 10.1128/MCB.21.2.655-662.2001; GIALLONGO A, 1986, P NATL ACAD SCI USA, V83, P6741, DOI 10.1073/pnas.83.18.6741; Graham FL, 2000, IMMUNOL TODAY, V21, P426, DOI 10.1016/S0167-5699(00)01676-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; LIU TJ, 1995, CANCER RES, V55, P3117; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Olopade OI, 1997, CANCER J SCI AM, V3, P230; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; RAY R, 1989, ONCOGENE, V4, P593; RAY RB, 1995, CELL GROWTH DIFFER, V6, P1089; RAY RB, 1995, CANCER RES, V55, P3747; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; RAY RB, 1994, INT J ONCOL, V5, P1433; Reed JC, 1998, CANCER J, V4, pS8; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shimizu S, 1996, ONCOGENE, V13, P21; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Subramanian A, 2000, J BIOL CHEM, V275, P5958, DOI 10.1074/jbc.275.8.5958; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tu YP, 1998, CANCER RES, V58, P256; White RA, 1997, GENOMICS, V39, P406, DOI 10.1006/geno.1996.4499; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YASUSHI F, 1997, J CLIN INVEST, V99, P2898; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	58	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2775	2784		10.1038/sj.onc.1205384	http://dx.doi.org/10.1038/sj.onc.1205384			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973636				2022-12-28	WOS:000175063700001
J	Mathai, JP; Germain, M; Marcellus, RC; Shore, GC				Mathai, JP; Germain, M; Marcellus, RC; Shore, GC			Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53	ONCOGENE			English	Article						BIK; E1A; p53; caspase; apoptosis	CYTOCHROME-C; CELL-DEATH; MITOCHONDRIAL-MEMBRANES; TUMOR-SUPPRESSOR; BCL-2 FAMILY; PROTEIN; ADENOVIRUS; ACTIVATION; RELEASE; INTERACTS	A DNA microarray analysis identified the BH3-only BCL-2 family member, BIK/NBK, as a transcript that is upregulated during induction of apoptosis by oncogenic E1A. E1A depended on wild-type p53 to induce BIK and activate the death program. Further, p53 independently induced BIK RNA and protein, and BIK alone stimulated cell death in p53-null cells, dependent on the activation of caspases. BIK function, however, was abrogated by a disabling point mutation within the BH3 domain. Collectively, these results argue that BIK is a downstream apoptotic effector of p53 in response to a physiological p53-mediated death stimulus provided by E1A. Elevated BCL-2 functioned downstream of p53 and BIK induction to inhibit the E1A death pathway, with the ratio of anti-apoptotic BCL-2 and pro-apoptotic BIK determining cell death or survival in E1A-expressing cells. Cells expressing BCL-2 or treated with the pan caspase inhibitor, zVAD-fmk, allowed accumulation of high levels of cytotoxic BIK compared to control cells. Of note, a significant fraction of either ectopic or endogenous BIK was found associated with the endoplasmic reticulum, suggesting that this organelle, in addition to mitochondria, may be a target of BIK function.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; GeminX Biotechnol Inc, Montreal, PQ H2X 3P9, Canada	McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.	Gordon.Shore@mcgill.ca						ABERICI A, 1999, J BIOL CHEM, V274, P30764; AKAO Y, 1994, CANCER RES, V54, P2468; Attardi LD, 2000, GENE DEV, V14, P704; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Boulakia CA, 1996, ONCOGENE, V12, P529; BOYD JM, 1995, ONCOGENE, V11, P1921; Breckenridge DG, 2000, CRIT REV EUKAR GENE, V10, P273; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 1996, MOL CELL BIOL, V16, P5857; HEDGE R, 1998, J BIOL CHEM, V273, P7783; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Juin P, 2000, NAT MED, V6, P498, DOI 10.1038/74966; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MIYASHITA T, 1995, CELL, V80, P293; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NG FWH, 1998, MOL CELL BIOL, V20, P6731; NG FWH, 1998, J BIOL CHEM, V139, P327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Nguyen M, 1998, J BIOL CHEM, V273, P33099, DOI 10.1074/jbc.273.50.33099; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Orth R, 1997, J BIOL CHEM, V272, P8841; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Prives C, 1999, J PATHOL, V187, P112; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	54	105	106	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2534	2544		10.1038/sj.onc.1205340	http://dx.doi.org/10.1038/sj.onc.1205340			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971188				2022-12-28	WOS:000174918400010
J	Ueki, T; Walter, KM; Skinner, H; Jaffee, E; Hruban, RH; Goggins, M				Ueki, T; Walter, KM; Skinner, H; Jaffee, E; Hruban, RH; Goggins, M			Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived	ONCOGENE			English	Article						CpG island methylation; pancreatic adenocarcinoma; cell line	DNA METHYLATION; DENOVO METHYLATION; EPITHELIAL-CELLS; SUPPRESSOR ROLE; INACTIVATION; GENE; HYPERMETHYLATION; CARCINOMA; EXPRESSION; PANCREAS	A higher prevalence of epigenetic inactivation of tumor suppressor genes has been reported in cancer cell tine populations compared to primary cancer populations. Cancer-related genes are commonly methylated in cancer cell lines but it is not known the extent to which tumor suppressor genes may be artificially methylated in vitro. We therefore examined 10 pancreatic cancer cell lines and corresponding primary tumors for aberrant DNA methylation of promoter CpG islands of eight genes and seven CpG islands. Using methylation-specific PCR (MSP), methylation was not detected at any of the 15 CpG islands in 15 normal pancreata or in an immortalized normal pancreatic duct epithelial (HPDE) cell line. Of 150 loci examined, 49 loci were methylated in both primary carcinomas and their corresponding cell lines, 95 loci were not methylated in either cell lines or their corresponding primary carcinomas. There were four loci methylated only in cell lines while another two loci were methylated only in primary carcinomas. Overall, the methylation status of primary carcinomas and their cell lines were concordant in 96% of cases (144 of 150) (J statistic; J=0.92, P<0.0001). We conclude that most of the DNA methylation of tumor suppressor genes observed in cancer cell lines is present in the primary carcinomas from which they were derived.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu	Skinner, Halcyon/A-1049-2009	Skinner, Halcyon G./0000-0002-0220-9110; Jaffee, Elizabeth/0000-0003-3841-6549	NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 1998, ADV CANCER RES, V72, P141; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Esteller M, 2001, CANCER RES, V61, P3225; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jarrard DF, 1999, CANCER RES, V59, P2957; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8; Markl IDC, 2001, CANCER RES, V61, P5875; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Schutte M, 1997, CANCER RES, V57, P3126; Toyota M, 1999, CANCER RES, V59, P2307; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wilentz RE, 2000, AM J PATHOL, V156, P1641, DOI 10.1016/S0002-9440(10)65035-3; Wilentz RE, 1998, CANCER RES, V58, P4740	24	47	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2114	2117		10.1038/sj.onc.1205275	http://dx.doi.org/10.1038/sj.onc.1205275			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960385				2022-12-28	WOS:000174827000019
J	De Maria, R; Maggiora, P; Biolatti, B; Prat, M; Comoglio, PM; Castagnaro, M; Di Renzo, MF				De Maria, R; Maggiora, P; Biolatti, B; Prat, M; Comoglio, PM; Castagnaro, M; Di Renzo, MF			Feline STK gene expression in mammary carcinomas	ONCOGENE			English	Article						tyrosine kinase receptors; mammary carcinomas; companion animals tumours	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; POSTSURGICAL PROGNOSIS; IMMUNOHISTOCHEMICAL ANALYSIS; ESTROGEN-RECEPTORS; MOLECULAR-CLONING; MET ONCOGENE; RON GENE; CYCLIN-A; OVEREXPRESSION	The human RON and its mouse homologue stk are members of the MET family of tyrosine kinase receptors. We have previously shown that the RON gene is over-expressed in human breast carcinomas. As cat mammary tumours have been proposed as a suitable model for aggressive human breast cancer, we identified the feline stk gene and studied its expression in cat mammary cancer. Feline stk sequences were found highly homologous to the stk and RON gene exons that encode the juxtamembrane and transmembrane domains of the stk and RON receptors. Feline stk-specific transcript was detected by RT - PCR in cat lung and in 7/8 feline mammary carcinomas and a synchronous skin metastasis examined. Western blot and immunohistochemical analyses were carried out with an antibody that recognized both the human RON and mouse stk receptors. This antibody specifically detected a 135 Kd feline protein and stained 10/34 mammary carcinoma archival samples. These data show that the pattern of expression and distribution of the stk protein in feline mammary cancer could be superimposed on that of the RON receptor in human breast cancer and suggest that these feline tumours are a suitable model to test innovative approaches to therapy of aggressive human breast carcinomas.	Univ Turin, Sch Med, Inst Canc Res & Treatment, Canc Genet Lab, I-10060 Turin, Italy; Univ Turin, Inst Canc Res & Treatment, Comparat Oncol Ctr, I-10060 Turin, Italy; Univ Turin, IRCC, Inst Canc Res & Treatment, Div Mol Oncol, I-10060 Turin, Italy; Univ Turin, Sch Vet Med, Dept Anim Pathol, Turin, Italy; Univ Novara, Sch Med, Dept Med Sci, Novara, Italy; Univ Padua, Sch Vet Med, Dept Publ Hlth Comparat Pathol & Vet Hyg, I-35100 Padua, Italy	University of Turin; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; University of Eastern Piedmont Amedeo Avogadro; University of Padua	Di Renzo, MF (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Canc Genet Lab, SP 142,Km 3-95, I-10060 Turin, Italy.	mfdirenzo@ircc.unito.it	DI RENZO, Maria Flavia/B-6091-2012	DI RENZO, Maria Flavia/0000-0002-5093-3373; DE MARIA, RAFFAELLA/0000-0002-7028-2280; CASTAGNARO, Massimo/0000-0003-3311-7806; Comoglio, Paolo/0000-0002-7056-5328; BIOLATTI, Bartolomeo/0000-0003-3657-3954				Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Castagnaro M, 1998, RES VET SCI, V64, P97, DOI 10.1016/S0034-5288(98)90002-9; Castagnaro M, 1998, RES VET SCI, V65, P223, DOI 10.1016/S0034-5288(98)90147-3; Castagnaro M, 1998, J COMP PATHOL, V119, P263, DOI 10.1016/S0021-9975(98)80049-2; de las Mulas JM, 2000, DOMEST ANIM ENDOCRIN, V18, P111, DOI 10.1016/S0739-7240(99)00067-3; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAMILTON JM, 1976, VET REC, V99, P477, DOI 10.1136/vr.99.24.477; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; JOHNSTON SD, 1984, AM J VET RES, V45, P379; Kobayashi Y, 2001, J VET MED SCI, V63, P211, DOI 10.1292/jvms.63.211; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Murakami Y, 2000, J VET MED SCI, V62, P783, DOI 10.1292/jvms.62.783; Murakami Y, 2000, J VET MED SCI, V62, P743, DOI 10.1292/jvms.62.743; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONSIN C, 1993, ONCOGENE, V8, P1195; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Tuck AB, 1996, AM J PATHOL, V148, P225; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; WEIJER K, 1972, J NATL CANCER I, V49, P1697, DOI 10.1093/jnci/49.6.1697	26	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1785	1790		10.1038/sj.onc.1205221	http://dx.doi.org/10.1038/sj.onc.1205221			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896610				2022-12-28	WOS:000174214200017
J	Hiromura, K; Pippin, JW; Blonski, MJ; Roberts, JM; Shankland, SJ				Hiromura, K; Pippin, JW; Blonski, MJ; Roberts, JM; Shankland, SJ			The subcellular localization of cyclin dependent kinase 2 determines the fate of mesangial cells: role in apoptosis and proliferation	ONCOGENE			English	Article						apoptosis; cell cycle; cyclin dependent kinase; mesangial cell	NUCLEAR EXPORT; BCL-2 FAMILY; IN-VITRO; CDK2; ACTIVATION; INHIBITION; P27(KIP1); DEATH; ROSCOVITINE; MECHANISMS	Apoptosis is closely linked to proliferation. In this study we showed that inducing apoptosis in mouse mesangial cells with ultraviolet (UV) irradiation was associated with increased cyclin A-cyclin dependent kinase (CDK) 2 activity. Inhibiting CDK2 activity with Roscovitine or dominant negative mutant reduced apoptosis. Because apoptosis typically begins in the cytoplasm, we tested the hypothesis that the subcellular localization of CDK2 determines the proliferative or apoptotic fate of the cell. Our results showed that cyclin A-CDK2 was nuclear in proliferating cells. However, inducing apoptosis in proliferating cells with UV irradiation was associated with a decrease in nuclear cyclin A and CDK2 protein levels. This coincided with an increase in protein and kinase activity for cyclin A-CDK2 in the cytoplasm. Translocation of cyclin A-CDK2 also occurred in p53(-/-) mesangial cells. Finally, we showed that caspase-3 activity was significantly reduced by inhibiting CDK2 activity with Roscovitine. In summary, our results show that apoptosis is associated with an increase in cytoplasmic cyclin A-CDK2 activity, which is p53 independent and upstream of caspase-3. We propose that the subcellular localization of CDK2 determines the proliferative or apoptotic fate of the cell.	Univ Washington, Sch Med, Div Nephrol, Dept Med, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Shankland, SJ (corresponding author), Univ Washington, Sch Med, Div Nephrol, Dept Med, Box 356521, Seattle, WA 98195 USA.	stuartjs@u.washington.edu			NIDDK NIH HHS [DK51096, DK56799, DK34198, DK47659, DK52121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034198, R01DK051096, P50DK047659, R01DK034198, R01DK056799, R01DK052121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi S, 2001, CIRC RES, V88, P408, DOI 10.1161/01.res.88.4.408; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; Baptist M, 1996, J CELL PHYSIOL, V166, P256; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; Bresnahan WA, 1996, CELL GROWTH DIFFER, V7, P1283; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; DANNO K, 1982, BRIT J DERMATOL, V107, P423, DOI 10.1111/j.1365-2133.1982.tb00385.x; Dobashi Y, 1998, BIOCHEM BIOPH RES CO, V253, P609, DOI 10.1006/bbrc.1998.9825; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; MARTIN SJ, 1991, INT J RADIAT BIOL, V59, P1001, DOI 10.1080/09553009114550891; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Miller LJ, 1998, SCIENCE, V281, P1301, DOI 10.1126/science.281.5381.1301; Minn AJ, 1998, ADV IMMUNOL, V70, P245, DOI 10.1016/S0065-2776(08)60388-0; Mooney A, 1997, J IMMUNOL, V159, P3949; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; NISHIOKA WK, 1994, J EXP MED, V179, P769, DOI 10.1084/jem.179.2.769; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; Pippin JW, 1997, J CLIN INVEST, V100, P2512, DOI 10.1172/JCI119793; Reed SI, 1997, CANCER SURV, V29, P7; Roussel ME, 1998, ADV CANCER RES, V74, P1, DOI 10.1016/S0065-230X(08)60763-0; Shankland SJ, 2000, AM J PHYSIOL-RENAL, V278, pF515, DOI 10.1152/ajprenal.2000.278.4.F515; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Syljuasen RG, 1999, RADIAT RES, V152, P328, DOI 10.2307/3580333; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yao SL, 1996, CANCER RES, V56, P4551; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	44	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1750	1758		10.1038/sj.onc.1205238	http://dx.doi.org/10.1038/sj.onc.1205238			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896606				2022-12-28	WOS:000174214200013
J	Vasseur, S; Hoffmeister, A; Garcia-Montero, A; Mallo, GV; Feil, R; Kuhbandner, S; Dagorn, JC; Iovanna, JL				Vasseur, S; Hoffmeister, A; Garcia-Montero, A; Mallo, GV; Feil, R; Kuhbandner, S; Dagorn, JC; Iovanna, JL			p8-deficient fibroblasts grow more rapidly and are more resistant to adriamycin-induced apoptosis	ONCOGENE			English	Article						p8; p53; cell-cycle; apoptosis; MEF	TATA-BINDING PROTEIN; CELL-CYCLE CONTROL; WILD-TYPE; P53 BINDS; IN-VITRO; EXPRESSION; STRESS; GENE; P8; TRANSCRIPTION	p8 is a stress-induced DNA-binding protein, biochemically related to the architectural chromatin binding HMG protein family and whose function is presently unknown. We obtained fibroblast from mice lacking p8 and found that p8 is involved in cell growth regulation and in apoptosis. p8(-/-) mouse embryonic fibroblasts (MEFs) grow more rapidly than p8(+/+) MEFs. This might be explained by the higher intracellular level and activity of the Cdk2 and Cdk4 observed in p8-/- MEFs, which in turn may result, at least in part, from the concomitant decrease observed in the amount of cyclin-dependent kinase inhibitor p27. We also report that p8 mRNA expression is strongly activated in fibroblasts after cell growth arrest induced by serum deprivation or confluence. As expected, MEFs expressing pS arrest their growth more rapidly after serum deprivation than MEFs lacking p8, which strongly suggests that p8 overexpression is implicated in cell growth arrest. On the other hand, P8(+/+) MEFs are more sensitive than p8(-/-)MEFs to the apoptosis induced by adriamycin treatment. p53 might be involved, as p8 expression increases its intracellular amount and trans-activation capacity. Finally, demonstration that p53 is a negative transactivator of p8 suggests the presence of a complex autoregulatory loop. In conclusion, p8 is a cell growth inhibitor that facilitates apoptosis induced in fibroblasts by DNA damage.	INSERM, Ctr Rech, F-13009 Marseille, France; Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm)	Iovanna, JL (corresponding author), INSERM, Ctr Rech, EMI 0116,Parc Sci & Technol Luminy,163 Av Luminy, F-13009 Marseille, France.	iovanna@inserm-adr.univ-mrs.fr	Feil, Robert/B-8918-2014; Feil, Susanne/AAF-7032-2019; vasseur, sophie/O-9803-2017; Garcia-Montero, Andres C/B-6558-2017; Montero, Andres/HGA-9093-2022; Iovanna, Juan/M-9805-2017	Feil, Robert/0000-0002-7335-4841; vasseur, sophie/0000-0002-2339-8854; Garcia-Montero, Andres C/0000-0003-4360-1386; Iovanna, Juan/0000-0003-1822-2237				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Bratland A, 2000, CANCER RES, V60, P5578; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Encinar JA, 2001, J BIOL CHEM, V276, P2742, DOI 10.1074/jbc.M008594200; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Goldschmidt-Clermont PJ, 1999, GENE EXPRESSION, V7, P255; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jiang YF, 1999, BIOCHEM BIOPH RES CO, V260, P686, DOI 10.1006/bbrc.1999.0953; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuhbandner S, 2000, GENESIS, V28, P15, DOI 10.1002/1526-968X(200009)28:1<15::AID-GENE20>3.0.CO;2-C; Mallo GV, 1997, J BIOL CHEM, V272, P32360, DOI 10.1074/jbc.272.51.32360; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Pesch J, 1996, J INTERF CYTOK RES, V16, P595, DOI 10.1089/jir.1996.16.595; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Ree AH, 1999, CANCER RES, V59, P4675; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Su SB, 2001, CLIN CANCER RES, V7, P309; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Vasseur S, 1999, EUR J BIOCHEM, V259, P670, DOI 10.1046/j.1432-1327.1999.00092.x; Vasseur S, 1999, BIOCHEM J, V343, P377, DOI 10.1042/0264-6021:3430377; Wang E, 1999, J CELL BIOCHEM, P95; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang LL, 2000, CANCER RES, V60, P3655	41	79	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1685	1694		10.1038/sj.onc.1205222	http://dx.doi.org/10.1038/sj.onc.1205222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896600				2022-12-28	WOS:000174214200007
J	Bhatia, N; Herter, JR; Slaga, TJ; Fuchs, SY; Spiegelman, VS				Bhatia, N; Herter, JR; Slaga, TJ; Fuchs, SY; Spiegelman, VS			Mouse homologue of HOS (mHOS) is overexpressed in skin tumors and implicated in constitutive activation of NF-kappa B	ONCOGENE			English	Article						NF-kappa B; ubiquitin ligase; skin carcinogenesis; beta TrCP; HOS; F-box	F-BOX PROTEIN; BETA-TRCP; HA-RAS; UBIQUITIN LIGASE; DEPENDENT DEGRADATION; TRANSCRIPTION FACTORS; INCREASED EXPRESSION; ELEVATED EXPRESSION; POINT MUTATION; ALPHA	NF-kappaB transcription factor is activated upon ubiquitination and subsequent proteolysis of its inhibitor IkappaB. The phosphorylation-dependent ubiquitination is mediated by SCIF E3 ubiquitin ligase. In this study, we identified a novel murine F-box/WD40 repeat-containing protein, mHOS (a homologue of HOS/betaTrCP2). mHOS efficiently binds Skp1 protein (a 'core' component of SCIF ubiquitin ligase), and phosphorylated IkappaBalpha. We found that mHOS associates with SCF-ROC1 E3 ubiquitin ligase activity. We have also observed that mHOS is overexpressed in chemically-induced mouse skin tumors, and its overexpression (but not accelerated IkappaB phosphorylation) coincides with the accelerated degradation of IkappaB in vivo. The role of mHOS in the constitutive activation of NF-kappaB in skin carcinogenesis is discussed.	AMC Canc Res Ctr, Ctr Canc Causat & Prevent, Lakewood, CO 80214 USA; Univ Penn, Dept Biol Anim, Philadelphia, PA 19104 USA	AMC Cancer Research Center; University of Pennsylvania	Spiegelman, VS (corresponding author), AMC Canc Res Ctr, Ctr Canc Causat & Prevent, 1600 Pierce St, Lakewood, CO 80214 USA.	spiegelman@amc.org		Spiegelman, Vladimir S/0000-0003-4847-155X	NCI NIH HHS [CA 92900, CA 76262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DIGIOVANNI J, 1993, MOL CARCINOGEN, V8, P272, DOI 10.1002/mc.2940080410; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; PELLING JC, 1988, CARCINOGENESIS, V9, P665, DOI 10.1093/carcin/9.4.665; PELLING JC, 1987, CARCINOGENESIS, V8, P1481, DOI 10.1093/carcin/8.10.1481; PELLING JC, 1986, CARCINOGENESIS, V7, P1599, DOI 10.1093/carcin/7.9.1599; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Suzuki H, 1999, FEBS LETT, V458, P343, DOI 10.1016/S0014-5793(99)01173-4; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zhang XY, 1997, AM J HEMATOL, V55, P205, DOI 10.1002/(SICI)1096-8652(199707)55:4<205::AID-AJH7>3.0.CO;2-W	38	30	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1501	1509		10.1038/sj.onc.1205311	http://dx.doi.org/10.1038/sj.onc.1205311			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896578				2022-12-28	WOS:000173956800005
J	Vail, ME; Chaisson, ML; Thompson, J; Fausto, N				Vail, ME; Chaisson, ML; Thompson, J; Fausto, N			Bcl-2 expression delays hepatocyte cell cycle progression during liver regeneration	ONCOGENE			English	Article						liver regeneration; cell cycle; Bcl-2; transgenic mice; hepatocyte	PROLIFERATION; FAMILY; DEATH; E2F; CARCINOGENESIS; INHIBITION; APOPTOSIS; PROTEINS; P130	Bcl-2 is the prototype of a family of genes that prevent apoptosis. However, several reports indicate that Bcl-2 may also act as a cell cycle modulator. In several human tumors, Bcl-2 expression correlates with a more favorable prognosis and lower tumor proliferative activity. We have shown that Bcl-2 expression delays liver tumor development in transgenic mice even when the gene is turned on shortly before the time of tumor development. We hypothesized that Bcl-2 may delay liver tumorigenesis by interfering with hepatocyte proliferation. To test whether Bcl-2 expression may act on hepatocyte replication we studied liver regeneration in Bcl-2 transgenic mice and wild-type littermates. DNA replication was delayed by approximately 8 h in Bcl-2 transgenic mice compared to the timing of the response in wild-type littermates. Cyclin D expression showed no alterations in the regenerating liver of Bcl-2 transgenic mice. In contrast, there was a delay in the expression of p107, cyclin E and in the activity of cyclin E/cdk 2 activity. These results show that Bcl-2 expression delays cell cycle progression in hepatocytes and suggests that it acts at a step involving cyclin E and p107.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Fausto, N (corresponding author), Univ Washington, Dept Pathol, K-078 Hlth Sci Bldg,Box 357705, Seattle, WA 98195 USA.	nfausto@u.washington.edu			NATIONAL CANCER INSTITUTE [T32CA009437, R01CA074131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09437, CA74131] Funding Source: Medline; NIGMS NIH HHS [T32 GMO7270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; de la Coste A, 1999, CANCER RES, V59, P5017; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; Kuwashima Y, 1997, ANTICANCER RES, V17, P3773; Lin HM, 2001, CELL DEATH DIFFER, V8, P44, DOI 10.1038/sj.cdd.4400770; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nelsen CJ, 2001, ONCOGENE, V20, P1825, DOI 10.1038/sj.onc.1204248; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Silvestrini R, 1996, J CLIN ONCOL, V14, P1604, DOI 10.1200/JCO.1996.14.5.1604; Sinicrope FA, 1995, CLIN CANCER RES, V1, P1103; Truchet I, 2000, EXP CELL RES, V254, P241, DOI 10.1006/excr.1999.4756; Tzung SP, 1997, AM J PATHOL, V150, P1985; Vail ME, 2001, CANCER RES, V61, P594; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; WEBBER EM, 1994, AM J PATHOL, V145, P398; Winter JN, 1998, BLOOD, V91, P1391, DOI 10.1182/blood.V91.4.1391; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674	29	30	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1548	1555		10.1038/sj.onc.1205212	http://dx.doi.org/10.1038/sj.onc.1205212			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896583				2022-12-28	WOS:000173956800010
J	Komata, T; Kanzawa, T; Kondo, Y; Kondo, S				Komata, T; Kanzawa, T; Kondo, Y; Kondo, S			Telomerase as a therapeutic target for malignant gliomas	ONCOGENE			English	Article						telomerase; telomerase RNA; telomerase reverse transcriptase; apoptosis; glioma	CATALYTIC SUBUNIT HTERT; PEPTIDE NUCLEIC-ACIDS; HUMAN BRAIN-TUMORS; REVERSE-TRANSCRIPTASE; CANCER-CELLS; IN-VITRO; HAMMERHEAD RIBOZYME; RNA COMPONENT; MAMMALIAN TELOMERASE; INTRACRANIAL TUMORS	Telomerase, a ribonucleoprotein enzyme, is considered as a potential target of cancer therapy because of its preferential expression in tumors. In particular, malignant gliomas are one of the best candidates for telomerase-targeted therapy. It is because malignant gliomas are predominantly telomerase-positive, while normal brain tissues do not express telomerase. In theory, there are two telomerase-associated therapeutic approaches for telomerase-positive tumors. One approach is the anti-telomerase cancer therapy to directly inhibit telomerase activity, resulting in apoptotic cell death or growth arrest. Two major components of the telomerase holoenzyme complex, the RNA template (hTER) and catalytic subunit (reverse transcriptase, hTERT) are well considered as therapeutic targets. The other approach is the telomerase-specific cancer therapy by targeting telomerase-expressing tumor cells as a means to directly kill the cells. Strategies using the transfer of therapeutic gene under the hTERT promoter system as well as immunotherapy directed against telomerase-positive cells are generally included. These telomerase-associated therapies are very promising for the treatment of malignant gliomas.	Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Neurosurg, New York, NY 10029 USA; Cleveland Clin Fdn, Surg Res Ctr, Cleveland, OH 44195 USA	Icahn School of Medicine at Mount Sinai; Cleveland Clinic Foundation	Kondo, S (corresponding author), Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Neurosurg, 1 Gustave L Levy Pl,Box 1136, New York, NY 10029 USA.			KANZAWA, TAKAO/0000-0002-8165-5652	NATIONAL CANCER INSTITUTE [R01CA080233, R01CA088936] Funding Source: NIH RePORTER; NCI NIH HHS [CA80233, CA88936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdul-Ghani R, 2000, MOL THER, V2, P539, DOI 10.1006/mthe.2000.0196; Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; Arai J, 2001, BLOOD, V97, P2903, DOI 10.1182/blood.V97.9.2903; BETTS L, 1995, SCIENCE, V270, P1838, DOI 10.1126/science.270.5243.1838; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; Carroll T, 1999, J PATHOL, V188, P395; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Chong EYY, 1998, HUM PATHOL, V29, P599, DOI 10.1016/S0046-8177(98)80009-9; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Davis FG, 1999, CANCER, V85, P485, DOI 10.1002/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.3.CO;2-C; DEEN DF, 1993, J NEURO-ONCOL, V16, P243, DOI 10.1007/BF01057041; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DeMasters BKK, 1997, AM J CLIN PATHOL, V107, P548; Falchetti ML, 1999, J CLIN PATHOL, V52, P234, DOI 10.1136/jcp.52.3.234; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gilley D, 1996, MOL CELL BIOL, V16, P66; Gu J, 2000, CANCER RES, V60, P5359; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Harada K, 2000, J NEUROSURG, V93, P618, DOI 10.3171/jns.2000.93.4.0618; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Heiser A, 2001, CANCER RES, V61, P3388; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Hiraga S, 1998, CANCER RES, V58, P2117; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Huang F, 1999, J NEURO-ONCOL, V43, P137, DOI 10.1023/A:1006258817785; Johnson OL, 1997, PHARM RES-DORDR, V14, P730, DOI 10.1023/A:1012142204132; Kanazawa Y, 1996, BIOCHEM BIOPH RES CO, V225, P570, DOI 10.1006/bbrc.1996.1213; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kleinschmidt-DeMasters BK, 1998, J CLIN PATHOL, V51, P284, DOI 10.1136/jcp.51.4.284; Kleinschmidt-Demasters BK, 2000, HUM PATHOL, V31, P905, DOI 10.1053/hupa.2000.9086; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Koga S, 2001, ANTICANCER RES, V21, P1937; Koga S, 2001, GENE THER, V8, P654, DOI 10.1038/sj.gt.3301449; Komata T, 2000, GENE THER, V7, P2071, DOI 10.1038/sj.gt.3301327; Komata T, 2001, CANCER RES, V61, P5796; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo Y, 2000, ONCOGENE, V19, P2205, DOI 10.1038/sj.onc.1203538; Kondo Y, 2001, INT J ONCOL, V18, P1287; Kushner DM, 2000, GYNECOL ONCOL, V76, P183, DOI 10.1006/gyno.1999.5668; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; Le SY, 1998, NEUROSURGERY, V42, P1120, DOI 10.1097/00006123-199805000-00099; Ludwig A, 2001, CANCER RES, V61, P3053; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; Majumdar AS, 2001, GENE THER, V8, P568, DOI 10.1038/sj.gt.3301421; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Melana SM, 1998, CLIN CANCER RES, V4, P693; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Minev B, 2000, P NATL ACAD SCI USA, V97, P4796, DOI 10.1073/pnas.070560797; Mukai S, 2000, CANCER RES, V60, P4461; Multani AS, 1998, INT J ONCOL, V13, P923; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Ostenfeld T, 2000, EXP NEUROL, V164, P215, DOI 10.1006/exnr.2000.7427; Piepmeier JM, 1997, J NEURO-ONCOL, V34, P1, DOI 10.1023/A:1005798901779; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153; Ramakrishnan S, 1998, CANCER RES, V58, P622; Roth W, 1999, CELL MOL LIFE SCI, V56, P481, DOI 10.1007/s000180050447; Sallinen P, 1997, AM J PATHOL, V150, P1159; Sano T, 1998, BRIT J CANCER, V77, P1633, DOI 10.1038/bjc.1998.267; Shammas MA, 1999, ONCOGENE, V18, P6191, DOI 10.1038/sj.onc.1203069; STRAHL C, 1994, NUCLEIC ACIDS RES, V22, P893, DOI 10.1093/nar/22.6.893; Strahl C, 1996, MOL CELL BIOL, V16, P53; Takakura M, 1999, CANCER RES, V59, P551; Tejera AM, 2001, BREAST CANCER RES TR, V65, P93, DOI 10.1023/A:1006477730934; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Weil RJ, 1999, MODERN PATHOL, V12, P41; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; Wright WE, 1996, DEV GENET, V18, P173; Yokoyama Y, 1998, CANCER RES, V58, P5406; Yokoyama Y, 2000, BIOCHEM BIOPH RES CO, V273, P316, DOI 10.1006/bbrc.2000.2939; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu J, 1996, GENE THER, V3, P472	84	61	79	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					656	663		10.1038/sj.onc.1205072	http://dx.doi.org/10.1038/sj.onc.1205072			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850793	Bronze			2022-12-28	WOS:000173390500020
J	Shea-Herbert, B; Pongracz, K; Shay, JW; Gryaznov, SM				Shea-Herbert, B; Pongracz, K; Shay, JW; Gryaznov, SM			Oligonucleotide N3 '-> P5 ' phosphoramidates as efficient telomerase inhibitors	ONCOGENE			English	Article						telomerase inhibitors; oligonucleotide; phosphoramidates	RNA COMPONENT; CANCER-CELLS; PROLIFERATION; THERAPY; GLIOMA; TARGET	Human telomerase is a unique reverse transcriptase that is expressed in multiple cancers, but not in the vast majority of normal cells. The enzyme is responsible for telomere protection and maintenance, and supports the proliferative immortality of cancer cells. Thus, it has been proposed that the specific inhibition of telomerase activity in tumors might have significant and beneficial therapeutic effects. To this goal we have designed, synthesized, and evaluated several oligonucleotide N3'-->P5' phosphoramidates as telomerase inhibitors. These oligonucleotides are complementary to the template region of the RNA domain of telomerase (hTR). The prepared compounds were evaluated in HME50-5E breast epithelial cells, where their effects on telomerase activity were determined using a cell-based telomerase (TRAP) assay at 24 as well as 72 h after exposure to compounds. The oligo-N3' -->P5' phosphoramidate inhibited telomerase activity in cells in the presence of the cellular up-take enhancer (FuGENE6(TM)) in a dose- and sequence-dependent manner, with IC50 values of approximately 1 nM. Inhibition of telomerase activity by this compound without the lipid carrier was not efficient. However, the isosequential oligonucleotide N3 '--> P5' thio-phosphoramidate was able to inhibit telomerase activity with or without lipid carriers at nM, or low-muM concentrations, respectively. This inhibition of telomerase activity in HME50-5E cells by the oligonucleotide thio-phosphoramidates was also sequence specific. Long-term treatment of the cells with 0.5 muM of FuGENE6 formulated 13-mer thio-phosphoramidates, fully complementary to hTR, resulted in gradual telomere shortening, followed by cellular senescence and apoptosis, as would be predicted for a telomerase inhibitor. The mismatched control compound had no effect on cell proliferation. The results suggest that the oligonucleotide N3'-->P5' phosphoramidates, and particularly thio-phosphoramidates, might be further developed as selective anti-telomerase reagents.	Geron Corp, Menlo Pk, CA 94025 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Geron Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gryaznov, SM (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Pk, CA 94025 USA.		Shay, Jerry W/F-7878-2011					Bare LA, 1998, DRUG DEVELOP RES, V43, P109, DOI 10.1002/(SICI)1098-2299(199802)43:2<109::AID-DDR4>3.0.CO;2-O; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Elayadi AN, 2001, NUCLEIC ACIDS RES, V29, P1683, DOI 10.1093/nar/29.8.1683; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Gryaznov S, 2001, NUCLEOS NUCLEOT NUCL, V20, P401, DOI 10.1081/NCN-100002314; Gryaznov SM, 1999, BBA-GENE STRUCT EXPR, V1489, P131, DOI 10.1016/S0167-4781(99)00151-7; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hisatake J, 1999, CANCER RES, V59, P4023; Hurley LH, 2000, PHARMACOL THERAPEUT, V85, P141, DOI 10.1016/S0163-7258(99)00068-6; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Matthes E, 1999, NUCLEIC ACIDS RES, V27, P1152, DOI 10.1093/nar/27.4.1152; Naasani I, 1999, CANCER RES, V59, P4004; Naasani I, 1998, BIOCHEM BIOPH RES CO, V249, P391, DOI 10.1006/bbrc.1998.9075; Neidle S, 2000, PHARMACOL THERAPEUT, V85, P133, DOI 10.1016/S0163-7258(99)00065-0; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Pongracz K, 1999, TETRAHEDRON LETT, V40, P7661, DOI 10.1016/S0040-4039(99)01584-1; Sharma HW, 1996, ANTISENSE NUCLEIC A, V6, P3, DOI 10.1089/oli.1.1996.6.3; SHEAHERBERT B, 1999, P NATL ACAD SCI USA, V96, P14276; Wan MSK, 1998, ANTISENSE NUCLEIC A, V8, P309, DOI 10.1089/oli.1.1998.8.309; Yamaguchi F, 1999, ONCOL REP, V6, P773	23	104	123	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					638	642		10.1038/sj.onc.1205064	http://dx.doi.org/10.1038/sj.onc.1205064			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850790				2022-12-28	WOS:000173390500017
J	Pozzi, A; LeVine, WF; Gardner, HA				Pozzi, A; LeVine, WF; Gardner, HA			Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis	ONCOGENE			English	Article						angiostatin; MMP9; doxycycline; angiogenesis	CHEMICALLY-MODIFIED TETRACYCLINES; INTEGRIN ALPHA-1-BETA-1; INHIBITION; DOXYCYCLINE; EXPRESSION; ANGIOSTATIN; ACTIVATION; METASTASIS; CARCINOMA; COLLAGEN	Angiogenesis is essential for tumor growth and blocking this process might be a valid tool for the control of cancer growth. We showed previously that tumor angiogenesis in integrin alpha1-null mice is reduced compared to that of wild type animals and that over-expression of matrix metalloproteinase 9 (MMP-9) in the alpha1-null and consequent generation of angiostatin (an inhibitor of endothetial cell growth) from circulating plasminogen was implicated in the mechanism of tumor inhibition. Our findings suggested that secretion of excess MMPs generates inhibitors of endothelial cell proliferation, including but not necessarily limited to angiostatin, resulting ultimately in auto-inhibition of angiogenesis. Thus MMP inhibitors used as anti-tumor drugs might in fact cause a paradoxical increase in tumor angiogenesis and tumor growth. In order to determine whether MMP-9 expression was directly involved in the regulation of tumor growth, we specifically inhibited or enhanced MMP-9 synthesis in vitro and in vivo, and subsequently analysed primary endothelial cell proliferation and angiostatin synthesis, as well as tumor vascularization and development. We provide evidence that reduction of plasma levels of MMP-9 in either normal or integrin alpha1-null mice leads to decreased synthesis of angiostatin and consequent increased tumor growth and vascularization. In contrast, specifically enhancing MMP-9 expression in vivo caused a reduction in tumor vascularization. These findings are the opposite to other studies suggesting a pro-tumorigenic role for MMP-9, and may account for some of the recently observed failures of anti MMP therapy in tumor treatment.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Pozzi, A (corresponding author), Vanderbilt Univ, Med Ctr N, Dept Med, Div Nephrol & Hypertens, Room B-3109, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044514, R55AR044514, R01AR044514] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44514] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Axisa B, 2000, J CHROMATOGR B, V744, P359, DOI 10.1016/S0378-4347(00)00261-9; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Bettany J T, 1998, Adv Dent Res, V12, P136; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Cornelius LA, 1998, J IMMUNOL, V161, P6845; Curci JA, 2000, J VASC SURG, V31, P325, DOI 10.1016/S0741-5214(00)90163-0; Fife R S, 1998, Adv Dent Res, V12, P94; FIFE RS, 1995, J LAB CLIN MED, V125, P407; Forget MA, 1999, CAN J PHYSIOL PHARM, V77, P465; Gardner H, 1999, J CELL SCI, V112, P263; Hanemaaijer R, 1998, Adv Dent Res, V12, P114; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Jia MC, 2000, ADV EXP MED BIOL, V476, P181; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kruger A, 2001, CANCER RES, V61, P1272; Lokeshwar BL, 1999, ANN NY ACAD SCI, V878, P271, DOI 10.1111/j.1749-6632.1999.tb07690.x; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi M, 1998, J CELL BIOL, V142, P587; RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Rivas MJG, 1998, HEPATOLOGY, V28, P986, DOI 10.1002/hep.510280413; Sang Q X, 1998, Cell Res, V8, P171; Sayers TJ, 1998, J IMMUNOL, V161, P3957; Seftor REB, 1998, CLIN EXP METASTAS, V16, P217, DOI 10.1023/A:1006588708131; SIPOS EP, 1994, ANN NY ACAD SCI, V732, P263, DOI 10.1111/j.1749-6632.1994.tb24741.x; Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7; Sobrin L, 2000, INVEST OPHTH VIS SCI, V41, P1703; Soloway PD, 1996, ONCOGENE, V13, P2307; Sorsa T, 1998, J RHEUMATOL, V25, P975; Standker L, 1997, FEBS LETT, V420, P129, DOI 10.1016/S0014-5793(97)01503-2; VANDENBOGERT C, 1985, LEUKEMIA RES, V9, P617, DOI 10.1016/0145-2126(85)90142-0; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Xiang R, 1998, CANCER RES, V58, P3918	34	122	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					272	281		10.1038/sj.onc.1205045	http://dx.doi.org/10.1038/sj.onc.1205045			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803470				2022-12-28	WOS:000173026200011
J	Gurova, KV; Roklin, OW; Krivokrysenko, VI; Chumakov, PM; Cohen, MB; Feinstein, E; Gudkov, AV				Gurova, KV; Roklin, OW; Krivokrysenko, VI; Chumakov, PM; Cohen, MB; Feinstein, E; Gudkov, AV			Expression of prostate specific antigen (PSA) is negatively regulated by p53	ONCOGENE			English	Article						prostate specific antigen; p53; transcription; prostate cancer	WILD-TYPE P53; ADENOCARCINOMA CELL-LINE; RADICAL PROSTATECTOMY; HORMONAL-REGULATION; GENE-EXPRESSION; MESSENGER-RNA; CANCER; CARCINOMA; LNCAP; REPRESSION	Although prostate-specific antigen (PSA) is considered a uniquely important tumor marker and is broadly used for early detection of prostate cancer, the molecular mechanisms underlying its elevated expression in tumors have been unknown. By using cDNA microarray gene expression profiling, we found a fourfold increase in the PSA mRNA level in prostatic carcinoma cell line LNCaP, in which the p53 pathway was suppressed by a dominant negative p53 mutant. Consistently, p53 suppression caused a 4-8-fold increase in secretion of PSA protein in culture medium, suggesting that PSA gene expression is under negative control of p53. While wild type p53 strongly repressed, dominant negative p53 mutants stimulated PSA promoter-driven transcription and secretion of PSA in transient transfection experiments. The inhibitory effect of wild type p53 was undetectable in the presence of trychostatin A, suggesting the involvement of histone deacetylation in negative regulation of PSA promoter activity. Thus, PSA is likely to be a tissue specific indicator of transformation-associated p53 suppression in prostate cells. This finding provides a plausible explanation for a frequent increase of PSA levels in advanced prostate cancer.	Cleveland Clin Fdn, Dept Mol Biol NC20, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Quark Biotech Inc, Pleasonton, CA 94566 USA	Cleveland Clinic Foundation; University of Iowa	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Dept Mol Biol NC20, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Chumakov, Peter M/E-7731-2014	Chumakov, Peter/0000-0002-8078-2908; Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R01CA076673, R01CA075179] Funding Source: NIH RePORTER; NCI NIH HHS [CA76673, CA75179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; COFFEY DS, 1993, CANCER, V71, P880, DOI 10.1002/1097-0142(19930201)71:3+<880::AID-CNCR2820711403>3.0.CO;2-6; CordonCardo C, 1997, SEMIN SURG ONCOL, V13, P319, DOI 10.1002/(SICI)1098-2388(199709/10)13:5<319::AID-SSU5>3.0.CO;2-G; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Kim J, 1999, UROL CLIN N AM, V26, P281, DOI 10.1016/S0094-0143(05)70068-9; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Osman I, 1999, CLIN CANCER RES, V5, P2082; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Ozen M, 2000, ANTICANCER RES, V20, P1905; Quinn DI, 2000, CANCER RES, V60, P1585; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Stackhouse GB, 1999, J UROLOGY, V162, P2040, DOI 10.1016/S0022-5347(05)68095-0; Steele RJC, 1998, BRIT J SURG, V85, P1460; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Szende B, 1999, UROL INT, V63, P115, DOI 10.1159/000030429; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yeung F, 2000, J BIOL CHEM, V275, P40846, DOI 10.1074/jbc.M002755200; YOUNG CYF, 1991, CANCER RES, V51, P3748; Zhang JY, 1997, NUCLEIC ACIDS RES, V25, P3143, DOI 10.1093/nar/25.15.3143; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197	25	41	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					153	157		10.1038/sj.onc.1205001	http://dx.doi.org/10.1038/sj.onc.1205001			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791186				2022-12-28	WOS:000172887800016
J	Shinagawa, T; Nomura, T; Colmenares, C; Ohira, M; Nakagawara, A; Ishii, S				Shinagawa, T; Nomura, T; Colmenares, C; Ohira, M; Nakagawara, A; Ishii, S			Increased susceptibility to tumorigenesis of ski-deficient heterozygous mice	ONCOGENE			English	Article						co-repressor; Ski/Sno; tumor suppressor; Mad; Rb	TRANSCRIPTIONAL CO-REPRESSOR; HISTONE DEACETYLASE COMPLEX; TRANSFORMING-GROWTH-FACTOR; THYROID-HORMONE RECEPTOR; TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; TGF-BETA; V-SKI; HEMATOPOIETIC-CELLS; SKELETAL-MUSCLE	The c-ski proto-oncogene product (c-Ski) acts as a corepressor and binds to other co-repressors N-CoR/ SMRT and mSin3A which form a complex with histone deacetylase (HDAC). c-Ski mediates the transcriptional repression by a number of repressors, including nuclear hormone receptors and Mad. c-Ski also directly binds to, and recruits the HDAC complex to Smads, leading to inhibition of tumor growth factor-beta (TGF-beta) signaling. This is consistent with the function of ski as an oncogene. Here we show that loss of one copy of c-ski increases susceptibility to tumorigenesis in mice. When challenged with a chemical carcinogen, c-ski heterozygous mice showed an increased level of tumor formation relative to wild-type mice. In addition, c-ski-deficient mouse embryonic fibroblasts (MEFs) had increased proliferative capacity, whereas overexpression of c-Ski suppressed the proliferation. Furthermore, the introduction of activated Ki-ras into c-ski-deficient MEFs resulted in neoplastic transformation. These findings demonstrate that c-ski acts as a tumor suppressor in some types of cells. The level of cdc25A mRNA, which is down regulated by two tumor suppressor gene products, Rb and Mad, was upregulated in e-ski-deficient MEFs, whereas it decreased by overexpressing c-Ski in MEFs. This is consistent with the fact that c-Ski acts as a co-repressor of Mad and Rb. These results support the view that the decreased activities of Mad and Rb in ski-deficient cells at least partly contribute to enhanced proliferation and susceptibility to tumorigenesis. Human c-ski gene was mapped to a region close to the p73 tumor suppressor gene at the 1p36.3 locus, which is already known to contain multiple uncharacterized tumor suppressor genes.	RIKEN, Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; Japan Sci & Technol Corp, Core Res Evolutionary Sci & Technol, Res Project, Tsukuba, Ibaraki 3050074, Japan; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan	RIKEN; Japan Science & Technology Agency (JST); Cleveland Clinic Foundation; Chiba Cancer Center	Ishii, S (corresponding author), RIKEN, Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD030728, R29HD030728] Funding Source: NIH RePORTER; NICHD NIH HHS [HD30728] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; BOYER PL, 1993, ONCOGENE, V8, P457; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHENG NC, 1995, ONCOGENE, V10, P291; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; DOUCAS V, 1996, BIOCHIM BIOPHYS ACTA, V1288, P25; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Imyanitov EN, 1999, ONCOGENE, V18, P4640, DOI 10.1038/sj.onc.1202863; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Knudson AG, 1997, ANN NY ACAD SCI, V833, P58, DOI 10.1111/j.1749-6632.1997.tb48593.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Kruzelock RP, 1997, CANCER RES, V57, P106; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MARTINSSON T, 1995, CANCER RES, V55, P5681; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NEVINS JR, 1992, SCIENCE, V258, P424; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEARSONWHITE S, 1995, BLOOD, V86, P2146, DOI 10.1182/blood.V86.6.2146.bloodjournal8662146; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; SLEEMAN JP, 1993, ONCOGENE, V8, P67; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; Wang ZG, 1998, SCIENCE, V279, P1547; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	69	75	84	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8100	8108		10.1038/sj.onc.1204987	http://dx.doi.org/10.1038/sj.onc.1204987			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781823				2022-12-28	WOS:000172396800007
J	Jiang, XH; Wong, BCY; Lin, MCM; Zhu, GH; Kung, HF; Jiang, SH; Yang, D; Lam, SK				Jiang, XH; Wong, BCY; Lin, MCM; Zhu, GH; Kung, HF; Jiang, SH; Yang, D; Lam, SK			Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappa B activation in gastric cancer cells	ONCOGENE			English	Article						apoptosis; NF-kappa B; AP-1; p53 status; gastric cancer	WILD-TYPE P53; TRIPTERYGIUM-WILFORDII HOOK; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION; INDUCTION; ARREST; PHOSPHORYLATION; CHEMOTHERAPY; EXPRESSION; INHIBITORS	Triptolide, a major component in the extract of Chinese herbal plant Tripterygium wilfordii Hook f (TWHf), has potential anti-neoplastic effect. In the present study we investigated the potential therapeutic effects and mechanisms of triptolide against human gastric cancer cells. Four gastric cancer cell lines with different p53 status, AGS and MKN-45 (wild type p53); MKN-28 and SGC-7901 (mutant p53) were observed as to cell growth inhibition and induction of apoptosis in response to triptolide treatment. We showed that triptolide inhibited cell growth, induced apoptosis and suppressed NK-kappaB and AP-1 transactivation in AGS cells with wild-type p53. Triptolide induced apoptosis by stimulating the expressions of p53, p21(waf1/cip1), bax protein, and increased the activity of caspases. In addition, it caused cell cycle arrest in the G(0)/G(1) phase. To examine the role of p53 in these functions, we showed that suppression of p53 level with antisense oligonucleotide abrogated triptolide-induced apoptosis and over-expression of dominant negative p53 abolished the inhibitory effect on NF-kappa dB activation. Furthermore, we demonstrated that triptolide had differential effects on gastric cancer cells with different p53 status. We showed that triptolide also inhibited cell growth and induced apoptosis in MKN-45 with wild-type p53, whereas it had no significant growth-inhibition and apoptosis induction effects on the MKN-28 and SGC-7901 cells with mutant p53. Our data suggest that triptolide exhibits anti-tumor and anti-inflammatory effects by inhibiting cell proliferation, inducing apoptosis and inhibiting NF-kappaB and AP-1 transcriptional activity. However, a functional p53 is required for these proapoptotic, anti-inflammatory and anti-tumor effects.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Rui Jin Hosp, Dept Gastroenterol, Shanghai, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Wong, BCY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.	bcywong@hku.hk	Wong, Benjamin Chun Yu/ABB-1962-2020; Yang, Dan/D-3151-2009; jiang, cynthia xiaohua/F-7580-2017	jiang, cynthia xiaohua/0000-0002-7372-4961				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; CALVERT AH, 1999, SEMIN ONCOL, V16, pS90; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GRANT S, 1992, CANCER RES, V52, P6270; JIANG XY, 1994, PEDIATR NEPHROL, V8, P343, DOI 10.1007/BF00866356; Kobayashi T, 1995, ONCOGENE, V11, P2311; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Li JJ, 1997, CANCER RES, V57, P3569; Linke SP, 1997, CANCER RES, V57, P1171; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; Mueller H, 1996, ANTICANCER RES, V16, P3845; NISHIZAKI M, 2000, ONCOGENE, V19, P726; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Penninger JM, 1998, ADV IMMUNOL, V68, P51, DOI 10.1016/S0065-2776(08)60558-1; PU LX, 1990, ACTA PHARM SINIC, V11, P76; QIN WZ, 1981, CHINESE MED J-PEKING, V94, P827; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TAO XL, 1989, CHINESE MED J-PEKING, V102, P327; Tetu B, 1998, MODERN PATHOL, V11, P823; Vasey PA, 1996, MOL PHARMACOL, V50, P1536; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WEI YS, 1991, ACTA PHARM SINIC, V12, P406; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; YANG SX, 1992, INT J IMMUNOPHARMACO, V14, P963; Yang YL, 1998, IMMUNOPHARMACOLOGY, V40, P139, DOI 10.1016/S0162-3109(98)00036-8; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhan QM, 1996, ONCOGENE, V13, P2287; ZHANG L X, 1990, Yaoxue Xuebao, V25, P573; Zhao GH, 2000, AM J PHYSIOL-LUNG C, V279, pL958, DOI 10.1152/ajplung.2000.279.5.L958; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhu GH, 2000, GASTROENTEROLOGY, V118, P507, DOI 10.1016/S0016-5085(00)70256-3; Zhu GH, 1999, DIGEST DIS SCI, V44, P2020, DOI 10.1023/A:1026670301787	45	170	193	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2001	20	55					8009	8018		10.1038/sj.onc.1204981	http://dx.doi.org/10.1038/sj.onc.1204981			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753684				2022-12-28	WOS:000172288700010
J	Gentile, M; Ahnstrom, M; Schon, F; Wingren, S				Gentile, M; Ahnstrom, M; Schon, F; Wingren, S			Candidate tumour suppressor genes at 11q23-q24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosis	ONCOGENE			English	Article						11q23-q24; early onset; breast cancer; PIG8; CHK1; LOH11CR2A	ATAXIA-TELANGIECTASIA; EARLY-ONSET; ATM GENE; SPORADIC BREAST; PPP2R1B GENE; MUTATIONS; HETEROZYGOSITY; REGION; IDENTIFICATION; DELETION	One of the most consistently deleted chromosomal regions in solid tumours is 11q23-q25, which consequently has been postulated to harbour one or more tumour suppressor loci. Despite large efforts to identify the responsible genes, the goal remains elusive, but as knowledge accumulates new candidates are emerging. The present study was undertaken in an attempt to assess the possible implication of four genes residing at 11q23-q24, in a population of early onset breast cancer (n = 41). The coding sequence of PIG8, CHK1, LOH11CR2A and PPP2R1B were screened for mutations using the protein truncation test or single-strand conformational polymorphism, in combination with direct DNA sequencing. Varying proportions of alterations were detected, ranging from 6% in PPP2R1B to 39% in PIG8. Many of these changes were deletions, in some cases corresponding to complete exons, thus likely to represent splice variants, while others were presumed to arise from aberrant splicing, since they occurred at sites with resemblance to exon/intron borders. Considering only bona fide mutations, the highest alteration frequency (17%) was again found in PIG8. Most of these alterations were likely to have an adverse impact on the translated protein as they either altered the reading frame or affected phylogenetically conserved residues. Our data represent the first evidence of alterations in the PIG8 gene in human malignancies, a finding that substantiates its role as a potential tumour suppressor gene as suggested by its involvement in p53-induced apoptosis.	Linkoping Univ Hosp, Div Oncol, Dept Biomed & Surg, S-58185 Linkoping, Sweden	Linkoping University	Wingren, S (corresponding author), Linkoping Univ Hosp, Div Oncol, Dept Biomed & Surg, S-58185 Linkoping, Sweden.	sten.wingren@onk.liu.se						Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Bebb DG, 1999, BRIT J CANCER, V80, P1979, DOI 10.1038/sj.bjc.6690630; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bertoni F, 1999, GENE CHROMOSOME CANC, V26, P176, DOI 10.1002/(SICI)1098-2264(199910)26:2<176::AID-GCC11>3.3.CO;2-V; Broeks A, 2000, AM J HUM GENET, V66, P494, DOI 10.1086/302746; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Evans MF, 1998, ONCOGENE, V16, P2557, DOI 10.1038/sj.onc.1202039; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gentile M, 1999, EUR J CANCER, V35, P1202, DOI 10.1016/S0959-8049(99)00121-5; Gentile M, 2001, INT J CANCER, V92, P208, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1169>3.0.CO;2-4; Gentile M, 1999, BRIT J CANCER, V80, P843, DOI 10.1038/sj.bjc.6690430; Gu Z, 2000, CYTOGENET CELL GENET, V89, P230, DOI 10.1159/000015620; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; HAMPTON GM, 1994, CANCER RES, V54, P4586; Haruki N, 2000, CANCER RES, V60, P4689; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; Herbst RA, 1999, INT J CANCER, V80, P205, DOI 10.1002/(SICI)1097-0215(19990118)80:2<205::AID-IJC8>3.0.CO;2-J; Hui ABY, 1996, CANCER RES, V56, P3225; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; Izatt L, 1999, EUR J HUM GENET, V7, P310, DOI 10.1038/sj.ejhg.5200288; Janin N, 1999, BRIT J CANCER, V80, P1042, DOI 10.1038/sj.bjc.6690460; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Koreth J, 1997, ONCOGENE, V14, P431, DOI 10.1038/sj.onc.1200847; Laake K, 1999, GENE CHROMOSOME CANC, V25, P212, DOI 10.1002/(SICI)1098-2264(199907)25:3<212::AID-GCC3>3.0.CO;2-G; Laake K, 2000, BRIT J CANCER, V83, P1650, DOI 10.1054/bjoc.2000.1519; Lehar SM, 1996, ONCOGENE, V12, P1181; Liu WG, 1997, NAT GENET, V16, P328, DOI 10.1038/ng0897-328; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; NEGRINI M, 1995, CANCER RES, V55, P3003; Olsen JH, 2001, JNCI-J NATL CANCER I, V93, P121, DOI 10.1093/jnci/93.2.121; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Siah SP, 2000, BREAST CANCER RES TR, V60, P135, DOI 10.1023/A:1006315315060; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Valentine CR, 1998, MUTAT RES-REV MUTAT, V411, P87, DOI 10.1016/S1383-5742(98)00010-6; Vorechovsky I, 1996, CANCER RES, V56, P2726; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017	45	53	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7753	7760		10.1038/sj.onc.1204993	http://dx.doi.org/10.1038/sj.onc.1204993			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753653				2022-12-28	WOS:000172161700006
J	Tureci, O; Sahin, U; Koslowski, M; Buss, B; Bell, C; Ballweber, P; Zwick, C; Eberle, T; Zuber, M; Villena-Heinsen, C; Seitz, G; Pfreundschuh, M				Tureci, O; Sahin, U; Koslowski, M; Buss, B; Bell, C; Ballweber, P; Zwick, C; Eberle, T; Zuber, M; Villena-Heinsen, C; Seitz, G; Pfreundschuh, M			A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing	ONCOGENE			English	Article						tumour-associated; antigen; N-myc; leucine zipper	CYTOLYTIC T-LYMPHOCYTES; PRE-MESSENGER-RNA; SECONDARY STRUCTURE PREDICTION; SEROLOGICAL IDENTIFICATION; AUTOIMMUNE SERA; HUMAN-MELANOMA; CDNA CLONING; ANTIGENS; CANCER; LOCALIZATION	We describe here the definition and characterization of antigen CT-8/HOM-TES-85 encoded by a previously unknown gene and identified by serological expression screening using antibodies from a seminoma patient. Intriguingly, the leucine zipper region of CT-8/HOM-TES-85 shows an atypical amphipathy with clusters of hydrophobic residues that is exclusively shared by the N-myc proto-oncogene. CT-8/HOM-TES-85 gene is tightly silenced in normal tissues except for testis. However, it is frequently activated in human neoplasms of different types including lung cancer, ovarian cancer, melanoma and glioma. Endogenous as well as heterogeneously expressed CT-8/HOM-TES-85 targets predominantly, to the nucleus forming a distinctive speckled pattern of nuclear dots arranged in macromolecular structures. By co-localization studies these speckles were identified as loci of transcriptional activity and splicing, suggesting that CT-8/HOM-TES-85 may be involved in these processes. The aberrant expression of CT-8/HOM-TES-85 in human neoplasms might therefore be involved in cancer associated alterations of transcriptional or post-transcriptional processes and thus may disclose new mechanisms involved in the manifestation of the cancer phenotype.	Univ Mainz, Med Klin & Poliklin 3, D-55131 Mainz, Germany; Klinikum Bamberg, Abt Pathol, Bamberg, Germany; Stadtklin, Abt Gynakol, Baden, Switzerland; Univ Leipzig, Inst Humangenet, Leipzig, Germany; Univ Klinikun Saarlandes, Med Klin & Poliklin 1, Saarlandes, Germany	Johannes Gutenberg University of Mainz; Leipzig University; Universitatsklinikum des Saarlandes	Sahin, U (corresponding author), Univ Mainz, Med Klin 3, D-55131 Mainz, Germany.	Sahin@mail.uni-mainz.de	Sahin, Ugur/L-4818-2017	Sahin, Ugur/0000-0003-0363-1564				ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; Bergsagel P L, 1992, Curr Top Microbiol Immunol, V182, P223; BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0; Boon T, 1997, CURR OPIN IMMUNOL, V9, P681, DOI 10.1016/S0952-7915(97)80049-0; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; CHAN EKL, 1989, J AUTOIMMUN, V2, P321, DOI 10.1016/0896-8411(89)90159-5; Chen YT, 1999, CANCER J SCI AM, V5, P16; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; Eichmuller S, 2001, P NATL ACAD SCI USA, V98, P629, DOI 10.1073/pnas.021386498; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GAUGLER B, 1995, J EXP MED, V79, P921; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; KALLENBERG CGM, 1990, CLIN RHEUMATOL, V9, P136, DOI 10.1007/BF02205562; Kim J, 2000, GENOME RES, V10, P1138, DOI 10.1101/gr.10.8.1138; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; Kramer H, 1996, J CELL BIOL, V133, P1205, DOI 10.1083/jcb.133.6.1205; Lethe B, 1998, INT J CANCER, V76, P903, DOI 10.1002/(SICI)1097-0215(19980610)76:6<903::AID-IJC22>3.0.CO;2-1; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; MCCAULIFFE DP, 1989, J AUTOIMMUN, V2, P375, DOI 10.1016/0896-8411(89)90166-2; MEUWISSEN RJL, 1997, GENOMICS, V37, P101; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Ono T, 2001, P NATL ACAD SCI USA, V98, P3282, DOI 10.1073/pnas.041625098; RUBINFELD B, 1997, CANCER RES, V57, P462; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2; Sahin U, 1998, INT J CANCER, V78, P387, DOI 10.1002/(SICI)1097-0215(19981029)78:3<387::AID-IJC22>3.0.CO;2-2; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; SZOSTECKI C, 1987, CLIN EXP IMMUNOL, V68, P108; Tureci O, 1996, CANCER RES, V56, P4766; Tureci O, 1997, MOL MED TODAY, V3, P342, DOI 10.1016/S1357-4310(97)01081-2; Tureci O, 1998, P NATL ACAD SCI USA, V95, P5211, DOI 10.1073/pnas.95.9.5211; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VENROOIJ WJ, 1989, CLIN EXP RHEUMATOL, V7, P635; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wynshaw-Boris A, 2001, GENE DEV, V15, P639, DOI 10.1101/gad.886801	53	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3879	3888		10.1038/sj.onc.1205481	http://dx.doi.org/10.1038/sj.onc.1205481			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032826				2022-12-28	WOS:000175847200007
J	Thompson, TA; Haag, JD; Lindstrom, MJ; Griep, AE; Lohse, JK; Gould, MN				Thompson, TA; Haag, JD; Lindstrom, MJ; Griep, AE; Lohse, JK; Gould, MN			Decreased susceptibility to NMU-induced mammary carcinogenesis in transgenic rats carrying multiple copies of a rat ras gene driven by the rat Harvey ras promoter	ONCOGENE			English	Article						mammary carcinogenesis; transgenic rats; ras genes; N-methyl-N-nitrosourea	MOLECULAR-WEIGHT; EXPRESSION; METHYLUREA; PROTEIN; P21; ACTIVATION; PROGNOSIS; APOPTOSIS; MUTATION; RECEPTOR	Ras protein over-expression has been observed in human breast cancers although the significance of Ras overexpression in the etiology of breast cancer is unknown and its contribution to breast cancer prognosis is still debated. In this study, the over-expression of both wildtype Harvey and Kirsten Ras proteins as contributors to rat mammary carcinogenesis were examined using a transgenic rat model. Three rat transgenic lines (designated HrHr transgenics) carrying three to six copies of wild-type rat Harvey ras driven by the wildtype rat Harvey ras promoter were produced. In addition, transgenic lines carrying either three or seven copies of the Kirsten ras gene under the same promoter (HrKr) were produced. No pathological changes in the mammary gland were observed in any of the HrHr or HrKr transgenic rat line heterozygote. Two of the Ras transgenic lines, HrHr (R8) and HrKr (4334), had a significant reduction in NMU-induced rat mammary cancer when compared to their non-transgenic litter-mates. All five Ras transgenic lines developed fewer carcinomas than their non-transgenic littermates following NMU exposure. The percentage of NMU-induced G35 to A35 activating mutations in the endogenous Harvey ras gene in mammary carcinomas from the HrHr, HrKr transgenic rats and their non-transgenic littermates was similar ( similar to50%). In contrast, less than 1% of the NMU-induced carcinomas in these Ras transgenic rats had an activating ras mutation in their transgenes. These findings highlight the potential of Ras to function as a modifier gene in repressing mammary carcinogenesis.	Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Environm Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Biotechnol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gould, MN (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, 1400 Univ Ave, Madison, WI 53706 USA.	gould@oncology.wisc.edu	Griep, Anne/ABA-9636-2020; Gould, Michael N/C-7414-2014		NCI NIH HHS [CA77527] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAZI EA, 1995, CARCINOGENESIS, V16, P965, DOI 10.1093/carcin/16.4.965; Asamoto M, 2000, CARCINOGENESIS, V21, P243, DOI 10.1093/carcin/21.2.243; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; CHAKRABORTY AK, 1991, P NATL ACAD SCI USA, V88, P2217, DOI 10.1073/pnas.88.6.2217; CLAIR T, 1987, CANCER RES, V47, P5290; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Gohring UJ, 1999, TUMOR BIOL, V20, P173, DOI 10.1159/000030061; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAND PH, 1984, P NATL ACAD SCI-BIOL, V81, P5227, DOI 10.1073/pnas.81.16.5227; Jin ZA, 1996, CANCER RES, V56, P4927; KUMAR R, 1989, ONCOGENE RES, V4, P235; LUNDY J, 1986, J CLIN ONCOL, V4, P1321, DOI 10.1200/JCO.1986.4.9.1321; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; OHUCHI N, 1986, CANCER RES, V46, P2511; QUERZOLI P, 1988, BREAST CANCER RES TR, V12, P23, DOI 10.1007/BF01805736; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schondorf T, 1999, ONCOL REP, V6, P1029; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shackney SE, 1998, CLIN CANCER RES, V4, P913; SPANDIDOS A, 1988, BRIT J CANCER, V58, P67; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; Thompson TA, 1998, CANCER RES, V58, P5097; Tsuda H, 2001, MUTAT RES-FUND MOL M, V477, P173, DOI 10.1016/S0027-5107(01)00118-X; WATSON DMA, 1991, BREAST CANCER RES TR, V17, P161, DOI 10.1007/BF01806365; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	30	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2797	2804		10.1038/sj.onc.1205391	http://dx.doi.org/10.1038/sj.onc.1205391			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973638				2022-12-28	WOS:000175063700003
J	Mirza, A; McGuirk, M; Hockenberry, TN; Wu, Q; Ashar, H; Black, S; Wen, SF; Wang, LQ; Kirschmeier, P; Bishop, WR; Nielsen, LL; Pickett, CB; Liu, SX				Mirza, A; McGuirk, M; Hockenberry, TN; Wu, Q; Ashar, H; Black, S; Wen, SF; Wang, LQ; Kirschmeier, P; Bishop, WR; Nielsen, LL; Pickett, CB; Liu, SX			Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway	ONCOGENE			English	Article						survivin; p53; transcription; repression; apoptosis	TATA-BINDING PROTEIN; TRANSCRIPTIONAL REPRESSION; GENE-THERAPY; HISTONE ACETYLATION; TARGET GENES; DNA-BINDING; IN-VIVO; EXPRESSION; ACTIVATION; PROMOTER	Survivin is an inhibitor of apoptosis protein, which is over-expressed in most tumors. Aberrant expression of survivin and loss of wild-type p53 in many tumors prompted us to investigate a possible link between these two events. Here we show that wild-type p53 represses survivin expression at both mRNA and protein levels. Transient transfection analyses revealed that the expression of wild-type p53, but not mutant p53, was associated with strong repression of the survivin promoter in various cell types. The over-expression of exogenous survivin protein rescues cells from p53-induced apoptosis in a dose-dependent manner, suggesting that loss of survivin mediates, at least, in part the p53-dependent apoptotic pathway. In spite of the presence of two putative p53-binding sites in the survivin promoter, deletion and mutation analyses suggested that neither site is required for transcriptional repression of survivin expression. This was confirmed by chromatin immunoprecipitation assays. Further analyses suggested that the modification of chromatin within the survivin promoter could be a molecular explanation for silencing of survivin gene transcription by p53.	Schering Plough Corp, Inst Res, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Canji Inc, San Diego, CA 92121 USA	Merck & Company; Schering Plough Corporation	Liu, SX (corresponding author), Schering Plough Corp, Inst Res, Dept Tumor Biol, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	suxing.liu@spcorp.com						Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Hirose S, 1998, J BIOCHEM-TOKYO, V124, P1060, DOI 10.1093/oxfordjournals.jbchem.a022220; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Kawasaki H, 1998, CANCER RES, V58, P5071; Kiermaier A, 1997, CURR BIOL, V7, pR505, DOI 10.1016/S0960-9822(06)00249-1; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lu CD, 1998, CANCER RES, V58, P1808; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Olie RA, 2000, CANCER RES, V60, P2805; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SANTOSO JT, 1995, GYNECOL ONCOL, V59, P171; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Takahashi Y, 2000, GENE DEV, V14, P804; Tamm I, 1998, CANCER RES, V58, P5315; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wen SF, 2000, CANCER GENE THER, V7, P1469, DOI 10.1038/sj.cgt.7700257; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; YAGINUMA Y, 1992, CANCER RES, V52, P4196	43	452	502	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2613	2622		10.1038/sj.onc.1205353	http://dx.doi.org/10.1038/sj.onc.1205353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965534				2022-12-28	WOS:000174996500001
J	Senoo, M; Matsumura, Y; Habu, S				Senoo, M; Matsumura, Y; Habu, S			TAp63 gamma (p51A) and dNp63 alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression	ONCOGENE			English	Article						p63; p51; p73L; p300; CBP; VEGF; HIF1 alpha	HYPOXIA-INDUCIBLE FACTOR-1; CELL LUNG-CANCER; WILD-TYPE P53; O-2 HOMEOSTASIS; FACTOR 1-ALPHA; TRANSCRIPTION; ACTIVATION; HOMOLOG; ANGIOGENESIS; PROTEIN	Tumor suppressor p53 has been shown to repress expression of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen and a key mediator of tumor angiogenesis. The p63 gene, recently identified as a p53-relative, encodes multiple isoforms with structural and functional similarities and differences from p53. In this study, we show the evidence that the two major isoforms of the p63 gene, TAp63gamma (p51A) and dNp63alpha (p73L), represses and upregulates VEGF expression, respectively, on transcription and protein levels. Transient transfection assays show that a hypoxia-inducible factor (HIF) 1 binding site within the VEGF promoter region is responsible for both upregulation and repression by dNp63alpha and by TAp63gamma, respectively, of the VEGF promoter activity. We also show that TAp63gamma targets HIF1alpha for promoting proteasomal degradation but that dNp63alpha targets HIF1alpha for stabilization. Mammalian two-hybrid assays show that HIF1alpha-dependent transcription is repressed by TAp63gamma as well as by p53, whereas it is upregulated by dNp63alpha in collaboration with a transcription coactivator p300. Our data also show that dNp63alpha acts as a dominant-negative reagent toward both p53- and TAp63gamma-mediated degradation of HIF1alpha and repression of HIF1alpha-dependent transcription. These results suggest that p63 is involved in the regulation of the VEGF gene expression and that modulation of VEGF expression by TAp63gamma and dNp63alpha is closely correlated with their distinct roles on the regulation of HIF1alpha stability.	Tokai Univ, Sch Med, Dept Immunol, Isehara, Kanagawa 2591193, Japan	Tokai University	Habu, S (corresponding author), Tokai Univ, Sch Med, Dept Immunol, Isehara, Kanagawa 2591193, Japan.	sonoko@is.icc.u-tokai.ac.jp		Senoo, Makoto/0000-0002-0155-0683				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Bouvet M, 1998, CANCER RES, V58, P2288; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; ENOO M, 2001, BIOCHEM BIOPH RES CO, V286, P628; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FOLKMAN J, 1997, CANC MED, P181; Fontanini G, 1998, EUR J CANCER, V34, P718, DOI 10.1016/S0959-8049(97)10145-9; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Nishi H, 1999, INT J ONCOL, V15, P1149; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Ravi R, 2000, GENE DEV, V14, P34; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Senoo M, 2001, BRIT J CANCER, V84, P1235, DOI 10.1054/bjoc.2000.1735; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Shimada A, 1999, CANCER RES, V59, P2781; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; Suzuki K, 1996, CANCER RES, V56, P3004; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, BIOL CHEM, V378, P609; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhong H, 1999, CANCER RES, V59, P5830	52	64	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2455	2465		10.1038/sj.onc.1205330	http://dx.doi.org/10.1038/sj.onc.1205330			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971180				2022-12-28	WOS:000174918400002
J	Frechet, M; Canitrot, Y; Bieth, A; Dogliotti, E; Cazaux, C; Hoffmann, JS				Frechet, M; Canitrot, Y; Bieth, A; Dogliotti, E; Cazaux, C; Hoffmann, JS			Deregulated DNA polymerase beta strengthens ionizing radiation-induced nucleotidic and chromosomal instabilities	ONCOGENE			English	Article						DNA polymerase beta; ionizing radiations; genetic instability; mutagenesis	STRAND-BREAK REPAIR; MUTATOR PHENOTYPE; SOMATIC MUTATIONS; CANCER-CELLS; OVEREXPRESSION; EXPRESSION; TUMORS; DAMAGE; GENE; SENSITIVITY	DNA polymerase beta (Pol beta) is an error-prone enzyme which has been found to be overexpressed in several human tumors. By using a couple of recombinant CHO cells differing only from the exogenous expression of Pol P, we showed here that cells overexpressing Pol beta are much more sensitive to IR treatments by increasing apoptosis. We also found that the surviving cells displayed an hypermutator phenotype which could be explained by different pathways involving Pol beta, such as (i) an increased capacity to incorporate into DNA the mutagenic dGTP analog, 8-oxo-dGTP, one of the most abundant purine-derived nucleotides exposed to gamma-irradiation, (ii) the induction of IR-induced DNA breaks and (iii) accumulation of chromosome aberrations induced by radiation. Alteration of Pol beta expression in irradiated cells thus appears to strengthen both cell death and genetic changes associated with a malignant phenotype. These data provide new insights into the cellular response to radiations and the associated carcinogenic consequences.	CNRS, IPBS, Grp Instabilite Genet & Canc, UMR 5089, F-31077 Toulouse, France; Ist Super Sanita, Lab Comparat Toxicol & Ecotoxicol, I-00161 Rome, Italy	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Istituto Superiore di Sanita (ISS)	Hoffmann, JS (corresponding author), CNRS, IPBS, Grp Instabilite Genet & Canc, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	cazaux@ipbs.fr; jseb@ipbs.fr	Hoffmann, Jean-Sebastien/O-9183-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X				Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bergoglio V, 2001, ONCOGENE, V20, P6181, DOI 10.1038/sj.onc.1204743; Bouayadi K, 1997, CANCER RES, V57, P110; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; GEDIK CM, 1992, INT J RADIAT BIOL, V62, P313, DOI 10.1080/09553009214552161; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; KUMAR A, 1990, J BIOL CHEM, V265, P2124; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; LOEB LA, 1991, CANCER RES, V51, P3075; Louat T, 2001, MOL PHARMACOL, V60, P553; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; Vamvakas S, 1997, CRIT REV TOXICOL, V27, P155, DOI 10.3109/10408449709021617; VELD CWOH, 1994, CANCER RES, V54, P3001; WARD JF, 1995, RADIAT RES, V142, P362, DOI 10.2307/3579145; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YANDELL DW, 1986, SOMAT CELL MOLEC GEN, V12, P255, DOI 10.1007/BF01570784; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	40	25	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2320	2327		10.1038/sj.onc.1205295	http://dx.doi.org/10.1038/sj.onc.1205295			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948415				2022-12-28	WOS:000174635600004
J	Koul, D; Jasser, SA; Lu, YL; Davies, MA; Shen, RJ; Shi, YX; Mills, GB; Yung, WKA				Koul, D; Jasser, SA; Lu, YL; Davies, MA; Shen, RJ; Shi, YX; Mills, GB; Yung, WKA			Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity	ONCOGENE			English	Article						MMAC; PTEN; phosphatidylinositol phosphatase; growth inhibition	FOCAL ADHESION KINASE; GLIOMA-CELLS; AKT PROTOONCOGENE; PDZ DOMAIN; PTEN; GROWTH; ONCOGENE; BREAST; PHOSPHORYLATION; INHIBITION	The tumor suppressor gene, MMAC/PTEN, has phosphatase, C2, and PDZ-binding domains as well as potential sites of regulation by phosphorylation, including tyrosine phosphorylation, which may contribute to its ability to modulate cell growth and viability. Several obvious and significant motifs were found in MMAC/PTEN, including most notably, a catalytic domain of tyrosine phosphatase (IHCxxGxxRS/T) and several potential tyrosine phosphorylation sites. To examine the functional significance of tyrosine phosphorylation of MMAC/PTEN, retroviral constructs were generated with mutations at two putative tyrosine phosphorylation sites (Y240A/Y240F and Y315A/Y315F). Stable expression of wild-type MMAC/PTEN in U251 human glioma cells (which do not normally produce a functional MMAC/PTEN gene product) resulted in a significant reduction of tumor growth in nude mice, decreased growth rate, saturation density, and colony formation in vitro, as well as dephosphorylation of D3-phosphorylated phosphatidylinositols (PtdIns) in vitro. Mutation of Y240 or Y315 to either alanine or phenylalanine abrogated the ability of MMAC/PTEN to alter growth rate, saturation density, and colony formation in vitro. The ability of MMAC/PTEN to limit tumor growth in nude mice was markedly decreased but not abrogated by mutation of Y240 or Y315 to alanine. Thus, Y240 and Y315 are required for MMAC/PTEN to decrease tumor growth in vitro and in vivo. In contrast to wild-type MMAC/PTEN, mutant MMAC/PTEN containing Y240A or Y315A was unable to dephosphorylate D3-phosphorylated PtdIns in vitro. Thus, Y240A and Y315A are involved in the ability of MMAC/PTEN to dephosphorylate PtdIns and regulate tumor cell growth in vitro and in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Brain Tumor Ctr, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yung, WKA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Brain Tumor Ctr, Box 100,1515 Holcombe Blvd, Houston, TX 77030 USA.	wyung@manderson.org	Davies, Michael/GWV-2527-2022		NCI NIH HHS [R01 CA82716, CA-16672, R01 CA51148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082716, P30CA016672, R01CA051148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BESSON A, 1999, EUR J BIOCHEM, V263, P237; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; LI DM, 1999, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pluskota E, 2000, J BIOL CHEM, V275, P30029, DOI 10.1074/jbc.M000240200; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	38	53	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2357	2364		10.1038/sj/onc/1205296	http://dx.doi.org/10.1038/sj/onc/1205296			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948419				2022-12-28	WOS:000174635600008
J	Lein, M; Jung, K; Ortel, B; Stephan, C; Rothaug, W; Juchem, R; Johannsen, M; Deger, S; Schnorr, D; Loening, S; Krell, HW				Lein, M; Jung, K; Ortel, B; Stephan, C; Rothaug, W; Juchem, R; Johannsen, M; Deger, S; Schnorr, D; Loening, S; Krell, HW			The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model	ONCOGENE			English	Article						prostate cancer; Dunning tumor; metalloproteinases; synthetic inhibitor; animal model	TISSUE INHIBITOR; BATIMASTAT BB-94; TIMP-2; ANGIOGENESIS; PROGRESSION; EXPRESSION; CARCINOMA; SECRETION; CULTURES; BENIGN	The therapeutic efficacy of synthetic inhibitors of matrix-metalloproteinases (MMPs) in various cancers has been demonstrated. A novel inhibitor, Ro 28-2653, with high selectivity for MMP2, MMP9 and membrane type 1-MMP was evaluated in an orthotopic prostate cancer rat model. Efficacy was determined by recording tumor growth and survival endpoints. Prostate cancer was induced by inoculating R3327 Dunning tumor cells (MatLyLu) into the ventral lobe of the prostates of 148 Copenhagen rats. Daily oral treatment with Ro 282653 (10-300 mg/kg per day) was started on day 1 or on day 6 after tumor cell injection. Animals were sacrificed on day 20 for determination of tumor weights. For survival studies, rats received daily oral Ro 28-2653 (100 mg/kg per day) or vehicle for up to 30 days. Tumor induction was successful in 100% of the animals. Ro 282653 reproducibly reduced the tumor weights by up to 90% in a dose-dependent manner. In addition, an inhibitory effect in rats with established tumors (treatment start at day 6) was shown. A significantly prolonged survival of Ro 28-2653-treated rats was also demonstrated. Selective inhibition of MMP activity is a novel therapeutic approach, which bears promise for studies in patients with prostate cancer.	Humboldt Univ, Univ Hosp Charite, Dept Urol, D-10098 Berlin, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Labs Photomed, Boston, MA USA; Roche Diagnost GmbH, Pharma Res Penzberg, Penzberg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Harvard Medical School; Massachusetts General Hospital; Roche Holding	Lein, M (corresponding author), Humboldt Univ, Univ Hosp Charite, Dept Urol, D-10098 Berlin, Germany.	Michael.Lein@charite.de	Ortel, Bernhard/AAF-7658-2019; Jung, Klaus/Z-2122-2018; Deger, Serpil Muge/ABG-5774-2021	Jung, Klaus/0000-0001-9797-5362; Stephan, Carsten/0000-0002-3270-258X				ANDERSON IC, 1995, CANCER RES, V55, P4120; BOASBERG P, 1997, P AN M AM SOC CLIN, V16, pA316; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DAVIES B, 1993, BRIT J CANCER, V67, P1126, DOI 10.1038/bjc.1993.207; Eccles SA, 1996, CANCER RES, V56, P2815; Festuccia C, 1996, INT J CANCER, V69, P386, DOI 10.1002/(SICI)1097-0215(19961021)69:5<386::AID-IJC6>3.0.CO;2-1; FIELDING J, 2000, P AN M AM SOC CLIN, V19, pA240; Grams F, 2001, BIOL CHEM, V382, P1277, DOI 10.1515/BC.2001.159; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Lein M, 2000, INT J CANCER, V85, P801, DOI 10.1002/(SICI)1097-0215(20000315)85:6<801::AID-IJC11>3.0.CO;2-C; Lein M, 2000, UROLOGY, V56, P167, DOI 10.1016/S0090-4295(00)00553-7; Lein M, 2000, PROSTATE, V43, P77; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LOKESHWAR BL, 1993, CANCER RES, V53, P4493; Lubaroff D M, 1980, Prog Clin Biol Res, V37, P243; Lucia MS, 1998, PROSTATE, V36, P49, DOI 10.1002/(SICI)1097-0045(19980615)36:1<49::AID-PROS9>3.0.CO;2-6; Macaulay VM, 1999, CLIN CANCER RES, V5, P513; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Price A, 1999, CLIN CANCER RES, V5, P845; Rabbani SA, 1998, IN VIVO, V12, P135; Rothenberg ML, 1999, STEM CELLS, V17, P237, DOI 10.1002/stem.170237; Shalinsky DR, 1999, CLIN CANCER RES, V5, P1905; Shalinsky DR, 2000, CANC DRUG DISC DEV, P143; Smith DC, 1999, J CLIN ONCOL, V17, P1664, DOI 10.1200/JCO.1999.17.6.1664; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; Steward WP, 1999, CANCER CHEMOTH PHARM, V43, pS56, DOI 10.1007/s002800051099; Still K, 2000, PROSTATE, V42, P18; Thomas AL, 2000, EXPERT OPIN INV DRUG, V9, P2913, DOI 10.1517/13543784.9.12.2913; Tierney GM, 1999, EUR J CANCER, V35, P563, DOI 10.1016/S0959-8049(99)00007-6; Walsh PC, 2000, J UROLOGY, V163, P1802, DOI 10.1016/S0022-5347(05)67547-7; Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	36	65	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2089	2096		10.1038/sj.onc.1205267	http://dx.doi.org/10.1038/sj.onc.1205267			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960381				2022-12-28	WOS:000174827000015
J	Sato, S; Fujita, N; Tsuruo, T				Sato, S; Fujita, N; Tsuruo, T			Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)	ONCOGENE			English	Article						UCN-01; PDK1; Akt; apoptosis; PKC	PROTEIN-KINASE-B; CANCER-CELLS; SELECTIVE INHIBITOR; ACTIVATION; APOPTOSIS; PHOSPHORYLATION; GROWTH; SUBSTRATE; CLEAVAGE; IDENTIFICATION	3-Phosphoinositide-dependent protein kinase-1 (PDKI) plays a central role in activating the AGC subfamily of protein kinases. In particular, PDKI plays an important role in the regulation of Akt/PKB survival pathway by phosphorylating Akt on Thr(308). Here we show that UCN-01 (7-hydroxystaurosporine), a drug now in clinical trials and with a unique fingerprint pattern, induced dephosphorylation and inactivation of Akt, resulting in the turnoff of the survival signals and the induction of apoptosis. Further analysis revealed that UCN-01-mediated Akt inactivation was caused by inhibiting upstream Akt kinase PDKI (IC50=33 nm) both in vitro and from cells, but not by suppressing Akt itself or phosphatidylinositide-3-OH kinase. UCN-01-induced PDKI inhibition was also observed in in vivo murine and human tumor xenografts. Overexpression of active form of Akt diminished the cytotoxic effects of UCN-01, suggesting that UCN-01 may in part exert its cytotoxicity by inhibiting PDKI-Akt survival pathway. Because UCN-01 has already proved to have potent anti-tumor activity in vivo, PDKI-Akt survival pathway is a new, attractive target for cancer chemotherapy.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Regulat, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Regulat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp	Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Abe S, 2001, JPN J CANCER RES, V92, P537, DOI 10.1111/j.1349-7006.2001.tb01127.x; AKINAGA S, 1991, CANCER RES, V51, P4888; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Ballif BA, 2001, J BIOL CHEM, V276, P12466, DOI 10.1074/jbc.M009939200; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Danley DE, 1996, J IMMUNOL, V157, P500; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; FUJITA N, 2002, IN PRESS J BIOL CHEM; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kurata N, 1999, CANCER CHEMOTH PHARM, V44, P12, DOI 10.1007/s002800050939; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nakashio A, 2000, CANCER RES, V60, P5303; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sugiyama K, 1999, CANCER RES, V59, P4406; TAKAHASHI I, 1989, J ANTIBIOT, V42, P571, DOI 10.7164/antibiotics.42.571; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	45	199	208	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1727	1738		10.1038/sj.onc.1205225	http://dx.doi.org/10.1038/sj.onc.1205225			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896604				2022-12-28	WOS:000174214200011
J	Kuschak, TI; Kuschak, BC; Taylor, CL; Wright, JA; Wiener, F; Mai, S				Kuschak, TI; Kuschak, BC; Taylor, CL; Wright, JA; Wiener, F; Mai, S			c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene	ONCOGENE			English	Article						c-Myc; genomic instability; amplification; DNA replication; ribonucleotide reductase R2	SYRIAN-HAMSTER CELLS; DIHYDROFOLATE-REDUCTASE; GENOMIC INSTABILITY; METHOTREXATE RESISTANCE; DNA-REPLICATION; CAD GENES; AMPLIFICATION; MOUSE; OVEREXPRESSION; TUMORIGENESIS	The mechanisms through which the oncoprotein c-Myc initiates locus-specific gene amplification are not understood. When analysing the initiation mechanism of c-Myc-dependent amplification of the mouse ribonucleotide reductase R2 (R2) gene, we observe c-Myc-dependent initiation of illegitimate DNA replication of the R2 gene. We demonstrate multiple simultaneous c-Myc-induced R2 replication forks, whereas R2 normally replicates with a single fork. In contrast, cyclin C replicates with only a single replication fork irrespective of c-Myc deregulation. In addition to de novo replication forks, c-Myc also initiates bi-allelic replication of R2, abrogating its normal mono-allelic replication pattern, Moreover, several chromosomal regions also display c-Myc-induced illegitimate replication profiles. Thus, c-Myc can act as an illegitimate replication-licensing factor that promotes de novo replication initiation and illegitimate replication timing that adversely impacts upon genomic stability.	Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag & CancerCare Manitoba, Dept Microbiol, Winnipeg, MB R3E 0V9, Canada; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	CancerCare Manitoba Foundation; University of Manitoba; Karolinska Institutet	Mai, S (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag & CancerCare Manitoba, Dept Microbiol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201				BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; Butler DK, 1996, CELL, V87, P1115, DOI 10.1016/S0092-8674(00)81805-X; CARROLL SM, 1988, MOL CELL BIOL, V8, P1525, DOI 10.1128/MCB.8.4.1525; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DENIS N, 1991, ONCOGENE, V6, P1453; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gandarillas A, 2000, ONCOGENE, V19, P3278, DOI 10.1038/sj.onc.1203630; HAMLIN JL, 1991, PROG NUCLEIC ACID RE, V41, P203; HAMLIN JL, 1990, BIOCHIM BIOPHYS ACTA, V1087, P107, DOI 10.1016/0167-4781(90)90195-8; HENRIKSSON M, 1988, CURR TOP MICROBIOL, V141, P202; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; KHAN F, 1994, GENOMICS, V21, P128, DOI 10.1006/geno.1994.1234; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Kuschak TI, 1999, GENE, V238, P351, DOI 10.1016/S0378-1119(99)00341-8; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li HM, 1996, GENOMICS, V32, P253, DOI 10.1006/geno.1996.0112; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; Mai S, 1996, ONCOGENE, V12, P277; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MAI S, 1994, CYCLIN D2 TARGET C M, P53; Mai Sabine, 1999, Neoplasia (New York), V1, P241, DOI 10.1038/sj.neo.7900030; MEINKOTH J, 1987, MOL CELL BIOL, V7, P1415, DOI 10.1128/MCB.7.4.1415; MORRIS T, 1993, P NATL ACAD SCI USA, V90, P1392, DOI 10.1073/pnas.90.4.1392; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; RUIZ JC, 1988, MOL CELL BIOL, V8, P4302, DOI 10.1128/MCB.8.10.4302; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; Simon I, 1999, NATURE, V401, P929, DOI 10.1038/44866; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; SPRADLING AC, 1981, CELL, V27, P193, DOI 10.1016/0092-8674(81)90373-1; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; TIsty T.D., 1989, P NATL ACAD SCI USA, V86, P9441; WAHL GM, 1979, J BIOL CHEM, V254, P8679; Wang ST, 1998, MOL CELL BIOL, V18, P39, DOI 10.1128/MCB.18.1.39; Wells J, 1996, MOL CELL BIOL, V16, P634; WIENER F, 2000, TECHNICAL TIPS ONLIN; STATSOFT ELECT STAT	49	29	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					909	920		10.1038/sj.onc.1205145	http://dx.doi.org/10.1038/sj.onc.1205145			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840336				2022-12-28	WOS:000173427100006
J	Itano, O; Ueda, M; Kikuchi, K; Hashimoto, O; Hayatsu, S; Kawaguchi, M; Seki, H; Aiura, K; Kitajima, M				Itano, O; Ueda, M; Kikuchi, K; Hashimoto, O; Hayatsu, S; Kawaguchi, M; Seki, H; Aiura, K; Kitajima, M			Correlation of postoperative recurrence in hepatocellular carcinoma with demethylation of repetitive sequences	ONCOGENE			English	Article						demethylation; repetitive sequence; hepatocellular carcinoma; postoperative recurrence; restriction landmark genomic scanning	GLOBAL DNA HYPOMETHYLATION; PROGNOSTIC FACTORS; METHYLATION; LIVER; EUKARYOTES; EXPRESSION; ONCOGENES	Restriction landmark genomic scanning (RLGS) was utilized to identify novel genomic alterations in hepatocellular carcinoma (HCC). Thirty-one HCC samples were examined by RLGS. Two high intensity spots were common to several RLGS profiles of different HCCs. Nucleotide sequencing and homology search analysis showed that these spots represented repetitive sequences, Human tandem repeat sequence (Genbank, L09552) and centromeric NotI cluster (Genbank, Y10752). These intensified signals were attributable to the occurrence of demethylated areas in the recognition sequence of the NotI site of the corresponding fragments. The intensity of these spots in the RLGS profile reflects their degree of demethylation, which was significantly correlated with postoperative recurrence, even in patients regarded as belonging to the good prognosis group by conventional prognostic factors. Multivariate analysis showed that the intensities of the two spots retained independent prognostic value. This is a new type of predictive factor for HCC based on epigenetic changes in hepatocarcinogenesis, and in the future it is expected to be of great value in making preoperative diagnosis and selecting postoperative therapy.	Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608582, Japan; Tokyo Denryoku Hosp, Dept Surg, Shinjuku Ku, Tokyo 1600016, Japan	Keio University	Ueda, M (corresponding author), Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.							Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; ARII S, 1992, CANCER, V69, P913, DOI 10.1002/1097-0142(19920215)69:4<913::AID-CNCR2820690413>3.0.CO;2-T; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender J, 1998, TRENDS BIOCHEM SCI, V23, P252, DOI 10.1016/S0968-0004(98)01225-0; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Cravo M, 1996, GUT, V39, P434, DOI 10.1136/gut.39.3.434; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HIMENO Y, 1988, LIVER, V8, P208; HSU HC, 1988, CANCER, V61, P2095, DOI 10.1002/1097-0142(19880515)61:10<2095::AID-CNCR2820611027>3.0.CO;2-H; Itano O, 2000, ONCOGENE, V19, P1676, DOI 10.1038/sj.onc.1203459; KIM YI, 1994, CANCER, V74, P893, DOI 10.1002/1097-0142(19940801)74:3<893::AID-CNCR2820740316>3.0.CO;2-B; Kubo S, 1998, JPN J CANCER RES, V89, P419, DOI 10.1111/j.1349-7006.1998.tb00580.x; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Lise M, 1998, CANCER, V82, P1028, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1028::AID-CNCR4>3.0.CO;2-A; *LIV CANC STUD GRO, 1997, CLASS PRIM LIV CANC, P1; MIWA W, 1995, ELECTROPHORESIS, V16, P227, DOI 10.1002/elps.1150160138; Nagai H, 1999, DNA Res, V6, P219, DOI 10.1093/dnares/6.4.219; Nagai H, 1999, GENE, V237, P15, DOI 10.1016/S0378-1119(99)00322-4; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; OHSUMI T, 1995, ELECTROPHORESIS, V16, P203, DOI 10.1002/elps.1150160135; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753; Shiraishi M, 1999, BIOL CHEM, V380, P81, DOI 10.1515/BC.1999.010; SIRABE K, 1991, HEPATOLOGY, V14, P913; Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.3.CO;2-K; TEUBNER B, 1994, EXP CELL RES, V2102, P192; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; ZHANG XK, 1987, BIOCHEM BIOPH RES CO, V142, P932, DOI 10.1016/0006-291X(87)91503-8; ZRIHANLICHT S, 1995, INT J CANCER, P245	30	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					789	797		10.1038/sj.onc.1205124	http://dx.doi.org/10.1038/sj.onc.1205124			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850807				2022-12-28	WOS:000173427000010
J	Brennan, PJ; Kumagai, T; Berezov, A; Murali, R; Greene, MI				Brennan, PJ; Kumagai, T; Berezov, A; Murali, R; Greene, MI			HER2/Neu: mechanisms of dimerization/oligomerization (vol 19, pg 6093, 2000)	ONCOGENE			English	Correction														Murali, Ramachandran/0000-0002-8384-2793				Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967	1	19	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					328	328		10.1038/sj/onc/1205119	http://dx.doi.org/10.1038/sj/onc/1205119			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11840330	Bronze			2022-12-28	WOS:000173026200017
J	Wu, GS; Ding, ZH				Wu, GS; Ding, ZH			Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line	ONCOGENE			English	Article						p53; chemosensitivity; apoptosis; caspases; DN-caspase 9; ovarian cancer cells	IN-VIVO; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; P53-INDUCED APOPTOSIS; CYTOCHROME-C; P53; GENE; DEATH; BCL-2; EXPRESSION	The p53 gene suppresses tumor cell growth by inducing cell cycle arrest or apoptosis. Loss of its apoptosis activity has been implicated not only in tumor development but also in chemoresistance. We previously reported that targeting p53 for degradation by the human HPV E6 gene in the ovarian cancer cell line PA1 leads to an increase in the chemoresistant phenotype. Here we investigate the relationship between loss of p53-dependent caspase activation and chemosensitivity. In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation. Importantly, we showed that loss of caspase activation in PA1-E6 cells correlates with increased cell survival. Moreover, PA1 cells overexpressing a dominant negative caspase 9 were found to have decreased caspase-dependent apoptosis, as compared with vector control cells. Furthermore, these dominant negative caspase 9 expressing cells were resistant to chemotherapeutic agent-induced killing. Our results suggest that caspase 9 may be an important target for anticancer drug development. Thus, identifying novel compounds that can activate caspase 9 may be a strategy for overcoming a defect in the p53 apoptosis pathway.	Wayne State Univ, Sch Med, Karmanos Canc Inst, Dev Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Wu, GS (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dev Therapeut Program, Room E216,Prentis Bldg,110 E Warren, Detroit, MI 48201 USA.	wug@karmanos.org						Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Attardi LD, 2000, GENE DEV, V14, P704; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; FAN SJ, 1995, CANCER RES, V55, P1649; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Perkins CL, 2000, CANCER RES, V60, P1645; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Velculescu VE, 1996, CLIN CHEM, V42, P858; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	49	74	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					1	8		10.1038/sj.onc.1205020	http://dx.doi.org/10.1038/sj.onc.1205020			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791171				2022-12-28	WOS:000172887800001
J	Schwarze, SR; Shi, Y; Fu, VX; Watson, PA; Jarrard, DF				Schwarze, SR; Shi, Y; Fu, VX; Watson, PA; Jarrard, DF			Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells	ONCOGENE			English	Article						cyclin-dependent kinase; p57; senescence; prostate; epithelial	CELLULAR SENESCENCE; TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; REPLICATIVE SENESCENCE; P57(KIP2); PROLIFERATION; EXPRESSION; CANCER; E7; IMMORTALIZATION	Cellular senescence has been proposed to be an in vitro and in vivo block that cells must overcome in order to immortalize and become tumorigenic. To characterize these pathways, we focused on changes in the cyclin-dependent kinase inhibitors and their binding partners that underlie the cell cycle arrest at senescence. As a model, we utilized normal human prostate epithelial cell (HPEC) and human uroepithelial cell (HUC) cultures. After 30-40 population doublings cells became growth-arrested in G0/1 with a threefold decrease in Cdk2-associated activity, a point defined as pre-senescence. Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta -galactosidase (SA-beta -gal). Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures. The induced expression of p57, similar to p16, produces a senescent-like phenotype. pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types. We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence. Analysis of p53, p21(CIP1), P15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells. These results indicate: (i) the existence of a subset of growth inhibiting genes elevated at the onset of the senescence, (ii) a distinct class of genes involved in the maintenance of senescence, and (iii) the frequent inactivation of these pathways during immortalization.	Univ Wisconsin, Ctr Comprehens Canc, Dept Surg, Madison, WI 53972 USA; Univ Wisconsin, Sch Med, Madison, WI 53972 USA; Univ Wisconsin, Ctr Comprehens Canc, Dept Oncol, Madison, WI 53972 USA; Univ Wisconsin, Ctr Comprehens Canc, Dept Environm Toxicol Ctr, Madison, WI 53972 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jarrard, DF (corresponding author), Univ Wisconsin, Ctr Comprehens Canc, Dept Surg, Madison, WI 53972 USA.				NCI NIH HHS [CA76184-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA076184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bright RK, 1997, CANCER RES, V57, P995; Burkhart BA, 1999, EXP CELL RES, V247, P168, DOI 10.1006/excr.1998.4345; Campisi J, 2000, IN VIVO, V14, P183; Chang BD, 1999, CANCER RES, V59, P3761; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Choi J, 2000, UROLOGY, V56, P160, DOI 10.1016/S0090-4295(00)00538-0; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dyer MA, 2000, DEVELOPMENT, V127, P3593; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; Fanton CP, 2001, J BIOL CHEM, V276, P18871, DOI 10.1074/jbc.M011514200; Fink JR, 2001, EXP HEMATOL, V29, P490, DOI 10.1016/S0301-472X(01)00619-1; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herman JG, 1996, CANCER RES, V56, P722; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jarrard DF, 1999, CANCER RES, V59, P2957; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nagahama H, 2001, ANAT EMBRYOL, V203, P77, DOI 10.1007/s004290000146; Nijjar T, 1999, CANCER RES, V59, P5112; Oya M, 2000, BRIT J CANCER, V83, P626, DOI 10.1054/bjoc.2000.1298; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Ran QT, 2000, EXP GERONTOL, V35, P7, DOI 10.1016/S0531-5565(99)00080-7; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; REZNIKOFF CA, 1987, J CELL PHYSIOL, V131, P285, DOI 10.1002/jcp.1041310302; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Reznikoff CA, 1996, CANCER RES, V56, P2886; REZNIKOFF CA, 1983, IN VITRO CELL DEV B, V19, P326; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sandhu C, 2000, CANCER RES, V60, P2616; Sarkar S, 2000, CANCER RES, V60, P3862; SASAKI M, 1994, CANCER RES, V54, P6090; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; Taniguchi T, 1997, ONCOGENE, V14, P1201, DOI 10.1038/sj.onc.1200934; Tsugu A, 2000, AM J PATHOL, V157, P919, DOI 10.1016/S0002-9440(10)64605-6; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	57	87	90	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8184	8192		10.1038/sj.onc.1205049	http://dx.doi.org/10.1038/sj.onc.1205049			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781834				2022-12-28	WOS:000172507800003
J	Gallimore, PH; Turnell, AS				Gallimore, PH; Turnell, AS			Adenovirus E1A: remodelling the host cell, a life or death experience	ONCOGENE			English	Review						adenovirus; E1A; transformation; transcription; tumour suppressors	EARLY REGION 1A; NATURAL-KILLER-CELLS; HIGHLY ONCOGENIC ADENOVIRUS-12; RETINOBLASTOMA GENE-PRODUCT; TRANSFORMED RAT-CELLS; LARGE TUMOR-ANTIGEN; C-TERMINAL REGION; CLASS-I ENHANCER; NF-KAPPA-B; HISTONE DEACETYLASE		Univ Birmingham, Sch Med, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Gallimore, PH (corresponding author), Univ Birmingham, Sch Med, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	P.H.Gallimore@bham.ac.uk; A.S.Turnell@bham.ac.uk						Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ALLISON AC, 1967, NATURE, V215, P185, DOI 10.1038/215185a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; BARBEAU D, 1994, ONCOGENE, V9, P359; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BERNARDS R, 1983, VIROLOGY, V127, P45, DOI 10.1016/0042-6822(83)90369-0; BOS JL, 1983, VIROLOGY, V131, P30; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREIDING DE, 1988, VIROLOGY, V164, P390, DOI 10.1016/0042-6822(88)90552-1; BROWN DT, 1975, J VIROL, V16, P366, DOI 10.1128/JVI.16.2.366-387.1975; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; BYRD PJ, 1988, VIROLOGY, V163, P155, DOI 10.1016/0042-6822(88)90242-5; BYRD PJ, 1988, ONCOGENE, V2, P477; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHATTERJEE PK, 1986, EMBO J, V5, P1633, DOI 10.1002/j.1460-2075.1986.tb04406.x; Chatterjee-Kishore M, 2000, J BIOL CHEM, V275, P20406, DOI 10.1074/jbc.M001861200; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERY CV, 1985, J GEN VIROL, V66, P2671, DOI 10.1099/0022-1317-66-12-2671; DIJKEMA R, 1982, GENE, V18, P143, DOI 10.1016/0378-1119(82)90112-3; DOUGLAS JL, 1995, J VIROL, V69, P8061, DOI 10.1128/JVI.69.12.8061-8065.1995; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; DUMONT DJ, 1989, J VIROL, V63, P987, DOI 10.1128/JVI.63.2.987-991.1989; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fax P, 2001, VIROLOGY, V285, P30, DOI 10.1006/viro.2001.0926; Fax P, 2000, J BIOL CHEM, V275, P40554, DOI 10.1074/jbc.M004626200; Fax P, 2000, J BIOL CHEM, V275, P8911, DOI 10.1074/jbc.275.12.8911; FLINT SJ, 1975, J MOL BIOL, V96, P47, DOI 10.1016/0022-2836(75)90181-3; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; FREEMAN AE, 1967, P NATL ACAD SCI USA, V58, P1205, DOI 10.1073/pnas.58.3.1205; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; FUCHS M, 2001, IN PRESS CELL; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; FUJINAGA K, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P375; FUJINAGA K, 1979, COLD SPRING HARB SYM, V44, P383; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; GALLIMORE PH, 1982, VIROLOGY, V120, P146, DOI 10.1016/0042-6822(82)90013-7; GALLIMORE PH, 1977, CELL, V10, P669, DOI 10.1016/0092-8674(77)90100-3; GALLIMORE PH, 1972, J GEN VIROL, V16, P99, DOI 10.1099/0022-1317-16-1-99; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GALLIMORE PH, 1985, CANCER RES, V45, P2670; Gallimore PH, 1984, VIRUSES CANCER, P125; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; GIRARDI AJ, 1964, P SOC EXP BIOL MED, V115, P1141, DOI 10.3181/00379727-115-29138; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRAHAM FL, 1978, VIROLOGY, V86, P10, DOI 10.1016/0042-6822(78)90003-X; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1974, NATURE, V251, P687, DOI 10.1038/251687a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GRAND RJA, 2001, VIRUSES CELL TRANSFO, P43; GROSS L, 1996, ONCOGENIC VIRUSES, P784; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; HALBERT DN, 1979, J VIROL, V31, P621, DOI 10.1128/JVI.31.3.621-629.1979; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARTER ML, 1978, J VIROL, V26, P736, DOI 10.1128/JVI.26.3.736-749.1978; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUEBNER RJ, 1962, P NATL ACAD SCI USA, V48, P2051, DOI 10.1073/pnas.48.12.2051; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; JELINEK T, 1994, J VIROL, V68, P888, DOI 10.1128/JVI.68.2.888-896.1994; JOCHEMSEN AG, 1986, J VIROL, V59, P684, DOI 10.1128/JVI.59.3.684-691.1986; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; JONES N, 1978, CELL, V13, P181, DOI 10.1016/0092-8674(78)90148-4; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; KIMELMAN D, 1986, MOL CELL BIOL, V6, P1487, DOI 10.1128/MCB.6.5.1487; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; KITCHINGMAN GR, 1977, P NATL ACAD SCI USA, V74, P4392, DOI 10.1073/pnas.74.10.4392; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Krantz CK, 1996, VIROLOGY, V217, P23, DOI 10.1006/viro.1996.0089; Kushner DB, 1996, ONCOGENE, V12, P143; Kushner DB, 1999, MOL CELL BIOL, V19, P2169; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Lei M, 2001, J CELL SCI, V114, P1447; LEWIS JB, 1976, CELL, V7, P141, DOI 10.1016/0092-8674(76)90264-6; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; MATSUMOTO K, 1995, J BIOL CHEM, V270, P9645, DOI 10.1074/jbc.270.16.9645; MCBRIDE WD, 1964, P SOC EXP BIOL MED, V115, P870, DOI 10.3181/00379727-115-29060; Melhuish TA, 2000, J BIOL CHEM, V275, P39762, DOI 10.1074/jbc.C000416200; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Molloy DP, 1999, J BIOL CHEM, V274, P3503, DOI 10.1074/jbc.274.6.3503; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Mymryk JS, 1997, BIOCHEM CELL BIOL, V75, P95, DOI 10.1139/bcb-75-2-95; Nemunaitis J, 2001, GENE THER, V8, P746, DOI 10.1038/sj.gt.3301424; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; PEREIRA DS, 1995, VIROLOGY, V211, P268, DOI 10.1006/viro.1995.1400; PEREIRA MS, 1965, LANCET, V1, P21; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; Pestell RG, 1996, CELL GROWTH DIFFER, V7, P1337; PETTERSSON U, 1973, J MOL BIOL, V73, P125, DOI 10.1016/0022-2836(73)90164-2; PHILPOTT N, 2001, VIRUSES CELL TRANSFO, P413; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Proffitt JA, 1997, FEBS LETT, V400, P141, DOI 10.1016/S0014-5793(96)01375-0; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RASKA K, 1982, VIROLOGY, V123, P8, DOI 10.1016/0042-6822(82)90290-2; ROTEMYEHUDAR R, 1994, J EXP MED, V180, P477, DOI 10.1084/jem.180.2.477; ROWE DT, 1983, VIROLOGY, V129, P456, DOI 10.1016/0042-6822(83)90183-6; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSSELL WC, 1971, J GEN VIROL, V11, P35, DOI 10.1099/0022-1317-11-1-35; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHARP PA, 1974, COLD SPRING HARB SYM, V39, P457, DOI 10.1101/SQB.1974.039.01.058; SHENK T, 1991, ADV CANCER RES, V57, P47; SHENK T, 1996, FIELDS VIROLOGY, P2111; Smirnov DA, 2001, VIROLOGY, V284, P13, DOI 10.1006/viro.2001.0913; Smirnov DA, 2000, VIROLOGY, V268, P319, DOI 10.1006/viro.1999.0181; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; SUGISAKI H, 1980, CELL, V20, P777, DOI 10.1016/0092-8674(80)90324-4; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; TELLING GC, 1994, J VIROL, V68, P877, DOI 10.1128/JVI.68.2.877-887.1994; TREMBLAY ML, 1988, J BIOL CHEM, V263, P6375; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; TRENTIN JJ, 1968, P SOC EXP BIOL MED, V127, P683, DOI 10.3181/00379727-127-32773; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; URBANELLI D, 1989, VIROLOGY, V173, P607, DOI 10.1016/0042-6822(89)90572-2; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VANDEREB AJ, 1979, COLD SPRING HARB SYM, V44, P383, DOI 10.1101/SQB.1980.044.01.043; VANORMONDT H, 1980, GENE, V11, P299, DOI 10.1016/0378-1119(80)90070-0; VANORMONDT H, 1978, GENE, V4, P309, DOI 10.1016/0378-1119(78)90048-3; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Whalen SG, 1996, J VIROL, V70, P5373, DOI 10.1128/JVI.70.8.5373-5383.1996; White E, 1998, SEMIN VIROL, V8, P505, DOI 10.1006/smvy.1998.0155; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS J, 1995, CURR TOP MICROBIOL, V199, P149; YABE Y, 1962, P SOC EXP BIOL MED, V111, P343, DOI 10.3181/00379727-111-27786; YABE Y, 1964, SCIENCE, V143, P46, DOI 10.1126/science.143.3601.46; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YOHN DS, 1965, J NATL CANCER I, V35, P617; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhang ZY, 2001, MOL BIOL CELL, V12, P699, DOI 10.1091/mbc.12.3.699	181	115	119	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7824	7835		10.1038/sj.onc.1204913	http://dx.doi.org/10.1038/sj.onc.1204913			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753665				2022-12-28	WOS:000172336500002
J	Kawamata, S; Du, CC; Li, KJ; Lavau, C				Kawamata, S; Du, CC; Li, KJ; Lavau, C			Overexpression of the Notch target genes Hes in vivo induces lymphoid and myeloid alterations	ONCOGENE			English	Article						Hes; Notch; B cells; hematopoiesis	DEVELOPING NERVOUS-SYSTEM; CELL-DEVELOPMENT; MOLECULAR CHARACTERIZATION; CHROMOSOMAL LOCUS; DROSOPHILA-HAIRY; LINEAGE DECISION; PRECURSOR CELLS; BONE-MARROW; DIFFERENTIATION; EXPRESSION	To examine the effects of Notch signaling on hematopoiesis, we transplanted mice with progenitors transduced with a constitutively active form of Notch1 (Notch1IC) or the Notch1 target genes Hes. Notch1IC-transduced cells induce T cell tumors and cannot generate B lymphocytes in vivo. Hes-transplanted mice remained healthy but cells transduced with Hes1 or Hes5 were partially impaired in their ability to differentiate into B cells. Both Hes1 and Hes5 were upregulated in the BM of Notch1IC mice and their ability to interfere with the transcriptional activity of E2A in a reporter assay was comparable to that of Notch1IC. This suggests that the inhibition of B cell development in the Notch1IC-transduced cells could be mediated by the interference of HES1/HES5 proteins with E2A. Hest1-, Hes5- and Notch1IC-transduced bone marrow cells cultured ex vivo in a colony forming assay in the presence of cytokines that promote myeloid differentiation remained very immature, indicating that the myeloid potential of these bone marrow cells was altered. Thymocytes overexpressing Hes1, Hes5 or Notch1IC matured normally into CD4 and CD8 single positive cells in vivo. Altogether our data suggest that Notch1IC induces T cell tumors independently of Hes genes but that its interference with lymphoid B and myeloid maturation is partly mediated by Hes1 and Hes5.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; SyStemix Inc, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Novartis	Lavau, C (corresponding author), Hop St Louis, CNRS UPR 9051, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.		Lavau, Catherine/Q-2928-2019; Du, Changchun/AAW-6540-2020	kawamata, shin/0000-0001-5148-1949; Lavau, Catherine/0000-0003-4800-1320				AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HAWLEY RG, 1994, GENE THER, V1, P136; Hirata H, 2000, J BIOL CHEM, V275, P19083, DOI 10.1074/jbc.M001075200; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; Kim HK, 1998, MOL CELL BIOL, V18, P7166, DOI 10.1128/MCB.18.12.7166; Koch U, 2001, IMMUNITY, V15, P225, DOI 10.1016/S1074-7613(01)00189-3; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SCREPANTI I, 1989, J IMMUNOL, V142, P3378; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Wilson A, 2001, J EXP MED, V194, P1003, DOI 10.1084/jem.194.7.1003; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294	43	99	101	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3855	3863		10.1038/sj.onc.1205487	http://dx.doi.org/10.1038/sj.onc.1205487			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032823				2022-12-28	WOS:000175847200004
J	Pandey, A; Dan, I; Kristiansen, TZ; Watanabe, NM; Voldby, J; Kajikawa, E; Khosravi-Far, R; Blagoev, B; Mann, M				Pandey, A; Dan, I; Kristiansen, TZ; Watanabe, NM; Voldby, J; Kajikawa, E; Khosravi-Far, R; Blagoev, B; Mann, M			Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain	ONCOGENE			English	Article						p2l-activated kinase; Ste20; CDC42; JNK; brain	ACTIVATED PROTEIN-KINASE; FAMILY; CELLS; APOPTOSIS; ACTIN; DEATH; RAS	The p21-activated kinase (PAK) family of protein kinases has recently attracted considerable attention as an effector of Rho family of small G proteins and as an upstream regulator of MAPK signalling pathways during cellular events such as re-arrangement of the cytoskeleton and apoptosis. We have cloned a novel human PAK family kinase that has been designated as PAK5. PAK5 contains a CDC42/Rac1 interactive binding (CRIB) motif at the N-terminus and a Ste20-like kinase domain at the C-terminus. PAK5 is structurally most related to PAK4 and PAK6 to make up the PAK-II subfamily. We have shown that PAK5 preferentially binds to CDC42 in the presence of GTP and that CRIB motif is essential for this interaction. PAK5 is a functional protein kinase but unlike PAK-I family kinases (PAKI, 2, and 3), the kinase activity of PAK5 does not seem to require the binding of CDC42. Overexpression of PAK5 activates the JNK kinase pathway but not p38 or ERK pathways. PAK5 transcript is predominantly expressed in brain as revealed by Northern blot and in situ hybridization. The expression pattern of PAK5 is distinct from that of PAK4 and PAK6, suggesting a functional division among PAK-11 subfamily kinases based on differential tissue distribution.	Univ So Denmark, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark; Harvard Med Ctr, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; Nagoya Univ, Grad Sch Sci, Dept Biol Sci,ERATO, JST,Kusumi Membrane Organizer Project,Chikusa Ku, Nagoya, Aichi 4648602, Japan	University of Southern Denmark; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Japan Science & Technology Agency (JST); Nagoya University	Mann, M (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, Campusvej 55, DK-5230 Odense M, Denmark.		Pandey, Akhilesh/B-4127-2009; Dan, Ippeita/F-9179-2011; Khosravi-Far, Roya/C-3789-2008; Mann, Matthias/A-3454-2013	Pandey, Akhilesh/0000-0001-9943-6127; Dan, Ippeita/0000-0002-1779-9205; Mann, Matthias/0000-0003-1292-4799; Blagoev, Blagoy/0000-0002-3596-0066	NATIONAL CANCER INSTITUTE [K01CA075447] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75447] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Cau J, 2001, J CELL BIOL, V155, P1029, DOI 10.1083/jcb.200104123; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Dieffenbach C.W., 1995, PCR PRIMER LAB MANUA; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Peri S, 2001, TRENDS GENET, V17, P685, DOI 10.1016/S0168-9525(01)02493-3; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	23	96	109	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3939	3948		10.1038/sj.onc.1205478	http://dx.doi.org/10.1038/sj.onc.1205478			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032833				2022-12-28	WOS:000175847200014
J	Bangur, CS; Switzer, A; Fan, LQ; Marton, MJ; Meyer, MR; Wang, TT				Bangur, CS; Switzer, A; Fan, LQ; Marton, MJ; Meyer, MR; Wang, TT			Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis	ONCOGENE			English	Article						small cell lung carcinoma (SCLC); microarray; subtractive hybridization; real-time PCR; gene expression	TUMOR-TRANSFORMING GENE; NEUROENDOCRINE CARCINOMA; BRONCHIAL EPITHELIUM; CANCER; PROTEINS; TISSUE; COMBINATION; MULTIPLE; REGIONS; FAMILY	To identify genes that are differentially over-expressed in Small Cell Lung Carcinoma (SCLC) we have used a combination of suppression subtractive hybridization and cDNA microarray to analyse the expression profiles of 2400 cDNAs clones. Genes that are over-expressed in SCLC were identified using 32 pairs of fluorescence-labeled cDNA samples representing various lung tumors and normal tissues. This comprehensive approach has resulted in the identification of 209 genes that are differentially over-expressed in SCLC. Quantitative real-time PCR was used to further validate the expression of 43 genes in SCLC tumors and various normal tissues. Discussed in this report are nine genes, which showed the most promising SCLC tumor to normal tissue differential expression profiles, including seven known and two novel genes. The large number of differentially expressed genes identified from this analysis and the characterization of these genes will provide valuable information in better understanding the biology of SCLC and help us in developing these gene products as potential targets for diagnostic as well as therapeutic usage.	Corixa Corp, Tumor Antigen Discovery, Seattle, WA 98104 USA; Rosetta Inpharm, Washington, WA 98034 USA	Corixa	Bangur, CS (corresponding author), Corixa Corp, Tumor Antigen Discovery, 1124 Columbia St, Seattle, WA 98104 USA.	bangur@corixa.com						Anbazhagan R, 1999, CANCER RES, V59, P5119; Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FELD R, 2000, STAGING PROGNOSTIC F, P612; GIACCONE G, 1994, ANTICANCER RES, V14, P269; GINSBERG RJ, 1997, NONSMALL CELL LUNG C, P858; Girard L, 2000, CANCER RES, V60, P4894; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; GUINEE DG, 1994, AM J CLIN PATHOL, V102, P406, DOI 10.1093/ajcp/102.4.406; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Honnorat J, 1999, EUR J NEUROSCI, V11, P4226, DOI 10.1046/j.1460-9568.1999.00864.x; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; IHDE DC, 1997, SMALL CELL LUNG CARC, P911; JACKSONYORK GL, 1991, CANCER, V68, P374, DOI 10.1002/1097-0142(19910715)68:2<374::AID-CNCR2820680227>3.0.CO;2-2; KALEMKERIAN GP, 2000, GROWTH FACTORS, P181; KIM J, 1992, INT J CANCER, V52, P718, DOI 10.1002/ijc.2910520509; Kitahara O, 2001, CANCER RES, V61, P3544; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Nacht M, 1999, CANCER RES, V59, P5464; Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D; Ono K, 2000, CANCER RES, V60, P5007; OSBORNE MA, 1994, J CELL BIOL, V125, P853, DOI 10.1083/jcb.125.4.853; OUD PS, 1989, CANCER, V64, P1304, DOI 10.1002/1097-0142(19890915)64:6<1304::AID-CNCR2820640623>3.0.CO;2-K; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Puri R, 2001, CANCER LETT, V163, P131, DOI 10.1016/S0304-3835(00)00688-1; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.0.CO;2-0; Sgroi DC, 1999, CANCER RES, V59, P5656; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Tannoch VJ, 2000, ADV EXP MED BIOL, V465, P127; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Williams C L, 1997, Chest Surg Clin N Am, V7, P1; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 2000, CLIN CANCER RES, V6, P2604; Xia Y, 2000, CANCER RES, V60, P6303; Xu JC, 2000, CANCER RES, V60, P1677; YAMAGUCHI K, 1983, CANCER RES, V43, P3932; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517; Yu R, 2000, J BIOL CHEM, V275, P36502, DOI 10.1074/jbc.C000546200; Yu ZY, 2001, ANN NEUROL, V49, P146; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	51	58	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3814	3825		10.1038/sj.onc.1205480	http://dx.doi.org/10.1038/sj.onc.1205480			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032850				2022-12-28	WOS:000175676000017
J	Mori, T; Anazawa, Y; Iiizumi, M; Fukuda, S; Nakamura, Y; Arakawa, H				Mori, T; Anazawa, Y; Iiizumi, M; Fukuda, S; Nakamura, Y; Arakawa, H			Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53	ONCOGENE			English	Article						IRF5; p53; target gene	PROTEIN; EXPRESSION; APOPTOSIS; ELEMENT; CLONING; GROWTH; BINDS	Interferon regulatory factors (IRFs) regulate transcription of interferon genes through DNA sequence-specific binding to these targets. Using a differential display method for examining gene expression in p53-defective cells infected with adenovirus containing wild-type p53, we found that expression of interferon regulatory, factor 5 (IRF-5) mRNA was increased in the presence of exogenous p53. An electrophoretic mobility-shift assay showed that a potential p53 binding site (p53BS) detected in exon 2 of the IRF-5 gene could in fact bind to p53 protein. Moreover, a heterologous reporter assay revealed that the p53BS possessed p53-dependent transcriptional activity. Expression of IRF-5 was induced in p53+/+ cells (MCF7 and NHDF), but not in p53-/- cells (H1299) when DNA was damaged by gamma-irradiation, UV-radiation, or adriamycin treatment in a wild-type p53-dependent manner. These results suggest that IRF-5 is a novel p53-target, and that it might mediate the p53-dependent immune response.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Arakawa, H (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	harakawa@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Furuhata T, 1996, ONCOGENE, V13, P1965; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HARPER JW, 1993, CELL, V75, P805; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; MIYASHITA T, 1995, CELL, V80, P293; Ng CC, 1999, GENE CHROMOSOME CANC, V26, P329, DOI 10.1002/(SICI)1098-2264(199912)26:4<329::AID-GCC7>3.0.CO;2-C; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; Shiraishi K, 2000, CANCER RES, V60, P3722; Takei Y, 1998, GENE CHROMOSOME CANC, V23, P1; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Urano T, 1997, CANCER RES, V57, P3281	25	117	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2914	2918		10.1038/sj.onc.1205459	http://dx.doi.org/10.1038/sj.onc.1205459			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973653				2022-12-28	WOS:000175063700018
J	Jiang, YQ; Harlocker, SL; Molesh, DA; Dillon, DC; Stolk, JA; Houghton, RL; Repasky, EA; Badaro, R; Reed, SG; Xu, JC				Jiang, YQ; Harlocker, SL; Molesh, DA; Dillon, DC; Stolk, JA; Houghton, RL; Repasky, EA; Badaro, R; Reed, SG; Xu, JC			Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays	ONCOGENE			English	Article						breast cancer; genes; PCR-based cDNA subtraction; cDNA microarray; quantitative PCR	TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR; PROSTATE-CANCER; IDENTIFICATION; MAMMAGLOBIN; TISSUE; IMMUNOTHERAPY; LYMPHOCYTES; MUSCIMOL; KERATIN	Identifying novel and known genes that are differentially expressed in breast cancer has important implications in understanding the biology of breast tumorigenesis and developing new diagnostic and therapeutic agents. In this study we have combined two powerful technologies, PCR-based cDNA subtraction and cDNA microarray, as a high throughput methodology designed to identify cDNA clones that are breast tumor- and tissue-specific and are overexpressed in breast tumors. Approximately 2000 cDNA clones generated from the subtracted breast tumor library were arrayed on the microarray chips. The arrayed target cDNAs were then hybridized with 30 pairs of fluorescent-labeled cDNA probes generated from breast tumors and normal tissues to determine the tissue distribution and tumor specificity. cDNA clones showing overexpression in breast tumors by microarray were further analysed by DNA sequencing, GenBank and EST database searches, and quantitative real time PCR. We identified several known genes, including mammaglobin, cytokeratin 19, fibronectin, and hair-specific type 11 keratin, which have previously been shown to be overexpressed in breast tumors and may play an important rote in the malignance of breast. We also discovered B726P which appears to be an isoform of NY-BR-1, a breast tissue-specific gene. Two additional clones discovered, B709P and GABA(A) receptor pi subunit, were not previously described for their overexpression profile in breast tumors. Thus, combining PCR-based cDNA subtraction and cDNA microarray allowed for an efficient way to identify and validate genes with elevated mRNA expression levels in breast cancer that may potentially be involved in breast cancer progression. These differentially expressed genes may be of potential utility as therapeutic and diagnostic targets for breast cancer.	Corixa Corp, Seattle, WA 98104 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; Hosp Aristides Maltez, Salvador, BA, Brazil; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	Corixa; Roswell Park Cancer Institute; University of Washington; University of Washington Seattle	Jiang, YQ (corresponding author), Corixa Corp, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.	jiang@corixa.com			NATIONAL CANCER INSTITUTE [R43CA075794, R44CA075794] Funding Source: NIH RePORTER; NCI NIH HHS [CA75794] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMENTA F, 1988, PHARMACOL RES, V20, P863, DOI 10.1016/0031-6989(88)90003-3; Apostolopoulos V, 1996, IMMUNOL CELL BIOL, V74, P457, DOI 10.1038/icb.1996.76; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Bertin N, 1997, CANCER RES, V57, P396; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bowden PE, 1998, J INVEST DERMATOL, V110, P158, DOI 10.1046/j.1523-1747.1998.00097.x; CHEEVER MA, 1995, IMMUNOL REV, V145, P33, DOI 10.1111/j.1600-065X.1995.tb00076.x; Colpitts TL, 2001, BIOCHEMISTRY-US, V40, P11048, DOI 10.1021/bi010284f; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Disis ML, 1997, ADV CANCER RES, V71, P343, DOI 10.1016/S0065-230X(08)60103-7; ERDO SL, 1989, BRIT J PHARMACOL, V96, P313, DOI 10.1111/j.1476-5381.1989.tb11819.x; Fleming TP, 2000, ANN NY ACAD SCI, V923, P78, DOI 10.1111/j.1749-6632.2000.tb05521.x; Hadden JW, 1999, INT J IMMUNOPHARMACO, V21, P79, DOI 10.1016/S0192-0561(98)00077-0; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Hoch RV, 1999, INT J CANCER, V84, P122; Houghton RL, 2001, MOL DIAGN, V6, P79, DOI 10.2165/00066982-200106020-00003; Jager D, 2001, CANCER RES, V61, P2055; Jones KA, 1995, CANCER SURV, V25, P315; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; LORIDONROSA B, 1990, CANCER RES, V50, P1608; MAJEWSKA MD, 1991, J ENDOCRINOL, V131, P427, DOI 10.1677/joe.0.1310427; MCKENZIE IFC, 1990, CANCER CELL-MON REV, V2, P75; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; OZTURK M, 1992, BONE MARROW TRANSPL, V9, P164; Regnier CH, 1998, BRIT J CANCER, V78, P1640, DOI 10.1038/bjc.1998.736; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Turner BC, 1998, CANCER RES, V58, P5466; Walker RA, 1997, CANCER METAST REV, V16, P5, DOI 10.1023/A:1005740222307; Watson MA, 1999, CANCER RES, V59, P3028; Watson MA, 1996, CANCER RES, V56, P860; Xu JC, 2000, CANCER RES, V60, P1677	38	66	74	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2270	2282		10.1038/sj.onc.1205278	http://dx.doi.org/10.1038/sj.onc.1205278			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948410				2022-12-28	WOS:000174555300016
J	Yuan, LWC; Giordano, A				Yuan, LWC; Giordano, A			Acetyltransferase machinery conserved in p300/CBP-family proteins	ONCOGENE			English	Article						p300; CBP; PCAT; histone/protein acetyltransferase; protein domains; protein structure	MULTIPLE SEQUENCE ALIGNMENT; TRANSCRIPTIONAL COACTIVATOR; DROSOPHILA CBP; DNA-BINDING; P300; ACETYLATION; CBP/P300; ACTIVATION; CHROMATIN; GENE	CREB-binding protein (CBP) and p300 are highly, conserved and functionally related transcription coactivators and histone/protein acetyltransferases. They are, tumor suppressors, participate in a wide variety of physiological events, and serve as integrators among different signal transduction pathways. In this study, 11 distinct proteins that have a high degree of homology with the amino acid sequence of p300 have been identified in current protein databases. All of these, 11 proteins belong to either animal or plant multicellular organisms (higher eucaryotes). Conservation of p300/ CBP domains among these proteins was examined further by sequence alignment and pattern search. The domains of p300/CBP that are required for the HAT function, including PHD, putative CoA-binding, and ZZ domains, are conserved in all of these 11 proteins. This observation is consistent with the previous functional assays and indicates that they are a family of acetyltransferases, i.e. p300/CBP acetyltransferases (PCAT). TAZ domains (TAZ1 and/or TAZ2) of PCAT proteins may allow them to participate in transcription regulation by either directly recruiting transcription factors, acetylating them subsequently, or directing targeted acetylation of nucleosomal histones.	Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Jefferson University; Boston University	Giordano, A (corresponding author), Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.	agiordan@lac.jci.tju.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P589, DOI 10.1093/nar/29.3.589; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Giles RH, 1997, GENOMICS, V42, P96, DOI 10.1006/geno.1997.4699; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Radhakrishnan I, 1999, J MOL BIOL, V287, P859, DOI 10.1006/jmbi.1999.2658; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Yuan YP, 1998, BIOINFORMATICS, V14, P285, DOI 10.1093/bioinformatics/14.3.285; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	54	38	42	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2253	2260		10.1038/sj.onc.1205283	http://dx.doi.org/10.1038/sj.onc.1205283			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948408				2022-12-28	WOS:000174555300014
J	Teitz, T; Wei, T; Liu, D; Valentine, V; Valentine, M; Grenet, J; Lahti, JM; Kidd, VJ				Teitz, T; Wei, T; Liu, D; Valentine, V; Valentine, M; Grenet, J; Lahti, JM; Kidd, VJ			Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN	ONCOGENE			English	Article						tumor suppressors; apoptosis; caspases; neuroblastoma; MYCN; Apaf-1; cytochrome c	CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; BCL-2 FAMILY; P53-DEPENDENT APOPTOSIS; MEDIATED APOPTOSIS; ANTICANCER AGENTS; ALLELIC LOSS; ACTIVATION; MITOCHONDRIA; NECROSIS	Important roles have been suggested for caspase-8, caspase-9 and Apaf-1 in controlling tumor development and their sensitivity to chemotherapeutic agents. Methylation and deletion of Apaf-1 and CASP8 results in the loss of their expression in melanoma and neuroblastoma, respectively, while CASP9 localization to 1p36.1 suggests it is a good candidate tumor suppressor. The status of CASP9 and Apaf-1 expression in numerous neuroblastoma cell lines with/without amplified MYCN and chromosome 1p36 loss-of-heterozygosity (LOH) was therefore examined to test the hypothesis that one or both of these genes are tumor suppressors in neuroblastoma. Although CASP9 is included in the region encompassing 1p36 LOH in all neuroblastoma cell lines examined, the remaining CASP9 allele(s) express a functional caspase-9 enzyme. Apaf-1 is also expressed in all neuroblastoma tumor cell lines examined. Thus, the CASP9 or Apaf-1 genes do not appear to function as tumor suppressors in MYCN amplified neuroblastomas. However, similar to20% of the neuroblastoma cell lines with methylated CASP8 alleles are also highly resistant to staurosporine (STS)- and radiation-induced cell death, presumably because cytochrome c is not released from mitochondria. This suggests that a second, smaller subgroup of MYCN amplified neuroblastoma tumors exists with defect(s) in apoptotic signaling components upstream of caspase-9 and Apaf-l. Since no consistent differences in Bcl-2, BCI-x(L) or Bax expression were seen in the STS- and radiation-resistant neuroblastomas, it suggests that a unique mitochondrial signaling factor(s) is responsible for the defect in cytochrome c release in this sub-group of tumors.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	vincent.kidd@stjude.org			NATIONAL CANCER INSTITUTE [R01CA067938, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [5 PO1 CA21765, 5 R01 CA67938] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asselin E, 2001, CANCER RES, V61, P1862; Bala S, 2000, GENE CHROMOSOME CANC, V28, P258, DOI 10.1002/1098-2264(200007)28:3<258::AID-GCC3>3.0.CO;2-R; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eggert A, 2001, CANCER RES, V61, P1314; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Ferreira CG, 2000, CANCER RES, V60, P7133; Gastman BR, 2000, CANCER RES, V60, P6811; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LaBonne C, 1999, ANNU REV CELL DEV BI, V15, P81, DOI 10.1146/annurev.cellbio.15.1.81; Lacour S, 2001, CANCER RES, V61, P1645; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tweddle DA, 2001, CANCER RES, V61, P8; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	45	42	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1848	1858		10.1038/sj.onc.1205180	http://dx.doi.org/10.1038/sj.onc.1205180			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896617				2022-12-28	WOS:000174284500007
J	Chung, JY; Chavez, PRG; Russell, RM; Wang, XD				Chung, JY; Chavez, PRG; Russell, RM; Wang, XD			Retinoic acid inhibits hepatic Jun N-terminal kinase-dependent signaling pathway in ethanol-fed rats	ONCOGENE			English	Article						alcohol; hepatocyte proliferation and apoptosis; retinoids; mitogen-activated protein kinases	MITOGEN-ACTIVATED PROTEIN; C-JUN; CELL-PROLIFERATION; AP-1; PHOSPHORYLATION; METABOLISM; EXPRESSION; APOPTOSIS; GROWTH; TRANSDUCTION	Retinoic acid (RA) supplementation suppresses ethanol-enhanced hepatocyte hyperproliferation in rats; however, little is known about the mechanism(s). Here, we investigated whether RA affects the protein kinase signaling pathways in the liver tissues of rats fed with a high dose of ethanol for a prolonged period of time (6 months). Results show that there were greater levels of phosphorylated Jun N-terminal kinase (JNK) and phosphorylated c-Jun protein, but not total JNK protein, in livers of ethanol-fed rats vs those of controls. Moreover, ethanol feeding to rats increased the levels of phosphorylated mitogen-activated protein kinase kinase-4 (MKK-4) and decreased the levels of mitogen-activated kinase phosphatase-1 (MKP-1) in liver tissue. However, hepatic levels of phosphorylated-p38 protein and total-p38 protein were not altered by the ethanol treatment. In contrast, all-trans-RA supplementation at two doses in ethanol-fed rats greatly attenuated the ethanol-induced hepatic phosphorylation of MKK-4, phosphorylated-JNK and c-Jun proteins. The level of MKP-1 was increased in ethanol-fed rats supplemented with all-trans-RA. Further, ethanol-induced hepatocyte hyperproliferation, measured by immunostaining for proliferating cell nuclear antigen, were markedly decreased by all-trans-RA supplementation. Interestingly, hepatic apoptosis in the liver of ethanol-fed rats after 6 months of treatment decreased significantly. This decrease of hepatic apoptosis in ethanol-fed rats was prevented by all-trans-RA supplementation in a dose-dependent manner. The results from these studies indicate that restoration of RA homeostasis is critical for the regulation of JNK-dependent signaling pathway and apoptosis in the liver of ethanol-fed rats.	Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr, Gastrointestinal Nutr Lab,Mol Carcinogenesis Sect, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA)	Wang, XD (corresponding author), Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr, Gastrointestinal Nutr Lab,Mol Carcinogenesis Sect, 711 Washington St, Boston, MA 02111 USA.	XWang@hnrc.tufts.edu			NCI NIH HHS [R01CA49195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BARONI GS, 1994, J HEPATOL, V20, P508, DOI 10.1016/S0168-8278(05)80498-2; Boylan JM, 1996, CELL GROWTH DIFFER, V7, P1261; CASINI A, 1991, HEPATOLOGY, V13, P758, DOI 10.1016/0270-9139(91)92576-T; CASINI A, 1994, ALCOHOL ALCOHOLISM, V29, P303; Cebers G, 1996, NEUROREPORT, V8, P217, DOI 10.1097/00001756-199612200-00044; Chen JP, 1998, BIOCHEM J, V334, P669, DOI 10.1042/bj3340669; CHEN N, 2001, CANCER RES, V15, P3908; Chung JG, 2001, CARCINOGENESIS, V22, P1213, DOI 10.1093/carcin/22.8.1213; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIEHL AM, 1988, HEPATOLOGY, V8, P237, DOI 10.1002/hep.1840080208; Ding WQ, 1996, NEUROREPORT, V7, P2191, DOI 10.1097/00001756-199609020-00027; Finch A, 2001, BIOCHEM J, V353, P275, DOI 10.1042/0264-6021:3530275; Fisher GJ, 1999, PHOTOCHEM PHOTOBIOL, V69, P154, DOI 10.1111/j.1751-1097.1999.tb03268.x; Fortunato F, 2000, PANCREAS, V21, P174, DOI 10.1097/00006676-200008000-00011; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gouillon Z.-Q., 1999, Frontiers in Bioscience, V4, pa16, DOI 10.2741/gouillon; Halsted CH, 1996, HEPATOLOGY, V23, P497, DOI 10.1002/hep.510230314; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; Jarvis WD, 1997, FEBS LETT, V412, P9, DOI 10.1016/S0014-5793(97)00705-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1993, BIOCHEM PHARMACOL, V45, P675, DOI 10.1016/0006-2952(93)90142-J; Kurie Jonathan M., 1999, Current Opinion in Oncology, V11, P497, DOI 10.1097/00001622-199911000-00011; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Liu C, 2001, GASTROENTEROLOGY, V120, P179, DOI 10.1053/gast.2001.20877; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Pandey SC, 1996, ALCOHOL CLIN EXP RES, V20, pA67, DOI 10.1111/j.1530-0277.1996.tb01749.x; Pfahl M, 1996, ANNU REV NUTR, V16, P257, DOI 10.1146/annurev.nu.16.070196.001353; Radominska-Pandya A, 2000, J BIOL CHEM, V275, P22324, DOI 10.1074/jbc.M907722199; RESNICOFF M, 1993, J BIOL CHEM, V268, P21777; Seitz HK, 2001, ALCOHOL CLIN EXP RES, V25, p137S, DOI 10.1097/00000374-200105051-00024; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; TAKADA A, 1986, HEPATOLOGY, V6, P65, DOI 10.1002/hep.1840060113; THURSTON AW, 1992, BIOCHEM BIOPH RES CO, V185, P1062, DOI 10.1016/0006-291X(92)91734-8; Uto H, 2001, CANCER RES, V61, P4779; WANDS JR, 1979, GASTROENTEROLOGY, V77, P528; Wang XD, 1998, HEPATOLOGY, V28, P744, DOI 10.1002/hep.510280321; Wang XD, 2001, ALCOHOL IN HEALTH AND DISEASE, P427; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	46	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1539	1547		10.1038/sj.onc.1205023	http://dx.doi.org/10.1038/sj.onc.1205023			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896582				2022-12-28	WOS:000173956800009
J	Mancini, A; Koch, A; Wilms, R; Tamura, T				Mancini, A; Koch, A; Wilms, R; Tamura, T			The SH2-containing inositol 5-phosphatase (SHIP)-1 is implicated in the control of cell-cell junction and induces dissociation and dispersion of MDCK cells	ONCOGENE			English	Article						SHIP-1; cell-cell-junctions; cell dispersion; c-Met tyrosine kinase; actin rearrangement	HEPATOCYTE GROWTH-FACTOR; MULTIFUNCTIONAL DOCKING SITE; SCATTER FACTOR; FACTOR-RECEPTOR; C-MET; IDENTIFICATION; PHOSPHATASE; 3-KINASE; SHIP; INDUCTION	Hepatocyte growth factor (HGF) induces the breakdown of cell junction and the dispersion of colonies of epithelial cells, providing a model system for the investigation of the molecular mechanisms of one of the important aspects of tumorogenesis. We have previously reported that the SH2-domain-containing inositol 5' phosphatase (SHIP)-1 binds to c-Met, and potentiated HGF-mediated branching tubulogenesis. In this study, we describe the establishment of MDCK cell lines which express MycHis-tagged SHIP-1 at different levels. Expression of SHIP-1 in MDCK cells at a high level resulted in cell morphology characteristic of an epithelial-mesenchymal like transition; cells lost cortical actin, developed actin stress fibers and gained spontaneous motility without treatment of HGF. When the level of MycHis-tagged SHIP-expression was relatively low, transfectants partially lost cortical actin and phalloidin stained puncta appeared at cell-cell junctions even in the absence of HGF. The treatment of MAP kinase inhibitor, PD98059, did not influence SHIP-1 mediated alteration of adherens-junction of MDCK cells, while, phosphatidylinositol 3 (PI 3)-kinase inhibitor, LY294002, drastically reduced SHIP-1 mediated phenotype. Furthermore, expression of a mutant SHIP-l lacking catalytic activity in MDCK cells did not alter the cortical actin distribution and HGF-mediated MAP and Akt kinase-phosphorylation, but suppressed HGF induced cell dispersion, suggesting that phosphatase activity is important for cytoskeleton rearrangement and cell dispersion.	Med Hochschule Hannover, Inst Biochem, D-30623 Hannover, Germany	Hannover Medical School	Tamura, T (corresponding author), Med Hochschule Hannover, Inst Biochem, OE 4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	Tamura.Teruko@MH-Hannover.de						Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PELICCI G, 1995, ONCOGENE, V10, P1631; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Rohrschneider LR, 2000, GENE DEV, V14, P505; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; STOKER M, 1985, J CELL SCI, V77, P209; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	30	11	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1477	1484		10.1038/sj.onc.1205224	http://dx.doi.org/10.1038/sj.onc.1205224			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896575				2022-12-28	WOS:000173956800002
J	Yin, XL; Pang, JCS; Ng, HK				Yin, XL; Pang, JCS; Ng, HK			Identification of a region of homozygous deletion on 8p22-23.1 in medulloblastoma	ONCOGENE			English	Article						rnedulloblastoma; chromosome 8p; homozygous deletion; allelotyping	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENES; SHORT ARM; PROSTATE-CANCER; ALLELIC LOSS; CHROMOSOME 8P; CELL LINES; HETEROZYGOSITY; CARCINOMA; ABNORMALITIES	To identify critical tumor suppressor loci that are associated with the development of medulloblastoma, we performed a comprehensive genome-wide allelotype analysis in a series of 12 medulloblastomas. Non-random allelic imbalances were identified on chromosomes 7q (58.3%), 8p (66.7%), 16q (58.3%), 17p (58.3%) and 17q (66.7%). Comparative genomic hybridization analysis confirmed that allelic imbalances on 8p, 16q and 17p were due to loss of genetic materials. Finer deletion mapping in an expanded series of 23 medulloblastomas localized the common deletion region on 8p to an interval of 18.14 cM on 8p22-23.2. We then searched within the region of loss on 8p for loci that might contain homozygous deletion using comparative duplex PCR. An overlapping homozygous deletion region was identified in a 1.8 cM interval on 8p22-23.1, between markers D8S520 and D8S1130, in two medulloblastomas. This region of homozygous deletion also encompasses the 1.4 cM minimal deletion region detected on 8p in ductal carcinoma in situ of breast. In conclusion, we reported for the first time a detailed deletion mapping on 8p in medulloblastoma and have identified a region of homozygous deletion on 8p22-23.1 that is likely to contain a critical tumor suppressor gene involved in the development of medulloblastoma.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anatom & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Ng, HK (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anatom & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.	hkng@cuhk.edu.hk	Ng, Ho Keung/I-3952-2015; Pang, Jesse CS/H-3549-2013	Pang, Jesse CS/0000-0002-8716-4045				Arbieva ZH, 2000, GENOME RES, V10, P244, DOI 10.1101/gr.10.2.244; Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293; Baffa R, 2000, CLIN CANCER RES, V6, P1372; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; Blaeker H, 1996, GENE CHROMOSOME CANC, V15, P54, DOI 10.1002/(SICI)1098-2264(199601)15:1<54::AID-GCC8>3.3.CO;2-4; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Farrington SM, 1996, ONCOGENE, V12, P1803; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GIANGASPERO F, 2000, PATHOLOGY GENETICS T, P129; Gilhuis HJ, 2000, CLIN NEUROL NEUROSUR, V102, P203, DOI 10.1016/S0303-8467(00)00112-8; HEIDEMAN RL, 1997, PRINCIPLES PRACTICE, P651; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Ishii H, 2001, P NATL ACAD SCI USA, V98, P10374, DOI 10.1073/pnas.181222898; Ishwad CS, 1999, INT J CANCER, V80, P25, DOI 10.1002/(SICI)1097-0215(19990105)80:1<25::AID-IJC6>3.3.CO;2-7; Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.0.CO;2-1; KAGAN J, 1995, ONCOGENE, V11, P2121; Lassus H, 2001, LAB INVEST, V81, P517, DOI 10.1038/labinvest.3780260; Leung YF, 2001, BIOTECHNIQUES, V30, P334, DOI 10.2144/01302tt02; Levy A, 1999, GENE CHROMOSOME CANC, V24, P42, DOI 10.1002/(SICI)1098-2264(199901)24:1<42::AID-GCC6>3.0.CO;2-F; Ng IOL, 2000, CANCER RES, V60, P6581; Nicholson JC, 1999, BRIT J CANCER, V80, P1322, DOI 10.1038/sj.bjc.6690525; Nihei N, 1996, GENE CHROMOSOME CANC, V17, P260, DOI 10.1002/(SICI)1098-2264(199612)17:4<260::AID-GCC8>3.0.CO;2-1; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Prasad MA, 1998, GENE CHROMOSOME CANC, V23, P255, DOI 10.1002/(SICI)1098-2264(199811)23:3<255::AID-GCC8>3.3.CO;2-Q; Reardon DA, 1997, CANCER RES, V57, P4042; SAYLORS RL, 1991, CANCER RES, V51, P4721; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sun PC, 1999, GENOMICS, V62, P184, DOI 10.1006/geno.1999.6020; Sunwoo JB, 1999, ONCOGENE, V18, P2651, DOI 10.1038/sj.onc.1202838; Takle LA, 1996, ONCOGENE, V12, P1083; Tanaka K, 1996, ONCOGENE, V12, P405; Tong CYK, 2001, J NEUROSURG, V95, P9, DOI 10.3171/jns.2001.95.1.0009; Vecchione A, 2001, CLIN CANCER RES, V7, P1546; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Wang JC, 1999, GENOMICS, V60, P1, DOI 10.1006/geno.1999.5905; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Wistuba II, 1999, CANCER RES, V59, P1973; Wright K, 1998, ONCOGENE, V17, P1185, DOI 10.1038/sj.onc.1202028; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Yin XL, 2000, J NEUROSURG, V93, P77, DOI 10.3171/jns.2000.93.1.0077; Yin XL, 2001, J NEUROSURG, V94, P799, DOI 10.3171/jns.2001.94.5.0799; Yuan BZ, 1998, CANCER RES, V58, P2196	43	24	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1461	1468		10.1038/sj.onc.1205204	http://dx.doi.org/10.1038/sj.onc.1205204			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857089				2022-12-28	WOS:000173861000016
J	Brennan, P; Mehl, AM; Jones, M; Rowe, M				Brennan, P; Mehl, AM; Jones, M; Rowe, M			Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells	ONCOGENE			English	Article						cyclin; survival; LY294002; PKB; latent membrane protein-1; EBNAZA	EPSTEIN-BARR-VIRUS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; LATENT MEMBRANE-PROTEIN; KINASE-B ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; BURKITTS-LYMPHOMA; C-MYC; BAD PHOSPHORYLATION; DOWN-REGULATION; CYCLE ARREST	B-cell lymphoma, which is increasing world wide, includes such varied conditions as post-transplant lymphoproliferative disease (PTLD) and Burkitt's lymphoma. This study has characterized a role for the signalling molecule phosphatidylinositol 3-kinase, PI3K, in the regulation of growth and survival of immortalized B-lymphocytes. Burkitt's lymphoma cells die rapidly following inhibition of PI3K with LY294002, a chemical inhibitor. Furthermore, Epstein-Barr virus (EBV) immortalized B-cells, lymphoblastoid cell lines, which are a model of PTLD, do not die but are growth inhibited. This growth inhibition is due to an accumulation at G1 phase of the cell cycle and is paralleled by a loss of E2F transcriptional activity, which is essential for cell cycle entry. An active form of PI3K promotes E2F transcriptional activity in lymphoblastoid cell lines. Treatment of LCL with LY294002 causes a reduction of the expression of both cyclin D2 and cyclin D3, two key cyclins required for cell cycle progression but does not affect the expression of the EBV latent genes, EBNA2A or LMP-1. LY294002 also causes an increase in p27kip1, a cyclin dependent kinase inhibitor and results in the dephosphorylation of members of the pocket protein family. These data describe a mechanism by which PI3K plays a role in B-lymphocyte growth and suggests that a pathway from PI3K to D-type cyclin expression may provide diagnostic or treatment opportunities.	Cardiff Univ, Sect Infect & Immun, Cardiff CF14 4XX, S Glam, Wales	Cardiff University	Brennan, P (corresponding author), Cardiff Univ, Sect Infect & Immun, Tenovus Bldg, Cardiff CF14 4XX, S Glam, Wales.	brennanp@cf.ac.uk	Brennan, Paul/B-9210-2009; Brennan, Paul/ABB-9196-2021; Rowe, Martin/B-2880-2009	Brennan, Paul/0000-0001-8792-0499; Brennan, Paul/0000-0001-8792-0499; Rowe, Martin/0000-0003-4139-7326				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brennan P, 2001, SEMIN CANCER BIOL, V11, P415, DOI 10.1006/scbi.2001.0408; Butler MP, 1999, GENE CHROMOSOME CANC, V24, P322, DOI 10.1002/(SICI)1098-2264(199904)24:4<322::AID-GCC5>3.0.CO;2-9; Carey GB, 2001, J IMMUNOL, V166, P1618, DOI 10.4049/jimmunol.166.3.1618; Chung TDK, 2000, PROSTATE, V42, P1; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Crawley JB, 1996, J BIOL CHEM, V271, P16357, DOI 10.1074/jbc.271.27.16357; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Fais F, 1996, INT J CANCER, V68, P810, DOI 10.1002/(SICI)1097-0215(19961211)68:6<810::AID-IJC20>3.0.CO;2-2; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Gold MR, 2000, IMMUNOL REV, V176, P47; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; Griffiths PD, 1999, J MED VIROL, V59, P496, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt;496::AID-JMV12&gt;3.0.CO;2-U; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hinton HJ, 1999, J IMMUNOL, V162, P7002; *IARC W, 1997, EPST VIR KAP SARC HE, V70, P47; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jones KD, 1999, BLOOD, V94, P2871; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MILNER AE, 1993, ONCOGENE, V8, P3385; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; Nalesnik MA, 1998, SPRINGER SEMIN IMMUN, V20, P325, DOI 10.1007/BF00838047; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALMERO I, 1993, ONCOGENE, V8, P1049; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROWE M, 1986, INT J CANCER, V37, P367, DOI 10.1002/ijc.2910370307; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Rowe M, 2001, Methods Mol Biol, V174, P229; Rowe M, 1998, SPRINGER SEMIN IMMUN, V20, P389, DOI 10.1007/BF00838051; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; SAMPLE J, 1990, J VIROL, V64, P1667, DOI 10.1128/JVI.64.4.1667-1674.1990; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Spender LC, 2001, J VIROL, V75, P3537, DOI 10.1128/JVI.75.8.3537-3546.2001; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Tosato G, 1998, SPRINGER SEMIN IMMUN, V20, P405, DOI 10.1007/BF00838052; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; YOUNG LS, 1987, J GEN VIROL, V68, P2853, DOI 10.1099/0022-1317-68-11-2853	58	51	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1263	1271		10.1038/sj.onc.1205182	http://dx.doi.org/10.1038/sj.onc.1205182			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850846				2022-12-28	WOS:000173729400014
J	Shou, J; Ali-Osman, F; Multani, AS; Pathak, S; Fedi, P; Srivenugopal, KS				Shou, J; Ali-Osman, F; Multani, AS; Pathak, S; Fedi, P; Srivenugopal, KS			Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA	ONCOGENE			English	Article						Wnt antagonist; apoptosis; p53; alkylating agents; brain tumors	MAMMARY EPITHELIAL-CELLS; BETA-CATENIN; DOWN-REGULATION; UP-REGULATION; P53-MEDIATED APOPTOSIS; MEDIATED TRANSCRIPTION; TELOMERASE ACTIVITY; SIGNALING PATHWAY; GLIOMA-CELLS; EXPRESSION	The human Dkk-1 (hDkk-1) gene, a transcriptional target of the p53 tumor suppressor, encodes a powerful inhibitor of the Wnt signaling pathway and regulates the spatial patterning/morphogenesis of the mammalian central nervous system. We investigated the p53-related functions of the hDkk-1 gene by studying its response to DNA damage and its modulation of apoptosis in human glioma cells. Various chemotherapeutic and other agents that induce DNA adducts and compromise its integrity (1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cisplatin, H2O2 and UV rays) enhanced the expression of hDkk-1 significantly. The damage-induced increase in hDkk-1 mRNA levels occurred in many human tumor cell lines, irrespective of their p53 gene status. The human glioblastorna cell line, U87MG, which had undetectable hDkk-1 expression, was engineered to express moderate levels of the hDkk protein by stable transfection. The engineered cells did not show any morphological changes, but underwent marked apoptosis after ceramide treatment. Further, the DNA cross-linking drugs BCNU and cisplatin, but not the microtubule poison vincristine, induced significant cell death in U87MG/hDkk cells, and this was accompanied by altered Bcl-2/Bax expression and a reduction in the amount of telomere DNA as visualized by fluorescence in situ hybridization. These results show that hDkk-1 is a pro-apoptotic gene and suggest that it may play important roles in linking the oncogenic Wnt and p53 tumor suppressor pathways.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Srivenugopal, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Box 64,1515 Holcombe Blvd, Houston, TX 77030 USA.	ksrivenu@mdanderson.org			NATIONAL CANCER INSTITUTE [R29CA074321, R01CA079644] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74321, CA 79644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Barker N, 2000, ADV CANCER RES, V77, P1; Burger AM, 1997, EUR J CANCER, V33, P638, DOI 10.1016/S0959-8049(96)00521-7; Burkhart BA, 1999, EXP CELL RES, V247, P168, DOI 10.1006/excr.1998.4345; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Dale TC, 1998, BIOCHEM J, V329, P209; DELANGE T, 1995, TELOMERES, P265; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; Henriksson M, 2001, APOPTOSIS, V6, P133, DOI 10.1023/A:1009644716727; Howe LR, 1999, CANCER RES, V59, P1572; Ishibashi T, 1998, P NATL ACAD SCI USA, V95, P4219, DOI 10.1073/pnas.95.8.4219; Ishii K, 2000, EXP CELL RES, V255, P95, DOI 10.1006/excr.1999.4777; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kazanskaya O, 2000, DEVELOPMENT, V127, P4981; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; MAO B, 2001, NATURE, V411, P255; McGrew LL, 1999, MECH DEVELOP, V87, P21, DOI 10.1016/S0925-4773(99)00136-7; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Molenaar M, 1999, INT J DEV BIOL, V43, P675; Moon RT, 1997, CELL, V88, P725, DOI 10.1016/S0092-8674(00)81915-7; Mukhopadhyay T, 1998, ONCOGENE, V17, P901, DOI 10.1038/sj.onc.1202011; Multani AS, 1999, ONCOL RES, V11, P455; Multani AS, 2000, NEOPLASIA, V2, P339, DOI 10.1038/sj.neo.7900105; Nagele RG, 2001, J CELL SCI, V114, P377; Naylor S, 2000, J CELL SCI, V113, P2129; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; PATHAK S, 1976, J REPROD MED, V17, P25; Polakis P, 2000, GENE DEV, V14, P1837; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Sawada M, 2001, ONCOGENE, V20, P1368, DOI 10.1038/sj.onc.1204207; Schneider VA, 2001, GENE DEV, V15, P304, DOI 10.1101/gad.855601; Scotting PJ, 2000, CHILD NERV SYST, V16, P261, DOI 10.1007/s003810050511; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Srivenugopal K. S., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P5; Srivenugopal KS, 1997, INT J ONCOL, V11, P1251; SRIVENUGOPAL KS, 1990, BIOCHEM PHARMACOL, V40, P473, DOI 10.1016/0006-2952(90)90545-V; TATE G, 1999, J BIOCH MOL BIOL BIO, V3, P239; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; Ueda Y, 2001, BIOCHEM BIOPH RES CO, V283, P327, DOI 10.1006/bbrc.2001.4788; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wolf V, 1997, FEBS LETT, V417, P385, DOI 10.1016/S0014-5793(97)01324-0; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yoshimura S, 1997, J NEUROCHEM, V69, P713; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zinda MJ, 2001, BIOCHEM BIOPH RES CO, V280, P1107, DOI 10.1006/bbrc.2000.4248	69	139	148	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					878	889		10.1038/sj.onc.1205138	http://dx.doi.org/10.1038/sj.onc.1205138			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840333				2022-12-28	WOS:000173427100003
J	Wentzensen, N; Ridder, R; Klaes, R; Vinokurova, S; Schaefer, U; Doeberitz, MV				Wentzensen, N; Ridder, R; Klaes, R; Vinokurova, S; Schaefer, U; Doeberitz, MV			Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions	ONCOGENE			English	Article						human papillomavirus (HPV); E6-E7 oncogenes; integration; insertional mutagenesis; fusion transcripts	HUMAN-PAPILLOMAVIRUS TYPE-16; GENE-EXPRESSION; CERVICAL-CANCER; FRAGILE SITES; INTEGRATION SITES; SEQUENCES; DNA; E7; E6; ONCOGENES	Persistent high risk type human papillomavirus (HR - HPVs) infections induce dysplasia or cancer of the anogenital tract, most notably of the uterine cervix. The viral genome usually persists and replicates as an episomal molecule in early dysplasia, whereas in advanced dysplasia or cervical cancer HPV genomes are frequently integrated into the chromosomal DNA of the host cell. Previous studies suggested that modification of critical cellular sequences by integration of HPV genomes might significantly contribute to the neoplastic transformation of anogenital epithelia (insertional mutagenesis). This prompted us to characterize the integration loci of high risk HPV genomes in a large set of genital lesions. We amplified E6/E7 oncogene transcripts derived from integrated HPV16 and HPV18 genomes and characterized in detail the co-transcribed cellular sequences! of 64 primary genital lesions and five cervical cancer cell lines. Database analyses of the cellular parts of these fusion transcripts revealed 51 different integration loci, including 26 transcribed genes (14 known genes, 12 EST sequences with unknown gene function). Seventeen sequences showed similarity to repetitive elements, and 26 sequences did not show any database match other than genomic sequence. Chromosomal integration loci were distributed over almost all human chromosomes. Although we found HPV sequences integrated into cancer related genes and close to fragile sites, no preferential site or integration motif could be identified. These data demonstrate that target directed insertional mutagenesis might occur in few HPV-induced anogenital lesions, however, it is rather the exception than the rule.	Heidelberg Univ, Dept Pathol, Div Mol Pathol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Doeberitz, MV (corresponding author), Heidelberg Univ, Dept Pathol, Div Mol Pathol, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	knebel@med.uni-heidelberg.de	Wentzensen, Nicolas/AAG-8522-2019					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; Carmody MW, 1996, MOL CELL PROBE, V10, P107, DOI 10.1006/mcpr.1996.0015; Chen M, 1996, NAT GENET, V12, P448, DOI 10.1038/ng0496-448; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, CANCER RES, V61, P2356; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hopper JL, 2001, BREAST CANCER RES, V3, P154, DOI 10.1186/bcr290; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Kessis TD, 1996, ONCOGENE, V13, P427; Klaes R, 1999, CANCER RES, V59, P6132; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; MacDonald JS, 1999, SEMIN ONCOL, V26, P556; MEYER T, 1995, BIOTECHNIQUES, V19, P632; MINCHEVA A, 1987, MED MICROBIOL IMMUN, V176, P245, DOI 10.1007/bf00190531; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; Remm M, 1999, J VIROL, V73, P3062, DOI 10.1128/JVI.73.4.3062-3070.1999; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHIRASAWA H, 1989, J GEN VIROL, V70, P1913, DOI 10.1099/0022-1317-70-7-1913; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH PP, 1992, GENE CHROMOSOME CANC, V5, P150, DOI 10.1002/gcc.2870050209; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; Sutherland GR, 1999, AM J HUM GENET, V64, P354, DOI 10.1086/302267; Thorland EC, 2000, CANCER RES, V60, P5916; Tu YZ, 1999, BBA-GENE STRUCT EXPR, V1489, P452, DOI 10.1016/S0167-4781(99)00197-9; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	44	109	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					419	426		10.1038/sj.onc.1205104	http://dx.doi.org/10.1038/sj.onc.1205104			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821954				2022-12-28	WOS:000173311200010
J	Deleu, L; Shellard, S; Alevizopoulos, K; Amati, B; Land, H				Deleu, L; Shellard, S; Alevizopoulos, K; Amati, B; Land, H			Recruitment of TRRAP required for oncogenic transformation by E1A	ONCOGENE			English	Article						TRRAP; E1A; Myc; adenovirus; oncogenic transformation	HISTONE ACETYLASE COMPLEX; C-MYC; ADENOVIRUS E1A; ESSENTIAL COFACTOR; PROTEINS; DOMAINS; EXPRESSION; TARGETS; VECTORS; CELLS	TRRAP links Myc with histone acetylases and appears to be an important mediator of its oncogenic function. Here we show that interaction with TRRAP is required for cellular transformation not only by Myc, but also by the adenovirus EIA protein. Substitution of the 262 N-terminal residues of Myc with a small domain of EIA (residues 12-54) restores Myc transforming function. EIA(12-54) contains a TRRAP-interaction domain, that recruits TRRAP to either E1A-Myc chimeras, or the native 12S E1A protein. Overexpression of a competing TRRAP fragment in vivo blocks interaction of cellular TRRAP with either E1A-Myc or EIA, and suppresses cellular transformation by both oncoproteins. Moreover, E1A(Delta 26-35) that fails to bind TRRAP but is capable of binding the Retinoblastoma (Rb)-family and p300/CBP proteins is defective in cellular immortalization, transformation and cell cycle deregulation. Thus in addition to disrupting Rb and p300/CBP functions, E1A must recruit TRRAP to transform cells.	Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA; ICRF, London WC2A, England; ISREC, CH-1066 Epalinges, Switzerland; DNAX Res Inst Mol & Cellular Biol Inc, Dept Oncol, Palo Alto, CA 94304 USA	University of Rochester; Swiss Institute Experimental Cancer Research; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Land, H (corresponding author), Univ Rochester, Med Ctr, Dept Biomed Genet, 601 Elmwood Ave, Rochester, NY 14642 USA.		Amati, Bruno/AAM-3418-2020	Amati, Bruno/0000-0002-2958-1799				Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BARBEAU D, 1994, ONCOGENE, V9, P359; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; DYSON N, 1992, CANCER SURV, V12, P161; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Hancock DC, 1998, METH MOL B, V80, P69; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; LAND H, 1995, METHOD ENZYMOL, V254, P37; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MACU KB, 1992, ANNU REV BIOCHEM, V61, P809; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	25	68	70	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8270	8275		10.1038/sj.onc.1205159	http://dx.doi.org/10.1038/sj.onc.1205159			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781841				2022-12-28	WOS:000172507800010
J	Garkavtsev, IV; Kley, N; Grigorian, IA; Gudkov, AV				Garkavtsev, IV; Kley, N; Grigorian, IA; Gudkov, AV			The Bloom syndrome protein interacts and cooperates with p53 in regulation of transcription and cell growth control	ONCOGENE			English	Article						Bloom syndrome; BLM protein; p53; interaction; two-hydrid system; transactivation	GENE; HELICASES; RADIATION	Bloom syndrome is an autosomal recessive disorder associated with mutations in BLM gene encoding protein that belongs to the family of DNA helicases. It is characterized by predisposition to cancer, immunodeficiency, high sensitivity to UV and genomic instability of somatic cells. Here we show physical and functional cooperation between BLM and p53 proteins. Ectopic expression of BLM causes anti-proliferative effect in p53 wild type, but not in p53-deficient cells; p53-mediated transactivation is attenuated in primary fibroblasts from Bloom syndrome patients. BLM and p53 proteins physically interact in the cells as demonstrated in yeast and mammalian two-hybrid systems; interaction sites are mapped to 237-272 aa residues of BML and 285-340 aa of P53. Ectopic expression of the fragment of wild type BML containing p53-interactive domain suppresses p53-mediated transcription and interferes with p53-mediated growth inhibition. These observations indicate that BLM might be an important component of p53 function and suggest that Bloom Syndrome phenotype may in part be the result of the deregulation of the p53 tumor suppressor pathway.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; GPC Biotech Inc, Waltham, MA 02451 USA; Univ Illinois, Dept Pharmacokinet & Pharmacodynam, Chicago, IL 60607 USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Garkavtsev, IV (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA.			Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi M, 1998, CLIN OBSTET GYNECOL, V41, P172, DOI 10.1097/00003081-199803000-00024; EL DW, 1993, CELL, V75, P817; ELLIS NA, 1994, AM J HUM GENET, V55, P453; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Prives C, 1999, J PATHOL, V187, P112; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200	16	31	32	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8276	8280		10.1038/sj.onc.1205120	http://dx.doi.org/10.1038/sj.onc.1205120			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781842				2022-12-28	WOS:000172507800011
J	Marienfeld, R; Berberich-Siebelt, F; Berberich, I; Denk, A; Serfling, E; Neumann, M				Marienfeld, R; Berberich-Siebelt, F; Berberich, I; Denk, A; Serfling, E; Neumann, M			Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-kappa B control	ONCOGENE			English	Article						phosphorylation; proteolysis; RelB; NF-kappa B; I kappa B	TRANSCRIPTION FACTORS; PROTEIN-KINASE; ALPHA; UBIQUITINATION; IDENTIFICATION; ACTIVATION; CANCER; FAMILY; CELLS; MICE	RelB is an unusual member of the ReI/NF-kappaB family of transcription factors which are involved in oncogenic processes. Due to a relaxed control by the I kappa Bs, the cytosolic NF-kappaB inhibitors, RelB is constitutively expressed in the nuclei of lymphoid cells. We show here that RelB is inducibly degraded upon activation of T cells in a fashion similar to the L kappa Bs. However, RelB degradation differs from that of I kappa Bs since it is not induced by TNF alpha but only by T cell receptor or TPA/ionomycin stimulation. Moreover, ReIB degradation occurs in three steps: (i) after stimulation RelB is rapidly phosphorylated at amino acids Thr84 and Ser552 followed by (U) an N-terminal cut and, finally, (iii) the complete degradation in the proteasomes. Since mutation of the two phosphoacceptor sites to non-acceptor sites abolished RelB phosphorylation in vivo and led to the stabilization of the mutated ReIBDM, site-specific phosphorylation appears to be a necessary prerequisite for RelB degradation. RelB is a crucial regulator of NF kappaB-dependent gene expression. Thus, the signal-induced degradation of RelB should be an important control mechanism of NF-kappaB activity.	Univ Wurzburg, Inst Pathol, Dept Mol Pathol, D-97080 Wurzburg, Germany; Univ Wurzburg, Inst Virol & Immunobiol, D-97074 Wurzburg, Germany; Univ Ulm, Inst Physiol Chem, D-89081 Ulm, Germany	University of Wurzburg; University of Wurzburg; Ulm University	Neumann, M (corresponding author), Univ Wurzburg, Inst Pathol, Dept Mol Pathol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.		Serfling, Edgar/X-7212-2019					Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1996, ONCOGENE, V13, P1367; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Marienfeld R, 1997, EUR J IMMUNOL, V27, P1601, DOI 10.1002/eji.1830270703; Neumann M, 1997, INT J ONCOL, V11, P1335; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Suhasini M, 1997, ONCOGENE, V15, P1859, DOI 10.1038/sj.onc.1201530; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; WEIH F, 1994, ONCOGENE, V9, P3289; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Xia YY, 1999, MOL CELL BIOL, V19, P7688	23	64	71	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8142	8147		10.1038/sj.onc.1204884	http://dx.doi.org/10.1038/sj.onc.1204884			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781828				2022-12-28	WOS:000172396800012
J	Hu, J; Schuster, AE; Fritsch, MK; Schneider, DT; Lauer, S; Perlman, EJ				Hu, J; Schuster, AE; Fritsch, MK; Schneider, DT; Lauer, S; Perlman, EJ			Deletion mapping of 6q21-26 and frequency of 1p36 deletion in childhood endodermal sinus tumors by microsatellite analysis	ONCOGENE			English	Article						germ cell tumor; endodermal sinus tumor; 6q; 1p36; IGF2R	GERM-CELL TUMORS; COMPARATIVE GENOMIC HYBRIDIZATION; PEDIATRIC-ONCOLOGY-GROUP; ALLELIC LOSS; GENETIC-ANALYSIS; PROSTATE-CANCER; SUPPRESSOR GENE; BREAST-CANCER; CHROMOSOME 6Q; HETEROZYGOSITY	The most common malignant germ cell tumor of early childhood is the endodermal sinus tumor (CEST), also known as yolk sac tumor. Previous cytogenetic studies of CEST have demonstrated recurrent deletion of distal regions of chromosomes lp and 6q. Studies utilizing comparative genomic hybridization have likewise demonstrated loss of distal 6q, however these studies show discrepant data concerning chromosome I abnormalities. This study analyses 18 CESTs for loss of heterozygosity (LOH) of distal chromosome 6q utilizing 17 microsatellite markers and 13 tumors were analysed for LOH of distal lp using two microsatellite markers. LOH of 6q was found in 13/18 tumors (72%). This data confirms that loss of genetic material on 6q is one of the most common abnormalities in CESTs and narrows the region of loss, enabling candidate tumor suppressor genes to be identified and analysed. In addition, LOH of 1p36 was identified in five of 11 informative tumors, clarifying prior conflicting data and confirming that lp deletion is a common event in CESTs.	Johns Hopkins Med Inst, Div Pediat Pathol, Baltimore, MD 21287 USA; Emory Univ, Div Pediat Hematol Oncol, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins Medicine; Emory University	Perlman, EJ (corresponding author), Johns Hopkins Univ Hosp, Meyer 7-181,600 N Wolfe St, Baltimore, MD 21287 USA.			Schneider, Dominik T./0000-0001-8153-1601; Hu, Jie/0000-0001-9314-9506; Perlman, Elizabeth/0000-0001-6853-6221	NATIONAL CANCER INSTITUTE [U10CA020549, U10CA028476] Funding Source: NIH RePORTER; NCI NIH HHS [CA28476, CA20549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGHORN A, 2001, AM J PATHOL, V158, P1903; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; CASTEDO SMMJ, 1989, CANCER RES, V49, P5696; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooney KA, 1996, CANCER RES, V56, P4150; DEMANOIR S, 1995, CYTOMETRY, V19, P27; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; GIBAS Z, 1984, J UROLOGY, V131, P762, DOI 10.1016/S0022-5347(17)50613-8; Hankins GR, 1996, ONCOGENE, V12, P2003; MATHEW S, 1994, CANCER RES, V54, P6265; OOSTERHUIS JW, 1988, CANCER GENET CYTOGEN, V36, P7; Perlman EJ, 1996, GENE CHROMOSOME CANC, V16, P15, DOI 10.1002/(SICI)1098-2264(199605)16:1<15::AID-GCC2>3.0.CO;2-6; Perlman EJ, 2000, J PEDIAT HEMATOL ONC, V22, P100, DOI 10.1097/00043426-200003000-00003; PERLMAN EJ, 1994, PEDIATR PATHOL, V14, P695, DOI 10.3109/15513819409023342; Riopel MA, 1998, CANCER RES, V58, P3105; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; SAITO S, 1992, CANCER RES, V52, P5815; Srikantan V, 1999, INT J CANCER, V84, P331, DOI 10.1002/(SICI)1097-0215(19990621)84:3<331::AID-IJC23>3.0.CO;2-J; STOCK C, 1994, GENE CHROMOSOME CANC, V11, P40, DOI 10.1002/gcc.2870110107; Theile M, 1996, ONCOGENE, V13, P677; Utada Y, 2000, JPN J CANCER RES, V91, P293, DOI 10.1111/j.1349-7006.2000.tb00944.x	24	10	10	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					8042	8044		10.1038/sj.onc.1204961	http://dx.doi.org/10.1038/sj.onc.1204961			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753688	Bronze			2022-12-28	WOS:000172288700014
J	Aydinlik, H; Nguyen, TD; Moennikes, O; Buchmann, A; Schwarz, M				Aydinlik, H; Nguyen, TD; Moennikes, O; Buchmann, A; Schwarz, M			Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors	ONCOGENE			English	Article						beta-catenin; Ha-ras; mouse hepatocarcinogenesis; phenobarbital; tumor promotion	HA-RAS GENE; HEPATOCELLULAR CARCINOMAS; HEPATOCARCINOGENESIS; MUTATIONS; MICE; DIETHYLNITROSAMINE; FREQUENT; CANCER	Tumor promoters are non-mutagenic chemicals which increase the probability of cancer by accelerating the clonal expansion of cells transformed during tumor initiation. Phenobarbital (PB) is an antiepileptic drug which promotes hepatocarcinogenesis in rodents when administered subsequent to an initiating carcinogen like diethylnitrosamine (DEN). Here we have investigated the prevalence and patterns of mutations in two genes, Haras and beta -catenin, both known mutational targets in mouse hepatocarcinogenesis. Liver tumors were generated by a single administration of DEN to 6 week old mice followed by feeding of PB (0.05%) containing or control diet for 39 weeks. Mutations at Ha-ras codon 61 were screened by allele-specific oligonucleotide hybridization; beta -catenin mutations were detected by direct sequencing of PCR products spanning exon 2. In tumors from mice treated with DEN alone, the prevalence of Ha-ras mutations was similar to 30% (6/20), while no beta -catenin mutations (0/13) were detectable in tumors of this treatment group. By contrast, Ha-ras mutations were undetectable in tumors from mice treated with DEN/PB (0/32), while similar to 80% (37/46) of tumors from this group showed beta -catenin mutations. These results demonstrate that PB strongly affects the prevalence of mutations in the two cancer-related genes, presumably by positive and negative selection for cells harboring the respective mutation.	Univ Tubingen, Inst Toxikol, D-72074 Tubingen, Germany	Eberhard Karls University of Tubingen	Schwarz, M (corresponding author), Univ Tubingen, Inst Toxikol, Wilhelmstr 56, D-72074 Tubingen, Germany.							BAUERHOFMANN R, 1992, MOL CARCINOGEN, V6, P60, DOI 10.1002/mc.2940060110; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; DRAGAN YP, 1992, CARCINOGENESIS, V13, P739, DOI 10.1093/carcin/13.5.739; Frey S, 2000, CARCINOGENESIS, V21, P161, DOI 10.1093/carcin/21.2.161; GRASLKRAUPP B, 1990, CANCER RES, V50, P3701; Marshall CJ, 1998, CURR OPIN GENET DEV, V8, P11, DOI 10.1016/S0959-437X(98)80055-5; Moennikes O, 2000, CANCER RES, V60, P5087; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Ogawa K, 1999, CANCER RES, V59, P1830; SCHULTEHERMANN R, 1995, LIVER REGENERATION C, P141; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199	14	139	140	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7812	7816		10.1038/sj.onc.1204982	http://dx.doi.org/10.1038/sj.onc.1204982			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753661				2022-12-28	WOS:000172161700014
J	Yu, JJ; Thornton, K; Guo, Y; Kotz, H; Reed, E				Yu, JJ; Thornton, K; Guo, Y; Kotz, H; Reed, E			An ERCC1 splicing variant involving the 5 '-UTR of the mRNA may have a transcriptional modulatory function	ONCOGENE			English	Article						ERCC1; nucleotide excision repair; ovarian cancer; transcriptional factor	NUCLEOTIDE EXCISION-REPAIR; OVARIAN-CANCER CELLS; MESSENGER-RNA LEVELS; CISPLATIN; CHEMOTHERAPY; EXPRESSION; ACID	Human ovarian cancer cells and tissues were examined for the presence or absence of a 42-bp splicing variant of ERCC1 gene, and for a possible functional role of this 42-bp sequence. This specific sequence exists in exon I, the 5'-UTR of the gene. Loss of this 42-bp sequence was associated with increased ERCC1 mRNA expression, in an assessment of 121 ovarian cancer specimens (p2 < 10(-6)). In cells in tissue culture, the absence of the 42-bp segment was associated with a twofold increased ability to drive transcription in a Luciferase reporter system. Protein can be demonstrated in ovarian cancer cells based on EMSA analysis. Computer analysis shows that this 42-bp sequence contains several binding sites, including a core-binding domain for protein RFX1, transcriptional repressor. These preliminary results lay the groundwork in determination of potential roles for a negative regulatory element in NER repair pathway.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA	West Virginia University	Reed, E (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, Robert C Byrd Hlth Sci Ctr, 1801 Hlth Sci S,POB 9300, Morgantown, WV 26506 USA.	ereed@hsc.wvu.edu						BEHRENS BC, 1987, CANCER RES, V47, P414; BONOVICH M, 2000, P AM ASSOC CANC RES, V41, P399; DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Li QD, 1998, J BIOL CHEM, V273, P23419, DOI 10.1074/jbc.273.36.23419; Metzger R, 1998, J CLIN ONCOL, V16, P309, DOI 10.1200/JCO.1998.16.1.309; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANVUUREN AJ, 1995, MUTAT RES-DNA REPAIR, V337, P25, DOI 10.1016/0921-8777(95)00009-9; Yang LY, 2000, CLIN CANCER RES, V6, P773	15	21	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2001	20	52					7694	7698		10.1038/sj.onc.1204977	http://dx.doi.org/10.1038/sj.onc.1204977			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753647				2022-12-28	WOS:000172124100012
J	Bacus, SS; Altomare, DA; Lyass, L; Chin, DM; Farrell, MP; Gurova, K; Gudkov, A; Testa, JR				Bacus, SS; Altomare, DA; Lyass, L; Chin, DM; Farrell, MP; Gurova, K; Gudkov, A; Testa, JR			AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival	ONCOGENE			English	Article						AKT; HER-2/neu; overexpression; breast tumors; apoptosis; hypoxia	FACTOR-INDUCED APOPTOSIS; AKT/PROTEIN KINASE-B; KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; MONOCLONAL-ANTIBODY; RECEPTOR; HEREGULIN; PHOSPHORYLATION; OVEREXPRESSION	Amplification or overexpression of the HER-2/neu gene in breast cancers is associated with aggressive behavior and resistance to therapeutic regimens. The molecular mechanisms that contribute to therapeutic resistance/survival of HER-2/neu-overexpressing tumor cells have not been well defined. To determine if phosphatidylinositol 3-kinase/AKT signaling contributes to cell survival in HER-2/neu-positive breast cancers, we performed immunohistochemical analyses to evaluate expression of HER-2/neu and AKT in a series of 52 breast carcinomas. Elevated expression of HER-2/neu was found to correlate with overexpression of AKT2 protein and activation of AKT kinase. HER-2/neu-overexpressing breast cancer cell lines were resistant to apoptosis induced by UV treatment and hypoxia, which was suppressed in the presence of the phosphatidylinositol 3-kinase inhibitors LY294002 and wortmannin, indicating a link between AKT activation and stress resistance in HER-2/neu-overexpressing cells. These observations suggest that AKT signaling augments resistance to stress-induced apoptosis in breast cancer cells over-expressing HER-2/neu.	Ventana Med Syst Inc, QDL, Westmont, IL 60559 USA; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA	Roche Holding; Ventana Medical Systems, Inc.; Fox Chase Cancer Center; Cleveland Clinic Foundation	Bacus, SS (corresponding author), Ventana Med Syst Inc, QDL, 610 Oakmont Lane, Westmont, IL 60559 USA.	sbacus@ventanamed.com; D_Altomare@fccc.edu		Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA077429] Funding Source: NIH RePORTER; NCI NIH HHS [CA77429, P30 CA006927, R01 CA077429, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alaoui-Jamali MA, 1997, BIOCHEM CELL BIOL, V75, P315, DOI 10.1139/bcb-75-4-315; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bacus S, 1997, ANAL QUANT CYTOL, V19, P316; Bacus S S, 2000, Breast Dis, V11, P63; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BACUS SS, 1992, CANCER RES, V52, P2580; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; BACUS SS, 1993, PATHOL ANNU, V28, P179; BACUS SS, 1994, COMPENDIUM COMPUTERI, P143; BACUS SS, 1996, MOL CARCINOG, V3, P350; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brognard J, 2001, CANCER RES, V61, P3986; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARPENTER G, 1979, J CELL PHYSIOL, V99, P101, DOI 10.1002/jcp.1040990112; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; HANCOCK MC, 1991, CANCER RES, V51, P4575; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Huang Y, 2000, CANCER RES, V60, P4426; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Ram TG, 2000, J CELL PHYSIOL, V183, P301, DOI 10.1002/(SICI)1097-4652(200006)183:3<301::AID-JCP2>3.0.CO;2-W; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; Shak S, 1999, SEMIN ONCOL, V26, P71; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Stal O, 2000, ANN ONCOL, V11, P1545, DOI 10.1023/A:1008313310474; Sun M, 2001, CANCER RES, V61, P5985; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	57	113	120	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3532	3540		10.1038/sj.onc.1205438	http://dx.doi.org/10.1038/sj.onc.1205438			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032855				2022-12-28	WOS:000175793700004
J	Todd, JL; Rigas, JD; Rafty, LA; Denu, JM				Todd, JL; Rigas, JD; Rafty, LA; Denu, JM			Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK)	ONCOGENE			English	Article						JNK; stress kinase; VHR; protein tyrosine phosphatase	MAP KINASE; INDUCED APOPTOSIS; CELL APOPTOSIS; IN-VIVO; ACTIVATION; PATHWAYS; HSP72; SUPPRESSION; MECHANISMS; SUBSTRATE	The JNK group (for c-Jun N-terminal kinase) of mitogen-activated protein kinases (MAP kinases) is activated in cells in response to environmental stress and cytokines. Activation of JNK is the result of dual phosphorylation by specific upstream kinases which phosphorylate the TxY motif. Much less is known concerning the down-regulation by protein phosphatases. Here, we demonstrate that the tyrosine-specific and constitutively-expressed phosphatase VHR (for VH1-Related) down-regulates the JNK signaling pathway at the level of JNK dephosphorylation. VHR was shown to efficiently dephosphorylate JNK and to form a tight complex with activated JNK when the catalytically-inactive C124S VHR mutant was employed as an in vivo substrate trap. Utilizing an in vitro assay, the transcription factor c-Jun specifically inhibited the ability of VHR to dephosphorylate JNK, likely by sterically blocking access to the phosphorylation sites when JNK and c-Jun form a complex. c-Jun has no effect on the ability of VHR to inactivate the ERK MAP kinases or to hydrolyze artificial substrates. The c-Jun inhibition results are discussed in terms of the resistant-nature of JNK dephosphorylation in cellular extracts and in terms of a general model in which VHR may be a general MAP kinase phosphatase whose specificity and activity are dictated by the presence of MAP kinase-associated proteins that inhibit dephosphorylation.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, Portland, OR 97201 USA	Oregon Health & Science University	Denu, JM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	denuj@ohsu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059785, R37GM059785] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 59785] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JarielEncontre I, 1997, MOL BIOL REP, V24, P51, DOI 10.1023/A:1006804723722; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kondo T, 2000, J BIOL CHEM, V275, P7668, DOI 10.1074/jbc.275.11.7668; Kondo T, 2000, J BIOL CHEM, V275, P8872, DOI 10.1074/jbc.275.12.8872; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; Patel R, 1998, J CELL SCI, V111, P2247; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Yaglom JA, 1999, J BIOL CHEM, V274, P20223, DOI 10.1074/jbc.274.29.20223	36	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2573	2583		10.1038/sj.onc.1205344	http://dx.doi.org/10.1038/sj.onc.1205344			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971192				2022-12-28	WOS:000174918400014
J	Theodosiou, A; Ashworth, A				Theodosiou, A; Ashworth, A			Differential effects of stress stimuli on a JNK-inactivating phosphatase	ONCOGENE			English	Article						JNK; phosphatase; tumour promotion; degradation	DUAL-SPECIFICITY PHOSPHATASES; MAP KINASE PHOSPHATASE; N-TERMINAL KINASE; C-JUN; SIGNAL-TRANSDUCTION; CATALYTIC ACTIVATION; GENE FAMILY; DELTA; INHIBITOR; PATHWAY	Stress signals elicit a wide variety of cellular responses, many of which converge on the phosphorylation of JNK and p38 kinases, the activation of which has been well-characterized. How these kinases are switched off by dephosphorylation is not well understood. Here we describe how diverse cellular stresses affect differently the stability and activity of a JNK-inactivating dual-specificity threonine-tyrosine phosphatase M3/6. Both anisomycin and arsenite activate the JNK pathway and, in addition, inactivate the M3/6 phosphatase. However, while anisomycin treatment of cells leads to M3/6 protein degradation, arsenite appears to inactivate M3/6 directly. These results might have implications for the mechanism of tumour promotion by arsenic.	Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, CRC, Gene Funct & Regulat Grp, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, CRC, Gene Funct & Regulat Grp, Fulham Rd, London SW3 6JB, England.	alana@icr.ac.uk						ADLER V, 1994, J BIOL CHEM, V269, P11186; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen YR, 2000, INT J ONCOL, V16, P651; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907	48	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2387	2397		10.1038/sj.onc.1205309	http://dx.doi.org/10.1038/sj.onc.1205309			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948422				2022-12-28	WOS:000174635600011
J	Vikis, HG; Stewart, S; Guan, KL				Vikis, HG; Stewart, S; Guan, KL			SmgGDS displays differential binding and exchange activity towards different Ras isoforms	ONCOGENE			English	Article						Ras; Rac; Rho; dominant negative mutants; smgGDS; guanine nucleotide exchange factor	KINASE SUPPRESSOR; PROTEIN; COMPLEX; SIGNAL; FORMS; PURIFICATION; INHIBITION; MUTANTS; GROWTH	Ras family GTPases play central roles in a wide variety of biological responses, including cell proliferation, differentiation, and oncogenic transformation. We searched for novel guanine nucleotide exchange factors of HRas and isolated small G-protein dissociation stimulator (smgGDS), a guanine nucleotide exchange factor known to act on numerous Ras and Rho family GTPases. SmgGDS specifically interacts with both dominant negative and nucleotide free forms of H and NRas, but not with the corresponding oncogenic forms. An effector domain mutant of HRas, HRasN17G37, selectively lost the ability to bind smgGDS. However, smgGDS does not catalyze guanine nucleotide exchange on either H or NRas in vitro. In contrast, substrates of smgGDS, such as KRas, Rac1, and RhoA, bind to smgGDS in both active and inactive forms which requires the presence of poly-basic residues in the C-termini of the GTPases. Our data suggest that the C-terminal poly-basic region of small GTPases is important for both binding and nucleotide exchange by smgGDS. Furthermore, these data underscore the idea that mammalian Ras isoforms are not functionally equivalent.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kunliang@umich.edu						BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOWMAN EP, 1995, METHOD ENZYMOL, V256, P246; CHEN SY, 1994, ONCOGENE, V9, P2691; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKANISHI H, 1994, J BIOL CHEM, V269, P15085; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	24	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2425	2432		10.1038/sj.onc.1205306	http://dx.doi.org/10.1038/sj.onc.1205306			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948427				2022-12-28	WOS:000174635600016
J	Godfried, MB; Veenstra, M; Von Sluis, P; Boon, K; Von Asperen, R; Hermus, MC; Von Schaik, BDC; Voute, TPA; Schwab, M; Versteeg, R; Caron, HN				Godfried, MB; Veenstra, M; Von Sluis, P; Boon, K; Von Asperen, R; Hermus, MC; Von Schaik, BDC; Voute, TPA; Schwab, M; Versteeg, R; Caron, HN			The N-myc and c-mjc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2	ONCOGENE			English	Article						nm23-H1; nm23-H2; N-myc; c-myc; chromosome 17; neuroblastoma	I HLA EXPRESSION; CELL-LINES; NEUROBLASTOMA; DIFFERENTIATION; LOCALIZATION; PROGRESSION; NUCLEOSIDE; MELANOMAS	Gain of chromosome 17q material is the most frequent genetic abnormality in neuroblastomas. The common region of gain is at least 375 cR large, which has precluded the identification of genes with a role in neuroblastoma pathogenesis. Neuroblastoma also frequently show amplification of the N-myc oncogene, which correlates closely with 17q gain. Both events are strong predictors of unfavorable prognosis. To identify genes that are part of the N-myc downstream pathway, we constructed SAGE libraries of an N-mjc transfected and a control cell line. This identified the chromosome 17q genes nm23-H1 and nm23-H2 as being 6-10 times induced in the N-myc expressing cells. Northern and Western blot analysis confirmed this up-regulation. Time-course experiment shows that both genes are induced within 4 h after N-myc is switched on. Furthermore, we demonstrate also that c-myc can upregulate nm23-H1 and nm23-H2 expression. Neuroblastoma tumor and cell line panels reveal a striking correlation between N-myc amplification and mRNA and protein expression of both nm23 genes. We show that the nm23 genes are located at the edge of the common region of chromosome 17q gain previously described in neuroblastoma cell lines. Our findings suggest that nm23-H1 and nm23-H2 expression is increased by 17q gain in neuroblastoma and can be further up-regulated by myc overexpression. These observations suggest a major role for nm23-H1 and nm23-H2 in tumorigenesis of unfavorable neuroblastomas.	Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Bioinformat Lab, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, Dept Pediat Oncol & Hematol, NL-1105 AZ Amsterdam, Netherlands; DKFZ, Berlin, Germany	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Helmholtz Association; German Cancer Research Center (DKFZ)	Caron, HN (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Genet, POB 22700, NL-1100 DE Amsterdam, Netherlands.	HNCaron@amc.uva.nl	Versteeg, Rogier/AAQ-1765-2020	Versteeg, Rogier/0000-0001-7172-0388; van Schaik, Barbera/0000-0002-5568-8127				BACKER JM, 1993, ONCOGENE, V8, P497; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Cheng NC, 1996, ONCOGENE, V13, P1737; FLORENES VA, 1992, CANCER RES, V52, P6088; Lastowska M, 1998, GENE CHROMOSOME CANC, V23, P116; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Lutz W, 1996, ONCOGENE, V13, P803; Malynn BA, 2000, GENE DEV, V14, P1390; Meddeb M, 1996, GENE CHROMOSOME CANC, V17, P156, DOI 10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3; Niitsu N, 2001, BLOOD, V97, P1202, DOI 10.1182/blood.V97.5.1202; Pinon VPB, 1999, EXP CELL RES, V246, P355, DOI 10.1006/excr.1998.4318; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; VANROY N, 1995, EUR J CANCER, V31A, P530, DOI 10.1016/0959-8049(95)00004-3; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x	17	67	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2097	2101		10.1038/sj.onc.1205259	http://dx.doi.org/10.1038/sj.onc.1205259			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960382				2022-12-28	WOS:000174827000016
J	Kawabe, T; Suganuma, M; Ando, T; Kimura, M; Hori, H; Okamoto, T				Kawabe, T; Suganuma, M; Ando, T; Kimura, M; Hori, H; Okamoto, T			Cdc25C interacts with PCNA at G2/M transition	ONCOGENE			English	Article						cell cycle; G2; M checkpoint; Cdc25C; PCNA; MPF	CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; PROTEIN-KINASE; HUMAN HOMOLOG; CHECKPOINT; REPLICATION; CYCLE; DAMAGE; BINDING; YEAST	Cdc25 activates maturation promoting factor (MPF) and promotes mitosis by removing the inhibitory phosphate from the Tyr-15 of Cdc2 in human cells. In this study, we searched the interacting protein(s) of human Cdc25C using the yeast two-hybrid screen and identified proliferating cell nuclear antigen (PCNA) as an interacting partner of Cdc25C. The interaction between Cdc25C and PCNA was confirmed in vitro and in vivo. Co-immunoprecipitation analyses using human T cell line, Jurkat, further revealed that Cdc25C interacted with PCNA transiently when cells began to enter mitosis. Immunofluorescence analysis also showed that Cdc25C and PCNA were transiently co-localized in the nucleus at the beginning of M phase. Together with the previous observations of the interaction between various cdc/cyclin and PCNA, our findings strongly suggested a potential role of PCNA at the G2 to M phase transition of cell cycle.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Internal Med 1, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	tokamoto@med.nagoya-cu.ac.jp						ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Gowdy PM, 1998, J CELL SCI, V111, P3401; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hindges R, 1997, BIOL CHEM, V378, P345; Kajino S, 2000, ONCOGENE, V19, P2233, DOI 10.1038/sj.onc.1203560; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LINDSAY HD, 1997, EMBO J, V16, P545; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Suganuma M, 1999, CANCER RES, V59, P5887; SZEPESI A, 1994, BLOOD, V84, P3413; TAN CK, 1986, J BIOL CHEM, V261, P2310; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; ZENG XR, 1994, J BIOL CHEM, V269, P24027; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	53	51	53	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1717	1726		10.1038/sj.onc.1205229	http://dx.doi.org/10.1038/sj.onc.1205229			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896603				2022-12-28	WOS:000174214200010
J	Suprynowicz, FA; Baege, A; Sunitha, I; Schlegel, R				Suprynowicz, FA; Baege, A; Sunitha, I; Schlegel, R			c-Src Activation by the E5 oncoprotein enables transformation independently of PDGF receptor activation	ONCOGENE			English	Article						ES oncoprotein; Src; papillomavirus; transformation	GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; FACTOR-BETA RECEPTOR; PROTEIN-TYROSINE KINASE; OPEN READING FRAME; BOVINE PAPILLOMAVIRUS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; BINDING; PHOSPHORYLATION	The E5 oncoprotein of bovine papillornavirus type I is a Golgi-resident, hydrophobic polypeptide that can transform immortalized fibroblasts by activating endogenous platelet-derived growth factor receptor P (PDGF-R). However, the existence of E5 mutants that dissociate transformation from PDGF-R activation implies that there are additional mechanism(s) by which E5 can transform cells. We now show that both wt E5, and transforming E5 mutants that are defective for PDGF-R activation, constitutively activate endogenous c-Src in NIH3T3 cell lines to levels normally associated with acute growth factor stimulation. The ubiquitous Src family protein tyrosine kinase (PTK) Fyn is not activated by these E5 constructs, nor are focal adhesion kinase and endogenous receptor PTKs for insulin, epidermal growth factor, basic fibroblast growth factor and insulin-like growth factor. We further demonstrate that transforming activity of the L26A E5 mutant, which is highly defective for PDGF-R activation, depends on its ability to activate Src. L26A E5 does not transform SYF cells that are deficient for Src, Fyn and Yes, unless Src expression is reconstituted, and does not transform NIH3T3 cells in which Src PTK activity is maintained at a basal level by means of kinase-defective K295R Src overexpression.	Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA	Georgetown University	Schlegel, R (corresponding author), Georgetown Univ, Med Ctr, Dept Pathol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	schleger@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA053371] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA53371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHEN EY, 1982, NATURE, V299, P529, DOI 10.1038/299529a0; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DiMaio D, 2000, CYTOKINE GROWTH F R, V11, P283, DOI 10.1016/S1359-6101(00)00012-5; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; Gazit A, 1996, BIOORGAN MED CHEM, V4, P1203, DOI 10.1016/0968-0896(96)00107-1; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KOVALENKO M, 1994, CANCER RES, V54, P6106; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; LANCASTER WD, 1982, MICROBIOL REV, V46, P191, DOI 10.1128/MMBR.46.2.191-207.1982; LIN PH, 1995, ONCOGENE, V10, P401; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MEISCHKE HRC, 1979, J GEN VIROL, V43, P473, DOI 10.1099/0022-1317-43-3-473; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SOLTOFF SP, 1992, COLD SPRING HARB SYM, V57, P75, DOI 10.1101/SQB.1992.057.01.010; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPARKOWSKI J, 1995, EMBO J, V14, P3055, DOI 10.1002/j.1460-2075.1995.tb07308.x; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; Suprynowicz FA, 2000, J BIOL CHEM, V275, P5111, DOI 10.1074/jbc.275.7.5111; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0	72	18	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1695	1706		10.1038/sj.onc.1205223	http://dx.doi.org/10.1038/sj.onc.1205223			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896601				2022-12-28	WOS:000174214200008
J	Haier, J; Nicolson, GL				Haier, J; Nicolson, GL			PTEN regulates tumor cell adhesion of colon carcinoma cells under dynamic conditions of fluid flow	ONCOGENE			English	Article						PTEN; cell adhesion; colon carcinoma; shear stress; laminar flow; focal adhesion kinase	EXTRACELLULAR-MATRIX COMPONENTS; PROTEIN-TYROSINE PHOSPHATASES; FOCAL ADHESION; JUVENILE POLYPOSIS; SIGNAL-TRANSDUCTION; COWDEN-DISEASE; SUPPRESSOR; GENE; INTEGRIN; MUTATIONS	The regulation of integrin-mediated cell adhesion and its stabilization involves different phosphorylation and dephosphorylation events. Focal adhesion kinase (FAK) has been recently found to be a substrate of the dual-specific phosphatase PTEN in glioma cells, where it appears to be involved in regulation of cell spreading and migration as part of focal adhesions. We have investigated the role of PTEN in cell adhesion of HT-29 human colon carcinoma cells under static and hydrodynamic conditions of fluid flow. PTEN coprecipitated with FAK and paxillin dependent on the formation of adhesions to collagens. This corresponded with an adhesion-dependent increase in Tyr-phosphatase activity of PTEN. Using preparations of native FAK and PTEN from HT-29 cells in a specific Tyr-phosphatase assay FAK was identified as substrate for this dephosphorylation. If expression of PTEN was reduced using antisense oligonucleotides cell adhesion under dynamic conditions of laminar flow, but not under static conditions was significantly increased. In addition, cell spreading was increased in cells with reduced PTEN expression. We conclude that PTEN appears to be involved in the regulation of integrin-mediated adhesion through dephosphorylation of FAK. This phosphatase might play a role as a negative regulator for the formation of stable HT-29 cell adhesion to extracellular matrix.	Inst Mol Med, Huntington Beach, CA 92649 USA; Univ Hosp Muenster, Dept Surg, Mol Biol Lab, D-48149 Munster, Germany	University of Munster	Haier, J (corresponding author), Inst Mol Med, 15162 Triton Lane, Huntington Beach, CA 92649 USA.	haier@uni-muenster.de						Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Cairns P, 1997, CANCER RES, V57, P4997; Chang JG, 1999, EUR J CANCER, V35, P647, DOI 10.1016/S0959-8049(98)00411-0; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Chi SG, 1998, GASTROENTEROLOGY, V115, P1084, DOI 10.1016/S0016-5085(98)70078-2; Cool D E, 1993, Semin Cell Biol, V4, P443, DOI 10.1006/scel.1993.1052; Dahia PLM, 1997, CANCER RES, V57, P4710; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Haier J, 1999, INT J COLORECTAL DIS, V14, P119, DOI 10.1007/s003840050196; Haier J, 1999, CLIN EXP METASTAS, V17, P377, DOI 10.1023/A:1006658414040; Haier J, 1999, CLIN EXP METASTAS, V17, P713, DOI 10.1023/A:1006754829564; Haier J, 2000, J CANCER RES CLIN, V126, P699, DOI 10.1007/s004320000161; Haier J, 1999, BRIT J CANCER, V80, P1867, DOI 10.1038/sj.bjc.6690614; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maier D, 1999, CANCER RES, V59, P5479; Manes S, 1999, MOL CELL BIOL, V19, P3125; Marsh DJ, 1997, CANCER RES, V57, P5017; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Olschwang S, 1998, NAT GENET, V18, P12, DOI 10.1038/ng0198-12; Pesche S, 1998, ONCOGENE, V16, P2879, DOI 10.1038/sj.onc.1202081; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Resnick N, 1997, ADV EXP MED BIOL, V430, P155; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; Risinger JI, 1997, CANCER RES, V57, P4736; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TAKAGI J, 1995, CELL STRUCT FUNCT, V20, P403, DOI 10.1247/csf.20.403; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tsuchiya KD, 1998, GENE CHROMOSOME CANC, V21, P113, DOI 10.1002/(SICI)1098-2264(199802)21:2<113::AID-GCC6>3.0.CO;2-3; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yano Y, 1996, AM J PHYSIOL-CELL PH, V271, pC635, DOI 10.1152/ajpcell.1996.271.2.C635; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	62	38	50	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1450	1460		10.1038/sj.onc.1205213	http://dx.doi.org/10.1038/sj.onc.1205213			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857088				2022-12-28	WOS:000173861000015
J	Thyrell, L; Erickson, S; Zhivotovsky, B; Pokrovskaja, K; Sangfelt, O; Castro, J; Einhorn, S; Grander, D				Thyrell, L; Erickson, S; Zhivotovsky, B; Pokrovskaja, K; Sangfelt, O; Castro, J; Einhorn, S; Grander, D			Mechanisms of Interferon-alpha induced apoptosis in malignant cells	ONCOGENE			English	Article						interferon; apoptosis; caspase; mitochondria	CASPASE ACTIVATION; MULTIPLE-MYELOMA; PROTEIN-KINASE; UP-REGULATION; FAS LIGAND; IFN-GAMMA; B-CELLS; DEATH; INDUCTION; EXPRESSION	Interferon alpha (IFNalpha) has been used in the treatment of several types of cancer for almost 30 years, yet the mechanism(s) responsible for its anti-tumoral action remains unknown. A variety of cellular responses, including inhibition of cell growth and induction of apoptosis are induced by IFNs, and apoptotic induction by this cytokine has been proposed to be of importance for both its anti-tumoral in addition to its anti-viral responses. The aim of the present study was to delineate the pathways activated during IFNalpha-induced apoptosis in malignant cell lines. We found that apoptosis induced by IFNalpha was associated with activation of caspases-1, -2, -3, -8 and -9 and that this activation was a critical event. Caspase-3 activation was dependent on activity of caspases-8 and -9, moreover, activation of caspase-8 seems to be the upstream event in IFNalpha-induced caspase cascade. We also found loss of mitochondrial membrane potential as well as release of cytochrome c post IFN-treatment, clearly implicating the involvement of mitochondria in IFN-mediated apoptosis. Furthermore, IFNalpha-induced apoptosis was found to be independent on interactions between the Fas-receptor and its ligand. These studies form the basis for further investigations aiming to improve IFN therapy and the development of future strategies to overcome the IFN resistance observed in some malignancies.	Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, Res Lab Radiumhemmet, S-17176 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Dept Toxicol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Grander, D (corresponding author), Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, Res Lab Radiumhemmet, S-17176 Stockholm, Sweden.		Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482; Pokrovskaja Tamm, Katja/0000-0001-6359-1256				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bernassola F, 1999, CELL DEATH DIFFER, V6, P652, DOI 10.1038/sj.cdd.4400537; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Dai CH, 1998, BLOOD, V91, P1235, DOI 10.1182/blood.V91.4.1235; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; GRANDER D, 1993, EUR J CANCER, V14, P1940; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Kaser A, 1999, CYTOKINE, V11, P736, DOI 10.1006/cyto.1998.0484; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Luchetti F, 1998, HAEMATOLOGICA, V83, P974; MANABE A, 1993, LEUKEMIA, V7, P1990; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; Raza A, 2000, LEUKEMIA RES, V24, P63, DOI 10.1016/S0145-2126(99)00152-6; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RHIM JS, 1989, ANTICANCER RES, V9, P1345; Roth W, 1998, J NEUROIMMUNOL, V87, P121, DOI 10.1016/S0165-5728(98)00079-4; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sarkar SN, 1999, J BIOL CHEM, V274, P25535, DOI 10.1074/jbc.274.36.25535; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sedger LM, 1999, J IMMUNOL, V163, P920; SILINS SL, 1995, INT J CANCER, V60, P65, DOI 10.1002/ijc.2910600110; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Spets H, 1998, BLOOD, V92, P2914, DOI 10.1182/blood.V92.8.2914.420k14_2914_2923; Stridh H, 1999, BIOCHEM BIOPH RES CO, V266, P460, DOI 10.1006/bbrc.1999.1821; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Witzig TE, 2000, CLIN CANCER RES, V6, P681; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	50	173	182	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1251	1262		10.1038/sj.onc.1205179	http://dx.doi.org/10.1038/sj.onc.1205179			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850845				2022-12-28	WOS:000173729400013
J	Gentiletti, F; Mancini, F; D'Angelo, M; Sacchi, A; Pontecorvi, A; Jochemsen, AG; Moretti, F				Gentiletti, F; Mancini, F; D'Angelo, M; Sacchi, A; Pontecorvi, A; Jochemsen, AG; Moretti, F			MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts	ONCOGENE			English	Article						MDMX; p53; proteolytic degradation; caspase cleavage	DNA-DAMAGE; TUMOR-SUPPRESSOR; P53 PROTEIN; P53-BINDING PROTEIN; ONCOPROTEIN MDM2; PHOSPHORYLATION; DEGRADATION; CELLS; INHIBITION; APOPTOSIS	MDMX is a p53 binding protein, which shares a high degree of homology with MDM2, a negative regulator of the tumor suppressor p53. MDMX has been shown to counteract MDM2-dependent p53 degradation and to stabilize p53 in its inactive form. In this study: we identify two MDMX proteolytic pathways that control its intracellular levels, and show that MDMX post-translational processing may be regulated by p53. Mouse MDMX is cleaved in vitro and in vivo by caspase activity, between aminoacids 358 and 361, producing a p54 minor form. In addition, MDMX is subjected to proteasome-mediated degradation, which concurs to MDMX proteolysis mainly through degradation of p54. A D361A-MDMX mutant, resistant to caspase cleavage, exhibits prolonged intracellular lifetime in comparison to wild-type protein, indicating that caspase cleavage affects stability of MDMX protein probably by modulating its further degradation. Overexpression of exogenous p53 increases the intracellular levels of p54 product. Similarly, activation of endogenous p53 by adriamycin enhances MDMX cleavage and produces a marked decrease of its intracellular levels, while not affecting the D361A-MDMX mutant. In addition, the D361AMDMX mutant lacks the ability to inhibit p53 transactivation in respect to wild-type MDMX, suggesting that MDMX caspase cleavage play an important functional role. In conclusion, our results demonstrate that, in analogy to MDM2, MDMX may be subjected to proteolytic modifications that regulate its intracellular levels. Moreover, decrease of MDMX protein levels following p53 activation suggests a p53-dependent regulatory feedback of MDMX function.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy; Catholic Univ, Med Pathol Inst, I-00100 Rome, Italy; Leiden Univ, Ctr Med, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands; CNR, Neurobiol & Mol Med Inst, I-00156 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Leiden University; Leiden University - Excl LUMC; Consiglio Nazionale delle Ricerche (CNR)	Moretti, F (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Via Messi Oro 156, I-00158 Rome, Italy.		Moretti, Fabiola/I-5647-2013; Mancini, Francesca/AAZ-1672-2021; mancini, francesca/K-6062-2016	Moretti, Fabiola/0000-0002-2691-1254; Mancini, Francesca/0000-0002-2459-8815; mancini, francesca/0000-0002-2459-8815				Baek SH, 1997, BIOCHEM J, V325, P325, DOI 10.1042/bj3250325; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Freedman DA, 1999, CANCER RES, V59, P1; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; GRAHAM F, 1991, METHOD MOL BIOL, P3587; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Jackson MW, 2001, J BIOL CHEM, V276, P25336, DOI 10.1074/jbc.M010685200; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1991, CANCER RES, V51, P6304; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Mayo LD, 1997, CANCER RES, V57, P5013; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moretti F, 1997, ONCOGENE, V14, P729, DOI 10.1038/sj.onc.1200887; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rallapalli R, 1999, J BIOL CHEM, V274, P8299, DOI 10.1074/jbc.274.12.8299; Ramos YFM, 2001, CANCER RES, V61, P1839; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Stad R, 2000, J BIOL CHEM, V275, P28039; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	51	35	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2002	21	6					867	877		10.1038/sj.onc.1205137	http://dx.doi.org/10.1038/sj.onc.1205137			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840332				2022-12-28	WOS:000173427100002
J	Kabsch, K; Alonso, A				Kabsch, K; Alonso, A			The human papillomavirus type 16 (HPV-16) E5 protein sensitizes human keratinocytes to apoptosis induced by osmotic stress	ONCOGENE			English	Article						fpapillomavirus; keratinocytes; apoptosis; osmotic shock	GROWTH-FACTOR RECEPTOR; EPITHELIAL-CELL LINE; ACTIVATION; GENE; CASPASES; FIBROBLASTS; ONCOPROTEIN; KINASE; HACAT; DEATH	We have studied the role of the HPV-16 E5 protein in apoptosis, using HaCaT cell lines stably transfected with either E5 (HaCaT/E5) or the empty vector (HaCaT/ pMSG) as control. When subjected to a hyperosmolar concentration of sorbitol, HaCaT/E5 cells respond with cytochrome e release, activation of caspase-3, -8, and -9, and PARP-cleavage, showing that the mitochondria and death-receptor mediated apoptotic pathways are involved in subsequent cell death. Similar effects are observed for the control cells only after extended sorbitol treatment. Thus, E5-expressing cells are more sensitive to osmotic stress, perhaps because of modifications of the cellular membranes caused by this strongly hydrophobic molecule.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Kabsch, K (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	k.kabsch@dkfz-heidelberg.de						Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; Crusius K, 2000, VIRUS GENES, V20, P65, DOI 10.1023/A:1008112207824; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; HACHISUKA H, 1990, CELL TISSUE RES, V260, P207, DOI 10.1007/BF00297507; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jost M, 2001, J INVEST DERMATOL, V116, P860, DOI 10.1046/j.1523-1747.2001.01356.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KELL B, 1994, J GEN VIROL, V75, P2451, DOI 10.1099/0022-1317-75-9-2451; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1992, J VIROL, V66, P1833; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; ULLMAN CG, 1994, BIOCHEM SOC T, V22, pS439, DOI 10.1042/bst022439s; Wang J, 2000, J CELL SCI, V113, P753	33	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					947	953		10.1038/sj.onc.1205147	http://dx.doi.org/10.1038/sj.onc.1205147			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840340				2022-12-28	WOS:000173427100010
J	Hackett, JA; Greider, CW				Hackett, JA; Greider, CW			Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis	ONCOGENE			English	Article						telomeres; telomerase; chromosomal instability	INDUCED DNA-REPLICATION; STRAND BREAK REPAIR; TO-END FUSIONS; BINDING-PROTEIN; FISSION YEAST; NONRECIPROCAL TRANSLOCATIONS; IMMORTAL CELLS; CANCER; KU; TRF2	Telomere shortening and telomerase activation both occur in human tumors. Telomere shortening has been proposed to have two conflicting roles in tumorigenesis: tumor suppression and initiation of chromosomal instability. Similarly, while telomerase activation is suggested to be necessary for tumor growth, telomerase may help to stabilize genomic instability. Here we review what is known about these conflicting roles and propose a framework to understand the role of telomerase in cancer progression.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Predoctoral Training Program Human Genet & Mol Bi, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Greider, CW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 617 Hunterian Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.			Greider, Carol/0000-0002-5494-8126	NIGMS NIH HHS [GM43080] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043080] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Baumann P, 2000, MOL BIOL CELL, V11, P3265, DOI 10.1091/mbc.11.10.3265; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bosco G, 1998, GENETICS, V150, P1037; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; CHADENEAU C, 1995, CANCER RES, V55, P2533; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 2002, HARVEY LECT SERIES, V96, P2000; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; HICKE BJ, 1990, P NATL ACAD SCI USA, V87, P1481, DOI 10.1073/pnas.87.4.1481; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Killan A, 1998, PLANT MOL BIOL, V37, P621, DOI 10.1023/A:1005994629814; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; Lewis LK, 2000, MUTAT RES-FUND MOL M, V451, P71, DOI 10.1016/S0027-5107(00)00041-5; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; McClintock B, 1941, GENETICS, V26, P234; McEachern MJ, 2000, P NATL ACAD SCI USA, V97, P11409, DOI 10.1073/pnas.210388397; Muller H, 1938, COLLECTING NET, V13, P181; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; SHAY JW, 1997, EUR J CAN, V33, P789; Shih IM, 2001, CANCER RES, V61, P818; Tang RP, 1998, CANCER RES, V58, P4052; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WANG WL, 1992, NUCLEIC ACIDS RES, V20, P6621, DOI 10.1093/nar/20.24.6621; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	62	195	202	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					619	626		10.1038/sj.onc.1205061	http://dx.doi.org/10.1038/sj.onc.1205061			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850787				2022-12-28	WOS:000173390500014
J	Ackler, S; Ahmad, S; Tobias, C; Johnson, MD; Glazer, RI				Ackler, S; Ahmad, S; Tobias, C; Johnson, MD; Glazer, RI			Delayed mammary gland involution in MMTV-AKT1 transgenic mice	ONCOGENE			English	Article						AKT1; transgenic; mammary gland; cyclin D1	BREAST-CANCER CELLS; AKT/PROTEIN KINASE-B; TRANSCRIPTION FACTOR FKHR; GROWTH-FACTOR PROTECTS; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLIN D1; AKT ACTIVATION; INDUCED APOPTOSIS; FACTOR I; KAPPA-B	AKT1/protein kinase B alpha is a protein-serine/threonine kinase that regulates multiple targets involved in cell survival and cell cycle progression in a variety of cell types including breast cancer cells. To explore the role of Akt1 in mammary gland function and tumorigenesis, transgenic mice were generated that express human AKT1 under the control of the MMTV promoter. Virgin transgenic mice did not exhibit a dominant phenotype, but upon cessation of lactation, a notable delay in involution occurred compared to age-matched nontransgenic mice. The delay in involution coincided with increased hyperplasia as evidenced by an increased number of binucleated epithelial cells and a marked elevation in cyclin D1 expression in mammary epithelium. The delayed involution phenotype corresponded to increased phosphorylation of Thr308 in AKT1 and Ser136 in BAD, but not phosphorylation of Ser21 in GSK-3 alpha. There was no evidence of mammary dysplasia or neoplasia during the lifespan of multiparous transgenic mice. These data suggest that AKT1 is involved in cell survival in the lactating and involuting mammary gland, but that overexpression of AKT1 alone is insufficient to induce transformation.	Georgetown Univ, Sch Med, Dept Pharmacol, Washington, DC 20007 USA; Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Oncol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Glazer, RI (corresponding author), Georgetown Univ, Sch Med, Dept Pharmacol, 3970 Reservoir Rd NW,Res Bldg,Room W318, Washington, DC 20007 USA.	glazerr@georgetown.edu			NATIONAL CANCER INSTITUTE [P50CA058185, P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA51008, P50-CA58185, R01 CA881565] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Bowers DC, 2000, CANCER RES, V60, P4277; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DEL PL, 1997, SCIENCE, V278, P687; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; HAYCOCK JW, 1993, ANAL BIOCHEM, V208, P397, DOI 10.1006/abio.1993.1068; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; Krane IM, 1996, ONCOGENE, V12, P1781; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; SMITH GH, 1995, AM J PATHOL, V147, P1081; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	47	76	77	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					198	206		10.1038/sj.onc.1205052	http://dx.doi.org/10.1038/sj.onc.1205052			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803463				2022-12-28	WOS:000173026200004
J	Murga, C; Zohar, M; Teramoto, H; Gutkind, JS				Murga, C; Zohar, M; Teramoto, H; Gutkind, JS			Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappa B	ONCOGENE			English	Article						RhoG; PI3K; Akt; cell survival	PROTEIN-KINASE B; PHOSPHATIDYLINOSITOL 3-KINASE; PC12 CELLS; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; PATHWAY; APOPTOSIS; RAS; GTPASES; TARGET	Small GTPases of the Rho family play a central role in cellular processes that involve the reorganization of the actin-based cytoskeleton. Rho-related GTPases, which include Rac and Cdc42, can also regulate gene expression often through the activation of kinase cascades leading to enhanced activity of stress activated protein kinases (SAPKs), including JNK and p38 MAP kinases. As SAPKs are implicated in programmed cell death, these observations suggest that Rho GTPases may promote the initiation of the apoptotic process. However, recent reports suggest that Rho GTPases can have either a protective or a proapoptotic role, depending on the particular cellular context. In an effort to explore the molecular mechanisms underlying these divergent biological activities, we asked whether there was indeed a correlation between the ability to induce SAPKs and apoptosis by Rho family members. We found that although constitutively activated (Q61L) mutants of Rac1, Cdc42, and RhoG, a Rac1 related GTPase of unknown function, potently induce JNK in COS 7 cells, none of these GTPases could induce apoptosis, nor enhance uv-induced cell death. In contrast, Rac1 and RhoG efficiently protected cells from uv-induced apoptosis. Furthermore, we provide evidence that Rac1 and RhoG can activate both apoptotic and anti-apoptotic pathways. Whereas the former is mediated through JNK, the latter is independent on the transcriptional activation of NF-KB, a pro-survival pathway, but results from the direct interaction of these GTPases with phosphatidylinositol 3-kinase (PI3K) and the stimulation of Akt. Together, these findings indicate that members of the Rho family of small GTP-binding proteins can provoke the concomitant stimulation of two counteracting signaling pathways, and that their balance ultimately determines the ability of these GTPases to promote cell survival or death.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Teramoto, H (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Room 211, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Murga, Cristina/E-1965-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Murga, Cristina/0000-0002-8964-4077	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Blangy A, 2000, J CELL SCI, V113, P729; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen YR, 2000, INT J ONCOL, V16, P651; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Gomez J, 1998, IMMUNOL CELL BIOL, V76, P125, DOI 10.1046/j.1440-1711.1998.00723.x; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Levresse V, 2000, J NEUROSCI RES, V62, P799; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Minamoto T, 2000, CANCER DETECT PREV, V24, P1; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	50	136	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					207	216		10.1038/sj.onc.1205036	http://dx.doi.org/10.1038/sj.onc.1205036			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803464				2022-12-28	WOS:000173026200005
J	Lasorella, A; Uo, T; Iavarone, A				Lasorella, A; Uo, T; Iavarone, A			Id proteins at the cross-road of development and cancer	ONCOGENE			English	Article						cell differentiation; cell cycle; retinoblastoma protein; Id2; neuroblastoma; angiogenesis	LOOP-HELIX PROTEIN; RETINOBLASTOMA PROTEIN; CELL-CYCLE; TRANSCRIPTION FACTORS; NEGATIVE REGULATOR; PANCREATIC-CANCER; HUMAN FIBROBLASTS; INHIBITOR ID2; EXPRESSION; DIFFERENTIATION	A large body of evidence has been, accumulated that demonstrates dominant effects of Id proteins on different aspects of cellular growth. Generally, constitutive expression of Id not only blocks cell differentiation but also drives proliferation. In some settings, it is sufficient to render cells immortal or induce oncogenic transformation. The participation of Id proteins in advanced human malignancy, where they are frequently deregulated, has been dramatically bolstered by the recent discovery that Id exert pivotal contributions to many of the essential alterations that collectively dictate malignant growth. Relentless proliferation associated with self-sufficiency in growth signals and insensitivity to growth inhibitory signals, sustained neoangiogenesis, tissue invasiveness and migration capabilities of tumor cells all share dependency on the unlimited availability of Id proteins. It is remarkable that many of these features recapitulate those physiologically propelled by Id proteins to support normal development. We propose that the participation of Id in multiple fundamental traits of cancer may be the basis for unprecedented therapeutic opportunities.	Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, Dev & Mol Biol & Comprehens Canc Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Iavarone, A (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, Dev & Mol Biol & Comprehens Canc Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [R01-CA85628] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085628] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Belletti B, 2001, J BIOL CHEM, V276, P13867, DOI 10.1074/jbc.M010509200; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen HP, 1999, BIOCHEM BIOPH RES CO, V256, P614, DOI 10.1006/bbrc.1999.0386; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Cooper CL, 1997, BLOOD, V89, P3155, DOI 10.1182/blood.V89.9.3155; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HARA E, 1994, J BIOL CHEM, V269, P2139; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; Israel MA, 1999, CANCER RES, V59, p1726S; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; Katzenstein Howard M., 1998, Current Opinion in Oncology, V10, P43, DOI 10.1097/00001622-199801000-00008; Kebebew E, 2000, SURGERY, V128, P952, DOI 10.1067/msy.2000.111082; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; Kim D, 1999, MOL CELL BIOL, V19, P8240; Kleeff J, 1998, CANCER RES, V58, P3769; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LASORELLA A, 2002, IN PRESS CANC RES, V62; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lin CQ, 2000, CANCER RES, V60, P1332; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; NAGATA Y, 1995, BIOCHEM BIOPH RES CO, V207, P916, DOI 10.1006/bbrc.1995.1273; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Polsky D, 2001, CANCER RES, V61, P6008; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Sablitzky F, 1998, CELL GROWTH DIFFER, V9, P1015; Schindl M, 2001, CANCER RES, V61, P5703; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5; Toma JG, 2000, J NEUROSCI, V20, P7648; Walterhouse D O, 1997, Cancer Treat Res, V92, P3; Wang SL, 2001, NEURON, V29, P603, DOI 10.1016/S0896-6273(01)00237-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	67	225	238	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 20	2001	20	58					8326	8333		10.1038/sj.onc.1205093	http://dx.doi.org/10.1038/sj.onc.1205093			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840325				2022-12-28	WOS:000173319500006
J	Dorey, K; Engen, JR; Kretzschmar, J; Wilm, M; Neubauer, G; Schindler, T; Superti-Furga, G				Dorey, K; Engen, JR; Kretzschmar, J; Wilm, M; Neubauer, G; Schindler, T; Superti-Furga, G			Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase	ONCOGENE			English	Article						activation loop; crystal structure; phosphorylation; tyrosine kinase	PROTEIN-KINASE; CRYSTAL-STRUCTURE; ONCOGENIC FORMS; BCR-ABL; SRC; DOMAIN; FAMILY; AUTOPHOSPHORYLATION; MUTATION; RESIDUES	c-Abl is a nuclear and cytoplasmic tyrosine kinase involved in a variety of cellular growth and differentiation processes. In contrast to its oncogenic counterparts, like BCR-Abl, c-Abl is not constitutively tyrosine phosphorylated and its catalytic activity is very low. Here we report tyrosine phosphorylation of endogenous c-Abl and a concomitant increase in catalytic activity. Using Abl -/- cells reconstituted with mutated c-Abl forms, we show that phosphorylation and activity depend on Tyr412 in the activation loop. Tyr412 is also required for stimulation by PDGF or by cotransfection of active Src. Phosphorylation of Tyr412 can occur autocatalytically by a trans-mechanism and cause activation of otherwise inactive c-Abl, suggesting a positive feedback loop on c-Abl activity. In the recent structure of the Abl catalytic domain bound to the STI-571 inhibitor, unphosphorylated Tyr412 in the activation loop points inward and appears to interfere with catalysis. We mutated residues involved in stabilizing this inhibited form of the activation loop and in positioning Tyr412. These mutations resulted in tyrosine phosphorylation and activation of c-Abl, as if relieving c-Abl from inhibition. Tyr412 is therefore necessary both for activity and for regulation of c-Abl, by stabilizing the inactive or the active conformation of the enzyme in a phosphorylation-dependent manner.	European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Biochem Instrumentat Programme, D-69117 Heidelberg, Germany; Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); Rockefeller University	Superti-Furga, G (corresponding author), European Mol Biol Lab, Dev Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Superti-Furga, Giulio/F-4755-2015; Superti-Furga, Giulio/AAE-5681-2019	Superti-Furga, Giulio/0000-0002-0570-1768; Wilm, Matthias/0000-0002-5461-6834; Dorey, Karel/0000-0003-0846-5286; Engen, John R./0000-0002-6918-9476				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Allen PB, 1996, J BIOL CHEM, V271, P19585, DOI 10.1074/jbc.271.32.19585; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Cong F, 1999, MOL CELL BIOL, V19, P8314; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; Dikstein R, 1996, P NATL ACAD SCI USA, V93, P2387, DOI 10.1073/pnas.93.6.2387; Dorey K, 1999, BIOL CHEM, V380, P223; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9; Hubbard SR, 1999, NAT STRUCT BIOL, V6, P711, DOI 10.1038/11468; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Juang JL, 1999, ONCOGENE, V18, P5138, DOI 10.1038/sj.onc.1202911; KINGHTON DR, 1991, SCIENCE, V253, P415; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; SAWYERS CL, 1994, CELL, V77, P1; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WITTE ON, 1981, J VIROL, V39, P870, DOI 10.1128/JVI.39.3.870-878.1981; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	39	70	71	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8075	8084		10.1038/sj.onc.1205017	http://dx.doi.org/10.1038/sj.onc.1205017			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781820				2022-12-28	WOS:000172396800004
J	Scandura, JM; Boccuni, P; Cammenga, J; Nimer, SD				Scandura, JM; Boccuni, P; Cammenga, J; Nimer, SD			Transcription factor fusions in acute leukemia: variations on a theme	ONCOGENE			English	Review						leukemia; transcription; PML; RAR alpha; TGF beta; NUP98; AML1/ETO; CBF beta	ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR-BETA; ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; ACUTE MYELOGENOUS LEUKEMIA; CORE BINDING-FACTOR; PML-RAR-ALPHA; MYOSIN HEAVY-CHAIN; HISTONE DEACETYLASE COMPLEX; MULTIPLE CHROMOSOMAL TRANSLOCATIONS	The leukemia-associated fusion proteins share several structural or functional similarities, suggesting that they may impart a leukemic phenotype through common modes of transcriptional dysregulation. The fusion proteins generated by these translocations usually contain a DNA-binding domain, domains responsible for homo- or hetero-dimerization, and domains that interact with proteins involved in chromatin remodeling (e.g., corepressor molecules or co-activator molecules). It is these shared features that constitute the 'variations on the theme' that underling the aberrant growth and differentiation that is the hallmark of acute leukemia cells.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, 1275 York Ave, New York, NY 10021 USA.	s-nimer@mskcc.org		Scandura, Joseph/0000-0002-9525-143X	NATIONAL CANCER INSTITUTE [T32CA009512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052208] Funding Source: NIH RePORTER; NCI NIH HHS [CA09512] Funding Source: Medline; NIDDK NIH HHS [R01 DK 52208] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler HT, 1999, MOL CELL BIOL, V19, P7050; Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Ahuja HG, 2000, CANCER RES, V60, P6227; Ahuja HG, 1999, BLOOD, V94, P3258, DOI 10.1182/blood.V94.9.3258.421a40_3258_3261; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Andrieu V, 1996, BRIT J HAEMATOL, V92, P855, DOI 10.1046/j.1365-2141.1996.415954.x; Arai Y, 1997, BLOOD, V89, P3936, DOI 10.1182/blood.V89.11.3936; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Babichuk CK, 1997, J BIOL CHEM, V272, P18564, DOI 10.1074/jbc.272.30.18564; Baer MR, 1997, BLOOD, V90, P1643, DOI 10.1182/blood.V90.4.1643.1643_1643_1648; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Batard P, 2000, J CELL SCI, V113, P383; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Bloomfield CD, 1998, CANCER RES, V58, P4173; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BREEN TR, 1991, MECH DEVELOP, V35, P113, DOI 10.1016/0925-4773(91)90062-B; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Broeker PL, 1996, CURR TOP MICROBIOL, V211, P259; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; BYRD JC, 1994, CANCER, V73, P2107, DOI 10.1002/1097-0142(19940415)73:8<2107::AID-CNCR2820730815>3.0.CO;2-W; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Cashman JD, 1999, BLOOD, V94, P3722, DOI 10.1182/blood.V94.11.3722.423k20_3722_3729; CASTAIGNE S, 1990, BLOOD, V76, P1704; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dann EJ, 2001, BEST PRACT RES CL HA, V14, P119, DOI 10.1053/beha.2000.0119; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DUBOIS CM, 1994, BLOOD, V83, P3138; Ducos K, 2000, J CELL PHYSIOL, V184, P80, DOI 10.1002/(SICI)1097-4652(200007)184:1<80::AID-JCP8>3.0.CO;2-Q; Dybedal I, 1997, BLOOD, V90, P3395, DOI 10.1182/blood.V90.9.3395; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Engel ME, 1998, J CELL BIOCHEM, P111; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Faretta M, 2001, SEMIN HEMATOL, V38, P42, DOI 10.1053/shem.2001.20866; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; FEINSTEIN PG, 1995, GENETICS, V140, P573; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fortunel NO, 2000, BLOOD, V96, P2022; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grimwade D, 2001, BLOOD, V98, P1312, DOI 10.1182/blood.V98.5.1312; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; JACOBSEN RJ, 1984, BRIT J HAEMATOL, V57, P539, DOI 10.1111/j.1365-2141.1984.tb02928.x; JACOBSEN SEW, 1993, J IMMUNOL, V151, P4534; JACOBSEN SEW, 1991, BLOOD, V77, P1706; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Jochum W, 1999, Verh Dtsch Ges Pathol, V83, P216; Joh T, 1996, ONCOGENE, V13, P1945; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Jones KA, 2000, GENE DEV, V14, P1992; KALWINSKY DK, 1990, J CLIN ONCOL, V8, P75, DOI 10.1200/JCO.1990.8.1.75; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; Kasper LH, 1999, MOL CELL BIOL, V19, P764; KEATING MJ, 1988, LEUKEMIA, V2, P403; Kim JH, 1999, INT J BIOCHEM CELL B, V31, P933, DOI 10.1016/S1357-2725(99)00048-5; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LAI JL, 1995, LEUKEMIA, V9, P370; Langabeer SE, 1997, BRIT J HAEMATOL, V99, P925, DOI 10.1046/j.1365-2141.1997.4663270.x; Langabeer SE, 1997, BRIT J HAEMATOL, V96, P736, DOI 10.1046/j.1365-2141.1997.d01-2096.x; Lardon F, 1996, LEUKEMIA, V10, P1937; LARSON RA, 1986, BLOOD, V68, P1242; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Leith CP, 1997, BLOOD, V89, P3323; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; LONGO L, 1993, LEUKEMIA LYMPHOMA, V11, P405, DOI 10.3109/10428199309067933; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; LU J, 1995, MOL CELL BIOL, V15, P1651; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Luo RT, 2001, MOL CELL BIOL, V21, P5678, DOI 10.1128/MCB.21.16.5678-5687.2001; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Mahmud N, 1999, BRIT J HAEMATOL, V105, P470, DOI 10.1046/j.1365-2141.1999.01324.x; Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MARLTON P, 1995, LEUKEMIA, V9, P965; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; McLean TW, 1996, BLOOD, V88, P4252; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; McNeil S, 2000, J CELL BIOCHEM, V79, P103, DOI 10.1002/1097-4644(2000)79:1<103::AID-JCB100>3.3.CO;2-2; Megonigal MD, 1998, ONCOGENE, V16, P1351, DOI 10.1038/sj.onc.1201637; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mrozek K, 2001, BEST PRACT RES CL HA, V14, P19, DOI 10.1053/beha.2000.0114; Mrozek K, 1997, SEMIN ONCOL, V24, P17; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Nakamura T, 1999, BLOOD, V94, P741, DOI 10.1182/blood.V94.2.741.414k04_741_747; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakao M, 1996, LEUKEMIA, V10, P1911; Nishiyama M, 1999, GENE CHROMOSOME CANC, V26, P215, DOI 10.1002/(SICI)1098-2264(199911)26:3<215::AID-GCC5>3.3.CO;2-T; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Odaka R, 2000, ONCOGENE, V19, P3584, DOI 10.1038/sj.onc.1203689; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Padua RA, 1998, LEUKEMIA, V12, P887, DOI 10.1038/sj.leu.2401044; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; PEARSONWHITE S, 1995, BLOOD, V86, P2146, DOI 10.1182/blood.V86.6.2146.bloodjournal8662146; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Pierelli L, 2000, BLOOD, V95, P3001; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Raimondi SC, 1999, BLOOD, V94, P3707; Rasio D, 1996, CANCER RES, V56, P1766; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rhoades KL, 2000, BLOOD, V96, P2108; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Robertson SC, 2000, TRENDS GENET, V16, P368, DOI 10.1016/S0168-9525(00)02077-1; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; Rogaia D, 1997, CANCER RES, V57, P799; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Rozovskaia T, 2000, ONCOGENE, V19, P351, DOI 10.1038/sj.onc.1203307; RUBNITZ JE, 1994, BLOOD, V84, P1747; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SARGIACOMO M, 1991, ANN NY ACAD SCI, V628, P84, DOI 10.1111/j.1749-6632.1991.tb17226.x; Satake N, 1999, LEUKEMIA, V13, P1013, DOI 10.1038/sj.leu.2401439; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; SHEN WPV, 1987, ONCOGENE, V1, P157; Shikami M, 1999, LEUKEMIA, V13, P358, DOI 10.1038/sj.leu.2401343; Shimada H, 2000, BLOOD, V96, P655; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Soignet S, 1997, CANCER CHEMOTH PHARM, V40, pS25, DOI 10.1007/s002800051057; Soignet SL, 2001, J CLIN ONCOL, V19, P3852, DOI 10.1200/JCO.2001.19.18.3852; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Stein GS, 2000, J CELL BIOCHEM, P84; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUPER HJG, 1994, BLOOD, V83, P641; SWIRSKY DM, 1984, BRIT J HAEMATOL, V56, P199, DOI 10.1111/j.1365-2141.1984.tb03948.x; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Takeuchi S, 1997, LEUKEMIA, V11, P1220, DOI 10.1038/sj.leu.2400743; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TESTA U, 1993, J IMMUNOL, V150, P2418; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Turley JM, 1996, CELL GROWTH DIFFER, V7, P1535; Uchida H, 1997, J IMMUNOL, V158, P2251; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; VAN DJ, 1995, P NATL ACAD SCI USA, V92, P7376; VanRanst PCF, 1996, EXP HEMATOL, V24, P1509; Visani G, 2001, LEUKEMIA, V15, P903, DOI 10.1038/sj.leu.2402142; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Warrell RP, 1996, ANNU REV MED, V47, P555, DOI 10.1146/annurev.med.47.1.555; Weekx SFA, 1999, LEUKEMIA, V13, P1266, DOI 10.1038/sj.leu.2401462; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1996, LEUKEMIA, V10, P735; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yang R, 1999, BLOOD, V93, P2067; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	289	76	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3422	3444		10.1038/sj.onc.1205315	http://dx.doi.org/10.1038/sj.onc.1205315			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032780				2022-12-28	WOS:000175633300015
J	Saucier, C; Papavasiliou, V; Palazzo, A; Naujokas, MA; Kremer, R; Park, M				Saucier, C; Papavasiliou, V; Palazzo, A; Naujokas, MA; Kremer, R; Park, M			Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis	ONCOGENE			English	Article						receptor tyrosine kinase; transformation; tumorigenesis; metastasis; Grb2; She	GROWTH-FACTOR RECEPTOR; TPR-MET ONCOPROTEIN; PHOSPHOLIPASE C-GAMMA; BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL MORPHOGENESIS; CARBOXY-TERMINUS; BETA-SUBUNIT; ACTIVATION; REQUIRES	Many human cancers have been associated with the deregulation of receptor tyrosine kinases (RTK). However, the individual contribution of receptor-associated signaling proteins in cellular transformation and metastasis is poorly understood. To examine the role of RTK activated signal transduction pathways to processes involved in cell transformation, we have exploited the oncogenic derivative of the Met RTK (Tpr-Met). Unlike other RTKs, twin tyrosine residues in the carboxy-terminal tail of the Met oncoprotein and receptor are required for all biological and transforming activities, and a mutant lacking these tyrosines is catalytically active but non transforming. Using this mutant we have inserted oligonucleotide cassettes, each encoding a binding site for a specific signaling protein derived from other RTKs. We have generated variant forms of the Tpr-Met oncoprotein with the ability to bind individually to the p85 subunit of P13'K, PLCgamma, or to the Grb2 or Shc adaptor proteins. Variants that recruit the Shc or Grb2 adaptor proteins generated foci of morphologically transformed fibroblast cells and induced anchorage-independent growth, scattering of epithelial cells and experimental metastasis. In contrast, variants that bind and activate P13'K or PLCgamma failed to generate readily detectable foci. Although cell lines expressing the P13'K variant grew in soft-agar, these cells were non metastatic. Using this unique RTK oncoprotein model, we have established that Grb2 or Shc dependent signaling pathways are sufficient for cell transformation and metastatic spread.	McGill Univ, Ctr Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada.	morag@molonc.mcgill.ca	Palazzo, Alexander/B-1270-2013; Saucier, Caroline/Q-9250-2019	Palazzo, Alexander/0000-0002-9700-1995; Saucier, Caroline/0000-0001-7678-9886; Kremer, Richard/0000-0002-7053-2139				Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chang JS, 1997, CANCER RES, V57, P5465; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; SALCINI AE, 1994, ONCOGENE, V9, P2827; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, J BIOL CHEM, V269, P29943	51	57	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1800	1811		10.1038/sj.onc.1205261	http://dx.doi.org/10.1038/sj.onc.1205261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896612	Bronze			2022-12-28	WOS:000174284500002
J	Baldassarre, G; Bruni, P; Boccia, A; Salvatore, G; Melillo, RM; Motti, ML; Napolitano, M; Belletti, B; Fusco, A; Santoro, M; Viglietto, G				Baldassarre, G; Bruni, P; Boccia, A; Salvatore, G; Melillo, RM; Motti, ML; Napolitano, M; Belletti, B; Fusco, A; Santoro, M; Viglietto, G			Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1)	ONCOGENE			English	Article						GDNF; RET; p27; embryonal carcinoma	EMBRYONAL CARCINOMA-CELLS; NEURONAL DIFFERENTIATION; RETINOIC ACID; TYROSINE KINASE; NTERA-2 CELLS; GROWTH-FACTOR; PC12 CELLS; ACTIVATION; RECEPTOR; SURVIVAL	Growth factors of the glial cell line-derived neurotrophic factor (GDNF) family control the differentiation of neuronal cells of the central and peripheral nervous systems. Intracellular signalling of these growth factors is, at least in part, mediated by activation of the RET receptor tyrosine kinase. Here, we demonstrate that GDNF triggering inhibits the proliferation of the embryonal carcinoma cell line NT2/Dl. This antiproliferative effect is accompanied by down-regulation of the SSEA-3 antigen, a marker typical of undifferentiated NT2/D1 cells. We show that these effects are mediated by activation of RET signalling. The block of RET by a kinase-deficient dominant negative mutant impairs GDNF-dependent growth inhibition, whereas the adoptive expression of a constitutively active RET, the RET-MEN2A oncogene, promotes effects similar to those exerted by GDNF. We show that RET signalling increases the expression of the cyclin-dependent kinase inhibitor P27(kip1) in NT2/Dl cells. Both DNA synthesis inhibition and SSEA-3 down-regulation are prevented if p27(kip1) expression is blocked by an antisense construct, which demonstrates that RET-triggered effects are mediated by p27(kip1).	Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Ist Nazl Tumori, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, BIOGEM, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II	Viglietto, G (corresponding author), Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	gvigliet@tin.it	Belletti, Barbara/J-2028-2018; Baldassarre, Gustavo/K-1350-2016; Viglietto, Giuseppe/AAC-2852-2019; melillo, rosa marina/O-5255-2015; napolitano, maria/K-1615-2016	Belletti, Barbara/0000-0003-2249-0285; Baldassarre, Gustavo/0000-0002-9750-8825; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197; MELILLO, Rosa Marina/0000-0002-9233-5275; napolitano, maria/0000-0002-8996-3297				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Billon N, 1996, ONCOGENE, V13, P2047; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; CALIFANO D, 1995, ONCOGENE, V11, P107; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; De Vita G, 2000, CANCER RES, V60, P3916; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LEE VMY, 1986, J NEUROSCI, V6, P514; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miyazono M, 1996, J COMP NEUROL, V376, P603, DOI 10.1002/(SICI)1096-9861(19961223)376:4<603::AID-CNE8>3.0.CO;2-5; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Rose GM, 1999, AGE, V22, P1, DOI 10.1007/s11357-999-0001-8; SAMBROOK J, 1989, MOL CLONINB LAB MANU; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; YAN GZ, 1995, J NEUROSCI, V15, P6200	38	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1739	1749		10.1038/sj.onc.1205226	http://dx.doi.org/10.1038/sj.onc.1205226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896605				2022-12-28	WOS:000174214200012
J	She, QB; Ma, WY; Dong, ZG				She, QB; Ma, WY; Dong, ZG			Role of MAP kinases in UVB-induced phosphorylation of p53 at serine 20	ONCOGENE			English	Article						JNKs; MAPKAPK-2; p53; phosphorylation; UV radiation	ACTIVATED PROTEIN-KINASE; RADIATION-INDUCED APOPTOSIS; N-TERMINAL KINASE; DNA-DAMAGE; AP-1 TRANSACTIVATION; ULTRAVIOLET-RADIATION; GAMMA-RADIATION; JNK ACTIVATION; IN-VITRO; T-CELLS	Phosphorylation of the p53 tumor suppressor protein is one of the key regulatory steps in its activation process. Serine 20 phosphorylation of p53 has been shown to be required for the activation of p53 following UV radiation, but the signaling pathway mediating UV-induced phosphorylation is unknown. Here, we determined the role of MAP kinases in UVB-induced phosphorylation and found that JNKs are directly involved in the phosphorylation of p53 at serine 20. In a mouse JB6 epidermal cell line, dominant negative JNK1 abrogated UVB-induced phosphorylation of p53 at serine 20, whereas dominant negative p38 kinase or its inhibitor, SB202190, partially attenuated the phosphorylation. In contrast, dominant negative ERK2 or the MEK1 inhibitor, PD98059, had no effect on p53 phosphorylation at serine 20. Importantly, UVB-activated or active recombinant JNK1/2, or the p38 kinase downstream target, MAPKAPK-2, but not ERKs or p38 kinase, phosphorylated p53 at serine 20 in vitro. Furthermore, phosphorylation of p53 at serine 20 by UVB-activated JNKs and UVB-induced p53-dependent transcriptional activity were suppressed in Jnk1 or Jnk2 knockout (Jnk1(-/-) or Jnk2(-/-)) cells. Additionally, Jnk1(-/-), Jnk2(-/-), and p53-deficient (p53(-/-)) cells, as well as re-introduction of a p53 mutant with substitution of serine 20 to alanine into p53(-/-) cells, were defective for UVB-induced apoptosis. These findings strongly suggest that JNKs are the major direct signaling mediators of UVB-induced p53 phosphorylation at serine 20.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu		She, Qing-Bai/0000-0002-7207-0599	NCI NIH HHS [CA 77646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRITSCHE M, 1993, ONCOGENE, V8, P307; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1991, CANCER RES, V51, P4279; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOO D, 1994, CELL BIOL LAB HDB, P45; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MERRITT AJ, 1994, CANCER RES, V54, P614; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Prives C, 1999, J PATHOL, V187, P112; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SOUSSI T, 1990, ONCOGENE, V5, P945; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200	58	55	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1580	1589		10.1038/sj.onc.1205239	http://dx.doi.org/10.1038/sj.onc.1205239			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896587	Bronze			2022-12-28	WOS:000173956800014
J	Ortiz-Vega, S; Khokhlatchev, A; Nedwidek, M; Zhang, XF; Dammann, R; Pfeifer, GP; Avruch, J				Ortiz-Vega, S; Khokhlatchev, A; Nedwidek, M; Zhang, XF; Dammann, R; Pfeifer, GP; Avruch, J			The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1	ONCOGENE			English	Article						Ras; Nore1; RASSF1; tumor suppressor; apoptosis	PHOSPHOLIPASE-C; IDENTIFICATION; EFFECTOR; KINASE; ACTIVATION; EPSILON; FAMILY	Nore and RASSF1A are noncatalytic proteins that share 50% identity over their carboxyterminal 300 AA, a segment that encompasses a putative Ras-Rap association (RA) domain. RASSF1 is expressed as several splice variants, each of which contain an RA domain, however the 340 AA RASSF1A, but not the shorter RASSF1C variant, is a putative tumor suppressor. Nore binds to Ras and several Ras-like GTPases in a GTP dependent fashion however neither RASSF1 (A or C) or the C. elegans Nore/RASSF1 homolog, T24F1.3 exhibit any interaction with Ras or six other Ras-like GTPases in a yeast two-hybrid expression assay. A low recovery of RASSF1A (but not RASSF1C) in association with RasG12V is observed however on transient expression in COS cells. Nore and RASSF1A can each efficiently homodimerize and heterodimerize with each other through their nonhomologous aminoterminal segments. Recombinant RASSF1C exhibits a much weaker ability to homodimerize or heterodimerize; thus the binding of RASSF1C to Nore is very much less than the binding of RASSF1A to Nore. The association of RASSF1A with RasG12V in COS cells appears to reflect the hetero-dimerization of RASSF1A with Nore, inasmuch the recovery of RASSF1A with RasG12V is increased by concurrent expression of full length Nore, and abolished by expression of Nore deleted of its RA domain. The preferential ability of RASSF1A to heterodimerize with Nore and thereby associate with Ras-like GTPases may be relevant to its putative tumor suppressor function.	Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabetes Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; City of Hope; Beckman Research Institute of City of Hope	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, 50 Blossom St, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32DK07028] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Barr MM, 1996, MOL CELL BIOL, V16, P5597; Baumann R, 1999, BLOOD, V94, P4314, DOI 10.1182/blood.V94.12.4314.424k16_4314_4320; Daniel TF, 2000, SYST BOT, V25, P15, DOI 10.2307/2666669; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Ehrhardt GRA, 2001, ONCOGENE, V20, P188, DOI 10.1038/sj.onc.1204053; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; Kalhammer G, 1997, FEBS LETT, V414, P599, DOI 10.1016/S0014-5793(97)01076-4; KEIKHOFT E, 1998, ONCOGENE, V17, P1457; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lerman MI, 2000, CANCER RES, V60, P6116; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	38	187	204	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1381	1390		10.1038/sj.onc.1205192	http://dx.doi.org/10.1038/sj.onc.1205192			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857081				2022-12-28	WOS:000173861000008
J	Djelloul, S; Tarunina, M; Barnouin, K; Mackay, A; Jat, PS				Djelloul, S; Tarunina, M; Barnouin, K; Mackay, A; Jat, PS			Differential protein expression, DNA binding and interaction with SV40 large tumour antigen implicate the p63-family of proteins in replicative senescence	ONCOGENE			English	Article						p63; p53; replicative senescence; DNA binding; SV40 T-antigen	LARGE-T-ANTIGEN; RAT EMBRYO FIBROBLASTS; P53 HOMOLOG; CELLULAR SENESCENCE; HUMAN-CELLS; LIFE-SPAN; P63; ANTIBODIES; DIVISION; DISTINCT	P53 activity plays a key role in mammalian cells when they undergo replicative senescence at their Hayflick limit. To determine whether p63 proteins, members of the family of p53-related genes, are also involved in this process, we examined their expression in serially passaged rat embryo fibroblasts. Upon senescence, two truncated DeltaNp63 proteins decreased in abundance whereas two TAp63 isoforms accumulated. 2-D get analysis showed that the DeltaNp63 proteins underwent post-translational modifications in both proliferating and senescent cells. Direct binding of DeltaNp63 proteins to a p53 consensus motif was greater in proliferating cells than senescent cells. In contrast p63alpha isoforms bound to DNA in a p53 dependent manner and this was higher in senescent cells than proliferating cells. An interaction of p63alpha proteins with SV40 large tumour antigen was also detected and ectopic expression of DeltaNp63alpha can extend the lifespan of rat embryo fibroblasts. Taken together the results indicate that p63 proteins may play a role in replicative senescence either by competition for p53 DNA binding sites or by direct interaction with p53 protein bound to DNA.	Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Royal Free & Univ Coll Sch Med, Dept Surg, LICR UCL Breast Canc Lab, London W1P 7LD, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London; University of London; University College London	Jat, PS (corresponding author), Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, Courtauld Bldg,91 Riding House St, London W1W 7BS, England.	parmjit@ludwig.ucl.ac.uk						Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Gonos ES, 1996, MOL CELL BIOL, V16, P5127; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayflick L, 1985, Clin Geriatr Med, V1, P15; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PEREIRASMITH OM, 1990, J CELL PHYSIOL, V144, P546, DOI 10.1002/jcp.1041440324; Powell AJ, 1999, ONCOGENE, V18, P7343, DOI 10.1038/sj.onc.1203154; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Roth J, 1999, J GEN VIROL, V80, P3251, DOI 10.1099/0022-1317-80-12-3251; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Stulik J, 1997, ELECTROPHORESIS, V18, P625, DOI 10.1002/elps.1150180347; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	33	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					981	989		10.1038/sj.onc.1205253	http://dx.doi.org/10.1038/sj.onc.1205253			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850815				2022-12-28	WOS:000173580100001
J	Honore, B; Baandrup, U; Nielsen, S; Vorum, H				Honore, B; Baandrup, U; Nielsen, S; Vorum, H			Endonuclein is a cell cycle regulated WD-repeat protein that is up-regulated in adenocarcinoma of the pancreas	ONCOGENE			English	Article						cell cycle regulated protein; nucleus, endoplasmic reticulum; signal transduction; chaperone activity	HUMAN CALUMENIN; CANCER; EXPRESSION; FAMILY; GENE; IDENTIFICATION; SECRETION; SURVIVAL; BINDING; MEMBERS	The transcript encoding endonuclein, the human homolog of yeast PWP1, was previously found up-regulated in pancreatic cancer tissue. By immunohistochemistry we detected a ubiquitous presence in several tissues examined: skin, liver, thyroid gland, heart muscle, neurons, kidney, bladder, pancreas, adrenal gland, ovary, uterus, testis and prostate gland. We especially noticed that normal pancreatic exocrine cells exhibited low protein levels while pancreatic adenocarcinoma cells revealed high levels. We found a heterogeneous subcellular distribution, especially with varying nuclear levels. In proliferating cells endonuclein protein expression and localization was cell cycle dependent, with increasing levels and nuclear focusing during the interphase toward mitosis. Ultrastructural analysis revealed ER and nuclear localization. Endonuclein contains five WD-repeats, indicating a putative role in crucial regulatory activities in the nucleus as well as in the ER.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Inst Anat, Dept Cell Biol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Pathol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University; Aarhus University	Honore, B (corresponding author), Aarhus Univ, Dept Med Biochem, Ole Worms Alle,Bldg 170, DK-8000 Aarhus C, Denmark.		Honoré, Bent/ABF-3650-2021	Honore, Bent/0000-0002-3459-7429				BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELIS JE, 1994, CELL BIOL LAB HDB, V1, P288; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; Coppola D, 2000, Cancer Control, V7, P421; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; Gress TM, 1996, ONCOGENE, V13, P1819; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Honore B, 1999, FEBS LETT, V456, P274, DOI 10.1016/S0014-5793(99)00911-4; HONORE B, 1995, J BIOL CHEM, V270, P28780; HONORE B, 1994, GENE, V151, P291, DOI 10.1016/0378-1119(94)90673-4; Kang SA, 1996, BRIT J PHARMACOL, V117, P1780, DOI 10.1111/j.1476-5381.1996.tb15354.x; Kore M, 1992, J CLIN INVEST, V90, P1352; Kornmann M, 1998, ONCOLOGY-BASEL, V55, P363, DOI 10.1159/000011879; LIU QY, 1995, ONCOGENE, V10, P619; MURR MM, 1994, CA-CANCER J CLIN, V44, P304, DOI 10.3322/canjclin.44.5.304; MYERS MH, 1989, CA-CANCER J CLIN, V39, P21, DOI 10.3322/canjclin.39.1.21; Naka T, 1998, INT J ONCOL, V12, P1111; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1993, NAT GENET, V5, P3, DOI 10.1038/ng0993-3; SIMON B, 1994, GASTROENTEROLOGY, V106, P1645, DOI 10.1016/0016-5085(94)90422-7; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; Vorum H, 1998, BBA-PROTEIN STRUCT M, V1386, P121, DOI 10.1016/S0167-4838(98)00089-2	27	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1123	1129		10.1038/sj.onc.1205186	http://dx.doi.org/10.1038/sj.onc.1205186			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850830				2022-12-28	WOS:000173580100016
J	Bradshaw, PS; Condie, A; Matutes, E; Catovsky, D; Yuille, MR				Bradshaw, PS; Condie, A; Matutes, E; Catovsky, D; Yuille, MR			Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif	ONCOGENE			English	Article						ATM; rearrangement; somatic hypermutation; T-PLL; T-ALL	ACUTE LYMPHOBLASTIC-LEUKEMIA; ATM GENE; B-CELLS; PROLYMPHOCYTIC LEUKEMIA; MISSENSE MUTATIONS; BCL-6 MUTATIONS; BREAST-CANCER; LYMPHOMA	The mature sporadic T-cell malignancy, T-cell prolymphocytic leukemia (T-PLL) is remarkable for frequently harbouring somatic mutations of the Ataxia Telangiectasia (A-T) gene, ATM. Because some data suggest ATM is frequently rearranged in T-PLL, it was decided to investigate such rearrangements in detail by cloning breakpoints. Among 17 T-PLL tumour samples, three rearrangements were detected by Southern blotting. Two cases harboured a unique type of intragenic duplication in which breakpoints arose at the consensus sequence RGYW/WRCY. The third case harboured a large deletion terminating within the ATM gene. Also, 13 T-cell acute lymphoblastic leukemia (T-ALL) samples were examined and one sample harboured a deletion - insertion with the RGYW motif at the breakpoint in ATM. This is the first known deleterious mutation detected in ATM in T-ALL. Interestingly, the RGYW motif is the signal for a cell-cycle regulated DNA double strand break (DSB) that initiates somatic hypermutation of immunoglobulin and, probably, T-cell receptor genes. The structures of the ATM duplications suggest they may arise from an error in somatic hypermutation. We suggest that aberrant components of somatic hypermutation may contribute to the defective DSB repair characteristic of cancer.	Inst Canc Res, Acad Dept Haematol & Cytogenet, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK	Yuille, MR (corresponding author), HGMP RC, MRC, Cambridge CB2 4AT, England.			Yuille, Martin/0000-0002-4992-5405				Hacia JC, 1998, GENOME RES, V8, P1245, DOI 10.1101/gr.8.12.1245; Haidar MA, 2000, CANCER-AM CANCER SOC, V88, P1057, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1057::AID-CNCR16>3.0.CO;2-6; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; Klein U, 1998, IMMUNOL REV, V162, P261; Luo LP, 1998, CANCER RES, V58, P2293; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Pasqualucci L, 2000, CANCER RES, V60, P5644; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; RAVID Z, 1980, INT J CANCER, V25, P705, DOI 10.1002/ijc.2910250604; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Stankovic T, 2001, BLOOD, V97, P1517, DOI 10.1182/blood.V97.5.1517; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; Stoppa-Lyonnet D, 2000, BLOOD, V96, P374, DOI 10.1182/blood.V96.1.374a.013k56e_374_377; Takeuchi S, 1998, BRIT J HAEMATOL, V103, P536, DOI 10.1046/j.1365-2141.1998.00993.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Vanasse GJ, 1999, BLOOD, V94, P3997, DOI 10.1182/blood.V94.12.3997.424k44_3997_4010; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Yuille MAR, 1998, ONCOGENE, V16, P789, DOI 10.1038/sj.onc.1201603; ZHENG B, 1994, NATURE, V372, P556, DOI 10.1038/372556a0	22	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					483	487		10.1038/sj.onc.1205105	http://dx.doi.org/10.1038/sj.onc.1205105			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821961				2022-12-28	WOS:000173311200017
J	Williams, KJ; Telfer, BA; Airley, RE; Peters, HPW; Sheridan, MR; van der Kogel, AJ; Harris, AL; Stratford, IJ				Williams, KJ; Telfer, BA; Airley, RE; Peters, HPW; Sheridan, MR; van der Kogel, AJ; Harris, AL; Stratford, IJ			A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis	ONCOGENE			English	Article						HIF-1; glucose; redox; tumorigenesis; cyanide; Glut-1	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; GENE-EXPRESSION; OXIDATIVE-PHOSPHORYLATION; FACTOR 1-ALPHA; FACTOR-I; TRANSCRIPTION; CELLS; HIF-1-ALPHA; OVEREXPRESSION; PROLIFERATION	We have investigated the role of HIF-1 in the cellular response to redox modulation via the inhibition of oxidative phosphorylation. We demonstrate that manipulation of redox in air, achieved by inhibiting cytochrome oxidase with cyanide, induces HIF-1 mediated transcription in wild-type CHO and HT1080 human tumour cells but not in CHO cells deficient in the oxygen responsive, HIF-1 alpha sub-unit of HIF-1. Hypoglycaemia attenuates cyanide-mediated transcription in nontransformed HIF-1 wild-type CHO cells but not the human tumour derived cell line. Cells lacking either HIF-1 alpha, or the second composite sub-unit of HIF-1, HIF-1 beta, were markedly more sensitive to the combined stress of perturbed redox and hypoglycaemia than wild-type cells. As such conditions together with hypoxia are prevalent in tumours, these data suggest that HIF-1 may have a protective role in adaptation to the tumour microenvironment. In support of this we demonstrate that HIF-1 alpha deficient cells are less tumorigenic than wild-type cells. They showed a reduced growth rate when grown as xenografts in nude mice. This was not related to vascular parameters that were identical to those found in HIF-1 wild-type tumours. The HIF-1 deficient tumours lacked focal expression of Glut-1 in hypoxic tumour regions. Compromized glucose uptake and metabolic adaptation to the tumour micro-environment may form the basis of the reduced tumorigenecity associated with these cells.	Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England; Christie Hosp NHS Trust, Paterson Inst, Expt Radiat Oncol Grp, Manchester M20 4BX, Lancs, England; Univ Nijmegen, Inst Radiotherapy, Nijmegen, Netherlands; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England	University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Radboud University Nijmegen; University of Oxford	Williams, KJ (corresponding author), Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England.		Harris, Adrian L/ABA-3343-2020; van der Kogel, A.J./L-4441-2015	Harris, Adrian L/0000-0003-1376-8409; stratford, ian/0000-0002-5222-4765; Telfer, Brian/0000-0003-1857-5120	Medical Research Council [G0500366] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; Airley R, 2001, CLIN CANCER RES, V7, P928; Behrooz A, 1997, J BIOL CHEM, V272, P5555, DOI 10.1074/jbc.272.9.5555; Birner P, 2000, CANCER RES, V60, P4693; Blancher C, 2000, CANCER RES, V60, P7106; Brown RS, 1996, J NUCL MED, V37, P1042; Bussink J, 1998, BRIT J CANCER, V77, P57, DOI 10.1038/bjc.1998.9; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chung JK, 1999, J NUCL MED, V40, P339; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; GRIFFITHS JR, IN PRESS CANC RES; HODGKISS RJ, 1991, BRIT J CANCER, V63, P119, DOI 10.1038/bjc.1991.24; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, CANCER RES, V57, P5328; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; NECAS E, 1972, AM J PHYSIOL, V222, P1187, DOI 10.1152/ajplegacy.1972.222.5.1187; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Raleigh JA, 1999, RADIAT RES, V151, P580, DOI 10.2307/3580034; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Stratford IJ, 1999, TUMOR HYPOXIA, P107; TAN CC, 1991, AM J PHYSIOL, V261, pF982, DOI 10.1152/ajprenal.1991.261.6.F982; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830	35	65	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					282	290		10.1038/sj.onc.1205047	http://dx.doi.org/10.1038/sj.onc.1205047			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803471				2022-12-28	WOS:000173026200012
J	Fan, SJ; Yuan, RQ; Ma, YX; Meng, QH; Goldberg, ID; Rosen, EM				Fan, SJ; Yuan, RQ; Ma, YX; Meng, QH; Goldberg, ID; Rosen, EM			Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1	ONCOGENE			English	Article						BRCA1; prostate cancer; breast cancer; DNA repair; apoptosis; estrogen receptor (ER)	BREAST-CANCER CELLS; INTERACT IN-VIVO; TUMOR-SUPPRESSOR; OVARIAN-CANCER; GERMLINE MUTATIONS; EXPRESSION; PROTEIN; INHIBITION; PROGRESSION; GROWTH	Unregulated expression of wild-type BRCA1 (wtBRCA1) confers an altered phenotype in cultured human prostate cancer cells, characterized by chemosensitivity, susceptibility to apoptosis, decreased DNA repair activity, and alterations of key cell regulatory proteins. We now report that the expression of truncated or mutant full-length BRCA1 genes can abrogate certain phenotypic characteristics and/or confer the opposite phenotype to the wild-type BRCA1 gene. In particular, several carboxyl-terminal truncated BRCA1 proteins conferred chemoresistance, decreased susceptibility to apoptosis, and decreased ability to suppress in vivo tumor growth. These truncated BRCA1 proteins also blocked the ability of ectopically expressed wtBRCA1 to induce chemosensitivity and to inhibit estrogen receptor transcriptional activity. Studies using epitope-tagged truncated proteins confirmed their expression, nuclear localization, and functionality. On the other hand, in cells with no endogenous wild-type BRCA1 (HCC1937 human breast cancer cells), the wtBRCA1 gene enhanced cellular DNA repair activity and rendered the cells resistant to DNA damage; while truncated BRCA1 proteins blocked the wtBRCA1-induced chemoresistance. Our findings suggest that truncated BRCA1 proteins can inhibit the function of wild-type BRCA1. They raise the possibility that some inherited BRCA1 mutations may actively promote oncogenesis by blocking the function of the remaining wild-type BRCA1 allele, although this hypothesis remains to be proved.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA	Northwell Health; Yeshiva University	Rosen, EM (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Pk, NY 11040 USA.	erosen@lij.edu	Meng, Q./GSI-6185-2022		NCI NIH HHS [R01-CA-80000, R01-CA82599] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080000, R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; ALLEY MC, 1988, CANCER RES, V48, P589; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; BERTRAND R, 1995, CELL GROWTH APOPTOSI, P97; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Freundlieb S, 1997, METHOD ENZYMOL, V283, P159; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Gao B, 2001, FEBS LETT, V488, P179, DOI 10.1016/S0014-5793(00)02430-3; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; LUKAS J, 1994, ONCOGENE, V9, P2159; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Taylor J, 1998, INT J CANCER, V79, P334, DOI 10.1002/(SICI)1097-0215(19980821)79:4<334::AID-IJC5>3.0.CO;2-W; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yuan RQ, 1999, PROSTATE, V40, P37; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	53	63	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2001	20	57					8215	8235		10.1038/sj.onc.1205033	http://dx.doi.org/10.1038/sj.onc.1205033			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781837				2022-12-28	WOS:000172507800006
J	Murata-Hori, M; Fukuta, Y; Ueda, K; Iwasaki, T; Hosoya, H				Murata-Hori, M; Fukuta, Y; Ueda, K; Iwasaki, T; Hosoya, H			HeLa ZIP kinase induces diphosphorylation of myosin II regulatory light chain and reorganization of actin filaments in nonmuscle cells	ONCOGENE			English	Article						myosin II regulatory light chain; diphosphorylation; actin filament reorganization; nonmuscle cells; apoptosis	SMOOTH-MUSCLE MYOSIN; PROTEIN-KINASE; RHO-KINASE; SERINE/THREONINE KINASE; DLK/ZIP KINASE; DAP-KINASE; 2ND SITE; IN-VIVO; PHOSPHORYLATION; APOPTOSIS	Dlk/ZIP kinase is a serine/threonine kinase highly homologous to DAP kinase. We have reported that HeLa ZIP kinase (hZIPK) phosphorylated the regulatory light chain of myosin II (MRLC) at both Ser19 and Thr18 in vitro. In this study, we demonstrate that hZIPK also induces the diphosphorylation of MRLC in nonmuscle cells. Peptide mapping revealed that transient transfection of hZIPK into HeLa cells caused diphosphorylation of MRLC. In contrast, transfection of the kinase inactive mutant of hZIPK did not induce any phosphorylation of MRLC. Using antibodies specific for mono- or diphosphorylated MRLC, we showed that diphosphorylated MRLC induced by the overexpression of hZIPK was concentrated in striking aggregates or bundles of actin filaments in HeLa cells, while monophosphorylated MRLC showed no prominent localization to these aggregates. Overexpression of hZIPK also induced dramatic changes in cell shape and disruption of nuclear morphology reminiscent of changes during apoptosis. These effects of hZIPK were suppressed by the coexpression of a mutant MRLC where both phosphorylation sites were replaced with alanine, indicating that the changes in actin organization were a consequence of MRLC diphosphorylation. These results suggested that hZIPK plays a role in regulating actin organization and cell morphology in non-muscles and at least part of its effects are mediated through the diphosphorylation of MRLC.	Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Higashihiroshima, Hiroshima 7398526, Japan	Hiroshima University	Hosoya, H (corresponding author), Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Higashihiroshima, Hiroshima 7398526, Japan.	hhosoya@sci.hiroshima-u.ac.jp		Hamao, Kozue/0000-0002-9594-1940				Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; FISHKIND DJ, 1991, J CELL BIOL, V114, P967, DOI 10.1083/jcb.114.5.967; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1989, BIOCHEMISTRY-US, V28, P8750, DOI 10.1021/bi00448a011; IKEBE M, 1988, J BIOL CHEM, V263, P6432; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Murata-Hori M, 1998, BIOMED RES-TOKYO, V19, P111, DOI 10.2220/biomedres.19.111; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; SELLERS JR, 1985, J CELL BIOL, V101, P1897, DOI 10.1083/jcb.101.5.1897; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797	30	74	75	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2001	20	57					8175	8183		10.1038/sj.onc.1205055	http://dx.doi.org/10.1038/sj.onc.1205055			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781833				2022-12-28	WOS:000172507800002
J	Bieche, I; Parfait, B; Laurendeau, I; Girault, I; Vidaud, M; Lidereau, R				Bieche, I; Parfait, B; Laurendeau, I; Girault, I; Vidaud, M; Lidereau, R			Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer	ONCOGENE			English	Article						breast cancer; estrogen receptor alpha; estrogen receptor beta; mRNA level; quantitative RT-PCR; real-time PCR detection	MESSENGER-RNA EXPRESSION; TRANSCRIPTION-PCR ASSAY; ER-ALPHA; CLONING	The recent cloning of a second estrogen receptor (ER), designated ER beta, has prompted a reevaluation of the role of ERs in breast cancer. We have developed and validated a real-time RT - PCR assay to quantify ER alpha and ER beta gene expression at the mRNA level in a series of 131 patients with unilateral invasive primary breast cancer. Although ER beta expression showed wide variations in tumor tissues, its range (nearly three orders of magnitude) was smaller than that of ER alpha (nearly four orders of magnitude), suggesting that ER beta is more tightly controlled than ER alpha. We observed a negative correlation between ER alpha and ER beta expression. 'ER alpha -negative' tumors (containing very low ER alpha mRNA levels) were associated with SBR histopathological grade III, RB1 underexpression and ERBB2 overexpression, confirming that ER alpha negativity delineates poorly differentiated tumors. The amount of ER alpha mRNA (but not that of ER beta mRNA) increased with age and was consequently higher in postmenopausal patients' tumors. Expression of ER alpha (but not that of ER beta) also correlated strongly with progesterone receptor (PR) and PS2 expression, suggesting that ER alpha has stronger transcriptional activity than ER beta towards genes containing an ERE (estrogen response element) in their promoters. Interestingly, we found a negative correlation between the expression of ER beta (but not ER alpha) and CCND1, which contains an AP1 element but not an ERE in its promoter. Taken together, these data confirm that ER alpha and ER beta play different roles in breast cancer, partly by mediating the transcription of various genes via different types of DNA enhancer. PR and PS2 seem to be mainly ER alpha -responsive genes, whereas CCND1 may be mainly ER beta -responsive. Our findings also underline the need for a reliable method, providing full range of quantitative values, to determine ER alpha and ER beta status in the clinical setting.	Univ Paris 05, Fac Sci Pharmaceut & Biol, UPRES JE 2195, Genet Mol Lab, F-75006 Paris, France; Ctr Rene Huguenin, Lab Oncogenet, INSERM E0017, F-92211 St Cloud, France	UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital	Bieche, I (corresponding author), Ctr Rene Huguenin, INSERM E0017, Lab Oncogenet, 35 Rue Dailly, F-92211 St Cloud, France.		PARFAIT, Beatrice/O-7392-2017; Bièche, Ivan/O-7399-2017; Vidaud, Michel/O-7346-2017	Bièche, Ivan/0000-0002-2430-5429; 				Bieche I, 2000, MOL CARCINOGEN, V29, P151, DOI 10.1002/1098-2744(200011)29:3<151::AID-MC4>3.3.CO;2-Y; Bieche I, 1999, CANCER RES, V59, P2759; Bieche I, 1999, CLIN CHEM, V45, P1148; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Clarke M, 1998, LANCET, V351, P1451; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Diab SG, 2000, J NATL CANCER I, V92, P550, DOI 10.1093/jnci/92.7.550; Dotzlaw H, 1999, CANCER RES, V59, P529; Fuqua SAW, 1999, CANCER RES, V59, P5425; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Jarvinen TAH, 2000, AM J PATHOL, V156, P29, DOI 10.1016/S0002-9440(10)64702-5; Jensen E V, 1987, Prog Clin Biol Res, V249, P283; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Knowlden JM, 2000, INT J CANCER, V89, P209, DOI 10.1002/(SICI)1097-0215(20000320)89:2<209::AID-IJC17>3.0.CO;2-6; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Leygue E, 1998, CANCER RES, V58, P3197; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PERSYN JP, 1980, EUR J CANCER, V16, P1513; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Planas-Silva MD, 1999, CANCER RES, V59, P4788; Soubeyran I, 1996, BRIT J CANCER, V74, P1120, DOI 10.1038/bjc.1996.500; Speirs V, 1999, CANCER RES, V59, P525	25	110	112	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8109	8115		10.1038/sj.onc.1204917	http://dx.doi.org/10.1038/sj.onc.1204917			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781824				2022-12-28	WOS:000172396800008
J	Lotem, J; Sachs, L				Lotem, J; Sachs, L			Cytokine control of developmental programs in normal hematopoiesis and leukemia	ONCOGENE			English	Review						hematopoiesis; in vitro colony forming cells; cytokine network; stem cells; reprograming leukemic cells; apoptosis	COLONY-STIMULATING FACTOR; WILD-TYPE P53; BONE-MARROW-CELLS; CANCER-CHEMOTHERAPY COMPOUNDS; GROWTH-FACTOR WITHDRAWAL; NORMAL MAST-CELLS; MYELOID-LEUKEMIA; NORMAL DIFFERENTIATION; INHIBITORY FACTOR; GENE-EXPRESSION	The establishment of a system for in vitro clonal development of hematopoietic cells made it possible to discover the cytokines that regulate hematopoiesis. These cytokines include colony stimulating factors and others, which interact in a network, and there is a cytokine cascade which couples growth and differentiation. A network allows considerable flexibility and a ready amplification of response to a particular stimulus. A network may also be necessary to stabilize the whole system. Cells called hematopoietic stem cells (HSC) can repopulate all hematopoietic lineages in lethally irradiated hosts, and under appropriate conditions give rise to neuronal, muscle, and epithelial cells. Granulocyte colony stimulating factor induces migration of both HSC and in vitro colony forming cells from the bone marrow to peripheral blood. Granulocyte colony stimulating factor is also used clinically to repair irradiation and chemotherapy associated suppression of normal hematopoiesis in cancer patients, and to stimulate normal granulocyte develpment in patients with infantile congenital agranulocytosis. It is suggested that there may also be appropriate conditions under which in vitro colony forming cells have a wider differentiation potential similar to that shown by HSC. An essential part of the developmental program is cytokine suppression of apoptosis by changing the balance in expression of apoptosis inducing and suppressing genes. Decreasing the level of cytokines that suppress therapeutic induction of apoptosis in malignant cells can improve cancer therapy. Cytokines and some other compounds can reprogram abnormal developmental programs in leukemia, so that the leukemic cells differentiate to mature non dividing cells, and this can also be used for therapy. There is considerable plasticity in the developmental programs of normal and malignant cells.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Sachs, L (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	leo.sachs@weizmann.ac.il						ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Amanullah A, 2000, BLOOD, V96, P475; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Attardi LD, 2000, GENE DEV, V14, P704; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; Bonifer C, 1998, IMMUNOL TODAY, V19, P236, DOI 10.1016/S0167-5699(98)01259-6; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN L, 1981, P NATL ACAD SCI-BIOL, V78, P353, DOI 10.1073/pnas.78.1.353; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEGOS L, 1992, INT J CELL CLONING, V10, P63, DOI 10.1002/stem.5530100202; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Dzierzak E, 1998, IMMUNOL TODAY, V19, P228, DOI 10.1016/S0167-5699(98)01258-4; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FIBACH E, 1972, NATURE-NEW BIOL, V237, P276, DOI 10.1038/newbio237276a0; FIBACH E, 1976, J CELL PHYSIOL, V89, P259, DOI 10.1002/jcp.1040890209; FIBACH E, 1973, P NATL ACAD SCI USA, V70, P343, DOI 10.1073/pnas.70.2.343; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Gazitt Y, 2001, J HEMATOTH STEM CELL, V10, P229, DOI 10.1089/15258160151134908; GERASSI E, 1976, P NATL ACAD SCI USA, V73, P4546, DOI 10.1073/pnas.73.12.4546; GINSBURG H, 1963, J NATL CANCER I, V31, P1; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GOOTWINE E, 1982, NATURE, V299, P63, DOI 10.1038/299063a0; GRIFFIN JD, 1986, BLOOD, V68, P1185; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gurdon JB, 1999, NATURE, V402, P743, DOI 10.1038/45429; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1981, DEV BIOL, V81, P255, DOI 10.1016/0012-1606(81)90289-X; Horsfall MJ, 2000, BRIT J HAEMATOL, V109, P751, DOI 10.1046/j.1365-2141.2000.02108.x; Hultner L, 1989, GROWTH FACTORS, V2, P43, DOI 10.3109/08977198909069080; ICHIKAWA Y, 1967, P NATL ACAD SCI USA, V58, P1480, DOI 10.1073/pnas.58.4.1480; ICHIKAWA Y, 1966, P NATL ACAD SCI USA, V56, P488, DOI 10.1073/pnas.56.2.488; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1982, J IMMUNOL, V129, P2431; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; JACOBSEN SEW, 1991, BLOOD, V77, P1706; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kaplinsky C, 1996, LEUKEMIA, V10, P460; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LANDAU T, 1971, P NATL ACAD SCI USA, V68, P2540, DOI 10.1073/pnas.68.10.2540; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIN EY, 1993, J IMMUNOL, V151, P1979; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lotem J, 1997, P NATL ACAD SCI USA, V94, P9349, DOI 10.1073/pnas.94.17.9349; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOTEM J, 1991, BLOOD, V78, P953; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOTEM J, 1983, INT J CANCER, V32, P127, DOI 10.1002/ijc.2910320120; Lotem J, 1998, P NATL ACAD SCI USA, V95, P4601, DOI 10.1073/pnas.95.8.4601; LOTEM J, 1992, BLOOD, V80, P1750; Lotem J, 1996, LEUKEMIA, V10, P925; LOTEM J, 1991, CELL GROWTH DIFFER, V2, P421; LOTEM J, 1986, EMBO J, V5, P2163, DOI 10.1002/j.1460-2075.1986.tb04480.x; LOTEM J, 1989, BLOOD, V74, P579; LOTEM J, 1987, INT J CANCER, V40, P532, DOI 10.1002/ijc.2910400417; LOTEM J, 1992, LEUKEMIA, V6, P426; LOTEM J, 1981, INT J CANCER, V28, P375, DOI 10.1002/ijc.2910280318; LOTEM J, 1988, BLOOD, V71, P375; LOTEM J, 1989, LEUKEMIA RES, V13, P13, DOI 10.1016/0145-2126(89)90026-X; LOTEM J, 1984, INT J CANCER, V33, P147, DOI 10.1002/ijc.2910330122; LOTEM J, 1990, BLOOD, V76, P1315; LOTEM J, 1977, P NATL ACAD SCI USA, V74, P5554, DOI 10.1073/pnas.74.12.5554; LOTEM J, 1974, P NATL ACAD SCI USA, V71, P3507, DOI 10.1073/pnas.71.9.3507; LOTEM J, 1982, P NATL ACAD SCI-BIOL, V79, P4347, DOI 10.1073/pnas.79.14.4347; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; Lotem J, 1999, APOPTOSIS, V4, P187, DOI 10.1023/A:1009614723237; LOTEM J, 1995, LEUKEMIA, V9, P685; LOTEM J, 1978, P NATL ACAD SCI USA, V75, P3781, DOI 10.1073/pnas.75.8.3781; LOTEM J, 2002, IN PRESS SEM CANC BI; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Masuda A, 2001, J BIOL CHEM, V276, P26107, DOI 10.1074/jbc.M011475200; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; METCALF D, 1975, J EXP MED, V142, P1534, DOI 10.1084/jem.142.6.1534; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PARAN M, 1969, J CELL PHYSIOL, V73, P91, DOI 10.1002/jcp.1040730113; PARAN M, 1970, P NATL ACAD SCI USA, V67, P1542, DOI 10.1073/pnas.67.3.1542; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; PIKE BL, 1970, J CELL PHYSIOL, V76, P77, DOI 10.1002/jcp.1040760111; PLUZNIK DH, 1966, EXP CELL RES, V43, P553, DOI 10.1016/0014-4827(66)90026-7; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Renne C, 1998, J BIOL CHEM, V273, P27213, DOI 10.1074/jbc.273.42.27213; SACHS L, 1980, P NATL ACAD SCI-BIOL, V77, P6152, DOI 10.1073/pnas.77.10.6152; SACHS L, 1990, CANCER-AM CANCER SOC, V65, P2196, DOI 10.1002/1097-0142(19900515)65:10<2196::AID-CNCR2820651006>3.0.CO;2-Y; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; SACHS L, 1986, SCI AM, V254, P40, DOI 10.1038/scientificamerican0186-40; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; Sachs L, 1996, P NATL ACAD SCI USA, V93, P4742, DOI 10.1073/pnas.93.10.4742; SACHS L, 1987, PROC R SOC SER B-BIO, V231, P289, DOI 10.1098/rspb.1987.0045; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SACHS L, 1995, ADV CANCER RES, V66, P1, DOI 10.1016/S0065-230X(08)60250-X; Sachs L, 1982, CANCER SURV, V1, P321; Sanz C, 2000, BLOOD, V95, P2742, DOI 10.1182/blood.V95.9.2742.009k24_2742_2747; Sanz C, 2001, EMBO J, V20, P2286, DOI 10.1093/emboj/20.9.2286; SCHNEIDER E, 1991, BLOOD, V78, P329; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHABO Y, 1989, LEUKEMIA, V3, P859; SHABO Y, 1988, BLOOD, V72, P2070; SHABO Y, 1989, MOL CELL BIOL, V9, P4109, DOI 10.1128/MCB.9.9.4109; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STEPHENSON JR, 1971, P NATL ACAD SCI USA, V68, P1542, DOI 10.1073/pnas.68.7.1542; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS G, 1983, EMBO J, V2, P663, DOI 10.1002/j.1460-2075.1983.tb01481.x; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, MOL CELL, V3, P159; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WEBB CG, 1984, DEV BIOL, V101, P221, DOI 10.1016/0012-1606(84)90132-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Welniak LA, 2001, J IMMUNOL, V166, P2923, DOI 10.4049/jimmunol.166.5.2923; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	166	92	98	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3284	3294		10.1038/sj.onc.1205319	http://dx.doi.org/10.1038/sj.onc.1205319			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032770				2022-12-28	WOS:000175633300005
J	Rane, SG; Reddy, EP				Rane, SG; Reddy, EP			JAKs, STATs and Src kinases in hematopoiesis	ONCOGENE			English	Review						hematopoiesis; Src kinases; JAK kinases; STATs; ras; PI3K	COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; DNA-BINDING ACTIVITY; RECEPTOR-ALPHA CHAIN; COMMON BETA-SUBUNIT; SIGNAL-TRANSDUCTION PATHWAYS; LEUKEMIA INHIBITORY FACTOR; GROWTH-HORMONE RECEPTOR; SEVERE COMBINED IMMUNODEFICIENCY; DEFECTIVE LYMPHOID DEVELOPMENT	Hematopoiesis is the cumulative result of intricately regulated signal transduction cascades that are mediated by cytokines and their cognate receptors. Proper culmination of these diverse signaling pathways forms the basis for an orderly generation of different cell types and aberrations in these pathways is an underlying cause for diseases such as leukemias and other myeloproliferative and lympho proliferative disorders. Over the past decade, downstream signal transduction events initiated upon cytokine/growth factor stimulation have been a major focus of basic and applied biomedical research. As a result, several key concepts have emerged allowing a better understanding of the complex signaling processes. A group of transcription factors, termed signal transducers and activators of transcription (STATs) appear to orchestrate the downstream events propagated by cytokine/growth factor interactions with their cognate receptors. Similarly, cytoplasmic Janus protein tyrosine kinases (JAKs) and Src family of kinases seem to play a critical role in diverse signal transduction pathways that govern cellular survival, proliferation, differentiation and apoptosis. Accumulating evidence suggests that STAT protein activation may be mediated by members of both JAK and Src family members following cytokine/growth factor stimulation. In addition, JAK kinases appear to be essential for the phosphorylation of the cytokine receptors which results in the creation of docking sites on the receptors for binding of SH2-containing proteins such as STATs, Src-kinases and other signaling intermediates. Cell and tissue-speciticity of cytokine action appears to be determined by the nature of signal transduction pathways activated by cytokine/receptor interactions. The integration of these diverse signaling cues from active JAK kinases, members of the Src-family kinases and STAT proteins, leads to cell proliferation, cell survival and differentiation, the end-point of the cytokine/growth factor stimulus.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	reddy@unix.temple.edu	Reddy, E. Premkumar/F-6233-2011		NIEHS NIH HHS [ES09225] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009225] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Bittorf T, 1999, BIOL CHEM, V380, P1201, DOI 10.1515/BC.1999.152; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Coffer PJ, 1998, BIOCHEM J, V329, P121; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CORNELIS S, 1995, EUR J IMMUNOL, V25, P1857, DOI 10.1002/eji.1830250710; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DASILVA L, 1994, J BIOL CHEM, V269, P18267; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; deGroot RP, 1997, J BIOL CHEM, V272, P2319; DEL PL, 1997, SCIENCE, V278, P687; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; DUHE RJ, 1995, J BIOL CHEM, V270, P23084, DOI 10.1074/jbc.270.39.23084; Durstin M, 1996, J IMMUNOL, V157, P534; EDER M, 1994, J BIOL CHEM, V269, P30173; Eilers A, 1996, CELL GROWTH DIFFER, V7, P833; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flores-Morales A, 1998, MOL CELL ENDOCRINOL, V138, P1, DOI 10.1016/S0303-7207(98)00054-9; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Frank DA, 1996, LEUKEMIA, V10, P1724; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; Grossman WJ, 1999, BLOOD, V94, P932, DOI 10.1182/blood.V94.3.932.415k30_932_939; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1997, STEM CELLS S1, V15, P112; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Iwamoto T, 2000, ONCOGENE, V19, P4795, DOI 10.1038/sj.onc.1203829; Jaster R, 1997, MOL CELL BIOL, V17, P3364, DOI 10.1128/MCB.17.6.3364; Jiang N, 1996, J BIOL CHEM, V271, P16472, DOI 10.1074/jbc.271.28.16472; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; JUBINSKY PT, 1993, BLOOD, V81, P587; JUCKER M, 1995, J BIOL CHEM, V270, P27817; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; KRUGER A, 1991, ONCOGENE, V6, P245; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Leonard WJ, 2000, J ALLERGY CLIN IMMUN, V105, P877, DOI 10.1067/mai.2000.106899; Leonard WJ, 1996, ANNU REV MED, V47, P229; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; MIURA O, 1994, BLOOD, V84, P1501; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1995, J LEUKOCYTE BIOL, V57, P799, DOI 10.1002/jlb.57.5.799; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nelson BH, 1996, MOL CELL BIOL, V16, P309; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; Nicola NA, 1996, BLOOD, V87, P2665, DOI 10.1182/blood.V87.7.2665.bloodjournal8772665; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OKUDA K, 1992, BLOOD, V79, P2880; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; OShea JJ, 1997, J CLIN IMMUNOL, V17, P431, DOI 10.1023/A:1027388508570; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pallen Catherine J., 1992, Current Opinion in Cell Biology, V4, P1000, DOI 10.1016/0955-0674(92)90132-V; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; Paulson R F, 1995, Semin Immunol, V7, P267, DOI 10.1006/smim.1995.0031; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAZDRAK K, 1995, J IMMUNOL, V155, P397; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pellegrini M, 1999, J CLIN IMMUNOL, V19, P365, DOI 10.1023/A:1020598632068; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1989, BIOCHIM BIOPHYS ACTA, V989, P179, DOI 10.1016/0304-419X(89)90042-5; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; RAINES MA, 1992, BLOOD, V79, P3350; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; ROVERA G, 1987, ONCOGENE, V1, P29; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Sattler M, 1996, ONCOGENE, V12, P839; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; TAKAKI S, 1994, INT ARCH ALLERGY IMM, V104, P36, DOI 10.1159/000236746; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; TORIGOE T, 1992, BLOOD, V80, P617; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Uchida K, 1997, CYTOGENET CELL GENET, V78, P209, DOI 10.1159/000134658; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; Ward AC, 2000, BLOOD, V95, P19; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Woodcock JM, 1999, INT J BIOCHEM CELL B, V31, P1017, DOI 10.1016/S1357-2725(99)00084-9; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yetter D, 1995, Nurs Manage, V26, P60; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Yoshimura A, 1998, CYTOKINE GROWTH F R, V9, P197, DOI 10.1016/S1359-6101(98)00019-7; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zhou YJ, 1997, P NATL ACAD SCI USA, V94, P13850, DOI 10.1073/pnas.94.25.13850; ZON LI, 1995, BLOOD, V86, P2876	253	179	197	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3334	3358		10.1038/sj.onc.1205398	http://dx.doi.org/10.1038/sj.onc.1205398			25	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032773				2022-12-28	WOS:000175633300008
J	Chazal, M; Marionnet, C; Michel, L; Mollier, K; Dazard, JE; Della Valle, V; Larsen, CJ; Gras, MP; Basset-Seguin, N				Chazal, M; Marionnet, C; Michel, L; Mollier, K; Dazard, JE; Della Valle, V; Larsen, CJ; Gras, MP; Basset-Seguin, N			P16(INK4A) is implicated in both the immediate and adaptative response of human keratinocytes to UVB irradiation	ONCOGENE			English	Article						p16(INK4A); keratinocyte; UVB	P53 TUMOR SUPPRESSION; HUMAN CANCER-CELLS; ULTRAVIOLET-RADIATION; G(1) ARREST; HUMAN SKIN; INK4A LOCUS; DNA-DAMAGE; EXPRESSION; PROTEIN; GENE	The P16(INK4A-ARF) locus plays a crucial role in the control of cellular proliferation via both the Rb and P53 pathways. We previously demonstrated that this locus is altered in human skin carcinomas. In the present study we have studied the expression of the p16(INK4A-ARF) locus following UVB irradiation of normal human keratinocytes both at the mRNA (RT-PCR) and at the protein (Western blotting) levels. Our data confirmed that P16(INK4A) protein is induced by UVB at low (30 mJ cm(2)) and high (100 mJ cm(2)) doses and is observed after a single or repeated exposure implying that this response is involved in both the immediate and adaptative response to UVB. The apparent absence of induction p16(INK4A) mRNA suggested that P16(INK4A) protein is upregulated at the post-transcriptional level. Analysis by flow cytometry and BrdU staining indicated that the highest protein level of P16(INK4A) in the cells was associated with a G(2) cell cycle arrest. Comparative analysis of P16(INK4A) and P53 showed that they were differentially modulated in keratinocytes according to the UVB dose and regimen. Low, acute or repeated UVB exposures led to accumulation of both P16(INK4A) and p53, whereas at high UVB doses, P53 and P53-dependent genes were not induced or even downregulated and only a slight but reproducible stabilization of P16(INK4A) protein was observed. In our conditions, P14(ARF) did not seem to participate in the UV response in these cells as P14(ARF) protein did not vary. These results infer that P16(INK4A) plays a role in cell cycle regulation of keratinocytes submitted to UVB irradiation. They also reinforce our previous demonstration of the importance of inactivation of this gene in UV-induced skin carcinogenesis.	Hop St Louis, INSERM, U532, Inst Rech Peau, F-75010 Paris, France; Inst Genet Mol, CNRS, UMR 5535, F-34090 Montpellier, France; Inst Genet Mol, INSERM, U434, F-75010 Paris, France; IBMIG, Oncol Mol Lab, F-86022 Poitiers, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers	Basset-Seguin, N (corresponding author), Hop St Louis, INSERM, U532, Inst Rech Peau, Pavillon Bazin,1 Ave C Vellefaux, F-75010 Paris, France.		Michel, Laurence/E-8605-2017					AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ahmed NU, 1999, J DERMATOL SCI, V19, P175, DOI 10.1016/S0923-1811(98)00068-1; BASSETSEGUIN N, 1994, J INVEST DERMATOL, V103, P102; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enders GH, 1996, ONCOGENE, V12, P1239; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; HALL PA, 1993, ONCOGENE, V8, P203; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1993, CELL, V75, P805; Inohara S, 1996, BRIT J DERMATOL, V135, P717; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1993, ENVIRON HEALTH PERSP, V101, P55, DOI 10.2307/3431842; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1998, BRIT J DERMATOL, V139, P3; Liefer KM, 2000, CANCER RES, V60, P4016; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; MIYASHITA T, 1995, CELL, V80, P293; Nielsen GP, 1999, LAB INVEST, V79, P1137; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Parker C.A, 1968, PHOTOLUMINESCENCE SO; Pavey S, 1999, CANCER RES, V59, P4185; Piepkorn M, 2000, J AM ACAD DERMATOL, V42, P741, DOI 10.1067/mjd.2000.103988; Reznikoff CA, 1996, CANCER RES, V56, P2886; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Soufir N, 2000, J NATL CANCER I, V92, P1841, DOI 10.1093/jnci/92.22.1841; Soufir N, 1999, ONCOGENE, V18, P5477, DOI 10.1038/sj.onc.1202915; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang XQ, 1996, CANCER RES, V56, P2510; WEINBERG WC, 1994, CANCER RES, V54, P5584; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	47	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2652	2661		10.1038/sj.onc.1205349	http://dx.doi.org/10.1038/sj.onc.1205349			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965538				2022-12-28	WOS:000174996500005
J	Dilla, T; Romero, J; Sanstisteban, P; Velasco, JA				Dilla, T; Romero, J; Sanstisteban, P; Velasco, JA			The mdm2 proto-oncogene sensitizes human medullary thyroid carcinoma cells to ionizing radiation	ONCOGENE			English	Article						radiation; MDM2; E2F-1; medullary thyroid carcinoma	TRANSCRIPTION FACTOR E2F-1; DOWN-REGULATION; DNA-DAMAGE; WILD-TYPE; P53; ONCOGENE; APOPTOSIS; CYCLE; OVEREXPRESSION; SUPPRESSION	We have analysed the radiation response of a human medullary thyroid carcinoma cell line (MTT), characterized by the absence of a functional p53 protein, and the consequences of MDM2 overexpression in this process. We show that the product of the mdm2 proto-oncogene is able to sensitize MTT cells to ionizing radiation. After radiation treatment, MTT cells display histograms consistent with a G2M arrest. MTT cells expressing MDM2 (MTT-mdm2) are unable to respond to DNA damage with G2M arrest, and display a high percentage of apoptosis. MTT-mdm2 cells show high levels of E2F-1 protein, suggesting that the induction of apoptosis observed upon MDM2 overexpression could be dependent on E2F-1. This observation is further supported with assays showing that E2F-1 binding to specific DNA sequences is enhanced in MTT-mdm2 cells. Likewise, transactivation of reporter constructs exclusively dependent on E2F-1 is also elevated after transfection with MDM2. This effect can be reverted by transient transfection with p19(ARF). To link the expression of E2F-1 with the induction of apoptosis, we generated clonal cell lines overexpressing E2F-1. Transfection with E2F-1 results in a low number of outgrowing colonies with reduced proliferation rates, indicating that E2F-1 is deleterious for cell growth. This negative regulation correlates with an increase in the percentage of the cell population with DNA content below 2N, suggesting that E2F-1 promotes apoptosis. Finally, overexpression of E2F-1 sensitizes MTT cells to radiation exposure. We conclude that the effects observed by MDM2 overexpression could be mediated by E2F-1.	CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Hosp Puerta Hierro, Dept Oncol Radioterap, Madrid, Spain; Ctr Nacl Invest Oncol Carlos III, Mol Oncol Lab, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda	Sanstisteban, P (corresponding author), CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	psantisteban@iib.uam.es	Romero, Jesús/AAE-1899-2021	Romero, Jesús/0000-0001-8778-1388				ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Banerjee D, 1998, CANCER RES, V58, P4292; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; CACHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235; CARLOMAGNO F, 1995, BIOCHEM BIOPH RES CO, V207, P1022, DOI 10.1006/bbrc.1995.1287; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Dilla T, 2000, ENDOCRINOLOGY, V141, P420, DOI 10.1210/en.141.1.420; Dong YB, 1999, CANCER, V86, P2021, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO;2-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; Giuffrida D, 1998, ANN ONCOL, V9, P695, DOI 10.1023/A:1008242302749; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Heshmati HM, 1997, AM J MED, V103, P60, DOI 10.1016/S0002-9343(97)00024-7; Hunt KK, 1997, CANCER RES, V57, P4722; Hwang A, 1998, RADIAT RES, V150, pS52, DOI 10.2307/3579808; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KELLE DE, 1995, CELL, V83, P993; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Leong S, 1981, ADV THYROID NEOPLASI, P95; Lin WC, 2001, GENE DEV, V15, P1833; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Lozano G, 1998, BBA-REV CANCER, V1377, pM55, DOI 10.1016/S0304-419X(97)00037-1; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Medina DL, 1999, ENDOCRINOLOGY, V140, P87, DOI 10.1210/en.140.1.87; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; NELKIN BD, 1989, JAMA-J AM MED ASSOC, V261, P3130, DOI 10.1001/jama.261.21.3130; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OSWALD F, 1994, ONCOGENE, V9, P2029; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; PIROLLO KF, 1993, RADIAT RES, V135, P234, DOI 10.2307/3578300; Pruschy M, 1999, CELL GROWTH DIFFER, V10, P141; Puxeddu E, 2001, ENDOCRIN METAB CLIN, V30, P493, DOI 10.1016/S0889-8529(05)70196-1; SAWEY MJ, 1987, MOL CELL BIOL, V7, P932, DOI 10.1128/MCB.7.2.932; Varghese S, 1998, ARCH PHARM RES, V21, P640, DOI 10.1007/BF02976750; Vecchio G, 2000, CLIN CHEM LAB MED, V38, P113, DOI 10.1515/CCLM.2000.017; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; Velasco JA, 1997, INT J CANCER, V73, P449, DOI 10.1002/(SICI)1097-0215(19971104)73:3<449::AID-IJC21>3.0.CO;2-6; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	52	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2376	2386		10.1038/sj.onc.1205307	http://dx.doi.org/10.1038/sj.onc.1205307			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948421				2022-12-28	WOS:000174635600010
J	Oneyama, C; Nakano, H; Sharma, SV				Oneyama, C; Nakano, H; Sharma, SV			UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug	ONCOGENE			English	Article						UCS15A; SH3; proline-rich domains; Src; Sam68; Grb2	GLUTATHIONE-S-TRANSFERASE; RECEPTOR TYROSINE KINASES; SRC HOMOLOGY-3 DOMAIN; BINDING-PROTEIN; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE EXCHANGE; E-CADHERIN; GRB2; FAMILY; SAM68	Protein-protein interactions play critical regulatory roles in mediating signal transduction. Previous studies have identified an unconventional, small-molecule, Src signal transduction inhibitor, UCS15A. UCS15A differed from conventional Src-inhibitors in that it did not alter the levels or the tyrosine kinase activity of Src. Our studies suggested that UCS15A exerted its Src-inhibitory effects by a novel mechanism that involved the disruption of protein-protein interactions mediated by Src. In the present study we have examined the ability of UCS15A to disrupt the interaction of Src-SH3 with Sam68, both in vivo and in vitro. This ability of UCS15A was not restricted to Src-SH3 mediated protein-protein interactions, since the drug was capable of disrupting the in vivo interactions of Sam68 with other SH3 domain containing proteins such as Grb2 and PLCgamma. In addition, UCS15A was capable of disrupting other typical SH3-mediated protein-protein interactions such as Grb2-Sos1, cortactin-ZO1, as well as atypical SH3-mediated protein-protein interactions such as Grb2-Gab1. However, UCS15A was unable to disrupt the non-SH3-mediated protein-protein interactions of P-catenin, with E-cadherin and g-catenin. In addition, UCS15A had no effect on the SH2-mediated interaction between Grb2 and activated Epidermal Growth Factor receptor. Thus, the ability of UCS15A, to disrupt protein-protein interactions appeared to be restricted to SH3-mediated protein-protein interactions. In this regard, UCS15A represents the first example of a non-peptide, small molecule agent capable of disrupting SH3-mediated protein-protein interactions. In vitro analyses suggested that UCS15A did not bind to the SH3 domain itself but rather may interact directly with the target proline-rich domains.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 194, Japan	Kyowa Kirin Ltd	Sharma, SV (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahi Cho,Machida Shi, Tokyo 194, Japan.	ssharma@kyowa.co.jp						Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Combs AP, 1996, J AM CHEM SOC, V118, P287, DOI 10.1021/ja953750v; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Finan PM, 1996, FEBS LETT, V389, P141, DOI 10.1016/0014-5793(96)00552-2; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jabado N, 1998, J IMMUNOL, V161, P2798; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Ladbury JE, 2000, CHEM BIOL, V7, pR3, DOI 10.1016/S1074-5521(00)00067-3; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Nguyen JT, 2000, CHEM BIOL, V7, P463, DOI 10.1016/S1074-5521(00)00130-7; Nguyen JT, 1997, NAT STRUCT BIOL, V4, P256, DOI 10.1038/nsb0497-256; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; PARKER MW, 1990, J MOL BIOL, V213, P221, DOI 10.1016/S0022-2836(05)80183-4; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Ponting CP, 1999, J MOL BIOL, V289, P729, DOI 10.1006/jmbi.1999.2827; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sharma SV, 2001, ONCOGENE, V20, P2068, DOI 10.1038/sj.onc.1204296; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; SMITHGALL TE, 1995, J PHARMACOL TOX MET, V34, P125, DOI 10.1016/1056-8719(95)00082-7; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Summy JM, 2000, ONCOGENE, V19, P155, DOI 10.1038/sj.onc.1203265; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Yamashita Y, 1996, JPN J CANCER RES, V87, P1106, DOI 10.1111/j.1349-7006.1996.tb03118.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	67	49	55	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2037	2050		10.1038/sj.onc.1205271	http://dx.doi.org/10.1038/sj.onc.1205271			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960376				2022-12-28	WOS:000174827000010
J	Chaudhry, MA; Chodosh, LA; McKenna, WG; Muschel, RJ				Chaudhry, MA; Chodosh, LA; McKenna, WG; Muschel, RJ			Gene expression profiling of HeLa cells in G1 or G2 phases	ONCOGENE			English	Article						microarray; genechip; cell cycle	B1 MESSENGER-RNA; CYCLIN B1; CLUSTER-ANALYSIS; IDENTIFICATION; TARGETS	The cell division cycle is regulated through both transcriptional and post-transcriptional mechanisms. The altered expression of a number of genes at the mRNA level is known to be essential for progression through the cell cycle, however, a comprehensive gene expression profile of human cells remains to be completed. Here we sought to monitor the differential gene expression of genes after the transition of G2 cells into G1 prior to the restriction point. GeneChip containing microarrays of oligonucleotides corresponding to over 12 000 human genes were employed to profile differential gene expression in G1 and G2. After three independent experiments the resultant data was filtered and a set of genes was compiled based on at least threefold-altered expression, no background noise in determining expression and observation in all experiments. Our analysis identified 154 genes that were elevated in G2 phase of cells as compared to early G1 phase including 15 novel genes. This number included mRNAs whose upregulation is known to occur in G2 phase. Surprisingly only 19 genes were upregulated in G1 phase, among these six genes were novel. Some of these genes are candidates for transition through early G1. This gene inventory for G1 and G2 phases of cell cycle will provide the basis for understanding of cell cycle delay as a result of DNA damage.	Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Abramson Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Muschel, RJ (corresponding author), Childrens Hosp, Dept Pathol & Lab Med, 269 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	muschel@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [P01CA075138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047439] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA75138] Funding Source: Medline; NIGMS NIH HHS [R01 GM47439] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1994, MOL BIOL CELL, P369; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Claverie JM, 2001, SCIENCE, V291, P1255, DOI 10.1126/science.1058969; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ghosh S, 1998, EXP CELL RES, V242, P1, DOI 10.1006/excr.1998.4115; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; Hitomi M, 2001, FEBS LETT, V490, P123, DOI 10.1016/S0014-5793(01)02115-9; KATO J, 1999, FRONT BIOSCI, V1, P787; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Murray AW, 2001, NATURE, V409, P844, DOI 10.1038/35057033; Nakanishi M, 2000, GENES CELLS, V5, P839, DOI 10.1046/j.1365-2443.2000.00367.x; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; Sakai N, 1999, EXP CELL RES, V251, P224, DOI 10.1006/excr.1999.4552; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Werner T, 2001, PHARMACOGENOMICS, V2, P25, DOI 10.1517/14622416.2.1.25; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9	30	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1934	1942		10.1038/sj.onc.1205264	http://dx.doi.org/10.1038/sj.onc.1205264			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896627				2022-12-28	WOS:000174284500017
J	Ekman, S; Kallin, A; Engstrom, U; Heldin, CH; Ronnstrand, L				Ekman, S; Kallin, A; Engstrom, U; Heldin, CH; Ronnstrand, L			SHP-2 is involved in heterodimer specific loss of phosphorylation of Tyr771 in the PDGF beta-receptor	ONCOGENE			English	Article						platelet-derived growth factor; receptor tyrosine kinase; SHP-2; heterodimer; dephosphorylation	FACTOR-ALPHA-RECEPTOR; PHOSPHOLIPASE-C-GAMMA; PHOSPHOTYROSINE PHOSPHATASE; AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; TYROSINE KINASE; DNA-SYNTHESIS; CDNA CLONING; GROWTH; IDENTIFICATION	We have previously shown that the binding site for GTPase activating protein of Ras (RasGAP) in the PDGF beta-receptor, Tyr771, is phosphorylated to a much lower extent in the heterodimeric configuration of PDGF alpha- and beta-receptors, compared to the PDGF beta-receptor homodimer. The decreased recruitment of the RasGAP to the receptor leads to prolonged activation of the Ras/MAP kinase pathway, which could explain the increase in mitogenicity seen upon induction of heterodimers. The molecular mechanism underlying these differences was investigated. We could show that the loss of phosphorylation of Tyr771 was dependent on presence of intact binding sites for the protein tyrosine phosphatase SHP-2 on the PDGF beta-receptor. Thus, in PDGF receptor mutants in which binding of SHP-2 was lost, a higher degree of phosphorylation of Tyr771 was seen, while other phosphorylation sites in the receptor remained virtually unaffected. Thus, SHP-2 appears to play an important role in modulating phosphorylation of Y771, thereby controlling RasGAP recruitment and Ras/MAP kinase signaling in the heterodimeric configuration of the PDGF receptors.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ronnstrand, L (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Ronnstrand, Lars/A-2429-2011; Ekman, Simon/AAB-9387-2021	Ronnstrand, Lars/0000-0003-1275-5809; 				ANDREWS DM, 1991, INT J PEPT PROT RES, V38, P469; BAZENET CE, 1994, ONCOGENE, V9, P517; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Pawson T, 2000, GENE DEV, V14, P1027; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RUPP E, 1994, EUR J BIOCHEM, V225, P29, DOI 10.1111/j.1432-1033.1994.00029.x; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yokote K, 1996, J BIOL CHEM, V271, P5101; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641	29	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1870	1875		10.1038/sj.onc.1205210	http://dx.doi.org/10.1038/sj.onc.1205210			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896619				2022-12-28	WOS:000174284500009
J	Yamada, Y; Pannell, R; Forster, A; Rabbitts, TH				Yamada, Y; Pannell, R; Forster, A; Rabbitts, TH			The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target	ONCOGENE			English	Article						transcriptional regulation; tumour angiogenesis; chromosomal translocation; endothelium; cancer; neo-vascularization	T-CELL LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; CANCER; TRANSCRIPTION; ONCOGENES; RBTN2	The growth of solid tumours requires a blood supply provided by re-modeling of existing blood vessel endothelium (angiogenesis). Little is known about transcription regulators which are specific for the control of tumour angiogenesis. The proto-oncogene LM02 encodes a LIM domain transcription regulator which controls angiogenesis during mouse embryogenesis where it regulates remodelling of the capillary network into mature vessels. We now show that Lmo2 expression is augmented in tumour endothelium such as mouse thymomas and human lung tumours. The functional significance of this Lmo2 expression was assessed in teratocarcinomas induced in nude mice by subcutaneous implantation of Lmo2-lacZ targeted ES cells. CD31-positive, sprouting endothelium of ES-cell origin occurred in teratocarcinomas from heterozygous Lmo2-lacZ ES cells but none occurred from null Lmo2-lacZ ES cells. Therefore, in this model Lmo2 is an obligatory regulator of neo-vascularization of tumours. These data suggest that LM02 function may be a drug target in cancer and other conditions characterized by neo-vascularization.	Med Res Council Lab Mol Biol, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	Rabbitts, TH (corresponding author), Med Res Council Lab Mol Biol, Hills Rd, Cambridge CB2 2QH, England.	thr@mrc.lmb.cam.ac.uk	Mordwinkin, Nicholas M/A-4347-2010; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Taniere P, 2001, AM J PATHOL, V158, P33, DOI 10.1016/S0002-9440(10)63941-7; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320	23	45	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1309	1315		10.1038/sj.onc.1205285	http://dx.doi.org/10.1038/sj.onc.1205285			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857074	Bronze			2022-12-28	WOS:000173861000001
J	Nozell, S; Chen, XB				Nozell, S; Chen, XB			p21B, a variant of p21(Waf1/Cip1), is induced by the p53 family	ONCOGENE			English	Article						p53; p2l; p218; apoptosis	CELL-CYCLE ARREST; DNA-DAMAGE; BINDING PROTEIN; GENE; APOPTOSIS; P73; INHIBITOR; SIGNALS; IDENTIFICATION; TRANSCRIPT	Alternative splicing or expression from an alternate promoter can produce variants of a gene. To determine whether the p21(Waf1/Cip1) locus is regulated by these mechanisms, we searched for and found two transcripts, p21B and p21C, that are expressed from an alternate promoter in the first intron of the p21 gene. While p21C encodes the p21. cyclin-dependent kinase inhibitor, p21B encodes a novel protein and the transcript is ubiquitously expressed in 16 human tissues tested. Like p21, both p21B and p21C are induced by DNA damage, p53, and other p53 family members through a proximal p53 response element in the promoter of p21B and p21C. However, unlike p21, which induces cell cycle arrest, we found that overexpression of p21B induces apoptosis. These findings indicate that the p21 locus expresses at least two structurally distinct, but functionally related, variants of the p21 gene from discrete promoters.	Univ Alabama, Dept Cell Biol, UAB, Ctr Comprehens Canc,MCLM 656, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Alabama, Dept Cell Biol, UAB, Ctr Comprehens Canc,MCLM 656, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [R01CA076069, R01CA081237, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [CA 81237, CA 76069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; DURO D, 1995, ONCOGENE, V11, P21; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARPER JW, 1993, CELL, V75, P805; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MAO L, 1995, CANCER RES, V55, P2995; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; QUELLE DE, 1995, CELL, V83, P993; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; STONE S, 1995, CANCER RES, V55, P2988; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Tsubari M, 1997, CANCER RES, V57, P2966; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	46	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1285	1294		10.1038/sj.onc.1205191	http://dx.doi.org/10.1038/sj.onc.1205191			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850848				2022-12-28	WOS:000173729400016
J	Silberstein, GB; Dressler, GR; Van Horn, K				Silberstein, GB; Dressler, GR; Van Horn, K			Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth	ONCOGENE			English	Article						breast cancer; mammary; PAX2; progesterone; Wilms' tumor	TUMOR SUPPRESSOR GENE; WILMS-TUMOR; GLAND DEVELOPMENT; WT1; APOPTOSIS; RECEPTOR; KIDNEY; DIFFERENTIATION; REPRESSION; PRODUCT	In this study, we first describe expression of the paired domain transcription factor PAX2 in the normal and cancerous human breast, then demonstrate in a murine model a novel function for PAX2 in the regulation of progesterone stimulation of secondary ductal growth. In human mammary tissue, PAX2 expression was coincident with sub-populations of mammary ductal cells, some of which possessed an undifferentiated histiotype, and was also found in >50% of the human breast tumors surveyed (n=38). In the mouse, mammary parenchyma with a targeted deletion of PAX2 developed normal ductal systems when grafted into wild-type host mammary fat pads, but failed to undergo higher order side-branching and lobular development in response to progesterone. A previously unsuspected PAX2/WT1 (Wilms' tumor suppressor gene) regulatory axis in the mammary gland was also indicated. Using RT-PCR, a significant reduction in WT1 mRNA expression was detected in the PAX2 mutant glands compared to wildtype counterparts and double-antibody immunohistochemistry detected the co-localization of PAX2 and WT1 in the nuclei of normal and cancerous breast cells. These data indicate a role for PAX2 (and possibly WT1) in the regulation of the progesterone response of the mature mammary gland. The potential contribution of PAX2 to breast tumor pathogenesis is discussed.	Univ Calif Santa Cruz, Sinsheimer Labs, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of California System; University of California Santa Cruz; University of Michigan System; University of Michigan	Silberstein, GB (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.				NIDDK NIH HHS [DK-48883, DK-54740] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054740, R01DK048883] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atwood CS, 2000, J ENDOCRINOL, V167, P39, DOI 10.1677/joe.0.1670039; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 2000, GENE DEV, V14, P650; Brunner E, 1999, DEV BIOL, V206, P178, DOI 10.1006/dbio.1998.9136; Dehbi M, 1996, ONCOGENE, V13, P447; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DRESSLER GR, 2002, MOUSE DEV PATTERNING, P395; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DUBOIS M, 1984, DEV BIOL, V106, P70; GNARRA JR, 1995, CANCER RES, V55, P4092; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lipponen P, 1999, ENDOCR-RELAT CANCER, V6, P13, DOI 10.1677/erc.0.0060013; Loeb DM, 2001, CANCER RES, V61, P921; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Ostrom L, 2000, DEV BIOL, V219, P250, DOI 10.1006/dbio.2000.9618; Porteous S, 2000, HUM MOL GENET, V9, P1, DOI 10.1093/hmg/9.1.1; ROBINSON GW, 2000, METHODS MAMMARY GLAN, P307; Silberstein GB, 1996, CELL GROWTH DIFFER, V7, P945; Silberstein GB, 2001, MICROSC RES TECHNIQ, V52, P155, DOI 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; SILBERSTEIN GB, 1982, DEV BIOL, V93, P272, DOI 10.1016/0012-1606(82)90259-7; SMITH GH, 1988, J CELL SCI, V89, P173; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1111/j.1432-0436.1998.00201.x; Stuart ET, 1996, CELL GROWTH DIFFER, V7, P405; TOKER C, 1967, J ULTRA MOL STRUCT R, V21, P9, DOI 10.1016/S0022-5320(67)80003-0; Torres MA, 1996, DEVELOPMENT, V122, P3381; Vicanek C, 1997, KIDNEY INT, V52, P614, DOI 10.1038/ki.1997.374; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; Zhang GJ, 1998, ONCOL REP, V5, P1211	34	61	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1009	1016		10.1038/sj.onc.1205172	http://dx.doi.org/10.1038/sj.onc.1205172			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850818				2022-12-28	WOS:000173580100004
J	Bar-Shira, A; Rashi-Elkeles, S; Zlochover, L; Moyal, L; Smorodinsky, NI; Seger, R; Shiloh, Y				Bar-Shira, A; Rashi-Elkeles, S; Zlochover, L; Moyal, L; Smorodinsky, NI; Seger, R; Shiloh, Y			ATM-dependent activation of the gene encoding MAP kinase phosphatase 5 by radiomimetic DNA damage	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; MAP kinases; MAP kinase phosphatase; JNK; p38	PROTEIN-KINASE PHOSPHATASE; ATAXIA-TELANGIECTASIA CELLS; C-JUN; SIGNAL-TRANSDUCTION; GAMMA-RADIATION; SACCHAROMYCES-CEREVISIAE; PERSISTENT ACTIVATION; NEGATIVE REGULATOR; GENOTOXIC STRESS; JNK	Cellular responses to DNA damage are mediated by an extensive network of signaling pathways. The ATM protein kinase is a master regulator of the response to double-strand breaks (DSBs), the most cytotoxic DNA lesion caused by ionizing radiation. ATM is the protein missing or inactive in patients with the pleiotropic genetic disorder ataxia-telangiectasia (A-T). A major response to DNA damage is altered expression of numerous genes. While studying gene expression in control and A-T cells following treatment with the radiomimetic chemical neocarzinostatin (NCS), we identified an expressed sequence tag that represented a gene that was induced by DSBs in an ATM-dependent manner. The corresponding cDNA encoded a dual specificity phosphatase of the MAP kinase phosphatase family, MKP-5. MKP-5 dephosphorylates and inactivates the stress-activated MAP kinases JNK and p38. The phosphorylation-dephosphorylation cycle of JNK and p38 by NCS was attenuated in A-T cells. Thus, ATM modulates this cycle in response to DSBs. These results further highlight ATM as a link between the DNA damage response and major signaling pathways involved in proliferative and apoptotic processes.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Hybridoma Unit, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Weizmann Institute of Science	Shiloh, Y (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel.	yossih@post.tau.ac.il			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS31763] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GOLDBERG IH, 1995, ENEDIYNE ANTIBIOTICS, P327; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Masuda K, 2000, CYTOGENET CELL GENET, V90, P71, DOI 10.1159/000015666; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; MELTZER B, 2001, J BIOL CHEM, V273, P33320; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaus SE, 2001, P NATL ACAD SCI USA, V98, P11075, DOI 10.1073/pnas.191340698; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SHILOH Y, 1983, CARCINOGENESIS, V4, P1317, DOI 10.1093/carcin/4.10.1317; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	46	26	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					849	855		10.1038/sj.onc.1205127	http://dx.doi.org/10.1038/sj.onc.1205127			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850813				2022-12-28	WOS:000173427000016
J	Chan, SWL; Blackburn, EH				Chan, SWL; Blackburn, EH			New ways not to make ends meet: telomerase, DNA damage proteins and heterochromatin	ONCOGENE			English	Review						telomere; telomerase; heterochromatin; telomere capping; DNA damage	SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; BINDING-PROTEIN; IN-VIVO; TERMINAL TRANSFERASE; FISSION YEAST; LIFE-SPAN; RNA; LENGTH; RAP1	Telomeres are stabilized, and telomeric DNA is replenished, by the action of the ribonucleoprotein reverse transcriptase telomerase. Telomere capping functions include the ability of telomeres to protect chromosome ends from cellular DNA-damage responses such as cell cycle arrest or apoptosis. This property of telomeres is especially important for cancer cells, which continue proliferating despite chromosome aberrations. Telomere capping is influenced by multiple, mutually reinforcing factors including telomere length, although telomere length is only one of several determinants of telomere functionality. For example, many cancer cells express high levels of telomerase yet maintain relatively short telomeres. We consider three aspects of telomere capping that have emerged relatively recently: (1) a new role for telomerase in telomere capping independent of its function in telomere elongation. Support for this novel function comes from experiments showing an increase in replicative potential with the reactivation of telomerase, without net telomere lengthening; (2) the role at telomeres of DNA damage proteins. We propose a model in which two factors specifically target telomeres for the action of telomerase, as opposed to recombination or non-homologous end-joining: binding by telomeric proteins that limits DNA damage responses at telomeres, and the affinity of the telomerase RNP for telomeric proteins and DNA; and (3) we discuss a potential protective role of amplified subtelomeric DNAs, which may aid capping of telomeres maintained by non-telomerase based mechanisms through the formation of heterochromatin.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Blackburn, EH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	telomer@itsa.ucsf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026259, R01GM026259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BAIRD SE, 1989, GENE DEV, V3, P585, DOI 10.1101/gad.3.5.585; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Blackburn EH, 2000, COLD SPRING HARB SYM, V65, P253, DOI 10.1101/sqb.2000.65.253; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blackburn EH, 1995, TELOMERES; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Chan SWL, 2001, CURR BIOL, V11, P1240, DOI 10.1016/S0960-9822(01)00391-8; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Craven RJ, 1999, GENETICS, V152, P1531; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DERNBURG AF, 1995, TELOMERES; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Dorer DR, 1997, GENETICS, V147, P1181; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; DuBois ML, 2000, COLD SPRING HARB SYM, V65, P281, DOI 10.1101/sqb.2000.65.281; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Evans SK, 2000, J CELL SCI, V113, P3357; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; Fulton TB, 1998, MOL CELL BIOL, V18, P4961, DOI 10.1128/MCB.18.9.4961; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hammond PW, 1997, MOL CELL BIOL, V17, P296, DOI 10.1128/MCB.17.1.296; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Huffman KE, 2000, J BIOL CHEM, V275, P19719, DOI 10.1074/jbc.M002843200; JARACZEWSKI JW, 1993, GENE DEV, V7, P95, DOI 10.1101/gad.7.1.95; KARATZA C, 1984, J CELL SCI, V65, P163; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Klapper W, 2001, J NEUROSCI RES, V64, P252, DOI 10.1002/jnr.1073.abs; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; Krauskopf A, 1998, P NATL ACAD SCI USA, V95, P12486, DOI 10.1073/pnas.95.21.12486; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mishra K, 1999, CURR BIOL, V9, P1123, DOI 10.1016/S0960-9822(99)80483-7; Moreau S, 1999, MOL CELL BIOL, V19, P556; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PARDUE M, 1995, TELOMERES; Pardue ML, 1999, GENETICA, V107, P189, DOI 10.1023/A:1003905210770; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Ritchie KB, 2000, GENETICS, V155, P475; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; Roy J, 1998, GENE DEV, V12, P3286, DOI 10.1101/gad.12.20.3286; Schulz VP, 1996, HUM GENET, V97, P750; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; Suja JA, 1994, CHROMOSOME RES, V2, P361, DOI 10.1007/BF01552795; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Weng NP, 1997, P NATL ACAD SCI USA, V94, P10827, DOI 10.1073/pnas.94.20.10827; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	110	238	253	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					553	563		10.1038/sj.onc.1205082	http://dx.doi.org/10.1038/sj.onc.1205082			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850780				2022-12-28	WOS:000173390500007
J	Ford, LP; Wright, WE; Shay, JW				Ford, LP; Wright, WE; Shay, JW			A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation	ONCOGENE			English	Article						telomerase; telomere; hnRNP	IN-VITRO; CATALYTIC SUBUNIT; BINDING-PROTEIN; PREMESSENGER RNA; RAT HEPATOCYTES; HNRNP PROTEINS; EST GENES; MATRIX; DNA; SEQUENCE	The heterogeneous nuclear ribonucleoproteins (hnRNPs) are a large family of nucleic acid binding proteins that are often found in, but not restricted to, the 40S-ribonucleoprotein particle. Subsets of huRNPs are strictly nuclear while others shuttle between the nucleus and cytoplasm. Members of the hnRNP family have been implicated to have roles in many aspects of mRNA maturation/turnover and in telomere and telomerase regulation. Telomeres are repetitive DNA elements mainly found at the ends of human chromosomes. In most normal cells, telomeres shorten with each cell division. Telomere shortening can be compensated for by a ribonucleoprotein complex, called telomerase. Telomerase, consisting of an integral RNA and catalytic protein component as well as several auxiliary factors, extends the 3'-G-rich strand of the ends of the telomeres. Here we present new data and describe a model that implicates the telomerase bound hnRNPs; in promoting telomere access by interacting with telomeres. Telomere bound hnRNPs include hnRNP A1, A2-B1, D and E and telomerase bound hnRNPs including hnRNPA1 C1/C2 and D. The telomere and telomerase bound hnRNPs; may prove to be good targets for regulating telomere length.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Ambion Inc, Austin, TX 78744 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jerry.shay@utsouthwestern.edu	Shay, Jerry W/F-7878-2011		NATIONAL INSTITUTE ON AGING [R01AG007992, R01AG001228, R37AG001228] Funding Source: NIH RePORTER; NIA NIH HHS [AG01228, AG07992] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aigner S, 2000, EMBO J, V19, P6230, DOI 10.1093/emboj/19.22.6230; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; Erlitzki R, 1997, J BIOL CHEM, V272, P15881, DOI 10.1074/jbc.272.25.15881; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Ford LP, 2001, RNA, V7, P1068, DOI 10.1017/S1355838201010159; Ford LP, 2000, MOL CELL BIOL, V20, P9084, DOI 10.1128/MCB.20.23.9084-9091.2000; GALLINARO H, 1983, EMBO J, V2, P953, DOI 10.1002/j.1460-2075.1983.tb01527.x; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; Greene EC, 1998, GENE DEV, V12, P2921, DOI 10.1101/gad.12.18.2921; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hinkley CS, 1998, NUCLEIC ACIDS RES, V26, P532, DOI 10.1093/nar/26.2.532; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; Johnston SD, 1999, MOL CELL BIOL, V19, P923; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Le SY, 2000, MOL BIOL CELL, V11, P999, DOI 10.1091/mbc.11.3.999; Lendvay TS, 1996, GENETICS, V144, P1399; LESTOURGEON WM, 1977, COLD SPRING HARB SYM, V42, P885, DOI 10.1101/SQB.1978.042.01.090; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Mattern KA, 1996, J CELL BIOCHEM, V62, P275, DOI 10.1002/(SICI)1097-4644(199608)62:2<275::AID-JCB15>3.0.CO;2-K; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; Mattern KA, 1997, J CELL BIOCHEM, V65, P42, DOI 10.1002/(SICI)1097-4644(199704)65:1<42::AID-JCB5>3.0.CO;2-Z; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Sarig G, 1997, J BIOL CHEM, V272, P4474, DOI 10.1074/jbc.272.7.4474; Schnapp G, 1998, NUCLEIC ACIDS RES, V26, P3311, DOI 10.1093/nar/26.13.3311; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Steiner BR, 1996, P NATL ACAD SCI USA, V93, P2817, DOI 10.1073/pnas.93.7.2817; VANEEKELEN CAG, 1981, J CELL BIOL, V88, P554, DOI 10.1083/jcb.88.3.554; Weighardt F, 1999, J CELL SCI, V112, P1465; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; Zhou JL, 2000, MOL CELL BIOL, V20, P1947, DOI 10.1128/MCB.20.6.1947-1955.2000	50	119	130	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					580	583		10.1038/sj.onc.1205086	http://dx.doi.org/10.1038/sj.onc.1205086			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850782				2022-12-28	WOS:000173390500009
J	Rivera, R; Murre, C				Rivera, R; Murre, C			The regulation and function of the Id proteins in lymphocyte development	ONCOGENE			English	Review						E-proteins; bHLH; Id	LOOP-HELIX PROTEIN; B-CELL DEVELOPMENT; T-CELL; DNA-BINDING; MAP KINASE; THYMOCYTE MATURATION; SIGNALING PATHWAYS; NEGATIVE REGULATOR; MESSENGER-RNA; E2A ACTIVITY	Helix - loop - helix (HLH) proteins are essential factors for lymphocyte development and function. One class of HLH proteins, the E-proteins, regulate many aspects of lymphocyte maturation, survival, proliferation, and differentiation. E-proteins are negatively regulated by another class of HLH proteins known as the Id proteins. The Id proteins function as dominant negative inhibitors of E-proteins by inhibiting their ability to bind DNA. Here we discuss the function and regulation of the Id proteins in lymphocyte development.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Rivera, R (corresponding author), Univ Calif San Diego, Div Biol, 0366, La Jolla, CA 92093 USA.	r3@biomail.ucsd.edu						ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bain G, 1997, IMMUNITY, V6, P145, DOI 10.1016/S1074-7613(00)80421-5; Bain G, 1999, J EXP MED, V189, P289, DOI 10.1084/jem.189.2.289; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Barndt R, 1999, J IMMUNOL, V163, P3331; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Carlyle JR, 1997, J EXP MED, V186, P173, DOI 10.1084/jem.186.2.173; CHANTRY D, 1989, EUR J IMMUNOL, V19, P783, DOI 10.1002/eji.1830190433; Chen BB, 1997, NUCLEIC ACIDS RES, V25, P423, DOI 10.1093/nar/25.2.423; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; DEED RW, 1993, ONCOGENE, V8, P599; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; Gartner F, 1999, IMMUNITY, V10, P537, DOI 10.1016/S1074-7613(00)80053-9; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; Goldfarb AN, 1996, MOL IMMUNOL, V33, P947, DOI 10.1016/S0161-5890(96)00047-8; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Ikawa T, 1999, J EXP MED, V190, P1617, DOI 10.1084/jem.190.11.1617; Ikawa T, 2001, P NATL ACAD SCI USA, V98, P5164, DOI 10.1073/pnas.091537598; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; KEE BL, 1995, INT REV CYTOL, V157, P129, DOI 10.1016/S0074-7696(08)62158-0; Kim D, 1999, MOL CELL BIOL, V19, P8240; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kleeff J, 1998, CANCER RES, V58, P3769; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Leclercq G, 1996, J EXP MED, V184, P325, DOI 10.1084/jem.184.2.325; LEE G, 1989, J IMMUNOL, V142, P3875; Lilja H, 1999, Mol Cell Biol Res Commun, V1, P188, DOI 10.1006/mcbr.1999.0131; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massy ZA, 1996, SEMIN NEPHROL, V16, P12; MATSUZAKI Y, 1993, J EXP MED, V178, P1283, DOI 10.1084/jem.178.4.1283; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; Miyazaki T, 1998, J EXP MED, V188, P715, DOI 10.1084/jem.188.4.715; Moldes M, 1997, MOL CELL BIOL, V17, P1796, DOI 10.1128/MCB.17.4.1796; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Pan LH, 1999, MOL CELL BIOL, V19, P5969; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; Quong MW, 1999, EMBO J, V18, P6307, DOI 10.1093/emboj/18.22.6307; Res PCM, 1999, BLOOD, V94, P2647, DOI 10.1182/blood.V94.8.2647.420k06_2647_2657; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; Romanow WJ, 2000, MOL CELL, V5, P343, DOI 10.1016/S1097-2765(00)80429-3; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ MJ, 1994, J EXP MED, V180, P569, DOI 10.1084/jem.180.2.569; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SHOJI W, 1994, J BIOL CHEM, V269, P5078; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Spits H, 2000, J EXP MED, V192, P1775, DOI 10.1084/jem.192.12.1775; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Tournay O, 1996, MOL CELL BIOL, V16, P2418; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yaswen L, 1996, BLOOD, V87, P1439, DOI 10.1182/blood.V87.4.1439.bloodjournal8741439; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZunigaPflucker JC, 1996, CURR OPIN IMMUNOL, V8, P215, DOI 10.1016/S0952-7915(96)80060-4	105	64	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8308	8316		10.1038/sj.onc.1205091	http://dx.doi.org/10.1038/sj.onc.1205091			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840323				2022-12-28	WOS:000173319500004
J	Xiang, H; Wang, J; Mao, YW; Liu, MY; Reddy, VN; Li, DWC				Xiang, H; Wang, J; Mao, YW; Liu, MY; Reddy, VN; Li, DWC			Human telomerase accelerates growth of lens epithelial cells through regulation of the genes mediating RB/E2F pathway	ONCOGENE			English	Article						human lens epithelial cells; telomerase; cell growth; E2F; RB; p53; GCIP	EXPRESSION; CYCLE; E2F; P53; IMMORTALIZATION; INHIBITOR; PROTEIN; PROLIFERATION; INDUCTION; APOPTOSIS	Telomerase is a specialized reverse transcriptase that extends telomeres of eukaryotic chromosomes. The catalytic core of human telomerase is composed of an RNA template known as hTER (human telomerase RNA) and a protein subunit named hTERT (human telomerase reverse transcriptase). We have been studying other functions of the telomerase besides its major role in telomere maintenance. In our previous work, we have demonstrated that the hTERT can functionally interact with a rabbit TER to regulate expression of other genes and also attenuate the induced apoptosis. Here we report that overexpression of hTERT in a human lens epithelial cell fine accelerates growth of the transfected lens epithelial cells. Associated with the acceleration of cell growth, expression of p53, p21 and GCIP (Grap2 cyclin-D interacting protein) is downregulated in the hTERT-transfected cells. With the downregulation of p21 and GCIP, the retinoblastoma protein (RB) is completely hyperphosphorylated in the hTERT-transfected cells. As expected, in the presence of RB hyperphosphorylation, the E2F transactivity is upregulated. Inhibition of telomerase activity abolishes the observed growth acceleration and also the related molecular changes. Furthermore, expression of hTERT in telomerase-negative human lens epithelial cells derived from primary cultures also accelerates growth of the transfected cells. Taken together, our results suggest that hTERT, when overexpressed in human lens epithelial cells, accelerates cell growth rate through regulation of RB/E2F pathway and possibly other genes.	Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Biol Mol, Stratford, NJ 08084 USA; Univ Texas, Hlth Sci Ctr, Dept Med Biochem & Genet, Inst Biosci & Technol,Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Texas System; University of Texas Health Science Center Houston; University of Michigan System; University of Michigan	Li, DWC (corresponding author), Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Biol Mol, 2 Med Ctr Dr, Stratford, NJ 08084 USA.	DWL168@att.net	Li, David/AAN-9205-2021	Liu, Mingyao/0000-0001-7339-5048; xiang, hua/0000-0003-0369-1225; Mao, Yingwei/0000-0001-7339-1565	NEI NIH HHS [EY 11372, EY 07003, EY 00484] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY000484, R29EY011372, R01EY000484] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; CHEN JD, 1992, ONCOGENE, V7, P1167; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gunes C, 2000, CANCER RES, V60, P2116; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hess RD, 1997, ONCOGENE, V15, P2501, DOI 10.1038/sj.onc.1201404; Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551; Klingelhutz AJ, 1999, ANTICANCER RES, V19, P4823; Kohli M, 1999, BIOCHEM BIOPH RES CO, V257, P168, DOI 10.1006/bbrc.1999.0389; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Lania L, 1999, J CELL PHYSIOL, V179, P134, DOI 10.1002/(SICI)1097-4652(199905)179:2<134::AID-JCP3>3.0.CO;2-O; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Magnenat L, 1999, MOL CELL BIOL, V19, P3457; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Mata JE, 1997, TOXICOL APPL PHARM, V144, P189, DOI 10.1006/taap.1997.8103; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang S, 1999, MOL CELL BIOL, V19, P7447; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	39	83	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3784	3791		10.1038/sj.onc.1205455	http://dx.doi.org/10.1038/sj.onc.1205455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032846				2022-12-28	WOS:000175676000013
J	Zhang, CJ; Vilk, G; Canton, DA; Litchfield, DW				Zhang, CJ; Vilk, G; Canton, DA; Litchfield, DW			Phosphorylation regulates the stability of the regulatory CK2 beta subunit	ONCOGENE			English	Article						protein kinase CK2; ubiquitin; phosphorylation; proteasome	CASEIN KINASE-II; TUMOR-SUPPRESSOR PROTEIN; BETA-SUBUNIT; CYCLIN-E; DNA-DAMAGE; CELL-CYCLE; INDUCIBLE EXPRESSION; CK2 SUBUNITS; C-JUN; P53	Protein kinase CK2 is a protein serine/threonine kinase that exhibits elevated expression in a number of cancers and displays oncogenic activity in mice. The regulatory CK2beta subunit has a central role in assembly of functional tetrameric CK2 complexes where it participates in modulation of catalytic activity and substrate specificity. Since overexpression of CK2beta results in elevated levels of CK2 activity, we investigated the molecular mechanisms that control its degradation since perturbations in these pathways could contribute to elevated CK2 in cancer. In this study, we demonstrate that CK2beta is degraded by a proteasome-dependent pathway and that it is ubiquitinated. We have also investigated the role of phosphorylation and a putative destruction box in regulating its stability in cells. Importantly, replacement of three serine residues within the autophosphorylation site of CK2beta with glutamic acid residues resulted in a significant decrease in its degradation indicating that autophosphorylation is involved in regulating its stability. Notably, although the autophosphorylation site of CUP is remarkably conserved between species, this is the first functional role ascribed to this site. Furthermore, based on these results, we speculate that alterations in the phosphorylation or dephosphorylation of the regulatory CK2beta subunit could underlie the elevated expression of CK2 that is observed in cancer cells.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Litchfield, DW (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	litchfi@uwo.ca	Canton, David/N-7463-2015; Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; Bosc DG, 2000, J BIOL CHEM, V275, P14295, DOI 10.1074/jbc.275.19.14295; Canton DA, 2001, BIOCHEM J, V358, P87, DOI 10.1042/0264-6021:3580087; Castro A, 2001, MOL BIOL CELL, V12, P2660, DOI 10.1091/mbc.12.9.2660; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; de Hoog CL, 2001, MOL CELL BIOL, V21, P2107, DOI 10.1128/MCB.21.6.2107-2117.2001; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Dick LR, 1997, J BIOL CHEM, V272, P182; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; FILHOL O, 1992, J BIOL CHEM, V267, P20577; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gerber DA, 2000, J BIOL CHEM, V275, P23919, DOI 10.1074/jbc.M002697200; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; Krippner-Heidenreich A, 2001, BIOCHEM J, V358, P705, DOI 10.1042/0264-6021:3580705; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; LIN WJ, 1994, BIOCHEMISTRY-US, V33, P6998, DOI 10.1021/bi00188a032; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; Pham CD, 1999, ONCOGENE, V18, P4287, DOI 10.1038/sj.onc.1202804; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Prowald A, 1997, FEBS LETT, V408, P99, DOI 10.1016/S0014-5793(97)00399-2; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Rifkin IR, 1998, J IMMUNOL, V161, P5164; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Sayed M, 2001, ONCOGENE, V20, P6994, DOI 10.1038/sj.onc.1204894; Schwab M, 2001, NATURE, V413, P268, DOI 10.1038/35095157; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shi XY, 2001, J BIOL CHEM, V276, P2075, DOI 10.1074/jbc.M008583200; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; Vilk G, 2002, J CELL BIOCHEM, V84, P84, DOI 10.1002/jcb.1268; Winston JT, 1999, GENE DEV, V13, P2751, DOI 10.1101/gad.13.21.2751; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; YOI OKO, 1993, EMBO J, V12, P1621; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	76	63	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3754	3764		10.1038/sj.onc.1205467	http://dx.doi.org/10.1038/sj.onc.1205467			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032843				2022-12-28	WOS:000175676000010
J	Sers, C; Husmann, K; Nazarenko, I; Reich, S; Wiechen, K; Zhumabayeva, B; Adhikari, P; Schroder, K; Gontarewicz, A; Schafer, R				Sers, C; Husmann, K; Nazarenko, I; Reich, S; Wiechen, K; Zhumabayeva, B; Adhikari, P; Schroder, K; Gontarewicz, A; Schafer, R			The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFN gamma-induced cell death in human ovarian carcinoma cells	ONCOGENE			English	Article						tumour suppressor; H-REV107-1; IRF-1; target gene; IRF gamma; apoptosis	BRCA1 PROMOTER REGION; TRANSCRIPTION FACTOR; LYSYL OXIDASE; DOWN-REGULATION; MESSENGER-RNAS; RETINOIC ACID; EXPRESSION; IRF-1; CANCER; TRANSFORMATION	H-rev107-1 is a growth inhibitory RAS target gene capable of suppressing anchorage independent growth in vitro and in vivo. Using a tumour tissue array with 241 matched tumour and normal tissue cDNA pools, we found down-regulation of H-REV107-1 in 7 out of 14 ovary-derived cDNAs. RT-PCR analysis and immunohistochemical investigation confirmed expression of H-REV107-1 in normal ovarian epithelial cells but down-regulation in high grade ovarian carcinomas. H-REV107-1 is also strongly expressed in immortalized rat and human ovarian epithelial cells in vitro, but suppressed in transformed cells by two different mechanisms. KRAS-transformed rat ovarian cells and PA1 teratocarcinoma cells, reversibly repress H-REV107-1 via MAP/ERK signaling. In contrast, treatment of A27/80 and OVCAR-3 epithelial ovarian cancer cells with IFN-gamma stimulated H-REV107-1 expression. In NIH3T3 cells harbouring an estrogen-inducible IRF-1, H-rev107-1 is directly induced after activation of IRF-1, indicating that H-rev107-1 is a target of IRF-1. Stimulation of H-REV107-1 expression was also observed in ovarian epithelial cells suggesting that IRF-1 is involved in H-REV107-1 regulation in human ovarian epithelium. In the IFNgamma-sensitive cell line A27/80, H-REV107-1 suppresses colony formation. A27/80 and OVCAR-3 cells overexpressing H-REV107-1 protein underwent apoptosis. These results demonstrate down-regulation of the class II tumour suppressor H-REV107-1 in human ovarian carcinomas and suggest an involvement of H-REV107-1 in interferon-dependent cell death.	Univ Hosp Charite, Inst Pathol, D-10117 Berlin, Germany; Natl Res Ctr Biotechnol, Braunschweig, Germany; Clontech Labs, Palo Alto, CA 94303 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Sers, C (corresponding author), Univ Hosp Charite, Inst Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.	christine.sers@charite.de	Nazarenko, Irina/E-5714-2010; Schäfer, Reinhold/AAB-5110-2021; Sers, Christine/B-5438-2010	Nazarenko, Irina/0000-0002-2633-1161; Schafer, Reinhold/0000-0001-7952-2124; Sers, christine/0000-0002-6219-1514				ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Baldwin RL, 2000, CANCER RES, V60, P5329; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Burke F, 1999, BRIT J CANCER, V80, P1236, DOI 10.1038/sj.bjc.6690491; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Demaeyer E., 1988, INTERFERONS OTHER RE; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Evans TRJ, 1999, BRIT J CANCER, V80, P1, DOI 10.1038/sj.bjc.6690312; Green WB, 1999, LEUKEMIA, V13, P1960, DOI 10.1038/sj.leu.2401596; HAJNAL A, 1993, CANCER RES, V53, P4670; HAJNAL A, 1994, ONCOGENE, V9, P479; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARADA H, 1994, ONCOGENE, V9, P3313; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; Jiang Ming-Chung, 2001, Molecular Cell Biology Research Communications, V4, P353, DOI 10.1006/mcbr.2001.0303; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Kuchinke W, 1995, NEUROIMMUNOMODULAT, V2, P347, DOI 10.1159/000097214; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; OBERHUBER H, 1995, MOL CARCINOGEN, V12, P198, DOI 10.1002/mc.2940120404; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; Patton SE, 1998, CANCER RES, V58, P2253; Rohwedel J, 1999, CELLS TISSUES ORGANS, V165, P190, DOI 10.1159/000016699; RONGLIN X, 2001, J BIOL CHEM, V276, P18624; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCHAFER R, 1994, REV PHYSIOL BIOCH P, V124, P29, DOI 10.1007/BFb0031031; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333; Tamura G, 1996, CANCER RES, V56, P612; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan RSP, 1996, CANCER RES, V56, P2417; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tchernitsa OI, 1999, ONCOGENE, V18, P5448, DOI 10.1038/sj.onc.1202987; Tnani M, 1999, BBA-MOL CELL RES, V1451, P59, DOI 10.1016/S0167-4889(99)00089-0; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Windbichler GH, 2000, BRIT J CANCER, V82, P1138; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zhumabayeva B, 2001, BIOTECHNIQUES, V30, P158, DOI 10.2144/01301pf01; ZHUMABAYEVA B, 2001, CLONTECHNIQUES, V16, P27; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	57	35	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2829	2839		10.1038/sj.onc.1205377	http://dx.doi.org/10.1038/sj.onc.1205377			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973642				2022-12-28	WOS:000175063700007
J	Chizhikov, V; Chikina, S; Gasparian, A; Zborovskaya, I; Steshina, E; Ungiadze, G; Samsonova, M; Chernyaev, A; Chuchalin, A; Tatosyan, A				Chizhikov, V; Chikina, S; Gasparian, A; Zborovskaya, I; Steshina, E; Ungiadze, G; Samsonova, M; Chernyaev, A; Chuchalin, A; Tatosyan, A			Molecular follow-up of preneoplastic lesions in bronchial epithelium of former Chernobyl clean-up workers	ONCOGENE			English	Article						lung cancer; preneoplastic lesions; radiation; smoking; loss of heterozygosity; FHIT expression	K-RAS GENES; LUNG-CANCER; SMOKING; P53; EXPOSURE; PCR	Ionizing radiation is a potent lung carcinogen, but the precise molecular damage associated with it is still unknown. In this study we investigated cancer-related molecular abnormalities including K-ras (codon 12) mutation, p16(INK4A) promoter hypermethylation and microsatellite alterations at seven chromosomal regions in successive biopsies obtained from former Chernobyl cleanup workers in comparison with smokers and nonsmokers who have never had radiation exposure. Our results indicate that prolonged persistence of inhaled radioactive particles is associated with appearance of allelic loss at 3p12, 3p14.2 (FHIT), 3p21, 3p22-24 (hMLH1) and 9p21 (p16(INK4A)) in bronchial epithelium of former Chernobyl clean-up workers. The prevalence of 3p14.2 allelic loss was associated with decreased expression of the FHIT mRNA in their bronchial epithelium in comparison with control group of smokers. During several years of our monitoring samples of epithelium were collected from the same area of bronchial tree. In epithelium exposed to carcinogens (tobacco smoke and/or radioactivity) the total number of molecular abnormalities was significantly higher in dysplasia and in morphologically normal foci progressed later to dysplasia than in these samples which never showed evidence of such progression. Our findings indicate that extensive cancer-related molecular abnormalities sequentially occur in radiation damaged bronchial epithelium of former Chernobyl clean-up workers.	RAMS, Canc Res Ctr, Inst Carcinogenesis, Moscow 117449, Russia; Inst Pulmonol, Moscow, Russia	Russian Academy of Medical Sciences	Tatosyan, A (corresponding author), RAMS, Canc Res Ctr, Inst Carcinogenesis, Kashirskoye Shosse 24, Moscow 117449, Russia.	tatosyan@space.ru	Chikina, Svetlana/GZH-0832-2022; Chikina, Svetlana Yu./P-5646-2018; Cucalin, Aleksandr/P-5678-2018	Chikina, Svetlana Yu./0000-0002-5536-9388; Chizhikov, Victor/0000-0003-2338-1267; Cucalin, Aleksandr/0000-0002-6808-5528				ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; AUERBACH O, 1961, NEW ENGL J MED, V265, P253, DOI 10.1056/NEJM196108102650601; Battey, 1986, BASIC METHODS MOL BI; Brambilla E, 1999, CLIN CANCER RES, V5, P243; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; Chizhikov V, 2001, MOL CARCINOGEN, V30, P151, DOI 10.1002/mc.1023; CHUCHALIN AG, 1995, STEM CELLS, V13, P276, DOI 10.1002/stem.5530130734; Chuchalin AG, 1997, SCHWEIZ MED WSCHR, V127, P165; Gealy R, 1999, CANCER EPIDEM BIOMAR, V8, P297; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Israel Yu.A., 1987, METEOROL J HYDROL, V2, P5; Ji L, 1999, CANCER RES, V59, P3333; JIANG W, 1989, ONCOGENE, V4, P923; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KAHN SM, 1991, ONCOGENE, V6, P1079; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Lam S, 1999, JNCI-J NATL CANCER I, V91, P691, DOI 10.1093/jnci/91.8.691; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LANG S, 1995, ENVIRON HEALTH PERSP, V103, P920, DOI 10.2307/3432738; Little JB, 1997, P NATL ACAD SCI USA, V94, P5996, DOI 10.1073/pnas.94.12.5996; LUNDGREN DL, 1982, RADIAT RES, V90, P374, DOI 10.2307/3575715; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; Pasanen M, 1995, ENVIRON RES, V70, P126, DOI 10.1006/enrs.1995.1057; SACCOMANNO G, 1974, CANCER-AM CANCER SOC, V33, P256, DOI 10.1002/1097-0142(197401)33:1<256::AID-CNCR2820330139>3.0.CO;2-G; Sanchez-Cespedes M, 2001, CANCER RES, V61, P2092; SANDERS CL, 1993, INT J RADIAT BIOL, V134, P29; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366	32	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2398	2405		10.1038/sj.onc.1205310	http://dx.doi.org/10.1038/sj.onc.1205310			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948423				2022-12-28	WOS:000174635600012
J	Mahoney, MG; Simpson, A; Jost, M; Noe, M; Kari, C; Pepe, D; Choi, YW; Uitto, J; Rodeck, U				Mahoney, MG; Simpson, A; Jost, M; Noe, M; Kari, C; Pepe, D; Choi, YW; Uitto, J; Rodeck, U			Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes	ONCOGENE			English	Article						anoikis; epidermal growth factor; epithelial cells	EPIDERMAL-GROWTH-FACTOR; BCL-X-L; FACTOR RECEPTOR; BCL-X(L) EXPRESSION; MONOCLONAL-ANTIBODY; ESTROGEN-RECEPTOR; MAMMALIAN-CELLS; GENE; MTA1; MATRIX	The human metastasis-associated gene (MTA1), a member of the nucleosome remodeling complex with histone deacetylase activity, is frequently overexpressed in biologically aggressive epithelial neoplasms. Here, we extend this observation to squamous carcinoma cells, which express high levels of MTA1 relative to normal or immortalized keratinocytes. To address functional aspects of MTA1 expression, we established variants of human immortalized keratinocytes (HaCaT cells) by expressing MTA1 cDNA in both the sense and antisense orientations. We demonstrate that (1) forced MAT1 expression enhances migration and invasion of immortalized keratinocytes; (2) MTA1 expression is necessary but not sufficient for cell survival in the anchorage independent state; (3) MTA1 contributes to expression of the anti-apoptotic Bcl-2 family member Bcl-x(L); (4) MTA1 expression in immortalized keratinocytes depends, in part, on activation of the epidermal growth factor receptor (EGFR). These results establish that, in keratinocytes, MTA1 expression contributes to several aspects of the metastatic phenotype including survival in the anchorage independent state, migration, and invasion.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Inst Mol Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Mahoney, MG (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA.	My.Mahoney@mail.tju.edu	Mahoney, My/A-2716-2009					Ahmed NU, 1997, BRIT J DERMATOL, V136, P908, DOI 10.1111/j.1365-2133.1997.tb03932.x; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BASU A, 1987, CANCER RES, V47, P2531; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Futamura M, 1999, J HUM GENET, V44, P52, DOI 10.1007/s100380050107; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Herman MA, 1999, DEVELOPMENT, V126, P1055; Jost M, 1999, J INVEST DERMATOL, V112, P443, DOI 10.1046/j.1523-1747.1999.00543.x; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Jost M, 1997, NUCLEIC ACIDS RES, V25, P3131, DOI 10.1093/nar/25.15.3131; KAWAHARA E, 1995, J CANCER RES CLIN, V121, P133, DOI 10.1007/BF01198094; Kleene R, 1999, J CELL SCI, V112, P2539; LEJEUNE S, 1993, CANCER RES, V53, P3597; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Mahoney MG, 1998, J INVEST DERMATOL, V111, P308, DOI 10.1046/j.1523-1747.1998.00279.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; MCNEILL H, 1990, CELL REGUL, V1, P843, DOI 10.1091/mbc.1.11.843; MUKAIDA H, 1991, CANCER, V68, P142, DOI 10.1002/1097-0142(19910701)68:1<142::AID-CNCR2820680126>3.0.CO;2-X; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; MURTHY U, 1990, BIOCHEM BIOPH RES CO, V172, P471, DOI 10.1016/0006-291X(90)90696-K; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; OZAWA S, 1989, CANCER, V63, P2169, DOI 10.1002/1097-0142(19890601)63:11<2169::AID-CNCR2820631117>3.0.CO;2-W; Paterno GD, 1997, J BIOL CHEM, V272, P25591, DOI 10.1074/jbc.272.41.25591; Pinkas-Kramarski R, 1998, ONCOGENE, V16, P1249, DOI 10.1038/sj.onc.1201642; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; RODECK U, 1987, CANCER RES, V47, P3692; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Simpson A, 2001, GENE, V273, P29, DOI 10.1016/S0378-1119(01)00563-7; TOH Y, 1995, GENE, V159, P97, DOI 10.1016/0378-1119(94)00410-T; Toh Y, 2000, J EXP CLIN CANC RES, V19, P105; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; YONEDA T, 1991, CANCER RES, V51, P4430; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhu Z, 2000, CANCER RES, V61, P1707	39	83	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2161	2170		10.1038/sj.onc.1205277	http://dx.doi.org/10.1038/sj.onc.1205277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948399				2022-12-28	WOS:000174555300005
J	Katsuda, K; Kataoka, M; Uno, F; Murakami, T; Kondo, T; Roth, JA; Tanaka, N; Fujiwara, T				Katsuda, K; Kataoka, M; Uno, F; Murakami, T; Kondo, T; Roth, JA; Tanaka, N; Fujiwara, T			Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells	ONCOGENE			English	Article						p16; adenovirus vector; apoptosis; caspase-3	RETINOBLASTOMA GENE-PRODUCT; KINASE-4 INHIBITOR GENE; S-PHASE ENTRY; POLY(ADP-RIBOSE) POLYMERASE; PROTEIN; EXPRESSION; P53; P16(INK4A); MDM2; P16	The p16 tumor suppressor gene is frequently inactivated in human cancer tissues and cell lines. We previously reported that wild-type p16 expression from an adenovirus vector (Adv/p16) induced p53-dependent apoptotic cell death in non-small cell lung cancer (NSCLC) cell fines. Here we show the potential mechanism of apoptosis induced by Adv/p16 infection. Infection of human NSCLC cell line A549, which carries the wild-type p53 gene, with Adv/p16 resulted in activation of caspase-3, accompanied by the cleavage of its substrate poly (ADP-ribose) polymerase (PARP), on day 3 of infection. The retinoblastoma (Rb) cell cycle regulator protein was also cleaved after activation of caspase-3; when the levels of Rb significantly diminished, apoptosis began. When A549 cells were pretreated with the caspase-inhibitory peptide N-acetyl-asp-Glu-Val-Asp-CHO (aldehyde) (Ac-DEVD-CHO), Adv/p16-mediated apoptosis and Rb cleavage were greatly inhibited. Furthermore, MDM2, a negative regulator of p53 expression was upregulated 3 days after Adv/p16 infection, and MDM2 was subsequently cleaved by caspase-3; MDM2 cleavage was inhibited by Ac-DEVD-CHO treatment. These data implied that cleavage of Rb, in addition to activation of caspase-3, represented a mechanism by which Adv/p16 induced apoptotic cell death in human NSCLC cells. Our results support the clinical relevance of Adv/p16 as a treatment for p16-null human NSCLC that express wild-type p53.	Okayama Univ, Grad Sch Med & Dent, Dept Surg, Div Surg Oncol, Okayama 7008558, Japan; Natl Canc Ctr, Res Inst, Canc Proteom Project, Tokyo 1040045, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	Okayama University; National Cancer Center - Japan; University of Texas System; UTMD Anderson Cancer Center	Fujiwara, T (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Surg, Div Surg Oncol, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp			NATIONAL CANCER INSTITUTE [P01CA078778, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, 2P50-CA70970-04, P01 CA78778-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An B, 1996, CANCER RES, V56, P438; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Hara E, 1996, MOL CELL BIOL, V16, P859; HAUPT Y, 1995, ONCOGENE, V10, P1563; Herman JG, 1996, CANCER RES, V56, P722; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hu YX, 1997, CLIN CANCER RES, V3, P1473; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JEN J, 1994, CANCER RES, V54, P6353; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Kawabe S, 2000, ONCOGENE, V19, P5359, DOI 10.1038/sj.onc.1203935; Kim M, 2000, CELL DEATH DIFFER, V7, P706, DOI 10.1038/sj.cdd.4400703; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MAO L, 1995, CANCER RES, V55, P2995; McConkey DJ, 1996, ONCOGENE, V13, P1693; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORI T, 1994, CANCER RES, V54, P3396; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Steiner MS, 2000, CANCER GENE THER, V7, P360, DOI 10.1038/sj.cgt.7700151; Takeuchi H, 1997, CLIN CANCER RES, V3, P2229; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang J, 1997, CANCER RES, V57, P351; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954	50	53	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2108	2113		10.1038/sj.onc.1205272	http://dx.doi.org/10.1038/sj.onc.1205272			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960384	Green Submitted			2022-12-28	WOS:000174827000018
J	Grinstein, E; Jundt, F; Weinert, I; Wernet, P; Royer, HD				Grinstein, E; Jundt, F; Weinert, I; Wernet, P; Royer, HD			Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells	ONCOGENE			English	Article						cell cycle; transcription factor Sp1; G1 phase	PROTEASOME-DEPENDENT DEGRADATION; DNA-BINDING ACTIVITY; GROWTH-FACTOR; GENE-EXPRESSION; RECEPTOR; ACTIVATION; TRANSACTIVATION; D1; PHOSPHORYLATION; INHIBITION	Sp1 binding sites have been identified in enhancer/promoter regions of several growth and cell cycle regulated genes, and it has been shown that Sp1 is increasingly phosphorylated in G1 phase of the cell cycle. Interactions of Sp1 with proteins involved in control of cell cycle and tumor formation have been reported. Here we show that expression of Sp1 protein predominates in the G1 phase of the cell cycle in epithelial cells. This is achieved by proteasome-dependent degradation. Inhibition of endogeneous Sp1 activity by a dominant-negative Sp1 mutant was associated with a cell cycle arrest in G1 phase, a strongly reduced expression of cyclin D1, the EGF-receptor and increased levels of p27Kip1. We have thus identified Sp1 as an important regulator of the cell cycle in G1 phase.	Univ Dusseldorf, Inst Transplantat Diagnost & Zelltherapeut, D-40225 Dusseldorf, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Humboldt Univ, Fak Med, Robert Rossle Klin, D-13122 Berlin, Germany	Heinrich Heine University Dusseldorf; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Grinstein, E (corresponding author), Univ Dusseldorf, Inst Transplantat Diagnost & Zelltherapeut, Moorenstr 5, D-40225 Dusseldorf, Germany.	Edgar.Grinstein@itz.uni-duesseldorf.de	Jundt, Franziska/E-9748-2014; Royer, Hans-dieter/AAH-6293-2019	Jundt, Franziska/0000-0002-8661-7110; 				Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Ben-Bassat H, 1999, J PHARMACOL EXP THER, V290, P1442; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grinstein E, 1996, J BIOL CHEM, V271, P9215, DOI 10.1074/jbc.271.16.9215; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; LABELLA F, 1991, MOL CELL BIOL, V11, P5825, DOI 10.1128/MCB.11.12.5825; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Lipson KE, 1998, J PHARMACOL EXP THER, V285, P844; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Opitz OG, 2000, CANCER RES, V60, P2825; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Su KH, 2000, BIOCHEM J, V348, P281, DOI 10.1042/0264-6021:3480281; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; Wu XP, 1996, ONCOGENE, V12, P1397; XU J, 1993, J BIOL CHEM, V268, P16065; Yan GZ, 1997, J NEUROSCI, V17, P6122; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O	49	91	97	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1485	1492		10.1038/sj.onc.1205211	http://dx.doi.org/10.1038/sj.onc.1205211			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896576				2022-12-28	WOS:000173956800003
J	Karsunky, H; Mende, I; Schmidt, T; Moroy, T				Karsunky, H; Mende, I; Schmidt, T; Moroy, T			High levels of the onco-protein Gfi-1 accelerate T-cell proliferation and inhibit activation induced T-cell death in Jurkat T-cells	ONCOGENE			English	Article						Gfi-1; T-cell activation; p21(WAF1); Rb; G1 checkpoint	ZINC-FINGER PROTEIN; TRANSCRIPTIONAL REPRESSOR; TRANSGENIC MICE; MYC; LYMPHOMAGENESIS; LYMPHOCYTES; APOPTOSIS; CYCLE; ELIMINATION; SELECTION	Gfi-1 is a nuclear zinc finger protein with the activity of a transcriptional repressor and the ability to predispose for the development of T-cell lymphoma when expressed constitutively at high levels. Whereas thymic T-cell precursors express endogenous Gfi-1, mature peripheral T-cells lack Gfi-1 but upregulate its expression transiently after antigenic stimulation and activation of Erk1/2 demonstrating a role of Gfi-1 in T-cell activation. Here we show that constitutive expression of Gfi-1 accelerates S phase entry of primary, resting T-cells upon antigenic stimulation. In addition, high level Gfi-1 expression inhibits phorbol ester induced G1 arrest and activation induced cell death in Jurkat T-cells. We demonstrate that these effects of Gfi-1 concur with lower absolute levels and hyperphosphorylation of the pocket protein pRb. Moreover, phorbol ester induced expression of the negative cell cycle regulator p21(WAF1) is blocked in the presence of Gfi-1. These findings suggest that Gfi-1 contributes to T-cell lymphomagenesis by overriding a late G1 cell cycle checkpoint which controls activation induced death and S phase entry of T-cells.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011					Brehm A, 1999, BRIT J CANCER, V80, P38; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; Karas M, 1999, MOL BIOL CELL, V10, P4441, DOI 10.1091/mbc.10.12.4441; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Lenardo M J, 1995, Int Rev Immunol, V13, P115, DOI 10.3109/08830189509061742; Li QS, 2000, EUR J IMMUNOL, V30, P3329, DOI 10.1002/1521-4141(200011)30:11<3329::AID-IMMU3329>3.0.CO;2-#; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Liu S, 2000, ANN HUM GENET, V64, P83, DOI 10.1017/S0003480000007971; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Stankunas K, 1999, COLD SPRING HARB SYM, V64, P505, DOI 10.1101/sqb.1999.64.505; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502; Zornig M, 1996, ONCOGENE, V12, P1789; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	27	63	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2002	21	10					1571	1579		10.1038/sj/onc/1205216	http://dx.doi.org/10.1038/sj/onc/1205216			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896586				2022-12-28	WOS:000173956800013
J	Sattler, M; Pride, YB; Quinnan, LR; Verma, S; Malouf, NA; Husson, H; Salgia, R; Lipkowitz, S; Griffin, JD				Sattler, M; Pride, YB; Quinnan, LR; Verma, S; Malouf, NA; Husson, H; Salgia, R; Lipkowitz, S; Griffin, JD			Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells	ONCOGENE			English	Article						CBL-B; BCR/ABL; gene expression; cell migration; signal transduction	ADAPTER PROTEINS CRKL; C-CBL; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATOR; BINDING-PROTEIN; SH2 DOMAIN; RING-TYPE; KINASE	CBL and the related CBL-B protein are two members of a family of RING finger type ubiquitin E3 ligases that are believed to function as negative regulators of signal transduction in hematopoietic and immune cells. In mice, expression of v-Cbl causes lymphomas, and targeted disruption of either the CBL gene or the CBL-B gene can result in a lymphoproliferative disorder or hypersensitivity of lymphocytes. CBL is one of the most prominent targets of the BCR/ABL tyrosine kinase oncogene. We compared the role of CBL and CBL-B in signal transduction of BCR/ABL using pairs of cell lines before and after expression of BCR/ABL. In contrast to CBL, BCR/ABL was found to rapidly downregulate the expression of CBL-B protein. The decrease in CBL-B protein induced by BCR/ABL was associated with down-regulation of CBL-B mRNA. Downregulation and tyrosine phosphorylation of CBL-B required BCR/ABL kinase activity. However, despite their known similarities in structure and function, we found CBL and CBL-B proteins to be involved in distinct signaling complexes. CBL was predominantly in a complex with phosphatidylinositol 3'-kinase and CRKL, while CBL-B was not associated with any significant phosphatidylinositol 3'-kinase activity. A major CBL-B associated protein was identified as mono-ubiquitinated Vav, a nucleotide exchange factor for Rac1. These results demonstrate that BCR/ABL signals differentially through CBL and CBL-B, with downregulation of the CBL-B protein potentially contributing to BCR/ABL-mediated transformation.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Natl Naval Med Ctr, Med Branch, Genet Dept, NCI, Bethesda, MD 20889 USA	Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center	Sattler, M (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	martin_sattler@dfci.harvard.edu		Pride, Yuri/0000-0002-5884-0964	NCI NIH HHS [CA78348] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; FREDRICKSON TN, 1984, J NATL CANCER I, V72, P447; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Hamilton E, 2001, J BIOL CHEM, V276, P9028, DOI 10.1074/jbc.M009386200; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Sattler M, 1999, BLOOD, V93, P2928; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Sattler M, 2001, INT J HEMATOL, V73, P278, DOI 10.1007/BF02981952; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985	49	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1423	1433		10.1038/sj.onc.1205202	http://dx.doi.org/10.1038/sj.onc.1205202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857085				2022-12-28	WOS:000173861000012
J	Rong, R; He, Q; Liu, Y; Sheikh, MS; Huang, Y				Rong, R; He, Q; Liu, Y; Sheikh, MS; Huang, Y			TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3-kinase/Akt and NF-kappa B signaling pathway	ONCOGENE			English	Article						TC21; PI3-K; Akt; transformation; cell survival; NF-kappa B	PHOSPHOINOSITIDE 3-KINASE; KINASE CASCADE; RAS; PROTEIN; AKT; EXPRESSION; INDUCTION; TARGET; FAMILY; DEATH	The signaling pathways of TC21-mediated transformation and cell survival are not well-established. In this study, we have investigated the role of PI3-K/Akt signaling pathway in oncogenic-TC21-mediated transformation and cell survival. We found that oncogenic-TC21 stimulated the PI3-K activity. This was associated with the activation of Akt, a key, component of PI3-K signaling pathway. We also found that TC21 interacted and formed complex with PI3-K. Mutations in the GTP-binding region of TC21, which enhanced GTP-binding potential of this protein, also stimulated its association with PI3-K, suggesting that PI3-K may preferentially interact with the GTP-bound form. Suppression of PI3-K and Akt by specific inhibitors LY294002 and Wortmannin reversed TC21-induced transformation. Likewise, inhibition of PI3-K activity by the PI3-K phosphotase PTEN reduced TC21-mediated focus formation in NIH3T3 cells. Investigation of TC21's effect on cell survival revealed that mutant-TC21 expressing cells were more resistant to etoposide- and cisplatin-induced cell death, and this was associated with the activation of anti-apoptotic protein NF-kappaB, a downstream target of Akt. Treatment of PI3-K inhibitor LY294002 significantly suppressed TC21-mediated NF-kappaB activation. In conclusion, we have identified PI3-K as an effector of TC21 and demonstrated that the PI3-K/Akt signaling pathway plays important roles in TC21-mediated transformation and cell survival.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@mail.upstate.edu	Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109				Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; AUGER KR, 1992, J BIOL CHEM, V267, P5408; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Clark GJ, 1996, ONCOGENE, V12, P169; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Graham WJ, 1996, HEALTH POLICY PLANN, V11, P16, DOI 10.1093/heapol/11.1.16; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUANG Y, 1995, ONCOGENE, V11, P1255; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; HUTTER D, 2000, BIOCH J 1, V15, P352; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marais R, 1996, CANCER SURV, V27, P101; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Ozes ON, 1999, NATURE, V401, P82; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; Woodgett JR, 1996, CANCER SURV, V27, P127; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	59	41	43	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1062	1070		10.1038/sj.onc.1205154	http://dx.doi.org/10.1038/sj.onc.1205154			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850823				2022-12-28	WOS:000173580100009
J	Imamura, O; Fujita, K; Itoh, C; Takeda, S; Furuichi, Y; Matsumoto, T				Imamura, O; Fujita, K; Itoh, C; Takeda, S; Furuichi, Y; Matsumoto, T			Werner and Bloom helicases are involved in DNA repair in a complementary fashion	ONCOGENE			English	Article							SYNDROME GENE-PRODUCT; SISTER-CHROMATID EXCHANGES; LYMPHOBLASTOID CELL-LINES; SYNDROME PROTEIN; ULTRAVIOLET-LIGHT; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; EXONUCLEASE ACTIVITY; SYNDROME FIBROBLASTS; MOLECULAR-CLONING	Werner syndrome (WS) is a recessive disorder characterized by premature senescence. Bloom syndrome (BS) is a recessive disorder characterized by short stature and immunodeficiency. A common characteristic of both syndromes is genomic instability leading to tumorigenesis. WRN and BLM genes causing WS and BS, encode proteins that are closely related to the RecQ helicase. We produced WRN-/-, BLM-/- and WRN-/-/BLM-/- mutants in the chicken B-cell line DT40. WRN-/- cells showed hypersensitivities to genotoxic agents, such as 4-nitroquinoline 1-oxide, camptothecin and methyl methanesulfonate. They also showed a threefold increase in targeted integration rate of exogenous DNAs, but not in sister chromatid exchange (SCE) frequency. BLM-/- cells showed hypersensitivities to the genotoxic agents as well as ultraviolet (UV) light, in addition to a 10-fold increase in targeted integration rate and an 11-fold increase in SCE frequency. In WRN-/-/BLM-/- cells, synergistically increased hypersensitivities to the genotoxic agents were observed whereas both SCE frequencies and targeted integration rates were partially diminished compared to the single mutants. Chromosomal aberrations were also synergistically increased in WRN-/-/ BLM-/- cells when irradiated with UV light in late S to G(2) phases. These results suggest that both WRN and BLM may be involved in DNA repair in a complementary fashion.	AGENE Res Inst, Kanagawa 2470063, Japan; Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Matsumoto, T (corresponding author), Japanese Fdn Canc Res, Genome Ctr, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	takehisa.matsumoto@jfcr.or.jp		Takeda, Shunichi/0000-0002-7924-7991				Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Elli R, 1996, CANCER GENET CYTOGEN, V87, P112, DOI 10.1016/0165-4608(95)00294-4; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; Fukagawa T, 1999, NUCLEIC ACIDS RES, V27, P1966, DOI 10.1093/nar/27.9.1966; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GALIEGUEZOUITINA S, 1984, ANAL BIOCHEM, V138, P454, DOI 10.1016/0003-2697(84)90839-X; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; HEARTLEIN MW, 1987, EXP CELL RES, V169, P245; HIGASHIKAWA T, 1978, EXP CELL RES, V113, P438, DOI 10.1016/0014-4827(78)90386-5; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Imamura O, 2001, ONCOGENE, V20, P1143, DOI 10.1038/sj.onc.1204195; KADYK LC, 1993, GENETICS, V133, P469; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KREPINSKY AB, 1980, MUTAT RES, V69, P357, DOI 10.1016/0027-5107(80)90100-1; KURIHARA T, 1987, MUTAT RES, V183, P197, DOI 10.1016/0167-8817(87)90062-9; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Okada M, 1998, BIOL PHARM BULL, V21, P235; Onoda F, 2001, MOL GEN GENET, V264, P702, DOI 10.1007/s004380000358; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROSIN MP, 1985, HUM GENET, V71, P187, DOI 10.1007/BF00284570; SALK D, 1985, ADV EXP MED BIOL, V190, P305; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; SHIRAISHI Y, 1985, P NATL ACAD SCI USA, V82, P5102, DOI 10.1073/pnas.82.15.5102; SMITH GJ, 1983, MUTAT RES, V111, P405, DOI 10.1016/0027-5107(83)90036-2; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Sonoda E, 2001, P NATL ACAD SCI USA, V98, P8388, DOI 10.1073/pnas.111006398; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; TSAO YP, 1993, CANCER RES, V53, P5908; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZHANG YL, 1992, J NAT PROD, V55, P1100, DOI 10.1021/np50086a011	69	86	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					954	963		10.1038/sj.onc.1205143	http://dx.doi.org/10.1038/sj.onc.1205143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840341				2022-12-28	WOS:000173427100011
J	Henry, H; Thomas, A; Shen, Y; White, E				Henry, H; Thomas, A; Shen, Y; White, E			Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death	ONCOGENE			English	Article						p53; apoptosis; Bcl-2 family; caspase	CYTOCHROME-C RELEASE; TUMOR-SUPPRESSOR P53; PORE-FORMING DOMAIN; ADENOVIRUS E1B 19K; BCL-2 FAMILY; P53-DEPENDENT APOPTOSIS; 19-KILODALTON PROTEIN; CONFORMATIONAL CHANGE; DELTA-ENDOTOXIN; BAX GENE	The p53 tumor suppressor protein inhibits tumor formation, in part by inducing apoptosis, which is inhibited by anti-apoptotic Bcl-2 family members Bcl-2 and adenovirus E1B 19K. We have identified p53-apoptotic signaling events which are targeted for inhibition by E1B 19K. Apoptotic signaling by p53 induced a Bid-independent conformational change in Bax, a Bax-Bak interaction, release of cytochrome c and Smac/DIABLO from mitochondria, caspase-9 and 3 activation, cleavage of known caspase substrates, and apoptosis. When p53-dependent apoptosis was blocked by E1B 19K expression, E1B 19K bound Bak, and the Bax-Bak interaction was inhibited. Cytochrome c and Smac/DIABLO release from mitochondria was also inhibited in E1B 19K expressing cells and cells remained viable. After a prolonged p53 death stimulus, the inhibition of the mitochondrial death checkpoint by E1B 19K failed, and cytochrome c and Smac/DIABLO were released from mitochondria, and became degraded. Despite this eventual failure to inhibit the mitochondrial checkpoint, caspase-9 and -3 were not activated, and cells remained viable even upon treatment with an exogenous death stimulus. Thus, p53 induces apoptosis in part through Bax and Bak, and even an incomplete inhibition of this mitochondrial checkpoint may be sufficient to confer resistance to cell death.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	White, E (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Howard Hughes Med Inst, 679 Hoes Lane, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA53370, CA60088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370, R01CA060088, R01CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; BOYD JM, 1995, ONCOGENE, V11, P1921; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Gao CF, 2001, EXP CELL RES, V265, P145; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; SUNDARARAJAN R, 2001, IN PRESS J BIOL CHEM, V276; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tan YJ, 1999, BIOCHEM BIOPH RES CO, V255, P334, DOI 10.1006/bbrc.1999.0222; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	54	53	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					748	760		10.1038/sj.onc.1205125	http://dx.doi.org/10.1038/sj.onc.1205125			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850803				2022-12-28	WOS:000173427000006
J	Saavedra, AP; Tsygankova, OM; Prendergast, GV; Dworet, JH; Cheng, G; Meinkoth, JL				Saavedra, AP; Tsygankova, OM; Prendergast, GV; Dworet, JH; Cheng, G; Meinkoth, JL			Role of cAMP, PKA and Rap1A in thyroid follicular cell survival	ONCOGENE			English	Article						thyroid; apoptosis; PKA; cAMP; Rap1	DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; MEDIATED APOPTOSIS; SIGNALING PATHWAYS; PHOSPHORYLATION; ACTIVATION; INHIBITION; GROWTH; RAS; MONOPHOSPHATE	Cyclic AMP (cAMP) rescues cells from apoptosis stimulated by diverse insults. We examined the role of cAMP as a survival factor, and the signaling pathways through which cAMP affords protection. Rat thyroid cells were selected for these studies given the predominant role of cAMP in thyrotropin (TSH)-stimulated proliferation and as an oncogene in thyroid cells. Wistar rat thyroid (WRT) cells perished via apoptosis following sodium nitroprusside (SNP) treatment. Elevations in cAMP following treatment with forskolin, 8BrcAMP or IBMX rescued cells from SNP-induced cell death. Notably, TSH prevented apoptosis, implicating an important role for this hormone as a survival factor. Cyclic AMP activates multiple signaling pathways including those mediated through PKA, PI3K, p70S6k and the Ras-related small G protein, Rap1. Intriguingly, multiple pathways modulate thyroid cell survival. Interference with cAMP-stimulated p70S6k, but not PI3K, activity abrogated cell survival. Treatment with PKA inhibitors was sufficient to stimulate apoptosis in hormone-deprived cells and markedly enhanced cell death in response to SNP. Cells expressing an activated Rap1A mutant exhibited an enhanced sensitivity to SNP-induced apoptosis, while those expressing dominant negative Rap1A were resistant to SNP-initiated cell death. Together, these findings establish an important role for PKA and Rap1 in the control of thyroid cell survival.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.	meinkoth@pharm.med.upenn.edu	Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [R01 DK02494, K 02 DK 55757] Funding Source: Medline; NINDS NIH HHS [5-F31-NS09883] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS009883] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Arscott PL, 1997, ENDOCRINOLOGY, V138, P5019, DOI 10.1210/en.138.11.5019; Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; BRANDI ML, 1987, MOL CELL ENDOCRINOL, V54, P91, DOI 10.1016/0303-7207(87)90142-0; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; BUBIS J, 1988, J BIOL CHEM, V263, P9668; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Cheng GJ, 2001, ONCOGENE, V20, P7334, DOI 10.1038/sj.onc.1204928; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DANIEL V, 1973, P NATL ACAD SCI USA, V70, P76, DOI 10.1073/pnas.70.1.76; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dremier S, 2000, BIOCHEM BIOPH RES CO, V267, P7, DOI 10.1006/bbrc.1999.1919; DREMIER S, 1994, BIOCHEM BIOPH RES CO, V200, P52, DOI 10.1006/bbrc.1994.1412; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Jun CD, 1998, CELL IMMUNOL, V183, P13, DOI 10.1006/cimm.1997.1232; Kawakami A, 1996, ENDOCRINOLOGY, V137, P3163, DOI 10.1210/en.137.8.3163; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Li X, 1999, ENDOCRINOLOGY, V140, P5962, DOI 10.1210/en.140.12.5962; LINTIG FCV, 2000, ONCOGENE, V19, P4029; MAENHAUT C, 1991, BIOCHIMIE, V73, P29, DOI 10.1016/0300-9084(91)90070-H; MALY FE, 1994, J BIOL CHEM, V269, P18743; Medina DL, 2000, EUR J ENDOCRINOL, V143, P161, DOI 10.1530/eje.0.1430161; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Motohashi S, 1996, LIFE SCI, V59, pPL227, DOI 10.1016/0024-3205(96)00437-7; Myklebust JH, 1999, J CELL PHYSIOL, V180, P71; Niwa M, 1999, EUR J PHARMACOL, V371, P59, DOI 10.1016/S0014-2999(99)00145-4; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; Ottonello L, 1998, EXP HEMATOL, V26, P895; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Polte T, 1998, BIOCHEM BIOPH RES CO, V251, P460, DOI 10.1006/bbrc.1998.9486; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Villone G, 1997, CELL GROWTH DIFFER, V8, P1181; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WALKER C, 1983, J IMMUNOL, V130, P1770; Walton M, 1999, J NEUROCHEM, V73, P1836; Webster CRL, 1998, HEPATOLOGY, V27, P1324, DOI 10.1002/hep.510270519; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yao R, 1996, ONCOGENE, V13, P343; Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200	62	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					778	788		10.1038/sj.onc.1205123	http://dx.doi.org/10.1038/sj.onc.1205123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850806				2022-12-28	WOS:000173427000009
J	Santilli, G; Cervellera, MN; Johnson, TK; Lewis, RE; Iacobelli, S; Sala, A				Santilli, G; Cervellera, MN; Johnson, TK; Lewis, RE; Iacobelli, S; Sala, A			PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites	ONCOGENE			English	Article						cell cycle; transformation; transcription; promoter	CELL-CYCLE REGULATION; POLY(ADP-RIBOSE) POLYMERASE; DNA-BINDING; IN-VIVO; S-PHASE; EXPRESSION; TRANSCRIPTION; PROTEIN; PROLIFERATION; TRANSACTIVATION	PARP is a multifunctional protein that can affect genome stability, transcription control, telomere length and cell death. Recently we have reported that PARP binds to and enhances B-MYB transactivating potential. B-MYB is a potentially oncogenic transcription factor involved in mammalian cell proliferation, survival and differentiation. B-MYB gene expression is growth regulated and B-MYB protein is phosphorylated during S phase by cyclin A or E/cdk2 kinase, resulting in augmented transactivating potential. Here we show that PARP induces phosphorylation of B-MVB protein at cdk2 phosphorylation sites, since a B-MYB protein with mutated cdk2 phosphorylation sites is refractory to PARP-induced phosphorylation and co-activation in mammalian cells. We propose that PARP functions as a B-MYB co-factor by promoting cyclin/cdk2-dependent B-MYB phosphorylation. These results highlight a novel role for PARP as a factor that integrates cyclin-dependent kinases signaling with gene transcription.	Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N, England; Univ G DAnnunzio, Dept Oncol & Neurosci, Sect Med Oncol, I-66100 Chieti, Italy; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	G d'Annunzio University of Chieti-Pescara; University of Nebraska System; University of Nebraska Medical Center	Sala, A (corresponding author), Inst Child Hlth, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N, England.		Lewis, Robert E./H-3404-2019; sala, arturo/C-4959-2008	Sala, Arturo/0000-0002-2841-7866				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kim T, 1999, FEBS LETT, V460, P363, DOI 10.1016/S0014-5793(99)01375-7; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Menegazzi M, 1999, MOL CARCINOGEN, V25, P256, DOI 10.1002/(SICI)1098-2744(199908)25:4<256::AID-MC4>3.0.CO;2-W; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Raschella G, 1999, CANCER RES, V59, P3365; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1999, J CELL PHYSIOL, V179, P245; Saville MK, 1998, ADV CANCER RES, V72, P109; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; Soldatenkov VA, 1999, ONCOGENE, V18, P3954, DOI 10.1038/sj.onc.1202778; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	36	21	21	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8167	8174		10.1038/sj.onc.1204943	http://dx.doi.org/10.1038/sj.onc.1204943			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781832				2022-12-28	WOS:000172507800001
J	White, E				White, E			Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus	ONCOGENE			English	Review						adenovirus; apoptosis; Bcl-2; p53; E1A; E1B	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; UBIQUITIN-PROTEIN LIGASE; INTERLEUKIN-1-BETA CONVERTING-ENZYME; CYTOCHROME-C RELEASE; PORE-FORMING DOMAIN; E1B 19K PROTEIN; P53-DEPENDENT APOPTOSIS; CONFORMATIONAL-CHANGE; OLIGOMERIZES BAK		Rutgers State Univ, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick	White, E (corresponding author), Rutgers State Univ, Howard Hughes Med Inst, 679 Hoes Lane,Room 140, Piscataway, NJ 08854 USA.	ewhite@cabm.rutgers.edu	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065				Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERENCSI K, 1994, LAB INVEST, V71, P350; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BROOKS MA, 1995, J VIROL, V69, P7688, DOI 10.1128/JVI.69.12.7688-7698.1995; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Chiou SK, 1998, VIROLOGY, V244, P108, DOI 10.1006/viro.1998.9077; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COOK JL, 1989, J IMMUNOL, V142, P4527; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; CUCONATI A, 2001, IN PRESS ONCOGENE; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; DSaEipper C, 1996, CANCER RES, V56, P3879; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; DUERKSENHUGHES PJ, 1991, J VIROL, V65, P1236, DOI 10.1128/JVI.65.3.1236-1244.1991; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; GINSBERG HS, 1994, INFECT AGENT DIS, V3, P1; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Han JH, 1998, ONCOGENE, V17, P2993, DOI 10.1038/sj.onc.1202215; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HENRY H, 2001, IN PRESS ONCOGENE; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Huang HK, 2000, J BIOL CHEM, V275, P26661; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MANOJ KAS, 1999, J BACTERIOL, V181, P6103; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; MIYASHITA T, 1995, CELL, V80, P293; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NEVINS JR, 1992, SCIENCE, V258, P424; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rao L, 1997, ONCOGENE, V15, P1587, DOI 10.1038/sj.onc.1201323; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Routes JM, 2000, J IMMUNOL, V165, P4522, DOI 10.4049/jimmunol.165.8.4522; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; Sparer TE, 1996, J VIROL, V70, P2431, DOI 10.1128/JVI.70.4.2431-2439.1996; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; SUNDARARAJAN R, 2001, IN PRESS J BIOL CHEM; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Taylor RM, 2000, BIOCHEMISTRY-US, V39, P12131, DOI 10.1021/bi000206c; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; THORNE M, 1997, NATURE, V386, P517; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WHITE E, 1994, SEMIN VIROL, V5, P341, DOI 10.1006/smvy.1994.1038; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1998, SEMIN VIROL, V8, P505, DOI 10.1006/smvy.1998.0155; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; Wold WSM, 1999, CURR OPIN IMMUNOL, V11, P380, DOI 10.1016/S0952-7915(99)80064-8; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZHANG YL, 1993, J BIOL CHEM, V268, P10176; Zhao RB, 2000, GENE DEV, V14, P981	122	108	108	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7836	7846		10.1038/sj.onc.1204861	http://dx.doi.org/10.1038/sj.onc.1204861			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753666				2022-12-28	WOS:000172336500003
J	Zwerner, JP; May, WA				Zwerner, JP; May, WA			Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines	ONCOGENE			English	Article						Ewing's sarcoma; Ewing family tumors; PDGF-C; EWS/FLI	TYROSINE KINASE; MONOCLONAL-ANTIBODY; ALPHA-RECEPTOR; BETA-RECEPTOR; HUMAN GLIOMA; LUNG-CANCER; V-SIS; SARCOMA; TRANSFORMATION; EXPRESSION	Nearly all cases of Ewing Family Tumors (EFT) harbor chimeric EWS/ETS transcription factors which are thought to aberrantly regulate transcriptional targets of phenotypic consequence. We have recently demonstrated that EWS/ETS proteins up-regulate platelet derived growth factor-C (PDGF-C), a novel transforming growth factor. To determine if PDGF-C signaling contributes to the malignant phenotype of EFT cell lines, we attempted to disrupt this presumed autocrine loop. AG1296, a PDGF receptor selective tyrosine kinase inhibitor, markedly inhibits anchorage-independent growth in an EFT cell line. To effect specific disruption, we have developed a dominant negative form of PDGF-C which is appropriately secreted and processed. This mutant has greatly reduced activity as a PDGF receptor agonist. When co-expressed with PDGF-C in a fibroblast transformation model, this dominant negative dramatically inhibits anchorage-independent growth. When this mutant is expressed in EFT cell lines, there is a similar reduction in anchorage-independent growth. This demonstrates that specific inhibition of PDGF-C signaling in EFT cell lines partially reverts their phenotype. These data support a significant role of PDGF-C in the biology of EFT. They also suggest that PDGF-C driven signaling may be a possible therapeutic target of more clinically relevant tyrosine kinase inhibitors.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL USA; Univ Alabama, Dept Pediat, Birmingham, AL USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	May, WA (corresponding author), 1824 6th Ave S,Room 569, Birmingham, AL 35242 USA.				NCI NIH HHS [CA 90666, R01 CA090666] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090666] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERMANSON M, 1992, CANCER RES, V52, P3213; HOROWITZ ME, 1997, EWINGS SARCOMA FAMIL; KOVALENKO M, 1994, CANCER RES, V54, P6106; Krystal GW, 1997, CANCER RES, V57, P2203; Kumar R, 2000, SEMIN ONCOL, V27, P84, DOI 10.1053/sonc.2000.19893; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Look AT, 1995, ADV CANCER RES, V67, P25, DOI 10.1016/S0065-230X(08)60709-5; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MERCOLA M, 1990, GENE DEV, V4, P2333, DOI 10.1101/gad.4.12b.2333; Nakayama Y, 1998, SURG NEUROL, V49, P181, DOI 10.1016/S0090-3019(97)00038-4; NANBERG E, 1993, J BIOL CHEM, V268, P18187; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Radig K, 1998, PATHOL RES PRACT, V194, P157, DOI 10.1016/S0344-0338(98)80016-2; Rice AB, 1999, AM J PATHOL, V155, P213, DOI 10.1016/S0002-9440(10)65115-2; Ricotti E, 1998, BLOOD, V91, P2397, DOI 10.1182/blood.V91.7.2397.2397_2397_2405; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Scotlandi K, 1998, CANCER RES, V58, P4127; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; Silvany RE, 2000, ONCOGENE, V19, P4523, DOI 10.1038/sj.onc.1203811; Sjoblom T, 2001, CANCER RES, V61, P5778; Sulzbacher I, 2000, MODERN PATHOL, V13, P632, DOI 10.1038/modpathol.3880109; Sundberg C, 1997, AM J PATHOL, V151, P479; Uutela M, 2001, CIRCULATION, V103, P2242; VASSBOTN FS, 1990, BIOCHIM BIOPHYS ACTA, V1054, P246, DOI 10.1016/0167-4889(90)90248-C; VIGNAUD JM, 1994, CANCER RES, V54, P5455; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	41	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3847	3854		10.1038/sj.onc.1205486	http://dx.doi.org/10.1038/sj.onc.1205486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032822				2022-12-28	WOS:000175847200003
J	Conejo, R; de Alvaro, C; Benito, M; Cuadrado, A; Lorenzo, M				Conejo, R; de Alvaro, C; Benito, M; Cuadrado, A; Lorenzo, M			Insulin restores differentiation of Ras-transformed C2C12 myoblasts by inducing NF-kappa B through an AKT/P70S6K/p38-MAPK pathway	ONCOGENE			English	Article						insulin signaling; differentiation; Ras-transformed; C2C12 cells	ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE DIFFERENTIATION; NITRIC-OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAYS; DOWN-REGULATION; PI 3-KINASE; IGF-II; K-RAS; MYOGENESIS	v-H-ras transformed C2C12 (C2Ras) myoblasts, over-expressing p21-Ras protein in the Ras-GTP active form, showed a differentiation-defective phenotype when cultured in low serum as compared with C2C12 myoblasts. Accordingly, the purpose of the present study was to delineate the signaling pathways that restore C2Ras myoblasts differentiation. Inhibition of p42/p44-MAPK with the chemical inhibitor PD98059, and activation of AKT/P70S6K and p38-MAPK with insulin, produced growth arrest (precluding the expression of PCNA, cyclin-D1 and retinoblastoma at the hyperphosphorylated state and inducing the expression of the cell cycle inhibitor p21(Cip)) and myogenesis (multinucleated myotubes formation and induction of creatine kinase, caveolin-3 and alpha-actin). Both events were accompanied by down-regulation of AP-1 and up-regulation of NF-kappaB transcriptional activities. Furthermore, inhibition of NF-kappaB transcriptional activity by the use of the proteasome inhibitor MG132 totally precluded differentiation by insulin + PD98059, demonstrating a direct role for NF-kappaB on C2Ras myogenesis. C2Ras myoblasts failed to restore differentiation when rapamycin or PD169316 were added in the presence of insulin + PD98059, indicating that the activation of both P70S6K and p38-MAPK was necessary to reach a fully differentiated phenotype. Finally, transient transfection of a constitutively active Myr-EGFP-AKT-HA construct (in the presence of PD98059) restored C2Ras myogenesis by its ability to activate P70S6K and p38-MAPK. A crosstalk between P70S6K and p38-MAPK was observed under rapamycin treatment in both insulin or active AKT induced myogenesis. Our results are delineating an AKT/P70S6K/p38-MAPK pathway involved in skeletal muscle differentiation.	Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, Madrid 28040, Spain; Univ Autonoma Madrid, Fac Med, Dept Bioquim, Madrid 28029, Spain	Complutense University of Madrid; Autonomous University of Madrid	Lorenzo, M (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, Madrid 28040, Spain.	mlorenzo@farm.ucm.es	; Benito, Manuel/J-5637-2014	Cuadrado, Antonio/0000-0002-4039-7140; Benito, Manuel/0000-0002-7218-406X; Cuadrado, Antonio/0000-0002-3444-9012				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BACH LA, 1995, ENDOCRINOLOGY, V136, P5061, DOI 10.1210/en.136.11.5061; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bertrand F, 1999, J BIOL CHEM, V274, P30596, DOI 10.1074/jbc.274.43.30596; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Canicio J, 2001, J BIOL CHEM, V276, P20228, DOI 10.1074/jbc.M100718200; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; EWTON DZ, 1994, J CELL PHYSIOL, V161, P277, DOI 10.1002/jcp.1041610212; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Galbiati F, 1999, J BIOL CHEM, V274, P30315, DOI 10.1074/jbc.274.42.30315; Garcia JM, 2000, BRIT J CANCER, V82, P1183; Genth H, 1999, J BIOL CHEM, V274, P29050, DOI 10.1074/jbc.274.41.29050; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; LAM K, 1994, J BIOL CHEM, V269, P20648; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lee KH, 1997, BIOCHEM J, V324, P237, DOI 10.1042/bj3240237; LYONS AB, 1992, CYTOMETRY, V13, P809; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mitin N, 2001, ONCOGENE, V20, P1276, DOI 10.1038/sj.onc.1204223; Mockridge JW, 2000, BIOCHEM BIOPH RES CO, V270, P947, DOI 10.1006/bbrc.2000.2522; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Navarro P, 1998, EXP CELL RES, V243, P213, DOI 10.1006/excr.1998.4168; Noda Satoshi, 2000, Journal of Medical Investigation, V47, P47; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salinas M, 2001, MOL CELL NEUROSCI, V17, P67, DOI 10.1006/mcne.2000.0921; Sarbassov DD, 1997, MOL ENDOCRINOL, V11, P2038, DOI 10.1210/me.11.13.2038; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; STRATTON MR, 1989, CANCER RES, V49, P6324; STRAUCH AR, 1986, J BIOL CHEM, V261, P849; Suzuki J, 2000, ONCOGENE, V19, P1138, DOI 10.1038/sj.onc.1203402; Tabata M, 2001, J BIOL CHEM, V276, P8029, DOI 10.1074/jbc.M009831200; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Teruel T, 1998, J CELL PHYSIOL, V176, P99, DOI 10.1002/(SICI)1097-4652(199807)176:1<99::AID-JCP12>3.3.CO;2-6; TILLY JL, 1995, ENDOCRINOLOGY, V136, P242, DOI 10.1210/en.136.1.242; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; Valverde AM, 1997, ENDOCRINOLOGY, V138, P3195, DOI 10.1210/en.138.8.3195; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Zarich N, 2000, ONCOGENE, V19, P5872, DOI 10.1038/sj.onc.1203955; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	63	56	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3739	3753		10.1038/sj.onc.1205469	http://dx.doi.org/10.1038/sj.onc.1205469			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032842				2022-12-28	WOS:000175676000009
J	Bandyopadhyay, A; Zhu, Y; Malik, SN; Kreisberg, J; Brattain, MG; Sprague, EA; Luo, J; Lopez-Casillas, F; Sun, LZ				Bandyopadhyay, A; Zhu, Y; Malik, SN; Kreisberg, J; Brattain, MG; Sprague, EA; Luo, J; Lopez-Casillas, F; Sun, LZ			Extracellular domain of TGF beta type III receptor inhibits angiogenesis and tumor growth in human cancer cells	ONCOGENE			English	Article						TGF beta type III receptor; angiogenesis; metastasis; tumor growth	TRANSFORMING GROWTH-FACTOR-BETA-1; SUPPRESSES TUMORIGENICITY; IN-VIVO; BETAGLYCAN; EXPRESSION; PROTEOGLYCAN; METASTASIS; ANTIBODIES; MEMBRANE; STIMULATION	TGFbeta overexpression in human cancer cells has been shown to promote tumor progression. In the present study, we sought to determine whether sequestration of endogenous TGFbeta by the expression of a soluble TGFbeta type III receptor (sRIII), can reduce malignancy in human carcinoma cells and whether the tumor-suppressive activity of sRIII is associated with the inhibition of angiogenesis. Ectopic expression of sRIII significantly inhibited the growth of tumors formed by human colon carcinoma HCT116 and breast carcinoma MDA-MB-435 cells in nude mice. It also reduced the metastatic potential of the MDA-MB-435 cells. Thus, endogenous TGFbeta appears to be necessary for the progression of these two carcinomas. Furthermore, when the tumor cells were mixed with Matrigel and embedded subcutaneously in nude mice, the blood volume in Matrigel plugs containing sRIII-expressing cells as indicated by hemoglobin levels was significantly lower than that in Matrigel plugs containing the respective control cells. Blood vessel counts in paraffin sections of the Matrigel plugs containing sRIII-expressing cells were also significantly lower than those in paraffin sections of the Matrigel plugs containing control cells. Treatment of human endothelial cells with a recombinant sRIII significantly inhibited their ability to form a capillary web structure on Matrigel. These results for the first time indicate that the sRIII-induced tumor suppression appears to be in part due to the inhibition of angiogenesis.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78229 USA; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Universidad Nacional Autonoma de Mexico	Sun, LZ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	SUNL@UTHSCSA.EDU	, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R01CA079683, R01CA075253, R01CA072001, R01CA050457] Funding Source: NIH RePORTER; NCI NIH HHS [CA79683, CA75253, CA72001, CA50457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chishima T, 1997, CANCER RES, V57, P2042; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; Fajardo LF, 1996, LAB INVEST, V74, P600; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harlow E., 1988, ANTIBODIES LAB MANUA; HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365; JOSEPH A, 1995, J NATL CANCER I, V87, P372, DOI 10.1093/jnci/87.5.372; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NORGAARD P, 1995, CANCER TREAT REV, V21, P367, DOI 10.1016/0305-7372(95)90038-1; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PASSANITI A, 1992, LAB INVEST, V67, P519; PRICE JE, 1990, CANCER RES, V50, P717; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; UEKI N, 1992, BIOCHIM BIOPHYS ACTA, V1137, P189; UEKI N, 1993, JPN J CANCER RES, V84, P589, DOI 10.1111/j.1349-7006.1993.tb02017.x; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731; Ye SC, 1999, CANCER RES, V59, P4725; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	43	69	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3541	3551		10.1038/sj.onc.1205439	http://dx.doi.org/10.1038/sj.onc.1205439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032856				2022-12-28	WOS:000175793700005
J	Kaushansky, K; Drachman, JG				Kaushansky, K; Drachman, JG			The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production	ONCOGENE			English	Review						thrombopoietin; hematopoiesis; megakaryocyte; signal transduction	HUMAN MEGAKARYOCYTE GROWTH; RECOMBINANT HUMAN THROMBOPOIETIN; HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE MYELOID-LEUKEMIA; PHASE-I TRIAL; MURINE C-MPL; TYROSINE-PHOSPHORYLATION; PERIPHERAL-BLOOD; MESSENGER-RNA; BONE-MARROW	The term thrombopoietin (TPO) was first coined in 1958 and used to describe the Immoral substance responsible for causing the platelet count to rise in response to thrombocytopenic stimuli. Despite much progress during the 1980s in the purification and characterization of the Immoral regulators of lymphocyte, erythrocyte, monocyte and granulocyte production, the successful search to purify and molecularly clone thrombopoietin did not begin until the oncogene v-mpl was discovered in 1990. Since that time the proto-oncogene c-mpl was identified and, based on homology arguments, believed to encode a hematopoietic cytokine receptor, a hypothesis later proven when the cytoplasmic domain was linked to the ligand binding domain of the IL-4 receptor and shown to support the IL-4 induced growth of hematopoietic cells (Skoda et al., 1993). Finally, two different strategies using c-mpl lead to the identification of a novel ligand for the receptor in 1994 (de Sauvage et al., 1994; Lok et al., 1994; Bartley et al., 1994), a protein that displays all the biologic properties of TPO. This review attempts to distill what has been learned of the molecular and cellular biology of TPO and its receptor during the past several years, and links this information to several new insights into human disease and its treatment.	Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kaushansky, K (corresponding author), Univ Washington, Sch Med, Div Hematol, 1959 NE Pacific St, Seattle, WA 98195 USA.	kkaushan@u.washington.edu						Al-Jefri AH, 2000, PEDIATR HEMAT ONCOL, V17, P299, DOI 10.1080/088800100276280; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; ALEXANDER WS, 1995, ONCOGENE, V10, P795; Ballmaier M, 2001, BLOOD, V97, P139, DOI 10.1182/blood.V97.1.139; Ballmaier M, 1997, BLOOD, V90, P612, DOI 10.1182/blood.V90.2.612.612_612_619; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; Basser RL, 2000, J CLIN ONCOL, V18, P2852, DOI 10.1200/JCO.2000.18.15.2852; Basser RL, 1997, BLOOD, V89, P3118; BENIT L, 1994, J VIROL, V68, P5270; Bolwell B, 2000, BONE MARROW TRANSPL, V26, P141, DOI 10.1038/sj.bmt.1702465; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; Case BC, 2000, STEM CELLS, V18, P360, DOI 10.1634/stemcells.18-5-360; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Cerutti A, 1997, BRIT J HAEMATOL, V99, P281, DOI 10.1046/j.1365-2141.1997.3823196.x; Chang M, 1996, BLOOD, V88, P3354, DOI 10.1182/blood.V88.9.3354.bloodjournal8893354; CHOI ES, 1995, BLOOD, V85, P402; Cole JL, 1998, BLOOD, V91, P3239, DOI 10.1182/blood.V91.9.3239.3239_3239_3246; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; de Serres M, 1999, STEM CELLS, V17, P203, DOI 10.1002/stem.170203; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; Enver T, 1998, BLOOD, V92, P348, DOI 10.1182/blood.V92.2.348.Con3_348_351; Fields KK, 2000, BONE MARROW TRANSPL, V26, P1083, DOI 10.1038/sj.bmt.1702662; Gaur M, 2001, BLOOD, V97, P1653, DOI 10.1182/blood.V97.6.1653; Griesshammer M, 1999, J INTERN MED, V245, P295, DOI 10.1046/j.1365-2796.1999.00452.x; Hacein-Bey S, 2001, HUM GENE THER, V12, P291, DOI 10.1089/10430340150218422; Harker LA, 1996, BLOOD, V88, P511, DOI 10.1182/blood.V88.2.511.bloodjournal882511; Harker LA, 2000, BLOOD, V95, P2514; Harker LA, 1998, BLOOD, V91, P4427, DOI 10.1182/blood.V91.12.4427.412k44_4427_4433; Hashimoto S, 2000, EUR J HAEMATOL, V64, P225, DOI 10.1034/j.1600-0609.2000.90001.x; HILL RJ, 1989, BLOOD CELLS, V15, P141; Hoffman RC, 1996, BIOCHEMISTRY-US, V35, P14849, DOI 10.1021/bi961075b; Hsu HC, 1999, J LAB CLIN MED, V134, P392, DOI 10.1016/S0022-2143(99)90154-3; Hume DA, 2000, BLOOD, V96, P2323, DOI 10.1182/blood.V96.7.2323.h8002323_2323_2328; Ihara K, 1999, P NATL ACAD SCI USA, V96, P3132, DOI 10.1073/pnas.96.6.3132; Ishida Y, 2001, THROMB HAEMOSTASIS, V85, P349; Italiano JE, 1999, J CELL BIOL, V147, P1299, DOI 10.1083/jcb.147.6.1299; Jorgensen MJ, 1998, BLOOD, V92, p205A; Kaser A, 2001, BLOOD, V98, P2720, DOI 10.1182/blood.V98.9.2720; Kaushansky K, 1998, NEW ENGL J MED, V339, P746, DOI 10.1056/NEJM199809103391107; KAUSHANSKY K, 1995, J CLIN INVEST, V96, P1683, DOI 10.1172/JCI118210; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; Kimura T, 1998, FEBS LETT, V428, P250, DOI 10.1016/S0014-5793(98)00536-5; KOBAYASHI M, 1995, BLOOD, V86, P2494; Kosugi S, 1996, BRIT J HAEMATOL, V93, P704, DOI 10.1046/j.1365-2141.1996.d01-1702.x; Kurre P, 2001, MOL THER, V3, P920, DOI 10.1006/mthe.2001.0328; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; Kuter DJ, 2001, BLOOD, V98, P1339, DOI 10.1182/blood.V98.5.1339; Li Y, 1996, BRIT J HAEMATOL, V92, P60, DOI 10.1046/j.1365-2141.1996.00297.x; Linden HM, 2000, BIOCHEMISTRY-US, V39, P3044, DOI 10.1021/bi991756h; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; MCCARTY JM, 1995, BLOOD, V86, P3668, DOI 10.1182/blood.V86.10.3668.bloodjournal86103668; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; Miyakawa Y, 2000, J BIOL CHEM, V275, P32214, DOI 10.1074/jbc.M005080200; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; Mukai HY, 1996, THROMB HAEMOSTASIS, V76, P675; Murray LJ, 1998, EXP HEMATOL, V26, P207; Muto T, 2000, J BIOL CHEM, V275, P12090, DOI 10.1074/jbc.275.16.12090; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; Nash RA, 2000, BIOL BLOOD MARROW TR, V6, P25, DOI 10.1016/S1083-8791(00)70049-8; Oda A, 1996, BLOOD, V88, P1330, DOI 10.1182/blood.V88.4.1330.bloodjournal8841330; OMalley CJ, 1996, BLOOD, V88, P3288, DOI 10.1182/blood.V88.9.3288.bloodjournal8893288; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Ooi J, 1998, BIOCHEM BIOPH RES CO, V246, P132, DOI 10.1006/bbrc.1998.8588; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park H, 1998, J BIOL CHEM, V273, P256, DOI 10.1074/jbc.273.1.256; Pearce KH, 1997, J BIOL CHEM, V272, P20595, DOI 10.1074/jbc.272.33.20595; Peck-Radosavljevic M, 1999, EUR J GASTROEN HEPAT, V11, P151, DOI 10.1097/00042737-199902000-00015; Piacibello W, 1998, VOX SANG, V74, P457, DOI 10.1111/j.1423-0410.1998.tb05456.x; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rojnuckarin P, 2001, BLOOD, V97, P154, DOI 10.1182/blood.V97.1.154; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Sabath DF, 1999, BLOOD, V94, P365, DOI 10.1182/blood.V94.1.365.413a46_365_367; Schiffer CA, 2000, BLOOD, V95, P2530, DOI 10.1182/blood.V95.8.2530.008k31_2530_2535; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; Somlo G, 1999, BLOOD, V93, P2798; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; Stoffel R, 1996, BLOOD, V87, P567, DOI 10.1182/blood.V87.2.567.bloodjournal872567; Strippoli P, 1998, BRIT J HAEMATOL, V103, P311, DOI 10.1046/j.1365-2141.1998.00991.x; Sungaran R, 1997, BLOOD, V89, P101, DOI 10.1182/blood.V89.1.101; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Torii Y, 1998, BRIT J HAEMATOL, V103, P1172, DOI 10.1046/j.1365-2141.1998.01113.x; Uppenkamp M, 1998, ANN HEMATOL, V77, P217, DOI 10.1007/s002770050446; Vadhan-Raj S, 2000, ANN INTERN MED, V132, P364, DOI 10.7326/0003-4819-132-5-200003070-00005; VadhanRaj S, 1997, ANN INTERN MED, V126, P673, DOI 10.7326/0003-4819-126-9-199705010-00001; van den Oudenrijn S, 2000, BRIT J HAEMATOL, V110, P441, DOI 10.1046/j.1365-2141.2000.02175.x; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wetzler M, 1997, J CLIN ONCOL, V15, P2262, DOI 10.1200/JCO.1997.15.6.2262; Wiestner A, 1998, NAT GENET, V18, P49, DOI 10.1038/ng0198-49; Wolff SN, 2001, BONE MARROW TRANSPL, V27, P261, DOI 10.1038/sj.bmt.1702772; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Yan XQ, 1996, BLOOD, V88, P402, DOI 10.1182/blood.V88.2.402.bloodjournal882402; Yin JAL, 2000, BRIT J HAEMATOL, V108, P743, DOI 10.1046/j.1365-2141.2000.01916.x; Ziegler S, 1998, BLOOD, V92, p713A	108	136	146	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3359	3367		10.1038/sj.onc.1205323	http://dx.doi.org/10.1038/sj.onc.1205323			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032774				2022-12-28	WOS:000175633300009
J	Leong, PL; Xi, SC; Drenning, SD; Dyer, KF; Wentzel, AL; Lerner, EC; Smithgall, TE; Grandis, JR				Leong, PL; Xi, SC; Drenning, SD; Dyer, KF; Wentzel, AL; Lerner, EC; Smithgall, TE; Grandis, JR			Differential function of STAT5 isoforms in head and neck cancer growth control	ONCOGENE			English	Article						STAT5; squamous cell carcinoma of the head and neck epidermal growth factor receptor	SQUAMOUS-CELL CARCINOMA; PERIPHERAL-BLOOD CELLS; DNA-BINDING ACTIVITY; FACTOR RECEPTOR; CONSTITUTIVE ACTIVATION; TGF-ALPHA; TRANSCRIPTION FACTORS; SIGNAL TRANSDUCERS; GENE FAMILY; PROTEINS	Up-regulation of the epidermal growth factor receptor (EGFR) is critical for the loss of growth control in a variety of human cancers, including squamous cell carcinoma of the head and neck (SCCHN). Stimulation of EGFR results in activation of mitogenic signaling pathways including Signal Transducers and Activators of Transcription (STATs). Stat5 activation has been primarily demonstrated in hematopoietic malignancies. Gene disruption studies suggest potentially distinct functions of the Stat5 isoforms, Stat5a and Stat5b, which are encoded by two genes closely linked on human chromosome 17. To determine the function of Stat5 in SCCHN growth control, we studied the expression and constitutive activation of Stat5a and Stat5b in normal and transformed human squamous epithelial cells. Increased constitutive activation of Stat5 was detected in transformed compared with normal squamous cells. Blockade of TGF-alpha or EGFR, abrogated Stat5 activation. Targeting of Stat5b using antisense oligonucleotides inhibited SCCHN growth. In addition, SCCHN cells stably transfected with dominant negative mutant Stat5b failed to proliferate in vitro. In contrast, targeting of Stat5a using either antisense or dominant negative strategies had no effect on cell growth. These results suggest that TGF-alpha/EGFR-mediated autocrine growth of transformed epithelial cells is dependent on activation of Stat5b but not Stat5a.	Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Eye & Ear Inst Pittsburgh, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA.	jgrandis@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA077308] Funding Source: NIH RePORTER; NCI NIH HHS [CA77308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Chai SK, 1997, J IMMUNOL, V159, P4720; CHRISTENSEN ME, 1992, EUR ARCH OTO-RHINO-L, V249, P243, DOI 10.1007/BF00714485; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Endo S, 2000, GENE THER, V7, P1906, DOI 10.1038/sj.gt.3301315; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CELL BIOCHEM, V69, P55, DOI 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U; Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; GRANDIS JR, 1993, J CELL BIOCHEM, P188; Grandis JR, 1997, ONCOGENE, V15, P409, DOI 10.1038/sj.onc.1201188; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hayakawa F, 1998, BRIT J HAEMATOL, V101, P521, DOI 10.1046/j.1365-2141.1998.00720.x; HEO DS, 1989, CANCER RES, V49, P5167; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; KUMAR V, 1995, CELL BIOL INT, V19, P373, DOI 10.1006/cbir.1995.1083; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lango MN, 2001, CURR OPIN ONCOL, V13, P168, DOI 10.1097/00001622-200105000-00007; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nieborowska-Skorska M, 2000, ONCOGENE, V19, P4117, DOI 10.1038/sj.onc.1203754; Okuda K, 1996, ONCOGENE, V13, P1147; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; SACKS PG, 1988, CANCER RES, V48, P2858; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shin DM, 2001, CLIN CANCER RES, V7, P1204; Shuai K, 1996, ONCOGENE, V13, P247; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VIROLAINEN E, 1983, OTOLARYNG HEAD NECK, V91, P126, DOI 10.1177/019459988309100204; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WeberNordt RM, 1996, BLOOD, V88, P809; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914	53	60	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2846	2853		10.1038/sj.onc.1205385	http://dx.doi.org/10.1038/sj.onc.1205385			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973644				2022-12-28	WOS:000175063700009
J	Meriane, M; Charrasse, S; Comunale, F; Mery, A; Fort, P; Roux, P; Gauthier-Rouviere, C				Meriane, M; Charrasse, S; Comunale, F; Mery, A; Fort, P; Roux, P; Gauthier-Rouviere, C			Participation of small GTPases Rac1 and Cdc42Hs in myoblast transformation	ONCOGENE			English	Article						Rho GTPases; myogenesis; transformations; rhabdomyosarcoma	SKELETAL-MUSCLE DIFFERENTIATION; KINASE PATHWAY; GROWTH-FACTOR; RAS; RHO; P38; ACTIVATION; EXPRESSION; PROLIFERATION; PROTEINS	We have previously shown that expression of active Rac1 and Cdc4Hs inhibits skeletal muscle cell differentiation. We show here, by bromodeoxyuridine incorporation and cyclin D1 expression, that the expression of active Rac1 and Cdc42Hs but not RhoA impairs cell cycle exit of L6 myoblasts cultured in differentiation medium. Furthermore, expression of activated forms of Rac1 and Cdc42Hs elicits the loss of cell contact inhibition and anchorage-dependent growth as measured by focus forming activity and growth in soft agar. RhoA was once again not found to have this effect. We found a constitutive Rac1 and Cdc42Hs activation in three human rhabdomyosarcoma-derived cell lines, one of the most common causes of solid tumours arising from muscle precursors during childhood. Finally, dominant negative forms of Rac1 and Cdc42Hs inhibit cell proliferation of the RD rhabdomyosarcoma cell line. These data suggest an important role for the small GTPases Rac1 and Cdc42Hs in the generation of skeletal muscle tumours.	CNRS, Ctr Rech Biochim Macromol, UPR 1086, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Gauthier-Rouviere, C (corresponding author), CNRS, Ctr Rech Biochim Macromol, UPR 1086, 1919 Route Mende, F-34293 Montpellier, France.	gauthier@erbm.cnrs.mop.fr	Fort, Philippe/M-9498-2015; Roux, Pierre/D-8833-2017	Fort, Philippe/0000-0001-5997-8722; GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882; Comunale, Franck/0000-0001-8838-2151				Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; HELLER H, 2001, J BIOL CHEM, V6, P6; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Mangues R, 1992, Semin Cancer Biol, V3, P229; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Puri PL, 2000, GENE DEV, V14, P574; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; VAN AL, 1997, GENE DEV, V11, P2295; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	36	30	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2901	2907		10.1038/sj.onc.1205396	http://dx.doi.org/10.1038/sj.onc.1205396			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973651				2022-12-28	WOS:000175063700016
J	Soldatenkov, VA; Trofimova, IN; Rouzaut, A; McDermott, F; Dritschilo, A; Notario, V				Soldatenkov, VA; Trofimova, IN; Rouzaut, A; McDermott, F; Dritschilo, A; Notario, V			Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1	ONCOGENE			English	Article						antisense apoptosis; ETS transcription factors; poly(ADP-ribose) polymerase	GROWTH-FACTOR-BETA; ANTISENSE RAF OLIGODEOXYRIBONUCLEOTIDE; HUMAN-TUMOR CELLS; EWS GENE; FUSION PROTEINS; DOWN-REGULATION; II RECEPTOR; EWS-FLI1; FAMILY; TRANSCRIPTION	Ewing's sarcoma (EWS) cells contain levels of poly (ADP-ribose) polymerase (PARP) significantly higher than other eukaryotic cells. Previously, we cloned the PARP gene promoter region from EWS cells, showed that it contained multiple ETS-binding sites and demonstrated a positive regulation of PARP by ETS1. We now report that, contrary to ETS1, EWS/FLI-1, an aberrant ETS transcription factor present in most EWS cells, is a negative effector of PARP transcription. Because PARP levels have been associated with cellular resistance or sensitivity to genotoxic agents, we studied the effect of modifying PARP levels in EWS cells on their response to DNA damage by modulating the expression of ETS1 or EWS/FLI-1 using antisense methodology. Results show that stable down-regulation of ETS1 increases the resistance of EWS cells to various genotoxic agents, whereas down-regulation of EWS/FLI-1 has pro-apoptotic effects. Because down-regulation EWS/FLI-1 does not dramatically change PARP levels, these results suggest a direct effect for EWS/FLI-1 in the DNA damage response of EWS cells. Since expression of the aberrant fusion proteins by EWS cells is essential for maintaining their neoplastic phenotype, our results suggest that the use of antisense oligonuleotides in combination with chemotherapeutic agents or radiation may be doubly effective by causing both an increase in sensitivity to therapeutic agents and a simultaneous down-regulation, or reversion, of the neoplastic phenotype of EWS cells.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med,Expt Carcinogenesis Lab, Washington, DC 20007 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med,Expt Carcinogenesis Lab, Res Bldg,Room E215,3970 Reservoir Rd NW, Washington, DC 20007 USA.	notariov@georgetown.edu	Rouzaut, Ana/I-2576-2017; /AFP-0764-2022; /AAB-6461-2022	Rouzaut, Ana/0000-0003-3226-9162; 	NCI NIH HHS [CA64472, P01-CA74175, P30-CA51008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064472, P01CA074175, P30CA051008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; de Alava E, 2000, AM J PATHOL, V156, P849, DOI 10.1016/S0002-9440(10)64953-X; Dohjima T, 2000, BRIT J CANCER, V82, P16, DOI 10.1054/bjoc.1998.0870; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Gokhale PC, 1997, GENE THER, V4, P1289, DOI 10.1038/sj.gt.3300543; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Im YH, 2000, CANCER RES, V60, P1536; KELLAND LR, 1988, INT J RADIAT ONCOL, V14, P1239, DOI 10.1016/0360-3016(88)90403-8; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LEITH JT, 1988, RADIAT RES, V114, P186, DOI 10.2307/3577154; Lin PP, 1999, CANCER RES, V59, P1428; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; Ohmori T, 1998, EXP CELL RES, V245, P350, DOI 10.1006/excr.1998.4261; OHNO T, 1994, ONCOGENE, V9, P3087; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; PRASAD SC, 1990, CANCER RES, V50, P38; RAO VN, 1993, ONCOGENE, V8, P2167; Raynal S, 1997, INT J CANCER, V72, P356, DOI 10.1002/(SICI)1097-0215(19970717)72:2<356::AID-IJC26>3.3.CO;2-J; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Seth A, 1999, CELL DEATH DIFFER, V6, P902, DOI 10.1038/sj.cdd.4400567; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Soldatenkov VA, 1999, ONCOGENE, V18, P3954, DOI 10.1038/sj.onc.1202778; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; THRAVES PJ, 1986, INT J RADIAT BIOL, V50, P961, DOI 10.1080/09553008614551381; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	37	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2890	2895		10.1038/sj.onc.1205393	http://dx.doi.org/10.1038/sj.onc.1205393			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973649				2022-12-28	WOS:000175063700014
J	Izutsu, K; Kurokawa, M; Imai, Y; Ichikawa, M; Asai, T; Maki, K; Mitani, K; Hirai, H				Izutsu, K; Kurokawa, M; Imai, Y; Ichikawa, M; Asai, T; Maki, K; Mitani, K; Hirai, H			The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP	ONCOGENE			English	Article						AML1/Evi-1; CtBP; AML1; dominant negative	ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; STIMULATING FACTOR-RECEPTOR; ACUTE MYELOGENOUS LEUKEMIA; AML1 GENE; TRANSCRIPTIONAL REGULATION; CELL-DIFFERENTIATION; GROWTH-FACTOR; CO-REPRESSOR; RUNT DOMAIN	AML1/Evi-1 is a chimeric protein that is derived from t(3;21), found in blastic transformation of chronic myelogenous leukemia. It is composed of the N-terminal AML1 portion with the DNA-binding Runt domain and the C-terminal Evi-1 portion. It has been shown to dominantly repress AML1-induced transactivation. The mechanism for it has been mainly attributed to competition with AML1 for the DNA-binding and for the interaction with PEBP2beta (CBFbeta), a partner protein which heterodimerizes with AML1 It was recently found that Evi-1 interacts with C-terminal binding protein (CtBP) to repress TGFbeta-induced transactivation. Here, we demonstrate that AML1/Evi-1 interacts with CtBP in SKH1 cells, a leukemic cell fine which endogenously overexpresses AML1/Evi-1 and that AML1/Evi-1 requires the interaction with CtBP to repress AML1-induced transactivation. The association with CtBP is also required when AML1/Evi-1 blocks myeloid differentiation of 32Dcl3 cells induced by granulocyte colony-stimulating factor. Taken together, it is suggested that one of the mechanisms for AML1/Evi-1-associated leukemogenesis should be an aberrant recruitment of a corepressor complex by the chimeric protein.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan; Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan	University of Tokyo; Dokkyo Medical University	Hirai, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	hhirai-tky@umin.ac.jp	Izutsu, Koji/AAI-1125-2019	Izutsu, Koji/0000-0001-9129-8057; Ichikawa, Motoshi/0000-0001-6497-0848; Imai, Yoichi/0000-0002-2938-6133				BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brannon M, 1999, DEVELOPMENT, V126, P3159; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Ferrara FF, 2001, CANCER RES, V61, P2; Fixe P, 1998, CYTOKINE, V10, P32, DOI 10.1006/cyto.1997.0249; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Guidez F, 2000, BLOOD, V96, P2557; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hirai H, 1999, INT J BIOCHEM CELL B, V31, P1367, DOI 10.1016/S1357-2725(99)00064-3; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kosugi H, 1999, LEUKEMIA, V13, P1316, DOI 10.1038/sj.leu.2401508; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; KUROKAWA M, 1995, ONCOGENE, V11, P833; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Mitani K, 1997, LEUKEMIA, V11, P863, DOI 10.1038/sj.leu.2400666; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Zent C, 1996, CURR TOP MICROBIOL, V211, P243; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	58	27	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2695	2703		10.1038/sj.onc.1205356	http://dx.doi.org/10.1038/sj.onc.1205356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965542				2022-12-28	WOS:000174996500009
J	Kiyoi, H; Ohno, R; Ueda, R; Saito, H; Naoe, T				Kiyoi, H; Ohno, R; Ueda, R; Saito, H; Naoe, T			Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain	ONCOGENE			English	Article						FLT3; receptor tyrosine kinase; juxtamembrane; internal tandem duplication; leukemia	ACUTE MYELOID-LEUKEMIA; RECEPTOR TYROSINE KINASE; C-KIT RECEPTOR; CELL-LINES; MYELODYSPLASTIC SYNDROME; MOLECULAR CHAPERONES; MYELOGENOUS LEUKEMIA; GENE; MUTATIONS; TRANSFORMATION	Internal tandem duplication (ITD) of the juxtamembrane (JM) domain of FLT3 is the most frequent mutation in human acute myeloid leukemia, and is significantly associated with leukocytosis and a poor prognosis. Previously we reported that FLT3 with ITD (FLT3/ ITD) formed a homodimer and was autophosphorylated on tyrosine residues, while the mechanism remains unclear. In this study, we elucidated the role of the JM domain in FLT3 activation. Mutant FLT3 with not only ITD but also an elongating or shortening JM domain transformed murine IL-3-dependent myeloid progenitor cell line 32D regardless of the tyrosine residues in the JM domain. These mutant FLT3s were constitutively tyrosine phosphorylated and activated signal-transduction molecules such as SHC, MAP kinase and STAT5a. Notably, co-transfection of the truncated FLT3/ITD lacking kinase and C-terminal domains with the wild type (Wt)-FLT3 into 32D cells resulted in the autonomous proliferation. In these cells, truncated FLT3/ITD generated a hetero-complex with Wt-FLT3 and Wt-FLT3 was constitutively tyrosine phosphorylated. These findings indicate that the FLT3 JM domain plays an important role in receptor activation, and that the length-mutated JM domain induces ligand-independent receptor activation but also activates Wt-FLT3 in a trans-manner.	Nagoya Univ, Sch Med, Dept Infect Dis, Showa Ku, Nagoya, Aichi 4668560, Japan; Aichi Canc Ctr Hosp, Nagoya, Aichi 4648681, Japan; Nagoya City Univ, Dept Med 2, Nagoya, Aichi 4678601, Japan; Nagoya Natl Hosp, Dept Med, Nagoya, Aichi 4600001, Japan	Nagoya University; Aichi Cancer Center; Nagoya City University	Kiyoi, H (corresponding author), Nagoya Univ, Sch Med, Dept Infect Dis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668560, Japan.	kiyoi@med.nagoya-u.ac.jp	Naoe, Tomoki/I-1888-2012					Boissan M, 2000, J LEUKOCYTE BIOL, V67, P135, DOI 10.1002/jlb.67.2.135; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Feiken E, 2000, J BIOL CHEM, V275, P15350, DOI 10.1074/jbc.275.20.15350; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; Iwai T, 1999, LEUKEMIA, V13, P38, DOI 10.1038/sj.leu.2401241; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; Kiyoi H, 1999, BLOOD, V93, P3074; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Kondo M, 1999, MED PEDIATR ONCOL, V33, P525; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Lam LPY, 1999, BIOCHEM J, V338, P131, DOI 10.1042/0264-6021:3380131; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Marchetto S, 1999, LEUKEMIA, V13, P1374, DOI 10.1038/sj.leu.2401527; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Meshinchi S, 2001, BLOOD, V97, P89, DOI 10.1182/blood.V97.1.89; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Nakao M, 1996, LEUKEMIA, V10, P1911; Robertson SC, 2000, TRENDS GENET, V16, P368, DOI 10.1016/S0168-9525(00)02077-1; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Tsujimura T, 1996, PATHOL INT, V46, P933, DOI 10.1111/j.1440-1827.1996.tb03571.x; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Xu F, 1999, BRIT J HAEMATOL, V105, P155, DOI 10.1111/j.1365-2141.1999.01284.x; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719; Zhang SL, 1999, J LEUKOCYTE BIOL, V65, P372, DOI 10.1002/jlb.65.3.372; Zhao M, 2000, LEUKEMIA, V14, P374, DOI 10.1038/sj.leu.2401680	34	207	217	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2555	2563		10.1038/sj.onc.1205332	http://dx.doi.org/10.1038/sj.onc.1205332			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971190				2022-12-28	WOS:000174918400012
J	Scelfo, RAM; Schwienbacher, C; Veronese, A; Gramantieri, L; Bolondi, L; Querzoli, P; Nenci, I; Calin, GA; Angioni, A; Barbanti-Brodano, G; Negrini, M				Scelfo, RAM; Schwienbacher, C; Veronese, A; Gramantieri, L; Bolondi, L; Querzoli, P; Nenci, I; Calin, GA; Angioni, A; Barbanti-Brodano, G; Negrini, M			Loss of methylation at chromosome 11p15.5 is common in human adult tumors	ONCOGENE			English	Article						chromosome 11p15.5; DNA hypomethylation	BECKWITH-WIEDEMANN-SYNDROME; DNA METHYLATION; IMPRINTED GENE; WILMS-TUMOR; SUPPRESSOR REGIONS; H19; LOCUS; IGF2; EXPRESSION; DISRUPTION	Chromosome 11p15 deletion is frequent in human tumors, suggesting the presence of at least one tumor suppressor gene within this region. While mutation analyses of local genes revealed only rare mutations, we have previously described a mechanism, gain of imprinting, that leads to loss of expression of genes located on the maternal 11p15 chromosome in human hepatocarcinomas. Loss of expression was often associated with loss of maternal-specific methylation at the KvDMR1 locus. Here, we show that loss of the maternal KvDMR1 methylation is common, ranging from 30 to 50%, to a variety of adult neoplasms, including liver, breast, cervical and gastric carcinomas. We found that other 11p15.5 loci were concomitantly hypomethylated, indicating that loss of KvDMR1 methylation occurred in the context of a common mechanism affecting the methylation of a large 11p15 subchromosomal domain. These epigenetic abnormalities were not detected in any normal somatic tissue. Therefore, it seems possible that, contrary to the repression of promoter activity caused by hypermethylation, loss of gene expression at 11p15.5 may result from the activation, by hypomethylation, of one or more negative regulatory elements.	Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Interdipartmentale Ric Canc, I-44100 Ferrara, Italy; Int Canc Ctr, Mol Biol Labs, Rovigo, Italy; Univ Bologna, Dipartimento Med Interna & Gastroenterol, Bologna, Italy; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Osped Pediat, Serv Immunotrasfus, Bambino Gesu IRCCS, Rome, Italy	University of Ferrara; University of Ferrara; University of Bologna; Jefferson University; IRCCS Bambino Gesu	Negrini, M (corresponding author), Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, Via Luigi Borsari 46, I-44100 Ferrara, Italy.	ngm@unife.it	Calin, George/E-9390-2011; angioni, adriano/G-1160-2014; Veronese, Angelo/I-4292-2019; Gramantieri, Laura/K-8603-2016; Negrini, Massimo/J-2377-2016; Gramantieri, Laura/J-3862-2019	angioni, adriano/0000-0003-0862-2456; Gramantieri, Laura/0000-0002-5187-9559; Negrini, Massimo/0000-0002-0007-1920; QUERZOLI, Patrizia/0000-0003-2873-8894; Calin, George/0000-0001-6704-5615; Veronese, Angelo/0000-0002-1451-1392				Baffa R, 1996, CANCER RES, V56, P268; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Brown KW, 1996, HUM MOL GENET, V5, P2027, DOI 10.1093/hmg/5.12.2027; Catchpoole D, 1997, J MED GENET, V34, P353, DOI 10.1136/jmg.34.5.353; Cleary MA, 2001, NAT GENET, V29, P78, DOI 10.1038/ng715; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Ehrlich Melanie, 2000, P273; Engel JR, 2000, J MED GENET, V37, P921, DOI 10.1136/jmg.37.12.921; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; KIECHLESCHWARZ M, 1993, CANCER, V72, P2423, DOI 10.1002/1097-0142(19931015)72:8<2423::AID-CNCR2820720821>3.0.CO;2-P; KOUFOS A, 1989, AM J HUM GENET, V44, P711; Lee MP, 1998, CANCER RES, V58, P4155; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Maniatis T., 1982, MOL CLONING; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; OBriant KC, 1997, GENE CHROMOSOME CANC, V18, P111, DOI 10.1002/(SICI)1098-2264(199702)18:2<111::AID-GCC5>3.0.CO;2-5; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Sabbioni S, 1999, CYTOGENET CELL GENET, V86, P214, DOI 10.1159/000015341; Schwienbacher C, 1998, P NATL ACAD SCI USA, V95, P3873, DOI 10.1073/pnas.95.7.3873; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Schwienbacher C, 2000, CANCER RES, V60, P1521; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143	36	45	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2564	2572		10.1038/sj.onc.1205336	http://dx.doi.org/10.1038/sj.onc.1205336			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971191				2022-12-28	WOS:000174918400013
J	Dell'Era, P; Coco, L; Ronca, R; Sennino, B; Presta, M				Dell'Era, P; Coco, L; Ronca, R; Sennino, B; Presta, M			Gene expression profile in fibroblast growth factor 2-transformed endothelial cells	ONCOGENE			English	Article						angiogenesis; endothelium; FGF; gene expression; vascular tumor	INHIBITORY FACTOR MIF; AUTOCRINE MECHANISM; PROTEIN; ANGIOGENESIS; IDENTIFICATION; HYPOXIA; ID3; TRANSCRIPTION; INDUCTION; RECEPTOR	Fibroblast growth factor-2 (FGF2) exerts paracrine and autocrine functions on endothelial cells. FGF2-overexpressing murine aortic endothelial cells (FGF2-T-MAE cells) induce opportunistic hemangioendothelioma-like tumors when inoculated in immunodeficient mice. To evaluate the impact of FGF2-mediated activation on gene expression profile in transformed endothelial cells, we performed subtractive suppression hybridization analysis between FGF2-T-MAE cells and parental MAE cells. The two cell populations were compared for differential gene expression also by gene macroarray hybridization with P-32-labeled cDNAs. The two approaches allowed the identification of 27 transcripts whose expression was upregulated by FGF2 in endothelial cells. With the exception of one unknown gene, the differentially expressed transcripts encoded for proteins involved in the modulation of cell cycle, differentiation, and cell adhesion. Among them, the stress-inducible genes A170, GADD45 and GADD153 are upregulated by FGF2 transfection or recombinant growth factor treatment. Their expression was also induced in vascular tumors originated by parental or FGF2-transfected MAE cells in nude mice. This study extends the number of genes involved in tumor angiogenesis and/or endothelial cell transformation, a finding with possible implications for the discovery of novel targets for angiostatic therapy.	Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy	University of Brescia	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy.	presta@med.unibs.it	Dell'Era, Patrizia/ABD-5848-2020; Dell'Era, Patrizia/N-6964-2019; Presta, Marco/B-4345-2010; Dell'Era, Patrizia/G-5294-2010	Dell'Era, Patrizia/0000-0001-6682-6321; PRESTA, Marco/0000-0002-4398-8376; RONCA, Roberto/0000-0001-8979-7068				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; CAREY I, 1995, CELL GROWTH DIFFER, V6, P899; Chen BB, 1997, J BIOL CHEM, V272, P2459, DOI 10.1074/jbc.272.4.2459; Chen BB, 1997, NUCLEIC ACIDS RES, V25, P423, DOI 10.1093/nar/25.2.423; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P579; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Glienke J, 2000, EUR J BIOCHEM, V267, P2820, DOI 10.1046/j.1432-1327.2000.01325.x; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hong NA, 2000, DEV BIOL, V220, P76, DOI 10.1006/dbio.2000.9615; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Ishii T, 1996, BIOCHEM BIOPH RES CO, V226, P456, DOI 10.1006/bbrc.1996.1377; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kroon ME, 2001, THROMB HAEMOSTASIS, V85, P296, DOI 10.1055/s-0037-1615683; KUWABARA K, 1995, P NATL ACAD SCI USA, V92, P4606, DOI 10.1073/pnas.92.10.4606; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Liekens S, 2001, CANCER RES, V61, P5057; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Nishihira J, 2000, J INTERF CYTOK RES, V20, P751, DOI 10.1089/10799900050151012; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; Orre RS, 2001, J BIOL CHEM, V276, P1794, DOI 10.1074/jbc.M008560200; Ribatti D, 1999, J PATHOL, V189, P590; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Roland I, 2000, EUR J BIOCHEM, V267, P3567, DOI 10.1046/j.1432-1327.2000.01385.x; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; St Croix B, 2000, SCIENCE, V289, P1197; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vasile E, 2001, FASEB J, V15, P458, DOI 10.1096/fj.00-0051com; Wang JL, 2000, MICROVASC RES, V59, P394, DOI 10.1006/mvre.2000.2242; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; Yanagawa T, 1997, BIOCHEM BIOPH RES CO, V241, P157, DOI 10.1006/bbrc.1997.7783; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	47	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2433	2440		10.1038/sj.onc.1205301	http://dx.doi.org/10.1038/sj.onc.1205301			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948428				2022-12-28	WOS:000174635600017
J	Huang, ZY; Baldwin, RL; Hedrick, NM; Gutmann, DH				Huang, ZY; Baldwin, RL; Hedrick, NM; Gutmann, DH			Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo	ONCOGENE			English	Article						glioma; astrocytoma; p53; retinoblastoma; tumor suppressor	HUMAN-MALIGNANT GLIOMAS; P53-DEPENDENT APOPTOSIS; MUTANT MICE; CELL-GROWTH; GENE; AMPLIFICATION; RB; GLIOBLASTOMAS; INACTIVATION; SUPPRESSION	The development of malignant gliomas (astrocytomas) involves the accumulation of multiple genetic changes, including mutations in the p53 and retinoblastoma (Rb) cell cycle regulatory pathways. One Rb pathway alteration seen in high-grade astrocytomas is amplification of cyclin dependent kinase-4 (CDK4). To define the function of CDK4 amplification/overexpression in astrocytoma pathogenesis, we generated three transgenic mouse lines that overexpress human CDK4 (hCDK4) in astrocytes using the human glial fibrillary acidic protein (GFAP) promoter. CFAP-hCDK4 mice do not develop brain tumors, but exhibit a small increase in astrocyte number. Cultured astrocytes from these mice do not demonstrate a cell-autonomous growth advantage in vitro and lack properties of transformed cells. To determine whether cdk4 overexpression provides a cooperative growth advantage in vitro, CDK4-overexpressing C6 glioma cell lines were generated and found to exhibit increased cell growth. In addition, GFAP-hCDK4; p53 + / - as well as p53 + / -; Rb + / - mice exhibited increased numbers of astrocytes compared to GFAP-hCDK4, p53 + / -, or Rb + / - mice in vivo. No cooperative effect was observed with CFAP-hCDK4; Rb+/- mice. These results support the hypothesis that cdk4 overexpression alone is not sufficient for astrocytoma formation, but can provide a cooperative growth advantage in concert with genetic alterations in the p53 pathway.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111 660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041097] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41097] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bajenaru ML, 2001, GLIA, V33, P314, DOI 10.1002/1098-1136(20010315)33:4<314::AID-GLIA1030>3.0.CO;2-Q; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Bogler O, 1999, CELL GROWTH DIFFER, V10, P73; BOGLER O, 1995, CANCER RES, V55, P2746; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; Ding H, 2001, CANCER RES, V61, P3826; DING H, 2000, NEURO-ONCOLOGY, V2, P259; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829; Gutmann DH, 2000, NEUROPATH APPL NEURO, V26, P361, DOI 10.1046/j.1365-2990.2000.00258.x; Hegi ME, 2000, CANCER RES, V60, P3019; HEWETT SJ, 1993, BRAIN RES, V625, P337, DOI 10.1016/0006-8993(93)91078-7; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; Ichimura K, 2000, CANCER RES, V60, P417; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kleihues P., 2000, WORLD HLTH ORG CLASS; Lau N, 2000, J NEUROPATH EXP NEUR, V59, P759, DOI 10.1093/jnen/59.9.759; LI FP, 1969, J NATL CANCER I, V43, P1365; Listernick R, 1999, AM J MED GENET, V89, P38, DOI 10.1002/(SICI)1096-8628(19990326)89:1<38::AID-AJMG8>3.0.CO;2-M; Marino S, 2000, GENE DEV, V14, P994; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; ROSE K, 1993, VITRO BIOL METHODS, P46; Schlegel J, 1999, PATHOBIOLOGY, V67, P202, DOI 10.1159/000028073; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Timiryasova TM, 1999, INT J ONCOL, V14, P845; Ueki K, 1996, CANCER RES, V56, P150; Wakabayashi T, 1999, BIOTECHNIQUES, V26, P302, DOI 10.2144/99262st04; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAHANDA AM, 1995, MOL CELL BIOL, V15, P4249; YIN DL, 1995, NEUROSURGERY, V37, P758, DOI 10.1227/00006123-199510000-00021; ZHOU L, 1997, DEV BIOL, V187, P36	41	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1325	1334		10.1038/sj.onc.1205206	http://dx.doi.org/10.1038/sj.onc.1205206			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857076				2022-12-28	WOS:000173861000003
J	Sheard, MA; Vojtesek, B				Sheard, MA; Vojtesek, B			Simian virus-40 infection inhibits DNA damage-induced enhancement of CD95 expression and function	ONCOGENE			English	Article						CD95/Fas; SV40; p53/Trp53/TP53; apoptosis	LARGE T-ANTIGEN; MURINE RENAL-CANCER; WILD-TYPE P53; CELL-DEATH; MONOCLONAL-ANTIBODIES; GAMMA-IRRADIATION; INDUCED APOPTOSIS; TUMOR-ANTIGEN; UP-REGULATION; FAS RECEPTOR	Many viruses are known to disarm or suppress the cell death machinery of infected cells. Apoptotic cell death can be activated by aggregation of the CD95 cell surface death receptor in sensitive cells, and in most insensitive cells treated with sensitizing agents such as interferon-gamma or inhibitors of protein synthesis. We show that, subsequent to sequestration and inactivation of the p53 tumour suppressor protein, SV40 abrogates p53-dependent, DNA damage-inducible up-regulation of CD95 surface expression. Loss of surface up-regulation of CD95 after sub-lethal mitomycin C treatment resulted in an impaired enhancement of both caspase-8 cleavage and apoptotic cell death following CD95 aggregation. We conclude that infection of human cells with SV40 virus strongly inhibits DNA damage-induced enhancement of CD95-mediated apoptosis.	Masaryk Mem Canc Inst, Lab Apoptosis Res, Brno 65653, Czech Republic; Masaryk Mem Canc Inst, Dept Expt Oncol, Brno 65653, Czech Republic	Masaryk Memorial Cancer Institute; Masaryk Memorial Cancer Institute	Sheard, MA (corresponding author), Masaryk Mem Canc Inst, Lab Apoptosis Res, Zluty Kopec 7, Brno 65653, Czech Republic.	sheard@mou.cz	Sheard, Michael/J-1374-2019	Sheard, Michael/0000-0002-4960-7650				Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Broome HE, 1998, CELL DEATH DIFFER, V5, P200, DOI 10.1038/sj.cdd.4400329; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Carbone M, 1999, J CELL PHYSIOL, V180, P167, DOI 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; del Arroyo AG, 2000, ONCOGENE, V19, P3647, DOI 10.1038/sj.onc.1203662; Dirks W, 1997, BRIT J HAEMATOL, V96, P584, DOI 10.1046/j.1365-2141.1997.d01-2048.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fulda S, 1998, INT J CANCER, V76, P105; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275; Hashimoto W, 1999, J IMMUNOL, V163, P583; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; JAATTELA M, 1995, ONCOGENE, V10, P2297; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Krammer P H, 1999, Adv Immunol, V71, P163; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee JK, 2000, J IMMUNOL, V164, P231, DOI 10.4049/jimmunol.164.1.231; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Levresse V, 1998, ONCOGENE, V16, P1041, DOI 10.1038/sj.onc.1201627; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Maecker HL, 2000, CANCER RES, V60, P4638; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; METCALF RA, 1992, CANCER RES, V52, P2610; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Mor O, 1997, ONCOGENE, V15, P3113, DOI 10.1038/sj.onc.1201549; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nguyen PL, 1996, AM J PATHOL, V148, P847; O'Connor L, 2000, CANCER RES, V60, P1217; Okayasu R, 1999, CANCER RES, V59, P298; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; Rodier F, 2000, ONCOGENE, V19, P6261, DOI 10.1038/sj.onc.1204015; Rosen D, 2000, J IMMUNOL, V164, P3229, DOI 10.4049/jimmunol.164.6.3229; ROUQUET N, 1995, ONCOGENE, V11, P1061; Sayers TJ, 2000, J LEUKOCYTE BIOL, V68, P81; Sayers TJ, 1998, J IMMUNOL, V161, P3957; Screpanti V, 2001, J IMMUNOL, V167, P2068, DOI 10.4049/jimmunol.167.4.2068; Sheard MA, 1999, BRIT J CANCER, V80, P1689, DOI 10.1038/sj.bjc.6690585; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Topham DJ, 1997, J IMMUNOL, V159, P5197; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wigginton JM, 2001, J CLIN INVEST, V108, P51	58	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					190	197						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803462				2022-12-28	WOS:000173026200003
J	Baptiste, N; Friedlander, P; Chen, XB; Prives, C				Baptiste, N; Friedlander, P; Chen, XB; Prives, C			The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells	ONCOGENE			English	Review						p53; apoptosis; anti-neoplastics; proline-rich domain	WILD-TYPE P53; C-TERMINAL DOMAIN; TEMPERATURE-SENSITIVE MUTANT; COLORECTAL-CARCINOMA CELLS; SEQUENCE-SPECIFIC DNA; DOUBLE-STRAND BREAKS; P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; CYCLE ARREST; P53-MEDIATED APOPTOSIS	In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wildtype p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53([gln22ser23]), is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53([gln22ser23]). Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	Columbia University; University System of Georgia; Augusta University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	prives@cubsps.bio.columbia.edu			NATIONAL CANCER INSTITUTE [R01CA077742] Funding Source: NIH RePORTER; NCI NIH HHS [CA77742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2000, PATHOL BIOL, V48, P227; Appella E, 2001, EUR J BIOCHEM, V268, P2763, DOI 10.1046/j.1432-1327.2001.02224.x; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Boulaire J, 2000, PATHOL BIOL, V48, P190; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chan TA, 2000, GENE DEV, V14, P1584; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chehab NH, 2000, GENE DEV, V14, P278; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; Darzynkiewicz Z, 1996, ANN NY ACAD SCI, V803, P93, DOI 10.1111/j.1749-6632.1996.tb26379.x; DEGTYAREVA N, 2000, J BIOL CHEM, V20, P20; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Engelborghs Y, 1998, EUR BIOPHYS J BIOPHY, V27, P437, DOI 10.1007/s002490050154; FADOK VA, 1992, J IMMUNOL, V148, P2207; Ferreira CG, 1999, ANN ONCOL, V10, P1011, DOI 10.1023/A:1008361818480; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gjerset RA, 2000, ADV EXP MED BIOL, V465, P273; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grem JL, 2000, INVEST NEW DRUG, V18, P299, DOI 10.1023/A:1006416410198; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1995, ONCOGENE, V11, P2311; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mee T, 1999, BRIT J CANCER, V81, P212, DOI 10.1038/sj.bjc.6690679; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MIYASHITA T, 1995, CELL, V80, P293; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; MYERS CE, 1990, CANC CHEMOTHERAPY PR, P356; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; Peller S, 1998, SEMIN CANCER BIOL, V8, P379, DOI 10.1006/scbi.1998.0100; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Roemer K, 1996, ONCOGENE, V12, P2069; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Seth P, 1997, CANCER GENE THER, V4, P383; Shieh SY, 2000, GENE DEV, V14, P289; Tang W, 1999, CANCER RES, V59, P2562; Thomas DM, 1998, CLIN EXP PHARMACOL P, V25, P887, DOI 10.1111/j.1440-1681.1998.tb02339.x; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; VANMAANEN JMS, 1988, J NATL CANCER I, V80, P1526, DOI 10.1093/jnci/80.19.1526; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zotchev SB, 2000, NUCLEIC ACIDS RES, V28, P4005, DOI 10.1093/nar/28.20.4005	115	108	111	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					9	21		10.1038/sj/onc/1205015	http://dx.doi.org/10.1038/sj/onc/1205015			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791172	Bronze			2022-12-28	WOS:000172887800002
J	Li, C; Ahlborn, TE; Tokita, K; Boxer, LM; Noda, A; Liu, JW				Li, C; Ahlborn, TE; Tokita, K; Boxer, LM; Noda, A; Liu, JW			The critical role of the PE21 element in oncostatin M-mediated transcriptional repression of the p53 tumor suppressor gene in breast cancer cells	ONCOGENE			English	Article						p53 tumor suppressor gene; transcriptional regulation; oncostatin M	NF-KAPPA-B; DOWN-REGULATION; SP1 SITES; NF1-LIKE PROTEIN; DNA-REPAIR; PROMOTER; EXPRESSION; ACTIVATION; GROWTH; IDENTIFICATION	Cytokine oncostatin M (OM) exerts growth-inhibitory and differentiative effects on breast cancer cells. Previously we showed that the transcription from the p53 gene in breast cancer cells was down regulated by OM. To elucidate the molecular mechanisms underlying the OM effect on p53 transcription, in this study, we dissected the p53 promoter region and analysed the p53 promoter activity in breast tumor cells. We showed that treatment of MCF-7 cells with OM induced a dose- and time-dependent suppression of p53 promoter activity. The p53 promoter activity was decreased to 35% of control at 24 h and further decreased to 20% at 48 h by OM at concentrations of 5 ng/ml and higher. Deletion of the F-flanking region of the p53 promoter from -426 to -97 did not affect the OM effect. However, further deletion to -40 completely abolished the repressive effect of OM. The p53 promoter region -96 to -41 contains NF-kappaB and c-myc binding sites, and a newly identified UV-inducible element PE21. Mutations to disrupt NF-KB binding or c-myc binding to the p53 promoter decreased the basal promoter activity without affecting the OM-mediated suppression, whereas mutation at the PE21 motif totally abolished the OM effect. We further demonstrated that insertion of PE21 element upstream of the thymidine kinase minimal promoter generated an OM response analogous to that of the p53 promoter. Finally, we detected the specific binding of a nuclear protein with a molecular mass of 87 kDa to the PE21 motif. Taken together, we demonstrate that OM inhibits the transcription of the p53 gene through the PE21 element. Thus, the PE21 element is functionally involved in p53 transcription regulated by UV-induction and OM suppression.	VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Kyoto Prefectural Univ Med, Dept Internal Med 3, Kamigyo Ku, Kyoto 6028566, Japan; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Kobe Univ, Sch Med, Dept Radiat Biophys & Genet, Chuo Ku, Kobe, Hyogo 6500017, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Kyoto Prefectural University of Medicine; Stanford University; Kobe University	Liu, JW (corresponding author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.			Noda, Asao/0000-0002-9029-9813	NCI NIH HHS [1R01CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balint E, 1996, CANCER RES, V56, P1648; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; BRIGGS J, 1996, J BIOL CHEM, V271, P901; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; ESTROV Z, 1995, J INTERF CYTOK RES, V15, P905, DOI 10.1089/jir.1995.15.905; Hirose Y, 2001, CANCER RES, V61, P1957; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jeffy BD, 2000, NEOPLASIA, V2, P460, DOI 10.1038/sj.neo.7900104; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Lee M, 1999, BIOCHEM CELL BIOL, V77, P209, DOI 10.1139/bcb-77-3-209; Lee MY, 1998, BIOL CHEM, V379, P1333, DOI 10.1515/bchm.1998.379.11.1333; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Liu HF, 1999, WORLD J GASTROENTERO, V5, P15; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; Mokdad-Gargouri R, 2001, NUCLEIC ACIDS RES, V29, P1222, DOI 10.1093/nar/29.5.1222; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nayak BK, 1999, MOL BIOL REP, V26, P223, DOI 10.1023/A:1007006011253; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Phan SC, 1996, MOL CELL BIOL, V16, P2387; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001; SOINI Y, 1992, VIRCHOWS ARCH A, V421, P415, DOI 10.1007/BF01606914; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Spence MJ, 1997, CANCER RES, V57, P2223; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Uberti D, 2000, AMINO ACIDS, V19, P253, DOI 10.1007/s007260070056; Wang JP, 2000, MOL CARCINOGEN, V29, P179, DOI 10.1002/1098-2744(200011)29:3<179::AID-MC7>3.0.CO;2-K; Wang XQ, 2001, CANCER RES, V61, P1598; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; Zeng XY, 2000, CANCER RES, V60, P6184; Zhu QZ, 2000, MOL CARCINOGEN, V28, P215	43	9	9	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8193	8202		10.1038/sj.onc.1205046	http://dx.doi.org/10.1038/sj.onc.1205046			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781835				2022-12-28	WOS:000172507800004
J	Umansky, M; Yasui, W; Hallak, A; Brill, S; Shapira, I; Halpern, Z; Hibshoosh, H; Rattan, J; Meltzer, S; Tahara, E; Arber, N				Umansky, M; Yasui, W; Hallak, A; Brill, S; Shapira, I; Halpern, Z; Hibshoosh, H; Rattan, J; Meltzer, S; Tahara, E; Arber, N			Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus	ONCOGENE			English	Article						cell cycle; Barrett's esophagus; cyclins; cyclin-dependent kinase inhibitors; proton pump inhibitors	PHOTODYNAMIC THERAPY; INCREASED EXPRESSION; GASTRIC CARDIA; CDK INHIBITORS; ADENOCARCINOMA; CANCER; GENE; PROGRESSION; D1; OVEREXPRESSION	Neoplastic progression in Barrett's esophagus is a multistep process in which the metaplastic columnar epithelium sequentially evolves through a metaplasia-dysplasia-carcinoma sequence. The expression and DNA copy number of key cell cycle regulatory genes in paired normal and Barrett's esophagus samples was evaluated. Protein levels were evaluated in 60 formalin-fixed, paraffin-embedded human tissues by immunohistochemistry. DNA copy number from 20 fresh tissue pairs was analysed by Southern blot analysis. All normal mucosal samples expressed the p27(kip1) protein, but did not display appreciable nuclear staining for p16(kip4), p22(cip1) or cyclins DI and E. Barrett's metaplastic specimens displayed increased expression levels of p16(kip4) (74%), p21(cip1) (89%) and cyclins DI (43%) and E (37%). p27 protein was absent in three cases. There was a significant correlation between the expression of p16(kip4) and cyclin E, and p21(cip1) and p27(kip4) with cyclin D1. DNA analysis did not reveal any amplification or deletion of these genes. Acid suppression, however, was associated with significantly lower expression levels of key cell cycle proteins. Increased expression of key cell cycle regulatory genes appears to occur early in the neoplastic progression associated with Barrett's esophagus. Treatment with proton pump inhibitors appears to alter this increased expression.	Tel Aviv Med Ctr & Sch Med, GI Oncol Unit, Dept Gastroenterol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, IL-69978 Tel Aviv, Israel; Columbia Univ, Dept Pathol, New York, NY USA; Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD USA; Hiroshima Med Ctr, Dept Pathol, Hiroshima, Japan	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Columbia University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Arber, N (corresponding author), Tel Aviv Med Ctr & Sch Med, GI Oncol Unit, Dept Gastroenterol, IL-64239 Tel Aviv, Israel.			Arber, Nadir/0000-0001-5283-6991	NATIONAL CANCER INSTITUTE [R01CA077057, R01CA078843, U01CA085069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA78843, CA85069, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457; Arber N, 1996, ONCOGENE, V12, P1903; Arber N, 1999, HUM PATHOL, V30, P1087, DOI 10.1016/S0046-8177(99)90227-7; BARRETT NR, 1957, SURGERY, V41, P881; BILIR N, 1994, GASTROENTEROLOGY, V106, pA372; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOT WJ, 1993, JAMA-J AM MED ASSOC, V270, P1320, DOI 10.1001/jama.270.11.1320; Brien TP, 2000, HUM PATHOL, V31, P35, DOI 10.1016/S0046-8177(00)80195-1; BRIER SS, 1980, BIOMETRIKA, V67, P591; CHOW WH, 1995, JAMA-J AM MED ASSOC, V274, P474, DOI 10.1001/jama.274.6.474; CLARK GWB, 1995, ANN CHIR GYNAECOL FE, V84, P139; FINKEL RG, 1994, GASTROENTEROLOGY, V106, pA431; Fitzgerald RC, 1996, J CLIN INVEST, V98, P2120, DOI 10.1172/JCI119018; Fitzgerald RC, 1998, DIGEST DIS, V16, P63, DOI 10.1159/000016850; FLEJOU JF, 1994, GASTROENTEROLOGY, V106, pA386; Gimenez A, 1999, ARCH PATHOL LAB MED, V123, P1260; GORE S, 1993, ALIMENT PHARM THERAP, V7, P623; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1992, CANCER RES, V52, P2980; KIM R, 1992, GASTROENTEROLOGY, V106, pA402; LIGHTDALE CJ, 1995, GASTROINTEST ENDOSC, V42, P96, DOI 10.1016/S0016-5107(95)70256-3; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; Overholt BF, 1996, AM J GASTROENTEROL, V91, P1719; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PERA M, 1993, GASTROENTEROLOGY, V104, P510, DOI 10.1016/0016-5085(93)90420-H; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; QUATOLASCAR O, 1999, GASTROENTEROLOGY, V117, P327; REDD JL, 1994, GASTROENTEROLOGY, V106, pA431; REID BJ, 1993, GASTROENTEROLOGY, V105, P119, DOI 10.1016/0016-5085(93)90017-7; REID BJ, 1991, GASTROENTEROL CLIN N, V20, P817; SAGAR PM, 1995, BRIT J SURG, V82, P806, DOI 10.1002/bjs.1800820628; Sampliner RE, 1996, GASTROINTEST ENDOSC, V44, P532, DOI 10.1016/S0016-5107(96)70004-4; SAMPLINER RE, 1994, AM J GASTROENTEROL, V89, P1844; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKINNER DB, 1983, ANN SURG, V198, P554, DOI 10.1097/00000658-198310000-00016; Spechler SJ, 1996, GASTROENTEROLOGY, V110, P614, DOI 10.1053/gast.1996.v110.agast960614; Younes M, 1999, HUM PATHOL, V30, P1309, DOI 10.1016/S0046-8177(99)90061-8	39	41	43	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7987	7991		10.1038/sj.onc.1204947	http://dx.doi.org/10.1038/sj.onc.1204947			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753681				2022-12-28	WOS:000172288700007
J	Hatzi, E; Murphy, C; Zoephel, A; Rasmussen, H; Morbidelli, L; Ahorn, H; Kunisada, K; Tontsch, U; Klenk, M; Yamauchi-Takihara, K; Ziche, M; Rofstad, EK; Schweigerer, L; Fotsis, T				Hatzi, E; Murphy, C; Zoephel, A; Rasmussen, H; Morbidelli, L; Ahorn, H; Kunisada, K; Tontsch, U; Klenk, M; Yamauchi-Takihara, K; Ziche, M; Rofstad, EK; Schweigerer, L; Fotsis, T			N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth	ONCOGENE			English	Article						N-myc; IL-6; STAT3; endothelial cell; neuroblastoma	DNA-BINDING; INTERLEUKIN-6; EXPRESSION; CELLS; ACTIVATION; GENE; INDUCTION; PROTEIN; STAT3; TRANSFORMATION	Angiogenesis is an indispensable prerequisite for the progression and metastasis of solid malignancies. Tumor angiogenesis appears to be governed by alterations of tumor suppressor or oncogenes operant in a broad range of tumors. We have addressed this issue in neuroblastoma, a malignancy characterized by the near-exclusive amplification and overexpression of the N-Myc oncogene. Here, we report that N-Myc overexpression results in down-regulation of interleukin-6 (IL-6) and that IL-6 is an inhibitor of endothelial cell proliferation and VEGF-induced rabbit corneal angiogenesis. STAT3 is instrumental for IL-6 activity as infection with adeno-viruses expressing a phosphorylation deficient STAT3 mutant renders endothelial cells insensitive to the antiproliferative action of IL-6. Finally, though IL-6 does not influence neuroblastoma cell growth, IL-6-expressing xenograft tumors in mice exhibit reduced neovascularization and suppressed growth. Our data shed new light on the mechanisms by which N-myc oncogene amplification enhances the malignant phenotype in neuroblastomas.	Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece; Ioannina Biomed Res Inst, Ioannina, Greece; Boehringer Ingelheim Austria GmbH, Vienna, Austria; Norwegian Radium Hosp, Inst Canc Res, Dept Biophys, Oslo, Norway; Univ Siena, Inst Pharmacol Sci, I-53100 Siena, Italy; Osaka Univ, Grad Sch Med, Dept Mol Med, Suita, Osaka, Japan; Univ Essen Gesamthsch, Kinderklin, Abt Hamatol Onkol & Endokrinol, Essen, Germany	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Boehringer Ingelheim; University of Oslo; University of Siena; Osaka University; University of Duisburg Essen	Fotsis, T (corresponding author), Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece.	thfotsis@cc.uoi.gr	Morbidelli, Lucia/AAC-7858-2020; Murphy, Carol/ABE-4282-2021; Morbidelli, Lucia/K-4053-2016	Murphy, Carol/0000-0003-1353-8558; Morbidelli, Lucia/0000-0001-8148-7049				Ambrosino C, 1997, J BIOL CHEM, V272, P14883, DOI 10.1074/jbc.272.23.14883; Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090; Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Breit S, 2000, CANCER RES, V60, P4596; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Danielsen T, 1998, INT J CANCER, V76, P836, DOI 10.1002/(SICI)1097-0215(19980610)76:6<836::AID-IJC12>3.0.CO;2-0; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Fotsis T, 1997, CANCER RES, V57, P2916; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; GRADYLEOPARDI EF, 1986, CANCER RES, V46, P3196; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Guo QM, 2000, CANCER RES, V60, P5922; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILLER S, 1991, ONCOGENE, V6, P969; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Mac SM, 2000, MOL CARCINOGEN, V29, P76, DOI 10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; Megeney LA, 1996, DEV GENET, V19, P139, DOI 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; OHE Y, 1993, BRIT J CANCER, V67, P939, DOI 10.1038/bjc.1993.174; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; Rofstad EK, 2000, CANCER RES, V60, P4932; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	40	49	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3552	3561		10.1038/sj.onc.1205440	http://dx.doi.org/10.1038/sj.onc.1205440			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032857				2022-12-28	WOS:000175793700006
J	Kikuchi, T; Toyota, M; Itoh, F; Suzuki, H; Obata, T; Yamamoto, H; Kakiuchi, H; Kusano, M; Issa, JPJ; Tokino, T; Imai, K				Kikuchi, T; Toyota, M; Itoh, F; Suzuki, H; Obata, T; Yamamoto, H; Kakiuchi, H; Kusano, M; Issa, JPJ; Tokino, T; Imai, K			Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors	ONCOGENE			English	Article						cell cycle; gene expression; CIMP; chromatin; acetylation	DEPENDENT KINASE INHIBITOR; ISLAND METHYLATOR PHENOTYPE; BECKWITH-WIEDEMANN-SYNDROME; CPG-ISLAND; ABERRANT METHYLATION; GASTRIC-CANCER; CHROMOSOME 11P15; PROTEIN MBD1; P57(KIP2); GENE	To clarify the role of DNA methylation in the silencing of the expression of cyclin-dependent kinase inhibitor p57KIP2 seen in certain tumors, we investigated the methylation status of its 5' CpG island in various tumor cell lines and primary cancers. Dense methylation of the region around the transcription start site was detected in I out of 10 colorectal, 2 out of 8 gastric, and 6 out of 14 hematopoietic tumor cell lines and in 5 out of 35 (14%) gastric, 6 out of 20 (30%) hepatocellular, and 2 out of IS (11%) pancreatic cancers; 7 out of 25 (28%) acute myeloid leukemia cases also showed methylation of the p57KIP2 gene, which strongly correlated with the CpG island methylator phenotype (P < 0.001). Detailed mapping revealed that dense methylation of the region around the transcription start site (-300 to +400), but not of the edges of the CpG island, was closely associated with gene silencing. 5-aza-2'-deoxycytidine, a methyltransferase inhibitor, restored expression of p57KIP2, and chromatin immunoprecipitation using anti-histone H3 and H4 antibodies showed histone to be deacetylated in cell lines where p57KIP2 was methylated at the transcription start site. Regional methylation and histone deacetylation thus appear to be crucially involved in the silencing of p57KIP2 expression in human tumors.	Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	Sapporo Medical University; Sapporo Medical University; University of Texas System; UTMD Anderson Cancer Center	Toyota, M (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan.		Tokino, Takashi/AAI-9887-2021	Issa, Jean-Pierre/0000-0003-2258-5030				Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Herman JG, 1996, CANCER RES, V56, P722; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Jackson SM, 2000, WILDLIFE RES, V27, P39, DOI 10.1071/WR98045; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Krskova-Honzatkova L, 2001, LEUKEMIA RES, V25, P45, DOI 10.1016/S0145-2126(00)00086-2; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Matsumoto M, 2000, ANTICANCER RES, V20, P1947; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Oya M, 2000, BRIT J CANCER, V83, P626, DOI 10.1054/bjoc.2000.1298; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Sherr CJ, 2000, CANCER RES, V60, P3689; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Shin JY, 2000, CANCER RES, V60, P262; Shin JY, 2000, EXP MOL MED, V32, P79, DOI 10.1038/emm.2000.14; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Toyota M, 2000, CANCER RES, V60, P4044; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Toyota M, 1999, CANCER RES, V59, P4535; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Ueki T, 2000, CANCER RES, V60, P1835; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; WINQVIST R, 1993, CANCER RES, V53, P4486; Wong DJ, 1999, MOL CELL BIOL, V19, P5642; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	48	101	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2741	2749		10.1038/sj.onc.1205376	http://dx.doi.org/10.1038/sj.onc.1205376			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965547				2022-12-28	WOS:000174996500014
J	Koike, C; Mizutani, T; Ito, T; Shimizu, Y; Yamamichi, N; Kameda, T; Michimukai, E; Kitamura, N; Okamoto, T; Iba, H				Koike, C; Mizutani, T; Ito, T; Shimizu, Y; Yamamichi, N; Kameda, T; Michimukai, E; Kitamura, N; Okamoto, T; Iba, H			Introduction of wild-type patched gene suppresses the oncogenic potential of human squamous cell carcinoma cell lines including A431	ONCOGENE			English	Article						squamous cell carcinoma; the patched gene; retrovirus vector; human gene therapy; Sonic hedgehog; A431	PSEUDOTYPED RETROVIRUS VECTOR; HEDGEHOG SIGNAL-TRANSDUCTION; SONIC-HEDGEHOG; HUMAN HOMOLOG; GORLIN-SYNDROME; DEVELOPMENTAL DEFECTS; MESSENGER-RNA; MUTATIONS; PATHWAY; INDUCTION	Defects in a developmental signaling pathway involving the mammalian homologue of the Drosophila segment polarity gene, patched are associated with human tumors such as basal cell carcinoma, medulloblastoma and squamous cell carcinoma. Loss of heterozygosity (LOH) in some of these tumor cells suggests that patched functions as a tumor suppressor gene. To evaluate the biological significance of patched mutations in human sporadic tumor cells, we constructed a VSV-G pseudotyped retrovirus vector carrying the wild-type patched gene and transduced it into two human squamous cell carcinoma (SCC) cell lines, A431 and KA, that express only mutant patched mRNA. When SSC cells were transduced with Ptc virus, colony forming activity in soft agar was drastically reduced and these cells recovered anchorage independent growth when Sonic hedgehog (Shh), the ligand of Patched (Ptc), was added into the soft agar culture. Expression of exogenous patched, however, had no effect on anchorage independent growth of Ras-transformed NIH3T3 cells or SCC cell line, NA, which expresses wild-type patched mRNA. Cyclopamine, a specific inhibitor of the Shh/Ptc/Smo signaling pathway, efficiently suppressed anchorage independent growth of A431 and KA cells. These results indicate that loss of patched function plays a major role in the acquisition of oncogenic potential in these SCCs and further that Ptc virus would be an effective reagent for suppressing tumorigenicity of such SCCs.	Univ Tokyo, Dept Microbiol & Immunol, Div Host Parasite Interact, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Hiroshima Univ, Dept Mol Oral Med & Maxillofacial Surg 1, Fac Dent, Minami Ku, Hiroshima 7348553, Japan	University of Tokyo; Hiroshima University	Iba, H (corresponding author), Univ Tokyo, Dept Microbiol & Immunol, Div Host Parasite Interact, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							Ahmadian A, 1998, ONCOGENE, V17, P1837, DOI 10.1038/sj.onc.1202080; Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; Arai T, 1999, VIROLOGY, V260, P109, DOI 10.1006/viro.1999.9773; Arai T, 1998, J VIROL, V72, P1115, DOI 10.1128/JVI.72.2.1115-1121.1998; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Bale AE, 2000, NATURE, V406, P944, DOI 10.1038/35023197; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DAHMANE N, 1997, NATURE, V389, P870; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Incardona JP, 2000, DEV BIOL, V224, P440, DOI 10.1006/dbio.2000.9775; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; Karpen HE, 2001, J BIOL CHEM, V276, P19503, DOI 10.1074/jbc.M010832200; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KWOK TT, 1994, CANCER RES, V54, P2834; Lee J, 1997, DEVELOPMENT, V124, P2537; Lench NJ, 1997, HUM GENET, V100, P497, DOI 10.1007/s004390050541; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; Liu CZ, 1998, GENE, V209, P1, DOI 10.1016/S0378-1119(97)00668-9; Maesawa C, 1998, GENE CHROMOSOME CANC, V21, P276, DOI 10.1002/(SICI)1098-2264(199803)21:3<276::AID-GCC15>3.3.CO;2-H; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEVELOPMENT, V122, P1225; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; Michimukai E, 2001, IN VITRO CELL DEV-AN, V37, P459; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; OKUNO H, 1991, ONCOGENE, V6, P1491; Palm K, 2000, MOL BRAIN RES, V78, P192, DOI 10.1016/S0169-328X(00)00075-9; Pietsch T, 1997, CANCER RES, V57, P2085; Ping XL, 2001, J INVEST DERMATOL, V116, P614, DOI 10.1046/j.1523-1747.2001.01301.x; Raffel C, 1997, CANCER RES, V57, P842; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Smyth I, 1998, HUM GENET, V102, P598, DOI 10.1007/s004390050747; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Ui M, 1999, GENE THER, V6, P1670, DOI 10.1038/sj.gt.3301009; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Unden AB, 1997, CANCER RES, V57, P2336; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Vorechovsky I, 1997, CANCER RES, V57, P4677; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wetmore C, 2000, CANCER RES, V60, P2239; WOLTER M, 1997, CANCER RES, V57, P2582; Xie JW, 1997, CANCER RES, V57, P2369; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	62	24	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2670	2678		10.1038/sj.onc.1205370	http://dx.doi.org/10.1038/sj.onc.1205370			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965540				2022-12-28	WOS:000174996500007
J	Simon, R; Struckmann, K; Schraml, P; Wagner, U; Forster, T; Moch, H; Fijan, A; Bruderer, J; Wilber, K; Mihatsch, MJ; Gasser, T; Sauter, G				Simon, R; Struckmann, K; Schraml, P; Wagner, U; Forster, T; Moch, H; Fijan, A; Bruderer, J; Wilber, K; Mihatsch, MJ; Gasser, T; Sauter, G			Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer	ONCOGENE			English	Article						bladder cancer; MDM2; CDK4; GLI; tissue microarray; TMA	DEPENDENT KINASE 4; CHROMOSOMAL IMBALANCES; TISSUE MICROARRAYS; CYCLIN D1; P53; EXPRESSION; OVEREXPRESSION; PROLIFERATION; P21; COAMPLIFICATION	The chromosomal region 12q13-q15 is recurrently amplified in bladder cancer. Putative target genes located in this region include MDM2, CDK4, and GLI. To evaluate the involvement of these genes in bladder cancer, we screened a tissue microarray (TMA) containing 2317 samples by fluorescence in situ hybridization (FISH). Amplification was found for MDM2 in 5.1%, for CDK4 in 1.1%, and for GLI in 0.4% of interpretable tumors. Among tumors having amplification of at least one of these 12q13-q15 genes, 76.6% had amplification of MDM2 alone and 6.4% had amplification of CDK4 alone. Coamplifications were seen of MDM2 and CDK4 in 10.6%, and of CDK4 and GLI in 6.4%. Neither coamplifications of all three genes nor isolated GLI amplifications were found. These data suggest a prominent role of MDM2 as a 12q13-q15 amplification target in bladder cancer. However, independent CDK4 amplifications do also occur suggesting either two nonoverlapping amplification sites or else a minimal overlapping region between MDM2 and CDK4 perhaps containing another yet unknown oncogene. The frequency of amplification increased significantly from stage pTa to pT1-4 (P<0.04) and from low to high grade (P<0.005). These data are consistent with a high level of genetic instability in invasively growing and high-grade bladder tumors.	Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; Univ Basel, Urol Clin, CH-4003 Basel, Switzerland; Vysis Inc, Downers Grove, IL 60515 USA; Cantonal Hosp Liestal, Urol Clin, CH-4410 Liestal, Switzerland	University of Basel; University of Basel; Kantonsspital Baselland	Sauter, G (corresponding author), Univ Basel, Inst Pathol, Schoenbeinstr 40, CH-4003 Basel, Switzerland.	Guido.Sauter@unibas.ch		Simon, Ronald/0000-0003-0158-4258				An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; Galanis E, 1998, INT J ONCOL, V13, P717; Gamberi G, 2000, CLIN ORTHOP RELAT R, P195; Gisselsson D, 2000, GENE CHROMOSOME CANC, V28, P347; HABUCHI T, 1994, J NATL CANCER I, V86, P1331, DOI 10.1093/jnci/86.17.1331; Ioachim E, 2000, HISTOL HISTOPATHOL, V15, P721, DOI 10.14670/HH-15.721; Jahnson S, 2000, CANCER, V89, P619, DOI 10.1002/1097-0142(20000801)89:3<619::AID-CNCR18>3.3.CO;2-W; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; Kanoe H, 1998, ANTICANCER RES, V18, P2317; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Korkolopoulou P, 1997, PATHOL RES PRACT, V193, P767, DOI 10.1016/S0344-0338(97)80055-6; LIANES P, 1994, J NATL CANCER I, V86, P1325, DOI 10.1093/jnci/86.17.1325; Lu S, 1997, CANCER RES, V57, P4511; Masciullo V, 1997, INT J CANCER, V74, P390, DOI 10.1002/(SICI)1097-0215(19970822)74:4<390::AID-IJC5>3.0.CO;2-Q; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Mostofi FK, 1973, HISTOLOGICAL TYPING; Oya M, 1998, JPN J CANCER RES, V89, P719, DOI 10.1111/j.1349-7006.1998.tb03276.x; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; Pfister C, 1999, CLIN CANCER RES, V5, P4079; Pfister C, 2000, INT J CANCER, V89, P100, DOI 10.1002/(SICI)1097-0215(20000120)89:1<100::AID-IJC16>3.3.CO;2-H; Pilotti S, 2000, BRIT J CANCER, V82, P1271; Reed SI, 1997, CANCER SURV, V29, P7; Reifenberger G, 1996, CANCER RES, V56, P5141; Richter J, 1999, CANCER RES, V59, P5687; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1; Richter J, 1997, CANCER RES, V57, P2860; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; SchmitzDrager BJ, 1997, EUR UROL, V32, P487; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Shiina H, 1999, ONCOLOGY-BASEL, V56, P239, DOI 10.1159/000011971; Simon R, 2000, INT J ONCOL, V17, P1025; Simon R, 1998, J PATHOL, V185, P345; Takano Y, 1999, J CANCER RES CLIN, V125, P505, DOI 10.1007/s004320050309; UICC/AJCC, 1997, TNM CLASS MAL TUM; VOORTER C, 1995, AM J PATHOL, V146, P1341; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; Wolf M, 1997, GENE CHROMOSOME CANC, V18, P66, DOI 10.1002/(SICI)1098-2264(199701)18:1<66::AID-GCC8>3.0.CO;2-#; Zhao JM, 1999, CANCER RES, V59, P4658	46	116	119	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2476	2483		10.1038/sj.onc.1205304	http://dx.doi.org/10.1038/sj.onc.1205304			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971182				2022-12-28	WOS:000174918400004
J	Janz, C; Susse, S; Wiesmuller, L				Janz, C; Susse, S; Wiesmuller, L			p53 and recombination intermediates: role of tetramerization at DNA junctions in complex formation and exonucleolytic degradation	ONCOGENE			English	Article						exonuclease; genomic stability; mispairing; oligomerization; protein-DNA complex formation; tumor suppressor	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; BINDING DOMAIN PEPTIDES; HOLLIDAY JUNCTIONS; HUMAN RAD51; PROTEIN; REPLICATION; INSTABILITY; DAMAGE; OLIGOMERIZATION; INACTIVATION	Heteroduplex joints represent intermediates of Rad51-dependent recombination processes, which are recognized by p53 with extremely high affinities, in a manner independent of the DNA sequence content. To determine the structural elements required for complex formation, we monitored DNA-binding by protection against restriction endonuclease cleavage. We show that wild-type (wt) p53 interacts with heteroduplex joints in the proximity of the flexible junction. Association of p53 within this junction region was also observed with preformed Rad51-heteroduplex complexes, whereas SSB counteracted p53 binding. At a distance of 31 bp from the junction p53 established very few contacts with the heteroduplex, despite the presence of an A - G mismatch. Consistently, p53-dependent exonucleolytic degradation decreased when we raised the distance between the junction and the heteroduplex terminus by 27 bp. Different from the cancer-related mutant p53(273H), which did not recognize the junction, tetramerization defective p53-1262 was protection competent but displayed reduced complex stability in gel shifts. Moreover, p53-1262 performed exonucleolytic activities towards ssDNA like wtp53, but reduced degradation of heteroduplex joints. These results suggest that during recombination wild-type p53, as a tetramer, stably binds to strand transfer regions, enabling the protein to exonucleolytically correct heteroduplex intermediates early after strand invasion.	Univ Ulm, Frauenklin & Poliklin, D-89075 Ulm, Germany	Ulm University	Wiesmuller, L (corresponding author), Univ Ulm, Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.	Lisa.Wiesmueller@medizin.uni-ulm.de						Ahrendt SA, 2000, CANCER RES, V60, P2488; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Atz J, 2000, J CELL BIOCHEM, V76, P572, DOI 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Chene P, 1999, J MOL BIOL, V288, P891, DOI 10.1006/jmbi.1999.2738; Chene P, 1999, J MOL BIOL, V286, P1269, DOI 10.1006/jmbi.1999.2563; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cleaver JE, 1999, CANCER RES, V59, P1102; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Honma M, 1997, MUTAT RES-FUND MOL M, V374, P89, DOI 10.1016/S0027-5107(96)00223-0; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Janus F, 1999, MOL CELL BIOL, V19, P2155; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jean D, 1997, NUCLEIC ACIDS RES, V25, P4004, DOI 10.1093/nar/25.20.4004; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Pham P, 2001, NATURE, V409, P366, DOI 10.1038/35053116; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Schwartz JL, 1999, RADIAT RES, V151, P385, DOI 10.2307/3579824; SHAKKED Z, 2000, J BIOMOL STRUCT DYN; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Tarunina M, 1996, ONCOGENE, V13, P589; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; Zotchev SB, 2000, NUCLEIC ACIDS RES, V28, P4005, DOI 10.1093/nar/28.20.4005	51	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2130	2140		10.1038/sj.onc.1205292	http://dx.doi.org/10.1038/sj.onc.1205292			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948396				2022-12-28	WOS:000174555300002
J	Lottin, S; Vercoutter-Edouart, AS; Adriaenssens, E; Czeszak, X; Lemoine, J; Roudbaraki, M; Coll, J; Hondermarck, H; Dugimont, T; Curgy, JJ				Lottin, S; Vercoutter-Edouart, AS; Adriaenssens, E; Czeszak, X; Lemoine, J; Roudbaraki, M; Coll, J; Hondermarck, H; Dugimont, T; Curgy, JJ			Thioredoxin post-transcriptional regulation by H19 provides a new function to mRNA-like non-coding RNA	ONCOGENE			English	Article						H19 gene; non-coding RNA; riboregulator; proteomic; thioredoxin; oncogene	REDOX REGULATION; POSSIBLE ASSOCIATION; GENE-EXPRESSION; IMPRINTED H19; TRANSCRIPT; CARCINOMA; ANTISENSE; RECEPTOR; PRODUCT; OVEREXPRESSION	Classically, the functional product of coding genes is a protein whose synthesis is directed by an mRNA-template. However, in the last few years several genes yielding an mRNA-like non-coding RNA as a functional product have been identified. In most cases these transcripts are synthesized by the RNA polymerase II, capped, spliced and polyadenylated, like classical mRNA. These latter have non-conserved open reading frames and seem to be untranslated. Consequently, it has been proposed and admitted that these genes act at the RNA level, and are so-called 'riboregulators'. H19 belongs to this class of gene and its role remains a matter of debate: for some authors it is an oncogene, for others a tumour suppressor. Here, we demonstrate, using a proteomic approach, that an H19 overexpression in human cancerous mammary epithelial cells stably transfected with genomic DNA containing the entire H19 gene is responsible for positively regulating at the post-transcriptional level the thioredoxin, a key protein of the cellular redox metabolism. Interestingly, this protein accumulates in many cancerous tissues, such as breast carcinomas in which we have also demonstrated an overexpression of the H19 gene.	USTL, UPRES EA 1033, Dev Biol Lab, F-59655 Villeneuve Dascq, France; Lab Immunopathol Cellulaire Malad Infect, UMR 8527, F-59021 Lille, France; USTL, CNRS, UMR 8576, Chim Biol Lab, F-59655 Villeneuve Dascq, France; USTL, INSERM 9938, Lab Physiol & Physiopathol Prostate Humaine, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Curgy, JJ (corresponding author), USTL, UPRES EA 1033, Dev Biol Lab, SN3, F-59655 Villeneuve Dascq, France.	curgy@univ-lille1.fr	lemoine, jerome/C-4272-2014	lemoine, jerome/0000-0002-5497-6880; Vercoutter-Edouart, Anne-Sophie/0000-0002-3243-7122; Morad, Roudbaraki/0000-0001-5751-3323				Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3; Adriaenssens E, 1999, ONCOGENE, V18, P4460, DOI 10.1038/sj.onc.1202819; Ariel I, 1997, J CLIN PATHOL-MOL PA, V50, P34, DOI 10.1136/mp.50.1.34; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOUCRASY S, 1993, INT J ONCOL, V2, P753; Dugimont T, 1995, BIOL CELL, V85, P117, DOI 10.1016/0248-4900(96)85272-5; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; Erdmann VA, 2000, NUCLEIC ACIDS RES, V28, P197, DOI 10.1093/nar/28.1.197; Erdmann VA, 2001, NUCLEIC ACIDS RES, V29, P189, DOI 10.1093/nar/29.1.189; Ferret PJ, 2000, BIOCHEM J, V346, P759, DOI 10.1042/0264-6021:3460759; FUJII S, 1991, CANCER, V68, P1583, DOI 10.1002/1097-0142(19911001)68:7<1583::AID-CNCR2820680720>3.0.CO;2-N; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; Grogan TM, 2000, HUM PATHOL, V31, P475, DOI 10.1053/hp.2000.6546; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Joubel A, 1996, CELL MOL BIOL, V42, P1159; Juan V, 2000, NUCLEIC ACIDS RES, V28, P1221, DOI 10.1093/nar/28.5.1221; Kawahara N, 1996, CANCER RES, V56, P5330; Kelley RL, 2000, CELL, V103, P9, DOI 10.1016/S0092-8674(00)00099-4; KONDO M, 1995, ONCOGENE, V10, P1193; Lease RA, 1998, P NATL ACAD SCI USA, V95, P12456, DOI 10.1073/pnas.95.21.12456; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Milligan L, 2000, ONCOGENE, V19, P5810, DOI 10.1038/sj.onc.1203965; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Ueno M, 2000, IMMUNOL LETT, V75, P15, DOI 10.1016/S0165-2478(00)00284-4; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Vercoutter-Edouart AS, 2001, EXP CELL RES, V262, P59, DOI 10.1006/excr.2000.5066; Wevrick R, 1997, HUM MOL GENET, V6, P325, DOI 10.1093/hmg/6.2.325; Wilkin F, 2000, EUR J BIOCHEM, V267, P4020, DOI 10.1046/j.1432-1327.2000.01438.x; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	49	41	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1625	1631		10.1038/sj.onc.1205233	http://dx.doi.org/10.1038/sj.onc.1205233			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896592				2022-12-28	WOS:000173956800019
J	Wiest, T; Schwarz, E; Enders, C; Flechtenmacher, C; Bosch, FX				Wiest, T; Schwarz, E; Enders, C; Flechtenmacher, C; Bosch, FX			Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control	ONCOGENE			English	Article						human papillomavirus; head and neck cancer; p53; pRb; E6; E7 oncogenes	HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL-CANCER; MEDIATED PCR; DNA; CARCINOMA; INFECTION; SEQUENCES; AMPLIFICATION; MUTATIONS; OVEREXPRESSION	We have identified parameters which define a causal role of HPV16 in head and neck cancer. Twenty-eight tumours which were typed positive for HPV16 DNA, were comprehensively analysed for expression of the viral oncogenes E6 and E7, the status of the p53 gene, and the protein status of pRb and p16(INK4a). In a subset of cases, we have searched for integrated viral DNA, and have determined the genomic status of the E6 gene. Expression of E6/E7 was found in 12 tumours most of which were derived from the oropharynx, whereas p53 mutations were present in 13 tumours from various sites. The tumours either carried p53 mutations but did not express E6/E7, or they did express E6/E7 but were p53-wild-type. Coexistence of E6/E7 expression with a mutated p53 was found in only one case. Strikingly, in most p53-mutated tumours without E6/E7 expression, we found the E6 gene to be disrupted. E6/E7 expression was associated with reduced pRb and overexpressed p16(INK4a). Viral-cellular fusion transcripts were found in two cases. Our data demonstrate that HPV16 DNA-positivity in head and neck cancers is not indicative of a causal role. A causal role of HPV16 in head and neck cancer is defined by: E6/E7 expression, viral integration with an intact E6 gene, and perturbation of pRb cell cycle control. Mostly, the p53 gene is wild-type.	Univ Hals Nasen Ohrenklin, Mol Biol Lab, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Bosch, FX (corresponding author), Univ Hals Nasen Ohrenklin, Mol Biol Lab, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Franz_Bosch@med.uni-heidelberg.de						Andl T, 1998, CANCER RES, V58, P5; BARTEN M, 1995, VIRCHOWS ARCH, V427, P153; BERUMEN J, 1994, INT J CANCER, V56, P640, DOI 10.1002/ijc.2910560506; Chiba I, 1996, ONCOGENE, V12, P1663; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DEVILLIERS EM, 1985, INT J CANCER, V36, P575, DOI 10.1002/ijc.2910360510; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; Erber R, 1998, ONCOGENE, V16, P1671, DOI 10.1038/sj.onc.1201690; FUJITA M, 1992, CANCER RES, V52, P5323; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gruttgen A, 2001, J PATHOL, V194, P311, DOI 10.1002/path.906; Harrington JJ, 2001, NAT BIOTECHNOL, V19, P440, DOI 10.1038/88107; He D, 1997, INT J CANCER, V72, P959; HOPPESEYLER F, 1994, MOL CARCINOGEN, V10, P134, DOI 10.1002/mc.2940100304; JACOBS MV, 1995, J CLIN MICROBIOL, V33, P901, DOI 10.1128/JCM.33.4.901-905.1995; KAHN T, 1994, CANCER RES, V54, P1305; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Klaes R, 1999, CANCER RES, V59, P6132; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; MAITLAND NJ, 1987, BRIT J CANCER, V56, P245, DOI 10.1038/bjc.1987.185; MATSUKURA T, 1989, VIROLOGY, V172, P63, DOI 10.1016/0042-6822(89)90107-4; MILDELANGOSCH K, 1995, INT J CANCER, V63, P639, DOI 10.1002/ijc.2910630507; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Rassekh CH, 1998, LARYNGOSCOPE, V108, P362, DOI 10.1097/00005537-199803000-00010; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Scholes AGM, 1997, INT J CANCER, V71, P796, DOI 10.1002/(SICI)1097-0215(19970529)71:5<796::AID-IJC17>3.0.CO;2-6; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SNIJDERS PJF, 1992, INT J CANCER, V51, P845, DOI 10.1002/ijc.2910510602; STEENBERGEN RDM, 1995, CANCER RES, V55, P5465; van Houten VMM, 2001, INT J CANCER, V93, P232, DOI 10.1002/ijc.1313; VANDENBRULE AJC, 1989, J MED VIROL, V29, P20, DOI 10.1002/jmv.1890290105; Wilczynski SP, 1998, AM J PATHOL, V152, P145; YEUDALL WA, 1991, J GEN VIROL, V72, P173, DOI 10.1099/0022-1317-72-1-173; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	40	285	297	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1510	1517		10.1038/sj.onc.1205214	http://dx.doi.org/10.1038/sj.onc.1205214			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896579				2022-12-28	WOS:000173956800006
J	Shimada, H; Liu, TL; Ochiai, T; Shimizu, T; Haupt, Y; Hamada, H; Abe, T; Oka, M; Takiguchi, M; Hiwasa, T				Shimada, H; Liu, TL; Ochiai, T; Shimizu, T; Haupt, Y; Hamada, H; Abe, T; Oka, M; Takiguchi, M; Hiwasa, T			Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells	ONCOGENE			English	Article						p33(ING1); p53; gene therapy; esophageal cancer; Mdm2	CYSTEINE PROTEINASE-INHIBITORS; CANDIDATE TUMOR-SUPPRESSOR; CYCLIN-DEPENDENT KINASES; NIH3T3 MOUSE FIBROBLASTS; P53 GENE; RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; GROWTH CONTROL; MESSENGER-RNA; CANCER-CELLS	To investigate the effect of p33(ING1) on wild-type p53 gene therapy, T.Tn human esophageal carcinoma cells were stably transfected with p33(ING1) cDNA. Infection with Adp53 (recombinant adenovirus containing wild-type p53) into p33-transfected cells reduced cell viability, while infection with empty vector had little effect. This reduced viability was shown to be due to apoptotic cell death by the TUNEL (terminal deoxynucleotidyl transferase-mediated nick end-labeling) assay. Following infection with Ad-p53, levels of p53 were similar in p33-expressing cells and in the parental tine. However, levels of p21 and Mdm2 were elevated in p33-transfected cells. Nonetheless, this enhanced expression of Mdm2 appeared to be ineffective in downregulating p53. Transient transfection with mutant Mdm2 prior to Ad-p53 infection provided a significant protection as compared with cells transfected with wild-type Mdm2. These results imply a synergistic effect between p33 and p53 in the induction of apoptosis of human esophageal carcinoma cells. A role for Mdm2 in this synergism is suggested.	Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Acad Dept Surg, Chuo Ku, Chiba 2608670, Japan; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Sapporo Med Univ, Dept Mol Med, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Yamaguchi Univ, Sch Med, Dept Surg 2, Yamaguchi 7558505, Japan	Chiba University; Chiba University; Hebrew University of Jerusalem; Sapporo Medical University; Yamaguchi University	Hiwasa, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	hiwasa@med.m.chiba-u.ac.jp		Haupt, Ygal/0000-0001-5925-0096				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; ASCHELE C, 1992, CANCER RES, V52, P1855; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; Bargou RC, 1996, J EXP MED, V183, P1205, DOI 10.1084/jem.183.3.1205; BENNETT WP, 1992, CANCER RES, V52, P6092; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chang YC, 2000, ONCOGENE, V19, P4713, DOI 10.1038/sj.onc.1203833; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LS, 2001, CANCER RES, V61, P4345; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Cheung KJ, 2001, CANCER RES, V61, P4974; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GORCZYCA W, 1992, INT J ONCOL, V1, P639; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Gunduz M, 2000, CANCER RES, V60, P3143; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Helbing CC, 1997, CANCER RES, V57, P1255; Hiwasa T, 1996, INT J ONCOL, V8, P125; Hiwasa T, 1996, J BIOL CHEM, V271, P9181, DOI 10.1074/jbc.271.16.9181; HIWASA T, 1987, CANCER RES, V47, P953; Hiwasa T, 1996, CANCER LETT, V99, P87, DOI 10.1016/0304-3835(95)04041-2; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HOUGHTON JA, 1986, BIOCHEM PHARMACOL, V35, P1351, DOI 10.1016/0006-2952(86)90281-9; Hsing A, 2000, J BIOL CHEM, V275, P26024, DOI 10.1074/jbc.M002455200; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kobayashi S, 1999, AM J SURG, V177, P497, DOI 10.1016/S0002-9610(99)00085-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; MIYASHITA T, 1995, CELL, V80, P293; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NABEYA Y, 1995, INT J CANCER, V64, P37, DOI 10.1002/ijc.2910640109; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohmori M, 1999, AM J HEMATOL, V62, P118; OKA M, 1995, J INTERF CYTOK RES, V15, P1005, DOI 10.1089/jir.1995.15.1005; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Oki E, 1999, CANCER LETT, V147, P157, DOI 10.1016/S0304-3835(99)00288-8; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimada H, 2001, SURG TODAY, V31, P597, DOI 10.1007/s005950170093; Shinoura N, 1999, CANCER RES, V59, P5521; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Takahashi K., 1990, JPN J ORAL MAXILLOFA, V36, P307; Tokunaga E, 2000, CANCER LETT, V152, P15, DOI 10.1016/S0304-3835(99)00434-6; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	71	40	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1208	1216		10.1038/sj.onc.1205176	http://dx.doi.org/10.1038/sj.onc.1205176			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850840				2022-12-28	WOS:000173729400008
J	Engedal, N; Korkmaz, CG; Saatcioglu, F				Engedal, N; Korkmaz, CG; Saatcioglu, F			C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP	ONCOGENE			English	Article						prostate cancer; apoptosis; MAPKs; JNK; caspases	ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; NH2-TERMINAL KINASE; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; T-LYMPHOCYTES; STRESS; DEATH; JNK; INHIBITION	In early, androgen dependent stages of prostate cancer, androgen withdrawal, the major course of therapy in prostate cancer, leads to a rapid regression of the tumor as a result of apoptosis. However, prostate cancer invariably progresses to an androgen independent and apoptosis resistant stage for which no curative treatment is available. The molecular details of regression upon androgen withdrawal and progression to a resistant state are largely unknown. Here we show that c-Jun N-terminal Kinase (JNK) is activated strongly and in a sustained fashion by 12-O-tetradecanoylphorbol 13-acetate (TPA) and thapsigargin (TG), two agents which were previously shown to lead to apoptosis in the androgen responsive prostate cancer cell line LNCaP. The time course of JNK induction by both compounds correlated very well with the onset and progression of apoptosis in LNCaP cells. Inhibition of either ERK or p38 pathways did not affect TPA-induced cell death. In the androgen-independent prostate cancer cell lines DU-145 and PC-3, and in the cervical carcinoma cell line HeLaS3, TPA did not lead to apoptosis and there were no significant changes in JNK activity upon TPA treatment. The failure of TPA to induce JNK activity in PC-3, DU-145, and HelaS3 cells was not due to a general defect in JNK signaling since ultraviolet (UV) irradiation dramatically increased JNK activity in all four cell lines. Specific inhibition of JNK by expression of the JNK Inhibitory Protein (JIP) dramatically inhibited both TPA- and TG-induced apoptosis. Furthermore, apoptosis induced by both agents was completely blocked by ectopic expression of the baculovirus caspase-inhibitor P35. Surprisingly, zVAD-fmk, a cell-permeable fluoromethylketone inhibitor of caspases, had no effect on TPA-induced apoptosis, whereas it completely inhibited TG-induced cell death; JNK activity was not affected in either case. This indicates that zVAD-fmk does not inhibit some of the caspases involved in TPA-induced apoptosis, and that despite the common requirement of JNK activation, TPA- and TG-induced cell death are mechanistically different. Furthermore, it also suggests that JNK is either upstream or independent of caspases in LNCaP cells. Collectively, these results indicate that apoptosis in LNCaP cells requires a sustained increase in JNK activity and caspase activation; components of these signaling pathways may be defective in the androgen independent prostate cancer cell lines.	Univ Oslo, Biotechnol Ctr Oslo, N-0349 Oslo, Norway; Univ Oslo, Dept Biochem, N-0349 Oslo, Norway; Univ Oslo, Inst Clin Med, N-0349 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Saatcioglu, F (corresponding author), Univ Oslo, Biotechnol Ctr Oslo, Gaustadalleen 21, N-0349 Oslo, Norway.		Engedal, Nikolai/AAJ-8951-2020	Engedal, Nikolai/0000-0003-3718-3464				Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Araki S, 1997, KIDNEY INT, V51, P631, DOI 10.1038/ki.1997.92; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Fronsdal K, 2000, PROSTATE, V43, P111, DOI 10.1002/(SICI)1097-0045(20000501)43:2<111::AID-PROS5>3.0.CO;2-4; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Garzotto M, 1998, CANCER RES, V58, P2260; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, CANCER RES, V1, P293; ISAACS JT, 1994, VITAM HORM, V49, P433; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KINZEL V, 1988, CANCER RES, V48, P1759; Kuroki DW, 1996, CANCER RES, V56, P637; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Magi-Galluzzi C, 1998, VIRCHOWS ARCH, V432, P407, DOI 10.1007/s004280050184; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Marcelli M, 1999, CANCER RES, V59, P382; McConkey DJ, 1996, CANCER RES, V56, P5594; Miller LK, 1997, J CELL PHYSIOL, V173, P178, DOI 10.1002/(SICI)1097-4652(199711)173:2<178::AID-JCP17>3.3.CO;2-Z; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Montironi R, 1998, UROL INT, V60, P25, DOI 10.1159/000056542; Moore RA, 1944, SURGERY, V16, P152; Nagahara A, 1998, AM J PHYSIOL-GASTR L, V275, pG740, DOI 10.1152/ajpgi.1998.275.4.G740; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Shrode LD, 1997, J BIOL CHEM, V272, P13653, DOI 10.1074/jbc.272.21.13653; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Stattin P, 1998, BRIT J CANCER, V77, P670, DOI 10.1038/bjc.1998.107; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; YOUNG CYF, 1994, ONCOL RES, V6, P203; Zhang PS, 1996, J NEUROSCI RES, V46, P114, DOI 10.1002/(SICI)1097-4547(19961001)46:1<114::AID-JNR14>3.0.CO;2-5; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V	63	48	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1017	1027		10.1038/sj.onc.1205167	http://dx.doi.org/10.1038/sj.onc.1205167			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850819				2022-12-28	WOS:000173580100005
J	Takata, M; Tachiiri, S; Fujimori, A; Thompson, LH; Miki, Y; Hiraoka, M; Takeda, S; Yamazaoe, M				Takata, M; Tachiiri, S; Fujimori, A; Thompson, LH; Miki, Y; Hiraoka, M; Takeda, S; Yamazaoe, M			Conserved domains in the chicken homologue of BRCA2	ONCOGENE			English	Article						BRCA2; homologous recombination; Rad51; BRC repeat	DNA RECOMBINATION; RADIATION HYPERSENSITIVITY; GENE; RAD51; REPAIR; MICE; EXPRESSION; REPEATS; IDENTIFICATION; CHECKPOINT	Germline mutation of the BRCA2 gene causes a high risk of developing breast and ovarian cancer. Although the BRCA2 protein has been implicated in homologous recombination (HR) of DNA and in transcription, it is still unclear how mutation leads to tumorigenesis. We have identified a nonmammalian homologue of BRCA2 from chicken, which encodes a protein with 3397 amino acids (aa) and shows only 40% identity to human BRCA2. However, comparison of the mammalian and chicken sequences revealed remarkably high homology in several segments. These include a N-terminal region (similar to100 aa), which was previously shown to possess intrinsic transcriptional activity, and a C-terminal region (aa residue similar to2480-similar to3180 in human BRCA2), which has not been clearly assigned any function. In contrast, although the eight BRC repeats of mammalian BRCA2 are believed to play an important role in HR by interacting with Rad51, the BRC3, BRC5, and BRC6 repeats exhibit virtually no similarity to their mammalian counterparts. Among 311 missense mutations listed as unclassified variants in the NIH Breast Cancer Information Core database, only 83 of these sites are identical in chicken BRCA2. Thus, chicken BRCA2 may provide a means to identify domains and residues associated with cancer predisposition.	Kawasaki Med Sch, Dept Immunol & Mol Genet, Kurashiki, Okayama 7010192, Japan; Kyoto Univ, Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Sch Med, Dept Therapeut Radiol & Oncol, Sakyo Ku, Kyoto 6068507, Japan; Lawrence Livermore Natl Lab, BBR Program, Livermore, CA 94551 USA; Japanese Fdn Canc Res, Toshima Ku, Tokyo 1708640, Japan	Kawasaki Medical School; Kyoto University; Kyoto University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Japanese Foundation for Cancer Research	Takata, M (corresponding author), Kawasaki Med Sch, Dept Immunol & Mol Genet, 577 Matsushima, Kurashiki, Okayama 7010192, Japan.	mtakata@med.kawasaki-m.ac.jp		Takata, Minoru/0000-0002-4926-3675; Takeda, Shunichi/0000-0002-7924-7991				Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen CH, 1998, HUM MUTAT, V11, P328; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Friedman LS, 1998, CANCER RES, V58, P1338; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Futamura M, 2000, CANCER RES, V60, P1531; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; McAllister KA, 1997, CANCER RES, V57, P3121; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Morimatsu M, 1998, CANCER RES, V58, P3441; Morrison C, 2000, INT J BIOCHEM CELL B, V32, P817, DOI 10.1016/S1357-2725(00)00033-9; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Orelli BJ, 2001, ONCOGENE, V20, P4433, DOI 10.1038/sj.onc.1204485; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 2001, PHILOS T ROY SOC B, V356, P111, DOI 10.1098/rstb.2000.0755; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Wagner TMU, 1999, HUM MOL GENET, V8, P413, DOI 10.1093/hmg/8.3.413; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	37	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1130	1134		10.1038/sj.onc.1205168	http://dx.doi.org/10.1038/sj.onc.1205168			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850831				2022-12-28	WOS:000173580100017
J	Valenzuela, MT; Guerrero, R; Nunez, MI; de Almodovar, JMR; Sarker, M; de Murcia, G; Oliver, FJ				Valenzuela, MT; Guerrero, R; Nunez, MI; de Almodovar, JMR; Sarker, M; de Murcia, G; Oliver, FJ			PARP-1 modifies the effectiveness of p53-mediated DNA damage response	ONCOGENE			English	Article						PARP-1; p53-mediated DNA damage response; ionising radiation; alkylating agent	POLY(ADP-RIBOSE) POLYMERASE GENE; IONIZING-RADIATION; EXCISION-REPAIR; MICE RESISTANT; CELL-LINES; P53; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; MDM2	The tumour supressor protein p53 plays a key role in the cell's decision to arrest the cell cycle or undergo apoptosis following a genotoxic insult. p53 is stabilized and activated after DNA damage, however the cascade of events signalling from DNA lesions to p53 stabilization and activation is still controversial. Poly (ADP-ribosylation) of different nuclear acceptors by PARP-1 is an early event when a single strand DNA lesion is produced. We present here evidences that interplay between PARP-1 and p53 is dependent on the type of damage induced to DNA. Primary mouse embryonic fibroblasts derived from parp-1-/- mice exhibited decreased p53 accumulation and activation following gamma-irradiation compared to parp-1 proficient cells. On the other hand. treatment with the single alklating agent 2'-methyl-2'-nitrose-urea (MNU), resulted in the rapid and sustained accumulation and activation of p53 in parp-1-deficient cells, while very little accumulation was observed in parp-1 +/+ cells. After IR, the turnover of the p53 inhibitory protein MDM-2 is perturbed and the level of phosphorylation of p53 at serine-15 is blunted in parp-1-/- cells. PARP-1 is determinant in the cytotoxic response to alkylating agents but only partially contributes to radiation-induced cell killing, as determined by colony forming assay. Altogether, these results suggest that PARP-1 participates in the p53 response following irradiation, resides upstream of p53 and indirectly modulates the level of phosphorylation of key substrates in this pathway while treatment with MNU results in an enhanced p53-mediated response in parp-1-null cells.	Hosp Univ San Cecilio, Unidad Mixta Invest Med, Granada 18012, Spain; Univ Granada, Fac Med, Dept Radiol, Granada 18012, Spain; CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Univ Louis Pasteur Strasbourg 1, Ecole Super Biotechnol, CNRS, UPR 9003, F-67400 Illkirch Graffenstaden, France	Hospital Universitario San Cecilio; University of Granada; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Oliver, FJ (corresponding author), Hosp Univ San Cecilio, Unidad Mixta Invest Med, Avda Dr Oloriz 16, Granada 18012, Spain.		Oliver, Javier/S-1725-2018; Núñez, María Isabel/L-9924-2014	Oliver, Javier/0000-0001-8468-1998; Núñez, María Isabel/0000-0001-8159-7969; Ruiz De Almodovar Rivera, Jose Mariano/0000-0002-7053-1072				Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beneke R, 2000, MOL CELL BIOL, V20, P6695, DOI 10.1128/MCB.20.18.6695-6703.2000; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CURTIS SB, 1986, RADIAT RES, V106, P252, DOI 10.2307/3576798; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEALMODOVAR JMR, 1994, BRIT J CANCER, V69, P457, DOI 10.1038/bjc.1994.83; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Fernet M, 2000, INT J RADIAT BIOL, V76, P1621, DOI 10.1080/09553000050201118; Freedman DA, 1999, CANCER RES, V59, P1; HALL EJ, 1994, RADIOBIOLOGY RADIOLO, P29; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Menissier De Murcia Josiane, 1997, Proceedings of the National Academy of Sciences of the United States of America, V94, P7303; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oliver FJ, 1999, AM J HUM GENET, V64, P1282, DOI 10.1086/302389; OLSON DC, 1993, ONCOGENE, V8, P2353; Schlicker A, 1999, INT J RADIAT BIOL, V75, P91, DOI 10.1080/095530099140843; STEEL GG, 1997, BASIC CLIN RADIOBIOL, P52; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wang YX, 1998, PANCREAS, V17, P289, DOI 10.1097/00006676-199810000-00011; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	37	101	104	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1108	1116		10.1038/sj.onc.1205169	http://dx.doi.org/10.1038/sj.onc.1205169			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850828				2022-12-28	WOS:000173580100014
J	Leonard, JR; D'Sa, C; Klocke, BJ; Roth, KA				Leonard, JR; D'Sa, C; Klocke, BJ; Roth, KA			Neural precursor cell apoptosis and glial tumorigenesis following transplacental ethyl-nitrosourea exposure	ONCOGENE			English	Article						p53; astrocytoma; Bcl-X-L; programmed cell death	CENTRAL-NERVOUS-SYSTEM; BCL-X; NEUROGENIC TUMORS; BRAIN-TUMORS; STEM-CELLS; DEATH; P53; NEURONS; MICE; BAX	Neural precursor cells (NPCs) populate the embryonic ventricular zone and persist in the subependymal zone of the adult brain. We hypothesized that hereditary and/or acquired mutations in apoptosis-associated genes, such as p53 and caspases, may protect NPCs from DNA damage-induced death and predispose them to subsequent neoplastic transformation. To test this hypothesis, we exposed NPCs from wild-type and targeted gene-disrupted mouse embryos (p53, caspase-9, caspase-3, and bax mutants) to ethyl-nitrosourea (ENU), a known DNA mutagen and neural carcinogen, and measured NPC viability. We found that ENU produced caspase-3 activation and apoptotic NPC death 6-24 h after administration both in vivo and in vitro. This effect was critically dependent on p53 and caspase-9 expression. The long-term effect of intrauterine ENU exposure was examined in control and p53-deficient mice. High grade glial tumors were found in 60% of p53(-/-) young adult mice exposed to ENU on gestational day 12.5 but not in p53(+/-) or P53(+/+) littermates or in untreated p53-deficient mice. All the tumors were located supratentorially and possessed strong immunoreactivity for glial fibrillary acidic protein and the anti-apoptotic molecule Bcl-X-L. These results suggest that intrauterine exposure of NPCs to certain DNA damaging agents may synergistically interact with specific genetic abnormalities (e.g. p53 deficiency) to produce glial neoplasms in the adult brain.	Washington Univ, Sch Med, Dept Pathol & Immunol, Div Neuropathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Roth, KA (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Div Neuropathol, 660 S Euclid Ave,Box 8118, St Louis, MO 63110 USA.	kroth@pathology.wustl.edu		Roth, Kevin/0000-0002-0643-995X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007296] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Armstrong RC, 1997, J NEUROSCI, V17, P553; BILZER T, 1989, NEUROTOXICOL TERATOL, V11, P551, DOI 10.1016/0892-0362(89)90036-6; Bruggers CS, 1999, J PEDIAT HEMATOL ONC, V21, P19, DOI 10.1097/00043426-199901000-00005; D'Sa-Eipper C, 2000, DEV NEUROSCI-BASEL, V22, P116, DOI 10.1159/000017433; D'Sa-Eipper C, 2001, DEVELOPMENT, V128, P137; DIWAN BA, 1974, CANCER RES, V34, P764; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; DRUCKREY H, 1966, NATURE, V210, P1378, DOI 10.1038/2101378a0; Eves EM, 1996, J NEUROCHEM, V67, P1908; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Haydar TF, 2000, J NEUROSCI, V20, P5764, DOI 10.1523/JNEUROSCI.20-15-05764.2000; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Johnson MD, 1999, J NEUROSCI, V19, P2996; Kleihues P., 2000, PATHOLOGY GENETICS T, P29; Klein MA, 2000, ONCOGENE, V19, P5329, DOI 10.1038/sj.onc.1203941; Krajewski S, 1997, AM J PATHOL, V150, P805; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Oda H, 1997, CANCER RES, V57, P646; Oppenheim RW, 2001, J NEUROSCI, V21, P4752, DOI 10.1523/JNEUROSCI.21-13-04752.2001; Rao MS, 1999, ANAT RECORD, V257, P137; Roth KA, 2000, P NATL ACAD SCI USA, V97, P466, DOI 10.1073/pnas.97.1.466; SCHLEGEL J, 1994, EXP TOXICOL PATHOL, V45, P455, DOI 10.1016/S0940-2993(11)80504-X; Shindler KS, 1997, J NEUROSCI, V17, P3112; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Stiles CD, 1998, BBA-REV CANCER, V1377, pR1, DOI 10.1016/S0304-419X(97)00030-9; TIMME TL, 1994, BIOTECHNIQUES, V17, P460; Watanabe K, 1997, CLIN CANCER RES, V3, P523; Wechsler W, 1979, Natl Cancer Inst Monogr, P219; WECHSLER W, 1969, ANN NY ACAD SCI, V159, P360, DOI 10.1111/j.1749-6632.1969.tb48291.x; Zaidi AU, 2001, J NEUROSCI, V21, P169, DOI 10.1523/JNEUROSCI.21-01-00169.2001; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	38	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2001	20	57					8281	8286		10.1038/sj.onc.1205024	http://dx.doi.org/10.1038/sj.onc.1205024			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781843				2022-12-28	WOS:000172507800012
J	Han, XS; Stewart, JE; Bellis, SL; Benveniste, EN; Ding, Q; Tachibana, K; Grammer, JR; Gladson, CL				Han, XS; Stewart, JE; Bellis, SL; Benveniste, EN; Ding, Q; Tachibana, K; Grammer, JR; Gladson, CL			TGF-beta 1 up-regulates paxillin protein expression in malignant astrocytoma cells: requirement for a fibronectin substrate	ONCOGENE			English	Article						paxillin; TGF-beta 1; fibronectin; integrin alpha 5 beta 1; astrocytoma; astrocytes; glioma; glioblastoma	INTEGRIN; GENE; VITRONECTIN; ACTIVATION; SENESCENCE; MOLECULES; COMPLEX; DOCK180; KINASE; HIC-5	Cytokines can influence the interactions between members of the integrin cell adhesion receptor family and the extracellular matrix thereby potentially affecting cell function and promoting cell adhesion, growth and migration of malignant astrocytoma tumor cells. As malignant astrocytoma cells synthesize TGF-beta1 in vivo, we analysed the effects of TGF-beta1 on signaling events associated with integrin receptor ligation, focusing on the effects on paxillin, a phosphorylated adaptor protein, that acts as a scaffold for signaling molecules recruited to focal adhesions. TGF-beta1 -stimulation of primary astrocytes and serum-starved U-251MG malignant astrocytoma cells attached to fibronectin induced a substantial increase in the levels of paxillin protein (fivefold increase at 2.0 ng/ml) in a dose- and time-dependent manner compared to the levels observed on plating onto fibronectin in the absence of stimulation. In the astrocytoma cells, this resulted in an increase in the pool of tyrosine-phosphorylated paxillin, although it did not appear to alter the extent of phosphorylation of the paxillin molecules. In contrast, in primary astrocytes the protein levels were upregulated in the absence of a parallel increase in phosphorylation. The TGF-beta1-stimulated increase in paxillin levels required ligation of the fibronectin receptor, as it was not induced when the cells were plated onto vitronectin, collagen or laminin. The increase in the pool of paxillin on TGF-beta1 stimulation of the fibronectin-plated astrocytoma cells was associated with an increase in translation, but was not associated with an increase in the steady-state levels of paxillin mRNA. Stimulation with TGF-beta1 on a fibronectin substrate increased subsequent attachment and spreading of U-251MG cells onto fibronectin and, to a lesser extent, vitronectin, but not collagen. Our results indicate that physiologic levels of TGF-beta1 stimulate the expression of paxillin protein at the level of translation through a process that requires engagement of the fibronectin receptor, and promotes attachment and spreading of malignant astrocytoma cells on fibronectin.	Univ Alabama, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Gladson, CL (corresponding author), Univ Alabama, Dept Pathol, Div Neuropathol, LHRB 567,701 S 19th St, Birmingham, AL 35294 USA.				NCI NIH HHS [CA59958, CA75682] Funding Source: Medline; NINDS NIH HHS [NS34856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075682, R01CA059958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENVENISTE EN, 1991, J BIOL CHEM, V266, P18119; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; GLADSON CL, 1995, J CELL SCI, V108, P947; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kjellman C, 2000, INT J CANCER, V89, P251, DOI 10.1002/1097-0215(20000520)89:3<251::AID-IJC7>3.0.CO;2-5; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Pijuan-Thompson V, 1999, EXP CELL RES, V249, P86, DOI 10.1006/excr.1999.4458; PijuanThompson V, 1997, J BIOL CHEM, V272, P2736, DOI 10.1074/jbc.272.5.2736; Riedy MC, 1999, EXP CELL RES, V251, P194, DOI 10.1006/excr.1999.4573; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Wang DY, 2000, J CELL SCI, V113, P4221; Wang HM, 2001, J CELL PHYSIOL, V187, P188, DOI 10.1002/jcp.1068; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	20	22	24	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7976	7986		10.1038/sj.onc.1204996	http://dx.doi.org/10.1038/sj.onc.1204996			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753680				2022-12-28	WOS:000172288700006
J	Im, HJ; Craig, TA; Pittelkow, MR; Kumar, R				Im, HJ; Craig, TA; Pittelkow, MR; Kumar, R			Characterization of a novel hexameric repeat DNA sequence in the promoter of the immediate early gene, IEX-1, that mediates 1 alpha,25-dihydroxyvitamin D-3-associated IEX-1 gene repression	ONCOGENE			English	Article						immediate early gene; IEX-1; VDRE; transcriptional suppression	VITAMIN-D-RECEPTOR; TRANSFORMING-GROWTH-FACTOR; RETINOID-X-RECEPTOR; PROTEIN-KINASE-C; MEMBRANE CALCIUM-PUMP; EARLY RESPONSE GENE; FACTOR-BETA 2; 1,25-DIHYDROXYVITAMIN D-3; THYROID-HORMONE; DEFICIENCIES INCREASE	1alpha,25-Dihydroxyvitamin D-3(1alpha,25(OH)(2)D-3), the active metabolite of vitamin D-3, mediates anti-proliferative effects in cells by regulating the expression of 1alpha,25(OH)(2)D-3-responsive genes. The expression of the proliferation-promoting immediate Early gene X-1 (IEX-1) is reduced by 1alpha,25(OH)(2)D-3 through unknown mechanisms. Here we report the presence of a novel inhibitory hexameric repeat DNA response element in the promoter of the human IEX-1 gene that mediates 1alpha,25(OH)(2)D-3-associated IEX-1 gene repression. To localize a vitamin D sensitive DIVA response element we transfected the keratinocyte-like cell line, HaCaT, (referred as HaCaT) with a series of plasmids containing full-length and truncated IEX-1 promoter elements fused to the luciferase reporter gene in the absence or presence of 1alpha,25(OH)(2)D-3, and we performed electrophoretic gel mobility assays in the presence of receptors for 1alpha,25(OH)(2)D-3 (vitamin D receptor, VDR) and 9-cis-retinoic acid (RXRalpha). We mapped a negative response element between nt -405 and -391(15 bp) of the IEX-1 promoter (5'-TGAACC AGG GAGTCA-3') that mediates transcriptional inhibition in response to 1alpha,25(OH)(2)D-3 and which requires expression of both nuclear receptors for 1alpha,25(OH)(2)D-3 and 9-cis-retinoic acid. Our data indicate that the physiological repression of IEX-1 gene expression by 1alpha,25(OH)(2)D-3 is directly mediated by nuclear VDR/RXRalpha heterodimers through a specific transcriptional element.	Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Kumar, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	rkumar@mayo.edu		Kumar, Rajiv/0000-0003-3497-3057	NATIONAL CANCER INSTITUTE [P30CA015083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR027032, R01AR027032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059505, R01DK058546, R01DK025409] Funding Source: NIH RePORTER; NCI NIH HHS [CA 015083] Funding Source: Medline; NIAMS NIH HHS [AR27032] Funding Source: Medline; NIDDK NIH HHS [DK58546, R01 DK025409, R01 DK058546, DK25409, DK59505] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CAI Q, 1993, P NATL ACAD SCI USA, V90, P1345, DOI 10.1073/pnas.90.4.1345; Candeliere GA, 1996, MOL CELL BIOL, V16, P584; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Craig TA, 1999, NAT BIOTECHNOL, V17, P1214, DOI 10.1038/70767; Craig TA, 1997, BIOCHEMISTRY-US, V36, P10482, DOI 10.1021/bi970561b; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; Elstner E, 1996, CANCER RES, V56, P3570; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Falzon M, 1996, MOL ENDOCRINOL, V10, P672, DOI 10.1210/me.10.6.672; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GIULIANO AR, 1991, ARCH BIOCHEM BIOPHYS, V285, P261, DOI 10.1016/0003-9861(91)90358-P; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GROSS M, 1986, J BONE MINER RES, V1, P457; Haugen JD, 1996, BIOCHEM BIOPH RES CO, V229, P618, DOI 10.1006/bbrc.1996.1853; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; Herdick M, 2000, J MOL BIOL, V304, P793, DOI 10.1006/jmbi.2000.4267; IM HJ, 2002, J BIOL CHEM     0213; ITIN PH, 1994, ENDOCRINOLOGY, V135, P1793, DOI 10.1210/en.135.5.1793; James SY, 1996, J STEROID BIOCHEM, V58, P395, DOI 10.1016/0960-0760(96)00048-9; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Koszewski NJ, 1999, MOL ENDOCRINOL, V13, P455, DOI 10.1210/me.13.3.455; Koszewski NJ, 2000, J STEROID BIOCHEM, V72, P125, DOI 10.1016/S0960-0760(00)00022-4; Kremer R, 1996, J BIOL CHEM, V271, P16310, DOI 10.1074/jbc.271.27.16310; KUMAR R, 1991, KIDNEY INT, V40, P1177, DOI 10.1038/ki.1991.332; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; Lutz W, 2000, BIOCHEM BIOPH RES CO, V271, P1, DOI 10.1006/bbrc.2000.2570; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; Mathiasen IS, 1999, CANCER RES, V59, P4848; Mehta RG, 1997, JNCI-J NATL CANCER I, V89, P212, DOI 10.1093/jnci/89.3.212; Narvaez CJ, 1997, ENDOCRINOLOGY, V138, P4690, DOI 10.1210/en.138.11.4690; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; OCONNELL TD, 1995, BIOCHEM BIOPH RES CO, V213, P59, DOI 10.1006/bbrc.1995.2098; PEEHL DM, 1994, CANCER RES, V54, P805; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS DE, 1993, ANTI-CANCER DRUG, V4, P201, DOI 10.1097/00001813-199304000-00012; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; SimboliCampbell M, 1997, BREAST CANCER RES TR, V42, P31, DOI 10.1023/A:1005772432465; SIMBOLICAMPBELL M, 1994, J BIOL CHEM, V269, P3257; Towers TL, 1998, J BIOL CHEM, V273, P10338, DOI 10.1074/jbc.273.17.10338; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; Veenstra TD, 1997, BIOCHEM BIOPH RES CO, V235, P15, DOI 10.1006/bbrc.1997.6718; Veenstra TD, 1998, BIOCHEMISTRY-US, V37, P5988, DOI 10.1021/bi972965+; Veenstra TD, 1998, NAT BIOTECHNOL, V16, P262, DOI 10.1038/nbt0398-262; Veenstra TD, 1998, J AM SOC MASS SPECTR, V9, P8, DOI 10.1016/S1044-0305(97)00229-8; WASSERMAN RH, 1992, GASTROENTEROLOGY, V102, P886, DOI 10.1016/0016-5085(92)90174-W; Wu YH, 1999, BIOCHEMISTRY-US, V38, P2654, DOI 10.1021/bi981944s; Wu YH, 1997, BIOCHEM BIOPH RES CO, V239, P734, DOI 10.1006/bbrc.1997.7544; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	64	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3706	3714		10.1038/sj.onc.1205450	http://dx.doi.org/10.1038/sj.onc.1205450			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032839				2022-12-28	WOS:000175676000006
J	Cantor, AB; Orkin, SH				Cantor, AB; Orkin, SH			Transcriptional regulation of erythropoiesis: an affair involving multiple partners	ONCOGENE			English	Article						GATA-1; FOG-1; PU.1; EKLF; transcription factor; cross-antagonism	T-CELL LEUKEMIA; ZINC-FINGER PROTEIN; FACTOR GATA-1; DNA-BINDING; MICE LACKING; ERYTHROID-DIFFERENTIATION; HEMATOPOIETIC LINEAGE; VASCULAR DEVELOPMENT; TARGETED DISRUPTION; HEART MORPHOGENESIS	Previous work has demonstrated that lineage-specific transcription factors play essential roles in red blood cell development. More recent studies have shown that these factors participate in critical protein-protein interactions in addition to binding DNA. The zinc finger transcription factor GATA-1, a central mediator of erythroid gene expression, interacts with multiple proteins including FOG-1, EKLF, SP1, CBP/p300 and PU.1. The mechanisms by which these interactions influence GATA-1 function, as well as any possible relationships between these seemingly disparate complexes, remain incompletely understood. However, several new findings have provided further insight into the functional significance of some of these interactions. Studies involving point mutants of GATA-1 have shown that a direct physical interaction between GATA-I and FOG-1 is essential for normal human erythroid and megakaryocyte maturation in vivo. In addition, evidence has emerged that physical interaction between GATA-I and the myeloid/lymphoid specific factor PU.1, an oncogene implicated in murine erythroleukemia, acts to functionally cross-antagonize one another. This provides a possible mechanism by which dysregulated expression of hematopoietic transcription factors leads to lineage maturation arrest in leukemias.	Childrens Hosp, Dept Pediat, Div Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Orkin, SH (corresponding author), Childrens Hosp, Dept Pediat, Div Hematol Oncol, Boston, MA 02115 USA.	orkin@bloodgroup.tch.harvard.edu		Cantor, Alan/0000-0002-5136-028X	NATIONAL CANCER INSTITUTE [K08CA082175] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA 82175-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BASH O, 1993, BLOOD, V86, P666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brownlie A, 1998, NAT GENET, V20, P244, DOI 10.1038/3049; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; Coghill E, 2001, BLOOD, V97, P1861, DOI 10.1182/blood.V97.6.1861; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Crispino JD, 2001, GENE DEV, V15, P839, DOI 10.1101/gad.875201; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; Fossett N, 2001, P NATL ACAD SCI USA, V98, P7342, DOI 10.1073/pnas.131215798; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Goodman RH, 2000, GENE DEV, V14, P1553; Hromas Robert, 1993, Blood, V82, P2998; Hung HL, 1999, MOL CELL BIOL, V19, P3496; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Jasinski M, 2001, BLOOD, V98, P2248, DOI 10.1182/blood.V98.7.2248; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Kung AL, 2000, GENE DEV, V14, P272; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Liao EC, 2000, DEVELOPMENT, V127, P5123; Lu JR, 1999, MOL CELL BIOL, V19, P4495; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; O'Neil J, 2001, ONCOGENE, V20, P3897, DOI 10.1038/sj.onc.1204519; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Porcher C, 1999, DEVELOPMENT, V126, P4603; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Querfurth E, 2000, GENE DEV, V14, P2515, DOI 10.1101/gad.177200; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Svensson EC, 2000, NAT GENET, V25, P353, DOI 10.1038/77146; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; Vyas P, 1999, BLOOD, V93, P2867; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	76	467	482	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3368	3376		10.1038/sj.onc.1205326	http://dx.doi.org/10.1038/sj.onc.1205326			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032775				2022-12-28	WOS:000175633300010
J	Oehler, MK; Hague, S; Rees, MCP; Bicknell, R				Oehler, MK; Hague, S; Rees, MCP; Bicknell, R			Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis	ONCOGENE			English	Article						adrenomedullin; angiogenesis; tumorigenesis; tamoxifen; endometrial cancer	INDUCIBLE FACTOR 1-ALPHA; GENE-EXPRESSION; CELL LINES; HYPOXIA; CANCER; TAMOXIFEN; ESTROGEN; MECHANISM; RECEPTOR; PEPTIDE	The angiogenic peptide adrenomedullin (ADM) has been implicated as a mediator of the increased risk of endometrial hyperplasia and cancer resulting from the use of tamoxifen for the treatment and prevention of breast cancer. ADM has been shown to be induced by tamoxifen in the endometrium and to be a growth factor for endometrial endothelial cells in vitro. We have now shown ADM to be strongly angiogenic in the mouse subcutaneous sponge angiogenesis assay. To examine the role of ADM in tumor growth, the ADM cDNA was transfected into endometrial carcinoma cells followed by xenografting into athymic mice. Two endometrial cancer cell lines were employed, those in which transfection and expression of ADM resulted in no effect on growth in vitro (Ishikawa cells) and those in which expression of exogenous ADM stimulated in virtro growth (RL95.2 cells). A clear enhancement of tumor growth was seen with both cell lines but the effect was far greater with the RL95.2 cells. We conclude that ADM is pro-tumorigenic by stimulating either angiogenesis alone or by stimulating angiogenesis and carcinoma cell growth directly. The combined activities lead to a striking increase in tumor growth. These results provide the first direct evidence of tumorigenic activity of ADM and provide further support for ADMs involvement in tamoxifen induced endometrial neoplasia.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Canc Res UK,Mol Angiogenesis Lab, Oxford OX3 9DS, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford; University of Oxford	Bicknell, R (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Canc Res UK,Mol Angiogenesis Lab, Oxford OX3 9DS, England.	r.bicknell@cancer.org.uk		Bicknell, Roy/0000-0002-0941-8919				Ali SH, 2000, CANCER RES, V60, P7094; ATTIA MAM, 1966, CANCER RES, V26, P1787; Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; Bilimoria MM, 1996, J STEROID BIOCHEM, V58, P479, DOI 10.1016/0960-0760(96)00078-7; Birner P, 2000, CANCER RES, V60, P4693; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; Cuzick J, 2000, EUR J CANCER, V36, P1298, DOI 10.1016/S0959-8049(00)00106-4; Dalton RR, 2001, SOUTH MED J, V94, P7; FOX SB, 1995, J PATHOL, V177, P275, DOI 10.1002/path.1711770310; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Hata K, 2000, MOL HUM REPROD, V6, P867, DOI 10.1093/molehr/6.10.867; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lal A, 1999, CANCER RES, V59, P5403; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Nikitenko LL, 2000, MOL HUM REPROD, V6, P811, DOI 10.1093/molehr/6.9.811; NIKITENKO LL, 2002, IN PRESS TRENDS PHAR; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; PIO R, 2000, BIOL CHEM, V486, P3; Rocchi P, 2001, CANCER RES, V61, P1196; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SUNDARESHAN P, 1992, IN VITRO CELL DEV-AN, V28A, P544; Walsh DA, 1996, HISTOCHEM J, V28, P759, DOI 10.1007/BF02272149; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; White INH, 1999, CARCINOGENESIS, V20, P1153, DOI 10.1093/carcin/20.7.1153; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213; ZHANG L, 1995, J CELL SCI, V108, P323; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768; Zhong H, 1999, CANCER RES, V59, P5830	36	94	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2815	2821		10.1038/sj.onc.1205374	http://dx.doi.org/10.1038/sj.onc.1205374			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973640				2022-12-28	WOS:000175063700005
J	Park, WS; Lee, JH; Shin, MS; Park, JY; Kim, HS; Lee, JH; Kim, YS; Lee, SN; Xiao, WH; Park, CH; Lee, SH; Yoo, NJ; Lee, JY				Park, WS; Lee, JH; Shin, MS; Park, JY; Kim, HS; Lee, JH; Kim, YS; Lee, SN; Xiao, WH; Park, CH; Lee, SH; Yoo, NJ; Lee, JY			Inactivating mutations of the caspase-10 gene in gastric cancer	ONCOGENE			English	Article						caspase-10; mutation; LOH; gastric cancer; apoptosis	FAS APO-1/CD95 GENE; DEATH DOMAIN; APOPTOSIS; LUNG; AMPLIFICATION; CARCINOMA; DELETION; LIGAND	We have analysed the genetic alteration of the entire coding region and all splice sites of caspase-8 and -10 genes in 99 gastric cancers by polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) and sequencing. We found LOH of the caspase-8 and -10 in nine (28%) of 32 and in four (15%) of 26 informative cases, respectively. Overall, three of 99 gastric cancers (3%) were found to have the caspase-10 mutations, which were identified in the coding regions of the death effector domain (codon 147) and the p17 large protease domain (codons 257 and 410), whereas no mutation was detected in caspase-8. In vitro expression studies, the M147T and Q257stop mutants severely impaired caspase-10-mediated apoptosis, whereas the V410I which was the same mutation detected in ALPS patient had a significant, albeit less severe, effect on apoptosis. The data presented here suggest that somatic alterations of the caspase-10 gene might contribute to the pathogenesis in a subset of gastric cancers through the loss of their apoptotic function.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea	Lee, JY (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.	stingray@cmc.cuk.ac.kr	kim, Hong Sug/G-2731-2014; Yoo, Nam Jin/GNM-9060-2022					FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Gronbaek K, 2000, BLOOD, V95, P2184; Gronbaek K, 1998, BLOOD, V92, P3018; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; KOHNO T, 1994, ONCOGENE, V9, P103; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1998, LAB INVEST, V78, P453; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Park WS, 2001, J PATHOL, V193, P162; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wyllie AH, 1999, BRIT J CANCER, V80, P34	25	73	79	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2919	2925		10.1038/sj.onc.1205394	http://dx.doi.org/10.1038/sj.onc.1205394			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973654				2022-12-28	WOS:000175063700019
J	Oku, N; Asai, T; Watanabe, K; Kuromi, K; Nagatsuka, M; Kurohane, K; Kikkawa, H; Ogino, K; Tanaka, M; Ishikawa, D; Tsukada, H; Momose, M; Nakayama, J; Taki, T				Oku, N; Asai, T; Watanabe, K; Kuromi, K; Nagatsuka, M; Kurohane, K; Kikkawa, H; Ogino, K; Tanaka, M; Ishikawa, D; Tsukada, H; Momose, M; Nakayama, J; Taki, T			Anti-neovascular therapy using novel peptides homing to angiogenic vessels	ONCOGENE			English	Article						anti-neovascular therapy; phage-displayed peptide library; liposome; PRP	ALPHA-V INTEGRINS; DRUG-DELIVERY; BINDING; CANCER; CELLS; LIGANDS; TUMORS	Cancer chemotherapy targeted to angiogenic vessels is expected to cause indirect tumor regression through the damage of the neovasculature without the induction of drug resistance. To develop a tool for neovasculature-specific drug delivery, we isolated novel peptides homing to angiogenic vessels formed by a dorsal air sac method from a phage-displayed peptide library. Three distinct phage clones that markedly accumulated in murine tumor xenografts presented PRPGAPLAGSWPGTS-, DRWRPALPVVLFPLH- or ASSSYPLIHWRPWAR-peptide respectively. After the determination of the epitope sequences of these peptides, we modified liposomes with epitope penta-peptides. Liposome modified with APRPG-peptide showed high accumulation in murine tumor xenografts, and APRPG-modified liposome encapsulating adriamycin effectively suppressed experimental tumor growth. Finally, specific binding of APRPG-modified liposome to human umbilical endothelial cells, and that of PRP-containing peptide to angiogenic vessels in human tumors, i.e., islet cell tumor and glioblastoma, were demonstrated. The present study indicates the usefulness of APRPG-peptide as a tool for anti-neovascular therapy, a novel modality of cancer treatment.	Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, Shizuoka 4228526, Japan; Otsuka Pharmaceut Co Ltd, Inst Mol Sci Med, Tokushima 7710192, Japan; Hamamatsu Photon KK, Shizuoka 4340041, Japan; Shinshu Univ Hosp, Dept Lab Med, Matsumoto, Nagano 3908621, Japan; Shinshu Univ Hosp, Cent Clin Labs, Matsumoto, Nagano 3908621, Japan	University of Shizuoka; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Otsuka Pharmaceutical; Hamamatsu Photonics; Shinshu University; Shinshu University	Oku, N (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, 52-1 Yada, Shizuoka 4228526, Japan.	oku@u-shizuoka-ken.ac.jp						Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Asai T, 1998, BIOL PHARM BULL, V21, P766; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Browder T, 2000, CANCER RES, V60, P1878; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; Brown JM, 1998, CANCER RES, V58, P1408; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Gho YS, 1997, CANCER RES, V57, P3733; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; Ishikawa D, 1998, FEBS LETT, V441, P20, DOI 10.1016/S0014-5793(98)01511-7; Ito H, 1999, CANCER RES, V59, P5875; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Kurohane K, 2001, CANCER LETT, V167, P49, DOI 10.1016/S0304-3835(01)00475-X; Langer R, 1998, NATURE, V392, P5; MARTENS CL, 1995, J BIOL CHEM, V270, P21129, DOI 10.1074/jbc.270.36.21129; Nishi T, 1996, FEBS LETT, V399, P237, DOI 10.1016/S0014-5793(96)01329-4; Oku N, 1999, ADV DRUG DELIVER REV, V37, P53, DOI 10.1016/S0169-409X(98)00110-0; Oku N, 1999, ADV DRUG DELIVER REV, V40, P63, DOI 10.1016/S0169-409X(99)00040-X; OKU N, 1994, INT J CANCER, V58, P415, DOI 10.1002/ijc.2910580318; OKU N, 1992, BIOCHIM BIOPHYS ACTA, V1126, P255, DOI 10.1016/0005-2760(92)90238-Q; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; St Croix B, 2000, SCIENCE, V289, P1197; Takikawa M, 2000, FEBS LETT, V466, P381, DOI 10.1016/S0014-5793(00)01110-8; Viti F, 1999, CANCER RES, V59, P347; Zetter BR, 1997, NAT BIOTECHNOL, V15, P1243, DOI 10.1038/nbt1197-1243	34	101	115	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2662	2669		10.1038/sj.onc.1205347	http://dx.doi.org/10.1038/sj.onc.1205347			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965539				2022-12-28	WOS:000174996500006
J	Yamamoto, Y; Mandai, K; Okabe, N; Hoshino, T; Nakanishi, H; Takai, Y				Yamamoto, Y; Mandai, K; Okabe, N; Hoshino, T; Nakanishi, H; Takai, Y			Localization of mLin-7 at nectin-based cell-cell junctions	ONCOGENE			English	Article						cell-cell junctions; nectin; afadin; cadherin; mLin-7	ADHESION MOLECULE UVOMORULIN; SYNAPTIC VESICLE EXOCYTOSIS; POLARIZED EPITHELIAL-CELLS; POLIOVIRUS RECEPTOR GENE; ALPHA-CATENIN; E-CADHERIN; ADHERENS JUNCTIONS; CYTOPLASMIC DOMAIN; ARMADILLO PROTEIN; NMDA RECEPTOR	In C. elegans, lin-7 as well as lin-2/lin-10 is involved in the proper localization of the LET-23 receptor tyrosine kinase that regulates vulval induction. The mammalian homologue, mLin-7, forms a ternary complex with the mammalian homologues of LIN-2 and LIN-10 and localizes at cell-cell junctions in epithelial cells, but the mechanism of this localization of mLin-7 is unknown. Nectin is an immunoglobulin-like cell-cell adhesion molecule that is involved in organization of adherens and tight junctions in epithelial cells. Nectin is indirectly associated with the cadherin-catenin system and the actin cytoskeleton through afadin, an actin filament-binding protein. We showed here that mLin-7 localized at the nectin-based cell-cell junctions. This localization of mLin-7 required the interaction of nectin with afadin, but not the cadherin-catenin system or the actin cytoskeleton. mLin-7 did not directly interact with nectin or afadin. The results indicate that mLin-7 localizes at cell-cell junctions through the nectin-afadin system.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp		Nakanishi, Hiroyuki/0000-0002-9765-0266; Mandai, Kenji/0000-0002-0115-6635				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; AOKI J, 1994, J BIOL CHEM, V269, P8431; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Bouchard MJ, 2000, MOL CELL BIOL, V20, P2865, DOI 10.1128/MCB.20.8.2865-2873.2000; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dimitratos SD, 1997, MECH DEVELOP, V63, P127, DOI 10.1016/S0925-4773(97)00668-0; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Hata Y, 1996, J NEUROSCI, V16, P2488; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Kemler R, 1992, Semin Cell Biol, V3, P149; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tseng TC, 2001, BBA-GENE STRUCT EXPR, V1518, P249, DOI 10.1016/S0167-4781(01)00191-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; YANAGIHARA K, 1991, CANCER RES, V51, P381; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595; YONEMURA S, 1995, J CELL SCI, V108, P127; Zhang Y, 2001, FEBS LETT, V497, P99, DOI 10.1016/S0014-5793(01)02450-4	69	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2545	2554		10.1038/sj.onc.1205335	http://dx.doi.org/10.1038/sj.onc.1205335			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971189				2022-12-28	WOS:000174918400011
J	Suzukawa, K; Colburn, NH				Suzukawa, K; Colburn, NH			AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers	ONCOGENE			English	Article						AP-1; JB6 cells; retinoic acid; transrepression; GAL4 transactivation assay	ANCHORAGE-INDEPENDENT GROWTH; TRANSCRIPTIONAL ACTIVATION; INDUCED TRANSFORMATION; PROMOTION-RESISTANT; TUMOR PROMOTERS; EPIDERMAL-CELLS; KAPPA-B; TRANSACTIVATION; INHIBITION; EXPRESSION	Retinoic acid (RA) inhibits tumor promotion in many models in vivo and in vitro, among them mouse epidermal JB6 cells. RA treatment suppresses 12-O-tetradecanoyl-phorbol-13-acetate (TPA) induced AP-1 activity, an activity that is required for transformation of JB6 P+ cells. The molecular mechanism of AP-1 transrepression by retinoids is unclear, especially as related to inhibition of transformation. Overexpression of AP-1 components did not rescue TPA induced AP-1 activation nor did a GST pull down experiment implicate direct binding, thus rendering unlikely both a Jun/Fos-RA-RAR direct interaction and a Jun/Fos sequestration mechanism. Overexpression of p300, SRC-1 or pCAF did not abrogate AP-1 suppression by RA, thus arguing against coactivator competition. Overexpression of the corepressor silencing mediator for retinoic acid and thyroid hormone receptors (SMRT) suppressed AP-1 activity. However, SMRT but not RA inhibited cJun transactivation, suggesting SMRT does not mediate RA transrepression. RA treatment also did not block TPA induced ERK phosphorylation, Jun/Fos family protein expression except for cFos, or DNA binding of the AP-1 complex. The transcriptional activities of full-length JunB and full-length Fra-1, but not the transactivation domain fusions, were increased by TPA treatment and suppressed by RA. Since these full-length fusions have bzip domains, the results suggest that JunB and/or Fra-1-containing dimers may constitute one target of RA for transrepression of AP-1.	Natl Canc Inst Frederick, Basic Res Lab, Gene Regulat Sect, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Colburn, NH (corresponding author), Natl Canc Inst Frederick, Basic Res Lab, Gene Regulat Sect, Bldg 560 Rm 21-89 POB B, Ft Detrick, MD 21702 USA.	Colburn@ncifcrf.gov		Suzukawa, Kazumi/0000-0001-9904-3905				Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bernstein LR, 1999, BBA-GENE STRUCT EXPR, V1489, P263, DOI 10.1016/S0167-4781(99)00191-8; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BOLLAG W, 1992, ANN ONCOL, V3, P513, DOI 10.1093/oxfordjournals.annonc.a058252; Boutwell R K, 1989, Prog Clin Biol Res, V298, P3; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; COLBURN NH, 1982, J CELL BIOCHEM, V18, P261, DOI 10.1002/jcb.1982.240180302; COLBURN NH, 1981, ANN NY ACAD SCI, V359, P251, DOI 10.1111/j.1749-6632.1981.tb12751.x; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DiSepio D, 1999, Mol Cell Biol Res Commun, V1, P7, DOI 10.1006/mcbr.1999.0101; Dong ZG, 1996, J BIOL CHEM, V271, P9942, DOI 10.1074/jbc.271.17.9942; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Fukasawa H, 2000, BIOL PHARM BULL, V23, P1414; Goyette P, 2000, J BIOL CHEM, V275, P16497, DOI 10.1074/jbc.M909382199; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; KAKIZAWA T, 2000, J BIOL CHEM, V27, P27; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Resche-Rigon M, 1998, CURR OPIN CHEM BIOL, V2, P501, DOI 10.1016/S1367-5931(98)80126-9; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; RUDD CJ, 1993, CANCER LETT, V73, P41, DOI 10.1016/0304-3835(93)90186-D; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SIMONSON MS, 1994, AM J PHYSIOL-RENAL, V267, pF805, DOI 10.1152/ajprenal.1994.267.5.F805; SMITH SE, 1992, CELL GROWTH DIFFER, V3, P523; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; VERMA AK, 1977, CANCER RES, V37, P2196; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	58	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2181	2190		10.1038/sj.onc.1205281	http://dx.doi.org/10.1038/sj.onc.1205281			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948401				2022-12-28	WOS:000174555300007
J	Bhat-Nakshatri, P; Sweeney, CJ; Nakshatri, H				Bhat-Nakshatri, P; Sweeney, CJ; Nakshatri, H			Identification of signal transduction pathways involved in constitutive NF-kappa B activation in breast cancer cells	ONCOGENE			English	Article						breast cancer; NF-kappa B; oncogenes; ErbB	TUMOR PROGRESSION; INDUCED APOPTOSIS; C-MYC; TRANSFORMATION; HEREGULIN; GROWTH; DIFFERENTIATION; PHOSPHORYLATION; PARTHENOLIDE; CONTRIBUTES	Nuclear factor-kappaB (NF-kappaB) is usually maintained in an, inactive form in the cytoplasm through its association with inhibitor of kappaB (IkappaB) proteins, and is activated upon stimulation of cells with a variety of signals. However, constitutive activation of NF-kappaB is observed in a number of cancers including breast cancer. The signaling pathways that are involved in constitutive NF-kappaB activation remain largely unknown. Using breast cancer cell lines derived from transgenic mice that overexpress specific oncogene/growth factors in the mammary gland, we show that heregulin but not her2/neu, c-Myc or v-Ha-ras plays a major role in constitutive NT-kappaB activation. Her2/neu potentiated tumor necrosis factor alpha (TNFchi)-inducible NF-kappaB activation whereas c-Myc potentiated 12-o-tetracecanyolphorbol-13-acetate (TPA)-induced NT-kappaB activation. Heregulin-mediated NF-kappaB activation correlated with phosphorylation of epidermal growth factor receptor (EGFR) and ErbB3 but not her2/neu. Tryphostin AG1517, which inhibits heregulin-mediated phosphorylation of EGFR, her2/neu and ErbB3 reduced NF-kappaB activation. In contrast, emodin, which blocks phosphorylation of her2/neu by heregulin, failed to reduce NF-kappaB activation. These results suggest that heregulin induces NF-kappaB independent of her2/neu. PI3 kinase/AKT, protein kinase A (PKA) and IkappaB kinase appear to be downstream signaling molecules involved in NF-kappaB activation as specific inhibitors of these kinases but not inhibitors of ERK/MAP kinase or protein kinase C reduced heregulin-mediated NF-kappaB activation. Based on these results, we propose that heregulin increases the expression of pro-invasive, prometastatic and anti-apoptotic genes in cancer cells through autocrine activation of NF-kappaB, which leads to invasive and drug-resistant growth of breast cancer.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Nakshatri, H (corresponding author), Indiana Canc Res Inst, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu		Nakshatri, Harikrishna/0000-0001-8876-0052				Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong G, 1999, CANCER RES, V59, P3495; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hehner SP, 1999, J IMMUNOL, V163, P5617; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; Lee H, 1998, ONCOGENE, V16, P3243, DOI 10.1038/sj.onc.1201866; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Nozaki S, 2000, BIOCHEM BIOPH RES CO, V275, P60, DOI 10.1006/bbrc.2000.3241; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ozes ON, 1999, NATURE, V401, P82; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685; ZHANG LS, 1995, CANCER RES, V55, P3890; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	47	100	107	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2066	2078		10.1038/sj.onc.1205243	http://dx.doi.org/10.1038/sj.onc.1205243			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960379				2022-12-28	WOS:000174827000013
J	Xia, H; Qi, HL; Li, YF; Pei, J; Barton, J; Blackstad, M; Xu, T; Tao, WF				Xia, H; Qi, HL; Li, YF; Pei, J; Barton, J; Blackstad, M; Xu, T; Tao, WF			LATS1 tumor suppressor regulates G2/M transition and apoptosis	ONCOGENE			English	Article						LATS1; tumor suppressor; G2/M transition; apoptosis	HUMAN BREAST-CANCER; CELL-CYCLE ARREST; PROTEIN-KINASE; MITOTIC APPARATUS; GENE; P53; MITOSIS; ENCODES; HOMOLOG; MICE	The LATS1 gene is a mammalian member of the novel lats tumor suppressor family. Both lats mosaic flies and LATS1 deficient mice spontaneously develop tumors. Our previous studies have shown that inactivation of Drosophila lats leads to up-regulation of cyclin A in the fly, and the human LATS1 protein associates with CDC2 in early mitosis in HeLa cells, suggesting that the lats gene family may negatively regulate cell proliferation by modulating CDC2/Cyclin A activity. We demonstrate here that transduction of the human breast cancer cell MCF-7 with recombinant LATS1 adenovirus (Ad-LATS1), but not with EGFP adenovirus (Ad-EGFP), inhibits in vitro cell proliferation. Ectopic expression of LATS1 in MCF-7 cells specifically downregulates Cyclin A and Cyclin B protein levels and dramatically reduces CDC2 kinase activity, leading to a G2/M blockade. Furthermore, Ad-LATS] suppresses anchorage-independent growth of MCF-7 cells in soft agar and tumor formation in athymic nude mice. We also demonstrate that ectopic expression of LATS1 in MCF-7 cells and human lung cancer cell H460 upregulates the level of BAX proteins and induces apoptosis. Finally, we show that LATS1 kinase activity is required for its ability to inhibit cell growth and induce apoptosis. The results indicate that the LATS1 tumor suppressor may play an important role in the control of human tumor development and that LATS1 suppresses tumorigenesis by negatively regulating cell proliferation and modulating cell survival.	Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Stem Cell Inst, Minneapolis, MN 55455 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06536 USA	University of Minnesota System; University of Minnesota Twin Cities; Yale University	Tao, WF (corresponding author), Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Stem Cell Inst, Minneapolis, MN 55455 USA.							Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gaumann A, 2001, CANCER-AM CANCER SOC, V92, P1237, DOI 10.1002/1097-0142(20010901)92:5<1237::AID-CNCR1443>3.0.CO;2-E; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; LEE JH, 1990, CANCER RES, V50, P2724; Mazurenko N, 1999, ONCOL REP, V6, P859; MIYASHITA T, 1995, CELL, V80, P293; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morinaga N, 2000, INT J ONCOL, V17, P1125; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Theile M, 1996, ONCOGENE, V13, P677; Turenchalk GS, 1999, BBA-REV CANCER, V1424, pM9, DOI 10.1016/S0304-419X(99)00021-9; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	35	129	133	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1233	1241		10.1038/sj.onc.1205174	http://dx.doi.org/10.1038/sj.onc.1205174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850843				2022-12-28	WOS:000173729400011
J	Song, JZ; Stirzaker, C; Harrison, J; Melki, JR; Clark, SJ				Song, JZ; Stirzaker, C; Harrison, J; Melki, JR; Clark, SJ			Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells	ONCOGENE			English	Article						DNA methylation; CpG islands; bisulphite genomic sequencing; GSTP1; prostate cancer	DE-NOVO METHYLATION; CPG ISLAND; PROMOTER HYPERMETHYLATION; DNA HYPERMETHYLATION; P1 GENE; EXPRESSION; TRANSCRIPTION; SP1; METHYLTRANSFERASES; DIFFERENTIATION	Understanding what triggers hypermethylation of tumour suppressor genes in cancer cells is critical if we are to discern the role of methylation in the oncogenic process. CpG sites in CpG island promoters, that span most tumour suppressor genes, remain unmethylated in the normal cell, despite the fact that CpG sites are the prime target for de novo methylation by the DNA methyltransferases. The CpG island-associated with the GSTP1 gene is an intriguing example of a CpG rich region which is susceptible to hypermethylation in the majority of prostate tumours and yet is unmethylated in the normal prostate cell. In this study we evaluate a number of factors purported to be involved in hypermethylation to test their role in triggering hypermethylation of GSTP1 in prostate cancer DU145 and LNCaP cells. We find that hypermethylation is not associated with (1) elevated expression of the DNA methyltranferases, or (2) removal of Sp1 transcription factor binding sites in the CpG island or (3) removal of CpG island boundary elements or (4) prior gene silencing. Instead our results support a model that requires a combination of prior gene silencing and random 'seeds' of methylation to trigger hypermethylation of the GSTP1 gene in the prostate cancer cell. We propose that the GSTP1 gene is initially silenced in the prostate cancer and random sites of methylation accumulate that result in subsequent hypermethylation and chromatin remodelling.	Royal Prince Alfred Hosp, Kanematsu Labs, Sydney Canc Ctr, Camperdown, NSW 2050, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; CSIRO, Sydney Lab, N Ryde, NSW 1670, Australia	University of Sydney; University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Clark, SJ (corresponding author), Royal Prince Alfred Hosp, Kanematsu Labs, Sydney Canc Ctr, Camperdown, NSW 2050, Australia.		Clark, Susan J/U-7365-2019; Clark, Susan J/B-2272-2008	Clark, Susan J/0000-0001-5925-5030; Clark, Susan J/0000-0001-5925-5030; Stirzaker, Clare/0000-0001-5601-3140				Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CLARK SJ, 1995, DNA NUCLEOPROTEIN ST, P123; Cookson MS, 1997, J UROLOGY, V157, P673, DOI 10.1016/S0022-5347(01)65248-0; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; Eads CA, 1999, CANCER RES, V59, P5860; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Huschtscha LI, 1998, CANCER RES, V58, P3508; Jhaveri MS, 1998, GENE, V210, P1, DOI 10.1016/S0378-1119(98)00021-3; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jost JP, 1997, NUCLEIC ACIDS RES, V25, P4545, DOI 10.1093/nar/25.22.4545; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kuzmin I, 1999, ONCOGENE, V18, P5672, DOI 10.1038/sj.onc.1202959; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Melki JR, 2000, BLOOD, V95, P3208; Melki JR, 1999, CANCER RES, V59, P3730; Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199; Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415; Moffat GJ, 1996, J BIOL CHEM, V271, P20740, DOI 10.1074/jbc.271.34.20740; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; Moskaluk CA, 1997, CANCER-AM CANCER SOC, V79, P1595, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1595::AID-CNCR23>3.0.CO;2-S; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Tchou JC, 2000, INT J ONCOL, V16, P663; Thalmann GN, 1996, J NATL CANCER I, V88, P794, DOI 10.1093/jnci/88.12.794; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; WARNECKE P, 1998, THESIS U SYDNEY SYDN; Warnecke PM, 1999, MOL CELL BIOL, V19, P164; Wong DJ, 1997, CANCER RES, V57, P2619	40	147	152	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1048	1061		10.1038/sj.onc.1205153	http://dx.doi.org/10.1038/sj.onc.1205153			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850822				2022-12-28	WOS:000173580100008
J	Thornborrow, EC; Patel, S; Mastropietro, AE; Schwartzfarb, EM; Manfredi, JJ				Thornborrow, EC; Patel, S; Mastropietro, AE; Schwartzfarb, EM; Manfredi, JJ			A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes	ONCOGENE			English	Article						bax; p53; transcription; DNA-binding	TUMOR-SUPPRESSOR P53; CYTOCHROME-C; CELL-DEATH; IN-VIVO; BINDING-SITE; APOPTOSIS; SEQUENCE; PROMOTER; PROTEIN; OVEREXPRESSION	Both the human and the mouse bax promoters contain p53 binding sites which are sufficient to confer p53-dependent transcriptional activation in a heterologous setting. Nevertheless in the context of the bax promoter, these sites do not mediate a p53-dependent response, suggesting that bax may not be a direct transcriptional target of p53. Here, data are presented identifying a conserved p53 response element in the first intron of both the human and the murine bax genes. This element both in isolation and in the context of the first intron conferred p53-dependent transcriptional activation upon a minimal promoter. Electrophoretic mobility shift assays demonstrated that this sequence also is capable of mediating sequence specific binding to p53. p53 effectively activated transcription through both human and murine bax gene reporter constructs, whereas deletion of the intronic response element abrogated the p53-responsiveness of both reporters. Interestingly, tumor-derived mutants of p53 which are defective in inducing an apoptotic response retain the ability to activate transcription via the bax intronic p53 site. Since these mutants are transcriptionally inactive on the p53 site in the bax promoter, the ability of these mutants to up-regulating endogenous bax mRNA levels supports a role for the intronic element in p53-dependent up-regulation of bax expression. Taken together, these results show the requirement for a novel intronic element in the p53-dependent transcriptional activation of bax, and demonstrate that bax is indeed a direct and evolutionarily conserved transcriptional target of p53.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Manfredi, JJ (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R29CA069161] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69161] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim CN, 1997, CANCER RES, V57, P3115; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	29	97	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					990	999		10.1038/sj.onc.1205069	http://dx.doi.org/10.1038/sj.onc.1205069			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850816				2022-12-28	WOS:000173580100002
J	Yamamoto, H; Ochiya, T; Tamamushi, S; Toriyama-Baba, H; Takahama, Y; Hirai, K; Sasaki, H; Sakamoto, H; Saito, I; Iwamoto, T; Kakizoe, T; Terada, M				Yamamoto, H; Ochiya, T; Tamamushi, S; Toriyama-Baba, H; Takahama, Y; Hirai, K; Sasaki, H; Sakamoto, H; Saito, I; Iwamoto, T; Kakizoe, T; Terada, M			HST-1/FGF-4 gene activation induces spermatogenesis and prevents adriamycin-induced testicular toxicity	ONCOGENE			English	Article						FGF-4; spermatogenesis; Cre/lox; testis; transgenic	ADENOVIRUS-MEDIATED TRANSFER; GERM-CELL TUMORS; RECOMBINANT ADENOVIRUS; TRANSFORMING GENE; INDUCED APOPTOSIS; SERTOLI CELLS; STEM-CELLS; GROWTH; LOCALIZATION; EXPRESSION	We previously demonstrated expression of the HST-1/FGF-4 gene in the testis of normal adult animals, which suggests its possible role in spermatogenesis. For an understanding of its functional significance in the testis, conditional transgene expression was used. Precise genetic switches can be efficiently generated in a straightforward manner using adenovirus-carrying Cre recombinase, which means our new strategies promise to contribute substantially to a better and prompt understanding of the functions of genes in vivo by controlling the expression of any gene to any organ at any desired time. Our new method demonstrated for the first time that the specific gain of function of the HST-1/FGF-4 gene in the testis resulted in markedly enhanced spermatogenesis. To further investigate the function and therapeutic potency of HST-1/FGF-4, transgenic mice with enhanced HST-1/FGF-4 expression in the testis were exposed to adriamycin (ADR), an anticancer drug causing severe testicular toxicity. Degree of damage to spermatogenesis was assessed by sperm count, testicular weight, histology, and DNA ploidy. Induced expression of HST-1/FGF-4 markedly enhanced the recovery of ADR-induced testicular damage. Furthermore, adenoviruses carrying the HST-1/FGF-4 gene ameliorated testicular toxicity of ADR. These results with new adenovirus-mediated Cre/lox conditional mice indicated that HST1/FGF-4 could be an important factor for spermatogenesis, presenting a new paradigm to treat impaired fertility.	Natl Canc Ctr, Res Inst, Chuo Ku, Div Genet, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Chuo Ku, Sect Studies Metastasis, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Chuo Ku, Chemotherapy Div, Tokyo 1040045, Japan; Natl Canc Ctr, Natl Canc Ctr, Inst Res, Chuo Ku, Tokyo 1040045, Japan; CLEA Japan Inc, Shizuoka 4190301, Japan; Nara Med Univ, Dept Surg 1, Nara 6348522, Japan; Univ Tokyo, Inst Med Sci, Mol Genet Lab, Minato Ku, Tokyo 1088639, Japan; St Marianna Univ, Sch Med, Dept Urol, Kawasaki, Kanagawa 2168511, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Nara Medical University; University of Tokyo; Saint Marianna University	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, Div Genet, 1-1 Tsukiji,5 Chome, Tokyo 1040045, Japan.	mterada@ncc.go.jp	Ochiya, Takahiro/AAH-7585-2019					Avarbock MR, 1996, NAT MED, V2, P693, DOI 10.1038/nm0696-693; Cancilla B, 1998, BIOL REPROD, V58, P1138, DOI 10.1095/biolreprod58.5.1138; Ford WCL, 2001, LANCET, V357, P1223, DOI 10.1016/S0140-6736(00)04452-4; GRELL RF, 1980, P NATL ACAD SCI-BIOL, V77, P6720, DOI 10.1073/pnas.77.11.6720; Griswold M D, 1988, Int Rev Cytol, V110, P133; GRISWOLD MD, 1988, OXFORD REV REPROD B, V10, P124; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; Hall SJ, 2000, HUM GENE THER, V11, P1705, DOI 10.1089/10430340050111359; HELLSTROM WJG, 1990, UROLOGY, V35, P321, DOI 10.1016/0090-4295(90)80155-G; HOGAN B, 1986, MANIPULATING MOUSE E; Ishii Y, 1997, DEV GROWTH DIFFER, V39, P643; Ivanova M, 1999, THERIOGENOLOGY, V52, P163, DOI 10.1016/S0093-691X(99)00118-1; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Konishi H, 1996, ONCOGENE, V13, P9; LEMARGUERESSEBA.B, 1994, ENDOCRINOLOGY, V1135, P2404; Matsui H, 1993, Eisei Shikenjo Hokoku, P39; Miho Y, 1999, CELL DEATH DIFFER, V6, P463, DOI 10.1038/sj.cdd.4400506; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; OAKBERG EF, 1976, STEM CELLS RENEWING, P287; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; Ogawa T, 2000, NAT MED, V6, P29, DOI 10.1038/71496; ORTH JM, 1990, ANAT REC, V226, P320, DOI 10.1002/ar.1092260308; RUSSO A, 1992, ENVIRON MOL MUTAGEN, V19, P125, DOI 10.1002/em.2850190206; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Sharpe Richard M., 1994, P1363; Shinoda K, 1999, ARCH TOXICOL, V73, P274, DOI 10.1007/s002040050617; SIMPKINS H, 1984, BIOCHIM BIOPHYS ACTA, V783, P293, DOI 10.1016/0167-4781(84)90040-X; SIMPKINS H, 1984, CANCER RES, V44, P613; Sjoblom T, 1998, ENVIRON MOL MUTAGEN, V31, P133, DOI 10.1002/(SICI)1098-2280(1998)31:2<133::AID-EM5>3.0.CO;2-N; Steger K, 1998, HISTOCHEM CELL BIOL, V110, P57, DOI 10.1007/s004180050265; STROHMEYER T, 1991, CANCER RES, V51, P1811; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; Takahama Y, 1999, ONCOGENE, V18, P5943, DOI 10.1038/sj.onc.1203171; vanDisselEmiliani FMF, 1996, ENDOCRINOLOGY, V137, P647, DOI 10.1210/en.137.2.647; Wagle A, 2000, J PHARMACOL EXP THER, V295, P889; Werdien D, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.11.e53; Wilkinson DG, 1992, SITU HYBRIDIZATION P; Yamamoto H, 2000, ONCOGENE, V19, P3805, DOI 10.1038/sj.onc.1203752; YOSHIDA T, 1991, METHOD ENZYMOL, V198, P124; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5	47	22	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					899	908		10.1038/sj.onc.1205135	http://dx.doi.org/10.1038/sj.onc.1205135			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840335				2022-12-28	WOS:000173427100005
J	Seth, P; Krop, I; Porter, D; Polyak, K				Seth, P; Krop, I; Porter, D; Polyak, K			Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression)	ONCOGENE			English	Article						estrogen; tamoxifen; SAGE (Serial Analysis of Gene Expression); breast cancer	SURGICAL ADJUVANT BREAST; FACTOR-RESPONSIVE GENE; MESSENGER-RNAS; CANCER; GROWTH; SM-20; POLYMORPHISM; DISPLAY	The breast cancer promoting effects of estrogen and the chemopreventive effects of tamoxifen are thought to be mediated by the estrogen receptor, a ligand-dependent transcription factor. Therefore, comprehensive analysis of gene expression profiles following estrogen or tamoxifen treatment may help us better understand the role estrogen plays in tumorigenesis. We utilized SAGE (Serial Analysis of Gene Expression) technology to identify genes regulated by estrogen and tamoxifen in the ZR75-1 estrogen dependent breast cancer cell line. In this manner we have identified several genes that were regulated by estrogen or tamoxifen. Here we report the identification and initial characterization of EIT-6 (Estrogen Induced Tag-6), a novel nuclear protein and a new member of the evolutionarily conserved SM-20 family of growth regulatory immediate-early genes. EIT-6 appears to be a direct transcriptional target of the estrogen receptor and constitutive expression of EIT-6 promotes colony growth in human breast cancer cells. These data indicate that EIT-6 may play a role in estrogen induced cell growth.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Polyak, K (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St D740C, Boston, MA 02115 USA.	Kornelia_Polyak@dfci.harvard.edu						Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751; Berry LD, 1997, J CELL BIOL, V137, P1337, DOI 10.1083/jcb.137.6.1337; Charpentier AH, 2000, CANCER RES, V60, P5977; deCupis A, 1997, TRENDS PHARMACOL SCI, V18, P245, DOI 10.1016/S0165-6147(97)90632-5; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Foca C, 2000, MOL HUM REPROD, V6, P712, DOI 10.1093/molehr/6.8.712; Freedman LP, 1999, TRENDS ENDOCRIN MET, V10, P403, DOI 10.1016/S1043-2760(99)00208-8; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Inadera H, 2000, BIOCHEM BIOPH RES CO, V275, P108, DOI 10.1006/bbrc.2000.3276; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Lal A, 1999, CANCER RES, V59, P5403; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Madden SL, 1996, CANCER RES, V56, P5384; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANNING DL, 1990, CANCER RES, V50, P4098; MANNING DL, 1995, ACTA ONCOL, V34, P641, DOI 10.3109/02841869509094041; MANNING DL, 1988, MOL CELL ENDOCRINOL, V59, P205, DOI 10.1016/0303-7207(88)90105-0; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Moschella MC, 1999, GENE EXPRESSION, V8, P59; Nakashiro K, 1998, CANCER RES, V58, P549; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Porter DA, 2001, CANCER RES, V61, P5697; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Seth P, 2000, CANCER RES, V60, P6859; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; TRENT C, 1983, GENETICS, V104, P619; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WAX SD, 1994, J BIOL CHEM, V269, P13041; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zheng W, 2001, CANCER EPIDEM BIOMAR, V10, P89	41	92	97	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					836	843		10.1038/sj.onc.1205113	http://dx.doi.org/10.1038/sj.onc.1205113			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850811				2022-12-28	WOS:000173427000014
J	Henson, JD; Neumann, AA; Yeager, TR; Reddel, RR				Henson, JD; Neumann, AA; Yeager, TR; Reddel, RR			Alternative lengthening of telomeres in mammalian cells	ONCOGENE			English	Review						telomere; alternative lengthening of telomeres; ALT-associated PML bodies; recombination.; immortalization; cancer	IMMORTAL HUMAN-CELLS; LI-FRAUMENI-SYNDROME; LINEAR MITOCHONDRIAL GENOMES; CIRCULAR DNA SPCDNA; HUMAN FIBROBLASTS; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; HOMOLOGOUS RECOMBINATION; INDEFINITE DIVISION; LACKING TELOMERASE	Some immortalized mammalian cell lines and tumors maintain or increase the overall length of their telomeres in the absence of telomerase activity by one or more mechanisms referred to as alternative lengthening of telomeres (ALT). Characteristics of human ALT cells include great heterogeneity of telomere size (ranging from undetectable to abnormally long) within individual cells, and ALT-associated PML bodies (APBs) that contain extrachromosomal telomeric DNA, telomere-specific binding proteins, and proteins involved in DNA recombination and replication. Activation of ALT during immortalization involves recessive mutations in genes that are as yet unidentified. Repressors of ALT activity are present in normal cells and some telomerase-positive cells. Telomere length dynamics in ALT cells suggest a recombinational mechanism. Inter-telomeric copying occurs, consistent with a mechanism in which single-stranded DNA at one telomere terminus invades another telomere and uses it as a copy template resulting in net increase in telomeric sequence. It is possible that t-loops, linear and/or circular extrachromosomal telomeric DNA, and the proteins found in APBs, may be involved in the mechanism. ALT and telomerase activity can co-exist within cultured cells, and within tumors. The existence of ALT adds some complexity to proposed uses of telomere-related parameters in cancer diagnosis and prognosis, and poses challenges for the design of anticancer therapeutics designed to inhibit telomere maintenance.	Childrens Med Res Inst, Sydney, NSW 2145, Australia	Children's Medical Research Institute - Australia; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, 214 Hawkesbury Rd, Sydney, NSW 2145, Australia.	rreddel@cmri.usyd.edu.au	Henson, Jeremy/ABD-3494-2021; Neumann, Axel/D-3319-2012; Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Henson, Jeremy/0000-0002-1594-9310; Yeager, Thomas/0000-0001-8539-5248				ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; Aogi K, 1998, CLIN CANCER RES, V4, P1965; Aogi K, 2000, CLIN CANCER RES, V6, P4776; Aogi K, 1999, CLIN CANCER RES, V5, P2790; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bovee JVMG, 2001, J PATHOL, V193, P354, DOI 10.1002/1096-9896(0000)9999:9999<::AID-PATH802>3.0.CO;2-Z; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Brousset P, 1997, J CLIN ENDOCR METAB, V82, P4214, DOI 10.1210/jc.82.12.4214; Bryan TM, 1998, EXP CELL RES, V239, P370, DOI 10.1006/excr.1997.3907; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Bucholc M, 2001, MOL CELL BIOL, V21, P6559, DOI 10.1128/MCB.21.19.6559-6573.2001; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Cheng AJ, 1998, BRIT J CANCER, V77, P2177, DOI 10.1038/bjc.1998.363; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Cohen S, 1997, ONCOGENE, V14, P977, DOI 10.1038/sj.onc.1200917; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DELANGE T, 1995, TELOMERES, P265; DELANGE T, 2001, IN PRESS COLD SPRING; Dessain SK, 2000, CANCER RES, V60, P537; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Grobelny JV, 2000, J CELL SCI, V113, P4577; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Hande MP, 2001, HUM MOL GENET, V10, P519, DOI 10.1093/hmg/10.5.519; Harley CB, 1997, CIBA F SYMP, V211, P129; Haugen BR, 1997, THYROID, V7, P337, DOI 10.1089/thy.1997.7.337; Henderson S, 1996, J CELL BIOL, V134, P1, DOI 10.1083/jcb.134.1.1; Herrera E, 2000, EMBO J, V19, P472, DOI 10.1093/emboj/19.3.472; Hickson ID, 2001, BIOCHEM SOC T, V29, P201, DOI 10.1042/0300-5127:0290201; Hiraga S, 1998, CANCER RES, V58, P2117; Hoare SF, 2001, CANCER RES, V61, P27; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kammori M, 2000, CANCER LETT, V159, P175, DOI 10.1016/S0304-3835(00)00547-4; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Katoh M, 1998, MOL CARCINOGEN, V21, P17, DOI 10.1002/(SICI)1098-2744(199801)21:1<17::AID-MC4>3.0.CO;2-M; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kishi S, 2001, ONCOGENE, V20, P1497, DOI 10.1038/sj.onc.1204229; Kreuzer KN, 2000, TRENDS BIOCHEM SCI, V25, P165, DOI 10.1016/S0968-0004(00)01559-0; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lansdorp P M, 1997, Ciba Found Symp, V211, P209; Le S, 1999, GENETICS, V152, P143; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; Lipps HJ, 1998, J MOL BIOL, V283, P1, DOI 10.1006/jmbi.1998.2074; Liu YL, 2000, EMBO REP, V1, P85, DOI 10.1093/embo-reports/kvd002; Lo CY, 1999, THYROID, V9, P1215, DOI 10.1089/thy.1999.9.1215; Lombard DB, 2000, CANCER RES, V60, P2331; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Martens UM, 2000, EXP CELL RES, V256, P291, DOI 10.1006/excr.2000.4823; Matthews P, 2001, J PATHOL, V194, P183, DOI 10.1002/path.848; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MCEACHERN MJ, 2001, IN PRESS TELOMERES T; Mehle C, 1996, ONCOGENE, V13, P161; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MKUNOZJORDAN JL, 2001, EMBO J, V20, P579; Montalto MC, 1999, J CELL PHYSIOL, V180, P46, DOI 10.1002/(SICI)1097-4652(199907)180:1<46::AID-JCP5>3.0.CO;2-K; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Murti KG, 1999, P NATL ACAD SCI USA, V96, P14436, DOI 10.1073/pnas.96.25.14436; Nakabayashi K, 1997, EXP CELL RES, V235, P345, DOI 10.1006/excr.1997.3678; Niida H, 2000, MOL CELL BIOL, V20, P4115, DOI 10.1128/MCB.20.11.4115-4127.2000; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Nosek J, 1998, TRENDS GENET, V14, P184, DOI 10.1016/S0168-9525(98)01443-7; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OGATA T, 1995, JPN J CANCER RES, V86, P35, DOI 10.1111/j.1349-7006.1995.tb02985.x; Ogino H, 1998, BIOCHEM BIOPH RES CO, V248, P223, DOI 10.1006/bbrc.1998.8875; Okabe J, 2000, HUM MOL GENET, V9, P2639, DOI 10.1093/hmg/9.18.2639; Okayasu I, 1997, JPN J CANCER RES, V88, P965, DOI 10.1111/j.1349-7006.1997.tb00316.x; Opitz OG, 2001, J CLIN INVEST, V108, P725, DOI 10.1172/JCI11909; Park KH, 1998, INT J ONCOL, V13, P489; Park PU, 1999, MOL CELL BIOL, V19, P3848; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Regev A, 1998, ONCOGENE, V17, P3455, DOI 10.1038/sj.onc.1202250; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Roth CW, 1997, MOL CELL BIOL, V17, P5176, DOI 10.1128/MCB.17.9.5176; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Saji M, 1997, SURGERY, V122, P1137, DOI 10.1016/S0039-6060(97)90219-1; Saji M, 1999, CLIN CANCER RES, V5, P1483; Scheel C, 2001, ONCOGENE, V20, P3835, DOI 10.1038/sj.onc.1204493; Schneider-Stock R, 1999, MOL CARCINOGEN, V24, P144, DOI 10.1002/(SICI)1098-2744(199902)24:2<144::AID-MC9>3.0.CO;2-7; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Shore D, 2001, CURR OPIN GENET DEV, V11, P189, DOI 10.1016/S0959-437X(00)00178-7; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Small MB, 1996, J CELL PHYSIOL, V168, P727, DOI 10.1002/(SICI)1097-4652(199609)168:3<727::AID-JCP26>3.0.CO;2-U; Smith J, 2000, BIOCHIMIE, V82, P71, DOI 10.1016/S0300-9084(00)00183-8; Sprung CN, 1997, MUTAT RES-FUND MOL M, V379, P177, DOI 10.1016/S0027-5107(97)00119-X; Strahl C, 1996, MOL CELL BIOL, V16, P53; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; Sugihara S, 1996, HUM GENET, V97, P1; Sugimoto M, 1999, MECH AGEING DEV, V107, P51, DOI 10.1016/S0047-6374(98)00131-6; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(00)00092-7; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tokutake Y, 1998, BIOCHEM BIOPH RES CO, V247, P765, DOI 10.1006/bbrc.1998.8876; Tomaska L, 2000, NUCLEIC ACIDS RES, V28, P4479, DOI 10.1093/nar/28.22.4479; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; TSUTSUI T, 1995, CARCINOGENESIS, V16, P25, DOI 10.1093/carcin/16.1.25; Tsutsui T, 1997, MOL CARCINOGEN, V18, P7, DOI 10.1002/(SICI)1098-2744(199701)18:1<7::AID-MC2>3.0.CO;2-F; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; WAHL GM, 1989, CANCER RES, V49, P1333; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Yan P, 1999, CANCER RES, V59, P3166; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yashima K, 1997, SURGERY, V122, P1141, DOI 10.1016/S0039-6060(97)90220-8; Yeager TR, 1999, CANCER RES, V59, P4175; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yoo J, 2000, ARCH PATHOL LAB MED, V124, P393; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	144	501	529	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					598	610		10.1038/sj.onc.1205058	http://dx.doi.org/10.1038/sj.onc.1205058			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850785				2022-12-28	WOS:000173390500012
J	Tham, WH; Zakian, VA				Tham, WH; Zakian, VA			Transcriptional silencing at Saccharomyces telomeres: implications for other organisms	ONCOGENE			English	Review						telomere; TPE; heterochromatin; telomerase; Ku complex; Sir proteins	D-GLUCOSYL-HYDROXYMETHYLURACIL; CELL-CYCLE PROGRESSION; DNA-BINDING PROTEIN; YEAST TELOMERES; FISSION YEAST; CHROMOSOME STABILITY; GENE-EXPRESSION; SIR4 PROTEINS; SCHIZOSACCHAROMYCES-POMBE; PLASMODIUM-FALCIPARUM	Telomeres are the natural ends of eukaryotic chromosomes. In most organisms, telomeres consist of simple, repeated DNA with the strand running 5' to 3' towards the end of the chromosome being rich in G residues. In cases where the very end of the chromosome has been examined, the G-strand is extended to form a short, single stranded tail. The chromatin structure of telomeric regions often has features that distinguish them from other parts of the genome. Because telomeres protect chromosome ends from degradation and end-to-end fusions and prevent the loss of terminal DNA by serving as a substrate for telomerase, the), are essential for the stable maintenance of eukaryotic chromosomes. In addition to their essential functions, telomeres in diverse organisms are specialized sites for gene expression. Transcription of genes located next to telomeres is repressed, a phenomenon termed telomere position effect (TPE). TPE is best characterized in the yeast Saccharomyces cerevisiae. This article will focus on the silencing properties of Saccharomyces telomeres and end with speculation on the role of TPE in yeasts and other organisms.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Zakian, VA (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Tham, Wai-Hong/L-3173-2018	Tham, Wai-Hong/0000-0001-7950-8699				Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Craven RJ, 2000, MOL CELL BIOL, V20, P2378, DOI 10.1128/MCB.20.7.2378-2384.2000; Cryderman DE, 1999, EMBO J, V18, P3724, DOI 10.1093/emboj/18.13.3724; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Haber JE, 1999, CELL, V97, P829, DOI 10.1016/S0092-8674(00)80795-3; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARLEY CB, 1995, TELOMERES, P247; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HILL A, 1987, MOL CELL BIOL, V7, P2397, DOI 10.1128/MCB.7.7.2397; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LAMAN H, 1995, MOL CELL BIOL, V15, P3608; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Laroche T, 2000, J STRUCT BIOL, V129, P159, DOI 10.1006/jsbi.2000.4240; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Louis EJ, 1995, YEAST, V11, P1553, DOI 10.1002/yea.320111604; LOUIS EJ, 1994, GENETICS, V136, P789; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Mangahas JL, 2001, MOL BIOL CELL, V12, P4078, DOI 10.1091/mbc.12.12.4078; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MASON JM, 1995, TRENDS GENET, V11, P58, DOI 10.1016/S0168-9525(00)88998-2; McAinsh AD, 1999, CURR BIOL, V9, P963, DOI 10.1016/S0960-9822(99)80424-2; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Mishra K, 1999, CURR BIOL, V9, P1123, DOI 10.1016/S0960-9822(99)80483-7; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Murti KG, 1999, P NATL ACAD SCI USA, V96, P14436, DOI 10.1073/pnas.96.25.14436; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Ritchie KB, 2000, GENETICS, V155, P475; Rudenko G, 1998, TRENDS MICROBIOL, V6, P113, DOI 10.1016/S0966-842X(97)01200-6; Runge KW, 1996, MOL CELL BIOL, V16, P3094; RUSSELL P, 1986, CELL, V45, P781, DOI 10.1016/0092-8674(86)90550-7; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SANDELL LL, 1994, P NATL ACAD SCI USA, V91, P12061, DOI 10.1073/pnas.91.25.12061; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; SNYDER M, 1988, MOL CELL BIOL, V8, P2184, DOI 10.1128/MCB.8.5.2184; STAVENHAGEN JB, 1994, GENE DEV, V8, P1411, DOI 10.1101/gad.8.12.1411; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tham WH, 2001, MOL CELL, V8, P189, DOI 10.1016/S1097-2765(01)00287-8; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tsukamoto Y, 2001, CURR BIOL, V11, P1328, DOI 10.1016/S0960-9822(01)00372-4; van Leeuwen F, 1998, P NATL ACAD SCI USA, V95, P2366, DOI 10.1073/pnas.95.5.2366; Vega-Palas MA, 2000, MOL GEN GENET, V263, P287, DOI 10.1007/s004380051170; VegaPalas MA, 1997, NAT GENET, V15, P232, DOI 10.1038/ng0397-232; WILEY EA, 1995, GENETICS, V139, P67; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; WRIGHT JH, 1995, NUCLEIC ACIDS RES, V23, P1454, DOI 10.1093/nar/23.9.1454; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zou S, 1996, GENE DEV, V10, P634, DOI 10.1101/gad.10.5.634	105	124	125	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					512	521		10.1038/sj.onc.1205078	http://dx.doi.org/10.1038/sj.onc.1205078			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850776				2022-12-28	WOS:000173390500003
J	Bishop, PC; Myers, T; Robey, R; Fry, DW; Liu, ET; Blagosklonny, MV; Bates, SE				Bishop, PC; Myers, T; Robey, R; Fry, DW; Liu, ET; Blagosklonny, MV; Bates, SE			Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family	ONCOGENE			English	Article						oncogenes; HER1/HER2 inhibitors; EGF; NCI drug screen; signal transduction	ANTICANCER DRUG SCREEN; BREAST-CANCER; PROGNOSTIC FACTOR; TUMOR-SUPPRESSOR; ONCOGENE; THERAPY; GENE; P53; AMPLIFICATION; EXPRESSION	Clinical responses to the HER1 (EGF receptor) inhibitors and HER2/neu/ErbB2 inhibitors correlate with high levels of receptor expression. However, a significant subset of patients with high receptor levels appear to be refractory to treatment. We have observed similar results in the 60 cell lines of the NCI Anti-Cancer Drug Screen using a panel of 11 selective HER1 inhibitors. As expected, low HER1-expressing cell lines were insensitive to HER1 inhibitors. In cell lines with high HER1 expression, low concentrations of HER1 inhibitors potently inhibit both HER1 phosphorylation and the mitogen-activated protein kinase (MAPK) pathway. However, this inhibition did not always correlate with cellular arrest. High HER1-expressing cell lines can be subdivided into two groups based on their sensitivity to HER1 inhibitors. In the sensitive group, receptor and growth inhibition was concordant and occurred at submicromolar concentrations of HER1 inhibitors. In the insensitive group, receptor inhibition occurred at a low concentration (<1 mum) but concentrations that were ten times or higher were required for growth inhibition. Also, neither induction of p21 and cyclin D1 nor p53 status could explain the difference between sensitive and insensitive cells. Although EGF activated the MAPK pathway in all cell lines, only drug-sensitive cell lines responded to EGF (accelerated entry from G1 to S) and to HER1 inhibitors (GI arrest) by changes in cell cycling. Furthermore, an EGF-dependent immortalized mammary epithelial cell line was extremely sensitive to a panel of HER1 inhibitors. We infer that independence from mitogen-mediated signaling confers insensitivity to HER1 inhibitors in a large subset of cancer cell lines.	NCI, Med Branch, DCS, MB,NIH, Bethesda, MD 20892 USA; US FDA, CBER, OTRR, DCTDA,Oncol Branch, Rockville, MD 20852 USA; NCI, DTP, Rockville, MD USA; Parke Davis Pharmaceut, Ann Arbor, MI USA; Natl Univ Singapore, Singapore Genom Programme, Singapore, Singapore; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pfizer; National University of Singapore; New York Medical College	Bates, SE (corresponding author), NCI, Med Branch, DCS, MB,NIH, Bldg 10,Room 12N226,9000 Rockville Pike, Bethesda, MD 20892 USA.		Liu, Edison/C-4141-2008; Bates, Susan/AFP-9514-2022	Myers, Timothy Gene/0000-0002-7059-5906; Robey, Rob/0000-0002-0857-3650				BISHOP PC, 1999, SEMINARS BREAST DIS, V2, P200; Blagosklonny MV, 2000, CANCER RES, V60, P3425; BLAGOSKLONNY MV, 2001, CELL CYCLE CHECKPOIN, P52; Bridges AJ, 1996, J MED CHEM, V39, P267, DOI 10.1021/jm9503613; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Gabrilove J, 1990, Curr Opin Oncol, V2, P163; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; Klohs Wayne D., 1997, Current Opinion in Oncology, V9, P562, DOI 10.1097/00001622-199711000-00012; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Monks A, 1997, ANTI-CANCER DRUG DES, V12, P533; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; Ritland SR, 2000, CANCER RES, V60, P4678; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Ross JS, 1999, AM J CLIN PATHOL, V112, pS53; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOULE HD, 1990, CANCER RES, V50, P6075; STINSON SF, 1992, ANTICANCER RES, V12, P1035; Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Wosikowski K, 1997, JNCI-J NATL CANCER I, V89, P1505, DOI 10.1093/jnci/89.20.1505; Zeng YX, 1996, ONCOGENE, V12, P1557	33	85	97	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					119	127		10.1038/sj.onc.1205028	http://dx.doi.org/10.1038/sj.onc.1205028			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791182				2022-12-28	WOS:000172887800012
J	Zebedee, Z; Hara, E				Zebedee, Z; Hara, E			Id proteins in cell cycle control and cellular senescence	ONCOGENE			English	Review						Id; cell cycle; senescence; Ets; CDKs; P16(INK4a)	LOOP-HELIX PROTEIN; RETINOBLASTOMA GENE FAMILY; DNA-BINDING PROTEIN; REPLICATIVE SENESCENCE; IMMUNOGLOBULIN ENHANCER; TRANSCRIPTION FACTOR; PREMATURE SENESCENCE; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR; G(1) PROGRESSION	The Id family of hefix-loop-helix (HLH) proteins are thought to affect the balance between cell growth and differentiation by negatively regulating the function of basic -helix -loop -helix (bHLH) transcription factors. Although it has been suggested for some time that Id is involved in cell cycle regulation, little is known about the molecular mechanism of this control. Recent studies, however, have revealed that Id binds to important cell cycle regulatory proteins other than bHLH proteins. Two such proteins, pRB (retinoblastoma tumour suppressor protein) family proteins and Ets-family transcription factors are known to play key roles in cell cycle regulation, transformation and tumour suppression. Through the characterization of these pathways we will begin to understand the mechanisms by which Id controls normal and abnormal cell cycle progression.	Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC Cell Cycle Grp, Manchester M20 4BX, Lancs, England; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester	Hara, E (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC Cell Cycle Grp, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	Ehara@picr.man.ac.uk						Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; CAMPISI J, 1996, HDB BIOL AGING, V4, P121; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Chu C, 2001, J BIOL CHEM, V276, P8524, DOI 10.1074/jbc.M008371200; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEED RW, 1993, ONCOGENE, V8, P599; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; EINARSON MB, 1995, MOL CELL BIOL, V15, P4175; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hara E, 1996, DEV GENET, V18, P161; Hara E, 1996, MOL CELL BIOL, V16, P859; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARA E, 1991, NUCLEIC ACIDS RES, V19, P7097, DOI 10.1093/nar/19.25.7097; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HARA E, 1994, J BIOL CHEM, V269, P2139; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Humbert PO, 2000, GENE DEV, V14, P690; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Inoue T, 2000, GENES CELLS, V5, P699, DOI 10.1046/j.1365-2443.2000.00362.x; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8; KILEDJIAN M, 1988, MOL CELL BIOL, V8, P145, DOI 10.1128/MCB.8.1.145; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEJOSSIC C, 1994, CANCER RES, V54, P6065; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LISTER J, 1995, J BIOL CHEM, V270, P17939, DOI 10.1074/jbc.270.30.17939; Loughran O, 1996, ONCOGENE, V13, P561; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mathon NF, 2001, SCIENCE, V291, P872, DOI 10.1126/science.1056782; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAGLIUCA A, 1995, GENOMICS, V27, P200, DOI 10.1006/geno.1995.1026; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Reznikoff CA, 1996, CANCER RES, V56, P2886; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shay JW, 2000, NAT REV MOL CELL BIO, V1, P72, DOI 10.1038/35036093; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; SKERJANC IS, 1996, J BIOL CHEM, V270, P24818; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Vooijs M, 1999, ONCOGENE, V18, P5293, DOI 10.1038/sj.onc.1202999; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Yang XH, 2000, ONCOGENE, V19, P2002, DOI 10.1038/sj.onc.1203515; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	113	214	229	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8317	8325		10.1038/sj.onc.1205092	http://dx.doi.org/10.1038/sj.onc.1205092			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840324				2022-12-28	WOS:000173319500005
J	Yasunaga, Y; Nakamura, K; Ko, DJ; Srivstava, S; Moul, JW; Sesterhenn, IA; McLeod, DG; Rhim, JS				Yasunaga, Y; Nakamura, K; Ko, DJ; Srivstava, S; Moul, JW; Sesterhenn, IA; McLeod, DG; Rhim, JS			A novel human cancer culture model for the study of prostate cancer	ONCOGENE			English	Article						human prostate cancer cell line; immortalization; telomerase	HUMAN PAPILLOMAVIRUS DNA; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; EXPRESSION; ADENOCARCINOMA; PROGRESSION; ACTIVATION; PHENOTYPE; TISSUE; LINES	Research into molecular and genetic mechanisms underlying prostate carcinogenesis would be greatly advanced by in vitro models of prostate tumors representing primary tumors. We have successfully established an immortalized human prostate epithelial (HPE) cell culture derived from a primary tumor with telomerase. The actively proliferating early passaged RC-58T cells were transduced through infection with a retrovirus vector expressing the human telomerase catalytic subunit (hTERT). A high level of telomerase was detected in RC-58T/hTERT cells but not RC-58T cells. RC-58T/hTERT cells are currently growing well at passage 50, whereas RC-58T cells senesced at passage 7. RC-58T/hTERT cells exhibit transformed morphology. More importantly, these immortalized cells showed anchorage-independent growth as they formed colonies in soft agar and grew above the agar laver. Expression of androgen-regulated prostate specific gene NKX3.1 and epithelial specific cytokeratin 8 (CK8) but not prostate specific antigen (PSA) and androgen receptor was detected in RC-58T/hTERT cells. Prostate stem cell antigen (PSCA) and p16 were also expressed in this cell line. RC-58T/hTERT cells showed growth inhibition when exposed to retinoic acid and transforming growth factor (TGF)-beta1 known potent inhibitors of prostate epithelial cell growth. A number of chromosome alterations were observed including the loss of chromosomes Y, 3p, 10p, 17p, 18q and the gain of chromosomes 16 and 20. These results demonstrate that this primary tumor-derived HPE cell line retained its transformed phenotypes and should allow studies to elucidate molecular and genetic alterations involved in prostate cancer. This is the first documented case of an established human prostate cancer cell line from a primary tumor of a prostate cancer patient with telomerase.	Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, Bethesda, MD 20814 USA; Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20307 USA; Walter Reed Army Med Ctr, Dept Surg, Serv Urol, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Rhim, JS (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.							Alers JC, 2000, LAB INVEST, V80, P931, DOI 10.1038/labinvest.3780096; ANWAR K, 1992, CANCER RES, V52, P5991; Bright RK, 1997, CANCER RES, V57, P995; Brothman AR, 1999, PROSTATE, V38, P303; Burger AM, 1998, INT J ONCOL, V13, P1043; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; Gibbs M, 1999, AM J HUM GENET, V64, P776, DOI 10.1086/302287; Greider CW, 1999, TRENDS GENET, V15, P109, DOI 10.1016/S0168-9525(98)01681-3; Hukku B, 2000, CANCER GENET CYTOGEN, V120, P117, DOI 10.1016/S0165-4608(00)00216-8; Ittmann MM, 1998, ONCOL REP, V5, P1329; Iype PT, 1998, INT J ONCOL, V12, P257; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; MCNICOL PJ, 1990, J CLIN MICROBIOL, V28, P409, DOI 10.1128/JCM.28.3.409-412.1990; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Peehl DM, 1989, GROWTH FACTORS, V1, P237, DOI 10.3109/08977198908998000; Perinchery G, 1999, INT J CANCER, V83, P610, DOI 10.1002/(SICI)1097-0215(19991126)83:5<610::AID-IJC7>3.0.CO;2-2; Ratsch SB, 2001, RADIAT RES, V155, P143, DOI 10.1667/0033-7587(2001)155[0143:MGCARF]2.0.CO;2; Rhim JS, 2000, PROSTATE CANCER P D, V3, P229, DOI 10.1038/sj.pcan.4500470; Sauter G, 1998, PATHOLOGE, V19, P63, DOI 10.1007/s002920050256; Serth J, 1999, CANCER RES, V59, P823; Sommerfeld HJ, 1996, CANCER RES, V56, P218; STEUER AF, 1977, J NATL CANCER I, V58, P917, DOI 10.1093/jnci/58.4.917; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; Xu LL, 2000, J UROLOGY, V163, P972, DOI 10.1016/S0022-5347(05)67867-6; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141	29	28	31	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					8036	8041		10.1038/sj.onc.1205002	http://dx.doi.org/10.1038/sj.onc.1205002			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753687				2022-12-28	WOS:000172288700013
J	Kim, WJ; Vo, QN; Shrivastav, M; Lataxes, TA; Brown, KD				Kim, WJ; Vo, QN; Shrivastav, M; Lataxes, TA; Brown, KD			Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line	ONCOGENE			English	Article						ataxia-telangiectasia; gene silencing; epigenetics	DNA MISMATCH REPAIR; ATAXIA-TELANGIECTASIA HETEROZYGOTES; IONIZING-RADIATION; BREAST-CANCER; GENE-MUTATIONS; PROTEIN; HYPERMETHYLATION; INACTIVATION; EXPRESSION; PHENOTYPE	Recent findings suggest that DNA alkylating agents trigger cellular responses that overlap those activated after ionizing radiation. Moreover, activation of these responses is dependent upon a functional mismatch repair (MMR) system. These developments led us to test if MMR-deficient cells may be compromised in their ability to activate appropriate cellular signaling pathways after ionizing radiation. An initial experiment to address this notion was to determine the level of radiosensitivity of several MMR-deficient cell lines derived from patients with Hereditary Non-Polyposis Colorectal Cancer (HNPCC). While two of the three HNPCC lines investigated show levels of radiosensitivity consistent with that displayed by normal human fibroblasts, HCT-116 cells display moderate radio sensitivity compared to the other MMR-deficient lines. This increased sensitivity to ionizing radiation correlates with lowered levels of ATM expression in HCT-116. Analysis of genomic DNA from HCT-116 cells determined that these cells possess aberrant methylation of multiple CpG dinucleotides within the proximal promoter region of the ATM gene. The significance of this finding is underscored by our observations that co-culturing HCT-116 cells with the DNA demethylating agent 5-azacytidine reverses promoter methylation, promotes normal levels of ATM expression, and restores normal radiosensitivity. The proximal ATM promoter is a similar to520 bp region shared with the NPAT gene, and current evidence suggests that this region functions as a bi-directional promoter. We found that, unlike ATM, the methylation status of this intergenic region does not effect the expression of the NPAT gene. In sum, these observations indicate that the ATM gene is a novel target for epigentic silencing through inappropriate methylation of its proximal promoter region.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Brown, KD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St,Room 7101, New Orleans, LA 70112 USA.							Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460; BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; Chen XG, 1997, MAMM GENOME, V8, P129, DOI 10.1007/s003359900371; Costello JF, 1996, CANCER RES, V56, P2405; Dork T, 2001, CANCER RES, V61, P7608; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Ejima Y, 2000, INT J CANCER, V86, P262, DOI 10.1002/(SICI)1097-0215(20000415)86:2<262::AID-IJC17>3.3.CO;2-9; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fritzell JA, 1997, CANCER RES, V57, P5143; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Gnarra JR, 1998, J NATL CANCER I, V90, P1685, DOI 10.1093/jnci/90.22.1685; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hiraguri S, 1998, CANCER RES, V58, P1972; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; Kane MF, 1997, CANCER RES, V57, P808; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; MORRELL D, 1986, J NATL CANCER I, V77, P89; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PANDITA TK, 1994, MUTAT RES-FUND MOL M, V310, P1, DOI 10.1016/0027-5107(94)90004-3; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Xu Y, 1999, ADV IMMUNOL, V72, P179, DOI 10.1016/S0065-2776(08)60020-6; Yan T, 2001, CANCER RES, V61, P8290; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	48	78	82	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3864	3871		10.1038/sj.onc.1205485	http://dx.doi.org/10.1038/sj.onc.1205485			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032824				2022-12-28	WOS:000175847200005
J	Vossio, S; Palescandolo, E; Pediconi, N; Moretti, F; Balsano, C; Levrero, M; Costanzo, A				Vossio, S; Palescandolo, E; Pediconi, N; Moretti, F; Balsano, C; Levrero, M; Costanzo, A			DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest	ONCOGENE			English	Article						p53; p73; oncogenes; tumor suppressor; apoptosis; cell cycle	KINASE C-ABL; APOPTOTIC RESPONSE; P53 HOMOLOG; P73; RNA; FAMILY; DEATH; P63; EXPRESSION; DELTA-NP73	p53 and p73 genes are both activated in response to DNA damage to induce either cell cycle arrest or apoptosis, depending on the strength and the quality of the damaging stimulus. p53/p73 transcriptional activity must be tightly regulated to ensure that the appropriate biological response is achieved and to allow the cell to re-enter into the cell cycle after the damage has been repaired. In addition to multiple transcriptionally active (TA) isoforms, dominant negative (DN) variants, that lack the amino-terminal transactivation domain and function as trans-repressors of p53, p63 and p73, are expressed from a second internal promoter (P2-p73Pr). Here we show that, in response to a non apoptotic DNA damage induced by low doses of doxorubicin, p53 binds in vivo, as detected by a p53-specific chromatin immunoprecipitation assay, and activates the P2-p73 promoter. DN-p73alpha protein accumulates under the same conditions and exogenously expressed DN-p73alpha is able to counteract the p53-induced activation of the P2-p73Pr. These results suggest that DN-p73 may contribute to the autoregulatory loops responsible for the termination of p53/p73 responses in cells that do not undergo apoptosis. Accordingly, the activation of the P2-p73Pr is markedly enhanced in both p73-/- murine fibroblasts and in human cells in which p73 transcripts are selectively knocked-out by p73-specific small interfering RNAs.	Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Policlin Umberto I, I-00161 Rome, Italy; Univ Aquila, Dip Med Interna, I-67100 Laquila, Italy; Univ Cagliari, Dip Sci Med Internist, Cagliari, Italy	Sapienza University Rome; University Hospital Sapienza Rome; University of L'Aquila; University of Cagliari	Levrero, M (corresponding author), Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Policlin Umberto I, Viale Policlin 155, I-00161 Rome, Italy.	levmax@tin.it	Balsano, Clara/AAK-9870-2020; Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875				Agami R, 1999, NATURE, V399, P809; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishimoto O, 2002, CANCER RES, V62, P636; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Liefer KM, 2000, CANCER RES, V60, P4016; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; Nishikura K, 2001, CELL, V107, P415, DOI 10.1016/S0092-8674(01)00581-5; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prives C, 1999, J PATHOL, V187, P112; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	27	67	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3796	3803		10.1038/sj.onc.1205465	http://dx.doi.org/10.1038/sj.onc.1205465			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032848				2022-12-28	WOS:000175676000015
J	Bingle, L; Singleton, V; Bingle, CD				Bingle, L; Singleton, V; Bingle, CD			The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms	ONCOGENE			English	Article						WAP domain; 4-disulphide core; gene expression; alternative splicing; chromosome 20; elafin	EPITHELIAL-CELLS; FAMILY; ELAFIN; CARCINOMAS; HYBRIDIZATION; EPIDIDYMIS; DISCOVERY	The whey acidic protein (WAP) domain is a conserved motif, containing eight cysteines found in a characteristic 4-disulphide core arrangement, that is present in a number of otherwise unrelated proteins. WAP motifs are present in SLPI and elafin, two antiproteinases located on chromosome 20q12-13, in a locus rich in poorly characterized WAP domain proteins. One of these proteins, which contains two WAP domains, is HE4 (also known as WFDC2), originally described as an epididymis specific protein but more recently suggested to be a putative serum tumour marker for ovarian cancer. We have shown that HE4 is expressed in a number of normal human tissues outside of the mate reproductive system, including regions of the respiratory tract and nasopharynx, as well as in a subset of lung tumour cell lines. Comparison of multiple HE4 cDNAs and RT-PCR products with genomic sequence allowed the elucidation of the genomic organization. These studies revealed that HE4 can undergo a complex series of alternative splicing events that can potentially yield five distinct WAP domain containing protein isoforms. These results cast doubt on the potential role of HE4 as a serum tumour marker specific for ovarian cancer and open the door to understanding the function of multiple WAP domain containing protein isoforms arising from a single gene.	Univ Sheffield, Sch Med, Resp Cell & Mol Biol Lab,Royal Hallamshire Hosp, Resp Med Unit,Div Genom Med, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield	Bingle, CD (corresponding author), Univ Sheffield, Sch Med, Resp Cell & Mol Biol Lab,Royal Hallamshire Hosp, Resp Med Unit,Div Genom Med, M128,Glossop Rd, Sheffield S10 2RX, S Yorkshire, England.	c.d.bingle@sheffield.ac.uk		Bingle, Colin/0000-0002-5405-6988				Bingle CD, 2000, BBA-GENE STRUCT EXPR, V1493, P363, DOI 10.1016/S0167-4781(00)00196-2; Bingle L, 2001, AM J RESP CELL MOL, V25, P84, DOI 10.1165/ajrcmb.25.1.4341; ELLERBROCK K, 1994, INT J ANDROL, V17, P314, DOI 10.1111/j.1365-2605.1994.tb01262.x; Hough CD, 2000, CANCER RES, V60, P6281; Imai FL, 2001, INT J MOL MED, V7, P43; Jia HP, 2001, GENE, V263, P211; Kirchhoff C, 1998, ANDROLOGIA, V30, P225; Kirchhoff C, 1998, REV REPROD, V3, P86; KIRCHHOFF C, 1991, BIOL REPROD, V45, P350, DOI 10.1095/biolreprod45.2.350; Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Perry ACF, 1999, BIOL REPROD, V61, P965, DOI 10.1095/biolreprod61.4.965; Ranganathan S, 1999, J MOL GRAPH MODEL, V17, P106, DOI 10.1016/S1093-3263(99)00023-6; Richardson RT, 2001, GENE, V270, P93, DOI 10.1016/S0378-1119(01)00462-0; Robinson PA, 1996, J ORAL PATHOL MED, V25, P135, DOI 10.1111/j.1600-0714.1996.tb00208.x; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733, DOI 10.1165/ajrcmb.11.6.7946401; Schalkwijk J, 1999, BIOCHEM J, V340, P569, DOI 10.1042/0264-6021:3400569; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Simpson KJ, 2000, J BIOL CHEM, V275, P23074, DOI 10.1074/jbc.M002161200; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; Trexler M, 2001, P NATL ACAD SCI USA, V98, P3705, DOI 10.1073/pnas.061028398; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Xu WD, 1996, ARCH ANDROLOGY, V37, P135, DOI 10.3109/01485019608988514; Yamamoto S, 1997, BRIT J CANCER, V76, P1081, DOI 10.1038/bjc.1997.511; Zhang M, 1997, CANCER RES, V57, P4631; ZHANG M, 1995, CANCER RES, V55, P2537	27	169	192	3	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2768	2773		10.1038/sj.onc.1205363	http://dx.doi.org/10.1038/sj.onc.1205363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965550				2022-12-28	WOS:000174996500017
J	Eymin, B; Gazzeri, S; Brambilla, C; Brambilla, E				Eymin, B; Gazzeri, S; Brambilla, C; Brambilla, E			Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors	ONCOGENE			English	Article						carcinogenesis; cell cycle; Mdm2; lung tumor; p14(ARF)	WILD-TYPE P53; ATM-DEPENDENT PHOSPHORYLATION; RING-FINGER DOMAIN; GENE-PRODUCT; UBIQUITIN LIGASE; BETA-TRANSCRIPT; NUCLEAR EXPORT; PROTEIN; EXPRESSION; P19(ARF)	Pathways involving p53 and pRb tumor suppressor genes are frequently deregulated during lung carcinogenesis. Through its location at the interface of these pathways, Mdm2 can modulate the function of both p53 and pRb genes. We have examined here the pattern of expression of Mdm2 in a series of 192 human lung carcinomas of all histological types using both immunohistochemical and Western blot analyses and four distinct antibodies mapping different epitopes onto the Mdm2 protein. Using Immunohistochemistry (MC), Mdm2 was overexpressed as compared to normal lung in 31% (60 out of 192) of all tumors analysed, whatever their histological types. Western blotting was performed on 28 out of the 192 tumoral samples. Overexpression of p85/90, p74/76 and p57 Mdm2 isoforms was detected in 18% (5 out of 28), 25% (7 out of 28) and 39% (11 out of 28) of the cases respectively. Overall, overexpression of at least one isoform was observed in 14 out of 28 (50%) lung tumors and concomittant overexpression of at least two isoforms in 7 out of 28 (25%) cases. A good concordance (82%) was observed between immunohistochemical and Western blot data. Interestingly, a highly significant inverse relationship was detected between p14(ARF) loss and Mdm2 overexpression either in NSCLC (P = 0.0089) or in NE lung tumors (P < 0.0001). Furthermore, a Mdm2/P14(ARF) > 1 ratio was correlated with a high grade phenotype among NE tumors overexpressing Mdm2 (P = 0.0021). Taken together, these data strongly suggest that p14(ARF) and Mdm2 act on common pathway(s) to regulate p53 and/or pRb-dependent or independent functions and that the Mdm2:p14(ARF) ratio might act as a rheostat in modulating the activity of both proteins.	Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, Equipe INSERM 9924, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, Equipe INSERM 9924, F-38706 La Tronche, France.	Sylvie.Gazzeri@ujf-grenoble.fr	Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; eymin, beatrice/U-4670-2019; Brambilla, Elisabeth MP/L-8796-2013; gazzeri, sylvie/M-1961-2013	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839				Aikawa H, 2000, INT J MOL MED, V5, P631; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brambilla E, 1999, J PATHOL, V188, P351, DOI 10.1002/(SICI)1096-9896(199908)188:4<351::AID-PATH385>3.0.CO;2-W; BRAMBILLA E, 1993, AM J PATHOL, V143, P199; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHIBA I, 1990, ONCOGENE, V5, P1603; CORDONCARDO C, 1994, CANCER RES, V54, P794; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Esteller M, 2001, CANCER RES, V61, P2816; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FOULKES WD, 1995, BRIT J CANCER, V72, P883, DOI 10.1038/bjc.1995.428; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; GAZZERI S, 1994, INT J CANCER, V58, P24, DOI 10.1002/ijc.2910580106; Gazzeri S, 1998, CANCER RES, V58, P3926; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gorgoulis VG, 2000, MOL MED, V6, P208, DOI 10.1007/BF03402115; Gorgoulis VG, 1996, MODERN PATHOL, V9, P544; Gorgoulis VG, 1996, J PATHOL, V180, P129; Gorgoulis VG, 1998, AM J PATHOL, V153, P1749, DOI 10.1016/S0002-9440(10)65690-8; GOUYER V, 1998, AM J RESP CELL MOL B, V17, P1; GUDAS JM, 1995, CLIN CANCER RES, V1, P71; Haidar MA, 1997, AM J HEMATOL, V54, P189, DOI 10.1002/(SICI)1096-8652(199703)54:3<189::AID-AJH3>3.0.CO;2-S; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashiyama M, 1997, BRIT J CANCER, V75, P1302, DOI 10.1038/bjc.1997.221; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Horie S, 2001, PATHOL INT, V51, P11, DOI 10.1046/j.1440-1827.2001.01159.x; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko JL, 2000, INT J CANCER, V89, P265, DOI 10.1002/1097-0215(20000520)89:3<265::AID-IJC9>3.0.CO;2-N; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LIANES P, 1994, J NATL CANCER I, V86, P1325, DOI 10.1093/jnci/86.17.1325; MARCHETTI A, 1995, DIAGN MOL PATHOL, V4, P93, DOI 10.1097/00019606-199506000-00004; Mariatos G, 2000, MUTAT RES-FUND MOL M, V456, P59, DOI 10.1016/S0027-5107(00)00110-X; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; O'Neill M, 1998, J PATHOL, V186, P254; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, ONCOGENE, V11, P635; Ralhan R, 2000, AM J PATHOL, V157, P587, DOI 10.1016/S0002-9440(10)64569-5; Rasidakis A, 1998, HYBRIDOMA, V17, P339, DOI 10.1089/hyb.1998.17.339; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; RODENHUIS S, 1992, CANCER RES, V52, pS2665; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Stefanaki K, 1998, ANTICANCER RES, V18, P1689; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Travis WD, 1999, HISTOLOGICAL TYPING; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	73	81	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2750	2761		10.1038/sj.onc.1205359	http://dx.doi.org/10.1038/sj.onc.1205359			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965548	Green Submitted			2022-12-28	WOS:000174996500015
J	Wang, YD; De Vos, J; Jourdan, M; Couderc, G; Lu, ZY; Rossi, JF; Klein, B				Wang, YD; De Vos, J; Jourdan, M; Couderc, G; Lu, ZY; Rossi, JF; Klein, B			Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells	ONCOGENE			English	Article						CD9; HB-EGF; ErbB1; IL-6; myeloma	HUMAN MULTIPLE-MYELOMA; DIPHTHERIA-TOXIN RECEPTOR; FACTOR (EGF)-LIKE DOMAIN; SIGNAL TRANSDUCER GP130; MONOCLONAL-ANTIBODY; GENE-EXPRESSION; SURVIVAL FACTOR; IFN-ALPHA; LINES; PROLIFERATION	Interleukin-6 (IL-6) is a major survival and proliferation factor of human malignant plasma cells and IL-6 dependent myeloma cell lines can be obtained from patients with terminal disease. We show here that mutated diphtheria toxin, a specific inhibitor of heparin-binding epidermal growth factor-like growth factor (HB-EGF), blocked the IL-6-induced growth of two myeloma cell lines (XG-1 and XG-14) and did not significantly affect that of two other cell lines (XG-6 and XG-13). The IL-6 mediated growth of myeloma cells was also inhibited by antibodies to ErbB1, a receptor for HB-EGF. The XG-1 and XG-14 cell lines that are sensitive to HB-EGF inhibitors overexpressed HB-EGF and EGF receptor (ErbB1) genes. They also overexpressed CD9, a tetraspanin that binds to the heparin-binding domain of HB-EGF and is critical for promoting ErbB1 activation by HB-EGF. The XG-6 and XG-13 myeloma cells that were not significantly sensitive to HB-EGF antagonists, poorly expressed HB-EGF, ErbB1 and CD9 genes or proteins. We demonstrated that recombinant HB-EGF supported the long-term growth of myeloma cells, as did IL-6. The myeloma cell growth factor activity of HB-EGF was completely inhited by antibodies to ErbB1, but also by antibodies to gp130 IL-6 transducer or to IL-6. These data indicate that in the XG-1 and XG-14 IL-6-dependent myeloma cell lines, the CD9/HB-EGF/erbB1 and the IL-6/IL-6R/ gp130 pathways cooperate synergistically to trigger myeloma cell growth. They suggest that inhibitors of the EGF receptor or HB-EGF may be useful for inducing myeloma cell apoptosis in patients with multiple myeloma.	CHU Montpellier, INSERM, U475, F-34197 Montpellier, France; CHU Montpellier, Unit Cellular Therapy, F-34197 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Klein, B (corresponding author), CHU Montpellier, INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier, France.	Klein@montp.inserm.fr	DE VOS, John/A-5703-2010	DE VOS, John/0000-0003-1880-4130				Badache A, 2001, CANCER RES, V61, P383; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Costes V, 1998, BRIT J HAEMATOL, V103, P1152, DOI 10.1046/j.1365-2141.1998.01101.x; Costes V, 1999, HUM PATHOL, V30, P1405, DOI 10.1016/S0046-8177(99)90160-0; DAVISFLEISCHER KM, 1998, FRONT BIOSCI, V3, P288; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Ferlin-Bezombes M, 1998, J IMMUNOL, V161, P2692; Gaillard JP, 1997, EUR J IMMUNOL, V27, P3332, DOI 10.1002/eji.1830271232; Garcia-Sanz R, 1999, BLOOD, V93, P1032, DOI 10.1182/blood.V93.3.1032.403a15_1032_1037; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; Gu ZJ, 2000, LEUKEMIA, V14, P188, DOI 10.1038/sj.leu.2401632; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; Jelinek DF, 1997, J IMMUNOL, V159, P487; JOURDAN M, 1991, J IMMUNOL, V147, P4402; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Jourdan M, 1999, EUR CYTOKINE NETW, V10, P65; Kaefer M, 2000, J UROLOGY, V163, P580, DOI 10.1016/S0022-5347(05)67936-0; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; LOKHORST HM, 1994, BLOOD, V84, P2269; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Nakamura K, 2000, J BIOL CHEM, V275, P18284, DOI 10.1074/jbc.M907971199; PORTIER M, 1991, EUR J IMMUNOL, V21, P1759, DOI 10.1002/eji.1830210727; PORTIER M, 1993, BRIT J HAEMATOL, V85, P514; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rebouissou C, 1998, BLOOD, V91, P4727, DOI 10.1182/blood.V91.12.4727.412k35_4727_4737; SHIMIZU S, 1989, J EXP MED, V169, P339, DOI 10.1084/jem.169.1.339; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZHANG XG, 1994, BLOOD, V83, P3654	41	53	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2584	2592		10.1038/sj.onc.1205355	http://dx.doi.org/10.1038/sj.onc.1205355			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971193				2022-12-28	WOS:000174918400015
J	Fulda, S; Debatin, KM				Fulda, S; Debatin, KM			IFN gamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway	ONCOGENE			English	Article						caspase-8; apoptosis; interferon; drugs; resistance	DRUG-INDUCED APOPTOSIS; CD95 APO-1/FAS SYSTEM; INTERFERON-GAMMA; DEATH; ACTIVATION; CELLS; METHYLATION; RECEPTORS; PROTEINS; PROMOTER	Resistance of tumors to cytotoxic therapy may be due to disrupted apoptosis programs and remains a major obstacle in cancer treatment. Here, we report that IFNgamma sensitizes resistant tumor cells with absent or low caspase-8 expression for apoptosis induced by death-inducing ligands or cytotoxic drugs by upregulating caspase-8 through a Stat1/IRF1 dependent pathway. Combined treatment using IFNgamma with TRAIL, APO1 TNFalpha or cytotoxic drugs cooperated to trigger apoptosis in various resistant tumor cell lines derived from Ewing tumor, neuroblastoma or medulloblastoma, while single agents exerted only a minimal effect. Importantly, IFN- induced caspase-8 expression also in cells with inactivation of the caspase-8 gene by hypermethylation, although no direct effect of IFNgamma on the methylation status of regulatory sequences of the caspase-8 gene was found. IFNgamma-mediated facilitation of apoptosis was inhibited by the caspase-8 specific inhibitor zIETD.fmk or in caspase8 mutant Jurkat cells implying a prominent role of caspase-8 in mediating sensitization by IFNgamma. Upregulation of caspase-8 and sensitization for apoptosis by IFNgamma was blocked by overexpression of dominant-negative mutants of Stat1 or in Stat1-deficient U3A cells, while complementation of Statl-deficient U3A cells with wildtype Stat1 restored the IFNgamma effect. Moreover, ectopic expression of IRFI induced caspase-8 expression thereby sensitizing cells for TRAIL-, APO1- or doxorubicin-induced apoptosis. These findings provide evidence that the Stat1/IRF1 pathway is involved in induction of caspase-8 expression and apoptosis initiated by IFN- and indicate that IFNgamma might be an effective strategy to sensitize various resistant tumor cells with deficient caspase-8 expression for chemotherapy- or death receptor-induced apoptosis.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Debatin KM, 1997, J NATL CANCER I, V89, P750, DOI 10.1093/jnci/89.11.750; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2000, CANCER RES, V60, P3947; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Iwase S, 1999, FEBS LETT, V450, P263, DOI 10.1016/S0014-5793(99)00515-3; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MONTALDO PG, 1994, J NATL CANCER I, V86, P1694, DOI 10.1093/jnci/86.22.1694; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; VANVALEN F, 1999, EWINGS SARCOMA FAMIL, P55; WADLER S, 1990, CANCER RES, V50, P3473	44	213	223	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2295	2308		10.1038/sj.onc.1205255	http://dx.doi.org/10.1038/sj.onc.1205255			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948413				2022-12-28	WOS:000174635600002
J	Hsiang, CH; Straus, DS				Hsiang, CH; Straus, DS			Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells	ONCOGENE			English	Article						MCF-7 breast cancer cells; cyclopentenone; cyclin D1; BTEB	GROWTH-FACTOR-I; NF-KAPPA-B; GENE-EXPRESSION; GENOMIC ORGANIZATION; PROSTAGLANDIN A(2); CARCINOMA CELLS; KINASE-ACTIVITY; SERUM-ALBUMIN; TRANSCRIPTION; PROTEIN	Evidence indicates that overexpression of cyclin D1 is an important event in malignant transformation of breast cancer cells. Therefore, cyclin D1 is a potential target for mechanistically-based chemoprevention/treatment of breast cancer. Treatment of serum-stimulated quiescent MCF-7 breast cancer cells with cyclopentenone (2-cyclopenten-1-one) blocked progression through G(1) and into S phase. Growth arrest of the cyclopentenone-treated cells in G(1) was associated with changes in the levels of several proteins that control the cell cycle, including a dramatic decrease in cyclin D1 protein expression. Cyclopentenone also decreased the abundance of cyclin D1 mRNA and nuclear transcripts, indicating that it regulated cyclin D1 expression at the transcriptional level. Cyclopentenone selectively inhibited the activity of the cyclin D1 and cyclin A promoters but not the activity of several other control promoters. Deletion analysis indicated that the cyclopentenone response element was located in the cyclin D1 core promoter. Additional functional studies showed that a sequence within the core promoter (CycY, located downstream from the initiator element) played an important role in activation of the cyclin D1 promoter in MCF-7 cells. Electrophoretic mobility shift assays demonstrated specific binding of the transcription factor BTEB to the CycY site. The cyclopentenone response element did not correspond to the CycY site but rather mapped to the initiator element itself The overall results suggest that cyclopentenone interferes with the transcription initiation complex that assembles over the cyclin D1 initiator element, leading to selective inhibition of cyclin D1 gene transcription.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Straus, DS (corresponding author), Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA.	daniel.straus@ucr.edu						Alle KM, 1998, CLIN CANCER RES, V4, P847; BAKER RT, 1989, AM J HUM GENET, V44, P534; Barnes DM, 1997, J PATHOL, V181, P267, DOI 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO;2-X; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bui T, 1997, ENDOCRINOLOGY, V138, P985, DOI 10.1210/en.138.3.985; Bui T, 1998, BBA-GENE STRUCT EXPR, V1397, P31, DOI 10.1016/S0167-4781(97)00214-5; Chen AP, 1999, J BIOL CHEM, V274, P158, DOI 10.1074/jbc.274.1.158; Ciufolini MA, 1998, J ORG CHEM, V63, P1668, DOI 10.1021/jo972073f; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fukami-Kobayashi J, 1998, EXP CELL RES, V241, P435, DOI 10.1006/excr.1998.4079; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Gillett CE, 1998, J PATHOL, V184, P396; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HAYDEN JM, 1994, ENDOCRINOLOGY, V134, P760, DOI 10.1210/en.134.2.760; HERBER B, 1994, ONCOGENE, V9, P1295; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hsiang CH, 1999, BIOCHEM J, V338, P241, DOI 10.1042/0264-6021:3380241; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Marten NW, 1999, BBA-GENE STRUCT EXPR, V1447, P160, DOI 10.1016/S0167-4781(99)00165-7; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; Nenoi M, 1996, GENE, V175, P179, DOI 10.1016/0378-1119(96)00145-X; Nielsen SJ, 1998, BIOCHEM J, V333, P511, DOI 10.1042/bj3330511; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Rossi A, 1996, J BIOL CHEM, V271, P32192, DOI 10.1074/jbc.271.50.32192; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Simpson JF, 1997, AM J PATHOL, V151, P161; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; STRAUS DS, 1994, J NUTR, V124, P1041, DOI 10.1093/jn/124.7.1041; Suh NJ, 1999, CANCER RES, V59, P336; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	58	21	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2212	2226		10.1038/sj.onc.1205293	http://dx.doi.org/10.1038/sj.onc.1205293			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948404				2022-12-28	WOS:000174555300010
J	Niu, GL; Wright, KL; Huang, M; Song, LX; Haura, E; Turkson, J; Zhang, SM; Wang, TH; Sinibaldi, D; Coppola, D; Heller, R; Ellis, LM; Karras, J; Bromberg, J; Pardoll, D; Jove, R; Yu, H				Niu, GL; Wright, KL; Huang, M; Song, LX; Haura, E; Turkson, J; Zhang, SM; Wang, TH; Sinibaldi, D; Coppola, D; Heller, R; Ellis, LM; Karras, J; Bromberg, J; Pardoll, D; Jove, R; Yu, H			Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis	ONCOGENE			English	Article						Stat3 activation; VEGF; tumor angiogenesis	ENDOTHELIAL GROWTH-FACTOR; DNA-BINDING; SUPPRESSES GROWTH; IN-VIVO; C-SRC; ACTIVATION; CANCER; GENE; INDUCTION; TRANSCRIPTION	Non-receptor and receptor tyrosine kinases, such as Src and EGF receptor (EGFR), are major inducers of vascular endothelial growth factor (VEGF), one of the most potent mediators of angiogenesis. While tyrosine kinases signal through multiple pathways, signal transducer and activation of transcription 3 (Stat3) is a point of convergence for many of these and is constitutively activated with high frequency in a wide range of cancer cells. Here, we show that VEGF expression correlates with Stat3 activity in diverse human cancer cell lines. An activated Stat3 mutant (Stat3C) up-regulates VEGF expression and stimulates tumor angiogenesis. Stat3C-induced VEGF up-regulation is abrogated when a Stat3-binding site in the VEGF promoter is mutated. Furthermore, interrupting Stat3 signaling with dominant-negative Stat3 protein or Stat3 antisense otigonucleotide in tumor cells down-regulates VEGF expression. Consistent with an important role of Stat3 in VEGF up-regulation induced by various oncogenic tyrosine kinases, v-Src-mediated VEGF expression is inhibited when Stat3 signaling is blocked. Moreover, chromatin immunoprecipitation assays indicate that Stat3 protein binds to the VEGF promoter in vivo and mutation of a Stat3-binding site in the VEGF promoter abrogates v-Src-induced VEGF promoter activity. These studies provide evidence that the VEGF gene is regulated directly by Stat3 protein, and indicate that Stat3 represents a common molecular target for blocking angiogenesis induced by multiple signaling pathways in human cancers.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Immunol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Clin Invest Program, Tampa, FL 33612 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Isis Pharmaceut Inc, Antisense Drug Discovery, Carlsbad, CA 92008 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center; Isis Pharmaceuticals Inc; Memorial Sloan Kettering Cancer Center	Jove, R (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Mol Oncol Program, Tampa, FL 33612 USA.	richjove@moffitt.usf.edu	Heller, Richard/ABF-1445-2020; Heller, Richard/I-6605-2012	Heller, Richard/0000-0003-1899-3859; YU, Hua/0000-0003-0931-1000	NATIONAL CANCER INSTITUTE [R01CA055652, R01CA089693, R29CA075243, P01CA082533] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652, CA75243, CA82533, CA89693] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi Y, 1998, CANCER RES, V58, P4008; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Coughlin CM, 1998, IMMUNITY, V9, P25, DOI 10.1016/S1074-7613(00)80585-3; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dong ZY, 1999, CANCER RES, V59, P872; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Grunstein J, 1999, CANCER RES, V59, P1592; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Ni Z, 2000, CANCER RES, V60, P1225; Niu GL, 1999, CANCER RES, V59, P5059; Pages G, 2000, ANN NY ACAD SCI, V902, P187; PASSANITI A, 1992, LAB INVEST, V67, P519; Petit AMV, 1997, AM J PATHOL, V151, P1523; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503	49	965	1081	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2000	2008		10.1038/sj.onc.1205260	http://dx.doi.org/10.1038/sj.onc.1205260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960372				2022-12-28	WOS:000174827000006
J	Porter, TR; Richards, FM; Houlston, RS; Evans, DGR; Jankowski, JA; Macdonald, F; Norbury, G; Payne, SJ; Fisher, SA; Tomlinson, I; Maher, ER				Porter, TR; Richards, FM; Houlston, RS; Evans, DGR; Jankowski, JA; Macdonald, F; Norbury, G; Payne, SJ; Fisher, SA; Tomlinson, I; Maher, ER			Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer	ONCOGENE			English	Article						colorectal cancer; E-cadherin; cyclin d1; CCND1; CDH1; genetics	MICROSATELLITE INSTABILITY; GASTRIC-CANCER; EARLY-ONSET; GENE; MUTATIONS; EXPRESSION; BREAST	The molecular basis for most non-HNPCC familial colorectal cancer cases is unknown, but there is increasing evidence that common genetic variants may play a role. We investigated the contribution of polymorphisms in two genes implicated in the pathogenesis of colorectal cancer, cyclin D1 (CCND1) and E-cadherin (CDH1), to familial and sporadic forms of the disease. The CCND1 870A/G polymorphism is thought to affect the expression of CCND1 through mRNA splicing and has been reported to modify the penetrance of HNPCC. Inactivation of E-cadherin is common in colorectal cancer, and truncating germline mutations have been reported to confer susceptibility to colorectal as well as diffuse gastric cancer. The - 160A/C CDH1 polymorphism appears to affect expression of CDH1 and may therefore also confer an increased risk. We found a significantly higher frequency of CCND1 870A allele in 206 familial cases compared to 171 controls (P=0.03). Odds ratios in heterozygotes and homozygotes were 1.7 (95% CI: 1.0-2.66) and 1.8 (95% CI: 1.0-3.3) respectively. The difference was accounted for by an over-representation of A allele in non-HNPCC familial cases (P = 0.007). Over-representation of the CCND1 A allele was also seen in sporadic colorectal cancer cases compared to controls but this did not attain statistical significance (P = 0.08). No significant differences between the frequency of CDH1 - 160A/C genotypes in familial, sporadic colorectal cancer cases and controls were seen, although a possible association between the low expressing A allele and right-sided tumours was detected in familial cases.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Univ Birmingham, Dept Med, Birmingham B15 2TH, W Midlands, England; Birmingham Womens Hosp, W Midlands Reg Genet Serv, Birmingham B15 2TG, W Midlands, England; Churchill Hosp, Reg Genet Serv, Oxford OX3 7LJ, England; Northwick Pk Hosp & Clin Res Ctr, Kennedy Galton Ctr, NW Thames Genet Serv, Harrow HA1 3UJ, Middx, England; Imperial Canc Res Fund, Mol & Populat Genet Lab, London WC2A 3PX, England	University of Birmingham; University of London; Institute of Cancer Research - UK; University of Manchester; University of Birmingham; Birmingham Women's Hospital; University of Oxford; Imperial College London; Cancer Research UK	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	ermaher@hgmp.mrc.ac.uk	Jankowski, Janusz/H-2706-2012; Evans, D Gareth/AAB-4308-2022; MAHER, EAMONN R/A-9507-2008	Jankowski, Janusz/0000-0003-2130-9181; Evans, D Gareth/0000-0002-8482-5784; MAHER, EAMONN R/0000-0002-6226-6918; Houlston, Richard/0000-0002-5268-0242				Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bala S, 2001, CANCER RES, V61, P6042; BECKER KF, 1994, CANCER RES, V54, P3845; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Brassett C, 1996, J MED GENET, V33, P981, DOI 10.1136/jmg.33.12.981; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Frayling IM, 1998, P NATL ACAD SCI USA, V95, P10722, DOI 10.1073/pnas.95.18.10722; Gayther SA, 1998, CANCER RES, V58, P4086; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HARDY RG, 2002, IN PRESS GUT; Ilyas M, 1997, GUT, V40, P654, DOI 10.1136/gut.40.5.654; Jankowski JAZ, 1998, LAB INVEST, V78, P1155; Kong SM, 2001, JNCI-J NATL CANCER I, V93, P1106, DOI 10.1093/jnci/93.14.1106; Kong SM, 2000, CANCER RES, V60, P249; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Li LC, 2000, CANCER RES, V60, P873; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lynch HT, 1999, J MED GENET, V36, P801; MacLeod Stewart L., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P149; McKay JA, 2000, INT J CANCER, V88, P77, DOI 10.1002/1097-0215(20001001)88:1<77::AID-IJC12>3.0.CO;2-O; Platz A, 2000, AM J HUM GENET, V67, P86; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; van de Wetering M, 2001, CANCER RES, V61, P278; Verma L, 1999, J MED GENET, V36, P678; Yoon Kyong-Ah, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P343	30	89	91	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1928	1933		10.1038/sj.onc.1205245	http://dx.doi.org/10.1038/sj.onc.1205245			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896626				2022-12-28	WOS:000174284500016
J	Nomoto, M; Yamaguchi, R; Kohno, K; Kasai, H				Nomoto, M; Yamaguchi, R; Kohno, K; Kasai, H			Relations between clusters of oxidatively damaged nucleotides and active or open nucleosomes in the rat Nth 1 gene	ONCOGENE			English	Article						nucleotide damage; 8-hydroxyguanine; micrococcal nuclease; active or open nucleosomes; Nth 1 gene	POLYCYSTIC KIDNEY-DISEASE; SITE-SPECIFIC MUTAGENESIS; DNA-DAMAGE; FERRIC NITRILOTRIACETATE; TRANSCRIPTION FACTORS; IONIZING-RADIATION; RENAL CARCINOGEN; HUMAN HOMOLOG; 8-HYDROXYGUANINE; REPAIR	The distribution of oxidative damage to bases such as 8-hydroxyguanine (8-OH-Gua), was determined at the nucleotide level of resolution using the ligation-mediated PCR technique. Administration of a renal carcinogen, ferric nitrilotriacetate (Fe-NTA), is known to induce oxidative stress and subsequent formation of 8-OH-Gua in the kidney. Whole genomic DNA was isolated from the rat kidney with or without Fe-NTA treatment and then digested with formamidopyrimidine-DNA glycosylase (Fpg). As a target, we focused on the gene of a DNA repair enzyme for thymine glycol, Nth 1. Cleaved signals were found in exon 1 and exon 3, but not exon 5. Nucleosomes in these regions, enriched in damaged nucleotides, were highly accessible to micrococcal nuclease, especially in the kidney. Taking into account the function of the protein segment encoded by these regions, we discussed the molecular mechanism of the restricted formation of the damaged nucleotides.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Urol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Dept Environm Oncol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Nomoto, M (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan.	m-nomoto@med.uoeh-u.ac.jp						AKMAN SA, 1991, MUTAT RES, V261, P123, DOI 10.1016/0165-1218(91)90058-T; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; AWAI M, 1979, AM J PATHOL, V95, P663; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; Burn TC, 1996, GENOME RES, V6, P525, DOI 10.1101/gr.6.6.525; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHUNG MH, 1992, BIOCHEM BIOPH RES CO, V188, P1, DOI 10.1016/0006-291X(92)92341-T; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; EBINA Y, 1986, J NATL CANCER I, V76, P107; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; Floyd R A, 1986, Free Radic Res Commun, V1, P163, DOI 10.3109/10715768609083148; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; KASAI H, 1993, ADV MUT RES, V4, P31; Kato K, 2000, BBA-GENE STRUCT EXPR, V1493, P91, DOI 10.1016/S0167-4781(00)00168-8; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Kobayashi T, 1999, CANCER RES, V59, P1206; KONISHI T, 1995, J BIOCHEM-TOKYO, V118, P1021, DOI 10.1093/jb/118.5.1021; LOEB LA, 1988, P NATL ACAD SCI USA, V85, P3918, DOI 10.1073/pnas.85.11.3918; MACCABEE M, 1994, J MOL BIOL, V236, P514, DOI 10.1006/jmbi.1994.1162; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER PR, 1991, CURRENT PROTOCOLS S, V14; NAKAE D, 1995, CANCER LETT, V97, P233, DOI 10.1016/0304-3835(95)03980-B; NELLIST M, 1993, CELL, V75, P1305; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOMOTO M, 1995, BBA-GENE STRUCT EXPR, V1264, P35, DOI 10.1016/0167-4781(95)00158-D; Nomoto M, 1999, CARCINOGENESIS, V20, P837, DOI 10.1093/carcin/20.5.837; OKADA S, 1987, BIOCHIM BIOPHYS ACTA, V922, P28, DOI 10.1016/0005-2760(87)90241-4; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; TATA JR, 1978, J MOL BIOL, V118, P249, DOI 10.1016/0022-2836(78)90227-9; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TKESHELASHVILI LK, 1991, J BIOL CHEM, V266, P6401; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Tu YQ, 1997, J BIOL CHEM, V272, P20747, DOI 10.1074/jbc.272.33.20747; UMEMURA T, 1990, CARCINOGENESIS, V11, P345, DOI 10.1093/carcin/11.2.345; WEITZMAN SA, 1990, BLOOD, V76, P655; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yamaguchi R, 1996, CARCINOGENESIS, V17, P2419, DOI 10.1093/carcin/17.11.2419	52	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1649	1657		10.1038/sj.onc.1205237	http://dx.doi.org/10.1038/sj.onc.1205237			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896596				2022-12-28	WOS:000174214200003
J	Basso, AD; Solit, DB; Munster, PN; Rosen, N				Basso, AD; Solit, DB; Munster, PN; Rosen, N			Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2	ONCOGENE			English	Article						Akt; HER2; cyclin D; ansamycins	HER2/NEU-OVEREXPRESSING METASTATIC BREAST; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOCORTICOID RECEPTOR; MONOCLONAL-ANTIBODY; PHASE-II; GELDANAMYCIN; HSP90	Ansamycin antibiotics, such as 17-allylaminogeldanamycin (17-AAG), bind to Hsp90 and regulate its function, resulting in the proteasomal degradation of a subset of signaling proteins that require Hsp90 for conformational maturation. HER2 is a very sensitive target of these drugs. Ansamycins cause RB-dependent G1 arrest that is associated with loss of D-cyclins via a PI3 kinase, Akt dependent pathway. Downregulation of D-cyclin was due, in part, to loss of Akt expression in response to drug. Moreover, in HER2 overexpressing breast cancer cells, 17-AAG caused rapid inhibition of Akt activity prior to any change in Akt protein. Ansamycins; caused rapid degradation of HER2 and a concomitant loss in HER3 associated PI3 kinase activity. This led to a loss of Akt activity, dephosphorylation of Akt substrates, and loss of D-cyclin expression. Introduction into cells of a constitutively membrane bound form of PI3 kinase prevented the effects of the drug on Akt activity and D-cyclins. Thus, in breast cancer cells with high HER2, Akt activation by HER2/HER3 heterodimers; is required for D-cyclin expression. In murine xenograft models, non-toxic doses of 17-AAG markedly reduced the expression of HER2 and phosphorylation of Akt and inhibited tumor growth. Thus, pharmacological inhibition of Akt activation is achievable with ansamycins and may be useful for the treatment of HER2 driven tumors.	Mem Sloan Kettering Canc Ctr, Program Cell Biol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Pharmacol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Rosen, N (corresponding author), Mem Sloan Kettering Canc Ctr, Program Cell Biol, 1275 York Ave, New York, NY 10021 USA.		Rosen, Neal/ABF-2677-2020; Solit, David B./AAC-5309-2019		NCI NIH HHS [P50 CA068425-05, CA0951, P50 CA 68425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA068425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gilewski T, 2000, CANCER CHEMOTH PHARM, V46, pS23, DOI 10.1007/PL00014044; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Munster PN, 2001, CLIN CANCER RES, V7, P2228; Page C, 2000, ANTICANCER RES, V20, P407; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TAL M, 1988, CANCER RES, V48, P1517; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Webb CP, 2000, CANCER RES, V60, P342; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200	39	236	243	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1159	1166		10.1038/sj.onc.1205184	http://dx.doi.org/10.1038/sj.onc.1205184			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850835	Green Accepted			2022-12-28	WOS:000173729400003
J	Gottlieb, TM; Leal, JFM; Seger, R; Taya, Y; Oren, M				Gottlieb, TM; Leal, JFM; Seger, R; Taya, Y; Oren, M			Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis	ONCOGENE			English	Article						p53; Akt; Mdm2; apoptosis; caspase	TUMOR-SUPPRESSOR PROTEIN; HEMATOPOIETIC-CELLS; CASPASE ACTIVATION; CLEAVAGE; SURVIVAL; AKT/PKB; DOMAIN; KINASE; DEATH	The p53 tumor suppressor protein and the Akt/PKB kinase play important roles in the transduction of proapoptotic and anti-apoptotic signals, respectively. We provide evidence that conflicting signals transduced by Akt and p53 are integrated via negative feedback between the two pathways. On the one hand, the combination of ionizing radiation and survival factor deprivation, which leads to rapid apoptosis of IL-3 dependent DA-1 cells, entails a caspase- and p53-dependent destruction of Akt. This destruction of Akt is not a secondary consequence of apoptosis, since it is not seen when the same cells are triggered to undergo apoptosis under different conditions. On the other hand upon serum stimulation, when Akt becomes active and enhances cell survival, phosphorylation occurs at an Akt consensus site (serine 166) within the Mdm2 protein, a key regulator of p53 function. Taken together, our findings suggest that depending on the balance of signals, p53-dependent downregulation of Akt may promote an irreversible commitment to apoptotic cell death, whereas effective recruitment of Akt by appropriate survival signals may lead to activation of Mdm2, inactivation of p53, and eventually inhibition of p53-dependent apoptosis.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Natl Canc Ctr, Div Radiobiol, Tokyo 1040045, Japan	Weizmann Institute of Science; Weizmann Institute of Science; National Cancer Center - Japan	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Leal, Juan F Martinez/N-6328-2013	Leal, Juan F Martinez/0000-0002-7538-0875; Oren, Moshe/0000-0003-4311-7172	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; GOTTLIEB TM, 1996, BIOCHIM BIOPHYS ACTA, V1267, P77; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Mathieu AL, 2001, J BIOL CHEM, V276, P10935, DOI 10.1074/jbc.M007147200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Someya Y, 2000, J BIOL CHEM, V275, P210, DOI 10.1074/jbc.275.1.210; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141	33	371	385	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1299	1303		10.1038/sj.onc.1205181	http://dx.doi.org/10.1038/sj.onc.1205181			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850850				2022-12-28	WOS:000173729400018
J	Miyazaki, YJ; Hamada, J; Tada, M; Furuuchi, K; Takahashi, Y; Kondo, S; Katoh, H; Moriuchi, T				Miyazaki, YJ; Hamada, J; Tada, M; Furuuchi, K; Takahashi, Y; Kondo, S; Katoh, H; Moriuchi, T			HOXD3 enhances motility and invasiveness through the TGF-beta-dependent and -independent pathways in A549 cells	ONCOGENE			English	Article						homeobox gene; HOXD3; microarray; lung cancer cells; TGF-beta; invasion	GROWTH-FACTOR-BETA; GENE-EXPRESSION; HOMEOBOX GENES; MYELOID-LEUKEMIA; CARCINOMA-CELLS; TUMOR BEHAVIOR; LATENT; FACTOR-BETA-1; ACTIVATION; TGF-BETA-1	Homeobox genes regulate sets of genes that determine cellular fates in embryonic morphogenesis and maintenance of adult tissue architecture by regulating cellular motility and cell-cell interactions. Our previous studies showed that a specific member, HOXD3, when overexpressed, upregulates integrin beta3 expression in human erythroleukemia HEL cells and lung cancer A549 cells, and enhances their motility and invasiveness. We performed a microarray study of over 7075 genes to determine the mechanisms underlying the HOXD3-enhanced motility and invasiveness in A549 cells. RT - PCR-based tracking gene analyses highlighted a set of TGF-beta-upregulated genes, which included matrix metalloproteinase-2, syndecan-1, CD44, and TGF-beta-induced 68 kDa protein. Exogenous TGF-beta also caused this pattern of upregulation in A549 cells and enhanced their migratory and invasive activity, confirming the involvement of TGF-beta signaling. However, HOXD3 reduced the expression of TGF-beta-independent genes coding for desmosomal components such as desmoglein, desmoplakin and plakoglobin which are known to suppress tumor invasion and metastasis. These results suggest that HOXD3 enhances the invasive and metastatic potential of cancer cells through the TGF-beta-dependent and -independent pathways.	Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Med, Div Canc Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University	Hamada, J (corresponding author), Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	jhamada@med.hokudai.ac.jp	Kondo, Satoshi/B-1114-2008; Hamada, Jun-ichi/D-7452-2012					ALBINI A, 1987, CANCER RES, V47, P3239; Apiou F, 1996, CYTOGENET CELL GENET, V73, P114, DOI 10.1159/000134320; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; CILLO C, 1994, INVAS METAST, V14, P38; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; CONN IG, 1990, BRIT J UROL, V65, P176, DOI 10.1111/j.1464-410X.1990.tb14694.x; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Hamada J, 2001, INT J CANCER, V93, P516, DOI 10.1002/ijc.1357; HARADA T, 1992, INT J ORAL MAX SURG, V21, P346, DOI 10.1016/S0901-5027(05)80759-3; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; Hiraki A, 1996, BRIT J CANCER, V73, P1491, DOI 10.1038/bjc.1996.282; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Khalil N, 1999, MICROBES INFECT, V1, P1255, DOI 10.1016/S1286-4579(99)00259-2; Kimelman D, 2000, CURR OPIN GENET DEV, V10, P350, DOI 10.1016/S0959-437X(00)00095-2; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LUCAS C, 1991, METHOD ENZYMOL, V198, P303; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Massague J, 2000, GENE DEV, V14, P627; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MOORADIAN DL, 1992, J NATL CANCER I, V84, P523, DOI 10.1093/jnci/84.7.523; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Nagayasu H, 1998, BRIT J CANCER, V77, P1371, DOI 10.1038/bjc.1998.229; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nakashio T, 1997, INT J CANCER, V70, P612, DOI 10.1002/(SICI)1097-0215(19970304)70:5<612::AID-IJC20>3.3.CO;2-Y; NEGOESCU A, 1995, EXP CELL RES, V217, P404, DOI 10.1006/excr.1995.1103; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; Penta K, 1999, J BIOL CHEM, V274, P11101, DOI 10.1074/jbc.274.16.11101; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Shinohara M, 1998, J PATHOL, V184, P369, DOI 10.1002/(SICI)1096-9896(199804)184:4<369::AID-PATH1236>3.0.CO;2-L; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; TANIGUCHI Y, 1995, BLOOD, V85, P2786, DOI 10.1182/blood.V85.10.2786.bloodjournal85102786; TIBERIO C, 1994, INT J CANCER, V58, P608, DOI 10.1002/ijc.2910580426; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Yehualaeshet T, 1999, AM J PATHOL, V155, P841, DOI 10.1016/S0002-9440(10)65183-8; Yu Q, 2000, GENE DEV, V14, P163	46	42	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					798	808		10.1038/sj.onc.1205126	http://dx.doi.org/10.1038/sj.onc.1205126			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850808				2022-12-28	WOS:000173427000011
J	Harley, CB				Harley, CB			Telomerase is not an oncogene	ONCOGENE			English	Article						telomere; telomerase; aging; cancer; immortalization; genetic instability	CATALYTIC SUBUNIT; REVERSE-TRANSCRIPTASE; LIFE-SPAN; REPLICATIVE SENESCENCE; HUMAN FIBROBLASTS; RNA COMPONENT; CELLS; EXPRESSION; LENGTH; GENE	In the decade since the telomere hypothesis of cellular aging was proposed, the two essential genes for human telomerase were cloned and characterized, allowing experimental proof of the causal relationships between telomere loss and replicative senescence, and telomerase activation and immortalization. These relationships were established using a variety of cultured human cell types from both normal and tumor tissues, and were largely confirmed in the telomerase knockout mouse. Taken together, the data provide strong support for the potential utility of telomerase detection and inhibition for cancer, and telomerase activation for degenerative diseases. The specificity of the promoter for the telomerase catalytic gene and the antigenicity of the protein product, hTERT, provide additional strategies for killing telomerase-positive tumor cells. Unfortunately, the strong link between telomerase and cancer has led some to confuse telomerase activation with cancer, and others to overstate the cancer risk of telomerase activation therapies for degenerative diseases. This review clarifies the difference between telomerase, which does not cause growth deregulation, and oncogenes, which do. It also addresses the concept of telomerase repression as a tumor suppressor mechanism early in life, with detrimental tissue degeneration and tumor-promoting consequences late in life. This extended view of the telomere hypothesis helps explain how telomerase inhibition can be therapeutic in cancer patients, while controlled telomerase activation for degenerative diseases may actually reduce, rather than increase, the frequency of age-related tumorigenesis.	Geron Corp, Menlo Pk, CA 94025 USA	Geron Corporation	Harley, CB (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Pk, CA 94025 USA.	charley@geron.com						Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Bandyopadhyay D, 2001, EXP GERONTOL, V36, P1265, DOI 10.1016/S0531-5565(01)00098-5; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLACKBURN EH, 1989, ANNU REV GENET, V23, P163; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; BRYAN TM, 1997, HUM MOL GENET, V6, P1; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Choi DH, 2001, FASEB J, V15, P1014, DOI 10.1096/fj.00-0104com; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Dessain SK, 2000, CANCER RES, V60, P537; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Effros RB, 1996, AIDS, V10, pF17, DOI 10.1097/00002030-199607000-00001; Engelhardt M, 2000, CANCER RES, V60, P610; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Franco S, 2001, EXP CELL RES, V268, P14, DOI 10.1006/excr.2001.5264; Funk WD, 2000, EXP CELL RES, V258, P270, DOI 10.1006/excr.2000.4945; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Halvorsen TL, 2000, J ENDOCRINOL, V166, P103, DOI 10.1677/joe.0.1660103; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Komata T, 2001, CANCER RES, V61, P5796; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; Majumdar AS, 2001, GENE THER, V8, P568, DOI 10.1038/sj.gt.3301421; Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197; McSharry BP, 2001, J GEN VIROL, V82, P855, DOI 10.1099/0022-1317-82-4-855; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Migliaccio M, 2000, J IMMUNOL, V165, P4978, DOI 10.4049/jimmunol.165.9.4978; Minev B, 2000, P NATL ACAD SCI USA, V97, P4796, DOI 10.1073/pnas.070560797; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Reynolds CP, 1997, EUR J CANCER, V33, P1929, DOI 10.1016/S0959-8049(97)00287-6; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Salmon P, 2000, MOL THER, V2, P404, DOI 10.1006/mthe.2000.0141; Seigneurin-Venin S, 2000, BIOCHEM BIOPH RES CO, V272, P362, DOI 10.1006/bbrc.2000.2735; Seigneurin-Venin S, 2000, GENE THER, V7, P619, DOI 10.1038/sj.gt.3301132; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; Ulaner GA, 1997, MOL HUM REPROD, V3, P769, DOI 10.1093/molehr/3.9.769; Ulaner GA, 1998, CANCER RES, V58, P4168; Usselmann B, 2001, AM J GASTROENTEROL, V96, P1106; Vaziri H, 1999, ONCOGENE, V18, P7676, DOI 10.1038/sj.onc.1203016; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; VONZGLINICKI T, 2000, ANN NY ACAD SCI, P99; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Weng NP, 1997, P NATL ACAD SCI USA, V94, P10827, DOI 10.1073/pnas.94.20.10827; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Wright WE, 1996, DEV GENET, V18, P173; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yudoh K, 2001, J BONE MINER RES, V16, P1453, DOI 10.1359/jbmr.2001.16.8.1453; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	84	133	152	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					494	502		10.1038/sj.onc.1205076	http://dx.doi.org/10.1038/sj.onc.1205076			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850774				2022-12-28	WOS:000173390500001
J	Deb, D; Scian, M; Roth, KE; Li, W; Keiger, J; Chakraborti, AS; Deb, SP; Deb, S				Deb, D; Scian, M; Roth, KE; Li, W; Keiger, J; Chakraborti, AS; Deb, SP; Deb, S			Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants	ONCOGENE			English	Article						p53; transcriptional activation; repression; oligomerization	WILD-TYPE P53; SUPPRESSOR PROTEIN P53; C-TERMINAL DOMAIN; DNA-BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; GROWTH SUPPRESSION; KINASE-C; P53-MEDIATED REPRESSION; FUNCTION PHENOTYPE	Tumor-derived p53 mutants activate transcription from promoters of various growth-related genes. We tested whether this transactivation function of the mutant protein is sufficient to induce tumorigenesis ('gain of function'). Tumor-derived mutant p53-281G transactivates. the promoters of human epidermal growth factor receptor (EGFR) and human multiple drug resistance gene (MDR-1). To determine whether the C-terminal domain functions only as an oligomerization domain in mutant p53-mediated transactivation, we have replaced the tetramerization domain of p53 by a heterologous tetramerization domain; although this mutant protein formed tetramers in solution, it failed to transactivate significantly. Therefore, for successful mutant p53-mediated transactivation, sequences near the C-terminus of mutant p53 are required to perform functions in addition to tetramerization. We also demonstrate that co-expression of a deletion mutant of p53 (p53 del 1-293), which retains the p53 oligomerization domain, inhibits this transactivation. p53 del 1-293 co-immunoprecipitates with p53-281G suggesting that hetero-oligomers of p53-281G and p53 del 1-293 are defective in transactivation. We also show that a cell line stably transfected with p53-281G expresses higher levels of endogenous NF-KB and proliferating cell nuclear antigen (PCNA) compared to that transfected with vector alone. On co-expression, p53 del 1-293 lowered the levels of NF-KB and PCNA in p53-281G-expressing cells. However, on co-expression, p53 del 1-293 did not inhibit the tumorigenicity and colony forming ability of p53-281G expressing cells. Our earlier work showed that a deletion of the C-terminal sequences of p53-281G overlapping the oligomerization domain obliterates 'gain of function'. Taken together, the above information suggests that the C-terminal sequences have some critical role in 'gain of function' in addition to transactivation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Deb, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA.	SDEB@HSC.VCU.EDU			NATIONAL CANCER INSTITUTE [R01CA074172, R01CA070712] Funding Source: NIH RePORTER; NCI NIH HHS [CA70712, CA74172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABARZUA P, 1995, CANCER RES, V55, P3490; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BRAIN R, 1994, ONCOGENE, V9, P1775; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Deb D, 2001, INT J ONCOL, V18, P401; Deb D, 1999, INT J ONCOL, V15, P413; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Kelavkar UP, 1999, P NATL ACAD SCI USA, V96, P4378, DOI 10.1073/pnas.96.8.4378; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LENG P, 1995, ONCOGENE, V10, P1275; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Reed Michael, 1993, Gene Expression, V3, P95; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tanguay RL, 2000, BBA-GENE STRUCT EXPR, V1494, P117, DOI 10.1016/S0167-4781(00)00225-6; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Waterman MJF, 1996, CANCER RES, V56, P158; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	91	19	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					176	189		10.1038/sj/onc/1205035	http://dx.doi.org/10.1038/sj/onc/1205035			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803461				2022-12-28	WOS:000173026200002
J	Joseph, B; Marchetti, P; Formstecher, P; Kroemer, G; Lewensohn, R; Zhivotovsky, B				Joseph, B; Marchetti, P; Formstecher, P; Kroemer, G; Lewensohn, R; Zhivotovsky, B			Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment	ONCOGENE			English	Article						lung cancer; apoptosis; staurosporine; caspases; AIF	PROTEIN-KINASE-C; CYTOCHROME-C; APOPTOSIS; STAUROSPORINE; CASPASES; INHIBITION; TRANSLOCATION; RELEASE; LINES	Apoptosis, a tightly controlled multi-step mechanism of cell death, is important for anti-cancer therapy-based elimination of tumor cells. However, this process is not always efficient. Small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) cells display different susceptibility to undergo apoptosis induced by anticancer treatment. In contrast to SCLC, NSCLC cells are cross-resistant to a broad spectrum of apoptotic stimuli, including receptor stimulation, cytotoxic drugs and gamma -radiation. Since resistance of tumor cells to treatment often accounts for the failure of traditional forms of cancer therapy, in the present study attempts to find a potent broad-range apoptosis inductor, which can kill therapy-resistant NSCLC cells were undertaken and the mechanism of apoptosis induction by this drug was investigated in detail. We found that staurosporine (STS) had cell killing effect on both types of lung carcinomas. Release of cytochrome c, activation of apical and effector caspases followed by cleavage of their nuclear substrates and morphological changes specific for apoptosis were observed in STS-treated cells. In contrast to treatment with radiation or chemotherapy drugs, STS induces mitochondrial dysfunction followed by translocation of AIF into the nuclei. These events preceded the activation of nuclear apoptosis. Thus, in lung carcinomas two cell death pathways, caspase-dependent and caspase-independent, coexist. In NSCLC cells, where the caspase-dependent pathway is less efficient, the triggering of an AIF-mediated caspase-independent mechanism circumvents the resistance of these cells to treatment.	Karolinska Inst, Inst Environm Med, Dept Toxicol, S-17177 Stockholm, Sweden; Fac Med Lille, INSERM, U459, F-59045 Lille, France; Inst Gustave Roussy, CNRS, ULR1599, F-94805 Villejuif, France; Karolinska Inst, Unit Med Radiobiol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden	Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Karolinska Institutet	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Dept Toxicol, Box 210, S-17177 Stockholm, Sweden.	Boris.Zhivotovsky@imm.ki.se	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Zhivotovsky, Boris/A-4346-2014	KROEMER, Guido/0000-0002-9334-4405; Zhivotovsky, Boris/0000-0002-2238-3482; Joseph, Bertrand/0000-0001-5655-9979; MARCHETTI, Philippe/0000-0002-4663-6800				Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; BERGH J, 1982, ACTA PATH MICRO IM A, V90, P149; Caponigro F, 1997, ANTI-CANCER DRUG, V8, P26, DOI 10.1097/00001813-199701000-00003; Comis RL, 1998, ONCOLOGY-NY, V12, P44; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Deas O, 1998, J IMMUNOL, V161, P3375; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; GALLI G, 1993, EXP CELL RES, V204, P54, DOI 10.1006/excr.1993.1008; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Gescher A, 2000, CRIT REV ONCOL HEMAT, V34, P127, DOI 10.1016/S1040-8428(00)00058-5; Han Z, 2000, CELL DEATH DIFFER, V7, P521, DOI 10.1038/sj.cdd.4400681; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jarvis WD, 1999, INVEST NEW DRUG, V17, P227, DOI 10.1023/A:1006328303451; Johnson VL, 2000, J CELL SCI, V113, P2941; Joseph B, 2000, ANN NY ACAD SCI, V926, P204; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OWENS AH, 1985, MED ONCOL, P715; SCHOTTENFELD D, 1996, LUNG CANC PRINCIPLES, P305; Sirzen F, 1998, LUNG CANCER-J IASLC, V22, P1, DOI 10.1016/S0169-5002(98)00066-X; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tafani M, 2001, CANCER RES, V61, P2459; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TRAVIS WD, 1996, LUNG CANC PRINCIPLES, P361; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	37	102	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					65	77		10.1038/sj/onc/1205018	http://dx.doi.org/10.1038/sj/onc/1205018			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791177				2022-12-28	WOS:000172887800007
J	Benezra, R; Rafii, S; Lyden, D				Benezra, R; Rafii, S; Lyden, D			The Id proteins and angiogenesis	ONCOGENE			English	Article						Id; angiogenesis; endothelial; precursor	ENDOTHELIAL GROWTH-FACTOR; LOOP-HELIX PROTEIN; RECEPTOR TYROSINE KINASE; FACTOR VEGF; MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTORS; HEMATOPOIETIC-CELLS; EXPRESSION PATTERN; DNA-BINDING; GENE	Since the identification of the Id proteins over a decade ago, a great many cell cycle and cell fate decisions have been shown to be under the control of these proteins as described in other sections of this review issue. Perhaps the most unsuspected activity of this class of proteins has been their essential role in angiogenesis, both in the forebrain during development and during the growth and metastasis of tumors in adults. This section of the review issue will focus on the key observations which have led to these conclusions, speculations about potential mechanisms and the outlook for potential therapeutic interventions.	Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Hematol Oncol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Benezra, R (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Cell Biol, 1275 York Ave, New York, NY 10021 USA.	r-benezra@ski.mskcc.org						Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Caprioli A, 1998, P NATL ACAD SCI USA, V95, P1641, DOI 10.1073/pnas.95.4.1641; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen BB, 1997, J BIOL CHEM, V272, P2459, DOI 10.1074/jbc.272.4.2459; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; ELLMEIER W, 1995, DEV DYNAM, V203, P163, DOI 10.1002/aja.1002030205; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FLAMME I, 1995, DEV BIOL, V169, P699, DOI 10.1006/dbio.1995.1180; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gill M, 2001, CIRC RES, V88, P167; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; KAGEYAMA R, 1995, CRIT REV NEUROBIOL, V9, P177; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ortega N, 1997, AM J PATHOL, V151, P1215; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; PERLMAN JM, 1986, AM J DIS CHILD, V140, P1122, DOI 10.1001/archpedi.1986.02140250048034; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; Rafii S, 1995, ANN THORAC SURG, V60, P1627, DOI 10.1016/0003-4975(95)00807-1; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; RIECHMANN V, 1995, CELL GROWTH DIFFER, V6, P837; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robert B, 1996, AM J PHYSIOL-RENAL, V271, pF744, DOI 10.1152/ajprenal.1996.271.3.F744; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	75	184	199	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8334	8341		10.1038/sj.onc.1205160	http://dx.doi.org/10.1038/sj.onc.1205160			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840326				2022-12-28	WOS:000173319500007
J	Pardo, OE; Arcaro, A; Salerno, G; Tetley, TD; Valovka, T; Gout, I; Seckl, MJ				Pardo, OE; Arcaro, A; Salerno, G; Tetley, TD; Valovka, T; Gout, I; Seckl, MJ			Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells	ONCOGENE			English	Article						S6K2; FGF-2; SCLC; signal transduction	FIBROBLAST-GROWTH-FACTOR; LUNG-CANCER CELLS; ACTIVATED PROTEIN-KINASE; STEM-CELL; SIGNAL-TRANSDUCTION; RECEPTOR ACTIVATION; ENDOTHELIAL-CELLS; LIGAND-BINDING; FACTOR FAMILY; IN-VIVO	Here, we show that fibroblast growth factor-2 (FGF-2) induces proliferation of H-510 and H-69 small cell lung cancer (SCLC) cells. However, the optimal response to FGF-2 was obtained at 10-fold lower concentrations in H-510 cells. This correlated with the selective activation of the mitogen-activated protein kinase kinase (MEK) pathway in H-510, but not H-69 cells. Moreover, inhibition of MEK with PD098059 blocked FGF-2-induced proliferation in H-510 cells only. Similarly, ribosomal protein S6 kinase 2 (S6K2), a recently identified homologue of S6K1 was activated by FGF-2 in H-510, but not H-69 cells. This activation was independent of phosphatidylinositol-3 kinase, but was sensitive to inhibition of the MEK pathway. These data suggest that S6K2 is a novel downstream target of MEK. The potency of FGF-2 in H-510 cells might reflect this additional MEK/S6K2 signalling. In contrast to S6K2, S6K1 was activated in both SCLC cell lines. Inhibition of the mammalian target of rapamycin with 10 ng/ml rapamycin blocked S6K1 activation and proliferation of both lines. However, even at 100 ng/ml, rapamycin only partially inhibited S6K2. Strikingly, this correlated with inhibition of MEK signalling. Our data indicate that S6K1, and possibly S6K2, are involved in FGF-2-induced SCLC cell growth, a notion supported by the overexpression and higher baseline activity of both isoforms in SCLC lines, as compared to normal human type-II pneumocytes.	Imperial Coll Sch Med, Div Med, Lung Canc Biol Grp, London W12 ONN, England; Imperial Coll Sch Med, Natl Heart & Lung Inst, London W6 8RF, England; UCL Royal Free & Univ Coll Med Sch, Ludwig Inst Canc Res, Cell Regulat Lab, London W1W 7BS, England; Inst Mol Biol & Genet, Kiev, Ukraine	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU	Seckl, MJ (corresponding author), Imperial Coll Sch Med, Div Med, Lung Canc Biol Grp, Hammersmith Campus, London W12 ONN, England.	m.seckl@ic.ac.uk	Pardo, Oliver/AEM-2071-2022	Pardo, Oliver/0000-0003-2223-1435				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Bailly K, 2000, FASEB J, V14, P333, DOI 10.1096/fasebj.14.2.333; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; BELINSKY SA, 1992, CANCER RES, V52, P3164; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BUNN PA, 1990, P NATL ACAD SCI USA, V87, P2162, DOI 10.1073/pnas.87.6.2162; CARNEY DN, 1980, CANCER RES, V40, P1820; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CORDONCARDO C, 1990, LAB INVEST, V63, P832; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FUJIMOTO K, 1991, BIOCHEM BIOPH RES CO, V180, P386, DOI 10.1016/S0006-291X(05)81305-1; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gazdar AF, 1981, SMALL CELL LUNG CANC, P145; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; HIBI K, 1991, ONCOGENE, V6, P2291; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Krystal GW, 1996, CANCER RES, V56, P370; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Linder C, 1998, ANTICANCER RES, V18, P2063; MACAULAY VM, 1990, CANCER RES, V50, P2511; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; Martin KA, 2001, J BIOL CHEM, V276, P7892, DOI 10.1074/jbc.M009972200; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; RON D, 1993, J BIOL CHEM, V268, P5388; Seckl MJ, 1998, RESP PHARM & PHARMAC, P129; SECKL MJ, 1994, CANCER RES, V54, P6143; SETHI T, 1991, CANCER RES, V51, P3621; Seufferlein T, 1996, CANCER RES, V56, P3895; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SMYTH JF, 1986, Q J MED, V61, P969; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TenHaveOpbroek AAW, 1997, HISTOL HISTOPATHOL, V12, P319; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; VALOVKA T, 1999, BIOPOLYMERS CELL, V15, P1; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; WENNSTROM S, 1994, ONCOGENE, V9, P651; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Yiangou C, 1997, BRIT J CANCER, V76, P1419, DOI 10.1038/bjc.1997.573; Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231; [No title captured]	53	62	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7658	7667		10.1038/sj.onc.1204994	http://dx.doi.org/10.1038/sj.onc.1204994			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753643				2022-12-28	WOS:000172124100008
J	Carlson, H; Ota, S; Song, YS; Chen, YW; Hurlin, PJ				Carlson, H; Ota, S; Song, YS; Chen, YW; Hurlin, PJ			Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation	ONCOGENE			English	Article						T-box; Tbx3; Myc; Ras; pl9ARF; p53	T-BOX GENES; FOOT MALFORMATION; MAMMARY SYNDROME; TYROSINE KINASE; P63 GENE; C-ABL; MUTATIONS; P19(ARF); MYC; EXPRESSION	Tbx3 is a member of the T-box family of transcription factors. Mutations in Tbx3 cause ulnar-mammary syndrome, an autosomal dominant disorder characterized by upper limb defects, apocrine-gland defects including mammary hypoplasia, and tooth, hair and genital defects. In cell culture, Tbx3 and its close relative Tbx2 are capable of immortalizing mouse embryo fibroblasts. We show that expression of Tbx3 together with Myc or oncogenic Ras (H-Ras(Val17)) leads to efficient transformation of mouse embryo fibroblasts. Oncogene cooperation by Tbx3 correlates with an ability of Tbx3 to suppress the induction of p19ARF and p53 that is typically caused by overexpression Myc and Ras, and to protect against Myc-induced apoptosis. Whereas Tbx3 is capable of interfering with apoptosis caused by excessive Myc levels, a Tbx3 mutant lacking its C-terminal repression domain shows no anti-apoptotic activity and fails to repress levels of p19ARF or p53. Consistent with an ability to suppress p53 pathway function, we find that Tbx3, but not a Tbx3 C-terminal mutant, efficiently blocks myogenic differentiation of C2C12 myoblasts. Our results support the idea that deregulation and/or excessive levels of Tbx3 may have oncogenic potential in vivo.	Oregon Hlth & Sci Univ, Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Hurlin, PJ (corresponding author), Oregon Hlth & Sci Univ, Shriners Hosp Children, 3101 Sam Jackson Pk Rd, Portland, OR 97201 USA.	pjh@shcc.org		Song, Youngsup/0000-0002-6268-5223				Agulnik SI, 1996, GENETICS, V144, P249; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Bamshad M, 1999, AM J HUM GENET, V64, P1550, DOI 10.1086/302417; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Braybrook C, 2001, NAT GENET, V29, P179, DOI 10.1038/ng730; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Carlson H, 2001, HUM MOL GENET, V10, P2403, DOI 10.1093/hmg/10.21.2403; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Cerone MA, 2000, CELL DEATH DIFFER, V7, P506, DOI 10.1038/sj.cdd.4400676; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gibson-Brown JJ, 1998, MECH DEVELOP, V74, P165, DOI 10.1016/S0925-4773(98)00056-2; He ML, 1999, P NATL ACAD SCI USA, V96, P10212, DOI 10.1073/pnas.96.18.10212; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HURLIN PJ, 1987, CANCER RES, V47, P5752; Ianakiev P, 2000, AM J HUM GENET, V67, P59, DOI 10.1086/302972; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li QY, 1997, NAT GENET, V15, P21; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Schinke M, 2001, NAT GENET, V27, P238, DOI 10.1038/85784; SCHINZEL A, 1987, J MED GENET, V24, P778, DOI 10.1136/jmg.24.12.778; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Smith J, 1999, TRENDS GENET, V15, P154, DOI 10.1016/S0168-9525(99)01693-5; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	76	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3827	3835		10.1038/sj.onc.1205476	http://dx.doi.org/10.1038/sj.onc.1205476			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032820				2022-12-28	WOS:000175847200001
J	Pelletier, N; Champagne, N; Stifani, S; Yang, XJ				Pelletier, N; Champagne, N; Stifani, S; Yang, XJ			MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2	ONCOGENE			English	Article						histone acetyltransferase; MYST; MOZ; MORF; Runx1; Runx2	ACUTE MYELOID-LEUKEMIA; RECEPTOR COACTIVATOR; DOSAGE COMPENSATION; MONOCYTIC LEUKEMIA; HUMAN GENES; CELL-CYCLE; PROTEIN; CBP; YEAST; MLL	The monocytic leukemia zinc finger protein MOZ and its homologue MORF have been implicated in leukemogenesis. Both MOZ and MORF are histone acetyltransferases with weak transcriptional repression domains and strong transcriptional activation domains, suggesting that they may function as transcriptional coregulators. Here we describe that MOZ and MORF both interact with Runx2 (or Cbfa1), a Runt-domain transcription factor that is known to play important roles in T cell lymphomagenesis and bone development. Through its C-terminal SM (serine- and methionine-rich) domain, MORF binds to Runx2 in vitro and in vivo. Consistent with this, the SM domain of MORF also binds to Runx1 (or AML1), a Runx2 homologue that is frequently altered by leukemia-associated chromosomal translocations. While MORF does not acetylate Runx2, its SM domain potentiates Runx2-dependent transcriptional activation. Moreover, endogenous MORF is required for transcriptional activation by Runx2. Intriguingly, Runx2 negatively regulates the transcriptional activation potential of the SM domain. Like that of MORF, the SM domain of MOZ physically and functionally interacts with Runx2. These results thus identify Runx2 as an interaction partner of MOZ and MORF and suggest that both acetyltransferases are involved in regulating transcriptional activation mediated by Runx2 and its homologues.	McGill Univ, Mol Oncol Grp, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ, Canada	McGill University; Royal Victoria Hospital; McGill University	Yang, XJ (corresponding author), McGill Univ, Mol Oncol Grp, Royal Victoria Hosp, Ctr Hlth, Room H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	yangxj@molonc.mcgill.ca		Stifani, Stefano/0000-0002-2376-7701				Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Chaffanet M, 1999, GENE CHROMOSOME CANC, V26, P161, DOI 10.1002/(SICI)1098-2264(199910)26:2<161::AID-GCC8>3.3.CO;2-Y; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; John S, 2000, GENE DEV, V14, P1196; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; Panagopoulos I, 2000, GENE CHROMOSOME CANC, V28, P415, DOI 10.1002/1098-2264(200008)28:4<415::AID-GCC7>3.0.CO;2-I; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Ran QT, 2000, GENE, V258, P141, DOI 10.1016/S0378-1119(00)00410-8; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Rowley JD, 1997, BLOOD, V90, P535; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Scott EK, 2001, CURR BIOL, V11, P99, DOI 10.1016/S0960-9822(01)00020-3; SEMENZA GL, 1998, MED GENETICS; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Speck NA, 1999, CANCER RES, V59, p1789S; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Thomas T, 2000, DEVELOPMENT, V127, P2537; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	77	109	118	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2729	2740		10.1038/sj.onc.1205367	http://dx.doi.org/10.1038/sj.onc.1205367			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965546				2022-12-28	WOS:000174996500013
J	Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Inga, A; Abbondandolo, A; Resnick, MA; Fronza, G				Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Inga, A; Abbondandolo, A; Resnick, MA; Fronza, G			Tumour p53 mutations exhibit promoter selective dominance over wild type p53	ONCOGENE			English	Article						dominance; p53; mutation; yeast functional assay; p53 responsive element	CELL-CYCLE; MUTANTS; YEAST; INHIBITION; PROTEIN; DNA; IDENTIFICATION; TRANSCRIPTION; CANCERS; ARREST	The tumour suppressor gene p53 is frequently mutated in human cancer. Tumour derived p53 mutants are usually transcriptionally inactive, but some mutants retain the ability to transactivate a subset of p53 target genes. In addition to simple loss of function, some p53 mutants may be carcinogenic through a dominant negative mechanism. Aiming at a more general classification of p53 mutants into predictive functional categories it is important to determine (i) which p53 mutants are dominant, (ii) what features characterize dominant mutants and (iii) whether dominance is target gene specific. The ability of 71 p53 mutants to inhibit wild type p53 was determined using a simple yeast transcriptional assay. Approximately 30% of the mutants were dominant. They preferentially affect highly conserved amino acids (P < 0.005), which are frequently mutated in turnours (P < 0.005), and usually located near the DNA binding surface of the protein (P < 0.001). Different tumour-derived amino acid substitutions at the same codon usually have the same dominance phenotype. To determine whether the ability of p53 mutants to inhibit wild type p53 is target gene specific, the dominance towards p21, bax, and PIG3 binding sites was examined. Approximately 40% of the 45 mutants examined were dominant for the p21 (17/45) or PIG3 (20/45) responsive elements and 71% (32/45) were dominant for the bax responsive element. These differences are statistically significant (p21 vs bax, P < 0.003; bax vs PIG3, P < 0.02, Fisher's exact test) and defined a hierarchy of dominance. Finally, we extended the analysis to a group of mutants isolated in BRCA-associated tumours, some of which retained wild type level of transcription in yeast as well as in human cells, but show gain of function in transformation assays. Since transformation assays require transdominant inhibition of the endogenous wild type allele, one possible explanation for the behaviour of the BRCA-associated mutants is that they adopt conformations able to bind DNA alone but not in mixed tetramers with wild type p53. The yeast data do not support this explanation, because all BRCA-associated mutants that behaved as wild type in transcription assay were recessive in dominance assays.	Natl Canc Res Inst, IST, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Insubria, DBSF, Human Genet Lab, Varese, Italy; NIEHS, Chromosome Stabil Grp, Res Triangle Pk, NC 27709 USA; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy	University of Insubria; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Genoa	Fronza, G (corresponding author), Natl Canc Res Inst, IST, Mutagenesis Lab, Largo R Benzi 10, I-16132 Genoa, Italy.	gilberto.fronza@istge.it	resnick, Michael/F-1668-2019; Inga, Alberto/AAC-3815-2022; Monti, Paola/Y-1118-2019; Ciribilli, Yari/K-2751-2018; Campomenosi, Paola/C-9729-2011; Fronza, Gilberto/AAG-8735-2019	resnick, Michael/0000-0002-8473-7506; Inga, Alberto/0000-0002-8767-1637; Monti, Paola/0000-0002-1978-4998; Ciribilli, Yari/0000-0001-9231-379X; Campomenosi, Paola/0000-0002-8853-1134; Fronza, Gilberto/0000-0003-3722-553X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065079, Z01ES065079] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Di Como CJ, 1998, ONCOGENE, V16, P2527; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FREBOURG T, 1994, CANCER RES, V54, P878; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; Joers A, 1998, ONCOGENE, V17, P2351, DOI 10.1038/sj.onc.1202146; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marutani M, 1999, CANCER RES, V59, P4765; Monti P, 2000, MUTAGENESIS, V15, P127, DOI 10.1093/mutage/15.2.127; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Waterman MJF, 1996, CANCER RES, V56, P158	27	57	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1641	1648		10.1038/sj.onc.1205250	http://dx.doi.org/10.1038/sj.onc.1205250			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896595				2022-12-28	WOS:000174214200002
J	Hsu, JH; Shi, YJ; Hu, LP; Fisher, M; Franke, TF; Lichtenstein, A				Hsu, JH; Shi, YJ; Hu, LP; Fisher, M; Franke, TF; Lichtenstein, A			Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses	ONCOGENE			English	Article						multiple myeloma; AKT; interleukin-6	PHOSPHATIDYLINOSITOL 3-KINASE; CELL-GROWTH; MONOCLONAL-ANTIBODY; INDUCED APOPTOSIS; PLASMA-CELLS; INTERLEUKIN-6; ACTIVATION; EXPRESSION; ONCOGENE; PROTOONCOGENE	IL-6 is an established growth factor for multiple myeloma tumor cells, stimulating proliferative and survival responses. Recent work indicates that IL-6 can activate the AKT kinase in myeloma cells. Thus, to test a potential role for AKT in IL-6-induced cellular responses, we transfected myeloma cell lines with an active 'E40K' or dominant negative 'PH' AKT construct using an adenoviral vector. Transfection of the E40K into myeloma cells resulted in enhanced tumor cell growth and expression of the PH dominant negative AKT resulted in both inhibition of the IL-6-dependent proliferative response and a decrease in S phase distribution. While transfection of E40K protected myeloma cells front dexamethasone-induced apoptosis, the dominant negative PH had no effect on the ability of IL-6 to protect these cells front dexamethasone. These results clearly demonstrate that AKT activation is critical for the IL-6 proliferative response. In addition, although the level of AKT activation can regulate sensitivity to dexamethasone-induced apoptosis, additional cytokine-induced AKT-independent pathways can mediate IL-6 protection against dexamethasone.	Univ Calif Los Angeles, Med Ctr, Dept Med & Pathol, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Columbia University	Lichtenstein, A (corresponding author), VA West LA Hosp, W111H 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	alichten@ucla.edu						ANDERSON KC, 1989, BLOOD, V73, P1915; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; HSU JH, 2001, IN PRESS BLOOD; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jin Z., 1994, OCEANOLOGY CHINA SEA, P179, DOI DOI 10.1007/978-94-011-0862-1_19; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Lee IS, 1997, FEBS LETT, V401, P133, DOI 10.1016/S0014-5793(96)01456-1; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Ogata A, 1997, J IMMUNOL, V159, P2212; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Prince HM, 1998, EXP HEMATOL, V26, P27; REIBNEGGER G, 1991, CANCER RES, V51, P6250; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Sekulic A, 2000, CANCER RES, V60, P3504; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; SOONYANG Z, 1997, P NATL ACAD SCI USA, V94, P11345; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Teoh G, 1998, BLOOD, V92, P4591, DOI 10.1182/blood.V92.12.4591.424k08_4591_4601; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tu YP, 2000, CANCER RES, V60, P6763; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251	44	76	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1391	1400		10.1038/sj/onc/1205194	http://dx.doi.org/10.1038/sj/onc/1205194			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857082				2022-12-28	WOS:000173861000009
J	Selaru, FM; Zou, T; Xu, Y; Shustova, V; Yin, J; Mori, Y; Sato, F; Wang, S; Olaru, A; Shibata, D; Greenwald, BD; Krasna, MJ; Abraham, JM; Meltzer, SJ				Selaru, FM; Zou, T; Xu, Y; Shustova, V; Yin, J; Mori, Y; Sato, F; Wang, S; Olaru, A; Shibata, D; Greenwald, BD; Krasna, MJ; Abraham, JM; Meltzer, SJ			Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays	ONCOGENE			English	Article						esophaegeal cancer; Barrett's esophagus; cDNA microassays; bioinformatics; cancer diagnosis	TRANSCRIPTIONAL PROGRAM; PATTERNS; TUMORS; YEAST	In order to identify and contrast global gene expression profiles defining the premalignant syndrome, Barrett's esophagus, as well as frank esophageal cancer, we utilized cDNA microarray technology in conjunction with bioinformatics tools. We hybridized microarrays, each containing 8000 cDNA clones, to RNAs extracted from 13 esophageal surgical or endoscopic biopsy specimens (seven Barrett's metaplasias and six esophageal carcinomas). Hierarchical cluster analysis was performed on these results and displayed using a color-coded graphic representation (Treeview). The esophageal samples clustered naturally into two principal groups, each possessing unique global gene expression profiles. After retrieving histologic reports for these tissues, we found that one main cluster contained all seven Barrett's samples, while the remaining principal cluster comprised the six esophageal cancers. The cancers also clustered according to histopathological subtype. Thus, squamous cell carcinomas (SCCAs) constituted one group, adenocarcinomas (ADCAs) clustered separately, and one signet-ring carcinoma was in its own cluster, distinct from the ADCA cluster. We conclude that cDNA microarrays and bioinformatics show promise in the classification of esophageal malignant and premalignant diseases, and that these methods can be applied to small biopsy samples.	Univ Maryland, Sch Med, Baltimore VA Hosp,Greenebaum Canc Ctr, Div Gastroenterol,Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med,Baltimore VA Hosp, Greenebaum Canc Ctr, Div Surg Oncol,Dept Surg, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Meltzer, SJ (corresponding author), Univ Maryland, Room N3W62,22 S Greene St, Baltimore, MD 21201 USA.			Selaru, Florin/0000-0001-7990-8238	NCI NIH HHS [CA77057, CA95323, CA85069] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095323, U01CA085069, R01CA077057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alizadeh A, 1998, J CLIN IMMUNOL, V18, P373, DOI 10.1023/A:1023293621057; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; Blot WJ, 1999, SEMIN ONCOL, V26, P2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Chu S, 1998, SCIENCE, V282, P1421; Daly JM, 2000, J AM COLL SURGEONS, V190, P562, DOI 10.1016/S1072-7515(00)00238-6; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Elek J, 2000, IN VIVO, V14, P173; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; PARKER EF, 1952, ANN SURG, V135, P697, DOI 10.1097/00000658-195205000-00013; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ransford RAJ, 2000, ACTA GASTRO-ENT BELG, V63, P18; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9	21	97	99	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					475	478		10.1038/sj.onc.1205111	http://dx.doi.org/10.1038/sj.onc.1205111			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821959				2022-12-28	WOS:000173311200015
J	Ohmine, K; Ota, J; Ueda, M; Ueno, S; Yoshida, K; Yamashita, Y; Kirito, K; Imagawa, S; Nakamura, Y; Saito, K; Akutsu, M; Mitani, K; Kano, Y; Komatsu, N; Ozawa, K; Mano, H				Ohmine, K; Ota, J; Ueda, M; Ueno, S; Yoshida, K; Yamashita, Y; Kirito, K; Imagawa, S; Nakamura, Y; Saito, K; Akutsu, M; Mitani, K; Kano, Y; Komatsu, N; Ozawa, K; Mano, H			Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells	ONCOGENE			English	Article						chronic myeloid leukemia; DNA microarray; AC133; PIASy	EXPRESSION; GENE; KINASE; TUMOR; CDNA	Chronic myeloid leukemia (CML) is characterized by the clonal expansion of hematopoietic stem cells (HSCs). Without effective treatment, individuals in the indolent, chronic phase (CP) of CML undergo blast crisis (BC), the prognosis for which is poor. It is therefore important to clarify the mechanism underlying stage progression in CML. DNA microarray is a versatile tool for such a purpose. However, simple comparison of bone marrow mononuclear cells from individuals at different disease stages is likely to result in the identification of pseudo-positive genes whose change in expression only reflects the different proportions of leukemic blasts in bone marrow. We have therefore compared with DNA microarray the expression profiles of 3456 genes in the purified HSC-like fractions that had been isolated from 13 CML patients and healthy volunteers. Interestingly, expression of the gene for PIASy, a potential inhibitor of STAT (signal transducer and activator of transcription) proteins, was down-regulated in association with stage progression in CML. Furthermore, forced expression of PIASy has induced apoptosis in a CML cell line. These data suggest that microarray analysis with background-matched samples is an efficient approach to identify molecular events underlying the stage progression in CML.	Jichi Med Sch, Div Funct Genom, Tochigi 3290498, Japan; Jichi Med Sch, Div Hematol, Tochigi 3290498, Japan; Jichi Med Sch, Div Cardiol, Tochigi 3290498, Japan; Univ Tsukuba, Sch Med, Dept Hematol, Tsukuba, Ibaraki 3058575, Japan; Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan; Tochigi Canc Ctr, Utsunomiya, Tochigi 3200834, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University; University of Tsukuba; Dokkyo Medical University; Tochigi Prefectural Cancer Center	Mano, H (corresponding author), Jichi Med Sch, Div Funct Genom, 3311-1 Yakushiji, Tochigi 3290498, Japan.	hmano@jichi.ac.jp	Kirito, Keita/AEO-6802-2022					Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Gouilleux-Gruart V, 1997, LEUKEMIA LYMPHOMA, V28, P83, DOI 10.3109/10428199709058334; HIN AH, 1997, BLOOD, V90, P5002; Iida A, 1996, J VIROL, V70, P6054, DOI 10.1128/JVI.70.9.6054-6059.1996; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KANTARJIAN HM, 1993, BLOOD, V82, P691; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Lethe B, 1998, INT J CANCER, V76, P903, DOI 10.1002/(SICI)1097-0215(19980610)76:6<903::AID-IJC22>3.0.CO;2-1; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Loeffen JLCM, 1998, BIOCHEM BIOPH RES CO, V253, P415, DOI 10.1006/bbrc.1998.9786; Miyazato A, 2001, BLOOD, V98, P422, DOI 10.1182/blood.V98.2.422; Onishi M, 1996, EXP HEMATOL, V24, P324; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Silver RT, 1999, BLOOD, V94, P1517; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; WATHELET MG, 1988, SOMAT CELL MOLEC GEN, V14, P415, DOI 10.1007/BF01534709; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200	23	63	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2001	20	57					8249	8257		10.1038/sj.onc.1205029	http://dx.doi.org/10.1038/sj.onc.1205029			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781839				2022-12-28	WOS:000172507800008
J	Beneke, R; Moroy, T				Beneke, R; Moroy, T			Inhibition of poly(ADO-ribose) polymerase activity accelerates T-cell lymphomagenesis in p53 deficient mice	ONCOGENE			English	Article						PARP-1; apoptosis; DNA repair; p53; T-cell lymphoma	DNA-BINDING DOMAIN; POLY(ADP-RIBOSE) POLYMERASE; TRANSDOMINANT INHIBITION; TRANSGENIC MICE; EXCISION-REPAIR; CD95 APO-1/FAS; APOPTOSIS; DAMAGE; EXPRESSION; RECOVERY	Cells that lack PARP-1 activity are limited in their ability to repair DNA single strand breaks and respond to DNA damage with a strong accumulation of p53 and enhanced rates of apoptotic cell death. We have generated combinatorial mutant mice that both lack p53 and PARP-1 activity due to the expression of a dominant negative PARP-1 allele targeted to T-cells by the lck promoter. Here we report that these double mutant mice develop T-cell lymphoma at a significantly reduced latency period compared to single p53 null mice that are already cancer prone. We demonstrate that the absence of p53 does not only protect T-cells from lck-PARP-DBD transgenic mice from apoptosis but also abrogates the DNA damage induced cell cycle arrest in the G1 phase. T-cells from double mutant mice continue to proliferate after the induction of DNA strand breaks, are limited in their DNA repair capacity and cannot be eliminated by apoptosis. These results indicate that PARP-1 and p53 cooperate in the suppression of tumorigenesis by maintaining genomic integrity after DNA damage through the activation of a G1/S cell cycle checkpoint the initiation of DNA repair and the induction of cell death.	Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumorforsch, 1FZ,Virchowstr 173, D-45122 Essen, Germany.	moeroey@uni-essen.de	Moroy, Tarik/D-9923-2011					ALTHAUS FR, 1994, MOL CELL BIOCHEM, V138, P53, DOI 10.1007/BF00928443; Beneke R, 2000, MOL CELL BIOL, V20, P6695, DOI 10.1128/MCB.20.18.6695-6703.2000; Conde C, 2001, EMBO J, V20, P3535, DOI 10.1093/emboj/20.13.3535; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; JOSHI VV, 1970, J NATL CANCER I, V44, P185; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kupper JH, 1996, CANCER RES, V56, P2715; KUPPER JH, 1990, J BIOL CHEM, V265, P18721; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; LIU LL, 1994, CANCER RES, V54, P4648; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PANZETER PL, 1993, J BIOL CHEM, V268, P17662; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Van Meyel DJ, 1998, INT J ONCOL, V13, P917; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509	41	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2001	20	56					8136	8141		10.1038/sj.onc.1205056	http://dx.doi.org/10.1038/sj.onc.1205056			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781827				2022-12-28	WOS:000172396800011
J	Branton, PE; Roopchand, DE				Branton, PE; Roopchand, DE			The role of adenovirus E4orf4 protein in viral replication and cell killing	ONCOGENE			English	Review						adenovirus; E4orf4; PP2A; apoptosis	2A REGULATORY SUBUNIT; SMALL-T-ANTIGEN; POLYOMAVIRUS MIDDLE-T; PHOSPHATASE 2A; SACCHAROMYCES-CEREVISIAE; EARLY REGION-4; E1A PROTEIN; P53-INDEPENDENT APOPTOSIS; SIGNAL-TRANSDUCTION; TRANSFORMED-CELLS	It has only been within the last few years that insights have been gained into the remarkable diversity of functions of the adenovirus early transcription region 4 (E4) products. The polypeptide encoded by E4 open reading frame 4 (E4orf4) has emerged as an enigmatic product. Although it accomplishes certain functions that propel viral replication, it has also been shown to be highly toxic, an effect that could dampen the infectious cycle, but that also might serve to facilitate release of viral progeny. When expressed alone, E4orf4 induces a novel form of p53-independent apoptosis in cancer cells but not in normal human cells, thus making it of potential use in cancer gene therapy. In addition, knowledge of its mechanism of action, especially with regard to its interaction with protein phosphatase 2A (MA), could provide insights to develop new small molecule anti-cancer drugs. Thus future studies on E4orf4 should be both informative and potentially valuable therapeutically. In this study we review the current status of knowledge on E4orf4.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; GeminX Biotechnol Inc, Montreal, PQ H2W 2M9, Canada	McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,3655 Promenade Sir Willian Osle, Montreal, PQ H3G 1Y6, Canada.	branton@med.mcgill.ca						Afifi R, 2001, J VIROL, V75, P4444, DOI 10.1128/JVI.75.9.4444-4447.2001; AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; Boivin D, 1999, J VIROL, V73, P1245, DOI 10.1128/JVI.73.2.1245-1253.1999; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; BONDESSON M, 1992, EMBO J, V11, P3347, DOI 10.1002/j.1460-2075.1992.tb05413.x; BRIDGE E, 1993, VIROLOGY, V193, P794, DOI 10.1006/viro.1993.1188; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; Colella S, 2001, INT J CANCER, V93, P798, DOI 10.1002/ijc.1423; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEL PL, 1997, SCIENCE, V278, P687; ENGEL DA, 1988, GENE DEV, V2, P1517, DOI 10.1101/gad.2.12a.1517; Evangelista CC, 1996, GENETICS, V142, P1083; Evans DRH, 2000, MOL GEN GENET, V264, P425; Evans DRH, 1997, GENETICS, V145, P227; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; FREYER GA, 1984, NUCLEIC ACIDS RES, V12, P3503, DOI 10.1093/nar/12.8.3503; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HERISSE J, 1981, NUCLEIC ACIDS RES, V9, P4023, DOI 10.1093/nar/9.16.4023; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; Kaplan JM, 1999, J VIROL, V73, P4489, DOI 10.1128/JVI.73.5.4489-4492.1999; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; Kleinberger T, 2000, APOPTOSIS, V5, P211, DOI 10.1023/A:1009644210581; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; Mannervik M, 1999, VIROLOGY, V256, P313, DOI 10.1006/viro.1999.9663; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 1996, J VIROL, V70, P6207, DOI 10.1128/JVI.70.9.6207-6215.1996; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; McCright B, 1996, GENOMICS, V36, P168, DOI 10.1006/geno.1996.0438; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; MULLER U, 1992, J VIROL, V66, P5867; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nilsson CE, 2001, EMBO J, V20, P864, DOI 10.1093/emboj/20.4.864; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; ROOPCHAND DE, 2001, IN PRESS ONCOGENE; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; Shu YM, 1997, MOL CELL BIOL, V17, P3242, DOI 10.1128/MCB.17.6.3242; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; TEODORO JG, 1995, ONCOGENE, V11, P467; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; VIRTANEN A, 1984, J VIROL, V51, P822, DOI 10.1128/JVI.51.3.822-831.1984; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Wei HJ, 2001, J BIOL CHEM, V276, P1570, DOI 10.1074/jbc.M008694200; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; Wu J, 2000, EMBO J, V19, P5672, DOI 10.1093/emboj/19.21.5672; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; Yang HF, 2000, MOL CELL BIOL, V20, P8143, DOI 10.1128/MCB.20.21.8143-8156.2000; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	99	67	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7855	7865		10.1038/sj.onc.1204862	http://dx.doi.org/10.1038/sj.onc.1204862			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753668				2022-12-28	WOS:000172336500005
J	Mantovani, F; Banks, L				Mantovani, F; Banks, L			The Human Papillomavirus E6 protein and its contribution to malignant progression	ONCOGENE			English	Review						HPV; E6; transformation; proteasome; PDZ domains	LARGE TUMOR-SUPPRESSOR; MAMMARY EPITHELIAL-CELLS; POSITIVE CANCER-CELLS; DISCS-LARGE PROTEIN; CERVICAL INTRAEPITHELIAL NEOPLASIA; CALCIUM-INDUCED DIFFERENTIATION; INTERFERON REGULATORY FACTOR-3; HUMAN FORESKIN KERATINOCYTES; MESSENGER-RNA LEVELS; PDZ DOMAIN PROTEIN	The Human Papillomavirus (HPV) E6 protein is one of three oncoproteins encoded by the virus. It has long been recognized as a potent oncogene and is intimately associated with the events that result in the malignant conversion of virally infected cells. In order to understand the mechanisms by which E6 contributes to the development of human malignancy many laboratories have focused their attention on identifying the cellular proteins with which E6 interacts. In this review we discuss these interactions in the light of their respective contributions to the malignant progression of RPV transformed cells.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	Banks@icgeb.trieste.it						Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; ASKEW DS, 1991, ONCOGENE, V6, P1915; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; BENTON C, 1996, PAPILLOMAVIRUS REV C, P271; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BURNETT AF, 1992, GYNECOL ONCOL, V47, P343, DOI 10.1016/0090-8258(92)90137-8; Butz K, 1999, ONCOGENE, V18, P2381, DOI 10.1038/sj.onc.1202557; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; BUTZ K, 1995, ONCOGENE, V10, P927; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Chen JJ, 1998, J BIOL CHEM, V273, P13537, DOI 10.1074/jbc.273.22.13537; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; COMERFORD SA, 1995, ONCOGENE, V10, P587; COOPER K, 1993, J PATHOL, V171, P27, DOI 10.1002/path.1711710107; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DALING JR, 1992, AM J EPIDEMIOL, V135, P180, DOI 10.1093/oxfordjournals.aje.a116270; Degenhardt YY, 2001, J VIROL, V75, P151, DOI 10.1128/JVI.75.1.151-160.2001; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DIPAOLO JA, 1989, ONCOGENE, V4, P395; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Doorbar J, 1997, VIROLOGY, V238, P40, DOI 10.1006/viro.1997.8768; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; Elbel M, 1997, VIROLOGY, V239, P132, DOI 10.1006/viro.1997.8860; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; ETSCHEID BG, 1994, VIROLOGY, V205, P583, DOI 10.1006/viro.1994.1684; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gao QS, 2000, J BIOL CHEM, V275, P14824, DOI 10.1074/jbc.275.20.14824; Gao QS, 2001, J VIROL, V75, P4459, DOI 10.1128/JVI.75.9.4459-4466.2001; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Goodman RH, 2000, GENE DEV, V14, P1553; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Hamada K, 1996, GYNECOL ONCOL, V63, P219, DOI 10.1006/gyno.1996.0310; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Isaacs JS, 1999, MOL CARCINOGEN, V24, P70, DOI 10.1002/(SICI)1098-2744(199901)24:1<70::AID-MC10>3.0.CO;2-5; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Jackson S, 2000, ONCOGENE, V19, P592, DOI 10.1038/sj.onc.1203339; KANDA T, 1991, VIROLOGY, V185, P536, DOI 10.1016/0042-6822(91)90523-E; Kao WH, 2000, J VIROL, V74, P6408, DOI 10.1128/JVI.74.14.6408-6417.2000; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Konig C, 1999, J VIROL, V73, P2253; Krajewski S, 1996, CANCER RES, V56, P2849; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; KURMAN RJ, 1988, AM J OBSTET GYNECOL, V159, P293, DOI 10.1016/S0002-9378(88)80070-X; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Lepik D, 1998, J VIROL, V72, P6822, DOI 10.1128/JVI.72.8.6822-6831.1998; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Lie AK, 1999, INT J GYNECOL PATHOL, V18, P5, DOI 10.1097/00004347-199901000-00002; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; LIU ZJ, 1994, VIROLOGY, V201, P388, DOI 10.1006/viro.1994.1306; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; Mancini A, 2000, FEBS LETT, V482, P54, DOI 10.1016/S0014-5793(00)02036-6; Mantovani F, 1999, ONCOGENE, V18, P3309, DOI 10.1038/sj.onc.1202688; MANTOVANI F, 2001, IN PRESS J CELL SCI; Marcello A, 2000, J VIROL, V74, P9090, DOI 10.1128/JVI.74.19.9090-9098.2000; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Menon AG, 1997, ONCOGENE, V14, P611, DOI 10.1038/sj.onc.1200853; MUNGER K, 1989, J VIROL, V63, P4417; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; Peng YC, 2000, J VIROL, V74, P5872, DOI 10.1128/JVI.74.13.5872-5879.2000; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Reuver SM, 1998, J CELL SCI, V111, P1071; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Sherman L, 1997, VIROLOGY, V237, P296, DOI 10.1006/viro.1997.8778; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Snijders PJF, 1998, CANCER RES, V58, P3812; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Steller MA, 1996, CANCER RES, V56, P5087; STOREY A, 1993, ONCOGENE, V8, P919; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Thomas M, 1999, J GEN VIROL, V80, P1513, DOI 10.1099/0022-1317-80-6-1513; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; THOMAS M, 1995, ONCOGENE, V10, P261; Tochio H, 2000, J MOL BIOL, V295, P225, DOI 10.1006/jmbi.1999.3350; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Turner CE, 2000, J CELL SCI, V113, P4139; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; WEIS K, 1994, J BIOL CHEM, V269, P19142; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; ZHANG JW, 1995, GYNECOL ONCOL, V57, P170, DOI 10.1006/gyno.1995.1120; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	185	361	382	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7874	7887		10.1038/sj.onc.1204869	http://dx.doi.org/10.1038/sj.onc.1204869			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753670				2022-12-28	WOS:000172336500007
J	Saenz-Robles, MT; Sullivan, CS; Pipas, JM				Saenz-Robles, MT; Sullivan, CS; Pipas, JM			Transforming functions of Simian Virus 40	ONCOGENE			English	Review						SV40; tumor suppressor; chaperone; tumor virus	LARGE-T-ANTIGEN; SV40 LARGE T; SIMIAN-VIRUS-40 LARGE-T; TRANSGENIC MOUSE MODEL; LARGE TUMOR-ANTIGEN; HUMAN ALPHA-1-ANTITRYPSIN GENE; VILLUS-ASSOCIATED ENTEROCYTES; RETINAL-PIGMENT EPITHELIUM; TISSUE-SPECIFIC EXPRESSION; AMINO-TERMINAL DOMAIN		Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pipas, JM (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.	pipas@pitt.edu						Asa SL, 1996, VIRCHOWS ARCH, V427, P595; Asamoto M, 2001, CANCER RES, V61, P4693; Baratin M, 2001, CANCER GENE THER, V8, P193, DOI 10.1038/sj.cgt.7700285; Beermann F, 1999, PIGM CELL RES, V12, P71, DOI 10.1111/j.1600-0749.1999.tb00746.x; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BELL RH, 1990, CARCINOGENESIS, V11, P1393, DOI 10.1093/carcin/11.8.1393; Bennoun M, 1998, ONCOGENE, V17, P1253, DOI 10.1038/sj.onc.1202047; Berjanskii MV, 2000, J BIOL CHEM, V275, P36094, DOI 10.1074/jbc.M006572200; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BUTEL JS, 1990, INTERVIROLOGY, V31, P85, DOI 10.1159/000150142; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CAVENDER JF, 1995, J VIROL, V69, P923, DOI 10.1128/JVI.69.2.923-934.1995; CECI JD, 1991, ONCOGENE, V6, P323; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHEAH KSE, 1995, J CELL BIOL, V128, P223, DOI 10.1083/jcb.128.1.223; CHEN JD, 1992, ONCOGENE, V7, P1167; CHEN JD, 1989, J VIROL, V63, P2204, DOI 10.1128/JVI.63.5.2204-2214.1989; CHEN JD, 1991, MOL CELL BIOL, V11, P5968, DOI 10.1128/MCB.11.12.5968; Chiu IM, 2000, ONCOGENE, V19, P6229, DOI 10.1038/sj.onc.1204021; Coopersmith CM, 1997, J CELL BIOL, V138, P167, DOI 10.1083/jcb.138.1.167; DAUD AI, 1993, AM J PHYSIOL, V264, pH1693, DOI 10.1152/ajpheart.1993.264.5.H1693; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; DYER KR, 1989, AM J PATHOL, V135, P401; Eckner R, 1996, MOL CELL BIOL, V16, P3454; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Fields BN., 1996, VIROLOGY; FOX N, 1989, SCIENCE, V244, P460, DOI 10.1126/science.2785714; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Gum JR, 2001, CANCER RES, V61, P3472; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Herring BP, 1999, J BIOL CHEM, V274, P17725, DOI 10.1074/jbc.274.25.17725; Herzig M, 1999, BIOL CHEM, V380, P203, DOI 10.1515/BC.1999.028; Husler MR, 1998, TRANSGENIC RES, V7, P253, DOI 10.1023/A:1008865911660; JENSEN NA, 1993, P NATL ACAD SCI USA, V90, P3192, DOI 10.1073/pnas.90.8.3192; JIANG D, 1993, ONCOGENE, V8, P2805; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KNOWLES BB, 1990, AM J PATHOL, V137, P259; KOHRMAN DC, 1992, J VIROL, V66, P1752, DOI 10.1128/JVI.66.3.1752-1760.1992; Le Menuet D, 2000, KIDNEY INT, V57, P1299, DOI 10.1046/j.1523-1755.2000.00966.x; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEE YC, 1992, J BIOL CHEM, V267, P10705; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LOPEZ MJ, 1995, J BIOL CHEM, V270, P885, DOI 10.1074/jbc.270.25.14989; Luo XL, 1996, NAT STRUCT BIOL, V3, P1034, DOI 10.1038/nsb1296-1034; Manickan E, 2001, J BIOL CHEM, V276, P13989, DOI 10.1074/jbc.M009770200; March KL, 1999, ONCOGENE, V18, P3773, DOI 10.1038/sj.onc.1202994; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MURPHY D, 1987, AM J PATHOL, V129, P552; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PASCALL JC, 1994, J MOL ENDOCRINOL, V12, P313, DOI 10.1677/jme.0.0120313; Pasumarthi KBS, 2001, CIRC RES, V88, P1004, DOI 10.1161/hh1001.090878; Penna D, 1998, ONCOGENE, V17, P2601, DOI 10.1038/sj.onc.1202196; PERRAUD F, 1992, ONCOGENE, V7, P993; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RASSOULZADEGAN M, 1978, J VIROL, V28, P1; Ratineau C, 2000, GASTROENTEROLOGY, V119, P1305, DOI 10.1053/gast.2000.19278; REYNOLDS RK, 1988, P NATL ACAD SCI USA, V85, P3135, DOI 10.1073/pnas.85.9.3135; Riley MI, 1997, J VIROL, V71, P6068, DOI 10.1128/JVI.71.8.6068-6074.1997; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Sachsenmeier KF, 2001, VIROLOGY, V283, P40, DOI 10.1006/viro.2001.0866; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; SANDMOLLER A, 1994, ONCOGENE, V9, P2805; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; SMITH MS, 1992, DNA CELL BIOL, V11, P345, DOI 10.1089/dna.1992.11.345; Sock E, 1999, MOL CELL BIOL, V19, P2455; SPENCE SL, 1994, J VIROL, V68, P4227, DOI 10.1128/JVI.68.7.4227-4240.1994; SPENCE SL, 1994, VIROLOGY, V204, P200, DOI 10.1006/viro.1994.1524; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Sullivan CS, 2001, J VIROL, V75, P1601, DOI 10.1128/JVI.75.4.1601-1610.2001; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; Tevethia MJ, 1997, J VIROL, V71, P8157, DOI 10.1128/JVI.71.11.8157-8166.1997; Tevethia MJ, 1997, J VIROL, V71, P1888, DOI 10.1128/JVI.71.3.1888-1896.1997; THEURING F, 1990, ONCOGENE, V5, P225; Thompson J, 2000, INT J CANCER, V86, P863, DOI 10.1002/(SICI)1097-0215(20000615)86:6<863::AID-IJC16>3.0.CO;2-4; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; WILKIE TM, 1994, ONCOGENE, V9, P2889; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915	100	82	86	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7899	7907		10.1038/sj.onc.1204936	http://dx.doi.org/10.1038/sj.onc.1204936			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753672				2022-12-28	WOS:000172336500009
J	Zur Hausen, H				Zur Hausen, H			Oncogenic DNA viruses	ONCOGENE			English	Review						viruses; cancer; transformation	HUMAN-PAPILLOMAVIRUS INFECTIONS; RENAL-TRANSPLANT RECIPIENTS; CERVICAL-CARCINOMA CELLS; HERPES-SIMPLEX VIRUS; NUCLEAR ANTIGEN-2; SKIN CANCERS; SEQUENCES; AMPLIFICATION; TRANSCRIPTION; APOPTOSIS		Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Zur Hausen, H (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	zurhausen@dkfz-heidelberg.de						Arbuthnot P, 2001, INT J EXP PATHOL, V82, P77, DOI 10.1111/j.1365-2613.2001.iep178.x; Astori G, 1998, J INVEST DERMATOL, V110, P752, DOI 10.1046/j.1523-1747.1998.00191.x; BACHMANN A, 2001, IN PRESS J VIROL; BEASLEY RP, 1981, LANCET, V2, P1129; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; Boxman ILA, 1997, J INVEST DERMATOL, V108, P712, DOI 10.1111/1523-1747.ep12292090; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; de Villiers EM, 1998, BIOMED PHARMACOTHER, V52, P26, DOI 10.1016/S0753-3322(97)86238-5; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; EVANS AS, 1976, YALE J BIOL MED, V49, P175; GROSS L, 1951, P SOC EXP BIOL MED, V76, P27; HAUSEN HZ, 1994, LANCET, V343, P955, DOI 10.1016/S0140-6736(94)90070-1; HEILBRONN R, 1989, J VIROL, V63, P3683, DOI 10.1128/JVI.63.9.3683-3692.1989; HEILBRONN R, 1993, P NATL ACAD SCI USA, V90, P11406, DOI 10.1073/pnas.90.23.11406; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jackson S, 2000, ONCOGENE, V19, P592, DOI 10.1038/sj.onc.1203339; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; SCHLEHOFER JR, 1983, INT J CANCER, V32, P99, DOI 10.1002/ijc.2910320116; SCHMITT J, 1989, VIROLOGY, V172, P73, DOI 10.1016/0042-6822(89)90108-6; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; Soto U, 2000, INT J CANCER, V86, P811, DOI 10.1002/(SICI)1097-0215(20000615)86:6<811::AID-IJC9>3.0.CO;2-J; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Vonka V, 2000, PHILOS T R SOC B, V355, P1831, DOI 10.1098/rstb.2000.0738; zur Hausen H, 1994, Curr Top Microbiol Immunol, V186, P131; zur Hausen H, 2001, LANCET, V357, P381, DOI 10.1016/S0140-6736(00)03652-7; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	34	79	83	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7820	7823		10.1038/sj.onc.1204958	http://dx.doi.org/10.1038/sj.onc.1204958			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753664				2022-12-28	WOS:000172336500001
J	Claij, N; Riele, HT				Claij, N; Riele, HT			Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level	ONCOGENE			English	Article						mismatch repair; methylation tolerance; microsatellite instability; mutation frequency; homologous recombination	GENE; PREDISPOSITION; HMSH2-HMSH6; DEFICIENCY; EXPRESSION; RESISTANCE; MUTATIONS; FREQUENCY; HMLH1; HMSH2	Loss of DNA mismatch repair has been found in tumors associated with the familial cancer predisposition syndrome HNPCC (hereditary non-polyposis colorectal cancer) and a subset of sporadic cancers. MSH2 deficiency abolishes the action of the mismatch repair system, resulting in a phenotype which is characterized by an increased accumulation of base substitutions and frameshifts, enhanced recombination between homologous but non-identical DNA sequences, and tolerance to the cytotoxic effects of methylating agents. In this study we describe an embryonic stem cell line in which the level of MSH2 protein is 10-fold reduced compared to that in wild-type cells. Remarkably, these MSH2-low cells were as resistant to killing by methylating agents as cells completely lacking MSH2, while they had retained almost maximal mismatch repair capacity as judged from their anti-mutagenic and anti-recombinogenic capacity and the absence of microsatellite instability. In contrast, MSH2-low cells were highly sensitive to methylation-damage induced mutagenesis. Thus, 10-fold reduced MSH2 protein levels render cells resistant to the toxic and highly sensitive to the mutagenic effects of methylating agents. This condition is not manifested by microsatellite instability and may have implications four both the etiology and treatment of cancer.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Riele, HT (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.t.riele@nki.nl						Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Berardini M, 2000, J BIOL CHEM, V275, P27851; BOCKER T, 1999, BIOCHIM BIOPHYS ACTA, V1423, P1; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Evans E, 2000, MOL CELL BIOL, V20, P7839, DOI 10.1128/MCB.20.21.7839-7844.2000; Fink D, 1998, CLIN CANCER RES, V4, P1; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Friedman HS, 1997, CANCER RES, V57, P2933; Fritzell JA, 1997, CANCER RES, V57, P5143; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Kane MF, 1997, CANCER RES, V57, P808; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; Lu SL, 1996, JPN J CANCER RES, V87, P279, DOI 10.1111/j.1349-7006.1996.tb00218.x; Lynch HT, 2000, J CLIN ONCOL, V18, p19S; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Shin KH, 2000, EUR J CANCER, V36, P925, DOI 10.1016/S0959-8049(00)00025-3; Shin KH, 1998, J CANCER RES CLIN, V124, P421, DOI 10.1007/s004320050194; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Umar A, 1998, GENETICS, V148, P1637; Zhu WB, 1998, MUTAT RES-FUND MOL M, V398, P93, DOI 10.1016/S0027-5107(97)00244-3	24	48	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2873	2879		10.1038/sj.onc.1205395	http://dx.doi.org/10.1038/sj.onc.1205395			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973647				2022-12-28	WOS:000175063700012
J	Al Moustafa, AE; Alaoui-Jamali, MA; Batist, G; Hernandez-Perez, M; Serruya, C; Alpert, L; Black, MJ; Sladek, R; Foulkes, WD				Al Moustafa, AE; Alaoui-Jamali, MA; Batist, G; Hernandez-Perez, M; Serruya, C; Alpert, L; Black, MJ; Sladek, R; Foulkes, WD			Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells	ONCOGENE			English	Article						cDNA microarray; gene expression; head and neck cancer	BETA-CATENIN EXPRESSION; S-TRANSFERASE-PI; E-CADHERIN; DIFFERENTIAL EXPRESSION; INTERMEDIATE-FILAMENTS; ADHESION; PROTEIN; CYTOKERATIN; COMBINATION; SUBTRACTION	In order to identify genes involved in head and neck carcinogenesis, we compared the gene expression profile in matched primary normal epithelial cells and primary head and neck cancer cells from the same patients. A cDNA microarray analysis consisting of 12530 human genes revealed significant changes in the expression of 213 genes, with 91 genes being up-regulated and 122 being dowm-regulated. This comprehensive list of genes includes those associated with signal transduction (growth factors), cell structure, cell cycle, transcription, apoptosis, and cell-cell adhesion. Further analysis of nine genes involved in cell-cell interaction, using Western blot and/or reverse transcription (RT)-PCR of four paired cell lines supported the reliability of our microarray analysis. More specifically, our study provides the first evidence that claudin-7 and connexin 31.1 are down-regulated in head and neck squamous cell carcinomas (HNSCC) compared to normal cells. These findings provide a large body of information regarding gene expression profiles associated with head and neck carcinogenesis, and also represent a source of potential targets for HNSCC prevention and/or therapeutics.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Pathol, Montreal, PQ H3T 1E2, Canada; McGill Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada; Sir MB Davis Jewish Gen Hosp, Dept Surg, Div Head & Neck Surg, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Inst Res, Montreal, PQ, Canada; McGill Univ, Montreal Genome Ctr, Montreal, PQ, Canada; McGill Univ, Program Canc Genet, Dept Human Genet, Montreal, PQ, Canada; McGill Univ, Program Canc Genet, Dept Oncol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University	Al Moustafa, AE (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada.	aalmoust@ldi.jgh.mcgill.ca; malaou@po-box.mcgill.ca	Foulkes, William D./AAR-9586-2021; Sladek, Robert/R-2391-2019	Foulkes, William D./0000-0001-7427-4651; Sladek, Robert/0000-0002-2730-1204				ALMOUSTAFA AE, 2002, IN PRESS LUNG CANC; Anttonen A, 1999, BRIT J CANCER, V79, P558, DOI 10.1038/sj.bjc.6690088; Bagutti C, 1998, J PATHOL, V186, P8, DOI 10.1002/(SICI)1096-9896(199809)186:1<8::AID-PATH156>3.0.CO;2-H; Bentz BG, 2000, LARYNGOSCOPE, V110, P1642, DOI 10.1097/00005537-200010000-00013; BEYER EC, 1990, J MEMBRANE BIOL, V3, P187; Bishop AJR, 2001, BBA-REV CANCER, V1471, pM109, DOI 10.1016/S0304-419X(01)00018-X; BRISSETTE JL, 1994, P NATL ACAD SCI USA, V91, P6453, DOI 10.1073/pnas.91.14.6453; BUDUNOVA IV, 1995, CARCINOGENESIS, V16, P2717, DOI 10.1093/carcin/16.11.2717; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chu YW, 1996, AM J PATHOL, V148, P63; Clavel CE, 2001, J PATHOL, V194, P20, DOI 10.1002/path.868; Duffey DC, 2000, BRIT J CANCER, V83, P1367, DOI 10.1054/bjoc.2000.1423; Gofuku J, 1999, AM J CLIN PATHOL, V111, P29; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Heiskala M, 2001, TRAFFIC, V2, P92, DOI 10.1034/j.1600-0854.2001.020203.x; Jeffries S, 2001, ORAL ONCOL, V37, P115, DOI 10.1016/S1368-8375(00)00065-8; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Li Z, 1998, J CELL SCI, V111, P1005; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Miura K, 1997, JPN J CANCER RES, V88, P143, DOI 10.1111/j.1349-7006.1997.tb00359.x; Morifuji M, 2000, AM J PATHOL, V156, P1317, DOI 10.1016/S0002-9440(10)65002-X; Ninomiya I, 2000, INT J CANCER, V85, P757, DOI 10.1002/(SICI)1097-0215(20000315)85:6<757::AID-IJC3>3.0.CO;2-O; Ono K, 2000, CANCER RES, V60, P5007; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Paterson IC, 2001, J PATHOL, V193, P458, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH822>3.0.CO;2-V; Pukkila MJ, 2001, J CLIN PATHOL, V54, P42, DOI 10.1136/jcp.54.1.42; Reid BC, 2000, ORAL ONCOL, V36, P414, DOI 10.1016/S1368-8375(00)00028-2; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Tomson AM, 1996, CLIN EXP METASTAS, V14, P501, DOI 10.1007/BF00115110; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Witt CJ, 2000, OTOLARYNG HEAD NECK, V122, P721, DOI 10.1016/S0194-5998(00)70204-X; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; Yamasaki H, 1999, CANCER DETECT PREV, V23, P273, DOI 10.1046/j.1525-1500.1999.99037.x; Yang YM, 1997, AM J PATHOL, V150, P693; Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2	43	180	189	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2634	2640		10.1038/sj.onc.1205351	http://dx.doi.org/10.1038/sj.onc.1205351			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965536				2022-12-28	WOS:000174996500003
J	Shiratori, M; Suzuki, T; Itoh, C; Goto, M; Furuichi, Y; Matsumoto, T				Shiratori, M; Suzuki, T; Itoh, C; Goto, M; Furuichi, Y; Matsumoto, T			WRN helicase accelerates the transcription of ribosomal RNA as a component of an RNA polymerase I-associated complex	ONCOGENE			English	Article						nucleolar localization; RNA polymerase 1; rRNA transcription; senescence; Werner syndrome; WRN	WERNER-SYNDROME PROTEIN; SYNDROME GENE; DNA HELICASE; NUCLEAR-LOCALIZATION; GENOMIC STRUCTURE; YEAST SGS1; TOPOISOMERASE; REPLICATION; INTERACTS; HOMOLOG	Werner syndrome (WS) is a rare autosmomal recessive genetic disorder causing premature aging. The gene (WRN) responsible for WS encodes a protein homologous to the RecQ-type helicase. WRN has a nucleolar localization signal and shows intranuclear trafficking between the nucleolus and the nucleoplasm. WRN is recruited into the nucleolus when rRNA transcription is reactivated in quiescent cells. Inhibition of mRNA transcription with alpha-amanitin has no effect on nucleolar localization of WRN whereas inhibition of rRNA transcription with actinomycin D releases WRN from nucleoli, suggesting that nucleolar WRN is closely related to rRNA transcription by RNA polymerase I (RPI). A possible function of WRN on rRNA transcription through interaction with RPI is supported by the results described here showing that WRN is co-immunoprecipitated with an RPI subunit, RPA40. Here we show that WS fibroblasts are characterized by a decreased level of rRNA transcription compared with wild-type cells, and that the decreased level of rRNA transcription in WS fibroblasts recovers when wild-type WRN is exogenously expressed. By contrast, exogenously expressed mutant-type WRN lacking an ability to migrate into the nucleolus fails to stimulate rRNA transcription. These results suggest that WRN promotes rRNA transcription as a component of an RPI-associated complex in the nucleolus.	AGENE Res Inst, Kanagawa 2470063, Japan; Tokyo Metropolitan Otsuka Hosp, Dept Rheumatol, Toshima Ku, Tokyo 1700005, Japan		Matsumoto, T (corresponding author), Japanese Fdn Canc Res, Genome Ctr, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	takehisa.matsumoto@jfcr.or.jp						Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Dammann R, 1998, BBA-GENE STRUCT EXPR, V1396, P153, DOI 10.1016/S0167-4781(97)00206-6; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Matsumoto T, 1997, HUM GENET, V100, P123, DOI 10.1007/s004390050477; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; RONG L, 1991, GENETICS, V127, P75; RONG L, 1993, J BIOL CHEM, V268, P1252; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; STEIN GH, 1994, METHOD ENZYMOL, V58, P279; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Suzuki T, 2001, ONCOGENE, V20, P2551, DOI 10.1038/sj.onc.1204344; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	44	63	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2447	2454		10.1038/sj.onc.1205334	http://dx.doi.org/10.1038/sj.onc.1205334			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971179				2022-12-28	WOS:000174918400001
J	Folberg-Blum, A; Sapir, A; Shilo, BZ; Oren, M				Folberg-Blum, A; Sapir, A; Shilo, BZ; Oren, M			Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila	ONCOGENE			English	Article						Mdm2; apoptosis; Drosophila	ONCOPROTEIN MDM2; P53-INDEPENDENT ROLE; S PHASE; P53; EXPRESSION; IDENTIFICATION; REGULATOR; CLEAVAGE; PROMOTES; HOMOLOG	The Mdm2 proto-oncogene is amplified and overexpressed in a variety of tumors. One of the major functions of Mdm2 described to date is its ability to modulate the levels and activity of the tumor suppressor protein p53. Mdm2 binds to the N-terminus of p53 and, through its action as an E3 ubiquitin ligase, targets p53 for rapid proteasomal degradation. Mdm2 can also bind to other cellular proteins such as hNumb, E2F1, Rb and Akt; however, the biological significance of these interactions is less clear. To gain insight into the function of Mdm2 in vivo, we have generated a transgenic Drosophila strain bearing the mouse Mdm2 gene. Ectopic expression of Mdm2, using the UAS/GAL4 system, causes eye and wing phenotypes in the fly. Analysis of wing imaginal discs from third instar larvae showed that expression of Mdm2 induces apoptosis. Crosses did not reveal genetic interactions between Mdm2 and the Drosophila homolog of E2F, Numb and Akt. These transgenic flies may provide a unique experimental model for exploring the molecular interactions of Mdm2 in a developmental context.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Sapir, Amir/C-5758-2015	Sapir, Amir/0000-0001-9888-1800; Oren, Moshe/0000-0003-4311-7172; Shilo, Ben Zion/0000-0003-4903-8889	NCI NIH HHS [R01 CA40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; CHANG HC, 1994, COLD SPRING HARB SYM, V59, P147, DOI 10.1101/SQB.1994.059.01.018; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; GOTTLIEB TM, 2002, IN PRESS ONCOGENE; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	37	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2413	2417		10.1038/sj.onc.1205305	http://dx.doi.org/10.1038/sj.onc.1205305			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948425				2022-12-28	WOS:000174635600014
J	Schempp, CM; Kirkin, V; Simon-Haarhaus, B; Kersten, A; Kiss, J; Termeer, CC; Gilb, B; Kaufmann, T; Borner, C; Sleeman, JP; Simon, JC				Schempp, CM; Kirkin, V; Simon-Haarhaus, B; Kersten, A; Kiss, J; Termeer, CC; Gilb, B; Kaufmann, T; Borner, C; Sleeman, JP; Simon, JC			Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis	ONCOGENE			English	Article						programmed cell death; Hypericum perforatum; mitochondrial membrane permeabilization; caspases; cytochrome c	CYTOCHROME-C; LIGAND TRAIL; MITOCHONDRIA; ACTIVATION; BCL-2; RELEASE; INVOLVEMENT; METABOLITE; DEATH; CD44	Hyperforin is a plant derived antibiotic from St. John's wort. Here we describe a novel activity of hyperforin, namely its ability to inhibit the growth of tumour cells by induction of apoptosis. Hyperforin inhibited the growth of various human and rat tumour cell lines in vivo, with IC50 values between 3-15 muM. Treatment of tumour cells with hyperforin resulted in a dose-dependent generation of apoptotic oligonucleosomes, typical DNA-laddering and apoptosis-specific morphological changes. In MT-450 mammary carcinoma cells hyperforin increased the activity of caspase-9 and caspase-3, and hyperforin-mediated apoptosis was blocked by the broad-range caspase inhibitor zVAD.fmk. When added to MT-450 cells, hyperforin, but not paclitaxel, induced a rapid loss of the mitochondrial transmembrane potential Deltapsi(m), and subsequent morphological changes such as homogenization and vacuolization of mitochondria. Monitoring of Deltapsi(m) revealed that the hyperforin-mediated mitochondrial permeability transition can not be prevented by zVAD.fmk. This indicates that mitochondrial permeabilization is a cause rather than a consequence of caspase activation. Moreover, hyperforin was capable of releasing cytochrome c from isolated mitochondria. These findings suggest that hyperforin activates a mitochondria-mediated apoptosis pathway. In vivo, hyperforin inhibited the growth of autologous MT-450 breast carcinoma in immunocompetent Wistar rats to a similar extent as the cytotoxic drug paclitaxel, without any signs of acute toxicity. Owing to the combination of significant antitumour activity, low toxicity in vivo and natural abundance of the compound, hyperforin holds the promise of being an interesting novel antineoplastic agent that deserves further laboratory and in vivo exploration.	Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Univ Freiburg, Inst Pathol, D-79104 Freiburg, Germany; HWI Analyt, D-78106 Rheinzabern, Germany; Univ Freiburg, Inst Mol Med, D-79106 Freiburg, Germany	University of Freiburg; Helmholtz Association; Karlsruhe Institute of Technology; University of Freiburg; University of Freiburg	Schempp, CM (corresponding author), Univ Freiburg, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	schempp@haut.ukl.uni-freiburg.de	Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687; Kirkin, Vladimir/0000-0002-8049-3663; Kaufmann, Thomas/0000-0001-9906-874X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BYSTROV NS, 1975, TETRAHEDRON LETT, P2791; Castedo M, 1996, J IMMUNOL, V157, P512; Debatin KM, 1999, ADV EXP MED BIOL, V457, P237; DECOSTERD LA, 1989, HELV CHIM ACTA, V72, P464, DOI 10.1002/hlca.19890720307; Erdelmeier CAJ, 1998, PHARMACOPSYCHIATRY, V31, P2, DOI 10.1055/s-2007-979339; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUREVICH AI, 1971, ANTIBIOT MED BIOTEK, V16, P510; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; KIM U, 1986, J SURG ONCOL, V33, P151, DOI 10.1002/jso.2930330303; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAISENBACHER P, 1992, PLANTA MED, V58, P351, DOI 10.1055/s-2006-961483; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Muller WE, 1998, PHARMACOPSYCHIATRY, V31, P16, DOI 10.1055/s-2007-979341; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Revillard JP, 1998, IMMUNOL TODAY, V19, P291, DOI 10.1016/S0167-5699(98)01279-1; ROTH L, 1990, ECOMED, P97; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Schempp CM, 1999, LANCET, V353, P2129, DOI 10.1016/S0140-6736(99)00214-7; Schempp CM, 2000, BRIT J DERMATOL, V142, P979, DOI 10.1046/j.1365-2133.2000.03482.x; Schempp CM, 2001, FEBS LETT, V493, P26, DOI 10.1016/S0014-5793(01)02268-2; Sleeman JP, 1996, CANCER RES, V56, P3134; Sleeman JP, 1999, ONCOGENE, V18, P4485, DOI 10.1038/sj.onc.1202808; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Termeer C, 2001, J LEUKOCYTE BIOL, V70, P715; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	44	194	213	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1242	1250		10.1038/sj.onc.1205190	http://dx.doi.org/10.1038/sj.onc.1205190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850844				2022-12-28	WOS:000173729400012
J	Recio, JA; Merlino, G				Recio, JA; Merlino, G			Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1	ONCOGENE			English	Article						melanoma; HGF/SF; p38; ATF-2; c-Met	FACTOR SCATTER FACTOR; ELEMENT-BINDING PROTEIN; FOCAL ADHESION KINASE; TYROSINE KINASE; C-MET; LEUCINE ZIPPER; SOMATIC MUTATIONS; RESPONSE ELEMENT; GENE-EXPRESSION; RECEPTOR	Members of the mitogen-activated protein kinase (MAPK) superfamily, including p38 kinase and SAPK/JNK, play a central role in mediating cellular response to environmental stress. growth factors and cytokines. Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional cytokine capable of eliciting mitogenic, motogenic and morphogenetic activities in responsive cells, and has been implicated in tumor development and metastasis. Binding of HGF/SF to its tyrosine kinase receptor c-Met stimulates multiple signal transduction pathways, leading to the activation of numerous transcription factors. We here report that HGF/SF can induce cyclin D1 expression in mouse melanoma cells. and that this up-regulation is mediated in part by the activating transcription factor-2 (ATF-2). HGF/SF-mediated phosphorylation of ATF-2 was reduced in the presence of either the p38 kinase-specific inhibitor SB203580, a dominant negative p38 mutant, the SAPK/JNK inhibitor JNK-interacting protein-1 (JIP-1), or the phosphatidylinositol 3-kinase (PI3K)-specific inhibitor LY294002. Activation of p38 kinase by HGF/SF was partially blocked by the PI3K-specific inhibitor as well. The upstream kinases for p38, MKK3/6, did not become activated following HGF/SF exposure, and ATF-2 activation was undiminished by transient transfection of a dominant negative MKK6 mutant. However, transcriptional up-regulation of cyclin D1 by HGF/SF was partially inhibited by the p38 kinase-specific inhibitor, and cyclin D1 protein induction was partially blocked by a dominant negative ATF-2 mutant. Notably, the p38 kinase-specific inhibitor was able to block melanoma cell proliferation but not motility. We conclude that the ATF-2 transcription factor becomes activated by HGF/SF through p38 MAPK and SAPK/JNK. Moreover, the p38-ATF-2 pathway can help mediate proliferation signals in tumor cells through transcriptional activation of key cell cycle regulators.	NCI, Mol Biol Lab, Mol Genet Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Merlino, G (corresponding author), NCI, Mol Biol Lab, Mol Genet Sect, NIH, Bldg 37,Room 5002,MSC 4264, Bethesda, MD 20892 USA.	gmerlino@helix.nih.gov		Recio, Juan Angel/0000-0002-7320-3832				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; Awasthi V, 2000, AM J PHYSIOL-LUNG C, V279, pL942, DOI 10.1152/ajplung.2000.279.5.L942; Bales ES, 1999, J INVEST DERMATOL, V113, P1039, DOI 10.1046/j.1523-1747.1999.00812.x; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Beviglia L, 1999, INT J CANCER, V83, P640, DOI 10.1002/(SICI)1097-0215(19991126)83:5<640::AID-IJC13>3.0.CO;2-D; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Chen RF, 2000, RARE METALS, V19, P231; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chuang SM, 2000, CARCINOGENESIS, V21, P1491, DOI 10.1093/carcin/21.8.1491; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coupland SE, 2000, J PATHOL, V191, P120; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; FILMUS J, 1994, ONCOGENE, V9, P3627; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nakanishi K, 1999, CLIN EXP METASTAS, V17, P507, DOI 10.1023/A:1006685218766; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Otsuka T, 1998, CANCER RES, V58, P5157; Park WS, 1999, CANCER RES, V59, P307; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; ROSEN EM, 1997, J BIOL CHEM, V270, P27780; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Shambaugh GE, 1996, J NEUROPATH EXP NEUR, V55, P1009, DOI 10.1097/00005072-199609000-00008; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Spector M, 2000, EXP CELL RES, V258, P109, DOI 10.1006/excr.2000.4907; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tolnay E, 1998, J CANCER RES CLIN, V124, P291, DOI 10.1007/s004320050171; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weimar IS, 1998, LEUKEMIA, V12, P1195, DOI 10.1038/sj.leu.2401080; YAMASHITA J, 1994, CANCER RES, V54, P1630; Yao Y, 1996, AM J PATHOL, V149, P1707; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	70	132	144	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1000	1008		10.1038/sj.onc.1205150	http://dx.doi.org/10.1038/sj.onc.1205150			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850817				2022-12-28	WOS:000173580100003
J	Zhong, MH; Lu, ZM; Foster, DA				Zhong, MH; Lu, ZM; Foster, DA			Downregulating PKC delta provides a PI3K/Akt-independent survival signal that overcomes apoptotic signals generated by c-Src overexpression	ONCOGENE			English	Article						apoptosis; c-Src; PKC delta; tumor promoter; TPA	PROTEIN-KINASE-C; V-SRC; EMBRYO FIBROBLASTS; CELL-SURVIVAL; ACTIVATION; RAS; CANCER; DEGRADATION; SUPPRESSION; CODON-531	3Y1 rat fibroblasts overexpressing the tyrosine kinase c-Src (3Y1(c-Src) cells) become transformed by downregulation of protein kinase C delta (PKC delta). However, when 3Y1(c-Src) cells were subjected to serum withdrawal, they underwent apoptosis via a cytochrome c/caspase 9 pathway. In contrast, neither parental nor v-Src-transformed 3Y1 cells underwent apoptosis when subjected to serum withdrawal. If PKC delta was downregulated, the apoptotic phenotypes induced by serum withdrawal in the 3Y1(c-Src) cells were suppressed. The apparent survival signal generated by PKC delta downregulation was independent of the phosphatidylinositol-3-kinase (PI3K)/Akt survival pathway. Collectively, these data indicate that (1) c-Src overexpression renders cells sensitive to apoptotic stress, and (2) that downregulation of PKC delta provides a novel PI3K/Akt-independent survival signal capable of suppressing apoptotic signals.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.				NCI NIH HHS [CA 46677] Funding Source: Medline; NCRR NIH HHS [RR 03037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CRESSMAN CM, 1995, FEBS LETT, V367, P223, DOI 10.1016/0014-5793(95)00543-I; Daigo Y, 1999, CANCER RES, V59, P4222; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DOTTO GP, 1985, NATURE, V318, P472; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Wang NM, 2000, CANCER LETT, V150, P201, DOI 10.1016/S0304-3835(99)00398-5; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	39	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1071	1078		10.1038/sj/onc/1205165	http://dx.doi.org/10.1038/sj/onc/1205165			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850824				2022-12-28	WOS:000173580100010
J	Kukushkin, AN; Abramova, MV; Svetlikova, SB; Darieva, ZA; Pospelova, TV; Pospelov, VA				Kukushkin, AN; Abramova, MV; Svetlikova, SB; Darieva, ZA; Pospelova, TV; Pospelov, VA			Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter	ONCOGENE			English	Article						c-fos repression; Elk-1; histone deacetylase; chromatin; E1A and ras oncogenes	SIGNAL-TRANSDUCTION PATHWAYS; SERUM RESPONSE ELEMENT; P38 MAP KINASE; HISTONE ACETYLATION; PROTEIN-KINASE; JUN PROMOTER; DNA-BINDING; IN-VIVO; INHIBITION; EXPRESSION	REF cells transformed by oncogenes E1A and cHa-ras reveal high and constitutive DNA-binding activity of AP-1 factor lacking in c-Fos protein. Consistently, the transcription of c-fos gene has been found to be downregulated. To elucidate the mechanisms of c-fos downregulation in E1A+cHa-ras transformants, we studied the levels of activity of ERK, JNK/SAPK and p38 kinases and phosphorylation state of Elk-1 transcription factor involved in regulation of c-fos gene. Using two approaches, Western blot analysis with phospho-specific antibodies to MAP kinases and in vitro kinase assay with specific substrates, we show here that ectopic expression of E1A and ras oncogenes leads to a sustained activation of ERK and p38 kinases, whereas JNK/SAPK kinase activity is similar to that in non-transformed REF52 cells. Due to sustained activity of the MAP kinase cascades, Elk-1 transcription factor is being phosphorylated even in serum-starved E1A+cHa-ras cells; moreover, serum does not additionally increase phosphorylation of Elk-1, which is predominant TCF protein bound to SRE region of c-fos gene promoter in these cells. Although the amount of ternary complexes SRE/SRF/TCF estimated by EMSA was similar both in serum-starved and serum-stimulated transformed cells, serum addition still caused a modest activation of c-fos gene transcription at the level of 20% to normal REF cells. In attempt to determine how serum caused the stimulatory effect, we found that PD98059, an inhibitor of MEK/ERK kinase cascade, completely suppressed serum-induced c-fos transcription both in REF and E1A+cHa-ras cells, implicating the ERK as primary kinase for c-fos transcription in these cells. In contrast, SB203580, an inhibitor of p38 kinase, augmented noticeably serum-stimulated transcription of c-fos gene in REF cells, implying the involvement of p38 kinase in negative regulation of c-fos. Furthermore, sodium butyrate, an inhibitor of histone deacetylase activity, was capable of activating c-fos transcription both in serum-stimulated and even in serum-starved E1A+cHa-ras cells. Conversely, serum-starved REF cells fail to respond to sodium butyrate treatment by c-fos activation confirming necessity of prior Elk-1 phosphorylation. Taken together, these data suggest that downregulation of c-fos in E1A+cHa-ras cells seems to occur due to a maintenance of a refractory state that arises in normal REF cells after serum-stimulation. The refractory state of c-fos in E1A+cHa-ras cells is likely a consequence of Ras-induced sustained activation of MAPK (ERK) cascade and persistent phosphorylation of TCF (Elk-1) bound to SRE. Combination of these events eventually does contribute to formation of an inactive chromatin structure at c-fos promoter mediated through recruitment of histone deacetylase activity.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Pospelov, VA (corresponding author), Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia.	vap@link.cytspb.rssi.ru	Igotti, Maria V/U-4868-2017; Kukushkin, Alexander/W-7241-2018	Igotti, Maria/0000-0001-9596-5195				ABRAMOVA MV, 2002, MOL BIOL MOSCOW, V36; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; Ding XZ, 2001, BIOCHEM BIOPH RES CO, V282, P447, DOI 10.1006/bbrc.2001.4595; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Herrera RE, 1997, CHROMOSOMA, V106, P284, DOI 10.1007/s004120050249; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kessler R, 1999, ONCOGENE, V18, P1733, DOI 10.1038/sj.onc.1202484; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; LAVARONE A, 1999, MOL CELL BIOL, V19, P916; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Malashicheva AB, 2000, ONCOGENE, V19, P3858, DOI 10.1038/sj.onc.1203736; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pospelova TV, 1999, GENE EXPRESSION, V8, P19; Pospelova TV, 1996, MOL BIOL+, V30, P394; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rosenberger SF, 1999, ONCOGENE, V18, P3626, DOI 10.1038/sj.onc.1202695; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; ROZEK D, 1995, J CELL BIOCHEM, V57, P479, DOI 10.1002/jcb.240570313; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	61	27	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					719	730		10.1038/sj.onc.1205118	http://dx.doi.org/10.1038/sj.onc.1205118			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850800				2022-12-28	WOS:000173427000003
J	Tulin, EE; Onoda, N; Hasegawa, M; Nomura, H; Kitamura, T				Tulin, EE; Onoda, N; Hasegawa, M; Nomura, H; Kitamura, T			Inhibition of human endothelial cell proliferation by ShIF, a vacuolar H+-ATPase-like protein	ONCOGENE			English	Article						ShIF; V-ATPase; endothelial cell proliferation; HUVEC	POLYPEPTIDE; SYNTHASE	ShIF is a bone marrow stroma cell-derived factor originally identified to support proliferation of bone marrow cells in vitro. This protein shares high sequence homology to the yeast vacuolar H+-ATPase subunit, Vph1p, and the 116 kDa proton pump of the rat and bovine synaptic vesicle, Vpp1. We examined the function of ShIF in the proliferation of human umbilical vein endothelial cells (HUVEC). ShIF inhibited HUVEC proliferation in a dose-dependent manner. Recombinant ShIF added at 10 and 20 ng/ml inhibited HUVEC proliferation by 21.6 and 44.3%, respectively and increasing the concentration of ShIF to 100 ng/ml inhibited proliferation by as much as 55.5%. When HUVEC cells were cultured at various concentrations of ShIF in the presence of anti-ShIF antibody, the inhibitory effects of ShIF to HUVEC proliferation were abrogated by 89-91% indicating that the activity of ShIF to HUVEC was specific. HUVEC cultured in the presence of ShIF and bafilomycin, a specific inhibitor of ATPase, resulted to a 90% growth inhibition. Thus, ShIF may act as an antagonist to the ATPase complex by disrupting the production of cellular ATP thereby decreasing the ability of HUVEC to proliferate.	Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan; Mol Med Inc, Chugai Res Inst, Niihari, Ibaraki 3004101, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy,Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Tulin, EE (corresponding author), Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Kitamura, Toshio/AAA-2071-2021					BODIN P, 1995, EXPERIENTIA, V51, P256, DOI 10.1007/BF01931108; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; KANE PM, 1992, J EXP BIOL, V172, P93; KANE PM, 1989, J BIOL CHEM, V264, P19236; Kawamura Y, 2001, EUR J BIOCHEM, V268, P2801, DOI 10.1046/j.1432-1327.2001.02139.x; LEE CK, 1990, MOL IMMUNOL, V27, P1137; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROZENGURT E, 1977, J BIOL CHEM, V252, P4584; Tulin EE, 2001, J BIOL CHEM, V276, P27519, DOI 10.1074/jbc.M101781200; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397; Zheng JB, 1999, BIOCHEM BIOPH RES CO, V261, P499, DOI 10.1006/bbrc.1999.1063	18	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					844	848		10.1038/sj.onc.1205114	http://dx.doi.org/10.1038/sj.onc.1205114			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850812				2022-12-28	WOS:000173427000015
J	Corey, DR				Corey, DR			Telomerase inhibition, oligonucleotides, and clinical trials	ONCOGENE			English	Article						telomerase; oligonucleotides; 2 '-methoxyethyl RNA; telomere	PEPTIDE NUCLEIC-ACIDS; ANTISENSE OLIGONUCLEOTIDES; RNA; CELLS; MECHANISMS; TARGET; GENE	Telomerase is expressed in most types of tumors but not in most somatic cells. This observation has led to two hypotheses; (i) telomerase activity is necessary for the proliferation of cancer cells; and (ii) telomerase inhibitors are a powerful strategy for cancer chemotherapy. Testing the latter hypothesis requires the development of potent and selective inhibitors of telomerase and their testing in clinical trials. Assaying the efficacy of telomerase inhibitors will not be simple because telomere erosion will be slow and antiproliferative effects will probably require weeks to become apparent. This review will describe the properties of 2'-O-alkyl oligonucleotide inhibitors of telomerase. Oligonucleotides that block expression of other cancer targets have favorable pharmacokinetic properties and are already in clinical trials. This experience is likely to facilitate clinical trials of anti-telomerase oligomers.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Corey, DR (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	david.corey@utsouthwestern.edu			NATIONAL CANCER INSTITUTE [P50CA070907, R01CA085363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060642] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85363, P50CA70907] Funding Source: Medline; NIGMS NIH HHS [GM 60642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; Baker BF, 1999, BBA-GENE STRUCT EXPR, V1489, P3, DOI 10.1016/S0167-4781(99)00146-3; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Bearss DJ, 2000, ONCOGENE, V19, P6632, DOI 10.1038/sj.onc.1204092; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; Crooke ST, 2000, ONCOGENE, V19, P6651, DOI 10.1038/sj.onc.1204093; Elayadi AN, 2001, NUCLEIC ACIDS RES, V29, P1683, DOI 10.1093/nar/29.8.1683; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Freier SM, 1997, NUCLEIC ACIDS RES, V25, P4429, DOI 10.1093/nar/25.22.4429; Geary R S, 2001, Curr Opin Investig Drugs, V2, P562; GEARY RS, 2000, ANTISENSE NUC ACID D, V10, P35; Grillone LR, 2001, DRUG TODAY, V37, P245, DOI 10.1358/dot.2001.37.4.620590; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hamilton SE, 1999, CHEM BIOL, V6, P343, DOI 10.1016/S1074-5521(99)80046-5; Hamilton SE, 1997, BIOCHEMISTRY-US, V36, P11873, DOI 10.1021/bi970438k; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Henry S, 2000, J PHARMACOL EXP THER, V292, P468; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Herbert BS, 2001, JNCI-J NATL CANCER I, V93, P39, DOI 10.1093/jnci/93.1.39; Khatsenko O, 2000, ANTISENSE NUCLEIC A, V10, P35, DOI 10.1089/oli.1.2000.10.35; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lebedeva I, 2001, ANNU REV PHARMACOL, V41, P403, DOI 10.1146/annurev.pharmtox.41.1.403; Levin AA, 1999, BBA-GENE STRUCT EXPR, V1489, P69, DOI 10.1016/S0167-4781(99)00140-2; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Ludwig A, 2001, CANCER RES, V61, P3053; Marwick C, 1998, JAMA-J AM MED ASSOC, V280, P871, DOI 10.1001/jama.280.10.871; Matthes E, 1999, NUCLEIC ACIDS RES, V27, P1152, DOI 10.1093/nar/27.4.1152; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Rusckowski M, 1997, CANCER, V80, P2699, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2699::AID-CNCR48>3.3.CO;2-A; Shammas MA, 1999, ONCOGENE, V18, P6191, DOI 10.1038/sj.onc.1203069; YUEN A, 2001, AM SOC CLIN ONCOLOGY; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	39	88	100	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					631	637		10.1038/sj.onc.1205063	http://dx.doi.org/10.1038/sj.onc.1205063			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850789				2022-12-28	WOS:000173390500016
J	Brasher, BB; Roumiantsev, S; Van Etten, RA				Brasher, BB; Roumiantsev, S; Van Etten, RA			Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain	ONCOGENE			English	Article						abelson; tyrosine kinase; retrovirus; chronic myeloid leukemia	TYROSINE KINASE-ACTIVITY; PROLINE-RICH LIGANDS; SH3 DOMAIN; TRANSFORMING ACTIVITY; PROTEIN-BINDING; GENE-PRODUCT; CELL-LINE; ACTIVATION; ABILITY; LYMPHOCYTES	The catalytic activity of the c-Abl tyrosine kinase is tightly regulated by its Src homology 3 (SH3) domain through a complex mechanism that may involve intramolecular binding to Pro242 in the linker region between the SH2 and catalytic domains as well as interactions with a trans-inhibitor. We analysed the effect of mutation or replacement of SH3 on c-Abl tyrosine kinase activity and transformation. Random mutagenesis of SH3 identified several novel point mutations that dysregulated c-Abl kinase activity in vivo, but the RT loop was insensitive to mutational activation. Activating SH3 mutations abolished binding of proline-rich SH3 ligands in vitro, while mutations at Ser140 in the connector between the SH3 and SH2 domains activated Abl kinase activity in vivo and in vitro but did not impair SH3 ligand-binding. Abl was regulated efficiently when its SH3 domain was replaced with a heterologous SH3 from c-Src that binds a different spectrum of proline-rich ligands, but not by substitution of a modular WW domain with similar ligand-binding specificity. These results suggest that the SH3 domain regulates Abl principally by binding to the atypical intramolecular ligand Pro242 rather than a canonical PxxP ligand. Coordination between the SH3 and SH2 domains mediated by the connector region may be required for regulation of Abl even in the absence of SH2 ligand binding.	Enanta Pharmaceut, Watertown, MA 02472 USA; Harvard Univ, Sch Med, Dept Genet, Ctr Blood Res, Boston, MA 02114 USA; Enanta Pharmaceut, Watertown, MA 02472 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Van Etten, RA (corresponding author), Harvard Univ, Sch Med, Dept Genet, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02114 USA.	vanetten@cbr.med.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA072465] Funding Source: NIH RePORTER; NCI NIH HHS [CA72465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Dorey K, 1999, BIOL CHEM, V380, P223; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; FINER MH, 1994, BLOOD, V83, P43; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEE JC, 1982, J IMMUNOL, V128, P2393; Leung DW, 1989, TECHNIQUE, V1, P11; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIU XQ, 1993, ONCOGENE, V8, P1119; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Pisabarro MT, 1996, BIOCHEMISTRY-US, V35, P10634, DOI 10.1021/bi960203t; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1995, ONCOGENE, V10, P1977; Walkenhorst J, 1996, ONCOGENE, V12, P1513; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	44	42	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7744	7752		10.1038/sj.onc.1204978	http://dx.doi.org/10.1038/sj.onc.1204978			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753652	Green Published			2022-12-28	WOS:000172161700005
J	Koch, CA; Huang, SC; Moley, JF; Azumi, N; Chrousos, GP; Gagel, RF; Zhuang, ZP; Pacak, K; Vortmeyer, AO				Koch, CA; Huang, SC; Moley, JF; Azumi, N; Chrousos, GP; Gagel, RF; Zhuang, ZP; Pacak, K; Vortmeyer, AO			Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma	ONCOGENE			English	Article						RET; MEN 2; medullary thyroid carcinoma; allelic imbalance	NONRANDOM DUPLICATION; PROTOONCOGENE	Germline mutations of the RET proto-oncogene are responsible for the familial tumor syndrome called multiple endocrine neoplasia type 2 (MEN 2) that includes medullary thyroid carcinoma (MTC). Although inherited mutations of RET lead to tumor formation in patients with MEN 2, it is not understood why only selected cells develop into tumors. We have recently shown that duplication of the mutated RET allele or loss of the wild-type allele might represent mechanisms of tumorigenesis in patients with MEN 2A-related pheochromocytoma. We now analysed 19 DNA samples of MTC (15 of which were non-microdissected, four of which were microdissected) from patients with MEN 2A. Using polymorphic marker and phosphorimage densitometry analyses, we found allelic imbalance of the mutated and wild-type RET allele in six of 19 DNA MTC samples. Of note, two of the four microdissected tumor DNA samples showed allelic imbalance of RET, whereas only four of the 15 non-microdissected MTC samples did. These results underscore the significance of microdissection in the analysis of tumor DNA. In our study, some of the non-microdissected tumor DNA samples may have failed to display allelic imbalance of RET, because of contamination of tumor DNA with nonneoplastic. DNA or noninformative microsatellite marker analysis. Taken together, our results suggest allelic imbalance between mutated and wild-type RET as a possible mechanism for tumor formation in some patients with MEN 2A-related MTC.	NINDS, Mol Pathogenesis Unit, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; NICHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO USA; Georgetown Univ, Washington, DC USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Washington University (WUSTL); Georgetown University; University of Texas System; UTMD Anderson Cancer Center	Koch, CA (corresponding author), NINDS, Mol Pathogenesis Unit, Surg Neurol Branch, NIH, Bldg 10,Rm 9D42, Bethesda, MD 20892 USA.	kochc@exchange.nih.gov	Koch, Christian A/A-4699-2008	Koch, Christian A/0000-0003-3127-5739; Koch, Christian/0000-0003-0678-1242	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; Cinti R, 2000, CYTOGENET CELL GENET, V88, P56, DOI 10.1159/000015485; Eng C, 1996, NEW ENGL J MED, V335, P943, DOI 10.1056/NEJM199609263351307; Huang SC, 2000, CANCER RES, V60, P6223; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Zhuang Z, 1998, Cell Vis, V5, P43; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727; ZHUANG ZP, 1995, AM J PATHOL, V146, P620	11	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7809	7811		10.1038/sj.onc.1204991	http://dx.doi.org/10.1038/sj.onc.1204991			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753660				2022-12-28	WOS:000172161700013
J	Heckman, CA; Mehew, JW; Boxer, LM				Heckman, CA; Mehew, JW; Boxer, LM			NF-kappa B activates Bcl-2 expression in t(14;18) lymphoma cells	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; NF-kappa B	UP-REGULATES BCL-2; ANTISENSE OLIGONUCLEOTIDES ENHANCE; BREAST-CANCER CELLS; TRANSCRIPTION FACTOR; FOLLICULAR LYMPHOMA; RESPONSE ELEMENT; CREB PROTEINS; E-SELECTIN; T-CELLS; C-REL	The t(14;18) translocation, which is characteristic of follicular lymphoma, results in the overexpression of the bcl-2 gene dependent upon regulatory elements within the bcl-2 5' flanking region and the immunoglobulin heavy chain gene enhancers. Conflicting evidence exists on the effects of NF-kappaB expression on Bel-2 levels in different cell types. Lymphoma cells with the t(141;18) translocation show high levels of nuclear NF-kappaB proteins. We observed decreased levels of endogenous Bcl-2 when the IkappaBchi-super-repressor was expressed in a t(14;18) cell line. Deletion analysis of the bcl-2 promoter indicated that the repressive effect of the IkappaBalpha-super-repressor occurred through a region that contained no NF-kappaB consensus sequences. This highly active region contained a c-AMP response element (CRE) and several Sp1 binding sites. Chromatin immunoprecipitation assays with antibodies specific for the NF-kappaB and CREB/ATF family members, as well as Sp1, resulted in the isolation of this IkappaBalpha-super-repressor responsive region of the bcl-2 promoter. Mutation of the CRE and the two Sp1 sites in different combinations in bel-2 reporter constructs resulted in the loss of bcl-2 promoter repression by the IkappaBalpha-super-repressor. We therefore conclude that the activation of bcl-2 by NF-kappaB in t(14;18) lymphoma cells is mediated through the CRE and Sp1 binding sites.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Stanford, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR 1155, Stanford, CA 94305 USA.			Heckman, Caroline/0000-0002-4324-8706	NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CRAWFORD MJ, 2001, BIOCHEM BIOPH RES CO, V281, P1034; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Feng ZW, 1999, J BIOL CHEM, V274, P30341, DOI 10.1074/jbc.274.43.30341; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; HEWITT SM, 1995, CANCER RES, V55, P5386; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; Klasa RJ, 2000, CLIN CANCER RES, V6, P2492; Konopleva M, 2000, BLOOD, V95, P3929; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Munzert G, 2000, LEUKEMIA LYMPHOMA, V38, P395, DOI 10.3109/10428190009087031; Pepper C, 2001, LEUKEMIA LYMPHOMA, V42, P491, DOI 10.3109/10428190109064606; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Phan SC, 1996, MOL CELL BIOL, V16, P2387; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SIF S, 1993, ONCOGENE, V8, P2501; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wacheck V, 2001, J MOL MED-JMM, V79, P587, DOI 10.1007/s001090100251; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	57	160	166	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3898	3908		10.1038/sj.onc.1205483	http://dx.doi.org/10.1038/sj.onc.1205483			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032828				2022-12-28	WOS:000175847200009
J	Liebermann, DA; Hoffman, B				Liebermann, DA; Hoffman, B			Myeloid differentiation (MyD) primary response genes in hematopoiesis	ONCOGENE			English	Review						IRF-1; EGR-1; Jun; MyD88; MyD118; GADD45	NF-KAPPA-B; FINGER TRANSCRIPTION FACTOR; HERPES-SIMPLEX-VIRUS; IMMEDIATE-EARLY RESPONSE; CELL NUCLEAR ANTIGEN; REGULATORY FACTOR-I; SIGNAL-TRANSDUCTION PATHWAY; RECEPTOR ACCESSORY PROTEIN; LEUKEMIA INHIBITORY FACTOR; INTERLEUKIN-1 RECEPTOR	Myeloid Differentiation (MyD) primary response and Growth Arrest DNA-Damage (Gadd) genes comprise a set of overlapping genes, including known (IRF-1, EGR-1, Jun) and novel (MyD88, Gadd45alpha MyD118/ Gadd45beta, GADD45gamma, MyD1161/Gadd34) genes, that have been cloned by virtue of there being co-ordinately induced upon the onset of terminal myeloid differentiation. This review delineates the role MyD genes play in blood cell development, where they function as positive regulators of terminal differentiation, lineage specific blood cell development and control of blood cell homeostasis, including growth inhibition and apoptosis.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@unix.temple.edu; hoffman@unix.temple.edu			NATIONAL CANCER INSTITUTE [R01CA059774, R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA43618, 1R01CA59774] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Adler HT, 1999, MOL CELL BIOL, V19, P7050; Aizawa S, 1997, J BIOL CHEM, V272, P2042; Amundson SA, 2000, CANCER RES, V60, P6101; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; Brown SM, 1997, J VIROL, V71, P9442, DOI 10.1128/JVI.71.12.9442-9449.1997; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chan TA, 2000, GENE DEV, V14, P1584; Cheung KJ, 2001, CANCER RES, V61, P4974; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DIXON LK, 1994, J GEN VIROL, V75, P1655, DOI 10.1099/0022-1317-75-7-1655; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Dupraz P, 2000, J BIOL CHEM, V275, P37672, DOI 10.1074/jbc.M005150200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDON E, 1994, DEVELOPMENT, V120, P885; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fantuzzi G, 2001, EUR J IMMUNOL, V31, P369, DOI 10.1002/1521-4141(200102)31:2<369::AID-IMMU369>3.0.CO;2-Y; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; Hardiman G, 1996, ONCOGENE, V13, P2467; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HARPER JW, 1993, CELL, V75, P805; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hasegawa T, 1999, BBA-GEN SUBJECTS, V1428, P161, DOI 10.1016/S0304-4165(99)00060-4; Hasegawa T, 2000, BIOCHEM BIOPH RES CO, V267, P593, DOI 10.1006/bbrc.1999.1991; Hasegawa T, 2000, BIOCHEM J, V352, P795, DOI 10.1042/0264-6021:3520795; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097-0215(20010220)96:1<22::AID-IJC3>3.0.CO;2-K; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; ITOH N, 1993, J BIOL CHEM, V268, P10932; Janeway C.A., 1999, IMMUNOBIOLOGY IMMUNE; Jaunin F, 1998, EXP CELL RES, V243, P67, DOI 10.1006/excr.1998.4131; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kaisho T, 2001, TRENDS IMMUNOL, V22, P78, DOI 10.1016/S1471-4906(00)01811-1; Karin M, 1998, CANCER J SCI AM, V4, pS92; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kojima S, 1999, FEBS LETT, V446, P313, DOI 10.1016/S0014-5793(99)00234-3; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; Kovalsky O, 2001, J BIOL CHEM, V276, P39330, DOI 10.1074/jbc.M105115200; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Krishnaraju K, 1997, BLOOD, V90, P1840, DOI 10.1182/blood.V90.5.1840; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Liebermann DA, 1998, INT J ONCOL, V12, P685; Liebermann DA, 1998, ONCOGENE, V17, P3319, DOI 10.1038/sj.onc.1202574; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; Liu CT, 1998, CANCER GENE THER, V5, P3; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Lovenberg TW, 1996, J NEUROIMMUNOL, V70, P113, DOI 10.1016/S0165-5728(96)00047-1; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakanishi K, 2001, NAT IMMUNOL, V2, P140, DOI 10.1038/84236; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Norris JL, 1996, GENE DEV, V10, P862, DOI 10.1101/gad.10.7.862; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Parker JE, 1997, PLANT CELL, V9, P879, DOI 10.1105/tpc.9.6.879; Parnet P, 1996, J BIOL CHEM, V271, P3967; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUSSMAN MD, 1992, J VIROL, V66, P5586, DOI 10.1128/JVI.66.9.5586-5589.1992; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tendler DS, 2001, CANCER RES, V61, P3682; Tourtellotte WG, 2000, MOL CELL BIOL, V20, P5261, DOI 10.1128/MCB.20.14.5261-5268.2000; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; VYDELINGUM S, 1993, J GEN VIROL, V74, P2125, DOI 10.1099/0022-1317-74-10-2125; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; YAMAGATA M, 1994, GENE, V139, P223, DOI 10.1016/0378-1119(94)90760-9; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang W, 2001, INT J ONCOL, V18, P749; ZHANG W, 2000, THESIS TEMPLE U; Zsak L, 1996, J VIROL, V70, P8865, DOI 10.1128/JVI.70.12.8865-8871.1996	173	42	43	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3391	3402		10.1038/sj.onc.1205312	http://dx.doi.org/10.1038/sj.onc.1205312			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032777				2022-12-28	WOS:000175633300012
J	Delpuech, O; Trabut, JB; Carnot, F; Feuillard, J; Brechot, C; Kremsdorf, D				Delpuech, O; Trabut, JB; Carnot, F; Feuillard, J; Brechot, C; Kremsdorf, D			Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinomas; hepatitis B Virus; Hepatitis C Virus; cDNA macroarray; distinct gene profiles	HEPATITIS-C VIRUS; BETA-CATENIN GENE; MESSENGER-RNA; CYCLIN D1; PROTEIN; GROWTH; OVEREXPRESSION; CANCER; INDUCTION; APOPTOSIS	It is still unclear as to whether the gene expression profile in HCV- or HBV-related HCC exhibits a degree of specificity and whether the development of HCC in a context of cirrhosis influences this gene profile. To address these issues, the expression profiles of 15 cases of HCC were analysed using cDNA macroarray. A global analysis and hierarchical clustering, demonstrated the heterogeneity of HCC patterns, with a majority of down-regulated genes. Statistical analysis clearly showed a distinction between the gene expression profiles of HCV- and HBV-related HCC. HBV-associated HCC exhibited involvement of different cellular pathways, those controlling apoptosis, p53 signalling and G1/S transition. In HCV-related HCC we identified a more heterogenous pattern with an over-expression of the TGF-beta induced gene. In HCC developing on noncirrhotic tissues, beta-catenin encoding gene and genes implicated in the PKC pathway were specifically up-regulated. In addition, our investigation highlighted a distinct profiles of TGF-beta superfamily encoding genes in well, moderately or poorly differentiated HCC. Overall, our study supports the hypothesis that despite the heterogeneity of the HCC pattern, the large-scale screening of gene expression may provide data significant to our understanding of the mechanism of liver carcinogenesis.	CHU Necker, INSERM, Inst Pasteur, U370, F-75015 Paris, France; Hop Europeen Georges Pompidou, Serv Anatomopathol, F-75015 Paris, France; Hop Avicenne, Serv Hematol Biol, F-93009 Bobigny, France; Hop Avicenne, EA ATHSCO, F-93009 Bobigny, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13	Kremsdorf, D (corresponding author), Fac Med Necker Enfants Malad, INSERM, U370, 156 Rue Vaugirard, F-75730 Paris 15, France.	kremsdor@necker.fr	Kremsdorf, Dina/O-9797-2017; Feuillard, Jean/O-8587-2016	Feuillard, Jean/0000-0001-6223-2454				Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Benvegnu L, 2001, ANTIVIR RES, V52, P199, DOI 10.1016/S0166-3542(01)00185-1; Benvegnu L, 2001, GUT, V48, P110, DOI 10.1136/gut.48.1.110; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P250, DOI 10.1159/000134349; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V174, pM43; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Endo K, 2000, HUM PATHOL, V31, P558, DOI 10.1053/hp.2000.6683; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; Feo F, 2000, CRIT REV ONCOGENESIS, V11, P19; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; Garrett SH, 1999, PROSTATE, V41, P196, DOI 10.1002/(SICI)1097-0045(19991101)41:3<196::AID-PROS7>3.0.CO;2-U; Gilles C, 1998, CANCER RES, V58, P5529; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Hayashi J, 1999, INTERVIROLOGY, V42, P205, DOI 10.1159/000024962; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; Hidalgo J, 1998, NEUROTOXICOLOGY, V19, P661; Hol FA, 1998, CLIN GENET, V53, P119; Honda M, 2001, GASTROENTEROLOGY, V120, P955, DOI 10.1053/gast.2001.22468; IREDALE JP, 1992, J CLIN INVEST, V90, P282, DOI 10.1172/JCI115850; Ito Y, 1999, HEPATOLOGY, V30, P90, DOI 10.1002/hep.510300114; Juengel JL, 1998, J REPROD FERTIL, V113, P299, DOI 10.1530/jrf.0.1130299; Jungmann RA, 1998, J EXP ZOOL, V282, P188, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2<188::AID-JEZ21>3.0.CO;2-P; Kamai T, 2001, BJU INT, V87, P227, DOI 10.1046/j.1464-410x.2001.02030.x; Kasai Y, 1996, SEMIN SURG ONCOL, V12, P155, DOI 10.1002/(SICI)1098-2388(199605/06)12:3<155::AID-SSU2>3.0.CO;2-6; Kim Hyung Gun, 2000, Korean Journal of Internal Medicine, V15, P165; Knight J, 2001, NATURE, V410, P860, DOI 10.1038/35073680; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Lau WY, 2000, ONCOL RES, V12, P59; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; LeBail B, 1997, J PATHOL, V181, P330; Liu CT, 1998, CANCER GENE THER, V5, P3; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; Millian NS, 1998, ARCH BIOCHEM BIOPHYS, V356, P93, DOI 10.1006/abbi.1998.0757; MIRA L, 1995, ARCH BIOCHEM BIOPHYS, V318, P53, DOI 10.1006/abbi.1995.1203; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; NAKAMURA H, 1989, CLIN CHIM ACTA, V183, P273, DOI 10.1016/0009-8981(89)90361-6; Okabe H, 2001, CANCER RES, V61, P2129; Okajima A, 1997, HEPATOLOGY, V25, P97, DOI 10.1002/hep.510250118; PATERON D, 1994, J HEPATOL, V20, P65, DOI 10.1016/S0168-8278(05)80468-4; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Podevin P, 2001, HEPATOLOGY, V33, P1503, DOI 10.1053/jhep.2001.24749; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Porte H, 1998, CLIN CANCER RES, V4, P1375; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sato Y, 1999, J GASTROENTEROL, V34, P486, DOI 10.1007/s005350050301; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Schulze K, 1995, EUR HEART J, V16, P64, DOI 10.1093/eurheartj/16.suppl_O.64; Shen L, 1999, MOL PHARMACOL, V55, P396, DOI 10.1124/mol.55.2.396; Shimotohno K, 2000, SEMIN CANCER BIOL, V10, P233, DOI 10.1006/scbi.2000.0322; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Stuver SO, 1998, SEMIN CANCER BIOL, V8, P299, DOI 10.1006/scbi.1998.0079; Takano T, 2001, CANCER LETT, V168, P51, DOI 10.1016/S0304-3835(01)00509-2; Takayasu H, 2001, CLIN CANCER RES, V7, P901; TERAMOTO T, 1994, CANCER RES, V54, P231; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Thorgeirsson SS, 1998, SEMIN LIVER DIS, V18, P115, DOI 10.1055/s-2007-1007148; Tornillo L, 2000, J PATHOL, V192, P307, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH706&gt;3.0.CO;2-O; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; VENEZIANI BM, 1990, J CELL BIOL, V111, P2703, DOI 10.1083/jcb.111.6.2703; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Xu L, 2001, CANCER RES, V61, P3176; Yamashita T, 2001, BIOCHEM BIOPH RES CO, V282, P647, DOI 10.1006/bbrc.2001.4610; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255; ZHAN QM, 1994, CANCER RES, V54, P2755	80	89	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2926	2937		10.1038/sj.onc.1205392	http://dx.doi.org/10.1038/sj.onc.1205392			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973655				2022-12-28	WOS:000175063700020
J	Aiba-Masago, S; Liu, XB; Masago, R; Vela-Roch, N; Jimenez, F; Lau, CMA; Frohlich, VC; Talal, N; Dang, H				Aiba-Masago, S; Liu, XB; Masago, R; Vela-Roch, N; Jimenez, F; Lau, CMA; Frohlich, VC; Talal, N; Dang, H			Bax gene expression alters Ca2+ signal transduction without affecting apoptosis in an epithelial cell fine	ONCOGENE			English	Article						calcium; Bcl-2 family; oxidative stress; glutathione; muscarinic receptor	CYTOCHROME-C RELEASE; GLUTATHIONE DEPLETION; SJOGRENS-SYNDROME; REDOX REGULATION; BCL-2; CALCIUM; DEATH; OVEREXPRESSION; BCL-X(L); ALPHA	Bax is an oncogene that has proapoptotic properties but not all cells that express Bax undergo apoptosis. Bax may have a function unrelated to apoptosis. To elucidate the role of Bax in cell signaling, an epithelial cell line called SMG-C6 was transfected with the human bax gene. Stable transfectants were studied for their response to carbachol, a muscarinic receptor agonist, by measuring the increase in intracellular free Ca2+ and Ca2+ influx. Carbachol-mediated release of Call from intracellular stores was significantly higher in Bax transfectants compared to control transfectants (empty vector). Ca2+ influx was also increased in Bax transfectants. Bax had no affect on the storage operated channels. However, the concentration of Ca2+d in the intracellular stores (i.e., mitochondria and granules) was 40-50% lower in the Bax transfectants. There was no significant difference in thapsigargin-mediated apoptosis in Bax transfectants compared to wild-type and control transfectants. Measurement of glutathione was reduced in the Bax transfectant. Restoration of glutathione levels with glutathione monoethyl ester partially normalized Ca2+ mobilization and storage capacity in the mitochondria to control levels. This study shows that subapoptotic levels of Bax can reduce Ca2+ content in intracellular stores and Ca2+ homeostasis. Bax may mediate these effects by reducing the levels of antioxidants resulting in mild oxidative stress.	Univ Texas, Hlth Sci Ctr, Dept Community Dent, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Harcourt Brace Educ Measurement, San Antonio, TX 78204 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10019 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Columbia University	Dang, H (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Community Dent, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	dang@uthscsa.edu			NIDCR NIH HHS [DE12203] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012203] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Azhar G, 1999, MECH AGEING DEV, V112, P5, DOI 10.1016/S0047-6374(99)00048-2; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bojes HK, 1997, BIOCHEM J, V325, P315, DOI 10.1042/bj3250315; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hehner SP, 2000, J IMMUNOL, V165, P4319, DOI 10.4049/jimmunol.165.8.4319; Ichimiya M, 1998, AM J PHYSIOL-CELL PH, V275, pC832, DOI 10.1152/ajpcell.1998.275.3.C832; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Kong LP, 1998, CLIN IMMUNOL IMMUNOP, V88, P133, DOI 10.1006/clin.1998.4556; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Masago R, 2001, ARTHRITIS RHEUM, V44, P693, DOI 10.1002/1529-0131(200103)44:3<693::AID-ANR119>3.0.CO;2-7; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Naarala J, 1997, LIFE SCI, V60, P1905, DOI 10.1016/S0024-3205(97)00152-5; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUTT LK, 2002, IN PRESS J BIOL CHEM; Ohlsson M, 2001, LAB INVEST, V81, P95, DOI 10.1038/labinvest.3780215; Olive M, 1999, J NEUROL SCI, V164, P76, DOI 10.1016/S0022-510X(99)00041-6; Penault-Llorca F, 1998, PATHOL RES PRACT, V194, P457, DOI 10.1016/S0344-0338(98)80114-3; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Polihronis M, 1998, CLIN EXP IMMUNOL, V114, P485; Quissell D O, 1997, In Vitro Cell Dev Biol Anim, V33, P164; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; Wang H, 2000, FREE RADICAL BIO MED, V28, P1222, DOI 10.1016/S0891-5849(00)00241-0; Wei HF, 1998, J NEUROCHEM, V70, P2305; Zhang GH, 1997, P SOC EXP BIOL MED, V216, P117; Zhou YP, 2000, AM J PHYSIOL-ENDOC M, V278, pE340, DOI 10.1152/ajpendo.2000.278.2.E340	36	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2762	2767		10.1038/sj.onc.1205369	http://dx.doi.org/10.1038/sj.onc.1205369			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965549				2022-12-28	WOS:000174996500016
J	Chen, J; Kremer, CS; Bender, TP				Chen, J; Kremer, CS; Bender, TP			A Myb dependent pathway maintains Friend murine erythroleukemia cells in an immature and proliferating state	ONCOGENE			English	Article						c-Myb; A-Myb; B-Myb; erythroleukemia; transcription factor; differentiation	HUMAN HEMATOPOIETIC-CELLS; UP-REGULATES BCL-2; C-MYB; B-MYB; A-MYB; ERYTHROID-DIFFERENTIATION; TERMINAL DIFFERENTIATION; DOWN-REGULATION; TRANSCRIPTION FACTOR; MESSENGER-RNA	Friend murine erythroleukemia (MEL) cells are transformed erythroid precursors that are held in an immature and proliferating state but can be induced to differentiate in vivo by treatment with a variety of chemical agents such as N, N-hexamethylene bisacetamide (HMBA). To investigate the role of Myb proteins in maintaining MEL cells in an immature and proliferating state we have produced stable transfectants in the C19 MEL cell line that contain a dominant interfering Myb allele (MEnT) under the control of an inducible mouse metallothionein I promoter. When expression of MEnT protein was induced with ZnCl2, the stable transfectants differentiated with kinetics that were similar to wild type C19 MEL cells treated with HMBA, including induction of alpha-globin mRNA expression, assembly of hemoglobin and growth arrest. Expression of endogenous c-myb and c-myc was also decreased in response to MEnT. Expression of mad-1 mRNA was rapidly increased in response to expression of MEnT resulting in a shift from predominantly c-Myc/Max complexes to predominantly Mad/Max containing complexes. These results strongly suggest that C19 MEL cells are held in an immature and proliferating state by a pathway that is dependent on Myb activity.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Mol Physiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Biol Phys, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Bender, TP (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, POB 800734, Charlottesville, VA 22908 USA.				NIGMS NIH HHS [GM55985] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; Bies J, 1996, ONCOGENE, V12, P355; CASADEVALL N, 1991, J BIOL CHEM, V266, P16015; CHERN YJ, 1991, BLOOD, V78, P991, DOI 10.1182/blood.V78.4.991.bloodjournal784991; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; CRAIG RW, 1984, CANCER RES, V44, P442; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1991, BLOOD, V77, P149; Golay J, 1996, BLOOD, V87, P1900; Golay J, 1998, J IMMUNOL, V160, P2786; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Lipsick JS, 1996, ONCOGENE, V13, P223; Lyon JJ, 1996, GENE, V182, P123, DOI 10.1016/S0378-1119(96)00531-8; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; Marks PA, 1996, INT J HEMATOL, V63, P1; Matushansky I, 2000, FRONT BIOSCI, V5, pD488, DOI 10.2741/Matushan; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; RICHON VM, 1989, ONCOGENE, V4, P165; Saville MK, 1998, ADV CANCER RES, V72, P109; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Spadaccini A, 1998, J BIOL CHEM, V273, P23793, DOI 10.1074/jbc.273.37.23793; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; YEN A, 1992, J CELL PHYSIOL, V153, P147, DOI 10.1002/jcp.1041530119; ZHUO SQ, 1995, P NATL ACAD SCI USA, V92, P4234, DOI 10.1073/pnas.92.10.4234; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	58	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1859	1869		10.1038/sj.onc.1205003	http://dx.doi.org/10.1038/sj.onc.1205003			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896618				2022-12-28	WOS:000174284500008
J	Foletti, A; Ackermann, J; Schmidt, A; Hummler, E; Beermann, F				Foletti, A; Ackermann, J; Schmidt, A; Hummler, E; Beermann, F			Absence of fibroblast growth factor 2 does not prevent tumor formation originating from the RPE	ONCOGENE			English	Article						eye; FGF; transgenic; gene targeting; pigment; RPE	RETINAL-PIGMENT EPITHELIUM; TRANSGENIC MICE; CELL-LINE; INDUCED TRANSDIFFERENTIATION; TRANSFORMED PHENOTYPE; TARGETED DISRUPTION; MELANOCYTIC LESIONS; T-ANTIGEN; EXPRESSION; GENE	We have analysed the importance of fibroblast growth factor 2 (FGF2) in tumor development. In a transgenic mouse model (Tyrpl-Tag) tumors form in the retinal pigment epithelium (RPE), invade surrounding tissues, and metastasize to lymph node and spleen. To address whether RPE tumor formation is dependent on FGF2, we generated FGF2-deficient mice. Such mice appeared healthy and exhibited no impairment of growth or development. Tyrpl-Tag transgenic mice, which are lacking FGF2 (FGF2-/-) developed RPE tumors that metastasize to spleen and lymph nodes. Tumor growth and survival rate are identical to Typpl-Tag transgenic littermates expressing FGF2. Cell lines were isolated from RPE tumors of wild-type and FGF2-deficient mice. They grow in culture, are pigmented and form vascularized tumors, when injected subcutaneously into nude mice of either FGF2-/- or FGF2+/+ genetic background. Kinetics of tumor growth was identical and independent of presence of FGF2. Together, these results demonstrate that FGF2 is not essential for tumor formation of the RPE thus suggesting that tumor growth in general may not be dependent on FGF2.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	Swiss Institute Experimental Cancer Research; University of Lausanne	Beermann, F (corresponding author), Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.							ANAND R, 1994, INVEST OPHTH VIS SCI, V35, P3533; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Beermann F, 1999, PIGM CELL RES, V12, P71, DOI 10.1111/j.1600-0749.1999.tb00746.x; Berking C, 2001, AM J PATHOL, V158, P943, DOI 10.1016/S0002-9440(10)64041-2; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; Bryckaert M, 1999, ONCOGENE, V18, P7584, DOI 10.1038/sj.onc.1203200; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; ELYAZIDI I, 1995, ANTICANCER RES, V15, P783; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Fiore F, 1997, INT J DEV BIOL, V41, P639; Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hackett SF, 1997, EXP EYE RES, V64, P865, DOI 10.1006/exer.1996.0256; HALABAN R, 1988, ONCOGENE RES, V3, P177; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Jordan S, 2000, PIGM CELL RES, V13, P70, DOI 10.1034/j.1600-0749.2000.130204.x; KAESTNER KH, 1994, GENE, V148, P67, DOI 10.1016/0378-1119(94)90234-8; Kato T, 1999, BRAIN DEV-JPN, V21, P138; LOEFFLER KU, 1996, GRAEFES ARCH CLIN EX, V234, P70; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MARET A, 1995, CANCER RES, V55, P5075; Menzel T, 1996, BLOOD, V87, P1056, DOI 10.1182/blood.V87.3.1056.bloodjournal8731056; Miller DL, 2000, MOL CELL BIOL, V20, P2260, DOI 10.1128/MCB.20.6.2260-2268.2000; MINTZ B, 1992, P NATL ACAD SCI USA, V89, P11421, DOI 10.1073/pnas.89.23.11421; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.3.CO;2-R; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; OBrien T, 1997, CANCER RES, V57, P136; Ogata N, 1996, CURR EYE RES, V15, P1008, DOI 10.3109/02713689609017649; OPAS M, 1994, DEV BIOL, V161, P440, DOI 10.1006/dbio.1994.1043; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2; PELLIEUX C, 2001, IN PRESS J CLIN INVE; Penna D, 1998, ONCOGENE, V17, P2601, DOI 10.1038/sj.onc.1202196; RAKOCZY PE, 1993, INVEST OPHTH VIS SCI, V34, P1845; REED JA, 1994, AM J PATHOL, V144, P329; Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E; Schmidt A, 1998, BRAIN RES PROTOC, V3, P54, DOI 10.1016/S1385-299X(98)00021-X; Schultz JE, 1999, J CLIN INVEST, V104, P709, DOI 10.1172/JCI7315; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; Sliutz G, 1995, ANTICANCER RES, V15, P2675; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Vaccarino FM, 1999, NAT NEUROSCI, V2, P246, DOI 10.1038/6350; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201; ZUNIGA MBA, 1996, DEV BIOL, V180, P680	57	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1841	1847		10.1038/sj.onc.1205030	http://dx.doi.org/10.1038/sj.onc.1205030			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896616				2022-12-28	WOS:000174284500006
J	Kyo, S; Inoue, M				Kyo, S; Inoue, M			Complex regulatory mechanisms of telomerase activity in normal and cancer cells: How can we apply them for cancer therapy?	ONCOGENE			English	Article						telomerase; regulation; normal cells; cancers	REVERSE-TRANSCRIPTASE GENE; CATALYTIC SUBUNIT HTERT; HISTONE DEACETYLASE INHIBITOR; HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN EPITHELIAL-CELLS; HUMAN TUMOR-CELLS; BREAST-CANCER; C-MYC; RNA COMPONENT; INTRAEPITHELIAL NEOPLASIA	Telomerase activation is observed in almost 90% of human cancers but not in normal tissues of somatic origin and thus is a critical step for multistep carcinogenesis. A more thorough understanding of telomerase regulation may provide not only a molecular basis of cancer progression but also as a way to manipulate telomerase activity as a potential therapeutic modality. Recent progress in studies on telomerase regulation has shown that telomerase activation is achieved at various steps, including transcriptional and post-transcriptional levels of the telomerase reverse transcriptase (hTERT) gene. Although a number of potentially important mechanisms of telomerase activation have been proposed, none of the current models can fully explain tumor-specific activation of telomerase, suggesting a need for further extensive analysis. This review includes a summary of recent works on telomerase regulation and a discussion of how we can overcome this situation.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan	Kanazawa University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan.							Akalin A, 2001, CANCER RES, V61, P4791; Aldous WK, 1999, CANCER, V85, P1523, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1523::AID-CNCR13>3.3.CO;2-G; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Burger AM, 1997, EUR J CANCER, V33, P638, DOI 10.1016/S0959-8049(96)00521-7; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Clark GM, 1997, J NATL CANCER I, V89, P1874, DOI 10.1093/jnci/89.24.1874; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dessain SK, 2000, CANCER RES, V60, P537; Devereux TR, 1999, CANCER RES, V59, P6087; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Ducrest AL, 2001, CANCER RES, V61, P7594; Engelhardt M, 1997, BLOOD, V90, P182; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Gu J, 2000, CANCER RES, V60, P5359; Gunes C, 2000, CANCER RES, V60, P2116; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Horikawa I, 1999, CANCER RES, V59, P826; Kagawa S, 1999, CELL DEATH DIFFER, V6, P765, DOI 10.1038/sj.cdd.4400549; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kinoshita T, 1997, VIROLOGY, V232, P53, DOI 10.1006/viro.1997.8536; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Komata T, 2001, CANCER RES, V61, P5796; Kunimura C, 1998, ONCOGENE, V17, P187, DOI 10.1038/sj.onc.1201916; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1996, CLIN CANCER RES, V2, P2023; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1998, INT J CANCER, V79, P66, DOI 10.1002/(SICI)1097-0215(19980220)79:1<66::AID-IJC13>3.0.CO;2-F; Kyo S, 1999, CANCER RES, V59, P5917; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Masutomi K, 2000, J BIOL CHEM, V275, P22568, DOI 10.1074/jbc.M000622200; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Sawa H, 1999, J NEURO-ONCOL, V42, P45, DOI 10.1023/A:1006176708928; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Snijders PJF, 1998, CANCER RES, V58, P3812; Soda H, 2000, PROSTATE, V43, P161, DOI 10.1002/(SICI)1097-0045(20000515)43:3<161::AID-PROS1>3.0.CO;2-O; Sowa Y, 1999, CANCER RES, V59, P4266; Stein GS, 2000, CANCER RES, V60, P2067; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Takakura M, 1998, CANCER RES, V58, P1558; Tanaka M, 1998, AM J PATHOL, V153, P1985, DOI 10.1016/S0002-9440(10)65712-4; Ulaner GA, 1998, CANCER RES, V58, P4168; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang Z, 2000, CANCER RES, V60, P5376; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yasumoto S, 1996, ONCOGENE, V13, P433; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Zhang WB, 1998, CANCER RES, V58, P619; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	93	141	157	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					688	697		10.1038/sj.onc.1205163	http://dx.doi.org/10.1038/sj.onc.1205163			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850797	Bronze			2022-12-28	WOS:000173390500024
J	Deroanne, CF; Bonjean, K; Servotte, S; Devy, L; Colige, A; Clausse, N; Blacher, S; Verdin, E; Foidart, JM; Nusgens, BV; Castronovo, V				Deroanne, CF; Bonjean, K; Servotte, S; Devy, L; Colige, A; Clausse, N; Blacher, S; Verdin, E; Foidart, JM; Nusgens, BV; Castronovo, V			Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling	ONCOGENE			English	Article						angiogenesis; trichostatin A; suberoylanilide hydroxamic acid; VEGF; neuropilin-1; semaphorin III	IN-VITRO; TRICHOSTATIN-A; ANTIANGIOGENIC THERAPY; UP-REGULATION; CANCER CELLS; EXPRESSION; DIFFERENTIATION; RECEPTOR; NEUROPILIN-1; SUPPRESSES	Angiogenesis is a complex biological process involving the coordinated modulation of many genes. Histone deacetylases (HDAC) are a growing family of enzymes that mediate the availability of chromatin to the transcriptional machinery. Trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA), two HDAC inhibitors known to relieve gene silencing, were evaluated as potential antiangiogenic agents. TSA and SAHA were shown to prevent vascular endothelial growth factor (VEGF)-stimulated human umbilical cord endothelial cells (HUVEC) from invading a type I collagen gel and forming capillary-like structures. SAHA and TSA inhibited the VEGF-induced formation of a CD31-positive capillary-like network in embryoid bodies and inhibited the VEGF-induced angiogenesis in the CAM assay. TSA also prevented, in a dose-response relationship, the sprouting of capillaries from rat aortic rings. TSA inhibited in a dose-dependent and reversible fashion the VEGF-induced expression of VEGF receptors, VEGFR1, VEGFR2, and neuropilin-1. TSA and SAHA upregulated the expression by HUVEC of semaphorin 111, a recently described VEGF competitor, at both mRNA and protein levels. This effect was specific to endothelial cells and was not observed in human fibroblasts neither in vascular smooth muscle cells., These observations provide a conspicuous demonstration that HDAC inhibitors are potent anti-angiogenic factors: altering VEGF signaling.	Univ Liege, Lab Connect Tissues Biol, B-4000 Liege, Sart Tilman, Belgium; Univ Liege, Res Ctr Expt Cancerol, B-4000 Liege, Belgium; Univ Liege, Lab Metastasis Res, B-4000 Liege, Belgium; Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ Calif San Francisco, San Francisco, CA 94143 USA; Gladstone Inst Virol & Immunol, San Francisco, CA USA	University of Liege; University of Liege; University of Liege; University of Liege; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Deroanne, CF (corresponding author), Univ Liege, Lab Connect Tissues Biol, B 24-3, B-4000 Liege, Sart Tilman, Belgium.		Verdin, Eric/AAB-7999-2019	Verdin, Eric/0000-0003-3703-3183				Angelov L, 1999, CANCER RES, V59, P5536; Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Butler LM, 2000, CANCER RES, V60, P5165; Deroanne CF, 1997, CANCER RES, V57, P5590; Deroanne CF, 2001, CARDIOVASC RES, V49, P647, DOI 10.1016/S0008-6363(00)00233-9; Deroanne CF, 1996, EXP CELL RES, V224, P215, DOI 10.1006/excr.1996.0131; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; FUTAMURA M, 1995, ONCOGENE, V10, P1119; Glick RD, 1999, CANCER RES, V59, P4392; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Nervi C, 2001, CANCER RES, V61, P1247; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NICOSIA RF, 1990, LAB INVEST, V63, P115; Niki T, 1999, HEPATOLOGY, V29, P858, DOI 10.1002/hep.510290328; Pepper MS, 1996, CURR TOP MICROBIOL, V213, P31; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Shaheen RM, 1999, CANCER RES, V59, P5412; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shimizu M, 2000, J CELL BIOL, V148, P1283, DOI 10.1083/jcb.148.6.1283; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; Wang JX, 1999, CANCER RES, V59, P2766; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	28	350	384	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					427	436		10.1038/sj.onc.1205108	http://dx.doi.org/10.1038/sj.onc.1205108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821955				2022-12-28	WOS:000173311200011
J	Lee, WP; Wen, Y; Varnum, B; Hung, MC				Lee, WP; Wen, Y; Varnum, B; Hung, MC			Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis	ONCOGENE			English	Article						E1A; Axl; Gas 6; Akt; BAD; apoptosis	E1A GENE-PRODUCTS; RECEPTOR TYROSINE KINASE; METASTASIS-SUPPRESSING FUNCTION; OVARIAN-CANCER CELLS; HUMAN TUMOR-CELLS; NF-KAPPA-B; ADENOVIRUS E1A; PHOSPHATIDYLINOSITOL 3-KINASE; SURVIVAL ACTIVITIES; INDUCE APOPTOSIS	Adenovirus type 5 E1A protein (E1A) associates with anti-tumor activities by reversing the transformed phenotype, inhibiting metastasis, and inducing apoptosis. We have previously identified that E1A suppresses the expression of Axl, a transforming tyrosine kinase and that Axl-Gas6 receptor-ligand interaction prevents E1A transfectants from apoptosis induced by serum deprivation. To determine how the Axl-Gas6 interaction prevents E1A-mediated apoptosis, we analysed the expression of anti-apoptotic molecules and found that the activated form of Akt was suppressed in the E1A transfectant ip 1-E1A and that Gas6 was able to activate Akt in ip 1-E1A cells reexpressing Axl (ip 1-E1A-Axl). To determine whether activated Akt is required to prevent E1A-mediated apoptosis, ip 1-E1A-Axl cells were treated with the phosphatidylinositol-3'-OH kinase inhibitor wortmannin or transfected with a dominant negative Akt mutant. In both cases, Gas6 no longer protected the cells from serum deprivation-induced apoptosis. Thus, we conclude that activated Akt is required for Axl-Gas6 signaling to prevent E1A-mediated apoptosis induced by serum deprivation. Downstream molecules of Akt, including NF-kappaB, Fas ligand, and BAD were examined, among which phosphorylation of BAD by Axl-Gas6 signaling is associated with the anti-apoptotic activity of Akt in our study.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Amgen	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA058880, R01CA077858, P50CA083639] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 58880, R01-CA 77858, 1 P50 CA83639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BYRD PJ, 1988, ONCOGENE, V2, P477; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEL PL, 1997, SCIENCE, V278, P687; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Frisch SM, 2001, ADV CANCER RES, V80, P39, DOI 10.1016/S0065-230X(01)80011-7; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1995, CANCER RES, V55, P5551; FRISCH SM, 1990, ONCOGENE, V5, P75; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422; LAMBERTI C, 1990, J VIROL, V64, P4997, DOI 10.1128/JVI.64.10.4997-5007.1990; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee WP, 1999, MOL CELL BIOL, V19, P8075; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Mymryk JS, 1996, ONCOGENE, V13, P1581; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Ozes ON, 1999, NATURE, V401, P82; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SHALLOWAY D, 1987, MOL CELL BIOL, V7, P3582, DOI 10.1128/MCB.7.10.3582; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TEODORO JG, 1995, ONCOGENE, V11, P467; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; YAN DH, 1991, ONCOGENE, V6, P343; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; Yu DH, 1998, CANCER METAST REV, V17, P195, DOI 10.1023/A:1006054421970; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1995, ONCOGENE, V11, P1383; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	49	66	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					329	336		10.1038/sj.onc.1205066	http://dx.doi.org/10.1038/sj.onc.1205066			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821945				2022-12-28	WOS:000173311200001
J	Radetzki, S; Kohne, CH; von Haefen, C; Gillissen, B; Strum, I; Dorken, B; Daniel, PT				Radetzki, S; Kohne, CH; von Haefen, C; Gillissen, B; Strum, I; Dorken, B; Daniel, PT			The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines	ONCOGENE			English	Article						Bak; Nbk; Bik; apoptosis; drug resistance; breast cancer	IN-VIVO; GENE BAX; DNA FRAGMENTATION; COLORECTAL-CANCER; PROTEIN FAMILY; OVARIAN-CANCER; TUMOR-GROWTH; CYTOCHROME-C; DEATH; EXPRESSION	We previously demonstrated that the forced expression of pro-caspase-3 can revert acquired chemoresistance in MT1-Adr breast cancer cells which show a defective activation of the mitochondrial pathway of apoptosis. We now asked whether the manipulation of mitochondrial apoptosis signaling can revert different types of drug resistance, i.e. the resistance due to impaired mitochondrial activation in the MT1-Adr cells and the resistance in MT3-Adr cells which is caused by increased expression of the Mdr-1/p-glycoprotein ABC transporter. Here we show that Bcl-2 overexpression is the underlying cause for the resistant phenotype in the MT1-Adr cells. Overexpression of the apoptosis-promoting Bax homologue Bak or the BH3 only protein Nbk/Bik reverts, as expected, acquired drug resistance in the MT1-Adr cells as recently demonstrated for pro-caspase-3. Moreover, we show that both apoptosis-promoters, Nbk/Bik and Bak, antagonize acquired chemoresistance for epirubicin-mediated apoptosis in MT3-Adr breast cancer cells. Neither drug uptake nor drug efflux were influenced by Bak or Nbk/Bik. Thus, our data show that manipulation of the downstream apoptosis signaling cascade by Bak and Nbk/Bik can overcome not only drug resistance due to mitochondrial apoptosis deficiency (in the MT1-Adr cells) but also classical, i.e. efflux-mediated, resistance for drug-induced cell death in the MT3-Adr cell line. Nbk/Bik and Bak could therefore be target genes to increase chemosensitivity and overcome different types of drug resistance.	Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Humboldt University of Berlin	Daniel, PT (corresponding author), Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, Charite Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.			Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BARGOU RC, 1995, EUR J IMMUNOL, V25, P770, DOI 10.1002/eji.1830250322; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; BOSANQUET AG, 2001, IN PRESS LEUKEMIA, V15; BOYD JM, 1995, ONCOGENE, V11, P1921; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Hermann S, 2001, INT J CANCER, V92, P805, DOI 10.1002/ijc.1284; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jones NA, 1998, MOL PHARMACOL, V53, P819; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON C, 1995, SCIENCE, V279, P96; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Krajewski S, 1996, CANCER RES, V56, P2849; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; NAUNDORF H, 1992, BREAST CANCER RES TR, V23, P87, DOI 10.1007/BF01831480; Nunez G, 1996, ADV EXP MED BIOL, V406, P75; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Stein U, 1997, INT J CANCER, V72, P885, DOI 10.1002/(SICI)1097-0215(19970904)72:5<885::AID-IJC28>3.0.CO;2-6; Strobel T, 1998, ONCOGENE, V17, P2419, DOI 10.1038/sj.onc.1202180; Strobel T, 1998, CANCER RES, V58, P4776; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	47	52	54	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					227	238		10.1038/sj/onc/1205010	http://dx.doi.org/10.1038/sj/onc/1205010			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803466				2022-12-28	WOS:000173026200007
J	Deng, J; Zhang, HF; Kloosterboer, F; Liao, Y; Klostergaard, J; Levitt, ML; Hung, MC				Deng, J; Zhang, HF; Kloosterboer, F; Liao, Y; Klostergaard, J; Levitt, ML; Hung, MC			Ceramide does not act as a general second messenger for ultraviolet-induced apoptosis	ONCOGENE			English	Article						apoptosis; UV; second messenger; ceramide; E1A	STRESS-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; IONIZING-RADIATION; CELL-DEATH; E1A; SPHINGOMYELIN; ACTIVATION; PRODUCT; PATHWAY; PROTEIN	Ceramide has been proposed as a second messenger for stress-induced apoptosis. By characterization of murine melanoma cells and their E1A transfectants, we found several tines of evidences against the role of ceramide as a second messenger for ultraviolet (UV)-induced apoptosis. First, although E1A transfected melanoma cells were more sensitive to UV-induced apoptosis than parental cells, the relative endogenous ceramide elevation induced by UV was greater in parental cells than in EI A transfectants. Second, UV-resistant melanoma cells were more sensitive to exogenous ceramide than UV-sensitive EIA transfectants. The differential responses to UV and ceramide by E1A require the same functional CR2 domain of E1A. Third, unlike the action of UV, transient exposure (up to 2 h) of lethal dose of ceramide was not sufficient to cause apoptosis in these cells, and persistent presence of ceramide was required for processing the apoptotic process. Finally, ceramide and UV do not share a common pathway in apoptosis induction. UV-induced apoptosis was blocked by interleukin-1 beta -converting enzyme (ICE) inhibitor z-VAD whereas ceramide-induced apoptosis was not. Therefore, we conclude that ceramide is not a general second messenger for UV-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Allegheny Univ Hlth Sci, Lung Canc Program, Pittsburgh, PA 15212 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA058880, P30CA016672, R01CA077858] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58880, CA 16672, CA77858] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cheng AC, 1996, BIOPHYS J, V70, P2212, DOI 10.1016/S0006-3495(96)79787-4; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1989, ONCOGENE, V4, P383; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HUS SC, 1998, BLOOD, V91, P2658; Karasavvas N, 1999, CELL DEATH DIFFER, V6, P115, DOI 10.1038/sj.cdd.4400482; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; McConkey DJ, 1996, ONCOGENE, V13, P1693; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; PIERCEALL WE, 1992, CANCER RES, V52, P3946; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	34	9	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					44	52		10.1038/sj.onc.1204900	http://dx.doi.org/10.1038/sj.onc.1204900			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791175	Bronze			2022-12-28	WOS:000172887800005
J	Wade, R; Bohl, J; Pol, SV				Wade, R; Bohl, J; Pol, SV			Paxillin null embryonic stem cells are impaired in cell spreading and tyrosine phosphorylation of focal adhesion kinase	ONCOGENE			English	Article						cytoskeleton; paxillin; FAK; integrin; kinases; actin	PHOSPHATASE-PEST; BINDING PROTEIN; C-ABL; ASSOCIATION; LOCALIZATION; MOTIF; IDENTIFICATION; FIBROBLASTS; MIGRATION; INTEGRINS	Paxillin is a focal-adhesion associated protein implicated in the regulation of integrin signaling and organization of the actin cytoskeleton. Paxillin associates with numerous signaling molecules including adaptor molecules (p130Cas, CRK), kinases (FAK, Pyk2, PAK and SRC), tyrosine phosphatases (PTP-PEST), ARF-GAP proteins (p95pkl, PAG3) and papillomavirus E6 oncoproteins. Although paxillin is tyrosine phosphorylated in cellular processes such as cell attachment and spreading, little direct evidence is available about paxillin's role in these events. Targeted gene disruption was used to generate paxillin null mouse embryonic stem (ES) cells and paxillin null differentiated cells. Paxillin null ES cells exhibit delayed spreading on integrin binding substrates fibronectin and laminin, and there is reduced tyrosine phosphorylation of Focal Adhesion Kinase (FAK). Both of these phenotypes are recovered in paxillin knockout cells upon exogenous re-expression of paxillin. The individual LD motifs of paxillin that are binding sites for FAK, vinculin and ARF-GAP proteins, as well as tyrosine residues that when phosphorylated create binding sites for CRK family members, are dispensable for FAK phosphorylation and early cell spreading. These results demonstrate that paxillin contributes to attachment-dependent tyrosine phosphorylation of FAK and early cell spreading in ES cells.	Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Pol, SV (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	sbv@po.cwru.edu	Pol, Scott Vande/AAO-1068-2020	Pol, Scott Vande/0000-0002-0587-4802	NCI NIH HHS [R29 CA069292, CA69292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069292, R01CA069292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Brown MC, 2000, J CELL BIOCHEM, V76, P99; Buckley CD, 1998, MOL MEMBR BIOL, V15, P167, DOI 10.3109/09687689709044318; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HUMPHRIES M, 1998, CURR PROT CELL BIOL, V1; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Matise M A W, 2000, PRODUCTION TARGETED; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; NIKOLOPOULOS SN, 2001, J BIOL CHEM, V13, P13; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, CELL STRUCT FUNCT, V21, P445, DOI 10.1247/csf.21.445; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Tozer EC, 1996, BIOCHEM CELL BIOL, V74, P785, DOI 10.1139/o96-085; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 2000, J CELL SCI, V113, P4139; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Wheeler GN, 2001, GENE, V262, P291, DOI 10.1016/S0378-1119(00)00512-6; WILES MV, 1993, METHOD ENZYMOL, V225, P900	55	71	71	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					96	107		10.1038/sj.onc.1205013	http://dx.doi.org/10.1038/sj.onc.1205013			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791180	Bronze			2022-12-28	WOS:000172887800010
J	Zhu, J; Emerson, SG				Zhu, J; Emerson, SG			Hematopoietic cytokines, transcription factors and lineage commitment	ONCOGENE			English	Review						transcription factor; cytokines; hematopoiesis	COLONY-STIMULATING FACTOR; STEM-CELL FACTOR; BINDING PROTEIN-ALPHA; TUMOR-NECROSIS-FACTOR; MYELOID PROGENITOR CELLS; HUMAN CD34(+) CELLS; T-CELL; B-CELL; IN-VIVO; TRANSFORMING GROWTH-FACTOR-BETA-1	The past two decades have witnessed significant advances in our understanding of the cellular physiology and molecular regulation of hematopoiesis. At the heart of stem cell self-renewal and lineage commitment decisions lies the relative expression levels of lineage-specific transcription factors. The expression of these transcription factors in early stem cells may be promiscuous and fluctuate, but ultimately comes under the influence of extracellular regulatory signals in the form of hematopoietic cytokines. In this review, we first summarize our current understanding of the phenotypic characterization of hematopoietic stem cells. Next, we describe key known transcription factors which govern stem cell self-renewal and lineage commitment decisions. Finally, we review data concerning the role of specific cytokines in influencing these decisions. From this review, a picture emerges in which stem cell fate decisions are governed by the integrated effects of intrinsic transcription factors and external signaling pathways initiated by regulatory cytokines.	Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Emerson, SG (corresponding author), Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Maloney 510,3600 Spruce St, Philadelphia, PA 19104 USA.	emersons@mail.med.upenn.edu						Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Akashi K, 2000, CURR OPIN IMMUNOL, V12, P144, DOI 10.1016/S0952-7915(99)00064-3; Allman D, 1999, J EXP MED, V189, P735, DOI 10.1084/jem.189.4.735; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; Batard P, 2000, J CELL SCI, V113, P383; Benbernou N, 2000, J BIOL CHEM, V275, P7060, DOI 10.1074/jbc.275.10.7060; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blazsek I, 2000, BLOOD, V96, P3763, DOI 10.1182/blood.V96.12.3763.h8003763_3763_3771; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Broudy VC, 1996, BLOOD, V88, P75; Bryder D, 2000, BLOOD, V96, P1748, DOI 10.1182/blood.V96.5.1748.h8001748_1748_1755; Busslinger M, 2000, CURR OPIN IMMUNOL, V12, P151, DOI 10.1016/S0952-7915(99)00065-5; CHEN HM, 1995, ONCOGENE, V11, P1549; Chen Z, 1997, PHARMACOL THERAPEUT, V76, P141, DOI 10.1016/S0163-7258(97)00090-9; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Chiang MY, 1999, BLOOD, V94, P3621, DOI 10.1182/blood.V94.11.3621.423k38_3621_3632; Choi K, 1998, DEVELOPMENT, V125, P725; Ciau-Uitz A, 2000, CELL, V102, P787, DOI 10.1016/S0092-8674(00)00067-2; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Cumano A, 2001, CURR OPIN IMMUNOL, V13, P166, DOI 10.1016/S0952-7915(00)00200-4; Daga A, 2000, EXP HEMATOL, V28, P569, DOI 10.1016/S0301-472X(00)00135-1; Deftos ML, 2000, CURR OPIN IMMUNOL, V12, P166, DOI 10.1016/S0952-7915(99)00067-9; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Drexler HG, 1998, LEUKEMIA RES, V22, P927, DOI 10.1016/S0145-2126(98)00088-5; Ducos K, 2000, J CELL PHYSIOL, V184, P80, DOI 10.1002/(SICI)1097-4652(200007)184:1<80::AID-JCP8>3.0.CO;2-Q; Dybedal I, 2001, BLOOD, V98, P1782, DOI 10.1182/blood.V98.6.1782; Egawa T, 2001, IMMUNITY, V15, P323, DOI 10.1016/S1074-7613(01)00185-6; Elwood NJ, 1998, BLOOD, V91, P3756; Engel I, 2001, J EXP MED, V194, P733, DOI 10.1084/jem.194.6.733; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; Francis JM, 2000, J BIOL CHEM, V275, P39137, DOI 10.1074/jbc.M007212200; Fujimaki S, 2001, BRIT J HAEMATOL, V113, P52, DOI 10.1046/j.1365-2141.2001.02736.x; Fuller JF, 1999, BLOOD, V93, P3391, DOI 10.1182/blood.V93.10.3391.410k26_3391_3400; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; Giannola DM, 2000, J EXP MED, V192, P1479, DOI 10.1084/jem.192.10.1479; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Harris KW, 1998, BLOOD, V92, P1219, DOI 10.1182/blood.V92.4.1219.416k07_1219_1224; Hartman ML, 2001, BLOOD, V97, P1086, DOI 10.1182/blood.V97.4.1086; Helgason CD, 1996, BLOOD, V87, P2740, DOI 10.1182/blood.V87.7.2740.bloodjournal8772740; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hsu HC, 2000, BLOOD, V96, P3757, DOI 10.1182/blood.V96.12.3757.h8003757_3757_3762; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; ICHIKAWA Y, 1970, J CELL PHYSIOL, V76, P175, DOI 10.1002/jcp.1040760207; Ikonomi P, 2000, EXP HEMATOL, V28, P1423, DOI 10.1016/S0301-472X(00)00553-1; Izon DJ, 2001, IMMUNITY, V14, P253, DOI 10.1016/S1074-7613(01)00107-8; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; Kapur R, 2001, J BIOL CHEM, V276, P1099, DOI 10.1074/jbc.M007442200; Kapur R, 1999, BLOOD, V94, P1915; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRYSTAL G, 1994, J EXP MED, V180, P851, DOI 10.1084/jem.180.3.851; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Maguer-Satta V, 2000, BLOOD, V96, P4118; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; Manaia A, 2000, DEVELOPMENT, V127, P643; Marshall CJ, 2000, BLOOD, V96, P1591, DOI 10.1182/blood.V96.4.1591.h8001591_1591_1593; Matsumura I, 2000, BLOOD, V96, P2440; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Montecino-Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Morimura T, 2001, J IMMUNOL, V166, P3277, DOI 10.4049/jimmunol.166.5.3277; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Nutt SL, 1999, BIOL CHEM, V380, P601, DOI 10.1515/BC.1999.077; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; Ohneda O, 1998, BLOOD, V92, P908; Okuda T, 2000, MOL CELL BIOL, V20, P319, DOI 10.1128/MCB.20.1.319-328.2000; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pan Q, 2001, J ENDOCRINOL, V169, P153, DOI 10.1677/joe.0.1690153; Pan QT, 1999, J BIOL CHEM, V274, P8437, DOI 10.1074/jbc.274.13.8437; Papayannopoulou T, 2000, BLOOD, V95, P1274, DOI 10.1182/blood.V95.4.1274.004k45_1274_1282; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pawlak G, 2000, EXP HEMATOL, V28, P1164, DOI 10.1016/S0301-472X(00)00522-1; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pierelli L, 2000, BLOOD, V95, P3001; Porcher C, 1999, DEVELOPMENT, V126, P4603; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Querfurth E, 2000, GENE DEV, V14, P2515, DOI 10.1101/gad.177200; Racke FK, 2001, J BIOL CHEM, V276, P522, DOI 10.1074/jbc.M005236200; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Rebel VI, 1999, J EXP MED, V190, P1493, DOI 10.1084/jem.190.10.1493; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robertson SM, 2000, DEVELOPMENT, V127, P2447; ROJNUCKARIN P, 2001, J BIOL CHEM, V4, P4; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Rothenberg EV, 2000, CURR OPIN GENET DEV, V10, P370, DOI 10.1016/S0959-437X(00)00098-8; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Sakamaki S, 1999, BLOOD, V94, P1961, DOI 10.1182/blood.V94.6.1961.418k17_1961_1970; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Schroeder T, 2000, EXP HEMATOL, V28, P1206, DOI 10.1016/S0301-472X(00)00534-8; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Semerad CL, 1999, IMMUNITY, V11, P153, DOI 10.1016/S1074-7613(00)80090-4; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Solanilla A, 2000, BLOOD, V95, P3758; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Tonelli R, 2000, HUM GENET, V107, P225, DOI 10.1007/s004390000357; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Uchida M, 2001, INT J HEMATOL, V73, P78, DOI 10.1007/BF02981906; Vannucchi AM, 2000, BLOOD, V95, P2559; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Winandy S, 1999, J EXP MED, V190, P1039, DOI 10.1084/jem.190.8.1039; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; Yang FC, 1998, BLOOD, V92, P4632, DOI 10.1182/blood.V92.12.4632.424k28_4632_4640; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhao Y, 2000, BLOOD, V96, P3016; Zhou YH, 1998, EMBO J, V17, P6689, DOI 10.1093/emboj/17.22.6689; Zhuang YA, 1998, MOL CELL BIOL, V18, P3340, DOI 10.1128/MCB.18.6.3340; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	180	227	239	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3295	3313		10.1038/sj.onc.1205318	http://dx.doi.org/10.1038/sj.onc.1205318			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032771				2022-12-28	WOS:000175633300006
J	Shao, CS; Yin, MY; Deng, L; Stambrook, PJ; Doetschman, T; Tischfield, JA				Shao, CS; Yin, MY; Deng, L; Stambrook, PJ; Doetschman, T; Tischfield, JA			Loss of heterozygosity and point mutation at Aprt locus in T cells and fibroblasts of Pms2(-/-) mice	ONCOGENE			English	Article						mismatch repair; PMS2; APRT; mouse model; somatic mutation; loss of heterozygosity	DNA MISMATCH REPAIR; MITOTIC RECOMBINATION; DEFICIENT; GENE; APOPTOSIS; TRANSITIONS; MLH1	Mice null for the Pms2 mismatch repair (MMR) gene exhibit a predisposition to lymphoma, microsatellite repeat instability, and failure of spermatogenesis. To study the role of Pms2 in the maintenance of in vivo genomic integrity in somatic cells, we characterized Aprt mutations in T cells and fibroblasts of 129 x C3H Pms2(-/-)Aprt(+/-) mice. The spontaneous frequency of DAP-resistant T lymphocytes, as a consequence of APRT-deficiency, was increased threefold. Point mutation, which accounted for less than 20% of the DAP(r) mutant clones in Pms2(+/+) mice, was predominant in the mutant T cell clones from Pms2(-/-) mice. These point mutations were predominantly TA to CG transitions. Fibroblasts of Pms2(-/-) mice exhibited only a modest increase in the frequency of clones with point mutations, such that mitotic recombination was still the primary cause of APRT deficiency. Thus, the mutator phenotype as a consequence of PMS2 deficiency is tissue-dependent, which may be related to the tissue-specific tumor proneness of Pms2(-/-)Aprt(+/-) mice.	Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	Rutgers State University New Brunswick; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Tischfield, JA (corresponding author), Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA.		Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342; Tischfield, Jay/0000-0003-3217-8287	NIDDK NIH HHS [R01DK38185] Funding Source: Medline; NIEHS NIH HHS [P01ES05652, P30ES05022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005652, P30ES005022] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; Bielas JH, 2000, P NATL ACAD SCI USA, V97, P11391, DOI 10.1073/pnas.190330997; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; DUSH MK, 1985, P NATL ACAD SCI USA, V82, P2731, DOI 10.1073/pnas.82.9.2731; Engle SJ, 1996, P NATL ACAD SCI USA, V93, P5307, DOI 10.1073/pnas.93.11.5307; Gong JG, 1999, NATURE, V399, P806; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; Meng QX, 1998, ENVIRON MOL MUTAGEN, V32, P236, DOI 10.1002/(SICI)1098-2280(1998)32:3<236::AID-EM6>3.3.CO;2-P; MIRSALIS JC, 1995, ANNU REV PHARMACOL, V35, P145; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rose JA, 2000, CANCER RES, V60, P3404; Shaddock J. G., 2001, Environmental and Molecular Mutagenesis, V37, P68; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Shao CS, 2001, NAT GENET, V28, P169, DOI 10.1038/88897; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850; Zeng M, 2000, CANCER RES, V60, P4889; Zhang H, 1999, CANCER RES, V59, P3021	26	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2840	2845		10.1038/sj.onc.1205358	http://dx.doi.org/10.1038/sj.onc.1205358			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973643				2022-12-28	WOS:000175063700008
J	Tommasi, S; Dammann, R; Jin, SG; Zhang, XF; Avruch, J; Pfeifer, GP				Tommasi, S; Dammann, R; Jin, SG; Zhang, XF; Avruch, J; Pfeifer, GP			RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1	ONCOGENE			English	Article						RASSF1; tumor suppressor gene; Ras association domain; Nore1	COMPARATIVE GENOMIC HYBRIDIZATION; EPIGENETIC INACTIVATION; CPG ISLAND; DNA METHYLATION; FAMILY; BREAST; CANCER; LUNG; HYPERMETHYLATION; 3P21.3	RASSF1A, one of the two major isoforms of the putative tumor suppressor gene RASSF1, located at 3p21.3, is inactivated in a variety of human cancers including lung, breast, bladder and renal cell carcinomas. We have isolated and cloned two human homologues of this gene, RASSF3 and NORE1, located at 12q14.1 and 1q32.1, respectively. Both RASSF3 and NORE1 share almost 60% homology, at the amino acid level, with RASSF1. The RASSF3 gene contains five exons and encodes a 247 amino acid protein (MW of 28.6 kDa) with a highly conserved Ras association (RalGDS/AF-6) (RA) domain at the C-terminus. RASSF3 is ubiquitously expressed in all normal tissues and cancer cell tines analysed. NORE1, which is homologous to the previously described mouse Nore1 gene, exists in at least two spliced isoforms, A and B. Transcript A encodes a protein of 418 amino acids (MW or 47 kDa) while transcript B contains an ORF of 265 aa (MW of 30.5 kDa). Both share a RA domain, encoded by exons 3 through 6. NORE1A and NORE1B are expressed in most of the normal tissues analysed but they appear to be down-regulated in several cancer cell lines. However, contrary to RASSF1A, gene silencing by methylation of the CpG islands at which the two NORE1 transcripts initiate is not a common event in human primary tumors. RASSF3 and NORE1B are very similar, at the N-terminus, to the splice variant C of RASSF1 (RASSF1C), which does not seem to be involved in tumorigenesis. NORE1A is most closely related to RASSF1A, for sequence homology and genomic organization. However, aberrations in tumors have so far not been found. The presence of a Ras association domain common to NORE1, RASSF1, and RASSF3 suggests their possible involvement in Ras-like signaling pathways.	Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Inst Humangenet & Med Biol, D-06097 Halle An Der Saale, Germany; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg; Harvard University; Massachusetts General Hospital	Tommasi, S (corresponding author), Beckman Res Inst, Dept Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	stommasi@coh.org		Tommasi, Stella/0000-0001-6897-4985; Jin, Seung-Gi/0000-0001-5041-0559	NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER; NCI NIH HHS [CA88873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Almeida A, 1998, ONCOGENE, V16, P2997, DOI 10.1038/sj.onc.1201828; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOS JL, 1989, CANCER RES, V49, P4682; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KHOKHLATCHEV A, 2002, IN PRESS CURR BIOL; Kros JM, 1999, J PATHOL, V188, P282; Lee MG, 2001, CANCER RES, V61, P6688; Lo KW, 2001, CANCER RES, V61, P3877; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; ORTIZVEGA S, 2002, IN PRESS ONCOGENE; Petersen C, 2000, J BIOL CHEM, V275, P4081, DOI 10.1074/jbc.275.6.4081; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RIED T, 1995, CANCER RES, V55, P5415; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Thompson L, 1994, Work, V4, P22, DOI 10.3233/WOR-1994-4104; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wistuba II, 2000, CANCER RES, V60, P1949; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	41	89	105	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2713	2720		10.1038/sj.onc.1205365	http://dx.doi.org/10.1038/sj.onc.1205365			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965544				2022-12-28	WOS:000174996500011
J	Gaymes, TJ; North, PS; Brady, N; Hickson, ID; Mufti, GJ; Rassool, FV				Gaymes, TJ; North, PS; Brady, N; Hickson, ID; Mufti, GJ; Rassool, FV			Increased error-prone non homologous DNA end-joining - a proposed mechanism of chromosomal instability in Bloom's syndrome	ONCOGENE			English	Article						Bloom's syndrome; chromosomal abnormalities; double strand break DNA repair; non homologous end-joining	SYNDROME GENE-PRODUCT; DOUBLE-STRAND BREAKS; CELL-FREE-EXTRACTS; NONHOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; HELICASES; REPAIR	BS is an inherited cancer predisposition disorder caused by inactivation of the RecQ family helicase, BLM. One of the defining features of cells from BS individuals is chromosomal instability, characterized by elevated sister chromatid exchanges (SCEs), as well as chromosomal breaks, deletions, and rearrangements. Although the basis for chromosomal instability is poorly understood, there is evidence that chromosomal abnormalities can arise through an alteration in the efficiency or fidelity of DNA double strand break (DSB) repair. Here, we show that BS cells demonstrate aberrant DSB repair mediated by the non-homologous end-joining (NHEJ) pathway for DNA repair, one of the two main pathways for the repair of DSBs in mammalian cells. Through a comparison of BS cell lines, and a derivative in which the BS phenotype has been reverted by expression of the BLM cDNA, we show that BS cells display aberrant end-joining of DSBs. Importantly, DNA end-joining in BS cells is highly error-prone and frequently results in DNA ligation at distant sites of microhomology, creating large DNA deletions. This aberrant repair is dependent upon the presence of the Ku70/86 heterodimer, a key component in the NHEJ pathway. We propose that aberrant NHEJ is a candidate mechanism for the generation of chromosomal instability in BS.	Rayne Inst, GKT Sch Med, Leukaem Sci Labs, Dept Haematol Med, London SE5 9NU, England; Univ Oxford, John Radcliffe Hosp, Imperial Canc Res Fund Labs, Weatherall Inst Mol Med, Oxford OX3 9DS, England	University of London; King's College London; Cancer Research UK; University of Oxford	Rassool, FV (corresponding author), Rayne Inst, GKT Sch Med, Leukaem Sci Labs, Dept Haematol Med, London SE5 9NU, England.	feyruz.rassool@kcl.ac.uk	Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, AM J HUM GENET, V57, P1019; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GERMAN J, 1974, CHROMOSOMA, V48, P361, DOI 10.1007/BF00290993; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kusano K, 2001, SCIENCE, V291, P2600, DOI 10.1126/science.291.5513.2600; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; Li L, 1998, MOL GENET METAB, V64, P286, DOI 10.1006/mgme.1998.2733; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; NORTH P, 1990, NUCLEIC ACIDS RES, V18, P6205, DOI 10.1093/nar/18.21.6205; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; RUNGER TM, 1989, EMBO J, V8, P1419, DOI 10.1002/j.1460-2075.1989.tb03523.x; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733	32	87	91	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2525	2533		10.1038/sj.onc.1205331	http://dx.doi.org/10.1038/sj.onc.1205331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971187				2022-12-28	WOS:000174918400009
J	Horie, R; Watanabe, T; Morishita, Y; Ito, K; Ishida, T; Kanegae, Y; Saito, I; Higashihara, M; Mori, S; Kadin, ME; Watanabe, T				Horie, R; Watanabe, T; Morishita, Y; Ito, K; Ishida, T; Kanegae, Y; Saito, I; Higashihara, M; Mori, S; Kadin, ME; Watanabe, T			Ligand-independent signaling by overexpressed CD30 drives NF-kappa B activation in Hodgkin-Reed-Sternberg cells	ONCOGENE			English	Article						Hodgkin-Reed-Sternberg cells; CD30; TRAF proteins; NF-kappa B; adenovirus vector	TNF RECEPTOR SUPERFAMILY; IMMUNOGLOBULIN GENE REARRANGEMENTS; CYTOPLASMIC DOMAIN; BINDING-SITES; TUMOR-CELLS; DISEASE; DEATH; EXPRESSION; PROTEINS; FAMILY	Overexpression of CD30 and constitutive NF-kappaB activation characterizes tumor cells of Hodgkin's disease (HD), Hodgkin and Reed-Sternberg (H-RS) cells. We report that in H-RS cells overexpression of CD30 leads to self-aggregation, recruitment of TRAF2 and TRAF5, and NF-kappaB activation, independent of CD30 ligand. CD30 and TRAF proteins co-localized in H-RS cell lines and in lymph nodes of HD. An adenovirus-vector carrying a decoy CD30 lacking the cytoplasmic region or a dominant negative IkappaBalpha mutant blocks NF-kappaB activation, down regulates IL-13 expression and induces apoptosis. Thus, in H-RS cells, ligand-independent activation of CD30 signaling drives NF-kappaB activation and this leads to constitutive cytokine expression, which provides a molecular basis for HD. Inhibition of NF-kappaB activation by adenovirus vector-mediated gene transfer may provide a novel strategy of cell- and target molecule-specific therapy for patients with HD.	Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, Tokyo 1088639, Japan; Kitasato Univ, Fac Med, Dept Hematol, Kanagawa, Japan; Univ Tokyo, Inst Med Sci, Mol Genet Lab, Minato Ku, Tokyo 1088639, Japan; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	University of Tokyo; Kitasato University; University of Tokyo; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Watanabe, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tnabe@ims.u-tokyo.ac.jp						ADAM D, 1995, J BIOL CHEM, V270, P17482; Aizawa S, 1997, J BIOL CHEM, V272, P2042; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cantwell MJ, 1996, BLOOD, V88, P4676, DOI 10.1182/blood.V88.12.4676.bloodjournal88124676; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cossman J, 1999, BLOOD, V94, P411, DOI 10.1182/blood.V94.2.411; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; FALINI B, 1995, BLOOD, V85, P1; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Gruss HJ, 1996, BAILLIERE CLIN HAEM, V9, P417, DOI 10.1016/S0950-3536(96)80019-9; GRUSS HJ, 1994, BLOOD, V83, P2045; Harris NL, 1999, SEMIN HEMATOL, V36, P220; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Horie R, 1998, INT IMMUNOL, V10, P203, DOI 10.1093/intimm/10.2.203; Horie R, 1998, SEMIN IMMUNOL, V10, P457, DOI 10.1006/smim.1998.0156; Horie R, 1996, BLOOD, V88, P2422, DOI 10.1182/blood.V88.7.2422.bloodjournal8872422; Hsu PL, 2000, LAB INVEST, V80, P1111, DOI 10.1038/labinvest.3780117; JOSIMOVICALASEVIC O, 1989, EUR J IMMUNOL, V19, P157, DOI 10.1002/eji.1830190125; Kadin ME, 1999, HODGKIN'S DISEASE, P139; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; Medina DJ, 1999, BLOOD, V94, P3499; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Papoff G, 1999, J BIOL CHEM, V274, P38241, DOI 10.1074/jbc.274.53.38241; Pinto A, 1996, BLOOD, V88, P3299, DOI 10.1182/blood.V88.9.3299.bloodjournal8893299; Prince HM, 1998, EXP HEMATOL, V26, P27; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; Teoh G, 1998, BLOOD, V92, P4591, DOI 10.1182/blood.V92.12.4591.424k08_4591_4601; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; von Wasielewski R, 2000, BLOOD, V95, P1207, DOI 10.1182/blood.V95.4.1207.004k34_1207_1213; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868	53	163	171	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2493	2503		10.1038/sj.onc.1205337	http://dx.doi.org/10.1038/sj.onc.1205337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971184				2022-12-28	WOS:000174918400006
J	Boyer, B; Bourgeois, Y; Poupon, MF				Boyer, B; Bourgeois, Y; Poupon, MF			Src kinase contributes to the metastatic spread of carcinoma cells	ONCOGENE			English	Article						epithelium-mesenchyme transition; cell scattering; tumor cells; cell differentiation; tyrosine phosphorylation	PROTEIN-TYROSINE KINASES; FIBROBLAST-GROWTH-FACTOR; FOCAL ADHESION KINASE; HUMAN BREAST-CANCER; C-SRC; V-SRC; PP60C-SRC ACTIVITY; CATALYTIC-ACTIVITY; TRANSFORMED CELLS; TUMOR-GROWTH	The involvement of Src kinase during carcinoma metastasis has been explored by using the NBT-II rat carcinoma cell line, which can be induced to scatter in vitro through Src activity. Here we show that Src activity was not required for growth of tumors derived from NBT-II cells injected into nude mice. In contrast, the presence of micrometastases was strictly dependent on Src, since the percentage of mice bearing metastases was dramatically reduced by the expression of a dominant-negative mutant of Src (SrcK(-)) or of Csk, the natural inhibitor of Src. Furthermore, metastatic cells originating from NBT-II cells displayed a Src activity higher than the parental cells, confirming that Src gives a selective advantage during the metastatic process. Finally, anatomopathological analysis of the primary tumors arising from NBT-II cells expressing Csk or SrcK(-) constructs revealed a highly differentiated epithelial phenotype contrasting with the poor differentiation of tumors derived from parental cells. The differentiated phenotype correlated with the presence of desmosomes at the cell periphery and the absence of vimentin intermediate filaments. Altogether, these data demonstrate that Src activity correlates with the loss of epithelial differentiation concomitantly with the increase of the metastatic potential of carcinoma cells.	Ctr Univ Paris Sud, Inst Curie, CNRS, UMR 146,Sect Rech, F-91405 Orsay, France; Inst Curie, CNRS, UMR 147, Sech Rech, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Boyer, B (corresponding author), Ctr Univ Paris Sud, Inst Curie, CNRS, UMR 146,Sect Rech, Batiment 110, F-91405 Orsay, France.	Brigitte.Boyer@curie.u-psud.fr						BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Birchmeier C, 1996, ACTA ANAT, V156, P217; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; Cary LA, 1996, J CELL SCI, V109, P1787; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CUPRITI S, 2000, EMBO J, V19, P4614; Daigo Y, 1999, CANCER RES, V59, P4222; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Duband JL, 1995, ACTA ANAT, V154, P63; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; Faraldo MM, 2001, EMBO REP, V2, P431, DOI 10.1093/embo-reports/kve086; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FURUTA Y, 1995, ONCOGENE, V11, P1989; GAVRILOVIC J, 1990, CELL REGUL, V1, P1003, DOI 10.1091/mbc.1.13.1003; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GREENBERG JM, 1989, ADV SPACE RES, V9, P3; GUARINO M, 1995, HISTOL HISTOPATHOL, V10, P171; Hall CL, 1996, ONCOGENE, V13, P2213; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hay ED, 1995, ACTA ANAT, V154, P8; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; ILLC D, 1995, NATURE, V377, P539; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Irby R, 1997, CELL GROWTH DIFFER, V8, P1287; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KELLIE S, 1991, J CELL SCI, V99, P207; Kirschmann DA, 1999, BREAST CANCER RES TR, V55, P127; KOPFMAIER P, 1991, CELL TISSUE RES, V264, P563, DOI 10.1007/BF00319046; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAREEL MM, 1993, CRIT REV ONCOGENESIS, V4, P559; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Mayer K, 1996, ANTICANCER RES, V16, P1733; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Morse-Gaudio M, 1998, INT J ONCOL, V12, P1349; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; POUPON MF, 1993, J NATL CANCER I, V85, P2023, DOI 10.1093/jnci/85.24.2023; Putz E, 1999, CANCER RES, V59, P241; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; Rodina A, 1999, FEBS LETT, V455, P145, DOI 10.1016/S0014-5793(99)00794-2; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sim SJ, 1999, MODERN PATHOL, V12, P351; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; TAKAYAMA T, 1993, INT J CANCER, V54, P875, DOI 10.1002/ijc.2910540525; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; Viebahn C, 1995, ACTA ANAT, V154, P79; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	72	96	101	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2347	2356		10.1038/sj.onc.1205298	http://dx.doi.org/10.1038/sj.onc.1205298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948418				2022-12-28	WOS:000174635600007
J	Coles, LC; Shaw, PE				Coles, LC; Shaw, PE			PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway	ONCOGENE			English	Article						Rho proteins; PAKs; MEKs; phospho-specific antibodies; regulatory phosphorylation	PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN; RAS; SERINE; BINDING; IDENTIFICATION; INHIBITION; RESIDUES; COMPLEX; SITES	The serine/threonine kinase Raf-1 acts downstream of Ras in the MAPK pathway leading to ERK activation in response to mitogens. Raf-1 has oncogenic potential, but is normally controlled by a complex interplay of inhibitory and activating mechanisms. Although Raf-1 is phosphorylated in unstimulated cells, mitogens cause its membrane recruitment by Ras and subsequent phosphorylation on additional sites. Some of these events modulate Raf-1 kinase activity while others determine interactions with other proteins. These changes regulate the ability of Raf-I to phosphorylate its downstream targets MEK1 and MEK2. Rho family small G proteins act synergistically with Raf-I to stimulate the ERK pathway by a cross-cascade mechanism that enhances MEK phosphorylation by Raf-1. Here we show that both Raf-1 and MEK1 are phosphorylated by PAK1 and that mutations at PAK1 phosphorylation sites in either protein prevent cross-cascade activation. In contrast, MEK1 activation by constitutively-active Raf-1 is refractory to mutations at PAK1 phosphorylation sites. Phosphorylation of MEK1 on serine 298 does not appear to regulate the interaction between Raf-1 and MEK1, but rather the ability of Raf-I to phosphorylate MEK1 with which it is complexed in vivo. Our findings indicate that PAK1 primes MEK1 for activation by Raf-1 and imply another level of regulation in the ERK cascade.	Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham	Shaw, PE (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.	peter.shaw@nottingham.ac.uk		SHAW, Peter/0000-0002-2598-4283				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	33	91	93	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2236	2244		10.1038/sj.onc.1205302	http://dx.doi.org/10.1038/sj.onc.1205302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948406				2022-12-28	WOS:000174555300012
J	Yu, DN; Thomas-Tikhonenko, A				Yu, DN; Thomas-Tikhonenko, A			A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis	ONCOGENE			English	Article						Myc; p53; B-lymphoma; immunoglobulins; gene rearrangement	EPSTEIN-BARR-VIRUS; C-MYC; BURKITT-LYMPHOMA; TRANSGENIC MICE; APOPTOSIS; GENE; REARRANGEMENTS; TRANSLOCATION; EXPRESSION; PROTEIN	The c-Myc oncoprotein is strongly implicated in B-cell neoplasms such as human Burkitt lymphomas and mouse plasmocytomas. Transgenic mice in which the myc gene is juxtaposed to an immunoglobulin enhancer (Emu-myc) also develop B-cell lymphomas, but relatively late in life. In addition, these neoplasms are invariably clonal, suggesting the involvement of additional mutations. Such mutations frequently affect the p53 tumour suppressor gene or its positive regulator Arf, hinting that inactivation of the p53 pathway might be the second hit required for the progression towards malignancy. However, even tumours arising in Emu-myc/Arf-null animals are thought to be clonal. This observation raised doubts whether overexpression of Myc in p53-null B-cell precursors is sufficient for tumorigenesis. To address this question, we have established a new, non-transgenic mouse model of B-lymphoma. This model is based on isolation of primary bone marrow (BM) cells, admixing them with packaging cells producing a Myc-encoding retrovirus (LMycSN), and subcutaneous injection into a host with which BM cells are syngeneic. Predictably, wild type BM cells infected in vivo by LMycSN were not tumorigenic. However, LMycSN-infected p53-null BM cells readily gave rise to B-cell lymphomas composed predominantly of late pro-B/small pre-B-cells. In these tumours, heavy chain gene rearrangements were analysed using two independent PCR-based assays. All neoplasms with DJ-rearrangements were found to be polyclonal. This result suggests that inactivation of p53 and overexpression of Myc is all that is necessary for the development of full-fledged B-lymphomas. Our model would also be instrumental in assessing the transforming potential of Myc mutants and in studying cooperation between Myc and other oncogenes.	Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Thomas-Tikhonenko, A (corresponding author), Univ Penn, Dept Pathobiol, 3800 Spruce St, Philadelphia, PA 19104 USA.	andreit@mail.vet.upenn.edu	Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206	NCI NIH HHS [CA 71881] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA071881, R29CA071881] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Bower M, 2001, BRIT J HAEMATOL, V112, P863, DOI 10.1046/j.1365-2141.2001.02654.x; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Cory S, 1999, CANCER RES, V59, p1685S; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HSU B, 1995, ONCOGENE, V11, P175; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; KLEIN G, 1993, GENE, V135, P189, DOI 10.1016/0378-1119(93)90065-B; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; NEWCOMB EW, 1995, LEUKEMIA LYMPHOMA, V17, P211, DOI 10.3109/10428199509056825; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PELICCI PG, 1986, J EXP MED, V164, P2049, DOI 10.1084/jem.164.6.2049; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TENBOEKEL E, 1995, INT IMMUNOL, V7, P1013; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Yu DN, 2001, CANCER LETT, V173, P145, DOI 10.1016/S0304-3835(01)00612-7; Zimber-Strobl U, 1999, CURR TOP MICROBIOL, V246, P315; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	49	41	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1922	1927		10.1038/sj.onc.1205244	http://dx.doi.org/10.1038/sj.onc.1205244			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896625				2022-12-28	WOS:000174284500015
J	Afrikanova, I; Yeh, E; Bartos, D; Watowich, SS; Longmore, GD				Afrikanova, I; Yeh, E; Bartos, D; Watowich, SS; Longmore, GD			Oncogene cooperativity in Friend erythroleukemia: erythropoietin receptor activation by the env gene of SFFV leads to transcriptional upregulation of PU.1, independent of SFFV proviral insertion	ONCOGENE			English	Article						erythroleukemia; oncogene cooperativity; PU. 1 transcription; Friend virus	FOCUS-FORMING VIRUS; LONG TERMINAL REPEAT; TRANSGENIC MICE DEVELOP; CONSTITUTIVE ACTIVATION; PUTATIVE ONCOGENE; SPLEEN; SPI-1; EXPRESSION; KINASE; GROWTH	Cancer is a multi-step, multi-genetic event. Whether oncogenic mutations cooperate with one another to transform cells and how is not well understood. The Friend murine retroviral erythroleukemia model involves mitogenic activation of the erythropoietin receptor (EpoR) by the virus env gene (F-gp55), aberrant over-expression of the transcription factor PU.1, and inactivating mutations in p53. In this report we demonstrate that concurrent expression of F-gp55 and PU.1 in erythroid target cells, in vivo, cooperate to accelerate erythroleukemia induction. Early in the disease, prior to the detection of clonal leukemic cells, activation of the EpoR by F-gp55, but not erythropoietin, resulted in transcriptional upregulation of PU.1 through a trans regulatory mechanism. This could occur in the absence of an integrated provirus within the PU.1 gene locus. The regulation of PU.1 transcription in established erythroleukemia cell lines differed depending upon the level of PU.1 protein present. Our results suggest that the action of F-gp55 contributes to both early and late stages of Friend erythroleukemia and that persistence of F-gp55 expression may be required not only to initiate erythroleukemia but to also maintain erythroleukemia following Friend virus infection.	Washington Univ, Sch Med, Dept Med, Div Hematol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	Washington University (WUSTL); Washington University (WUSTL); University of Texas System; UTMD Anderson Cancer Center	Longmore, GD (corresponding author), Washington Univ, Sch Med, Dept Med, Div Hematol, Campus Box 8125,660 S Euclid Ave, St Louis, MO 63110 USA.	longmorg@medicine.wustl.edu		Watowich, Stephanie/0000-0003-1969-659X	NCI NIH HHS [R01 CA 75315, R01 CA077447-02, R01 CA077447-03, R01 CA 77447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077447, R01CA075315] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; Beckman DL, 1999, BLOOD, V94, P2667, DOI 10.1182/blood.V94.8.2667.420k27_2667_2675; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; Chen HM, 1996, J BIOL CHEM, V271, P15743, DOI 10.1074/jbc.271.26.15743; CHEN HM, 1995, ONCOGENE, V11, P1549; CHOI SY, 1995, J VIROL, V69, P7054, DOI 10.1128/JVI.69.11.7054-7060.1995; Elnitski L, 1999, BLOOD CELL MOL DIS, V25, P299, DOI 10.1006/bcmd.1999.0257; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Ghosh SK, 1999, J VIROL, V73, P4931, DOI 10.1128/JVI.73.6.4931-4940.1999; Hoatlin Maureen E., 1995, Trends in Microbiology, V3, P51, DOI 10.1016/S0966-842X(00)88875-7; HOWARD JC, 1993, ONCOGENE, V8, P2721; HROMAS R, 1993, BLOOD, V82, P2998; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; LI JP, 1987, J VIROL, V61, P2782, DOI 10.1128/JVI.61.9.2782-2792.1987; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Muszynski KW, 1998, J VIROL, V72, P919, DOI 10.1128/JVI.72.2.919-925.1998; Muszynski KW, 2000, J VIROL, V74, P8444, DOI 10.1128/JVI.74.18.8444-8451.2000; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; Pereira R, 2000, ONCOGENE, V19, P5106, DOI 10.1038/sj.onc.1203886; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROSEN CA, 1985, SCIENCE, V227, P320, DOI 10.1126/science.2981432; Ruscetti SK, 1999, INT J BIOCHEM CELL B, V31, P1089, DOI 10.1016/S1357-2725(99)00074-6; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; Tarr K, 1997, J BIOL CHEM, V272, P9099; TRAN QC, 1997, EMBO J, V16, P5639; Vannucchi AM, 2000, BLOOD, V95, P2559; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P307; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	45	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1272	1284		10.1038/sj.onc.1205183	http://dx.doi.org/10.1038/sj.onc.1205183			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850847	Green Accepted, Bronze			2022-12-28	WOS:000173729400015
J	Miyakoda, M; Suzuki, K; Kodama, S; Watanabe, M				Miyakoda, M; Suzuki, K; Kodama, S; Watanabe, M			Activation of ATM and phosphorylation of p53 by heat shock	ONCOGENE			English	Article						ATM; p53; heat shock; serine 15; phosphorylation	TUMOR-SUPPRESSOR PROTEIN; DAMAGE-INDUCED PHOSPHORYLATION; CELL-CYCLE CHECKPOINT; DOUBLE-STRAND BREAKS; N-TERMINAL SITES; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; DEPENDENT PHOSPHORYLATION; IONIZING-RADIATION; POTENTIAL MEDIATOR	p53 protein is phosphorylated in response to various stresses. Here we examined phosphorylation of p53 protein in normal human diploid cells after heat shock at 43degreesC for 2 h. We found that heat shock stimulates phosphorylation of p53 at Ser15 but not at Ser20, while X-irradiation at 4 Gy and 10 J/m(2) of UV induces phosphorylation of p53 at Ser15 and less significantly at Ser20. Increased phosphorylation of Ser15 was also observed in heat shocked GM638, the SV40-transformed human fibroblast cell line. Although X-ray irradiation induced phosphorylation of Ser6, 9, 20, and 37 in GM638 cells, heat shock did not affect the phosphorylation level of these serines. We observed little or no phosphorylation of p53 at Ser15 in two primary ataxia telangiectasia fibroblast cells, that are defective in ATM. Using an in vitro kinase assay, we confirmed that immunoprecipitated ATM from both heat-shocked and X-irradiated normal human diploid cells can phosphorylate p53 at Ser15 to a similar extent. These results indicate that heat shock induces phosphorylation of p53, especially at Ser15, and its phosphorylation is mediated by ATM kinase.	Nagasaki Univ, Sch Pharmaceut Sci, Lab Radiat & Life Sci, Nagasaki 8528521, Japan	Nagasaki University	Watanabe, M (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Radiat & Life Sci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	nabe@net.nagasaki-u.ac.jp						Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ikeda M, 1999, BIOL REPROD, V61, P393, DOI 10.1095/biolreprod61.2.393; JORRITSMA JBM, 1984, RADIAT RES, V98, P198, DOI 10.2307/3576063; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lavin MF, 2000, NAT CELL BIOL, V2, pE215, DOI 10.1038/35046628; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILNE DM, 1992, ONCOGENE, V7, P1361; Miyakoda M, 1999, BIOCHEM BIOPH RES CO, V266, P377, DOI 10.1006/bbrc.1999.1829; MIYASHITA T, 1995, CELL, V80, P293; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; WATANABE M, 1992, INT J RADIAT BIOL, V62, P711, DOI 10.1080/09553009214552661; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	54	41	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1090	1096		10.1038/sj.onc.1205196	http://dx.doi.org/10.1038/sj.onc.1205196			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850826				2022-12-28	WOS:000173580100012
J	Zamo, A; Chiarle, R; Piva, R; Howes, J; Fan, Y; Chilosi, M; Levy, DE; Inghirami, G				Zamo, A; Chiarle, R; Piva, R; Howes, J; Fan, Y; Chilosi, M; Levy, DE; Inghirami, G			Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death	ONCOGENE			English	Article						ALCL; t(2;5); NPM-ALK signaling; Stat3; Bcl-x(L), apoptosis	NON-HODGKINS-LYMPHOMA; RECEPTOR TYROSINE KINASE; SIGNAL TRANSDUCER; GENE; TRANSCRIPTION; APOPTOSIS; INHIBITOR; FUSION; NPM; EXPRESSION	The anaplastic lymphoma kinase (ALK) gene is characteristically translocated in Anaplastic Large Cell Lymphomas (ALCL) and the juxtaposion of the ALK gene to multiple partners results in its constitutive protein tyrosine kinase activity. We show here that expression of activated ALK induces the constitutive phosphorylation of Stat3 in transfected cells as well as in primary human ALCLs. Furthermore, immunohistochemical studies demonstrate that among distinct human B and T cell lymphomas, activation of Stat3 nuclear translocation is uniquely associated with ALK expression. NPM-ALK also binds and activates Jak3; however, Jak3 is not required for Stat3 activation or for cell transformation in vitro. Moreover, src family kinases are not necessary for NPM-ALK-mediated Stat3 activation or transformation, suggesting that Stat3 may be phosphorylated directly by ALK. To evaluate relevant targets of ALK-activated Stat3, we investigated the regulation of the anti-apoptotic protein Bcl-x(L) and its role in cell survival in NPM-ALK positive cells. NPM-ALK expression caused enhanced Bcl-x(L) transcription, largely mediated by Stat3. Increased expression of Bcl-x(L) provided sufficient anti-apoptotic signals to protect cells from treatment with specific inhibitors of the Jaks/Stat pathway or the Brc-Abl kinase. These studies support a pathogenic mechanism whereby stimulation of anti-apoptotic signals through activation of Stat3 contributes to the successful outgrowth of ALK positive tumor cells.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Univ Verona, Dept Pathol, Rome, Italy; Univ Turin, Dept Pathol, Turin, Italy	New York University; New York University; University of Verona; University of Turin	Inghirami, G (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.		Levy, David/GPS-4945-2022; Piva, Roberto/H-7315-2013; Levy, David/AAG-6202-2019; Zamò, Alberto/ABF-4436-2020; Piva, Roberto/B-9580-2018	Levy, David/0000-0002-7320-7788; Piva, Roberto/0000-0002-2273-3470; CHIARLE, Roberto/0000-0003-1564-8531; Zamo, Alberto/0000-0001-6203-7966	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 28900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Chiarle R, 1999, J IMMUNOL, V163, P194; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Donato NJ, 2001, BLOOD, V97, P2846, DOI 10.1182/blood.V97.9.2846; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Grignani F, 1998, CANCER RES, V58, P14; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARRIS NL, 1994, BLOOD, V84, P1361; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Slupianek A, 2001, CANCER RES, V61, P2194; Takeda K, 1998, J IMMUNOL, V161, P4652; Trinei M, 2000, CANCER RES, V60, P793; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548	34	292	303	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1038	1047		10.1038/sj.onc.1205152	http://dx.doi.org/10.1038/sj.onc.1205152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850821	Bronze			2022-12-28	WOS:000173580100007
J	Crish, JF; Bone, F; Banks, EB; Eckert, RL				Crish, JF; Bone, F; Banks, EB; Eckert, RL			The human involucrin gene contains spatially distinct regulatory elements that regulate expression during early versus late epidermal differentiation	ONCOGENE			English	Article						transgenic mice; activator protein-1; AP1; jun; fos; Sp1; gene regulation; epidermal keratinocyte; keratinocyte differentiation; tissue specific	PROTEIN-KINASE-C; CORNIFIED CELL-ENVELOPE; CROSS-LINKED ENVELOPE; HUMAN KERATIN-1 GENE; PROMOTER ACTIVITY; TRANSGENIC MICE; TERMINAL DIFFERENTIATION; AP-1 ELEMENT; TRANSCRIPTION; FOS	Human involucrin (hINV) is a keratinocyte protein that is expressed in the suprabasal compartment of the epidermis and other stratifying surface epithelia. Involucrin gene expression is initiated early in the differentiation process and is maintained until terminal cell death. The distal regulatory region (DRR) is a segment of the hINV promoter (nucleotides -2473/ -1953) that accurately recapitulates the normal pattern of suprabasal (spinous and granular layer) expression in transgenic mouse epithelia. To identify sequences that mediate expression at specific stages of differentiation, we divided the DRR into two segments, a 376 nucleotide upstream region (DRR-2473/-2100) and a 147 nucleotide downstream region (DRR-2100/-1953), and evaluated the ability of these sequences to drive expression in transgenic mice. The DRR-2473/-2100 segment drives expression at a level comparable to that observed for the DRR, but expression is restricted to the upper granular layers (i.e., no spinous layer expression). In contrast, the DRR-2100/-1953 segment does not drive expression. However, reassembling the DRR restores the complete range of expression. These results suggest that two distinct, spatially-separate elements are required to specify the complete differenation-dependent program of involucrin gene expression. To identify specific transcription factor binding sites involved in this regulation, we mutated an activator protein-1 binding site, AP1-5, located within DRR-2473/-2100 segment. This site binds AP1 transcription factors present in mouse epidermal extracts, and its mutation eliminates appropriate hINV expression. This result suggests that AP1 factors participate as components of a multicomponent transcription factor complex that is required for regulation.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Room E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39750] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Bernerd Francoise, 1993, Gene Expression, V3, P187; BICKENBACH JR, 1995, J INVEST DERMATOL, V104, P405, DOI 10.1111/1523-1747.ep12665896; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; FEI YJ, 1995, BIOTECHNIQUES, V18, P984; FISHER C, 1991, DEVELOPMENT, V111, P253; Green H, 1980, Harvey Lect, V74, P101; HOHL D, 1993, DIFFERENTIATION, V54, P25, DOI 10.1111/j.1432-0436.1993.tb00656.x; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HUFF CA, 1993, J BIOL CHEM, V268, P377; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; LU B, 1994, J BIOL CHEM, V269, P7443; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; MURTHY S, 1993, J STRUCT BIOL, V111, P68, DOI 10.1006/jsbi.1993.1037; Ng DC, 2000, J BIOL CHEM, V275, P24080, DOI 10.1074/jbc.M002508200; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; Rutberg SE, 1996, ONCOGENE, V13, P167; Steinert P M, 1995, Cell Death Differ, V2, P33; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; Takahashi H, 1998, J INVEST DERMATOL, V110, P218, DOI 10.1046/j.1523-1747.1998.00110.x; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yamada K, 1997, HUM MOL GENET, V6, P2223, DOI 10.1093/hmg/6.13.2223	49	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					738	747		10.1038/sj.onc.1205038	http://dx.doi.org/10.1038/sj.onc.1205038			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850802				2022-12-28	WOS:000173427000005
J	Westwood, G; Dibling, BC; Cuthbert-Heavens, D; Burchill, SA				Westwood, G; Dibling, BC; Cuthbert-Heavens, D; Burchill, SA			Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway	ONCOGENE			English	Article						bFGF; cell death; caspase; Ewing's sarcoma	CYTOCHROME-C RELEASE; EWING TUMOR-CELLS; INDUCED APOPTOSIS; P53; MITOCHONDRIAL; PROTEIN; SARCOMA; MODULATION; BCL-2; BAX	The mechanism of bFGF-induced cell death in tumours of the Ewing's sarcoma family (ESFT) has been investigated. bFGF-induces phosphorylation of FGFr 1 and activation of Ras/ERK in ESFT cells that die when exposed to bFGF. Induction of cell death was associated with activation of both initiator (caspases-2, -8 and -10) and effector (caspases-3, -6 and -7) caspases. Moreover, the general caspase inhibitor Z-VAD-FMK protected cells from bFGF-induced cell death. After treatment with bFGF, a loss of mitochondrial transmembrane potential was accompanied by down-regulation of Bcl-2. However, the observed cell death was not associated with release of cytochrome c from the mitochondria. Furthermore, expression of wild-type p53 was not required for bFGF-induced cell death. These observations suggest that bFGF-induced cell death may be mediated through a cell death receptor mechanism, supported by up-regulation of the p75 neurotrophin receptor. bFGF-induced cell death was associated with up-regulation of p21 and p53, down-regulation of PCNA and cyclin A and a decrease in active pRb1, changes consistent with accumulation of cells in G1. These data demonstrate that bFGF-induced cell death is effected through a caspase-dependent and p53-independent mechanism, that may be mediated through a cell death receptor pathway.	Univ Leeds, St James Hosp, Imperial Canc Res Fund, Canc Med Res Unit,Candlelighters Childrens Canc R, Leeds LS9 7TF, W Yorkshire, England; Univ Leeds, St James Hosp, Imperial Canc Res Fund, Canc Med Res Unit,Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds	Burchill, SA (corresponding author), Univ Leeds, St James Hosp, Imperial Canc Res Fund, Canc Med Res Unit,Candlelighters Childrens Canc R, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Heavens, Darren/0000-0001-5418-7868				Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074/jbc.M005267200; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BARTEK J, 1990, ONCOGENE, V5, P893; BIEDLER JL, 1973, CANCER RES, V33, P2643; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dobrowsky RT, 2000, J NEUROSCI RES, V61, P237, DOI 10.1002/1097-4547(20000801)61:3<237::AID-JNR1>3.0.CO;2-M; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; ITOH N, 1993, J BIOL CHEM, V268, P10932; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Kontny HU, 1998, CANCER RES, V58, P5842; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 2000, ONCOGENE, V19, P4096, DOI 10.1038/sj.onc.1203780; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; Kumar A, 2001, ONCOGENE, V20, P1010, DOI 10.1038/sj.onc.1204154; Kusaka K, 1998, CURR EYE RES, V17, P524, DOI 10.1076/ceyr.17.5.524.5196; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; OConnor PM, 1997, CANCER RES, V57, P4285; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; OWENSCHAUB LB, 1995, CANCER LETT, V94, P1, DOI 10.1016/0304-3835(95)03834-J; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Radig K, 1998, PATHOL RES PRACT, V194, P157, DOI 10.1016/S0344-0338(98)80016-2; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Schuelke M, 2000, NAT BIOTECHNOL, V18, P233, DOI 10.1038/72708; SCHWEIGERER L, 1987, J CLIN INVEST, V80, P1516, DOI 10.1172/JCI113236; Smits VAJ, 2000, J BIOL CHEM, V275, P19375, DOI 10.1074/jbc.M001764200; Sturla LM, 2000, CANCER RES, V60, P6160; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wang HS, 1997, CANCER RES, V57, P1750; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; Wang X, 2001, J BIOL CHEM, V276, P33812, DOI 10.1074/jbc.M010548200; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	49	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					809	824		10.1038/sj.onc.1205128	http://dx.doi.org/10.1038/sj.onc.1205128			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850809				2022-12-28	WOS:000173427000012
J	Cerni, C; Skrzypek, B; Popov, N; Sasgary, S; Schmidt, G; Larsson, LG; Luscher, B; Henriksson, M				Cerni, C; Skrzypek, B; Popov, N; Sasgary, S; Schmidt, G; Larsson, LG; Luscher, B; Henriksson, M			Repression of in vivo growth of Myc/Ras transformed tumor cells by Mad1	ONCOGENE			English	Article						Mad1ER; Myc; cell cycle; gene repression; telomerase activity; tumor growth	MYC ANTAGONIST MAD1; HISTONE DEACETYLASE ACTIVITY; C-MYC; TRANSCRIPTIONAL REPRESSION; TELOMERASE ACTIVITY; INDUCIBLE EXPRESSION; ESSENTIAL COFACTOR; HTERT GENE; IN-VIVO; N-COR	The Myc/Max/Mad network of transcriptional regulatory proteins plays an essential role in cell proliferation, growth, apoptosis, and differentiation. Whereas, Myc proteins affect cell cycle progression positively,, Mad proteins are negative regulators of cell proliferation. It has been shown in several in vitro systems that Mad proteins antagonize c-Myc functions. In this report we describe the inhibition of tumor cell outgrowth in vivo by Mad1 expression. Transformed cell lines were generated by co-transfection of c-myc, c-H-ras, and a chimeric mad1ER construct into primary rat embryo cells (MRMad1ER cells). Activation of Mad1 by 4-Hydroxy-Tamoxifen (OHT) resulted in abrogation of telomerase activity, reduced cloning efficiency, and decreased proportion of cells in S phase. Injection of MRMad1ER cells into syngenic rats induced aggressively growing tumors after a short latency period. This tumor growth was inhibited by OHT-treatment of animals, with the extent of inhibition correlating with the amount of OHT injected. No effect of OHT on tumor growth was observed with similarly transformed Myc/Ras cell lines which did not express Mad1ER. These data demonstrate that Mad1 is able to suppress Myc/Ras-mediated transformation under in vivo conditions.	Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Swedish Univ Agr Sci, Uppsala Genet Ctr, Dept Plant Biol, SE-75007 Uppsala, Sweden; Rhein Westfal TH Aachen, Inst Biochem, Abt Biochem & Mol Biol, D-52074 Aachen, Germany	University of Vienna; Karolinska Institutet; Swedish University of Agricultural Sciences; RWTH Aachen University	Cerni, C (corresponding author), Univ Vienna, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	Christa.Cerni@univie.ac.at; Marie.Henriksson@mtc.ki.se	Henriksson, Marie Arsenian/F-5010-2015; Larsson, Lars-Gunnar/D-9747-2012; Luscher, Bernhard/A-7330-2011	Arsenian Henriksson, Marie/0000-0001-6376-7792; Luscher, Bernhard/0000-0002-9622-8709				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Avilion AA, 1996, CANCER RES, V56, P645; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bazarov AV, 2001, CANCER RES, V61, P1178; Bejarano MT, 2000, EXP CELL RES, V260, P61, DOI 10.1006/excr.2000.4996; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5; CERNI C, 1995, ONCOGENE, V11, P587; CERNI C, 1990, VIROLOGY, V177, P427, DOI 10.1016/0042-6822(90)90506-M; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Eilers M, 1999, MOL CELLS, V9, P1; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Falchetti ML, 1999, ONCOGENE, V18, P1515, DOI 10.1038/sj.onc.1202438; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Gehring S, 2000, J BIOL CHEM, V275, P10413, DOI 10.1074/jbc.275.14.10413; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504; Gunes C, 2000, CANCER RES, V60, P2116; Guo QM, 2000, CANCER RES, V60, P5922; Han S, 2000, CANCER-AM CANCER SOC, V88, P1623, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1623::AID-CNCR17>3.0.CO;2-W; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hurlin PJ, 1999, EMBO J, V18, P7019, DOI 10.1093/emboj/18.24.7019; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Larcher F, 1996, CANCER RES, V56, P5391; LARSSON LG, 1994, ONCOGENE, V9, P1247; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; Pulverer B, 2000, J CELL PHYSIOL, V183, P399, DOI 10.1002/(SICI)1097-4652(200006)183:3<399::AID-JCP13>3.3.CO;2-Z; Queva C, 1999, CELL GROWTH DIFFER, V10, P785; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RAK J, 1995, CANCER RES, V55, P4575; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY B, 1995, CELL BIOL INT, V19, P307, DOI 10.1006/cbir.1995.1073; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Treon SP, 1998, BLOOD, V92, P1749, DOI 10.1182/blood.V92.5.1749.417k38_1749_1757; Ulaner GA, 1998, CANCER RES, V58, P4168; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	72	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					447	459		10.1038/sj.onc.1205107	http://dx.doi.org/10.1038/sj.onc.1205107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821957				2022-12-28	WOS:000173311200013
J	Lawlor, ER; Scheel, C; Irving, J; Sorensen, PHB				Lawlor, ER; Scheel, C; Irving, J; Sorensen, PHB			Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors	ONCOGENE			English	Article						Ewing tumor; spheroids; cyclin D1; PI3K-AKT; ERK	FACTOR-I RECEPTOR; PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; CYCLIN D1; PHOSPHATIDYLINOSITOL 3-KINASE; CHROMOSOME-TRANSLOCATION; CONSTITUTIVE ACTIVATION; NEUROECTODERMAL TUMOR; TRANSCRIPTION FACTOR; DNA-SYNTHESIS	Little is known about the growth-signaling pathways that govern the proliferation of Ewing tumor (ET) cells either in vitro or in vivo. We have studied signal transduction pathways in ET cell lines and compared kinase expression levels and proliferation rates with primary tumors. Cell lines were studied both as conventional adherent monolayers and as anchorage-independent multi-cellular spheroids. Importantly, we observed significant differences between these in vitro models and found that ET spheroids were more closely related to primary tumors with respect to cell morphology, cell-cell junctions, proliferative index and kinase activation. Monolayer ET cells demonstrated serum-dependent phosphorylation of ERK1/2 and AKT and constitutively high serum-independent cyclin D1 protein expression. However, when ET cells were placed in suspension culture, there was immediate serum-independent activation of ERK1/2 and AKT. In addition, cyclin DI protein expression was completely blocked until stable multicellular spheroids had formed, indicating that cell-cell adhesion is necessary for the proliferation of anchorage independent ET cells. This reduction in cyclin D1 expression was post-transcriptional and could be mimicked in monolayer cells by treatment with phosphatidyl inositol-3 kinase (PI3K) inhibitors. Moreover, PI3K inhibition significantly reduced ET cell proliferation and, in primary ET samples, cyclin DI expression correlated with expression of activated AKT. Thus, the PI3K-AKT pathway appears to be critical for the proliferation of ET cells both in vitro and in vivo and tumor cell growth in vivo may be better represented by the study of anchorage-independent multi-cellular spheroids.	Childrens & Womens Hlth Ctr British Columbia, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; Childrens & Womens Hlth Ctr British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Vancouver, BC V5Z 4H4, Canada	BC Women's Hospital & Health Centre; BC Women's Hospital & Health Centre; University of British Columbia	Sorensen, PHB (corresponding author), BC Res Inst Childrens & Womens Hlth, Room 3082-950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	psor@interchange.ubc.ca			NCI NIH HHS [CA88199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Baserga R, 1997, EXP CELL RES, V236, P1, DOI 10.1006/excr.1997.3732; Bates RC, 2000, CRIT REV ONCOL HEMAT, V36, P61, DOI 10.1016/S1040-8428(00)00077-9; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; de Alava E, 2000, AM J PATHOL, V156, P849, DOI 10.1016/S0002-9440(10)64953-X; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Kawamura K, 2000, ANAL QUANT CYTOL, V22, P107; Kopnin BP, 2000, BIOCHEMISTRY-MOSCOW+, V65, P2; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lawlor ER, 1998, CANCER RES, V58, P2469; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mellin W, 1989, Curr Top Pathol, V80, P115; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NIGGLI FK, 1994, BRIT J CANCER, V69, P1106, DOI 10.1038/bjc.1994.217; PONTEN J, 1971, SPONTANEOUS VIRUS IN; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V24, P1, DOI 10.1002/(SICI)1098-2744(199901)24:1<1::AID-MC1>3.0.CO;2-E; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santini MT, 2000, CRIT REV ONCOL HEMAT, V36, P75, DOI 10.1016/S1040-8428(00)00078-0; Santini MT, 1999, PATHOBIOLOGY, V67, P148, DOI 10.1159/000028065; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; SCOTLANDI K, 1995, CANCER, V75, P806, DOI 10.1002/1097-0142(19950201)75:3<806::AID-CNCR2820750310>3.0.CO;2-S; Scotlandi K, 1996, CANCER RES, V56, P4570; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Sherr CJ, 2000, CANCER RES, V60, P3689; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Silvany RE, 2000, ONCOGENE, V19, P4523, DOI 10.1038/sj.onc.1203811; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Toretsky JA, 1999, CANCER RES, V59, P5745; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Treinies I, 1999, MOL CELL BIOL, V19, P321; TRICHE TJ, 1993, PRINCIPLES PRACTICE, V2, P115; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vollmer E, 1989, Curr Top Pathol, V80, P91; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; Wong CW, 2001, CANCER RES, V61, P333; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	53	64	67	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					307	318		10.1038/sj.onc.1205053	http://dx.doi.org/10.1038/sj.onc.1205053			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803474				2022-12-28	WOS:000173026200015
J	Nakamura, T; Komiya, M; Gotoh, N; Koizumi, S; Shibuya, M; Mori, N				Nakamura, T; Komiya, M; Gotoh, N; Koizumi, S; Shibuya, M; Mori, N			Discrimination between phosphotyrosine-mediated signaling properties of conventional and neuronal Shc adapter molecules	ONCOGENE			English	Article						Shc family; NGF; Trk; tyrosine kinase; Ras; Erk	NERVE GROWTH-FACTOR; PROTEIN-KINASE ACTIVATION; PC12 CELLS; TYROSINE PHOSPHORYLATION; TRANSDUCTION PATHWAYS; BINDING DOMAIN; ROADS LEAD; CRK-II; N-SHC; RAS	The phosphotyrosine (pTyr) adapter Shc/ShcA is a major connector in various tyrosine kinase signalings following a variety of stimulation such as growth factor/neurotrophin, as well as in those following calcium influx and integrin activation. As in other tissues, Shc has been implicated in neuronal signalings; however, recent evidence suggests that N-Shc/ShcC and Sck/ShcB would take over most of the roles of Shc in mature central neurons, and switching phenomena between Shc and N-Shc expression were observed in several neuronal paradigms. Little is, however, known as to the signal-output differences between Shc and N-Shc. Here we determined the efficacy of Shc and N-Shc toward Erk activation in NGF-treated PC12 cells, and found that N-Shc transduced Grb2/Sos/Ras-dependent Erk activation less efficiently than Shc. This was mainly because N-Shc has only one high-affinity Grb2-binding site, whereas Shc has two such sites. Phosphopeptide mapping revealed that N-Shc has novel tyrosine-phosphorylation sites at Y259/Y260 and Y286; in vivo-phosphorylation of these tyrosines was demonstrated by site-specific anti-pTyr antibodies. Phosphorylated Y286 bound to several proteins, of which one was Crk. The pY221/pY222 site, corresponding to one of the Grb2-binding sites of Shc, also preferentially bound to Crk. The phosphorylation-dependent interaction between N-Shc and Crk was demonstrated in vitro and in vivo. These results indicate that N-Shc has specific features of signal-output, and further suggest that the switching between Shc and N-Shc during neural development and regeneration would lead to differentiation of downstream signalings.	Natl Inst Longev Sci, Dept Mol Genet, Aichi 4748522, Japan; JST, Program Protecting Brain, CREST, Aichi 4748522, Japan; Sumitomo Elect Ind Ltd, Biomed R&D Dept, Sakae Ku, Yokohama, Kanagawa 2448588, Japan; Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1080071, Japan; Novartis, Takarazuka Res Inst, Takarazuka, Hyogo 6658666, Japan	Japan Science & Technology Agency (JST); Sumitomo Electric Industries; University of Tokyo; Novartis	Mori, N (corresponding author), Natl Inst Longev Sci, Dept Mol Genet, Gengo 36-3, Aichi 4748522, Japan.	morinos@nils.go.jp	GOTOH, Noriko/D-8430-2015	Gotoh, Noriko/0000-0003-3733-260X				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Conti L, 1997, P NATL ACAD SCI USA, V94, P8185, DOI 10.1073/pnas.94.15.8185; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HAUSER CA, 1995, METHOD ENZYMOL, V255, P395; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Iwasaki Y, 1997, BIOCHEMISTRY-US, V36, P2694, DOI 10.1021/bi962057x; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kojima T, 2001, BIOCHEM BIOPH RES CO, V284, P1039, DOI 10.1006/bbrc.2001.5080; Lai KMV, 2000, GENE DEV, V14, P1132; Luschnig S, 2000, MOL CELL, V5, P231, DOI 10.1016/S1097-2765(00)80419-0; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; MIKI H, 1994, J BIOL CHEM, V269, P5489; Minichiello L, 1998, NEURON, V21, P335, DOI 10.1016/S0896-6273(00)80543-7; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OBryan JP, 1996, J BIOL CHEM, V271, P11787, DOI 10.1074/jbc.271.20.11787; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Pelicci G, 1996, ONCOGENE, V13, P633; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SIMCOX ME, 1994, STRATEGIES, V7, P68; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Tanabe K, 1998, MOL BRAIN RES, V53, P291, DOI 10.1016/S0169-328X(97)00264-7; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; Torres M, 1996, ONCOGENE, V12, P77; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	52	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					22	31		10.1038/sj.onc.1205019	http://dx.doi.org/10.1038/sj.onc.1205019			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791173				2022-12-28	WOS:000172887800003
J	Reed, CC; Gauldie, J; Iozzo, RV				Reed, CC; Gauldie, J; Iozzo, RV			Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin	ONCOGENE			English	Article						decorin proteoglycan; adenovirus gene therapy; colon carcinoma; squamous carcinoma	LEUCINE-RICH PROTEOGLYCANS; GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; DOWN-REGULATION; UP-REGULATION; EXPRESSION; CARCINOMA; CELLS; INHIBITION; REGULATORS	There is mounting evidence that decorin inhibits the growth of various tumor cell lines when either over-expressed in vitro or provided as a recombinant protein. The mechanism of action is primarily via a protracted inactivation of the epidermal growth factor receptor (EGFR) tyrosine kinase. In this study we explored the possibility of retarding the growth of tumor xenografts by decorin gene delivery into the growing neoplastic tissues. We demonstrate that transient transgene expression of replication-deficient adenovirus-containing decorin causes a significant growth inhibition of colon and squamous carcinoma tumor xenografts. These cytostatic effects were achieved with relatively low viral titers and correlated with a reduced proliferative index and an attenuation of the EGFR phosphorylation in vivo. Thus, decorin gene therapy helps in retarding the growth of human tumors in immunocompromised animals and could represent a new independent or adjunctive therapeutic modality against cancer.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; McMaster University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 249,JAH,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@lac.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, J BIOL CHEM, V265, P11389; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Fischer JW, 2001, ARTERIOSCL THROM VAS, V21, P777, DOI 10.1161/01.ATV.21.5.777; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; MANN DM, 1990, J BIOL CHEM, V265, P5317; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nash MA, 1999, CANCER RES, V59, P6192; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Shridhar V, 2001, CANCER RES, V61, P5895; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Zhao JS, 1999, AM J PHYSIOL-LUNG C, V277, pL412, DOI 10.1152/ajplung.1999.277.2.L412	38	123	138	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3688	3695		10.1038/sj.onc.1205470	http://dx.doi.org/10.1038/sj.onc.1205470			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032837				2022-12-28	WOS:000175676000004
J	Gemmill, RM; Bemis, LT; Lee, JP; Sozen, MA; Baron, A; Zeng, C; Erickson, PF; Hooper, JE; Drabkin, HA				Gemmill, RM; Bemis, LT; Lee, JP; Sozen, MA; Baron, A; Zeng, C; Erickson, PF; Hooper, JE; Drabkin, HA			The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway	ONCOGENE			English	Article						TRC8; VHL; renal cell carcinoma; JAB1/CSN-5; patched; RING-H2 finger	26S PROTEASOME; HUMAN HOMOLOG; RENAL-CARCINOMA; JAB1 INTERACTS; CNS MIDLINE; CELL-CYCLE; HIF-ALPHA; DROSOPHILA; PROTEIN; COMPLEX	VHL is part of an SCF related E3-ubiquitin ligase complex with 'gatekeeper' function in renal carcinoma. However, no mutations have been identified in VHL interacting proteins in wild type VHL tumors. We previously reported that the TRC8 gene was interrupted by a t(3;8) translocation in a family with hereditary renal and non-medullary thyroid cancer. TRC8 encodes a multi-membrane spanning protein containing a RING-H2 finger with in vitro ubiquitin ligase activity. We isolated the Drosophila homologue, DTrc8, and studied its function by genetic manipulations and a yeast 2-hybrid screen. Human and Drosophila TRC8 proteins localize to the endoplasmic reticulum. Loss of either DTrc8 or DVhl resulted in an identical ventral midline defect. Direct interaction between DTrc8 and DVhl was confirmed by GST-pulldown and co-immunoprecipitation experiments. CSN-5/JAB1 is a component of the COP9 signalosome, recently shown to regulate SCF function. We found that DTrc8 physically interacts with CSN-5 and that human JAB1 localization is dependent on VHL mutant status. Lastly, overexpression of DTrc8 inhibited growth consistent with its presumed role as a tumor suppressor gene. Thus, VHL, TRC8, and JAB1 appear to be linked both physically and functionally and all three may participate in the development of kidney cancer.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gemmill, RM (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Box B-171,4200 E 9th Ave, Denver, CO 80262 USA.	robert.gemmill@uchsc.edu		Bemis, Lynne/0000-0001-9986-7154	NATIONAL CANCER INSTITUTE [R01CA076035, P30CA046934] Funding Source: NIH RePORTER; NCI NIH HHS [CA76035, CA46934] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adryan B, 2000, ONCOGENE, V19, P2803, DOI 10.1038/sj.onc.1203611; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	48	42	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3507	3516		10.1038/sj.onc.1205437	http://dx.doi.org/10.1038/sj.onc.1205437			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032852				2022-12-28	WOS:000175793700001
J	Scheijen, B; Griffin, JD				Scheijen, B; Griffin, JD			Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease	ONCOGENE			English	Review						leukemia; lymphoma; protein tyrosine kinase; signal transduction; translocation	COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; ACUTE MYELOID-LEUKEMIA; SRC HOMOLOGY-2 DOMAIN; FACTOR-BETA-RECEPTOR; INTERNAL TANDEM DUPLICATION; C-FES PROTOONCOGENE	Tyrosine kinase oncogenes are formed as a result of mutations that induce constitutive kinase activity. Many of these tyrosine kinase oncogenes that are derived from genes, such as c-Abl, c-Fes, FIt3, c-Fms, c-Kit and PDGFRbeta, that are normally involved in the regulation of hematopoiesis or hematopoietic cell function. Despite differences in structure, normal function, and subcellular location, many of the tyrosine kinase oncogenes signal through the same pathways, and typically enhance proliferation and prolong viability. They represent excellent potential drug targets, and it is likely that additional mutations will be identified in other kinases, their immediate downstream targets, or in proteins regulating their function.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Griffin, JD (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	james_griffin@dfci.harvard.edu	Scheijen, Blanca/E-3523-2016	Scheijen, Blanca/0000-0001-8029-9230				Abe A, 1997, BLOOD, V90, P4271, DOI 10.1182/blood.V90.11.4271.4271_4271_4277; Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; Agami R, 1999, NATURE, V399, P809; ALAI M, 1992, J BIOL CHEM, V267, P18021; Alimandi M, 1997, ONCOGENE, V15, P585, DOI 10.1038/sj.onc.1201221; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; ASHMUN RA, 1989, BLOOD, V73, P827; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; BirchenallRoberts MC, 1997, J BIOL CHEM, V272, P8905; BIRG F, 1992, BLOOD, V80, P2584; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BITTER MA, 1990, AM J SURG PATHOL, V14, P305, DOI 10.1097/00000478-199004000-00001; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOULTWOOD J, 1991, P NATL ACAD SCI USA, V88, P6176, DOI 10.1073/pnas.88.14.6176; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourette RP, 2001, J BIOL CHEM, V276, P22133, DOI 10.1074/jbc.M101878200; Brasel K, 1996, BLOOD, V88, P2004, DOI 10.1182/blood.V88.6.2004.bloodjournal8862004; BRASEL K, 1995, LEUKEMIA, V9, P1212; Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Brizzi MF, 1996, ONCOGENE, V13, P2067; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; BROSNAN CF, 1993, ADV NEUROL, V59, P349; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chen KY, 1997, CANCER RES, V57, P3511; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; Cheng HY, 1999, MOL CELL BIOL, V19, P8335; Cheng HY, 2001, MOL CELL BIOL, V21, P6170, DOI 10.1128/MCB.21.18.6170-6180.2001; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; Coffin CM, 1998, SEMIN DIAGN PATHOL, V15, P102; Coffin CM, 2001, MODERN PATHOL, V14, P569, DOI 10.1038/modpathol.3880352; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cong F, 1999, MOL CELL BIOL, V19, P8314; Cook JR, 2001, AM J SURG PATHOL, V25, P1364, DOI 10.1097/00000478-200111000-00003; Coutinho S, 2000, BLOOD, V96, P618; Csar XF, 2001, J BIOL CHEM, V276, P26211, DOI 10.1074/jbc.M100213200; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 2001, J BIOL CHEM, V276, P28954, DOI 10.1074/jbc.M101170200; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; DAYNES RA, 1991, J EXP MED, V174, P1323, DOI 10.1084/jem.174.6.1323; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; De Sepulveda P, 1999, EMBO J, V18, P904; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DELWICHE F, 1985, J CLIN INVEST, V76, P137, DOI 10.1172/JCI111936; DEPARSEVAL N, 1993, CYTOKINE, V5, P8, DOI 10.1016/1043-4666(93)90018-Z; Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; FELDMAN RA, 1983, J VIROL, V45, P782, DOI 10.1128/JVI.45.2.782-791.1983; FELLER SM, 1995, ONCOGENE, V10, P1465; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fenski R, 2000, BRIT J HAEMATOL, V108, P322; FERRARI S, 1994, LEUKEMIA, V8, pS91; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; Foss B, 2001, EUR J HAEMATOL, V66, P365, DOI 10.1034/j.1600-0609.2001.066006365.x; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gari M, 1999, BRIT J HAEMATOL, V105, P894, DOI 10.1046/j.1365-2141.1999.01449.x; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; GERSUK GM, 1991, SCAND J IMMUNOL, V33, P521, DOI 10.1111/j.1365-3083.1991.tb02522.x; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gommerman JL, 1998, BLOOD, V91, P1891, DOI 10.1182/blood.V91.6.1891.1891_1891_1900; Gommerman JL, 2000, BLOOD, V96, P3734, DOI 10.1182/blood.V96.12.3734.h8003734_3734_3742; Gong JG, 1999, NATURE, V399, P806; GOTOH A, 1994, LEUKEMIA, V8, P115; Greenland C, 2001, ONCOGENE, V20, P7386, DOI 10.1038/sj.onc.1204870; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129; Griffin CA, 1999, CANCER RES, V59, P2776; GROFFEN J, 1983, VIROLOGY, V125, P480, DOI 10.1016/0042-6822(83)90219-2; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Hackenmiller R, 2000, IMMUNITY, V13, P397, DOI 10.1016/S1074-7613(00)00039-X; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Hardin JD, 1996, CELL IMMUNOL, V172, P100, DOI 10.1006/cimm.1996.0220; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Hernandez L, 1999, BLOOD, V94, P3265; HIRAYAMA F, 1995, BLOOD, V85, P1762, DOI 10.1182/blood.V85.7.1762.bloodjournal8571762; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Hongyo T, 2000, CANCER RES, V60, P2345; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; HUDAK S, 1995, BLOOD, V85, P2747, DOI 10.1182/blood.V85.10.2747.bloodjournal85102747; Iijima Y, 2000, BLOOD, V95, P2126; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Ito Y, 2001, J BIOL CHEM, V276, P18130, DOI 10.1074/jbc.M007294200; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; JACOBSEN SEW, 1995, J EXP MED, V181, P1357, DOI 10.1084/jem.181.4.1357; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; Jiang H, 2001, J IMMUNOL, V166, P2627, DOI 10.4049/jimmunol.166.4.2627; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; JUCKER M, 1992, ONCOGENE, V7, P943; Jucker M, 1997, J BIOL CHEM, V272, P2104; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kaminski WE, 2001, BLOOD, V97, P1990, DOI 10.1182/blood.V97.7.1990; KARLSSON T, 1995, ONCOGENE, V10, P1475; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; KIN Y, 2001, J BIOL CHEM, V13, P13; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Kulkarni S, 2000, CANCER RES, V60, P3592; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; Lamant L, 1999, BLOOD, V93, P3088; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lavagna-Sevenier C, 1998, LEUKEMIA, V12, P301, DOI 10.1038/sj.leu.2400921; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Law SF, 1996, MOL CELL BIOL, V16, P3327; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lee AWM, 2000, MOL CELL BIOL, V20, P6779, DOI 10.1128/MCB.20.18.6779-6798.2000; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Li JZ, 1998, J BIOL CHEM, V273, P13828, DOI 10.1074/jbc.273.22.13828; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl P, 1998, DEVELOPMENT, V125, P3313; LINNEKIN D, 1995, J BIOL CHEM, V270, P4950, DOI 10.1074/jbc.270.9.4950; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Lisovsky M, 1996, BLOOD, V88, P3987, DOI 10.1182/blood.V88.10.3987.bloodjournal88103987; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Lu LW, 2001, EXP HEMATOL, V29, P596, DOI 10.1016/S0301-472X(01)00621-X; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Lynch DH, 1997, NAT MED, V3, P625, DOI 10.1038/nm0697-625; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; Magnusson MK, 2001, BLOOD, V98, P2518, DOI 10.1182/blood.V98.8.2518; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; Manfredini R, 1997, BLOOD, V89, P135, DOI 10.1182/blood.V89.1.135.135_135_145; Maraskovsky E, 2000, BLOOD, V96, P878, DOI 10.1182/blood.V96.3.878.015k15_878_884; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Marchetto S, 1999, LEUKEMIA, V13, P1374, DOI 10.1038/sj.leu.2401527; MARU Y, 1995, MOL CELL BIOL, V15, P835; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; Mason DY, 1998, CANCER RES, V58, P1057; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; McClanahan T, 1996, BLOOD, V88, P3371, DOI 10.1182/blood.V88.9.3371.bloodjournal8893371; McGlynn H, 1997, LEUKEMIA RES, V21, P919, DOI 10.1016/S0145-2126(97)00024-6; McKenna HJ, 2000, BLOOD, V95, P3489, DOI 10.1182/blood.V95.11.3489; McKenna HJ, 1996, EXP HEMATOL, V24, P378; McMahon KA, 2001, BIOCHEM J, V358, P431, DOI 10.1042/0264-6021:3580431; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MECKLINGGILL KA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P65, DOI 10.1016/0167-4889(92)90101-G; Meech SJ, 2001, BLOOD, V98, P1209, DOI 10.1182/blood.V98.4.1209; MEIERHOFF G, 1995, LEUKEMIA, V9, P1368; Meshinchi S, 2001, BLOOD, V97, P89, DOI 10.1182/blood.V97.1.89; Michaelson MD, 1996, DEVELOPMENT, V122, P2661; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakao M, 1996, LEUKEMIA, V10, P1911; NAKATA Y, 1995, BRIT J HAEMATOL, V91, P661, DOI 10.1111/j.1365-2141.1995.tb05364.x; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nicholls SE, 1999, EXP HEMATOL, V27, P663, DOI 10.1016/S0301-472X(98)00072-1; Niebylski J, 2000, MARINE MARITIME, V1, P61; Ning ZQ, 2001, LEUKEMIA LYMPHOMA, V41, P513, DOI 10.3109/10428190109060342; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; ODA T, 1994, J BIOL CHEM, V269, P22925; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Park WY, 1998, CANCER LETT, V129, P29, DOI 10.1016/S0304-3835(98)00077-9; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Piacibello W, 2000, J HEMATOTH STEM CELL, V9, P945, DOI 10.1089/152581600750062408; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Pulendran B, 2000, J IMMUNOL, V165, P566, DOI 10.4049/jimmunol.165.1.566; Pulford K, 1999, AM J PATHOL, V154, P1657, DOI 10.1016/S0002-9440(10)65421-1; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RAMBALDI A, 1988, J CLIN INVEST, V81, P1030, DOI 10.1172/JCI113413; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; Ritchie KA, 1999, LEUKEMIA, V13, P1790, DOI 10.1038/sj.leu.2401494; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; Rogers JA, 2000, CELL GROWTH DIFFER, V11, P581; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Salgia R, 1996, EXP HEMATOL, V24, P310; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Savvides SN, 2000, NAT STRUCT BIOL, V7, P486; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Schwaller J, 2001, BLOOD, V97, P3910, DOI 10.1182/blood.V97.12.3910; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHIOTA M, 1994, ONCOGENE, V9, P1567; Siebert R, 1999, BLOOD, V94, P3614; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; SKORSKI T, 1995, CANCER RES, V55, P2275; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Slupianek A, 2001, CANCER RES, V61, P2194; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SMITHGALL TE, 1991, J NATL CANCER I, V83, P42, DOI 10.1093/jnci/83.1.42; SONOYAMA J, 2002, J BIOL CHEM, V4, P4; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; Stein H, 2000, BLOOD, V96, P3681; Sternberg DW, 2001, BLOOD, V98, P3390, DOI 10.1182/blood.V98.12.3390; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tallquist MD, 2000, GENE DEV, V14, P3179, DOI 10.1101/gad.844700; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; Theis S, 1998, ONCOGENE, V17, P557, DOI 10.1038/sj.onc.1201973; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; TOBAL K, 1990, LEUKEMIA, V4, P486; Tomasson MH, 1999, BLOOD, V93, P1707, DOI 10.1182/blood.V93.5.1707.405k24_1707_1714; Tomasson MH, 2000, J CLIN INVEST, V105, P423, DOI 10.1172/JCI8902; Tort F, 2001, LAB INVEST, V81, P419, DOI 10.1038/labinvest.3780249; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; van Dijk TB, 2000, BLOOD, V96, P3406; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Vosseller K, 1997, MOL BIOL CELL, V8, P909, DOI 10.1091/mbc.8.5.909; Wang BL, 1996, ONCOGENE, V13, P193; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WELLMANN A, 1995, BLOOD, V86, P2321, DOI 10.1182/blood.V86.6.2321.bloodjournal8662321; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Whang YE, 2000, P NATL ACAD SCI USA, V97, P5486, DOI 10.1073/pnas.97.10.5486; Whitman SP, 2001, CANCER RES, V61, P7233; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wlodarska I, 1998, BLOOD, V92, P2688, DOI 10.1182/blood.V92.8.2688.420a42_2688_2695; Wong S, 2001, ONCOGENE, V20, P5644, DOI 10.1038/sj.onc.1204638; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; Xu F, 1999, BRIT J HAEMATOL, V105, P155, DOI 10.1111/j.1365-2141.1999.01284.x; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YAN XQ, 1993, J IMMUNOL, V150, P2440; YANG M, 1995, BRIT J HAEMATOL, V91, P285, DOI 10.1111/j.1365-2141.1995.tb05291.x; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YATES KE, 1995, ONCOGENE, V10, P1239; YEE SP, 1989, MOL CELL BIOL, V9, P5491, DOI 10.1128/MCB.9.12.5491; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; YU G, 1989, J BIOL CHEM, V264, P10276; YU G, 1987, J BIOL CHEM, V262, P17543; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhang SL, 2000, BIOCHEM BIOPH RES CO, V277, P195, DOI 10.1006/bbrc.2000.3662; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zhang XW, 2001, BLOOD, V97, P277, DOI 10.1182/blood.V97.1.277; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; Zirngibl R, 2001, EXP CELL RES, V266, P87, DOI 10.1006/excr.2001.5217	371	133	168	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3314	3333		10.1038/sj.onc.1205317	http://dx.doi.org/10.1038/sj.onc.1205317			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032772				2022-12-28	WOS:000175633300007
J	Li, D; Williams, JI; Pietras, RJ				Li, D; Williams, JI; Pietras, RJ			Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression	ONCOGENE			English	Article						VEGF; erb B2/neu; MAP kinase; carboplatin; vascular endothelial cells	HUMAN-BREAST; TUMOR XENOGRAFTS; FACTOR VEGF; IN-VIVO; RECEPTOR; EXPRESSION; KINASE; TRANSFORMATION; AMINOSTEROL; MECHANISMS	Angiogenesis is important for growth and progression of ovarian cancers. Squalamine is a natural antiangiogenic sterol, and its potential role in treatment of ovarian cancers with or without standard cisplatin chemotherapy was assessed. Since HER-2 gene overexpression is associated with cisplatin resistance in vitro and promotion of tumor angiogenesis in vivo, the response of ovarian cancer cells with or without HER-2 gene overexpression to squalamine and cisplatin was evaluated both in tumor xenograft models and in tissue culture. Ovarian cancer cells with or without HER-2 overexpression were grown as subcutaneous xenografts in nude mice. Animals were treated by intraperitoneal injection with control vehicle, cisplatin, squalamine or cisplatin combined with squalamine. At the end of the experiment, tumors were assessed for tumor growth inhibition and for changes in microvessel density and apoptosis. Additional in vitro studies evaluated effects of squalamine on tumor and endothelial cell growth and on signaling pathways in human endothetial cells. Profound growth inhibition was elicited by squalamine alone and by combined treatment with squalamine and cisplatin for both parental and HER-2-overexpressing ovarian tumor xenografts. Immunohistochemical evaluation of tumors revealed decreased microvessel density and increased apoptosis. Although HER-2-overexpressing tumors had more angiogenic and less apoptotic activity than parental cancers, growth of both tumor types was similarly suppressed by treatment with squalamine combined with cisplatin. In in vitro studies, we found that squalamine does not directly affect proliferation of ovarian cells. However, squalamine significantly blocked VEGF-induced activation of MAP kinase and cell proliferation in human vascular endothelial cells. The results suggest that squalamine is anti-angiogenic for ovarian cancer xenografts and appears to enhance cytotoxic effects of cisplatin chemotherapy independent of HER-2 tumor status.	Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Genaera Corp, Plymouth Meeting, PA 19462 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pietras, RJ (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Sch Med, 10833 Le Conte Ave,11-934 Factor Bldg, Los Angeles, CA 90095 USA.	rpietras@ucla.edu		Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [R29CA60835] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060835] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Akhter S, 1999, AM J PHYSIOL-CELL PH, V276, pC136, DOI 10.1152/ajpcell.1999.276.1.C136; Alvarez AA, 1999, CLIN CANCER RES, V5, P587; BERCHUCK A, 1990, CANCER RES, V50, P4087; CHAZIN VR, 1992, ONCOGENE, V7, P1859; Chen Q, 1999, CLIN CANCER RES, V5, p3768S; DISAIA PJ, 1972, AM J OBSTET GYNECOL, V114, P979, DOI 10.1016/0002-9378(72)90109-3; Eckhardt SG, 1999, HOSP PRACT, V34, P63, DOI 10.3810/hp.1999.01.124; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GOLDMAN JM, 1993, STEM CELLS, V11, P4, DOI 10.1002/stem.5530110903; Hellstrom I, 2001, CANCER RES, V61, P2420; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kolfschoten GM, 2000, GYNECOL ONCOL, V76, P362, DOI 10.1006/gyno.1999.5689; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; MOORE KS, 1993, P NATL ACAD SCI USA, V90, P1354, DOI 10.1073/pnas.90.4.1354; MORALES DE, 1995, CIRCULATION, V91, P755, DOI 10.1161/01.CIR.91.3.755; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ozols RF, 1999, SEMIN ONCOL, V26, P84; Paley PJ, 1997, CANCER, V80, P98, DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A; PATNAIK A, 1999, P AN M AM SOC CLIN, V622, P1999; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; PIETRAS RJ, 1981, J BIOL CHEM, V256, P8536; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Plumb JA, 2000, CANCER RES, V60, P6039; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schiller JH, 1999, CLIN CANCER RES, V5, P4287; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Teicher BA, 1998, ANTICANCER RES, V18, P2567; WONG YF, 1995, GYNECOL OBSTET INVES, V40, P209, DOI 10.1159/000292337; Yamamoto S, 1997, BRIT J CANCER, V76, P1221, DOI 10.1038/bjc.1997.537; Zebrowski BK, 1999, ANN SURG ONCOL, V6, P373, DOI 10.1007/s10434-999-0373-0	43	61	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2805	2814		10.1038/sj.onc.1205410	http://dx.doi.org/10.1038/sj.onc.1205410			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973639				2022-12-28	WOS:000175063700004
J	Gonzales, M; Bowden, GT				Gonzales, M; Bowden, GT			The role of PI 3-kinase in the UVB-induced expression of c-fos	ONCOGENE			English	Article						UVB; c-fos; PI 3-kinase; GSK-3 beta	GLYCOGEN-SYNTHASE KINASE-3; KERATINOCYTE CELL-LINE; P38 MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; AP-1 TRANSACTIVATION; PROTEIN-1 ACTIVATION; BINDING PROTEIN; GENE-EXPRESSION; TRANSGENIC MICE; DNA-SYNTHESIS	The role of the PI 3-kinase signaling pathway in UVB-induced c-fos gene expression was investigated in a human keratinocyte cell line, HaCaT. The enzymatic activity of PI 3-kinase was increased threefold by 250 J/m(2) UVB. Inhibition of PI 3-kinase activity, via expression of a mutant p85 subunit or treatment with wortmannin, resulted in decreased levels of c-fos promoter activity and c-fos protein. Two members of the PI 3-kinase signaling pathway, Akt and GSK-3beta, were also found to affect c-fos transactivation. Expression of dominant negative Akt or wild-type GSK-3beta significantly inhibited UVB-induced c-fos promoter activity. In addition, when GSK-3beta activity was inhibited by lithium chloride, both c-fos promoter activity and protein levels increased. These results demonstrate that both Akt activation and GSK-3beta inactivation are required in the UVB-induction of c-fos. Our results demonstrate for the first time that UVB induction of c-fos is in part mediated by the PI 3-kinase signaling pathway in the HaCaT cell line. By identifying the multiple signaling pathways that are induced by UVB and contribute to the induction of c-fos expression, more drug targets may be identified to aid attempts to prevent and treat skin cancer.	Univ Arizona, Coll Med, Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), 1515 N Campbell,Radiat 1,Rm 4999, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [P01CA027502] Funding Source: NIH RePORTER; NCI NIH HHS [CA 27502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barthelman M, 1998, CANCER RES, V58, P711; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Funakoshi M, 2001, INT IMMUNOPHARMACOL, V1, P595, DOI 10.1016/S1567-5769(00)00035-7; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Ibuki Y, 2000, BIOCHEM BIOPH RES CO, V279, P872, DOI 10.1006/bbrc.2000.4018; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Kabuyama Y, 1998, FEBS LETT, V441, P297, DOI 10.1016/S0014-5793(98)01565-8; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; POWIS G, 1994, CANCER RES, V54, P2419; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tang QB, 2001, CANCER RES, V61, P4329; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wan YS, 2001, INT J ONCOL, V18, P461; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685	45	35	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2721	2728		10.1038/sj.onc.1205366	http://dx.doi.org/10.1038/sj.onc.1205366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965545				2022-12-28	WOS:000174996500012
J	Ghiso, JAA				Ghiso, JAA			Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo	ONCOGENE			English	Article						FAK; uPAR; integrins; MAPK	FOCAL ADHESION KINASE; INTEGRIN-MEDIATED ADHESION; MALIGNANT PHENOTYPE; DOWN-REGULATION; INVASION; FIBRONECTIN; EXPRESSION; REDUCTION; CAVEOLIN; SRC	Activation of focal adhesion kinase (FAK), overexpressed in several human cancers, induces survival, proliferation and motility of cells in culture, but its functional importance in human tumor growth in vivo has not been elucidated. I explored the role of FAK in regulating tumorigenicity of human carcinoma cells, HEp3. These cells overexpress urokinase receptor (uPAR) which, by activating x5beta1 integrin, initiates an intracellular signal through FAK and Src leading to ERK activation and tumorigenicity in vivo. Down regulation of uPAR in these cells led to a similar to3-5-fold reduction in FAK phosphorylation and association with Src and dormancy in vivo. Both FAK phosphorylation and ability to grow in vivo were restored by re-expression of uPAR. The FAK signaling pathway in T-HEp3 cells, measured by FAK phosphorylation, GTP-loaded Ras and ERK activation, was inhibited by transient or stable transfection of FAK related non-kinase (FRNK), known to have a dominant negative function, but not by a FRNK mutant version (S1034-FRNK). Most importantly, while vector- and mutant-S1034-FRNK transfected cells inoculated onto chicken embryo CAMs formed progressively growing tumors, the HA-FRNK-expressing T-HEp3 cells did not proliferate in vivo and remained dormant for at least 6 weeks. Both cell types had similar rate of apoptosis in vivo and the p38(SAPK) or PI3K-Akt signaling pathways were unaffected by FRNK. FRNK induced dormancy could be reverted by expression of an active-R4F-Mek1 mutant. These results show that active FAK is an important mediator of uPAR-regulated tumorigenicity of HEp3 cells and that interruption of FAK mitogenic signaling either through down-regulation of uPAR or by expression of FRNK can force human carcinoma cells into dormancy.	NYU, Mt Sinai Sch Med, Div Med Oncol, Dept Med,Rochelle Belfer Chemotherapy Fdn Lab, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University	Ghiso, JAA (corresponding author), NYU, Mt Sinai Sch Med, Div Med Oncol, Dept Med,Rochelle Belfer Chemotherapy Fdn Lab, Atran Bldg Room 610,Box 1178, New York, NY 10029 USA.	aguirj01@doc.mssm.edu			NATIONAL CANCER INSTITUTE [R01CA040758] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Bender FC, 2000, CANCER RES, V60, P5870; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARY LA, 1999, FRONT BIOSCI, V4, P102; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Ilic D, 2001, AM J PATHOL, V159, P93, DOI 10.1016/S0002-9440(10)61677-X; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; OSSOWSKI L, 1983, CELL, V33, P323, DOI 10.1016/0092-8674(83)90414-2; OWENS LV, 1995, CANCER RES, V55, P2752; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sanders MA, 2000, J BIOL CHEM, V275, P38040, DOI 10.1074/jbc.M003871200; SCHILLER JH, 1995, CANCER RES, V55, P6215; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; TOOLAN HW, 1954, CANCER RES, V14, P660; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Wang DY, 2000, J CELL SCI, V113, P4221; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	35	192	196	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2513	2524		10.1038/sj/onc/1205342	http://dx.doi.org/10.1038/sj/onc/1205342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971186				2022-12-28	WOS:000174918400008
J	Tomicic, MT; Thust, R; Kaina, B				Tomicic, MT; Thust, R; Kaina, B			Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation	ONCOGENE			English	Article						apoptosis; Bcl-2 cleavage; caspase-9; ganciclovir; DNA breakage; suicide gene therapy	CYTOCHROME-C; GENE-THERAPY; CANCER-CELLS; VIRUS; DEATH; P53; PROTEASE; SIGNALS; RELEASE; DAMAGE	Although ganciclovir (GCV) is most often used in suicide anticancer gene therapy, the mechanism of GCV-induced cell killing and apoptosis is not fully understood. We analysed the mechanism of apoptosis triggered by GCV using a model system of CHO cells stably transfected with HSV-1 thymidine kinase (HSVtk). GCV-induced apoptosis is due to incorporation of the drug into DNA resulting in replication-dependent formation of DNA double-strand breaks and, at later stages, S and G2/M arrest. GCV-provoked DNA instability was likely to be responsible for the observed initial decline in Bcl-2 level and caspase-9/-3 activation. Further decline in the Bcl-2 level was due to cleavage of the protein by caspase-9 as demonstrated by use of caspase inhibitors and transfection with trans-dominant negative caspase expression vectors. Bcl-2 cleavage resulted in the appearance of a pro-apoptotic 23 kDa Bcl-2 fragment and in excessive cytochrome c release, dephosphorylation of BAD, cleavage of PARP and finally DNA degradation. Since Fas/CD95 and caspase-8 were only slightly activated we conclude GCV-induced apoptosis to occur in this cell system mainly by activating the mitochondrial damage pathway. This process is independent of p53 for which the cells are mutated. Caspase-9 mediated cleavage of Bel-2 accelerates the apoptotic process and may explain the high potential of GCV to induce apoptosis. Data are also discussed as to implications for HSVtk gene therapy utilizing GCV.	Johannes Gutenberg Univ Mainz, Fac Med, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany; Univ Jena, Fac Med, Inst Antiviral Chemotherapy, D-07745 Jena, Germany	Johannes Gutenberg University of Mainz; Friedrich Schiller University of Jena	Kaina, B (corresponding author), Johannes Gutenberg Univ Mainz, Fac Med, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	kaina@mail.uni-mainz.de	Tomicic, Maja/S-1377-2019	Tomicic, Maja/0000-0001-9289-4168				Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Beltinger C, 2000, CANCER RES, V60, P3212; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Craperi D, 1999, HUM GENE THER, V10, P679, DOI 10.1089/10430349950018751; Crumpacker CS, 1996, NEW ENGL J MED, V335, P721, DOI 10.1056/NEJM199609053351007; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Feinmesser M, 1999, HUM PATHOL, V30, P1367, DOI 10.1016/S0046-8177(99)90070-9; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Gallo O, 1999, INT J CANCER, V84, P573, DOI 10.1002/(SICI)1097-0215(19991222)84:6<573::AID-IJC6>3.0.CO;2-R; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Halloran PJ, 1998, CANCER RES, V58, P3855; Hamel W, 1996, CANCER RES, V56, P2697; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Ioannou YA, 1996, NUCLEIC ACIDS RES, V24, P992; Izquierdo M, 1996, GENE THER, V3, P491; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Klatzmann D, 1996, HUM GENE THER, V7, P109, DOI 10.1089/hum.1996.7.1-109; Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; MOOLTEN FL, 1986, CANCER RES, V46, P5276; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OBE G, 1985, MUTAT RES, V150, P359; Ochs K, 2000, CANCER RES, V60, P5815; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; OLIVE PL, 1991, CANCER RES, V51, P4671; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P229, DOI 10.1080/09553009414550261; Rubsam LZ, 1998, CANCER RES, V58, P3873; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1999, CANCER RES, V59, P999; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Thust R, 2000, CANCER GENE THER, V7, P107, DOI 10.1038/sj.cgt.7700106; Thust R, 2000, MUTAGENESIS, V15, P177, DOI 10.1093/mutage/15.2.177; Tomicic M, 1997, MUTAT RES-DNA REPAIR, V383, P155, DOI 10.1016/S0921-8777(96)00055-9; Tomicic MT, 2001, BIOCHEM BIOPH RES CO, V281, P404, DOI 10.1006/bbrc.2001.4367; Tomicic MT, 2000, BIOCHEM BIOPH RES CO, V275, P899, DOI 10.1006/bbrc.2000.3386; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang XN, 1997, EXP CELL RES, V235, P210, DOI 10.1006/excr.1997.3667; Wei SJ, 1999, GENE THER, V6, P420, DOI 10.1038/sj.gt.3300817; Wei SJ, 1998, EXP CELL RES, V241, P66, DOI 10.1006/excr.1998.4005; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053	53	102	109	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2141	2153		10.1038/sj.onc.1205280	http://dx.doi.org/10.1038/sj.onc.1205280			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948397				2022-12-28	WOS:000174555300003
J	Konduri, SD; Osman, FA; Rao, CN; Srinivas, H; Yanamandra, N; Tasiou, A; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Kouraklis, G; Rao, JS				Konduri, SD; Osman, FA; Rao, CN; Srinivas, H; Yanamandra, N; Tasiou, A; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Kouraklis, G; Rao, JS			Minimal and inducible regulation of tissue factor pathway inhibitor-2 in human gliomas	ONCOGENE			English	Article						promoter; transcriptional regulation; TFPI-2; gliomas	SERINE PROTEINASE-INHIBITORS; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; COAGULATION INHIBITOR; PLASMINOGEN-ACTIVATOR; LESS PROMOTER; MESSENGER-RNA; GENE; EXPRESSION; IDENTIFICATION	Tissue factor pathway inhibitor-2 (TFPI-2), a serine protease inhibitor abundant in the extra cellular matrix, is highly expressed in non-invasive cells but undetectable levels in highly invasive human glioma cells. The mechanisms responsible for its transcriptional regulation are not well elucidated. In this study, we made several deletion constructs from a 3.6 kb genomic fragment from Hs683 cells containing the 5'-flanking region of the TFPI-2 gene, transiently transfected with these constructs into non-invasive (Hs683) and highly invasive (SNB19) human glioma cells, and assessed their expression by using a luciferase reporter gene. Three constructs showed high promoter activity (pTF5, -670 to +1; pTF6, -312 to +1; pTF2, -1511 to +1). Another construct, pTF8 (-81 to +1), showed no activity. PTF9, a variant of pTF5 in which a further 231 bp fragment (-312 to -81) was deleted, from the [-670 to +1] pTF5 region, also showed no promoter activity. Hence, (-312 to -81) this region is essential for the transcription of TFPI-2 in glioma cells. Sequencing of this promoter region revealed that it has a high G+C content, contains potential SP1 and AP1 binding motifs, and lacks canonical TATA and CAAT boxes immediately upstream of the major transcriptional initiation site, although CAAT boxes were found about -3000 bp upstream of the transcription start site. We also found a strong repressor in the region between -927 to -1181, upstream of the major transcriptional initiation site, followed by positive elements or enhancers between -1511 to -1181. These positive elements masked the silencer effect. Finally TFPI-2 was induced in Hs683 cells transfected with the pTF6 construct (-312 to + 1) and stimulated with phorbol-12-myristate-13-acetate (PMA). We conclude that the -312 to +1 region is critical for the minimal and inducible regulation of TFPI-2 in non-invasive (Hs683) and highly invasive (SNB19) human glioma cell lines.	Univ Illinois, Sch Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Dept Neuropathol, Peoria, IL 61656 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Ctr Prostate Dis Res, Rockville, MD USA; Zymogenet Inc, Seattle, WA 98105 USA; Univ New Mexico, Ctr Hlth Sci, Albuquerque, NM 87131 USA; Univ Athens, Sch Med, Dept Propedeut Surg, GR-11527 Athens, Greece	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Zymogenet Inc.; University of New Mexico; Athens Medical School; National & Kapodistrian University of Athens	Rao, JS (corresponding author), Univ Illinois, Sch Med, Dept Biomed & Therapeut Sci, Div Canc Biol, 1 Illini Dr, Peoria, IL 61656 USA.	jsrao@uic.edu		Tasiou, Anastasia/0000-0002-8853-540X	NATIONAL CANCER INSTITUTE [R01CA075557, R01CA076350] Funding Source: NIH RePORTER; NCI NIH HHS [CA-75557, CA-76350, CA-75692] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAJAJ MS, 1990, P NATL ACAD SCI USA, V87, P8869, DOI 10.1073/pnas.87.22.8869; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BUTZOW R, 1988, BIOCHEM BIOPH RES CO, V150, P483, DOI 10.1016/0006-291X(88)90546-3; Chabannes E, 2001, CELL SIGNAL, V13, P585, DOI 10.1016/S0898-6568(01)00184-X; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; CHEN L, 1992, J BIOL CHEM, V267, P12380; ENJYOJI K, 1993, GENOMICS, V17, P423, DOI 10.1006/geno.1993.1342; GIRARD TJ, 1991, J BIOL CHEM, V266, P5036; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; HASCALL VC, 1991, CELL BIOL EXTRA CELL; Huber R, 1998, GENE, V214, P35, DOI 10.1016/S0378-1119(98)00233-9; Iino M, 1998, ARTERIOSCL THROM VAS, V18, P40, DOI 10.1161/01.ATV.18.1.40; Kamei S, 2001, BBA-GENE STRUCT EXPR, V1517, P430, DOI 10.1016/S0167-4781(00)00298-0; Kazama Y, 2000, THROMB HAEMOSTASIS, V83, P141; Kim MS, 2001, CANCER LETT, V171, P79, DOI 10.1016/S0304-3835(01)00505-5; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; KORNER G, 1993, J CELL PHYSIOL, V154, P456, DOI 10.1002/jcp.1041540303; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEE JK, 1992, J BIOL CHEM, V267, P4638; MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210; MIMURO J, 1987, BLOOD, V70, P721; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Miyagi Y, 1996, GENOMICS, V35, P267, DOI 10.1006/geno.1996.0353; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Petersen LC, 1996, EUR J BIOCHEM, V235, P310, DOI 10.1111/j.1432-1033.1996.0310f.x; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V319, P55, DOI 10.1006/abbi.1995.1266; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; RAO CN, 1995, J INVEST DERMATOL, V104, P379, DOI 10.1111/1523-1747.ep12665851; Rao CN, 2001, CLIN CANCER RES, V7, P570; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Udagawa K, 1998, PLACENTA, V19, P217, DOI 10.1016/S0143-4004(98)90011-X; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; WERLING RW, 1993, THROMB HAEMOSTASIS, V69, P366	41	14	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					921	928		10.1038/sj.onc.1204983	http://dx.doi.org/10.1038/sj.onc.1204983			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840337				2022-12-28	WOS:000173427100007
J	Montagna, C; Andrechek, ER; Padilla-Nash, H; Muller, WJ; Ried, T				Montagna, C; Andrechek, ER; Padilla-Nash, H; Muller, WJ; Ried, T			Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu	ONCOGENE			English	Article						HER2/neu; spectral karyotyping (SKY); breast cancer model; genomic instability; double minutes (DMs); centrosome	TRANSGENIC MICE; BREAST-CANCER; C-MYC; TUMORS; HYBRIDIZATION; ABERRATIONS; TUMORIGENESIS; INSTABILITY; ONCOGENE; GENES	The conditional expression of activated HER2/neu gene under its endogenous promoter in the mammary epithelium of the mouse results in accelerated lobular development and focal mammary tumors. Carcinogenesis, however, requires amplification and considerably increased expression levels of oncogenic neu. Deducing from the multiple genetic aberrations required for human breast cancer to develop, we hypothesized that in addition to the over-expression of an activated HER2/neu, secondary aberrations would occur. We have therefore conducted a genomic screen for chromosomal imbalances and translocations using comparative genomic hybridization and spectral karyotyping. The results reveal a moderate degree of chromosomal instability and micronuclei formation in short-term cultures established from primary tumors. Genomic instability appears to be linked to the amplification of functional centrosomes, a phenomenon that we frequently observed in other tumor types. Seventy per cent of the tumors revealed genomic amplification of HER2/neu, often in the form of double minute chromosomes, which correlated with recurring loss of mouse chromosome 4D-E, a region that is orthologous to distal human chromosome 1p. It is likely that this region contains putative tumor suppressor genes whose inactivation is required for tumor formation in this model of human breast cancer.	NCI, Ctr Canc Res, Genet Branch, NIH, Bethesda, MD 20892 USA; McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, Hamilton, ON L8S 4K1, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); McMaster University	Ried, T (corresponding author), NCI, Ctr Canc Res, Genet Branch, NIH, Bldg 9,Rm 1N105,9 Mem Dr, Bethesda, MD 20892 USA.			Andrechek, Eran/0000-0002-8680-3423	NCI NIH HHS [U01 CA105490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA105490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1985, LANCET, V2, P1035; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; BIECHE I, 1994, CANCER RES, V54, P4274; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; DAVISSON MT, 1994, GENE, V147, P157, DOI 10.1016/0378-1119(94)90060-4; Garini Y., 1996, Bioimaging, V4, P65, DOI 10.1002/1361-6374(199606)4:2<65::AID-BIO4>3.3.CO;2-4; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Heim S, 1995, CANC CYTOGENETICS; Hennighausen L, 2000, ONCOGENE, V19, P966, DOI 10.1038/sj.onc.1203346; ISOLA JJ, 1995, AM J PATHOL, V147, P905; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; O'Brien SJ, 1999, SCIENCE, V286, P458, DOI 10.1126/science.286.5439.458; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; RIED T, 1995, CANCER RES, V55, P5415; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Schrock E, 1996, HUM GENET, V97, P256, DOI 10.1007/BF02265277; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	33	81	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2002	21	6					890	898		10.1038/sj.onc.1205146	http://dx.doi.org/10.1038/sj.onc.1205146			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840334				2022-12-28	WOS:000173427100004
J	Seo, YR; Fishel, ML; Amundson, S; Kelley, MR; Smith, ML				Seo, YR; Fishel, ML; Amundson, S; Kelley, MR; Smith, ML			Implication of p53 in base excision DNA repair: in vivo evidence	ONCOGENE			English	Article						p53; DNA-repair; polymerase-beta	DAMAGE; PROTEIN; CELLS; SENSITIVITY; FIBROBLASTS; EXPRESSION; MUTATIONS; AGENTS; GADD45; REF-1	The tumor suppressor p53 plays an important role in response to DNA damage, including DNA repair. One DNA repair pathway, nucleotide excision repair (NER), has been well-documenteav6d to be regulated by p53. It seemed probable that p53 may affect other DNA repair pathways. We employed matched isogenic pairs of cell lines, wild-type or p53-deficient, to investigate this question using methyl methanesulfonate (MMS), a base-damaging agent. Alkylation damage induced by MMS is repaired exclusively by the base excision repair (BER) pathway. Cells carrying mutant or no p53 genes exhibited slow BER of MMS-induced DNA damage, and exhibited MMS-sensitivity. One contributing factor is the abundance of DNA polymerase beta (beta-pol), an enzyme required for BER, which was almost absent in p53 mutant and p53-null cells. Our findings demonstrate an in vivo requirement for p53 in regulating the base excision repair response, a novel finding of great potential importance in understanding the DNA repair branch of the p53 pathway.	Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN USA; Indiana Univ, Ctr Canc, Dept Biochem, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Wells Ctr Pediat Oncol, Indianapolis, IN 46202 USA; NCI, Bethesda, MD 20892 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Smith, ML (corresponding author), Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, 1044 W Walnut,R-155, Indianapolis, IN 46202 USA.		Fishel, Melissa L./AAH-6608-2020	Fishel, Melissa L./0000-0002-9436-6382; Kelley, Mark/0000-0002-6120-9532				Brown JM, 1999, CANCER RES, V59, P1391; COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; FAN SJ, 1995, CANCER RES, V55, P1649; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fortini P, 2000, NUCLEIC ACIDS RES, V28, P3040, DOI 10.1093/nar/28.16.3040; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hawkins DS, 1996, CANCER RES, V56, P892; Hollander MC, 2001, CANCER RES, V61, P2487; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Morris EJ, 1999, BIOTECHNIQUES, V26, P282, DOI 10.2144/99262st02; Offer H, 2001, CANCER RES, V61, P88; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Okorokov AL, 1999, MOL CELL BIOL, V19, P7501; SEO YR, 2001, IN PRESS BREAST CANC; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	29	89	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					731	737		10.1038/sj.onc.1205129	http://dx.doi.org/10.1038/sj.onc.1205129			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850801				2022-12-28	WOS:000173427000004
J	de Lange, T				de Lange, T			Protection of mammalian telomeres	ONCOGENE			English	Article						TRF2; telomere; p53; capping; apoptosis; senescence; genome instability; ATM; DNA-PK; Ku	DEPENDENT PROTEIN-KINASE; DNA-BINDING PROTEIN; CELL-CYCLE ARREST; EXONUCLEASE ACTIVITY; CATALYTIC SUBUNIT; HUMAN-CHROMOSOMES; END PROTECTION; FISSION YEAST; KU; LENGTH	Telomeres allow cells to distinguish natural chromosome ends from damaged DNA. When telomere function is disrupted, a potentially lethal DNA damage response can ensue, DNA repair activities threaten the integrity of chromosome ends, and extensive genome instability can arise. It is not clear exactly how the structure of telomere ends differs from sites of DNA damage and how telomeres protect chromosome ends from DNA repair activities. What are the defining structural features of telomeres and through which mechanisms do they ensure chromosome end protection? What is the molecular basis of the telomeric cap and how does it act to sequester the chromosome end? Here I discuss data gathered in the last few years, suggesting that the protection of human chromosome ends primarily depends on the telomeric protein TRF2 and that telomere capping involves the formation of a higher order structure, the telomeric loop or t-loop.	Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, Box 159,1230 York Ave, New York, NY 10021 USA.	delange@mail.rockefeller.edu	de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X				Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; ALINE RF, 1989, EXP PARASITOL, V68, P57, DOI 10.1016/0014-4894(89)90008-8; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; BENN PA, 1976, AM J HUM GENET, V28, P465; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CANMAN CE, 1994, CANCER RES, V54, P5054; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; De Lange T, 2000, COLD SPRING HARB SYM, V65, P265, DOI 10.1101/sqb.2000.65.265; de Lange T, 2001, SCIENCE, V292, P1075; DELANGE T, 1995, TELOMERES, P265; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Diede SJ, 2001, CURR BIOL, V11, P1336, DOI 10.1016/S0960-9822(01)00400-6; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Grandin N, 2001, EMBO J, V20, P1173, DOI 10.1093/emboj/20.5.1173; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Huffman KE, 2000, J BIOL CHEM, V275, P19719, DOI 10.1074/jbc.M002843200; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Lustig AJ, 2001, NAT STRUCT BIOL, V8, P297, DOI 10.1038/86157; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Marcand S, 1998, CIBA F SYMP, V211, P76; McClintock B, 1941, GENETICS, V26, P234; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Murti KG, 1999, P NATL ACAD SCI USA, V96, P14436, DOI 10.1073/pnas.96.25.14436; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Qi HY, 2000, GENE DEV, V14, P1777; Rathmell WK, 1997, CANCER RES, V57, P68; Riha K, 2001, SCIENCE, V291, P1797, DOI 10.1126/science.1057110; Ritchie KB, 2000, GENETICS, V155, P475; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Stansel RM, 2001, EMBO J, V20, P5532; Teo SH, 2001, EMBO REP, V2, P197, DOI 10.1093/embo-reports/kve038; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	79	756	785	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					532	540		10.1038/sj.onc.1205080	http://dx.doi.org/10.1038/sj.onc.1205080			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850778				2022-12-28	WOS:000173390500005
J	Li, M; Song, SM; Lippman, SM; Zhang, XK; Liu, XM; Lotan, R; Xu, XC				Li, M; Song, SM; Lippman, SM; Zhang, XK; Liu, XM; Lotan, R; Xu, XC			Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells	ONCOGENE			English	Article						retinoids; retinoic acid receptor-beta; cyclooxygenase-2; esophageal cancer	ACTIVATOR PROTEIN-1 ACTIVITY; UP-REGULATION; SELECTIVE-INHIBITION; EPITHELIAL-CELLS; APOPTOSIS; GROWTH; TRANSCRIPTION; ASPIRIN; N-(4-HYDROXYPHENYL)RETINAMIDE; DIFFERENTIATION	Since retinoic acid receptor (RAR)-beta mRNA is frequently lost during esophageal carcinogenesis and esophageal cancer cells that do not express RAR-beta are resistant to retinoic acid (RA), we stably transfected RAR-beta expression vector into an esophageal cancer cell line TE-8 and an antisense RAR-beta into TE-3 cells. Transfection of RAR-beta decreased cell growth and colony formation and induced apoptosis in TE-8 cells. Antisense RAR-beta-transfected TE-3 cells had a shorter doubling time and became resistant to RA. Induction of RAR-beta decreased COX-2 expression in RAR-beta transfected TE-8 cells, whereas antisense RAR-beta transfected TE-3 cells increased COX-2 expression. The inhibitory effect of RAR-beta on COX-2 expression was further enhanced in the presence of RA, which was blocked by an RAR antagonist. The synthetic retinoid N-(4-hydroxyphenyl)-retinamide, which does not bind effectively to RAR-beta, had no effect on COX-2 suppression. Furthermore, RA blocked bile acid-induced COX-2 expression and prostaglandin E-2 production only in the RAR-beta positive cells. Our data demonstrated that anticancer effect of RAR-beta may be related to its ability to suppress COX-2 expression and support that the loss of RAR-beta expression may contribute to esophageal carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Sanford Burnham Prebys Medical Discovery Institute	Xu, XC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, 1515 Holcombe Blvd,Box 236, Houston, TX 77030 USA.	xxu@mdanderson.org						Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Carey M, 2000, TRANSCRIPTIONAL REGU; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Clifford JL, 1999, CANCER RES, V59, P14; DE LUCA LM, 1991, FASEB J, V5, P2924; Dmitrovsky E, 1997, J NATL CANCER I, V89, P1179, DOI 10.1093/jnci/89.16.1179; Dong ZG, 1997, J BIOL CHEM, V272, P9962; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; FUNKHOUSER EM, 1995, CANCER-AM CANCER SOC, V76, P1116, DOI 10.1002/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO;2-I; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GOLDSTEIN SM, 1984, CANCER RES, V44, P120; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Li M, 2000, CANCER EPIDEM BIOMAR, V9, P545; Li M, 2001, INT J CANCER, V93, P218, DOI 10.1002/ijc.1322; Lin F, 2000, CANCER RES, V60, P3271; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; MARNETT LJ, 1992, CANC RES, V52; Mestre JR, 1997, CANCER RES, V57, P2890; Mestre JR, 1997, ANN NY ACAD SCI, V833, P173, DOI 10.1111/j.1749-6632.1997.tb48605.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pfahl M, 1996, ANNU REV NUTR, V16, P257, DOI 10.1146/annurev.nu.16.070196.001353; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Song SM, 2001, BIOCHEM BIOPH RES CO, V281, P872, DOI 10.1006/bbrc.2001.4433; Souza RF, 2000, CANCER RES, V60, P5767; Sporn M.B., 1994, RETINOIDS BIOL CHEM; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Xu X.-C., 1999, HANDB EXP PHARM, P323; Xu XC, 1999, CANCER RES, V59, P2477; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zimmermann KC, 1999, CANCER RES, V59, P198	49	50	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					411	418		10.1038/sj.onc.1205106	http://dx.doi.org/10.1038/sj.onc.1205106			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821953	Bronze			2022-12-28	WOS:000173311200009
J	Ashrafi, GH; Tsirimonaki, E; Marchetti, B; O'Brien, PM; Sibbet, GJ; Andrew, L; Campo, MS				Ashrafi, GH; Tsirimonaki, E; Marchetti, B; O'Brien, PM; Sibbet, GJ; Andrew, L; Campo, MS			Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins	ONCOGENE			English	Article						papillomavirus; E5; MHC class I; Golgi apparatus; cell transformation	GROWTH-FACTOR RECEPTOR; COMPLEX CLASS-I; CERVICAL CARCINOMAS; INTERCELLULAR COMMUNICATION; TRANSFORMING FUNCTIONS; CELL-TRANSFORMATION; E7 ONCOPROTEINS; KINASE-ACTIVITY; E8 PROTEIN; TYPE-4 E8	The papillomavirus E5 protein is localized in the endoplasmic reticulum (ER) and Golgi apparatus (GA) of the host cell. Transformed bovine fibroblasts expressing bovine papillomavirus (BPV) E5 are highly vacuolated and have a much enlarged, distorted and fragmented GA. Major histocompatibility complex class I (MHC I) is processed and transported to the cell surface through the GA. Given the cellular localization of E5 in the GA and the morphologically abnormal GA, we investigated the expression of MHC I in cells transformed by E5 from BPV-1 and BPV-4. Two cell lines were used: bovine cells that also express E6, E7 and activated ras, and NIH3T3 cells that express only E5. In addition, PalF cells acutely infected with a recombinant retrovirus expressing E5 were also examined. In contrast to non-transformed normal cells, or transformed cells expressing other papillomavirus proteins, cells expressing E5 do not express MHC I on their surface, but retain it intracellularly, independently of the presence of other viral or cellular oncogenes, or of whether the cells are long-term transformants or acutely infected. We conclude that expression of E5 prevents expression of MHC I to the cell surface and causes its retention within the cell. In addition, lower amounts of total MHC I heavy chain and of heavy chain RNA are detected in E5-transformed cells than in control cells. As surface expression of another glycosylated membrane protein, the transferrin receptor, is not affected, it appears that E5 targets MHC I with at least a degree of specificity. In papillomavirus lesions this effect would have important implications for antigen presentation by, and immunosurveillance of, virally infected cells.	Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Papillomavirus Res Grp, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Dept Vet Pathol, LRF Virus Ctr, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow; University of Glasgow	Campo, MS (corresponding author), Beatson Inst Canc Res, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.			Ashrafi, G. Hossein/0000-0002-4516-5111				Anderson RA, 1997, VET J, V154, P69, DOI 10.1016/S1090-0233(05)80010-3; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Ashby ADM, 2001, J GEN VIROL, V82, P2353, DOI 10.1099/0022-1317-82-10-2353; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; BELL SC, 1981, J REPROD IMMUNOL, V3, P3, DOI 10.1016/0165-0378(81)90024-3; BENSAID A, 1989, ANIM GENET, V20, P241; Bontkes HJ, 1998, LANCET, V351, P187, DOI 10.1016/S0140-6736(05)78209-X; Brady CS, 2000, TISSUE ANTIGENS, V55, P401, DOI 10.1034/j.1399-0039.2000.550502.x; Briggs MW, 2001, VIROLOGY, V280, P169, DOI 10.1006/viro.2000.0783; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURNETT S, 1992, P NATL ACAD SCI USA, V89, P5665, DOI 10.1073/pnas.89.12.5665; Chang JL, 2001, J BIOMED SCI, V8, P206, DOI 10.1007/BF02256414; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; CROMME FV, 1993, ONCOGENE, V8, P2969; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FIMBOW ME, 1991, MOL CARCINOG, V4, P441; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; Frazer IH, 1999, IMMUNOL REV, V168, P131, DOI 10.1111/j.1600-065X.1999.tb01288.x; FRAZER JH, 1996, PAPILLOMAVIRUS REV, P151; Georgopoulos NT, 2000, ONCOGENE, V19, P4930, DOI 10.1038/sj.onc.1203860; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; JACKSON ME, 1991, MOL CARCINOGEN, V4, P382, DOI 10.1002/mc.2940040510; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; KEATING PJ, 1995, BRIT J CANCER, V72, P405, DOI 10.1038/bjc.1995.346; Kubbutat MHG, 1996, SEMIN VIROL, V7, P295, DOI 10.1006/smvy.1996.0037; KUNHE C, 1999, PAPILLOMAVIRUS REPOR, V10, P139; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; Morgan IM, 2000, PAPILLOMAVIRUS REP, V11, P127; Naessens J, 1996, VET IMMUNOL IMMUNOP, V52, P257, DOI 10.1016/0165-2427(96)05572-9; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; O'Brien V, 1999, VIROLOGY, V255, P385, DOI 10.1006/viro.1998.9563; O'Brien V, 1998, ONCOGENE, V17, P293, DOI 10.1038/sj.onc.1201937; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; SAWHNEY SMS, 1995, IMMUNOGENETICS, V41, P246, DOI 10.1007/BF00172066; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Seliger B, 1997, IMMUNOL TODAY, V18, P292, DOI 10.1016/S0167-5699(97)01052-9; Sibbet G, 2000, J GEN VIROL, V81, P327, DOI 10.1099/0022-1317-81-2-327; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Suprynowicz FA, 2000, J BIOL CHEM, V275, P5111, DOI 10.1074/jbc.275.7.5111; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; TOYE PG, 1990, IMMUNOLOGY, V70, P20; Vambutas A, 2000, CLIN DIAGN LAB IMMUN, V7, P79, DOI 10.1128/CDLI.7.1.79-85.2000; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; Yewdell JW, 1999, ANNU REV CELL DEV BI, V15, P579, DOI 10.1146/annurev.cellbio.15.1.579	63	81	86	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					248	259						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803468				2022-12-28	WOS:000173026200009
J	Cuenco, GM; Ren, RB				Cuenco, GM; Ren, RB			Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia	ONCOGENE			English	Article						BCR - ABL; AML1/MDS1/EVI1; AML; differentiation	INTERNAL TANDEM DUPLICATION; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; MYELOPROLIFERATIVE DISEASE; FUSION GENE; FLT3 GENE; FETAL LIVER; MICE; HEMATOPOIESIS; PROTEIN; AML1	The development of acute myelogenous leukemia (AML), which is characterized by a block of myeloid differentiation, is a multi-step process that involves several genetic abnormalities, but the molecular mechanisms by which these genetic alterations cooperate in leukemogenesis are poorly understood. The human chronic myelogenous leukemia (CML) is a model for multi-step leukemogenesis. BCR-ABL, a constitutively active tyrosine kinase, is a fusion protein generated by the t(9;22)(q34;q11) translocation found in the vast majority of CML patients. BCR-ABL efficiently induces a myeloproliferative disorder (MPD) in mice. but progression to CML blast phase requires additional mutations. The AML1/MDS1/EVI1 (AME) transcription factor fusion protein, is a product of the human t(3;21)(q26;q22) translocation found as a secondary mutation in some cases of CML during the blast phase. We have previously shown that AME can induce an AML in mice but with a greatly extended latency, suggesting a requirement for additional mutations. Here we demonstrate that AME alone does not block myeloid differentiation in vivo during the 4-month pre-leukemia stage, yet co-expression of BRC-ABL and AME in mice can block myeloid differentiation and rapidly induce an AML. Our results suggest that block of myeloid differentiation and induction of AML involves cooperation between mutations that dysregulate protein tyrosine kinase signaling and those that disrupt hematopoietic gene transcription.	Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, MS029, Waltham, MA 02454 USA.				NIGMS NIH HHS [GM07122] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007122] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHUJA HG, 1990, BLOOD, V75, P1684; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; FIALKOW PJ, 1991, BLOOD, V77, P1415; FREDERICKSON TN, 2000, ATLAS MOUSE HEMATOPA; Goldman J M, 1997, Curr Opin Hematol, V4, P277; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; HEUTTNE CS, 2000, NAT GENET, V24, P57; HOFFMAN R, 2000, HEMATOLOGY BASIC PRI; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; JACOBS A, 1991, LEUKEMIA, V5, P277; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Louz D, 2000, LEUKEMIA, V14, P1876, DOI 10.1038/sj.leu.2401887; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; Nakao M, 1996, LEUKEMIA, V10, P1911; NEUBAUER A, 1994, BLOOD, V83, P1603; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Nucifora G, 1997, LEUKEMIA, V11, P2022, DOI 10.1038/sj.leu.2400880; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	42	61	65	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8236	8248		10.1038/sj.onc.1205095	http://dx.doi.org/10.1038/sj.onc.1205095			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781838				2022-12-28	WOS:000172507800007
J	Yang, LM; Ostrowski, J; Reczek, P; Brown, P				Yang, LM; Ostrowski, J; Reczek, P; Brown, P			The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGF beta and causing cell cycle arrest	ONCOGENE			English	Article						retinoic acid; cell cycle; cyclin-dependent kinase (CDK); CDK inhibitors and normal breast cells; TGF beta; proliferation	MAMMARY EPITHELIAL-CELLS; PHASE-II TRIAL; CANCER CELLS; CARCINOMA CELLS; 13-CIS-RETINOIC ACID; APOPTOSIS INDUCTION; RAR-ALPHA; EXPRESSION; PROLIFERATION; ACTIVATION	We have previously shown that a retinoic acid receptor (RAR) antagonist BMS453, which does not activate RAR-dependent gene transcription in breast cells, inhibits normal breast cell growth. In this study we have investigated the mechanisms by which this retinoid receptor antagonist inhibits cell growth. Both all traits retinoic acid (atRA) and BMS453 inhibited the proliferation of normal breast cell growth without significantly inducing apoptosis. Both retinoids caused a GI block in the cell cycle with an increase in the proportion of cells in G0/G1 and a decrease in the proportion of cells in S phase. We then investigated the effects of the retinoids on molecules that regulate the G1 to S transition. These studies demonstrated that both atRA and BMS453 induce Rb hypophosphorylation and decrease CDK2 kinase activity. We then studied the effect of the retinoids on the expression of CDK inhibitors. atRA and BMS453 increased total p21 protein levels and CDK2-bound p21 protein, but did not change CDK4-bound p21. These results suggest that atRA and BMS453 increase p21, decrease CDK2 kinase activity, which in turn leads to hypophosphorylation of Rb and GI arrest. Because transforming growth factor beta (TGF beta) has been proposed as a mediator of retinoid-induced growth inhibition, we next investigated whether TGF beta mediates the anti-proliferative effect of atRA and BMS453 in normal breast cells. These studies showed that atRA and BMS453 increased total TGF beta activity by 3-5-fold. However, BMS453 increased active TGF beta activity by 33-fold while atRA increased active TGF beta activity by only threefold. These results suggest that BMS453 treatment induces conversion of latent TGF beta to active TGF beta. To investigate whether this increase in active TGF beta mediates the anti-proliferative effects of these retinolds, a TGF beta -blocking antibody was used in an attempt to prevent retinoid-induced growth inhibition. Results from these experiments showed that the anti-TGF beta antibody prevented the inhibition of cell proliferation induced by BMS453, but did not prevent the inhibition of cell proliferation induced by atRA. 2001 These results demonstrate that BMS453 inhibits breast cell growth predominantly through the induction of active TGF beta, while atRA inhibits growth through other mechanisms. These results suggest that retinoid analogs that increase active TGF beta may be promising agents for the prevention of breast cancer.	Baylor Coll Med, Baylor Breast Ctr, Houston, TX 77030 USA; Bristol Myers Squibb Co, Princeton, NJ USA	Baylor College of Medicine; Bristol-Myers Squibb	Brown, P (corresponding author), Baylor Coll Med, Baylor Breast Ctr, 1 Baylor Plaza,MS600, Houston, TX 77030 USA.			Brown, Powel/0000-0002-3398-163X	NCI NIH HHS [R01CA78480] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; CASSIDY J, 1982, EUR J CANCER CLIN ON, V18, P925, DOI 10.1016/0277-5379(82)90239-5; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Fanjul AN, 1998, CANCER RES, V58, P4607; Gangemi RMR, 1996, ANN NY ACAD SCI, V784, P550, DOI 10.1111/j.1749-6632.1996.tb16279.x; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Imai S, 1997, FEBS LETT, V411, P102, DOI 10.1016/S0014-5793(97)00673-X; Jing YK, 1996, DIFFERENTIATION, V60, P109, DOI 10.1046/j.1432-0436.1996.6020109.x; KIM SJ, 1989, J BIOL CHEM, V264, P402; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Langenfeld J, 1996, ONCOGENE, V13, P1983; LEE JS, 1993, J CLIN ONCOL, V11, P959, DOI 10.1200/JCO.1993.11.5.959; LEE PPH, 1995, ENDOCRINOLOGY, V136, P1707, DOI 10.1210/en.136.4.1707; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; Li XS, 1996, CANCER RES, V56, P5055; Lin F, 2000, CANCER RES, V60, P3271; Liu XJ, 1998, CANCER RES, V58, P4752; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Miller VA, 1996, CLIN CANCER RES, V2, P471; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; Nunes I, 1996, CANCER RES, V56, P495; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; ROBERTS AB, 1984, RETINOIDS, V2, P209; Rocha RL, 1996, J NATL CANCER I, V88, P601, DOI 10.1093/jnci/88.9.601; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Sutton LM, 1997, CANCER CHEMOTH PHARM, V40, P335, DOI 10.1007/s002800050666; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Toma S, 1998, ANTICANCER RES, V18, P935; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3; Yang L, 1999, BREAST CANCER RES TR, V56, P277, DOI 10.1023/A:1006219411078; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Zhang YX, 2000, CANCER RES, V60, P2025; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	45	22	24	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					8025	8035		10.1038/sj.onc.1204911	http://dx.doi.org/10.1038/sj.onc.1204911			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753686				2022-12-28	WOS:000172288700012
J	Tauber, B; Dobner, T				Tauber, B; Dobner, T			Adenovirus early E4 genes in viral oncogenesis	ONCOGENE			English	Review						Ad E4 gene function; transformation; oncogenesis	REGION-4 34-KILODALTON PROTEIN; CELLULAR TRANSCRIPTION FACTOR; PRODUCTIVELY INFECTED-CELLS; READING FRAME-1 ENCODES; P53 TUMOR-SUPPRESSOR; DNA-BINDING ACTIVITY; E4ORF6 PROTEIN; MAMMARY-TUMORS; 55-KILODALTON PROTEIN; LYTIC INFECTION	Previous investigations into potential transforming activities of adenovirus (Ad) early genes were largely overshadowed by the more obvious roles of EIA and E1B products. One exception was an Ad9 E4 protein (ORF1) shown to enhance transformation of cultured cells and promote mammary tumors in female rats. Recently, significant advances in understanding Ad E4 gene products at the molecular level have revealed that these proteins possess an unexpectedly diverse collection of functions, which not only orchestrate many viral processes, but overlap with oncogenic transformation of primary mammalian cells. Operating through a. complex network of protein interactions with key viral and cellular regulatory components, Ad E4 products are apparently involved in transcription, apoptosis, cell cycle control, DNA repair, cell signaling, posttranslational modifications and the integrity of nuclear multiprotein complexes known as PML oncogenic domains (POD). Some of these functions directly relate to known transforming and oncogenic processes, or implicate mechanisms such as modulating the function and subcellular localization of cellular PDZ domain-containing proteins, POD reorganization, targeted proteolytic degradation, inhibition of DNA double-strand break repair and 'hit-and-run' mutagenesis. Here, we summarize the recent data and discuss how E4 gene product interactions may contribute to viral oncogenesis.	Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany	University of Regensburg	Dobner, T (corresponding author), Univ Regensburg, Inst Med Mikrobiol & Hyg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	thomas.dobner@klinik.uni-regensburg.de						ANKERST J, 1974, INT J CANCER, V13, P286, DOI 10.1002/ijc.2910130303; ANKERST J, 1989, J NATL CANCER I, V81, P294, DOI 10.1093/jnci/81.4.294; BERNARDS R, 1984, J VIROL, V50, P847, DOI 10.1128/JVI.50.3.847-853.1984; Boyer J, 1999, VIROLOGY, V263, P307, DOI 10.1006/viro.1999.9866; Boyer JL, 2000, J BIOL CHEM, V275, P14969, DOI 10.1074/jbc.M000566200; BRACKMANN KH, 1980, J BIOL CHEM, V255, P6772; BRIDGE E, 1990, VIROLOGY, V174, P345, DOI 10.1016/0042-6822(90)90088-9; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Cathomen T, 2000, J VIROL, V74, P11407, DOI 10.1128/JVI.74.23.11407-11412.2000; Cress WD, 1996, MOL CELL BIOL, V16, P2119; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; CUTT JR, 1987, J VIROL, V61, P543, DOI 10.1128/JVI.61.2.543-552.1987; DIX I, 1995, J GEN VIROL, V76, P1051, DOI 10.1099/0022-1317-76-4-1051; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DOWNEY JF, 1983, J VIROL, V45, P514, DOI 10.1128/JVI.45.2.514-523.1983; ESCHE H, 1979, J VIROL, V30, P21, DOI 10.1128/JVI.30.1.21-31.1979; ESCHE H, 1982, J VIROL, V41, P1076, DOI 10.1128/JVI.41.3.1076-1082.1982; ESCHE H, 1982, J GEN VIROL, V60, P99, DOI 10.1099/0022-1317-60-1-99; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLINT SJ, 1976, J MOL BIOL, V106, P749, DOI 10.1016/0022-2836(76)90263-1; FLINT SJ, 1975, J MOL BIOL, V96, P47, DOI 10.1016/0022-2836(75)90181-3; FLINT SJ, 1976, VIROLOGY, V72, P456, DOI 10.1016/0042-6822(76)90174-4; FREYER GA, 1984, NUCLEIC ACIDS RES, V12, P3503, DOI 10.1093/nar/12.8.3503; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Goodrum FD, 1999, J VIROL, V73, P7474, DOI 10.1128/JVI.73.9.7474-7488.1999; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAHAM FL, 1984, ADENOVIRUSES, P339; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grifman M, 1999, J VIROL, V73, P10010, DOI 10.1128/JVI.73.12.10010-10019.1999; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HERISSE J, 1981, NUCLEIC ACIDS RES, V9, P4023, DOI 10.1093/nar/9.16.4023; HORWITZ MS, 1996, FIELDS VIROLOGY, V2, P2149; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; Javier R, 1996, BREAST CANCER RES TR, V39, P57, DOI 10.1007/BF01806078; JAVIER R, 1991, J VIROL, V65, P3192, DOI 10.1128/JVI.65.6.3192-3202.1991; JAVIER R, 1992, SCIENCE, V257, P1267, DOI 10.1126/science.1519063; JAVIER RT, 1994, J VIROL, V68, P3917, DOI 10.1128/JVI.68.6.3917-3924.1994; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JONSSON N, 1977, CANCER, V39, P2513, DOI 10.1002/1097-0142(197706)39:6<2513::AID-CNCR2820390631>3.0.CO;2-7; Kleinberger T, 2000, APOPTOSIS, V5, P211, DOI 10.1023/A:1009644210581; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Konig C, 1999, J VIROL, V73, P2253; KOVESDI I, 1986, SCIENCE, V231, P719, DOI 10.1126/science.2935935; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 1999, ONCOGENE, V18, P9, DOI 10.1038/sj.onc.1202284; Nevels M, 1999, J VIROL, V73, P1591, DOI 10.1128/JVI.73.2.1591-1600.1999; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; NEVINS JR, 1996, FIELDS VIROLOGY, V1, P301; Nicolas AL, 2000, VIROLOGY, V266, P211, DOI 10.1006/viro.1999.0062; O'Connor RJ, 2000, J VIROL, V74, P5819, DOI 10.1128/JVI.74.13.5819-5824.2000; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OCONNOR RJ, 1991, NUCLEIC ACIDS RES, V19, P6579, DOI 10.1093/nar/19.23.6579; OHMAN K, 1995, INT J ONCOL, V6, P663; Orlando JS, 1999, J VIROL, V73, P4600, DOI 10.1128/JVI.73.6.4600-4610.1999; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SARNOW P, 1982, J MOL BIOL, V162, P565, DOI 10.1016/0022-2836(82)90389-8; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; Schaley J, 2000, J VIROL, V74, P2084, DOI 10.1128/JVI.74.5.2084-2093.2000; SHIROKI K, 1984, J VIROL, V50, P854, DOI 10.1128/JVI.50.3.854-863.1984; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; TAUBER B, 2001, IN PRESS GENE; TERRIS B, 1995, CANCER RES, V55, P1590; Thomas DL, 1999, J VIROL, V73, P3071, DOI 10.1128/JVI.73.4.3071-3079.1999; Thomas DL, 2001, J VIROL, V75, P557, DOI 10.1128/JVI.75.2.557-568.2001; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; VIRTANEN A, 1984, J VIROL, V51, P822, DOI 10.1128/JVI.51.3.822-831.1984; WEIDEN MD, 1994, P NATL ACAD SCI USA, V91, P153, DOI 10.1073/pnas.91.1.153; Weiss RS, 1997, J VIROL, V71, P4385, DOI 10.1128/JVI.71.6.4385-4394.1997; Weiss RS, 1996, J VIROL, V70, P862, DOI 10.1128/JVI.70.2.862-872.1996; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Wienzek S, 2001, J VIROL, V75, P5391, DOI 10.1128/JVI.75.11.5391-5397.2001; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamano S, 1999, J VIROL, V73, P10095, DOI 10.1128/JVI.73.12.10095-10103.1999; ZALMANZON ES, 1987, EKSP ONKOL, V9, P3; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	106	39	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7847	7854		10.1038/sj.onc.1204914	http://dx.doi.org/10.1038/sj.onc.1204914			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753667				2022-12-28	WOS:000172336500004
J	Miyazono, F; Schneider, PM; Metzger, R; Warnecke-Eberz, U; Baldus, SE; Dienes, HP; Aikou, T; Hoelscher, AH				Miyazono, F; Schneider, PM; Metzger, R; Warnecke-Eberz, U; Baldus, SE; Dienes, HP; Aikou, T; Hoelscher, AH			Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma in Barrett's esophagus	ONCOGENE			English	Article						mitochondrial DNA; D-Loop; mutation; Barrett's cancer; carcinogenesis	SOMATIC MUTATIONS; OXIDATIVE DAMAGE; GASTRIC TUMORS; NUCLEAR-DNA; CANCER; GENOME; P53; INSTABILITY; PROGRESSION; SEQUENCE	Mitochondrial DNA (mtDNA) is known for high mutation rates caused by lack of protective histones, inefficient DNA repair systems, and continuous exposure to mutagenic effects of oxygen radicals. We examined the frequency of mutations in the mtDNA D-Loop region in 20 patients with Barrett's carcinoma and associated Barrett's epithelium by automated DNA sequencing. Mutations were detected in eight of 20 (40%) patients in tumor and/or tumor-associated Barrett's epithelium. In six of eight positive cases, the mutations were detected only in the tumor, one of eight showed mutations in tumor and Barrett's epithelium, and one of eight only in Barrett's epithelium. The degree of dysplasia in Barrett's epithelium was classified low-grade in one and high grade in the two specimens. There was no association of mtDNA D-Loop mutations with histopathological stage of disease or tumor grading. We present the first study of frequent occurrence of mutations in the mtDNA D-Loop regions in adenocarcinomas in Barrett's esophagus. Furthermore, this study supports the hypothesis that oxidative damage might be a mechanism for the induction of adenocarcinoma in Barrett's esophagus. Since mutations were identified in tumor-associated dysplastic Barrett's epithelium, they also might become a marker for the malignant potential of Barrett's epithelium.	Univ Cologne, Dept Visceral & Vasc Surg, D-50931 Cologne, Germany; Univ Cologne, Inst Pathol, D-50931 Cologne, Germany; Kagoshima Univ, Sch Med, Dept Surg 1, Kagoshima 8908520, Japan	University of Cologne; University of Cologne; Kagoshima University	Schneider, PM (corresponding author), Univ Cologne, Dept Visceral & Vasc Surg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	Paul.Schneider@Medizin.Uni-Koeln.de		Warnecke-Eberz, Ute/0000-0002-2833-5633				Alonso A, 1997, ELECTROPHORESIS, V18, P682, DOI 10.1002/elps.1150180504; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Armstrong J, 2000, PEDIATR NEUROL, V23, P85, DOI 10.1016/S0887-8994(00)00158-2; BURGART LJ, 1995, AM J PATHOL, V147, P1105; Chen XX, 2000, CARCINOGENESIS, V21, P257, DOI 10.1093/carcin/21.2.257; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4; Habano W, 1999, INT J CANCER, V83, P625, DOI 10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.0.CO;2-N; Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7; HEERDT BG, 1994, CANCER RES, V54, P3912; HERMANEK P, 1992, UICC TNM KLASSIFIKAT, P9; Levin BC, 1999, GENOMICS, V55, P135, DOI 10.1006/geno.1998.5513; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Miller KWP, 1996, INT J LEGAL MED, V109, P107, DOI 10.1007/BF01369668; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLYAEE M, 1995, GUT, V37, P168, DOI 10.1136/gut.37.2.168; Polkowski W, 1999, HISTOL HISTOPATHOL, V14, P927, DOI 10.14670/HH-14.927; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; Reid BJ, 1996, EUR J CANCER PREV, V5, P57, DOI 10.1097/00008469-199612002-00009; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; REIDDEL RH, 1985, BARRETTS ESOPHAGUS, P224; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Schneider PM, 1996, J THORAC CARDIOV SUR, V111, P323, DOI 10.1016/S0022-5223(96)70441-5; Schneider PM, 2000, CLIN CANCER RES, V6, P3153; Schrump DS, 1999, DIS ESOPHAGUS, V12, P181; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Tamura G, 1999, EUR J CANCER, V35, P316, DOI 10.1016/S0959-8049(98)00360-8; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Wetscher GJ, 1998, AM J SURG, V176, P569, DOI 10.1016/S0002-9610(98)00258-X; WILLIAMSON WA, 1991, ARCH INTERN MED, V151, P2212, DOI 10.1001/archinte.151.11.2212; WILSON MR, 1995, BIOTECHNIQUES, V18, P662	36	61	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3780	3783		10.1038/sj.onc.1205532	http://dx.doi.org/10.1038/sj.onc.1205532			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032845				2022-12-28	WOS:000175676000012
J	Jiang, YF; Goldberg, ID; Shi, YE				Jiang, YF; Goldberg, ID; Shi, YE			Complex roles of tissue inhibitors of metalloproteinases in cancer	ONCOGENE			English	Review						TIMP; MMP; MMP inhibitors; angiogenesis; metastasis; apoptosis	GROWTH-PROMOTING ACTIVITY; MESSENGER-RNA EXPRESSION; MATRIX-METALLOPROTEINASE; TUMOR-GROWTH; CELL-DEATH; MAMMARY-CARCINOMA; BREAST CARCINOMAS; LIVER METASTASES; PROSTATE-CANCER; MELANOMA-CELLS	Matrix metalloproteinases (MMPs) is tightly associated with extracellular matrix (ECM) turnover, which plays a very active role in tumor invasion and metastasis. Tissue inhibitors of metalloproteinases (TIMPs) plays a critical role in the homeostasis of ECM by regulating the activity of MMPs. TIMPs are well-known for their ability to inhibit MMP activity thereby inhibiting tumor growth and metastasis. However, many evidences suggest that TIMPs are multifunctional proteins, which regulate cell proliferation, apoptosis, proMMP-2 activation, and angiogenesis. These effects may be through MMP-dependent or MMP-independent pathways. Recent data indicate that TIMPs have many paradoxical roles in tumorigenesis. In particular, both inhibitory effect and stimulatory effect on tumorigenesis have been demonstrated in many animal models in which TIMPs were overexpressed in cancer cells or in mice. Elevated TIMP levels are reported in association with cancer progression and identified as poor prognostic indicators in several human tumor types. Herein, we review the complex roles of TIMPs in cancer growth and metastasis.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New York, NY 11040 USA	Northwell Health; Yeshiva University	Shi, YE (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,New Hyde Pk, New York, NY 11040 USA.	shi@lij.edu	Jiang, Yangfu/AAX-2645-2020	Jiang, Yangfu/0000-0002-8696-2651	NATIONAL CANCER INSTITUTE [R29CA068064] Funding Source: NIH RePORTER; NCI NIH HHS [CA68064-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahonen M, 1998, CANCER RES, V58, P2310; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; ALVAREZ OA, 1990, J NATL CANCER I, V82, P589, DOI 10.1093/jnci/82.7.589; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Boulay A, 2001, CANCER RES, V61, P2189; Brand K, 2000, CANCER RES, V60, P5723; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; Celiker MY, 2001, ONCOGENE, V20, P4337, DOI 10.1038/sj.onc.1204508; Cornelius LA, 1998, J IMMUNOL, V161, P6845; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Davidson B, 1999, GYNECOL ONCOL, V73, P372, DOI 10.1006/gyno.1999.5381; Denhardt D T, 1992, Matrix Suppl, V1, P281; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Fernandez HA, 1999, J SURG RES, V82, P156, DOI 10.1006/jsre.1998.5534; Fletcher L, 2000, NAT BIOTECHNOL, V18, P1138, DOI 10.1038/81111; Fong KM, 1996, CLIN CANCER RES, V2, P1369; Goss KJH, 1998, INT J CANCER, V78, P629; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 2001, AM J PATHOL, V158, P1207, DOI 10.1016/S0002-9440(10)64070-9; Hammani K, 1996, GENE, V170, P287, DOI 10.1016/0378-1119(95)00864-0; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2001, BIOCHEM BIOPH RES CO, V281, P126, DOI 10.1006/bbrc.2001.4323; Hewitt R, 1996, ENZYME PROTEIN, V49, P163, DOI 10.1159/000468623; Hewitt RE, 2000, J PATHOL, V192, P455; Holten-Andersen MN, 2000, CLIN CANCER RES, V6, P4292; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; Itoh Y, 1998, J BIOL CHEM, V273, P24360, DOI 10.1074/jbc.273.38.24360; Jiang YF, 2001, CANCER RES, V61, P2365; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Joo YE, 2000, DIGEST DIS SCI, V45, P114, DOI 10.1023/A:1005421713137; Karrison TG, 1999, JNCI-J NATL CANCER I, V91, P80, DOI 10.1093/jnci/91.1.80; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; Koshiba T, 1998, CANCER, V82, P642, DOI 10.1002/(SICI)1097-0142(19980215)82:4<642::AID-CNCR5>3.0.CO;2-N; KOSSAKOWSKA AE, 1991, BLOOD, V77, P2475; Kruger A, 2001, CANCER RES, V61, P1272; Lein M, 1999, ANN NY ACAD SCI, V878, P544, DOI 10.1111/j.1749-6632.1999.tb07722.x; Lein M, 2000, PROSTATE, V43, P77; Li GY, 1999, CANCER RES, V59, P6267; Low JA, 1996, CLIN CANCER RES, V2, P1207; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Luparello C, 1999, BREAST CANCER RES TR, V54, P235, DOI 10.1023/A:1006121129382; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; Matsuzawa K, 1996, J NEUROPATH EXP NEUR, V55, P88, DOI 10.1097/00005072-199601000-00009; McCarthy K, 1999, INT J CANCER, V84, P44, DOI 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.3.CO;2-G; Michael M, 1999, J CLIN ONCOL, V17, P1802, DOI 10.1200/JCO.1999.17.6.1802; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nii M, 2000, INT J ONCOL, V16, P119; Noel A, 1997, INVAS METAST, V17, P221; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Powe DG, 1997, BRIT J CANCER, V75, P1678, DOI 10.1038/bjc.1997.285; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Prontera C, 1999, INT J CANCER, V81, P761, DOI 10.1002/(SICI)1097-0215(19990531)81:5<761::AID-IJC16>3.0.CO;2-1; Ree AH, 1997, CLIN CANCER RES, V3, P1623; Ritter LM, 1999, BIOCHEM BIOPH RES CO, V257, P494, DOI 10.1006/bbrc.1999.0408; Rowe TF, 1997, AM J OBSTET GYNECOL, V176, P915, DOI 10.1016/S0002-9378(97)70621-5; Rudolph-Owen LA, 1998, J MAMMARY GLAND BIOL, V3, P177, DOI 10.1023/A:1018746923474; SCHULTZ RM, 1988, CANCER RES, V48, P5539; Sehgal G, 1998, AM J PATHOL, V152, P591; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; Still K, 2000, PROSTATE, V42, P18; Thomas AL, 2000, EXPERT OPIN INV DRUG, V9, P2913, DOI 10.1517/13543784.9.12.2913; Uhr JW, 1997, NAT MED, V3, P505, DOI 10.1038/nm0597-505; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; VISSCHER DW, 1994, INT J CANCER, V59, P339, DOI 10.1002/ijc.2910590308; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; Wen W, 1999, CANCER RES, V59, P6052; WITTY JP, 1995, CANCER RES, V55, P1401; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Wylie S, 1999, CLIN EXP METASTAS, V17, P111, DOI 10.1023/A:1006573417179; Yamada E, 2001, HISTOL HISTOPATHOL, V16, P87, DOI 10.14670/HH-16.87; Yamashita K, 1996, FEBS LETT, V396, P103, DOI 10.1016/0014-5793(96)01066-6; Ylisirnio S, 2000, ANTICANCER RES, V20, P1311; Yoshiji H, 1998, INT J CANCER, V75, P81, DOI 10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.3.CO;2-J; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C; Yoshikawa T, 2000, CANCER LETT, V151, P81, DOI 10.1016/S0304-3835(99)00420-6; Zeng ZS, 1995, CLIN CANCER RES, V1, P899	102	388	413	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2245	2252		10.1038/sj.onc.1205291	http://dx.doi.org/10.1038/sj.onc.1205291			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948407				2022-12-28	WOS:000174555300013
J	Nakamura, S; Gomyo, Y; Roth, JA; Mukhopadhyay, T				Nakamura, S; Gomyo, Y; Roth, JA; Mukhopadhyay, T			C-terminus of p53 is required for G(2) arrest	ONCOGENE			English	Article						p53; p21; G(2) arrest	DNA-DAMAGE; CELL-CYCLE; PHOSPHORYLATION; INHIBITION; APOPTOSIS; CANCER; MDM2; CHECKPOINTS; ACETYLATION; EXPRESSION	Mutation of four lysine residues in the p53 C-terminal domain inhibits MDM2-dependent ubiquitination of p53 and alters its subcellular distribution. This implies that modification (such as acetylation and phosphorylation) of amino acid residues in p53 C-terminal domain, regulate the biological functions of p53. In this study, we demonstrated that p53 with lysine residues 372, 373, 381, and 382 mutated to alanine (the A4 mutant) retained the transactivation activity of wild-type p53, although the transactivation activity of p21 promoter by the A4 mutant was slightly reduced. The inducible expression of wild-type p53 and the A4 mutant in H1299 cells caused growth inhibition due to cell-cycle arrest. Consistent with previous studies, the expression of wild-type p53 elicited G(1) and G(2) arrests. However, the cells expressing the A4 mutant underwent G(1) arrest but not G(2) arrest. Cyclin B1-associated kinase activity was reduced in cells expressing wild-type p53 but not A4, when the cells underwent G(2) arrest. This suggests that modification of the p53 C-terminal domain might inhibit p53-mediated G(2) arrest. In other words, p53 requires an intact C-terminus to induce G(2) arrest.	Univ Texas, MD Anderson Canc Ctr, Sect Thorac Mol Oncol, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sect Thorac Mol Oncol, Dept Thorac & Cardiovasc Surg, Box 109,1515 Holcombe Blvd, Houston, TX 77030 USA.	tmukhopa@mail.mdanderson.org			NCI NIH HHS [2P50 CA70970-04, P50-CA70907, P01 CA78778-01A1, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907, P01CA078778, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; STEWART N, 1995, ONCOGENE, V10, P109; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	31	13	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2102	2107		10.1038/sj.onc.1205251	http://dx.doi.org/10.1038/sj.onc.1205251			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960383				2022-12-28	WOS:000174827000017
J	Shin, CY; Mellon, I; Turker, MS				Shin, CY; Mellon, I; Turker, MS			Multiple mutations are common at mouse Aprt in genotoxin-exposed mismatch repair deficient cells	ONCOGENE			English	Article						multiple mutations; genetic instability; DNA mismatch repair; genotoxin exposure	TRANSCRIPTION-COUPLED REPAIR; NUCLEOTIDE-EXCISION-REPAIR; SILENT MUTATIONS; APC MUTATIONS; P53 MUTATIONS; SKIN TUMORS; MICE; HYPERMUTABILITY; UV; SPECIFICITY	Mismatch repair deficiency is known to contribute to elevated rates of mutations, particularly at mono- and dinucleotide repeat sequences. However, such repeats are often missing from the coding regions of endogenous genes. To determine the types of mutations that can occur within an endogenous gene lacking highly susceptible repeat sequences, we examined mutagenic events at the 2.3 kb mouse Aprt gene in kidney cell lines derived from mice deficient for the PMS2 and MLH1 mismatch repair proteins. The Aprt mutation rate was increased 33-fold and 3.6-20-fold for Mlh1 and Pms2 null cell lines. respectively, when compared with a wildtype kidney cell line. For the Pms2 null cells this increase resulted from both intragenic events, which were predominantly base-pairs substitutions, and loss of heterozygosity events. Almost all mutations in the,Mlh1 null cells were due to base-pair substitutions. A:T-->G:C transitions (54% of small events) were predominant in the Pms2 null cells whereas G:C-A:T transitions (36%) were the most common base-pair change in the Mlh1 null cells. Interestingly, 4-9% of the spontaneous mutant alleles in the mismatch repair deficient cells exhibited two well-separated base-pair substitution events. The percentage of mutant alleles with two and occasionally three base-pair substitutions increased when the Pms2 and Mlh1 null cells were treated with ultraviolet radiation (15-21%) and when the Mlh1 null cells were treated with hydrogen peroxide (35%). In most cases the distance separating the multiple base-pair substitutions on a given allele was in excess of 100 base-pairs, suggesting that the two mutational events were not linked directly to a single DNA lesion. The significance of these results is discussed with regards to the roles for the PMS2 and MLH1 proteins in preventing spontaneous and genotoxin-related mutations.	Oregon Hlth & Sci Univ, CROET, Portland, OR 97201 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Univ Kentucky, Dept Pathol & Lab Med, Lexington, KY USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Oregon Health & Science University; Oregon State University; University of Kentucky; Oregon Health & Science University	Turker, MS (corresponding author), Oregon Hlth & Sci Univ, CROET, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	turkerm@ohsu.edu			NATIONAL CANCER INSTITUTE [R01CA076528, R01CA056383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045535, R29GM045535] Funding Source: NIH RePORTER; NCI NIH HHS [CA56383, CA76528] Funding Source: Medline; NIEHS NIH HHS [1P42 ES10338] Funding Source: Medline; NIGMS NIH HHS [GM45535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Baross-Francis A, 1998, P NATL ACAD SCI USA, V95, P8739, DOI 10.1073/pnas.95.15.8739; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Buettner VL, 2000, MUTAT RES-FUND MOL M, V452, P219, DOI 10.1016/S0027-5107(00)00090-7; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; Glaab WE, 2000, CANCER RES, V60, P4921; Glaab WE, 1998, MUTAT RES-FUND MOL M, V398, P197, DOI 10.1016/S0027-5107(98)00004-9; Hardman RA, 2001, CANCER RES, V61, P1392; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HARWOOD J, 1991, MOL CELL BIOL, V11, P3163, DOI 10.1128/MCB.11.6.3163; HORN PL, 1984, J CELL PHYSIOL, V121, P309, DOI 10.1002/jcp.1041210207; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KANJILAL S, 1993, CANCER RES, V53, P2961; Kato T, 1998, MUTAT RES-FUND MOL M, V422, P279, DOI 10.1016/S0027-5107(98)00208-5; Khattar NH, 1997, SOMAT CELL MOLEC GEN, V23, P51, DOI 10.1007/BF02679955; KOZAK C, 1975, SOMAT CELL GENET, V1, P371, DOI 10.1007/BF01538668; Kuraguchi M, 2000, ONCOGENE, V19, P5755, DOI 10.1038/sj.onc.1203962; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Li GM, 1999, ONCOL RES, V11, P393; Liu HB, 2000, GENETICS, V154, P503; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; LOEB LA, 1991, CANCER RES, V51, P3075; Luria SE, 1943, GENETICS, V28, P491; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; O'Driscoll M, 1999, CARCINOGENESIS, V20, P799, DOI 10.1093/carcin/20.5.799; Ohzeki S, 1997, CARCINOGENESIS, V18, P1127, DOI 10.1093/carcin/18.6.1127; PARSONS R, 1995, CANCER RES, V55, P5548; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Phear G, 1996, MOL CELL BIOL, V16, P6516; Rose JA, 2000, CANCER RES, V60, P3404; Schmutte C, 1998, BIOL CHEM, V379, P377; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Strauss BS, 2000, MUTAT RES-FUND MOL M, V457, P93, DOI 10.1016/S0027-5107(00)00135-4; Strauss BS, 1998, GENETICS, V148, P1619; Strauss BS, 1997, CARCINOGENESIS, V18, P1445, DOI 10.1093/carcin/18.8.1445; Strauss BS, 1998, SEMIN CANCER BIOL, V8, P431, DOI 10.1006/scbi.1998.0092; Takeuchi S, 1998, CANCER RES, V58, P641; Tobi SE, 1999, CARCINOGENESIS, V20, P1293, DOI 10.1093/carcin/20.7.1293; Tomita-Mitchell A, 2000, MUTAT RES-FUND MOL M, V450, P125, DOI 10.1016/S0027-5107(00)00020-8; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; TURKER M, 1995, MUTAT RES-FUND MOL M, V329, P97, DOI 10.1016/0027-5107(95)00046-L; Turker MS, 1998, SEMIN CANCER BIOL, V8, P407, DOI 10.1006/scbi.1998.0112; Turker MS, 1999, CANCER RES, V59, P1837; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	57	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1768	1776		10.1038/sj.onc.1205241	http://dx.doi.org/10.1038/sj.onc.1205241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896608				2022-12-28	WOS:000174214200015
J	Liberto, M; Cobrinik, D; Minden, A				Liberto, M; Cobrinik, D; Minden, A			Rho regulates p21(CIP1) cyclin D1, and checkpoint control in mammary epithelial cells	ONCOGENE			English	Article						Rho; p21(CIP1); cyclin D1; MCF10A; epithelial cells	ADP-RIBOSYLATION; CDC42 GTPASES; DBL FAMILY; EXPRESSION; KINASE; RAC; TRANSFORMATION; ACTIVATION; OVEREXPRESSION; GROWTH	The small GTPase Rho is important for cell cycle progression and Ras transformation in fibroblasts. However, it is unclear whether Rho is needed for proliferation in other cell types, and its targets in promoting normal cell cycle progression are unknown. Here, we demonstrate that Rho is required for G1 to S progression in MCF10A mammary epithelial cells, both in response to EGF and in response to oncogenic Ras. We describe two effects of Rho, the repression of p21(CIP1) and the induction of cyclin D1, that may underlie its role in promoting S phase entry. The Rho inhibitor, C3 exotransferase, induced p21(CIP1) both in EGF-stimulated and V12Ras-expressing cells. In addition, C3 blocked EGF-stimulated cyclin D1 promoter activity whereas V14RhoA induced the cyclin D1 promoter and cooperated with V12Ras in cyclin D1 induction. Finally, a high proportion of cells co-expressing V14RhoA and V12Ras displayed lobulated, polyploid nuclei that were actively synthesizing DNA. Our results demonstrate that Rho plays a fundamental role in promoting Ras-dependent S phase entry in mammary epithelial cells, whether in response to normal or oncogenic signaling, and indicate that in cells expressing oncogenic Ras, the activation of Rho diminishes p21(CIP1) expression, increases cyclin D1 promoter activity, and uncouples DNA synthesis from mitosis.	Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Sherman Fairchild Ctr, New York, NY 10027 USA	Columbia University; Columbia University	Cobrinik, D (corresponding author), Columbia Univ, Coll Phys & Surg, 650 W 168th St,BB20-09, New York, NY 10032 USA.	dc197@columbia.edu; agm24@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA076342] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76342] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GILLETT C, 1994, CANCER RES, V54, P1812; GUDAS J, 1995, ONCOGENE, V11, P253; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KHOSRAVIFAR R, 1997, ADV CANCER RES, V72, P72; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; LI Y, 1994, ONCOGENE, V9, P2261; Liberto M, 2000, CANCER LETT, V154, P151, DOI 10.1016/S0304-3835(00)00378-5; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MICHIELI P, 1994, CANCER RES, V54, P3391; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; SOULE HD, 1990, CANCER RES, V50, P6075; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Tombes RM, 1998, BIOCHEM J, V330, P1451; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VAN AL, 1997, GENE DEV, V11, P2295; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhou P, 1996, CANCER RES, V56, P36	48	53	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1590	1599		10.1038/sj.onc.1205242	http://dx.doi.org/10.1038/sj.onc.1205242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896588				2022-12-28	WOS:000173956800015
J	Mahmud, DL; G-Amlak, M; Deb, DK; Platanias, LC; Uddin, S; Wickrema, A				Mahmud, DL; G-Amlak, M; Deb, DK; Platanias, LC; Uddin, S; Wickrema, A			Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells	ONCOGENE			English	Article						forkhead transcription factors; erythropoietin; stem cell factor; acetylation; p300	CREB-BINDING PROTEIN; FACTOR GATA-1; KINASE; ACTIVATION; AKT; SIGNALS; DEATH; SURVIVAL; PATHWAY; FKHRL1	The mammalian forkhead transcription factors, FOXO3a (FKHRL1), FOXO1a (FKHR) and FOXO4 (AFX) are negatively regulated by PKB/Akt kinase. In the present study we examined the engagement of forkhead family of transcription factors in erythropoietin (Epo)- and stem cell factor (SCF)-mediated signal transduction. Our data show that all three forkhead family members, FOXO3a, FOXO1a and FOXO4 are phosphorylated in human primary erythroid progenitors. Experiments performed to determine various upstream signaling pathways contributing to phosphorylation of forkhead family members show that only PI-3-kinase pathway is required for inactivation of FOXO3a. Our data also demonstrate that during Epo deprivation FOXO3a interacts with the transcriptional coactivator p300 and such interaction is disrupted by stimulation of cells with Epo. To determine the domains in FOXO3a, mediating its interaction with p300, we performed GST pull-down assays and found that the N-terminus region containing the first 52 amino acids was sufficient for binding p300. Finally, our data demonstrate that FOXO3a and FOXO1a are acetylated during growth factor deprivation and such acetylation is reversed by stimulation with Epo. Thus mammalian forkhead transcription factors are involved in Epo and SCF signaling in primary erythroid progenitors and may play a role in the induction of apoptotic and mitogenic signals.	Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Illinois, Med Ctr, Chicago, IL USA	University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wickrema, A (corresponding author), Univ Chicago, Hematol Oncol Sect, MC 2115,5841 S Maryland Ave, Chicago, IL 60637 USA.	Awickrem@medicine.bsd.uchicago.edu		Uddin, Shahab/0000-0003-1886-6710				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Kaestner KH, 2000, GENE DEV, V14, P142; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; Lee A, 1996, INT J OPER PROD MAN, V16, P12, DOI 10.1108/01443579610119063; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Tanaka M, 2001, J BIOL CHEM, V276, P15082, DOI 10.1074/jbc.M007958200; Uddin S, 2000, BIOCHEM BIOPH RES CO, V275, P16, DOI 10.1006/bbrc.2000.3266; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000	33	89	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1556	1562		10.1038/sj.onc.1205230	http://dx.doi.org/10.1038/sj.onc.1205230			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896584				2022-12-28	WOS:000173956800011
J	Ala-Aho, R; Grenman, R; Seth, P; Kahari, VM				Ala-Aho, R; Grenman, R; Seth, P; Kahari, VM			Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells	ONCOGENE			English	Article						p53; collagenase; matrix metalloproteinase; squamous cell carcinoma	WILD-TYPE; MATRIX METALLOPROTEINASES; MESSENGER-RNA; HUMAN HEAD; GROWTH; CANCER; KERATINOCYTES; ACTIVATION; APOPTOSIS; PROMOTER	Squamous cell carcinomas (SCCs) of the head and neck are characterized by high tendency to invade locally and metastasize to lymph nodes. SCC cells express several matrix metalloproteinases (MMPs) and they often harbor mutations in p53 tumor suppressor gene. Collagenase-3 (MMP-13) is specifically expressed by tumor cells of SCCs and it apparently plays an important role in their invasion and metastasis. We used adenoviral gene delivery to examine the effect of wild-type p53 on MMP-13 expression in four head and neck SCC cell lines with mutated p53. Adenoviral delivery of p53 resulted in potent inhibition in production of proMMP-13 (by 71 to 92%) and collagenase-1 (MMP-1) (by 27 to 93%) by all cell lines in 24 h, whereas production of gelatinase-A (MMP-2) and gelatinase-B (MMP-9) was not altered. Adenoviral expression of p53 also suppressed invasion of SCC cells through Matrigel by 35%. Expression of cyclin-dependent kinase inhibitor p21(Waf1/Cip1) was induced 24 h after p53 gene delivery in all SCC cell lines, except one, which lacked detectable p21(Waf1/Cip1) expression. Number of viable cells was not altered and no apoptotic cells were seen 24 h after p53 delivery. These results show, that wild-type p53 potently inhibits expression of MMP-13 and MMP-1 by SCC cells independently of its pro-apoptotic effect. Together there results indicate, that p53 exerts a bi-phasic tumor suppressor effect on SCC cells: inhibition of cell invasion followed by induction of programmed cell death.	Univ Turku, Dept Med Biochem, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, FIN-20520 Turku, Finland; Des Moines Univ, Univ Res, Des Moines, IA 50312 USA; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; University of Turku; University of Turku	Kahari, VM (corresponding author), Univ Turku, Dept Med Biochem, Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Kahari, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368				Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Ala-Aho R, 2002, INT J CANCER, V97, P283, DOI 10.1002/ijc.1619; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bostrom PJ, 2000, INT J CANCER, V88, P417, DOI 10.1002/1097-0215(20001101)88:3<417::AID-IJC14>3.3.CO;2-7; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clayman GL, 1999, CLIN CANCER RES, V5, P1715; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; Eicheler W, 2002, J HISTOCHEM CYTOCHEM, V50, P197, DOI 10.1177/002215540205000207; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Etoh T, 2000, GUT, V47, P50, DOI 10.1136/gut.47.1.50; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Heppner KJ, 1996, AM J PATHOL, V149, P273; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Johansson N, 2000, J CELL SCI, V113, P227; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Nikkola J, 2001, MELANOMA RES, V11, P157, DOI 10.1097/00008390-200104000-00011; OGRADY RL, 1984, ANAL BIOCHEM, V140, P490, DOI 10.1016/0003-2697(84)90199-4; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PYKE C, 1992, CANCER RES, V52, P1336; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Servomaa K, 1996, CELL PROLIFERAT, V29, P219, DOI 10.1046/j.1365-2184.1996.01009.x; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	58	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1187	1195		10.1038/sj.onc.1205198	http://dx.doi.org/10.1038/sj.onc.1205198			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850838				2022-12-28	WOS:000173729400006
J	Bluteau, O; Beaudoin, JC; Pasturaud, P; Belghiti, J; Franco, D; Bioulac-Sage, P; Laurent-Puig, P; Zucman-Rossi, J				Bluteau, O; Beaudoin, JC; Pasturaud, P; Belghiti, J; Franco, D; Bioulac-Sage, P; Laurent-Puig, P; Zucman-Rossi, J			Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping	ONCOGENE			English	Article						hepatocellular carcinoma; loss of heterozygosity; chromosome 4; mutation; alcohol intake	PRIMARY LIVER-CANCER; MUTATIONS; PROTEIN; GENE; HETEROZYGOSITY; DISEASE; 4Q	One of the most frequent deletions in hepatocellular carcinoma (HCC) is that involving the long arm of chromosome 4 (30 to 70% of the cases). These chromosomal deletions are closely related to hepatitis B virus (HBV) infection. A tumor suppressor gene (TSG) located on 4q has been proposed in liver carcinogenesis, but has not been identified as yet. Despite previous LOH studies focused on 4q in HCC, a clear minimal common region of deletion (MCRD) could not be delimited. To further investigate the role of chromosome 4q LOH in the pathogenesis of HCC, 85 microsatellite markers spanning chromosome 4q were systematically analysed in a series of 154 well-characterized primary liver tumors. In 59 tumors (38%), LOHs were observed for at least two adjacent markers. Analysis of 31 tumors demonstrating a partial or interstitial 4q deletion allowed to define three MCRDs of 15, 9 and 8 Mb at the 4q22, 4q34 and 4q35 regions, respectively. Seven putative candidate genes located in 4q22, DAPP1, BMPR1B, PKD2, HERC3, SMARCAD1, CEB1 and ENH were screened for mutations but no somatic alterations were identified. Search for relationships between the specific regions of deletion and clinical parameters showed a significant association between loss of the 4q34-35 region with alcohol intake (P=0.005) and with high grade of differentiation (P=0.02). These results are in contrast with the close association between HBV infection and the whole 4q LOH and reveal heterogeneity of 4q LOH in relation to different risk factors. In the light of these new findings, which link different 4q LOH regions to different etiologic factors, the molecular mechanisms underlying 4q deletions in HCC and the targeted gene(s) remain to be identified.	Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Hop Beaujon, F-92110 Clichy, France; Hop Antoine Beclere, F-92140 Clamart, France; Hop Pellegrin, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; CHU Bordeaux	Zucman-Rossi, J (corresponding author), Ctr Etud Polymorphisme Humain, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.	Zucman@cephb.fr	Laurent-Puig, Pierre/K-3641-2019; zucman-rossi, Jessica/B-5098-2009; Bluteau, Olivier/T-9907-2017; laurent-puig, pierre/B-2226-2013; bluteau, olivier/A-8844-2008	Laurent-Puig, Pierre/0000-0001-8475-5459; zucman-rossi, Jessica/0000-0002-5687-0334; Bluteau, Olivier/0000-0002-6943-8858; laurent-puig, pierre/0000-0001-8475-5459; 				Adra CN, 2000, GENOMICS, V69, P162, DOI 10.1006/geno.2000.6281; Bando K, 1999, GENE CHROMOSOME CANC, V25, P284, DOI 10.1002/(SICI)1098-2264(199907)25:3<284::AID-GCC11>3.0.CO;2-I; Bluteau O, 1999, GASTROEN CLIN BIOL, V23, P1225; Boige V, 1997, CANCER RES, V57, P1986; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Cruz C, 2001, FEBS LETT, V488, P74, DOI 10.1016/S0014-5793(00)02371-1; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Marchio AS, 2000, ONCOGENE, V19, P3733, DOI 10.1038/sj.onc.1203713; Mitsui K, 1999, BIOCHEM BIOPH RES CO, V266, P115, DOI 10.1006/bbrc.1999.1777; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Piao Z, 1998, INT J CANCER, V79, P356, DOI 10.1002/(SICI)1097-0215(19980821)79:4<356::AID-IJC8>3.0.CO;2-U; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Wong N, 2000, CLIN CANCER RES, V6, P4000; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; ZHANG X, 1994, CANCER RES, V54, P4177	27	49	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1225	1232		10.1038/sj.onc.1205197	http://dx.doi.org/10.1038/sj.onc.1205197			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850842				2022-12-28	WOS:000173729400010
J	Le Bras, M; Delattre, V; Bensaad, K; Blandino, G; Soussi, T				Le Bras, M; Delattre, V; Bensaad, K; Blandino, G; Soussi, T			Monoclonal antibodies raised against Xenopus p53 interact with human p73	ONCOGENE			English	Article						p53; p73; antibodies; xenopus laevis	PROTEIN; MUTATIONS; DOMAIN	The p53 tumor suppressor gene belongs to a multigene family that includes two paralogues, p63 and p73. The structure of the p63 and p73 genes is quite similar, but both have common activities with p53, such as DNA binding and transactivation. Both p53 and p73 bind to mdm2, but only p53 is degraded through the activity of mdm2. p63 neither binds to nor is degraded by mdm2 despite important conservation in the key interacting residues. Using a panel of monoclonal antibodies raised against human and Xenopus p53, we have been able to find several antibodies that cross-react strongly with human p73. These antibodies react both with exogenous p73 expressed in mammalian cells and with endogenous p73. Interestingly, all these antibodies react with the same epitope localized in the amino-terminus of p53, but have no cross-reaction with p63. This epitope corresponds to the exact mdm2 binding site to p53. These antibodies inhibit the interaction between either p53 or p73 and mdm2, and may be useful tools for the study of these proteins. Furthermore, our studies suggest that there exist specific spatial requirements for the interaction between p53 or p73 and mdm2.	Inst Curie, Lab Genotoxicol Tumeurs, F-75005 Paris 05, France; Univ Paris 06, F-75005 Paris, France; Mol Oncogenesis Lab, I-00158 Rome, Italy	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite	Soussi, T (corresponding author), Inst Curie, Lab Genotoxicol Tumeurs, 26 Rue Ulm, F-75005 Paris 05, France.		Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241; soussi, thierry/0000-0001-8184-3293; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591				Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Portefaix JM, 2000, J IMMUNOL METHODS, V244, P17, DOI 10.1016/S0022-1759(00)00246-5; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Tominaga O, 2001, BRIT J CANCER, V84, P57, DOI 10.1054/bjoc.2000.1542; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127	15	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1304	1308		10.1038/sj.onc.1205189	http://dx.doi.org/10.1038/sj.onc.1205189			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850851				2022-12-28	WOS:000173729400019
J	Lebedeva, IV; Su, ZZ; Chang, Y; Kitada, S; Reed, JC; Fisher, PB				Lebedeva, IV; Su, ZZ; Chang, Y; Kitada, S; Reed, JC; Fisher, PB			The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells	ONCOGENE			English	Article						melanoma differentiation associated gene-7; tumor suppressor cell cycle; cancer specific cytokine; gene therapy; BCL-family	DIFFERENTIATION-ASSOCIATED GENE; TERMINAL DIFFERENTIATION; NUDE-MICE; IN-VITRO; EXPRESSION; PROGRESSION; DNA; INHIBITOR; CLONING; ARREST	Human melanoma cells growth arrest irreversibly, lose tumorigenic potential and terminally differentiate after treatment with a combination of fibroblast interferon (IFN-beta) and the protein kinase C activator mezerein (MEZ). Applying subtraction hybridization to this model differentiation system permitted cloning of melanoma differentiation associated gene-7, mda-7. Expression of mda-7 inversely correlates with melanoma development and progression, with elevated expression in normal melanocytes and nevi and increasingly reduced expression in radial growth phase, vertical growth phase and metastatic melanoma. When expressed by means of a replication incompetent adenovirus (Ad.mda-7) growth of melanoma, but not normal early passage or immortal human melanocytes, is dramatically suppressed and cells undergo programmed cell death (apoptosis). Infection of metastatic melanoma cells with Ad.mda-7 results in an increase in cells in the G(2)/M phase of the cell cycle and changes in the ratio of pro-apoptotic (BAX, BAK) to anti-apoptotic (BCL-2, BCL-XL) proteins. Ad.mda-7 infection results in a temporal increase in mda-7 mRNA and intracellular MDA-7 protein in most of the melanocyte/melanoma cell lines and secretion of MDA-7 protein is readily detected following Ad.mda-7 infection of both melanocytes and melanoma cells. The present studies document a differential response of melanocytes versus melanoma cells to ectopic expression of mda-7 and support future applications of mda-7 for the gene-based therapy of metastatic melanoma.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Burnham Inst, La Jolla, CA 92037 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Sanford Burnham Prebys Medical Discovery Institute; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, 630 W 168th St,BB-1501, New York, NY 10032 USA.	pbfl@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA035675, R21CA087170] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA87170] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ARMSTRONG BK, 1994, CANCER SURV, V20, P219; Chaiken IM, 1996, TRENDS BIOTECHNOL, V14, P369, DOI 10.1016/0167-7799(96)10050-0; CIRIELLI C, 1995, INT J CANCER, V63, P673, DOI 10.1002/ijc.2910630512; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Ekmekcioglu S, 2001, INT J CANCER, V94, P54, DOI 10.1002/ijc.1437; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; Fechner H, 2000, GENE THER, V7, P1954, DOI 10.1038/sj.gt.3301321; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARPER JW, 1993, CELL, V75, P805; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; Hidaka C, 1999, J CLIN INVEST, V103, P579, DOI 10.1172/JCI5309; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; JIAN Y, 1993, GAIT POSTURE, V1, P1; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1995, ONCOGENE, V11, P1179; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; KERBEL RS, 1984, J NATL CANCER I, V72, P93, DOI 10.1093/jnci/72.1.93; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2; Li DQ, 1999, CLIN CANCER RES, V5, P4175; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; Madireddi MT, 2000, J CELL PHYSIOL, V185, P36, DOI 10.1002/1097-4652(200010)185:1<36::AID-JCP3>3.0.CO;2-V; Madireddi MT, 2000, ONCOGENE, V19, P1362, DOI 10.1038/sj.onc.1203424; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MELBER K, 1989, CANCER RES, V49, P3650; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Pearson AS, 1999, CLIN CANCER RES, V5, P4208; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 1995, ANTICANCER RES, V15, P1841; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VOLKERT FC, 1983, VIROLOGY, V125, P175, DOI 10.1016/0042-6822(83)90072-7; WAXMAN S, 1996, DIFFERENTIATION THER; Wilson MR, 1998, CELL DEATH DIFFER, V5, P646, DOI 10.1038/sj.cdd.4400394; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Yang FC, 2001, SEMIN CANCER BIOL, V11, P261, DOI 10.1006/scbi.2000.0376; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	57	191	227	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					708	718		10.1038/sj.onc.1205116	http://dx.doi.org/10.1038/sj.onc.1205116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850799				2022-12-28	WOS:000173427000002
J	Bren, GD; Solan, NJ; Miyoshi, H; Pennington, KN; Pobst, LJ; Paya, CV				Bren, GD; Solan, NJ; Miyoshi, H; Pennington, KN; Pobst, LJ; Paya, CV			Transcription of the RelB gene is regulated by NF-kappa B	ONCOGENE			English	Article						RelA; RelB; promoter; NF-kappa B; p21WAF1	HUMAN-IMMUNODEFICIENCY-VIRUS; DENDRITIC CELLS; DIFFERENTIAL EXPRESSION; MULTIORGAN INFLAMMATION; B/REL FAMILY; C-MYB; ALPHA; INDUCTION; ACTIVATION; APOPTOSIS	ReA and RelB are two members of the NF-kappaB family that differ structurally and functionally. While RelA is regulated through its cytosolic localization by inhibitor proteins or I kappaB and not through transcriptional mechanisms, the regulation of RelB is poorly understood. In this study we demonstrate that stimuli (TNF or LPS) lead within minutes to the nuclear translocation of RelA, but require hours to result in the nuclear translocation of RelB. The delayed nuclear translocation of RelB correlates with increases in its protein synthesis which are secondary to increases in RelB gene transcription. RelA is alone sufficient to induce RelB gene transcription and to mediate the stimuli-driven increase in RelB transcription. Cloning and characterization of the RelB 5 ' untranslated gene region indicates that RelB transcription is dependent on a TATA-less promoter containing two NF-kappaB binding sites. One of the NF-kappaB sites is primarily involved in the binding of p50 while the other one in the binding and transactivation by RelA and also RelB. Lastly, it is observed that p21, a protein involved in cell cycle control and oncogenesis known to be regulated by NF-kappaB, is upregulated at the transcriptional level by RelB. Thus, RelB is regulated at least at the level of transcription in a RelA and RelB dependent manner and may exert an important role in p21 regulation.	Mayo Clin, Dept Expt Pathol & Lab Med, Rochester, MN 55905 USA; Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Paya, CV (corresponding author), Mayo Clin, Dept Expt Pathol & Lab Med, 200 1st St SW GU501, Rochester, MN 55905 USA.			MacIver, Nancie/0000-0003-3676-9391	NIAID NIH HHS [R01 AI36076] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036076] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammon C, 2000, BIOCHEM BIOPH RES CO, V268, P99, DOI 10.1006/bbrc.1999.2083; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Asin S, 1999, J VIROL, V73, P3893, DOI 10.1128/JVI.73.5.3893-3903.1999; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Ferreira V, 1998, J BIOL CHEM, V273, P592, DOI 10.1074/jbc.273.1.592; Francis DA, 1998, INT IMMUNOL, V10, P285, DOI 10.1093/intimm/10.3.285; HANNINK M, 1990, ONCOGENE, V5, P1843; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Jiang YL, 1998, BIOCHEM BIOPH RES CO, V245, P691, DOI 10.1006/bbrc.1998.8390; Kistler B, 1998, J IMMUNOL, V160, P2308; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; Menetski JP, 2000, J BIOL CHEM, V275, P7619, DOI 10.1074/jbc.275.11.7619; Neumann M, 1996, J IMMUNOL, V157, P4862; Neumann M, 2000, BLOOD, V95, P277; Olashaw NE, 1996, J BIOL CHEM, V271, P30307; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Pettit AR, 1997, J IMMUNOL, V159, P3681; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Suhasini M, 1997, ONCOGENE, V15, P1859, DOI 10.1038/sj.onc.1201530; Suhasini M, 1999, ONCOGENE, V18, P7360, DOI 10.1038/sj.onc.1203158; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Weih F, 1996, J IMMUNOL, V157, P3974; WEIH F, 1994, ONCOGENE, V9, P3289; Weih F, 1996, ONCOGENE, V12, P445; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6	40	162	167	1	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7722	7733		10.1038/sj.onc.1204868	http://dx.doi.org/10.1038/sj.onc.1204868			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753650				2022-12-28	WOS:000172161700003
J	Prathapam, T; Kuhne, C; Banks, L				Prathapam, T; Kuhne, C; Banks, L			The HPV-16 E7 oncoprotein binds Skip and suppresses its transcriptional activity	ONCOGENE			English	Article						human papillomavirus (HPV); oncoproteins; E7; Skip; SNW	HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; MUTATIONAL ANALYSIS; HUMAN KERATINOCYTES; PROTEIN; CELLS; IDENTIFICATION; IMMORTALIZATION; TRANSACTIVATION; ADENOVIRUS-E1A	E7 is the major transforming protein of human papillomavirus (HPV), which is implicated in the development of cervical cancer. The transforming activity of E7 has been attributed in part to its interaction with the retinoblastoma (Rb) tumour suppressor; however, the Rb interaction alone is not sufficient for transformation by E7. In a screen for cellular targets of HPV E7, we identified the Ski interacting protein, Skip, as a new interacting partner of E7. We show that HPV-16 E7 associates with Skip via sequences in its carboxy terminal region, and the evolutionarily conserved proline rich sequences (PRS) of the SNW domain of Skip. E7 functionally targets Skip in vivo and inhibits its transcriptional activation activity. Two transformation defective mutants of E7 were identified that failed both to bind Skip and to inhibit its transcriptional activity. These results suggest that inhibition of Skip function may contribute to cell transformation by HPV-16 E7.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; DURFEE T, 1993, GENE DEV, V7, P55; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; JansenDurr P, 1996, TRENDS GENET, V12, P270, DOI 10.1016/0168-9525(96)81455-7; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASSIMI P, 1997, J GEN VIROL, V78, P2601; MUNGER K, 1989, J VIROL, V63, P4417; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1994, ONCOGENE, V9, P1869; Prathapam T, 2001, NUCLEIC ACIDS RES, V29, P3469, DOI 10.1093/nar/29.17.3469; QUIN XQ, 1992, GENE DEV, V6, P953; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Zhou SF, 2000, J VIROL, V74, P1939, DOI 10.1128/JVI.74.4.1939-1947.2000; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL, P245	32	31	32	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7677	7685		10.1038/sj.onc.1204960	http://dx.doi.org/10.1038/sj.onc.1204960			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753645				2022-12-28	WOS:000172124100010
J	Delhalle, S; Deregowski, V; Benoit, V; Merville, MP; Bours, V				Delhalle, S; Deregowski, V; Benoit, V; Merville, MP; Bours, V			NF-kappa B-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis	ONCOGENE			English	Article						NF-kappa B; TNF-alpha; MnSOD; apoptosis; cancer	MANGANESE SUPEROXIDE-DISMUTASE; NECROSIS-FACTOR-ALPHA; BREAST-CANCER CELLS; NUCLEAR-FACTOR; EPITHELIAL-CELLS; BCL-2 FAMILY; TRANSCRIPTION FACTORS; GENE-EXPRESSION; DOWN-REGULATION; UP-REGULATION	NFkappaB is known to exert a cytoprotective action against TNF-alpha-induced apoptosis. To study the role of NF-kappaB in various TNF-alpha-treated epithelial cell lines, we generated stable transfectants overexpressing a mutated unresponsive form of the IkappaBalpha inhibitor (MT cells), As NF-kappaB prevented TNF-alpha-induced apoptosis in various epithelial cancer cell lines, we searched for NF-kappaB target gene products responsible for this difference of sensitivity. We observed an increased Bcl-X-L expression level in OVCAR-3 cells compared with OVCAR-3 cells expressing a mutated IkappaBalpha inhibitor (MT cells). Induction of the antioxidant enzyme MnSOD was detected only, in TNF-a-treated OVCAR, MCF7A/Z and HCT116 cells but not in MT cells. Moreover, reactive oxygen species were involved in TNF-a-induced apoptosis, as various antioxidants partially protected these cells from apoptosis. At last, transfection of the MnSOD cDNA in MT cells, which do not express this protein after TNF-alpha stimulation, partially restored resistance to TNF-alpha-induced cell death, as observed by clonogenic assays. However, transfection of the Bel-X-L cDNA did not induce any protective effect. Therefore, MnSOD expression is induced by NF-kappaB in epithelial cancer cells in response to TNF-alpha, and is at least partially responsible for their resistance to TNF-alpha-induced apoptosis, presumably through the clearance of death-inducing ROS.	Univ Liege, CHU B35, Ctr Cellular & Mol Therapy, Lab Med Chem & Human Genet, B-4000 Liege, Belgium	University of Liege	Bours, V (corresponding author), Univ Liege, CHU B35, Ctr Cellular & Mol Therapy, Lab Med Chem & Human Genet, Sart Tilman, B-4000 Liege, Belgium.			BENOIT, Valerie/0000-0002-1098-9452				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bernard D, 2001, CANCER RES, V61, P2656; BEYAERT R, 1998, TUMOR NECROSIS FACTO, P335; Bonizzi G, 2000, BIOCHEM PHARMACOL, V59, P7, DOI 10.1016/S0006-2952(99)00290-7; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Fiers W, 1988, Dev Biol Stand, V69, P143; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GIBBS LS, 1992, FREE RADICAL BIO MED, V12, P107, DOI 10.1016/0891-5849(92)90003-Y; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GWINNER W, 1995, KIDNEY INT, V48, P354, DOI 10.1038/ki.1995.303; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; JACOBY DB, 1994, FREE RADICAL BIO MED, V16, P821, DOI 10.1016/0891-5849(94)90198-8; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kifle Y, 1996, J NEUROCHEM, V66, P2128; Kim KH, 2001, ANTIOXID REDOX SIGN, V3, P361, DOI 10.1089/15230860152409013; LARSEN CJ, 1994, ANN GENET-PARIS, V37, P121; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LI JJ, 1995, ONCOGENE, V10, P1989; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; OBERLEY LW, 1979, CANCER RES, V39, P1141; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; VAN AD, 1996, SCIENCE, V274, P787; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Zhao YF, 2001, CANCER RES, V61, P6082; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	56	105	108	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3917	3924		10.1038/sj.onc.1205489	http://dx.doi.org/10.1038/sj.onc.1205489			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032830				2022-12-28	WOS:000175847200011
J	Bisson, SA; Ujack, EE; Robbins, SM				Bisson, SA; Ujack, EE; Robbins, SM			Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line	ONCOGENE			English	Article						E3-ubiquitin ligase; Src-family kinase; J-774; cells; Fc receptors	PHOSPHOTYROSINE-BINDING DOMAIN; GROWTH-FACTOR RECEPTOR; MEDIATED NEGATIVE REGULATION; SRC-FAMILY KINASES; FC-GAMMA-RI; TYROSINE KINASE; SH3 DOMAIN; PROTEIN PRODUCT; DOWN-REGULATION; IN-VIVO	The c-Cbl proto-oncogene acts as an E3 ubiquitin ligase via its RING finger domain to negatively regulate activated cellular signal transduction pathways. We have identified an aberrant Cbl-protein of approximately 95 kDa, which we have called p95Cbl, from the murine reticulum sarcoma cell-line, J-774. Cloning of the p95Cbl cDNA revealed that it contains a deletion resulting in the loss of 111 amino acids, eliminating two critical tyrosine residues in the linker region as well as the entire RING finger domain. p95Cbl displays a propensity for its interaction with the Src-family kinase Hck over cellular Cbl expressed in the same cells. Like its wildtype counterpart, p95Cbl is inducibly tyrosine phosphorylated in response to Fcgamma receptor engagement on hematopoietic cells, however this phosphorylation is sustained beyond that of cellular Cbl. NIH3T3 fibroblasts stably expressing p95Cbl acquire the typical refractile morphology associated with cellular transformation and form colonies in a focus-formation assay. The exogenously expressed mutant protein is constitutively phosphorylated in fibroblasts and partitions into the particulate fraction of cells, while cellular Cbl is exclusively cytoplasmic. p95Cbl is a novel, oncogenic mutant of the c-Cbl proto-oncogene, which might act in a dominant negative fashion to prolong normal cellular signaling responses by interfering with the down-regulation of activated signaling complexes through c-Cbl.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Robbins, SM (corresponding author), Univ Calgary, Dept Oncol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	srobbins@ucalgary.ca		Robbins, Stephen/0000-0001-7475-1665				Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Brizzi MF, 1998, EXP HEMATOL, V26, P1229; COHN M, 1967, COLD SPRING HARB SYM, V32, P211, DOI 10.1101/SQB.1967.032.01.029; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DURDEN DL, 1995, J IMMUNOL, V154, P4039; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Hirst JW, 1971, J IMMUNOL, V107, P926; Horita DA, 1998, J MOL BIOL, V278, P253, DOI 10.1006/jmbi.1998.1690; Howlett CJ, 2002, ONCOGENE, V21, P1707, DOI 10.1038/sj.onc.1205228; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAPLAN G, 1978, EXP CELL RES, V115, P53, DOI 10.1016/0014-4827(78)90401-9; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kuwae A, 2001, J BIOL CHEM, V276, P32230, DOI 10.1074/jbc.M103831200; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1998, ONCOGENE, V16, P3159, DOI 10.1038/sj.onc.1201859; PAIGE CJ, 1978, J IMMUNOL, V121, P641; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; RALPH P, 1975, J IMMUNOL, V114, P898; RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sato N, 1999, J IMMUNOL, V163, P6123; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; Scaife RM, 2000, J CELL SCI, V113, P215; SCHOLT G, 2000, J BIOL CHEM, V273, P14615; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9	59	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3677	3687		10.1038/sj.onc.1205510	http://dx.doi.org/10.1038/sj.onc.1205510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032836				2022-12-28	WOS:000175676000003
J	Gupta, S; Afaq, F; Mukhtar, H				Gupta, S; Afaq, F; Mukhtar, H			Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells	ONCOGENE			English	Article						apigenin; prostate cancer; apoptosis; cell-cycle arrest; chemoprevention; nuclear factor-kappa B (NF-kappa B)	CANCER-CELLS; FLAVONOIDS; GROWTH; INHIBITION; ANTIGEN; GENE; CYCLOOXYGENASE; PROLIFERATION; EXPRESSION; REGULATORS	Apigenin, a common dietary flavonoid abundantly present in fruits and vegetables, may have the potential for prevention and therapy for prostate cancer. Here, we report for the first time that apigenin inhibits the growth of androgen-responsive human prostate carcinoma LNCaP cells and provide molecular understanding of this effect. The cell growth inhibition achieved by apigenin treatment resulted in a significant decrease in AR protein expression along with a decrease in intracellular and secreted forms of PSA. These effects were also observed in DHT-stimulated cells. Further, apigenin treatment of LNCaP cells resulted in G1 arrest in cell cycle progression which was associated with a marked decrease in the protein expression of cyclin D1, D2 and E and their activating partner cdk2, 4 and 6 with concomitant induction of WAFT/p21 and KIP1/p27. The induction of WAFT/p21 appears to be transcriptionally upregulated and is p53 dependent. In addition, apigenin inhibited the hyperphosphorylation of the pRb protein in these cells. Apigenin treatment also resulted in induction of apoptosis as determined by DNA fragmentation, PARP cleavage, fluorescence microscopy and flow cytometry. These effects were found to correlate with a shift in Bax/Bcl-2 ratio more towards apoptosis. Apigenin treatment also resulted in down-modulation of the constitutive expression. of NF-kappaB/p65. Taken together, these findings suggest that apigenin has strong potential for development as an agent for prevention against prostate cancer.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Inst Res, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland	Gupta, S (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.	gxs44@po.cwru.edu		Gupta, Sanjay/0000-0002-9492-3249	NATIONAL CANCER INSTITUTE [R01CA078809] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA 78809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ahmad N, 1999, ONCOGENE, V18, P1891, DOI 10.1038/sj.onc.1202493; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Birt DF, 1997, ANTICANCER RES, V17, P85; BIRT DF, 1998, CHEMOPREVENTION CANC, P1263; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5; CHAUMONTET C, 1994, CARCINOGENESIS, V15, P2325, DOI 10.1093/carcin/15.10.2325; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Duthie G, 2000, CURR OPIN LIPIDOL, V11, P43, DOI 10.1097/00041433-200002000-00007; Fotsis T, 1998, BAILLIERE CLIN ENDOC, V12, P649, DOI 10.1016/S0950-351X(98)80009-8; Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672; HENTTU P, 1990, INT J CANCER, V45, P654, DOI 10.1002/ijc.2910450414; Herness EA, 2001, FRONT BIOSCI-LANDMRK, V6, pD1083, DOI 10.2741/Herness; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hollman PCH, 1999, FREE RADICAL RES, V31, pS75, DOI 10.1080/10715769900301351; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Kim HP, 1998, PROSTAG LEUKOTR ESS, V58, P17, DOI 10.1016/S0952-3278(98)90125-9; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; KUO ML, 1994, CANCER LETT, V87, P91, DOI 10.1016/0304-3835(94)90414-6; KUO ML, 1992, MUTAT RES, V270, P87, DOI 10.1016/0027-5107(92)90119-M; Lamb DJ, 2001, VITAM HORM, V62, P199, DOI 10.1016/S0083-6729(01)62005-3; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lee JI, 1998, J CLIN PHARMACOL, V38, P981, DOI 10.1177/009127009803801101; Lepley DM, 1997, MOL CARCINOGEN, V19, P74, DOI 10.1002/(SICI)1098-2744(199707)19:2<74::AID-MC2>3.0.CO;2-L; Lepley DM, 1996, CARCINOGENESIS, V17, P2367, DOI 10.1093/carcin/17.11.2367; Liang YC, 1999, CARCINOGENESIS, V20, P1945, DOI 10.1093/carcin/20.10.1945; Masciullo V, 2000, INT J ONCOL, V17, P897; McVean M, 2000, CARCINOGENESIS, V21, P633, DOI 10.1093/carcin/21.4.633; Meyers FJ, 1998, CANCER, V83, P2534, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.3.CO;2-M; MIDDLETON E, 1984, TRENDS PHARMACOL SCI, V5, P335; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Mueller A, 1997, CANCER RES, V57, P5542; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Panes Julian, 1996, Microcirculation (Philadelphia), V3, P279, DOI 10.3109/10739689609148302; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Sandhu C, 2000, CANCER DETECT PREV, V24, P107; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; Takahashi T, 1998, BIOSCI BIOTECH BIOCH, V62, P2199, DOI 10.1271/bbb.62.2199; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LG, 1997, CANCER RES, V57, P714; Wang WQ, 2000, MOL CARCINOGEN, V28, P102; WEI HC, 1990, CANCER RES, V50, P499; Yin F, 2001, ANTICANCER RES, V21, P413; Yin F, 1999, THYROID, V9, P369, DOI 10.1089/thy.1999.9.369; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; Zornig M, 2001, BBA-REV CANCER, V1551, pF1, DOI 10.1016/S0304-419X(01)00031-2	51	226	247	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3727	3738		10.1038/sj.onc.1205474	http://dx.doi.org/10.1038/sj.onc.1205474			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032841				2022-12-28	WOS:000175676000008
J	Coll, ML; Rosen, K; Ladeda, V; Filmus, J				Coll, ML; Rosen, K; Ladeda, V; Filmus, J			Increased Bcl-x(L) expression mediates v-Src-induced resistance to anoikis in intestinal epithelial cells	ONCOGENE			English	Article						Bcl-x(L); v-Src; anoikis; intestinal epithelial cells	ADVANCED COLORECTAL CANCERS; BCL-X; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS; DOWN-REGULATION; ACTIVATED RAS; MAP KINASE; TRANSFORMATION; GROWTH; PP60(C-SRC)	Acquisition of resistance to anoikis (detachment-induced apoptosis) is considered to be a requirement for transformed intestinal epithelial cells to invade surrounding tissues and metastasize to distant organs. Increased Src kinase activity, which is a feature of a large proportion of colorectal cancers, has been identified as one of the factors that can contribute to anoikis resistance. However, the molecular mechanism by which high levels of Src activity contribute to anoikis resistance in intestinal epithelial cells is unknown. Here we show that high Src activity confers resistance to anoikis in intestinal epithelial cells, at least in part, by inducing Bcl-x(L) overexpression, and that this induction is mediated by the MEK/MAPK pathway. Based on the findings reported here. and on our previous study showing that Bcl-x(L), plays a critical role in ras-induced resistance to anoikis, we propose that the increased Bel-x(L) levels found in colorectal cancers play a significant role in the induction of resistance to anoikis during the progression of this disease.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Cell & Mol Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Filmus, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Cell & Mol Biol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	filmus@sten.sunnybrook.utoronto.ca		Loza Coll, Mariano/0000-0002-3123-1229; Rosen, Kirill/0000-0002-4317-9907				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Daigo Y, 1999, CANCER RES, V59, P4222; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Grossmann J, 1998, AM J PATHOL, V153, P53, DOI 10.1016/S0002-9440(10)65545-9; Han NM, 1996, CLIN CANCER RES, V2, P1397; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JAMAL HH, 1994, ONCOGENE, V9, P417; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Krajewska M, 1996, CANCER RES, V56, P2422; Laghi L, 2001, BRIT J CANCER, V84, P196, DOI 10.1054/bjoc.2000.1560; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Pories SE, 1998, GASTROENTEROLOGY, V114, P1287, DOI 10.1016/S0016-5085(98)70435-4; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200	41	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2908	2913		10.1038/sj.onc.1205388	http://dx.doi.org/10.1038/sj.onc.1205388			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973652				2022-12-28	WOS:000175063700017
J	Chesire, DR; Ewing, CM; Gage, WR; Isaacs, WB				Chesire, DR; Ewing, CM; Gage, WR; Isaacs, WB			In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis	ONCOGENE			English	Article						beta-catenin; prostate cancer; nuclear staining; T cell factor; androgen receptor	ANDROGEN RECEPTOR; CANCER-CELLS; TRANSCRIPTIONAL ACTIVITY; TUMOR-SUPPRESSOR; GENE-EXPRESSION; CARCINOMA CELLS; MAMMARY-GLAND; UP-REGULATION; E-CADHERIN; MUTATIONS	Understanding the molecular etiology of prostate cancer (CaP) progression is paramount for broadening current diagnostic and therapeutic modalities. Current interest in the role of wnt pathway signaling in prostate tumorigenesis was generated with the finding of beta-catenin mutation and corresponding nuclear localization in primary lesions. The recent finding of beta-catenin-induced enhancement of androgen receptor (AR) function potentially ties beta-catenin to key regulatory steps of prostate cell growth, differentiation, and transformation. By immunohistological analysis of metastatic tumors, we detected nuclear beta-catenin in 20% of lethal CaP cases, suggesting a more common role for beta-catenin in advanced disease than would be predicted by its mutation rate. Interestingly, beta-catenin nuclear localization was found to occur concomitantly with androgen-induced regrowth of normal rat prostate. These in vivo observations likely implicate beta-catenin involvement in both normal and neoplastic prostate physiology, thus prompting our interest in further characterizing modes of beta-catenin signaling in prostate cells. Extending our previous findings, we demonstrate that transient beta-catenin over-expression stimulates T cell factor (TCF) signaling in most CaP cell lines. Further, this activity is not subject to cross- regulation by phosphoinositide-3-kinase (PI3-K)/Akt signaling, a stimulatory pathway often upregulated in CaP upon PTEN inactivation. Consistent with a previous report, we observed that transient beta-catenin overexpression enhances AR-mediated transcription off two natural target gene promoters. However, we were unable to recapitulate beta-catenin-induced stimulation of ectopically expressed AR in AR-negative cells, suggesting that other AR-associated factors are required for this activity. Although LNCaP cells are capable of this mode of AR co-stimulation, stable expression of mutant beta-catenin did not alter their proliferative response to androgen. In total, our characterization of beta-catenin signaling in CaP reveals the complex nature of its activity in prostate tissue, indicating that beta-catenin potentially contributes to multiple stimulatory inputs required for disease progression.	Johns Hopkins Med Inst, Brady Urol Inst Res Labs, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Isaacs, WB (corresponding author), Johns Hopkins Univ Hosp, Dept Urol, Marburg 115,600 N Wolfe St, Baltimore, MD 21287 USA.	wisaacs@mail.jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER; NCI NIH HHS [CA58236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Bubendorf L, 1999, CANCER RES, V59, P803; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cude KJ, 1999, J MOL MED, V77, P419, DOI 10.1007/s001090050372; Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I; CULIG Z, 1994, CANCER RES, V54, P5474; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Duval A, 2000, CANCER RES, V60, P3872; Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hayes SA, 2001, CANCER RES, V61, P2112; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; Kinoshita H, 2000, CANCER RES, V60, P3623; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; KYPRIANOU N, 1987, PROSTATE, V11, P41, DOI 10.1002/pros.2990110106; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Linja MJ, 2001, CANCER RES, V61, P3550; LUKE MC, 1994, J ANDROL, V15, P41; Luo J, 2001, CANCER RES, V61, P4683; McDonald S, 2000, CANCER RES, V60, P2317; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miyazawa K, 2000, VIRCHOWS ARCH, V437, P508, DOI 10.1007/s004280000283; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Park WS, 1999, CANCER RES, V59, P4257; Planz B, 1998, J UROLOGY, V160, P1850, DOI 10.1016/S0022-5347(01)62431-5; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDFORD NL, 1984, PATHOLOGY, V16, P406, DOI 10.3109/00313028409084731; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shih IM, 2000, CANCER RES, V60, P1671; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tindall DJ, 1999, PROSTATE, V38, P166, DOI 10.1002/(SICI)1097-0045(19990201)38:2<166::AID-PROS11>3.0.CO;2-A; Truica CI, 2000, CANCER RES, V60, P4709; UMBAS R, 1992, CANCER RES, V52, P5104; van Bokhoven A, 2001, CANCER RES, V61, P6340; Voeller HJ, 1998, CANCER RES, V58, P2520; Wen Y, 2000, CANCER RES, V60, P6841; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhu AJ, 1999, DEVELOPMENT, V126, P2285; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	73	143	148	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2679	2694		10.1038/sj.onc.1205352	http://dx.doi.org/10.1038/sj.onc.1205352			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965541				2022-12-28	WOS:000174996500008
J	Kontou, M; Adelfalk, C; Ramirez, MH; Ruppitsch, W; Hirsch-Kauffmann, M; Schweiger, M				Kontou, M; Adelfalk, C; Ramirez, MH; Ruppitsch, W; Hirsch-Kauffmann, M; Schweiger, M			Overexpressed thioredoxin compensates Fanconi anemia related chromosomal instability	ONCOGENE			English	Article						Fanconi anemia; thioredoxin; oxidoreduction potential	REDOX REGULATION; TRANSCRIPTION FACTOR; ACTIVATION; CELLS; ANTIOXIDANTS; SECRETION; PREVENTS; PROTEINS	The cause of the molecular defect of Fanconi anemia (FA) remains unknown. Cells from patients with FA exert an elevated spontaneous chromosomal instability which is further triggered by mitomycin C. The induced lability is reduced by overexpression of thioredoxin which is not the case for spontaneous instability. However, both are eliminated by overexpression of thioredoxin cDNA with an added nuclear localization signal. This implies that thioredoxin is lacking in the nuclei of FA cells. The total thioredoxin content in all FA cells tested is reduced. The resultant lack of nuclear thioredoxin can be the explanation for the major symptomatology in FA. Since thioredoxin is known to be the reactive cofactor of ribonucleotid reductase its shortcoming reduces the supply of deoxyribonucleotides thus hindering the DNA and replication repair with resultant chromosomal breaks. Furthermore, depression of tyrosine hydroxylase, the key enzyme of melanine synthesis, could be the basis for the pathognomotic 'cafe au lait' spots of FA. The observation of thioredoxin reduction in FA cells permits insight into the molecular phathophysiology of FA.	Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Univ Innsbruck, Inst Med Biol & Humangenet, A-6020 Innsbruck, Austria	Free University of Berlin; University of Innsbruck	Schweiger, M (corresponding author), Free Univ Berlin, Inst Biochem, Thielallee 63, D-14195 Berlin, Germany.	mschweig@chemie.fu-berlin.de	Ruppitsch, Werner/AAC-9295-2019	Ruppitsch, Werner/0000-0001-9940-3333				ALTER BP, 1993, BRIT J HAEMATOL, V85, P9, DOI 10.1111/j.1365-2141.1993.tb08638.x; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; DALLAPICCOLA B, 1985, HUM GENET, V69, P62, DOI 10.1007/BF00295530; Fanconi G., 1927, JAHRB KINDERHEILK, V117, P257; FUJII S, 1991, VIRCHOWS ARCH A, V419, P317, DOI 10.1007/BF01606523; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GILLE JJP, 1987, HUM GENET, V77, P28; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; JOENJE H, 1981, NATURE, V290, P142, DOI 10.1038/290142a0; KORKINA LG, 1992, J LEUKOCYTE BIOL, V52, P357, DOI 10.1002/jlb.52.3.357; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Oliveira L, 1999, J BIOL CHEM, V274, P516, DOI 10.1074/jbc.274.1.516; Ramirez MH, 1999, BIOCHEM BIOPH RES CO, V264, P518, DOI 10.1006/bbrc.1999.1482; RUBARTELLI A, 1995, CANCER RES, V55, P675; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; Ruppitsch W, 1997, HUM GENET, V99, P710, DOI 10.1007/s004390050437; Ruppitsch W, 1998, FEBS LETT, V422, P99, DOI 10.1016/S0014-5793(97)01608-6; SAMBROOK J, 1989, MOL CLONING LAB MANU, P712; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHINDLER D, 1988, AM J HUM GENET, V43, P429; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sittler A, 1996, HUM MOL GENET, V5, P95, DOI 10.1093/hmg/5.1.95; WOOD JM, 1991, BIOCHIM BIOPHYS ACTA, V1074, P378, DOI 10.1016/0304-4165(91)90088-X	26	26	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2406	2412		10.1038/sj.onc.1205299	http://dx.doi.org/10.1038/sj.onc.1205299			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948424				2022-12-28	WOS:000174635600013
J	Bartholin, L; Maguer-Satta, V; Hayette, S; Martel, S; Badoux, M; Corbo, L; Magaud, JP; Rimokh, R				Bartholin, L; Maguer-Satta, V; Hayette, S; Martel, S; Badoux, M; Corbo, L; Magaud, JP; Rimokh, R			Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function	ONCOGENE			English	Article						FLRG; follistatin; activin; TGF beta; Smad	BONE MORPHOGENETIC PROTEINS; BINDING-PROTEIN; TGF; CELL; EXPRESSION; PROMOTER; RECEPTOR; GROWTH; GENE; ANTAGONIST	Signaling of TGFbeta family members such as activin is tightly regulated by soluble binding proteins. Follistatin binds to activin A with high affinity, and prevents activin binding to its own receptors, thereby blocking its signaling. We previously identified FLRG gene from a B-cell leukemia carrying a t(11;19)(q13;p13) translocation. We and others have already shown that FLRG, which is highly homologous to follistatin, may be involved in the regulation of the activin function through its binding to activin. In this study, we found that, like follistatin, FLRG protein inhibited activin A signaling as demonstrated by the use of a transcriptional reporter assay, and blocked the activin A-induced growth inhibition of HepG2 cells. We have recently shown that the TGFbeta-induced expression of FLRG occurs at a transcriptional level through the action of Smad proteins. Here we show that activin A increases FLRG and follistatin at both the mRNA and protein levels. We found that Smad proteins are involved in the activin A-induced transcription activation of FLRG and follistatin. Finally we demonstrate that FLRG protein regulates its own activin-induced expression. In conclusion, activin A induces FLRG and follistatin expression. This observation, in conjunction with the antagonistic effect of FLRG and follistatin on activin signaling, indicates that these two proteins participate in a negative feedback loop which regulates the activin function.	Hop Edouard Herriot, Lab Cytogenet Mol, F-69437 Lyon, France; Ctr Leon Berard, INSERM U453, F-69373 Lyon, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Rimokh, R (corresponding author), Ctr Leon Berard, INSERM U453, F-69373 Lyon, France.	rimokh@lyon.fnclcc.fr	Bartholin, Laurent/Q-6655-2017; HAYETTE, sandrine/Z-2283-2019; Rimokh, Ruth/G-7506-2014; Maguer-Satta, Veronique/U-8857-2019	Bartholin, Laurent/0000-0002-5637-3223; Maguer-Satta, Veronique/0000-0002-1556-068X				Bartholin L, 2001, ONCOGENE, V20, P5409, DOI 10.1038/sj.onc.1204720; Bitzer M, 2000, GENE DEV, V14, P187; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DePaolo LV, 1997, P SOC EXP BIOL MED, V214, P328; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Gamer LW, 1999, DEV BIOL, V208, P222, DOI 10.1006/dbio.1998.9191; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hayette S, 1998, ONCOGENE, V16, P2949, DOI 10.1038/sj.onc.1201807; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Maguer-Satta V, 2001, EXP HEMATOL, V29, P301, DOI 10.1016/S0301-472X(00)00675-5; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pereira RC, 2000, ENDOCRINOLOGY, V141, P4558, DOI 10.1210/en.141.12.4558; Phillips DJ, 2000, BIOESSAYS, V22, P689, DOI 10.1002/1521-1878(200008)22:8<689::AID-BIES2>3.0.CO;2-5; Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Reddi AH, 2001, ARTHRITIS RES, V3, P1; Russell CE, 1999, MOL CELL ENDOCRINOL, V148, P129, DOI 10.1016/S0303-7207(98)00226-3; SCHWALL RH, 1993, HEPATOLOGY, V18, P347, DOI 10.1016/0270-9139(93)90018-I; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; Smith WC, 1999, TRENDS GENET, V15, P3, DOI 10.1016/S0168-9525(98)01641-2; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsuchida K, 2000, J BIOL CHEM, V275, P40788, DOI 10.1074/jbc.M006114200; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; YAMASHITA T, 1992, BLOOD, V79, P304; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727; Ying SY, 1997, P SOC EXP BIOL MED, V214, P114; Yu J, 1997, CYTOKINES CELL MOL T, V3, P169; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhang YQ, 1997, BBA-GENE STRUCT EXPR, V1354, P204, DOI 10.1016/S0167-4781(97)00085-7	44	68	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2227	2235		10.1038/sj.onc.1205294	http://dx.doi.org/10.1038/sj.onc.1205294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948405				2022-12-28	WOS:000174555300011
J	Schaefer, LK; Ren, ZY; Fuller, GN; Schaefer, TS				Schaefer, LK; Ren, ZY; Fuller, GN; Schaefer, TS			Constitutive activation of Stat3 alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2)	ONCOGENE			English	Article						brain tumor; receptor tyrosine kinase; endothelial cells; VEGF; angiogenesis	GROWTH-FACTOR EXPRESSION; TRANSCRIPTIONAL ACTIVITY; DNA-BINDING; SIGNALING PATHWAY; STAT3 ACTIVATION; SRC; GENE; AMPLIFICATION; INDUCTION; APOPTOSIS	Members of the normally latent family of transcription factors signal/inducers and activators of transcription (Stat) are activated in a number of human tumors and tumor-derived cell lines. In the case of Stat3, it is believed that this activation leads to the induction of survival signals as well as increased proliferation. In this study, we demonstrate that Stat3 is constitutively activated in glioma and medulloblastoma tumors and that the activated protein localizes predominantly to the tumor endothelial cells in the highly vascularized glioma tumors. Our efforts to elucidate potential mechanism(s) for this activated protein have shown that coexpression of Stat3)c and the vascular endothelial growth factor receptor-2 (VEGFR-2) result in ligand-independent activation of Stat3chi tyrosine phosphorylation and subsequent transcriptional activation in non-endothelial cells. We also show that activated Stat3alpha can increase transcription from the vascular endothelial growth factor (VEGF) gene. Taken together, these results suggest that the activated Stat3chi found in brain tumors may be due to the endothelial tyrosine kinase VEGFR-2 and that Stat3chi may play a central role in autocrine VEGF activation.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Schaefer, TS (corresponding author), Box 064,1515 Holcombe Blvd, Houston, TX 77030 USA.	tschaefe@jmdanderson.org		Fuller, Gregory/0000-0001-9447-2647				BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carroll RS, 1999, CANCER-AM CANCER SOC, V86, P1335, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1335::AID-CNCR32>3.0.CO;2-Z; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V131, P207, DOI 10.1016/0006-291X(85)91790-5; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; HATVA E, 1995, AM J PATHOL, V146, P368; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; IJICHI A, 1995, GLIA, V14, P87, DOI 10.1002/glia.440140203; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIBERMANN TA, 1984, CANCER RES, V44, P753; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Ni Z, 2000, CANCER RES, V60, P1225; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Pietsch T, 1997, ACTA NEUROPATHOL, V93, P109, DOI 10.1007/s004010050591; Schaefer LK, 2000, CELL SIGNAL, V12, P143, DOI 10.1016/S0898-6568(99)00077-7; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schaefer LK, 2000, CYTOKINE, V12, P1647, DOI 10.1006/cyto.2000.0774; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHLEGEL J, 1994, INT J CANCER, V56, P72; SCHWECHHEIMER K, 1995, INT J CANCER, V62, P145, DOI 10.1002/ijc.2910620206; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Theurillat JP, 1999, AM J PATHOL, V154, P581, DOI 10.1016/S0002-9440(10)65303-5; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WeberNordt RM, 1996, BLOOD, V88, P809; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Xia Z, 1998, CANCER RES, V58, P3173; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	39	154	167	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2058	2065		10.1038/sj.onc.1205263	http://dx.doi.org/10.1038/sj.onc.1205263			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960378				2022-12-28	WOS:000174827000012
J	Horiguchi, N; Takayama, H; Toyoda, M; Otsuka, T; Fukusato, T; Merlino, G; Takagi, H; Mori, M				Horiguchi, N; Takayama, H; Toyoda, M; Otsuka, T; Fukusato, T; Merlino, G; Takagi, H; Mori, M			Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine	ONCOGENE			English	Article						HGF transgenic; hepatocellular carcinoma; c-Met; diethylnitrosamine; VEGF	FACTOR SCATTER FACTOR; FULMINANT HEPATIC-FAILURE; FACTOR-ALPHA; HEPATOCELLULAR CARCINOMAS; ABNORMAL-DEVELOPMENT; LIVER-REGENERATION; MOLECULAR-CLONING; SOMATIC MUTATIONS; EPITHELIAL-CELLS; GENE-EXPRESSION	Hepatocyte growth factor (HGF) is a mitogen for hepatocytes, but it is not clear whether HGF stimulates or inhibits hepatocarcinogenesis. We previously reported that HGF transgenic mice under the metallothionein gene promoter developed benign and malignant liver tumors spontaneously after 17 months of age. To elucidate the role of HGF in hepatocarcinogenesis, diethylnitrosamine (DEN) was administered to HGF transgenic mice. HGF overexpression accelerated DEN-induced hepatocarcinogenesis, often accompanied by abnormal blood vessel formation. In this study, 59% of transgenic mates (versus 20% of wild-type males) and 39% of transgenic females (versus 2% of wild-type females) developed either benign or malignant liver tumors by 48 weeks (P<0.005, P<0.001, respectively). Moreover, 33% of males and 23% of female transgenic mice developed hepatocellular carcinoma (HCC), while none of the wild-type mice developed HCC (P<0.001, P<0.005, respectively). Enhanced kinase activity of the HGF receptor, Met, was detected in most of these tumors. Expression of vascular endothelial growth factor (VEGF) was up-regulated in parallel with HGF transgene expression. Taken together, our results suggest that HGF promotes hepatocarcinogenesis through the autocrine activation of the HGF-Met signaling pathway in association with stimulation of angiogenesis by HGF itself and/or indirectly through VEGF.	Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan; Gunma Univ, Sch Med, Div Diagnost Pathol, Gunma 3718511, Japan; NCI, Mol Biol Lab, Bethesda, MD 20892 USA	Gunma University; Gunma University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Takagi, H (corresponding author), Gunma Univ, Sch Med, Dept Internal Med 1, Showa Machi 3-39-15, Gunma 3718511, Japan.							Bell A, 1999, ONCOGENE, V18, P887, DOI 10.1038/sj.onc.1202379; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CRAIG JR, 1989, ATLAS TUMOR PATHOLOG; DErrico A, 1996, HEPATOLOGY, V24, P60, DOI 10.1002/hep.510240112; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; FARBER E, 1987, LAB INVEST, V56, P4; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FUJIWARA K, 1993, HEPATOLOGY, V18, P1443, DOI 10.1016/0270-9139(93)90237-H; Gille J, 1998, J INVEST DERMATOL, V111, P1160, DOI 10.1046/j.1523-1747.1998.00418.x; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HSIA CC, 1992, CANCER, V70, P1049, DOI 10.1002/1097-0142(19920901)70:5&lt;1049::AID-CNCR2820700507&gt;3.0.CO;2-C; ISHIKI Y, 1992, HEPATOLOGY, V16, P1227, DOI 10.1016/0270-9139(92)90019-6; Jeffers M, 1996, ONCOGENE, V13, P853; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kosai K, 1998, BIOCHEM BIOPH RES CO, V244, P683, DOI 10.1006/bbrc.1998.8293; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; LIU ML, 1995, CARCINOGENESIS, V16, P841, DOI 10.1093/carcin/16.4.841; LIU YH, 1993, BIOCHIM BIOPHYS ACTA, V1216, P299, DOI 10.1016/0167-4781(93)90159-B; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Mise M, 1996, HEPATOLOGY, V23, P455; MIYAZAKI M, 1992, CELL BIOL INT REP, V16, P145, DOI 10.1016/S0309-1651(06)80108-6; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Morishita R, 2000, ANN NY ACAD SCI, V902, P369; Moriyama T, 1998, BIOCHEM BIOPH RES CO, V249, P73, DOI 10.1006/bbrc.1998.9078; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Ogasawara H, 1998, GASTROENTEROLOGY, V114, P775, DOI 10.1016/S0016-5085(98)70591-8; Otsuka T, 1998, CANCER RES, V58, P5157; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 1999, CANCER RES, V59, P307; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRESUMANN R, 1988, BIOCH CHEM CARCINOGE, P25; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosen EM, 1997, CIBA F SYMP, V212, P215; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SHIOTA G, 1995, RES COMMUN MOL PATH, V90, P17; Suzuki K, 1996, CANCER RES, V56, P3004; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TAKAGI H, 1992, CANCER RES, V52, P5171; TAKAGI H, 1993, CANCER RES, V53, P4329; Takayama H, 1997, LAB INVEST, V77, P131; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 2001, LAB INVEST, V81, P297, DOI 10.1038/labinvest.3780238; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tuck AB, 1996, AM J PATHOL, V148, P225; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; Van Belle E, 1998, CIRCULATION, V97, P381; WU JC, 1994, CANCER RES, V54, P5964; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; YAONO M, 1995, JPN J CANCER RES, V86, P718, DOI 10.1111/j.1349-7006.1995.tb02459.x; YEH YC, 1987, CANCER RES, V47, P896; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	65	102	120	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1791	1799		10.1038/sj.onc.1205248	http://dx.doi.org/10.1038/sj.onc.1205248			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896611				2022-12-28	WOS:000174284500001
J	Ahmed, N; Niu, J; Dorahy, DJ; Gu, XH; Andrews, S; Meldrum, CJ; Scott, RJ; Baker, MS; Macreadie, IG; Agrez, MV				Ahmed, N; Niu, J; Dorahy, DJ; Gu, XH; Andrews, S; Meldrum, CJ; Scott, RJ; Baker, MS; Macreadie, IG; Agrez, MV			Direct integrin alpha v beta 6-ERK binding: implications for tumour growth	ONCOGENE			English	Article						alpha v beta 6 integrin; colon cancer; ERK2; tumour growth	ACTIVATED PROTEIN-KINASE; SIGNALING PATHWAY; EXPRESSION; CELLS; TRANSDUCTION; SUBUNIT; ALPHA-NU-BETA-6; FIBRONECTIN; SPECIFICITY; ERK	Blockade of the mitogen-activated protein (MAP) kinase pathway suppresses growth of colon cancer in vivo. Here we demonstrate a direct link between the extracellular signal-regulated kinase ERK2 and the growth-promoting cell adhesion molecule, integrin alphavbeta6, in colon cancer cells. Down-regulation of beta6 integrin subunit expression inhibits tumour growth in vivo and MAP kinase activity in response to serum stimulation. In alphavbeta6-expressing cells ERK2 is bound only to the beta6 subunit. The increase in cytosolic MAP kinase activity upon epidermal growth factor stimulation is all accounted for by beta6-bound ERK. Deletion of the ERK2 binding site on the beta6 cytoplasmic domain inhibits tumour growth and leads to an association between ERK and the beta5 subunit. The physical interaction between integrin alphavbeta6 and ERK2 defines a novel paradigm of integrin-mediated signalling and provides a therapeutic target for cancer treatment.	Univ Newcastle, Fac Med & Hlth Sci, Discipline Surg Sci, Newcastle, NSW 2308, Australia; John Hunter Hosp, Hunter Med Res Inst, Newcastle Bowel Canc Res Collaborat, Newcastle, NSW, Australia; Royal Womens Hosp, Gynaecol Canc Res Ctr, Melbourne, Vic, Australia; Univ Melbourne, Melbourne, Vic, Australia; CSIRO Hlth Sci & Nutr, Parkville, Vic, Australia	University of Newcastle; Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle; University of Melbourne; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Agrez, MV (corresponding author), Univ Newcastle, Fac Med & Hlth Sci, Discipline Surg Sci, Newcastle, NSW 2308, Australia.	Michael.Agrez@newcastle.edu.au	Macreadie, Ian/L-4437-2019; Macreadie, Ian/Q-7430-2019; Macreadie, Ian G/F-5997-2010; Scott, Rodney J/B-2827-2013	Macreadie, Ian/0000-0001-5335-7220; Macreadie, Ian G/0000-0001-5335-7220; Scott, Rodney J/0000-0001-7724-3404; Baker, Mark/0000-0001-5858-4035; Meldrum, Cliff/0000-0002-5685-1918				Agrez M, 1999, INT J CANCER, V81, P90, DOI 10.1002/(SICI)1097-0215(19990331)81:1<90::AID-IJC16>3.0.CO;2-K; AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; Agrez MV, 1996, BRIT J CANCER, V73, P887, DOI 10.1038/bjc.1996.158; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Arihiro K, 2000, Breast Cancer, V7, P19, DOI 10.1007/BF02967183; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREUSS JM, 1995, J CELL SCI, V108, P2241; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Duesbery NS, 1999, NAT MED, V5, P736, DOI 10.1038/10457; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hamidi S, 2000, BRIT J CANCER, V82, P1433, DOI 10.1054/bjoc.1999.1130; HEWITT RE, 1991, INT J CANCER, V49, P666, DOI 10.1002/ijc.2910490507; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Johansson N, 2000, J CELL SCI, V113, P227; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Niu J, 2001, INT J CANCER, V92, P40, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1157>3.0.CO;2-B; Partik G, 1999, J CANCER RES CLIN, V125, P379, DOI 10.1007/s004320050290; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; Thomas GJ, 1997, ORAL ONCOL, V33, P381, DOI 10.1016/S0964-1955(97)00021-3; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	37	81	90	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1370	1380		10.1038/sj.onc.1205286	http://dx.doi.org/10.1038/sj.onc.1205286			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857080				2022-12-28	WOS:000173861000007
J	Baldeyron, C; Jacquemin, E; Smith, J; Jacquemont, C; De Oliveira, I; Gad, S; Feunteun, J; Stoppa-Lyonnet, D; Papadopoulo, D				Baldeyron, C; Jacquemin, E; Smith, J; Jacquemont, C; De Oliveira, I; Gad, S; Feunteun, J; Stoppa-Lyonnet, D; Papadopoulo, D			A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining	ONCOGENE			English	Article						BRCA1; DNA repair; double strand break; end-joining fidelity; heterozygous state	HISTONE H2AX; DNA; REPAIR; CANCER; CELLS; COMPLEX; IDENTIFICATION; REARRANGEMENTS; RECOMBINATION; ASSOCIATION	Heterozygosity for mutations in the BRCA1 gene in humans confers high risk for developing breast cancer, but a biochemical basis for this phenotype has not yet been determined. Evidence has accumulated implicating BRCA1, in the maintenance of genomic integrity and the protection of cells against DNA double strand breaks (DSB). Here we present evidence that human cells heterozygous for BRCA1 mutations exhibit impaired DNA end-joining, which is the major DSB repair pathway in mammalian somatic cells. Using an in vivo host cell end-joining assay, we observed that the fidelity of DNA end-joining is strongly reduced in three BRCA1(+/-) cell lines in comparison to two control cell lines. Moreover, cell-free BRCA1(+/-) extracts are unable to promote accurate DNA end-joining in an in vitro reaction. The steady-state level of the wild type BRCA1 protein was significantly lower than the 50% expected in BRCA1(+/-) cells and thus may underlie the observed end-joining defect. Together, these data strongly suggest that BRCA1 is necessary for faithful rejoining of broken DNA ends and that a single mutated BRCA1 allele is sufficient to impair this process. This defect will compromise genomic stability in BRCA1 germ-line mutation carriers, triggering the genetic changes necessary for the initiation of neoplastic transformation.	CNRS, UMR 218, Inst Curie, Sect Rech, F-75248 Paris 05, France; Sect Med, Inst Curie, Serv Genet Oncol, F-75248 Paris 05, France; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Papadopoulo, D (corresponding author), CNRS, UMR 218, Inst Curie, Sect Rech, F-75248 Paris 05, France.	papadopoulo@curie.fr	Feunteun, Jean/AAZ-1267-2020; Baldeyron, Céline/F-6990-2019	Baldeyron, Céline/0000-0003-2311-1523; Feunteun, Jean/0000-0003-1212-9189; GAD (LAPITEAU), Sophie/0000-0002-3158-6791				Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; GOVEN LC, 1998, SCIENCE, V281, P1009; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Le Page F, 2000, CANCER RES, V60, P5548; Lee MS, 2000, ENDOCRINOLOGY, V141, P883, DOI 10.1210/en.141.3.883; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Pluth JM, 2001, CANCER RES, V61, P2649; Puget N, 1999, CANCER RES, V59, P455; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothfuss A, 2000, CANCER RES, V60, P390; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Smith J, 1998, J MOL BIOL, V281, P815, DOI 10.1006/jmbi.1998.1971; Smith J, 2001, NUCLEIC ACIDS RES, V29, P4783, DOI 10.1093/nar/29.23.4783; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; Wang HC, 2001, CANCER RES, V61, P270; Wang Y, 2000, GENE DEV, V14, P927; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	37	92	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1401	1410		10.1038/sj.onc.1205200	http://dx.doi.org/10.1038/sj.onc.1205200			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857083				2022-12-28	WOS:000173861000010
J	Croxton, R; Ma, YH; Song, LX; Haura, EB; Cress, WD				Croxton, R; Ma, YH; Song, LX; Haura, EB; Cress, WD			Direct repression of the Mcl-1 promoter by E2F1	ONCOGENE			English	Article						apoptosis; cell cycle; E2F; Mcl-1; microarray	S-PHASE ENTRY; BCL-2 FAMILY-MEMBER; DNA-SYNTHESIS; RETINOBLASTOMA PROTEIN; SIGNALING PATHWAY; BINDING PROTEIN; STABILIZES P53; CYTOCHROME-C; CELL-DEATH; APOPTOSIS	E2F1 induces apoptosis via both p53-dependent and p53-independent mechanisms. The direct targets in the p53-independent pathway remain enigmatic; however, the induction of this pathway does not require the transactivation domain of E2F1. Using cells that are defective in p53 activation, we show that E2F1 potently represses the expression of Mcl-1 - an anti-apoptotic Bcl-2 family member whose depletion results in apoptosis. We also show that this transcriptional repression is direct and dependent upon E2F1's DNA-binding domain, but does not require the transactivation domain of E2F1. Consistent with this DNA binding requirement of E2F1 to repress Mcl-1, we show that E2F1 binds to the Mcl-1 promoter both in vitro and in vivo, and have identified the DNA element (- 143/ -117) within this promoter that is required for E2F1 binding and repression. Additionally, cell lines constitutively expressing Mcl-1 are resistant to E2F1-mediated apoptosis - suggesting that Mcl-1 downregulation is a necessary event in the p53-independent apoptotic process. Thus, we identify a p53 family-independent mechanism of E2F1-induced apoptosis in which E2F1 directly represses Mcl-1 expression.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Res Inst, Tampa, FL 33612 USA; Univ S Florida, Clin Invest Program, H Lee Moffitt Comprehens Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Inst Biomol Sci, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cress, WD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER; NCI NIH HHS [CA78214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dong YB, 1999, CANCER, V86, P2021, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO;2-1; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsu SY, 2000, PHYSIOL REV, V80, P593, DOI 10.1152/physrev.2000.80.2.593; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; Lomo J, 1996, CANCER RES, V56, P40; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Takahashi Y, 2000, GENE DEV, V14, P804; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yang HL, 2000, CLIN CANCER RES, V6, P1579; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao RB, 2000, GENE DEV, V14, P981; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829	72	123	126	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1359	1369		10.1038/sj.onc.1205157	http://dx.doi.org/10.1038/sj.onc.1205157			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857079				2022-12-28	WOS:000173861000006
J	Aouacheria, A; Ory, S; Schmitt, JR; Rigal, D; Jurdic, P; Gillet, G				Aouacheria, A; Ory, S; Schmitt, JR; Rigal, D; Jurdic, P; Gillet, G			p60(v-src) and serum control cell shape and apoptosis via distinct pathways in quail neuroretina cells	ONCOGENE			English	Article						v-src; cytoskeleton; apoptosis; MAP kinases; G-proteins; retina	FOCAL ADHESION KINASE; PP60C-SRC PROTEIN-KINASE; SRC TYROSINE KINASE; V-SRC; SUBSTRATUM ADHESIONS; SIGNALING PATHWAYS; TRANSFORMATION; RAS; ACTIVATION; RHO	We made use of QNR cells transformed by a thermosensitive (tsNY68) strain of the Rous sarcoma virus (RSV) to compare the effect of p60(v-src) and serum in cultured nerve cells. In this system, both p60(v-src) heat inactivation and serum removal resulted in growth arrest in G1. In both cases, growth arrest was reversible since cell proliferation was rapidly re-induced following respectively p60v-src renaturation or serum re-addition. However, cells did not fully recover their ability to grow in soft agar, suggesting that, in contrast to the cell cycle machinery, the transforming capacities of these cells have been irreversibly altered. We found that p60(v-src) kinase activity prevented detachment from the substratum and cell death following serum removal. Thermal inactivation of p60(v-src) at restrictive temperature (41.5degreesC), but not serum removal, resulted in dramatic morphological changes, which occured 4 h after temperature shift up to 41.5degreesC. Later on, typical features of apoptotic cells could be observed. Cell death was greatly reduced by the caspase-3 inhibitor ZVAD.FMK, but not by the caspase-1 inhibitor Ac-YVAD.CHO. Together, these results suggested that p60(v-src) and serum factors act on distinct pathways, at least in part. In an attempt to identify the signalling pathways involved in the cell response to p60(v-src) down regulation, we found that Erk and Rac were rapidly inactivated following temperature shift up to 41.5degreesC. Thus, the combined effects of p60(v-src) and serum factors on the cytoskeleton dynamics and the apoptosis machinery are essential for full neoplastic transformation of neuroretina cells.	Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Ecole Normale Super Lyon, UMR 5665, Biol Cellulaire & Mol Lab, CNRS, F-69364 Lyon 07, France; Etab Transfus Sanguine, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Gillet, G (corresponding author), NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA.	g.gillet@ibcp.fr	Ory, Stéphane/G-9714-2019; gillet, germain/A-9095-2013; Ory, Stéphane/E-9947-2010	Ory, Stéphane/0000-0003-4359-1157; Ory, Stéphane/0000-0003-4359-1157; GILLET, Germain/0000-0002-1514-327X				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; Armstrong RC, 1997, J NEUROSCI, V17, P553; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Castellani L, 1996, J CELL SCI, V109, P1335; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVAZZI I, 1989, J CELL SCI, V94, P85; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; Gillet G, 1996, TRENDS MICROBIOL, V4, P312, DOI 10.1016/0966-842X(96)10047-0; GILLET G, 1993, ONCOGENE, V8, P565; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Meijne AML, 1997, EXP CELL RES, V234, P477, DOI 10.1006/excr.1997.3637; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; NERMUT MV, 1991, EXP CELL RES, V193, P382, DOI 10.1016/0014-4827(91)90111-7; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Ory S, 2000, J CELL SCI, V113, P1177; PATCH LA, 1995, J CELL SCI, V108, P1371; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Routes JM, 2000, J IMMUNOL, V165, P4522, DOI 10.4049/jimmunol.165.8.4522; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; WU LW, 1995, ONCOGENE, V11, P1459; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	66	9	9	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1171	1186		10.1038/sj.onc.1205170	http://dx.doi.org/10.1038/sj.onc.1205170			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850837				2022-12-28	WOS:000173729400005
J	Goytisolo, FA; Blasco, MA				Goytisolo, FA; Blasco, MA			Many ways to telomere dysfunction: in vivo studies using mouse models	ONCOGENE			English	Review						telomeres; telomerase; mouse models	SEVERE COMBINED IMMUNODEFICIENCY; POLY(ADP-RIBOSE) POLYMERASE; CATALYTIC SUBUNIT; DEFICIENT MICE; CELLS LACKING; ATAXIA-TELANGIECTASIA; REVERSE-TRANSCRIPTASE; TARGETED DISRUPTION; MAMMALIAN TELOMERES; DNA-REPAIR	The existence of a capping structure at the extremities of chromosomes was first deduced in the 1930s by Herman Muller (Muller, 1938), who showed that X-irradiation of Drosophila rarely resulted in terminal deletions or inversions of chromosomes, suggesting that chromosome ends have protective structures that distinguish them from broken chromosomes, which he named telomeres. In this review, we will focus on mammalian telomeres and, in particular, on the analysis of different mouse models for proteins that are important for telomere function, such as telomerase and various telomere-binding proteins. These murine models are helping us to understand the consequences of telomere dysfunction for cancer, aging and DNA repair, as well as, the molecular mechanisms by which telomeres exert their protective function.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Blasco, MA (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.	mblasco@cnb.uam.es	Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barkle A., 2000, DNA DAMAGE STRESS SI, P80; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Blasco Maria A., 1999, Genes and Development, V13, P2353, DOI 10.1101/gad.13.18.2353; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; de Lange T, 2001, SCIENCE, V292, P1075; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; di Fagagna FD, 1999, NAT GENET, V23, P76; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Greider CW, 1999, CELL, V97, P419, DOI 10.1016/S0092-8674(00)80750-3; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Guarente L, 1997, SCIENCE, V275, P943, DOI 10.1126/science.275.5302.943; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Hande MP, 2001, HUM MOL GENET, V10, P519, DOI 10.1093/hmg/10.5.519; Hande P, 1999, GENOMICS, V56, P221, DOI 10.1006/geno.1998.5668; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Hemann MT, 1999, NUCLEIC ACIDS RES, V27, P3964, DOI 10.1093/nar/27.20.3964; Herrera E, 2000, EMBO J, V19, P472, DOI 10.1093/emboj/19.3.472; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Le S, 1999, GENETICS, V152, P143; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ohki R, 2001, MOL CELL BIOL, V21, P5753, DOI 10.1128/MCB.21.17.5753-5766.2001; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Samper E, 2001, EMBO REP, V2, P800, DOI 10.1093/embo-reports/kve174; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Wu L, 2001, SCIENCE, V292, P229, DOI 10.1126/science.1060832; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yuan XM, 1999, GENES CELLS, V4, P563, DOI 10.1046/j.1365-2443.1999.00284.x; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423; Zumstein LA, 1999, NAT MED, V5, P1129, DOI 10.1038/13451	106	83	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					584	591		10.1038/sj.onc.1205085	http://dx.doi.org/10.1038/sj.onc.1205085			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850783				2022-12-28	WOS:000173390500010
J	Yao, J; Xiong, SB; Klos, K; Nguyen, N; Grijalva, R; Li, P; Yu, D				Yao, J; Xiong, SB; Klos, K; Nguyen, N; Grijalva, R; Li, P; Yu, D			Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta 1 in human breast cancer cells	ONCOGENE			English	Article						MMP-9; heregulin-beta 1; signaling; breast cancer; invasion	EPIDERMAL GROWTH-FACTOR; GA-BINDING-PROTEIN; IV COLLAGENASE; GENE-EXPRESSION; MAMMARY ADENOCARCINOMA; DIFFERENTIATION FACTOR; REGULATED KINASE; TUMOR-CELLS; IN-VITRO; GELATINASE	Matrix metalloproteinase-9 (MMP-9) plays important roles in tumor,invasion and angiogenesis. Secretion of MMP-9 has been reported in various cancer types including lung cancer, colon cancer, and breast cancer. In our investigation of MMP-9 regulation by growth factors, MMP-9 was activated by heregulin-beta1 as shown by zymography in both SKBr3 and MCF-7 breast cancer cell lines. Increase in MMP-9 activity was due to increased MMP-9 protein and mRNA levels, which mainly results from transcriptional upregulation of MMP-9 by heregulin-beta1. Heregulin-beta1. activates multiple signaling pathways in breast cancer cells, including Erk, p38 kinase, PKC, and PI3-K pathways. We examined the pathways involved in heregulin-beta1-mediated MMP-9 activation using chemical inhibitors that specifically inhibit each of these heregulin-beta1-activated pathways. The PKC inhibitor RO318220 and p38 kinase inhibitor SB203580 completely blocked heregulin-beta1-mediated activation of MMP-9. MEK-1 inhibitor PD098059 partially blocked MMP-9 activation, whereas PI3-K inhibitor wortmannin had no effect on heregulin-beta1-mediated MMP-9 activation. Therefore, at least three signaling pathways are involved in the activation of MMP-9 by heregulin-beta1. Since MMP-9 is tightly associated with invasion/metastasis and angiogenesis, our studies suggest that blocking heregulin-beta1-mediated activation of MMP-9 by inhibiting the related signaling pathways may provide new strategies for inhibition of cancer metastasis and angiogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Yu, D (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Box 107, Houston, TX 77030 USA.		Xiong, Shunbin/AAR-5823-2021	Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA16672, 2R01-CA60448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; DAVIES B, 1993, CANCER RES, V53, P5365; DAVIES B, 1993, CANCER RES, V53, P2087; GARBISA S, 1987, CANCER RES, V47, P1523; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; HUJANEN ES, 1994, INT J CANCER, V58, P582, DOI 10.1002/ijc.2910580422; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; Kozawa O, 2000, CELL SIGNAL, V12, P375, DOI 10.1016/S0898-6568(00)00061-9; Lozonschi L, 1999, CANCER RES, V59, P1252; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MOLL UM, 1990, CANCER RES, V50, P6162; NAKAJIMA M, 1993, CANCER RES, V53, P5802; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; PARKS WC, MATRIX METALLOPROTEI; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RAO JS, 1993, CANCER RES, V53, P2208; SAMUEL SK, 1992, EMBO J, V11, P1599, DOI 10.1002/j.1460-2075.1992.tb05205.x; SATO H, 1993, J BIOL CHEM, V268, P23460; Segain JP, 1996, CANCER RES, V56, P5506; Sehgal I, 1996, CANCER RES, V56, P3359; SHIMA I, 1993, BRIT J CANCER, V67, P721, DOI 10.1038/bjc.1993.132; Simon C, 1998, CANCER RES, V58, P1135; Simon C, 1999, BRIT J CANCER, V80, P1412, DOI 10.1038/sj.bjc.6690537; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Tan M, 1999, CANCER RES, V59, P1620; Tan M, 1997, CANCER RES, V57, P1199; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; Xiong SB, 2001, CANCER RES, V61, P1727; Yu Q, 2000, GENE DEV, V14, P163	42	171	188	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8066	8074		10.1038/sj.onc.1204944	http://dx.doi.org/10.1038/sj.onc.1204944			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781819				2022-12-28	WOS:000172396800003
J	Trinei, M; Giorgio, M; Cicalese, A; Barozzi, S; Ventura, A; Migliaccio, E; Milia, E; Padura, IM; Raker, VA; Maccarana, M; Petronilli, V; Minucci, S; Bernardi, P; Lanfrancone, L; Pelicci, PG				Trinei, M; Giorgio, M; Cicalese, A; Barozzi, S; Ventura, A; Migliaccio, E; Milia, E; Padura, IM; Raker, VA; Maccarana, M; Petronilli, V; Minucci, S; Bernardi, P; Lanfrancone, L; Pelicci, PG			A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis	ONCOGENE			English	Article						Shc; p53; ageing; oxidative stress; apoptosis	P53-INDUCED APOPTOSIS; MITOCHONDRIAL-DNA; GROWTH ARREST; LIFE-SPAN; OXIDANTS; MEMBRANE; MODEL; MICE; SHC	Correlative evidence links stress, accumulation of oxidative cellular damage and ageing in lower organisms and in mammals. We investigated their mechanistic connections in p66Shc knockout mice, which are characterized by increased resistance to oxidative stress and extended hie span. We report that p66Shc acts as a downstream target of the tumour suppressor p53 and is indispensable for the ability of stress-activated p53 to induce elevation of intracellular oxidants, cytochrome c release and apoptosis. Other functions of p53 are not influenced by p66Shc expression. In basal conditions, p66Shc -/- and p53 -/- cells have reduced amounts of intracellular oxidants and oxidation-damaged DNA. We propose that steady-state levels of intracellular oxidants and oxidative damage are genetically determined and regulated by a stress-induced signal transduction pathway involving p53 and p66Shc.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; CNR, Unita Study Biomembranes, I-35100 Padua, Italy; FIRC, Inst Mol Oncol, I-20139 Milan, Italy	IRCCS European Institute of Oncology (IEO); Consiglio Nazionale delle Ricerche (CNR); IFOM - FIRC Institute of Molecular Oncology	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Giorgio, Marco/I-9425-2012; Franzeck, Fabian C/B-5055-2011; Bernardi, Paolo/C-3656-2008; Lanfrancone, Luisa/AAC-8671-2019; Minucci, Saverio/J-9669-2012; Petronilli, Valeria/C-3558-2015; Pelicci, Pier Giuseppe/AAL-6572-2020; Ventura, Andrea/F-1789-2011; maccarana, marco/AAB-4764-2021; Migliaccio, Enrica/AAQ-8880-2020	Giorgio, Marco/0000-0002-5842-6042; Bernardi, Paolo/0000-0001-9187-3736; Lanfrancone, Luisa/0000-0002-4523-3815; Petronilli, Valeria/0000-0003-4026-6404; Ventura, Andrea/0000-0003-4320-9907; Maccarana, Marco/0000-0003-3549-8921				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gniadecki R, 2000, J CELL BIOCHEM, V80, P216; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Helbock HJ, 1999, METHOD ENZYMOL, V300, P156; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PURDIE CA, 1994, ONCOGENE, V9, P603; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	28	363	387	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3872	3878		10.1038/sj.onc.1205513	http://dx.doi.org/10.1038/sj.onc.1205513			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032825				2022-12-28	WOS:000175847200006
J	Freemantle, SJ; Kerley, JS; Olsen, SL; Gross, RH; Spinella, MJ				Freemantle, SJ; Kerley, JS; Olsen, SL; Gross, RH; Spinella, MJ			Developmentally-related candidate retinoic acid target genes regulated early during neuronal differentiation of human embryonal carcinoma	ONCOGENE			English	Article						retinoic acid; embryonal carcinoma; development; microarray differentiation; mammalian embryogenesis	CELL-LINE; ALL-TRANS; HOMEOBOX GENES; CLONING; IDENTIFICATION; EXPRESSION; MOUSE; CDNA; BIOLOGY; PROTEIN	Embryonal carcinoma is a model of embryonic development as well as tumor cell differentiation. In response to all-trans retinoic acid (RA), the human embryonal carcinoma (EC) cell line, NT2/D1, differentiates toward a neuronal lineage with associated loss of cell growth and tumorigenicity. Through the use of cDNA-based micro-arrays we sought to identify the early downstream targets of RA during differentiation commitment of NT2/D1 cells. A total of 57 genes were induced and 37 genes repressed by RA. RA regulated genes were restricted at 8 h with 27 genes induced and five repressed. The total number of RA-responsive transcripts increased at 24 and 48 h and their pattern of expression was more symmetrical. For a given time point less than 1% of the 128 cDNAs on the expression array were regulated by RA. Many of these gene products are associated with developmental pathways including those of TGF-beta (Lefty A, NMA, follistatin), homeo domain (HoxD1, Meis2, Meis1, Gbx2), IGF (IGFBP3, IGFBP6, CTGF), Notch (manic fringe, ADAM 11), Hedgehog (patched) and Wnt (Frat2, secreted frizzled-related protein 1) signaling. In addition a large cassette of genes induced by RA at 2448 h are associated with cell adhesion, cytoskeletal and matrix remodeling, growth suppression and intracellular signaling cascades. The majority of repressed genes are associated with protein/RNA processing, turnover or metabolism. The early induced genes identified may play a regulatory role in RA-mediated growth suppression and terminal differentiation and may have physiologic or pharmacologic importance during normal human development and retinoid-based cancer therapy or prevention.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03755 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Spinella, MJ (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NATIONAL CANCER INSTITUTE [K01CA075154] Funding Source: NIH RePORTER; NCI NIH HHS [K01-CA75154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allan GJ, 2001, REPRODUCTION, V122, P31, DOI 10.1530/reprod/122.1.31; Altmann CR, 2001, INT REV CYTOL, V203, P447; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bani-Yaghoub M, 2001, BIOCHEM CELL BIOL, V79, P387, DOI 10.1139/bcb-79-4-387; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BOUILLET P, 1995, DEV DYNAM, V204, P372, DOI 10.1002/aja.1002040404; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Calvo R, 2000, ANN ONCOL, V11, P207, DOI 10.1023/A:1011152704791; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; DMITROVSKY E, 1990, ONCOGENE, V5, P543; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Edwards DP, 1999, VITAM HORM, V55, P165; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Glass CK, 2000, GENE DEV, V14, P121; Gudas Lorraine J., 1994, P443; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; Heidenreich A, 2000, EUR UROL, V37, P121, DOI 10.1159/000020128; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; INIGUEZ MA, 1994, MOL BRAIN RES, V27, P205, DOI 10.1016/0169-328X(94)90002-7; Janciauskiene S, 2001, BBA-MOL BASIS DIS, V1535, P221, DOI 10.1016/S0925-4439(01)00025-4; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kelly DL, 2000, MOL REPROD DEV, V56, P113, DOI 10.1002/(SICI)1098-2795(200006)56:2&lt;113::AID-MRD1&gt;3.0.CO;2-Q; Kerley JS, 2001, BIOCHEM BIOPH RES CO, V285, P969, DOI 10.1006/bbrc.2001.5274; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KURIE JM, 1993, DIFFERENTIATION, V54, P123; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Leypoldt F, 2001, J NEUROCHEM, V76, P806, DOI 10.1046/j.1471-4159.2001.00079.x; Mangelsdorf David J., 1994, P319; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; Matin A, 1998, APMIS, V106, P174, DOI 10.1111/j.1699-0463.1998.tb01333.x; MICHIKAWA M, 1993, BIOCHEM BIOPH RES CO, V192, P1312, DOI 10.1006/bbrc.1993.1559; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; NASONBURCHENAL K, 1999, RETINOIDS HDB EXPT P, P301; Nichols J, 2001, DEVELOPMENT, V128, P2333; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oulad-Abdelghani M, 1998, INT J DEV BIOL, V42, P23; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; PENG HQ, 1993, CANCER RES, V53, P3574; Pera MF, 2000, J CELL SCI, V113, P5; PERA MF, 1990, CANCER SURV, V9, P243; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; Przyborski SA, 2000, EUR J NEUROSCI, V12, P3521, DOI 10.1046/j.1460-9568.2000.00230.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Satoh J, 2000, J NEUROSCI METH, V94, P155, DOI 10.1016/S0165-0270(99)00143-0; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; SCHOTTENFELD D, 1980, AM J EPIDEMIOL, V112, P232, DOI 10.1093/oxfordjournals.aje.a112989; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; YUAN SX, 1995, CANCER RES, V55, P3456; Zile MH, 2001, J NUTR, V131, P705, DOI 10.1093/jn/131.3.705	66	80	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2880	2889		10.1038/sj.onc.1205408	http://dx.doi.org/10.1038/sj.onc.1205408			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973648				2022-12-28	WOS:000175063700013
J	Gapuzan, MER; Yufit, PV; Gilmore, TD				Gapuzan, MER; Yufit, PV; Gilmore, TD			Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-kappa B have a malignantly transformed phenotype	ONCOGENE			English	Article						NF-kappa B; RelA; Rel; malignant transformation; mouse knockout cells; apoptosis	TUMOR-NECROSIS-FACTOR; INCREASED APOPTOSIS; MICE; ACTIVATION; PATHWAY; BINDING; CANCER; GENES; CELLS	The RelA transcription factor is part of dimeric complexes, most commonly either p50-RelA (NF-kappaB) heterodimers or RelA homodimers, that control a variety of cellular processes. Immortalized embryonic fibroblasts established from rela knockout mice have previously been shown to be more sensitive to apoptosis induced by tumor necrosis factor (TNF) than are control fibroblasts. In this report, we show that one line of rela-/- fibroblasts has additional phenotypes that distinguish them from control mouse fibroblasts. As compared to normal 3T3 cells, RelA-deficient fibroblasts have a spindled morphology, are less adherent to culture dishes, grow to a higher saturation density, and can form colonies in soft agar. These properties are consistent with a weakly transformed phenotype for rela-/- cells. Furthermore, RelA-deficient fibroblasts can form tumors in immunodeficient mice, but these tumors regress, probably because of the sensitivity of these cells to TNF. The ability of rela-/- fibroblasts to form colonies in soft agar can be reverted by re-expression of wild-type mouse RelA, but not by expression of RelA mutants that cannot form homodimers. There is no clear correlation between the absence of RelA and the levels of expression of other Rel/NF-kappaB family members or adhesion proteins (ICAM-1 and VCAM-1) whose genes have upstream kappaB sites. Taken together, these results suggest that RelA has tumor suppressing activity under some circumstances and that RelA complexes are involved in the control of a variety of cellular properties associated with oncogenesis.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NCI NIH HHS [CA 47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANCROFT GJ, 1989, J IMMUNOL, V143, P127; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; GILMORE TD, 2002, IN PRESS CANC LETT; HANNINK M, 1990, ONCOGENE, V5, P1843; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; LADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ricca A, 2001, BRIT J CANCER, V85, P1914, DOI 10.1054/bjoc.2001.2174; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; Trecca D, 1997, ONCOGENE, V14, P791, DOI 10.1038/sj.onc.1200895; van Hogerlinden M, 1999, CANCER RES, V59, P3299; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	27	44	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2484	2492		10.1038/sj.onc.1205333	http://dx.doi.org/10.1038/sj.onc.1205333			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971183				2022-12-28	WOS:000174918400005
J	Huang, SY; Bucana, CD; Van Arsdall, M; Fidler, IJ				Huang, SY; Bucana, CD; Van Arsdall, M; Fidler, IJ			Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells	ONCOGENE			English	Article						Stat1; angiogenesis; tumor growth; metastasis	SIGNAL-TRANSDUCTION PATHWAY; FIBROBLAST-GROWTH-FACTOR; PHASE RESPONSE FACTOR; DNA-BINDING PROTEINS; HUMAN-MELANOMA CELLS; NF-KAPPA-B; INTERFERON-ALPHA; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; GENE-EXPRESSION	Stat1 is deficient or inactive in many types of human tumors whereas some tumors have activated Stat1. Whether Stat1 affects tumor growth and metastasis is unclear. In the present study, we used Stat1 knockout tumor cells to determine (1) whether Stat1 can regulate angiogenesis, growth, and metastasis of tumor cells; and (2) whether Stat1 is required for the inhibitory effect of IFN-beta on the expression of angiogenic factor bFGF. Highly tumorigenic and metastatic RAD-105 tumor cells derived from a fibrosarcoma of a Stat1 knockout mouse were reconstituted with a Stat1 expression vector. The reconstitution of Stat1 suppressed the tumorigenicity and metastasis of RAD-105 cells in nude mice which correlated with a decreased microvessel density and decreased expression of proangiogenic molecules bFGF, MMP-2, and MMP-9 in vivo. Moreover, noncytotoxic concentrations of IFN-beta significantly inhibited the in vitro expression of bFGF in the Stat1-reconstituted cells but not in the Stat1-deficient cells, which was consistent with decreased bFGF expression of Stat1-reconstituted tumors in vivo. Therefore, Stat1 is essential for IFN-mediated inhibition of bFGF production, suggesting that tumor-intrinsic Stat1 is an important mediator for antiangiogenic signals, such as IFN. Collectively, these data demonstrate that Stat1 expressed by tumor cells is a negative regulator of tumor angiogenesis and, hence, tumor growth and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fidler, IJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	ifidler@mdanderson.org			NATIONAL CANCER INSTITUTE [R35CA042107, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 42107, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; BALKWILL FR, 1977, INT J CANCER, V20, P500, DOI 10.1002/ijc.2910200405; Bielenberg DR, 1999, INT J ONCOL, V14, P401; Bielenberg DR, 1998, J INVEST DERMATOL, V111, P864, DOI 10.1046/j.1523-1747.1998.00378.x; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BROUTYBOYE D, 1980, SCIENCE, V208, P516, DOI 10.1126/science.6154315; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dinney CPN, 1998, CANCER RES, V58, P808; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FABRA A, 1992, DIFFERENTIATION, V52, P101, DOI 10.1111/j.1432-0436.1992.tb00504.x; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1992, Semin Cancer Biol, V3, P65; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang S, 2000, CLIN CANCER RES, V6, P2573; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Min W, 1996, MOL CELL BIOL, V16, P359; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Pestka S, 1997, Semin Oncol, V24, pS9; Qin HW, 1998, J IMMUNOL, V161, P6664; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SEN GC, 1992, J BIOL CHEM, V267, P5017; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779	58	135	140	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2504	2512		10.1038/sj.onc.1205341	http://dx.doi.org/10.1038/sj.onc.1205341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971185				2022-12-28	WOS:000174918400007
J	Abdulkarim, B; Sabri, S; Deutsch, E; Chagraoui, H; Maggiorella, L; Thierry, J; Eschwege, F; Vainchenker, W; Chouaib, S; Bourhis, J				Abdulkarim, B; Sabri, S; Deutsch, E; Chagraoui, H; Maggiorella, L; Thierry, J; Eschwege, F; Vainchenker, W; Chouaib, S; Bourhis, J			Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers	ONCOGENE			English	Article						HPV E6/E7; p53; human carcinoma; Cidofovir; ionizing radiation	HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL-CARCINOMA CELLS; ACYCLIC NUCLEOSIDE PHOSPHONATES; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; HUMAN KERATINOCYTES; E7 PROTEIN; INHIBITION; DNA; DEGRADATION	High-risk human papillomaviruses (HPVs) have been associated to the development of cervical and some other human cancers. Most of them express E6 and E7 oncoproteins, able to bind to p53 and retinoblastoma (pRb) tumor suppressor proteins respectively and neutralize their function. Restoration of these pathways by blocking E6 and E7 expression would provide a selective therapeutic effect. Here, we show that a clinically approved antiviral agent Cidofovir reduced E6 and E7 expression in cervical carcinoma Me180 and head and neck squamous cell carcinoma HEP2 cells at the transcriptional level. Cidofovir induced the accumulation of active p53 and pRb associated to induction of cyclin dependent kinase inhibitor p21(WAF1/CIP1) in Me180 and HEP2 cells. p53 induction was also shown in Hela HPV-positive cervical carcinoma cell line. In addition, S phase cell cycle accumulation with concomitant decrease of cyclin A expression were associated to the antiproliferative activity of Cidofovir in HPV-treated cells. Combining Cidofovir to irradiation both in vivo and in nude mice xenografts resulted in a marked radiosensitization in HPV-positive cells, which was not observed in virus negative cells. This study provides the basis for a new anticancer strategy to enhance the antitumor effect of ionizing radiation in HPV-related cancers, without increase deleterious effects.	Inst Gustave Roussy, Lab UPRES EA 27 10, F-94805 Villejuif, France; Inst Gustave Roussy, Unite METSI, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Bourhis, J (corresponding author), Inst Gustave Roussy, Lab UPRES EA 27 10, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	bourhis@igr.fr	THIERY, Jerome/N-2469-2018; Chouaib, Salem/F-7939-2016; Sabri, Siham/K-1101-2015	THIERY, Jerome/0000-0002-0998-3627; deutsch, eric/0000-0002-8223-3697; Bourhis, Jean/0000-0001-5162-1171; Sabri, Siham/0000-0001-5792-689X; Vainchenker, William/0000-0003-4705-202X				Abdulkarim B, 2001, LANCET ONCOL, V2, P622, DOI 10.1016/S1470-2045(01)00520-4; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Andrei G, 1998, ONCOL RES, V10, P523; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Boyer SN, 1996, CANCER RES, V56, P4620; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; BUTZ K, 1995, ONCOGENE, V10, P927; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Chiba I, 1996, ONCOGENE, V12, P1663; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DIPAOLO JA, 1993, CRIT REV ONCOGENESIS, V4, P337; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Francis DA, 2000, J VIROL, V74, P2679, DOI 10.1128/JVI.74.6.2679-2686.2000; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gallardo D, 1996, CANCER RES, V56, P4891; Gillam R, 1999, C++ REP, V11, P9; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; GOUBIN F, 1995, ONCOGENE, V10, P2281; He JK, 1997, CANCER RES, V57, P3993; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; HU GY, 1995, CANCER GENE THER, V2, P19; Hwang ES, 1996, ONCOGENE, V12, P795; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Johnson JA, 1999, ANTIMICROB AGENTS CH, V43, P1198, DOI 10.1128/AAC.43.5.1198; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kamradt MC, 2000, BRIT J CANCER, V82, P1709; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liekens S, 2001, INT J CANCER, V92, P161, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1183>3.0.CO;2-K; Mantovani F, 1999, ONCOGENE, V18, P3309, DOI 10.1038/sj.onc.1202688; MORAN E, 1993, CURR OPIN GENE DEV, V13, P261; Neyts J, 1998, CANCER RES, V58, P384; Pisarev VM, 1997, MOL PHARMACOL, V52, P63, DOI 10.1124/mol.52.1.63; Safrin S, 1997, REV MED VIROL, V7, P145, DOI 10.1002/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0; Santin AD, 1998, CANCER-AM CANCER SOC, V83, P2346, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2346::AID-CNCR14>3.0.CO;2-G; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHIFFMAN MH, 1995, J NATL CANCER I, V87, P1345, DOI 10.1093/jnci/87.18.1345; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; Spitz FR, 1996, CLIN CANCER RES, V2, P1665; STEELE C, 1992, CANCER RES, V52, P4706; STEELE C, 1993, CANCER RES, V53, P2330; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; TAN TMC, 1995, CANCER RES, V55, P4599; Venturini F, 1999, NUCLEIC ACIDS RES, V27, P1585, DOI 10.1093/nar/27.7.1585; Villa LL, 1997, ADV CANCER RES, V71, P321, DOI 10.1016/S0065-230X(08)60102-5; Wu LL, 2000, MOL CELL BIOL, V20, P7059, DOI 10.1128/MCB.20.19.7059-7067.2000; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	64	105	108	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2334	2346		10.1038/sj.onc.1205006	http://dx.doi.org/10.1038/sj.onc.1205006			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948417				2022-12-28	WOS:000174635600006
J	Paumelle, R; Tulasne, D; Kherrouche, Z; Plaza, S; Leroy, C; Reveneau, S; Vandenbunder, B; Fafeur, V				Paumelle, R; Tulasne, D; Kherrouche, Z; Plaza, S; Leroy, C; Reveneau, S; Vandenbunder, B; Fafeur, V			Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway	ONCOGENE			English	Article						HGF/SF; RAS; ERK; ETS; morphogenesis	RECEPTOR TYROSINE KINASE; SCATTER FACTOR; MAP-KINASE; EPITHELIAL-CELLS; PROTEIN-KINASES; PHOSPHORYLATION; DOMAIN; EXPRESSION; TRANSDUCTION; MOTILITY	Hepatocyte growth factor/scatter factor (HGF/SF) induces scattering and morphogenesis of epithelial cells through the activation of the MET tyrosine kinase receptor. Although the activated MET receptor recruits a number of signaling proteins, little is known of the downstream signaling pathways activated by HGF/SF. In this study, we wished to examine the signaling pathway leading to activation of the ETS1 transcription factor. Using in vitro and in vivo kinase assays, we found that HGF/SF activates the ERK1 MAP kinase, leading to the phosphorylation of the threonine 38 residue of ETS1 within a putative MAP kinase phosphorylation site (PLLT38P). This threonine residue was neither phosphorylated by JNK1, nor by p38 MAP kinases and was required for the induction of transcriptional activity of ETS1 by HGF/SF. Using kinase and transcription assays, we further demonstrated that phosphorylation and activation of ETS1 occurs downstream of a RAS-RAF-MEK-ERK pathway. The functional involvement of this pathway in HGF/SF action was demonstrated using U0126, a pharmacological inhibitor of MEK, which blocked phosphorylation and activation of ETS1, RAS-dependent transcriptional responses, cell scattering and morphogenesis. These data demonstrated that ETS1 is a downstream target of HGF/SF acting through a RAS-RAF-MEK-ERK pathway and provides a signaling pathway leading to the regulation of gene expression by HGF/SF.	Inst Pasteur, Inst Biol Lille, CNRS, FRE 2353, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Fafeur, V (corresponding author), Inst Pasteur, Inst Biol Lille, CNRS, FRE 2353, BP 447, F-59021 Lille, France.	veronique.fefeur@ibl.fr	KHERROUCHE, Zoulika/HHN-0213-2022; Fafeur, Veronique/L-9072-2018; Tulasne, David/A-8705-2008; plaza, serge/F-5290-2015; Tulasne, David/AAR-5287-2020; Paumelle, Réjane/R-6675-2018; KHERROUCHE, Zoulika/L-6549-2019	Tulasne, David/0000-0002-6764-7242; Paumelle, Réjane/0000-0002-4489-0717; 				Baker DA, 2001, NATURE, V411, P330, DOI 10.1038/35077122; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHANG CB, 1993, MOL CELL BIOL, V13, P7469, DOI 10.1128/MCB.13.12.7469; CHEN JH, 1990, ONCOGENE RES, V5, P277; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gambarotta G, 1996, ONCOGENE, V13, P1911; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kim KR, 2000, ONCOGENE, V19, P1764, DOI 10.1038/sj.onc.1203502; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Paumelle R, 2000, MOL BIOL CELL, V11, P3751, DOI 10.1091/mbc.11.11.3751; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rabault B, 1996, ONCOGENE, V13, P877; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Terauchi R, 2000, EXP CELL RES, V256, P411, DOI 10.1006/excr.2000.4850; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	44	126	140	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2309	2319		10.1038/sj.onc.1205297	http://dx.doi.org/10.1038/sj.onc.1205297			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948414				2022-12-28	WOS:000174635600003
J	Ashcroft, M; Ludwig, RL; Woods, DB; Copeland, TD; Weber, HO; MacRae, EJ; Vousden, KH				Ashcroft, M; Ludwig, RL; Woods, DB; Copeland, TD; Weber, HO; MacRae, EJ; Vousden, KH			Phosphorylation of HDM2 by Akt	ONCOGENE			English	Article						HDM2; Akt; P53; phosphorylation	ATM-DEPENDENT PHOSPHORYLATION; NUCLEOLAR-LOCALIZATION; MDM2; P53; PROTEIN; IDENTIFICATION; ACTIVATION; INDUCTION; UBIQUITINATION; PREVENTS	The HDM2 protein is a key regulator of the tumour suppressor, p53. Control of HDM2 function is critical for normal cell proliferation and stress responses, and it is becoming evident that multiple modifications of HDM2 can regulate its function within cells. In this study we show that HDM2 associated with the serinethreonine kinase, Akt, in response to growth factor stimulation of human primary cells. This association was concurrent with phosphorylation of Akt (at Ser 473), and resulted in elevated expression of HDM2 and enhanced nuclear localization. However, analysis of HDM2 proteins mutated at the consensus Akt recognition sites at serines 166 and 186 indicated that modification at these residues was not sufficient for the increased expression of the protein, which was blocked by the PI3 kinase inhibitor LY294002. Tryptic peptide and mutational analyses revealed evidence for an Akt phosphorylation site in HDM2 additional to the two consensus sites.	NCI, FCRDC, Regulat Cell Growth Lab, Frederick, MD 21702 USA; Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of London; Institute of Cancer Research - UK	Vousden, KH (corresponding author), NCI, FCRDC, Regulat Cell Growth Lab, Frederick, MD 21702 USA.	ashcroft@icr.ac.uk						Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Leri A, 1999, AM J PATHOL, V154, P567, DOI 10.1016/S0002-9440(10)65302-3; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	37	166	169	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1955	1962		10.1038/sj.onc.1205276	http://dx.doi.org/10.1038/sj.onc.1205276			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960368				2022-12-28	WOS:000174827000002
J	Tsai, MS; Bogart, DF; Li, P; Mehmi, I; Lupu, R				Tsai, MS; Bogart, DF; Li, P; Mehmi, I; Lupu, R			Expression and regulation of Cyr61 in human breast cancer cell lines	ONCOGENE			English	Article						Cyr61; estradiol; tamoxifen; ICI-182; 780; regulation; breast cancer	IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; ACID RECEPTOR-ALPHA; RETINOIC ACID; EXTRACELLULAR-MATRIX; DIFFERENTIAL REGULATION; PHORBOL ESTER; PRODUCT; ADHESION; INVOLVEMENT	We have shown that Cyr61, an angiogenic regulator, is overexpressed in invasive and metastatic human breast cancer cells and tumor biopsies. We have further demonstrated that Cyr61 promotes acquisition of estrogen-independence and anti-estrogen resistance in vivo in breast cancer cells. Moreover, we have demonstrated that Cyr61 induces tumor formation and tumor vascularization in vivo, events mediated through the activation of the MAPK and the Akt signaling pathways. Here we investigate how Cyr61 expression is regulated in both estrogen receptor (ER)-positive and ER-negative breast cancer cells. We demonstrate that Cyr61 mRNA and protein expression is inducible by estrogen and anti-estrogens in ER-positive breast cancer cells. We show that a labile protein as well as a negative regulator might be involved in Cyr61 expression in estrogen-dependent breast cancer cells. Other important regulators of Cyr61 expression in breast cancer cells that we found are the phorbol ester TPA, vitamin D, and retinoic acid. TPA causes positive regulation of Cyr61 expression in ER-positive MCF-7 cells. Vitamin D induces a transient stimulatory effect on Cyr61 gene expression. Lastly, retinoic acid has a negative effect on Cyr61 expression and downregulates its expression in MCF-7 cells. Interestingly, most of these effects are not seen in aggressive breast cancer cells that do not express ER and express high levels of Cyr61, such as the MDA-MB-231 cells. Our results are in agreement with our knowledge that Cyr61 promotes tumor growth, and that tumor-promoting agents have a positive impact on cells that express low, levels of Cyr61, such as the ER-positive breast cancer cells; however, these agents have no significant effect on cells that express high levels of Cyr61. Our findings suggest an association between increased Cyr61. expression and an aggressive phenotype of breast cancer cells.	Univ Calif Berkeley, Ernest Orlando Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Lupu, R (corresponding author), Univ Calif Berkeley, Ernest Orlando Lawrence Berkeley Natl Lab, 1 Cyclotron Rd, Berkeley, CA 94720 USA.	rlupu@lbl.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049049] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49049] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Albrecht C, 2000, J BIOL CHEM, V275, P28929, DOI 10.1074/jbc.M003053200; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; BUNNER A, 1991, DNA CELL BIOL, V10, P293; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Chung KC, 1998, NEUROSCI LETT, V255, P155, DOI 10.1016/S0304-3940(98)00733-2; Escaleira MTF, 1999, BREAST CANCER RES TR, V54, P123, DOI 10.1023/A:1006198107805; Flicker SH, 1997, CANCER LETT, V115, P63, DOI 10.1016/S0304-3835(97)04715-0; Folgueira MAAK, 2000, BRAZ J MED BIOL RES, V33, P559, DOI 10.1590/S0100-879X2000000500011; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; HAUSSLER MR, 1995, BONE S, V17, P33; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kolesnikova TV, 1998, ONCOGENE, V16, P747, DOI 10.1038/sj.onc.1201572; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; MACGREGOR JI, 1988, PHARMACOL REV, V50, P151; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; Nolan E, 1998, MOL CELL BIOCHEM, V188, P13, DOI 10.1023/A:1006879213501; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Rivera-Gonzalez R, 1998, J STEROID BIOCHEM, V64, P13, DOI 10.1016/S0960-0760(97)00142-8; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; Schneider SM, 1999, BREAST CANCER RES TR, V58, P171, DOI 10.1023/A:1006377006816; Schutze N, 1998, ENDOCRINOLOGY, V139, P1761, DOI 10.1210/en.139.4.1761; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SMITH JB, 1995, J BIOL CHEM, V270, P16756, DOI 10.1074/jbc.270.28.16756; Srivastava RK, 1999, CLIN CANCER RES, V5, P1892; Tang CK, 1996, CANCER RES, V56, P3350; Tsai MS, 2000, CANCER RES, V60, P5603; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	41	67	74	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					964	973		10.1038/sj/onc/1205131	http://dx.doi.org/10.1038/sj/onc/1205131			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840342				2022-12-28	WOS:000173427100012
J	Spiegelman, V; Tang, WG; Katoh, M; Slaga, TJ; Fuchs, SY				Spiegelman, V; Tang, WG; Katoh, M; Slaga, TJ; Fuchs, SY			Inhibition of HOS expression and activities by Wnt pathway	ONCOGENE			English	Article						beta TrCP; HOS; ubiquitin ligase; F-box protein; beta-catenin; NF-kappa B	I-KAPPA-B; F-BOX PROTEIN; BETA-CATENIN; UBIQUITIN LIGASE; ALPHA UBIQUITINATION; SIGNALING PATHWAYS; COMPLEX; TRCP; ACTIVATION; SCF	betaTrCP and HOS are closely related F-box proteins, which play key roles in ubiquitination and degradation of beta-catenin and IkappaB through associating with those phosphorylated substrates and recruiting SCF E3 ubiquitin ligase. Here we report that activation of Wnt/beta-catenin signal transduction pathway elevates betaTrCP levels but inhibits expression of HOS in 293T cells. Similar disparity is likely to exist in human colorectal tumors. In the NIH3T3 cells, which express HOS, but not betaTrCP, Wnt/beta-catenin signaling leads to inhibition of HOS promoter activity and NF-kappaB-driven transcription as well as to stabilization of P-catenin. These results indicate that expression and activities of HOS are negatively regulated by Wnt/beta-catenin pathway.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; AMC Canc Res Ctr, Lakewood, CO 80214 USA; Natl Canc Ctr, Res Inst, Div Genet, Tokyo 1040045, Japan	University of Pennsylvania; AMC Cancer Research Center; National Cancer Center - Japan	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Room 161E,VET, Philadelphia, PA 19104 USA.			Spiegelman, Vladimir S/0000-0003-4847-155X	NCI NIH HHS [CA 92900, CA 76262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koike J, 2000, BIOCHEM BIOPH RES CO, V269, P103, DOI 10.1006/bbrc.2000.2241; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Saitoh T, 2001, INT J ONCOL, V18, P959; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; SPIEGELMAN VS, 2001, J BIOL CHEM, V24, P24; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	30	62	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					856	860		10.1038/sj.onc.1205132	http://dx.doi.org/10.1038/sj.onc.1205132			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850814				2022-12-28	WOS:000173427000017
J	Collins, K; Mitchell, JR				Collins, K; Mitchell, JR			Telomerase in the human organism	ONCOGENE			English	Review						telomerase; RNA; ribonucleoprotein; somatic cell; cancer; dyskeratosis congenita	HEMATOPOIETIC STEM-CELLS; LINKED DYSKERATOSIS-CONGENITA; HOYERAAL-HREIDARSSON-SYNDROME; CATALYTIC SUBUNIT GENE; REVERSE-TRANSCRIPTASE; IN-VITRO; TETRAHYMENA-TELOMERASE; RNA COMPONENT; EPITHELIAL-CELLS; RIBOSOMAL-RNA	The intent of this review is to describe what is known and unknown about telomerase in somatic cells of the human organism. First, we consider the telomerase enzyme. Human telomerase ribonucleoproteins undergo at least three stages of cellular biogenesis: accumulation, catalytic activation and recruitment to the telomere. Next, we describe the patterns of telomerase regulation in the human soma. Telomerase activation in some cell types appears to offset proliferation-dependent telomere shortening, delaying but not defeating the inherent mitotic clock. Finally, we elaborate the connection between telomerase misregulation and human disease, in the contexts of inappropriate telomerase activation and telomerase deficiency. We discuss how our current perspectives on telomerase function could be applied to improving human health.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Collins, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.							Aigner S, 2000, EMBO J, V19, P6230, DOI 10.1093/emboj/19.22.6230; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Avilion AA, 1996, CANCER RES, V56, P645; Bachand F, 1999, J BIOL CHEM, V274, P38027, DOI 10.1074/jbc.274.53.38027; Bachor C, 1999, J CANCER RES CLIN, V125, P453, DOI 10.1007/s004320050302; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bickenbach JR, 1998, J INVEST DERMATOL, V111, P1045, DOI 10.1046/j.1523-1747.1998.00420.x; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brummendorf TH, 2001, ANN NY ACAD SCI, V938, P1; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; Chapon C, 1997, RNA, V3, P1337; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Coulthard S, 1998, BRIT J HAEMATOL, V102, P1162, DOI 10.1046/j.1365-2141.1998.00893.x; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; Devriendt K, 1997, AM J HUM GENET, V60, P581; Dez C, 2001, NUCLEIC ACIDS RES, V29, P598, DOI 10.1093/nar/29.3.598; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Dokal I, 1996, BRIT J HAEMATOL, V92, P775, DOI 10.1046/j.1365-2141.1996.355881.x; Dokal I, 2000, BRIT J HAEMATOL, V110, P768, DOI 10.1046/j.1365-2141.2000.02109.x; DOKAL I, 1992, BLOOD, V80, P3090; DRACHTMAN RA, 1992, AM J PEDIAT HEMATOL, V14, P297; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; Effros RB, 2000, MICROBES INFECT, V2, P69, DOI 10.1016/S1286-4579(00)00283-5; Evans SK, 2000, J CELL SCI, V113, P3357; Fan XQ, 1997, MOL BIOL CELL, V8, P2145, DOI 10.1091/mbc.8.11.2145; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Ford LP, 2001, RNA, V7, P1068, DOI 10.1017/S1355838201010159; Ford LP, 2000, MOL CELL BIOL, V20, P9084, DOI 10.1128/MCB.20.23.9084-9091.2000; Frenck RW, 1998, P NATL ACAD SCI USA, V95, P5607, DOI 10.1073/pnas.95.10.5607; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Globerson A, 1999, EXP GERONTOL, V34, P137, DOI 10.1016/S0531-5565(98)00069-2; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Haddad MM, 1999, EXP CELL RES, V253, P561, DOI 10.1006/excr.1999.4688; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1995, TELOMERES, P247; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Heiss NS, 1999, HUM MOL GENET, V8, P2515, DOI 10.1093/hmg/8.13.2515; Heiss NS, 2001, GENET COUNSEL, V12, P129; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Henras A, 1998, EMBO J, V17, P7078, DOI 10.1093/emboj/17.23.7078; Hinkley CS, 1998, NUCLEIC ACIDS RES, V26, P532, DOI 10.1093/nar/26.2.532; Hirose T, 2001, P NATL ACAD SCI USA, V98, P12914, DOI 10.1073/pnas.231490998; Hirose Y, 2000, GENE DEV, V14, P1415; Hiyama E, 1996, INT J ONCOL, V9, P453; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hoare SF, 2001, CANCER RES, V61, P27; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Hu BT, 1999, EUR J IMMUNOL, V29, P3745, DOI 10.1002/(SICI)1521-4141(199911)29:11<3745::AID-IMMU3745>3.0.CO;2-1; Hu BT, 1997, J IMMUNOL, V159, P1068; Huffman KE, 2000, J BIOL CHEM, V275, P19719, DOI 10.1074/jbc.M002843200; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; Knight S, 1998, BRIT J HAEMATOL, V103, P990, DOI 10.1046/j.1365-2141.1998.01103.x; Knight SW, 1999, BRIT J HAEMATOL, V107, P335, DOI 10.1046/j.1365-2141.1999.01690.x; Knight SW, 2001, HUM GENET, V108, P299, DOI 10.1007/s004390100494; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; Kufel J, 2000, MOL CELL BIOL, V20, P5415, DOI 10.1128/MCB.20.15.5415-5424.2000; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Le SY, 2000, MOL BIOL CELL, V11, P999, DOI 10.1091/mbc.11.3.999; Leteurtre F, 1999, BRIT J HAEMATOL, V105, P883, DOI 10.1046/j.1365-2141.1999.01445.x; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Licht JD, 1999, GENE DEV, V13, P1116, DOI 10.1101/gad.13.9.1116; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Liu KB, 1999, P NATL ACAD SCI USA, V96, P5147, DOI 10.1073/pnas.96.9.5147; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Luzzatto L, 1998, NAT GENET, V19, P6, DOI 10.1038/ng0598-6; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; Marciniak RA, 2000, TRENDS GENET, V16, P193, DOI 10.1016/S0168-9525(00)01984-3; Martin-Rivera L, 2001, J BIOL CHEM, V276, P5856, DOI 10.1074/jbc.M008419200; Masutomi K, 2000, J BIOL CHEM, V275, P22568, DOI 10.1074/jbc.M000622200; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; *OMIM, 2001, ONL MED INH MAN; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; Rufer N, 1999, J EXP MED, V190, P157, DOI 10.1084/jem.190.2.157; Schnapp G, 1998, NUCLEIC ACIDS RES, V26, P3311, DOI 10.1093/nar/26.13.3311; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Steinmetz EJ, 2001, NATURE, V413, P327, DOI 10.1038/35095090; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; Tanaka M, 1998, AM J PATHOL, V153, P1985, DOI 10.1016/S0002-9440(10)65712-4; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Tesmer VM, 1999, MOL CELL BIOL, V19, P6207; Ulaner GA, 1997, MOL HUM REPROD, V3, P769, DOI 10.1093/molehr/3.9.769; Ulaner GA, 1998, CANCER RES, V58, P4168; Ulaner GA, 2001, INT J CANCER, V91, P644, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1103>3.3.CO;2-M; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy TJ, 2001, BLOOD CELL MOL DIS, V27, P353, DOI 10.1006/bcmd.2001.0389; Vulliamy TJ, 1997, BLOOD, V90, P2213; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Weng NP, 1997, P NATL ACAD SCI USA, V94, P10827, DOI 10.1073/pnas.94.20.10827; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Wright WE, 1996, DEV GENET, V18, P173; Yaghmai R, 2000, J PEDIATR-US, V136, P390, DOI 10.1067/mpd.2000.104295; Yashima K, 1998, CELL GROWTH DIFFER, V9, P805; Yasumoto S, 1996, ONCOGENE, V13, P433; Yi XM, 1999, MOL CELL BIOL, V19, P3989; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Yokoyama Y, 1998, MOL HUM REPROD, V4, P985, DOI 10.1093/molehr/4.10.985; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zebarjadian Y, 1999, MOL CELL BIOL, V19, P7461	141	457	485	2	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					564	579		10.1038/sj.onc.1205083	http://dx.doi.org/10.1038/sj.onc.1205083			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850781				2022-12-28	WOS:000173390500008
J	Harrington, L; Robinson, MO				Harrington, L; Robinson, MO			Telomere dysfunction: multiple paths to the same end	ONCOGENE			English	Article						telomere; telomerase; genome stability; DNA damage; apoptosis; p53	HUMAN-CELLS LEADS; HUMAN TUMOR-CELLS; LIFE-SPAN; HUMAN FIBROBLASTS; MOUSE TELOMERASE; HUMAN CANCER; LENGTH; TRF2; RNA; RECONSTITUTION	The molecular cloning of telomerase and telomere components has enabled the analysis and precise manipulation of processes that regulate telomere length maintenance. In mammalian cells and in other organisms, we now recognize that disruption of telomere integrity via any one of a number of perturbations induces chromosome instability and the activation of DNA damage responses. Thus, telomere dysfunction may represent a physiological trigger of the DNA damage or apoptotic response in an analogous fashion to other genotoxic insults that introduce chromosome breaks. Initial studies in mice lacking the murine telomerase RNA and in cells expressing a dominant negative version of the telomere binding protein TRF2 revealed a strong p53-dependent response to telomere dysfunction. Yet, telomere dysfunction exhibits p53-independent effects as well, an observation supported by p53-independent responses to telomere dysfunction in p53 mutant human tumor cell lines and mouse cells. As most tumors are compromised for p53 function, examination of this p53-independent response warrants closer attention. A better understanding of this p53-independent response may prove critical for determining the ultimate utility of telomerase inhibitors in the clinic. This review will summarize our current understanding of the molecular responses to telomere dysfunction in mammalian cells.	Amgen Inc, Thousand Oaks, CA 91320 USA; Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Amgen Res Inst, Toronto, ON M5G 2C1, Canada	Amgen; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Robinson, MO (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.			Robinson, Murray/0000-0003-4462-0685				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Engelhardt M, 1998, LEUKEMIA, V12, P13, DOI 10.1038/sj.leu.2400889; Engelhardt M, 1997, CLIN CANCER RES, V3, P1931; GREIDER CW, 1996, ANNU REV BIOCHEM, V65, P377; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Guo CH, 2001, J UROLOGY, V166, P694, DOI 10.1016/S0022-5347(05)66045-4; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1996, TELOMERES, P247; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Ludwig A, 2001, CANCER RES, V61, P3053; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	49	55	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					592	597		10.1038/sj.onc.1205084	http://dx.doi.org/10.1038/sj.onc.1205084			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850784				2022-12-28	WOS:000173390500011
J	Kim, S; Kaminker, P; Campisi, J				Kim, S; Kaminker, P; Campisi, J			Telomeres, aging and cancer: In search of a happy ending	ONCOGENE			English	Review						antagonistic pleiotropy; cellular senescence; genomic instability; immortalization; telomerase; tumor suppression	CELL-CYCLE; POLY(ADP-RIBOSE) POLYMERASE; REPLICATIVE SENESCENCE; LENGTH REGULATION; HUMAN FIBROBLASTS; MOUSE TELOMERASE; LIFE-SPAN; IN-VITRO; EXPRESSION; MICE	Telomeres are distinctive structures, composed of a repetitive DNA sequence and associated proteins, that cap the ends of linear chromosomes. Telomeres are essential for maintaining the integrity and stability of eukaryotic genomes. In addition, under some circumstances, telomeres can influence cellular gene expression. In mammals, the length, structure, and function of telomeres have been proposed to contribute to cellular and organismal phenotypes associated with cancer and aging. Here, we discuss what is known about the basis for the links between telomeres, aging and cancer, and some of the known and proposed consequences of telomere dysfunction and maintenance for mammalian cells and organisms.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Campisi, J (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Mailstop 84-171,1 Cyclotron Rd, Berkeley, CA 94720 USA.	JCAMPISI@LBL.GOV						ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 1999, MOLECULAR BASIS OF CELL CYCLE AND GROWTH CONTROL, P348; Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531-5565(00)00230-8; Campisi Judith, 1996, P121; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CovielloMcLaughlin GM, 1997, NUCLEIC ACIDS RES, V25, P3051, DOI 10.1093/nar/25.15.3051; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; di Fagagna FD, 1999, NAT GENET, V23, P76; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; Dolle MET, 2000, P NATL ACAD SCI USA, V97, P8403, DOI 10.1073/pnas.97.15.8403; Dubrana K, 2001, CURR OPIN CELL BIOL, V13, P281, DOI 10.1016/S0955-0674(00)00210-6; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Effros RB, 1998, AM J HUM GENET, V62, P1003, DOI 10.1086/301845; Funk WD, 2000, EXP CELL RES, V258, P270, DOI 10.1006/excr.2000.4945; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Herrera E, 2000, EMBO J, V19, P472, DOI 10.1093/emboj/19.3.472; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kakuo S, 1999, BIOCHEM BIOPH RES CO, V263, P308, DOI 10.1006/bbrc.1999.1385; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Klapper W, 2001, MECH AGEING DEV, V122, P695, DOI 10.1016/S0047-6374(01)00223-8; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MILLER RA, 1991, CANCER, V68, P2496, DOI 10.1002/1097-0142(19911201)68:11+<2496::AID-CNCR2820681503>3.0.CO;2-B; Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Paradis V, 2001, HUM PATHOL, V32, P327, DOI 10.1053/hupa.2001.22747; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Pendergrass WR, 1999, J CELL PHYSIOL, V180, P123, DOI 10.1002/(SICI)1097-4652(199907)180:1<123::AID-JCP14>3.0.CO;2-W; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Rinehart CA, 1997, MOL CARCINOGEN, V18, P187, DOI 10.1002/(SICI)1098-2744(199704)18:4<187::AID-MC1>3.3.CO;2-4; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay J W, 2001, Novartis Found Symp, V235, P116; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wei S, 1999, CANCER RES, V59, P1539; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Wright Woodring E., 1996, V16, P153; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yang LQ, 2001, MECH AGEING DEV, V122, P1685, DOI 10.1016/S0047-6374(01)00280-9; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu LX, 1998, P NATL ACAD SCI USA, V95, P8648, DOI 10.1073/pnas.95.15.8648; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	105	154	169	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					503	511		10.1038/sj.onc.1205077	http://dx.doi.org/10.1038/sj.onc.1205077			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850775				2022-12-28	WOS:000173390500002
J	Ohyashiki, JH; Sashida, G; Tauchi, T; Ohyashiki, K				Ohyashiki, JH; Sashida, G; Tauchi, T; Ohyashiki, K			Telomeres and telomerase in hematologic neoplasia	ONCOGENE			English	Article						telomere; telomerase; leukemia; lymphoma; hematopoietic stem cell	MALIGNANT HEMATOPOIETIC-CELLS; ACUTE MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; REPEAT AMPLIFICATION PROTOCOL; MYELODYSPLASTIC SYNDROMES; BONE-MARROW; HODGKINS-DISEASE; STEM-CELLS; JUMPING TRANSLOCATION; REVERSE-TRANSCRIPTASE	Normal hematopoietic cells express telomerase activity, however the presence of telomerase does not necessarily imply stable and thus unchanging telomere length. Gradual telomere loss with aging and rapid cycling of hematopoietic stem cells might contribute to immunosenescence, exhausted hematopoiesis, and increased likelihood of malignant transformation. In leukemias and lymphomas, telomere length may reflect the cellular proliferative history, prior to immortalization. The level of telomerase activity is generally influenced by the fraction of cells in the proliferative pool. Shortened telomeres and high telomerase activity almost always correlates with disease severity in hematologic neoplasias such as relapsed leukemia and high-grade lymphomas, indicating that measurement of telomere length and telomerase activity might be useful to monitor disease condition. Since the mode of action of telomerase inhibitors may require telomeric shortening before induction of apoptosis, anti-telomerase therapy might be helpful for adjuvant therapy following conventional chemotherapy, in vitro purging of neoplastic cells in stem cell transplantation, and treating minimal residual disease. Some promising areas of tissue engineering include rejuvenation of hematopoietic stem cells for improving stem cell transplants or enhancing general immunity for older patients.	Tokyo Med & Dent Univ, Med Res Inst, Dept Virol, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical University	Ohyashiki, JH (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Virol, Bunkyo Ku, 4-45,1 Chome, Tokyo 1138510, Japan.		Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987				Akiyama M, 1998, BONE MARROW TRANSPL, V21, P167, DOI 10.1038/sj.bmt.1701060; Akiyama M, 2000, BONE MARROW TRANSPL, V25, P441, DOI 10.1038/sj.bmt.1702144; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Arai J, 2001, BLOOD, V97, P2903, DOI 10.1182/blood.V97.9.2903; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Bearss DJ, 2000, ONCOGENE, V19, P1114, DOI 10.1038/sj.onc.1203275; Bechter OE, 1998, CANCER RES, V58, P4918; BERGEMANN J, 1995, NUCLEIC ACIDS RES, V23, P4451, DOI 10.1093/nar/23.21.4451; Boultwood J, 1997, AM J HEMATOL, V56, P266; Boultwood J, 2000, BLOOD, V96, P358, DOI 10.1182/blood.V96.1.358.013k16_358_361; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brousset P, 1997, BLOOD, V89, P26, DOI 10.1182/blood.V89.1.26.26_26_31; Brousset P, 1998, LEUKEMIA LYMPHOMA, V30, P189, DOI 10.3109/10428199809050942; Brummendorf TH, 2000, BLOOD, V95, P1883, DOI 10.1182/blood.V95.6.1883; Brummendorf TH, 2001, BLOOD, V97, P895, DOI 10.1182/blood.V97.4.895; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; Cuthbert G, 1999, GENE CHROMOSOME CANC, V24, P295, DOI 10.1002/(SICI)1098-2264(199904)24:4<295::AID-GCC1>3.0.CO;2-8; Daibata M, 1999, BLOOD, V94, P1545, DOI 10.1182/blood.V94.5.1545.417a25_1545_1549; Ely SA, 2000, CANCER, V89, P445, DOI 10.1002/1097-0142(20000715)89:2<445::AID-CNCR33>3.0.CO;2-T; Engelhardt M, 2000, CANCER RES, V60, P610; Engelhardt M, 1997, BLOOD, V90, P182; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Harada K, 1999, CANCER, V86, P1050, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1050::AID-CNCR22>3.0.CO;2-K; Hatakeyama S, 1999, ONCOGENE, V18, P2085, DOI 10.1038/sj.onc.1202510; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; Igarashi H, 1996, BIOCHEM BIOPH RES CO, V219, P649, DOI 10.1006/bbrc.1996.0288; Iwama H, 1997, CANCER-AM CANCER SOC, V79, P1552, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1552::AID-CNCR17>3.0.CO;2-X; Iwama H, 1998, HUM GENET, V102, P397, DOI 10.1007/s004390050711; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Le Coniat MB, 2000, LEUKEMIA, V14, P1630, DOI 10.1038/sj.leu.2401876; Lee JJ, 1999, BONE MARROW TRANSPL, V24, P411, DOI 10.1038/sj.bmt.1701923; Li BR, 2000, LEUKEMIA LYMPHOMA, V36, P579, DOI 10.3109/10428190009148406; Nakajima A, 2001, LEUKEMIA, V15, P989, DOI 10.1038/sj.leu.2402137; NILSSON P, 1994, ONCOGENE, V9, P3043; Norrback KF, 1998, BLOOD, V92, P567, DOI 10.1182/blood.V92.2.567.414a18_567_573; Norrback KF, 1997, EUR J CANCER, V33, P774, DOI 10.1016/S0959-8049(97)00059-2; Norrback KF, 1996, BLOOD, V88, P222; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; Ohyashiki JH, 1999, CLIN CANCER RES, V5, P1155; Ohyashiki JH, 1996, TRENDS GENET, V12, P395; Ohyashiki JH, 2001, INT J ONCOL, V18, P593; OHYASHIKI JH, 1994, CANCER RES, V54, P3557; Ohyashiki JH, 1997, CLIN CANCER RES, V3, P619; Ohyashiki K, 1997, LEUKEMIA, V11, P190, DOI 10.1038/sj.leu.2400560; Pan CG, 1997, EXP CELL RES, V231, P346, DOI 10.1006/excr.1997.3475; Remes K, 2000, BRIT J CANCER, V82, P601, DOI 10.1054/bjoc.1999.0970; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Rufer N, 2001, BLOOD, V97, P575, DOI 10.1182/blood.V97.2.575; Sakabe H, 1998, LEUKEMIA, V12, P728, DOI 10.1038/sj.leu.2401001; Shay JW, 1998, LANCET, V351, P153, DOI 10.1016/S0140-6736(05)78218-0; Shay JW, 1996, LEUKEMIA, V10, P1255; Shay JW, 2000, NAT BIOTECHNOL, V18, P22, DOI 10.1038/71872; Steinert S, 2000, BIOCHEM BIOPH RES CO, V273, P1095, DOI 10.1006/bbrc.2000.3080; TAKEUCHI K, 1994, JPN J CANCER RES, V85, P127; Tatematsu K, 1996, ONCOGENE, V13, P2265; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; Trentin L, 1999, BRIT J HAEMATOL, V106, P662, DOI 10.1046/j.1365-2141.1999.01620.x; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Wynn RF, 1998, LANCET, V351, P178, DOI 10.1016/S0140-6736(97)08256-1; Xu D, 1999, BRIT J CANCER, V80, P1156, DOI 10.1038/sj.bjc.6690480; Xu DW, 1998, BRIT J HAEMATOL, V102, P1367, DOI 10.1046/j.1365-2141.1998.00969.x; YAMADA O, 1995, J CLIN INVEST, V95, P1117, DOI 10.1172/JCI117759; Yeager TR, 1999, CANCER RES, V59, P4175; Yui J, 1998, BLOOD, V91, P3255, DOI 10.1182/blood.V91.9.3255.3255_3255_3262; Zhang W, 1996, CLIN CANCER RES, V2, P799	72	112	130	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					680	687		10.1038/sj.onc.1205075	http://dx.doi.org/10.1038/sj.onc.1205075			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850796				2022-12-28	WOS:000173390500023
J	Vonderheide, RH				Vonderheide, RH			Telomerase as a universal tumor-associated antigen for cancer immunotherapy	ONCOGENE			English	Article						telomerase; hTERT; tumor-associated antigen; immunotherapy	PULSED DENDRITIC CELLS; CATALYTIC SUBUNIT; MELANOMA PATIENTS; T-CELLS; REVERSE-TRANSCRIPTASE; IMMORTAL CELLS; LIFE-SPAN; EXPRESSION; LYMPHOCYTES; VACCINATION	Although the search for pharmacologic inhibitors of telomerase activity represents a promising approach for telomerase-based anti-cancer therapy, the immunological properties of the telomerase reverse transcriptase hTERT suggest that the enzyme is also an attractive target for novel immunotherapies against cancer. Data from both human and murine systems demonstrate that cytotoxic T-lymphocytes (CTL) can recognize peptides derived from TERT and kill TERT-positive tumor cells of multiple histologies. Given the vast overexpression of hTERT in human tumors and its low-level expression in rare normal tissues, clinical trials have begun that test the credentials of hTERT as a broadly applicable target for immunotherapy of cancer.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Vonderheide, RH (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, 421 Curie Blvd, Philadelphia, PA 19104 USA.							Arai J, 2001, BLOOD, V97, P2903, DOI 10.1182/blood.V97.9.2903; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chames P, 2000, P NATL ACAD SCI USA, V97, P7969, DOI 10.1073/pnas.97.14.7969; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Heiser A, 2001, CANCER RES, V61, P3388; Heiser A, 2001, J IMMUNOL, V166, P2953, DOI 10.4049/jimmunol.166.5.2953; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Jager E, 1996, INT J CANCER, V66, P470, DOI 10.1002/(SICI)1097-0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Liu KB, 1999, P NATL ACAD SCI USA, V96, P5147, DOI 10.1073/pnas.96.9.5147; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Minev B, 2000, P NATL ACAD SCI USA, V97, P4796, DOI 10.1073/pnas.070560797; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Norrback KF, 1997, EUR J CANCER, V33, P774, DOI 10.1016/S0959-8049(97)00059-2; Pittet MJ, 1999, J EXP MED, V190, P705, DOI 10.1084/jem.190.5.705; Ramakrishnan S, 1998, CANCER RES, V58, P622; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Rosenberg SA, 1997, IMMUNOL TODAY, V18, P175, DOI 10.1016/S0167-5699(97)84664-6; Schirle M, 2000, EUR J IMMUNOL, V30, P2216, DOI 10.1002/1521-4141(2000)30:18<2216::AID-IMMU2216>3.3.CO;2-F; Schultze JL, 2001, TRENDS IMMUNOL, V22, P516, DOI 10.1016/S1471-4906(01)02015-4; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Simon RM, 2001, J CLIN ONCOL, V19, P1848, DOI 10.1200/JCO.2001.19.6.1848; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Valmori D, 1999, CANCER RES, V59, P4050; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7; VANPEL A, 1995, IMMUNOL REV, V145, P229, DOI 10.1111/j.1600-065X.1995.tb00084.x; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Vonderheide RH, 2001, CLIN CANCER RES, V7, P3343; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Yasumoto S, 1996, ONCOGENE, V13, P433; Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	47	128	149	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					674	679		10.1038/sj.onc.1205074	http://dx.doi.org/10.1038/sj.onc.1205074			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850795				2022-12-28	WOS:000173390500022
J	Saintigny, Y; Lopez, BS				Saintigny, Y; Lopez, BS			Homologous recombination induced by replication inhibition, is stimulated by expression of mutant p53	ONCOGENE			English	Article						homologous recombination; replication inhibition; p53; RAD51	HUMAN RAD51 PROTEIN; CELL-CYCLE CHECKPOINT; G1 CHECKPOINT; BREAK REPAIR; MICE; DISSOCIATION; CHROMOSOMES; MECHANISMS; DEFICIENT; SEQUENCES	Cell cycle control, faithful DNA replication, repair and recombination are associated in a network of pathways controlling genome maintenance. In mammalian cells, inhibition of replication produces DNA breaks and induces RAD51-dependent recombination, in a late step. Here we examine whether the status of p53 affects this process in mouse L-cells containing a recombination substrate. We show that expression of the mutant (His175)p53 strongly stimulates recombination induced by aphidicolin, in a late step (kinetically related to the RAD51 step). Mutant p53 stimulates recombination induced by the replication elongation inhibitors (aphidicolin, hydroxyurea and Ara-C) but is without effect on recombination induced by the initiation inhibitors (mimosine and ciclopirox olamine). We compared the impact of several p53 mutations showing different effects on the G1 checkpoint and on recombination. We show that the mutant 1,273 p53 protein, which does not alter the G1 checkpoint, strongly stimulates recombination induced by elongation inhibitors. These results show that p53 can act on recombination induced by replication arrest independently of its role in the G1 checkpoint. An action of p53 via the RAD51 pathway is discussed.	CEA, UMR217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, UMR217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, 60-68 Ave Gen Leclerc, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017; Saintigny, Yannick/C-2697-2008	Lopez, Bernard S/0000-0001-5088-0155; Saintigny, Yannick/0000-0002-3839-3562				Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hyrien O, 2000, BIOCHIMIE, V82, P5, DOI 10.1016/S0300-9084(00)00344-8; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LISKAY RM, 1984, COLD SPRING HARB SYM, V49, P183, DOI 10.1101/SQB.1984.049.01.021; Maacke H, 2000, ONCOGENE, V19, P2791, DOI 10.1038/sj.onc.1203578; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; ONNO M, 1992, ONCOGENE, V7, P2519; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; Rothstein R, 2000, GENE DEV, V14, P1; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142	33	52	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					488	492		10.1038/sj.onc.1205040	http://dx.doi.org/10.1038/sj.onc.1205040			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821962	Green Published			2022-12-28	WOS:000173311200018
J	Carraresi, L; Tripodi, SA; Mulder, LCF; Bertini, S; Nuti, S; Schuerfeld, K; Cintorino, M; Bensi, G; Rossini, M; Mora, M				Carraresi, L; Tripodi, SA; Mulder, LCF; Bertini, S; Nuti, S; Schuerfeld, K; Cintorino, M; Bensi, G; Rossini, M; Mora, M			Thymic hyperplasia and lung carcinomas in a line of mice transgenic for keratin 5-driven HPV16 E6/E7 oncogenes	ONCOGENE			English	Article						human Papillomavirus type 16; E6/E7 oncogenes; transgenic mice; lung carcinomas; thymic hyperplasia	HUMAN-PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; E7 ONCOPROTEIN; BRONCHOPULMONARY CARCINOMAS; EPIDERMAL HYPERPLASIA; E6 ONCOPROTEINS; CDK INHIBITORS; HPV-16 E6; EXPRESSION; PROTEIN	Human Papillomavirus type 16 (HPV-16) is the cause of both benign lesions and ano-genital cancers. In HPV-associated cancers the transforming properties of the expressed viral E6 and E7 proteins have been revealed by a number of different assays. We have generated transgenic mice expressing HPV-16 E6/E7 genes under the control of the murine keratin 5 gene promoter, which should confer cell-type specific expression in the basal cells of squamous stratified epithelia. Transgenic mice developed thymic hyperplasia and lung neoplasia with 100% frequency, the thymus showing a size increase at 2 months and reaching the maximum dimension at 6 months, when lung carcinomas appeared. After this time the size of hyperplastic thymi decreased, while malignant formations invaded the mediastinal area. Hepatic metastasis could be also observed in some of the animals at the autopsy and death invariably occurred around 10 - 11 months of age.	Univ Siena, Dept Physiopathol & Expt Med, I-53100 Siena, Italy; Univ Siena, Inst Pathol Anat & Histol, I-53100 Siena, Italy; Chiron Res Ctr, I-53100 Siena, Italy	University of Siena; University of Siena; Novartis	Rossini, M (corresponding author), Univ Siena, Dept Physiopathol & Expt Med, Via Aldo Moro, I-53100 Siena, Italy.	rossini@unisi.it	TRIPODI, SERGIO ANTONIO/AAK-7569-2021					ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.3.CO;2-7; Boyer SN, 1996, CANCER RES, V56, P4620; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clavel CE, 2000, CANCER, V88, P1347, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1347::AID-CNCR10>3.0.CO;2-2; COMERFORD SA, 1995, ONCOGENE, V10, P587; Coussens LM, 1996, AM J PATHOL, V149, P1899; Damak S, 1996, MOL CARCINOGEN, V17, P84, DOI 10.1002/(SICI)1098-2744(199610)17:2<84::AID-MC5>3.0.CO;2-T; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eckert RL, 2000, INT J ONCOL, V16, P853; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; GRANA X, 1995, ONCOGENE, V11, P573; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; HARPER JW, 1993, CELL, V75, P805; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Hennig EM, 1999, ACTA ONCOL, V38, P639; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Hirayasu T, 1996, J CLIN PATHOL, V49, P810, DOI 10.1136/jcp.49.10.810; HOGAN B, 1986, MANIPULATING MOUSE E; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klug DB, 1998, P NATL ACAD SCI USA, V95, P11822, DOI 10.1073/pnas.95.20.11822; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LEDENT C, 1995, ONCOGENE, V10, P1789; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; MISSERO C, 1993, J CELL BIOL, V121, P1109, DOI 10.1083/jcb.121.5.1109; MOLL R, 1989, VIRCHOWS ARCH B, V58, P129, DOI 10.1007/BF02890064; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; Morris G F, 1998, J La State Med Soc, V150, P179; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Ogawa K, 1996, CARCINOGENESIS, V17, P341, DOI 10.1093/carcin/17.2.341; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rodriguez-Puebla ML, 2000, AM J PATHOL, V157, P1039, DOI 10.1016/S0002-9440(10)64616-0; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; Sampietro G, 2000, APPL IMMUNOHISTO M M, V8, P49, DOI 10.1097/00022744-200003000-00008; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; Sunday ME, 1999, ONCOGENE, V18, P4336, DOI 10.1038/sj.onc.1202810; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	83	22	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2001	20	56					8148	8153		10.1038/sj.onc.1205007	http://dx.doi.org/10.1038/sj.onc.1205007			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781829				2022-12-28	WOS:000172396800013
J	Li, G; Schaider, H; Satyamoorthy, K; Hanakawa, Y; Hashimoto, K; Herlyn, M				Li, G; Schaider, H; Satyamoorthy, K; Hanakawa, Y; Hashimoto, K; Herlyn, M			Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development	ONCOGENE			English	Review						HGF; autocrine; E-cadherin; Desmoglein; melanoma	FACTOR SCATTER FACTOR; PEMPHIGUS-VULGARIS ANTIGEN; CELL-CELL ADHESION; EFFICIENT GENE ACTIVATION; C-MET; INTERMEDIATE FILAMENTS; MALIGNANT-MELANOMA; CATENIN COMPLEX; FACTOR-RECEPTOR; BETA-CATENIN	During melanoma development, transformed cells evade keratinocyte-mediated control by downregulating cell adhesion molecules. This study investigated the regulation of cell adhesion by hepatocyte growth factor (HGF) in melanoma. Melanocytes and two melanoma lines, WM164 and WM35, expressed normal level E-cadherin and Desmoglein 1, whereas most melanomas (18 out of 20) expressed no E-cadherin and significantly reduced Desmoglein 1. Overexpression of dominant negative E-cadherin and Desmoglein in melanocytes demonstrated that both molecules contribute to adhesion between melanocytes and keratinocytes. In contrast to melanocytes, most melanomas expressed HGF. All melanocytic cells expressed the HGF receptor c-Met, and autocrine HGF caused constitutive activation of c-Met, MAPK and PI3K. When autocrine activation was induced with HGF-expressing adenovirus, E-cadherin and Desmoglein I were decreased in melanocytes, WM164 and WM35. MAPK inhibitor PD98059 and PI3K inhibitor wortmannin partially blocked the downregulation, suggesting that both pathways are involved in this process. c-Met was coimmunoprecipitated with E-cadherin, Desmoglein I and Plakoglobin, suggesting that they form a complex (es) that acts to regulate intercellular adhesion. Together, the results indicate that autocrine HGF decouples melanomas from keratinocytes by downregulating E-cadherin and Desmoglein 1, therefore frees melanoma cells from the control by keratinocytes and allows dissemination of the tumor mass.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Program Cell & Mol Biol Biomed Grad Studies, Philadelphia, PA 19104 USA; Ehime Univ, Sch Med, Dept Dermatol, Matsuyama, Ehime 790, Japan	The Wistar Institute; University of Pennsylvania; Ehime University	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.upenn.edu	Satyamoorthy, Kapaettu/H-3254-2015	Schaider, Helmut/0000-0003-3195-2517; Satyamoorthy, Kapaettu/0000-0002-2368-5490	NATIONAL CANCER INSTITUTE [R01CA047159, R01CA080999, P30CA010815, P01CA025874, R01CA076674] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47159, CA-80999, CA-76674, CA-10815, CA-25874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABERLE H, 1994, J CELL SCI, V107, P3655; ALBELDA SM, 1990, CANCER RES, V50, P6757; AMAGAI M, 1994, J INVEST DERMATOL, V102, P402, DOI 10.1111/1523-1747.ep12372164; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; Amagai M, 1996, J INVEST DERMATOL, V106, P351, DOI 10.1111/1523-1747.ep12343081; Bauer A, 1998, J BIOL CHEM, V273, P28314, DOI 10.1074/jbc.273.43.28314; BELLUSCI S, 1994, ONCOGENE, V9, P1091; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUTZ S, 1994, FEBS LETT, V355, P195, DOI 10.1016/0014-5793(94)01205-9; CONN IG, 1990, BRIT J UROL, V65, P176, DOI 10.1111/j.1464-410X.1990.tb14694.x; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Danen EHJ, 1996, MELANOMA RES, V6, P127, DOI 10.1097/00008390-199604000-00007; De Bruin A, 1999, CELL ADHES COMMUN, V7, P13; Depondt J, 1999, EUR J ORAL SCI, V107, P183, DOI 10.1046/j.0909-8836.1999.eos1070305.x; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Halaban R, 1993, EXS, V65, P329; HALABAN R, 1992, ONCOGENE, V7, P2195; Hanakawa Y, 2000, J CELL SCI, V113, P1803; Hendrix MJC, 1998, AM J PATHOL, V152, P855; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hiscox S, 1999, ANTICANCER RES, V19, P509; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Imokawa G, 1998, BIOCHEM J, V330, P1235, DOI 10.1042/bj3301235; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Jouneau A, 2000, PIGM CELL RES, V13, P260, DOI 10.1034/j.1600-0749.2000.130408.x; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Kos L, 1999, PIGM CELL RES, V12, P13, DOI 10.1111/j.1600-0749.1999.tb00503.x; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Krunic ALJ, 1996, ACTA DERM-VENEREOL, V76, P394; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Li G, 2001, CANCER RES, V61, P3819; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Moriyama T, 1999, INT J MOL MED, V3, P531; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Noonan FP, 2000, CANCER RES, V60, P3738; North AJ, 1999, J CELL SCI, V112, P4325; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; Otsuka T, 1998, CANCER RES, V58, P5157; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Phaneuf D, 2000, MOL MED, V6, P96, DOI 10.1007/BF03401777; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; POSER I, 2001, J BIOL CHEM, V25, P25; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rickman L, 1999, HUM MOL GENET, V8, P971, DOI 10.1093/hmg/8.6.971; Ries LAG, 2000, CANCER-AM CANCER SOC, V88, P2398, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; ROH JY, 1995, J INVEST DERMATOL, V104, P720, DOI 10.1111/1523-1747.ep12606963; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rusciano D, 1998, TUMOR BIOL, V19, P335, DOI 10.1159/000030026; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Scott GA, 1998, J INVEST DERMATOL, V111, P243, DOI 10.1046/j.1523-1747.1998.00276.x; Shinohara M, 1998, J PATHOL, V184, P369, DOI 10.1002/(SICI)1096-9896(199804)184:4<369::AID-PATH1236>3.0.CO;2-L; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STANLEY JR, 1993, ADV IMMUNOL, V53, P291, DOI 10.1016/S0065-2776(08)60503-9; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; Steinberg MS, 1996, DEV BIOL, V180, P377, DOI 10.1006/dbio.1996.0312; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tada H, 2000, J CUTAN PATHOL, V27, P24, DOI 10.1034/j.1600-0560.2000.027001024.x; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TAKEICHI M, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P28; Tamatani T, 1999, CARCINOGENESIS, V20, P957, DOI 10.1093/carcin/20.6.957; TANG A, 1994, J CELL SCI, V107, P983; To CTT, 1998, ONCOL REP, V5, P1013; Troyanovsky S M, 1998, Subcell Biochem, V31, P263; Trusolino L, 1998, J CELL BIOL, V142, P1145, DOI 10.1083/jcb.142.4.1145; Van Belle PA, 1999, HUM PATHOL, V30, P562, DOI 10.1016/S0046-8177(99)90202-2; VANDEWOUDE GF, 1997, CIBA F SYMP, V212, P130	102	142	149	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2001	20	56					8125	8135		10.1038/sj.onc.1205034	http://dx.doi.org/10.1038/sj.onc.1205034			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781826				2022-12-28	WOS:000172396800010
J	Chakravarti, D; Mailander, PC; Li, KM; Higginbotham, S; Zhang, HL; Gross, ML; Meza, JL; Cavalieri, EL; Rogan, EG				Chakravarti, D; Mailander, PC; Li, KM; Higginbotham, S; Zhang, HL; Gross, ML; Meza, JL; Cavalieri, EL; Rogan, EG			Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene	ONCOGENE			English	Article						estradiol-3,4-quinone; depurinating adducts; abasic sites; DNA repair; mismatched heteroduplex; H-ras mutation in SENCAR mouse skin	BASE EXCISION-REPAIR; HAMSTER OVARY CELLS; DEOXYRIBONUCLEIC ACID; TUMOR INITIATION; IN-VITRO; ADDUCTS; GLYCOSYLASE; SITES; OVEREXPRESSION; IDENTIFICATION	Treatment of SENCAR mouse skin with dibenzo[a,l]pyrene results in abundant formation of abasic sites that undergo error-prone excision repair, forming oncogenic H-ras mutations in the early preneoplastic period. To examine whether the abundance of abasic sites causes repair infidelity, we treated SENCAR mouse skin with estradiol-3,4-quinone (E-2-3,4-Q) and determined adduct levels I h after treatment, as well as mutation spectra in the H-ras gene between 6 h and 3 days after treatment. E-2-3,4-Q formed predominantly (greater than or equal to 99%) the rapidly-depurinating 4-hydroxy estradiol (4-OHE2)-1-N3Ade adduct and the slower-depurinating 4-OHE2-1-N7Gua adduct. Between 6 h and 3 days, E-2-3,4-Q induced abundant A to G mutations in H-ras DNA, frequently in the context of a 3'-G residue. Using a T.G-DNA glycosylase (TDG)-PCR assay, we determined that the early A to G mutations (6 and 12 h) were in the form of G.T heteroduplexes, suggesting misrepair at A-specific depurination sites. Since G-specific mutations were infrequent in the spectra, it appears that the slow rate of depurination of the N7Gua adducts during active repair may not generate a threshold level of G-specific abasic sites to affect repair fidelity. These results also suggest that E-2-3,4-Q, a suspected endogenous carcinogen, is a genotoxic compound and could cause mutations.	Univ Nebraska, Med Ctr 986805, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr 986805, Dept Prevent & Societal Med, Omaha, NE 68198 USA; Washington Univ, Dept Chem, St Louis, MO 63130 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Washington University (WUSTL)	Chakravarti, D (corresponding author), Univ Nebraska, Med Ctr 986805, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.				NCI NIH HHS [P01 CA49210, CA 36727] Funding Source: Medline; NCRR NIH HHS [P41 RR 00954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049210, P30CA036727] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; BOWDEN GT, 1974, CHEM-BIOL INTERACT, V8, P379, DOI 10.1016/0009-2797(74)90044-1; Braithwaite E, 1998, CARCINOGENESIS, V19, P1239, DOI 10.1093/carcin/19.7.1239; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CAVALIERI EL, 1998, HDB ENV CHEM PAHS J, V3, P81; CHAKRAVARTI D, 1995, P NATL ACAD SCI USA, V92, P10422, DOI 10.1073/pnas.92.22.10422; Chakravarti D, 1998, ONCOGENE, V16, P3203, DOI 10.1038/sj.onc.1201853; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; Chakravarti D, 2000, MUTAT RES-FUND MOL M, V456, P17, DOI 10.1016/S0027-5107(00)00102-0; Chakravarti D, 1998, DNA CELL BIOL, V17, P529, DOI 10.1089/dna.1998.17.529; Chen L, 1996, CHEM RES TOXICOL, V9, P897, DOI 10.1021/tx960004a; Choi DJ, 1996, J MOL BIOL, V264, P213, DOI 10.1006/jmbi.1996.0635; COQUERELLE T, 1995, MUTAT RES-DNA REPAIR, V336, P9, DOI 10.1016/0921-8777(94)00035-5; Dean SW, 1998, MUTAGENESIS, V13, P515, DOI 10.1093/mutage/13.5.515; DWIVEDY I, 1992, CHEM RES TOXICOL, V5, P828, DOI 10.1021/tx00030a016; GILL RD, 1991, ENVIRON MOL MUTAGEN, V18, P200, DOI 10.1002/em.2850180307; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; GORELICK NJ, 1995, MOL CARCINOGEN, V14, P53, DOI 10.1002/mc.2940140110; IBEANU G, 1992, CARCINOGENESIS, V13, P1989, DOI 10.1093/carcin/13.11.1989; Jankowiak R, 1998, CHEM RES TOXICOL, V11, P1339, DOI 10.1021/tx980119+; Jankowiak R, 1998, CHEM RES TOXICOL, V11, P674, DOI 10.1021/tx970232k; KAUFMANN WK, 1995, CANCER METAST REV, V14, P31, DOI 10.1007/BF00690209; KLUGLAND A, 1992, EMBO J, V11, P4439; Kong LY, 2000, INT J ONCOL, V17, P1141; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; Li K.-M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P636; Li K.-M., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P46; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1973, BIOCHEMISTRY-US, V12, P5151, DOI 10.1021/bi00749a020; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; MAHER VM, 1987, MECH CELLULAR TRANSF, P135; Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875; Nakamura J, 1999, CANCER RES, V59, P2522; Nakamura J, 1998, CANCER RES, V58, P222; *NIH, 1981, NIH GUID LAB US CHEM; PAULES RS, 1988, P NATL ACAD SCI USA, V85, P2176, DOI 10.1073/pnas.85.7.2176; Robertson KA, 2001, CANCER RES, V61, P2220; ROGAN EG, 1993, CHEM RES TOXICOL, V6, P356, DOI 10.1021/tx00033a017; ROMENTY B, 2000, NUCLEIC ACIDS RES, V28, pE50; SAWYER TW, 1988, CARCINOGENESIS, V9, P1197, DOI 10.1093/carcin/9.7.1197; Skopek TR, 1996, ENVIRON MOL MUTAGEN, V28, P376; SLAGA TJ, 1974, CANCER RES, V34, P771; SLAGA TJ, 1973, CANCER RES, V33, P769; Stack D E, 1998, Adv Pharmacol, V42, P833; Terashima I, 2001, BIOCHEMISTRY-US, V40, P166, DOI 10.1021/bi002273c; Tsutsui T, 2000, INT J CANCER, V86, P8, DOI 10.1002/(SICI)1097-0215(20000401)86:1<8::AID-IJC2>3.0.CO;2-V; WATANABE M, 1985, MUTAT RES, V146, P285, DOI 10.1016/0167-8817(85)90070-7	49	162	167	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7945	7953		10.1038/sj.onc.1204969	http://dx.doi.org/10.1038/sj.onc.1204969			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753677				2022-12-28	WOS:000172288700003
J	Zhang, DM; Vuocolo, S; Masciullo, V; Sava, T; Giordano, A; Soprano, DR; Soprano, KJ				Zhang, DM; Vuocolo, S; Masciullo, V; Sava, T; Giordano, A; Soprano, DR; Soprano, KJ			Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression	ONCOGENE			English	Article						RB; RB-2/p130; ovarian carcinoma; retinoic acid	NEURONAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; ADENOCARCINOMA CELLS; CARCINOMA-CELLS; B-LYMPHOCYTES; CANCER CELLS; G(1) CONTROL; ACID; PHOSPHORYLATION; INHIBITION	We have examined the effect of all-trans-retinoic acid (RA) on cell cycle gene expression in RA sensitive CAOV3 and RA resistant SK-OV3 ovarian carcinoma cell lines. Gene expression was analysed by multiprobe RNAse protection, Western blotting and in vitro kinase assays. No differences were observed between RA sensitive and RA resistant ovarian carcinoma cells in the levels of expression of many cell cycle genes including cyclin A, B and E, cdk 2,4 and 6, E2F-1, E2F-2, E2F-3, E2F-4, E2F-5, DP-1 and DP-2. However, RA sensitive CA-OV3 cells expressed higher levels of p53, p27, p21, and p16 compared to RA resistant SK-OV3 cells. In addition, RA treatment of CA-OV3 cells resulted in a significant decrease in hyperphosphorylated RB and RB-2/p130 and corresponding significant increases in the levels of hypophosphorylated and/or partially phosphorylated RB-2/p130 protein and hypophosphorylated RB. Also, RA treatment increased expression of the cdk inhibitor p27 and decreased activity of cdk 2, cdk 4 and cdk 6. Finally, amounts of p27-cyclin E and RB-2/p130-E2F4 complexes were found to increase in CA-OV3 cells growth arrested by RA. These results suggest that the pocket protein pathways are critical targets for retinoid suppression of ovarian carcinoma cell growth.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3400 N Broad St, Philadelphia, PA 19140 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X	NATIONAL CANCER INSTITUTE [R01CA064945, R01CA060999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NCI NIH HHS [CA60999, CA64945] Funding Source: Medline; NIDDK NIH HHS [DK 49045] Funding Source: Medline; NINDS NIH HHS [NS36466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Claudio PP, 1996, CANCER RES, V56, P2003; Daly M, 1998, SEMIN ONCOL, V25, P255; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; GRUNT TW, 1991, J CELL SCI, V100, P657; GRUNT TW, 1992, J CELL PHYSIOL, V151, P13, DOI 10.1002/jcp.1041510104; GRUNT TW, 1992, J CELL SCI, V103, P501; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hoskins WJ, 1995, J CELL BIOCHEM, P189; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Mangelsdorf David J., 1994, P319; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MAYOL X, 1995, ONCOGENE, V11, P801; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Seewaldt VL, 1999, EXP CELL RES, V249, P70, DOI 10.1006/excr.1999.4462; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Soprano DR, 1996, ONCOGENE, V12, P577; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sueoka N, 1999, CANCER RES, V59, P3838; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Watanabe Y, 1999, BRAIN RES, V842, P342, DOI 10.1016/S0006-8993(99)01844-2; Weber E, 1999, INT J CANCER, V80, P935, DOI 10.1002/(SICI)1097-0215(19990315)80:6<935::AID-IJC21>3.0.CO;2-E; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Wu SJ, 1998, ONCOGENE, V17, P2839, DOI 10.1038/sj.onc.1202208; Wu SJ, 1997, EXP CELL RES, V237, P118, DOI 10.1006/excr.1997.3769; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	52	39	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2001	20	55					7935	7944		10.1038/sj.onc.1204971	http://dx.doi.org/10.1038/sj.onc.1204971			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753676				2022-12-28	WOS:000172288700002
J	Wu, WS; Xu, ZX; Ran, RX; Meng, F; Chang, KS				Wu, WS; Xu, ZX; Ran, RX; Meng, F; Chang, KS			Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions	ONCOGENE			English	Article						PML; Nur77; transcriptional regulation; apoptosis	CREB BINDING-PROTEIN; RAR-ALPHA; ORPHAN RECEPTOR; GROWTH-FACTORS; NGFI-B; NUCLEAR; GENE; APOPTOSIS; NUR77; TRANSFORMATION	The promyelocytic leukemia protein PML is a tumor and growth suppressor and plays an important role in a multiple pathways of apoptosis and regulation of cell cycle progression. Our previous studies and others also documented a role of PML in transcriptional regulation through its association with transcription coactivator CBP and transcription corepressor HDAC. Here, we showed that PML is a potent transcriptional repressor of Nur77, an orphan receptor and a member of the steroid receptor superfamily of proteins. We found that PML represses Nur77-mediated transactivation through a physical and functional interaction between the two proteins. PML interacts with Nur-77 in vitro in a GST-pull down assay and in vivo by coimmunoprecipitation assay. PML/Nur77 colocalized in vivo in a double immunofluorescent staining and confocal microscopic analysis. Our study further showed that the coiled-coil domain of PML interacts with the DNA-binding domain of Nur77 (amino acids 267-332). Electrophoretic mobility shift assay demonstrated that PML interferes with Nur77 DNA binding in a dose-dependent manner. This study indicates that PML interacts with the DNA-binding domain of Nur77 and represses transcription by preventing it from binding to the target promoter. This study supports a role of PML/Nur77 interaction in regulating cell growth and apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Chang, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	kchang@mail.mdanderson.org	Wu, Wen-Shu/I-1258-2014	Wu, Wen-Shu/0000-0002-0225-2522	NCI NIH HHS [CA-11627, CA-55577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055577, R01CA011627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amsen D, 1999, P NATL ACAD SCI USA, V96, P622, DOI 10.1073/pnas.96.2.622; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; CALNAN BJ, 1995, IMMUNITY, V3, P273; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Duprez E, 1999, J CELL SCI, V112, P381; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NAKAI A, 1990, MOL ENDOCRINOL, V4, P1438, DOI 10.1210/mend-4-10-1438; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VALLIAN S, 1998, ONCOGENE, V90, P3265; Wang ZG, 1998, SCIENCE, V279, P1547; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	48	29	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3925	3933		10.1038/sj.onc.1205491	http://dx.doi.org/10.1038/sj.onc.1205491			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032831				2022-12-28	WOS:000175847200012
J	van Engeland, M; Roemen, GMJM; Brink, M; Paachen, MMM; Weijenberg, MP; de Bruine, AP; Arends, JW; van den Brandt, PA; de Goeij, AFPM; Herman, JG				van Engeland, M; Roemen, GMJM; Brink, M; Paachen, MMM; Weijenberg, MP; de Bruine, AP; Arends, JW; van den Brandt, PA; de Goeij, AFPM; Herman, JG			K-ras mutations and RASSF1A promoter methylation in colorectal cancer	ONCOGENE			English	Article						K-Ras; methylation; RASSF1A; silencing	TUMOR-SUPPRESSOR GENE; FREQUENT EPIGENETIC INACTIVATION; CPG ISLAND; HYPERMETHYLATION; 3P21.3; LUNG; CELL; BREAST; PROTEIN; OVARIAN	Human cancer is characterized by genetic and epigenetic alterations. In this study we provide evidence for the interruption of Ras signaling in sporadic colorectal cancer (CRC) by either genetic activation of the K-ras oncogene or epigenetic silencing of the putative tumor suppressor gene RASSF1A. Paraffin embedded tumor tissue samples from 222 sporadic CRC patients were analysed for K-ras codon 12 and codon 13 activating mutations and RASSF1A promoter hypermethylation. Overall, K-ras mutations were observed in 87 of 222 (39%) and RASSF1A methylation was observed in 45 of 222 (20%) of CRCs. Mutation of K-ras alone was detected in 76 of 222 (34%) CRCs. RASSF1A promoter methylation with wild-type K-ras was observed in 34 of 222 (15%) CRCs. In 101 of 222 (46%) CRCs neither K-ras mutations nor RASSF1A methylation was observed and 11 of 222 (5%) CRCs showed both K-ras mutations and RASSF1A methylation. These data show that the majority of the studied CRCs with K-ras mutations lack RASSF1A promoter methylation, an event which occurs predominantly in K-ras wild-type CRCs (P=0.023, Chi-square test).	Johns Hopkins Oncol Ctr, 1650 Orleans St,Room 543, Baltimore, MD 21231 USA; Univ Maastricht, Dept Pathol, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Dept Epidemiol, NL-6200 MD Maastricht, Netherlands	Johns Hopkins University; Johns Hopkins Medicine; Maastricht University; Maastricht University	Herman, JG (corresponding author), Johns Hopkins Oncol Ctr, 1650 Orleans St,Room 543, Baltimore, MD 21231 USA.	hermanji@jhmi.edu	van Engeland, Manon/A-7479-2009	van Engeland, Manon/0000-0002-7952-6843; van den Brandt, Piet/0000-0001-8781-8099				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; BOS JL, 1989, CANCER RES, V49, P4682; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 2000, CANCER RES, V60, P129; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2001, CANCER RES, V61, P8659; Morrissey C, 2001, CANCER RES, V61, P7277; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sparks AB, 1998, CANCER RES, V58, P1130; VANDENBRANDT PA, 1990, J CLIN EPIDEMIOL, V43, P285, DOI 10.1016/0895-4356(90)90009-E; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	25	156	170	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3792	3795		10.1038/sj.onc.1205466	http://dx.doi.org/10.1038/sj.onc.1205466			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032847	Bronze, Green Submitted			2022-12-28	WOS:000175676000014
J	Krause, DS				Krause, DS			Regulation of hematopoietic stem cell fate	ONCOGENE			English	Article						hematopoiesis; microenvironment; differentiation; niche; notch	GROWTH-FACTOR; STROMAL CELLS; HUMAN HOMOLOG; ERYTHROID-DIFFERENTIATION; NOTCH LIGAND; IN-VITRO; EXPRESSION; LEUKEMIA; TRANSCRIPTION; PROGENITORS		Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA	Yale University	Krause, DS (corresponding author), Yale Univ, Sch Med, Dept Lab Med, 333 Cedar St, New Haven, CT 06520 USA.	diane.krause@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL063357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63357] Funding Source: Medline; NIDDK NIH HHS [DK 53037] Funding Source: Medline; PHITPO CDC HHS [HK 69207] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHITPO CDC HHS		Becker PS, 1999, EXP HEMATOL, V27, P533, DOI 10.1016/S0301-472X(98)00037-X; Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324; Billia F, 2001, BLOOD, V97, P2257, DOI 10.1182/blood.V97.8.2257; Bond HM, 1998, STEM CELLS, V16, P136, DOI 10.1002/stem.160136; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brouard N, 1998, LEUKEMIA, V12, P1128, DOI 10.1038/sj.leu.2401081; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Coulombel L, 1997, ACTA HAEMATOL-BASEL, V97, P13, DOI 10.1159/000203655; Craddock CF, 1997, BLOOD, V90, P4779, DOI 10.1182/blood.V90.12.4779.4779_4779_4788; Dao MA, 1999, LEUKEMIA, V13, P1473, DOI 10.1038/sj.leu.2401537; Detmer K, 2000, BLOOD CELL MOL DIS, V26, P360, DOI 10.1006/bcmd.2000.0318; DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; EAVES CJ, 1991, BLOOD, V78, P110; Florence B, 1998, GENETICS, V150, P1497; Fortunel N, 2000, STEM CELLS, V18, P102, DOI 10.1634/stemcells.18-2-102; Goodman RH, 2000, GENE DEV, V14, P1553; Hayflick L, 1998, EXP GERONTOL, V33, P639, DOI 10.1016/S0531-5565(98)00023-0; HENSCHLER R, 1994, BLOOD, V84, P2898, DOI 10.1182/blood.V84.9.2898.bloodjournal8492898; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; JACOBSEN FW, 1995, BLOOD, V86, P2957; Jensen UB, 1999, DEVELOPMENT, V126, P2409; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Koyano-Nakagawa N, 1999, MOL CELL NEUROSCI, V14, P327, DOI 10.1006/mcne.1999.0783; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Levesque JP, 1999, EXP HEMATOL, V27, P579, DOI 10.1016/S0301-472X(98)00069-1; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; McNiece I, 2001, EXP HEMATOL, V29, P3, DOI 10.1016/S0301-472X(00)00610-X; MILNER LA, 1994, BLOOD, V83, P2057; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Montecino-Rodriguez E, 2001, J LEUKOCYTE BIOL, V70, P341; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PAPAYANNOPOULOU T, 1993, P NATL ACAD SCI USA, V90, P9374, DOI 10.1073/pnas.90.20.9374; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; Rosendaal Martin, 2000, Pathology and Oncology Research, V6, P243; Sharma AK, 2001, BLOOD, V97, P426, DOI 10.1182/blood.V97.2.426; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sitnicka E, 1996, BLOOD, V88, P82; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai S, 2000, BLOOD, V96, P950, DOI 10.1182/blood.V96.3.950.015k43_950_957; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Valdez P, 1999, COLD SPRING HARB SYM, V64, P27, DOI 10.1101/sqb.1999.64.27; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Walker L, 1999, STEM CELLS, V17, P162, DOI 10.1002/stem.170162; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320; Zandstra PW, 1997, P NATL ACAD SCI USA, V94, P4698, DOI 10.1073/pnas.94.9.4698; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	68	71	74	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3262	3269		10.1038/sj.onc.1205316	http://dx.doi.org/10.1038/sj.onc.1205316			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032767				2022-12-28	WOS:000175633300002
J	Miller, WH; Waxman, S				Miller, WH; Waxman, S			Differentiation induction as a treatment for hematologic malignancies	ONCOGENE			English	Review						differentiation therapy; acute promyelocytic leukemia; retinoids; arsenic trioxide; transcriptional repression	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; PML-RAR-ALPHA; ARSENIC TRIOXIDE AS2O3; HISTONE DEACETYLASE; IN-VITRO; MYELOID-LEUKEMIA; RECEPTOR-ALPHA; TRANSCRIPTION FACTORS; COMPLETE REMISSION		Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res & SMBD, Montreal, PQ H3T 1E2, Canada	Icahn School of Medicine at Mount Sinai; Lady Davis Institute; McGill University	Waxman, S (corresponding author), Mt Sinai Sch Med, Dept Med, Box 1178,1 Gustave L Levy Pl, New York, NY 10029 USA.	Samuel.Wadman@mssm.edu			NATIONAL CANCER INSTITUTE [R01CA059936, R01CA085748] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85748, R01 CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN MJ, 1995, ONCOGENE, V10, P2307; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Atweh GF, 2001, CURR OPIN HEMATOL, V8, P123, DOI 10.1097/00062752-200103000-00010; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Chikayama S, 1998, HAEMATOLOGIA, V29, P115; COMIC M, 1994, LEUKEMIA, V8, P914; Cote S, 2000, BLOOD, V96, P3200, DOI 10.1182/blood.V96.9.3200.h8003200_3200_3208; CUNNINGHAM ML, 1994, EUR J BIOCHEM, V221, P285, DOI 10.1111/j.1432-1033.1994.tb18740.x; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Dalla-Favera Riccardo, 1996, P139; Davis AF, 1997, J CELL BIOCHEM, V65, P308, DOI 10.1002/(SICI)1097-4644(19970601)65:3<308::AID-JCB2>3.0.CO;2-W; DAVISON K, 1999, AM ASS CANC RES, V40, P120; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; DELVA L, 1993, BLOOD, V82, P2175; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Ding W, 1998, BLOOD, V92, P1172, DOI 10.1182/blood.V92.4.1172.416k02_1172_1183; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Douer D, 2001, BLOOD, V97, P73, DOI 10.1182/blood.V97.1.73; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Downing JR, 2001, LEUKEMIA, V15, P664, DOI 10.1038/sj.leu.2402035; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FENAUX P, 1994, LEUKEMIA, V8, pS42; Fenaux P, 2001, SEMIN HEMATOL, V38, P13, DOI 10.1053/shem.2001.20862; Ferrari A C, 1994, Cancer Chemother Biol Response Modif, V15, P337; Finch RA, 2000, BLOOD, V96, P2262; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; GambacortiPasserini C, 1996, BLOOD, V88, P1411, DOI 10.1182/blood.V88.4.1411.bloodjournal8841411; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 2001, CURR TOP MICROBIOL, V254, P165; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Han ZT, 1998, P NATL ACAD SCI USA, V95, P5357, DOI 10.1073/pnas.95.9.5357; HASSAN HT, 1991, EUR J CLIN PHARMACOL, V41, P531, DOI 10.1007/BF00314980; Hisatake J, 2001, BLOOD, V97, P2427, DOI 10.1182/blood.V97.8.2427; Hozumi M, 1998, INT J HEMATOL, V68, P107; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huang YC, 1998, CLIN CANCER RES, V4, P2503; Huang Yicong, 1994, Molecular and Cellular Differentiation, V2, P83; Huang Yicong, 1995, Molecular and Cellular Differentiation, V3, P241; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Jing YK, 2000, BLOOD, V96, p309A; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Kosugi H, 2001, JPN J CANCER RES, V92, P529, DOI 10.1111/j.1349-7006.2001.tb01126.x; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Makishima M, 1999, BIOCHEM PHARMACOL, V57, P521, DOI 10.1016/S0006-2952(98)00329-3; MANN KK, 2001, JOINT INT C APL DIFF, P44; MATUSHANSKY I, 2000, FRONT BIOSCI, V5, pD4848; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MUINDI J, 1992, BLOOD, V79, P299; Nervi C, 1998, BLOOD, V92, P2244; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Niitsu N, 1997, BIOCHEM BIOPH RES CO, V238, P100, DOI 10.1006/bbrc.1997.7250; Niitsu N, 1999, LEUKEMIA LYMPHOMA, V34, P261, DOI 10.3109/10428199909050951; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Novick S, 1999, BLOOD, V94, p61A; Novitzky N, 2000, AM J HEMATOL, V63, P212, DOI 10.1002/(SICI)1096-8652(200004)63:4<212::AID-AJH9>3.0.CO;2-D; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; RAZA A, 1993, AM J HEMATOL, V42, P147, DOI 10.1002/ajh.2830420202; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Richon VM, 2001, BLOOD CELL MOL DIS, V27, P260, DOI 10.1006/bcmd.2000.0376; Rifkind RA, 1996, PHARMACOL THERAPEUT, V69, P97, DOI 10.1016/0163-7258(95)02044-6; ROWINSKY EK, 1992, LEUKEMIA, V6, P526; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Saba H I, 2001, Cancer Control, V8, P79; Sanz MA, 2000, BLOOD, V96, P1247; SCHER BM, 1982, CANCER RES, V42, P1300; SCHER W, 1983, CURRENT CONCEPTS ERY, P301; SCHWARTZ EL, 1983, CANCER RES, V43, P2725; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shiohara M, 2001, CANCER RES, V61, P3361; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; STRAIR RK, 2001, JOINT INT C APL DIFF, P39; SUH N, 1999, CANCER RES, P336; Takeuchi M, 1998, LEUKEMIA LYMPHOMA, V31, P441, DOI 10.3109/10428199809057604; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Teofili L, 2001, BLOOD, V98, P495, DOI 10.1182/blood.V98.2.495; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; TRUMP DL, 2001, JOINT INT C APL DIFF, V47; VANDRIEL R, 1991, J CELL BIOCHEM, V47, P311, DOI 10.1002/jcb.240470405; Wang JX, 1999, CANCER RES, V59, P2766; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZG, 1998, SCIENCE, V279, P1547; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Waxman S, 2000, LEUKEMIA, V14, P491, DOI 10.1038/sj.leu.2401714; WAXMAN S, 1990, CANCER RES, V50, P3878; WAXMAN S, 2001, JOINT INT C APL DIFF, P22; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WITCHER M, 2001, JOINT INT C APL DIFF, P28; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yang CH, 1999, BRIT J CANCER, V81, P796, DOI 10.1038/sj.bjc.6690766; Zhu J, 2001, BLOOD, V98, P2563, DOI 10.1182/blood.V98.8.2563; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	118	24	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3496	3506		10.1038/sj/onc/1205328	http://dx.doi.org/10.1038/sj/onc/1205328			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032784				2022-12-28	WOS:000175633300019
J	He, Q; Lee, DI; Rong, R; Yu, M; Luo, X; Klein, M; El-Deiry, WS; Huang, Y; Hussain, A; Sheikh, MS				He, Q; Lee, DI; Rong, R; Yu, M; Luo, X; Klein, M; El-Deiry, WS; Huang, Y; Hussain, A; Sheikh, MS			Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway	ONCOGENE			English	Article						ER-stress; thapsigargin; death receptors; caspases; apoptosis; TRAIL	GENE-EXPRESSION; GENOTOXIC STRESS; KILLER/DR5 GENE; RELEASE; PROTEIN; INHIBITOR; LIGAND	Thapsigargin (TG), by inducing perturbations in cellular Ca2+ homeostasis, has been shown to induce apoptosis. The molecular mechanisms of Ca2+ perturbation-induced apoptosis are not fully understood. In this study, we demonstrate for the first time that TG-mediated perturbations in Ca2+ homeostasis are coupled with activation of the death receptor 5 (DR5)-dependent apoptotic pathway in human cancer cells. TG selectively upregulated DR5 but had no effect on the expression 4 the other TRAIL receptor, DR4. TG also upregulated the expression of the DR5 ligand TRAIL (tumor necrosis factor-related apoptosis inducing ligand), albeit in a cell-type specific manner. TG-induced apoptosis has been shown to be associated with activation of the mitochondrial pathway. We found that TG upregulation of DR5 and TRAIL was coupled with caspase 8 activation and Bid cleavage, suggesting that the TG-regulated DR5 pathway could be linked to the mitochondrial pathway. TG enhanced not only DR5 mRNA stability but also increased induction of the DR5 genomic promoter-reporter gene. The TG-induced increase in DR5 expression appeared to occur as a consequence of TG-induced endoplasmic reticulum (ER) Ca2+ pool depletion. Thus, we report our novel findings that ER Ca2+ pool depletion-induced apoptotic signals are mediated, at least in part, via a DR5-dependent apoptotic pathway and there appears to be a cross-talk between the death receptor and mitochondrial pathways.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; Univ Maryland, Sch Med, Dept Biochem, Greenebaum Canc Ctr,Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Univ Penn, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Sch Med, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute; University of Pennsylvania	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NATIONAL CANCER INSTITUTE [R21CA089043] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NCI NIH HHS [CA89043] Funding Source: Medline; NHLBI NIH HHS [P01HL27867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; FURUYA Y, 1994, CANCER RES, V54, P6167; Griffith TS, 1999, J IMMUNOL, V162, P2597; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Huang Y, 2001, CANCER RES, V61, P6918; JACKMAN J, 1994, CANCER RES, V54, P5656; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI WWF, 1993, J BIOL CHEM, V268, P12003; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ruth JH, 1999, AM J RESP CELL MOL, V21, P621, DOI 10.1165/ajrcmb.21.5.3694; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547; Wei MC, 2000, GENE DEV, V14, P2060; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805	28	85	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2623	2633		10.1038/sj.onc.1205345	http://dx.doi.org/10.1038/sj.onc.1205345			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965535				2022-12-28	WOS:000174996500002
J	Day, RM; Soon, L; Breckenridge, D; Bridges, B; Patel, BKR; Wang, LM; Corey, SJ; Bottaro, DP				Day, RM; Soon, L; Breckenridge, D; Bridges, B; Patel, BKR; Wang, LM; Corey, SJ; Bottaro, DP			Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways	ONCOGENE			English	Article						growth factor; cytokine; signal transduction; cell proliferation	FACTOR SCATTER FACTOR; C-MET; TYROSINE KINASE; FACTOR ISOFORMS; FACTOR-RECEPTOR; MAP KINASE; CELLS; TRANSDUCTION; ACTIVATION; HGF/SF	Hepatocyte growth factor (HGF) regulates various physiological and developmental processes in concerti with other growth factors, cytokines and hormones. We examined interactions between cell signaling events elicited by HGF and the cytokine interleukin (IL)-4, in the IL-3-dependent murine myeloid cell line 32D transfected with the human HGF receptor, c-Met. HGF was a potent mitogen in these cells, and prevented apoptosis in response to IL-3 withdrawal. IL-4 showed modest anti-apoptotic activity, but no significant mitogenic activity. IL-4 synergistically enhanced HGF-stimulated DNA synthesis, whereas only additive prevention of apoptosis was observed. IL-4 did not enhance HGF-dependent tyrosine phosphorylation of c-Met or She. In contrast, HGF-stimulated activation of MAP kinases was enhanced by IL-4, suggesting that the IL-4 and HGF signaling pathways converge upstream of these events. Although phosphatidylinositol 3-kinase (PI3K) inhibitors diminished HGF-induced mitogenesis, antiapoptosis, and MAP kinase activation, IL-4 enhanced HGF signaling persisted even in the presence of these inhibitors. IL-4 enhancement of HGF signaling was partially blocked in 32D/c-Met cells treated with inhibitors of MEK1 or c-Src kinases, completely blocked by expression of a catalytically inactive mutant of Janus kinase 3 (Jak3), and increased in 32D/c,Met cells overexpressing STAT6. Our results suggest that the IL-4 and HGF pathways converge at multiple levels, and that IL-4-dependent Jak3 and STAT6 activities modulate signaling events independent of PI3K to enhance, HGF-dependent mitogenesis in myeloid cells, and possibly other common cellular targets.	NCI, Cellular & Mol Biol Lab, Div Basic Sci, Natl Inst Hlth, Bethesda, MD USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bottaro, DP (corresponding author), EntreMed Inc, Dept Cell & Mol Biol, Rockville, MD 20850 USA.	donb@entremed.com	Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Balkovetz DF, 1999, INT REV CYTOL, V186, P225; BARDELLI A, 1992, ONCOGENE, V7, P1973; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Borset M, 1999, LEUKEMIA LYMPHOMA, V32, P249, DOI 10.3109/10428199909167385; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; DELANEY B, 1993, LIFE SCI, V53, pPL89, DOI 10.1016/0024-3205(93)90654-L; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GOHDA E, 1995, LEUKEMIA LYMPHOMA, V19, P197; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hassuneh MR, 1997, BLOOD, V89, P610, DOI 10.1182/blood.V89.2.610; HOON DSB, 1991, CANCER RES, V51, P5687; Iguchi T, 1999, STEM CELLS, V17, P82, DOI 10.1002/stem.170082; Ikehara S, 1996, LEUKEMIA LYMPHOMA, V23, P297, DOI 10.3109/10428199609054832; IKIZAWA K, 1994, J ALLERGY CLIN IMMUN, V94, P620, DOI 10.1016/0091-6749(94)90138-4; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KMIECIK TE, 1992, BLOOD, V80, P2454; Machide M, 1998, J NEUROCHEM, V71, P592; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; MORISAKI T, 1992, CANCER RES, V52, P6059; MORISAKI T, 1994, CANCER RES, V54, P1113; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; PAUL WE, 1991, BLOOD, V77, P1859; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; POSTLETHWAITE AE, 1991, J CLIN INVEST, V87, P2147, DOI 10.1172/JCI115247; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schaper F, 1997, FEBS LETT, V405, P99, DOI 10.1016/S0014-5793(97)00167-1; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SOON L, 1999, MOL CELL BIOL, V38, P16; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; Streit ACE, 1997, CIBA F SYMP, V212, P155; Sunitha I, 1999, EXP CELL RES, V250, P86, DOI 10.1006/excr.1999.4550; TORIGOE T, 1992, BLOOD, V80, P617; Uchiyama A, 1996, J CELL BIOCHEM, V62, P443, DOI 10.1002/(SICI)1097-4644(19960915)62:4<443::AID-JCB2>3.3.CO;2-H; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Weimar IS, 1998, EXP HEMATOL, V26, P885; Weimar IS, 1997, BLOOD, V89, P990, DOI 10.1182/blood.V89.3.990; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; Yashiro M, 1996, INT J CANCER, V67, P289, DOI 10.1002/(SICI)1097-0215(19960717)67:2<289::AID-IJC22>3.0.CO;2-5; Yu CZ, 1998, STEM CELLS, V16, P66, DOI 10.1002/stem.160066; Zamorano J, 1996, J IMMUNOL, V157, P4926; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	61	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2201	2211		10.1038/sj.onc.1205289	http://dx.doi.org/10.1038/sj.onc.1205289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948403				2022-12-28	WOS:000174555300009
J	Krutovskikh, VA; Piccoli, C; Yamasaki, H				Krutovskikh, VA; Piccoli, C; Yamasaki, H			Gap junction intercellular communication propagates cell death in cancerous cells	ONCOGENE			English	Article						gap junctions; apoptosis; Connexin43	CONNEXIN GENES; CALCIUM; GROWTH; TUMORIGENICITY; LOCALIZATION; HEMICHANNELS; SUPPRESSION; INHIBITION; EXPRESSION; TUMORS	Gap junction intercellular communication (GJIC) or cell coupling has an important function in maintaining tissue homeostasis and is thus a critical factor in the life and death balance of cells. While the role of GJIC in cell growth regulation has been much studied, its involvement in apoptosis remains unclear. In this study we elucidated the possibility that cell death is propagated via gap junctions, employing the rat bladder carcinoma cell line BC31. BC31 cells proliferate quickly, are tumorigenic, and are well-coupled via gap junctions that contain the gap junction protein Connexin43 (Cx43). In addition, these cells are predisposed to spontaneous death by apoptosis, particularly upon achieving confluency. We found that many dying BC31 cells express Cx43 just as their non-apoptotic counterparts do. Furthermore, Cx43 in apoptotic cells could be functionally competent, supporting coupling of these cells with their non-apoptotic neighbors, and as a result, clusters of coordinately dying cells were observed. The role of Cx43 and GJIC in propagating cell death was shown by analysing clones of BC31 cells expressing a mutant of Cx43 that is a dominant negative inhibitor of GJIC, and by using beta-glycyrrhetinic acid to inhibit intrinsic cell coupling in BC31 cells: in both cases the formation of clusters of dying cells was abrogated, and the intensity of cell death was considerably decreased. These results suggest that GJIC spreads cell-killing signals initially generated by a single cell that spontaneously initiates apoptosis, into healthy surrounding cells, thus increasing the level of cell death. Treatment of BC31 cells with the sleep-inducing lipid Oleamide, which selectively restricts gap junction permeability to Ca2+ ions, did not abrogate coordinated cell death by clusters, indicating that Ca2+ ions are the most probable cell-killing signals spread through gap junctions.	Int Agcy Res Canc, Unit Gene Environm Interact, F-69372 Lyon, France; Kwansei Gakuin Univ, Nishinomiya, Hyogo 6628501, Japan	World Health Organization; International Agency for Research on Cancer (IARC); Kwansei Gakuin University	Krutovskikh, VA (corresponding author), Int Agcy Res Canc, Unit Gene Environm Interact, 150 Cours Albert Thomas, F-69372 Lyon, France.	krutovskikh@iarc.fr						ASAMOTO M, 1994, CARCINOGENESIS, V15, P2163, DOI 10.1093/carcin/15.10.2163; Blanc EM, 1998, J NEUROCHEM, V70, P958; Budd SL, 1998, NAT NEUROSCI, V1, P431, DOI 10.1038/2147; CHIPMAN TK, 1995, HUM EXP TOXICOL, V14, P539; CORTINA ML, 1998, J NEUROSCI, V18, P2520; DAVIDSON JS, 1986, BIOCHEM BIOPH RES CO, V134, P29, DOI 10.1016/0006-291X(86)90522-X; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; Estin D, 1999, NEUROSURGERY, V44, P361, DOI 10.1097/00006123-199902000-00068; FITZGERALD DJ, 1983, CANCER RES, V43, P3614; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; Guan XJ, 1996, MOL CARCINOGEN, V16, P157; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; Krutovskikh VA, 1998, MOL CARCINOGEN, V23, P254, DOI 10.1002/(SICI)1098-2744(199812)23:4<254::AID-MC9>3.0.CO;2-4; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; LOEWENSTEIN WR, 1992, SEMIN CELL BIOL, V2, P59; MARTIKAINEN P, 1990, PROSTATE, V17, P175, DOI 10.1002/pros.2990170302; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; Mehta P, 1999, DEV GENET, V24, P91, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<91::AID-DVG10>3.0.CO;2-#; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; Pfahnl A, 1999, PFLUG ARCH EUR J PHY, V437, P345, DOI 10.1007/s004240050788; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; Reznikov K, 2000, FASEB J, V14, P1754, DOI 10.1096/fj.99-0890com; WOLSZON LR, 1994, J NEUROSCI, V14, P3437; YAMASAKI H, 1990, CARCINOGENESIS, V11, P1051, DOI 10.1093/carcin/11.7.1051; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhang ZQ, 1998, CARCINOGENESIS, V19, P1889, DOI 10.1093/carcin/19.11.1889	31	170	183	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1989	1999		10.1038/sj.onc.1205187	http://dx.doi.org/10.1038/sj.onc.1205187			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960371				2022-12-28	WOS:000174827000005
J	Morcinek, JC; Weisser, C; Geissinger, E; Schartl, M; Wellbrock, C				Morcinek, JC; Weisser, C; Geissinger, E; Schartl, M; Wellbrock, C			Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase	ONCOGENE			English	Article						STAT5; Xmrk; melanoma; bcl-x; apoptosis; proliferation	RECEPTOR TYROSINE KINASE; EPIDERMAL-GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-RESPONSE; FAMILY-MEMBER; CELLS; EGF; TRANSFORMATION; PHOSPHORYLATION; SUPPRESSION	Extensive studies of primary tumors and tumor derived cell lines revealed that inappropriate activation of specific STATs (particularly of STAT3 and STAT5) occurs with high frequency in a wide variety of human cancers. We reported recently that the melanoma inducing EGFR-related receptor Xmrk specifically induces constitutive activation of STAT5 in fish melanoma cells. However. little is known about the role of STAT5 in solid tumours in general and its function in melanoma in particular. Recent examinations suggest that activated STAT signalling participates in oncogenesis by stimulating cell proliferation and preventing apoptosis. As an initial approach to understanding the consequences of Xmrk-induced STAT5 signalling we used the well characterized pro B-cell line Ba/F3 as a sensitive system to analyse mitogenic as well as anti-apoptotic signalling. We identified STAT5 activation as being involved in both growth and survival signalling triggered by the Xmrk kinase possibly due to STAT5 induced expression of phnI and bcl-x. We also found a new mechanism of activation of STAT5 by receptor tyrosine kinases, whereby direct interaction of the receptor kinase domain with the STAT protein in a phosphotyrosine independent way led to activation of STAT5 in terms of DNA binding and target gene expression.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, D-97074 Wurzburg, Germany	University of Wurzburg	Wellbrock, C (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, Hubland, D-97074 Wurzburg, Germany.	wellbrock@biozentrum.uni-wuerzburg.de		Schartl, Manfred/0000-0001-9882-5948; Wellbrock, Claudia/0000-0002-3825-6381				Baudler M, 1999, EXP CELL RES, V249, P212, DOI 10.1006/excr.1999.4470; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; FENDLY BM, 1990, CANCER RES, V50, P1550; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Jaster R, 1999, CELL SIGNAL, V11, P769, DOI 10.1016/S0898-6568(99)00050-9; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Lischke A, 1996, ANAL BIOCHEM, V236, P322, DOI 10.1006/abio.1996.0173; Mayr S, 1998, EUR J BIOCHEM, V258, P784, DOI 10.1046/j.1432-1327.1998.2580784.x; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Paukku K, 2000, BIOCHEM J, V345, P759, DOI 10.1042/0264-6021:3450759; PERIS K, 1991, ARCH DERMATOL RES, V283, P500, DOI 10.1007/BF00371922; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wellbrock C, 1999, EUR J BIOCHEM, V260, P275, DOI 10.1046/j.1432-1327.1999.00180.x; Wellbrock C, 1998, ONCOGENE, V16, P3047, DOI 10.1038/sj.onc.1201844; Wellbrock C, 2000, EUR J BIOCHEM, V267, P3513, DOI 10.1046/j.1432-1327.2000.01378.x; WINKLER C, 1994, ONCOGENE, V9, P1517; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	42	46	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1668	1678		10.1038/sj.onc.1205148	http://dx.doi.org/10.1038/sj.onc.1205148			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896598				2022-12-28	WOS:000174214200005
J	Dajee, M; Tarutani, M; Deng, H; Cai, T; Khavari, PA				Dajee, M; Tarutani, M; Deng, H; Cai, T; Khavari, PA			Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation	ONCOGENE			English	Article						epithelium; growth control; Ras; differentiation; skin	CELL-CYCLE ARREST; H-RAS; ONCOGENIC RAS; N-RAS; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; GENE-TRANSFER; STEM-CELLS; EXPRESSION; SKIN	While important in carcinogenesis, the role of Ras in normal self-renewing tissues such as epidermis is unclear. To address this, we altered Ras function in undifferentiated and differentiating epidermal layers. Ras blockade within undifferentiated basal epidermal cells leads to decreased integrin expression, diminished growth capacity and induction of differentiation. Ras blockade in post-mitotic suprabasal epidermis exerts no effect. In contrast, regulated Ras and Raf activation inhibits differentiation. These findings indicate that spatially restricted Ras/Raf signaling divides epidermis into an undifferentiated proliferative compartment and a differentiating post-mitotic compartment and suggest a new role for Ras in tissue homeostasis.	VA Palo Alto Healthcare Syst, Menlo Pk, CA 94025 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Khavari, PA (corresponding author), 269 Campus Dr,Room 2145, Stanford, CA 94305 USA.	khavari@CMGM.stanford.edu			NIAMS NIH HHS [AR43799, AR45192] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043799, R01AR045192, R29AR043799] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Choate KA, 1996, HUM GENE THER, V7, P2247, DOI 10.1089/hum.1996.7.18-2247; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; DALE BA, 1987, J INVEST DERMATOL, V88, P306, DOI 10.1111/1523-1747.ep12466185; Deng H, 1998, BIOTECHNIQUES, V25, P274, DOI 10.2144/98252gt02; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Ewen M E, 2000, Prog Cell Cycle Res, V4, P1; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Ferbeyre G, 2000, GENE DEV, V14, P2015; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GREENHALGH DA, 1993, CANCER RES, V53, P5071; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halfar K, 2001, DEVELOPMENT, V128, P1687; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; IVANYI D, 1989, J PATHOL, V159, P7, DOI 10.1002/path.1711590105; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Marshall CJ, 1999, BIOCHEM SOC T, V27, P363, DOI 10.1042/bst0270363; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Robbins PB, 2001, P NATL ACAD SCI USA, V98, P5193, DOI 10.1073/pnas.091484998; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Ruiz-Hidalgo MJ, 1999, INT J ONCOL, V14, P777; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shi B, 2000, BIOCHEM CELL BIOL, V78, P469, DOI 10.1139/bcb-78-4-469; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; STOCKSCHLADER MAR, 1994, GENE THER, V1, P317; Takahashi H, 2001, J BIOL CHEM, V276, P36632, DOI 10.1074/jbc.M102021200; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Watt FM, 1998, PHILOS T R SOC B, V353, P831, DOI 10.1098/rstb.1998.0247; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YUSPA SH, 1983, CANCER RES, V43, P6021; YUSPA SH, 1994, CANCER RES, V54, P1178; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	59	84	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1527	1538		10.1038/sj.onc.1205287	http://dx.doi.org/10.1038/sj.onc.1205287			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896581				2022-12-28	WOS:000173956800008
J	Wang, DM; Lipsick, JS				Wang, DM; Lipsick, JS			Mutational analysis of the transcriptional activation domains of v-Myb	ONCOGENE			English	Article						v-Myb; transcriptional activation; transformation; leukemia; oncogene	TRANSFORMATION; TRANSACTIVATION; COACTIVATOR; ONCOGENE; CBP	A minimal transcription activation domain of the v-Myb oncoprotein was initially mapped to a central cluster of charged residues using GAL4-Myb fusion proteins. This region has been proposed to interact directly with the CBP co-activator in animal cells. Regions flanking this central domain of v-Myb are required for transcriptional activation by the native, unfused protein in both mammalian cells and in budding yeast. To identify the critical residues for transcriptional activation, we have now subjected the minimal activation domain and flanking regions including the heptad leucine repeat to random PCR-mediated mutagenesis. We found that the entire region examined can endure extensive substitutions without affecting transcriptional activation by v-Myb in budding yeast. The few mutations that did affect transcriptional activation altered acidic residues within the minimal activation domain or the heptad leucine repeat region, rather than leucine residues. Remarkably, there was a strong concordance between transcriptional activation in animal cells and in budding yeast, even though budding yeast have no known homologue of CBP or related co-activators. In contrast, there was not a strong correlation between transcriptional activation and oncogenic transformation.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	lipsick@stanford.edu			NATIONAL CANCER INSTITUTE [T32CA009151, R01CA043592] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09151, R01 CA43592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; CHEN RH, 1995, ONCOGENE, V11, P1771; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Leung DW, 1989, TECHNIQUE, V1, P11; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	14	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1611	1615		10.1038/sj.onc.1205236	http://dx.doi.org/10.1038/sj.onc.1205236			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896590				2022-12-28	WOS:000173956800017
J	Arentson, E; Faloon, P; Seo, J; Moon, E; Studts, JM; Fremont, DH; Choi, KH				Arentson, E; Faloon, P; Seo, J; Moon, E; Studts, JM; Fremont, DH; Choi, KH			Oncogenic potential of the DNA replication licensing protein CDT1	ONCOGENE			English	Article						CDT1; retroviral insertional activation; oncogene	APRT LOCUS; CELL-CYCLE; COILED COILS; GENE; HETEROZYGOSITY; SEQUENCES; MUTATION; CANCER; YEAST; RETINOBLASTOMA	The expression of a gene, designated as Retroviral insertion site (Ris)2, was activated by retroviral DNA integration in an immortalized primitive erythroid cell line, EB-PE. Ris2 was also expressed at high levels in all human tumor cell lines analysed. Consistently, NIH3T3 fibroblasts overexpressing Ris2 formed tumors in Rag2(-/-) mice when injected subcutaneously. The putative RIS2 protein shows a high sequence similarity to Xenopus CDT1, Drosophila DUP, and human CDT1, a newly identified DNA replication licensing protein, suggesting that Ris2 is a mouse homologue of CDT1. Cells overexpressing Ris2/Cdt1 exhibited a quicker entry into S phase when released from serum starvation compared to controls. Our results suggest that CDT1, an essential licensing protein for DNA replication, can function as an oncogene in mammals.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Ajou Univ, Dept Biol Sci, Suwon 441749, South Korea	Washington University (WUSTL); Ajou University	Choi, KH (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	kchoi@pathology.wustl.edu		Fremont, Daved/0000-0002-8544-2689				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Blow JJ, 2000, NATURE, V404, P560, DOI 10.1038/35007187; Choi K, 1998, DEVELOPMENT, V125, P725; DEWYSE P, 1989, SOMAT CELL MOLEC GEN, V15, P19, DOI 10.1007/BF01534666; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fujita Masatoshi, 1999, Frontiers in Bioscience, V4, pd816, DOI 10.2741/Fujita; GUPTA PK, 1994, ADV EXP MED BIOL, V370, P653; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HARWOOD J, 1995, SOMAT CELL MOLEC GEN, V21, P151, DOI 10.1007/BF02254767; HIRAMA T, 1995, BLOOD, V86, P841; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lygerou Z, 2000, SCIENCE, V290, P2271; Madine M, 2001, NAT CELL BIOL, V3, pE49, DOI 10.1038/35055158; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; MOIR D, 1982, GENETICS, V100, P547; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PHEAR G, 1989, J MOL BIOL, V209, P577, DOI 10.1016/0022-2836(89)90595-0; QUINTANA DG, 1999, FRONT BIOSCI, V4, P805, DOI DOI 10.2741/QUINTANA; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Stambrook PJ, 1996, ENVIRON MOL MUTAGEN, V28, P471; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Van Sloun PPH, 1998, NUCLEIC ACIDS RES, V26, P4888, DOI 10.1093/nar/26.21.4888; Whittaker AJ, 2000, GENE DEV, V14, P1765; Wijnhoven SWP, 1998, P NATL ACAD SCI USA, V95, P13759, DOI 10.1073/pnas.95.23.13759; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Yuen D, 1998, BLOOD, V91, P3202, DOI 10.1182/blood.V91.9.3202.3202_3202_3209; ZHU Y, 1993, MOL CARCINOGEN, V8, P138, DOI 10.1002/mc.2940080304	45	106	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1150	1158		10.1038/sj.onc.1205175	http://dx.doi.org/10.1038/sj.onc.1205175			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850834				2022-12-28	WOS:000173729400002
J	Moll, F; Katsaros, D; Lazennec, G; Hellio, N; Roger, P; Giacalone, PL; Chalbos, D; Maudelonde, T; Rochefort, H; Pujol, P				Moll, F; Katsaros, D; Lazennec, G; Hellio, N; Roger, P; Giacalone, PL; Chalbos, D; Maudelonde, T; Rochefort, H; Pujol, P			Estrogen induction and overexpression of fibutin-1C mRNA in ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; fibulin-1C; fibulin-1D; estrogen; competitive PCR	EXON-INTRON ORGANIZATION; RECEPTOR-ALPHA; EXTRACELLULAR-MATRIX; CARCINOMA CELLS; HUMAN FIBULIN-1; IN-VITRO; EXPRESSION; GROWTH; PROTEIN; BETA	Fibulin-1 is an extracellular matrix protein induced by estradiol in estrogen receptor (ER) positive ovarian cancer cell lines. Alternative splicing of fibulin-1 mRNA results in four different variants named A, B, C and D that may have distinct biological functions. We studied the relative expression of fibulin-1 mRNA variants and their estrogen regulation in human ovarian cancer cells. In ovarian tissues and cancer cell lines, fibulin-1C and -1D are the predominant forms, whereas fibulin-1A and -1B are weakly expressed. We developed a competitive PCR assay based on coamplification of fibulin-1C and -1D to study the relative expression of these fibulin-1 variants in human ovarian samples. In ovarian cancer cell lines and ovarian cancer samples, there was a marked increase in the fibutin-1C:1D and fibulin-1C:HPRT mRNA ratios as compared to normal ovaries. In the BG1 estrogen receptor positive ovarian cancer cell line, fibulin-1C mRNA was induced by estradiol in a dose- and time-dependent manner. Since others and we have previously shown an increased expression of ERalpha as compared to ERbeta in ovarian cancer cells, we investigated whether ERalpha or ERbeta is involved in this induction. For this aim, MDA-MB-231 breast cancer cell line, which expresses both low basal levels of ERs and fibulin-1, was infected with recombinant ERalpha or ERbeta encoding adenovirus and treated with estradiol. Fibulin-1C was induced by estradiol in ERalpha- but not ERbeta-infected cells, suggesting that fibulin-1C induction is mediated through ERa. In ovarian tumors, a trend towards a correlation between fibulin-1C and ERalpha expression levels was noted. In conclusion, this study showed an increased fibulin-1C: -1D mRNA ratio in ovarian cancer cells as compared to normal ovaries. This finding suggests that the C variant may be involved in ovarian carcinogenesis. Fibulin-1C overexpression may thus be a clue for the understanding of a putative role of estrogens in ERalpha promoted ovarian tumor progression.	Hop Arnaud de Villeneuve, Serv Biol Cellulaire, F-34295 Montpellier, France; Hop Arnaud de Villeneuve, Serv Hormonale, F-34295 Montpellier, France; INSERM, U540, F-34095 Montpellier, France; Dept Obstet & Gynecol, I-10126 Turin, Italy; CHU Montpellier, Hop Arnaud de Villeneuve, F-34295 Montpellier, France	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Pujol, P (corresponding author), Hop Arnaud de Villeneuve, Serv Biol Cellulaire, 271 Av G Giraud, F-34295 Montpellier, France.	p-pujol@chu-montpellier.fr		Lazennec, Gwendal/0000-0002-8522-1763; ROGER, Pascal/0000-0002-4040-5892				Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; AHLGREN JD, 1993, J CLIN ONCOL, V11, P1957, DOI 10.1200/JCO.1993.11.10.1957; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; BALBONA K, 1992, J BIOL CHEM, V267, P20120; Brandenberger AW, 1998, J CLIN ENDOCR METAB, V83, P1025, DOI 10.1210/jc.83.3.1025; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; CHIEN CH, 1994, MOL CELL ENDOCRINOL, V99, P11; Clinton GM, 1996, P NATL ACAD SCI USA, V93, P316, DOI 10.1073/pnas.93.1.316; GALTIERDEREURE F, 1992, J CLIN ENDOCR METAB, V75, P1497, DOI 10.1210/jc.75.6.1497; GEISINGER KR, 1989, CANCER-AM CANCER SOC, V63, P280, DOI 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N; Grassel S, 1999, EUR J BIOCHEM, V263, P471, DOI 10.1046/j.1432-1327.1999.00523.x; Greenwood M, 2000, HIST TODAY, V50, P3; Hamilton TC, 1999, ANN ONCOL, V10, P69, DOI 10.1023/A:1008367620240; HATCH KD, 1991, CANCER, V68, P269, DOI 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O; Havrilesky LJ, 2001, J SOC GYNECOL INVEST, V8, P104, DOI 10.1016/S1071-5576(01)00093-4; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Hillier SG, 1998, MOL HUM REPROD, V4, P811, DOI 10.1093/molehr/4.8.811; JABARA AG, 1962, AUST J EXP BIOL MED, V40, P139, DOI 10.1038/icb.1962.17; KORENBERG JR, 1995, CYTOGENET CELL GENET, V68, P192, DOI 10.1159/000133911; KRYWICKI RF, 1993, EUR J CANCER, V29A, P2015, DOI 10.1016/0959-8049(93)90464-Q; LANGDON SP, 1990, BRIT J CANCER, V62, P213, DOI 10.1038/bjc.1990.263; LANGDON SP, 1993, INT J CANCER, V55, P459, DOI 10.1002/ijc.2910550323; LANGDON SP, 1994, EUR J CANCER, V30A, P682, DOI 10.1016/0959-8049(94)90545-2; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Makar AP, 2000, ENDOCR-RELAT CANCER, V7, P85, DOI 10.1677/erc.0.0070085; MAZARS R, 1991, ONCOGENE, V6, P1685; NASH JD, 1989, OBSTET GYNECOL, V73, P1009; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; Pan TC, 1999, FEBS LETT, V444, P38, DOI 10.1016/S0014-5793(99)00024-1; PAVLIK EJ, 1991, GYNECOL ONCOL, V42, P245, DOI 10.1016/0090-8258(91)90353-7; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Pujol P, 1998, CANCER RES, V58, P5367; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Rey JM, 2000, J MOL ENDOCRINOL, V24, P433, DOI 10.1677/jme.0.0240433; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; ROCHEFORT H, 1984, RECENT RESULTS CANC, V91, P289; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X; Romagnolo D, 1998, MOL CARCINOGEN, V22, P102, DOI 10.1002/(SICI)1098-2744(199806)22:2<102::AID-MC5>3.0.CO;2-O; Rutherford T, 2000, OBSTET GYNECOL, V96, P417, DOI 10.1016/S0029-7844(00)00917-0; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4	47	87	93	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1097	1107		10.1038/sj.onc.1205171	http://dx.doi.org/10.1038/sj.onc.1205171			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850827				2022-12-28	WOS:000173580100013
J	Leem, SH; Londono-Vallejo, JA; Kim, JH; Bui, H; Tubacher, E; Solomon, G; Park, JE; Horikawa, I; Kouprina, N; Barrett, JC; Larionov, V				Leem, SH; Londono-Vallejo, JA; Kim, JH; Bui, H; Tubacher, E; Solomon, G; Park, JE; Horikawa, I; Kouprina, N; Barrett, JC; Larionov, V			The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions	ONCOGENE			English	Article						hTERT; VNTR; polymorphism	REVERSE-TRANSCRIPTASE HTERT; EMBRYONIC STEM-CELLS; CATALYTIC SUBUNIT; AFFECTIVE-DISORDERS; VARIABLE NUMBER; C-MYC; PROMOTER; IDENTIFICATION; MINISATELLITE; CLONING	In this work, the full-length hTERT gene was isolated and the sequence of the previously unknown region in intron 6 as well as that of upstream and downstream hTERT regions was determined. We have shown that intron 6 includes a variable number of tandem repeats (VNTR) of a 38 bp sequence, (hTERT-VNTR 6-1). Eight alleles of hTERT-VNTR 6-1 were identified among 103 unrelated individuals, ranging front 27 to 47 repeats. hTERT-VNTR 2-2 is another new 61 bp minisatellite repeat found in intron 2 of hTERT. At least four alleles of hTERT-VNTR 2-2 can be distinguished. Previous studies have described polymorphisms for minisatellites hTERT-VNTR 2-1, a 42 bp repeat in intron 2, and hTERT-VNTR 6-2, a 36 bp repeat in intron 6. These, together with another minisatellite found in intron 12, add up to five such structures within the hTERT gene. The segregation of hTERT minisatellites was analysed in families, revealing that the VNTRs are transmitted through meiosis following a Mendelian inheritance. Minisatellites in hTERT were also analysed in matching normal and cancer tissues from patients with tumors; in one patient with a kidney tumor, the two VNTRs in intron 6 had undergone concomitant rearrangements. This observation suggests that chromosomal rearrangements implicating these VNTRs may be associated with the activation of telomerase expression in cancer cells.	NCI, Lab Biosyst & Canc, NIH, Bethesda, MD 20892 USA; DongA Univ, Dept Biol, Pusan 604714, South Korea; NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Dong A University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Larionov, V (corresponding author), NCI, Lab Biosyst & Canc, NIH, Bldg 49,Room 4A56, Bethesda, MD 20892 USA.		Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Alakurtti K, 2000, GENE, V242, P65, DOI 10.1016/S0378-1119(99)00550-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Armstrong L, 2000, MECH DEVELOP, V97, P109, DOI 10.1016/S0925-4773(00)00423-8; Avilion AA, 1996, CANCER RES, V56, P645; Bailly S, 1996, MOL IMMUNOL, V33, P999, DOI 10.1016/S0161-5890(96)00042-9; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Blackburn EH, 2000, NAT STRUCT BIOL, V7, P847, DOI 10.1038/79594; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Choi YM, 2000, J HUM GENET, V45, P218, DOI 10.1007/s100380070030; Chowdhury MR, 2000, HAEMOPHILIA, V6, P625, DOI 10.1046/j.1365-2516.2000.00442.x; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Desseyn JL, 1999, ELECTROPHORESIS, V20, P493, DOI 10.1002/(SICI)1522-2683(19990301)20:3<493::AID-ELPS493>3.0.CO;2-7; FAIK P, 1994, GENOMICS, V21, P122, DOI 10.1006/geno.1994.1233; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fiskerstrand CE, 1999, FEBS LETT, V458, P171, DOI 10.1016/S0014-5793(99)01150-3; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Horikawa I, 1999, CANCER RES, V59, P826; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kouprina N, 1998, P NATL ACAD SCI USA, V95, P4469, DOI 10.1073/pnas.95.8.4469; KOUPRINA N, 1999, CURRENT PROTOCOLS HU, V1; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; MacKenzie A, 1999, P NATL ACAD SCI USA, V96, P15251, DOI 10.1073/pnas.96.26.15251; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakamura Y, 1998, J HUM GENET, V43, P149, DOI 10.1007/s100380050059; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; ROYLE NJ, 1988, GENOMICS, V3, P352, DOI 10.1016/0888-7543(88)90127-9; Shay JW, 1999, SCIENCE, V286, P2284, DOI 10.1126/science.286.5448.2284; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; Takakura M, 1999, CANCER RES, V59, P551; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TURRI MG, 1995, NUCLEIC ACIDS RES, V23, P1854, DOI 10.1093/nar/23.11.1854; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yang F, 2000, AM J MED GENET, V95, P385, DOI 10.1002/1096-8628(20001211)95:4<385::AID-AJMG16>3.0.CO;2-V; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200	46	61	69	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					769	777		10.1038/sj.onc.1205122	http://dx.doi.org/10.1038/sj.onc.1205122			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850805				2022-12-28	WOS:000173427000008
J	Liu, Y; Emilion, G; Mungall, AJ; Dunham, I; Beck, S; Le Meuth-Metzinger, VG; Shelling, AN; Charnock, FML; Ganesan, TS				Liu, Y; Emilion, G; Mungall, AJ; Dunham, I; Beck, S; Le Meuth-Metzinger, VG; Shelling, AN; Charnock, FML; Ganesan, TS			Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer	ONCOGENE			English	Article						ovarian cancer chromosome 6q27	SELF-INCOMPATIBILITY GENE; PROTEIN-COUPLED RECEPTOR; DISTINCT REGIONS; NICOTIANA-ALATA; HUMAN DNA; LONG ARM; TUMORS; DELETION; RIBONUCLEASES; CLONING	We have previously shown a high frequency of allele loss at D6S193 (62%) on chromosomal arm 6q27 in ovarian tumours and mapped the minimal region of allele loss between D6S297 and D6S264 (3 cM). We isolated and mapped a single non-chimaeric YAC (17IA12, 260 - 280 kb) containing D6S193 and D6S297. A further extended bacterial contig (between D6S264 and D6S149) has been established using PACs and BACs and a transcript map has been established. We have mapped six new markers to the YAC; three of them are ESTs (WI-15078, WI-8751, and TCP10). We have isolated three cDNA clones of EST WI-15078 and one clone contains a complete open reading frame. The sequence shows homology to a new member of the ribonuclease family. The other two clones are splice variants of this new gene. The gene is expressed ubiquitously in normal tissues. It is expressed in 4/8 ovarian cancer cell lines by Northern analysis. The gene encodes for a 40 kDa protein. Direct sequencing of the gene in all the eight ovarian cancer cell lines did not identify any mutations. Clonogenic assays were performed by transfecting the full-length gene in to ovarian cancer cell lines and no suppression of growth was observed.	John Radcliffe Hosp, Imperial Canc Res Fund, Mol Oncol Labs, Oxford OX3 9DS, England; Sanger Ctr, Cambridge CB10 1SA, England; INRA, UMR Genet Anim, F-35042 Rennes, France; Natl Womens Hosp, Dept Obstet & Gynaecol, Res Ctr Reprod Med, Auckland, New Zealand	University of Oxford; Wellcome Trust Sanger Institute; INRAE	Ganesan, TS (corresponding author), John Radcliffe Hosp, Imperial Canc Res Fund, Mol Oncol Labs, Oxford OX3 9DS, England.	ganesan@icrf.icnet.uk	GANESAN, Trivadi Sundaram/AAU-1499-2020; Meuth, Valérie Metzinger-Le/H-6338-2016; Mungall, Andrew J./U-7067-2018; Shelling, Andrew/E-7496-2010	GANESAN, Trivadi Sundaram/0000-0002-4671-8099; Meuth, Valérie Metzinger-Le/0000-0003-1718-5083; Mungall, Andrew J./0000-0002-0905-2742; Shelling, Andrew/0000-0002-5300-1934; Liu, Ying/0000-0003-3703-2498; Dunham, Ian/0000-0003-2525-5598				Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; ANDERSON MA, 1989, PLANT CELL, V1, P483, DOI 10.1105/tpc.1.5.483; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BLANCHE H, 1992, GENOMICS, V12, P826, DOI 10.1016/0888-7543(92)90317-L; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; FRANCESCONI M, 1984, CANCER, V53, P1927, DOI 10.1002/1097-0142(19840501)53:9<1927::AID-CNCR2820530920>3.0.CO;2-#; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; HIME G, 1995, GENE, V158, P203, DOI 10.1016/0378-1119(94)00896-Z; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; ISLAM SD, 1993, HUM MOL GENET, V2, P2075, DOI 10.1093/hmg/2.12.2075; Katso RMT, 1997, CANCER METAST REV, V16, P81, DOI 10.1023/A:1005796307286; Kurihara H, 1996, J MOL BIOL, V255, P310, DOI 10.1006/jmbi.1996.0025; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Liao F, 1997, BIOCHEM BIOPH RES CO, V236, P212, DOI 10.1006/bbrc.1997.6936; Liao F, 1997, GENOMICS, V40, P175, DOI 10.1006/geno.1996.4544; LIU Y, 2001, IN PRESS RE REPROD; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; Mungall AJ, 1997, DNA SEQUENCE, V8, P151, DOI 10.3109/10425179709034066; Obata K, 1998, CANCER RES, V58, P2095; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; SAHA V, 1995, GENE CHROMOSOME CANC, V14, P220, DOI 10.1002/gcc.2870140311; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Sassa H, 1996, MOL GEN GENET, V252, P222, DOI 10.1007/BF02173225; Schein CH, 1997, NAT BIOTECHNOL, V15, P529, DOI 10.1038/nbt0697-529; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; Trubia M, 1997, GENOMICS, V42, P342, DOI 10.1006/geno.1997.4679; Walter MH, 1996, EUR J BIOCHEM, V239, P281, DOI 10.1111/j.1432-1033.1996.0281u.x; WAN MH, 1994, INT J ONCOL, V5, P1043; Ye ZH, 1996, PLANT MOL BIOL, V30, P697, DOI 10.1007/BF00019005; Zingoni A, 1997, GENOMICS, V42, P519, DOI 10.1006/geno.1997.4754; [No title captured]	46	24	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					387	399		10.1038/sj.onc.1205067	http://dx.doi.org/10.1038/sj.onc.1205067			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821951				2022-12-28	WOS:000173311200007
J	Ueda, C; Akasaka, T; Kurata, M; Maesako, Y; Nishikori, M; Ichinohasama, R; Imada, K; Uchiyama, T; Ohno, H				Ueda, C; Akasaka, T; Kurata, M; Maesako, Y; Nishikori, M; Ichinohasama, R; Imada, K; Uchiyama, T; Ohno, H			The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma	ONCOGENE			English	Article						BCL6 gene; non-immunoglobulin gene; t(3;16)(q27;p11) translocation; interleukin-21 receptor gene; diffuse large B-cell lymphoma	GERMINAL-CENTER FORMATION; NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; POZ DOMAIN; BETA-CHAIN; TRANSCRIPTIONAL REPRESSION; LAZ3/BCL6 ONCOPROTEIN; TRANSLOCATION; PROTEIN; DIFFERENTIATION	BCL6 translocation affecting the chromosomal band 3q27 can involve a number of non-immunoglobulin (non-IG) gene loci as partners. We report here that the gene for interleukin-21 receptor (IL-21R) is the partner of BCL6 in t(3;16)(q27;p11) translocation. The two breakpoints on 16p11 of a lymphoma cell line YM and case no. 1012 with diffuse large B-cell lymphoma, both of which carried t(3;16), were localized within the similar to27-kb intron I of IL-21R. As a result of t(3;16), the promoter region of IL-21R was substituted for the regulatory sequences of BCL6 in the same transcriptional orientation. Reverse transcriptase-mediated polymerase chain reaction revealed chimeric mRNA consisting of two noncoding exons 1a/1b of IL-21R and coding exons of BCL6 in both lymphoma cells. Fluorescence in situ chromosomal hybridization of YM metaphase cells revealed fusion signals that contained both the BCL6 and IL-21R sequences on the der(3)t(3;16) chromosome. IL-21R was actively transcribed in YM cells, while BCL6 that was under the control of the IL-21R promoter was only moderately expressed at the mRNA and protein level. We constructed expression plasmid of BCL6 that followed the promoter sequences of IL-21R. COS-7 cells transiently transfected with the plasmid expressed high level Bcl-6 protein and displayed nuclear staining with a characteristic punctate pattern by immunofluorescence, indicating that expression of BCL6 can be enhanced by t(3;16). This study added to the list of non-IG partners of BCL6 translocations a new class of gene, i.e. cytokine receptor gene, the expression of which is closely associated with lymphoid cells.	Kyoto Univ, Fac Med, Dept Internal Med, Sakyo Ku, Kyoto 6068507, Japan; Tohoku Univ, Sch Dent, Dept Oral Pathol, Aoba Ku, Sendai, Miyagi 9808575, Japan	Kyoto University; Tohoku University	Ohno, H (corresponding author), Kyoto Univ, Fac Med, Dept Internal Med, Sakyo Ku, Div 1,54 Shogoin Kawaramachi, Kyoto 6068507, Japan.			Imada, Kazunori/0000-0002-0945-0513				Akasaka H, 2000, CANCER RES, V60, P2335; Akasaka T, 1997, CANCER RES, V57, P7; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; DALLERY E, 1995, ONCOGENE, V10, P2171; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Galiegue-Zouitina S, 1999, GENE CHROMOSOME CANC, V26, P97, DOI 10.1002/(SICI)1098-2264(199910)26:2<97::AID-GCC1>3.0.CO;2-9; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Hosokawa Y, 2000, BLOOD, V95, P2719; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Ichinohasama R, 1998, CANCER GENET CYTOGEN, V103, P133, DOI 10.1016/S0165-4608(97)00390-7; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; MIKI T, 1994, BLOOD, V83, P26; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Ozaki K, 2000, P NATL ACAD SCI USA, V97, P11439, DOI 10.1073/pnas.200360997; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Xu WS, 2000, GENE CHROMOSOME CANC, V27, P69, DOI 10.1002/(SICI)1098-2264(200001)27:1<69::AID-GCC9>3.0.CO;2-5; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yonetani N, 1998, ONCOGENE, V17, P971, DOI 10.1038/sj.onc.1202027; Yoshida S, 1999, ONCOGENE, V18, P7994, DOI 10.1038/sj.onc.1203293; ZOLA H, 1991, IMMUNOLOGY, V72, P167	38	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					368	376		10.1038/sj.onc.1205099	http://dx.doi.org/10.1038/sj.onc.1205099			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821949	Green Submitted			2022-12-28	WOS:000173311200005
J	Richie, ER; Schumacher, A; Angel, JM; Holloway, M; Rinchik, EM; Magnuson, T				Richie, ER; Schumacher, A; Angel, JM; Holloway, M; Rinchik, EM; Magnuson, T			The Polycomb-group gene eed regulates thymocyte differentiation and suppresses the development of carcinogen-induced T-cell lymphomas	ONCOGENE			English	Article						lymphomagenesis; Polycom-group gene; eed; thymocyte differentiation	EXTRA SEX COMBS; METHYL-N-NITROSOUREA; MURINE THYMIC LYMPHOMAS; MOUSE CHROMOSOME-7; EVOLUTIONARY CONSERVATION; RAPID DEVELOPMENT; MICE; DROSOPHILA; PROTEIN; EXPRESSION	The mouse Polycomb-group gene, embryonic ectoderm development (eed), appears to regulate cellular growth and differentiation in a developmental and tissue specific manner. During embryogenesis, eed regulates axial patterning, whereas in the adult eed represses proliferation of myeloid and B cell precursors. The present report demonstrates two novel functional activities of eed:alteration of thymocyte maturation and suppression of thymic lymphoma development. Mice that inherit the viable hypomorphic 17Rn5(1989SB) eed allele sustain a partial developmental block at or before the CD4(-)CD8(-)CD44(-) CD25(+) stage of thymocyte differentiation. Furthermore, mice that are homozygous or heterozygous for the hypomorphic eed allele have an increased incidence and decreased latency of N-methyl-N-nitrosourea-induced thymic lymphoma compared to wild-type littermates. These findings support the notion that Polycomb-group genes exert pleiotrophic effects dictated by developmental stage and cellular context.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of North Carolina; University of North Carolina Chapel Hill	Richie, ER (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, POB 389, Smithville, TX 78957 USA.			Richie, Ellen/0000-0003-0786-973X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024462, R37HD024462] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NHGRI NIH HHS [HG00370] Funding Source: Medline; NICHD NIH HHS [HD24462] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akasaka T, 1996, DEVELOPMENT, V122, P1513; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; ANGEL JM, 1989, J NATL CANCER I, V81, P1652, DOI 10.1093/jnci/81.21.1652; ANGEL JM, 1993, MOL CARCINOGEN, V7, P151, DOI 10.1002/mc.2940070305; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; FAUST C, 1995, DEVELOPMENT, V121, P273; Faust C, 1998, DEVELOPMENT, V125, P4495; Fehling HJ, 1997, CURR OPIN IMMUNOL, V9, P263, DOI 10.1016/S0952-7915(97)80146-X; FREI JV, 1974, CHEM-BIOL INTERACT, V9, P65, DOI 10.1016/0009-2797(74)90068-4; FREI JV, 1980, CARCINOGENESIS, V1, P721, DOI 10.1093/carcin/1.8.721; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Gomez G, 2000, INT IMMUNOL, V12, P263, DOI 10.1093/intimm/12.3.263; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kung AL, 2000, GENE DEV, V14, P272; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; NEWCOMB EW, 1988, CANCER RES, V48, P5514; Ng J, 1997, MOL CELL BIOL, V17, P6663, DOI 10.1128/MCB.17.11.6663; RICHIE ER, 1988, LEUKEMIA RES, V12, P233, DOI 10.1016/0145-2126(88)90141-5; RICHIE ER, 1996, PROGR CLIN BIOL RES, P23; RINCHIK EM, 1993, MAMM GENOME, V4, P349, DOI 10.1007/BF00360583; RINCHIK EM, 1990, P NATL ACAD SCI USA, V87, P896, DOI 10.1073/pnas.87.3.896; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; ROMACH E, 1994, CARCINOGENESIS, V15, P2275, DOI 10.1093/carcin/15.10.2275; SATHE SS, 1995, MECH DEVELOP, V52, P77, DOI 10.1016/0925-4773(95)00392-E; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Schumacher A, 1998, GENOMICS, V54, P79, DOI 10.1006/geno.1998.5509; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; STETTNER SL, 1991, CANCER RES, V51, P737; STRUHL G, 1982, CELL, V31, P285, DOI 10.1016/0092-8674(82)90428-7; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; ZAIDI NH, 1995, CARCINOGENESIS, V16, P1047, DOI 10.1093/carcin/16.5.1047	45	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					299	306		10.1038/sj.onc.1205051	http://dx.doi.org/10.1038/sj.onc.1205051			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803473				2022-12-28	WOS:000173026200014
J	Spalding, AC; Jotte, RM; Scheinman, RI; Geraci, MW; Clarke, P; Tyler, KL; Johnson, GL				Spalding, AC; Jotte, RM; Scheinman, RI; Geraci, MW; Clarke, P; Tyler, KL; Johnson, GL			TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappa B-dependent, genotoxin-induced apoptosis of cancer cells	ONCOGENE			English	Article						TRAIL; IAP; NF-kappa B; apoptosis; chemotherapy	PACLITAXEL-INDUCED APOPTOSIS; INTESTINAL TREFOIL FACTOR; NECROSIS-FACTOR-ALPHA; ZINC FINGER PROTEIN; CYTOCHROME-C; TRANSCRIPTIONAL ACTIVATION; FORKHEAD PROTEINS; DECOY RECEPTORS; DEATH RECEPTORS; EXPRESSION	Opposing pro- and anti-apoptotic actions of TRAIL and the inhibitors of apoptosis (IAPs) contribute to the cell's decision to survive or die. We demonstrate that in H157 human lung carcinoma cells, etoposide and doxorubicin induce the NF-kappaB-dependent expression of both pro- and anti-apoptotic proteins including TRAIL and its death receptor, DR5, and IAPs. Inhibition of NF-kappaB activation in H157 cells in response to genotoxin resulted in loss of cell surface expression of TRAIL and DR5, aggressive growth and chemotherapy resistance of tumors in nude mice. Similar to the paracrine TRAIL response in H157 cells, the sensitivity of normal lung and breast epithelium and carcinomas to undergo genotoxin-induced apoptosis correlates strongly with cell surface expression of TRAIL. Suppression of TRAIL signaling by expression of the TRAIL decoy receptor, DeR1, confers chemo-resistance to cancer cells. These findings demonstrate that TRAIL signaling via its death receptors is a significant contributor to genotoxin-induced apoptosis in human epithelial carcinomas.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, SOM,Canc Ctr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Sch Pharm, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Johnson, GL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, SOM,Canc Ctr, C236,Room 2809,4200 E 9th Ave, Denver, CO 80262 USA.		Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888				Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; HAN JY, 2001, P ASCO, V20; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee SH, 1999, CANCER RES, V59, P5683; Lee SH, 2001, ONCOGENE, V20, P399, DOI 10.1038/sj.onc.1204103; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mahlapuu M, 1998, DEV BIOL, V202, P183, DOI 10.1006/dbio.1998.9010; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakamura M, 2000, ACTA NEUROPATHOL, V99, P1, DOI 10.1007/PL00007399; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Ozoren N, 2000, INT J ONCOL, V16, P917; Pai SI, 1998, CANCER RES, V58, P3513; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sedger LM, 1999, J IMMUNOL, V163, P920; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; VERHAEGEN S, 1995, BIOCHEM PHARMACOL, V50, P1021, DOI 10.1016/0006-2952(95)00233-P; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang SW, 1999, ANN CLIN LAB SCI, V29, P192; Wu WG, 2000, ANTICANCER RES, V20, P4525; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	50	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					260	271		10.1038/sj.onc.1205048	http://dx.doi.org/10.1038/sj.onc.1205048			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803469				2022-12-28	WOS:000173026200010
J	DiMaio, D; Mattoon, D				DiMaio, D; Mattoon, D			Mechanisms of cell transformation by papillomavirus E5 proteins	ONCOGENE			English	Review						E5 protein; growth factor receptor; transmembrane protein; V-ATPase; viral oncogene	GROWTH-FACTOR RECEPTOR; FACTOR-BETA RECEPTOR; VACUOLAR H+-ATPASE; MOUSE C127 CELLS; PORE-FORMING PROTEIN; BOVINE PAPILLOMAVIRUS; SIGNAL-TRANSDUCTION; MUTATIONAL ANALYSIS; AMINO-ACIDS; TUMORIGENIC TRANSFORMATION	The papillomavirus E5 proteins are short, hydrophobic transforming proteins. The transmembrane E5 protein encoded by bovine papillomavirus transforms cells by activating the platelet-derived growth factor beta receptor tyrosine kinase in a ligand-independent fashion. The bovine papillomavirus E5 protein forms a stable complex with the receptor, thereby inducing receptor dimerization and activation, trans-phosphorylation, and recruitment of cellular signaling proteins to the receptor. The E5 proteins of the human papillomaviruses also appear to affect the activity of growth factor receptors and their signaling pathways. The interaction of papillomavirus E5 proteins with a subunit of the vacuolar ATPase may also contribute to transformation. Further analysis of these unique mechanisms of viral transformation will yield new insight into the regulation of growth factor receptor activity and cellular signal transduction pathways.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	Yale University	DiMaio, D (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.				NCI NIH HHS [CA37157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037157, R01CA037157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam JL, 2000, VIROLOGY, V272, P315, DOI 10.1006/viro.2000.0376; Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; Bohl J, 2001, J VIROL, V75, P513, DOI 10.1128/JVI.75.1.513-521.2001; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; Briggs MW, 2001, VIROLOGY, V280, P169, DOI 10.1006/viro.2000.0783; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURNETT S, 1992, P NATL ACAD SCI USA, V89, P5665, DOI 10.1073/pnas.89.12.5665; Chen SL, 1996, J VIROL, V70, P3502, DOI 10.1128/JVI.70.6.3502-3508.1996; CHEN SL, 1990, J VIROL, V64, P3226, DOI 10.1128/JVI.64.7.3226-3233.1990; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; CONRAD M, 1994, VIROLOGY, V200, P796, DOI 10.1006/viro.1994.1244; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; DiMaio D, 1998, ANNU REV MICROBIOL, V52, P397, DOI 10.1146/annurev.micro.52.1.397; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; Ghai J, 1996, P NATL ACAD SCI USA, V93, P12879, DOI 10.1073/pnas.93.23.12879; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, VIROLOGY, V190, P889, DOI 10.1016/0042-6822(92)90932-F; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; HORWITZ BH, 1989, J VIROL, V63, P4515, DOI 10.1128/JVI.63.11.4515-4519.1989; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; Lai CC, 2000, J BIOL CHEM, V275, P9832, DOI 10.1074/jbc.275.13.9832; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1991, J VIROL, V66, P1833; Liu DW, 2000, J VIROL, V74, P9083, DOI 10.1128/JVI.74.19.9083-9089.2000; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MARUO T, 1992, CANCER, V69, P1182; Mattoon D, 2001, ONCOGENE, V20, P3824, DOI 10.1038/sj.onc.1204523; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Oetke C, 2000, ARCH VIROL, V145, P2183, DOI 10.1007/s007050070048; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Petti LM, 2000, CELL GROWTH DIFFER, V11, P395; PIM D, 1992, ONCOGENE, V7, P27; Rho J, 1996, VIRUS RES, V44, P57, DOI 10.1016/0168-1702(96)01348-2; RIESE DJ, 1995, ONCOGENE, V10, P1431; Rodriguez MI, 2000, ONCOGENE, V19, P3727, DOI 10.1038/sj.onc.1203718; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SETTLEMAN J, 1989, MOL CELL BIOL, V9, P5563, DOI 10.1128/MCB.9.12.5563; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; STAEBLER A, 1995, J VIROL, V69, P6507, DOI 10.1128/JVI.69.10.6507-6517.1995; Stoppler MC, 1996, VIROLOGY, V223, P251, DOI 10.1006/viro.1996.0475; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Suprynowicz FA, 2000, J BIOL CHEM, V275, P5111, DOI 10.1074/jbc.275.7.5111; Surti T, 1998, PROTEINS, V33, P601; TERVAHAUTA A, 1994, INT J GYNECOL PATHOL, V13, P230; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Tomakidi P, 2000, EUR J CELL BIOL, V79, P407, DOI 10.1078/0171-9335-00060; Tsao YP, 1996, J VIROL, V70, P7535, DOI 10.1128/JVI.70.11.7535-7539.1996; Vali U, 2001, INT J BIOCHEM CELL B, V33, P227, DOI 10.1016/S1357-2725(01)00015-2; Venuti A, 1998, VIROLOGY, V248, P1, DOI 10.1006/viro.1998.9227; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	73	136	140	0	20	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	2001	20	54					7866	7873		10.1038/sj.onc.1204915	http://dx.doi.org/10.1038/sj.onc.1204915			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753669				2022-12-28	WOS:000172336500006
J	Rovida, E; Baccarini, M; Olivotto, M; Dello Sbarba, P				Rovida, E; Baccarini, M; Olivotto, M; Dello Sbarba, P			Opposite effects of different doses of MCSF on ERK phosphorylation and cell proliferation in macrophages	ONCOGENE			English	Article						macrophage; proliferation; MAPK; fes; MCSF	PROTEIN PHOSPHATASE 2A; MAP-KINASE; TRANSFORMING ACTIVITY; TYROSINE KINASE; V-RAF; GROWTH; ACTIVATION; SPECIFICITY; FAMILY; PATHWAYS	We had previously shown that murine macrophages expressing v-Fes, the oncogenically activated counterpart of the c-Fes cytoplasmic tyrosine kinase, proliferate independently of Macrophage Colony-Stimulating Factor (MCSF) and that the Extracellular signal-Regulated Kinase (ERK) pathway mediates the mitogenic effect of v-Fes. In this study, the response of c-fes- and v-fes-overexpressing cells to MCSF was investigated. A critical modulation of the activation of Mitogen-activated ERK Kinase (MEK) and ERK based on the MCSF dose was characterized. ERK activation was increased by MCSF doses capable to elicit a mitogenic response (2-5 U/ml). On the contrary, MCSF doses as low as 0.05 U/ml markedly reduced ERK phosphorylation and nuclear content and moderately but significantly reduced cell proliferation. The reduction of MEK and ERK phosphorylation was very rapid, suggesting the involvement of cytosolic phosphatases. Among these, phospho-tyrosine protein phosphatases and phosphoserine/threonine protein phosphatase-2A were found involved. These findings represent the first observation that different doses of the same growth factor, MCSF in particular, can exert opposite effects on cell proliferation by switching on or off ERK signaling.	Univ Florence, Dipartimento Patol & Oncol Sperimentali, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; Univ Vienna, Inst Microbiol & Genet, Vienna Bioctr, A-1090 Vienna, Austria	University of Florence; University of Vienna; Vienna Biocenter (VBC)	Dello Sbarba, P (corresponding author), Univ Florence, Dipartimento Patol & Oncol Sperimentali, Dept Expt Pathol & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	persio@unifi.it	Baccarini, Manuela/B-6481-2014; Dello Sbarba, Persio/AAX-9887-2020; Rovida, Elisabetta/F-3565-2015	Baccarini, Manuela/0000-0002-3033-391X; Rovida, Elisabetta/0000-0002-5949-3239				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; BUSCHER D, 1993, ONCOGENE, V8, P3323; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1990, ONCOGENE RES, V5, P187; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Jaworowski A, 1999, J BIOL CHEM, V274, P15127, DOI 10.1074/jbc.274.21.15127; Jaworowski A, 1996, BIOCHEM J, V320, P1011, DOI 10.1042/bj3201011; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KRAUTWALD S, 1995, ONCOGENE, V10, P1187; KRAUTWALD S, 1993, BIOCHEM BIOPH RES CO, V192, P720, DOI 10.1006/bbrc.1993.1474; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Rovida E, 2000, BLOOD, V95, P3959; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Wilson NJ, 1999, BIOCHEM J, V339, P517, DOI 10.1042/0264-6021:3390517; YEUNG YG, 1992, J BIOL CHEM, V267, P23447	28	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3670	3676		10.1038/sj.onc.1205409	http://dx.doi.org/10.1038/sj.onc.1205409			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032835				2022-12-28	WOS:000175676000002
J	Mey, A; Gandrillon, O; McNagny, KM; Clegg, DO; Samarut, J				Mey, A; Gandrillon, O; McNagny, KM; Clegg, DO; Samarut, J			The v-erbA oncogene blocks expression of alpha 2/beta 1 integrin a normal inhibitor of erythroid progenitor proliferation	ONCOGENE			English	Article						erythropoiesis; self-renewal; oncogene; v-erbA; VLA-2	MARROW STROMAL CELLS; GROWTH-FACTOR-BETA; HORMONE-RECEPTOR; HEMATOPOIETIC PROGENITORS; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; ADHERENT CELLS; SELF-RENEWAL; ADHESION; COLLAGEN	T2EC are chicken erythrocytic progenitors that balance between self-renewal and differentiation as a function of response to specific growth factors. Their transformation by the v-erbA oncogene locks them into the self-renewal program. We show here that the expression of the VLA-2 integrin alpha2 subunit mRNA is downregulated by v-erbA and that VLA-2 engagement and clustering, brought about by treatment with an alpha-specific antibody or by culture on the VLA-2 ligand collagen I, inhibits T2EC proliferation. From competition studies using antibodies, VLA-2 was shown to be involved in the collagen-induced response. While engagement of VLA-2 inhibited proliferation, it was not sufficient to induce differentiation. The transformation of T2EC by v-erbA decreased their interaction with collagen I and the VLA-2 brake on cell proliferation, which may account for the increased proliferation potential of transformed erythrocytic progenitors and for their shedding into the blood of infected chickens. Our data suggest that the interaction between erythroid progenitors and collagen, mediated by VLA-2, play a major role in the control of erythropoiesis in vitro and that this pathway is a target of the v-erbA oncogene.	Ecole Normale Super Lyon, Biol Cellulaire & Mol Lab, CNRS, UMR 5665, F-69008 Lyon, France; Univ Lyon 1, CNRS, Ctr Genet Mol & Cellulaire, UMR 5534, F-69622 Villeurbanne, France; Univ British Columbia, Dept Med Genet, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of British Columbia; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Samarut, J (corresponding author), Ecole Normale Super Lyon, Biol Cellulaire & Mol Lab, CNRS, UMR 5665, 46 Allee Italie, F-69008 Lyon, France.	Jacques.Samarut@ens-lyon.fr	McNagny, Kelly/P-5239-2014; Samarut, Jacques/AAD-2587-2019	McNagny, Kelly/0000-0003-4737-3499; MEY, Anne/0000-0002-2643-5702	NEI NIH HHS [EY 09736] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009736] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arroyo AG, 1999, IMMUNITY, V11, P555, DOI 10.1016/S1074-7613(00)80131-4; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BENTLEY SA, 1982, BRIT J HAEMATOL, V50, P491, DOI 10.1111/j.1365-2141.1982.tb01945.x; BENTLEY SA, 1980, BLOOD, V56, P1006; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; BRADSHAW AD, 1995, DEVELOPMENT, V121, P3593; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; Cann GM, 1996, DEV BIOL, V180, P82, DOI 10.1006/dbio.1996.0286; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; Coulombel L, 1997, ACTA HAEMATOL-BASEL, V97, P13, DOI 10.1159/000203655; DAINIAK N, 1978, NATURE, V272, P260, DOI 10.1038/272260a0; DINNEN RD, 1994, CELL GROWTH DIFFER, V5, P855; DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; Goltry KL, 1997, BLOOD, V90, P138; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREVE JM, 1982, J CELL BIOCHEM, V18, P221, DOI 10.1002/jcb.1982.240180209; Hamamura K, 1996, BLOOD, V87, P2513, DOI 10.1182/blood.V87.6.2513.bloodjournal8762513; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; KERST JM, 1993, BLOOD, V81, P344; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KOENIGSMANN M, 1992, BLOOD, V79, P657; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Lemischka IR, 1997, STEM CELLS, V15, P63, DOI 10.1002/stem.5530150810; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; Mey A, 1998, INFECT IMMUN, V66, P2547, DOI 10.1128/IAI.66.6.2547-2552.1998; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SPOONCER E, 1983, J CELL BIOL, V96, P510, DOI 10.1083/jcb.96.2.510; STONE EM, 1985, P NATL ACAD SCI USA, V82, P1628, DOI 10.1073/pnas.82.6.1628; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; Whetton AD, 1998, CURR OPIN CELL BIOL, V10, P721, DOI 10.1016/S0955-0674(98)80113-0; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; YANAI N, 1994, BLOOD, V83, P2844, DOI 10.1182/blood.V83.10.2844.2844; YODER MC, 1995, EXP HEMATOL, V23, P961; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZUCKERMAN KS, 1983, BLOOD, V61, P540	51	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2864	2872		10.1038/sj.onc.1205411	http://dx.doi.org/10.1038/sj.onc.1205411			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973646				2022-12-28	WOS:000175063700011
J	Hochedlinger, K; Wagner, EF; Sabapathy, K				Hochedlinger, K; Wagner, EF; Sabapathy, K			Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis	ONCOGENE			English	Article						JNK; c-Jun; apoptosis; UV irradiation; TNF-alpha; sorbitol	C-JUN; ACTIVATION; KINASE; ABSENCE	The c-Jun N-terminal kinases (JNKs) are activated by a variety of stress inducing agents and are thought to regulate apoptosis in a cell type and signal-specific manner. We have used fibroblasts lacking JNK1 or JNK2 to define their roles in response to different stress signals. Lack of JNK1 results in reduced c-Jun phosphorylation and resistance to UV-induced cell death. JNK2 deficient cells show increased sensitivity to UV irradiation which correlates with elevated and sustained phosphorylation of JNK1 and c-Jun. On the contrary, both Jnk1(-/-) and Jnk2(-1) cells were more sensitive to tumor necrosis factor - alpha (TNF-alpha) and sorbitol-induced cell death. Treatment of Jnk1(-/-) cells with these reagents resulted in reduced JNK activity and a concomitant reduction of c-Jun phosphorylation, suggesting that phosphorylation of c-Jun does not influence TNF-alpha and sorbitol-induced apoptosis in fibroblasts. Moreover, both JNK1 and JNK2 appear to negatively regulate apoptosis independent of c-Jun phosphorylation. These data provide genetic evidence that although the JNK pathway is activated by a plethora of signals, it is required only for the induction of UV-induced cell death in a c-Jun phosphorylation-dependent manner, but not for TNF-alpha and sorbitol-induced apoptosis.	Natl Canc Ctr, Mol Carcinogenesis Lab, Div Cellular & Mol Res, Singapore 169610, Singapore; Res Inst Mol Pathol, A-1030 Vienna, Austria	National Cancer Centre Singapore (NCCS); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Sabapathy, K (corresponding author), Natl Canc Ctr, Mol Carcinogenesis Lab, Div Cellular & Mol Res, 11 Hosp Dr, Singapore 169610, Singapore.	emrksb@nccs.com.sg		Wagner, Erwin F/0000-0001-7872-0196				Behrens A, 2001, P NATL ACAD SCI USA, V98, P1769, DOI 10.1073/pnas.98.4.1769; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	15	88	90	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2441	2445		10.1038/sj.onc.1205348	http://dx.doi.org/10.1038/sj.onc.1205348			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948429				2022-12-28	WOS:000174635600018
J	Ababou, M; Dumaire, V; Lecluse, Y; Amor-Gueret, M				Ababou, M; Dumaire, V; Lecluse, Y; Amor-Gueret, M			Bloom's syndrome protein response to ultraviolet-C radiation and hydroxyurea-mediated DNA synthesis inhibition	ONCOGENE			English	Article						Bloom's syndrome; UVC radiation; hydroxyurea-mediated DNA synthesis inhibition; cell cycle checkpoints; phosphorylation	SYNDROME GENE-PRODUCT; WERNERS-SYNDROME GENES; SYNDROME FIBROBLASTS; IONIZING-RADIATION; REPLICATION; CELLS; CHECKPOINT; P53; PHOSPHORYLATION; P21(WAF1/CIP1)	Bloom's syndrome (BS) arises through mutations in both copies of the BLM gene that encodes a RecQ 3'-5' DNA helicase. BS patients are predisposed to developing all the cancers that affect the general population, and BS cells exhibit marked genetic instability. We showed recently that BLM protein contributes to the cellular response to ionizing radiation by acting as downstream ATM kinase effector. We now show that following UVC treatment, BLM-deficient cells exhibit a reduction in the number of replicative cells, a partial escape from the G2/M cell cycle checkpoint, and have an altered p21 response. Surprisingly, we found that hydroxyureatreated BLM-deficient cells exhibit an intact S phase arrest, proper recovery from the S phase arrest, and intact p53 and p21 responses. We also show that the level of BLM falls sharply in response to UVC radiation. This UVC-induced reduction in BLM does not require a functional ATM gene and does not result from a subcellular compartment change. Finally, we demonstrate that exposure to UVC and hydroxyurea treatment both induce BLM phosphorylation via an ATM-independent pathway. These results are discussed in the light of their potential physiological significance with regard to the role of BLM in the cellular pathways activated by UVC radiation or HU-mediated inhibition of DNA synthesis.	Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France; Inst Gustave Roussy, Serv Cytometr Flux, IFR 54, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Amor-Gueret, M (corresponding author), Inst Gustave Roussy, CNRS, UMR 1598, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	amor@igr.fr		ababou, mouna/0000-0003-4276-3754				Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; ANDO T, 2001, J BIOL CHEM, V14, P14; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Barakat A, 2000, Hum Mutat, V15, P584, DOI 10.1002/1098-1004(200006)15:6<584::AID-HUMU28>3.0.CO;2-I; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, GENE DEV, V14, P81; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HAND R, 1977, HUM GENET, V38, P297, DOI 10.1007/BF00402156; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KURIHARA T, 1987, MUTAT RES, V183, P197, DOI 10.1016/0167-8817(87)90062-9; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; Li L, 1998, MOL GENET METAB, V64, P286, DOI 10.1006/mgme.1998.2733; LONN U, 1990, CANCER RES, V50, P3141; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAMADA A, 1989, PHOTODERMATOLOGY, V6, P124; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang SC, 2001, CANCER RES, V61, P2838; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733	43	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2079	2088		10.1038/sj.onc.1205246	http://dx.doi.org/10.1038/sj.onc.1205246			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960380				2022-12-28	WOS:000174827000014
J	Maher, P				Maher, P			Phorbol esters inhibit fibroblast growth factor-2-stimulated fibroblast proliferation by a p38 MAP kinase dependent pathway	ONCOGENE			English	Article						FGF; p38 MAPK; ERK; PKC; proliferation; fibroblasts	ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR-1; CYTOSKELETAL REORGANIZATION; TYROSINE PHOSPHORYLATION; CELL-PROLIFERATION; NEURITE OUTGROWTH; MITOGEN; PHOSPHATASE; EXPRESSION; ROLES	Treatment of fibroblasts with the phorbol ester, 12-O-tetradecanoyl phorbol 13-acetate (TPA), specifically inhibits fibroblast growth factor-2 (FGF-2) induced proliferation. TPA treatment has little or no effect on FGF receptor activation but specifically inhibits the activation of p38 MAPK but not other downstream signaling pathways implicated in cell proliferation. p38 MAPK was recently shown to be required for the FGF-2-stimulated proliferation of fibroblasts. The effect of TPA on both p38 MAPK activation and cell proliferation can be reversed by treatment with the PKC inhibitor Go6983. The TPA-mediated inhibition of p38 MAPK activation requires phosphatase activity and is at least partially mediated by ERKs since it is reduced by treatment with the MEK inhibitor PD98059. In contrast, the FGF-2-stimulated differentiation of PC12 cells, which express the same FGF receptor as Swiss 3T3 fibroblasts, is not affected by TPA treatment, consistent with a lack of involvement of p38 MAPK activity in this process. These data indicate that the effects of TPA treatment on cellular function are not only cell type but also stimulus specific and are dependent upon the distinct pathways activated downstream of each stimulus.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Maher, P (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pmaher@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054604] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54604] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARITA Y, 1994, INT J CANCER, V56, P229, DOI 10.1002/ijc.2910560215; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Cross MJ, 2000, J CELL SCI, V113, P643; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; Keyse SM, 1999, FREE RADICAL RES, V31, P341, DOI 10.1080/10715769900300911; KLINT P, 1999, FRONT BIOSCI, V4, P165; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEWIS TS, 1998, CANCER RES, P47; Lin HY, 1996, J NEUROSCI, V16, P4579; Maher P, 1999, J BIOL CHEM, V274, P17491, DOI 10.1074/jbc.274.25.17491; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PASQUALE EB, 1988, J CELL PHYSIOL, V137, P146, DOI 10.1002/jcp.1041370118; Presta M, 1998, J BIOL CHEM, V273, P7911, DOI 10.1074/jbc.273.14.7911; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SIGMUND O, 1990, J BIOL CHEM, V265, P2257; Skaletz-Rorowski A, 1999, ARTERIOSCL THROM VAS, V19, P1608, DOI 10.1161/01.ATV.19.7.1608; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tanaka K, 1999, JPN J CANCER RES, V90, P647, DOI 10.1111/j.1349-7006.1999.tb00796.x; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Tsuchida M, 2000, J BIOL CHEM, V275, P1344, DOI 10.1074/jbc.275.2.1344; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Weinstein IB, 1997, ADV EXP MED BIOL, V400, P313; Weiss RH, 1996, AM J PHYSIOL-CELL PH, V270, pC619, DOI 10.1152/ajpcell.1996.270.2.C619; WEISS RH, 1995, KIDNEY INT, V48, P738, DOI 10.1038/ki.1995.345; ZACHARY I, 1985, CANCER SURV, V4, P729; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zeidman R, 1999, INT J CANCER, V81, P494, DOI 10.1002/(SICI)1097-0215(19990505)81:3<494::AID-IJC26>3.0.CO;2-L; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	56	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1978	1988		10.1038/sj.onc.1205268	http://dx.doi.org/10.1038/sj.onc.1205268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960370				2022-12-28	WOS:000174827000004
J	Sarafan-Vasseur, N; Lamy, A; Bourguignon, J; Le Pessot, F; Hieter, P; Sesboue, R; Bastard, C; Frebourg, T; Flaman, JM				Sarafan-Vasseur, N; Lamy, A; Bourguignon, J; Le Pessot, F; Hieter, P; Sesboue, R; Bastard, C; Frebourg, T; Flaman, JM			Overexpression of B-type cyclins alters chromosomal segregation	ONCOGENE			English	Article						genetic instability; chromosomes; Clb5; cyclin B; yeast	CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; KINETOCHORE PROTEIN; MESSENGER-RNA; MUTATIONS; ANAPHASE; GENE; TRANSFORMATION; INSTABILITY; PROMOTERS	To identify genes which overexpression results into chromosomal instability (CIN), we developed a biological approach based on a yeast indicator strain in which CIN can be detected by a sectoring phenotype. Screening in this strain of a yeast genomic Library cloned into a high copy vector led us to identify, among the clones generating 100% of sectoring colonies, Clb5, one of the six B-type cyclins present in yeast. Overexpression of cyclin B2 and cyclin B1, the two human homologs of Clb5, in the CIN indicator strain resulted also into a sectoring phenotype and induced, like overexpression of Clb5, an abnormal sensitivity to benomyl, indicating that overexpression of B-type cyclins alters the spindle checkpoint. In a series of 38 primary colorectal cancers, we detected in five tumors (13%) an accumulation of cyclin B1, which was neither related to mRNA overexpression nor to mutation within the coding region, and in five other tumors (13%) a 2-10-fold increase of cyclin B2 mRNA which was not related to gene amplification. These results suggest that overexpression of cyclins B, resulting from different mechanisms, could contribute, through an alteration of the spindle checkpoint, to the chromosomal instability observed in cancer.	IFRMP, INSERM, EMI 9906, Fac Med & Pharm, F-76183 Rouen, France; Ctr Hosp Univ, Serv Anat & Cytol Pathol, F-76031 Rouen, France; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Rouen; University of British Columbia	Frebourg, T (corresponding author), IFRMP, INSERM, EMI 9906, Fac Med & Pharm, 22 Blvd Gambetta, F-76183 Rouen, France.	Frebourg@chu-rouen.fr	Frebourg, Thierry/AAK-8390-2020; Flaman, Jean-Michel/K-8415-2018	Flaman, Jean-Michel/0000-0003-3544-0199				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hyland KM, 1999, J CELL BIOL, V145, P15, DOI 10.1083/jcb.145.1.15; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; Kotani T, 2001, MOL REPROD DEV, V59, P199, DOI 10.1002/mrd.1023; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; OHSUMI K, 1994, J CELL SCI, V107, P3005; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Segal M, 1998, J CELL BIOL, V143, P135, DOI 10.1083/jcb.143.1.135; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Soria JC, 2000, CANCER RES, V60, P4000; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tsukasaki K, 2001, ONCOGENE, V20, P3301, DOI 10.1038/sj.onc.1204421; Wang AJ, 1997, J CANCER RES CLIN, V123, P124, DOI 10.1007/BF01269891; Yin XY, 2001, CANCER RES, V61, P6487; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	32	61	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2051	2057		10.1038/sj.onc.1205257	http://dx.doi.org/10.1038/sj.onc.1205257			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960377				2022-12-28	WOS:000174827000011
J	Huang, JM; Kirk, B; Favis, R; Soussi, T; Paty, P; Cao, WG; Barany, F				Huang, JM; Kirk, B; Favis, R; Soussi, T; Paty, P; Cao, WG; Barany, F			An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue	ONCOGENE			English	Article						mutation detection; endonuclease V; thermostable ligase; mismatch recognition	SINGLE-NUCLEOTIDE POLYMORPHISMS; DEOXYINOSINE-SPECIFIC ENDONUCLEASE; ENZYME MISMATCH CLEAVAGE; HIPPEL-LINDAU-DISEASE; RAS POINT MUTATIONS; K-RAS; GERMLINE MUTATIONS; CARRIER FREQUENCY; CHEMICAL CLEAVAGE; SENSITIVE METHOD	Knowledge of inherited and sporadic mutations in known and candidate cancer genes may influence clinical decisions. We have developed a mutation scanning method that combines thermostable EndonucleaseV (Endo V) and DNA ligase. Variant and wild-type PCR amplicons are generated using fluorescently labeled primers, and heteroduplexed. Thermotoga maritima (Tma) EndoV recognizes and primarily cleaves heteroduplex DNA one base 3' to the mismatch, as well as nicking matched DNA at low levels. Thermus species (Tsp.) AK16D DNA ligase reseals the background nicks to create a highly sensitive and specific assay. The fragment mobility on a DNA sequencing gel reveals the approximate position of the mutation. This method identified 31/35 and 8/8 unique point mutations and insertions/deletions, respectively, in the p53, VHL, K-ras, APC, BRCA1, and BRCA2 genes. The method has the sensitivity to detect K-ras mutations diluted 1 :20 with wildtype DNA, a p53 mutation in a 1.7 kb amplicon, and unknown p53 mutations in pooled DNA samples. EndoV/Ligase mutation scanning combined with PCR/LDR/Universal array proved superior to automated DNA sequencing for detecting p53 mutations in colon tumors. This technique is well suited for scanning low-frequency mutations in pooled samples and for analysing tumor DNA containing a minority of the unknown mutation.	Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, New York, NY 10021 USA; Inst Curie, Lab Genotoxicol Tumeurs, F-75248 Paris, France; Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, New York, NY 10021 USA	Cornell University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Memorial Sloan Kettering Cancer Center	Barany, F (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, Box 62,Room B-406,1300 York Ave, New York, NY 10021 USA.	barany@med.cornell.edu		soussi, thierry/0000-0001-8184-3293	NATIONAL CANCER INSTITUTE [R01CA081467, P01CA065930] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA81467, P01-CA65930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abeliovich D, 1997, AM J HUM GENET, V60, P505; Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Aurelio ON, 1998, CANCER RES, V58, P2190; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Beller U, 1997, GYNECOL ONCOL, V67, P123, DOI 10.1006/gyno.1997.4844; Berman DB, 1996, CANCER RES, V56, P3409; Broll R, 1999, EUR J CANCER, V35, P1083, DOI 10.1016/S0959-8049(99)00058-1; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Chen F, 1996, J MED GENET, V33, P716, DOI 10.1136/jmg.33.8.716; CHEN J, 1994, ENV HLTH PERSPECT, V3, P227; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Fahy E, 1997, NUCLEIC ACIDS RES, V25, P3102, DOI 10.1093/nar/25.15.3102; Favis R, 2000, NAT BIOTECHNOL, V18, P561, DOI 10.1038/75452; FODDE R, 1994, HUM MUTAT, V3, P83, DOI 10.1002/humu.1380030202; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gerry NP, 1999, J MOL BIOL, V292, P251, DOI 10.1006/jmbi.1999.3063; Giunta C, 1996, DIAGN MOL PATHOL, V5, P265, DOI 10.1097/00019606-199612000-00007; GULDBERG P, 1994, NUCLEIC ACIDS RES, V22, P880, DOI 10.1093/nar/22.5.880; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Hansen Lise Lotte, 1995, P275; HARIS II, 1994, PCR METH APPL, V3, P268; Hayashi K, 1991, PCR Methods Appl, V1, P34; Heide I, 1997, EUR J CANCER, V33, P1314, DOI 10.1016/S0959-8049(97)00118-4; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; Huang JM, 2001, BIOCHEMISTRY-US, V40, P8738, DOI 10.1021/bi010183h; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; Khanna M, 1999, ONCOGENE, V18, P27, DOI 10.1038/sj.onc.1202291; KHRAPKO K, 1994, NUCLEIC ACIDS RES, V22, P364, DOI 10.1093/nar/22.3.364; KORN SH, 1993, J CLIN PATHOL, V46, P621, DOI 10.1136/jcp.46.7.621; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Libutti SK, 2000, SURGERY, V128, P1022, DOI 10.1067/msy.2000.110239; Liu J, 2000, MUTAT RES-DNA REPAIR, V461, P169, DOI 10.1016/S0921-8777(00)00054-9; LIU Q, 1995, BIOTECHNIQUES, V18, P470; Makino R, 1992, PCR Methods Appl, V2, P10; Mohr VH, 2000, AM J PATHOL, V157, P1615, DOI 10.1016/S0002-9440(10)64799-2; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Oleykowski CA, 1998, NUCLEIC ACIDS RES, V26, P4597, DOI 10.1093/nar/26.20.4597; PERUCHO M, 1989, CANCER CEL, V7, P137; POMP D, 1991, BIOTECHNIQUES, V10, P58; Prives C, 1999, J PATHOL, V187, P112; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; RIDANPAA M, 1993, HUM MOL GENET, V2, P639, DOI 10.1093/hmg/2.6.639; RIDANPAA M, 1995, MUTAT RES-ENVIR MUTA, V334, P357, DOI 10.1016/0165-1161(95)90073-X; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Sgambati MT, 2000, AM J HUM GENET, V66, P84, DOI 10.1086/302726; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; Taylor GR, 1999, ELECTROPHORESIS, V20, P1125, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1125::AID-ELPS1125>3.0.CO;2-O; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Tong J, 1999, NUCLEIC ACIDS RES, V27, P788, DOI 10.1093/nar/27.3.788; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Underhill PA, 1996, P NATL ACAD SCI USA, V93, P196, DOI 10.1073/pnas.93.1.196; Walther MM, 1999, J UROLOGY, V162, P659, DOI 10.1097/00005392-199909010-00004; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Webley KM, 2000, J PATHOL, V191, P361; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575; Xu JF, 1996, CARCINOGENESIS, V17, P321; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659; YAO M, 1994, ANN NY ACAD SCI, V726, P315, DOI 10.1111/j.1749-6632.1994.tb52837.x; YAO M, 1994, J BIOL CHEM, V269, P31390; Yen H, 2000, SCIENCE, V289, P1890; YOUIL R, 1995, P NATL ACAD SCI USA, V92, P87, DOI 10.1073/pnas.92.1.87; Zirvi M, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e40; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	77	32	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1909	1921		10.1038/sj.onc.1205109	http://dx.doi.org/10.1038/sj.onc.1205109			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896624				2022-12-28	WOS:000174284500014
J	Chano, T; Ikegawa, S; Kontani, K; Okabe, H; Baldini, N; Saeki, Y				Chano, T; Ikegawa, S; Kontani, K; Okabe, H; Baldini, N; Saeki, Y			Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells	ONCOGENE			English	Article						RB1CC1 (RB1-inducible coiled-coil 1); RB1 (retinoblastoma 1); MDR (multidrug resistance); neoplasm	P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; HUMAN OSTEOSARCOMA; EXPRESSION; CHILDHOOD; PROTEIN	Multidrug resistance to anti-cancer agents (MDR) is a major barrier to successful cancer treatment. Current knowledge about genes that contribute to MDR is limited, however, and its mechanisms remain unclear. To identify genes involved in MDR, we performed differential display analysis and isolated a novel human gene, RB1CC1 (RBI-inducible Coiled-Coil 1). The 6.6-kb RB1CC1 cDNA encodes a putative 1594-amino-acid protein that contains a nuclear localization signal, a leucine zipper motif and a coiled-coil structure. Western blot analysis and immunocytochemical staining with anti-RB1CC1 antibody showed that endogenously expressed RB1CC1 protein localized to the nucleus. In MDR variants of human osteosarcoma cells, RB1CC1 expression increased in response to doxorubicin-induced cytotoxic stress and remained elevated for the duration of drug treatment. RB1CC1 expression levels correlated closely with those of RB1 (retinoblastoma 1) in cancer cell lines as well as in various normal human tissues. Moreover, introduction of wild-type RB1CC1 significantly induced RB1 expression in human leukemic cells. These data suggest that RB1CC1 may be a key regulator of RB1 gene expression.	Shiga Univ Med Sci, Dept Basic Sci Hlth & Nursing, Otsu, Shiga 5202192, Japan; Shiga Univ Med Sci, Dept Clin Lab Med, Shiga 5202192, Japan; RIKEN, SNP Res Ctr, Lab Bone & Joint Dis, Tokyo 1088639, Japan; Rizzoli Inst, Lab Onc Res, I-40136 Bologna, Italy; Shiga Univ Med Sci, Dept Surg 2, Otsu, Shiga 5202192, Japan	Shiga University of Medical Science; Shiga University of Medical Science; RIKEN; Shiga University of Medical Science	Chano, T (corresponding author), Shiga Univ Med Sci, Dept Basic Sci Hlth & Nursing, Tsukinowa Cho, Otsu, Shiga 5202192, Japan.		Baldini, Nicola/J-4806-2016; Chano, Tokuhiro/F-5816-2018; Ikegawa, Shiro/N-6895-2015	Baldini, Nicola/0000-0003-2228-3833; Chano, Tokuhiro/0000-0002-9959-1183; Ikegawa, Shiro/0000-0003-0316-2147				Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; BIEDLER JL, 1994, CANCER METAST REV, V13, P191, DOI 10.1007/BF00689636; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; Chano T, 2000, OSTEOARTHR CARTILAGE, V8, P115, DOI 10.1053/joca.1999.0279; FERRACINI R, 1995, ONCOGENE, V10, P739; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; PINEDO HM, 1995, NEW ENGL J MED, V333, P1417, DOI 10.1056/NEJM199511233332111; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; Sauerbrey A, 1996, BRIT J HAEMATOL, V94, P99, DOI 10.1046/j.1365-2141.1996.d01-1753.x; Scotlandi K, 1996, CANCER RES, V56, P2434; Scotlandi K, 1999, ONCOGENE, V18, P739, DOI 10.1038/sj.onc.1202330; TANG A, 1989, ONCOGENE, V4, P401; TAYA Y, 1997, TIBS, V21, P14; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343	20	61	67	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1295	1298		10.1038/sj.onc.1205178	http://dx.doi.org/10.1038/sj.onc.1205178			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850849				2022-12-28	WOS:000173729400017
J	Nesterov, A; Ivashchenko, Y; Kraft, AS				Nesterov, A; Ivashchenko, Y; Kraft, AS			Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells	ONCOGENE			English	Article						TRAIL; apoptosis; primary; prostate; human	DEATH; INHIBITION; RECEPTORS; INDUCTION; MEMBER; FAMILY	TRAIL is a pro-apoptotic cytokine believed to selectively kill cancer cells without harming normal ones. However, we found that in normal human prostate epithelial cells (PrEC) TRAIL is capable of inducing apoptosis as efficiently as in some tumor cell lines. At the same time, TRAIL did not cause apoptosis in several other human primary cell lines: aorta smooth muscle cells, foreskin fibroblasts, and umbilical vein endothelial cells. Compared to these primary cells, PrEC were found to contain significantly fewer TRAIL receptors DcR1 and DcR2 which are not capable of conducting the apoptotic signal. This result suggests that the unusual sensitivity of PrEC to TRAIL may result from their deficiency in antiapoptotic decoy receptors. The protein synthesis inhibitor cycloheximide significantly enhanced TRAIL toxicity toward PrEC as measured by tetrazolium conversion but had little or no effect on other TRAIL-induced apoptotic responses. Although cycloheximide did not further accelerate the processing of caspases 3 and 8, it significantly enhanced cleavage of the caspase 3 substrate gelsolin, indicating that in PrEC a protein(s) with a short half-life may inhibit the activity of the executioner caspases toward specific substrates. As the majority of prostate cancers are derived from epithelial cells, our data suggest the possibility that TRAIL could be a useful treatment for the early stages of prostate cancer.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Aventis Pharmaceut, D-65926 Frankfurt, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Sanofi-Aventis	Nesterov, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL CANCER INSTITUTE [R01CA078631] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78631] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J IMMUNOL, V162, P2597; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Leverkus M, 2000, CANCER RES, V60, P553; Loo DT, 1998, METHOD CELL BIOL, V57, P251; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; STAMEY TA, 1992, CAMPBELLS UROLOGY, P1159; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Warner HR, 1997, J AM GERIATR SOC, V45, P1140, DOI 10.1111/j.1532-5415.1997.tb05981.x; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	23	88	92	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1135	1140		10.1038/sj.onc.1205151	http://dx.doi.org/10.1038/sj.onc.1205151			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850832				2022-12-28	WOS:000173580100018
J	Jarboe, EA; Liaw, KL; Thompson, LC; Heinz, DE; Baker, PL; McGregor, JA; Dunn, T; Woods, JE; Shroyer, KR				Jarboe, EA; Liaw, KL; Thompson, LC; Heinz, DE; Baker, PL; McGregor, JA; Dunn, T; Woods, JE; Shroyer, KR			Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma	ONCOGENE			English	Article						telomerase; hTR; hTERT; TRAP; cervix neoplasia	SQUAMOUS-CELL CARCINOMA; CATALYTIC SUBUNIT GENE; HUMAN PAPILLOMAVIRUS TYPE-16; INTRAEPITHELIAL NEOPLASIA; RNA COMPONENT; PRECANCEROUS LESIONS; PAPANICOLAOU SMEARS; UTERINE CERVIX; ACETIC-ACID; CANCER	Telomerase expression is a potentially important marker of high-grade cervical dysplasia and squamous cell carcinoma (SCC). The routine practice of cervical cytology is limited by problems of false negative diagnoses as well as by poor specificity for clinically significant lesions in patients with low-grade cytologic abnormalities. Telomerase is widely expressed in most SCCs as well as in a high proportion of high-grade squamous intraepithelial lesions. Histochemical studies have confirmed that telomerase is expressed in the lower portions of normal or metaplastic squamous mucosa but that telomerase positive cells extend into the upper epithelial layers in cases of high-grade dysplasia. Since the cervical smear samples the uppermost cell layers of the cervical mucosa, but does not normally include cells derived from the lower layers of the squamous mucosa, the detection of telomerase in exfoliated cells of the cervical smear may have specificity for clinically significant lesions. The analysis of hTR, hTERT, and telomerase activity are complicated by a number of technical factors that may lead to either false negative or false positive test results. Thus, the practical application of telomerase analysis as a diagnostic adjunct for cervical cytopathology may depend on the development of more reliable and sensitive assay systems, possibly formatted for cytochemical applications.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Obstet & Gynecol, Denver, CO 80262 USA; Merck Res Labs, Dept Epidemiol, West Point, PA 19486 USA; Denver Hlth Med Ctr, Dept Obstet & Gynecol, Denver, CO 80204 USA; Denver Hlth Med Ctr, Dept Pathol, Denver, CO 80204 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Merck & Company; Denver Health Medical Center; Denver Health Medical Center	Shroyer, KR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, 4200 E 9th Ave, Denver, CO 80262 USA.	Ken.Shroyer@UCHSC.edu			NCI NIH HHS [R01 CA78442-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078442] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM CANC SOC, 2001, CANC FACTS FIG 2001; Anderson S, 1997, AM J PATHOL, V151, P25; BENOIT AG, 1984, AM J OBSTET GYNECOL, V148, P690, DOI 10.1016/0002-9378(84)90775-0; BERKELEY AS, 1980, LANCET, V2, P375; BIRLEY HDL, 1995, ANN TROP MED PARASIT, V89, P453, DOI 10.1080/00034983.1995.11812977; Brien TP, 1997, CANCER RES, V57, P2760; ChangChien CC, 1998, GYNECOL ONCOL, V71, P99, DOI 10.1006/gyno.1998.5143; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; DeMay RM, 1996, AM J OBSTET GYNECOL, V175, P1110, DOI 10.1016/S0002-9378(96)70013-3; DEMAY RM, 1996, EXFOLIATIVE CYTOLOGY, P61; ENOMOTO T, 1997, INT J CANCER, V73, P1; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Frost M, 2000, AM J CLIN PATHOL, V114, P726, DOI 10.1309/XWFE-ARMN-HG2D-AJYV; GAY JD, 1985, ACTA CYTOL, V29, P1043; Gorham H, 1997, J CLIN PATHOL, V50, P501, DOI 10.1136/jcp.50.6.501; Guidozzi F, 1996, Obstet Gynecol Surv, V51, P247; Gullu IH, 1999, BRIT J CANCER, V81, P186, DOI 10.1038/sj.bjc.6690674; HATCH KD, 1995, AM J OBSTET GYNECOL, V172, P1150, DOI 10.1016/0002-9378(95)91473-0; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; Iwasaka T, 1998, OBSTET GYNECOL, V91, P260, DOI 10.1016/S0029-7844(97)00595-4; Kawai K, 1998, EUR J CANCER, V34, P2082, DOI 10.1016/S0959-8049(98)00242-1; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KRIEGER P, 1994, ACTA CYTOL, V38, P291; Kyo S, 1996, CLIN CANCER RES, V2, P2023; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1998, INT J CANCER, V79, P66, DOI 10.1002/(SICI)1097-0215(19980220)79:1<66::AID-IJC13>3.0.CO;2-F; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mutirangura A, 1998, BRIT J CANCER, V78, P933, DOI 10.1038/bjc.1998.604; Nagai N, 1999, ONCOL REP, V6, P325; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakano K, 1998, AM J PATHOL, V153, P857, DOI 10.1016/S0002-9440(10)65627-1; Naryshkin S, 1997, ARCH PATHOL LAB MED, V121, P270; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; PAIRWUTI S, 1991, ACTA CYTOL, V35, P40; Pao CC, 1997, J CLIN ONCOL, V15, P1932, DOI 10.1200/JCO.1997.15.5.1932; Park TW, 1996, J NATL CANCER I, V88, P355, DOI 10.1093/jnci/88.6.355; PARK TW, 1995, CANCER-AM CANCER SOC, V76, P1902, DOI 10.1002/1097-0142(19951115)76:10+<1902::AID-CNCR2820761306>3.0.CO;2-0; Reddy VG, 2001, INT J GYNECOL CANCER, V11, P100; RICHART RM, 1993, PATHOL ANNU, V8, P301; Riethdorf S, 2001, INT J GYNECOL PATHOL, V20, P177, DOI 10.1097/00004347-200104000-00011; ROBERTSON JH, 1993, J CLIN PATHOL, V46, P700, DOI 10.1136/jcp.46.8.700; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Shroyer KR, 1998, AM J CLIN PATHOL, V109, P153, DOI 10.1093/ajcp/109.2.153; Shroyer KR, 1997, INT J GYNECOL PATHOL, V16, P225, DOI 10.1097/00004347-199707000-00006; Snijders PJF, 1998, CANCER RES, V58, P3812; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; Solomon D, 1994, BETHESDA SYSTEM REPO, P9; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; Tabbara SO, 1996, DIAGN CYTOPATHOL, V14, P84, DOI 10.1002/(SICI)1097-0339(199602)14:1<84::AID-DC17>3.0.CO;2-9; Takakura M, 1998, CANCER RES, V58, P1558; Tkeshelashvili V. T., 1993, European Journal of Gynaecological Oncology, V14, P89; Ulaner GA, 1998, CANCER RES, V58, P4168; VANDERGRAAF Y, 1987, ACTA CYTOL, V31, P434; VANDERGRAAF Y, 1987, J CLIN PATHOL, V40, P438, DOI 10.1136/jcp.40.4.438; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wisman GBA, 2000, HUM PATHOL, V31, P1304, DOI 10.1053/hupa.2000.19299; Wisman GBA, 1998, J CLIN ONCOL, V16, P2238, DOI 10.1200/JCO.1998.16.6.2238; Wisman GBA, 2001, INT J CANCER, V91, P658, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1099>3.0.CO;2-7; Wolf JK, 2001, CANCER INVEST, V19, P621, DOI 10.1081/CNV-100104290; WRIGHT TC, 1995, OBSTET GYNECOL, V85, P202, DOI 10.1016/0029-7844(94)00373-L; Wright TC, 1994, BLAUSTEINS PATHOLOGY, P229; WRIGHT TC, 1994, BLAUSTEINS PATHOLOGY, P287; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Wu YY, 2000, CLIN CHIM ACTA, V293, P199, DOI 10.1016/S0009-8981(99)00238-7; Yahata N, 1999, INT J ONCOL, V14, P709; Yashima K, 1998, CANCER, V82, P1319; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Yokoyama Y, 1998, GYNECOL ONCOL, V68, P145, DOI 10.1006/gyno.1997.4921; Zhang DK, 1999, EUR J CANCER, V35, P154, DOI 10.1016/S0959-8049(98)00303-7; Zheng PS, 1997, GYNECOL ONCOL, V66, P222, DOI 10.1006/gyno.1997.4757; zur Hausen H, 1999, P ASSOC AM PHYSICIAN, V111, P581, DOI 10.1046/j.1525-1381.1999.99723.x; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	75	45	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					664	673		10.1038/sj.onc.1205073	http://dx.doi.org/10.1038/sj.onc.1205073			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850794				2022-12-28	WOS:000173390500021
J	Pandita, TK				Pandita, TK			ATM function and telomere stability	ONCOGENE			English	Article						ATM; telomeres; telomerase; hTERT; DNA damage; signal transduction	ABL TYROSINE KINASE; EXTENDED-LIFE-SPAN; ATAXIA-TELANGIECTASIA; C-ABL; PROTEIN-KINASE; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; RECOMBINATION NODULES; SYNAPTONEMAL COMPLEX	Accumulation of DNA damage has been associated with the onset of senescence and predisposition to cancer. The gene responsible for ataxia telangiectasia (A-T) is ATM (ataxia-telangiectasia mutant), a master controller of cellular pathways and networks, orchestrating the responses to a specific type of DNA damage: the double strand break. Based on the homology of the human ATM gene to the TEL1, MEC1 and rad3 genes of yeast, it has now been demonstrated that mutations in ATM lead to defective telomere maintenance in mammalian cells. While ATM has both nuclear and cytoplasmic functions, this review will focus on its roles in telomere metabolism and how ATM and telomeres serve as controllers of cellular responses to DNA damage.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA	Columbia University	Pandita, TK (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, VC11-213,630 W 168th St, New York, NY 10032 USA.	tkp1@columbia.edu	Pandita, Tej K/AAM-9188-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Agami R, 1999, NATURE, V399, P809; ALBINI SM, 1984, EXP CELL RES, V155, P588, DOI 10.1016/0014-4827(84)90219-2; ANDEGEKO Y, 2001, IN PRESS J BIOL CHEM; ASHLEY T, 1994, HUM GENET, V94, P587, DOI 10.1007/BF00206950; Barlow C, 1998, DEVELOPMENT, V125, P4007; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan SWL, 2001, CURR BIOL, V11, P1240, DOI 10.1016/S0960-9822(01)00391-8; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Dahlen M, 1998, MOL BIOL CELL, V9, P611, DOI 10.1091/mbc.9.3.611; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; DERNBURG AF, 1995, SPRING HARBOR MONOGR, P295; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Fang Z. H., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P142; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; FUSSELL C P, 1987, P275; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gilson Eric, 1993, Trends in Cell Biology, V3, P128, DOI 10.1016/0962-8924(93)90175-Z; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HITTELMAN WN, 1994, INT J RADIAT BIOL, V66, pS109; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; LOIDL J, 1990, GENOME, V33, P759, DOI 10.1139/g90-115; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Mallory JC, 2000, P NATL ACAD SCI USA, V97, P13749, DOI 10.1073/pnas.250475697; Matsuura A, 1999, GENETICS, V152, P1501; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; Pandita TK, 2001, RADIAT RES, V156, P642, DOI 10.1667/0033-7587(2001)156[0642:TROAIT]2.0.CO;2; Pandita TK, 2000, RADIAT RES, V154, P133; PANDITA TK, 2001, ADV CELL AGING GERON, V8, P61; PANDITA TK, 1992, RAD RAS, V130, P104; RASMUSSEN SW, 1980, HEREDITAS, V93, P187; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Rockmill B, 1998, GENE DEV, V12, P2574, DOI 10.1101/gad.12.16.2574; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Scherthan H, 2000, MOL CELL BIOL, V20, P7773, DOI 10.1128/MCB.20.20.7773-7783.2000; Scherthan H, 1997, CHROMOSOM T, V12, P217; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Smilenov LB, 1998, ONCOGENE, V17, P2137, DOI 10.1038/sj.onc.1202138; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; SVOBODA A, 1995, CHROMOSOMA, V104, P203, DOI 10.1007/s004120050109; THERMAN E, 1977, HUM GENET, V35, P137, DOI 10.1007/BF00393963; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615	80	140	149	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					611	618		10.1038/sj.onc.1205060	http://dx.doi.org/10.1038/sj.onc.1205060			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850786				2022-12-28	WOS:000173390500013
J	Adachi, Y; Chandrasekar, N; Kin, Y; Lakka, SS; Mohanam, S; Yanamandra, N; Mohan, PM; Fuller, GN; Fang, BL; Fueyo, J; Dinh, DH; Olivero, WC; Tamiya, T; Ohmoto, T; Kyritsis, AP; Rao, JS				Adachi, Y; Chandrasekar, N; Kin, Y; Lakka, SS; Mohanam, S; Yanamandra, N; Mohan, PM; Fuller, GN; Fang, BL; Fueyo, J; Dinh, DH; Olivero, WC; Tamiya, T; Ohmoto, T; Kyritsis, AP; Rao, JS			Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences	ONCOGENE			English	Article						glioblastoma; invasion; adenovirus; antisense; urokinase plasminogen receptor	PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN GLIOBLASTOMA CELLS; UROKINASE RECEPTOR; IN-VITRO; TUMOR SUPPRESSION; MALIGNANT-CELLS; CYCLE ARREST; EXPRESSION; INTEGRIN; LOCALIZATION	Our previous studies showed that the urokinase-type plasminogen activator receptor (uPAR) and the p16 tumor suppressor gene play a significant role in glioma invasion. We expected that downregulation of uPAR and overexpression of p16 using a bicistronic vector might cause a additive and cooperative effect in the suppression of glioma invasion and growth. The bicistronic construct (Ad-uPAR/p16)-infected glioblastoma cell lines had significantly lower levels of uPAR and higher levels of p16 than controls. Cell cycle analysis showed the bicistronic vector caused G0/G1 arrest of the cell cycle. In vitro glioblastoma cell growth and invasiveness were inhibited in Ad-uPAR/p16-infected cells compared with controls. Ad-uPAR/p16 suppressed the tumor growth of glioblastoma cell lines in an ex vivo intracerebral tumor model and an in vivo subcutaneous tumor model. Our results support the therapeutic potential of simultaneously targeting uPAR and p16 in the treatment of gliomas.	Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 7008558, Japan; Osmania Univ, Dept Biochem, Hyderabad 500007, Andhra Pradesh, India; Univ Texas, MD Anderson Canc Ctr, Dept Neuropathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; Okayama University; Osmania University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rao, JS (corresponding author), Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Fueyo, Juan/0000-0001-6941-2335; Fuller, Gregory/0000-0001-9447-2647	NCI NIH HHS [CA 76350, CA 75557, CA80748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076350, R01CA075557, R01CA080748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ARAP W, 1995, CANCER RES, V55, P1351; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Chintala SK, 1996, CANCER LETT, V103, P201, DOI 10.1016/0304-3835(96)04215-2; Chintala SK, 1997, ONCOGENE, V15, P2049, DOI 10.1038/sj.onc.1201382; Costello JF, 1996, CANCER RES, V56, P2405; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Frizelle SP, 1998, ONCOGENE, V16, P3087, DOI 10.1038/sj.onc.1201870; Fueyo J, 1996, ONCOGENE, V12, P103; Fueyo J, 1996, ONCOGENE, V13, P1615; Fueyo J, 1998, NEUROLOGY, V51, P1250, DOI 10.1212/WNL.51.5.1250; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; GLADSON CL, 1995, AM J PATHOL, V146, P1150; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Go Y, 1996, CANCER LETT, V110, P225, DOI 10.1016/S0304-3835(96)04515-6; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Gotoh A, 1997, J UROLOGY, V158, P636, DOI 10.1016/S0022-5347(01)64574-9; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Harada H, 1999, CANCER RES, V59, P3783; Ichimura K, 1996, ONCOGENE, V13, P1065; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kyritsis AP, 1996, ONCOGENE, V12, P63; KYRITSIS AP, 1997, PRACTICE GUIDELINES, P473; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Mohan PM, 1999, CANCER RES, V59, P3369; Mohanam S, 1998, INT J ONCOL, V13, P1285; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; MOHANAM S, 1993, CANCER RES, V53, P4143; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; Naruse I, 1998, ANTICANCER RES, V18, P4275; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; POLLANEN J, 1991, ADV CANCER RES, V57, P273; REED JA, 1995, CANCER RES, V55, P2713; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; Wang J, 1997, CANCER RES, V57, P351; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	48	29	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					87	95		10.1038/sj.onc.1204999	http://dx.doi.org/10.1038/sj.onc.1204999			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791179				2022-12-28	WOS:000172887800009
J	Campuzano, S				Campuzano, S			Emc, a negative HLH regulator with multiple functions in Drosophila development	ONCOGENE			English	Article						Drosophila; extramacrochaetae; HLH; transcription factor; development	LOOP-HELIX PROTEINS; ACHAETE-SCUTE COMPLEX; PERIPHERAL NERVOUS-SYSTEM; SENSORY ORGAN DEVELOPMENT; SEX DETERMINATION SIGNAL; X-A RATIO; DNA-BINDING; PRONEURAL CLUSTERS; EXTRAMACROCHAETAE PROTEIN; WING MORPHOGENESIS	Expression and functional analyses of Emc have demonstrated that it is a prototype for a protein required for multiple processes in development. Initially characterized as a negative regulator of sensory organ development, it was later found to regulate many other developmental processes and cell proliferation. Its ability to block the function of bRLH proteins by forming heterodimers, which are ineffective in DNA binding, accounts for the role of Emc in preventing the acquisition of several cell fates which are under the control of bHLH proteins. However, while maintaining this repressive molecular mechanism, emc also appears to act as a positive regulator of differentiation.	Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Campuzano, S (corresponding author), Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.		Campuzano Corrales, Sonsoles/K-1363-2014	Campuzano Corrales, Sonsoles/0000-0003-1834-0508				Affolter M, 2000, CURR OPIN CELL BIOL, V12, P731, DOI 10.1016/S0955-0674(00)00160-5; ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; ARMAND P, 1994, MOL CELL BIOL, V14, P4145, DOI 10.1128/MCB.14.6.4145; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; Baonza A, 1999, MECH DEVELOP, V80, P133, DOI 10.1016/S0925-4773(98)00198-1; Baonza A, 2001, DEVELOPMENT, V128, P3889; Baonza A, 2000, DEVELOPMENT, V127, P2383; BATE M, 1978, HDB SENSORY PHYSL, V1; BAUMANN P, 1993, DEVELOPMENT, P65; Baylies MK, 1998, CELL, V93, P921, DOI 10.1016/S0092-8674(00)81198-8; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BROWN NL, 1995, CELL, V80, P879, DOI 10.1016/0092-8674(95)90291-0; CABRERA CV, 1994, DEVELOPMENT, V120, P3595; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CARMENA A, 1995, GENE DEV, V9, P2373, DOI 10.1101/gad.9.19.2373; Carrera P, 1998, P NATL ACAD SCI USA, V95, P10779, DOI 10.1073/pnas.95.18.10779; Castanon I, 2001, DEVELOPMENT, V128, P3145; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; Chen CM, 1996, MECH DEVELOP, V57, P215, DOI 10.1016/0925-4773(96)00548-5; CLINE TW, 1988, GENETICS, V119, P829; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; CUBAS P, 1994, DEVELOPMENT, V120, P2555; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1988, ROUX ARCH DEV BIOL, V197, P419, DOI 10.1007/BF00398993; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; De Celis JF, 1998, INT J DEV BIOL, V42, P335; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; DECELIS JF, 1995, MECH DEVELOP, V53, P209, DOI 10.1016/0925-4773(95)00436-5; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P246; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Dokucu ME, 1996, DEVELOPMENT, V122, P4139; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ELLIS HM, 1994, MECH DEVELOP, V47, P65, DOI 10.1016/0925-4773(94)90096-5; ERICKSON JW, 1993, GENE DEV, V7, P1688, DOI 10.1101/gad.7.9.1688; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; Freeman M, 1997, DEVELOPMENT, V124, P261; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1978, GENETICS, V88, P469; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GOMEZSKARMETA JL, 1995, GENE DEV, V9, P1869, DOI 10.1101/gad.9.15.1869; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HOCH M, 1994, DEVELOPMENT, V120, P3439; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; KING PH, 1994, J NEUROSCI, V14, P1943; Lai EC, 1998, CELL, V93, P1103, DOI 10.1016/S0092-8674(00)81454-3; Lai EC, 1997, DEVELOPMENT, V124, P4847; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; Leviten MW, 1997, DEVELOPMENT, V124, P4039; Lisbin MJ, 2001, GENE DEV, V15, P2546, DOI 10.1101/gad.903101; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MARTINEZ C, 1993, MOL CELL BIOL, V13, P3514, DOI 10.1128/MCB.13.6.3514; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Modolell J, 1998, INT J DEV BIOL, V42, P275; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Norton JD, 2000, J CELL SCI, V113, P3897; Ohshiro T, 1997, DEVELOPMENT, V124, P3975; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; SKAER H, 1993, DEV DROSPHILE MELANO; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; Takahisa M, 1996, GENE DEV, V10, P1783, DOI 10.1101/gad.10.14.1783; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; TORRES M, 1991, DEVELOPMENT, V113, P715; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WIE X, 2001, MECH DEVELOP, V100, P217; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5	86	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 20	2001	20	58					8299	8307		10.1038/sj.onc.1205162	http://dx.doi.org/10.1038/sj.onc.1205162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840322				2022-12-28	WOS:000173319500003
J	Nair, PN; De Armond, DT; Adamo, ML; Strodel, WE; Freeman, JW				Nair, PN; De Armond, DT; Adamo, ML; Strodel, WE; Freeman, JW			Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-IR) are mediated by an induction of IGF-IR promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2	ONCOGENE			English	Article						IGF-IR; pancreatic cancer; growth regulation; signal transduction; apoptosis	INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; CONSTITUTIVE ACTIVATION; GENE-EXPRESSION; DOWN-REGULATION; PROTEIN-KINASE; APOPTOSIS; PATHWAYS	In the present study we investigated the mechanisms responsible for and the biological consequences of the constitutive activation of the insulin-like growth factor-1 receptor (IGF-IR) in the MIA PaCa-2 cells. An aberrant increase in the expression and activation of the IGF-IR was observed during the transition of growth states from exponential to quiescent. The increase in IGF-1R expression is preceded by an increase in IGF-1R mRNA transcript and is associated with an increase in the IGF-IR promoter activity. Inhibition of de novo transcription by actinomycin D increased the stability of IGF-IR mRNA in exponentially growing cells, thereby increasing the expression of IGF-IR to a level similar to that seen in quiescent cells. Increased IGF-IR signaling mediated the growth factor independence of quiescent MIA PaCa-2 cells through the constitutive activation of mitogen-activated protein kinase (MAPK). Exogenous IGF-I increased cell proliferation and activated MAPK and AKT signaling pathways. The resistance of cells to apoptosis by IGF-IR signaling was mediated through MAPK and phosphatidylinositol 3-kinase (PI3K) pathways and a yet unidentified pathway(s). Thus, aberrant regulation of IGF-1R signaling is required for resistance to apoptosis and growth factor independence of MIA PaCa-2 cells. This likely protects cells from unfavorable conditions and allows cells to rapidly re-enter the cell cycle when conditions are favorable.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Freeman, JW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.							Baron V, 2000, J BIOL CHEM, V275, P39318, DOI 10.1074/jbc.M003618200; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; BERGMANN U, 1995, CANCER RES, V55, P2007; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Chen Jie, 1994, Zentralblatt fuer Pathologie, V140, P265; Chi MMY, 2000, ENDOCRINOLOGY, V141, P4784, DOI 10.1210/en.141.12.4784; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Coppola D, 2000, Cancer Control, V7, P421; Devi GR, 2000, ENDOCRINOLOGY, V141, P4171, DOI 10.1210/en.141.11.4171; DiGiovanni J, 2000, CANCER RES, V60, P1561; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Flossmann-Kast BBM, 1998, CANCER RES, V58, P3551; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GIANNELLANETO D, 1992, CIRC RES, V71, P646, DOI 10.1161/01.RES.71.3.646; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Grothey A, 1999, J CANCER RES CLIN, V125, P166, DOI 10.1007/s004320050259; HERNANDEZ ER, 1992, J CLIN ENDOCR METAB, V74, P419, DOI 10.1210/jc.74.2.419; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; Ignatoski KMW, 1999, ENDOCRINOLOGY, V140, P3615, DOI 10.1210/en.140.8.3615; Ishiwata T, 1997, PANCREAS, V15, P367, DOI 10.1097/00006676-199711000-00006; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Kornmann M, 1998, CANCER RES, V58, P4250; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lee CT, 1996, CANCER RES, V56, P3038; Lin JQ, 1999, CANCER RES, V59, P2891; Liu RY, 1999, BLOOD, V93, P2369, DOI 10.1182/blood.V93.7.2369.407k18_2369_2379; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Ricort JM, 2001, ENDOCRINOLOGY, V142, P108, DOI 10.1210/en.142.1.108; Supino-Rosin L, 2000, J BIOL CHEM, V275, P21850, DOI 10.1074/jbc.M001834200; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Tominaga S, 1998, SEMIN SURG ONCOL, V15, P3, DOI 10.1002/(SICI)1098-2388(199807/08)15:1<3::AID-SSU2>3.0.CO;2-9; Wang L, 2000, ENDOCRINOLOGY, V141, P2481, DOI 10.1210/en.141.7.2481; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Zahradka P, 1998, BBA-BIOMEMBRANES, V1375, P131, DOI 10.1016/S0005-2736(98)00144-8; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	50	63	66	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8203	8214		10.1038/sj.onc.1205044	http://dx.doi.org/10.1038/sj.onc.1205044			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781836				2022-12-28	WOS:000172507800005
J	Munger, K; Basile, JR; Duensing, S; Eichten, A; Gonzalez, SL; Grace, M; Zacny, VL				Munger, K; Basile, JR; Duensing, S; Eichten, A; Gonzalez, SL; Grace, M; Zacny, VL			Biological activities and molecular targets of the human papillomavirus E7 oncoprotein	ONCOGENE			English	Review						viral oncoproteins; papillomaviruses; p53; retinoblastoma; tumor suppressor; centrosomes	GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; LARGE T-ANTIGEN; PRIMARY HUMAN KERATINOCYTES; TUMOR-SUPPRESSOR PROTEIN; KINASE-II PHOSPHORYLATION; TRANSCRIPTION FACTOR E2F; PRB-RELATED PROTEINS; REGULATORY FACTOR-I; VIRAL LIFE-CYCLE	The human papillomavirus (HPV) E7 protein is one of only two viral proteins that remain expressed in HPV-associated human cancers. HPV E7 proteins share structural and functional similarities with oncoproteins encoded by other small DNA tumor viruses such as adenovirus EIA and SV40 large tumor antigen. The HPV E7 protein plays an important role in the viral life cycle by subverting the tight link between cellular differentiation and proliferation in normal epithelium, thus allowing the virus to replicate in differentiating epithelial cells that would have normally withdrawn from the cell division cycle. The transforming activities of E7 largely reflect this important function.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Ctr Canc Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Munger, Karl/0000-0003-3288-9935	NCI NIH HHS [R01 CA66980, R01 CA81135] Funding Source: Medline; NIDCR NIH HHS [P01 DE12467, K16 DE00275] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081135, R01CA066980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467, K16DE000275] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alani RM, 1998, MOL CARCINOGEN, V23, P226, DOI 10.1002/(SICI)1098-2744(199812)23:4<226::AID-MC5>3.0.CO;2-N; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Armstrong DJ, 1997, VIROLOGY, V239, P238, DOI 10.1006/viro.1997.8885; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANKS L, 1990, ONCOGENE, V5, P1383; Bannasch P, 1997, J BIOENERG BIOMEMBR, V29, P303, DOI 10.1023/A:1022438528634; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; Barnard P, 2000, VIROLOGY, V277, P411, DOI 10.1006/viro.2000.0584; Barnard P, 1999, VIROLOGY, V259, P305, DOI 10.1006/viro.1999.9771; Basile JR, 2001, J BIOL CHEM, V276, P22522, DOI 10.1074/jbc.M010505200; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Borger DR, 2000, VIROLOGY, V270, P397, DOI 10.1006/viro.2000.0282; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Boyer SN, 1996, CANCER RES, V56, P4620; Braspenning J, 1998, ONCOGENE, V16, P1085, DOI 10.1038/sj.onc.1201617; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; BROKAW JL, 1994, VIROLOGY, V205, P603, DOI 10.1006/viro.1994.1688; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Chang YJE, 2000, J VIROL, V74, P4174, DOI 10.1128/JVI.74.9.4174-4182.2000; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CICCOLINI F, 1994, ONCOGENE, V9, P2633; CLEMENS KE, 1995, VIROLOGY, V214, P289, DOI 10.1006/viro.1995.9926; Clements A, 2000, BIOCHEMISTRY-US, V39, P16033, DOI 10.1021/bi002111g; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; CREEK KE, 1995, ADV EXP MED BIOL, V375, P117; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Duensing S, 2001, CANCER RES, V61, P2356; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; Flores ER, 2000, J VIROL, V74, P6622, DOI 10.1128/JVI.74.14.6622-6631.2000; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; GREENFIELD I, 1991, P NATL ACAD SCI USA, V88, P11217, DOI 10.1073/pnas.88.24.11217; GUO K, 1995, MOL CELL BIOL, V15, P3823; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Jian YC, 1998, ONCOGENE, V17, P2027, DOI 10.1038/sj.onc.1202142; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Jones DL, 1999, VIROLOGY, V258, P406, DOI 10.1006/viro.1999.9733; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Katich SC, 2001, ONCOGENE, V20, P543, DOI 10.1038/sj.onc.1204130; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Marx J, 2001, SCIENCE, V292, P426, DOI 10.1126/science.292.5516.426; Massimi P, 2000, VIROLOGY, V276, P388, DOI 10.1006/viro.2000.0514; Massimi P, 1997, VIROLOGY, V227, P255, DOI 10.1006/viro.1996.8315; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Mavromatis KO, 1997, VIRUS RES, V52, P109, DOI 10.1016/S0168-1702(97)00090-7; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; MAZZARELLI JM, 1995, ONCOGENE, V11, P1859; McDonald ER, 2001, ANN MED, V33, P113, DOI 10.3109/07853890109002066; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; Mi YD, 2000, VIROLOGY, V270, P408, DOI 10.1006/viro.2000.0283; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, J VIROL, V63, P4417; Murray AW, 2001, SCIENCE, V291, P1499, DOI 10.1126/science.291.5508.1499; Nees M, 2000, CANCER RES, V60, P4289; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Noya F, 2001, J VIROL, V75, P6121, DOI 10.1128/JVI.75.13.6121-6134.2001; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; PEDERSEN S N, 1975, Acta Obstetricia et Gynecologica Scandinavica, V54, P443; Perea SE, 2000, INT J MOL MED, V5, P661; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Phillips AC, 1997, J GEN VIROL, V78, P905, DOI 10.1099/0022-1317-78-4-905; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rey O, 2000, VIROLOGY, V268, P372, DOI 10.1006/viro.1999.0175; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; SANG BC, 1992, P NATL ACAD SCI USA, V89, P8063, DOI 10.1073/pnas.89.17.8063; SATO H, 1989, VIROLOGY, V170, P311, DOI 10.1016/0042-6822(89)90386-3; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; Schonning BH, 2000, J GEN VIROL, V81, P1009, DOI 10.1099/0022-1317-81-4-1009; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; Skyldberg B, 2001, MODERN PATHOL, V14, P279, DOI 10.1038/modpathol.3880303; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; Southern SA, 2001, CANCER RES, V61, P4858; Stearns T, 2001, CELL, V105, P417, DOI 10.1016/S0092-8674(01)00366-X; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Stubenrauch F, 1999, SEMIN CANCER BIOL, V9, P379, DOI 10.1006/scbi.1999.0141; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; VILLA LL, 1992, MOL CARCINOGEN, V6, P5, DOI 10.1002/mc.2940060103; VOUSDEN KH, 1989, ONCOGENE, V4, P153; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zatsepina O, 1997, ONCOGENE, V14, P1137, DOI 10.1038/sj.onc.1200946; ZerfassThome K, 1996, ONCOGENE, V13, P2323; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 2000, ADV CANCER RES, V78, P1; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291; Zwerschke W, 2000, J BIOL CHEM, V275, P9534, DOI 10.1074/jbc.275.13.9534	159	442	467	0	23	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	2001	20	54					7888	7898		10.1038/sj.onc.1204860	http://dx.doi.org/10.1038/sj.onc.1204860			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753671				2022-12-28	WOS:000172336500008
J	Chen, WY; Palanisamy, N; Schmidt, H; Teruya-Feldstein, J; Jhanwar, SC; Zelenetz, AD; Houldsworth, J; Chaganti, RSK				Chen, WY; Palanisamy, N; Schmidt, H; Teruya-Feldstein, J; Jhanwar, SC; Zelenetz, AD; Houldsworth, J; Chaganti, RSK			Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas	ONCOGENE			English	Article						FCGR2B; 1q21; follicular lymphoma; translocation	FC-GAMMA-RIIB; NON-HODGKINS-LYMPHOMA; B-CELLS; CHROMOSOMAL-ABNORMALITIES; CYTOGENETIC ANALYSIS; NEGATIVE REGULATION; MALIGNANT-LYMPHOMA; PROTEIN P62(DOK); RECEPTOR; TRANSLOCATIONS	We report here the molecular cloning and characterization of a t(1;14)(q21;q32) in a follicular lymphoma (FL) with an unusual BCL2 aberration. Fluorescence in situ hybridization (FISH) and Southern blot analysis of tumor cells identified the translocation breakpoint within the 5' switch region of IGHG (S gamma). We cloned the chimeric breakpoint region approximately 1.5 kbp downstream from the HindIII site of 5'S gamma2 on chromosome 14q32 and identified a 360-bp novel segment with homology to the CpG island clone 11h8. Two BAC clones containing this sequence were isolated and mapped to 1q21 by FISH. BAC 342/P13 contained sequences homologous to Fc gamma receptors 2A, 3A, 2B, 3B, and a heat shock protein gene HSP70B. The translocation brought the S gamma2 region of a productive IGH allele 20 similar to 30 kbp upstream of FCGR2B. As a result of the translocation, the b2 isoform of FCGR2B was overexpressed in the tumor. Screening of a panel of 76 B-cell lymphomas with 1q21-23 cytogenetic aberrations by Southern blot analysis using breakpoint probes identified an additional FL with a t(14;18)(q32;q21) and a breakpoint in the FCGR2B region. These results suggest that FCGR2B may be deregulated by 1q21 aberration in BCL2 rearranged FLs and possibly play a role in their progression.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.		Palanisamy, Nallasivam/ABC-8844-2020	Palanisamy, Nallasivam/0000-0002-0633-9772	NCI NIH HHS [CA-80814, CA-66999, CA-34775] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080814, R01CA066999, R01CA034775] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; BUDDE P, 1994, J BIOL CHEM, V269, P30636; Callanan MB, 2000, P NATL ACAD SCI USA, V97, P309, DOI 10.1073/pnas.97.1.309; Chaganti RSK, 2000, SEMIN HEMATOL, V37, P396; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P328, DOI 10.1002/(SICI)1098-2264(199812)23:4<328::AID-GCC8>3.0.CO;2-M; Cigudosa JC, 1999, GENE CHROMOSOME CANC, V25, P123, DOI 10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.0.CO;2-4; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dalla-Favera R, 1999, CURR TOP MICROBIOL, V246, P257; Dyomin VG, 2000, BLOOD, V95, P2666; Hatzivassiliou G, 2001, IMMUNITY, V14, P277, DOI 10.1016/S1074-7613(01)00109-1; Metes D, 1998, BLOOD, V91, P2369, DOI 10.1182/blood.V91.7.2369.2369_2369_2380; OFFIT K, 1991, BLOOD, V77, P1508; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Pearse RN, 1999, IMMUNITY, V10, P753, DOI 10.1016/S1074-7613(00)80074-6; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; SARMAY G, 1995, EUR J IMMUNOL, V25, P262, DOI 10.1002/eji.1830250143; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; TILLY H, 1994, BLOOD, V84, P1043; TWEEDDALE ME, 1987, BLOOD, V69, P1307; Willis TG, 1998, BLOOD, V91, P1873, DOI 10.1182/blood.V91.6.1873.1873_1873_1881; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; WITZ IP, 1992, IMMUNOL RES, V11, P283, DOI 10.1007/BF02919134; Yamanashi Y, 2000, GENE DEV, V14, P11; Zusman T, 1996, INT J CANCER, V68, P219, DOI 10.1002/(SICI)1097-0215(19961009)68:2<219::AID-IJC14>3.0.CO;2-5	28	31	31	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7686	7693		10.1038/sj.onc.1204989	http://dx.doi.org/10.1038/sj.onc.1204989			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753646				2022-12-28	WOS:000172124100011
